PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ly, P; Kim, SB; Kaisani, AA; Marian, G; Wright, WE; Shay, JW				Ly, P.; Kim, S. B.; Kaisani, A. A.; Marian, G.; Wright, W. E.; Shay, J. W.			Aneuploid human colonic epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation	ONCOGENE			English	Article						aneuploidy; EGFR; AICAR; chromosomal instability; trisomy	CHROMOSOMAL INSTABILITY; RECEPTOR; CANCER; UBIQUITINATION; TRISOMY; PROLIFERATION; POPULATIONS; METABOLISM; MUTATIONS; PROTEOME	Trisomy for chromosome 7 is frequently observed as an initiating event in sporadic colorectal cancer. Although unstable chromosome numbers and recurrent aneuploidies drive a large fraction of human cancers, targeted therapies selective to pre-neoplastic trisomic cells are non-existent. We have previously characterized a trisomy 7 cell line (1CT+7) spontaneously derived from normal diploid human colonic epithelial cells that aberrantly expresses the epidermal growth factor receptor (EGFR, chromosome 7p11). Recent studies identified AICAR (5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside) as a pharmacological inhibitor of aneuploid murine fibroblast proliferation. Here, we report that AICAR induces profound cytostatic and metabolic effects on 1CT+7 cells, but not on their isogenic diploid counterpart. Dose-response experiments indicate that 1CT+7 cells are fourfold preferentially sensitive to AICAR compared to diploid cells. Unexpectedly, treatment of 1CT+7 cells with AICAR led to a reversible 3.5-fold reduction (P = 0.0025) in EGFR overexpression. AICAR-induced depletion of EGFR protein can be abrogated through inhibition of the proteasome with MG132. AICAR also heavily promoted EGFR ubiquitination in cell-based immunoprecipitation assays, suggesting enhanced degradation of EGFR protein mediated by the proteasome. Moreover, treatment with AICAR reduced EGFR protein levels in a panel of human colorectal cancer cells in vitro and in xenograft tumors in vivo. Our data collectively support the pharmacological compound AICAR as a novel inhibitor of EGFR protein abundance and as a potential anticancer agent for aneuploidy-driven colorectal cancer.	[Ly, P.; Kim, S. B.; Kaisani, A. A.; Marian, G.; Wright, W. E.; Shay, J. W.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Shay, J. W.] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah 21413, Saudi Arabia	University of Texas System; University of Texas Southwestern Medical Center Dallas; King Abdulaziz University	Shay, JW (corresponding author), Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jerry.shay@utsouthwestern.edu	Ly, Peter/B-3722-2012	Ly, Peter/0000-0001-8946-7069; Kim, Sang Bum/0000-0001-5965-3354	CPRIT [RP101496]; NASA [NNX09AU95G, NNX11AC15G, NNX11AC54G]; NCI [SPORE CA70907]; NATIONAL CANCER INSTITUTE [P30CA142543, P50CA070907] Funding Source: NIH RePORTER	CPRIT; NASA(National Aeronautics & Space Administration (NASA)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank RY Quach for figure artwork and U Eskiocak, G Stadler and AR Mullen (UT Southwestern) for technical assistance. We also express gratitude to YC Tang and A Amon (MIT) for providing xenograft tumors for IHC analysis and for critical reading of the manuscript. HA-tagged ubiquitin plasmids and anti-HA antibodies were a kind gift from LJ Huang (UT Southwestern). EGFR-V5 expression constructs and human bronchial epithelial cell-EGFR cell lines were provided by C Nirodi (UT Southwestern). This work was supported by CPRIT Training Grant RP101496 to PL, NASA Grants NNX09AU95G, NNX11AC15G, and NNX11AC54G and NCI SPORE CA70907 to JWS.	Aschenbach WG, 2002, DIABETES, V51, P567, DOI 10.2337/diabetes.51.3.567; Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; BOMME L, 1994, GENE CHROMOSOME CANC, V10, P190, DOI 10.1002/gcc.2870100307; Briand P, 1996, CANCER RES, V56, P2039; Chen GB, 2012, NATURE, V482, P246, DOI 10.1038/nature10795; Cohen G, 2006, CANCER RES, V66, P5656, DOI 10.1158/0008-5472.CAN-05-0308; Das AK, 2007, CANCER RES, V67, P5267, DOI 10.1158/0008-5472.CAN-07-0242; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; GAREWAL H, 1990, DIGEST DIS SCI, V35, P1115, DOI 10.1007/BF01537584; Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Habermann JK, 2007, GENE CHROMOSOME CANC, V46, P10, DOI 10.1002/gcc.20382; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Lamprecht SA, 2002, CARCINOGENESIS, V23, P1777, DOI 10.1093/carcin/23.11.1777; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Ly P, 2011, NEOPLASIA, V13, P348, DOI 10.1593/neo.101580; Manchado E, 2011, CELL, V144, P465, DOI 10.1016/j.cell.2011.01.037; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; MELTZER SJ, 1994, CANCER RES, V54, P3379; Messersmith WA, 2008, NEW ENGL J MED, V359, P1834, DOI 10.1056/NEJMe0806778; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; Sareen D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007630; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Sheltzer JM, 2011, TRENDS GENET, V27, P446, DOI 10.1016/j.tig.2011.07.003; Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058	36	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3139	3146		10.1038/onc.2012.339	http://dx.doi.org/10.1038/onc.2012.339			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22890317	Green Accepted			2022-12-17	WOS:000321004600004
J	Heo, K; Kim, JS; Kim, K; Kim, H; Choi, J; Yang, K; An, W				Heo, K.; Kim, J-S; Kim, K.; Kim, H.; Choi, J.; Yang, K.; An, W.			Cell-penetrating H4 tail peptides potentiate p53-mediated transactivation via inhibition of G9a and HDAC1	ONCOGENE			English	Article						p53; histone; transcription; acetylation; methylation	TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REGULATION; CANCER-CELLS; COMPLEX; PROTEIN; RECRUITMENT; TRANSDUCTION; ACTIVATION; REPRESSION; PHYSIOLOGY	Histone acetylation has a central role in establishing an active chromatin environment. The functional contribution of histone acetylation to chromatin transcription is accomplished by a dominant action of histone acetyltransferases over repressive histone-modifying activities at gene promoters; misregulation of these dynamic events can lead to various diseases. Here, we describe the synthesis and characterization of transducible peptides derived from histone H4 N-terminal tail as a molecular tool to establish and maintain the active state of p53 target genes. Cellular experiments demonstrate a distinct increase in p53 transactivation by acetylated H4 tail peptides, but only a modest change by unmodified H4 tail peptides. The molecular basis underlying the observed effects involves the selective interaction of the tail peptides with G9a histone methyltransferase and histone deacetylase 1 (HDAC1) and the disruption of their occupancy at p53 target promoters. Furthermore, treatment of xenograft models and cancer cell lines with the tail peptides sharply decline tumor cell growth and enhances apoptosis in response to DNA damage. These results indicate that H4 tail peptide mimics upregulate p53 transcription pathway and may be used as a novel strategy for anticancer therapy.	[Heo, K.; Kim, K.; Kim, H.; Choi, J.; An, W.] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; [Heo, K.; Kim, J-S; Yang, K.] Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Pusan, South Korea; [Kim, H.] Harvard Univ, Sch Med, Dept Pediat,Dana Farber Canc Inst,Childrens Hosp, Dept Pediat Oncol,Div Hematol Oncol, Boston, MA 02115 USA	University of Southern California; Korea Institute of Radiological & Medical Sciences; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	An, W (corresponding author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, 1450 Biggy St NRT6507, Los Angeles, CA 90089 USA.	woojinan@usc.edu		Heo, Kyu/0000-0001-8833-4731	National Institutes of Health [R01GM84209]; American Cancer Society [RSG DMC1005001]; DIRAMS from the Ministry of Education, Science and Technology [50595-2012]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084209] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); DIRAMS from the Ministry of Education, Science and Technology; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Michael Stallcup and Mr Dan Gerke for the gift of pSG5-FLAG-G9a and G9a shRNA constructs. The technical assistance of Drs Balachandra Hegde and Ralph Langen in circular dichroism analysis is greatly acknowledged. We also thank Dr Jing Huang for p53K373me2 antibody. This work was supported by R01GM84209 to WA from the National Institutes of Health, RSG DMC1005001 to WA from the American Cancer Society and DIRAMS (50595-2012) to KH from the Ministry of Education, Science and Technology.	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Harada Y, 2010, CANCER RES, V70, P5829, DOI 10.1158/0008-5472.CAN-10-0255; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Heo K, 2008, MOL CELL, V30, P86, DOI 10.1016/j.molcel.2008.02.029; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Muntean AG, 2009, AM J PATHOL, V175, P1353, DOI 10.2353/ajpath.2009.081142; Nishiyama A, 2008, FEBS LETT, V582, P1501, DOI 10.1016/j.febslet.2008.03.044; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Spannhoff A, 2009, CHEMMEDCHEM, V4, P1568, DOI 10.1002/cmdc.200900301; Spotswood HT, 2002, J CLIN INVEST, V110, P577, DOI 10.1172/JCI200216547; Stimson L, 2009, ANN ONCOL, V20, P1293, DOI 10.1093/annonc/mdn792; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191	33	14	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2013	32	20					2510	2520		10.1038/onc.2012.273	http://dx.doi.org/10.1038/onc.2012.273			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751130				2022-12-17	WOS:000319274300002
J	Sharma, A; Sen, JM				Sharma, A.; Sen, J. M.			Molecular basis for the tissue specificity of beta-catenin oncogenesis	ONCOGENE			English	Article						beta-catenin; hypocellular thymus; p53; apoptosis; intestinal adenoma; c-Myc	ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL DEVELOPMENT; MULTIPLE INTESTINAL NEOPLASIA; IN-VIVO; MEDIATED TRANSCRIPTION; THYMOCYTE DEVELOPMENT; APC(MIN/+) MOUSE; GENE-EXPRESSION; APC DEFICIENCY; MYC DELETION	Wnt-beta-catenin-T-cell factor signaling is causally linked to c-myc-dependent tumorigenesis in mouse and human colon epithelial cells. By contrast, beta-catenin is not similarly associated with oncogenic transformation of other tissues, including T cells. The molecular basis for tissue specificity of beta-catenin-dependent oncogenesis is unknown. Here, we demonstrate that adenomatous polyposis coli mutant APC(Min/-) mice, which have increased expression of beta-catenin in all tissues, develop severe intestinal neoplasia, but fail to develop thymic lymphoma. Whereas beta-catenin-dependent signals elicit a proliferative response from intestinal cells, thymocytes experience oncogene-induced senescence (OIS), growth arrest and apoptosis. We demonstrate that the differential cellular response of thymocytes and intestinal epithelial cells is a direct consequence of the gene expression elicited by beta-catenin expression in each tissue. We find that whereas intestinal cells induce genes that promote proliferation thymocytes induce expression of genes associated with OIS, growth arrest and p53-dependent apoptosis. We correlate gene expression pattern with the role beta-catenin plays in the development of each tissue and suggest that susceptibility of transformation by beta-catenin is intimately related to its function during development. We propose that when oncogenes are used as signaling molecules, safety nets in the form of OIS, growth arrest and apoptosis prevent accidental transformation. Oncogene (2013) 32, 1901-1909; doi:10.1038/onc.2012.215; published online 11 June 2012	[Sharma, A.; Sen, J. M.] NIA, Lymphocyte Dev Unit, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sen, JM (corresponding author), NIA, Lymphocyte Dev Unit, Lab Mol Biol & Immunol, NIH, Baltimore, MD 21224 USA.	Jyoti-Sen@NIH.GOV	Sharma, Archna/R-9377-2016	Sharma, Archna/0000-0003-4745-0220	National Institute on Aging; National Institutes of Health; NATIONAL INSTITUTE ON AGING [ZIAAG000772, ZIAAG000768, ZIAAG000771] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Q Yu for doing IP BrdU injections; R Wersto and the FACS facility team for cell sorting; the animal facility of National Institute on Aging for maintaining animals; S Luo and team for genotyping. This research was supported by Intramural Research Program of the National Institute on Aging and National Institutes of Health.	Bellei B, 2004, MODERN PATHOL, V17, P1275, DOI 10.1038/modpathol.3800181; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Ciofani M, 2006, IMMUNOL RES, V34, P117, DOI 10.1385/IR:34:2:117; Cole AM, 2010, EMBO MOL MED, V2, P472, DOI 10.1002/emmm.201000101; Coletta PL, 2004, BLOOD, V103, P1050, DOI 10.1182/blood-2003-03-0707; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dorfman DM, 2003, AM J PATHOL, V162, P1539, DOI 10.1016/S0002-9440(10)64287-3; Gandhirajan RK, 2010, NEOPLASIA, V12, P326, DOI 10.1593/neo.91972; Gounari F, 2005, NAT IMMUNOL, V6, P800, DOI 10.1038/ni1228; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Groen RWJ, 2008, CANCER RES, V68, P6969, DOI 10.1158/0008-5472.CAN-08-1322; Guo ZY, 2007, BLOOD, V109, P5463, DOI 10.1182/blood-2006-11-059071; Ignatenko NA, 2006, CANCER BIOL THER, V5, P1658, DOI 10.4161/cbt.5.12.3376; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; LUONGO C, 1994, CANCER RES, V54, P5947; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Mulroy T, 2003, INT IMMUNOL, V15, P1485, DOI 10.1093/intimm/dxg146; Pajari AM, 2003, INT J CANCER, V106, P653, DOI 10.1002/ijc.11270; Polakis P, 2000, GENE DEV, V14, P1837; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Reed KR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-162; Reed KR, 2008, P NATL ACAD SCI USA, V105, P18919, DOI 10.1073/pnas.0805778105; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sansom OJ, 2005, ONCOGENE, V24, P8205, DOI 10.1038/sj.onc.1208956; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Serinsoz E, 2004, BRIT J HAEMATOL, V126, P313, DOI 10.1111/j.1365-2141.2004.05049.x; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Staal FJT, 2008, HAEMATOLOGICA, V93, P493, DOI 10.3324/haematol.12917; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tang XW, 2007, J CLIN INVEST, V117, P3753, DOI 10.1172/JCI32481; Tsutsui J, 1996, J BIOCHEM-TOKYO, V120, P1034; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Weerkamp F, 2006, LEUKEMIA, V20, P1197, DOI 10.1038/sj.leu.2404255; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Xu M, 2008, MOL CELL BIOL, V28, P1713, DOI 10.1128/MCB.01360-07; Xu M, 2009, J IMMUNOL, V182, P759, DOI 10.4049/jimmunol.182.2.759; Xu M, 2009, J IMMUNOL, V182, P751, DOI 10.4049/jimmunol.182.2.751; Xu YY, 2003, NAT IMMUNOL, V4, P1177, DOI 10.1038/ni1008; Xu YY, 2003, EUR J IMMUNOL, V33, P12, DOI 10.1002/immu.200390002; You L, 2008, MOL CANCER THER, V7, P1633, DOI 10.1158/1535-7163.MCT-08-0155; Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107; Yu Q, 2010, IMMUNOL RES, V47, P45, DOI 10.1007/s12026-009-8137-2	54	14	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 11	2013	32	15					1901	1909		10.1038/onc.2012.215	http://dx.doi.org/10.1038/onc.2012.215			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22689057	Green Accepted			2022-12-17	WOS:000317599900004
J	Kyrkou, A; Soufi, M; Bahtz, R; Ferguson, C; Bai, M; Parton, RG; Hoffmann, I; Zerial, M; Fotsis, T; Murphy, C				Kyrkou, A.; Soufi, M.; Bahtz, R.; Ferguson, C.; Bai, M.; Parton, R. G.; Hoffmann, I.; Zerial, M.; Fotsis, T.; Murphy, C.			RhoD participates in the regulation of cell-cycle progression and centrosome duplication	ONCOGENE			English	Article						RhoD; proliferation; centrosome cycle	CENTRIOLE DUPLICATION; ENDOSOME DYNAMICS; GTPASES; EXPRESSION; BINDING; PROTEIN; RAC1; NUCLEOPHOSMIN/B23; PHOSPHORYLATION; MICROTUBULES	We have previously identified a Rho protein, RhoD, which localizes to the plasma membrane and the early endocytic compartment. Here, we show that a GTPase-deficient mutant of RhoD, RhoDG26V, causes hyperplasia and perturbed differentiation of the epidermis, when targeted to the skin of transgenic mice. In vitro, gain-of-function and loss-of-function approaches revealed that RhoD is involved in the regulation of G1/S-phase progression and causes overduplication of centrosomes. Centriole overduplication assays in aphidicolin-arrested p53-deficient U2OS cells, in which the cell and the centrosome cycles are uncoupled, revealed that the effects of RhoD and its mutants on centrosome duplication and cell cycle are independent. Enhancement of G1/S-phase progression was mediated via Diaph1, a novel effector of RhoD, which we have identified using a two-hybrid screen. These results indicate that RhoD participates in the regulation of cell-cycle progression and centrosome duplication. Oncogene (2013) 32, 1831-1842; doi: 10.1038/onc.2012.195; published online 4 June 2012	[Kyrkou, A.; Soufi, M.; Fotsis, T.] Univ Ioannina, Sch Med, Lab Biol Chem, GR-45110 Ioannina, Greece; [Kyrkou, A.; Fotsis, T.; Murphy, C.] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Dept Biomed Res, Ioannina 45110, Greece; [Bahtz, R.; Hoffmann, I.] German Canc Res Ctr, Heidelberg, Germany; [Ferguson, C.; Parton, R. G.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Ferguson, C.; Parton, R. G.] Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld, Australia; [Bai, M.] Univ Ioannina, Sch Med, Dept Pathol, GR-45110 Ioannina, Greece; [Zerial, M.] Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Helmholtz Association; German Cancer Research Center (DKFZ); University of Queensland; University of Queensland; University of Ioannina; Max Planck Society	Murphy, C (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Dept Biomed Res, Univ Campus Ioannina, Ioannina 45110, Greece.	cmurphy@cc.uoi.gr	Murphy, Carol/ABE-4282-2021; Parton, Robert/C-5673-2009	Murphy, Carol/0000-0003-1353-8558; Parton, Robert/0000-0002-7494-5248	European Commission [HRPN-CT-2000-00081]; short-term EMBO fellowship; Biotechnology of the University of Ioannina; Ministry of Education and Religious Affairs of Greece; E.U.-European Social Fund; Greek Ministry of Development-GSRT; National Health and Medical Research Council of Australia	European Commission(European CommissionEuropean Commission Joint Research Centre); short-term EMBO fellowship; Biotechnology of the University of Ioannina; Ministry of Education and Religious Affairs of Greece; E.U.-European Social Fund(European Social Fund (ESF)European Commission); Greek Ministry of Development-GSRT(Greek Ministry of Development-GSRT); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank the confocal laser microscope facility of the University of Ioannina for the use of the Leica TCS-SP confocal microscope. We thank George Bartholomatos for FACS analysis; Zoi Lygerou, University of Patras, Greece for critical reading of the manuscript; George Keech for excellent animal husbandry; and Angelika Giner for expert technical assistance. This work was supported by a Research Training Network grant (to MZ and CM) of the European Commission (contract no: HRPN-CT-2000-00081). CM was supported by a short-term EMBO fellowship. MS was supported by the Postgraduate Master's Program of Biotechnology of the University of Ioannina funded by the Ministry of Education and Religious Affairs of Greece. AK was supported by the PENED 03E Delta 688 program, which was co-financed by E.U.-European Social Fund (75%) and the Greek Ministry of Development-GSRT (25%). RGP was supported by grants from the National Health and Medical Research Council of Australia.	BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bellou S, 2009, AM J PHYSIOL-CELL PH, V297, pC1477, DOI 10.1152/ajpcell.00058.2009; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Christoforidis S, 2000, METHODS, V20, P403, DOI 10.1006/meth.2000.0953; Cizmecioglu O, 2008, CELL CYCLE, V7, P3548, DOI 10.4161/cc.7.22.7071; Cizmecioglu O, 2010, J CELL BIOL, V191, P731, DOI 10.1083/jcb.201007107; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eckerdt F, 2011, CURR BIOL, V21, P428, DOI 10.1016/j.cub.2011.01.072; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kato T, 2001, J CELL SCI, V114, P775; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Krause A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009849; Kubo A, 2003, J CELL SCI, V116, P919, DOI 10.1242/jcs.00282; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06; Mammoto A, 2004, J BIOL CHEM, V279, P26323, DOI 10.1074/jbc.M402725200; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Murphy C, 2001, EUR J CELL BIOL, V80, P391, DOI 10.1078/0171-9335-00173; Nagasaki T, 1996, J CELL SCI, V109, P2461; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Panopoulou E, 2005, CANCER RES, V65, P1877, DOI 10.1158/0008-5472.CAN-04-2828; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Sflomos G, 2011, J CELL SCI, V124, P3209, DOI 10.1242/jcs.062307; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Tong Y, 2007, J BIOL CHEM, V282, P37215, DOI 10.1074/jbc.M703800200; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Villalonga P, 2006, GROWTH FACTORS, V24, P159, DOI 10.1080/08977190600560651; Warnke S, 2004, CURR BIOL, V14, P1200, DOI 10.1016/j.cub.2004.06.059; Wen YD, 2004, KENYON REV, V26, P1; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Zanata SM, 2002, J NEUROSCI, V22, P471, DOI 10.1523/JNEUROSCI.22-02-00471.2002	47	14	15	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1831	1842		10.1038/onc.2012.195	http://dx.doi.org/10.1038/onc.2012.195			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22665057				2022-12-17	WOS:000317043900009
J	Traves, PG; Lopez-Fontal, R; Cuadrado, I; Luque, A; Bosca, L; de las Heras, B; Hortelano, S				Traves, P. G.; Lopez-Fontal, R.; Cuadrado, I.; Luque, A.; Bosca, L.; de las Heras, B.; Hortelano, S.			Critical role of the death receptor pathway in the antitumoral effects induced by hispanolone derivatives	ONCOGENE			English	Article						hispanolone derivatives; apoptosis; death receptors; TRAIL; caspase-8	NF-KAPPA-B; INDUCED APOPTOSIS; NITRIC-OXIDE; ACTIVATION; CANCER; INHIBITION; DITERPENES; MECHANISM; THERAPY; KINASE	Labdane diterpenoids have a broad spectrum of biological activities including antibacterial, antiviral and anti-inflammatory properties. However, little is known about their possible role in the apoptotic cell death machinery. Here, we report that hispanolone derivatives, a group of labdane diterpenoids, induce apoptosis in different tumor cell lines by activating caspase-8 with subsequent participation of mitochondrial signaling. Activation of caspase-8 by hispanolone derivatives was followed by a decrease in mitochondrial membrane potential, the release of apoptotic factors from mitochondria to the cytosol, and activation of caspases-9 and 3. Hispanolone derivatives also led to a time-dependent cleavage of Bid. Inhibition of caspase-8 abrogated these processes, suggesting that the death receptor pathway has a critical role in the apoptotic events induced by hispanolone derivatives. In addition, silencing death receptors with small interfering RNA s or pretreating cells with neutralizing antibodies to Fas ligand, tumor necrosis factor receptor 1 (TNF-R1), and TNF-alpha receptor 2 (TRAIL) inhibited diterpenoid-induced apoptosis, revealing it to be dependent on these death receptors. Interestingly, hispanolone derivatives had no effect on non-tumor cells. Consistently, in vivo bioluminescence imaging corroborates this antineoplasic effect, as hispanolone derivatives significantly decrease cancer growth in tumor xenograft assays. These data demostrate the antitumoral effects of hispanolone derivatives and provide relevant preclinical validation for the use of these compounds as potent therapeutic agents in cancer treatment. Oncogene (2013) 32, 259-268; doi:10.1038/onc.2012.23; published online 6 February 2012	[Traves, P. G.; Bosca, L.] UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Lopez-Fontal, R.] Ctr Nacl Invest Cardiovasc, Madrid, Spain; [Cuadrado, I.; de las Heras, B.] Univ Complutense Madrid, Fac Farm, Dept Farmacol, E-28040 Madrid, Spain; [Luque, A.] FIB Hosp Univ Nino Jesus, Madrid, Spain; [Luque, A.] IIS Hosp La Princesa, Madrid, Spain; [Hortelano, S.] Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Inflamac & Canc, Area Biol Celular & Desarrollo, Madrid 28220, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Complutense University of Madrid; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM)	Hortelano, S (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Unidad Inflamac & Canc, Area Biol Celular & Desarrollo, Ctra Majadahonda Pozuelo,Km 2,200, Madrid 28220, Spain.	lasheras@farm.ucm.es; shortelano@isciii.es	de las Heras, Beatriz/K-1811-2014; de las Heras, Beatriz/ABB-9645-2021; Cuadrado-Berrocal, Irene/K-7761-2014; Bosca, Lisardo/A-2059-2008; Cuadrado-Berrocal, Irene/P-1360-2014; Luque, Alfonso/C-5846-2018; G. Traves, Paqui/L-5693-2014; Cuadrado-Berrocal, Irene/AAZ-1917-2021; Hortelano, Sonsoles/A-7954-2010	de las Heras, Beatriz/0000-0001-5089-8988; de las Heras, Beatriz/0000-0001-5089-8988; Cuadrado-Berrocal, Irene/0000-0003-0727-9633; Bosca, Lisardo/0000-0002-0253-5469; Cuadrado-Berrocal, Irene/0000-0003-0727-9633; G. Traves, Paqui/0000-0001-5749-8426; Cuadrado-Berrocal, Irene/0000-0003-0727-9633; Hortelano, Sonsoles/0000-0003-2528-0072	FIS [PI08.0070]; ISCIII [MPY 1410/09]; Santander-Complutense grant	FIS(Instituto de Salud Carlos III); ISCIII(Instituto de Salud Carlos III); Santander-Complutense grant	This study was supported by grant PI08.0070 from the FIS and MPY 1410/09 from ISCIII to SH, and by a Santander-Complutense grant to SH and B de las H. We thank Gemma Benito for excellent technical assistance and Simon Bartlett for critical reading of the manuscript. We thank Dr S Alemany and Dr K Roby for kindly provide luc-B16F10 and ID8 cells, respectively.	Castrillo A, 2001, J BIOL CHEM, V276, P15854, DOI 10.1074/jbc.M100010200; Chinou I, 2005, CURR MED CHEM, V12, P1295, DOI 10.2174/0929867054020990; de las Heras B, 2001, LIFE SCI, V70, P269, DOI 10.1016/S0024-3205(01)01402-3; Dirsch VM, 2002, LEUKEMIA, V16, P74, DOI 10.1038/sj.leu.2402337; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Giron N, 2008, TOXICOL APPL PHARM, V228, P179, DOI 10.1016/j.taap.2007.12.006; Hueso-Falcon I, 2011, EUR J MED CHEM, V46, P1291, DOI 10.1016/j.ejmech.2011.01.052; Hwang BY, 2001, PLANTA MED, V67, P406, DOI 10.1055/s-2001-15808; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kuo PL, 2004, J PHARM PHARMACOL, V56, P1399, DOI 10.1211/0022357044625; Lee JH, 2006, BIOCHEM PHARMACOL, V72, P1311, DOI 10.1016/j.bcp.2006.08.014; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liby KT, 2007, NAT REV CANCER, V7, P357, DOI 10.1038/nrc2129; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723; Nagashima F, 2003, CHEM PHARM BULL, V51, P1189, DOI 10.1248/cpb.51.1189; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; RODRIGUEZ B, 1980, PHYTOCHEMISTRY, V19, P1805, DOI 10.1016/S0031-9422(00)83817-0; SAVONA G, 1978, HETEROCYCLES, V9, P257; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; Wajant H, 2006, CANC TREAT, V130, P141; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207; Zeini M, 2006, J IMMUNOL, V177, P3327, DOI 10.4049/jimmunol.177.5.3327; Zhou J, 2008, MOL CANCER THER, V7, P2170, DOI 10.1158/1535-7163.MCT-08-0071; Zhou J, 2006, BIOCHEM PHARMACOL, V72, P132, DOI 10.1016/j.bcp.2006.04.019	30	14	14	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					259	268		10.1038/onc.2012.23	http://dx.doi.org/10.1038/onc.2012.23			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22310289				2022-12-17	WOS:000314075500014
J	Ursini-Siegel, J; Hardy, WR; Zheng, Y; Ling, C; Zuo, D; Zhang, C; Podmore, L; Pawson, T; Muller, WJ				Ursini-Siegel, J.; Hardy, W. R.; Zheng, Y.; Ling, C.; Zuo, D.; Zhang, C.; Podmore, L.; Pawson, T.; Muller, W. J.			The ShcA SH2 domain engages a 14-3-3/PI3 ' K signaling complex and promotes breast cancer cell survival	ONCOGENE			English	Article						ShcA; SH2 domain; breast cancer; polyoma virus middle T; AKT; signal transduction	DEPENDENT ACTIVATION; ADAPTER PROTEIN; TYROSINE; BINDING; PROGRESSION; TUMORS; GROWTH; GRB2; PHOSPHORYLATION; ASSOCIATION	The ShcA adapter protein transmits activating signals downstream of receptor and cytoplasmic tyrosine kinases through the establishment of phosphotyrosine-dependent complexes. In this regard, ShcA possesses both a phosphotyrosine-binding domain (PTB) and Src homology 2 domain (SH2), which bind phosphotyrosine residues in a sequence-specific manner. Although the majority of receptor tyrosine kinases expressed in breast cancer cells bind the PTB domain, very little is known regarding the biological importance of SH2-driven ShcA signaling during mammary tumorigenesis. To address this, we employed transgenic mice expressing a mutant ShcA allele harboring a non-functional SH2 domain (ShcR397K) under the transcriptional control of the endogenous ShcA promoter. Using transplantation approaches, we demonstrate that SH2-dependent ShcA signaling within the mammary epithelial compartment is essential for breast tumor outgrowth, survival and the development of lung metastases. We further show that the ShcA SH2 domain activates the AKT pathway, potentially through a novel SH2-mediated complex between ShcA, 14-3-3 xi and the p85 regulatory subunit of phosphatidylinositol 3 (PI3') kinase. This study is the first to demonstrate that the SH2 domain of ShcA is critical for tumor survival during mammary tumorigenesis. Oncogene (2012) 31, 5038-5044; doi:10.1038/onc.2012.4; published online 30 January 2012	[Ursini-Siegel, J.; Podmore, L.] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Hardy, W. R.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Zheng, Y.; Zhang, C.; Pawson, T.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Ling, C.; Zuo, D.; Muller, W. J.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada	Lady Davis Institute; McGill University; University of Massachusetts System; University of Massachusetts Worcester; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University	Ursini-Siegel, J (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.	giuseppina.ursini-siegel@mcgill.ca	Pawson, Tony J/E-4578-2013		CBCRA; CIHR [MOP-89751, MOP-111143, MOP6849]; Terry Fox team [020002]; Terry Fox Foundation/CIHR [TFF105268]; CIHR/FRSQ	CBCRA; CIHR(Canadian Institutes of Health Research (CIHR)); Terry Fox team; Terry Fox Foundation/CIHR(Canadian Institutes of Health Research (CIHR)); CIHR/FRSQ(Fonds de la Recherche en Sante du QuebecCanadian Institutes of Health Research (CIHR))	We thank Dr Peter Siegel for critical reading of this manuscript and Vasilios Papavasiliou for assisting with the injection studies. This work was supported by CBCRA, CIHR (MOP-89751) and Terry Fox team (020002) grants to WJM, a CIHR operating grant to JU-S (MOP-111143) and CIHR (MOP6849) and Terry Fox Foundation/CIHR (TFF105268) grants to TP JU-S is the recipient of a CIHR New Investigator Salary Support award. LP is supported by a CIHR/FRSQ training grant in cancer research of the McGill Integrated Cancer Research Training Program (MICRTP). WJM is supported by a CRC chair in molecular oncology. TP is a CIHR distinguished scientist.	ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Barry EF, 2009, J BIOL CHEM, V284, P12080, DOI 10.1074/jbc.M807637200; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Cook RS, 2011, CANCER RES, V71, P3941, DOI 10.1158/0008-5472.CAN-10-3775; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Davol PA, 2003, CANCER RES, V63, P6772; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; Frackelton AR, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1631; George R, 2008, J MOL BIOL, V377, P740, DOI 10.1016/j.jmb.2007.12.040; Gillgrass A, 2003, ONCOGENE, V22, P9151, DOI 10.1038/sj.onc.1206983; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hardy WR, 2007, SCIENCE, V317, P251, DOI 10.1126/science.1140114; Hodgson JG, 2005, CANCER RES, V65, P9695, DOI 10.1158/0008-5472.CAN-05-0755; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79; Komiya Y, 2008, J BIOL CHEM, V283, P18753, DOI 10.1074/jbc.M802530200; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Ling C, 2010, GENE DEV, V24, P947, DOI 10.1101/gad.1896810; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Neal CL, 2011, ONCOGENE; Orlando FA, 2009, ANN SURG ONCOL, V16, P2270, DOI 10.1245/s10434-009-0500-y; Patrussi L, 2005, ONCOGENE, V24, P2218, DOI 10.1038/sj.onc.1208384; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Rauh MJ, 1999, MOL CELL BIOL, V19, P8169; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Su CH, 2011, CANCER RES, V71, P884, DOI 10.1158/0008-5472.CAN-10-2518; Telles E, 2009, EXP CELL RES, V315, P1448, DOI 10.1016/j.yexcr.2009.01.018; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Ursini-Siegel J, 2007, MOL CELL BIOL, V27, P6361, DOI 10.1128/MCB.00686-07; Ursini-Siegel J, 2010, CANCER RES, V70, P7776, DOI 10.1158/0008-5472.CAN-10-2229; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Zhang ZG, 2004, STEROIDS, V69, P523, DOI 10.1016/j.steroids.2004.05.012; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	45	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					5038	5044		10.1038/onc.2012.4	http://dx.doi.org/10.1038/onc.2012.4			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22286768				2022-12-17	WOS:000311888600008
J	Ferrero, GO; Velazquez, FN; Caputto, BL				Ferrero, G. O.; Velazquez, F. N.; Caputto, B. L.			The kinase c-Src and the phosphatase TC45 coordinately regulate c-Fos tyrosine phosphorylation and c-Fos phospholipid synthesis activation capacity	ONCOGENE			English	Article						cytoplasmic c-Fos; phospholipid synthesis regulation; c-Fos-tyr phosphorylation; c-Src; TC45 phosphatase	GROWTH-FACTOR RECEPTOR; NEGATIVE REGULATOR; SIGNALING PATHWAY; INSULIN-RECEPTOR; PC12 CELLS; PROTEIN; LIGHT; TCPTP; NUCLEUS; RETINA	Our previous work showed that in T98G cells, a human glioblastoma multiforme-derived cell line, the association of c-Fos to the endoplasmic reticulum (ER) and consequently, the capacity of c-Fos to activate phospholipid synthesis, is regulated by the phosphorylation state of tyrosine (tyr) residues # 10 and # 30 of c-Fos. The small amount of c-Fos present in quiescent cells is tyrphosphorylated, is dissociated from the ER membranes and does not activate phospholipid synthesis. However, on induction of the cell to re-enter growth, c-Fos expression is rapidly induced, it is found dephosphorylated, associated to ER membranes and activating phospholipid synthesis (Portal et al., 2007). Herein, using in vivo and in vitro experimental strategies, we show that the kinase c-Src is capable of phosphorylating tyr residues of c-Fos whereas the phosphatase TC45 T-cell protein-tyr phosphatase (TC-PTP) dephosphorylates them, thus enabling c-Fos/ER association and activation of phospholipid synthesis. Results also suggest that the regulation of the phosphorylation/dephosphorylation cycle of c-Fos occurs at the TC-PTP level: induction of cells to re-enter growth promotes the translocation of TC45 from a nuclear to a cytoplasmic location concomitant with its activation. Activated TC45 in its turn promotes dephosphorylation of pre-formed c-Fos, enabling cells to rapidly activate phospholipid synthesis to respond to its growth demands. Oncogene (2012) 31, 3381-3391; doi: 10.1038/onc.2011.510; published online 21 November 2011	[Ferrero, G. O.; Velazquez, F. N.; Caputto, B. L.] Univ Nacl Cordoba, CIQUIBIC, CONICET, Dept Quim Biol,Fac Ciencias Quim, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Caputto, BL (corresponding author), Univ Nacl Cordoba, CIQUIBIC, CONICET, Dept Quim Biol,Fac Ciencias Quim, Ciudad Univ, RA-5000 Cordoba, Argentina.	bcaputto@fcq.unc.edu.ar			ANPCyT; CONICET; Ministerio de Ciencia, Tecnologi a e Innovacio n Productiva de Argentina; SECyT-Universidad Nacional de Cordoba, Argentina; JS McDonnell Foundation	ANPCyT(ANPCyT); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Ministerio de Ciencia, Tecnologi a e Innovacio n Productiva de Argentina; SECyT-Universidad Nacional de Cordoba, Argentina(Secretaria de Ciencia y Tecnologia (SECYT)); JS McDonnell Foundation	We thank HJF Maccioni for helpful discussions and H Carbonneau (Pardue University, West Lafayette, IN, USA) for providing pET-TC45a. pCG-TC45 and pCG-D182A were kind gifts from T Tiganis (Cold Spring Harbor Laboratory, New York, NY, USA) and pET-c-Src from MA Seelinger (University of California, Berkeley, CA, USA). Excellent technical assistance from Susana Deza and Gabriela Schachner is acknowledged. This work was supported by grants from the ANPCyT and CONICET, Ministerio de Ciencia, Tecnologi a e Innovacio n Productiva de Argentina, SECyT-Universidad Nacional de Cordoba, Argentina and the JS McDonnell Foundation. BLC is a career member and GOF and FV are fellows of CONICET.	ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Borioli GA, 2001, BIOCHEM BIOPH RES CO, V280, P9, DOI 10.1006/bbrc.2000.4081; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussolino DF, 2001, FASEB J, V15, P556; Bussolino DF, 1998, MOL BRAIN RES, V58, P10, DOI 10.1016/S0169-328X(98)00065-5; Caputto BL, 2000, NEUROCHEM RES, V25, P153, DOI 10.1023/A:1007508020173; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Crespo PM, 2008, J BIOL CHEM, V283, P31163, DOI 10.1074/jbc.M709257200; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Gil GA, 2004, MOL BIOL CELL, V15, P1881, DOI 10.1091/mbc.E03-09-0705; GUIDO ME, 1990, J NEUROCHEM, V55, P1855, DOI 10.1111/j.1471-4159.1990.tb05768.x; Guido ME, 1996, J NEUROSCI RES, V43, P93, DOI 10.1002/jnr.490430112; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Hu X, 2007, CHEM BIOL, V14, P764, DOI 10.1016/j.chembiol.2007.05.010; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; Meng TC, 2004, J BIOL CHEM, V279, P37716, DOI 10.1074/jbc.M404606200; Morgan James J., 1995, Trends in Neurosciences, V18, P66, DOI 10.1016/0166-2236(95)93874-W; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; Portal MM, 2007, ONCOGENE, V26, P3551, DOI 10.1038/sj.onc.1210137; Sambrook J, 2001, MOL CLONING LAB MANU; Silvestre DC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009544; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Zerpa GAD, 1999, J NEUROCHEM, V73, P1228, DOI 10.1046/j.1471-4159.1999.0731228.x	39	14	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3381	3391		10.1038/onc.2011.510	http://dx.doi.org/10.1038/onc.2011.510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22105363				2022-12-17	WOS:000306367600007
J	Leung, JY; Andrechek, ER; Cardiff, RD; Nevins, JR				Leung, J. Y.; Andrechek, E. R.; Cardiff, R. D.; Nevins, J. R.			Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence	ONCOGENE			English	Article						mouse; mammary; EMT; MYC; cancer	EPITHELIAL-MESENCHYMAL TRANSITIONS; HUMAN BREAST; GENOME; IDENTIFICATION; TUMORIGENESIS; INACTIVATION; CANCERS; MODELS; CELLS; EMT	A hallmark of human cancer is heterogeneity, reflecting the complex series of changes resulting in the activation of oncogenes coupled with inactivation of tumor suppressor genes. Breast cancer is no exception and indeed, many studies have revealed considerable complexity and heterogeneity in the population of primary breast tumors and substantial changes in a recurrent breast tumor that has acquired metastatic properties and drug resistance. We have made use of a Myc-inducible transgenic mouse model of breast cancer in which elimination of Myc activity following tumor development initially leads to a regression of a subset of tumors generally followed by de novo Myc-independent growth. We have observed that tumors that grow independent of Myc expression have gene profiles that are distinct from the primary tumors with characteristics indicative of an epithelial-mesenchymal transition (EMT) phenotype. Phenotypic analyses of Myc-independent tumors confirm the acquisition of an EMT phenotype suggested to be associated with invasive and migratory properties in human cancer cells. Further genomic analyses reveal mouse mammary tumors growing independent of myc have a higher probability of exhibiting a gene signature similar to that observed for human 'tumor-initiating' cells. Collectively, the data reveal genetic alterations that underlie tumor progression and an escape from Myc-dependent growth in a transgenic mouse model that can provide insights to what occurs in human cancers as they acquire drug resistance and metastatic properties. Oncogene (2012) 31, 2545-2554; doi:10.1038/onc.2011.433; published online 26 September 2011	[Leung, J. Y.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA; [Andrechek, E. R.] Michigan State Univ, Dept Biomed & Integrat Physiol, E Lansing, MI 48824 USA; [Cardiff, R. D.] Univ Calif Davis, Dept Pathol & Lab Med, Ctr Comparat Med, Davis, CA 95616 USA; [Nevins, J. R.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University; Michigan State University; University of California System; University of California Davis; Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Inst Genome Sci & Policy, 101 Sci Dr,Box 3382, Durham, NC 27710 USA.	j.nevins@duke.edu		Andrechek, Eran/0000-0002-8680-3423	NIH [CA104663, CA112952]; National Cancer Institute's Mouse Models of Human Cancers Consortium [U01 CA141541, U01 CA141582]; JRN from the National Cancer Institute [RO1-CA104663, U54-CA112952]; NATIONAL CANCER INSTITUTE [U54CA112952, U01CA141582, R01CA104663, U01CA141541, R01CA106520] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute's Mouse Models of Human Cancers Consortium; JRN from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The MTB/TOM mouse was a kind gift from Lewis A Chodosh. We thank Kenichiro Fujiwara for his assistance in animal husbandry and Rachel E Rempel for her helpful advice. We are grateful to Kaye Culler for her assistance with the manuscript. This work was supported by grants from the NIH (CA104663, CA112952) and grants U01 CA141541 and U01 CA141582 from the National Cancer Institute's Mouse Models of Human Cancers Consortium (RDC). We also thank Ms Katie Bell and Judith Walls of the CCM MMPL for their excellent immunohistochemistry. This work was also supported by grants from the JRN (RO1-CA104663 and U54-CA112952) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914; Cardiff RD, 2010, J MAMMARY GLAND BIOL, V15, P225, DOI 10.1007/s10911-010-9184-y; Carvalho CM, 2008, J AM STAT ASSOC, V103, P1438, DOI 10.1198/016214508000000869; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Damonte P, 2007, LAB INVEST, V87, P1218, DOI 10.1038/labinvest.3700683; Diehn M, 2009, SEMIN RADIAT ONCOL, V19, P78, DOI 10.1016/j.semradonc.2008.11.002; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Iseri OD, 2011, BIOMED PHARMACOTHER, V65, P40, DOI 10.1016/j.biopha.2010.10.004; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Lucas J, 2009, STAT APPL GENET MOL, V8, DOI 10.2202/1544-6115.1436; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nicolini A, 2011, CURR PHARM BIOTECHNO, V12, P196, DOI 10.2174/138920111794295657; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Radaelli E, 2009, FUTURE ONCOL, V5, P1113, DOI [10.2217/fon.09.93, 10.2217/FON.09.93]; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358	31	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2545	2554		10.1038/onc.2011.433	http://dx.doi.org/10.1038/onc.2011.433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996730	Green Accepted			2022-12-17	WOS:000304191800005
J	Lu, C; Zhu, X; Willingham, MC; Cheng, SY				Lu, C.; Zhu, X.; Willingham, M. C.; Cheng, S-Y			Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma	ONCOGENE			English	Article						thyroid hormone; follicular thyroid carcinoma; animal model; protein kinase B/AKT; PTEN	BETA-CATENIN; GENETIC ALTERATIONS; RECEPTOR-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; METASTATIC SPREAD; TRANSFORMING GENE; PROTEIN-KINASE; GROWTH-FACTOR; PATHWAY; CANCER	Thyroid cancers are the most common malignancy of the endocrine system in humans. To understand the molecular genetic events underlying thyroid carcinogenesis, we have generated a mouse model that spontaneously develops follicular thyroid carcinoma similar to human thyroid cancer (Thrb(PV/PV) mouse). This mutant mouse harbors a dominant-negative mutated thyroid hormone receptor beta (denoted PV). The PV mutation was identified in a patient with resistance to thyroid hormone (TH). Thrb(PV/PV) mice exhibit highly elevated serum thyroid-stimulating hormone levels and increased TH. We have previously shown that thyroid-stimulating hormone is required, but not sufficient to induce metastatic follicular thyroid cancer in Thrb(PV/PV) mice. However, whether the elevated TH also contributes to the thyroid carcinogenesis of Thrb(PV/PV) mice was not elucidated. To understand the role of TH in thyroid carcinogenesis, we blocked the production of TH by treating Thrb(PV/PV) mice with propylthiouracil (Thrb(PV/PV)-PTU mice) and compared the development of thyroid cancer in Thrb(PV/PV)-PTU and untreated ThrbPV/PV mice. We found that thyroid tumor growth was reduced by similar to 42% in Thrb(PV/PV)-PTU mice as compared with Thrb(PV/PV) mice. Analysis by bromodeoxyuridine-nuclear labeling showed decreased incorporation of bromodeoxyuridine in thyroid tumor cells of Thrb(PV/PV)-PTU mice, indicative of decreased tumor cell proliferation. However, cleaved-caspase 3 staining showed no apparent changes in apoptosis of tumor cells in Thrb(PV/PV)-PTU mice. Molecular studies identified a marked attenuation of the PI3K-AKT-beta-catenin signaling pathway that led to decreased protein levels of cyclin D2, thereby decreasing tumor cell proliferation in Thrb(PV/PV)-PTU mice. Furthermore, matrix metalloproteinase-2, a downstream target of beta-catenin and a key regulator during tumor invasion and metastasis, was also decreased. Thus, the present study uncovers a critical role of TH in promoting the thyroid carcinogenesis of Thrb(PV/PV) mice via membrane signaling events. Importantly, these findings suggest that anti-thyroid drugs could be considered as possible therapeutic agents of thyroid cancer. Oncogene (2012) 31, 2007-2016; doi: 10.1038/onc.2011.390; published online 12 September 2011	[Lu, C.; Zhu, X.; Cheng, S-Y] NCI, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			National Institutes of Health, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011191] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of National Institutes of Health, National Cancer Institute, Center for Cancer Research.	Abbosh PH, 2005, THYROID, V15, P551, DOI 10.1089/thy.2005.15.551; Antico-Arciuch VG, 2010, ONCOGENE, V29, P5678, DOI 10.1038/onc.2010.308; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Cao X, 2005, MOL ENDOCRINOL, V19, P102, DOI 10.1210/me.2004-0093; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Davis FB, 2004, CIRC RES, V94, P1500, DOI 10.1161/01.RES.0000130784.90237.4a; Davis PJ, 2009, AM J PHYSIOL-ENDOC M, V297, pE1238, DOI 10.1152/ajpendo.00480.2009; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Furuya F, 2007, CARCINOGENESIS, V28, P2451, DOI 10.1093/carcin/bgm174; Glinskii AB, 2009, CELL CYCLE, V8, P3562, DOI 10.4161/cc.8.21.9963; Guigon CJ, 2008, MOL CELL BIOL, V28, P4598, DOI 10.1128/MCB.02192-07; Guigon CJ, 2010, ENDOCRINOLOGY, V151, P5528, DOI 10.1210/en.2010-0475; Guigon CJ, 2009, MOL CELL ENDOCRINOL, V308, P63, DOI 10.1016/j.mce.2009.01.007; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lin HY, 2007, STEROIDS, V72, P180, DOI 10.1016/j.steroids.2006.11.014; Lin HY, 2009, AM J PHYSIOL-CELL PH, V296, pC980, DOI 10.1152/ajpcell.00305.2008; Lu CX, 2011, AM J CANCER RES, V1, P1; Lu CX, 2011, STEROIDS, V76, P885, DOI 10.1016/j.steroids.2011.03.016; Lu CX, 2010, ENDOCRINOLOGY, V151, P1929, DOI 10.1210/en.2009-1017; Mousa SA, 2006, INT ANGIOL, V25, P407; Nikiforov YE, 2004, ENDOCR PATHOL, V15, P319, DOI 10.1385/EP:15:4:319; Nikiforova MN, 2009, THYROID, V19, P1351, DOI 10.1089/thy.2009.0240; ONO S, 1991, J CLIN ENDOCR METAB, V73, P990, DOI 10.1210/jcem-73-5-990; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Puxeddu E, 2011, CURR OPIN ONCOL, V23, P13, DOI 10.1097/CCO.0b013e328340cf94; Rego-Iraeta A, 2009, THYROID, V19, P333, DOI 10.1089/thy.2008.0210; Rowlands TM, 2004, CELL CYCLE, V3, P145; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Sassolas G, 2009, EUR J ENDOCRINOL, V160, P71, DOI 10.1530/EJE-08-0624; Sipos JA, 2010, CLIN ONCOL-UK, V22, P395, DOI 10.1016/j.clon.2010.05.004; Sonderegger S, 2010, ENDOCRINOLOGY, V151, P211, DOI 10.1210/en.2009-0557; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Verga Falzacappa C, 2007, J MOL ENDOCRINOL, V38, P221, DOI DOI 10.1677/JME.1.02166; Weinberger PM, 2007, ARCH OTOLARYNGOL, V133, P503, DOI 10.1001/archotol.133.5.503; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Yalcin M, 2010, THYROID, V20, P281, DOI 10.1089/thy.2009.0249; Ying H, 2008, ONCOGENE, V27, P823, DOI 10.1038/sj.onc.1210680; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2006, J CLIN INVEST, V116, P2972, DOI 10.1172/JCI28598	50	14	15	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2007	2016		10.1038/onc.2011.390	http://dx.doi.org/10.1038/onc.2011.390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909131	Green Accepted			2022-12-17	WOS:000303008600002
J	Bruno, RD; Boulanger, CA; Smith, GH				Bruno, R. D.; Boulanger, C. A.; Smith, G. H.			Notch-induced mammary tumorigenesis does not involve the lobule-limited epithelial progenitor	ONCOGENE			English	Article						lobular progenitor; PI-MEC; Int3; Notch4; mammary development	TUMOR VIRUS; PROGESTERONE-RECEPTOR; CELLS; STEM; DIFFERENTIATION; EXPRESSION; INT-3; GENE	The mouse mammary epithelial cell hierarchy contains both multipotent stem cell as well as lineage-limited duct and lobular progenitor cell functions. The latter-also termed parity-identified mammary epithelial cells (PI-MECs)-are marked by beta-galactosidase (beta Gal) expression following pregnancy and involution in whey acidic protein promoter (WAP)-Cre/Rosa26-flox-stop-flox-lacZ (WC/R26) mice, and are the targets of tumorigenic transformation in mouse mammary tumor virus-erbB2 transgenic mice. In this study, we demonstrate that an epithelial population distinct from PI-MECs is transformed during WAP-Int3 tumorigenesis. As expected, WAP-Int3/WC/R26 triple-transgenic mice failed to undergo secretory alveolar development, failed to lactate and developed mammary tumors. Following pregnancy and involution, beta Gal+ mammary epithelial cells were found in the normal mammary tissue, but the resulting mammary tumors were all beta Gal-. WAP-Int3/WC/R26 mammary glands contained ample estrogen receptor alpha (ER alpha)+ MECs, but only rare (<1%) progesterone receptor (PR)+ and RANKL+ cells. In addition, dissociated MECs from WAP-Int3/WC/R26 glands failed to regenerate a mammary tree upon transplantation into a cleared fat-pad of a nu/nu recipient mouse. However, when mixed with normal MECs, PI-MECs from WAP-Int3/WC/R26 mice contributed progeny to the resulting functional outgrowth. The WAP-Int3/WC/R26-derived PI-MECs displayed all of the properties of fully functional lobular progenitors including giving rise to ER alpha+, PR+, smooth muscle actin+ and RANKL+ epithelial progeny. These results demonstrate that WAP-Int3 has no oncogenic effect upon PI-MECs and that the expansion of functional lobular progenitors is required for secretory alveolar development and lactation. Furthermore, lobular progenitor function is ultimately controlled by signals within its microenvironment. Oncogene (2012) 31, 60-67; doi: 10.1038/onc.2011.215; published online 13 June 2011	[Smith, G. H.] NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, GH (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 1112B, Bethesda, MD 20892 USA.	smithg@mail.nih.gov		Bruno, Robert/0000-0003-3329-9478	NCI's Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010021] Funding Source: NIH RePORTER	NCI's Center for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The NCI's Center for Cancer Research Intramural Research Program funded this work.	Booth BW, 2011, ONCOGENE, V30, P679, DOI 10.1038/onc.2010.439; Booth BW, 2008, P NATL ACAD SCI USA, V105, P14891, DOI 10.1073/pnas.0803214105; Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Boulanger CA, 2007, P NATL ACAD SCI USA, V104, P3871, DOI 10.1073/pnas.0611637104; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Bruno RD, 2011, STEM CELL REV REP, V7, P238, DOI 10.1007/s12015-010-9191-9; Bussard KM, 2010, CANCER RES, V70, P6336, DOI 10.1158/0008-5472.CAN-10-0591; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Gallahan D, 1996, CANCER RES, V56, P1775; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; Mukherjee A, 2010, FASEB J, V24, P4408, DOI 10.1096/fj.10-157982; Raafat A, 2009, ONCOGENE, V28, P219, DOI 10.1038/onc.2008.379; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323	23	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					60	67		10.1038/onc.2011.215	http://dx.doi.org/10.1038/onc.2011.215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666720	Green Accepted			2022-12-17	WOS:000299176200006
J	Kuroshima, T; Aoyagi, M; Yasuda, M; Kitamura, T; Jehung, JP; Ishikawa, M; Kitagawa, Y; Totsuka, Y; Shindoh, M; Higashino, F				Kuroshima, T.; Aoyagi, M.; Yasuda, M.; Kitamura, T.; Jehung, J. P.; Ishikawa, M.; Kitagawa, Y.; Totsuka, Y.; Shindoh, M.; Higashino, F.			Viral-mediated stabilization of AU-rich element containing mRNA contributes to cell transformation	ONCOGENE			English	Article						adenovirus; AU-rich element; E4orf6; transformation; stabilization	ADENOVIRUS E4ORF6 PROTEIN; ORAL-CANCER CELLS; NUCLEAR EXPORT; E1B55K PROTEINS; LIGASE COMPLEX; HUR; DEGRADATION; P53; MECHANISM; SEQUENCE	E4orf6 is one of the oncogene products of adenovirus, and it also has an important role for transportation of cellular and viral messenger RNA (mRNA) during the late phase of virus infection. We previously revealed that E4orf6 controls the fate of AU-rich element (ARE) containing mRNA by perturbing the chromosome maintenance region 1-dependent export mechanism. Here, we show that E4orf6 stabilizes ARE-mRNA through the region required for its oncogenic activity and ubiquitin E3 ligase assembly. Cells that failed to stabilize ARE-mRNA after HuR knockdown were unable to produce colonies in soft agar, even when E4orf6 was expressed. Furthermore, the stabilized ARE-mRNA induced the transformation of rodent immortalized cells. These findings indicate that stabilized ARE-mRNA is necessary, if not all, for the oncogenic activity of E4orf6 and has the potential to transform cells, at least under a certain condition. Oncogene (2011) 30, 2912-2920; doi:10.1038/onc.2011.14; published online 14 February 2011	[Higashino, F.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathol & Biol, Kita Ku, Sapporo, Hokkaido 0608586, Japan; [Kuroshima, T.; Ishikawa, M.; Kitagawa, Y.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Diag & Med, Sapporo, Hokkaido 0608586, Japan; [Yasuda, M.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Mol Microbiol, Sapporo, Hokkaido 0608586, Japan; [Totsuka, Y.] Hokkaido Univ, Grad Sch Dent Med, Dept Oral & Maxillofacial Surg, Sapporo, Hokkaido 0608586, Japan	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University	Higashino, F (corresponding author), Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathol & Biol, Kita Ku, North 13 West 7, Sapporo, Hokkaido 0608586, Japan.	fhigashi@den.hokudai.ac.jp	Shindoh, Masanobu/A-4799-2012; Kitagawa, Yoshimasa/F-6909-2012; Higashino, Fumihiro/F-8510-2012; Ishikawa, Makoto/D-5488-2012	Shindoh, Masanobu/0000-0002-7782-5823; 	Ministry of Education, Science and Culture of Japan; Akiyama Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Akiyama Foundation	We thank T Dobner for donating the E4orf6 mutant and mutant adenovirus expression plasmids, H Ariga for donating the c-myc expression vector, K Yoshida for donating the c-fos expression vector and L Agami for donating the pSUPER plasmid. This work was supported, in part, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan, and by a Grant-in Aid from the Akiyama Foundation.	Aoyagi M, 2003, ONCOGENE, V22, P6919, DOI 10.1038/sj.onc.1206743; Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Blanchette P, 2008, J VIROL, V82, P2642, DOI 10.1128/JVI.02309-07; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; DOBBELSTEIN M, 1997, EMBO J, V16, P4267; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Esclatine A, 2004, P NATL ACAD SCI USA, V101, P3603, DOI 10.1073/pnas.0400354101; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Hasegawa H, 2009, BRIT J CANCER, V100, P1943, DOI 10.1038/sj.bjc.6605084; Higashino F, 2005, J CELL BIOL, V170, P15, DOI 10.1083/jcb.200405112; Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6; Kakuguchi W, 2010, MOL CANCER RES, V8, P520, DOI 10.1158/1541-7786.MCR-09-0367; Lopez de Silanes I., 2005, RNA BIOL, V2, P11, DOI DOI 10.4161/RNA.2.1.1552; McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Orlando JS, 2002, J VIROL, V76, P1475, DOI 10.1128/JVI.76.3.1475-1487.2002; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; Shenk T. E., 2001, Fundamental virology, P1053; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Woo JL, 2007, J VIROL, V81, P575, DOI 10.1128/JVI.01725-06	32	14	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2912	2920		10.1038/onc.2011.14	http://dx.doi.org/10.1038/onc.2011.14			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317928	Green Submitted			2022-12-17	WOS:000292245100002
J	Pong, WW; Gutmann, DH				Pong, W. W.; Gutmann, D. H.			The ecology of brain tumors: lessons learned from neurofibromatosis-1	ONCOGENE			English	Review						glioma; astrocytoma; neurofibromatosis type 1; NF1; stroma; microenvironment	MONOCYTE CHEMOTACTIC ACTIVITY; TRANSFORMING-GROWTH-FACTOR; OPTIC PATHWAY GLIOMAS; NF1(+/-) MAST-CELLS; MOUSE MODEL; IN-VIVO; K-RAS; MAMMALIAN TARGET; EPITHELIAL-CELLS; NATURAL-HISTORY	Traditionally, cancer studies have primarily focused on mutations that activate growth or survival pathways in susceptible pre-neoplastic/neoplastic cells. However, recent research has revealed a critical role for nonneoplastic cells within the tumor microenvironment in the process of cancer formation and progression. In addition, the existence of regional and developmental variations in susceptible cell types and supportive microenvironments support a model of tumorigenesis in which the dynamic symbiotic relationship between neoplastic and non-neoplastic cell types dictate where and when cancers form and grow. In this review, we highlight advances in neurofibromatosis type 1 (NF1) genetically engineered mouse brain tumor (glioma) modeling to reveal how cellular and molecular heterogeneity in both the pre-neoplastic/neoplastic and non-neoplastic cellular compartments contribute to gliomagenesis and glioma growth. Oncogene (2011) 30, 1135-1146; doi:10.1038/onc.2010.519; published online 15 November 2010	[Pong, W. W.; Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu	Pong, Winnie/J-4471-2012	Pong, Winnie/0000-0001-8254-3305; Gutmann, David/0000-0002-3127-5045	National Cancer Institute [U01-CA141549]; NATIONAL CANCER INSTITUTE [U01CA141549] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Gutmann Laboratory for their suggestions and comments during the preparation of this manuscript. We also thank Ms Samantha Higer for generating the illustrations. This work was supported in part by a grant from the National Cancer Institute (U01-CA141549) to DHG.	Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Badie B, 1999, NEUROSURGERY, V44, P1077, DOI 10.1097/00006123-199905000-00075; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bajenaru ML, 2005, ANN NEUROL, V57, P119, DOI 10.1002/ana.20337; Bajenaru ML, 2003, CANCER RES, V63, P8573; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Banerjee S, 2010, CANCER RES, V70, P1356, DOI 10.1158/0008-5472.CAN-09-2178; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; Brown JA, 2010, J NEUROSCI, V30, P5579, DOI 10.1523/JNEUROSCI.3994-09.2010; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Charles NA, 2010, CELL STEM CELL, V6, P6, DOI 10.1016/j.stem.2009.12.005; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DABBOUS MK, 1986, BRIT J CANCER, V54, P459, DOI 10.1038/bjc.1986.198; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; Daginakatte GC, 2008, CANCER RES, V68, P10358, DOI 10.1158/0008-5472.CAN-08-2506; Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058; Dasgupta B, 2005, CANCER RES, V65, P236; Dasgupta B, 2003, J NEUROSCI, V23, P8949; De Haas AH, 2008, GLIA, V56, P888, DOI 10.1002/glia.20663; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423; Donovan S, 2002, CANCER CELL, V2, P507, DOI 10.1016/S1535-6108(02)00214-3; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Elkabes S, 1996, J NEUROSCI, V16, P2508; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6; GABBIANI G, 1978, J CELL BIOL, V76, P561, DOI 10.1083/jcb.76.3.561; GABBIANI G, 1972, J EXP MED, V135, P719, DOI 10.1084/jem.135.4.719; Giordano MJ, 1996, J NEUROSCI RES, V43, P246; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; GRAVES DT, 1989, SCIENCE, V245, P1490, DOI 10.1126/science.2781291; Green SR, 2006, J IMMUNOL, V176, P7412, DOI 10.4049/jimmunol.176.12.7412; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HART IR, 1980, CANCER RES, V40, P2281; Hawes JJ, 2007, NEUROGENETICS, V8, P121, DOI 10.1007/s10048-006-0078-5; Hegedus B, 2008, CANCER RES, V68, P1520, DOI 10.1158/0008-5472.CAN-07-5916; Hegedus B, 2009, J NEUROPATH EXP NEUR, V68, P542, DOI 10.1097/NEN.0b013e3181a3240b; Held-Feindt J, 2010, EXP CELL RES, V316, P1553, DOI 10.1016/j.yexcr.2010.02.018; Huettner C, 1997, ANTICANCER RES, V17, P3217; HUETTNER C, 1995, AM J PATHOL, V146, P317; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; Kerber M, 2008, CANCER RES, V68, P7342, DOI 10.1158/0008-5472.CAN-07-6241; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Khalaf WF, 2007, J IMMUNOL, V178, P2527, DOI 10.4049/jimmunol.178.4.2527; Klein RS, 2004, TRENDS IMMUNOL, V25, P306, DOI 10.1016/j.it.2004.04.002; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kunkel P, 2001, NEURO-ONCOLOGY, V3, P82, DOI 10.1093/neuonc/3.2.82; Lee DY, 2010, GENE DEV, V24, P2317, DOI 10.1101/gad.1957110; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Leung SY, 1997, ACTA NEUROPATHOL, V93, P518, DOI 10.1007/s004010050647; Li F, 2006, HUM MOL GENET, V15, P1921, DOI 10.1093/hmg/ddl114; Li HM, 2009, PEDIATR RES, V65, P613, DOI 10.1203/PDR.0b013e3181a1c607; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; LISTERNICK R, 1994, J PEDIATR-US, V125, P63, DOI 10.1016/S0022-3476(94)70122-9; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; LISTERNICK R, 1995, J PEDIATR-US, V127, P718, DOI 10.1016/S0022-3476(95)70159-1; LISTERNICK R, 1989, J PEDIATR-US, V114, P778, DOI 10.1016/s0022-3476(89)80137-4; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Louis DN, 2007, WHO CLASSIFICATION T; Ludwig HC, 2000, ANTICANCER RES, V20, P299; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; MARTINET N, 1992, CANCER, V70, P854, DOI 10.1002/1097-0142(19920815)70:4<854::AID-CNCR2820700422>3.0.CO;2-#; McDaniel AS, 2008, BLOOD, V112, P4646, DOI 10.1182/blood-2008-04-155085; Morgan KJ, 2007, LEUKEMIA RES, V31, P1107, DOI 10.1016/j.leukres.2006.11.022; Munchhof AM, 2006, HUM MOL GENET, V15, P1858, DOI 10.1093/hmg/ddl108; Olumi AF, 1999, CANCER RES, V59, P5002; Pemov A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-194; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Prendergast GC, 2001, EXPERT OPIN INV DRUG, V10, P2105, DOI 10.1517/13543784.10.12.2105; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; Roumier A, 2004, J NEUROSCI, V24, P11421, DOI 10.1523/JNEUROSCI.2251-04.2004; Rozario T, 2010, DEV BIOL, V341, P126, DOI 10.1016/j.ydbio.2009.10.026; Sandsmark DK, 2007, CANCER RES, V67, P4790, DOI 10.1158/0008-5472.CAN-06-4470; Sasaki A, 2001, Brain Tumor Pathol, V18, P13, DOI 10.1007/BF02478920; SCHOR SL, 1988, J CELL SCI, V90, P391; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma MK, 2007, CANCER RES, V67, P890, DOI 10.1158/0008-5472.CAN-06-0973; Singhal S, 2002, ARCH DIS CHILD, V87, P65, DOI 10.1136/adc.87.1.65; Sonoda Y, 2001, CANCER RES, V61, P4956; STERN J, 1980, ARCH OPHTHALMOL-CHIC, V98, P505; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; SUN T, 2010, J NEUROIMMUNOL, V1, P1; Suzuki M, 2006, AM J PATHOL, V169, P673, DOI 10.2353/ajpath.2006.060053; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Thiagalingam S, 2004, OPHTHALMOLOGY, V111, P568, DOI 10.1016/j.ophtha.2003.06.008; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; TREMBLAY G, 1979, EXP MOL PATHOL, V31, P248, DOI 10.1016/0014-4800(79)90026-1; Ueoka DI, 2009, J NEUROL SCI, V281, P20, DOI 10.1016/j.jns.2009.03.009; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wagner S, 1999, INT J CANCER, V82, P12, DOI 10.1002/(SICI)1097-0215(19990702)82:1<12::AID-IJC3>3.0.CO;2-O; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wang H, 2009, STEM CELLS, V27, P2393, DOI 10.1002/stem.188; Warrington NM, 2007, CANCER RES, V67, P8588, DOI 10.1158/0008-5472.CAN-06-2220; Warrington NM, 2010, CANCER RES, V70, P5717, DOI 10.1158/0008-5472.CAN-09-3769; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; Widemann BC, 2006, J CLIN ONCOL, V24, P507, DOI 10.1200/JCO.2005.03.8638; Williams JA, 2000, J INTERF CYTOK RES, V20, P291, DOI 10.1089/107999000312423; Xu J, 2007, CIRCULATION, V116, P2148, DOI 10.1161/CIRCULATIONAHA.107.707752; Yan JC, 2008, HUM MOL GENET, V17, P936, DOI 10.1093/hmg/ddm366; Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092; Yeh TH, 2009, GLIA, V57, P1239, DOI 10.1002/glia.20845; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162	123	14	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1135	1146		10.1038/onc.2010.519	http://dx.doi.org/10.1038/onc.2010.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21076468				2022-12-17	WOS:000288202400001
J	Qiu, JJ; Chu, H; Lu, X; Jiang, X; Dong, S				Qiu, J. J.; Chu, H.; Lu, X.; Jiang, X.; Dong, S.			The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia	ONCOGENE			English	Article						PAX5; PAX5-PML; dimerization; FRAP; acute lymphocytic leukemia (ALL)	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR PAX5; B-CELL DIFFERENTIATION; PML-RAR-ALPHA; INTRANUCLEAR MOBILITY; DECREASED MOBILITY; RECEPTOR-ALPHA; GENES; DIMERIZATION	The paired box domain of PAX5 was reported to fuse with the sequence of promyelocytic leukemia (PML) to produce PAX5-PML chimeric protein in two patients with B-cell acute lymphoblastic leukemia. In the present studies, we found, by gel shift assays, that PAX5-PML bound to a panel of PAX5-consensus sequence acts as a homodimer with reduction of its DNA-binding affinities in comparison with wild-type PAX5. In transient transfection assays using 293T and HeLa cells, and retrovirus transduction of murine hematopoietic stem/progenitor cells together with quantitative real-time polymerase chain reaction analysis, PAX5-PML inhibited wild-type PAX5 target gene transcriptional activity. Studies comparing PAX5-PML with PAX5-PML(Delta CC) demonstrated that the coiled-coil (CC) protein interaction domain located within the PML moiety was required for PAX5-PML homodimer complex formation and partial transcriptional repression of genes controlled by PAX5. Fluorescent microscopic examination of transiently expressed YFP-tagged proteins in HeLa and 293T cells demonstrated that YFP-PAX5-PML and YFP-PAX5-PML(Delta CC) exhibited a diffuse granular pattern within the nucleus, similar to PAX5 but not PML. By fluorescent recovery after photobleach (FRAP), we have shown that PAX5-PML fusion protein has reduced intranuclear mobility compared with wild-type PAX5. Furthermore, the dimerization domain (CC) of PML was responsible for the reduced intranuclear mobility of PAX5-PML. These results indicate that the CC domain of PAX5-PML is important for each of the known activities of PAX5-PML fusion proteins. Oncogene (2011) 30, 967-977; doi:10.1038/onc.2010.473; published online 25 October 2010	[Dong, S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Dong, S (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,BCM 286,Room N1317-03, Houston, TX 77030 USA.	jqiu@bcm.edu; sdong@bcm.edu			Albert and Margaret alkek Foundation; Leukemia Research Foundation (LRF)	Albert and Margaret alkek Foundation; Leukemia Research Foundation (LRF)	We thank Dr M Busslinger (Research Institute of Molecular Pathology, Vienna, Austria) for the CD19-luciferase and PAX5 expression vectors, Dr AS Belmont (University of Illinois Champagne-Urbana) for the A03_1 cell line, and Dr CWE So (King's College London, London, UK) for critical reading of the manuscript. This work was supported in part, by funds from the Albert and Margaret alkek Foundation and Leukemia Research Foundation (LRF).	ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Delogu A, 2006, IMMUNITY, V24, P269, DOI 10.1016/j.immuni.2006.01.012; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dong S, 2003, ONCOGENE, V22, P858, DOI 10.1038/sj.onc.1206182; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; Huang Y, 2008, BIOCHEM BIOPH RES CO, V365, P258, DOI 10.1016/j.bbrc.2007.10.184; Kawamata N, 2008, P NATL ACAD SCI USA, V105, P11921, DOI 10.1073/pnas.0711039105; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kwok C, 2009, P NATL ACAD SCI USA, V106, P2853, DOI 10.1073/pnas.0810558106; Lauring J, 1999, MOL CELL BIOL, V19, P2601; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mikkola I, 2002, SCIENCE, V297, P110, DOI 10.1126/science.1067518; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nebral K, 2009, LEUKEMIA, V23, P134, DOI 10.1038/leu.2008.306; Nebral K, 2007, BRIT J HAEMATOL, V139, P269, DOI 10.1111/j.1365-2141.2007.06731.x; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Pridans C, 2008, J IMMUNOL, V180, P1719, DOI 10.4049/jimmunol.180.3.1719; Qiu J, 2006, ONCOGENE, V25, P3982, DOI 10.1038/sj.onc.1209431; Qiu J, 2003, LEUKEMIA, V17, P1891, DOI 10.1038/sj.leu.2403073; Qiu J, 2007, MOL BIOL CELL, V18, P3941, DOI 10.1091/mbc.E07-03-0245; Qiu JH, 2010, CELL RES, V20, P908, DOI 10.1038/cr.2010.81; Qiu JHJ, 2010, BLOOD, V115, P643, DOI 10.1182/blood-2009-07-232652; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Schebesta A, 2007, IMMUNITY, V27, P49, DOI 10.1016/j.immuni.2007.05.019; Schebesta M, 2002, IMMUNITY, V17, P473, DOI 10.1016/S1074-7613(02)00418-1; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006	35	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					967	977		10.1038/onc.2010.473	http://dx.doi.org/10.1038/onc.2010.473			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20972455				2022-12-17	WOS:000287695900008
J	Savelyeva, I; Dobbelstein, M				Savelyeva, I.; Dobbelstein, M.			Infection with E1B-mutant adenovirus stabilizes p53 but blocks p53 acetylation and activity through E1A	ONCOGENE			English	Article						adenovirus; E1A; E1B; p53; Sp1; p300	TUMOR-SUPPRESSOR P53; CELL-CYCLE; PROTEIN; ONYX-015; TYPE-5; TRANSCRIPTION; REPLICATION; PROMOTER; P300/CBP; BINDING	Wild-type adenovirus type 5 eliminates p53 through the E1B-55 kDa and E4-34 kDa gene products. Deletion or mutation of E1B-55 kDa has long been thought to confer p53-selective replication of oncolytic viruses. We show here that infection with E1B-defective adenovirus mutants induces massive accumulation of p53, without obvious defects in p53 localization, phosphorylation, conformation and oligomerization. Nonetheless, p53 completely failed to induce its target genes in this scenario, for example, p21/CDKN1A, Mdm2 and PUMA. Two regions of the E1A gene products independently contributed to the suppression of p21 transcription. Depending on the E1A conserved region 3, E1B-defective adenovirus impaired the ability of the transcription factor Sp1 to bind the p21 promoter. Moreover, the amino terminal region of E1A, binding the acetyl transferases p300 and CREB-binding protein, blocked p53 K382 acetylation in infected cells. Mutating either of these E1A regions, in addition to E1B, partially restored p21 mRNA levels. Our findings argue that adenovirus attenuates p53-mediated p21 induction, through at least two E1B-independent mechanisms. Other virus species and cancer cells may employ analogous strategies to impair p53 activity. Oncogene (2011) 30, 865-875; doi:10.1038/onc.2010.461; published online 11 October 2010	[Savelyeva, I.; Dobbelstein, M.] Univ Gottingen, Gottingen Ctr Mol Biosci, Dept Mol Oncol, D-37077 Gottingen, Lower Saxony, Germany; [Savelyeva, I.; Dobbelstein, M.] Univ So Denmark, Inst Med Biol, Ctr Med Biotechnol, Odense C, Denmark	University of Gottingen; University of Southern Denmark	Dobbelstein, M (corresponding author), Univ Gottingen, Gottingen Ctr Mol Biosci, Dept Mol Oncol, Ernst Caspari Haus,Justus von Liebig Weg 11, D-37077 Gottingen, Lower Saxony, Germany.	mdobbel@uni-goettingen.de		Dobbelstein, Matthias/0000-0001-5052-3967	German Cancer Aid/Dr Mildred Scheel Stiftung; EU; German Research Foundation (DFG); Wilhelm Sander Stiftung; Statens Sundhedsvidenskabelige Forskningsrad of Denmark; Danish Cancer Society; Novonordisk fonden	German Cancer Aid/Dr Mildred Scheel Stiftung(Deutsche Krebshilfe); EU(European Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); Wilhelm Sander Stiftung; Statens Sundhedsvidenskabelige Forskningsrad of Denmark; Danish Cancer Society(Danish Cancer Society); Novonordisk fonden(Novo Nordisk Foundation)	We thank JS Mymryk, RJA Grand, X Zhang and G Ketner for viruses, K Roemer for plasmids, AJ Levine for antibodies, OG Opitz for cells, C Hippel and A Dickmanns for excellent technical assistance, and S Johnsen for the help with ChIP experiments. The work was supported by the German Cancer Aid/Dr Mildred Scheel Stiftung, the EU 6th Framework Program (Integrated Project Active p53), the German Research Foundation (DFG), the Wilhelm Sander Stiftung, the Statens Sundhedsvidenskabelige Forskningsrad of Denmark, the Danish Cancer Society, and the Novonordisk fonden.	Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Beckerman R, 2009, GENE DEV, V23, P1364, DOI 10.1101/gad.1795709; Bernat A, 2003, ONCOGENE, V22, P7871, DOI 10.1038/sj.onc.1206896; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; CARLOCK LR, 1981, J VIROL, V40, P657, DOI 10.1128/JVI.40.3.657-664.1981; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Faiola F, 2005, MOL CELL BIOL, V25, P10220, DOI 10.1128/MCB.25.23.10220-10234.2005; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Ferreon JC, 2009, P NATL ACAD SCI USA, V106, P13260, DOI 10.1073/pnas.0906770106; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Harada H, 2003, MOL CANCER RES, V1, P729; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Hsu CH, 2004, EMBO J, V23, P2269, DOI 10.1038/sj.emboj.7600239; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Koch P, 2001, CANCER RES, V61, P5941; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; Wang XY, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-44; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Wong KS, 2005, J BIOL CHEM, V280, P9390, DOI 10.1074/jbc.M408643200; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	49	14	17	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					865	875		10.1038/onc.2010.461	http://dx.doi.org/10.1038/onc.2010.461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20935676				2022-12-17	WOS:000287444600010
J	Ahn, J; Ko, M; Lee, C; Kim, J; Yoon, H; Seong, RH				Ahn, J.; Ko, M.; Lee, C.; Kim, J.; Yoon, H.; Seong, R. H.			Srg3, a mouse homolog of BAF155, is a novel p53 target and acts as a tumor suppressor by modulating p21(WAF1/CIP1) expression	ONCOGENE			English	Article						SWI/SNF chromatin remodeling complex; tumor suppressor; Srg3; DNA damage signal; p53; p21	CHROMATIN REMODELING COMPLEX; STRAND BREAK REPAIR; CELL-CYCLE ARREST; MAMMALIAN SWI/SNF COMPLEXES; PROTEASOMAL DEGRADATION; RHABDOID TUMORS; DNA-DAMAGE; IN-VIVO; APOPTOSIS; CANCER	Some subunits of the SWI/SNF complex function as tumor suppressors. However, underlying mechanisms are still incompletely defined. Here, we show that Srg3, a mouse homolog of BAF155 that function as a core subunit of this complex, suppresses tumorigenesis in vivo. DNA damage signals promoted Srg3 degradation by inducing p53. Deficiency of Srg3 promoted G1 cell-cycle arrest, but antagonized apoptotic response to DNA damage by robustly inducing p53 and p21 proteins. Srg3 heterozygous mice were prone to sarcoma formation, which was further enhanced by haploinsufficiency of p53. These tumors highly expressed p53 and p21 but lacked Srg3 expression. Our results establish a novel function of Srg3 in tumor suppression and provide insights into genetic pathways dictating tumor suppression by the SWI/SNF complex. Oncogene (2011) 30, 445-456; doi: 10.1038/onc.2010.424; published online 11 October 2010	[Seong, R. H.] Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Res Ctr Funct Cellul, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Seong, RH (corresponding author), Seoul Natl Univ, Dept Biol Sci, Gwanak Ro 599,Bldg 105, Seoul 151742, South Korea.	rhseong@snu.ac.kr		Ko, Myunggon/0000-0002-6007-2570; Seong, Rho/0000-0001-5699-0718	Ministry of Education, Science and Technology [20090094022]; MEST	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); MEST(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from the National Research Foundation of Korea (NRF), funded by Ministry of Education, Science and Technology, in part through the Research Center for Functional Cellulomics and in part through the Priority Research Centers Program (20090094022). JA, MK, JK, HY and CL were supported by the BK21 program from MEST.	Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Chan TA, 2000, GENE DEV, V14, P1584; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Gartel AL, 2002, MOL CANCER THER, V1, P639; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Han D, 2008, DEV BIOL, V315, P136, DOI 10.1016/j.ydbio.2007.12.024; Han SM, 2001, J IMMUNOL, V167, P805, DOI 10.4049/jimmunol.167.2.805; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hu G, 1999, MOL CELL BIOL, V19, P724; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Kaneuchi M, 1999, MOL CARCINOGEN, V26, P44, DOI 10.1002/(SICI)1098-2744(199909)26:1<44::AID-MC6>3.3.CO;2-V; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martin-Caballero J, 2001, CANCER RES, V61, P6234; McKenna ES, 2008, MOL CELL BIOL, V28, P6223, DOI 10.1128/MCB.00658-08; Moshkin YM, 2007, MOL CELL BIOL, V27, P651, DOI 10.1128/MCB.01257-06; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ring HZ, 1998, GENOMICS, V51, P140, DOI 10.1006/geno.1998.5343; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Sohn DH, 2007, J BIOL CHEM, V282, P10614, DOI 10.1074/jbc.M610563200; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wong AKC, 2000, CANCER RES, V60, P6171; Yang XF, 2007, NAT STRUCT MOL BIOL, V14, P540, DOI 10.1038/nsmb1238; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	55	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2011	30	4					445	456		10.1038/onc.2010.424	http://dx.doi.org/10.1038/onc.2010.424			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20935679				2022-12-17	WOS:000286621600007
J	Li, C; Xin, W; Sy, MS				Li, C.; Xin, W.; Sy, M-S			Binding of pro-prion to filamin A: by design or an unfortunate blunder	ONCOGENE			English	Review						prion protein; filamins; cancer	COMPARATIVE GENOMIC HYBRIDIZATION; GPI TRANSAMIDASE SUBUNITS; GENE-EXPRESSION PROFILES; SQUAMOUS-CELL CARCINOMA; CENTRAL-NERVOUS-SYSTEM; GLYCOPROTEIN-IB-ALPHA; CARBONIC-ANHYDRASE-IV; RESOLUTION ARRAY CGH; CHROMOSOME ARM 20Q; DNA COPY NUMBER	Over the last decades, cancer research has focused on tumor suppressor genes and oncogenes. Genes in other cellular pathways has received less attention. Between 0.5% to 1% of the mammalian genome encodes for proteins that are tethered on the cell membrane via a glycosylphosphatidylinositol (GPI)-anchor. The GPI modification pathway is complex and not completely understood. Prion (PrP), a GPI-anchored protein, is infamous for being the only normal protein that when misfolded can cause and transmit a deadly disease. Though widely expressed and highly conserved, little is known about the functions of PrP. Pancreatic cancer and melanoma cell lines express PrP. However, in these cell lines the PrP exists as a proPrP as defined by retaining its GPI anchor peptide signal sequence (GPI-PSS). Unexpectedly, the GPI-PSS of PrP has a filamin A (FLNA) binding motif and binds FLNA. FLNA is a cytolinker protein, and an integrator of cell mechanics and signaling. Binding of pro-PrP to FLNA disrupts the normal FLNA functions. Although normal pancreatic ductal cells lack PrP, about 40% of patients with pancreatic ductal cell adenocarcinoma express PrP in their cancers. These patients have significantly shorter survival time compared with patients whose cancers lack PrP. Pro-PrP is also detected in melanoma in situ but is undetectable in normal melanocyte, and invasive melanoma expresses more pro-PrP. In this review, we will discuss the underlying mechanisms by which binding of pro-PrP to FLNA disrupts normal cellular physiology and contributes to tumorigenesis, and the potential mechanisms that cause the accumulation of pro-PrP in cancer cells. Oncogene (2010) 29, 5329-5345; doi: 10.1038/onc.2010.307; published online 9 August 2010	[Li, C.; Sy, M-S] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Xin, W.] Univ Hosp Case Med Ctr, Dept Pathol, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital	Sy, MS (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, Wolstein Res Bldg,Room 5131, Cleveland, OH 44106 USA.	man-sun.sy@case.edu			Department of Pathology; NIH [R21-CA133559-01, 5P30AR039750]; SDRC; NATIONAL CANCER INSTITUTE [R21CA133559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER	Department of Pathology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SDRC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank all the collaborators who have contributed to these studies, and Pearl Ling for careful reading of the paper, suggestion and editorial assistant. Start-up funds from the Department of Pathology to WX. Supported by R21-CA133559-01 from NIH and a pilot Grant from SDRC#5P30AR039750 from NIH.	Abujiang P, 1998, ONCOGENE, V17, P3029, DOI 10.1038/sj.onc.1202230; ADAMSON R, 1994, ONCOGENE, V9, P2077; Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; Alper O, 2009, CANCER SCI, V100, P1748, DOI 10.1111/j.1349-7006.2009.01244.x; Amundadottir L, 2009, NAT GENET, V41, P986, DOI 10.1038/ng.429; Anantharam V, 2008, FREE RADICAL BIO MED, V45, P1530, DOI 10.1016/j.freeradbiomed.2008.08.028; Antonacopoulou AG, 2008, ANTICANCER RES, V28, P1221; Argos M, 2008, CANCER GENET CYTOGEN, V182, P69, DOI 10.1016/j.cancergencyto.2008.01.001; Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; Bedolla RG, 2009, CLIN CANCER RES, V15, P788, DOI 10.1158/1078-0432.CCR-08-1402; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bempt IV, 2006, J PATHOL, V208, P486, DOI 10.1002/path.1911; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bisgaard ML, 2001, SCAND J GASTROENTERO, V36, P405, DOI 10.1080/003655201300051252; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983; BOSCHMAN CR, 1994, AM J PATHOL, V145, P1291; BOUFFARD D, 1994, HUM PATHOL, V25, P709, DOI 10.1016/0046-8177(94)90305-0; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brown KM, 2008, NAT GENET, V40, P838, DOI 10.1038/ng.163; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BYERS HR, 1991, AM J PATHOL, V139, P423; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Campana V, 2005, TRENDS CELL BIOL, V15, P102, DOI 10.1016/j.tcb.2004.12.002; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; Chen R, 2002, J CELL BIOCHEM, V84, P68, DOI 10.1002/jcb.1267; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Choi YW, 2007, INT J GYNECOL CANCER, V17, P687, DOI 10.1111/j.1525-1438.2007.00834.x; Creutzfeldt HG, 1920, Z GESAMTE NEUROL PSY, V57, P1, DOI 10.1007/BF02866081; Cukier IH, 2007, FEBS LETT, V581, P1661, DOI 10.1016/j.febslet.2007.03.041; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Daley D, 2008, AM J HUM GENET, V82, P723, DOI 10.1016/j.ajhg.2008.01.007; Davies P, 2008, BIOCHEM J, V410, P237, DOI 10.1042/BJ20071477; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; Dimova I, 2009, TUMORI, V95, P357; Dohna M, 2000, GENE CHROMOSOME CANC, V28, P145, DOI 10.1002/(SICI)1098-2264(200006)28:2<145::AID-GCC3>3.0.CO;2-7; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; Fang XF, 2010, CELL MOL IMMUNOL, V7, P100, DOI 10.1038/cmi.2009.119; Fanjul M, 2004, HISTOCHEM CELL BIOL, V121, P91, DOI 10.1007/s00418-003-0616-2; Fanjul M, 2007, J HISTOCHEM CYTOCHEM, V55, P783, DOI 10.1369/jhc.6A7112.2007; Feng SJ, 2003, BLOOD, V102, P2122, DOI 10.1182/blood-2002-12-3805; Feng YY, 2006, P NATL ACAD SCI USA, V103, P19836, DOI 10.1073/pnas.0609628104; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Fiori JL, 2009, ENDOCRINOLOGY, V150, P2551, DOI 10.1210/en.2008-1344; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Franscini N, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000071; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; Fujita Y, 2003, HEPATO-GASTROENTEROL, V50, P1857; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Gajdusek DC, 2008, PHILOS T R SOC B, V363, P3697, DOI 10.1098/rstb.2008.0070; GAJDUSEK DC, 1957, NEW ENGL J MED, V257, P974, DOI 10.1056/NEJM195711142572005; Garcea G, 2005, EUR J CANCER, V41, P2213, DOI 10.1016/j.ejca.2005.04.044; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; GOLDFARB LG, 1994, PHILOS T R SOC B, V343, P379, DOI 10.1098/rstb.1994.0032; Goldmann WH, 2002, CELL BIOL INT, V26, P567, DOI 10.1006/cbir.2002.0900; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GREIG JR, 1950, J COMP PATHOL THERAP, V60, P263, DOI 10.1016/S0368-1742(50)80024-3; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Guan Y, 2008, INT J CANCER, V122, P1820, DOI 10.1002/ijc.23297; Guedj N, 2009, J HEPATOL, V51, P93, DOI 10.1016/j.jhep.2009.03.017; Guled M, 2008, MODERN PATHOL, V21, P770, DOI 10.1038/modpathol.2008.57; Guo ZM, 2004, NAT MED, V10, P374, DOI 10.1038/nm1010; Han HY, 2002, CANCER RES, V62, P2890; Hart AW, 2006, HUM MOL GENET, V15, P2457, DOI 10.1093/hmg/ddl168; He HJ, 2003, J BIOL CHEM, V278, P27096, DOI 10.1074/jbc.M301003200; He XQ, 2000, MOL IMMUNOL, V37, P603, DOI 10.1016/S0161-5890(00)00070-5; Hegde RS, 2003, TRENDS NEUROSCI, V26, P337, DOI 10.1016/S0166-2236(03)00143-7; Helfand BT, 2009, J UROLOGY, V181, P2502, DOI 10.1016/j.juro.2009.01.109; Herlyn M, 2006, INT J CANCER, V118, P523, DOI 10.1002/ijc.21605; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hidaka S, 2003, ANTICANCER RES, V23, P3353; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; Ho JC, 2006, INT J CANCER, V119, P1330, DOI 10.1002/ijc.22005; HOGGARD N, 1995, GENOMICS, V30, P233, DOI 10.1006/geno.1995.9882; Hruban RH, 2009, ARCH PATHOL LAB MED, V133, P347, DOI 10.1043/1543-2165-133.3.347; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; HSIAO K, 1990, NEUROLOGY, V40, P1820, DOI 10.1212/WNL.40.12.1820; Hulsebos TJM, 1997, GENE CHROMOSOME CANC, V18, P279, DOI 10.1002/(SICI)1098-2264(199704)18:4<279::AID-GCC5>3.0.CO;2-Y; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; Ishihara T, 2008, CANCER SCI, V99, P1940, DOI 10.1111/j.1349-7006.2008.00900.x; Ishkanian AS, 2009, PROSTATE, V69, P1091, DOI 10.1002/pros.20959; Ittmann M, 2009, NEOPLASIA, V11, P305, DOI 10.1593/neo.81530; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang WW, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-74; Johnson-Pais TL, 2003, INT J CANCER, V105, P285, DOI 10.1002/ijc.11070; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Kamochi N, 2008, CANCER SCI, V99, P2417, DOI 10.1111/j.1349-7006.2008.00978.x; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; Kayed H, 2006, INT J ONCOL, V29, P1139; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Keshet GI, 2000, J NEUROCHEM, V75, P1889, DOI 10.1046/j.1471-4159.2000.0751889.x; Kiema T, 2006, MOL CELL, V21, P337, DOI 10.1016/j.molcel.2006.01.011; Kim H, 2008, EXP CELL RES, V314, P834, DOI 10.1016/j.yexcr.2007.11.022; Kim JH, 2007, CANCER RES, V67, P8229, DOI 10.1158/0008-5472.CAN-07-1297; Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Kinoshita T, 2008, J BIOCHEM, V144, P287, DOI 10.1093/jb/mvn090; Kley RA, 2007, BRAIN, V130, P3250, DOI 10.1093/brain/awm271; Krakow D, 2004, NAT GENET, V36, P405, DOI 10.1038/ng1319; Kresse SH, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-39; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lad Y, 2007, EMBO J, V26, P3993, DOI 10.1038/sj.emboj.7601827; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; LI C, 2010, J BIOL CHEM; Li CY, 2007, BIOCHEM J, V406, P333, DOI 10.1042/BJ20061857; Li CY, 2009, J CLIN INVEST, V119, P2725, DOI 10.1172/JCI39542; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li M, 2002, BIOCHEM PHARMACOL, V63, P859, DOI 10.1016/S0006-2952(01)00932-7; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Li RL, 2003, BIOCHEM BIOPH RES CO, V303, P446, DOI 10.1016/S0006-291X(03)00354-1; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Liang J, 2009, FEBS J, V276, P685, DOI 10.1111/j.1742-4658.2008.06816.x; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Lindholm PM, 2007, CYTOGENET GENOME RES, V119, P46, DOI 10.1159/000109618; Liu ET, 2008, CURR OPIN GENET DEV, V18, P251, DOI 10.1016/j.gde.2008.07.014; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Logsdon CD, 2003, CANCER RES, V63, P2649; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Lu J, 2005, EPILEPSY BEHAV, V7, P143, DOI 10.1016/j.yebeh.2005.05.001; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; Ma J, 2006, J PATHOL, V210, P205, DOI 10.1002/path.2050; Maeda Y, 2006, METHOD ENZYMOL, V416, P182, DOI 10.1016/S0076-6879(06)16012-7; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Mani K, 2003, J BIOL CHEM, V278, P38956, DOI 10.1074/jbc.M300394200; Maqani N, 2006, MOL CANCER RES, V4, P449, DOI 10.1158/1541-7786.MCR-06-0058; Mastracci TL, 2006, GENE CHROMOSOME CANC, V45, P1007, DOI 10.1002/gcc.20368; Mhawech-Fauceglia P, 2008, INT J GYNECOL PATHOL, V27, P539, DOI 10.1097/PGP.0b013e31816bcda4; Millhauser GL, 2007, ANNU REV PHYS CHEM, V58, P299, DOI 10.1146/annurev.physchem.58.032806.104657; Miozzo M, 2000, INT J CANCER, V87, P68, DOI 10.1002/1097-0215(20000701)87:1<68::AID-IJC10>3.0.CO;2-V; Miyoshi E, 2008, J BIOCHEM, V143, P725, DOI 10.1093/jb/mvn011; Morel E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003000; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Myllykangas S, 2008, INT J CANCER, V123, P817, DOI 10.1002/ijc.23574; Naghibalhossaini F, 2007, MOL BIOL CELL, V18, P1366, DOI 10.1091/mbc.E06-10-0884; Nagpal JK, 2008, MODERN PATHOL, V21, P979, DOI 10.1038/modpathol.2008.76; Nakamura F, 2006, BLOOD, V107, P1925, DOI 10.1182/blood-2005-10-3964; Nakamura F, 2007, J CELL BIOL, V179, P1011, DOI 10.1083/jcb.200707073; Nakanishi H, 2009, CANCER RES, V69, P1615, DOI 10.1158/0008-5472.CAN-08-3218; Narang HK, 2005, EXP BIOL MED, V230, P343, DOI 10.1177/153537020523000508; Narayan G, 2007, GENE CHROMOSOME CANC, V46, P373, DOI 10.1002/gcc.20418; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Nicholson TB, 2007, J CELL BIOL, V177, P211, DOI 10.1083/jcb.200701158; Nomachi A, 2008, J BIOL CHEM, V283, P27973, DOI 10.1074/jbc.M802325200; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Notterman DA, 2001, CANCER RES, V61, P3124; Nowak NJ, 2005, CANCER GENET CYTOGEN, V161, P36, DOI 10.1016/j.cancergencyto.2005.01.009; O'Connell MP, 2009, J INVEST DERMATOL, V129, P1782, DOI 10.1038/jid.2008.433; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Ottenhof NA, 2009, ARCH PATHOL LAB MED, V133, P375, DOI 10.1043/1543-2165-133.3.375; Paitel E, 2004, J BIOL CHEM, V279, P612, DOI 10.1074/jbc.M310453200; Paladino S, 2008, J CELL SCI, V121, P4001, DOI 10.1242/jcs.036038; Pan T, 2002, BIOCHEM J, V368, P81, DOI 10.1042/BJ20020773; PERIS K, 1995, J INVEST DERMATOL, V105, P625, DOI 10.1111/1523-1747.ep12323809; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ravid D, 2008, EXP CELL RES, V314, P2762, DOI 10.1016/j.yexcr.2008.06.004; Robertson SP, 2005, CURR OPIN GENET DEV, V15, P301, DOI 10.1016/j.gde.2005.04.001; Sahar S, 2009, NAT REV CANCER, V9, P886, DOI 10.1038/nrc2747; Saito S, 2006, ONCOL REP, V16, P949; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Schmitt-Ulms G, 2004, NAT BIOTECHNOL, V22, P724, DOI 10.1038/nbt969; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; Selvarajah S, 2008, CYTOGENET GENOME RES, V122, P5, DOI 10.1159/000151310; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Sharom FJ, 2002, BIOCHEM CELL BIOL, V80, P535, DOI 10.1139/O02-146; Shi CJ, 2008, ADV ANAT PATHOL, V15, P185, DOI 10.1097/PAP.0b013e31817bf57d; Shivapurkar N, 1999, CANCER RES, V59, P3576; Sibley K, 2000, GENE CHROMOSOME CANC, V29, P378, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1045>3.0.CO;2-K; Simoneau S, 2003, BIOL CHEM, V384, P243, DOI 10.1515/BC.2003.027; Skawran B, 2008, MODERN PATHOL, V21, P505, DOI 10.1038/modpathol.3800998; Spielhaupter C, 2001, J BIOL CHEM, V276, P44604, DOI 10.1074/jbc.M103289200; Stanford JL, 2009, HUM MOL GENET, V18, P1839, DOI 10.1093/hmg/ddp100; Steele AD, 2009, PRION, V3, P240, DOI 10.4161/pri.3.4.10135; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Sun JL, 2008, PROSTATE, V68, P691, DOI 10.1002/pros.20754; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Sverdlov M, 2009, MOL BIOL CELL, V20, P4531, DOI 10.1091/mbc.E08-10-0997; Taylor DR, 2006, MOL MEMBR BIOL, V23, P89, DOI 10.1080/09687860500449994; Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133; Thelin WR, 2007, J CLIN INVEST, V117, P364, DOI 10.1172/JCI30376; Thomassen M, 2009, BREAST CANCER RES TR, V113, P239, DOI 10.1007/s10549-008-9927-2; Tigges U, 2003, J BIOL CHEM, V278, P23561, DOI 10.1074/jbc.M302302200; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Torring N, 2007, BRIT J CANCER, V96, P499, DOI 10.1038/sj.bjc.6603476; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; van Dartel M, 2002, CANCER GENET CYTOGEN, V139, P91, DOI 10.1016/S0165-4608(02)00627-1; VANDUI, 2007, CYTOGENET GENOME RES, V118, P130; WANECK GL, 1988, SCIENCE, V241, P697, DOI 10.1126/science.3399901; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Wang Y, 2007, ONCOGENE, V26, P6061, DOI 10.1038/sj.onc.1210435; Wescott MP, 2008, CANCER PREV RES, V1, P503, DOI 10.1158/1940-6207.CAPR-08-0195; White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487; Williamson D, 2002, J BIOL CHEM, V277, P2151, DOI 10.1074/jbc.M109384200; Wong N, 2003, J HEPATOL, V38, P298, DOI 10.1016/S0168-8278(02)00412-9; Woo MS, 2004, MOL CELL BIOL, V24, P3025, DOI 10.1128/MCB.24.7.3025-3035.2004; Wu GJ, 2006, CANCER RES, V66, P9829, DOI 10.1158/0008-5472.CAN-06-0506; Yan H, 2009, CANCER RES, V69, P9157, DOI 10.1158/0008-5472.CAN-09-2650; Yin S, 2008, J BIOL CHEM, V283, P25446, DOI 10.1074/jbc.M800814200; Yu JC, 2008, HEPATO-GASTROENTEROL, V55, P1487; Yue JY, 2009, CANCER RES, V69, P7978, DOI 10.1158/0008-5472.CAN-09-2177; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812; Zhu TN, 2007, J BIOL CHEM, V282, P14816, DOI 10.1074/jbc.M611430200; Zielinski B, 2005, GENE CHROMOSOME CANC, V43, P294, DOI 10.1002/gcc.20186	228	14	15	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5329	5345		10.1038/onc.2010.307	http://dx.doi.org/10.1038/onc.2010.307			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20697352	Green Accepted			2022-12-17	WOS:000282944500001
J	Sloss, CM; Wang, F; Palladino, MA; Cusack, JC				Sloss, C. M.; Wang, F.; Palladino, M. A.; Cusack, J. C., Jr.			Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells	ONCOGENE			English	Article						proteasome inhibition; NPI-0052; EGFR; HB-EGF; pancreatic cancer	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; EXPRESSION; BORTEZOMIB; RESISTANCE; P38; CHEMOTHERAPY; CONTRIBUTES; SENSITIVITY; ERLOTINIB	Resistance to drug treatments underlies the high lethality of pancreatic ductal adenocarcinoma. Along with others, we have recently identified that proteasome inhibition is a promising therapeutic option in this highly refractory disease. The pleiotropic effects of proteasome inhibition include the activation of apoptotic signaling pathways and also antiapoptotic signaling pathways such as EGFR, AKT and the MAP kinases that reduce the apoptotic potential of this class of drug. In this study, we sought to determine the mechanism behind the activation of EGFR in response to proteasome inhibition in pancreatic cancer cells. We found that the second-generation proteasome inhibitor NPI-0052 induced the mRNA transcription of several EGFR family ligands (EGF, HB-EGF and epiregulin), however only increases in HB-EGF were detected at the protein level. Using both pharmacological inhibitors and lentiviral-mediated shRNA knockdown of EGFR ligand expression, we discovered that ligand cleavage by MMP/ADAMs and HB-EGF expression is required for activation of EGFR in response to proteasome inhibition. Furthermore, we discover that induction of HB-EGF is dependent on reactive oxygen species and p38-MAPK signaling but not ERK and that the transcription factor SP-1 is involved in NPI-0052-induced HB-EGF transcription. Together, these results indicate that stress signaling leading to induction of HB-EGF expression and increases in MMP/ADAM-dependent HB-EGF cleavage are responsible for proteasome inhibitor-induced activation of EGFR in pancreatic cancer cells. Oncogene (2010) 29, 3146-3152; doi: 10.1038/onc.2010.52; published online 8 March 2010	[Sloss, C. M.; Wang, F.; Cusack, J. C., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Boston, MA 02114 USA; [Palladino, M. A.] Nereus Pharmaceut, San Diego, CA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Cusack, JC (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Dept Surg, Yawkey Bldg 7th Floor,55 Fruit St, Boston, MA 02114 USA.	jcusack@partners.org			NIH [CA98871]; NATIONAL CANCER INSTITUTE [R01CA098871] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH Grant no. CA98871 (JC Cusack).	Blaine SA, 2009, AM J PHYSIOL-GASTR L, V297, pG434, DOI 10.1152/ajpgi.00152.2009; Buck E, 2006, MOL CANCER THER, V5, P2051, DOI 10.1158/1535-7163.MCT-06-0007; Codony-Servat J, 2006, MOL CANCER THER, V5, P665, DOI 10.1158/1535-7163.MCT-05-0147; D'Addario M, 2006, GENE, V379, P51, DOI 10.1016/j.gene.2006.04.012; Edwards JP, 2009, J IMMUNOL, V182, P1929, DOI 10.4049/jimmunol.0802703; Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004; Giovannetti E, 2006, MOL CANCER THER, V5, P1387, DOI 10.1158/1535-7163.MCT-06-0004; Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341; Ingram JL, 2003, AM J PHYSIOL-LUNG C, V284, pL774, DOI 10.1152/ajplung.00189.2002; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Liu XG, 2007, CANCER RES, V67, P4981, DOI 10.1158/0008-5472.CAN-06-4274; Lorch JH, 2007, CANCER RES, V67, P727, DOI 10.1158/0008-5472.CAN-06-2162; McConkey DJ, 2008, DRUG RESIST UPDATE, V11, P164, DOI 10.1016/j.drup.2008.08.002; Means AL, 2003, GASTROENTEROLOGY, V124, P1020, DOI 10.1053/gast.2003.50150; Milano A, 2007, EUR J CANCER, V43, P1125, DOI 10.1016/j.ejca.2007.01.038; Miyamoto H, 2004, PANCREAS, V28, P38, DOI 10.1097/00006676-200401000-00006; Miyamoto S, 2006, CANCER SCI, V97, P341, DOI 10.1111/j.1349-7006.2006.00188.x; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Shi YY, 2006, BREAST CANCER RES TR, V100, P33, DOI 10.1007/s10549-006-9232-x; Sloss CM, 2008, CLIN CANCER RES, V14, P5116, DOI 10.1158/1078-0432.CCR-07-4506; Suganuma K, 2003, CANCER SCI, V94, P355, DOI 10.1111/j.1349-7006.2003.tb01446.x; Takenobu H, 2003, J BIOL CHEM, V278, P17255, DOI 10.1074/jbc.M211835200; Wang F, 2007, ONCOGENE, V26, P2006, DOI 10.1038/sj.onc.1209999; Wang F, 2007, CANCER RES, V67, P8486, DOI 10.1158/0008-5472.CAN-07-0498; Zhu KY, 2009, CANCER RES, V69, P1836, DOI 10.1158/0008-5472.CAN-08-4103; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	30	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	2010	29	21					3146	3152		10.1038/onc.2010.52	http://dx.doi.org/10.1038/onc.2010.52			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20208558	Green Accepted			2022-12-17	WOS:000278133100011
J	Masuda, K; Ishikawa, Y; Onoyama, I; Unno, M; de Alboran, IM; Nakayama, KI; Nakayama, K				Masuda, K.; Ishikawa, Y.; Onoyama, I.; Unno, M.; de Alboran, I. M.; Nakayama, K. I.; Nakayama, K.			Complex regulation of cell-cycle inhibitors by Fbxw7 in mouse embryonic fibroblasts	ONCOGENE			English	Article						cell cycle; CDK inhibitor; ubiquitin ligase; SCF complex; Notch; conditional knockout mouse	F-BOX PROTEIN; FBW7 UBIQUITIN LIGASE; C-MYC; TUMOR-SUPPRESSOR; MICE LACKING; P27(KIP1); NUCLEOPHOSMIN; DEGRADATION; P57(KIP2); EXIT	The F-box protein Fbxw7 (also known as Fbw7, SEL-10, hCdc4 or hAgo) mediates the ubiquitylation and thereby contributes to the degradation of proteins that positively regulate cell cycle. Conditional ablation of Fbxw7 in mouse embryonic fibroblasts (MEFs) induces cell-cycle arrest accompanied by abnormal accumulation of the intracellular domain of Notch1 (NICD1) and c-Myc. However, the molecular mechanisms by which the accumulation of NICD1 and c-Myc induces cell-cycle arrest have remained unclear. We have now examined the expression of cell-cycle inhibitors in Fbxw7-deficient MEFs and found that the abundance of p27(Kip1) and p57(Kip2) is paradoxically decreased. This phenomenon appears to be attributable to the accumulation of NICD1, given that it was recapitulated by overexpression of NICD1 and blocked by ablation of RBP-J. Conversely, the expression of p16(Ink4a) and p19(ARF) was increased in an NICD1-independent manner in Fbxw7-null MEFs. The increased expression of p19(ARF) was recapitulated by overexpression of c-Myc and abolished by ablation of c-Myc, suggesting that the accumulation of c-Myc is primarily responsible for that of p19(ARF). In contrast, the upregulation of p16(Ink4a) appeared to be independent of c-Myc. These results indicate that cell-cycle inhibitors undergo complex regulation by the Fbxw7-mediated proteolytic system. Oncogene (2010) 29, 1798-1809; doi:10.1038/onc.2009.469; published online 21 December 2009	[Masuda, K.; Ishikawa, Y.; Nakayama, K.] Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res,Aoba Ku, Sendai, Miyagi 9808575, Japan; [Masuda, K.; Unno, M.] Tohoku Univ, Grad Sch Med, Dept Surg, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Masuda, K.; Ishikawa, Y.; Onoyama, I.; Nakayama, K. I.; Nakayama, K.] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama, Japan; [Onoyama, I.; Nakayama, K. I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan; [de Alboran, I. M.] CSIC, Dept Immunol & Oncol, Natl Biotechnol Ctr, Madrid, Spain	Tohoku University; Tohoku University; Japan Science & Technology Agency (JST); Kyushu University; Consejo Superior de Investigaciones Cientificas (CSIC)	Nakayama, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Dev Genet, Ctr Translat & Adv Anim Res,Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	nakayak2@mail.tains.tohoku.ac.jp	Moreno de Alboran, Ignacio/K-1044-2017; Unno, Michiaki/AAX-5246-2020; Unno, Michiaki/A-8633-2010	Unno, Michiaki/0000-0002-2145-6416; Unno, Michiaki/0000-0002-2145-6416	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Honjo for providing Rbpj<SUP>F/F</SUP> mice; R Tsunematsu for an NICD1 plasmid; T Kitamura for pMX-puro and Plat-E cells; T Senga, Y Ono and N Kobayashi for technical assistance; and N Yanagihara, N Ishida and other laboratory members for helpful discussion and Y Akaida for help in preparation of the paper. This study was supported in part by a Grant-in-Aid and the Network Medicine Global COE Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; de Alboran IM, 2004, CELL DEATH DIFFER, V11, P61, DOI 10.1038/sj.cdd.4401319; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Georgia S, 2006, DEV BIOL, V298, P22, DOI 10.1016/j.ydbio.2006.05.036; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Ishikawa Y, 2008, ONCOGENE, V27, P6164, DOI 10.1038/onc.2008.216; Jia JL, 2007, MOL CELL BIOL, V27, P7236, DOI 10.1128/MCB.00780-07; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kato H, 1996, FEBS LETT, V395, P221, DOI 10.1016/0014-5793(96)01046-0; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Li ZL, 2008, P NATL ACAD SCI USA, V105, P18794, DOI 10.1073/pnas.0806879105; Lomas J, 2008, FRONT BIOSCI-LANDMRK, V13, P5071, DOI 10.2741/3065; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Onoyama I, 2008, CELL CYCLE, V7, P3307, DOI 10.4161/cc.7.21.6931; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Riccio O, 2008, EMBO REP, V9, P377, DOI 10.1038/embor.2008.7; Sarmento LM, 2005, J EXP MED, V202, P157, DOI 10.1084/jem.20050559; Solomon DA, 2008, CANCER RES, V68, P8657, DOI 10.1158/0008-5472.CAN-08-2084; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SUNDARAM M, 1993, GENETICS, V135, P765; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; Vernon AE, 2006, EMBO REP, V7, P643, DOI 10.1038/sj.embor.7400691; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	14	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1798	1809		10.1038/onc.2009.469	http://dx.doi.org/10.1038/onc.2009.469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023701				2022-12-17	WOS:000276022800009
J	Li, H; Choi, YJ; Hanes, MA; Marple, T; Vogel, H; Hasty, P				Li, H.; Choi, Y. J.; Hanes, M. A.; Marple, T.; Vogel, H.; Hasty, P.			Deleting Ku70 is milder than deleting Ku80 in p53-mutant mice and cells	ONCOGENE			English	Article						DNA double-strand break; non-homologous end joining; pro-B-cell lymphoma; medulloblastoma; T-cell lymphoma	V(D)J RECOMBINATION; RAG-1-INDUCED DSBS; SPONTANEOUS TUMORS; DNA-DAMAGE; PROTEIN; P53; DEFICIENT; TRANSLOCATION; MECHANISM; BINDING	Ku70 forms a heterodimer with Ku80, called Ku that is well known for repairing DNA double-strand breaks through non-homologous end joining. As a result, deletion of either causes a very similar phenotype in mice that includes hypersensitivity to clastogens and early aging. In addition, deletion of Ku80 along with the cell cycle checkpoint protein, p53, dramatically increases the incidence of pro-B-cell lymphoma. Even though Ku70-p53-mutant mice have not been analysed, a logical assumption is they would exhibit the same cancer phenotype. Here, we test this assumption by comparing p53-mutant littermates deleted for either Ku70 or Ku80 or both. We find this assumption to be incorrect as p53-mutants live significantly longer when deleted for Ku70 rather than Ku80 or Ku70 + Ku80. We also find the former cohort displays much lower levels of pro-B-cell lymphoma than the latter two cohorts. As pro-B-cell lymphoma is caused by a translocation between chromosomes 12 and 15, we tested fibroblasts for DNA repair capacity, and found that p53-mutant fibroblasts are more sensitive to streptonigrin and paraquat when deleted for Ku80 as compared with Ku70. Thus, Ku80 may function outside the Ku heterodimer to influence DNA damage repair presenting the possibility that Ku80 influenced the open coding ends in a manner that suppressed a cancer-causing translocation.	[Li, H.; Choi, Y. J.; Marple, T.; Hasty, P.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78245 USA; [Li, H.; Choi, Y. J.; Marple, T.; Hasty, P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA; [Hanes, M. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Lab Anim Resources, San Antonio, TX 78245 USA; [Vogel, H.] Stanford Univ, Med Ctr, Dept Pathol, Palo Alto, CA 94304 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University	Hasty, P (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.	hastye@uthscsa.edu		Hasty, Paul/0000-0003-3046-0131; Vogel, Otto Hannes/0000-0002-0960-3508	NIH [R01 CA76317-05A1, 3P30 CA054174-16S2, P01 AG17242, UO1 ES11044]; NATIONAL CANCER INSTITUTE [P30CA054174, R01CA076317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017242] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the following grants from the NIH: R01 CA76317-05A1, 3P30 CA054174-16S2, P01 AG17242 and UO1 ES11044 to PH.	Bolzan AD, 2001, MUTAT RES-REV MUTAT, V488, P25, DOI 10.1016/S1383-5742(00)00062-4; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; Gomez JA, 2007, BIOCHEM SOC T, V35, P797, DOI 10.1042/BST0350797; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Holcomb VB, 2008, CANCER RES, V68, P9497, DOI 10.1158/0008-5472.CAN-08-2085; Holcomb VB, 2007, MECH AGEING DEV, V128, P601, DOI 10.1016/j.mad.2007.08.006; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Koike M, 2000, BIOCHEM BIOPH RES CO, V276, P1105, DOI 10.1006/bbrc.2000.3567; Li H, 2007, MOL CELL BIOL, V27, P8205, DOI 10.1128/MCB.00785-07; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Lim JW, 2008, INT J BIOCHEM CELL B, V40, P2065, DOI 10.1016/j.biocel.2008.02.015; Marple T, 2004, MUTAT RES-FUND MOL M, V554, P253, DOI 10.1016/j.mrfmmm.2004.05.004; Mazumder S, 2007, MOL CELL BIOL, V27, P3511, DOI 10.1128/MCB.01448-06; Munakata Y, 2005, BLOOD, V106, P3449, DOI 10.1182/blood-2005-02-0536; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Romero F, 1996, MOL CELL BIOL, V16, P37; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Song KY, 2001, J BIOL CHEM, V276, P8321, DOI 10.1074/jbc.M008779200; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; Zhu PC, 2006, EMBO REP, V7, P431, DOI 10.1038/sj.embor.7400622	33	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1875	1878		10.1038/onc.2009.57	http://dx.doi.org/10.1038/onc.2009.57			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19330025				2022-12-17	WOS:000265640500006
J	Matta, H; Punj, V; Schamus, S; Mazzacurati, L; Chen, AM; Song, R; Yang, T; Chaudhary, PM				Matta, H.; Punj, V.; Schamus, S.; Mazzacurati, L.; Chen, A. M.; Song, R.; Yang, T.; Chaudhary, P. M.			A nuclear role for Kaposi's sarcoma-associated herpesvirus-encoded K13 protein in gene regulation	ONCOGENE			English	Article						K13; vFLIP; KSHV; RTA; IKK; NF-kappa B	NF-KAPPA-B; KINASE COMPLEX; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; KSHV VFLIP; IKK-GAMMA; ACTIVATION; EXPRESSION; ALPHA; PATHWAY	Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded viral FLICE inhibitory protein K13 interacts with a cytosolic I kappa B kinase (IKK) complex to activate nuclear factor-kappa B (NF-kappa B). We recently reported that K13 antagonizes KSHV lytic regulator RTA ( replication and transcription activator) and blocks lytic replication, but spares RTA-induced viral interleukin-6 (vIL6). Here we report that K13 is also present in the nuclear compartment, a property not shared by its structural homologs. K13 interacts with and activates the nuclear IKK complex, and binds to the I kappa B alpha promoter. K13 mutants that are retained in the cytosol lack NF-kappa B activity. However, neither the IKKs nor NF-kappa B activation is required for nuclear localization of K13. Instead, this ability is dependent on a nuclear localization signal located in its N-terminal 40 amino acids. Finally, K13, along with p65/RelA, binds to the promoters of a number of KSHV lytic genes, including RTA, ORF57 and vGPCR, but not to the promoter of the vIL6 gene. Thus, K13 has an unexpected nuclear role in viral and cellular gene regulation and its differential binding to the promoters of lytic genes may not only contribute to the inhibition of KSHV lytic replication, but may also account for the escape of vIL6 from K13-induced transcriptional suppression.	[Matta, H.; Punj, V.; Schamus, S.; Mazzacurati, L.; Chen, A. M.; Song, R.; Chaudhary, P. M.] Univ Pittsburgh, Hillman Canc Ctr, Dept Med, Div Hematol Oncol,Canc Inst, Pittsburgh, PA 15213 USA; [Yang, T.] Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Spang Translat Res Core Facil, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chaudhary, PM (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Med, Div Hematol Oncol,Canc Inst, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018	mazzacurati, lucia/0000-0002-8336-8032	ational Institutes of Health [CA85177, CA124621]; Leukemia and Lymphoma Society; Mario Lemieux Foundation; NATIONAL CANCER INSTITUTE [R01CA124621, R01CA085177] Funding Source: NIH RePORTER	ational Institutes of Health; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Mario Lemieux Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Inder Verma for providing the IKK deficient MEFs, Dr Shao-Cong Sun for NEMO-deficient Jurkat cells and Dr Mary Collins for a K13 monoclonal antibody. This work was supported by grants from the National Institutes of Health (CA85177 and CA124621), the Leukemia and Lymphoma Society and the Mario Lemieux Foundation.	An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Ear T, 2005, J IMMUNOL, V175, P1834, DOI 10.4049/jimmunol.175.3.1834; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1081, DOI 10.1016/j.bcp.2006.06.017; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Han Z, 2006, J VIROL, V80, P5251, DOI 10.1128/JVI.02570-05; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Kirshner JR, 2000, J VIROL, V74, P3586, DOI 10.1128/JVI.74.8.3586-3597.2000; Kumar A, 2001, J BIOL CHEM, V276, P2668, DOI 10.1074/jbc.M008356200; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Matta H, 2007, ONCOGENE, V26, P1656, DOI 10.1038/sj.onc.1209931; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Matta H, 2007, J BIOL CHEM, V282, P24858, DOI 10.1074/jbc.M700118200; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; Nekorchuk M, 2007, J VIROL, V81, P9990, DOI 10.1128/JVI.00896-07; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; Schulz TF, 2006, J PATHOL, V208, P187, DOI 10.1002/path.1904; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Wang SZE, 2004, J VIROL, V78, P4248, DOI 10.1128/JVI.78.8.4248-4267.2004; West JT, 2003, ONCOGENE, V22, P5150, DOI 10.1038/sj.onc.1206555; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067	40	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5243	5253		10.1038/onc.2008.150	http://dx.doi.org/10.1038/onc.2008.150			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469854				2022-12-17	WOS:000258915100008
J	LaFiura, KM; Edwards, H; Taub, JW; Matherly, LH; Fontana, JA; Mohamed, AN; Ravindranath, Y; Ge, Y				LaFiura, K. M.; Edwards, H.; Taub, J. W.; Matherly, L. H.; Fontana, J. A.; Mohamed, A. N.; Ravindranath, Y.; Ge, Y.			Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group	ONCOGENE			English	Article						t(8;21); AML1-ETO; acute myeloid leukemia; fusion transcripts	ACUTE MYELOBLASTIC-LEUKEMIA; HIGH-DOSE CYTARABINE; DOWN-SYNDROME; AML1/ETO; EXPRESSION; REMISSION; GENE; AML; INTENSIFICATION; PROMOTER	t(8;21)(q22;q22) results in the AML1-ETO (A1E) fusion gene and is a common cytogenetic abnormality in acute myeloid leukemia (AML). Although insertions at the breakpoint region of the A1E fusion transcripts have been reported, additional structural alterations are largely uncharacterized. By RT-PCR amplifications and DNA sequencing, numerous in-frame and out-of-frame AML1b-ETO and AML1c-ETO transcripts were identified in 13 pediatric t(8; 21) AMLs, likely resulting from alternate splicing, internal deletions and/or breakpoint region insertions involving both the AML1 (RUNX1) and ETO regions. The in-frame A1E fusion transcript forms represented minor forms. These structure alterations were found in AML1c-ETO but not AML1b-ETO transcripts in two adult t(8;21) AMLs. Although no analogous alterations were detected in native AML1b transcripts, identical alterations in native ETO transcripts were identified. When transfected into HeLa cells, only AML1b, and not the in-frame A1E forms, transactivated the GM-CSF promoter. In co-transfection experiments, the effects of A1E proteins on GM-CSF transactivation by AML1b ranged from repressive to activating. Our results demonstrate a remarkable and unprecedented heterogeneity in A1E fusion transcripts in t(8;21) myeloblasts and suggest that synthesis of alternate A1E transcript and protein forms can significantly impact the regulation of AML1 responsive genes.	[LaFiura, K. M.; Edwards, H.; Taub, J. W.; Matherly, L. H.; Fontana, J. A.; Ravindranath, Y.; Ge, Y.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA; [Taub, J. W.; Ravindranath, Y.] Childrens Hosp Michigan, Div Pediat Hematol Oncol, Detroit, MI 48201 USA; [Taub, J. W.; Ravindranath, Y.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA; [Matherly, L. H.; Ge, Y.] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; [Fontana, J. A.] John D Dingell Vet Affairs Med Ctr, Dept Med, Detroit, MI USA; [Mohamed, A. N.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Children's Hospital of Michigan; Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Ge, Y (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	gey@karmanos.org		Ge, Yubin/0000-0002-8748-716X; Fontana, Joseph/0000-0003-3829-3358	Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute [CA92308, CA76641]; Pediatric Oncology Group [CA30969]; Children's Oncology Group [CA98543]; NATIONAL CANCER INSTITUTE [P30CA022453, U10CA098543, R01CA076641, U10CA030969, R01CA092308] Funding Source: NIH RePORTER	Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute; Pediatric Oncology Group; Children's Oncology Group; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert J Arceci and the Children's Oncology Group AML Biology Subcommittee for authorizing and providing the clinical specimens that made this study possible. This work was supported by grants from the Karmanos Cancer Institute, Leukemia Research Life, the Children's Research Center of Michigan, the Children's Leukemia Foundation of Michigan, the National Cancer Institute (CA92308 and CA76641), the Leukemia and Lymphoma Society, BPCT Golf Charity, the Sehn Family Foundation and the Dale Meyer Memorial Endowment for Leukemia Research. JW Taub is a Scholar in Clinical Research of the Leukemia and Lymphoma Society. This work was also supported by the Pediatric Oncology Group Grant CA30969 and the Children's Oncology Group Grant CA98543.	Becton D, 2006, BLOOD, V107, P1315, DOI 10.1182/blood-2004-08-3218; Bloomfield CD, 1998, CANCER RES, V58, P4173; Byrd JC, 1999, J CLIN ONCOL, V17, P3767, DOI 10.1200/JCO.1999.17.12.3767; Chang M, 2000, LEUKEMIA, V14, P1201, DOI 10.1038/sj.leu.2401832; Entz-Werle N, 2005, LEUKEMIA, V19, P2072, DOI 10.1038/sj.leu.2403932; ERICKSON P, 1992, BLOOD, V80, P1825; Erickson PF, 1996, BLOOD, V88, P1813; Frank R, 1995, ONCOGENE, V11, P2667; Ge YB, 2005, JNCI-J NATL CANCER I, V97, P226, DOI 10.1093/jnci/dji026; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Kardos G, 2005, LEUKEMIA, V19, P2063, DOI 10.1038/sj.leu.2403873; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Leroy H, 2005, LEUKEMIA, V19, P367, DOI 10.1038/sj.leu.2403627; Lu Y, 2006, LEUKEMIA, V20, P987, DOI 10.1038/sj.leu.2404218; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Marcucci G, 2000, CANCER INVEST, V18, P768, DOI 10.3109/07357900009012209; Michaud J, 2003, CANCER INVEST, V21, P105, DOI 10.1081/CNV-120018821; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; NUCIFORA G, 1993, BLOOD, V81, P883; Perel Y, 2005, LEUKEMIA, V19, P2082, DOI 10.1038/sj.leu.2403867; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Raimondi SC, 1999, BLOOD, V94, P3707; Rubnitz JE, 2002, LEUKEMIA, V16, P2072, DOI 10.1038/sj.leu.2402633; Saunders MJ, 1996, LEUKEMIA, V10, P1139; Schlenk RF, 2004, J CLIN ONCOL, V22, P3741, DOI 10.1200/JCO.2004.03.012; Schnittger S, 2003, BLOOD, V102, P2746, DOI 10.1182/blood-2003-03-0880; Smith FO, 2005, LEUKEMIA, V19, P2054, DOI 10.1038/sj.leu.2403925; Strout MP, 1999, ANN HEMATOL, V78, P251, DOI 10.1007/s002770050511; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yoo SJ, 2005, HAEMATOLOGICA, V90, P1493	34	14	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2008	27	36					4933	4942		10.1038/onc.2008.134	http://dx.doi.org/10.1038/onc.2008.134			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469864	Green Accepted			2022-12-17	WOS:000258596900007
J	Porlan, E; Vidaurre, OG; Rodriguez-Pena, A				Porlan, E.; Vidaurre, O. G.; Rodriguez-Pena, A.			Thyroid hormone receptor-beta (TR beta 1) impairs cell proliferation by the transcriptional inhibition of cyclins D1, E and A2	ONCOGENE			English	Article						thyroid hormone receptor; cyclins; E2F-1; AP-1; nuclear receptors; cell cycle	NEGATIVE REGULATOR; E2F; SUPPRESSOR; GENE; RECRUITMENT; EXPRESSION; REPRESSION; MECHANISM; DEPENDS; PATHWAY	Thyroid hormone receptor-beta 1 (TR beta 1) belongs to the ligand-inducible transcription factor superfamily. We have previously described that stable TRb1 expression impairs fibroblast proliferation diminishing levels and activity of the main regulators of the G(1)/S transition. To unmask the underlying molecular mechanism of this action, we have investigated the expression of cyclin D1, E and A2 upon serum stimulation in TR beta 1 expressing cells, finding a strong downregulation of their mRNAs, concomitant with low protein levels. The inhibition of the transcriptional activation in response to serum of these cyclins is differently exerted. For cyclin D1, we demonstrate that TR beta 1 represses its promoter as a consequence of the downregulation of c-jun levels, diminished AP-1 activation and loss of c-jun recruitment to its binding sites on cyclin D1 promoter. For cyclin E and A2, it is the impairment of the cyclinD/Rb/E2F pathway by TR beta 1 that prevents the activation of these two E2F target genes. Indeed, recruitment of E2F-1 to cyclin A2 promoter could not be detected. In summary, we propose that apo-TR beta 1 exerts its antiproliferative action through a mechanism that could constitute a model by which other nuclear receptors may control cell division.	[Porlan, E.; Vidaurre, O. G.; Rodriguez-Pena, A.] Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Rodriguez-Pena, A (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	arodriguez@iib.uam.es	porlan, Eva/AAE-6561-2022	porlan, Eva/0000-0003-0934-9711; Rodriguez-Pena, Angeles/0000-0002-2515-4626				Barrera-Hernandez G, 1998, DNA CELL BIOL, V17, P743, DOI 10.1089/dna.1998.17.743; Benkoussa M, 2002, MOL CELL BIOL, V22, P4522, DOI 10.1128/MCB.22.13.4522-4534.2002; Bhat MK, 1997, J BIOL CHEM, V272, P28989, DOI 10.1074/jbc.272.46.28989; Botz J, 1996, MOL CELL BIOL, V16, P3401; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Chan IH, 2006, ONCOGENE, V25, P3576, DOI 10.1038/sj.onc.1209389; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; Deogracias R, 2004, MOL CELL NEUROSCI, V26, P470, DOI 10.1016/j.mcn.2004.03.007; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; O'Shea PJ, 2002, J ENDOCRINOL, V175, P553, DOI 10.1677/joe.0.1750553; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Porlan E, 2004, ONCOGENE, V23, P8756, DOI 10.1038/sj.onc.1208126; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Sanz-Gonzalez SM, 2004, BIOCHEM BIOPH RES CO, V317, P972, DOI 10.1016/j.bbrc.2004.03.143; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yamaguchi K, 2005, J BIOL CHEM, V280, P32569, DOI 10.1074/jbc.M503201200; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	31	14	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2008	27	19					2795	2800		10.1038/sj.onc.1210936	http://dx.doi.org/10.1038/sj.onc.1210936			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18037966				2022-12-17	WOS:000255259500015
J	Iwai, A; Hijikata, M; Hishiki, T; Isono, O; Chiba, T; Shimotohno, K				Iwai, A.; Hijikata, M.; Hishiki, T.; Isono, O.; Chiba, T.; Shimotohno, K.			Coiled-coil domain containing 85B suppresses the beta-catenin activityin a p53-dependent manner	ONCOGENE			English	Article						oncogenesis; Siah-1L; Wnt signal; tumor suppressor	P53; PATHWAY; TRANSCRIPTION; LOCALIZATION; ACCUMULATION; EXPRESSION; CANCER; TARGET; CELLS	Aberrant accumulation of beta-catenin is closely related to carcinogenesis. Mutations in the p53 gene are reported to induce the aberrant accumulation of beta-catenin in the absence of dysfunction in the glycogen synthase kinase 3 beta (GSK3 beta)-mediated degradation pathway, but the mechanism remains incompletely understood. Here, we show that human coiled-coil domain containing 85B (CCDC85B) is induced by p53 and regulates beta-catenin activity via interaction with the T-cell factor 4 in the nucleus. Moreover, CCDC85B enhances the degradation of beta-catenin and suppresses tumor cell growth. In conclusion, we revealed that CCDC85B-induced degradation of beta-catenin is independent of GSK3b and other p53-inducible products, Siah-1L, suggesting that CCDC85B constitutes the one of the frameworks of p53-induced multiple regulatory pathways for beta-catenin activity.	[Iwai, A.; Hijikata, M.; Hishiki, T.; Isono, O.; Shimotohno, K.] Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyoku, Kyoto 6068507, Japan; [Iwai, A.; Chiba, T.] Kyoto Univ, Dept Med, Div Gastroenterol & Hepatol, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyoku, Shogoin Kawara Cho 54, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp						Brazas R, 1996, SCIENCE, V274, P90, DOI 10.1126/science.274.5284.90; Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Park WS, 2001, J PATHOL, V193, P483; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2001, DEVELOPMENT, V128, P2107; Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3	22	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1520	1526		10.1038/sj.onc.1210801	http://dx.doi.org/10.1038/sj.onc.1210801			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873903				2022-12-17	WOS:000253815800003
J	Chung, SH; Weiss, RS; Frese, KK; Prasad, BVV; Javier, RT				Chung, S-H; Weiss, R. S.; Frese, K. K.; Prasad, B. V. V.; Javier, R. T.			Functionally distinct monomers and trimers produced by a viral oncoprotein	ONCOGENE			English	Article						adenovirus; E4-ORF1; monomer; PDZ; trimer	PAPILLOMAVIRUS E6 ONCOPROTEINS; STAPHYLOCOCCAL ALPHA-TOXIN; TUMOR-SUPPRESSOR PROTEIN; ADENOVIRUS E4-ORF1; EPITHELIAL-CELLS; PDZ DOMAINS; BINDING; POLARITY; OLIGOMERIZATION; VESICLES	While the process of homo-oligomer formation and disassembly into subunits represents a common strategy to regulate protein activity, reports of proteins in which the subunit and homo-oligomer perform independent functions are scarce. Tumorigenesis induced by the adenovirus E4-ORF1 oncoprotein depends on its binding to a select group of cellular PDZ proteins, including MUPP1, MAGI-1, ZO-2 and Dlg1. We report here that in cells E4-ORF1 exists as both a monomer and trimer and that monomers specifically bind and sequester MUPP1, MAGI-1 and ZO-2 within insoluble complexes whereas trimers specifically bind Dlg1 and promote its translocation to the plasma membrane. This work exposes a novel strategy wherein the oligomerization state of a protein not only determines the capacity to bind separate related targets but also couples the interactions to different functional consequences.	[Chung, S-H; Weiss, R. S.; Frese, K. K.; Javier, R. T.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Prasad, B. V. V.] Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Javier, RT (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza,Mail Stop 385, Houston, TX 77030 USA.	rjavier@bcm.tmc.edu	Chung, Sanghyuk/ABH-2697-2020	Prasad, B.V.Venkataram/0000-0002-1172-2071	NCI NIH HHS [T32 CA009197, R01 CA058541, T32 CA09197, CA58541] Funding Source: Medline; NIAID NIH HHS [AI36040, R01 AI036040, R37 AI036040] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009197, R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036040, R01AI036040] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; Chung SH, 2007, J VIROL, V81, P4787, DOI 10.1128/JVI.02855-06; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Long JF, 2003, J MOL BIOL, V327, P203, DOI 10.1016/S0022-2836(03)00113-X; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Raffy S, 1999, BIOPHYS J, V76, P2072, DOI 10.1016/S0006-3495(99)77363-7; Ramachandran R, 2004, NAT STRUCT MOL BIOL, V11, P697, DOI 10.1038/nsmb793; Shin K, 2005, J CELL BIOL, V168, P705, DOI 10.1083/jcb.200408064; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	25	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1412	1420		10.1038/sj.onc.1210784	http://dx.doi.org/10.1038/sj.onc.1210784			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828302	Green Accepted			2022-12-17	WOS:000253548200008
J	Ciuffini, L; Castellani, L; Salvati, E; Galletti, S; Falcone, G; Alema, S				Ciuffini, L.; Castellani, L.; Salvati, E.; Galletti, S.; Falcone, G.; Alema, S.			Delineating v-Src downstream effector pathways in transformed myoblasts	ONCOGENE			English	Article						v-Src; myogenic differentiation; p38 MAPK; Ras-MEK signalling	SKELETAL-MUSCLE DIFFERENTIATION; SIGNALING PATHWAYS; MYOGENIC DIFFERENTIATION; CELL-TRANSFORMATION; GENE-EXPRESSION; FAMILY KINASES; MAP KINASE; RAS; P38; ACTIVATION	In this study, we delineate the intracellular signalling pathways modulated by a conditional v-Src tyrosine kinase that lead to unrestrained proliferation and block of differentiation of primary avian myoblasts. By inhibiting Ras-MAPK kinase and phosphatidylinositol 3-kinase with different means, we find that both pathways play crucial roles in controlling v-Src-sustained growth factor and anchorage independence for proliferation. The Ras-MAPK kinase pathway also contributes to block of differentiation independently of cell proliferation since inhibition of this pathway both in proliferating and growth-arrested v-Src-transformed myoblasts induces expression of muscle-specific genes, fusion into multinucleated myotubes and assembly of specialized contractile structures. Importantly, we find that the p38 MAPK pathway is inhibited by v-Src in myoblasts and its forced activation results in growth inhibition and expression of differentiation, indicating p38 MAPK as a critical target of v-Src in growth transformation and myogenic differentiation. Furthermore, we show that downregulation of p38 MAPK activation may occur via Ras-MAPK kinase, thus highlighting a cross-regulation between the two pathways. Finally, we report that the simultaneous inhibition of MAPK kinase and calpain, combined to activation of p38 MAPK, are sufficient to reconstitute largely the differentiation potential of v-Src-transformed myoblasts.	[Ciuffini, L.; Castellani, L.; Salvati, E.; Galletti, S.; Falcone, G.; Alema, S.] CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; [Castellani, L.] Univ Cassino, Dipartimento Sci Motor & Salute, I-03043 Cassino, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Cassino	Falcone, G (corresponding author), CNR, Ist Biol Cellulare, Via Ramarini 32, I-00016 Monterotondo, Italy.	gfalcone@ibc.cnr.it; alema@ibc.cnr.it	Falcone, Germana/A-3735-2016	Castellani, Loriana/0000-0002-8519-3504; Salvati, Erica/0000-0002-3373-7442; Falcone, Germana/0000-0002-3508-7623				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 2006, J BIOL CHEM, V281, P15249, DOI 10.1074/jbc.M601390200; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; FALCONE G, 1992, ONCOGENE, V7, P1913; Falcone G, 2003, ONCOGENE, V22, P8302, DOI 10.1038/sj.onc.1206915; Faust D, 2005, ONCOGENE, V24, P7941, DOI 10.1038/sj.onc.1208948; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Keren A, 2006, MOL CELL ENDOCRINOL, V252, P224, DOI 10.1016/j.mce.2006.03.017; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Li RH, 1996, P NATL ACAD SCI USA, V93, P7522, DOI 10.1073/pnas.93.15.7522; Lluis F, 2006, TRENDS CELL BIOL, V16, P36, DOI 10.1016/j.tcb.2005.11.002; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	44	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					528	539		10.1038/sj.onc.1210665	http://dx.doi.org/10.1038/sj.onc.1210665			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637741				2022-12-17	WOS:000252426100013
J	Mei, Y; Xie, C; Xie, W; Wu, Z; Wu, M				Mei, Y.; Xie, C.; Xie, W.; Wu, Z.; Wu, M.			Siah-1S, a novel splice variant of Siah-1 (seven in absentia homolog), counteracts Siah-1-mediated downregulation of beta-catenin	ONCOGENE			English	Article						Siah-1S; beta-catenin; splice variant; self-ubiquitination; tumorigenesis	UBIQUITIN-PROTEASOME PATHWAY; INHIBITS CELL-GROWTH; TRANSCRIPTIONAL REPRESSOR; DEGRADATION PATHWAY; STRUCTURAL-ANALYSIS; MAMMALIAN HOMOLOGS; SIGNALING PATHWAYS; RAPID DEGRADATION; TUMOR SUPPRESSION; SINA GENE	Siah-1 ( seven in absentia homolog) is known to cause indirect degradation of beta-catenin through formation of a complex with Siah-interacting protein ( SIP), Skp1 and Ebi. Here, we report the characterization of a novel splice variant of human Siah-1, designated Siah-1S, which is produced by an alternative splicing mechanism. The novel intron/exon junctions used to generate Siah-1S follow a non-conventional CT-AC rule. Siah-1S exhibits an even shorter half-life than Siah-1 and is able to catalyse self-ubiquitination that results in its subsequent degradation by proteasome. Siah-1S is shown to upregulate beta-catenin-dependent Tcf/Lef transcriptional activation and antagonize Siah-1's potentiation effect on the apoptosis induced by etoposide in MCF-7 cells. Additionally, Siah-1S is found to interact with Siah-1 to form heterodimer or with itself to form homodimer. Unlike homodimer Siah-1*Siah-1, neither Siah-1*Siah-1S nor Siah-1S*Siah-1S is able to bind to Siah-1-interacting protein, which may explain the underlying mechanism for Siah-1S's dominant negative effect on Siah-1. Importantly, results from in vitro soft agar assay demonstrated that Siah-1S displays a promotion effect on cells tumorigenicity.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wumian@ustc.edu.cn	Wu, Mian/H-2494-2018; Mei, Yide/M-4468-2013; Xie, Chongwei/GOP-0158-2022	Wu, Mian/0000-0002-2714-0500				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Dong XZ, 1999, GENE DEV, V13, P954, DOI 10.1101/gad.13.8.954; French C, 1999, VIROLOGY, V262, P139, DOI 10.1006/viro.1999.9875; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Gutierrez GJ, 2006, NAT CELL BIOL, V8, P1084, DOI 10.1038/ncb1472; Habelhah H, 2004, J BIOL CHEM, V279, P53782, DOI 10.1074/jbc.M410315200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Kim H, 2004, J AM SOC NEPHROL, V15, P2042, DOI 10.1097/01.ASN.0000133490.00348.59; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; Nakamura N, 2004, J PHYS CONF SER, V2, P1, DOI 10.1088/1742-6596/2/1/001; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Oliver PL, 2004, P NATL ACAD SCI USA, V101, P14901, DOI 10.1073/pnas.0406196101; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Santelli E, 2005, J BIOL CHEM, V280, P34278, DOI 10.1074/jbc.M506707200; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	49	14	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6319	6331		10.1038/sj.onc.1210449	http://dx.doi.org/10.1038/sj.onc.1210449			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17420721				2022-12-17	WOS:000249583300008
J	Park, IW; Reddy, MVR; Reddy, EP; Groopman, JE				Park, I-W; Reddy, M. V. R.; Reddy, E. P.; Groopman, J. E.			Evaluation of novel cell cycle inhibitors in mantle cell lymphoma	ONCOGENE			English	Article						mantle cell lymphoma; cell cycle; cytotoxicity; apoptosis; novel sulfonyl compounds (ON013100 and ON01370)	CDK INHIBITORS; CANCER CELLS; KINASE; PROTEIN; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; SURVIVAL; DIFFERENTIATION; EXPRESSION	Signature abnormalities in the cell cycle and apoptotic pathway have been identified in mantle cell lymphoma (MCL), affording the opportunity to develop targeted therapies. In this study, we tested a novel class of kinase inhibitors, styryl sulfones, which differ from prior cell cycle inhibitors in that they are not related to purines or pyrimidines. We observed that two closely related compounds, ON013100 and ON01370, altered the growth and cell cycle status of MCL lines and potently inhibited the expression of several important molecules, including cyclin-dependent kinase4, p53, mouse double minute 2 (MDM2), and cyclin D as well as increased cyclin B expression. Using both terminal deoxy transferase uridine triphosphate nick end-labelling and poly ADP-ribose polymerase assays, we found that these compounds caused apoptosis in MCL cells. In addition, using molecular analyses, we observed the modulation of caspase-3 activity but not the expression of B-cell lymphoma family molecules. Next, we investigated the cytotoxicity of the MCL lines upon treatment with styryl sulfone compounds in combination with other currently used chemotherapeutic agents, such as doxorubicin (DOX) or vincristine (VCR). We found that the combination of DOX plus styryl sulfone or VCR plus styryl sulfone increased cytotoxicity by one log scale, compared with the single styryl sulfone compound. Thus, styryl sulfones alone, or in combination with chemotherapeutic agents, present attractive opportunities for new drug development in MCL.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Dept Med,Med Sch, Boston, MA 02115 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Groopman, JE (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med,Dept Med,Med Sch, 4 Blackfan Circle, Boston, MA 02115 USA.	jgroopma@bidmc.harvard.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA109820] Funding Source: NIH RePORTER; NCI NIH HHS [CA109820] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSCH F, 1994, BLOOD, V84, P2725; Boutros R, 2005, EXP CELL RES, V310, P152, DOI 10.1016/j.yexcr.2005.07.009; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Brauns SC, 2005, ANTICANCER RES, V25, P4197; Campo E, 1999, SEMIN HEMATOL, V36, P115; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Choi S, 2005, CANCER RES, V65, P2035, DOI 10.1158/0008-5472.CAN-04-3616; CROWE DL, 2005, HEAD NECK-J SCI SPEC, V21, P15; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; DEBOER CJ, 1995, ONCOGENE, V10, P1833; Elias B, 2005, ONCOGENE, V24, P2574, DOI 10.1038/sj.onc.1208488; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; FERBABDEZ V, 2005, J CLIN ONCOL, V23, P6364; Fukuda T, 2005, GENES CELLS, V10, P655, DOI 10.1111/j.1365-2443.2005.00866.x; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIMBY E, 2005, ANN ONC 9 INT C M S5, V16, pV168; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; LARDELLI P, 1990, AM J SURG PATHOL, V14, P752, DOI 10.1097/00000478-199008000-00007; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Martin SA, 2005, CANCER RES, V65, P10657, DOI 10.1158/0008-5472.CAN-05-2087; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Nozoe T, 2005, J CANCER RES CLIN, V131, P179, DOI 10.1007/s00432-004-0607-2; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365-2141.2005.05630.x; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Swerdlow SH, 2002, HUM PATHOL, V33, P7, DOI 10.1053/hupa.2002.30221; Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226; Tiemann M, 2005, BRIT J HAEMATOL, V131, P29, DOI 10.1111/j.1365-2141.2005.05716.x; Witzig TE, 2005, J CLIN ONCOL, V23, P6409, DOI 10.1200/JCO.2005.55.017; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; ZUCCA E, 1995, ANN ONCOL, V6, P257, DOI 10.1093/oxfordjournals.annonc.a059155	36	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5635	5642		10.1038/sj.onc.1210350	http://dx.doi.org/10.1038/sj.onc.1210350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369860				2022-12-17	WOS:000248801900009
J	Saito, H; Yoshida, T; Yamazaki, H; Suzuki, N				Saito, H.; Yoshida, T.; Yamazaki, H.; Suzuki, N.			Conditional N-rasG12V expression promotes manifestations of neuro. bromatosis in a mouse model	ONCOGENE			English	Article						neurofibromatosis type 1; neurofibromatosis type 2; N-Ras	SUPPRESSOR GENE-PRODUCT; NEUROFIBROMATOSIS; RAS; INHIBITION; MERLIN; DEFICIENCY; PROTEIN; GROWTH; NF1; P53	Human clinical neurofibromatosis type 1 (NF1) and type 2 (NF2) result from mutations and inactivation of neurofibromin and merlin genes, respectively, which negatively regulate Ras pathways. To evaluate the contribution of N-Ras activity to the development of NF, we generated a novel transgenic mouse expressing oncogenic N-ras specifically in central nerve cells, neural crest-derived cells and lens epithelial cells. Soon after birth, the mouse skin showed hyperpigmentation of the epidermis and melanin-laden macrophages in the dermis, as observed in the cafe-au-lait spots of human cases. At 3 months of age, all the mice had neurofibromas in the skin and neurofibroma-like tumors with structure similar to Wagner Meissner bodies in the adrenal medulla. At 4 months of age, all the mice developed subcapsular cataract. In the 5th month, some developed protruding dermal neurofibromas involving subcutaneous fat. However, plexiform neurofibroma, schwannoma, astrocytoma and pheochromocytoma were not observed in the mice, suggesting a requirement for signal(s) other than the activated N-Ras pathway to induce these tumors. Thus, the activated N-Ras signal may be a main pathway for the development of the disease phenotypes characteristic of NF.	Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, Tsu, Mie 5148507, Japan; Mie Univ, Grad Sch Med, Dept Pathol & Matrix Biol, Tsu, Mie 514, Japan; Mie Univ, Grad Sch Med, Dept Physiol & Regenerat Med, Tsu, Mie 514, Japan	Mie University; Mie University; Mie University	Suzuki, N (corresponding author), Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	nsuzuki@doc.medic.mie-u.ac.jp	Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217				Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Buchanan J.M., 1990, CONST POLITICAL ECON, V1, P1, DOI DOI 10.1007/BF02393031; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; ENZINGER FM, 1988, SOFT TISSUE TUMOR, P852; Evans DGR, 2000, J MED GENET, V37, P897, DOI 10.1136/jmg.37.12.897; Giovannini M, 2000, GENE DEV, V14, P1617; HOGAN B, 1994, MANIPULATING MOUSE E; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Kunisada T, 2000, MECH DEVELOP, V94, P67, DOI 10.1016/S0925-4773(00)00308-7; Lakkis MM, 1999, DEV BIOL, V212, P80, DOI 10.1006/dbio.1999.9327; Lim JY, 2003, BIOCHEM BIOPH RES CO, V302, P238, DOI 10.1016/S0006-291X(03)00124-4; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mattingly RR, 2006, J PHARMACOL EXP THER, V316, P456, DOI 10.1124/jpet.105.091454; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; North K, 2000, AM J MED GENET, V97, P119, DOI 10.1002/1096-8628(200022)97:2<119::AID-AJMG3>3.0.CO;2-3; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; Saito H, 2005, BIOCHEM BIOPH RES CO, V331, P1216, DOI 10.1016/j.bbrc.2005.04.043; SATO N, 1992, J CELL SCI, V103, P131; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Tsumura H, 2006, ONCOGENE, V25, P7673, DOI 10.1038/sj.onc.1209749; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452	26	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4714	4719		10.1038/sj.onc.1210250	http://dx.doi.org/10.1038/sj.onc.1210250			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17237809				2022-12-17	WOS:000248037900011
J	Roche, KC; Rocha, S; Bracken, CP; Perkins, ND				Roche, K. C.; Rocha, S.; Bracken, C. P.; Perkins, N. D.			Regulation of ATR-dependent pathways by the FHA domain containing protein SNIP1	ONCOGENE			English	Article						p53; NF-kappa B; ARF; checkpoint kinases; DNA damage	NF-KAPPA-B; ARF TUMOR-SUPPRESSOR; DNA-DAMAGE; PHOSPHORYLATION EVENTS; CELL-CYCLE; P53; EXPRESSION; BINDING; CHK1; ACTIVATION	The forkhead associated (FHA) domain-containing protein Smad nuclear interacting protein 1 (SNIP1) has multiple cellular functions, including the ability to interact with DNA-binding transcription factors and transcriptional coactivators. Moreover, we have demonstrated previously that SNIP1 regulates cyclin D1 expression and promoter activity. Here, we identify a new function for SNIP1 as a regulator of ATR checkpoint kinase-dependent pathways in human U-2 OS osteosarcoma cells: SNIP1 is required for p53 induction in response to ultraviolet light treatment and selectively regulates the phosphorylation of known ATR target proteins, including p53, Chk1 and the histone variant H2AX. These activities are independent of its ability to regulate cyclin D1 expression. Significantly, SNIP1 is also required for ATR-dependent functions of the human p14(ARF) tumour suppressor, including its ability to modulate the activity of the RelA(p65) NF-kappa B subunit. This, together with its other described functions, suggests that SNIP1 could have an important role during tumorigenesis and cancer therapy.	Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; Univ Galway, Dept Biochem, Genome Stabil Lab, Galway, Ireland	University of Dundee; Ollscoil na Gaillimhe-University of Galway	Perkins, ND (corresponding author), Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, MSI WTB JBC Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk		Rocha, Sonia/0000-0002-2413-4981; Bracken, Cameron/0000-0001-7722-625X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Jowsey PA, 2004, J BIOL CHEM, V279, P55562, DOI 10.1074/jbc.M411021200; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Kim RH, 2000, GENE DEV, V14, P1605; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Lin WC, 2001, GENE DEV, V15, P1833; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Roche KC, 2004, ONCOGENE, V23, P8185, DOI 10.1038/sj.onc.1208025; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100	25	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4523	4530		10.1038/sj.onc.1210233	http://dx.doi.org/10.1038/sj.onc.1210233			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260016				2022-12-17	WOS:000247836100006
J	Reiter, F; Hartl, M; Karagiannidis, AI; Bister, K				Reiter, F.; Hartl, M.; Karagiannidis, A. I.; Bister, K.			WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential	ONCOGENE			English	Article						cell transformation; gene expression; C/EBP; Pmel17; GPNMB	DOXYCYCLINE-CONTROLLED EXPRESSION; CONDITIONAL CELL-TRANSFORMATION; C-MYC; V-MYC; C/EBP-ALPHA; ACTIVATION; JUN; DNA; ONCOPROTEIN; METASTASIS	We have isolated a gene (WS5) that is specifically expressed at the mRNA and protein level in avian fibroblasts transformed by the v-myc oncogene of avian acute leukemia virus MC29. In a conditional cell transformation system, WS5 gene expression was tightly correlated with v-myc activation. The WS5 gene contains 11 exons, encoding a 733-amino acid protein with a transmembrane region and a polycystic kidney disease (PKD) domain. Near the transcriptional start site, the WS5 promoter contains a cluster of four binding sites for the Myc-Max complex and a binding site for transcription factor C/EBP alpha. Electrophoretic mobility shift assays and chromatin immunoprecipitation showed that Myc, Max and C/EBP alpha bind specifically to these sites. Functional promoter analyses revealed that both the Myc-binding site cluster and the C/EBP alpha-binding site are essential for strong transcriptional activation, and that Myc and C/EBP alpha synergistically activate the WS5 promoter. Ectopic expression of WS5 led to cell transformation documented by anchorage-independent growth. The human melanoma antigen Pmel17, a type I transmembrane glycoprotein, is the mammalian protein with the highest amino acid sequence identity (38%) to WS5. The Pmel17 gene is regulated by the MITF protein, a bHLHZip transcription factor with DNA binding specificities similar to those of Myc/Max. WS5 is also related to human glycoprotein GPNMB expressed in metastatic melanoma cells and implicated in the progression of brain and liver tumors.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria; Univ Innsbruck, Ctr Mol Biosci Innsbruck, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Bister, K (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	klaus.bister@uibk.ac.at	Hartl, Markus/O-4655-2014; Bister, Klaus/AFA-9400-2022	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653	Austrian Science Fund FWF [P 18148, P 17041] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Clark LA, 2006, P NATL ACAD SCI USA, V103, P1376, DOI 10.1073/pnas.0506940103; Dang CV, 1999, MOL CELL BIOL, V19, P1; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Grabe Niels, 2002, In Silico Biology, V2, pS1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hartl M, 2006, ONCOGENE, V25, P4043, DOI 10.1038/sj.onc.1209441; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; Hartl M, 2003, J MOL BIOL, V333, P33, DOI 10.1016/j.jmb.2003.08.018; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Jing H, 2002, STRUCTURE, V10, P1453, DOI 10.1016/S0969-2126(02)00840-7; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Liu YN, 2004, ONCOGENE, V23, P278, DOI 10.1038/sj.onc.1207022; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8; Theos AC, 2005, PIGM CELL RES, V18, P322, DOI 10.1111/j.1600-0749.2005.00269.x; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102	47	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1769	1779		10.1038/sj.onc.1209975	http://dx.doi.org/10.1038/sj.onc.1209975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964280				2022-12-17	WOS:000244955600011
J	Leong, CTC; Ong, CK; Tay, SK; Huynh, H				Leong, C. T. C.; Ong, C. K.; Tay, S. K.; Huynh, H.			Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro	ONCOGENE			English	Article						HuUO-44; CUB; zona pellucida; cisplatin; RNAi and ovarian cancer	GENE-EXPRESSION; APOPTOSIS; INHIBITION; PACLITAXEL; PROTEIN; LINES; RESISTANCE; THERAPY; UTERUS; GROWTH	Ovarian cancer is currently the second leading cause of gynecological malignancy and cisplatin or cisplatin-based regimens have been the standard of care for the treatment of advance epithelial ovarian cancers. However, the efficacy of cisplatin treatment is often limited by the development of drug resistance either through the inhibition of apoptotic genes or activation of antiapoptotic genes. We have previously reported the overexpression of human UO-44 (HuUO-44) in ovarian cancers and the HuUO-44 antisera markedly inhibitedNIH-OVCAR3 ovarian cancer cell attachment and proliferation (Oncogene 23: 5707-5718, 2004). In the present study, we observed through the cancer cell line pro. ling array that the expression of HuUO-44 was suppressed in the ovarian cancer cell line (SKOV-3) after treatment with several chemotherapeutic drugs. Similarly, this suppression in HuUO-44 expression was also correlated to the cisplatin sensitivity in two other ovarian cancer cell lines NIH-OVCAR3 and OV-90 in a dose-dependent manner. To elucidate the function of HuUO-44 in cisplatin chemoresistance in ovarian cancer cell, small interfering RNAs (siRNAs) were employed to mediate HuUO-44 silencing in ovarian cancer cell line, NIH-OVCAR3. HuUO-44 RNA interference (RNAi) resulted in the inhibition of cell growth and proliferation. Importantly, HuUO-44 RNAi significantly increased sensitivity of NIH-OVCAR3 to cytotoxic stress induced by cisplatin (P < 0.01). Strikingly, we have also demonstrated that overexpression of HuUO-44 significantly conferred cisplatin resistance in NIH-OVCAR3 cells (P < 0.05). Taken together, UO-44 is involved in conferring cisplatin resistance; the described HuUO-44-specific siRNA oligonucleotides that can potently silence HuUO-44 gene expression may prove to be valuable pretreatment targets for antitumor therapy or other pathological conditions that involves aberrant HuUO-44 expression.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Natl Univ Singapore, Dept Pharmacol, Singapore 117548, Singapore; Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 0316, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore; Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore.	cmrhth@nccs.com.sg		Ong, Choon Kiat/0000-0001-6402-4288				Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497; Cioca DP, 2003, CANCER GENE THER, V10, P125, DOI 10.1038/sj.cgt.7700544; DEVI GR, 2006, IN PRESS CANC GENE T; Duan ZF, 2004, MOL CANCER THER, V3, P833; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Harborth J, 2001, J CELL SCI, V114, P4557; Huynh H, 2001, ENDOCRINOLOGY, V142, P2985, DOI 10.1210/en.142.7.2985; Imamura T, 2002, J BIOL CHEM, V277, P50725, DOI 10.1074/jbc.M204159200; Judson PL, 1999, CANCER RES, V59, P2425; July LV, 2004, MOL CANCER THER, V3, P223; Kasik JW, 1998, BIOCHEM J, V330, P947; Leong CTC, 2004, ONCOGENE, V23, P5707, DOI 10.1038/sj.onc.1207754; McGuire WP, 2003, BRIT J CANCER, V89, pS3, DOI 10.1038/sj.bjc.6601494; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Muggia FM, 2000, J CLIN ONCOL, V18, P106, DOI 10.1200/JCO.2000.18.1.106; Ryther RCC, 2005, GENE THER, V12, P5, DOI 10.1038/sj.gt.3302356; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tebes SJ, 2005, GYNECOL ONCOL, V99, P736, DOI 10.1016/j.ygyno.2005.08.031; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200	25	14	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					870	880		10.1038/sj.onc.1209836	http://dx.doi.org/10.1038/sj.onc.1209836			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862170				2022-12-17	WOS:000244063800008
J	Raafat, A; Zoltan-Jones, A; Strizzi, L; Bargo, S; Kimura, K; Salomon, D; Callahan, R				Raafat, A.; Zoltan-Jones, A.; Strizzi, L.; Bargo, S.; Kimura, K.; Salomon, D.; Callahan, R.			Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis	ONCOGENE			English	Article						Kit; PDGFR-alpha; Notch4/Int3; Gleevec; phosphorylation; siRNA	GASTROINTESTINAL STROMAL TUMORS; TRUNCATED INT3 GENE; C-KIT; GROWTH-FACTOR; NEOPLASTIC TRANSFORMATION; ENDOTHELIAL-CELLS; BREAST-CANCER; MOUSE MODEL; STEM-CELLS; MAMMARY	Transgenic mice overexpressing Notch4 intracellular domain (Int3) under the control of the whey acidic protein (WAP) or mouse mammary tumor virus-long terminal repeat promoters, develop mammary tumors. Microarray analysis of these tumors revealed high levels of c-Kit expression. Gleevec is a tyrosine kinase inhibitor that targets c-Kit, platelet-derived growth factor receptors (PDGFRs) and c-Abl. This led us to speculate that tyrosine kinase receptor activity might be a driving force in the development of Int3 mammary tumors. WAP-Int3 tumor-bearing mice were treated with continuous release of Gleevec using subcutaneously implanted Alzet pumps. Phoshorylation of c-Kit, PDGFRs and c-Abl is inhibited in Int3 transgenic mammary tumors by Gleevec. Inhibition of these enzymes is associated with a decrease in cell proliferation and angiogenesis, and an induction of apoptosis. To examine the signaling mechanisms underlying Notch4/Int3 tumorigenesis, we employed small interfering RNA (siRNA) to knock down c-Kit, PDGFRs and c-Abl alone or in combination and observed the effects on soft agar growth of HC11 cells overexpressing Int3. Only siRNA constructs for c-Kit and/or PDGFR-alpha were able to inhibit HC11-Int3colony formation in soft agar. Our data demonstrate an inhibitory effect of Gleevec on Int3-induced transformation of HC11 cells and mammary tumors and indicate an oncogenic role for c-Kit and PDGFR-alpha tyrosine kinases in the context of Int3 signaling.	NCI, Mammary Biol & Tumorigenesis Lab, Oncogenet Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Callahan, R (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Oncogenet Sect, NIH, 37 Convent Dr,Bldg 37,Rm 1118A, Bethesda, MD 20892 USA.	rc54d@nih.gov						Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Basciani S, 2005, CANCER RES, V65, P1897, DOI 10.1158/0008-5472.CAN-04-2181; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Betsholtz Christer, 2003, Birth Defects Research, V69, P272, DOI 10.1002/bdrc.10030; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Chiaramonte R, 2005, CANCER LETT, V219, P113, DOI 10.1016/j.canlet.2004.07.022; Cortes J, 2004, BLOOD, V104, P2204, DOI 10.1182/blood-2004-04-1335; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Dang TP, 2003, ONCOGENE, V22, P1988, DOI 10.1038/sj.onc.1206230; Das AV, 2004, DEV BIOL, V273, P87, DOI 10.1016/j.ydbio.2004.05.023; De Jong JS, 1998, J PATHOL, V184, P44; Diallo R, 2006, HUM PATHOL, V37, P205, DOI 10.1016/j.humpath.2005.10.015; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kim MK, 2000, APPL IMMUNOHISTO M M, V8, P147, DOI 10.1097/00022744-200006000-00009; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Marley SB, 2005, CLIN SCI, V109, P13, DOI 10.1042/CS20040336; Matsui J, 2004, J BIOL CHEM, V279, P18600, DOI 10.1074/jbc.M311643200; Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9; Pear WS, 2004, CURR OPIN HEMATOL, V11, P426, DOI 10.1097/01.moh.0000143965.90813.70; Raafat A, 2004, ONCOGENE, V23, P9401, DOI 10.1038/sj.onc.1208187; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Taniguchi M, 1999, CANCER RES, V59, P4297; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Tsuda H, 2005, CANCER SCI, V96, P48, DOI 10.1111/j.1349-7006.2005.00009.x; Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458; Ulivi P, 2004, BREAST CANCER RES TR, V83, P33, DOI 10.1023/B:BREA.0000010694.35023.9e; VARVALHO I, 2005, BREAST CANCER RES, V7, pR788; Wang DG, 1999, CANCER RES, V59, P1464; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754	46	14	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					662	672		10.1038/sj.onc.1209823	http://dx.doi.org/10.1038/sj.onc.1209823			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878155				2022-12-17	WOS:000243902200004
J	Chao, OSP; Clement, MV				Chao, O. S. P.; Clement, M-V			Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells	ONCOGENE			English	Article						LNCaP; BAD; BAX; survival; prostate carcinoma; phosphatidylinositol 3-kinase	CANCER CELLS; IN-VITRO; SIGNALING PATHWAY; INDUCED APOPTOSIS; BCL-XL; SURVIVAL; KINASE; OVEREXPRESSION; PHOSPHORYLATION; EXPRESSION	A better understanding of pathways involved in survival of prostate cancer cells is the key to develop effective and target-selective therapies. Presence of serum or epidermal growth factor in the culture medium of LNCaP cells decreases apoptosis induced by the inhibition of phosphatidylinositol 3-kinase with LY294002. However, intracellular pathway(s) involved in this survival signaling are not well defined. Here, we investigated the mechanism(s) involved in serum or epidermal growth factor-mediated inhibition of LY294002-induced death in LNCaP cells. Cell death was assessed by the percentage of cells in sub-G1 phase and caspase 3 activity. Phosphorylation status of BAD, ERK1/2 and RSKs were assessed by Western blot. Specific gene expression knock down of BAD, BAX, RSK1 and RSK2 were performed using siRNA transfections. Our results demonstrate that cell death induced by LY294002 is mediated by translocation of BAD and BAX proteins from the cytosol to the mitochondria. Whereas, epidermal growth factor activates a MAPK/ERK/RSK1 module leading to inactivation of BAD via Ser75 phosphorylation, the presence of serum, on the other hand, induces a nonconducive intracellular environment for mitochondrial translocation of dephosphorylated BAD. Taken together, these results indicate that phosphorylation of BAD or inhibition of its translocation to the mitochondria are critical phosphatidylinositol 3-kinase-independent survival pathways in LNCaP cells.	Natl Univ Singapore, Dept Biochem, Fac Med, Singapore 117597, Singapore; NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore	National University of Singapore; National University of Singapore	Clement, MV (corresponding author), Natl Univ Singapore, Dept Biochem, Fac Med, 8 Med Dr,MD7, Singapore 117597, Singapore.	bchmvc@nus.edu.sg						Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Boldt S, 2004, CURR PHARM DESIGN, V10, P1885, DOI 10.2174/1381612043384420; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Carson JP, 1999, CANCER RES, V59, P1449; Chang FM, 2003, INT J ONCOL, V22, P469; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Eisenmann KM, 2003, CANCER RES, V63, P8330; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Kajiwara T, 1999, INT J UROL, V6, P520, DOI 10.1046/j.1442-2042.1999.00102.x; Kooijman R, 2003, CELL SIGNAL, V15, P1091, DOI 10.1016/S0898-6568(03)00069-X; Lebedeva I, 2000, CANCER RES, V60, P6052; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li XY, 2001, CANCER RES, V61, P1699; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Lyons-Darden T, 2004, J MOL ENDOCRINOL, V33, P165, DOI 10.1677/jme.0.0330165; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; RAFFO AJ, 1995, CANCER RES, V55, P4438; Sato S, 2004, J BIOL CHEM, V279, P33759, DOI 10.1074/jbc.M402055200; Shahbazi M, 2002, LANCET, V359, P397, DOI 10.1016/S0140-6736(02)07600-6; Shi XB, 2001, CANCER BIOTHER RADIO, V16, P421, DOI 10.1089/108497801753354320; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; Yang CC, 2003, J BIOL CHEM, V278, P25872, DOI 10.1074/jbc.M301744200; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhang M, 2005, PROSTATE, V64, P293, DOI 10.1002/pros.20263	37	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4458	4469		10.1038/sj.onc.1209421	http://dx.doi.org/10.1038/sj.onc.1209421			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16767165				2022-12-17	WOS:000239326000009
J	Shih, WL; Yu, MW; Chen, PJ; Yeh, SH; Lo, MT; Chang, HC; Liaw, YF; Lin, SM; Liu, CJ; Lee, SD; Lin, CL; Hsiao, CK; Yang, SY; Chen, CJ				Shih, W-L; Yu, M-W; Chen, P-J; Yeh, S-H; Lo, M-T; Chang, H-C; Liaw, Y-F; Lin, S-M; Liu, C-J; Lee, S-D; Lin, C-L; Hsiao, C. K.; Yang, S-Y; Chen, C-J			Localization of a susceptibility locus for hepatocellular carcinoma to chromosome 4q in a hepatitis B hyperendemic area	ONCOGENE			English	Article						chromosome 4q; family-based association analysis; hepatocellular carcinoma; linkage analysis; microsatellite markers; single-nucleotide polymorphism	SEGREGATION ANALYSIS; LINKAGE ANALYSIS; ASSOCIATION; HEPATOCARCINOGENESIS; DISEQUILIBRIUM; ALLELOTYPE; PATHWAYS; VIRUS	Chromosome 4q is one of the most common regions with a high frequency of allelic loss in hepatocellular carcinoma (HCC). To identify the HCC-susceptibility locus on chromosome 4q, we have performed linkage and family-based association analyses on Chinese families with HCC from Taiwan, where hepatitis B is hyperendemic. Using 77 microsatellite markers spanning chromosome 4q on 52 multiplex families, we found suggestive evidence of linkage to 4q22.3 - 28.1 with a maximum two-point heterogeneity LOD (HLOD) score of 2.55 at marker D4S3240 on chromosome 4q25. Multipoint analyses with microsatellite markers in the region 4q22.3 - 28.1 resulted in a maximum HLOD score of 3.12 and a maximum nonparametric linkage (NPL) Z score of 1.98 (pointwise P = 0.0080; region-wide empirical P = 0.021) for D4S3240. The evidence for linkage to D4S3240 was seen mostly in a subset of 28 families lacking affected parents, which showed multipoint HLOD and NPL scores of 3.25 and 2.79 (pointwise P = 0.0028; region-wide empirical P = 0.008), respectively. Family-based association analyses of the 77 microsatellite markers in 191 families ( 53 multiplex plus 138 singleton families) using the pedigree disequilibrium test provide further support for observed linkage. Additional genotyping in the 52 multiplex families informative for linkage analyses was performed for 29 single-nucleotide polymorphisms around D4S3240. A common haplotype (at markers rs7442180 and rs221330) positioned similar to 873 kb away from D4S3240 was associated with HCC, with P = 0.0074.	Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan; Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei, Taiwan; Chang Gung Univ, Chang Gung Mem Hosp, Liver Res Unit, Taoyuan, Taiwan; Natl Yang Ming Univ, Dept Med, Vet Gen Hosp, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; Taipei Municipal Jen Ai Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; Shin Kong Wu Ho Su Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Yu, MW (corresponding author), Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, 1 Jen Ai Rd,Sec 1,Rm 1550, Taipei 100, Taiwan.	mingwhei@ha.mc.ntu.edu.tw	Liaw, Yun-Fan/B-4305-2009; Chen, Chien-Jen/C-6976-2008; Chen, Chien-Jen/N-4723-2019	Chen, Pei-Jer/0000-0001-8316-3785; LIU, CHUN-JEN/0000-0002-6202-0993; /0000-0003-4509-180X; SHIH, WEI-LIANG/0000-0002-4160-7541; hsiao, chuhsing kate/0000-0003-4905-8484; Yu, Ming-Whei/0000-0002-8371-6236				Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; Befeler AS, 2002, GASTROENTEROLOGY, V122, P1609, DOI 10.1053/gast.2002.33411; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cai RL, 2003, WORLD J GASTROENTERO, V9, P2428; Chen CJ, 2002, HEPATOLOGY, V36, P1046, DOI 10.1053/jhep.2002.37084; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Kong X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; MITRA AB, 1994, CANCER RES, V54, P4481; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; OTT J, 1986, GENET EPIDEMIOL, P251; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.0.CO;2-U; Roeder K, 2005, GENET EPIDEMIOL, V28, P207, DOI 10.1002/gepi.20050; SHEN FM, 1991, AM J HUM GENET, V49, P88; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Wands JR, 2004, NEW ENGL J MED, V351, P1567, DOI 10.1056/NEJMe048237; Wang XL, 1999, ONCOGENE, V18, P823, DOI 10.1038/sj.onc.1202318; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; YU MW, 1994, CRIT REV ONCOL HEMAT, V17, P71, DOI 10.1016/1040-8428(94)90020-5; Yu MW, 2000, J NATL CANCER I, V92, P1159, DOI 10.1093/jnci/92.14.1159	30	14	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3219	3224		10.1038/sj.onc.1209345	http://dx.doi.org/10.1038/sj.onc.1209345			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407824	Green Published			2022-12-17	WOS:000237951000013
J	Thornton, JK; Dalgleish, C; Venables, JP; Sergeant, KA; Ehrmann, IE; Lu, X; Saunders, PTK; Elliott, DJ				Thornton, J. K.; Dalgleish, C.; Venables, J. P.; Sergeant, K. A.; Ehrmann, I. E.; Lu, X.; Saunders, P. T. K.; Elliott, D. J.			The tumour-suppressor protein ASPP1 is nuclear in human germ cells and can modulate ratios of CD44 exon V5 spliced isoforms in vivo	ONCOGENE			English	Article						spermatogenesis; gene expression; tumour suppressor	MESSENGER-RNA EXPRESSION; KH-DOMAIN; FUNCTIONAL INTERACTION; CYCLE PROGRESSION; SAM68; P53; FAMILY; GENE; INTERACTS; MEMBERS	The ASPP1 (Apoptosis Stimulating Protein of p53) protein is an important tumour-suppressor. We have detected a novel protein interaction between the human ASPP1 (hASPP1) protein and the predominantly nuclear adaptor protein SAM68. In the human testis, full-length endogenous hASPP1 protein is located in the nucleus like SAM68, predominantly within meiotic and postmeiotic cells. Mouse ASPP1 (mASPP1) protein is mainly expressed in the brain and testis. The interaction with nuclear SAM68 is likely to be restricted to human germ cells, since endogenous mASPP1 protein is exclusively cytoplasmic. The C-terminal region of hASPP1 efficiently targeted a fused GFP molecule to the nucleus, whereas the N-terminus of hASPP1 targeted GFP to the cytoplasm. In the context of the full-length molecule this cytoplasmic targeting sequence is dominant in HEK293 and Saos-2 cells, since full-length hASPP1-GFP is almost exclusively cytoplasmic. Despite its predominantly cytoplasmic location, we show that ASPP1-GFP expression in HEK293 cells can regulate the ratio of alternative spliced isoforms derived from a pre-mRNA regulated downstream of cytoplasmic signalling pathways, and our data suggest that ASPP1 may operate in this case downstream or parallel to RAS signalling pathways.	Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; UCL, Ludwig Inst Canc Res, London, England; MRC, Ctr Reprod Biol, Human Reprod Sci Unit, Edinburgh, Midlothian, Scotland	Newcastle University - UK; Ludwig Institute for Cancer Research; University of London; University College London	Elliott, DJ (corresponding author), Newcastle Univ, Inst Human Genet, Int Ctr Life, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	david.elliott@ncl.ac.uk	Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380; Lu, Xin/0000-0002-6587-1152; Elliott, David/0000-0002-6930-0699	MRC [MC_U127685844, MC_U127685841] Funding Source: UKRI; Medical Research Council [MC_U127685841, MC_U127661055, U.1276.00.002(61055), MC_U127685844] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Elliott DJ, 2000, P NATL ACAD SCI USA, V97, P5717, DOI 10.1073/pnas.97.11.5717; Elliott DJ, 2000, HUM MOL GENET, V9, P2117, DOI 10.1093/hmg/9.14.2117; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Harlow ED., 1999, USING ANTIBODIES; Hong W, 2002, MOL CANCER RES, V1, P48; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Liu ZJ, 2004, LEUKEMIA, V18, P880, DOI 10.1038/sj.leu.2403300; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Paronetto MP, 2003, ONCOGENE, V22, P8707, DOI 10.1038/sj.onc.1207016; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Reddy TR, 2002, J BIOL CHEM, V277, P5778, DOI 10.1074/jbc.M106836200; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sjoblom T, 1996, ONCOGENE, V12, P2499; Slee EA, 2004, ONCOGENE, V23, P9007, DOI 10.1038/sj.onc.1208088; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 2002, HUM MOL GENET, V11, P2409, DOI 10.1093/hmg/11.20.2409; Takahashi N, 2004, BIOCHEM BIOPH RES CO, V315, P434, DOI 10.1016/j.bbrc.2004.01.079; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Yang HP, 2002, ONCOGENE, V21, P7187, DOI 10.1038/sj.onc.1205759; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhang XW, 2005, LEUKEMIA RES, V29, P179, DOI 10.1016/j.leukres.2004.07.001	38	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3104	3112		10.1038/sj.onc.1209341	http://dx.doi.org/10.1038/sj.onc.1209341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16474851				2022-12-17	WOS:000237951000002
J	Bose, S; Morgan, LJ; Booth, DR; Goudie, DR; Ferguson-Smith, MA; Richards, FM				Bose, S; Morgan, LJ; Booth, DR; Goudie, DR; Ferguson-Smith, MA; Richards, FM			The elusive multiple self-healing squamous epithelioma (MSSE) gene: further mapping, analysis of candidates, and loss of heterozygosity	ONCOGENE			English	Article						skin cancer; tumour suppressor gene; chromosome 9q22.3; CDC14B; MSSE	ANEMIA GROUP-C; CELL CARCINOMA; HUMAN GENOME; CHROMOSOMAL LOCALIZATION; HUMAN HOMOLOG; HUMAN CDNA; REGION; 9Q22.3; CANCER; MAPS	The MSSE gene predisposes to multiple invasive but self-healing skin tumours ( multiple self-healing epitheliomata). MSSE was previously mapped to chromosome 9q22-q31 and a shared haplotype in affected families suggested a founder mutation. We have refined the MSSE critical region (< 1 cM, < 1 Mb) between the zinc-finger gene ZNF169 and the Fanconi anaemia gene FANCC. By genetic mapping we have excluded ZNF169 and FANCC as well as PTCH (PATCHED) and TGFBR1 ( transforming growth factor beta receptor type-1) genes. The CDC14B cell cycle phosphatase gene also lies in the region but screening of the complete coding region revealed no mutation in MSSE patients. Somatic cell hybrids created by haploid conversion of an MSSE patient's cells enabled screening of the MSSE chromosome 9 and showed no CDC14B deletion or mutation that abrogates CDC14B mRNA expression. Thus, CDC14B is unlikely to be the MSSE gene. We also report the first molecular analysis of MSSE tumours showing loss of heterozygosity of the MSSE region, with loss of the normal allele, providing the first evidence that MSSE is a tumour suppressor gene.	Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham, W Midlands, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Ninewells Hosp & Med Sch, Dept Pathol, Dundee, Scotland; Univ Cambridge, Dept Vet Clin Med, Cambridge, England	University of Birmingham; University of Cambridge; University of Dundee; University of Cambridge	Richards, FM (corresponding author), Univ Birmingham, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	fran.richards@daniolabs.com		Booth, Daniel/0000-0001-6231-5911				Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Byrom J, 2004, INT J ONCOL, V24, P1271; Chadwick BP, 1998, GENOMICS, V47, P58, DOI 10.1006/geno.1997.5084; Chadwick BP, 1997, GENOMICS, V41, P390, DOI 10.1006/geno.1997.4692; Chatterjee TK, 1997, GENOMICS, V45, P429, DOI 10.1006/geno.1997.4929; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P250, DOI 10.1159/000134349; Eichler EE, 2004, NAT REV GENET, V5, P345, DOI 10.1038/nrg1322; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gong YQ, 1999, AM J HUM GENET, V64, P570, DOI 10.1086/302249; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; Jorgenson E, 2005, AM J HUM GENET, V76, P276, DOI 10.1086/427926; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kong X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405; Levanat S, 1997, CYTOGENET CELL GENET, V76, P208, DOI 10.1159/000134551; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Martignetti JA, 2000, GENE CHROMOSOME CANC, V27, P191, DOI 10.1002/(SICI)1098-2264(200002)27:2<191::AID-GCC11>3.0.CO;2-L; Nishiu J, 1998, GENOMICS, V52, P378, DOI 10.1006/geno.1998.5455; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Richards FM, 1997, HUM GENET, V101, P317, DOI 10.1007/s004390050635; Savoia A, 1996, MOL CELL PROBE, V10, P213, DOI 10.1006/mcpr.1996.0029; SLAUGENHAUPT SA, 1995, GENOMICS, V25, P730, DOI 10.1016/0888-7543(95)80019-I; Suzuki M, 1999, J HUM GENET, V44, P300, DOI 10.1007/s100380050164; WICKING C, 1995, CYTOGENET CELL GENET, V68, P119, DOI 10.1159/000133904; Zaphiropoulos PG, 1996, DNA CELL BIOL, V15, P1049, DOI 10.1089/dna.1996.15.1049; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	31	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					806	812		10.1038/sj.onc.1209092	http://dx.doi.org/10.1038/sj.onc.1209092			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16170343				2022-12-17	WOS:000235068800015
J	Quaranta, MT; Spinello, I; Testa, U; Mariani, G; Diverio, D; Foa, R; Peschle, C; Labbaye, C				Quaranta, MT; Spinello, I; Testa, U; Mariani, G; Diverio, D; Foa, R; Peschle, C; Labbaye, C			PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells	ONCOGENE			English	Article						PLZF; VLA-4; mobilization; acute myeloid leukemia	ZINC-FINGER; HEMATOPOIETIC PROGENITORS; STEM-CELLS; PROTEIN; MOBILIZATION; DIFFERENTIATION; GENE; PROLIFERATION; FIBRONECTIN; INTERACTS	The promyelocytic leukemia zinc-finger protein (PLZF) is a transcriptional repressor. To investigate the role of PLZF in the regulation of cytoadhesion molecules involved in the mobilization of hemopoietic cells, we have analysed PLZF and very late antigen 4 ( VLA-4) expression in normal and leukemic cells. In hematopoiesis, we found a negative correlation between PLZF and VLA4 expression, except for the megakaryocytic lineage. In contrast, we observed a positive correlation between PLZF and VLA-4 expression in a panel of acute myeloid leukemia (AML) samples. In K562 cells expressing PLZF (K562-PLZF), we found that the expression of VLA-4 and c-kit was downmodulated. We have investigated the possibility for VLA-4 or the c-kit receptor to be direct target genes of PLZF in K562-PLZF cells and identified a PLZF DNA-binding site within the VLA-4 promoter. Furthermore, decrease in VLA-4 expression was associated with loss of adhesion on. bronectin-coated plates, which promotes drug-induced apoptosis of K562-PLZF cells. Our findings indicate that VLA-4 is a potential target gene of PLZF. However, in primary AMLs the control of PLZF on VLA-4 expression is lost. Altogether, we suggest that VLA-4 modulation by PLZF may represent an important step in the control of normal and leukemic cell mobilization.	Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy	Istituto Superiore di Sanita (ISS); Sapienza University Rome	Labbaye, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	clabbaye@iss.it	Testa, Ugo/J-6472-2016; Quaranta, Maria Teresa/AAC-2134-2019; SPINELLO, ISABELLA/J-8779-2016; Labbaye, Catherine/J-9930-2016	Testa, Ugo/0000-0001-7900-8942; Quaranta, Maria Teresa/0000-0002-5886-507X; Labbaye, Catherine/0000-0003-1255-4396				Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chauchereau A, 2004, ONCOGENE, V23, P8777, DOI 10.1038/sj.onc.1208128; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Craddock CF, 1997, BLOOD, V90, P4779, DOI 10.1182/blood.V90.12.4779.4779_4779_4788; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gazitt Y, 2004, STEM CELLS, V22, P65, DOI 10.1634/stemcells.22-1-65; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; GUERRIERO R, 1995, BLOOD, V86, P3725, DOI 10.1182/blood.V86.10.3725.bloodjournal86103725; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Labbaye C, 1999, ONCOGENE, V18, P3529, DOI 10.1038/sj.onc.1202682; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mossuz P, 1997, BRIT J HAEMATOL, V98, P819, DOI 10.1046/j.1365-2141.1997.3013118.x; Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; Seftor REB, 1998, AM J PATHOL, V153, P1347, DOI 10.1016/S0002-9440(10)65719-7; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Yuan Q, 1997, J EXP MED, V186, P313, DOI 10.1084/jem.186.2.313	31	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					399	408		10.1038/sj.onc.1209060	http://dx.doi.org/10.1038/sj.onc.1209060			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16158049				2022-12-17	WOS:000234714100008
J	Wei, JS; Whiteford, CC; Cenacchi, N; Son, CG; Khan, J				Wei, JS; Whiteford, CC; Cenacchi, N; Son, CG; Khan, J			BBC3 mediates fenretinide-induced cell death in neuroblastoma	ONCOGENE			English	Article						fenretinide (4-HPR); apoptosis; microarray; BBC3; neuroblastoma; N-[4-hydroxyphenyl]retinamide; PUMA	INDUCED APOPTOSIS; BH3-ONLY PROTEINS; GENE-EXPRESSION; RETINOIC-ACID; IN-VITRO; LINES; INDUCTION; DIFFERENTIATION; SENSITIVITY; GADD153	Fenretinide (4-HPR) is a synthetic retinoid whose apoptosis-inducing effects have been demonstrated in many tumor types. The precise mechanism of its apoptotic action is not fully understood. To further study the mechanism by which 4-HPR exerts its biological effects in neuroblastoma ( NB) and to identify the genes that contribute to the induction of apoptosis, we determined the sensitivity of eight NB cell lines to 4-HPR. Additionally, cDNA microarray analysis was performed on a 4-HPR-sensitive cell line to investigate the temporal changes in gene expression, primarily focusing on the induction of proapoptotic genes. BBC3, a transcriptionally regulated proapoptotic member of the BCL2 family, was the most highly induced proapoptotic gene. Western analysis confirmed the induction of BBC3 protein by 4-HPR. Furthermore, the induction of BBC3 was associated with the sensitivity to this agent in the cell lines tested. Finally we demonstrated that BBC3 alone is sufficient to induce cell death in the 4-HPR-sensitive and resistant NB cell lines, and that siRNA against BBC3 significantly decreases apoptosis induced by 4-HPR. Our results indicate that BBC3 mediates cell death in NB cells in response to 4-HPR.	NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA; Daejeon Univ, Coll Oriental Med, Dept Internal Med, Taejon, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Daejeon University	Khan, J (corresponding author), NCI, Pediat Oncol Branch, 8717 Grovemont Circle, Bethesda, MD 20892 USA.	khanjav@mail.nih.gov	Khan, Javed/P-9157-2014; son, chang gue/ABC-2215-2021		NCI NIH HHS [Z01 BC010594-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010594, ZIABC010594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; Bouillet P, 2002, J CELL SCI, V115, P1567; Brodeur Garrett M., 1997, P761; Chen Y., 1997, BIOMED OPTICS, V2, P364; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ferrari N, 2003, ONCOL REP, V10, P973; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hsieh TC, 1995, BIOCHEM MOL BIOL INT, V37, P499; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; LOTAN R, 1990, METHOD ENZYMOL, V190, P100; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Lovat PE, 2003, CANCER LETT, V197, P157, DOI 10.1016/S0304-3835(03)00098-3; Lovat PE, 2003, CANCER RES, V63, P7310; Lovat PE, 2002, CANCER RES, V62, P5158; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; Myatt SS, 2005, CLIN CANCER RES, V11, P3136, DOI 10.1158/1078-0432.CCR-04-2050; Pahlman S, 2000, NEUROBLASTOMA, P9; Pearson ADJ, 2000, NEUROBLASTOMA, P551; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; PONZONI M, 1995, CANCER RES, V55, P853; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reynolds CP, 2000, MED PEDIATR ONCOL, V35, P597, DOI 10.1002/1096-911X(20001201)35:6<597::AID-MPO23>3.0.CO;2-B; ROSS RA, 1983, J NATL CANCER I, V71, P741; SLAWIN K, 1993, CANCER RES, V53, P4461; Wei J.S., 2002, DNA MICROARRAYS MOL, P110; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZIV Y, 1994, ANTICANCER RES, V14, P2005	33	14	14	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7976	7983		10.1038/sj.onc.1208947	http://dx.doi.org/10.1038/sj.onc.1208947			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16091745	Green Accepted			2022-12-17	WOS:000233656600004
J	Hut, HMJ; Rembacz, KP; van Waarde, MAWH; Lemstra, W; van Cappellen, WA; Kampinga, HH; Sibon, OCM				Hut, HMJ; Rembacz, KP; van Waarde, MAWH; Lemstra, W; van Cappellen, WA; Kampinga, HH; Sibon, OCM			Dysfunctional BRCA1 is only indirectly linked to multiple centrosomes	ONCOGENE			English	Article						BRCA1; EGFP; BRCA1; BF3; cancer; centrosomes	AMPLIFICATION; INSTABILITY	A remarkable and yet unexplained phenomenon in cancer cells is the presence of multiple centrosomes, organelles required for normal cell division. Previously, it was demonstrated that the tumor suppressor BRCA1 is a component of centrosomes. This observation led to the hypothesis that defective BRCA1 results in malfunctioning centrosomes and faulty centrosomes are a possible cause of cancer. Using EGFP-tagged fusion proteins and BRCA1-/- cells we show that although some BRCA1 antibodies do label centrosomes under certain. xation conditions, BRCA1 is not a centrosomal protein. Therefore, it is unlikely that a mutation in BRCA1 directly alters centrosome structure and function. BRCA1 plays an established role in DNA damage repair and in G(2)/M checkpoint regulation. We present evidence that multiple centrosomes can arise in any cell when G(2)/M checkpoint fails and entrance into mitosis occurs in the presence of DNA damage.	Univ Groningen, Dept Radiat & Stress Cell Biol, UMCG, NL-9713 AV Groningen, Netherlands; Erasmus Univ, Fac Med & Hlth Sci, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	University of Groningen; Erasmus University Rotterdam	Sibon, OCM (corresponding author), Univ Groningen, Dept Radiat & Stress Cell Biol, UMCG, Ant Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	o.c.m.sibon@med.umcg.nl		Kampinga, Harm/0000-0002-8966-8466; Sibon, Ody/0000-0002-6836-6063				BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Fisk HA, 2002, CURR OPIN CELL BIOL, V14, P700, DOI 10.1016/S0955-0674(02)00385-X; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Johannsson OT, 2003, LAB INVEST, V83, P387, DOI 10.1097/01.LAB.0000060030.10652.8C; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	22	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7619	7623		10.1038/sj.onc.1208859	http://dx.doi.org/10.1038/sj.onc.1208859			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16205648				2022-12-17	WOS:000233333800011
J	Nakamura, Y; Yujiri, T; Nawata, R; Tagami, K; Tanizawa, Y				Nakamura, Y; Yujiri, T; Nawata, R; Tagami, K; Tanizawa, Y			MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells	ONCOGENE			English	Article						Bcr-Abl; MEKK1; STAT3; embryonic stem cell	CHRONIC MYELOID-LEUKEMIA; CYTOKINE RECEPTORS; ACTIVATION; SURVIVAL; BINDING; GROWTH; RAC	BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia, arises in a primitive hematopoietic stem cell that has the capacity for both differentiation and self-renewal. Its product, Bcr-Abl protein, has been shown to activate signal transducers and activators of transcription 3 (STAT3) and to promote self-renewal in embryonic stem (ES) cells, even in the absence of leukemia inhibitory factor (LIF). MEK kinase 1 (MEKK1) is a 196-kDa mitogen-activated protein kinase (MAPK) kinase kinase involved in Bcr-Abl signal transduction. To investigate the role of MEKK1 in Bcr-Abl-induced transformation of stem cells, p210 Bcr-Abl was stably transfected into wildtype (WTp210) and MEKK1-/- (MEKK1-/-(p210)) ES cells. Bcr-Abl enhanced MEKK1 expression in ES transfectants, as it does in other Bcr-Abl-transformed cells. In the absence of LIF, WTp210 cells showed constitutive STAT3 activation and formed rounded, compact colonies having strong alkaline phosphatase activity, a characteristic phenotype of undifferentiated ES cells. MEKK1-/-(p210) cells, by contrast, showed less STAT3 activity than WTp210 cells and formed large, flattened colonies having weak alkaline phosphatase activity, a phenotype of differentiated ES cells. These results indicate that MEKK1 plays a key role in Bcr-Abl-induced STAT3 activation and in ES cells' capacity for LIF-independent self-renewal, and may thus be involved in Bcr-Abl-mediated leukemogenesis in stem cells.	Yamaguchi Univ, Grad Sch Med, Dept Bio Signal Anal, Ube, Yamaguchi 7558505, Japan	Yamaguchi University	Yujiri, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Bio Signal Anal, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	yujirit@yamaguchi-u.ac.jp	Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456				Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	18	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7592	7598		10.1038/sj.onc.1208899	http://dx.doi.org/10.1038/sj.onc.1208899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044153				2022-12-17	WOS:000233333800008
J	Xue, LY; Chiu, SM; Oleinick, NL				Xue, LY; Chiu, SM; Oleinick, NL			Differential responses of Mcl-1 in photosensitized epithelial vs lymphoid-derived human cancer cells	ONCOGENE			English	Article						Mcl-1; Bcl-2; apoptosis; photodynamic therapy	THERAPY-INDUCED APOPTOSIS; BCL-2 FAMILY-MEMBERS; PHOTODYNAMIC THERAPY; ENDOPLASMIC-RETICULUM; MEDIATED APOPTOSIS; INDUCED DEATH; CYTOCHROME-C; CLEAVAGE; PROTEIN; STAUROSPORINE	The antiapoptotic Bcl-2-family proteins, Bcl-2 and BclxL, are recognized phototargets of photodynamic therapy (PDT) with the mitochondrion-targeting phthalocyanine photosensitizer Pc 4. In the present study, we found that myeloid cell leukemia 1 (Mcl-1), another antiapoptotic member of the Bcl-2 family, was not photodamaged in Pc 4-PDT-treated human carcinoma cells MCF-7c3, MDA-MB468, DU145, and A431, although Mcl-1 turnover was observed after exposure of HeLa or MCF-7c3 cells to a supralethal dose of UVC. In contrast, when human lymphoma U937 and Jurkat cells were treated with Pc 4-PDT, staurosporine (STS) or UVC, Mcl-1 was cleaved to generate a 28-kDa fragment over a 2 - 4 h period. The cleavage of Mcl-1 was accompanied by the activation of caspases-3, - 9, and - 8. The broad-specificity caspase inhibitor z-VAD-fmk completely blocked Mcl-1 cleavage induced by PDT, STS or UVC, providing evidence for Mcl-1 as a substrate for caspases. Western blot analysis localized Mcl-1 to mitochondria, ER, and cytosol of both MCF-7c3 and U937 cells, suggesting that Mcl-1 protein, unlike Bcl-2 and Bcl-xL, is not a target for Pc 4-PDT, probably due to its localization to sites removed from those of Pc 4 binding. The 28-kDa cleaved fragment of Mcl-1, which has proapoptotic activity, was produced in PDT-treated lymphoid-derived cells, but not in cells of epithelial origin, suggesting that PDT-induced rapid and extensive apoptosis in lymphoma cells may result in part from the sensitivity of their Mcl-1 to caspase cleavage, removing an important negative control on apoptosis.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	nlo@po.cwru.edu			NCI NIH HHS [R01 CA83917, P30 CA43703, P01 CA48735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA083917, P01CA048735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chiu SM, 2001, CANCER LETT, V165, P51, DOI 10.1016/S0304-3835(01)00422-0; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; Kitada S, 2000, BLOOD, V96, P393; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Separovic D, 1998, PHOTOCHEM PHOTOBIOL, V68, P101, DOI 10.1111/j.1751-1097.1998.tb03259.x; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Varela N, 2001, J BIOL CHEM, V276, P17779, DOI 10.1074/jbc.M100815200; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Vrana JA, 2002, CANCER RES, V62, P892; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Xue LY, 2003, ONCOGENE, V22, P9197, DOI 10.1038/sj.onc.1207019; Xue LY, 2003, EXP CELL RES, V283, P135, DOI 10.1016/S0014-4827(02)00032-0; Xue LY, 2001, EXP CELL RES, V263, P145, DOI 10.1006/excr.2000.5108; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	49	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6987	6992		10.1038/sj.onc.1208837	http://dx.doi.org/10.1038/sj.onc.1208837			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007152				2022-12-17	WOS:000232701700014
J	Bjorling-Poulsen, M; Siehler, S; Wiesmuller, L; Meek, D; Niefind, K; Issinger, OG				Bjorling-Poulsen, M; Siehler, S; Wiesmuller, L; Meek, D; Niefind, K; Issinger, OG			The 'regulatory' beta-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation	ONCOGENE			English	Article						Chk2; p53; CK2; protein kinase; phosphorylation	TOPOISOMERASE-II-ALPHA; CELL-CYCLE; MITOTIC PHOSPHORYLATION; SUPPRESSOR PROTEIN; CK2-BETA SUBUNIT; DOCKING-SITE; DNA-BINDING; P53; DOMAIN; CHECKPOINT	The 'regulatory' beta-subunit of protein kinase CK2 has previously been shown to interact with protein kinases such as A-Raf, c-Mos, Lyn and Chk1 in addition to the catalytic subunit of CK2. Sequence alignments suggest that these interactions have a structural basis, and hence other protein kinases harboring corresponding sequences may be potential interaction partners for CK2 beta. We show here that Chk2 specifically interacts with CK2 beta in vitro and in cultured cells, and that activation of Chk2 leads to a reduction of this interaction. Additionally, we show that the presence of the CK2 beta subunit significantly reduces the Chk2-catalysed phosphorylation of p53 in vitro. These findings support the notion that CK2 beta can act as a general modulator of remote docking sites in protein kinase substrate interactions.	Syddansk Univ, Inst Biokem Mol Biol, Odense, Denmark; Univ Ulm, Univ Frauenklin, Ulm, Germany; Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 4HN, Scotland; Univ Cologne, Inst Biochem, D-5000 Cologne, Germany	University of Southern Denmark; Ulm University; University of Dundee; University of Cologne	Issinger, OG (corresponding author), Univ So Denmark, BMB, Campusvej 55, DK-5230 Odense, Denmark.	ogi@bmb.sdu.dk	Niefind, Karsten/F-8726-2019	Niefind, Karsten/0000-0002-0183-6315				Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; APPEL K, 1995, ONCOGENE, V11, P1971; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bell S, 2002, BIOPHYS CHEM, V96, P243, DOI 10.1016/S0301-4622(02)00011-X; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Boehden GS, 2004, CARCINOGENESIS, V25, P1305, DOI 10.1093/carcin/bgh092; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Guerra B, 2003, ONCOGENE, V22, P4933, DOI 10.1038/sj.onc.1206721; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Korn I, 1999, MOL CELL BIOCHEM, V191, P75, DOI 10.1023/A:1006818513560; Kusk M, 1999, MOL CELL BIOCHEM, V191, P51, DOI 10.1023/A:1006840613986; Lehner B, 2004, GENOMICS, V83, P153, DOI 10.1016/S0888-7543(03)00235-0; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; LORENZ P, 1994, CELL MOL BIOL RES, V40, P519; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Prowald A, 1997, FEBS LETT, V408, P99, DOI 10.1016/S0014-5793(97)00399-2; Schuster N, 2001, J CELL BIOCHEM, V81, P172, DOI 10.1002/1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O; Schwindling SL, 2004, ONCOGENE, V23, P4155, DOI 10.1038/sj.onc.1207566; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Theis-Febvre N, 2003, ONCOGENE, V22, P220, DOI 10.1038/sj.onc.1206107; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X	47	14	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6194	6200		10.1038/sj.onc.1208762	http://dx.doi.org/10.1038/sj.onc.1208762			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940255				2022-12-17	WOS:000231718100013
J	Rossetti, S; Van Unen, L; Touw, IP; Hoogeveen, AT; Sacchi, N				Rossetti, S; Van Unen, L; Touw, IP; Hoogeveen, AT; Sacchi, N			Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation	ONCOGENE			English	Article						epigenetic regulation; AML1-MTG16; Csf1r; myelogenesis	STIMULATING FACTOR-RECEPTOR; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LEUKEMIC-CELLS; METHYLATION; AML1; IDENTIFICATION; PROMOTER; FUSION	De novo epigenetic changes at histone and DNA level that affect gene transcription in cancer may be less random than we originally thought. Leukemia fusion proteins associated with specific chromosome translocations could mechanistically determine the epigenetic fate of specific target genes critical for normal hematopoiesis. This seems to be the case with AML1-MTG16, a fusion protein resulting from the t(16;21) translocation, a hallmark of therapy-related leukemia and myelodysplastic syndrome. Here we show that AML1-MTG16 blocks both myeloid differentiation and proliferation in the 32D/WT1-mouse myeloid cell line. These biological effects can be traced to the AML1 and MTG16 moieties of the fusion protein, respectively. Further, we show that AML1-MTG16 can induce epigenetic repressive changes at the histone and DNA level of the AML1 target gene Csf1r (c-fms), encoding the macrophage colony stimulating factor receptor. We observed that, concomitant with Csf1r downregulation, 32D/WT1 cells lost the ability to undergo myeloid differentiation in response to the granulocyte macrophage colony-stimulating factor (GM-CSF). Thus, there seems to be an association between AML1-MTG16-induced myeloid maturation block and epigenetic changes of a myeloid master gene.	Erasmus Med Ctr, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Erasmus Med Ctr, Dept Hematol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Roswell Park Cancer Institute; Erasmus University Rotterdam; Erasmus MC	Hoogeveen, AT (corresponding author), Erasmus Med Ctr, Dept Clin Genet, Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	a.hoogeveen@erasmusmc.nl; nicoletta.sacchi@roswellpark.org						Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; ERICKSON P, 1992, BLOOD, V80, P1825; Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286; FELGNER J, 1991, PATHOBIOLOGY, V59, P293; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoogeveen AT, 2002, ONCOGENE, V21, P6703, DOI 10.1038/sj.onc.1205882; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KOZU T, 1993, BLOOD, V82, P1270; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Rossetti S, 2004, GENOMICS, V84, P1, DOI 10.1016/j.ygeno.2004.02.011; Shi HD, 2003, CANCER RES, V63, P2164; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	27	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5325	5332		10.1038/sj.onc.1208651	http://dx.doi.org/10.1038/sj.onc.1208651			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007222				2022-12-17	WOS:000231158500006
J	Balasubramanian, S; Chandraratna, RAS; Eckert, RL				Balasubramanian, S; Chandraratna, RAS; Eckert, RL			A novel retinoid-related molecule inhibits pancreatic cancer cell proliferation by a retinoid receptor independent mechanism via suppression of cell cycle regulatory protein function and induction of caspase-associated apoptosis	ONCOGENE			English	Article						pancreatic cancer; retinoids; apoptosis; caspases; cell cycle; AGN193198	OVARIAN-CARCINOMA CELLS; ACID RECEPTOR; SELECTIVE RETINOIDS; PROSTATE-CANCER; LEUKEMIA-CELLS; BREAST-CANCER; X-RECEPTOR; SYNTHETIC RETINOIDS; FENRETINIDE 4-HPR; GROWTH-INHIBITION	Retinoid-related molecules are important potential agents for the treatment of cancer. In the present study, we test the effect of a novel retinoid-related ligand, AGN193198 (4-[3-(1-heptyl-4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6- yl)-3-oxo-prophenyl] benzoic acid), on pancreatic cancer cell proliferation and survival. AGN193198 treatment reduces BxPC-3 cell proliferation more efficiently than high-affinity retinoid acid receptor (RAR)- or retinoid X receptor (RXR)- selective retinoids. Moreover, AGN193198 does not activate transcription from RAR or RXR response elements and its effects on cell survival are not reversed by treatment with RAR- or RXR receptor-selective antagonists. These results suggest that the AGN193198-dependent inhibition of BxPC-3 cell function is not mediated via activation of the classical retinoid receptors. Cell cycle analysis of AGN193198-treated BxPC-3 cells indicates that AGN193198 causes accumulation of cells in G2/M. This change is associated with a marked reduction in regulators of S ( cyclin A, cyclin-dependent kinase (cdk) 2), G2/M ( cyclin B1, cdk1, cdc25c) and G1 ( cyclin D1, cyclin E, cdk2, cdk4) phase, and an increase in p21 and p27 level. Kinases assays reveal that cdk1, cdk2 and cdk4 activity are suppressed in AGN193198-treated cells. In addition, reduced cell proliferation is associated with enhanced procaspase ( 3, 8 and 9) and PARP cleavage. Z-VAD-FMK, a pancaspase inhibitor, inhibits AGN193198-dependent caspase activation and attenuates cell death. Z-VAD-FMK inhibits PARP cleavage, but does not alter the AGN193198-dependent reduction in cell cycle regulatory protein expression and activity, suggesting that caspase activation and suppression of cell cycle regulatory protein levels are independent processes. AGN193198 produces similar responses in other pancreatic cancer cell lines including AsPC-1 and MIA PaCa-2. These studies suggest that AGN193198 may be useful for the treatment of pancreatic cancer.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Dept Chem, Irvine, CA 92623 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; AbbVie; Allergan; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Case Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu			NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA134274] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albrechtsson E, 2002, PANCREAS, V25, P49, DOI 10.1097/00006676-200207000-00013; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; ARBUCK SG, 1990, BAILLIERE CLIN GASTR, V4, P953, DOI 10.1016/0950-3528(90)90029-G; Balasubramanian S, 2004, CARCINOGENESIS, V25, P1377, DOI 10.1093/carcin/bgh122; Balasubramanian S, 2002, J BIOL CHEM, V277, P1828, DOI 10.1074/jbc.M110376200; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Benbrook DM, 1998, J MED CHEM, V41, P3753, DOI 10.1021/jm980308p; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Brembeck FH, 1998, BRIT J CANCER, V78, P1288, DOI 10.1038/bjc.1998.673; Brembeck FH, 1998, CANCER, V83, P2317, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2317::AID-CNCR11>3.0.CO;2-P; CHIESA F, 1992, ORAL ONCOL, V28B, P97; Chun KH, 2003, CANCER RES, V63, P3826; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; Dawson MI, 2001, CANCER RES, V61, P4723; Egawa N, 1996, VIRCHOWS ARCH, V429, P59, DOI 10.1007/BF00196822; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Fujimoto K, 1999, INT J CANCER, V81, P637, DOI 10.1002/(SICI)1097-0215(19990517)81:4<637::AID-IJC21>3.0.CO;2-4; Garattini E, 2004, CURR PHARM DESIGN, V10, P433, DOI 10.2174/1381612043453351; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Hammond LA, 2002, ANTI-CANCER DRUG, V13, P781, DOI 10.1097/00001813-200209000-00001; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hsieh TC, 1997, PROSTATE, V33, P97; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; JI BT, 1995, CANCER EPIDEM BIOMAR, V4, P885; Johnson A, 1999, BRIT J DERMATOL, V140, P12; Kaiser A, 1998, GASTROENTEROLOGY, V115, P967, DOI 10.1016/S0016-5085(98)70269-0; Kawa S, 1997, INT J CANCER, V72, P906, DOI 10.1002/(SICI)1097-0215(19970904)72:5<906::AID-IJC31>3.0.CO;2-3; Keedwell RG, 2004, CANCER RES, V64, P3302, DOI 10.1158/0008-5472.CAN-03-2763; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Liu SQ, 2004, J MED CHEM, V47, P999, DOI 10.1021/jm030346v; Lopez-Hernandez FJ, 2004, CELL DEATH DIFFER, V11, P154, DOI 10.1038/sj.cdd.4401329; Lotan R, 2003, J BIOL REG HOMEOS AG, V17, P13; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; McGowan Clare H, 2003, Prog Cell Cycle Res, V5, P1; Nagpal S, 2000, CURR PHARM DESIGN, V6, P919, DOI 10.2174/1381612003400146; Nicoletti VG, 2003, NEUROCHEM RES, V28, P187, DOI 10.1023/A:1022316914492; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Ortiz MA, 2002, DRUG RESIST UPDATE, V5, P162, DOI 10.1016/S1368-7646(02)00050-X; Paik J, 2003, CANCER INVEST, V21, P304, DOI 10.1081/CNV-120016425; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Pettersson F, 2002, BRIT J CANCER, V87, P555, DOI 10.1038/sj.bjc.6600496; Pettersson F, 2001, PANCREAS, V23, P273, DOI 10.1097/00006676-200110000-00008; Pettersson F, 2000, BRIT J CANCER, V83, P239; PIENTA KJ, 1993, CANCER RES, V53, P224; Rosenberg L, 2003, EXPERT OPIN BIOL TH, V3, P319, DOI 10.1517/14712598.3.2.319; Rosenberg L, 2000, DRUGS, V59, P1071, DOI 10.2165/00003495-200059050-00004; Rosewicz S, 1996, ENDOCRINOLOGY, V137, P3340, DOI 10.1210/en.137.8.3340; ROSEWICZ S, 1995, GASTROENTEROLOGY, V109, P1646, DOI 10.1016/0016-5085(95)90655-X; SHAO ZM, 1995, ONCOGENE, V11, P493; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SPRUCE LW, 1991, J MED CHEM, V34, P430, DOI 10.1021/jm00105a065; Standeven AM, 2001, BIOCHEM PHARMACOL, V62, P1501, DOI 10.1016/S0006-2952(01)00803-6; STRICKLAND S, 1983, CANCER RES, V43, P5268; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1999, CLIN CANCER RES, V5, P431; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; TEELMANN K, 1993, CANCER RES, V53, P2319; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Vuligonda V, 2001, J MED CHEM, V44, P2298, DOI 10.1021/jm0100584; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; Zuco V, 2004, CELL DEATH DIFFER, V11, P280, DOI 10.1038/sj.cdd.4401304; Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359-6446(02)02526-6	66	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4257	4270		10.1038/sj.onc.1208586	http://dx.doi.org/10.1038/sj.onc.1208586			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15856029				2022-12-17	WOS:000229815300009
J	Paltoglou, SM; Roberts, BJ				Paltoglou, SM; Roberts, BJ			Role of the von Hippel-Lindau tumour suppressor protein in the regulation of HIF-1 alpha and its oxygen-regulated transactivation domains at high cell density	ONCOGENE			English	Article						HIF-1 alpha; VHL; RCC	HIF-ALPHA; CYTOPLASMIC LOCALIZATION; PROLYL HYDROXYLATION/; HYPOXIA; VHL; NUCLEAR; BINDING; UBIQUITYLATION; TRANSCRIPTION; DESTRUCTION	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) induction and associated transcription were investigated during high cell density, focusing on the negative regulator of HIF-1 alpha expression, the von Hippel-Lindau (VHL) protein. In 293T and HeLa cells, HIF-1 alpha protein levels and associated transcription were induced as cells approached confluence. To determine whether these changes were due to a deficit in nuclear VHL-mediated ubiquitination of HIF-1 alpha at confluence, cells were stably transfected with VHL. Overexpression of VHL in 293T cells had no demonstrable effect on the induction and nuclear accumulation of HIF-1 alpha during high cell density or associated transcription. Moreover, RCC cells stably transfected with full-length VHL failed to exhibit the cell-density-dependent induction of HIF-1 alpha noted in other cell lines. Investigation of both N-terminal and C-terminal (aa 727 826) oxygen-regulated proline and asparagine hydroxylation of HIF-1 alpha revealed that both are inhibited during high cell density, as determined by impaired capture of HIF-1 alpha by VHL and enhanced C-terminal transactivation. Finally, cell-density-mediated induction of HIF-1 alpha and GLUT1 in RCC cells could be completely reconstituted by mutations in VHL binding affinity, suggesting that cell-density dependent induction of HIF-1 alpha and transactivation may underpin some of the deregulated gene expression observed in VHL disease.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au						Bemis L, 2004, GENE DEV, V18, P739, DOI 10.1101/gad.1180104; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P599, DOI 10.1016/S0955-0674(96)80099-8; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Lewis MD, 2004, ONCOGENE, V23, P2315, DOI 10.1038/sj.onc.1207384; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	28	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3830	3835		10.1038/sj.onc.1208531	http://dx.doi.org/10.1038/sj.onc.1208531			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15750626				2022-12-17	WOS:000229346300013
J	Dennler, S; Pendaries, V; Tacheau, C; Costas, MA; Mauviel, A; Verrecchia, F				Dennler, S; Pendaries, V; Tacheau, C; Costas, MA; Mauviel, A; Verrecchia, F			The steroid receptor co-activator-1 (SRC-1) potentiates TGF-beta/Smad signaling: role of p300/CBP	ONCOGENE			English	Article						p300; Smad; SRC-1 TGF-beta	GROWTH-FACTOR-BETA; CREB-BINDING-PROTEIN; BREAST-CANCER; TRANSCRIPTIONAL COACTIVATORS; MEDIATED TRANSACTIVATIONS; PROGESTERONE-RECEPTOR; NUCLEAR RECEPTORS; C-JUN; AIB1; GENE	The three related 160-kDa proteins, SRC-1, TIF-2 and RAC-3, were initially identified as factors interacting with nuclear receptors. They have also been reported to potentiate the activity of other transcription factors such as AP-1 or NF-kappa B. The aim of this work was to identify whether SRC-1 interferes with the TGF-beta/Smad signaling pathway, and if so, to identify its underlying mechanisms of action. Using transient cell transfection experiments performed in human dermal fibroblasts with the Smad3/4-specific (SBE)(4)-lux reporter construct, as well as the human PAI-1 promoter, we determined that SRC-1 enhances TGF-beta-induced, Smad-mediated, transcription. Likewise, SRC-1 overexpression potentiated TGF-beta-induced upregulation of PAI-1 steady-state mRNA levels. Using a mammalian two-hybrid system, we demonstrated that SRC-1 interacts with the transcriptional co-activators p300/CBP, but not with Smad3. Overexpression of the adenovirus E1A oncoprotein, an inhibitor of CBP/p300 activity, prevented the enhancing effect of SRC-1 on Smad3/4-mediated transcription, indicating that p300/CBP may be required for SRC-1 effect. Such hypothesis was validated, as expression of a mutant form of SRC-1 lacking the CBP/p300-binding site failed to upregulate Smad3/4-dependent transcription, while full-length SRC-1 potentiated p300. Smad3 interactions. These results identify SRC-1 as a novel Smad3/4 transcriptional partner, facilitating the functional link between Smad3 and p300/CBP.	Hop St Louis, INSERM, U697, Inst Rech Peau, F-75475 Paris 10, France; Univ Buenos Aires, Dept Cs Biol, Fac Ciencias Exactas & Nat, RA-1053 Buenos Aires, DF, Argentina	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Buenos Aires	Verrecchia, F (corresponding author), Hop St Louis, INSERM, U697, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	franck.verrecchia@stlouis.inserm.fr	Verrecchia, Franck/G-5535-2018; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793; Costas, Monica/0000-0002-4773-3389				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Berns EMJJ, 1998, BREAST CANCER RES TR, V48, P87, DOI 10.1023/A:1005903226483; Bouras T, 2001, CANCER RES, V61, P903; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Cottone E, 2001, INT J BIOL MARKER, V16, P151, DOI 10.1177/172460080101600301; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Glass CK, 2000, GENE DEV, V14, P121; Guan XY, 1996, CANCER RES, V56, P3446; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CANCER SURV, V27, P41; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; ONATE SA, 1995, SCIENCE, V270, P1354; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Powell SM, 2004, ENDOCR-RELAT CANCER, V11, P117, DOI 10.1677/erc.0.0110117; Sakakura C, 2000, INT J CANCER, V89, P217; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	46	14	14	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1936	1945		10.1038/sj.onc.1208343	http://dx.doi.org/10.1038/sj.onc.1208343			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688032	Green Published			2022-12-17	WOS:000227542000012
J	Schmittwolf, C; Porsch, M; Greiner, A; Avots, A; Muller, AM				Schmittwolf, C; Porsch, M; Greiner, A; Avots, A; Muller, AM			HOXB4 confers a constant rate of in vitro proliferation to transduced bone marrow cells	ONCOGENE			English	Article						HOXB4; bone marrow cells; proliferation; differentiation; cell cycle regulation	HEMATOPOIETIC STEM-CELLS; CELLULAR PROLIFERATION; VIVO EXPANSION; EXPRESSION; JUNB; DIFFERENTIATION; OVEREXPRESSION; PROTEINS; DIVISION; MICE	HOXB4 overexpression mediates increased self-renewal of haematopoietic stem cells (HSCs) ex vivo. Since HOXB4-expanded HSCs retain normal differentiation potential and there is no leukaemia development from transduced HSCs, HOXB 4 represents a promising tool for human HSC therapy. However, the increased proliferation capacity of HOXB4 overexpressing fibroblasts resulting from upregulation of JunB, Fra-1 and cyclin D1 protein levels may indicate a potential risk associated with the HOXB4 overexpression approach. This prompted us to investigate the proliferation rate, differentiation and expression of cell cycle regulators directly in bone marrow cultures overexpressing HOXB4. Here we show that in comparison to neo-transduced control bone marrow cultures, HOXB4-overexpressing cultures had a more homogenous morphology and increased numbers of haematopoietic progenitor cells capable to generate primitive colonies in vitro. In contrast, neo-transduced bone marrow cells in long-term cultures showed hallmarks of myeloid differentiation and a reduced secondary colony forming activity. We further show that multilineage repopulating activity in vivo, which was present only in HOXB4 long-term cultures, declined over time. HOXB4 overexpression in vitro did not result in an increase but in a stabilization of the proliferation rate (1.4 - 1.8 cell divisions per day), while the proliferation rate of control neo-transduced bone marrow cultures gradually declined. Correspondingly, increased HOXB4 expression was paralleled by decreased expression levels of cyclins, CDKs and AP-1 family members. These results suggest that the growth rate of HOXB4- compared to neo-transduced bone marrow cells remains constant in long-term cultures along with a suppression of myeloid differentiation. In contrast to HOXB4 overexpression in fibroblasts, bone marrow cells engineered to overexpress HOXB4 do not upregulate AP-1 complex members or cyclins indicating that HOXB4 acts in a cell type-specific way.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Muller, AM (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacherstr 5, D-97078 Wurzburg, Germany.	andris@ema-avoti.de; albrecht.mueller@mail.uni-wuerzburg.de						Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Brun ACM, 2003, MOL THER, V8, P618, DOI 10.1016/S1525-0016(03)00237-5; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Dai MS, 2000, BLOOD, V96, P3985, DOI 10.1182/blood.V96.12.3985.h8003985_3985_3987; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; Furukawa Y, 2002, LEUKEMIA LYMPHOMA, V43, P225, DOI 10.1080/10428190290005973; Israels ED, 2001, STEM CELLS, V19, P88, DOI 10.1634/stemcells.19-1-88; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Loeffler M, 2002, CELLS TISSUES ORGANS, V171, P8, DOI 10.1159/000057688; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Moore KA, 1997, BLOOD, V89, P4337, DOI 10.1182/blood.V89.12.4337; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Oostendorp RAJ, 2000, BLOOD, V95, P855, DOI 10.1182/blood.V95.3.855.003k41_855_862; Oostendorp RAJ, 2002, BLOOD, V99, P1183, DOI 10.1182/blood.V99.4.1183; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; Rowlands TM, 2004, CELL CYCLE, V3, P145; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schiedlmeier B, 2003, BLOOD, V101, P1759, DOI 10.1182/blood-2002-03-0767; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611	38	14	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					561	572		10.1038/sj.onc.1208202	http://dx.doi.org/10.1038/sj.onc.1208202			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580301				2022-12-17	WOS:000226420400004
J	Gelman, MS; Ye, XK; Stull, R; Suhy, D; Jin, L; Ng, D; Than, B; Ji, M; Pan, A; Perez, P; Sun, Y; Yeung, P; Garcia, LM; Harte, R; Lu, Y; Lamar, E; Tavassoli, R; Kennedy, S; Osborn, S; Chin, DJ; Meshaw, K; Holzmayer, TA; Axenovich, SA; Abo, A				Gelman, MS; Ye, XK; Stull, R; Suhy, D; Jin, L; Ng, D; Than, B; Ji, M; Pan, A; Perez, P; Sun, Y; Yeung, P; Garcia, LM; Harte, R; Lu, Y; Lamar, E; Tavassoli, R; Kennedy, S; Osborn, S; Chin, DJ; Meshaw, K; Holzmayer, TA; Axenovich, SA; Abo, A			Identification of cell surface and secreted proteins essential for tumor cell survival using a genetic suppressor element screen	ONCOGENE			English	Article						genetic suppressor element (GSE); cancer therapeutic target; tumor cell; apoptosis; essential gene; xenograft	FACTOR-II RECEPTOR; MONOCLONAL-ANTIBODY; CANCER-CELLS; EXPRESSION SELECTION; RETROVIRAL VECTORS; INDUCED APOPTOSIS; RNA INTERFERENCE; CARCINOMA CELLS; MAMMALIAN-CELLS; CDNA LIBRARIES	Survival factors play critical roles in regulating cell growth in normal and cancer cells. We designed a genetic screen to identify survival factors which protect tumor cells from apoptosis. A retroviral expression library of random cDNA fragments was constructed from cancer cells and used to transduce the colon carcinoma cell line HCT116. Recipient cells were functionally selected for induction of caspase 3-mediated apoptosis. Analyses of over 10000 putative genetic suppression elements (GSEs) sequences revealed cognate gene candidates that are implicated in apoptosis. We further analysed 26 genes encoding cell surface and secreted proteins that can potentially serve as targets for therapeutic antibodies. Tetracycline-inducible GSEs from several gene candidates induced apoptosis in stable HCT 116 cell lines. Similar phenotypes were caused by RNAi derived from the same genes. Our data suggest requirement for the cell surface targets IGF2R, L1CAM and SLC31A1 in tumor cell growth in vitro, and suggests that IGF2R is required for xenograft tumor growth in a mouse model.	PPD Discovery Inc, Menlo Pk, CA 94025 USA; PPD Discovery Inc, Piedmont Res Ctr, Morrisville, NC 27560 USA		Axenovich, SA (corresponding author), 1018 4th Av,Suite 119, Oakland, CA 94606 USA.	sergey.axenovich@gmail.com; arieabo@yahoo.com						Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; Chen ZH, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-18; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Dunn SJ, 1999, GENE THER, V6, P130, DOI 10.1038/sj.gt.3300791; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Gallagher WM, 1997, ONCOGENE, V14, P185; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gros L, 2003, CANCER RES, V63, P164; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Gudkov A V, 1997, Methods Mol Biol, V69, P221; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFMANN MA, 1991, BIOTECHNIQUES, V11, P30; HOLZMAYER TA, 1992, NUCLEIC ACIDS RES, V20, P711, DOI 10.1093/nar/20.4.711; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; Levenson VV, 2000, CANCER RES, V60, P5027; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; Neznanov N, 2003, J BIOL CHEM, V278, P3809, DOI 10.1074/jbc.M210698200; Ouyang H, 1997, CANCER RES, V57, P1851; Pegues JC, 1997, CANCER LETT, V117, P73, DOI 10.1016/S0304-3835(97)00209-7; Primiano T, 2003, CANCER CELL, V4, P41, DOI 10.1016/S1535-6108(03)00169-7; RONINSON IB, 1995, CANCER RES, V55, P4023; Schaffer BS, 2003, ENDOCRINOLOGY, V144, P955, DOI 10.1210/en.2002-220751; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Torrance CJ, 2001, NAT BIOTECHNOL, V19, P940, DOI 10.1038/nbt1001-940; Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; Yang XD, 1999, CANCER RES, V59, P1236; Zhou GY, 2002, J VIROL, V76, P6197, DOI 10.1128/JVI.76.12.6197-6204.2002	42	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8158	8170		10.1038/sj.onc.1208054	http://dx.doi.org/10.1038/sj.onc.1208054			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361835				2022-12-17	WOS:000224692500014
J	Carson, DJ; Santoro, IM; Groden, J				Carson, DJ; Santoro, IM; Groden, J			Isoforms of the APC tumor suppressor and their ability to inhibit cell growth and tumorigenicity	ONCOGENE			English	Article						adenomatous polyposis coli; tumor suppressor; writ signaling	TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; WILD-TYPE; GENE; ASSOCIATION; PROTEIN; CANCER	Mutation of the APC tumor suppressor gene is one of the earliest events in the development of most colorectal tumors. The APC gene encodes multiple protein isoforms through a complicated pattern of expression and alternative splicing. The role that each isoform plays in cellular physiology is unknown, although the presence of some of these isoforms in postmitotic cells suggests a role in controlling cell growth or promoting differentiation. Three APC isoforms that differ in their amino-terminal domains were evaluated by gene transfer experiments using a colon cancer cell line that lacks functional APC. All three isoforms alter cellular morphology and affect cell growth by elongating the G1 phase of the cell cycle. The conventional APC and brain-specific APC isoforms suppress the tumorigenic phenotype of cultured cells, while the 0.3 APC isoform does not. In support of these experiments, BrdU incorporation as a marker for S-phase entry occurs at a higher level in transiently transfected cells with 0.3 APC when compared to cells transfected with the other isoforms. All three APC isoforms colocalize with microtubules and dramatically reduce beta-catenin activity to the same extent in transiently transfected cancer cells, suggesting that the different effects of each isoform on tumorigenesis may be nontranscriptional in origin.	Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Howard Hughes Medical Institute; University of Cincinnati	Groden, J (corresponding author), Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.	joanna.groden@uc.edu			NCI NIH HHS [CA-63057] Funding Source: Medline; NIDDK NIH HHS [T32-DK-64581-1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK064581] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Heinen CD, 2002, GASTROENTEROLOGY, V123, P751, DOI 10.1053/gast.2002.35382; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Pyles RB, 1998, ONCOGENE, V16, P77, DOI 10.1038/sj.onc.1201505; Santoro IM, 1997, CANCER RES, V57, P488; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1993, CANCER RES, V53, P2728	14	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7144	7148		10.1038/sj.onc.1207954	http://dx.doi.org/10.1038/sj.onc.1207954			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273719				2022-12-17	WOS:000223885100015
J	Huang, D; Liu, XH; Plymate, SR; Idowu, M; Grimes, M; Best, AM; McKinney, JL; Ware, JL				Huang, D; Liu, XH; Plymate, SR; Idowu, M; Grimes, M; Best, AM; McKinney, JL; Ware, JL			Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12	ONCOGENE			English	Article						proteomics; 14-3-3 sigma; androgen receptor; epidermal growth factor receptor; prostate	GLUCOCORTICOID-RECEPTOR; CANCER; ASSOCIATION; PROTEINS	The epidermal growth factor receptor and androgen receptor (AR) bot h play major roles in the control of prostate growth. Our hypothesis is that shared downstream components of these two signaling pathways are significant participants in androgen-independent growth. Our first objective was to identify proteins whose activation and/or expression in AR-positive prostate epithelial cells are induced by both epidermal growth factor (EGF) and dihydrotestosterone (DHT). AR expression was induced in a tumorigenic, metastatic subline of the SV40 large T-antigen immortalized human prostate epithelial subline M12 by stable transfection with human wild-type AR cDNA. These M12AR (+) cells with functional AR were treated in parallel with EGF (10 ng/ml) or DHT (10(-8) M) for 24 h before 2D gel electrophoresis and Western immunoblotting with antiphosphotyrosine monoclonal antibody. Coomassie blue-stained spots on a 2D gel run in parallel were aligned with the phosphoproteins on the Western immunoblot, and identified by matrix-assisted laser desorption ionization/time-of-flight mass spectroscopy. The most interesting of the seven proteins that appeared to be phosphorylated by these criteria was 14-3-3 protein sigma. Protein extracted after either EGF or DHT treatment, immunoprecipitated with antiphosphotyrosine monoclonal antibody, and immunoblotted by anti-14-3-3 sigma confirmed phosphorylation of 14-3-3 sigma. Addition of either DHT or EGF to the M12AR(+) cells induced subcellular migration of 14-3-3 sigma and activated a 14-3-3 sigma reporter construct. Immunohistochemical analysis revealed nuclear localization of 14-3-3 sigma in higher Gleason grade prostate cancers relative to benign glands. These findings implicate 14-3-3 sigma in the development of human prostate cancer cells and could provide a new target for intervention in prostate cancer.	Virginia Commonwealth Univ, Med Ctr, Dept Pathol, Richmond, VA 23298 USA; Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA; Virginia Commonwealth Univ, Med Ctr, Dept Biostat, Richmond, VA 23298 USA	Virginia Commonwealth University; University of Washington; University of Washington Seattle; Virginia Commonwealth University	Ware, JL (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Pathol, 1101 E Marshall St,Sanger Hall Rm 5-014,POB 98066, Richmond, VA 23298 USA.	jlware@vcu.edu	Best, Al/F-6425-2012	Idowu, Michael/0000-0002-7416-5444; Best, Al/0000-0002-6300-3925; Ketchum, Jessica/0000-0002-5566-3691	NIDDK NIH HHS [R01 DK52683] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052683] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CULIG Z, 1994, CANCER RES, V54, P5474; El Sheikh SS, 2003, NEOPLASIA, V5, P99, DOI 10.1016/S1476-5586(03)80001-5; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Haendler B, 2001, MOL CELL ENDOCRINOL, V173, P63, DOI 10.1016/S0303-7207(00)00434-2; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kino T, 2003, J BIOL CHEM, V278, P25651, DOI 10.1074/jbc.M302818200; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Liu XH, 2003, ELECTROPHORESIS, V24, P3445, DOI 10.1002/elps.200305574; Martel CL, 2003, CANCER TREAT REV, V29, P171, DOI 10.1016/S0305-7372(02)00090-7; Myers RB, 1999, INT J CANCER, V82, P424, DOI 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B; Orio F, 2002, MOL CELL ENDOCRINOL, V198, P105, DOI 10.1016/S0303-7207(02)00374-X; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; PLYMATE SR, 2004, IN PRESS PROSTATE; Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/me.15.4.501	28	14	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6881	6889		10.1038/sj.onc.1207788	http://dx.doi.org/10.1038/sj.onc.1207788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15300238				2022-12-17	WOS:000223750700005
J	Skinner, J; Bounacer, A; Bond, JA; Haughton, MF; DeMicco, C; Wynford-Thomas, D				Skinner, J; Bounacer, A; Bond, JA; Haughton, MF; DeMicco, C; Wynford-Thomas, D			Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis	ONCOGENE			English	Article						ras oncogene; cell cycle; human tumours; epithelial; fibroblast; senescence	HUMAN BREAST-CANCER; INDUCED SENESCENCE; ACTIVATION; P16(INK4A); MUTATIONS; P21(CIP1); TUMORS; GROWTH; KINASE; GENES	Using microinjection of recombinant protein to directly control 'expression' levels, we have compared the proliferative response to ras oncogene activation in two normal cell types - fibroblast and thyroid epithelial cell which give rise to human tumours with very low and high frequencies of ras mutation respectively. A concentration-dependent stimulation of DNA synthesis was observed in thyrocytes, matched by an almost perfectly reciprocal inhibition in fibroblasts. A concentration-dependent induction of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1) was observed in both cell types, but p16(Ink4a) was induced by ras only in fibroblasts. This difference could not account for the fibroblast specificity of the growth-inhibitory response, however, since proliferation of p16-deficient fibroblasts was also inhibited by mutant ras. We conclude that the striking contrast in proliferative response to ras between fibroblasts and thyroid epithelial cells cannot readily be explained by differential induction of either of the two key CDK inhibitors, p16(Ink4a) and p21(WAF1), but is consistent with a differential ability of p21(WAF1) to antagonize ras-induced mitogenic signals in the two cell types. Such tissue-specific differences provide an attractive explanation for the observed specificity of ras mutation for particular human tumour types, and emphasize the inappropriateness of fibroblasts as a model for ras-induced tumorigenesis.	Cardiff Univ, Canc Res UK Labs, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales; Fac Med Nord, F-13916 Marseille, France	Cardiff University; UDICE-French Research Universities; Aix-Marseille Universite	Wynford-Thomas, D (corresponding author), Cardiff Univ, Canc Res UK Labs, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales.	kingtd@cardiff.ac.uk						ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Bredel M, 1999, BRAIN RES REV, V29, P232, DOI 10.1016/S0165-0173(98)00057-5; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; CAMPBELL C, 1993, BRIT J DERMATOL, V128, P111, DOI 10.1111/j.1365-2133.1993.tb15137.x; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LEMOINE NR, 1989, ONCOGENE, V4, P159; Rich JN, 2001, CANCER RES, V61, P3556; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUAREZ HG, 1990, ONCOGENE, V5, P565; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	26	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5994	5999		10.1038/sj.onc.1207798	http://dx.doi.org/10.1038/sj.onc.1207798			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208687				2022-12-17	WOS:000222941100014
J	Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR				Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR			MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR	ONCOGENE			English	Article						MBD4; MMR; DNA methylation; cancer	MSH2; MED1; CARCINOMAS; APOPTOSIS; GENE	Mbd4 (methyl-binding domain 4) has been shown to be mutated in a high percentage of mismatch repair (MMR)deficient colorectal tumours that exhibit microsatellite instability (MSI). However, the significance of these mutations is still unclear as they are predominantly monoallelic and the majority occur at a poly-A tract. Apart from MMR-deficient tumours, no other reports of mutations of Mbd4 in human neoplasia are as yet published. To address the significance of loss of Mbd4 in the absence of MMR, we have crossed Mbd4-deficient mice to mice lacking DNA MMR. We show that, in the context of MMR deficiency, additional loss of Mbd4 does not alter spontaneous mutation frequency at the endogenous DIb-1b locus, nor does it modify tumour onset, tumour spectrum or MSI compared to singly mutant Msh2 or Mlh1 mice. Taken together, these findings show that nullizygosity or heterozygosity for Mbd4 does not affect MMR-dependent tumorigenesis.	Univ Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Clarke, Alan/0000-0002-4281-426X; Bird, Adrian/0000-0002-8600-0372				Bacon AL, 2000, HUM MOL GENET, V9, P2707, DOI 10.1093/hmg/9.18.2707; Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bader S, 2000, BRIT J CANCER, V83, P1646, DOI 10.1054/bjoc.2000.1482; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cortellino S, 2003, P NATL ACAD SCI USA, V100, P15071, DOI 10.1073/pnas.2334585100; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Drummond JT, 2001, NUCLEIC ACIDS RES, V29, P2234, DOI 10.1093/nar/29.11.2234; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2003, ONCOGENE, V22, P7130, DOI 10.1038/sj.onc.1206850; Sansom OJ, 2003, DNA REPAIR, V2, P1029, DOI 10.1016/S1568-7864(03)00111-3; Sansom OJ, 2001, CANCER RES, V61, P7060; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299	23	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5693	5696		10.1038/sj.onc.1207767	http://dx.doi.org/10.1038/sj.onc.1207767			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184874				2022-12-17	WOS:000222629500015
J	Robb, VA; Li, W; Gutmann, DH				Robb, VA; Li, W; Gutmann, DH			Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression	ONCOGENE			English	Article						14-3-3; Protein 4.1B; DAL-1; meningioma	TYROSINE KINASE SUBSTRATE; TUMOR-SUPPRESSOR; SPORADIC MENINGIOMAS; NF2 GENE; MERLIN EXPRESSION; HUMAN GLIOMA; CELL-GROWTH; LUNG-CANCER; DAL-1; ASSOCIATION	Meningiomas are common central nervous system tumors; however, the mechanisms underlying their pathogenesis are largely unknown. Collaborative studies from our laboratory demonstrated a direct association of 14-3-3 with the meningioma tumor suppressor Protein 4.1B, which was not observed with other members of the Protein 4.1 family, including the NF2 meningioma tumor suppressor, merlin/schwannomin. Given the role of 14-3-3 in the regulation of cell proliferation and apoptosis, we sought to determine the functional significance of 14-3-3 binding to Protein 4.1B growth suppression. Based on comparative binding studies performed with additional members of the Protein 4.1 family, we generated specific missense mutations within the minimal growth suppressor fragment of Protein 4.1B (DAL-1, differentially expressed in adenocarcinoma of the lung). Complementary in vitro GST affinity chromatography and in vivo interaction experiments demonstrated that the F359Y mutation abrogated binding to 14-3-3, but did not impair DAL-1 binding to other known Protein 4.1B interacting proteins. Similar to wild-type DAL-1, the expression of the F359Y DAL-1 14-3-3-binding mutant resulted in reduced Protein 4.1B-deficient IOMM-Lee and CH157-MN meningioma cell line colony formation. Moreover, similar to wild-type DAL-1, the stable expression of the DAL-1 F359Y mutant significantly reduced cell proliferation in independently isolated IOMM-Lee clones, as assessed by thymidine incorporation. Collectively, these results suggest that binding to 14-3-3 is not essential for the growth suppressor function of Protein 4.1B in meningiomas.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NCI NIH HHS [1-F32-CA-097816-01] Funding Source: Medline; NINDS NIH HHS [NS35848, NS41520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848, R01NS041520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 2001, HUM MOL GENET, V10, P825, DOI 10.1093/hmg/10.8.825; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 2002, HUM MOL GENET, V11, P3179, DOI 10.1093/hmg/11.25.3179; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sun CX, 2002, HUM MOL GENET, V11, P3167, DOI 10.1093/hmg/11.25.3167; Tran YK, 1999, CANCER RES, V59, P35; Tsai JC, 1999, LASER SURG MED, V24, P296, DOI 10.1002/(SICI)1096-9101(1999)24:4<296::AID-LSM7>3.3.CO;2-6; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Ueki K, 1999, CANCER RES, V59, P5995; Weber RG, 1997, P NATL ACAD SCI USA, V94, P14719, DOI 10.1073/pnas.94.26.14719; Yageta M, 2002, CANCER RES, V62, P5129; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	33	14	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3589	3596		10.1038/sj.onc.1207445	http://dx.doi.org/10.1038/sj.onc.1207445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116094				2022-12-17	WOS:000221101700010
J	Kontou, M; Will, RD; Adelfalk, C; Wittig, R; Poustka, A; Hirsch-Kauffmann, M; Schweiger, M				Kontou, M; Will, RD; Adelfalk, C; Wittig, R; Poustka, A; Hirsch-Kauffmann, M; Schweiger, M			Thioredoxin, a regulator of gene expression	ONCOGENE			English	Article						Fanconi anemia; GAPDH; redox potential; thioredoxin	NF-KAPPA-B; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CHROMOSOMAL INSTABILITY; BIOLOGICAL-ACTIVITIES; CEREBELLAR NEURONS; REDOX REGULATION; REDUCTASE; CELLS; PHOSPHORYLATION; ACTIVATION	Cancer cells have high levels of thioredoxin ( Trx) and of glyceraldehyde 3- phosphate dehydrogenase ( GAPDH). Cells from patients with the cancer- prone disease Fanconi anemia ( FA) exhibit reduced Trx levels. We found the activity of GAPDH to correlate directly with the endogenous Trx content and mRNA transcripts for GAPDH and TRx reduced in FA cells. The treatment of cells with reduced human Trx stimulated the synthesis of GAPDH mRNA. Similarly, the transfection of cells with an expression plasmid for Trx increased GAPDH mRNA synthesis. Trx treatment of cells and subsequent analysis of the differential gene expression by human cDNA arrays containing about 50 000 different PCR products resulted in more than 300 up- or downregulated genes. Two representative genes, GAPDH and IkappaBalpha/ MAD- 3, were further investigated to confirm their stimulation by Trx. Trx besides being the major carrier of redox potential of cells is also a regulator of gene expression on the transcriptional level. By regulation via Trx, cells are able to adapt to the prevailing redox conditions. These findings also enlighten the pathophysiology of FA in the respect that the characteristic diminution of Trx that results in the dysregulation of gene expression is a basis for the major symptoms of this disease.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany	Free University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Schweiger, M (corresponding author), Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.	schweigm@molgen.mpg.de	Wittig, Rainer/AAT-5361-2021	Wittig, Rainer/0000-0002-3735-9370; Will, Rainer/0000-0001-6049-2690				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; ASHMARINA LI, 1988, FEBS LETT, V231, P413, DOI 10.1016/0014-5793(88)80861-5; BAXI MD, 1995, J PHARMACOL TOX MET, V33, P121, DOI 10.1016/1056-8719(94)00127-P; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; BROT N, 1991, BIOFACTORS, V3, P91; DALTON TP, 1999, ANN REV PHARM TOXICO, V93, P67; Das KC, 1997, AM J RESP CELL MOL, V17, P713, DOI 10.1165/ajrcmb.17.6.2809; Dastoor Z, 2001, J CELL SCI, V114, P1643; DURRIEU C, 1987, ARCH BIOCHEM BIOPHYS, V252, P32, DOI 10.1016/0003-9861(87)90005-1; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Ishitani R, 1996, J NEUROCHEM, V66, P928; Ishitani R, 1998, MOL PHARMACOL, V53, P701, DOI 10.1124/mol.53.4.701; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; Kerblat I, 1999, IMMUNOLOGY, V97, P62; Kontou M, 2003, BIOL CHEM, V384, P1501, DOI 10.1515/BC.2003.166; Kontou M, 2002, ONCOGENE, V21, P2406, DOI 10.1038/sj.onc.1205299; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Messmer UK, 1996, EUR J PHARMACOL, V302, P171, DOI 10.1016/0014-2999(96)00055-6; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MURONETZ VI, 1994, ARCH BIOCHEM BIOPHYS, V313, P253, DOI 10.1006/abbi.1994.1385; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Nakamura H, 1996, INT IMMUNOL, V8, P603, DOI 10.1093/intimm/8.4.603; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Pekkari K, 2000, J BIOL CHEM, V275, P37474, DOI 10.1074/jbc.M001012200; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Ramirez MH, 1999, BIOCHEM BIOPH RES CO, V264, P518, DOI 10.1006/bbrc.1999.1482; Reiss N, 1996, BIOCHEM MOL BIOL INT, V40, P1191; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P1181; SCHULTZ DE, 1996, J BIOL CHEM, V270, P2755; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SILBERSTEIN DS, 1993, J BIOL CHEM, V268, P9138; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Sumida Y, 2000, J HEPATOL, V33, P616, DOI 10.1034/j.1600-0641.2000.033004616.x; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Warburg O, 1943, BIOCHEM Z, V314, P399; WILLINGALETHEUNE J, 1989, J CELL SCI, V93, P651; Wittig R, 2002, CANCER RES, V62, P6698	45	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2146	2152		10.1038/sj.onc.1207334	http://dx.doi.org/10.1038/sj.onc.1207334			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14730345				2022-12-17	WOS:000220280900004
J	Luo, Q; Li, J; Cenkci, B; Kretzner, L				Luo, Q; Li, J; Cenkci, B; Kretzner, L			Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product	ONCOGENE			English	Article						transcriptional repression; c-Myc; Mxi1; p107; initiator; E2F binding sites	TRANSCRIPTIONAL REPRESSION; NEGATIVE AUTOREGULATION; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; CELL-PROLIFERATION; TRANS-ACTIVATION; IN-VIVO; PROMOTER; MAX; E2F	Myc proteins are transcriptional activators, but also repress transcription through initiator (Inr) elements. Repression requires the conserved Myc Box II, but the cis-acting element(s) required for c-myc autorepression have eluded definition. Since the gene has a candidate Inr at the P2 promoter, we tested whether Myc autorepression operates through the Inr/BoxII mechanism. Overexpression of c-Myc but not a Box II deletion mutation represses both c-myc P2 reporter genes and endogenous c-myc, as does Mxi1 expression. Only 45 nucleotides surrounding the P2 start suffice to mediate autorepression, but Myc and Mxi1 also downregulate P2 Inr mutations, suggesting other core promoter sequence requirements for autorepression. We tested the importance of conserved E2F sites, based on known Myc interaction with the pRb-related p107 and on the transrepressive effects of Rb family proteins. Myc, Mxi1, and p107 repress c-myc somewhat less well in the absence of E2F binding sites, while an E2F + Inr double mutation is not repressed at all by these gene products. Further, Myc repression at the c-myc P2 core promoter is augmented by p107, but not by pRb or p130, nor by p107 lacking the conserved pocket domain. Our data suggest that Myc autorepression requires both the c-myc Inr and E2F sites in cis, as well as p107 in trans. Consistent with this, we found that retrovirally transduced c-Myc cannot downregulate endogenous c-myc in p107-null fibroblasts, and show evidence that both Myc and p107 are present in a complex assembled at the c-myc P2 core promoter.	Univ S Dakota, Sch Med, Dept Cellular & Mol Biol, Div Basic Biomed Sci, Vermillion, SD 57069 USA	University of South Dakota	Kretzner, L (corresponding author), City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.	lkretzner@coh.org						AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIPP M, 1989, ONCOGENE, V4, P535; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; MANGO SE, 1989, MOL CELL BIOL, V9, P3482, DOI 10.1128/MCB.9.8.3482; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Peters MA, 1998, CRIT REV EUKAR GENE, V8, P277, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.30; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Starostik P, 1996, MOL CELL BIOL, V16, P3606; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	46	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1088	1097		10.1038/sj.onc.1207225	http://dx.doi.org/10.1038/sj.onc.1207225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14716294				2022-12-17	WOS:000188749900007
J	Young, AP; Longmore, GD				Young, AP; Longmore, GD			Differences in stability of repressor complexes at promoters underlie distinct roles for Rb family members	ONCOGENE			English	Article						Rb; E2F; p130; p107; tumor suppression; repressor complex stability	RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; E2F-INDUCED S-PHASE; CELL-CYCLE; HISTONE H3; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; E2F PROTEINS; TGF-BETA; LYSINE 9; IN-VIVO	Oncogenic transformation of cells can induce the cyclin-dependent kinase inhibitor, p16, which leads to hypophosphorylation and activation of retinoblastoma (Rb). Rb is capable of causing permanent growth arrest, which may underlie its role as a tumor suppressor. We show that repression by Rb at E2F target gene promoters involves the establishment of a stable repressor complex that is not displaced by the overexpression of E2F-1. Rather than displacing Rb, excess E2F-1 instead recruits more Rb, leading to direct transcriptional repression. In contrast, the Rb family members, p130 and p107, which have not been demonstrated to be tumor suppressors, bind preferentially to target promoters in the absence of growth factors and in proliferating cells, respectively, and these repressor complexes are displaceable by E2F-1. Heterochromatin protein 1 (HP1), which interacts with Rb, is associated with these distinct repressor complexes and follows a similar pattern of stability/displaceability. Efficient growth arrest by p16/Rb is dependent on histone H3 lysine 9 methylation, which provides a binding site for HP1. We propose that these differences in the stability of repressor complexes at promoters may, in part, underlie the different roles of Rb vs p130 and p107 in cell cycle regulation and tumor suppression.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	glongmor@im.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA085839] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HUBER HE, 1994, J BIOL CHEM, V269, P6999; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; LIPINSKI MM, 1999, P NATL ACAD SCI USA, V92, P6289; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Palmero I, 1996, CANCER SURV, V27, P351; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Takahashi Y, 2000, GENE DEV, V14, P804; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	53	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					814	823		10.1038/sj.onc.1207187	http://dx.doi.org/10.1038/sj.onc.1207187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737116				2022-12-17	WOS:000188304900020
J	Florensa, R; Bachs, O; Agell, N				Florensa, R; Bachs, O; Agell, N			ATM/ATR-independent inhibition of cyclin B accumulation in response to hydroxyurea in nontransformed cell lines is altered in tumour cell lines	ONCOGENE			English	Article						hydroxyurea; ATM; ATR; caffeine; cyclin B1; replication checkpoint	DNA-DAMAGE; S-PHASE; REPLICATION CHECKPOINT; POLYMERASE-ALPHA; G2/M TRANSITION; PROTEIN-KINASE; ATR; ACTIVATION; PHOSPHORYLATION; MITOSIS	The DNA replication checkpoint is an inhibitory pathway ensuring that mitosis occurs only after completion of DNA synthesis. Its function may be relevant to the stability of the genome. The essential elements of this checkpoint are ATM/ATR kinases that indirectly lead to the phosphorylation and inhibition of the mitosis-promoting factor (Cdc2/cyclin B1). The function of this checkpoint was analysed in diverse nontransformed and tumour-derived cell lines. All cell lines tested arrested mitosis entry when DNA synthesis was inhibited by hydroxyurea (HU) treatment. But, unlike what has been described in yeast and Xenopus, in normal rat kidney (NRK) cells and NIH 3T3 fibroblasts, the arrest induced by HU treatment was not abrogated by caffeine, an ATM and ATR inhibitor. This indicated the presence of an ATM/ATR-independent response to DNA synthesis inhibition in these nontransformed mammalian cell lines. Interestingly, the behaviour of different tumour cell lines after caffeine treatment varied. While SW480, NP29, NP18 and HeLa cells did not enter mitosis in the presence of caffeine after HU treatment, in CaCo2, DLD1, HCT116 and HT29 caffeine abrogated the checkpoint response. In nontransformed cell lines, lack of cyclin B1 accumulation was observed when DNA synthesis was inhibited. This response was not abrogated by caffeine. In the tumour cell lines, a good correlation between the ability to arrest cell cycle when DNA synthesis was inhibited in the presence of caffeine and the lack of cyclin B1 accumulation was observed. Thus, there is an ATM/ATR-independent checkpoint response that leads to a decrease in cyclin B1 accumulation. However, this response is not functional in some tumour cell lines. Using inhibitors of p38alpha and beta, Mek1, 2 and p53-/- knocked-out fibroblasts, we showed that these proteins were also not involved in this particular checkpoint response. Lack of cyclin B1 accumulation after DNA synthesis inhibition in NRK cells was not due to increased degradation of the protein, but correlated with a decrease in mRNA accumulation.	Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi i Sunyer IDIBAPS, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Agell, N (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi i Sunyer IDIBAPS, E-08036 Barcelona, Spain.	agell@medicina.ub.es	Agell, Neus/E-9640-2016	Agell, Neus/0000-0002-1205-6074				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; DURSO G, 1995, J CELL SCI, V108, P3109; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hwang A, 1998, J BIOL CHEM, V273, P31505, DOI 10.1074/jbc.273.47.31505; HWANG A, 1995, J BIOL CHEM, V270, P28419; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KREK W, 1992, NEW BIOL, V4, P323; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1999, CANCER RES, V59, P4375; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Ye X S, 1997, Prog Cell Cycle Res, V3, P221; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	56	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8283	8292		10.1038/sj.onc.1207159	http://dx.doi.org/10.1038/sj.onc.1207159			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614452				2022-12-17	WOS:000186541500007
J	Knauf, JA; Ouyang, B; Croyle, M; Kimura, E; Fagin, JA				Knauf, JA; Ouyang, B; Croyle, M; Kimura, E; Fagin, JA			Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKC epsilon in PCCL3 thyroid cells	ONCOGENE			English	Article						thyroid; protein kinase C; phospholipase C gamma; apoptosis; RET/PTC	PROTEIN-KINASE-C; GENE-EXPRESSION; RET ACTIVATION; CANCER; RAS; APOPTOSIS; ONCOGENE; GROWTH; TRANSLOCATION; INVOLVEMENT	Most papillary thyroid carcinomas (PTC) have an isozyme-specific reduction of protein kinase C (PKC)epsilon, which occurs through a post-transcriptional mechanism. Here, we test whether the oncoprotein RET/PTC could be responsible for this effect, since RET/PTC rearrangements are quite prevalent in PTC and RET/PTC activates PLCgamma, an upstream modulator of PKCs. At 3 h after induction of RET/PTC1 or RET/PTC3 expression, there was evidence of PKCepsilon activation. Activation was restricted to PKCepsilon, as acute expression of RET/PTC did not change the subcellular distribution of other PKC isozymes expressed in PCCL3 cells. Prolonged RET/PTC expression (2-6 days) produced an isozyme-specific change in PKCepsilon subcellular localization and a decrease in total PKCepsilon levels. The expression of RET/PTC3(Y541F), which does not interact with PLCgamma, but signals normally through other RET effectors, had no effect on PKCepsilon distribution at any of the time points examined. However, downregulation of total PKCepsilon levels was only partially prevented by expression of RET/PTCY541F. Cells with decreased PKCepsilon following prolonged expression of RET/ PTC were relatively resistant to doxorubicin-induced apoptosis. Based on our previous observation that PCCL3 cells expressing a dominant-negative PKCepsilon are also markedly resistant to apoptosis, we propose that selective downregulation of PKCepsilon following prolonged RET/ PTC activation promotes cell survival and clonal expansion.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knauf, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Mail Locat 0547, Cincinnati, OH 45267 USA.	Jeffrey.Knauf@UC.EDU	Croyle, Maria/L-4586-2019; Kimura, Edna/D-7334-2012	Croyle, Maria/0000-0003-0809-901X; Kimura, Edna/0000-0001-8403-4459	NATIONAL CANCER INSTITUTE [R29CA050706, R01CA050706, R01CA072597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002781] Funding Source: NIH RePORTER; NCI NIH HHS [CA50706, CA72597] Funding Source: Medline; NIDDK NIH HHS [K01DK02781] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Borrello MG, 1995, ONCOGENE, V11, P2419; CACACE AM, 1993, ONCOGENE, V8, P2095; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1587, DOI 10.1210/en.130.3.1587; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Kim MJ, 2000, EXP MOL MED, V32, P101, DOI 10.1038/emm.2000.18; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Knauf JA, 2002, J CLIN ENDOCR METAB, V87, P2150, DOI 10.1210/jc.87.5.2150; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Maddens S, 2002, BLOOD, V100, P1294, DOI 10.1182/blood.V100.4.1294.h81602001294_1294_1301; Marks F, 1995, MUTAT RES-FUND MOL M, V333, P161, DOI 10.1016/0027-5107(95)00142-5; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, FASEB J, V12, P35; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; Neri LM, 2002, MOL BIOL CELL, V13, P947, DOI 10.1091/mbc.01-02-0086; OBRIAN CA, 1989, CANCER METAST REV, V8, P199, DOI 10.1007/BF00047337; Ohmori T, 1998, CELL GROWTH DIFFER, V9, P345; Plo I, 2001, ONCOGENE, V20, P6752, DOI 10.1038/sj.onc.1204877; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Vecchio G, 2000, CLIN CHEM LAB MED, V38, P113, DOI 10.1515/CCLM.2000.017; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; Zhuang SG, 1997, BIOCHEM BIOPH RES CO, V240, P273, DOI 10.1006/bbrc.1997.7474	44	14	16	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6830	6838		10.1038/sj.onc.1206829	http://dx.doi.org/10.1038/sj.onc.1206829			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534528				2022-12-17	WOS:000185843400002
J	Schreiner, B; Greten, FR; Baur, DM; Fingerle, AA; Zechner, U; Bohm, C; Schmid, M; Hameister, H; Schmid, RM				Schreiner, B; Greten, FR; Baur, DM; Fingerle, AA; Zechner, U; Bohm, C; Schmid, M; Hameister, H; Schmid, RM			Murine pancreatic tumor cell line TD2 bears the characteristic pattern of genetic changes with two independently amplified gene loci	ONCOGENE			English	Article						murine pancreatic tumor cell line; c-Myc and Egfr amplification; p53 deletion; p16(Ink4a) hypermethylation	PROGRESSION MODEL; TRANSGENIC MICE; SOLID TUMORS; AMPLIFICATION; DNA; ADENOCARCINOMA; P16(INK4A); ACTIVATION; DELETIONS; INDUCTION	TGFalpha/p53(+/-) transgenic mice represent a genetically engineered mouse model for pancreatic adenocarcinoma. The tumors develop a characteristic pattern of secondary genetic changes. From one of these tumors, the permanent cell line TD2 was established. Here, we describe in detail the genetic changes by molecular - cytogenetic techniques. The original tumor-specific CGH profile has been retained unchanged. The most characteristic aberration pattern bears chromosome 11. Egfr, localized on proximal chromosome 11, is amplified two to three times and leads to an easily identifiable, stable marker chromosome with a large amplification unit, which is present in each metaphase. The wild-type p53 gene on distal chromosome 11 is lost. The p16(Ink4a) locus on chromosome 4 is hypermethylated. For c-Myc a 15-fold amplification, present in a 1.65 Mb amplification unit, is detected on chromosome 15. Transition between presence in the form of several double minutes, DMs, or a single homogeneously staining region, HSR, was observed for c-Myc. Molecular - cytogenetic analysis of both amplification units show that Egfr amplification and c-Myc amplification represent two alternative modes by which genes get amplified in tumor cells. The expression level of the respective genes was proven by Northern blot analysis. The cell line TD2 represents a valuable in vitro model for pancreatic adenocarcinoma.	Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany; Univ Wurzburg, Inst Human Genet, D-97074 Wurzburg, Germany; Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany; Univ Ulm, Dept Human Genet, D-89069 Ulm, Germany; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Technical University of Munich; University of Wurzburg; Ulm University; Ulm University; University of California System; University of California San Diego	Schmid, RM (corresponding author), Tech Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany.		Greten, Florian R/AAF-5196-2020; Zechner, Ulrich/G-2116-2010	Greten, Florian R/0000-0002-3928-6080; 				Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; Bardeesy N, 2001, SEMIN CANCER BIOL, V11, P201, DOI 10.1006/scbi.2000.0371; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Greten FR, 2002, GASTROENTEROLOGY, V123, P2052, DOI 10.1053/gast.2002.37075; Hajkova Petra, 2002, Methods Mol Biol, V200, P143; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Steinle AU, 1999, GASTROENTEROLOGY, V116, P420, DOI 10.1016/S0016-5085(99)70140-X; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; WAHL GM, 1989, CANCER RES, V49, P1333; Wang WX, 1999, CLIN CANCER RES, V5, P119; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wu YF, 2002, ONCOGENE, V21, P1518, DOI 10.1038/sj.onc.1205208	24	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6802	6809		10.1038/sj.onc.1206836	http://dx.doi.org/10.1038/sj.onc.1206836			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555993				2022-12-17	WOS:000185799300015
J	Kamel-Reid, S; Zhang, T; Wells, RA				Kamel-Reid, S; Zhang, T; Wells, RA			Expression of NPM-RAR alpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis	ONCOGENE			English	Article						PPAR gamma; apoptosis; NPM-RAR alpha; acute myelogenous leukemia	PROLIFERATOR-ACTIVATED RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN BREAST-CANCER; RETINOID-X-RECEPTOR; PPAR-GAMMA; MONOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; CYTOSINE-ARABINOSIDE; GROWTH-INHIBITION; LUNG-CANCER	We have investigated the effects of acute promyelocytic leukemia (APL) fusion gene NPM-RARalpha on the function of PPARgamma using the monoblastic cell line U937. U937 cells were transduced using a retrovirus carrying NPM-RARalpha. While treatment with the synthetic PPARgamma ligand troglitazone (TG) had no effect on the viability of U937 cells, TG treatment of U937/NPM-RARalpha cells resulted in a dramatic decrease in cell viability, dependent upon both the concentration of TG and the level of expression of NPM-RARalpha. Analysis of the cell cycle pro. le and flow cytometry with annexin V confirmed that these effects of TG were due to induction of apoptosis. Induction of apoptosis was accompanied by caspase-8 and caspase-9 activation, and could be blocked by treatment with the caspase inhibitor Z-VAD-FMK. Cotreatment of U937/NPM-RARalpha cells with all-trans retinoic acid (atRA) abrogated the induction of apoptosis by TG. Induction of apoptosis was seen also in the PML-RARalpha-expressing APL cell line NB4, and in several other atRA-sensitive leukemia cell lines, demonstrating that this effect is limited neither to the monocyte lineage nor to the rare NPM-RARalpha fusion variant. RXRalpha/NPM-RARalpha heterodimers were found to interact directly with a PPARgamma-responsive element in vitro. We conclude that in the presence of X-RARalpha, TG induces cell death due to apoptosis via the caspase pathway. These observations suggest the investigation of PPARgamma ligands as therapeutic agents in acute leukemia.	Univ Toronto, Inst Med Sci, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Hlth Network, Ontario Canc Inst, Dept Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Wells, RA (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Room 8-209,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rwells@uhnres.utoronto.ca		Kamel-Reid, Suzanne/0000-0002-4386-0292				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Asou H, 1999, INT J ONCOL, V15, P1027; ATSUMI Y, 1986, AM J MED SCI, V292, P152, DOI 10.1097/00000441-198609000-00006; BENITO A, 1995, AM J PATHOL, V146, P481; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chang TH, 2000, CANCER RES, V60, P1129; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fujimura S, 1998, INT J ONCOL, V13, P1263; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Greene M. E., 1995, Gene Expression, V4, P281; HASS R, 1989, EUR J CELL BIOL, V48, P282; Hirase N, 1999, ONCOLOGY-BASEL, V57, P17, DOI 10.1159/000055271; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOISTINEN P, 1991, LEUKEMIA, V5, P704; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Padilla J, 2002, CLIN IMMUNOL, V103, P22, DOI 10.1006/clim.2001.5181; Pizzimenti S, 2002, FREE RADICAL BIO MED, V32, P233, DOI 10.1016/S0891-5849(01)00798-5; Rebel VI, 1999, BLOOD, V93, P2217, DOI 10.1182/blood.V93.7.2217.407a01_2217_2224; RIGBY WFC, 1984, BLOOD, V64, P1110; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; TESTA U, 1994, CANCER RES, V54, P4508; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG C, 1989, LEUKEMIA, V3, P699; YANG GS, 1993, LEUKEMIA, V7, P1012; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	48	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6424	6435		10.1038/sj.onc.1206696	http://dx.doi.org/10.1038/sj.onc.1206696			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508522				2022-12-17	WOS:000185535300012
J	Reddy, MN; Tang, LY; Lee, TL; Shen, CKJ				Reddy, MN; Tang, LY; Lee, TL; Shen, CKJ			A candidate gene for Drosophila genome methylation	ONCOGENE			English	Article						DNA methylation; Drosophila cells; enzyme	DNA METHYLATION; DE-NOVO; METHYLTRANSFERASES; MELANOGASTER; DNMT3A	Like vertebrates, the genome of Drosophila melanogaster also contains methylated cytosines. However, the enzyme( s) responsible for this methylation has been elusive. By DNA transfection and sodium bisulfite sequencing, we show here that overexpression of dDnmt2, which is the only expressed and cloned Drosophila protein consisting of motifs conserved among the DNA cytosine methyltransferases, results in genomic DNA methylation of Drosophila S2 cells. The data provide the first evidence for dDnmt2 being one candidate gene encoding the Drosophila DNA methyltransferase(s).	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan	Academia Sinica - Taiwan	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.		shen, Che-Kun James/L-1343-2015					Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Dong AP, 2001, NUCLEIC ACIDS RES, V29, P439, DOI 10.1093/nar/29.2.439; Gowher H, 2000, EMBO J, V19, P6918, DOI 10.1093/emboj/19.24.6918; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; Lyko F, 2000, NATURE, V408, P538, DOI 10.1038/35046205; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Tweedie S, 1999, NAT GENET, V23, P389, DOI 10.1038/70490; Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	15	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6301	6303		10.1038/sj.onc.1206650	http://dx.doi.org/10.1038/sj.onc.1206650			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679869				2022-12-17	WOS:000185506200020
J	Figueroa, C; Vojtek, AB				Figueroa, C; Vojtek, AB			Akt negatively regulates translation of the ternary complex factor Elk-1	ONCOGENE			English	Article						Elk-1; Sap1a; Akt/PKB; translational control; Ets; cross-talk	PROTEIN-KINASE-B; C-FOS TRANSCRIPTION; EPITHELIAL-CELLS; RAS; DIFFERENTIATION; EXPRESSION; PATHWAY; BINDING; MOUSE; PHOSPHORYLATION	Cross-talk between signaling pathways plays an important role in regulation of cell growth, differentiation, survival, and death. Here, we show that Akt regulates the Elk-1 transcription factor, independent of its negative regulation of Raf kinases. Using a constitutively active Mek1 to bypass the regulation of Raf by Akt, we find that the Elk-1 and Sap1a proteins are dramatically decreased in the presence of activated Akt. Akt catalytic activity is required. Also, Mek-dependent activation of a TCF (Etk-1/Sap-1a)-dependent c-fos reporter is decreased by activated Akt. Neither the level of Elk-1 mRNA nor the stability of the Elk-1 protein is altered by activated Akt. Instead, the rate of incorporation of labeled methionine into Elk-1 protein is decreased in the presence of Akt. In addition, the level of the Elk-1 protein but not GFP is significantly decreased in the presence of activated Akt, when GFP is expressed from an IRES element in a bicistronic message with Elk-1. We conclude that Akt negatively regulates translation of the Elk-1 mRNA. A coding region determinant that maps within the first 279 nts of the Elk-1 message is necessary and sufficient for Akt-mediated regulation of Elk-1.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vojtek, AB (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.			Figueroa-Romero, Claudia/0000-0001-7546-4190				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; CHOUDHURY GG, 1997, AM J PHYSIOL, V273, P931; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Guan KL, 2000, J BIOL CHEM, V275, P27354; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JUN T, 1999, SCI STKE, P10591; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARTI A, 1994, ONCOGENE, V9, P1213; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Preston GA, 2000, CELL DEATH DIFFER, V7, P215, DOI 10.1038/sj.cdd.4400637; Preston GA, 1996, MOL CELL BIOL, V16, P211; Rich KA, 1997, J NEUROBIOL, V32, P593, DOI 10.1002/(SICI)1097-4695(19970605)32:6<593::AID-NEU5>3.0.CO;2-V; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sheng HM, 2001, CANCER RES, V61, P2670; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; VOJTEK AB, 1993, J CELL SCI, V105, P777; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5554	5561		10.1038/sj.onc.1206496	http://dx.doi.org/10.1038/sj.onc.1206496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944902				2022-12-17	WOS:000184865900003
J	Rothenberger, S; Burns, K; Rousseaux, M; Tschopp, J; Bron, C				Rothenberger, S; Burns, K; Rousseaux, M; Tschopp, J; Bron, C			Ubiquitination of the Epstein-Barr virus-encoded latent membrane protein 1 depends on the integrity of the TRAF binding site	ONCOGENE			English	Article						LMP1; ubiquitin; TRAF3; lipid rafts	LIPID RAFTS; SIGNAL-TRANSDUCTION; PROTEIN; CELLS; DEGRADATION; LMP1; TRANSFORMATION; RECOGNITION; ASSOCIATION; ACTIVATION	The latent membrane protein 1 (LMP1) encoded by the Epstein-Barr virus functions as a constitutively activated receptor of the tumor necrosis factor receptor family. LMP1 is a short-lived protein that is ubiquitinated and degraded by the proteasome. We have previously shown that LMP1 recruits the adapter protein tumor necrosis factor receptor-associated factor 3 (TRAF3) to lipid rafts. To test if TRAFs are involved in LMP1's ubiquitination, we have mutated the LMP1 CTAR1 site that has been identified as a TRAF binding site. We show that the CTAR1 mutant (CTAR1(-)) is expressed after transfection at a similar level to wild-type LMP1, and behaves as wild-type LMP1 with respect to membrane localization. However, CTAR1(-) does not bind TRAF3. We demonstrate that ubiquitination of CTAR1(-) is significantly reduced when compared to wild-type LMP1. In addition, the expression of wild-type LMP1 induces the ubiquitination, an effect that is significantly reduced when the CTAR1(-) is expressed. Taken together, our results suggest that TRAF proteins are involved in the ubiquitination of LMP1, and that their binding to LMP1 may facilitate their own ubiquitination.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Rothenberger, S (corresponding author), Univ Lausanne, Inst Biochem, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	Sylvia.RothenbergerAubert@ib.unil.ch		Rothenberger, Sylvia/0000-0001-8633-2994				Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chung JY, 2002, J CELL SCI, V115, P679; Ciechanover A, 2000, J CELL BIOCHEM, P40; Clausse B, 1997, VIROLOGY, V228, P285, DOI 10.1006/viro.1996.8380; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Rothenberger S, 2002, CELL MOL LIFE SCI, V59, P171, DOI 10.1007/s00018-002-8413-y; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Strous GJ, 1999, J CELL SCI, V112, P1417; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	31	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5614	5618		10.1038/sj.onc.1206497	http://dx.doi.org/10.1038/sj.onc.1206497			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944909				2022-12-17	WOS:000184865900010
J	Taylor, ER; Boner, W; Dornan, ES; Corr, EM; Morgan, IM				Taylor, ER; Boner, W; Dornan, ES; Corr, EM; Morgan, IM			UVB irradiation reduces the half-life and transactivation potential of the human papillomavirus 16 E2 protein	ONCOGENE			English	Article						HPV; E2; transcription; protein solubility; UV	HUMAN-PAPILLOMAVIRUS TYPE-18; E2 PROTEIN; DNA-DAMAGE; FUNCTIONAL INTERACTION; TRANSCRIPTIONAL ACTIVATOR; BINDING PROTEIN; P53; PROMOTER; CELLS; DEGRADATION	Human papillomaviruses (HPV) are causative agents of human cancers including those of the cervix and also of the head and neck; HPV16 is the most commonly found type in these diseases. The viral E2 protein regulates transcription from the viral genome by interacting with DNA-binding sequences in the HPV transcriptional control region; it also regulates replication by interacting with and recruiting the HPV replication factor El to the viral origin. Therefore, E2 is essential for the viral life cycle. The E2 protein interacts with several proteins involved in the cellular response to DNA damage including p53, TopBP1, and PARP. We therefore set out to establish whether DNA-damaging agents can regulate E2 activity. Here we show that UVB irradiation downregulates transcriptional activity of both HPV16 and HPV8 E2, while hydroxyurea and etoposide do not. This downregulation of E2 activity is independent of p53 function as it occurs in p53 wild type and null cell types as well as in the presence of functional HPV16 E6 that degrades p53. Using stable cell lines expressing E2 we show that this downregulation of E2 function by UVB is due to a reduction of the E2 protein half-life. The identification of the pathway(s) through which UVB downregulates E2 transcriptional activity and protein levels will present a novel target for the treatment of HPV-related diseases.	Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Morgan, IM (corresponding author), Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	i.morgan@vet.gla.ac.uk						Bellanger S, 2001, J VIROL, V75, P7244, DOI 10.1128/JVI.75.16.7244-7251.2001; Beniston RG, 2001, CARCINOGENESIS, V22, P1069, DOI 10.1093/carcin/22.7.1069; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Boner W, 2002, J BIOL CHEM, V277, P22297, DOI 10.1074/jbc.M202163200; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Chao SF, 1999, BIOCHEMISTRY-US, V38, P4586, DOI 10.1021/bi982616v; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; HIBMA MH, 1995, EUR J BIOCHEM, V229, P517, DOI 10.1111/j.1432-1033.1995.tb20493.x; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lee D, 2002, ONCOGENE, V21, P5877, DOI 10.1038/sj.onc.1205723; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Mantovani F, 1999, SEMIN CANCER BIOL, V9, P387, DOI 10.1006/scbi.1999.0142; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165-4608(01)00575-1; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Penrose KJ, 2000, J VIROL, V74, P6031, DOI 10.1128/JVI.74.13.6031-6038.2000; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; Ruhland A, 2001, INT J CANCER, V91, P828, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1129&gt;3.0.CO;2-B; SANDERS CM, 1995, VIROLOGY, V211, P418, DOI 10.1006/viro.1995.1424; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; STUBENRAUCH F, 1994, J VIROL, V68, P6959, DOI 10.1128/JVI.68.11.6959-6966.1994; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Titolo S, 1999, J VIROL, V73, P5282, DOI 10.1128/JVI.73.7.5282-5293.1999; Vance KW, 1999, J BIOL CHEM, V274, P27839, DOI 10.1074/jbc.274.39.27839; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	47	14	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4469	4477		10.1038/sj.onc.1206746	http://dx.doi.org/10.1038/sj.onc.1206746			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881703				2022-12-17	WOS:000184054700002
J	Walters, DK; French, JD; Arendt, BK; Jelinek, DF				Walters, DK; French, JD; Arendt, BK; Jelinek, DF			Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex	ONCOGENE			English	Article						ErbB3; interferon-alpha; multiple myeloma	EPIDERMAL GROWTH-FACTOR; MULTIPLE-MYELOMA; RECEPTOR; INTERLEUKIN-6; ACTIVATION; CARCINOMA; PATHWAYS; LEUKEMIA; THERAPY; CANCER	We have previously demonstrated that the responsiveness of multiple myeloma (MM) cells to interferon-alpha (IFN-alpha) stimulation is variable, with an atypical growth response displayed by some cells. Here we report the ability of IFN-alpha to induce tyrosine phosphorylation of a 180 kDa band in the KAS-6/1 MM cell line, which is growth responsive to IFN-alpha. Further characterization demonstrated that this band corresponds to ErbB3. To our knowledge, this is the first report of ErbB3 expression in a cell type of the hematopoietic lineage. Although ErbB receptors have been shown to crosscommunicate with various other receptors, our results show for the first time that the IFN-alpha: receptor can crosscommunicate with ErbB3. To address the significance of these observations, we transfected ErbB3-negative DP-6 MM cells with ErbB3 and used siRNA to silence ErbB3 in the KAS-6/1 cell line. Although IFN-alpha transactivated ErbB3 in the DP-6 transfectants, it did not confer growth responsiveness to IFN-alpha. Interestingly, silencing ErbB3 expression in the KAS-6/1 cells decreased the overall growth response to IFN-alpha and to interleukin-6. These results suggest that ErbB3 expression alone does not uniquely confer IFN-alpha growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Jelinek, DF (corresponding author), Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.				NCI NIH HHS [CA62228, CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA062228, R01CA062228, P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arora T, 1999, J IMMUNOL, V162, P3289; BLADE J, 1991, BRIT J HAEMATOL, V79, P523, DOI 10.1111/j.1365-2141.1991.tb08068.x; BREGMAN MD, 1986, INT J CELL CLONING, V4, P224, DOI 10.1002/stem.5530040401; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; French JD, 2002, LEUKEMIA, V16, P1189, DOI 10.1038/sj.leu.2402516; Hill SM, 1998, ANAT REC, V253, P42, DOI 10.1002/(SICI)1097-0185(199804)253:2<42::AID-AR7>3.0.CO;2-G; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; JOURDAN M, 1991, J IMMUNOL, V147, P4402; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pestka Sidney, 1997, Seminars in Oncology, V24, P18; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; SALMON SE, 1991, SEMIN ONCOL, V18, P33; SAWAMURA M, 1992, BRIT J HAEMATOL, V82, P631, DOI 10.1111/j.1365-2141.1992.tb06484.x; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Walters DK, 2002, ANTISENSE NUCLEIC A, V12, P411, DOI 10.1089/108729002321082483; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	23	14	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3598	3607		10.1038/sj.onc.1206512	http://dx.doi.org/10.1038/sj.onc.1206512			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789268				2022-12-17	WOS:000183399200010
J	Tanuma, N; Shima, H; Shimada, S; Kikuchi, K				Tanuma, N; Shima, H; Shimada, S; Kikuchi, K			Reduced tumorigenicity of murine leukemia cells expressing protein-tyrosine phosphatase, PTP epsilon C	ONCOGENE			English	Article						PTP; PTP epsilon; tumorigenicity; M1	MACROPHAGE DIFFERENTIATION; MICE; M1; TRANSFORMATION; TRANSMEMBRANE; SUPPRESSES; FAMILY	Recently, we reported that a cytosolic isoform of protein-tyrosine phosphatase epsilon (PTPepsilonC), when overexpressed, inhibits terminal differentiation and apoptosis of murine M1 myeloblastic leukemia cells induced by interleukin-6. To determine whether these observed effects in vitro correspond to a tumorigenicity of PTPepsilonC-expresser (M1-epsilonC) cells in vivo, parent M1 and M1-epsilonC cells were intravenously inoculated into scid or nude mice, and survival of mice receiving these cell lines was monitored. Unexpectedly, both scid and nude mice inoculated with M1-epsilonC cells showed significantly prolonged survival time than those receiving parent M1 cells. While parent M1 cells inoculated by intravenous injection formed metastatic tumors in the spleen, expression of PTPepsilonC suppressed tumor development in the spleen. The results suggest a suppressive role of PTPepsilonC in tumorigenesis.	Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Inst Med Genet, Div Immunobiol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University; Hokkaido University	Kikuchi, K (corresponding author), Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0600815, Japan.	kikuchi@imm.hokudai.ac.jp	Tanuma, Naoyuki/V-7911-2019					Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; McArdle L, 2001, J INVEST DERMATOL, V117, P1255, DOI 10.1046/j.0022-202x.2001.01534.x; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Qiao S, 2001, J BIOL CHEM, V276, P9460, DOI 10.1074/jbc.M008744200; Smith SI, 2000, CANCER RES, V60, P808; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tanuma N, 2001, BLOOD, V98, P3030, DOI 10.1182/blood.V98.10.3030; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Urushibara N, 1998, INT J ONCOL, V12, P603; Warabi M, 2000, EXP MOL PATHOL, V68, P187, DOI 10.1006/exmp.2000.2303; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	25	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1758	1762		10.1038/sj.onc.1206267	http://dx.doi.org/10.1038/sj.onc.1206267			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660811				2022-12-17	WOS:000181678200002
J	Kuefer, MU; Chinwalla, V; Zeleznik-Le, NJ; Behm, FG; Naeve, CW; Rakestraw, KM; Mukatira, ST; Raimondi, SC; Morris, SW				Kuefer, MU; Chinwalla, V; Zeleznik-Le, NJ; Behm, FG; Naeve, CW; Rakestraw, KM; Mukatira, ST; Raimondi, SC; Morris, SW			Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14)	ONCOGENE			English	Article						t(11;15)(q23;q14); 11q23; MLL; AF15q14; leukemia	ACUTE MYELOID-LEUKEMIA; E1A-ASSOCIATED PROTEIN P300; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; 11Q23 TRANSLOCATIONS; HRX-ENL; DE-NOVO; BREAKPOINT; REGION; HOMOLOG	Translocations interrupting the mixed lineage leukemia gene (MLL) occur in 7-10% of acute lymphoblastic leukemia (ALL) and 5-6% of acute myeloid leukemia (AML) cases. One of these translocations, t(11;15)(q23;q14), occurs rarely in both ALL and AML. The gene on chromosome 15, AF15q14, was cloned recently in a patient with AML-M4. We have identified the same gene in a de novo T-ALL patient. However, both the MLL and AF15q14 breakpoints in these patients differed: in the previously reported AML-M4, both gene breaks were within exons, while in our ALL case the MLL break is intronic and the AF15q14 break is exonic. The MLL-AF15q14 fusion described previously shares no AF15q14 residues in common with the chimera reported here. The fusion proteins also differ with respect to MLL - the previously described fusion contains 55 extra amino acids as its MLL break is in exon 11, while the chimera we report breaks in intron 9. Contrary to the originally described normal AF15q14 (5925-bp cDNA encoding a 1833-aa protein), we identify a 7542-bp cDNA and a 2342-aa AF15q14 protein. AF15q14 appears identical to an mRNA previously found to be expressed in melanoma rendered nontumorigenic by microcell-mediated introduction of normal chromosome 6, suggesting the gene may function normally to suppress cell growth and/or enhance maturation.	St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Landratsamt Ostallgau, Abt Gesundheitswesen, D-87610 Marktoberdorf, Germany; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; St Jude Childrens Res Hosp, Hartwell Ctr Biotechnol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA	St Jude Children's Research Hospital; University of Chicago; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Morris, SW (corresponding author), St Jude Childrens Res Hosp, Dept Pathol, Room 4026,Thomas Tower,332 N Lauderdale St, Memphis, TN 38105 USA.	steve.morris@stjude.org	Raimondi, Susana C/N-8166-2018		NCI NIH HHS [CA76301, CA21756, CA40046, CA78438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078438, R01CA076301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Archimbaud E, 1998, LEUKEMIA, V12, P25, DOI 10.1038/sj.leu.2400853; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Chinwalla V, 2003, ONCOGENE, V22, P1400, DOI 10.1038/sj.onc.1206273; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; GREGOIRE MJ, 1993, LEUKEMIA, V7, P10; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayette S, 2000, ONCOGENE, V19, P4446, DOI 10.1038/sj.onc.1203789; HERNANDEZ JM, 1995, LEUKEMIA, V9, P1162; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kuefer M. U., 1997, Blood, V90, p318A; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; RAIMONDI SC, 1991, BLOOD, V77, P2016; Ray ME, 1996, ONCOGENE, V12, P2527; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Takimoto M, 2002, BRIT J CANCER, V86, P1757, DOI 10.1038/sj.bjc.6600328; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	25	14	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1418	1424		10.1038/sj.onc.1206272	http://dx.doi.org/10.1038/sj.onc.1206272			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618768				2022-12-17	WOS:000181360900017
J	Mikkers, H; Allen, J; Berns, A				Mikkers, H; Allen, J; Berns, A			Proviral activation of the tumor suppressor E2 alpha contributes to T cell lymphomagenesis in E mu Myc transgenic mice	ONCOGENE			English	Article						E2A; lymphoma; MuLv; c-Myc; transgene	MURINE LEUKEMIA-VIRUS; DNA-BINDING PROTEINS; ZINC-FINGER PROTEIN; LOOP-HELIX PROTEINS; C-MYC; TRANSCRIPTION FACTOR; E2A; GENE; PROGRESSION; APOPTOSIS	The basic helix-loop-helix factor E2A plays an important role in the development of B and T lymphocytes. In addition, E2a has been implicated as a gene with tumor suppressor activity, since mice deficient for E2a succumb to T cell lymphomas. We have performed retroviral tagging in EmuMyc transgenic mice to identify genes that contribute to lymphomagenesis. The EmuMyc transgenic mouse is a well-established model of a common translocation in human B cell lymphomas. Analyses of the proviral insertion sites in the MuLV-induced lymphomas revealed that a number of T cell lymphomas carried proviral insertions in the promoter region of E2a. These proviral insertions yield hybrid viral-E2a mRNAs resulting in a marked rise in E2A protein levels. The proviral insertions in E2a were predominantly of clonal origin indicating that E2a insertions are early events in these T cell lymphomas. The primary oncogenic effect of E2A is likely to be associated with enhancement of transcription of the c-Myc transgene via binding to the regulatory immunoglobulin enhancers. The results herein thus provide the first evidence that in a specific setting E2A overexpression can contribute to T-lymphomagenesis. This implies that E2a contains oncogenic features in addition to the previously described tumor suppressive properties.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GORER PA, 1950, BRIT J CANCER, V4, P372, DOI 10.1038/bjc.1950.36; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; HSU B, 1995, ONCOGENE, V11, P175; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kochetov AV, 1998, FEBS LETT, V440, P351, DOI 10.1016/S0014-5793(98)01482-3; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MIKKERS H, 2002, IN PRESS NATURE GENE; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Sakamuro D, 1995, ONCOGENE, V11, P2411; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1979, CELL, V18, P109, DOI 10.1016/0092-8674(79)90359-3; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Zhao F, 2001, MOL CELL BIOL, V21, P6346, DOI 10.1128/MCB.21.18.6346-6357.2001; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	51	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6559	6566		10.1038/sj.onc.1205930	http://dx.doi.org/10.1038/sj.onc.1205930			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242653				2022-12-17	WOS:000178202300001
J	Hansen, DV; Hsu, JY; Kaiser, BK; Jackson, PK; Eldridge, AG				Hansen, DV; Hsu, JY; Kaiser, BK; Jackson, PK; Eldridge, AG			Control of the centriole and centrosome cycles by ubiquitination enzymes	ONCOGENE			English	Review						ubiquitin ligases; ubiquitination; centrosome duplication	ANAPHASE-PROMOTING COMPLEX; AURORA-A KINASE; TUMOR-SUPPRESSOR COMPLEX; POLO-LIKE KINASE-1; CELL-CYCLE; MITOTIC SPINDLE; PROTEIN-KINASE; SUBSTRATE RECOGNITION; DESTRUCTION BOX; GAMMA-TUBULIN		Stanford Univ, Sch Med, Program Chem Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Canc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Jackson, PK (corresponding author), Stanford Univ, Sch Med, Program Chem Biol, 300 Pasteur Dr, Stanford, CA 94305 USA.	pjackson@stanford.edu		Hansen, David/0000-0001-9679-7189; Jackson, Peter/0000-0002-1742-2539				Arlot-Bonnemains Y, 2001, FEBS LETT, V508, P149, DOI 10.1016/S0014-5793(01)03048-4; Avides MD, 2001, NAT CELL BIOL, V3, P421, DOI 10.1038/35070110; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Balczon R, 2001, CHROMOSOMA, V110, P381, DOI 10.1007/s004120100157; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Bukholm IRK, 2001, INT J CANCER, V93, P283, DOI 10.1002/ijc.1311; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burton JL, 2000, MOL CELL BIOL, V20, P4614, DOI 10.1128/MCB.20.13.4614-4625.2000; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2000, J CELL SCI, V113, P1973; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, BIOL CELL, V91, P461, DOI 10.1016/S0248-4900(99)80087-2; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Glotzer M, 2002, CURR BIOL, V12, pR344, DOI 10.1016/S0960-9822(02)00854-0; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Gstaiger M, 1999, EXP CELL RES, V247, P554, DOI 10.1006/excr.1999.4386; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hames RS, 2002, BIOCHEM J, V361, P77, DOI 10.1042/0264-6021:3610077; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MACK G, 1993, CELL MOTIL CYTOSKEL, V26, P239, DOI 10.1002/cm.970260307; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Marshall WF, 2001, CURR BIOL, V11, pR487, DOI 10.1016/S0960-9822(01)00289-5; Marx J, 2001, SCIENCE, V292, P426, DOI 10.1126/science.292.5516.426; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Meek DW, 2000, PATHOL BIOL, V48, P246; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; Michalides R, 2002, BRIT J CANCER, V86, P402, DOI 10.1038/sj.bjc.6600072; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ou YY, 2002, CELL MOTIL CYTOSKEL, V51, P123, DOI 10.1002/cm.10019; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PATTERSON C, 2002, SCI STKE; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Roghi C, 1998, J CELL SCI, V111, P557; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Setoguchi A, 2001, AM J VET RES, V62, P1134, DOI 10.2460/ajvr.2001.62.1134; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tanaka T, 1999, CANCER RES, V59, P2041; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vidwans SJ, 1999, J CELL BIOL, V147, P1371, DOI 10.1083/jcb.147.7.1371; Wakefield JG, 2000, CURR BIOL, V10, P1367, DOI 10.1016/S0960-9822(00)00776-4; Wigley WC, 1999, J CELL BIOL, V145, P481; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	149	14	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6209	6221		10.1038/sj.onc.1205824	http://dx.doi.org/10.1038/sj.onc.1205824			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214251				2022-12-17	WOS:000177840500010
J	Yamamoto, Y; Mandai, K; Okabe, N; Hoshino, T; Nakanishi, H; Takai, Y				Yamamoto, Y; Mandai, K; Okabe, N; Hoshino, T; Nakanishi, H; Takai, Y			Localization of mLin-7 at nectin-based cell-cell junctions	ONCOGENE			English	Article						cell-cell junctions; nectin; afadin; cadherin; mLin-7	ADHESION MOLECULE UVOMORULIN; SYNAPTIC VESICLE EXOCYTOSIS; POLARIZED EPITHELIAL-CELLS; POLIOVIRUS RECEPTOR GENE; ALPHA-CATENIN; E-CADHERIN; ADHERENS JUNCTIONS; CYTOPLASMIC DOMAIN; ARMADILLO PROTEIN; NMDA RECEPTOR	In C. elegans, lin-7 as well as lin-2/lin-10 is involved in the proper localization of the LET-23 receptor tyrosine kinase that regulates vulval induction. The mammalian homologue, mLin-7, forms a ternary complex with the mammalian homologues of LIN-2 and LIN-10 and localizes at cell-cell junctions in epithelial cells, but the mechanism of this localization of mLin-7 is unknown. Nectin is an immunoglobulin-like cell-cell adhesion molecule that is involved in organization of adherens and tight junctions in epithelial cells. Nectin is indirectly associated with the cadherin-catenin system and the actin cytoskeleton through afadin, an actin filament-binding protein. We showed here that mLin-7 localized at the nectin-based cell-cell junctions. This localization of mLin-7 required the interaction of nectin with afadin, but not the cadherin-catenin system or the actin cytoskeleton. mLin-7 did not directly interact with nectin or afadin. The results indicate that mLin-7 localizes at cell-cell junctions through the nectin-afadin system.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp		Nakanishi, Hiroyuki/0000-0002-9765-0266; Mandai, Kenji/0000-0002-0115-6635				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bouchard MJ, 2000, MOL CELL BIOL, V20, P2865, DOI 10.1128/MCB.20.8.2865-2873.2000; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.3.CO;2-Y; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hata Y, 1996, J NEUROSCI, V16, P2488; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kemler R, 1992, Semin Cell Biol, V3, P149; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tseng TC, 2001, BBA-GENE STRUCT EXPR, V1518, P249, DOI 10.1016/S0167-4781(01)00191-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; YANAGIHARA K, 1991, CANCER RES, V51, P381; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; YONEMURA S, 1995, J CELL SCI, V108, P127; Zhang Y, 2001, FEBS LETT, V497, P99, DOI 10.1016/S0014-5793(01)02450-4	69	14	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2545	2554		10.1038/sj.onc.1205335	http://dx.doi.org/10.1038/sj.onc.1205335			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971189				2022-12-17	WOS:000174918400011
J	Foletti, A; Ackermann, J; Schmidt, A; Hummler, E; Beermann, F				Foletti, A; Ackermann, J; Schmidt, A; Hummler, E; Beermann, F			Absence of fibroblast growth factor 2 does not prevent tumor formation originating from the RPE	ONCOGENE			English	Article						eye; FGF; transgenic; gene targeting; pigment; RPE	RETINAL-PIGMENT EPITHELIUM; TRANSGENIC MICE; CELL-LINE; INDUCED TRANSDIFFERENTIATION; TRANSFORMED PHENOTYPE; TARGETED DISRUPTION; MELANOCYTIC LESIONS; T-ANTIGEN; EXPRESSION; GENE	We have analysed the importance of fibroblast growth factor 2 (FGF2) in tumor development. In a transgenic mouse model (Tyrpl-Tag) tumors form in the retinal pigment epithelium (RPE), invade surrounding tissues, and metastasize to lymph node and spleen. To address whether RPE tumor formation is dependent on FGF2, we generated FGF2-deficient mice. Such mice appeared healthy and exhibited no impairment of growth or development. Tyrpl-Tag transgenic mice, which are lacking FGF2 (FGF2-/-) developed RPE tumors that metastasize to spleen and lymph nodes. Tumor growth and survival rate are identical to Typpl-Tag transgenic littermates expressing FGF2. Cell lines were isolated from RPE tumors of wild-type and FGF2-deficient mice. They grow in culture, are pigmented and form vascularized tumors, when injected subcutaneously into nude mice of either FGF2-/- or FGF2+/+ genetic background. Kinetics of tumor growth was identical and independent of presence of FGF2. Together, these results demonstrate that FGF2 is not essential for tumor formation of the RPE thus suggesting that tumor growth in general may not be dependent on FGF2.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne	Beermann, F (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							ANAND R, 1994, INVEST OPHTH VIS SCI, V35, P3533; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Beermann F, 1999, PIGM CELL RES, V12, P71, DOI 10.1111/j.1600-0749.1999.tb00746.x; Berking C, 2001, AM J PATHOL, V158, P943, DOI 10.1016/S0002-9440(10)64041-2; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Fiore F, 1997, INT J DEV BIOL, V41, P639; Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Jordan S, 2000, PIGM CELL RES, V13, P70, DOI 10.1034/j.1600-0749.2000.130204.x; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; Kato T, 1999, BRAIN DEV-JPN, V21, P138; LOEFFLER KU, 1996, GRAEFES ARCH CLIN EX, V234, P70; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MARET A, 1995, CANCER RES, V55, P5075; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Miller DL, 2000, MOL CELL BIOL, V20, P2260, DOI 10.1128/MCB.20.6.2260-2268.2000; MINTZ B, 1992, P NATL ACAD SCI USA, V89, P11421, DOI 10.1073/pnas.89.23.11421; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.3.CO;2-R; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; OBrien T, 1997, CANCER RES, V57, P136; Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649; OPAS M, 1994, DEV BIOL, V161, P440, DOI 10.1006/dbio.1994.1043; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; PELLIEUX C, 2001, IN PRESS J CLIN INVE; Penna D, 1998, ONCOGENE, V17, P2601, DOI 10.1038/sj.onc.1202196; RAKOCZY PE, 1993, INVEST OPHTH VIS SCI, V34, P1845; REED JA, 1994, AM J PATHOL, V144, P329; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; Schmidt A, 1998, BRAIN RES PROTOC, V3, P54, DOI 10.1016/S1385-299X(98)00021-X; Schultz JE, 1999, J CLIN INVEST, V104, P709, DOI 10.1172/JCI7315; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Sliutz G, 1995, ANTICANCER RES, V15, P2675; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Vaccarino FM, 1999, NAT NEUROSCI, V2, P246, DOI 10.1038/6350; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201; ZUNIGA MBA, 1996, DEV BIOL, V180, P680	57	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1841	1847		10.1038/sj.onc.1205030	http://dx.doi.org/10.1038/sj.onc.1205030			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896616				2022-12-17	WOS:000174284500006
J	Konduri, SD; Osman, FA; Rao, CN; Srinivas, H; Yanamandra, N; Tasiou, A; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Kouraklis, G; Rao, JS				Konduri, SD; Osman, FA; Rao, CN; Srinivas, H; Yanamandra, N; Tasiou, A; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Kouraklis, G; Rao, JS			Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas	ONCOGENE			English	Article						promoter; transcriptional regulation; TFPI-2; gliomas	SERINE PROTEINASE-INHIBITORS; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; COAGULATION INHIBITOR; PLASMINOGEN-ACTIVATOR; LESS PROMOTER; MESSENGER-RNA; GENE; EXPRESSION; IDENTIFICATION	Tissue factor pathway inhibitor-2 (TFPI-2), a serine protease inhibitor abundant in the extra cellular matrix, is highly expressed in non-invasive cells but undetectable levels in highly invasive human glioma cells. The mechanisms responsible for its transcriptional regulation are not well elucidated. In this study, we made several deletion constructs from a 3.6 kb genomic fragment from Hs683 cells containing the 5'-flanking region of the TFPI-2 gene, transiently transfected with these constructs into non-invasive (Hs683) and highly invasive (SNB19) human glioma cells, and assessed their expression by using a luciferase reporter gene. Three constructs showed high promoter activity (pTF5, -670 to +1; pTF6, -312 to +1; pTF2, -1511 to +1). Another construct, pTF8 (-81 to +1), showed no activity. PTF9, a variant of pTF5 in which a further 231 bp fragment (-312 to -81) was deleted, from the [-670 to +1] pTF5 region, also showed no promoter activity. Hence, (-312 to -81) this region is essential for the transcription of TFPI-2 in glioma cells. Sequencing of this promoter region revealed that it has a high G+C content, contains potential SP1 and AP1 binding motifs, and lacks canonical TATA and CAAT boxes immediately upstream of the major transcriptional initiation site, although CAAT boxes were found about -3000 bp upstream of the transcription start site. We also found a strong repressor in the region between -927 to -1181, upstream of the major transcriptional initiation site, followed by positive elements or enhancers between -1511 to -1181. These positive elements masked the silencer effect. Finally TFPI-2 was induced in Hs683 cells transfected with the pTF6 construct (-312 to + 1) and stimulated with phorbol-12-myristate-13-acetate (PMA). We conclude that the -312 to +1 region is critical for the minimal and inducible regulation of TFPI-2 in non-invasive (Hs683) and highly invasive (SNB19) human glioma cell lines.	Univ Illinois, Sch Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Dept Neuropathol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Ctr Prostate Dis Res, Rockville, MD USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Ctr Hlth Sci, Albuquerque, NM 87131 USA; Univ Athens, Sch Med, Dept Propedeut Surg, GR-11527 Athens, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Zymogenet Inc.; University of New Mexico; Athens Medical School; National & Kapodistrian University of Athens	Rao, JS (corresponding author), Univ Illinois, Sch Med, Dept Biomed & Therapeut Sci, Div Canc Biol, 1 Illini Dr, Peoria, IL 61656 USA.	jsrao@uic.edu		Tasiou, Anastasia/0000-0002-8853-540X	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA076350] Funding Source: NIH RePORTER; NCI NIH HHS [CA-75557, CA-76350, CA-75692] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BUTZOW R, 1988, BIOCHEM BIOPH RES CO, V150, P483, DOI 10.1016/0006-291X(88)90546-3; Chabannes E, 2001, CELL SIGNAL, V13, P585, DOI 10.1016/S0898-6568(01)00184-X; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHEN L, 1992, J BIOL CHEM, V267, P12380; ENJYOJI K, 1993, GENOMICS, V17, P423, DOI 10.1006/geno.1993.1342; GIRARD TJ, 1991, J BIOL CHEM, V266, P5036; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; HASCALL VC, 1991, CELL BIOL EXTRA CELL; Huber R, 1998, GENE, V214, P35, DOI 10.1016/S0378-1119(98)00233-9; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Kazama Y, 2000, THROMB HAEMOSTASIS, V83, P141; Kim MS, 2001, CANCER LETT, V171, P79, DOI 10.1016/S0304-3835(01)00505-5; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; KORNER G, 1993, J CELL PHYSIOL, V154, P456, DOI 10.1002/jcp.1041540303; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEE JK, 1992, J BIOL CHEM, V267, P4638; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; MIMURO J, 1987, BLOOD, V70, P721; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Miyagi Y, 1996, GENOMICS, V35, P267, DOI 10.1006/geno.1996.0353; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Petersen LC, 1996, EUR J BIOCHEM, V235, P310, DOI 10.1111/j.1432-1033.1996.0310f.x; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V319, P55, DOI 10.1006/abbi.1995.1266; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Rao CN, 2001, CLIN CANCER RES, V7, P570; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Udagawa K, 1998, PLACENTA, V19, P217, DOI 10.1016/S0143-4004(98)90011-X; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WERLING RW, 1993, THROMB HAEMOSTASIS, V69, P366	41	14	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					921	928		10.1038/sj.onc.1204983	http://dx.doi.org/10.1038/sj.onc.1204983			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840337				2022-12-17	WOS:000173427100007
J	Hu, XT; Zhang, XH; Zhong, Q; Fisher, AB; Bryington, M; Zuckerman, KS				Hu, XT; Zhang, XH; Zhong, Q; Fisher, AB; Bryington, M; Zuckerman, KS			Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells	ONCOGENE			English	Article						cell cycle; transforming growth factor; cell line; Rb protein; cdk inhibitor	DEPENDENT-KINASE INHIBITOR; FACTOR-BETA; CDK INHIBITOR; MAMMALIAN-CELLS; TGF-BETA; G1 PHASE; PROTEIN-PHOSPHORYLATION; EPITHELIAL-CELLS; G(1) CYCLINS; P27(KIP1)	In this report we have studied the mechanism by which Transforming Growth Factor beta (TGF beta) inhibits growth of human myeloid leukemia cell lines. TGF beta1 arrested cells in G1 phase and significantly downregulated the expression of cyclin D2, cyclin D3, cdk4, cyclin A, and cdk2. The downregulation of the molecules resulted in approximately 50-90% decrease of the molecule-dependent kinase activity, varying with each molecule. Although treatment of cells with TGF beta1 upregulated accumulation of p27(kip1) in both nucleus and cytoplasm, the association of the p27(kip1) with cdk2, cyclin A, cyclin D2, cyclin D3, and cdk4 was markedly downregulated, suggesting that p27(kip1) is not responsible for the downregulation of the kinase activity. In contrast, TGF beta1 upregulated cyclin E-associated p27(kip1) with no effect on the expression of cyclin E. p27(kip1)-immunodepletion upregulated cyclin E-dependent kinase activity by more than 10-fold in TGF beta1-treated cells but not in proliferating cells; whereas immunodepletion of p27(kip1) from cdk2-immunoprecipitates markedly downregulated cdk2 kinase activity in the lysates extracted from both proliferating and TGF beta -treated cells. Consistent with this observation, TGF beta1 and p27(kip1) antisense cDNA had a synergistic or additive inhibitory effect on cdk2 but not cyclin E-dependent kinase activity. Our data suggest that (1) TGF beta1-mediated growth inhibition is accomplished through multiple pathways and (2) p27(kip1) has opposing effects on cdk2 and cyclin E activity in response to TGF beta1.	Univ S Florida, Hematol Malignancies Program, Interdisciplinary Oncol Program, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Hu, XT (corresponding author), Univ S Florida, Hematol Malignancies Program, Interdisciplinary Oncol Program, MCC 3142,12902 Magnolia Dr, Tampa, FL 33612 USA.	hu@moffitt.usf.edu						ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BATES S, 1994, ONCOGENE, V9, P71; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Drexler HG, 1998, LEUKEMIA RES, V22, P927, DOI 10.1016/S0145-2126(98)00088-5; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAUTSCH MP, 1995, J CELL BIOCHEM, V58, P517, DOI 10.1002/jcb.240580415; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hu XT, 1999, EXP HEMATOL, V27, P605, DOI 10.1016/S0301-472X(99)00004-1; Hu XT, 2000, BIOCHEM BIOPH RES CO, V276, P930, DOI 10.1006/bbrc.2000.3556; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singh SP, 1998, CANCER RES, V58, P1730; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; Wang G, 1999, ONCOGENE, V18, P5204, DOI 10.1038/sj.onc.1202912; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	49	14	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6840	6850		10.1038/sj.onc.1204790	http://dx.doi.org/10.1038/sj.onc.1204790			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687963				2022-12-17	WOS:000171641000005
J	Futamura, M; Kamiya, S; Tsukamoto, M; Hirano, A; Monden, Y; Arakawa, H; Nishimura, S				Futamura, M; Kamiya, S; Tsukamoto, M; Hirano, A; Monden, Y; Arakawa, H; Nishimura, S			Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells	ONCOGENE			English	Article						malolactomycin D; Ras-responsive element; MMP; tansformation	ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; FACTOR-BINDING-SITES; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; PROMOTER ACTIVITY; HUMAN CANCER; C-FOS; INVASION; ONCOGENES	To search for anti-cancer agents, a screening system for Ras signal inhibitors was developed using a NIH3T3 cell Hue with an introduced reporter gene which is controlled by the Ras-responsive element (RRE). With this screening system, malolactomycin D was identified as a selective inhibitor of transcription from the RRE. This compound was found to preferentially inhibit the anchorage-independent growth rather than the anchorage-dependent growth of Ras-transformed NIH3T3 cells. The expression of matrix metalloproteinases MMP-1 and MMP-9, which have RRE in their promoters, were reduced by treatment with malolactomycin D at the translational and transcriptional levels. Analysis of the activity of mitogen-activated protein (MAP) kinases, which play important roles in transduction of the Ras signal, showed that malolactomycin D inhibits the activation of p38 MAP kinase and Jun N-terminal-kinase (JNK) but not extracellular signal-regulated kinase 1 or 2 (ERK1 or 2). These findings suggest that by inhibiting the pathway that leads to the activation of p38 MAP kinase and JNK, malolactomycin D suppresses the expression of MMPs. Since MMPs play important roles in metastasis and maintenance of the microenvironment of tumor cells, both of which facilitate tumor growth, the inhibition of MMPs by malolactomycin D is believed to contribute to its ability to inhibit Ras-mediated tumorigenesis.	Merck Res Labs, Banyu Tsukuba Res Inst Collaborat, Tsukuba, Ibaraki 3002611, Japan	Merck & Company	Nishimura, S (corresponding author), Merck Res Labs, Banyu Tsukuba Res Inst Collaborat, Okubo 3, Tsukuba, Ibaraki 3002611, Japan.							Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOS JL, 1989, CANCER RES, V49, P4682; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Buttice G, 1996, ONCOGENE, V13, P2297; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; COROMINAS M, 1991, ENVIRON HEALTH PERSP, V93, P19, DOI 10.2307/3431163; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GOUSTIN AS, 1986, CANCER RES, V46, P1015; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Johansson N, 2000, J CELL SCI, V113, P227; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Simon C, 1998, CANCER RES, V58, P1135; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Tanaka Y, 1997, J ANTIBIOT, V50, P194, DOI 10.7164/antibiotics.50.194; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; White LA, 1997, CONNECT TISSUE RES, V36, P321, DOI 10.3109/03008209709160231; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Zhao A, 1999, J ANTIBIOT, V52, P1086, DOI 10.7164/antibiotics.52.1086	39	14	14	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6724	6730		10.1038/sj.onc.1204878	http://dx.doi.org/10.1038/sj.onc.1204878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709707				2022-12-17	WOS:000171551600009
J	Brandvold, KA; Ewert, DL; Kent, SC; Neiman, P; Ruddell, A				Brandvold, KA; Ewert, DL; Kent, SC; Neiman, P; Ruddell, A			Blocked B cell differentiation and emigration support the early growth of Myc-induced lymphomas	ONCOGENE			English	Article						Myc; lymphoma; retrovirus; B cell differentiation	AVIAN-LEUKOSIS VIRUS; C-MYC; TRANSGENIC MICE; STEM-CELLS; EXPRESSION; APOPTOSIS; FABRICIUS; BURSA; INDUCTION; PROTEIN	Avian leukosis virus induces lymphoma in chickens after proviral integration within the c-Myc gene, and subsequent expansion of Myc-overexpressing lymphocytes within transformed bursal follicles, The clonal expansion of these follicles allowed us to examine how Myc influences cell differentiation, growth, and apoptosis in lymphoid progenitors soon after the onset of Myc overexpression, Immunohistochemical analysis of developmental markers established that Myc overexpression consistently blocks lymphocyte differentiation at a late embryonic stage. Myc-transformed follicles also grow much more rapidly than normal follicles, This rapid growth is not mediated by suppression of apoptosis, as normal and Myc-transformed follicles showed similar rates of cell death by TUNEL immunohistochemical analyis of cells undergoing DNA degradation. Measurements of DNA synthesis and mitotic index showed modest effects of Myc to increase lymphocyte proliferation, as normal lymphocytes already divide rapidly. The major mechanism mediating rapid growth of transformed follicles instead involved failure of myc-overexpressing lymphocytes to emigrate from transformed follicles, while normal lymphocytes actively emigrate after hatching, as measured by BrdU pulse-chase labeling and immunohistochemical measurements. This failure to undergo the normal program of differentiation and subsequent bursal retention of lymphocytes accounts for most of the growth of transformed follicles, while Myc-induced proliferation makes a smaller contribution.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Wistar Inst Anat & Biol, Philadelphia, PA USA; Harvard Univ, Brigham & Womens Hosp, Inst Med, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Washington, Dept Med, Washington, DC USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; The Wistar Institute; Harvard University; Brigham & Women's Hospital; University of Washington; University of Washington; University of Washington Seattle	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,Mailstop C2-023,POB 19024, Seattle, WA 98109 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA20068, R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brabletz T, 2000, AM J PATHOL, V156, P865, DOI 10.1016/S0002-9440(10)64955-3; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Flenghi L, 1996, AM J PATHOL, V148, P1543; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MAAS HJL, 1982, AVIAN PATHOL, V11, P309, DOI 10.1080/03079458208436103; MASTELLER EL, 1995, DEVELOPMENT, V121, P1657; MASTELLER EL, 1995, J IMMUNOL, V155, P5550; NATH P, 1987, EXP CELL RES, V169, P215, DOI 10.1016/0014-4827(87)90239-4; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1988, CURR TOP MICROBIOL, V141, P67; NEIMAN PE, 1994, COLD SPRING HARB SYM, V59, P509, DOI 10.1101/SQB.1994.059.01.056; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; PARAMITHIOTIS E, 1995, J EXP MED, V181, P105, DOI 10.1084/jem.181.1.105; PARAMITHIOTIS E, 1994, EUR J IMMUNOL, V24, P458, DOI 10.1002/eji.1830240229; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Prasad VS, 1997, MOL CARCINOGEN, V18, P66, DOI 10.1002/(SICI)1098-2744(199702)18:2<66::AID-MC2>3.0.CO;2-O; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RATCLIFFE MJH, 1985, IMMUNOL TODAY, V6, P223, DOI 10.1016/0167-5699(85)90039-8; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SCHOENWOLF GC, 1981, J MORPHOL, V167, P35, DOI 10.1002/jmor.1051670104; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	38	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3226	3234		10.1038/sj.onc.1204431	http://dx.doi.org/10.1038/sj.onc.1204431			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423972				2022-12-17	WOS:000169163500006
J	Cures, A; House, C; Kanei-Ishii, C; Kemp, B; Ramsay, RG				Cures, A; House, C; Kanei-Ishii, C; Kemp, B; Ramsay, RG			Constitutive c-Myb amino-terminal phosphorylation and DNA binding activity uncoupled during entry and passage through the cell cycle	ONCOGENE			English	Article						c-Myb; casein kinase 2; DNA binding; phosphorylation	PROTO-ONCOGENE; LEUCINE-ZIPPER; MESSENGER-RNA; EXPRESSION; PROLIFERATION; ACTIVATION; PROTEINS; GENE; DIFFERENTIATION; INHIBITION	The c-myb gene encodes a transcription factor that is central to hematopoietic cell growth, Phosphorylation of c-Myb by casein kinase 2 (CK2) at serines 11 and 12 has been variously implicated in the regulation of DNA binding. However, it is unclear when c-Myb phosphorylation at serines II and 12 occurs during the cell cycle and how this is regulated, We generated specific antisera that recognize phosphoserines II and 12 of c-Myb, C-Myb protein levels, extent of CK2 phosphorylation and DNA binding were then monitored following mitogenic stimulus and passage through the cell cycle in normal peripheral T-cells and the T leukemia cell line CCRF-CEM, We found that endogenous c-Myb is constitutively phosphorylated at serines 11 and 12, The amount of phosphorylated c-Myb correlates with DNA binding activity in cycling CEM cells but not upon entry of T-cells into the cell cycle, Exogenous expression of c-Myb with substitutions of serines 11 and 12 with glutamic acid or alanine had no effect on the transactivation of a c-Myb responsive reporter. These data strongly suggest that c-Myb is constitutively phosphorylated on serines 11 and 12 by CK2 or like activity and is not regulated during the cell cycle.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 3000, Australia; RIKEN, Tsukuba Inst, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan	Peter Maccallum Cancer Center; RIKEN	Ramsay, RG (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, 481 Little Lonsdale St, Melbourne, Vic 3000, Australia.		Ramsay, Robert G/C-3291-2015; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Ramsay, Robert G/0000-0001-5003-0433; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; DARZYNKIEWICZ Z, 1976, P NATL ACAD SCI USA, V73, P2881, DOI 10.1073/pnas.73.8.2881; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1991, BLOOD, V77, P149; HODGES RS, 1975, ANAL BIOCHEM, V65, P241, DOI 10.1016/0003-2697(75)90509-6; KAUFFMAN MG, 1990, ANAL BIOCHEM, V191, P41, DOI 10.1016/0003-2697(90)90384-L; Lam MHC, 1999, J BIOL CHEM, V274, P18559, DOI 10.1074/jbc.274.26.18559; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCARTHY RE, 1965, EXP CELL RES, V40, P197, DOI 10.1016/0014-4827(65)90316-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NORMAN MR, 1977, CANCER RES, V37, P3785; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; Ramsay R G, 1995, Methods Mol Biol, V37, P369; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1995, ONCOGENE, V11, P2113; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sala A, 1996, CANCER RES, V56, P1991; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TIGANIS T, 1993, BIOCHIM BIOPHYS ACTA, V1203, P282, DOI 10.1016/0167-4838(93)90095-9; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Zorbas M, 1999, ONCOGENE, V18, P5821, DOI 10.1038/sj.onc.1202971	38	14	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1784	1792		10.1038/sj.onc.1204345	http://dx.doi.org/10.1038/sj.onc.1204345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313925				2022-12-17	WOS:000167750900011
J	MacCarthy-Morrogh, L; Wood, L; Brimmell, M; Johnson, PWM; Packham, G				MacCarthy-Morrogh, L; Wood, L; Brimmell, M; Johnson, PWM; Packham, G			Identification of a novel human BCL-X promoter and exon	ONCOGENE			English	Article						apoptosis; BCL-X-L; splicing; promoter; transcription	INDUCED APOPTOSIS; BCL-X(L); EXPRESSION; GENE; CANCER; CELLS	BCL-X-L is a key anti-apoptotic BCL-2 family protein that is widely expressed in human cancer cells and is induced in response to diverse survival signals. The translation initiation codon for BCL-X-L is located in BCL-X exon II and previous analyses have indicated that BCL-X-L RNAs initiate close to the start of exon IT or additionally contain a non-coding first exon (exon IA) spliced to exon TI, Using 5' RACE we have now identified a novel BCL-X non-coding exon (exon IB) which is spliced directly to exon IJ[ in place of exon IA, Exon IB-containing RNAs encoded BCL-X-L and were detected in non-malignant lymphocytes and lymphoma cells from lymph node biopsies and mere expressed at significant levels in cell lines derived from ovarian, colon and breast cancers. We identified two TATA-hox sequences upstream of exon TB and demonstrated that surrounding genomic sequences contained strong promoter activity in lymphoma cells (approximately 300-fold active relative to controls). We have therefore identified a powerful new BCL-X promoter and a novel exon that contributes to BCL-X-L expression.	Univ Southampton, Southampton Gen Hosp, Sch Med, CRC Wessex Med Oncol Unit,Canc Sci Div, Southampton SO16 6YD, Hants, England; Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, Sch Med, London W12 1PG, England	University of Southampton; Imperial College London; Ludwig Institute for Cancer Research	Packham, G (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, CRC Wessex Med Oncol Unit,Canc Sci Div, Ctr Block,Level F, Southampton SO16 6YD, Hants, England.		Johnson, Peter/L-2403-2018; Johnson, Peter/O-3529-2019	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Packham, Graham/0000-0002-9232-5691				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; FANG W, 1994, J IMMUNOL, V153, P4388; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Harigai M, 1996, ONCOGENE, V12, P1369; Krajewska M, 1996, CANCER RES, V56, P2422; Lohmann CM, 2000, CYTOMETRY, V42, P61, DOI 10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pena JC, 1998, CANCER RES, V58, P2111; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x	19	14	14	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5534	5538		10.1038/sj.onc.1203949	http://dx.doi.org/10.1038/sj.onc.1203949			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114731				2022-12-17	WOS:000165396100014
J	Cinti, C; Claudio, PP; De Luca, A; Cuccurese, M; Howard, CM; D'Esposito, M; Paggi, MG; La Sala, D; Azzoni, L; Halazonetis, TD; Giordano, A; Maraldi, NM				Cinti, C; Claudio, PP; De Luca, A; Cuccurese, M; Howard, CM; D'Esposito, M; Paggi, MG; La Sala, D; Azzoni, L; Halazonetis, TD; Giordano, A; Maraldi, NM			A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line	ONCOGENE			English	Article						drug resistance; p53 mutations; apoptotic genes; T-lymphoblastoid cells	TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONALLY ACTIVE P53; PROTEIN-KINASE; P53-DEPENDENT APOPTOSIS; MUTANT P53; BAX GENE; PHOSPHORYLATION; CHEMOTHERAPY; GROWTH; CANCER	The p53 protein accumulates rapidly through posttranscriptional mechanisms following cellular exposure to DNA damaging agents and is also activated as a transcription factor leading to growth arrest or apoptosis, Phosphorylation of p53 occurs after DNA damage thereby modulating its activity and impeding the interaction of p53 with its negative regulator oncogene Mdm2. The serines 15 and 37 present in the amino terminal region of p53 are phosphorylated by the DNA-dependent protein kinase (DNA-PK) in response to DNA damage, In order to verify if specific p53 mutations occur in the multi-drug resistance phenotype, we analysed the p53 gene in two T-lymphoblastoid cell lines, CCRF-CEM and its multi-drug-resistant clone CCRF-CEM VLB100, selected for resistance to vinblastine sulfate and cross-resistant to other cytotoxic drugs, Both cell lines showed two heterozygous mutations in the DNA binding domain at codons 175 and 248. The multi-drug resistant cell line, CCRF-CEM VLB100, showed an additional mutation that involves the serine 37 whose phosphorylation is important to modulate the protein activity in response to DNA damage, The effects of these mutations on p53 transactivation capacity were evaluated, The activity of p53 on pro-apoptotic genes expression in response to DNA damage induced by (-irradiation, was affected in the vinblastine (VLB) resistant cell line but not in CCRF-CEM sensitive cell Line resulting in a much reduced apoptotic cell death of the multi-drug resistant cells.	IOR, CNR, Ist Citomorfol Normale & Patol, I-40136 Bologna, Italy; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Naples Federico II, Lab Cell Odontostomatol & Maxillofacciali, I-80131 Naples, Italy; Regina Elena Inst Canc Res, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, I-00158 Rome, Italy; CNR, Int Inst Genet & Biophys, Genome Res & Sequencing Lab, I-80125 Naples, Italy; Wistar Inst Anat & Biol, Dept Mol Oncol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; IOR, Lab Cell Biol & Electron Microscopy, I-40136 Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Jefferson University; University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); The Wistar Institute; Jefferson University	Cinti, C (corresponding author), IOR, CNR, Ist Citomorfol Normale & Patol, Via Barbiano 1-10, I-40136 Bologna, Italy.		Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021; Halazonetis, Thanos/D-7923-2011; De Luca, Antonio/AAD-9562-2020; Paggi, Marco G./K-3494-2018	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; De Luca, Antonio/0000-0002-3905-6154; Cinti, Caterina/0000-0001-8049-0369; Howard, Candace/0000-0001-6537-3551				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CIANFRIGLIA M, 1991, INT J CANCER, V49, P394, DOI 10.1002/ijc.2910490314; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOOPER ML, 1994, J CELL SCI, P13; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAYR GA, 1995, CANCER RES, V55, P2410; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MEEK DW, 1997, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MIYASHITA T, 1995, CELL, V80, P293; MOYRET C, 1994, ONCOGENE, V9, P1739; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OITVAI ZN, 1993, CELL, V74, P609; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARK DJ, 1994, ONCOGENE, V9, P1899; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Righetti SC, 1996, CANCER RES, V56, P689; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; Shelling AN, 1997, LANCET, V349, P744, DOI 10.1016/S0140-6736(05)60195-X; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; TISHLER RB, 1995, CANCER RES, V55, P6021; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2000	19	44					5098	5105		10.1038/sj.onc.1203848	http://dx.doi.org/10.1038/sj.onc.1203848			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042698				2022-12-17	WOS:000089930100007
J	Laham, LE; Mukhopadhyay, N; Roberts, TM				Laham, LE; Mukhopadhyay, N; Roberts, TM			The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity	ONCOGENE			English	Article						Lck; tyrosine kinase; activation loop; substrate specificity	RECEPTOR TYROSINE KINASE; AFFINITY PHOSPHOTYROSYL PEPTIDE; CRYSTAL-STRUCTURE; PROTEIN-KINASE; SH2 DOMAIN; C-SRC; INSULIN-RECEPTOR; AUTOPHOSPHORYLATION; PHOSPHORYLATION; MUTATION	The activities of Src-family non-receptor tyrosine kinases are regulated by structural changes that alter the orientation of key residues within the catalytic domain. In this study, we investigate the effects of activation loop mutations on regulation of the lymphocyte-specific kinase Lck (p56(lck)). Substitution of 5-7 residues amino terminal to the conserved activation loop tyrosine (Y-394) increases kinase activity and oncogenic potential regardless of regulatory C-terminal tail phosphorylation levels (Y-505), while most mutations in the 13 residues carboxyl to Y-394 decrease kinase activity. Phosphorylation of the C-terminal regulatory tail is carried out by the cytosolic tyrosine kinase Csk and we find that mutations upstream or downstream of Y394 or mutation of Y-394 do not affect the level of Y-505 phosphorylation, In addition, we report that mutations on either side of Y-394 affect substrate specificity in vivo. We conclude that the high degree of conservation across the entire activation loop of Src-family kinases is critical for normal regulation of kinase activity and oncogenicity as well as substrate selection.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Roberts, TM (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER; NCI NIH HHS [CA43803-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Bougeret C, 1996, J BIOL CHEM, V271, P7465, DOI 10.1074/jbc.271.13.7465; CARRERA AC, 1995, ONCOGENE, V10, P2379; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TRAFNY EAM, 1994, PROTEIN SCI, V3, P176; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEIL R, 1994, J BIOL CHEM, V269, P22830; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	33	14	14	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3961	3970		10.1038/sj.onc.1203738	http://dx.doi.org/10.1038/sj.onc.1203738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962552				2022-12-17	WOS:000088825300001
J	Jiang, H; Karnezis, AN; Tao, MY; Guida, PM; Zhu, L				Jiang, H; Karnezis, AN; Tao, MY; Guida, PM; Zhu, L			pRB and p107 have distinct effects when expressed in pRB-deficient tumor cells at physiologically relevant levels	ONCOGENE			English	Article						tumor suppressor; retinoblastoma protein; p107; E2F; growth suppression	CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA GENE-PRODUCT; RB-RELATED P107; GROWTH SUPPRESSION; TRANSCRIPTION FACTORS; FAMILY MEMBERS; MICE LACKING; MUSCLE-CELLS; IN-VIVO; PROTEIN	A key difference among the three structurally similar pRB family members is that only pRB is a tumor suppressor. Identification of distinctive functional differences between pRB and p107/p130 therefore holds promise for a better understanding of the tumor suppression mechanisms of pRB, Enigmatically, pRB and p107 have been shown to have indistinguishable growth suppression activities when studied in the pRB-deficient Saos-2 cell system. In this study, we discovered that, when expressed at physiologically relevant levels, pRB and p107 had distinctive effects in causing growth suppression, pRB induced cellular p130 levels while p107 repressed them, p107, but not pRB, blocked cells inside S phase in addition to G1 arrest. In contrast, no qualitative differences were identified in their abilities to repress the expression of a set of suspected pRB/E2F repression target genes. These results indicate that pRB and p107 possess different growth suppression effects, despite the fact that they have similar E2F repression effects.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhu, L (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, 1300 Morris Pk Ave,Room U-519, Bronx, NY 10461 USA.							Ausubel FA, 1990, CURRENT PROTOCOLS MO; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Buchmann AM, 1998, MOL CELL BIOL, V18, P4565, DOI 10.1128/MCB.18.8.4565; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLBRINIK D, 1996, GENE DEV, V10, P1633; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; DYSON N, 1994, J CELL SCI, P81; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARPER JW, 1993, CELL, V75, P805; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Tiemann F, 1998, EMBO J, V17, P1040, DOI 10.1093/emboj/17.4.1040; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3878	3887		10.1038/sj.onc.1203722	http://dx.doi.org/10.1038/sj.onc.1203722			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951581				2022-12-17	WOS:000088614300006
J	Jansen, AP; Colburn, NH; Verma, AK				Jansen, AP; Colburn, NH; Verma, AK			Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation	ONCOGENE			English	Article						c-Jun; phorbol ester; TPA; ODC; cell transformation	PROTEIN KINASE-C; ALPHA-DIFLUOROMETHYLORNITHINE; MOUSE SKIN; IRREVERSIBLE INHIBITOR; INDUCED TRANSFORMATION; PHORBOL ESTERS; JB6 CELLS; RECEPTOR; MYC; 12-O-TETRADECANOYLPHORBOL-13-ACETATE	Activator protein 1 (AP-1) transactivation and ornithine decarboxylase (ODC) activity have been established as essential downstream effecters of mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA), Previous studies have shown that inhibition of either AP-1 transactivation or ODC activity suppressed tumor promoter-induced transformation. By utilizing the JB6 mouse epidermal cell system, the present study determined whether TPA-induced ODC gene expression and activity is independent of AP-1 transactivation. In three independent JB6 (P+) clones, stably expressing dominant negative c-jun, TPA-induced ODC gene expression and activity were similar compared to JB6 P+ cells expressing vector-control alone, while AP-1-dependent transcription was inhibited, Transformation-insensitive JB6 (P-) cells, which lack TPA-inducible c-jun expression, also exhibited similar induction of ODC activity by TPA. alpha-Difluoromethylornithine, an irreversible inhibitor of ODC, attenuated, at an equivalent IC50, both TPA-induced ODC activity and anchorage-independent growth of JB6 P+ cells, despite no inhibition of AP-1 transactivation. Taken together, the results presented indicate that TPA-induced ODC gene expression and activity are independent of AP-1 transactivation. Because inhibition of either AP-1 or ODC precludes TPA-induced transformation, and because ODC is independent of AP-1, we propose that there are at least two pathways to transformation. Each pathway is required but not sufficient for transformation.	Univ Wisconsin, Sch Med, Ctr Comprehens Canc, Dept Human Oncol, Madison, WI 53792 USA; NCI, Lab Biochem Physiol, Frederick, MD 21702 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Verma, AK (corresponding author), Univ Wisconsin, Sch Med, Ctr Comprehens Canc, Dept Human Oncol, K4-532,CSC,600 Highland Ave, Madison, WI 53792 USA.				NATIONAL CANCER INSTITUTE [R01CA042585] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA42585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHENDEL CL, 1983, CANCER RES, V43, P4327; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BROWN LD, 1993, HEALTH AFFAIR, V12, P8, DOI 10.1377/hlthaff.12.2.7; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Carbone PP, 1998, CANCER EPIDEM BIOMAR, V7, P907; Cmarik J.L., 1997, FOOD FACTORS CANC PR, P67, DOI [10.1007/978-4-431-67017-9_13, DOI 10.1007/978-4-431-67017-9_13]; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FURSTENBERGER G, 1985, SCIENCE, V230, P76, DOI 10.1126/science.3929385; GILMOUR SK, 1987, CANCER RES, V47, P1221; HSIEH JT, 1990, CANCER RES, V50, P2239; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KIM YJ, 1994, MOL CARCINOGEN, V10, P169, DOI 10.1002/mc.2940100308; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Love RR, 1998, CANCER EPIDEM BIOMAR, V7, P989; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OBrien TG, 1997, CANCER RES, V57, P2630; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Ray RM, 1999, AM J PHYSIOL-GASTR L, V276, pG773, DOI 10.1152/ajpgi.1999.276.3.G773; Reddig PJ, 1996, MOL CARCINOGEN, V17, P92, DOI 10.1002/(SICI)1098-2744(199610)17:2<92::AID-MC6>3.0.CO;2-V; TAKIGAWA M, 1982, BIOCHEM BIOPH RES CO, V105, P969, DOI 10.1016/0006-291X(82)91065-8; TSENG CP, 1995, MOL CELL BIOCHEM, V146, P7, DOI 10.1007/BF00926875; VERMA AK, 1992, CELLULAR AND MOLECULAR TARGETS FOR CHEMOPREVENTION, P207; VERMA AK, 1980, CARCINOGENESIS, V1, P271, DOI 10.1093/carcin/1.3.271; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028	41	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5806	5813		10.1038/sj.onc.1202965	http://dx.doi.org/10.1038/sj.onc.1202965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523861				2022-12-17	WOS:000083095100009
J	FitzGerald, MJ; Arsura, M; Bellas, RE; Yang, W; Wu, M; Chin, L; Mann, KK; DePinho, RA; Sonenshein, GE				FitzGerald, MJ; Arsura, M; Bellas, RE; Yang, W; Wu, M; Chin, L; Mann, KK; DePinho, RA; Sonenshein, GE			Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc	ONCOGENE			English	Article						Max; Myc; Mad/Mxi; apoptosis; proliferation	HELIX-LOOP-HELIX; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; NEOPLASTIC TRANSFORMATION; GROWTH-FACTOR; CELL-GROWTH; B-CELLS; S-PHASE; HLA-A	dMax, a naturally occurring splice variant of the Myc binding protein Mas, lacks the DNA binding basic region and helix 1 of the Helix-Loop-Helix domain; dMax interacts with c-Myc in vitro and in vivo, and inhibits E-bos Myc site driven transcription in transient transfection assays, Here we have investigated the expression, function and interactions of dMax, RT/PCR analyses detected dmax mRNA in multiple tissues of the developing, newborn and adult mouse. Functionally, dMax reduced the ability of c-Myc to cooperate,vith the progression factor A-Myb to promote S phase entry of quiescent smooth muscle cells. In contrast, dMax failed to ablate inhibition of initiator element (Inr)-mediated transcription by c-Myc in Jurkat T cells. In in vitro protein:protein association assays, dMax interacted with c-Myc, N-Myc, L-Myc, Mad1, Mxi1, Mad3 and Mad4, but not,vith itself or wild-type Max, These interactions required an intact leucine zipper. Inhibition of E-box-mediated transactivation by induction of dMax overexpression resulted in apoptosis of WEHI 231 B cells. Thus, dMax is a widely expressed, naturally occurring protein, with the capacity to bind most members of the Myc/Max superfamily; dMax has little effect on Inr-mediated repression by c-Myc, but can significantly decrease E-bos-mediated events promoting proliferation and cell survival.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Boston University; Boston University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA36355, T32-CA64070] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA064070, R01CA036355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CROUCH DH, 1993, ONCOGENE, V8, P1849; DAVIS LJ, 1993, ONCOGENE, V8, P125; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; Hatton KS, 1996, MOL CELL BIOL, V16, P1794; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HINOSHITA F, 1992, TOXICOLOGY, V73, P203, DOI 10.1016/0300-483X(92)90103-L; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; REDDY CD, 1992, ONCOGENE, V7, P2085; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEMSEI I, 1989, ONCOGENE, V4, P465; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TIBENSKY D, 1990, IMMUNOGENETICS, V32, P210, DOI 10.1007/BF02114976; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Wu M, 1996, MOL CELL BIOL, V16, P5015; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	62	14	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2489	2498		10.1038/sj.onc.1202611	http://dx.doi.org/10.1038/sj.onc.1202611			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229200				2022-12-17	WOS:000079703300009
J	Calabro, V; Parisi, T; Di Cristofano, A; La Mantia, G				Calabro, V; Parisi, T; Di Cristofano, A; La Mantia, G			Suppression of Ras-mediated NIH3T3 transformation by p19(ARF) does not involve alterations of cell growth properties	ONCOGENE			English	Article						cellular transformation; tumor suppressor genes; cell cycle regulation; INK4a locus	CYCLE ARREST; IN-VITRO; LOCUS; P16(INK4); P16; MUTATIONS; PROTEIN; CANCER; MDM2; P53	The INK4a gene, one of the most frequently disrupted loci in human cancer, encodes two unrelated proteins, p16(INK4a) and p19(ARF), that both block cell proliferation. p16(INK4a) is a component of the Rb regulatory pathway, while p19(ARF) has been functionally related to p53, Moreover, p16(INK4a) is inactivated in many human tumors, while it has been very recently reported that p19(ARF) null mice develop tumors early in life. We show here that p19(ARF) iS able to inhibit the formation of G418-resistant colonies when transfected into human and mouse cell lines expressing wild-type p53, regardless of p16 status. Moreover its amino terminal domain encoded by exon 1 beta is still sufficient to obtain the same effect. We have analysed the ability of p19(ARF) to interfere with Ras-mediated cellular transformation in the NIH3T3 cell line. Cotransfection of p19(ARF) together with activated ras potently inhibited the formation of transformed foci in a dose-dependent manner. We have also isolated stable NIH3T3 transfectants expressing p19(ARF) and we have measured their growth properties as well as their efficiency of transformation by activated ras, Our results suggest that p19(ARF) can interfere,vith oncogene-mediated transformation, without significantly affecting NIH3T3 cell growth, at least at the levels of expression achieved in these experiments.	Univ Naples Federico II, Dept Genet Gen & Mol Biol, I-80134 Naples, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico II, Dept Genet Gen & Mol Biol, Via Mezzocannone 8, I-80134 Naples, Italy.		di cristofano, antonio/AAJ-3796-2020; Calabro, Viola/H-6156-2013; Di Cristofano, Antonio/B-4148-2016	di cristofano, antonio/0000-0003-2537-3228; Calabro, Viola/0000-0002-6508-8889				Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; CALABRO V, 1996, INT J CANCER, V66, P1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P435; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Liggett WH, 1996, CANCER RES, V56, P4119; MAO L, 1995, CANCER RES, V55, P2995; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; STONE S, 1995, CANCER RES, V55, P2988; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	20	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2157	2162		10.1038/sj.onc.1202532	http://dx.doi.org/10.1038/sj.onc.1202532			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321741				2022-12-17	WOS:000079346200014
J	Kessler, R; Zacharova-Albinger, A; Laursen, NB; Kalousek, M; Klemenz, R				Kessler, R; Zacharova-Albinger, A; Laursen, NB; Kalousek, M; Klemenz, R			Attenuated expression of the serum responsive T1 gene in ras transformed fibroblasts due to the inhibition of c-fos gene activity	ONCOGENE			English	Article						AP-1; fos; fra; T1; ras; transformation; serum induction	GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; H-RAS; INTERLEUKIN-1 RECEPTOR; CELL-TRANSFORMATION; SIGNAL-TRANSDUCTION; MEDIATED INDUCTION; BINDING-PROTEINS; MAMMALIAN-CELLS; AP-1 ACTIVITY	The T1 gene encodes a protein, which shares homology with the IL-1 receptors, In fibroblasts, T1 is induced by growth factors and in response to the onset of oncogene expression. The c-fos gene is transiently activated in these situations and was shown to be the major mediator of T1 gene induction, In contrast, the sustained expression of a ras oncogene in NIH3T3 cells resulted in the downregulation of basal T1 gene activity and the attenuation of T1 gene induction in response to mitogenic signals, Likewise, the immediate early genes encoding c-Fos, FosB, and Fra-2 are repressed in these cells. T1 gene repression could be overcome by the forced expression of c-fos in ras transformed fibroblasts, Thus, the lack of c-fos gene expression is the likely cause for ns mediated T1 gene repression. Fra-1, in contrast to the other three members of the Fos family, is permanently synthesized in high amounts in ms transformed NIH3T3 fibroblasts, We show that AP-1, which is abundant in these cells throughout the whole cell cycle, consists predominantly of Fra-1/c-Jun and Fra1/JunD heterodimers, We provide evidence that Fra1/c-Jun heterodimers are responsible for the repression of c-fos gene induction following serum stimulation, The introduction of a dominant negative version of c-Jun into rns transformed fibroblasts was able to rescue c-fos gene induction in response to serum stimulation, further demonstrating that AP-1 is indeed involved in c-fos gene repression, We conclude that oncogenic ms mediates the activation of the fra-1 gene which results in elevated AP-1 activity throughout the cell cycle. Fra-1 containing AP-1 complexes repress the c-fos and possibly other immediate early genes thereby preventing the induction of certain delayed early genes such as the T1 gene in response to mitogenic stimulation.	Univ Zurich Hosp, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Klemenz, R (corresponding author), Univ Zurich Hosp, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Angel P. E., 1994, FOS JUN FAMILIES TRA; BAR SD, 1986, SCIENCE, V233, P1061; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; BRASELMANN S, 1992, J CELL SCI, P97; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chen CY, 1996, MOL CELL BIOL, V16, P6582; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; Foulkes, 1991, HORMONAL CONTROL REG, P257; Gachter T, 1996, J BIOL CHEM, V271, P124; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GROSKOPF JC, 1994, MOL CELL BIOL, V14, P6013, DOI 10.1128/MCB.14.9.6013; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HINO O, 1995, J CANCER RES CLIN, V121, P602, DOI 10.1007/BF01197777; ITO E, 1990, ONCOGENE, V5, P1755; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Kessler R, 1997, BIOL CHEM, V378, P657; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Laursen NB, 1998, ONCOGENE, V16, P575, DOI 10.1038/sj.onc.1201522; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORITZ D, 1998, IN PRESS J IMMUNOL; Moritz DR, 1998, HYBRIDOMA, V17, P107, DOI 10.1089/hyb.1998.17.107; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; Okimoto T, 1996, ONCOGENE, V12, P1625; OSEIFRIMPONG J, 1994, MOL CARCINOGEN, V10, P72, DOI 10.1002/mc.2940100204; Rosl F, 1997, J VIROL, V71, P362; ROSSLER U, 1993, ONCOGENE, V8, P609; SANTOS E, 1984, FED PROC, V43, P2280; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUZUKI H, 1989, EXP CELL RES, V184, P524, DOI 10.1016/0014-4827(89)90350-9; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TRUB T, 1994, P NATL ACAD SCI USA, V91, P3896, DOI 10.1073/pnas.91.9.3896; Urakami S, 1997, BIOCHEM BIOPH RES CO, V241, P24, DOI 10.1006/bbrc.1997.7731; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YANAGISAWA K, 1992, FEBS LETT, V302, P51, DOI 10.1016/0014-5793(92)80282-L; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	77	14	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1733	1744		10.1038/sj.onc.1202484	http://dx.doi.org/10.1038/sj.onc.1202484			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208434				2022-12-17	WOS:000079025000008
J	Soulie, P; Poupon, MF; Remvikos, Y; Dutrillaux, B; Muleris, M				Soulie, P; Poupon, MF; Remvikos, Y; Dutrillaux, B; Muleris, M			Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers	ONCOGENE			English	Article						gene amplification; human colon cancer; p53; drug resistance; chromosome; PALA	WILD-TYPE P53; DIHYDROFOLATE-REDUCTASE GENE; CHINESE-HAMSTER CELLS; MUTANT P53; MULTIPLE MECHANISMS; HUMAN FIBROBLASTS; CYCLE REGULATION; AMPLIFICATION; DNA; LINES	This study investigates the chromosomal alterations involved in the acquisition of PALA resistance of LoVo colorectal cancer cells homozygous for wild-type TP53 before and after transfection with a 143Ala-mutated TP53 gene. PALA resistance was always associated with an increased number of CAD gene copies, but gene amplification sensu stricto was rarely observed, Interestingly, distinct chromosome patterns were found in relation to the TP53 status of the cells. In parental LoVo cells, the CAD copy number was increased through gains of normal chromosome 2 whereas in transfectant clones, resistance mostly occurred through chromosome rearrangements. The relationship with the two different cytogenetic patterns described in colorectal tumors is discussed.	Inst Curie, CNRS, UMR 147, Lab Cytogenet Mol & Oncol, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Muleris, M (corresponding author), Inst Curie, CNRS, UMR 147, Lab Cytogenet Mol & Oncol, 26 Rue dUlm, F-75248 Paris 05, France.							Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1; Chen CYM, 1996, CANCER RES, V56, P3659; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Cottu PH, 1996, ONCOGENE, V13, P2727; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FREBOURG T, 1994, CANCER RES, V54, P878; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Lesec G, 1997, INT J ONCOL, V10, P747; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Muleris M, 1996, CANCER GENET CYTOGEN, V92, P11, DOI 10.1016/S0165-4608(96)00116-1; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; PARK DJ, 1994, ONCOGENE, V9, P1899; Pocard M, 1996, ONCOGENE, V12, P875; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; Remvikos Y, 1997, CANCER GENET CYTOGEN, V93, P63, DOI 10.1016/S0165-4608(96)00305-6; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SHARMA RC, 1994, MUTAT RES, V304, P243, DOI 10.1016/0027-5107(94)90217-8; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; Smith KA, 1997, P NATL ACAD SCI USA, V94, P1816, DOI 10.1073/pnas.94.5.1816; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; STARK GR, 1986, CANCER SURV, V5, P1; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; TOLEDO F, 1993, CURR BIOL, V3, P255, DOI 10.1016/0960-9822(93)90175-N; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; TRASK BJ, 1989, GENE DEV, V3, P1913, DOI 10.1101/gad.3.12a.1913; UMAR A, 1994, J BIOL CHEM, V269, P14367; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	44	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					775	781		10.1038/sj.onc.1202336	http://dx.doi.org/10.1038/sj.onc.1202336			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989828				2022-12-17	WOS:000078394400023
J	Serfas, MS; Tyner, AL				Serfas, MS; Tyner, AL			Ryk is expressed in a differentiation-specific manner in epithelial tissues and is strongly induced in decidualizing uterine stroma	ONCOGENE			English	Article						Ryk; tyrosine kinase; differentiation; epithelia	PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; MOUSE SMALL-INTESTINE; VULVAL CELL LINEAGES; MOLECULAR-CLONING; CAENORHABDITIS-ELEGANS; STEM-CELLS; GENE; FAMILY; IDENTIFICATION	Ryk is a ubiquitously expressed tyrosine kinase-like receptor of unknown activity and associations, We examined ryk expression in adult mouse epithelial tissues and during embryonic development at the histological level. Ryk RNA is present at greatly increased le, els in cells at particular stages of epithelial differentiation: the basal layer of skin and tongue epithelia, the intervillous layer and some crypt bases of the intestine and the lower matrix region of the hair follicle, Although ryk RNA is expressed at similar levels in a variety of tissues from embryonic day 10.5 to 18.5, specific induction of ryk RNA can be seen by ill situ hybridization in the basal layer of skin and hair follicle at day 15.5-16.5, and protein staining localizes to the hair follicle by immunohistochemistry. At day 4.5 and 6.5, little if any ryk is present in the blastocyst, but it is transiently induced at a high le, el in mature decidual cells of the uterine stroma, We review a number of independent isolations of ryk, including fruit fly and nematode members of the ryk family, Because ryk is induced in epithelial cells seeking a final place in a differentiated tissue, or during remodeling of the endometrium, and a homologous gene, derailed, is known to regulate muscle and nerve target seeking in Drosophila, ryk mag also be involved in cellular recognition of appropriate contest.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,Mol Biol Res Bldg, Chicago, IL 60607 USA.			Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK044525] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44525, R01 DK044525-06, R01 DK044525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSOHN PA, 1993, J EXP ZOOL, V266, P603, DOI 10.1002/jez.1402660610; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; GOUGH NM, 1995, MAMM GENOME, V6, P255, DOI 10.1007/BF00352411; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUME WJ, 1976, J CELL SCI, V22, P149; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Kee NJ, 1997, KIDNEY INT, V52, P309, DOI 10.1038/ki.1997.336; KELMAN Z, 1993, ONCOGENE, V8, P37; LARSSONBLOMBERG L, 1994, FEBS LETT, V348, P119, DOI 10.1016/0014-5793(94)00577-X; LEE JJ, 1992, DEVELOPMENT, V115, P277; Lim H, 1997, ENDOCRINOLOGY, V138, P1328, DOI 10.1210/en.138.3.1328; MAMINTA MLD, 1992, BIOCHEM BIOPH RES CO, V189, P1077; MOSSIE K, 1995, ONCOGENE, V11, P2179; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; Potworowski EF, 1996, IMMUNOL LETT, V50, P65, DOI 10.1016/0165-2478(96)02520-5; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMONEAUX DK, 1995, J IMMUNOL, V154, P1157; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; STACKER SA, 1993, ONCOGENE, V8, P1347; STARK KL, 1991, DEVELOPMENT, V113, P641; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; Wang XC, 1996, MOL MED, V2, P189, DOI 10.1007/BF03401616; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; WELSH AO, 1985, AM J ANAT, V172, P1, DOI 10.1002/aja.1001720102; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YEE K, 1993, BLOOD, V82, P1335	37	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3435	3444		10.1038/sj.onc.1202266	http://dx.doi.org/10.1038/sj.onc.1202266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030667				2022-12-17	WOS:000078086200004
J	Yamazaki, H; Kunisada, T; Ishizu, A; Ikeda, H; Miyoshi, I; Sudo, T; Hayashi, SI; Yoshiki, T				Yamazaki, H; Kunisada, T; Ishizu, A; Ikeda, H; Miyoshi, I; Sudo, T; Hayashi, SI; Yoshiki, T			Promotion of early osteoclastogenesis and B lymphopoiesis in the bone marrow of transgenic rats with the env-pX gene of human T-cell lymphotropic virus type I	ONCOGENE			English	Article						HTLV-I; env-pX transgenic rat; hematopoiesis; osteoclastogenesis; B lymphopoiesis	COLLAGEN-INDUCED ARTHRITIS; HORMONE-RELATED PROTEIN; HTLV-I; RHEUMATOID-ARTHRITIS; LEUKEMIA-VIRUS; TAX GENE; MICE; LYMPHOMA; DIFFERENTIATION; PATHOGENESIS	Human T-cell lymphotropic virus type I(HTLV-I) is associated with various clinical disorders including adult T cell leukemia, myelopathy, arthropathy. Hypercalcemia resulting from osteoclast activation and a variety of hematopoietic abnormalities have been also observed in HTLV-I infected patients, however, precise mechanism about initial trigger(s) prior to presenting symptoms is still unknown. In this study, to assess effects of HTLV-I on hematopoiesis, we analysed characteristics of early hematopoietic precursors in HTLV-I env-pX transgenic rats. Progenitor cells for osteoclasts were significantly increased even in the marrow of asymptomatic env-pX rats. Progenitors for B cells were also highly enriched, while colony forming cells (CFC) elicited by GM-CSF(CFU-GM) and M-CSF(CFU-M) were comparable to normal littermates. Following arthritis in env-pX transgenic rats, osteoclastogenesis was further augmented and the CFCs were increased. Bone marrow cells carrying adjuvant-induced arthritis retained a constant number of progenitors for osteoclast and B lymphocytes, whereas the number of CFU-CM and CFU-M increased. These results indicate that the env-pX transgene affect early stages of osteoclast and B-cell lineages prior to developing diseases, in contrast, an increase of the CFCs was caused indirectly by arthritis. This study provides a novel standpoint for the mechanisms of pathogenesis by HTLV-I.	Tottori Univ, Fac Med, Sch Life Sci, Dept Immunol, Yonago, Tottori 6830826, Japan; Hokkaido Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0600815, Japan; Tohoku Univ, Sch Med, Inst Anim Expt, Sendai, Miyagi 9800872, Japan; Toray Industries Ltd, Basic Res Labs, Kamakura, Kanagawa 2480036, Japan	Tottori University; Hokkaido University; Tohoku University; Toray Industries, Inc.	Yamazaki, H (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Immunol, Yonago, Tottori 6830826, Japan.		Ishizu, Akihiro/D-9607-2012					Cardoso EA, 1996, J CLIN PATHOL, V49, P938, DOI 10.1136/jcp.49.11.938; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; DEAN LM, 1987, SCIENCE, V236, P1103; DUGGAN DB, 1988, BLOOD, V71, P1027; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HAMILTON JA, 1993, LANCET, V342, P536, DOI 10.1016/0140-6736(93)91653-4; Hayashi S, 1997, J CELL PHYSIOL, V170, P241, DOI 10.1002/(SICI)1097-4652(199703)170:3<241::AID-JCP4>3.0.CO;2-O; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HAYASHI SI, 1988, J IMMUNOL, V140, P2139; HAYASHIDA K, 1992, ARTHRITIS RHEUM, V35, P241, DOI 10.1002/art.1780350219; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HONDA S, 1988, JPN J CANCER RES, V79, P1264, DOI 10.1111/j.1349-7006.1988.tb01554.x; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8; METCALF D, 1995, HEMATOPOIETIC COLONY; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NIMER SD, 1989, ONCOGENE, V4, P671; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; PEEBLES RS, 1995, ONCOGENE, V10, P1045; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006/viro.1993.1580; SHEVDE N, 1994, P SOC EXP BIOL MED, V205, P306; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUDA T, 1995, ENDOCR REV, V131, P251; TANAKA H, 1992, J BONE MINER RES, V7, pS307; TAO D, 1993, INT J HEMATOL, V57, P139; TAUROG JD, 1985, J EXP MED, V162, P962, DOI 10.1084/jem.162.3.962; TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405; THOMSON BM, 1987, J IMMUNOL, V138, P775; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TOBINAI K, 1991, LEUKEMIA RES, V15, P837, DOI 10.1016/0145-2126(91)90468-9; TOKIOKA T, 1994, HAEMATOLOGIA, V26, P1; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YAMADA S, 1995, CANCER RES, V55, P2524; Yamazaki H, 1997, INT IMMUNOL, V9, P339, DOI 10.1093/intimm/9.2.339; YOSHIKI T, 1974, J EXP MED, V140, P1011, DOI 10.1084/jem.140.4.1011	40	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	1998	17	23					2955	2960		10.1038/sj.onc.1202222	http://dx.doi.org/10.1038/sj.onc.1202222			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881697				2022-12-17	WOS:000077427800002
J	Joers, A; Kristjuhan, A; Kadaja, L; Maimets, T				Joers, A; Kristjuhan, A; Kadaja, L; Maimets, T			Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization	ONCOGENE			English	Article						p53; transcription; oligomerization	WILD-TYPE P53; DNA-BINDING FUNCTION; PROTEIN-KINASE-C; MONOCLONAL-ANTIBODIES; REPRESSION FUNCTIONS; SUPPRESSOR PROTEIN; ACTIVATION DOMAINS; TYROSINE KINASE; GENE-EXPRESSION; GROWTH	Tumour suppressor protein p53 is the most frequent target of mutations occurring in different types of human cancers. Most of these are point mutations clustered in certain 'hot spots'. Because p53 is a tetramer in solution, it can form heterooligomers when both wild-type and mutant forms of p53 are expressed in the same cell. Inactivation of wt p53 by heterooligomerization has been proposed as a mechanism for dominant negative effect of mutant protein. In this paper we show that other mechanisms can also be involved in the inhibition of transcriptional activity of wt p53 by mutant proteins. In addition to suppressing the wt p53 activity, mutant proteins are also able to suppress the activity of p53 protein unable to oligomerize. Either N- or C-terminus of mutant p53 are needed for this activity. The suppression of transcriptional activity described is restricted to p53-dependent promoters and no effect is seen with the promoter not containing p53 binding site. Point mutants also inhibit the growth suppressing activity of monomeric p53. Our data allow to propose the existence of a cofactor specifically needed for p53-dependent transcription. Depletion of this cofactor could be an alternative mechanism of inactivation of wt p53 by its point mutants.	Tartu State Univ, Inst Mol & Cell Biol, Dept Cell Biol, EE-2400 Tartu, Estonia	University of Tartu	Maimets, T (corresponding author), Tartu State Univ, Inst Mol & Cell Biol, Dept Cell Biol, Riia 23, EE-2400 Tartu, Estonia.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365; Kristjuhan, Arnold/0000-0002-5842-4952; Joers, Arvi/0000-0003-2083-3977				BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GOGA A, 1995, ONCOGENE, V11, P791; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Knippschild U, 1996, ONCOGENE, V13, P1387; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PELLEGATA NS, 1995, ONCOGENE, V11, P337; Sambrook J, 1989, MOL CLONING LAB MANU; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUBLER MA, 1994, ONCOGENE, V9, P1351; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TARUNINA M, 1993, ONCOGENE, V8, P3165; Thomas M, 1996, ONCOGENE, V13, P265; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	60	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2351	2358		10.1038/sj.onc.1202146	http://dx.doi.org/10.1038/sj.onc.1202146			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811466				2022-12-17	WOS:000076723300009
J	Derrington, EA; Dufay, N; Rudkin, BB; Belin, MF				Derrington, EA; Dufay, N; Rudkin, BB; Belin, MF			Human primitive neuroectodermal tumour cells behave as multipotent neural precursors in response to FGF2	ONCOGENE			English	Article						medulloblastoma; stem cells; FGF; proliferation; differentiation; signal transduction	CENTRAL-NERVOUS-SYSTEM; FIBROBLAST GROWTH-FACTOR; STEM-CELLS; HUMAN MEDULLOBLASTOMA; SIGNAL-TRANSDUCTION; PROGENITOR CELLS; FACTOR RECEPTORS; CEREBRAL-CORTEX; HUMAN HOMOLOG; BRAIN-TUMORS	Primitive neuroectodermal tumours (PNET) are thought to derive from the malignant transformation of pluripotent CNS precursors although this hypothesis has yet to be tested in vitro. Here we show that cells of a human PNET cell line 'Dev' express functional fibroblast growth factor (FGF) receptors (FGFR) and respond to FGF2 as multipotent CNS precursors. FGF2 induces tyrosine phosphorylation of FGFR-1 and FGFR-2 and many cellular substrates including MAP kinases and stimulates proliferation. Cells detach from plastic substrates and proliferate to form large clusters of undifferentiated cells. After adhesion to polylysine, cells migrate out from the clusters and differentiate. The majority of differentiated cells express neuronal phenotypes but distinct subpopulations express oligodendrocytic and astrocytic markers. Mature neural differentiation markers are not otherwise detected in Del cells in defined medium. Identical results were obtained with 12 monoclonal subclones as well as the parent cell line, confirming that Dev cells are multipotent, This extends evidence that multipotent CNS precursors are the cellular substrate from which certain PNET develop and shows that FGF2 is a potent proliferation and differentiation inducer for PNET cells in vitro, suggesting that FGF2 may also modulate the evolution of PNET in vivo. Finally our results suggest that PNET cell lines may provide models to elucidate the biology of human multipotent CNS precursors.	Lyon Neurol Hosp, Dept Neuropathol, INSERM U433, F-69003 Lyon, France; Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, UMR 49, F-69364 Lyon 07, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON)	Derrington, EA (corresponding author), Lyon Neurol Hosp, Dept Neuropathol, INSERM U433, Bvd Pinel, F-69003 Lyon, France.		Derrington, Ed/G-9478-2017	RUDKIN, Brian B./0000-0003-3700-1982				BIEGEL JA, 1989, GENE CHROMOSOME CANC, V1, P139, DOI 10.1002/gcc.2870010206; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Billon N, 1996, ONCOGENE, V13, P2047; Burnett ME, 1997, CANCER GENET CYTOGEN, V97, P25, DOI 10.1016/S0165-4608(96)00319-6; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; Dubois PM, 1996, J IMMUNOL, V156, P1356; DUFAY N, 1994, EUR J NEUROSCI, V6, P1633, DOI 10.1111/j.1460-9568.1994.tb00554.x; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GHOSH A, 1995, NEURON, V15, P1; GIRAUDON P, 1993, NEUROSCIENCE, V52, P1069, DOI 10.1016/0306-4522(93)90553-R; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Gritti A, 1996, J NEUROSCI, V16, P1091; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KILPATRICK TJ, 1995, J NEUROSCI, V15, P3653; Kleihues P, 1993, HISTOLOGICAL TYPING; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; MCKAY R, 1993, CR ACAD SCI III-VIE, V316, P1452; MIYAKE A, 1995, MOL BRAIN RES, V31, P95, DOI 10.1016/0169-328X(95)00039-U; PACKER RJ, 1984, J NEUROSURG, V61, P296, DOI 10.3171/jns.1984.61.2.0296; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PIETSCH T, 1994, CANCER RES, V54, P3278; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; REID CB, 1995, NEURON, V15, P299, DOI 10.1016/0896-6273(95)90035-7; Rorke LB, 1997, BRAIN PATHOL, V7, P765, DOI 10.1111/j.1750-3639.1997.tb01063.x; Schutz BR, 1996, GENE CHROMOSOME CANC, V16, P196; SHAOUL E, 1995, ONCOGENE, V10, P1553; Smits A, 1996, LAB INVEST, V74, P188; Stemple DL, 1997, NEURON, V18, P1, DOI 10.1016/S0896-6273(01)80018-0; TOHYAMA T, 1992, LAB INVEST, V66, P303; TROJANOWSKI JQ, 1994, MOL CHEM NEUROPATHOL, V21, P219, DOI 10.1007/BF02815352; VALTZ NLM, 1991, NEW BIOL, V3, P364; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; WILLIAMS BP, 1995, NEURON, V14, P1181, DOI 10.1016/0896-6273(95)90265-1	40	14	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1663	1672		10.1038/sj.onc.1202025	http://dx.doi.org/10.1038/sj.onc.1202025			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796695				2022-12-17	WOS:000076200100004
J	Yin, XY; Grove, L; Prochownik, EV				Yin, XY; Grove, L; Prochownik, EV			Lack of transcriptional repression by max homodimers	ONCOGENE			English	Article						myc; max; mad; mnt; USF; transcriptional repression	C-MYC PROTEIN; DNA-BINDING; EPIDERMAL DIFFERENTIATION; PHOSPHORYLATION SITES; OPPOSITE REGULATION; ONCOGENIC ACTIVITY; LEUCINE ZIPPER; B/HLH/Z DOMAIN; IN-VIVO; GENE	Max, a basic-helix-loop-helix-leucine zipper (bHLH-ZIP) protein, plays a central role in the transcriptional regulation of myc oncoprotein-responsive genes, Myc-max heterodimers bind to consensus E-box motifs near or within the promoters of these genes and activate gene expression, whereas heterodimers between max and members of the mad family of bHLH-ZIP proteins promote transcriptional repression. In contrast to all other members of the myc network, max readily homodimerizes and binds to identical E-box sites in vitro. However, the role for max homodimers in transcriptional repression in vivo is unclear. Upstream stimulatory factor (USF) is a bHLH-ZIP protein which does not interact with members of the myc-max-mad family. By replacing the HLH-ZIP domain of max with that from USF, we created a chimeric protein, max(USF), which was indistinguishable from max with respect to its ability to homodimerize and bind DNA. As expected, however, max(USF) was unable to heterodimerize with any of the tested max partner proteins and was incapable of suppressing c-myc target genes. Thus, transcriptional repression is an exclusive property of max-mad heterodimers and cannot be achieved by max homodimers alone.	Childrens Hosp Pittsburgh, Dept Pediat, Sect Hematol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Sect Hematol, Pittsburgh, PA 15213 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1998, CELL, P211; Bartel PL, 1993, CELLULAR INTERACTION, P153; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE LA, 1995, J CLIN INVEST, V95, P900, DOI 10.1172/JCI117741; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MIN S, 1992, ONCOGENE, V9, P1531; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, 1994, CELL, V79, P389; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	54	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2629	2637		10.1038/sj.onc.1201777	http://dx.doi.org/10.1038/sj.onc.1201777			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632139				2022-12-17	WOS:000073698200007
J	Norris, PS; Haas, M				Norris, PS; Haas, M			A fluorescent p53GFP fusion protein facilitates its detection in mammalian cells while retaining the properties of wild-type p53	ONCOGENE			English	Article						p53; green fluorescent proteins; retrovirus; fusion protein	TUMOR-SUPPRESSOR P53; HIGH-TITER; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; HELPER-FREE; GENE; DNA; TRANSFECTION; RETROVIRUSES; EXPRESSION	Tumor progression is often characterized by the cumulative loss of crucial cell cycle control genes and the concomitant loss of genome stability, Progressed tumors are often resistant to conventional therapies, Gene-transfer of key growth-regulatory genes, such as the p53 gene, is one potential approach to treating advanced tumors, To this end, we have produced high-titer retroviruses, based on the pCL vector system, which encode a chimeric protein consisting of human wild-type p53 and the green fluorescent protein (wtp53GFP). The fluorescent wtp53GFP protein and the wild-type p53 protein are recognized equally by several monoclonal p53-specific antibodies, have similar half-lives and function comparably in transactivating a p53-responsive element as well as in suppressing the growth of tumor cells, Additionally, due to its fluorescent nature, wtp53GFP facilitates the direct identification of cells expressing the p53 fusion protein, Combining the features of the pCL retroviral production system with the highly visible green fluorescent protein provides a potent tool for the delivery of p53 into cells and the subsequent detection of the protein, both in vitro and in vivo.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [R01CA56075] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG J, 1992, CANCER RES, V52, P222; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fink D, 1997, CANCER RES, V57, P1841; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MILNER J, 1987, ONCOGENE, V1, P453; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAMQVIST T, 1993, ONCOGENE, V8, P1495; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; YEE JK, 1994, METHOD CELL BIOL, V43, P99	29	14	14	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2241	2247		10.1038/sj.onc.1201406	http://dx.doi.org/10.1038/sj.onc.1201406			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393983				2022-12-17	WOS:A1997YD01900013
J	Halachmy, S; Bern, O; Schreiber, L; Carmel, M; Sharabi, Y; Shoham, J; Nir, U				Halachmy, S; Bern, O; Schreiber, L; Carmel, M; Sharabi, Y; Shoham, J; Nir, U			p94(fer) facilitates cellular recovery of gamma irradiated pre-T cells	ONCOGENE			English	Article						ionizing-radiation; nuclear; p94(fer); T cell; tyrosine kinase	PROTEIN-TYROSINE KINASE; FES-ENCODED PROTEIN; ABL MESSENGER-RNAS; C-ABL; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAY; TRANSCRIPT FERT; TRANSGENIC MICE; LYMPHOID-CELLS; MOUSE-TISSUES	p94(fer) is a ubiquitous, nuclear and cytoplasmic tyrosine kinase, whose accumulation has been demonstrated in all mammalian cell Lines analysed. In the present work, the p94(fer) expression profile was determined in cell lines which were not tested before. While being present in several hematopoietic and non hematopoietic cell lines including thymic stromal cells, the p94(fer) kinase could not be detected in pre-T and T cell lines. p94(fer) was also absent in pre-B line, but accumulated in these cells upon their induced development to antibody producing cells. This is in agreement with the absence of p94(fer) in primary th,mic and splenic T lymphocytes and its induced accumulation in stimulated B cells. Relatively high p94(fer) levels were detected in primary thymic and splenic stromal cells. Ectopic expression of p94(fer) in pre-T cells slightly affected their cell cycle profile but it did not affect their apoptotic death which was induced by ionizing radiation. However, p94(fer) facilitated dramatically, the cellular recovery of gamma irradiated pre-T cells which have escaped the apoptotic death. The enhanced recovery of the irradiated, p94(fer) expressing pre-T cells, resulted most probably from their increased survival, rather than from a prominent change in their proliferation rate. The absence of p94(fer) from pre-B and pre-T cells, may thus contribute to the relative sensitivity of these cells to ionizing radiation and to their dependence on the functioning of other nuclear tyrosine kinasese.	BAR ILAN UNIV,DEPT LIFE SCI,IL-52900 RAMAT GAN,ISRAEL	Bar Ilan University								BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; CARE A, 1994, ONCOGENE, V9, P739; COFFER PJ, 1995, ONCOGENE, V11, P561; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ESHEL I, 1990, J IMMUNOL, V144, P1554; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; GLIMCHER LH, 1983, SCAND J IMMUNOL, V17, P1, DOI 10.1111/j.1365-3083.1983.tb00759.x; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; IRLIN Y, 1992, IMMUNOL LETT, V33, P233, DOI 10.1016/0165-2478(92)90067-X; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KIM L, 1995, MOL CELL BIOL, V15, P4553; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LETWIN K, 1988, ONCOGENE, V3, P621; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARKS PA, 1983, P NATL ACAD SCI-BIOL, V80, P2281, DOI 10.1073/pnas.80.8.2281; MCWHIRTER JR, 1993, EMBO J, V12, P1523; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PAWSON T, 1989, MOL CELL BIOL, V9, P5722, DOI 10.1128/MCB.9.12.5722; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAMBROOK J, 1989, MOL CLONE LAB MANUAL; SCHIEVEN GL, 1993, MOL BIOL CELL, V4, P523, DOI 10.1091/mbc.4.5.523; SCHREIBER L, 1996, IN PRESS SCAND J IMM; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SOKAGUCHI N, 1980, J IMMUNOL, V125, P2654; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WADSWORTH SA, 1995, J IMMUNOL, V154, P2125; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WILKS AF, 1988, ONCOGENE, V3, P289; YAFFE A, 1996, IN PRESS CELL GROWTH; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; YATES KE, 1995, ONCOGENE, V10, P1239	52	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2871	2880		10.1038/sj.onc.1201145	http://dx.doi.org/10.1038/sj.onc.1201145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205095				2022-12-17	WOS:A1997XF55500002
J	Jung, YK; Yuan, JY				Jung, YK; Yuan, JY			Suppression of Interleukin-1 beta converting enzyme (ICE)-induced apoptosis by SV40 large T antigen	ONCOGENE			English	Article						ICE; ICH-1; SV40 large T antigen; p53	PROGRAMMED CELL-DEATH; TEMPERATURE-SENSITIVE MUTANT; IN-VIVO; GENE CED-3; C-ELEGANS; IL-1-BETA-CONVERTING ENZYME; TRANSGENIC MICE; CRMA GENE; BAX GENE; P53	The Interleukin-1 beta converting enzyme (ICE) family of proteins, homologs of the C elegans cell death gene product CED-3, play important roles in controlling vertebrate programmed cell death. Because inhibition of apoptosis may be an essential step in tumorigenesis, we investigated the interaction of the simian virus 40 large T antigen (T ag) with the ICE family, COS-1 cells which were transformed by the simian virus 40 do not die when transfected,vith expression constructs of Ice or Ich-1(L). We found that expression of T ag alone significantly prevents the ICE-induced apoptosis. p53, but not pRb or p107, antagonizes the effect of T ag on the suppression of ICE-induced cell death, but not on ICH-1(L)-mediated cell death. Thus, wild type p53 may potentiate ICE-induced apoptosis. Expression of a temperature sensitive mutant p53Val(135) sensitizes COS-1 cells to apoptosis induced by ICE at permissive but not at non-permissive temperature. While induction of bax, p21(WAF1/CIP), Or cyclin DI gene expression is observed in the COS-1 p53Val(135) cells at the permissive temperature, overexpression of bax, but not p2l(WAF1/CIP) Or cyclin D1, potentiates ICE-induced COS-1 cell death. Taken together, these results suggest that Tag may modulate the cells' susceptibility to death by suppressing activity of the ICE family through inhibiting p53.	MASSACHUSETTS GEN HOSP EAST, CARDIOVASC RES CTR, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Jung, Yong-Keun/0000-0002-9686-3120	NIA NIH HHS [AG12859-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012859, R37AG012859] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P39761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU J, 1991, J VIOL, V65, P6972	40	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1207	1214		10.1038/sj.onc.1200943	http://dx.doi.org/10.1038/sj.onc.1200943			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121770				2022-12-17	WOS:A1997WM78200010
J	Chao, JR; Chen, CS; Wang, TF; Tseng, LH; Tsai, JJ; Kuo, ML; Yen, JJY; Yen, HFY				Chao, JR; Chen, CS; Wang, TF; Tseng, LH; Tsai, JJ; Kuo, ML; Yen, JJY; Yen, HFY			Characterization of factor-independent variants derived from TF-1 hematopoietic progenitor cells: The role of the Raf/MAP kinase pathway in the anti-apoptotic effect of GM-CSF	ONCOGENE			English	Article						apoptosis; GM-CSF signalling; Raf-1; MAP; kinase	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; RAPID PHOSPHORYLATION; PROTOONCOGENE RAF-1; MYELOID-LEUKEMIA; GROWTH-FACTORS; ACTIVATION; INTERLEUKIN-3	Human hematopoietic progenitor cells (TF-I) undergo apoptosis upon deprivation of their dependent cytokine, In this report, we have isolated and characterized some spontaneously derived cytokine-independent variants from TF-1 cells, Analysis of several signaling molecules known to be activated by the GM-CSF pathway revealed that two non-autocrine variants were still responsive to GM-CSF stimulation, However, both variants, without ligand stimulation, already had some activated forms of Raf and MAP kinases, Given current knowledge, the activated Raf/MAP kinase pathway was likely to be responsible for the survival of both variants in the cytokine-free medium, However, the growth of hybrids between wild type and either variant was unexpectedly dependent on GM-CSF, Both variants like the wild type cells were still susceptible to apoptosis induced by other stimuli, These results suggest that either the activated Raf/MAP kinase pathway in both variants fs not sufficient to repress the 'two-fold' death signals generated from the hybrids or that there is another mechanism that is responsible for the factor-independent growth of both variants.	ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN; ACAD SINICA,INST BIOMED SCI,TAIPEI 11529,TAIWAN; CATHAY GEN HOSP,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,TAIPEI,TAIWAN; NATL TAIWAN UNIV HOSP,DEPT MED GENET,TAIPEI,TAIWAN; CHINESE CULTURE UNIV,INST BIOTECHNOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,SCH MED,INST TOXICOL,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; Academia Sinica - Taiwan; Cathay General Hospital; National Taiwan University; National Taiwan University Hospital; Chinese Culture University; National Taiwan University			Yen, Jeffrey Jong-Young/Q-5134-2018; Kuo, Min-Liang/C-4872-2009	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; KUO, MIN-LIANG/0000-0002-7139-0144; TSENG, LI-HUI/0000-0002-8308-6772				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; KANAKURA Y, 1991, BLOOD, V77, P243; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWENBERG B, 1993, NEW ENGL J MED, V328, P614, DOI 10.1056/NEJM199303043280904; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1993, BLOOD, V82, P1960; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKUDA K, 1994, EXP HEMATOL, V22, P1111; OKUDA K, 1992, BLOOD, V79, P2880; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TOMPSON CB, 1995, SCIENCE, V267, P1456, DOI DOI 10.1126/SCIENCE.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; YEN JJY, 1995, J IMMUNOL, V154, P2144	29	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					721	728		10.1038/sj.onc.1200884	http://dx.doi.org/10.1038/sj.onc.1200884			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038380	Bronze			2022-12-17	WOS:A1997WG43000011
J	Okumura, K; Kaneko, Y; Nonoguchi, K; Nishiyama, H; Yokoi, H; Higuchi, T; Itoh, K; Yoshida, O; Miki, T; Fujita, J				Okumura, K; Kaneko, Y; Nonoguchi, K; Nishiyama, H; Yokoi, H; Higuchi, T; Itoh, K; Yoshida, O; Miki, T; Fujita, J			Expression of a novel isoform of Vav, Vav-T, containing a single Src homology 3 domain in murine testicular germ cells	ONCOGENE			English	Article						testis; vav; vav-T; Src homology 3	TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; EXCHANGE FACTOR; STEEL FACTOR; SH2 DOMAIN; B-CELLS; PROTEIN; KINASE; FIBROBLASTS	Vav is a signal transducing molecule containing C-terminal Src homology 3 (SH3)-SH2-SH3 domains, and has been thought to be expressed exclusively in hematopoietic and trophoblastic cells, By Northern blot analysis, vav transcripts of unique sizes, 4.8 kb and 1.0 kb, were detected in the testis among various tissues examined, From a mouse spermatocyte cDNA library, a novel isoform of vav (vav-T) was cloned, which corresponded to a part of the 4.8 kb transcript, Vav-T had an alternative 5' sequence up to the middle of SH2-coding region, and encoded 163 amino acids with a single SH3 domain, Northern blot analysis of fractionated testicular cells and in situ hybridization histochemistry demonstrated that vav-T transcripts were expressed in the differentiating germ cells, especially spermatocytes. A 24 kD protein was detected by anti-Vav antibodies in the testis, but not in the spleen or bone marrow, Transcripts of heterogeneous nuclear ribonucleoprotein K, known to associate with the most C-terminal SH3 domain of Vav, were also detected in the differentiating male germ cells, These results demonstrate expression of previously nondescribed Vav-isoform in the testicular germ cells, and suggest that it interacts with RNA-binding proteins and plays an important role in spermatogenesis.	KYOTO UNIV,FAC MED,DEPT CLIN MOL BIOL,KYOTO 60601,JAPAN; KYOTO UNIV,FAC MED,DEPT UROL,KYOTO 60601,JAPAN; NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	Kyoto University; Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GOLDBERG E, 1977, ISOZYMES CURRENT TOP, P79; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; HIGUCHI T, 1995, BIOL REPROD, V53, P840, DOI 10.1095/biolreprod53.4.840; Hobert O, 1996, ONCOGENE, V12, P1577; HOBERT O, 1994, J BIOL CHEM, V269, P20225; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; Romero F, 1996, MOL CELL BIOL, V16, P37; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	40	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					713	720		10.1038/sj.onc.1200878	http://dx.doi.org/10.1038/sj.onc.1200878			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038379	Green Submitted			2022-12-17	WOS:A1997WG43000010
J	Saito, H; Nakatsuru, S; Inazawa, J; Nishihira, T; Park, JG; Nakamura, Y				Saito, H; Nakatsuru, S; Inazawa, J; Nishihira, T; Park, JG; Nakamura, Y			Frequent association of alternative splicing of NER, a nuclear hormone receptor gene in cancer tissues	ONCOGENE			English	Article						nuclear hormone receptor; alternative splicing; cancer cell lines and primary cancers; NER	ACTIVATION	We have detected frequent alternative splicing of a gene that encodes NER, a protein homologous to the retinoic acid receptors, in cancer cells, Western and immunohistochemical analyses disclosed accumulation of a large amount of the aberrant NER product, generated by alternative splicing that caused skipping of an exon corresponding to the DNA-binding domain, in the nucleoli of cells of cancer cell lines and primary cancer tissues, The aberrant protein was detected in 116 of 228 primary cancers developed in various tissues including breast and colon, but was absent in the corresponding normal tissues; it was also detected in 31 of 39 cancer cell lines, This observation may imply that the aberrant NER product has some relation to the development and/or progression of cancers in a variety of human tissues.	JAPANESE FDN CANC RES,INST CANC,DEPT HUMAN GENOME ANAL,TOSHIMA KU,TOKYO 170,JAPAN; UNIV TOKYO,INST MED SCI,MOL MED LAB,MINATO KU,TOKYO 108,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIKYO KU,KYOTO 602,JAPAN; TOHOKU UNIV,DEPT SURG 2,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; SEOUL NATL UNIV,SCH MED,SEOUL 110744,SOUTH KOREA	Japanese Foundation for Cancer Research; University of Tokyo; Kyoto Prefectural University of Medicine; Tohoku University; Seoul National University (SNU)			Park, Jae-Gahb/J-5494-2012					BANIAHMAD A, 1993, J CELL BIOCHEM, V51, P151, DOI 10.1002/jcb.240510206; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GRIFFIOEN AW, 1994, CELL ADHES COMMUN, V2, P195, DOI 10.3109/15419069409004437; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ragsdale CW, 1991, CURR OPIN CELL BIOL, V3, P928, DOI 10.1016/0955-0674(91)90109-C; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SUDO K, 1994, GENOMICS, V24, P276, DOI 10.1006/geno.1994.1616; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3	11	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					617	621		10.1038/sj.onc.1200859	http://dx.doi.org/10.1038/sj.onc.1200859			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053861				2022-12-17	WOS:A1997WF52400014
J	ElRouby, S; Newcomb, EW				ElRouby, S; Newcomb, EW			Identification of Bcd a novel proto-oncogene expressed in B-cells	ONCOGENE			English	Article						transfection; transforming activity; chronic lymphocytic leukemia; B-cell differentiation	CHRONIC LYMPHOCYTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; TRANSFORMING GENES; SEQUENCES; VAV; DNA; ACTIVATION; LYMPHOMAS; CLONING; DOMAINS	A novel B-cell derived (Bcd) oncogene has been isolated from the peripheral blood lymphocytes of one B-cell chronic lymphocytic leukemia (B-CLL) patient using DNA transfer and a mouse tumorigenicity assay. The Bcd proto-oncogene was activated by a truncation in the 5' UTR, It predicts for two open reading frames (ORFs). ORF1 consists of 240 bp that would encode 80 amino acids, while the major ORF2 consists of 648 bp capable of coding for 216 amino acids, Predicted peptide sequence of ORF2 contained a zinc finger domain which showed significant homology to GC box binding proteins BTEB2 and SP1. Transfection of an expression vector containing ORF2 but not full length cDNA was able to transform NIH3T3 cells and induce tumors in nude mice. Bcd mRNA transcripts of less than or equal to 2.6 kb were selectively expressed in PBL and testis of healthy individuals. Within the PBL, Bcd gene expression was restricted to CD19(+) B-cells and absent from CD14(+) monocytes and T-cells. Bcd transcripts were detected in all normal PBL samples tested but not in several malignant human B-cell lines and not in 50% of B-cells from B-CLL patients, However, stimulation of B-cells from B-CLL patients under conditions which induced differentiation into plasma cells was associated with induction of Bcd gene expression, The Bcd gene may therefore play an important role in B-cell growth and development.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; KAPLAN CANC CTR,NEW YORK,NY 10016	New York University					NCI NIH HHS [P30-CA16087, CA53572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016087, R01CA053572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNSTEIN JM, 1994, HDB MUCOSAL IMMUNOLO, P625; BLAIR DG, 1982, SCIENCE, V28, P1122; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER GM, 1980, NATURE, V284, P418, DOI 10.1038/284418a0; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; ELROUBY S, 1993, BLOOD, V82, P3452; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORDON J, 1984, J IMMUNOL, V132, P541; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIPPS TJ, 1988, BLOOD, V72, P422; KODONAGA JT, 1987, CELL, V51, P1079; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NEWCOMB EW, 1988, CANCER RES, V48, P5514; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	34	14	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2623	2630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000136				2022-12-17	WOS:A1996VZ65400012
J	Roy, B; Reisman, D				Roy, B; Reisman, D			Positive and negative regulatory elements in the murine p53 promoter	ONCOGENE			English	Article						p53 expression; transcription; promoter	TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; HELIX-LOOP-HELIX; TRANSCRIPTIONAL REPRESSION; PROTEIN; EXPRESSION; ANTIGEN; CELLS; TRANSFORMATION; BINDING	In order to understand the basis for regulated as well as de-regulated expression of the p53 tumor suppressor gene, we have focused on characterizing the transcriptional regulation of the p53 gene. Here we present evidence for the existence of two additional upstream regulatory elements in the murine p53 promoter. One of these sites maps to a region between -296 to -270 and the second one between -255 to -226 relative to the major transcription initiation site. These two sites are referred to as binding sites for PBF I and II, respectively. Nucleotide bases that have been found to be critical for the binding of nuclear factors to these sites are 5'-AGA-3' (-282 to -280) in binding site I and 5'-ACAG-3' (-246 to -243) in binding site II. Mutational analyses in conjunction with transient transfection assays indicated that the factor that binds to the region between -245 to -242 (PBF II) plays a positive regulatory role p53 promoter activity. This was demonstrated by the observation that promoter mutations that abolished binding to this site, showed a decreased level of activity as compared to the wild type promoter. In analogous experiments, mutational anlayses and transient transfection assays indicated that the factor that binds to the region between -282 to -280 (PBF I) plays a negative regulatory role in p53 promoter activity. This was demonstrated by the observation that promoter mutations that abolished binding to this site, showed an increased level of activity as compared to the wild type promoter.	UNIV S CAROLINA,DEPT BIOL SCI,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL CANCER INSTITUTE [R29CA059986] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA59986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Balint E, 1996, CANCER RES, V56, P1648; BEINZTADMOR B, 1985, EMBO J, V4, P3209; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1990, ONCOGENE, V5, P1285; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OLTIVAI ZN, 1993, CELL, V74, P609; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU HY, 1994, J BIOL CHEM, V269, P20067; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2359	2366						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957077				2022-12-17	WOS:A1996VX10800008
J	Aroca, P; Mahadevan, D; Santos, E				Aroca, P; Mahadevan, D; Santos, E			Functional interactions between isolated SH2 domains and insulin/Ras signaling pathways of Xenopus oocytes: Opposite effects of the carboxy- and amino-terminal SH2 domains of p85 PI 3-kinase	ONCOGENE			English	Article						SH2; Ras; insulin signaling; p85 alpha PI 3-kinase; Xenopus	RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; MEIOTIC MATURATION; ONCOGENE PRODUCT; BETA-RECEPTOR; HIGH-AFFINITY; RAS PROTEINS; SPECIFICITY; ACTIVATION	Purified amino-terminal Src homology 2 (SH2) domains of GAP, PLC gamma 1 and the p85 alpha subunit of PI 3-kinase, as well as the carboxy-terminal SH2 domain of the latter protein and the unique SH2 domain of Grb2, were injected into full grown, stage VI Xenopus laevis oocytes, None of the injected domains showed any effect when injected alone, nor did they affect the rate of GVBD induced by progesterone, an adenylate cyclase-dependent process, On the other hand, the unique Grb2 SH2 domain and all N-terminal SH2 domains injected inhibited to various degrees the rate of insulin-induced GVBD, a tyrosine kinase dependent pathway, Interestingly, and in contrast to the behavior shown by the N-terminal domain of the same molecule, the C-terminal SH2 domain of p85 did not inhibit, but slightly accelerated the rate of GVBD induced by insulin, Furthermore, whereas the Grb SH2 domain and all N-terminal SH2 domains tested failed to co-operate with normal Ras protein to induce GVBD, the C-terminal SH2 domain of p85 alpha exhibited significant synergy when coinjected with normal Pas protein, indicating that the C- and N-terminal SH2 domains of p85 alpha exert opposite (positive and negative, respectively) regulatory roles in the control of oocyte insulin/Ras signaling pathways, Our results demonstrate that the purified, isolated SH2 domains retain structural and functional specificity and that Xenopus oocytes constitute an useful biological system to analyse their functional role in tyrosine kinase signaling pathways.	NCI, DBS, CELLULAR & MOL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017	Aroca, Pilar/0000-0002-7557-6931				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AROCA P, 1995, J BIOL CHEM, V270, P14229, DOI 10.1074/jbc.270.23.14229; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; Gotoh N, 1995, ONCOGENE, V11, P2525; GRAZIANI G, 1992, ONCOGENE, V7, P229; GRIGORESCU F, 1994, HORM RES, V42, P55, DOI 10.1159/000184146; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KATZAV S, 1995, ONCOGENE, V11, P1079; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHADEVAN D, 1994, BIOCHEMISTRY-US, V33, P746, DOI 10.1021/bi00169a016; Maller James L., 1994, Seminars in Developmental Biology, V5, P183, DOI 10.1006/sedb.1994.1024; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PINES J, 1990, New Biologist, V2, P389; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; YOAKIM M, 1994, MOL CELL BIOL, V14, P5929, DOI 10.1128/MCB.14.9.5929; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1839	1846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934529				2022-12-17	WOS:A1996VR79500002
J	Davis, P; Bazar, K; Huper, G; Lozano, G; Marks, J; Iglehart, JD				Davis, P; Bazar, K; Huper, G; Lozano, G; Marks, J; Iglehart, JD			Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells	ONCOGENE			English	Article						p53; transactivation; tumor suppressor	TUMOR-SUPPRESSOR P53; MUTANT P53; BINDING PROTEIN; CANCER CELLS; E6 PROTEINS; T-ANTIGEN; GENE; TRANSACTIVATION; MUTATIONS; TRANSFORMATION	The p53 gene is a recessive oncogene whose loss of function can result in cell transformation, Approximately 25% of human breast cancers contain missense mutations in one p53 allele, leading to inactivation of the mutated protein. In almost all of these cases, the wild-type allele is also lost, However, it remains uncertain whether mutant p53 acts in a dominant negative fashion over the wild-type protein, Two parameters of p53 function, transcriptional activation and transcriptional repression, were studied under a variety of experimental conditions within malignant and normal breast epithelial cells, Transient transfection of DNA encoding wild-type p53 was able to transactivate p53-responsive promoters, Wild-type p53 functioned equally wed in malignant cells which harbored an endogenous mutation in p53, in malignant cells containing normal p53 and in normal mammary epithelial cells, Co-transfection of cDNAs encoding mutant p53 proteins mere unable to inhibit the ability of wild-type p53 to transactivate the reporter constructs, Repression of viral promoters by normal p53 protein was not inhibited transfected mutant p53 proteins, regulated gene WBF1/CIP1/p21 was induced following gamma irradiation in normal mammary cells, containing endogenous wild-type p53 and in the same cells transfected with mutant p53 genes, From these experiments me conclude that mutant p53 proteins do not inactivate the transactivating (or repressing) function of a co-expressed normal p53 protein in these cells implying that complete loss of mild-type p53 is required to eliminate these functions in breast epithelium.	DUKE UNIV,MED CTR,SCH MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030	Duke University; Duke University; Duke University; University of Texas System; UTMD Anderson Cancer Center	Davis, P (corresponding author), DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710, USA.				NCI NIH HHS [1P50-CA68438, R01-CA56749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056749, P50CA068438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BARTEK J, 1990, ONCOGENE, V5, P893; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAN SJ, 1995, CANCER RES, V55, P1649; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORRESTER K, 1995, ONCOGENE, V10, P2103; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPER G, 1992, IN VITRO CELL DEV-AN, V28A, P730; IGLEHART JD, 1990, CANCER RES, V50, P6701; JING H, 1994, ONCOGENE, V9, P3397; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MICHIELI P, 1994, CANCER RES, V54, P3391; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OROURKE RW, 1990, ONCOGENE, V5, P1829; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PARK DJ, 1994, ONCOGENE, V9, P1899; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RON D, 1994, P NATL ACAD SCI USA, V91, P10985; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10567; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAYLORS RL, 1991, CANCER RES, V51, P4721; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; UNGER T, 1992, EMBO J, V11, P1393; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYLLIE FS, 1996, ONCOGENE, V10, P1077; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	57	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1315	1322						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808706				2022-12-17	WOS:A1996VJ20200023
J	Sunitha, I; Avigan, MI				Sunitha, I; Avigan, MI			The apical membranes of maturing gut columnar epithelial cells contain the enzymatically active form of a newly identified fyn-related tyrosine kinase	ONCOGENE			English	Article						gtk; intestinal epithelium; tyrosine kinase	HEPATOCYTE GROWTH-FACTOR; SRC-FAMILY KINASES; SIGNAL TRANSDUCTION; C-SRC; PROTEIN-KINASES; FACTOR-RECEPTOR; SUBCELLULAR-LOCALIZATION; GASTROINTESTINAL-TRACT; TISSUE DISTRIBUTION; ANCHORED PROTEINS	Recently, we isolated a new src family member from a rat small intestinal cDNA library which by RNase protection analysis is selectively expressed in the columnar epithelium of gut. Complete nucleotide sequencing of the gastrointestinal associated tyrosine kinase (gtk) has revealed that it is a rat homologue of frk/rak - a fyn related human tyrosine kinase. Unlike frk/rak, gtk is myristylated, in vivo. Furthermore, by immunohistochemical analysis, the kinase is concentrated in the brush border membranes of epithelial cells, throughout the maturation axis of the adult small intestine. In vitro analysis revealed that gtk kinase activity is present in intestinal cells throughout their maturation, suggesting that the enzyme might influence signal transduction pathways in both mitotic and post-mitotic states. Gtk is expressed in all regions of the gastrointestinal tract which contain columnar epithelium, but is absent in the stratified epithelium of the esophagus. Moreover, during gestation, the kinase dramatically appears at high levels in plasma membranes, at the time of transition of gut cells from an undifferentiated to a simple columnar phenotype. After solubilization of cellular membranes with Triton X-100, sucrose gradient analysis of gtk revealed that it partitions differently than c-yes, demonstrating that the brush border src kinases associate with different components of the plasma membranes. These findings suggest that gtk plays a specialized role in the growth/differentiation of gut columnar epithelial cells.	GEORGETOWN UNIV,SCH MED,DEPT PATHOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DEPT MED,WASHINGTON,DC 20007	Georgetown University; Georgetown University					NCI NIH HHS [CA 54818] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ALLAND L, 1994, J BIOL CHEM, V269, P16701; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BERARDI RS, 1983, SURG GYNECOL OBSTET, V156, P521; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CHAN AML, 1988, ONCOGENE, V2, P593; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; CRAVEN RJ, 1995, CANCER RES, V55, P3969; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DENARDI FG, 1992, HISTOLOGY PATHOLOGIS, P515; ENGLE MJ, 1995, J BIOL CHEM, V270, P11935, DOI 10.1074/jbc.270.20.11935; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HANCOCK JF, 1990, EMBO J, V8, P4133; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JOHNS BAE, 1952, J ANAT, V86, P431; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cellbio.8.1.157; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIRCHEFF AK, 1990, METHOD ENZYMOL, V192, P341; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MOIJNA A, 1992, NATURE, V357, P161; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NEUTRA M, 1989, MODERN CELL BIOL, V8, P363; OBERGWELSH C, 1995, GENE, V152, P239, DOI 10.1016/0378-1119(94)00718-8; OKADA M, 1991, J BIOL CHEM, V266, P24249; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RIDER LG, 1994, GENE, V138, P219, DOI 10.1016/0378-1119(94)90811-7; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUNITHA I, 1994, BBA-MOL CELL RES, V1221, P348, DOI 10.1016/0167-4889(94)90260-7; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; Walter K., 1974, METHODS ENZYMATIC AN, V2nd ed., P856; WEISER MM, 1973, J BIOL CHEM, V248, P2536; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZHAO YH, 1990, ONCOGENE, V5, P1629	69	14	15	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					547	559						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760296				2022-12-17	WOS:A1996VB32800012
J	Feinmesser, RL; Gray, K; Means, AR; Chantry, A				Feinmesser, RL; Gray, K; Means, AR; Chantry, A			HER-2/c-erbB2 is phosphorylated by calmodulin-dependent protein kinase II on a single site in the cytoplasmic tail at threonine-1172	ONCOGENE			English	Article						tyrosine kinases; HER-2/c-erbB2; calmodulin-dependent protein kinase; desensitisation	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; NEU ONCOGENE; CELLS; RESIDUES	Calmodulin-dependent protein kinase II (Cam kinase II) is known to desensitise epidermal growth factor receptor (HER-1) tyrosine kinase activity by a process involving phosphorylation at serines 1046/47 in the cytoplasmic tail, We have developed an experimental system to investigate phosphorylation of the related HER-2/cerbB2 proto-oncogene utilising purified Cam kinase II and recombinant glutathione-S-transferase (GST) fusion proteins, The cDNA for rat Cam kinase II-alpha was transfected into human embryonic kidney (HEK) 293 fibroblasts and the expressed protein purified to homogeneity by calmodulin-agarose affinity chromatography, A GST fusion protein comprising residues 1126-1255 of HER-2 was phosphorylated by purified Cam kinase II, in contrast to a GST protein comprising residues 1005-1125, Phosphoamino-acid analysis and site-directed mutagenesis indicated that HER-2 was phosphorylated on a single site at threonine-1172 which resides within a consensus Cam kinase II phosphorylation site (RAKT), HER-2 (threonine-1172-alanine), in the form of a ligand-inducible chimaera HER-1/2, was co-transfected into HEK-293 fibroblasts with a constitutively active form of Cam kinase II, followed by in vivo labelling of these cells with P-32-orthophosphate, Immunoprecipitation of ligand-activated receptors followed by two-dimensional phosphopeptide mapping indicated that threonine-1172 in HER-2 is a newly identified in vivo site which can be hyper-phosphorylated by constitutively active Cam kinase II, In addition, when over-expressed in HEK 293 fibroblasts, HER-1/2 (threonine-1172-alanine) showed a defect in desensitisation and underwent a more sustained EGF-induced receptor autophosphorylation compared to wild-type HER-1/2.	CHARING CROSS & WESTMINSTER MED SCH, DEPT BIOCHEM, LONDON W6 8RP, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT MED ONCOL, LONDON W6 8RP, ENGLAND; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	Imperial College London; Imperial College London; Duke University					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MORRISON P, 1993, J BIOL CHEM, V268, P15536; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	24	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2725	2730						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700533				2022-12-17	WOS:A1996UW48700028
J	Fujii, M; Minamino, T; Nomura, M; Miyamoto, KI; Tanaka, J; Seiki, M				Fujii, M; Minamino, T; Nomura, M; Miyamoto, KI; Tanaka, J; Seiki, M			Selective activation of the proto-oncogene c-jun promoter by the transforming protein v-Rel	ONCOGENE			English	Article						v-Rel; transcription; c-jun; NF-kB	NF-KAPPA-B; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTIONAL ACTIVATION; BINDING-PROTEIN; GENE-EXPRESSION; FAMILY; SEQUENCES; DOMAIN; REQUIRES; CELLS	The transcription factor v-Rel is a transforming protein of the reticuloendotheliosis virus. We found that v-Rel activates the promoter of the proto-oncogene c-jun, Two elements in the c-jun promoter were required for the activation by v-Rel, One was a kB-site (v-Rel binding site), and the other was a c-jun promoter region between -52 and +148 (c-jun promoter (-52/+148)). Two promoters with the kB-site(s), those of human immunodeficiency virus (HIV) and SV40, were not activated by v-Rel, but their kB-sites were activated when introduced upstream of the c-jun promoter (-52/+148), Thus, the c-jun promoter (-52/+148) had information for the selective activation of the c-jun promoter by v-Rel, v-Rel bound to the c-jun kB-site with the higher affinity than c-Rel, thereby activating the c-jun promoter more efficiently than c-Rel, Moreover, the activity of v-Rel mutants upon the c-jun promoter correlates with their transforming activity, Thus, the c-jun promoter activation by v-Rel may play a role in the transformation caused by v-Rel.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; HOKURIKU UNIV,SCH PHARM,RES LAB DEV MED,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Hokuriku University			Seiki, Motoharu/K-9443-2015					ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1992, CANCER SURV, V15, P69; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MCDONNELL PC, 1992, ONCOGENE, V7, P163; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; SARKAR S, 1993, ONCOGENE, V8, P2245; SHIPP MA, 1987, J IMMUNOL, V139, P2143; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	38	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2193	2202						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668346				2022-12-17	WOS:A1996UP28300019
J	Latham, KE; Cosenza, S; Reichenbach, NL; Mordechai, E; Adelson, ME; Kon, N; Horvath, SE; Charubala, R; Mikhailov, SN; Pfleiderer, W; Suhadolnik, RJ				Latham, KE; Cosenza, S; Reichenbach, NL; Mordechai, E; Adelson, ME; Kon, N; Horvath, SE; Charubala, R; Mikhailov, SN; Pfleiderer, W; Suhadolnik, RJ			Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA-etherA, a stable 2-5A derivative	ONCOGENE			English	Article						2-5A; breast cancer; AA-etherA; estrogen receptor; 2D gel	PHOSPHOROTHIOATE ANALOGS; 2',5'-OLIGOADENYLATE-DEPENDENT ENDORIBONUCLEASE; PPP(A2'P)NA-DEPENDENT RNASE; REVERSE-TRANSCRIPTASE; INTERFERON TREATMENT; VACCINIA VIRUS; DIFFERENTIATION; REPLICATION; ACTIVATION; TRIMER	The design, chemical synthesis and biological activities of a nuclease-resistant, nontoxic bioactive 2-5A derivative, AA-etherA [i.e., adenylyl-(2'-5')-adenylyl-(2'-2 '')-9-[(2'-hydroxyethoxy)-methyl]adenine], are described as a new approach to the inhibition of breast cancer cell growth, AA-etherA inhibits DNA replication and cell division of both estrogen receptor positive (MCF-7) and estrogen receptor negative (BT-20) breast cancer cells in culture in a dose-dependent manner. Maximal inhibition in MCF-7 and BT-20 cells was obtained with 100 mu M AA-etherA after four days of treatment, with an GI(50) of 58 and 37 mu M, respectively, AA-etherA is stable in the cytoplasm. Treated cells accumulate within the late G(1)/early S phase of the cell cycle and then progress only very slowly through S phase. AA-etherA does not activate RNase L, as do 2-5A and other 2-5A derivatives, nor does it increase p68 kinase (PKR) content of the cells. High resolution, two-dimensional protein gel electrophoresis reveals twofold or greater inhibition of synthesis of 92 proteins out of 682 proteins that were reproducibly detected as high quality spots with average rates of synthesis of greater than or equal to 20 p.p.m. in untreated cells. The specificity of the effects of AA-etherA on select proteins and its failure to activate RNase L indicate that AA-etherA does not act through a general effect on mRNA translation or stability, but rather inhibits cell proliferation through a block to DNA replication, with a concommitant reduction in the synthesis of specific proteins, some of which may be required for cell cycle transit. Two likely targets to account for the AA-etherA inhibition of DNA replication are DNA topoisomerase I, which is inhibited by AA-etherA in other cell lines, and thymidine kinase, which could be inhibited in a manner similar to the effect of acyclovir. These data indicate that 2-5A analogs, particularly bifunctional 2-5A analogs like AA-etherA, will be useful for controlling cancer cell growth. Further development of such 2-5A analogs may provide highly specific compounds for chemotherapy and chemoprevention.	UNIV KONSTANZ,FAK CHEM,W-7750 CONSTANCE,GERMANY; RUSSIAN ACAD SCI,INST MOLEC BIOL,MOSCOW,RUSSIA; TEMPLE UNIV,DEPT BIOCHEM,SCH MED,PHILADELPHIA,PA 19140	University of Konstanz; Russian Academy of Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Latham, KE (corresponding author), TEMPLE UNIV,FELS INST CANC RES & MOL BIOL,SCH MED,PHILADELPHIA,PA 19140, USA.		Mikhailov, Sergey/B-4576-2008; Mikhailov, Sergey/F-3414-2013	Mikhailov, Sergey/0000-0002-1363-9706	NATIONAL CANCER INSTITUTE [R01CA065779, P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049489] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA12227, CA65779] Funding Source: Medline; NIGMS NIH HHS [GM49489] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHARACHON G, 1990, BIOCHEMISTRY-US, V29, P2550, DOI 10.1021/bi00462a017; EPSTEIN DA, 1983, J INTERFERON RES, V3, P305; FERBUS D, 1985, MOL CELL BIOCHEM, V67, P125, DOI 10.1007/BF02370171; GAO WY, 1990, J BIOL CHEM, V265, P20172; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GARRELS JI, 1989, J BIOL CHEM, V264, P5269; HERDEWIJN P, 1989, HELV CHIM ACTA, V42, P1739; HERSH CL, 1984, J BIOL CHEM, V259, P1731; HUBBELL HR, 1985, INT J CANCER, V36, P389, DOI 10.1002/ijc.1985.36.3.389; KARIKO K, 1987, BIOCHEMISTRY-US, V26, P7136, DOI 10.1021/bi00396a040; KARIKO K, 1987, BIOCHEMISTRY-US, V26, P7127, DOI 10.1021/bi00396a039; KIMCHI A, 1981, EUR J BIOCHEM, V114, P5; KRAUSE D, 1985, J BIOL CHEM, V260, P9501; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; KVASYUK EI, 1995, HELV CHIM ACTA, V78, P1777, DOI 10.1002/hlca.19950780711; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MIKHAILOV SN, 1974, IAN SSSR KH, P2582; MORDECHAI E, 1995, VIROLOGY, V206, P913, DOI 10.1006/viro.1995.1014; MORDECHAI E, UNPUB; MULLER WEG, 1991, BIOCHEMISTRY-US, V30, P2027, DOI 10.1021/bi00222a004; PATTERSON SD, 1993, BIOTECHNIQUES, V15, P1076; PESTKA S, 1981, METHOD ENZYMOL, V78, P79; RICE AP, 1984, J VIROL, V50, P220, DOI 10.1128/JVI.50.1.220-228.1984; ROBINS MJ, 1982, CAN J CHEM, V60, P547, DOI 10.1139/v82-081; SAVINOVA O, 1995, J INTERFERON CYTOKIN, V15, pS167; SCHRODER HC, 1994, CHEM-BIOL INTERACT, V90, P169, DOI 10.1016/0009-2797(94)90101-5; SOBOL RW, 1993, BIOCHEMISTRY-US, V32, P12112, DOI 10.1021/bi00096a023; SOBOL RW, 1995, J BIOL CHEM, V270, P5963, DOI 10.1074/jbc.270.11.5963; TAYLOR JL, 1995, J INTERF CYTOK RES, V15, P27, DOI 10.1089/jir.1995.15.27; VIANO I, 1990, J BIOL REGULATORS HO, V3, P167; VISSER GM, 1986, RECL TRAV CHIM PAY B, V105, P528; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571	35	14	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					827	837						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632905				2022-12-17	WOS:A1996TW68600014
J	Athanasiou, M; Mavrothalassitis, GJ; Yuan, CC; Blair, DG				Athanasiou, M; Mavrothalassitis, GJ; Yuan, CC; Blair, DG			The Gag-Myb-Ets fusion oncogene alters the apoptotic response and growth factor dependence of interleukin-3 dependent murine cells	ONCOGENE			English	Article						v-ets; ETS oncogene; apoptosis; IT-3 dependent; erythropoietin; erythroid differentiation	TRANSCRIPTION FACTOR GATA-1; AVIAN LEUKEMIA-VIRUS; HEMATOPOIETIC-CELLS; ERYTHROPOIETIN RECEPTOR; NEURORETINA CELLS; GENE-EXPRESSION; LINE; E26; TRANSACTIVATION; DIFFERENTIATION	Expression of the avian E26-derived Gag-Myb-Ets fusion oncogene in interleukin-3(IL3)-dependent murine hematopoietic cell lines results in a pattern of cell line dependent changes in growth factor-induced proliferation and apoptosis. A drug-selectable retrovirus expressing p135(Gag-Myb-Ets) induced an erythropoietin(Epo)-responsive phenotype in the cell lines FDC-P2, BaF3 and 32Dc123. Gag-Myb-Ets expression alone did not increase expression of GATA-1 or the Epo receptor(EpoR) in the presence of IL3, and infected cell lines express increased GATA-1 and EpoR only when IL3 was replaced by Epo in the culture media. Indicative of Epo-induced erythroid differentiation, these cells also began to express beta-globin after 3-5 days growth in Epo. Unlike control cells, infected FDC-P2 cells failed to undergo programmed cell death (apoptosis) when transferred from IL3- to Epo-containing media, although a fraction of the cells failed to proliferate following the media shift. Three other IL3-dependent cell Lines showed no changes in growth behavior when induced to express the fusion oncogene. Our data shows that Gag-Myb-Ets can have different affects on growth factor pathways depending on the cell background, suggesting a model in which the p135(gag-myb-ets) fusion oncogene promotes these different responses through its affect on apoptosis.	SAIC,LAB CELLULAR BIOCHEM,FREDERICK,MD 21702; NCI,MOLEC ONCOL LAB,FREDERICK,MD	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; Ascione R., 1993, Genome research in molecular medicine and virology., P199; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BERRIDGE MV, 1993, EXP HEMATOL, V21, P269; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUBART A, 1994, MOL CELL BIOL, V14, P4834, DOI 10.1128/MCB.14.7.4834; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; ICHIKAWA H, 1994, CANCER RES, V54, P2865; ISFORT RJ, 1990, SOMAT CELL MOLEC GEN, V16, P109, DOI 10.1007/BF01233041; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JURDIC P, 1987, J VIROL, V61, P3058, DOI 10.1128/JVI.61.10.3058-3065.1987; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRAUT N, 1995, ONCOGENE, V10, P1027; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NUNN M, 1984, VIROLOGY, V133, P330; ORKIN SH, 1992, BLOOD, V80, P575; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SETH A, 1993, ONCOGENE, V8, P1783; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARIO G, 1990, J BIOL CHEM, V265, P2692; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	51	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					337	344						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570210				2022-12-17	WOS:A1996TR53800012
J	Froeschle, A; Carnac, G; Alric, S; Montarras, D; Pinset, C; RochetteEgly, C; Bonnieu, A				Froeschle, A; Carnac, G; Alric, S; Montarras, D; Pinset, C; RochetteEgly, C; Bonnieu, A			RXR alpha is essential for mediating the all-trans retinoic acid-induced growth arrest of C2 myogenic cells	ONCOGENE			English	Article						retinoic acid; RXR alpha; growth arrest; muscle cell	ACUTE PROMYELOCYTIC LEUKEMIA; X-RECEPTOR; THYROID-HORMONE; TERMINAL DIFFERENTIATION; LINE BA-HAN-1C; MUSCLE-CELLS; EXPRESSION; CLONING; MYOD1; GENE	In C2 muscle cells, retinoic acid (RA) induces growth arrest associated with terminal differentiation. These RA actions are presumed to be mediated through nuclear receptors (RARs and RXRs) that belong to the superfamily of ligand-dependent transcription factors, In this study, we have characterized a myogenic C2 subclone, that unlike parental cells, is resistant to growth inhibition and differentiation by RA, Examination of these RA-sensitive and resistant C2 cells for the expression of retinoid acid receptors revealed a lack of RXR alpha expression at the myoblast stage in resistant C2 cells, To determine the functions of RXR alpha, we introduced an RXR alpha expression vector into RA-resistant C2 cells by transient or stable transfections, Our results show that RXR alpha restores the response to RA in this subclone with respect to AP1 inhibition and growth arrest, These observations indicate that RXR alpha plays a crucial role in mediating RA induced growth arrest of C2 myogenic cells.	INRA,LAB DIFFERENCIAT CELLULAIRE & CROISSANCE,F-34060 MONTPELLIER 01,FRANCE; INST PASTEUR,DEPT BIOL MOLEC,URA 1148 CNRS,F-75724 PARIS 15,FRANCE; INST GENET & BIOL MOLEC & CELLULAIRE,CNRS,INSERM,ULP,F-67404 ILLKIRCH GRAFFENS,FRANCE	INRAE; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; CARNAC G, 1993, ENDOCRINOLOGY, V133, P2171, DOI 10.1210/en.133.5.2171; CARNAC G, 1993, ONCOGENE, V8, P3103; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DE LUCA LM, 1991, FASEB J, V5, P2924; DEFACQUE H, 1994, BIOCHEM BIOPH RES CO, V203, P272, DOI 10.1006/bbrc.1994.2178; DOWNES M, 1994, ENDOCRINOLOGY, V134, P2658, DOI 10.1210/en.134.6.2658; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GABBERT HE, 1988, CANCER RES, V48, P5264; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gudas Lorraine J., 1994, P443; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; KIZAKI M, 1993, BLOOD, V82, P3592; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MOASSER MM, 1994, ONCOGENE, V9, P833; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAGY L, 1995, MOL CELL BIOL, V15, P3540; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	53	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					411	421						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570219				2022-12-17	WOS:A1996TR53800021
J	Huff, JL; Jelinek, MA; Jamieson, TA; Parsons, JT				Huff, JL; Jelinek, MA; Jamieson, TA; Parsons, JT			Expression and maturation of the cellular sea receptor, a member of the hepatocyte growth factor (HGF) receptor family of protein tyrosine kinases	ONCOGENE			English	Article						c-sea; receptor; protein tyrosine kinase; hepatocyte growth factor	MACROPHAGE STIMULATING PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; SCATTER FACTOR-RECEPTOR; C-MET; AVIAN RETROVIRUS; EPITHELIAL-CELLS; SRC GENE; MYC GENE; PROTOONCOGENE; ONCOGENE	The c-sea proto-oncogene is a member of the Met/hepatocyte growth factor/scatter factor family of receptor protein tyrosine kinases. A distinguishing feature of this family, whose other member is the Ron/Stk receptor, is a novel heterodimeric structure. We have previously described cDNA clones encoding the avian Sea receptor. In this report we show that a fun length c-sea cDNA directed the synthesis of a single 155 kDa polypeptide chain in vitro, while irt vivo two polypeptides of 160 and 180 kDa were observed. We analysed the structure of the Sea receptor using a soluble chimeric protein consisting of the Sea extracellular domain linked to the hinge and constant regions of human IgG gamma 1. These studies indicated that the receptor undergoes proteolytic processing in the extracellular domain yielding an approximate 35 kDa alpha and a 160 kDa beta chain, and thus the Sea receptor appears to display a structure similar to that of the Met and Ron proteins. An examination of embryonic avian tissues using Sea extracellular domain-specific monoclonal antibodies revealed low levels of Sea receptor in a variety of tissues including kidney, intestine, liver, stomach, white blood cells and allantochorion. Elevated levels of expression were observed upon transformation of chicken embryo cells by the Src oncoprotein.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia				Huff, Janice/0000-0003-4236-7698	NCI NIH HHS [CA 27578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CHAN AML, 1988, ONCOGENE, V2, P593; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; FRIEZNER DSJ, 1991, BIOCHEMISTRY-US, V30, P9781; FURLONG RA, 1991, J CELL SCI, V100, P173; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAEMMLI UK, 1994, NATURE, V269, P19457; LEE CC, 1994, J BIOL CHEM, V269, P19457; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; MARK MR, 1992, J BIOL CHEM, V267, P26166; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONSIN C, 1993, ONCOGENE, V8, P1195; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STOKER M, 1985, J CELL SCI, V77, P209; Stubbs EL, 1935, J EXP MED, V61, P593, DOI 10.1084/jem.61.5.593; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; WANG MH, 1994, SCIENCE, V266, P177; WEIDNER KM, 1993, AM J RESP CELL MOL, V8, P229, DOI 10.1165/ajrcmb/8.3.229; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097	58	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					299	307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570207				2022-12-17	WOS:A1996TR53800009
J	Ino, T; Yasui, H; Hirano, M; Kurosawa, Y				Ino, T; Yasui, H; Hirano, M; Kurosawa, Y			Identification of a member of the TIS11 early response gene family at the insertion point of a DNA fragment containing a gene for the T-cell receptor beta chain in an acute T-cell leukemia	ONCOGENE			English	Article						TIS11d gene; gene rearrangement; T-cell receptor gene; T-cell leukemia; leukemogenesis	SWISS 3T3 CELLS; CIRCULAR DNA; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; CONSTANT REGION; CYCLIC-AMP; PROTEIN; TRANSCRIPTION; RECOMBINATION; DELETION	In a previous paper (Proc. Natl. Acad. Sci. USA 84, 4264, 1987) we reported that a DNA fragment containing a gene for the T-cell receptor beta chain, which had been excised from chromosome 7q35 during D beta-J beta joining, was inserted into chromosome 6p21.3 in a patient with acute T-cell leukemia. We have since screened for genes in the vicinity of the insertion point and have identified a gene that is equivalent to the murine TIS11d gene, a member of TIS11 early response gene family, that contains unique Cysteine-Histidine motifs. The human TIS11d gene consists of two exons and encodes a polypeptide of 492 amino acids. The insertion of the DNA fragment observed in this patient is located at the carboxy-terminal portion of the TIS11d protein.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University	Ino, T (corresponding author), FUJITA HLTH UNIV,SCH MED,DEPT INTERNAL MED,TOYOAKE,AICHI 47011,JAPAN.							BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; GOMPERTS M, 1990, ONCOGENE, V5, P1081; INO T, 1987, P NATL ACAD SCI USA, V84, P4264, DOI 10.1073/pnas.84.12.4264; INO T, 1988, BIOCHEM BIOPH RES CO, V152, P257, DOI 10.1016/S0006-291X(88)80708-3; INO T, 1988, ACTA HEMATOL JPN, V51, P185; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; KANEDA N, 1987, BIOCHEM BIOPH RES CO, V146, P971, DOI 10.1016/0006-291X(87)90742-X; LAI WS, 1990, J BIOL CHEM, V265, P16556; LIM RW, 1987, ONCOGENE, V1, P263; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0	24	14	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2705	2710						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545129				2022-12-17	WOS:A1995TP18800028
J	ASKER, CE; MAGNUSSON, KP; PICCOLI, SP; ANDERSSON, K; KLEIN, G; COLE, MD; WIMAN, KG				ASKER, CE; MAGNUSSON, KP; PICCOLI, SP; ANDERSSON, K; KLEIN, G; COLE, MD; WIMAN, KG			MOUSE AND RAT B-MYC SHARE AMINO-ACID-SEQUENCE HOMOLOGY WITH THE C-MYC TRANSCRIPTIONAL ACTIVATOR DOMAIN AND CONTAIN A B-MYC SPECIFIC CARBOXY-TERMINAL REGION	ONCOGENE			English	Article						B-MYC; SEQUENCE; MOUSE; RAT; NUCLEAR PROTEIN	MURINE ERYTHROLEUKEMIA-CELLS; DNA-BINDING PROTEINS; N-MYC; NUCLEOTIDE-SEQUENCE; TRANSGENIC MICE; LEUCINE ZIPPER; NEOPLASTIC TRANSFORMATION; DIFFERENTIATION; EXPRESSION; GENE	B-myc is a member of the myc gene family. Previous studies indicate that the rat B-myc gene contains a single exon which shows 77% nucleotide homology to the second exon of the rat c-myc gene. Its open reading frame (ORF) encodes a polypeptide with a predicted molecular weight of 20 kD. We have isolated a new, larger rat B-myc genomic clone. Sequence analysis of this clone confirmed the presence of one single coding exon. Furthermore, a genomic mouse B-myc clone was identified and compared to the rat homolog. Nucleotide analysis of B-myc coding and non-coding sequences suggests that it may be a functional gene evolved by selective duplication of part of the second c-myc exon. Analysis of the rodent B-myc open reading frames revealed two in-frame amino acid duplications in mouse B-myc and a 96% conservation at the amino acid level. Both rat and mouse B-myc proteins contain an identical and unique stretch of 14 carboxy terminal amino acid residues not found in other myc proteins. In vitro translation of rat and mouse B-myc ORF's yielded proteins that migrated as 26 kD bands in SDS-PAGE and could be immunoprecipitated by a polyclonal panmyc antiserum. Immunostaining of human lymphoma cells transiently transfected with a B-myc expression vector showed that the protein was mainly localized to the nucleus.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; IMMUNOCOM, HUNTINGDON VALLEY, PA 19006 USA	Princeton University	ASKER, CE (corresponding author), KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN.		Wiman, Klas/AAB-8399-2021; Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011	Wiman, Klas/0000-0002-7113-524X; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826	NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1 CA 14054-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKER C, 1989, ONCOGENE, V4, P1523; BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1993, GENE, V133, P153, DOI 10.1016/0378-1119(93)90633-E; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; INGVARSSON S, 1988, ONCOGENE, V3, P679; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOROY T, 1991, ONCOGENE, V6, P1941; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	48	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					1963	1969						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478514				2022-12-17	WOS:A1995TF29700005
J	JURDIC, P; TREILLEUX, I; VANDEL, L; TABONE, E; HUGUIER, S; SERGEANT, A; CASTELLAZZI, M				JURDIC, P; TREILLEUX, I; VANDEL, L; TABONE, E; HUGUIER, S; SERGEANT, A; CASTELLAZZI, M			TUMOR-INDUCTION BY V-JUN HOMODIMERS IN CHICKENS	ONCOGENE			English	Article						V-JUN; HOMODIMERS; VISCERAL TUMORS; LEIOMYOSARCOMA; IMMORTALIZATION; CHICKENS	DNA-BINDING ACTIVITY; AVIAN-SARCOMA VIRUS-17; C-JUN; EMBRYO FIBROBLASTS; TRANSCRIPTION FACTORS; CELL-TRANSFORMATION; TRANSGENIC MICE; PROTEIN-KINASE; FOS-GENE; ONCOGENE	To study the contribution of v-Jun homodimers to oncogenesis, me constructed artificial v-Jun derivatives in which the natural dimerization domain of v-Jun was replaced by an heterologous homodimerization domain from either the viral EB1 or the yeast GCN4 transcription factor. The resulting v-Jun chimeric proteins, called v-Jun(eb1) and v-Jun(gcn4), which can no longer dimerize with Jun or Fos, should only form homodimers in the cell. Helper-independent retroviruses expressing v-Jun, v-Jun(eb1) and v-Jun(gcn4) were generated. AU three viruses transformed primary cultures of chick embryo cells with the same high efficiency and promoted local tumor growth after subcutaneous injection of infected cells in young animals. In contrast, after intravenous injection of viral suspensions into chick embryos, only the chimeric proteins produced internal tumors that were lethal. These tumors were leiomyosarcomas located within the liver and along the digestive tract. Thus, in vivo, v-Jun(eb1) and v-Jun(gcn4) are more potent oncoproteins than v-Jun. These data demonstrate that when forced to accumulate, v-Jun homodimers can induce tumors efficiently. They also show that the oncogenic potential of v-Jun can be regulated through the properties of its dimerization domain.	ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,F-69364 LYON 07,FRANCE; CTR LEON BERARD,DEPT ANAT & CYTOL PATHOL,F-69373 LYON 08,FRANCE; LAB BIOL MOLEC & CELLULAIRE,CNRS,UMR 49,F-69373 LYON 08,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet				Vandel, Laurence/0000-0002-3692-2942				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1994, J BIOL CHEM, V269, P11186; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALL AR, 1988, COLD SPRING HARB SYM, V53, P687, DOI 10.1101/SQB.1988.053.01.078; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3241; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P269; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P491; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P8837, DOI 10.1073/pnas.90.19.8837; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GROSSI M, 1991, ONCOGENE, V6, P1767; HADMAN M, 1993, ONCOGENE, V8, P1895; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HARTL M, 1991, ONCOGENE, V6, P1623; HARVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL GM, 1992, VIROLOGY, V188, P373, DOI 10.1016/0042-6822(92)90768-K; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN IM, 1994, ONCOGENE, V9, P2793; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1982, ADV VIRAL ONCOL, V1, P82; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OEHLER T, 1993, ONCOGENE, V8, P1141; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; PURCHASE HG, 1977, INFECT IMMUN, V15, P423, DOI 10.1128/IAI.15.2.423-428.1977; SCHUH AC, 1992, ONCOGENE, V7, P667; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SHALABY F, 1994, ONCOGENE, V9, P2579; SU HY, 1991, ONCOGENE, V6, P1759; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VANDEL L, 1995, ONCOGENE, V10, P495; VANHOEVEN KH, 1993, AM J SURG PATHOL, V17, P1176, DOI 10.1097/00000478-199311000-00011; VOGT, 1994, VOGT PK, P203; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	65	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1699	1709						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478597				2022-12-17	WOS:A1995TD09400004
J	TRIVEDI, P; ZHANG, QJ; CHEN, F; MINAROVITS, J; EKMAN, M; BIBERFELD, P; KLEIN, G; WINBERG, G				TRIVEDI, P; ZHANG, QJ; CHEN, F; MINAROVITS, J; EKMAN, M; BIBERFELD, P; KLEIN, G; WINBERG, G			PARALLEL EXISTENCE OF EPSTEIN-BARR-VIRUS (EBV) POSITIVE AND NEGATIVE CELLS IN A SPORADIC CASE OF BURKITT-LYMPHOMA	ONCOGENE			English	Article						EBV; EBNA; BL; SPORADIC; VIRUS LOSS	LINES; DNA; MOLECULES; ANTIGENS; EXPRESSION; PATTERNS; GENOME; HLA	In the Burkitt lymphoma line Oma-BL1, EBV positive and negative cells coexist. We demonstrate that EBV positive and negative subclones are identical with respect to chromosome markers and HLA type and that the same c-myc rearrangement occurs in all the subclones. This shows that the tumor cells are derived from the same patient and are of monoclonal origin. In the positive subclones, the EBV genome was stably maintained in the episomal form. The EBV negative subclones could be derived from previously uncloned tumor cells in early passage, but not from the EBV positive subclones.			TRIVEDI, P (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL MTC,S-17177 STOCKHOLM,SWEDEN.		Winberg, Gosta/I-5686-2013	Winberg, Gosta/0000-0002-3371-4056	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2ROI CA 30264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; CASPERSSON T, 1971, HEREDITAS-GENETISK A, V67, P89; DELECLUSE HJ, 1993, J VIROL, V67, P1292, DOI 10.1128/JVI.67.3.1292-1299.1993; DETHE G, 1985, BURKITTS LYMPHOMA HU, P165; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HURLEY EA, 1991, J VIROL, V65, P1245, DOI 10.1128/JVI.65.3.1245-1254.1991; JOSHI SS, 1991, INT J CANCER, V47, P643, DOI 10.1002/ijc.2910470502; KLEIN G, 1981, NATURE, V299, P313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenoir G. M., 1987, ADV VIRAL ONCOL, P173; Maniatis T., 1982, MOL CLONING; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MORGAN J, 1989, J VIROL, V63, P3190, DOI 10.1128/JVI.63.7.3190-3194.1989; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; PATARROYO M, 1988, INT J CANCER, V41, P901, DOI 10.1002/ijc.2910410623; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; REISMAN D, 1984, VIROLOGY, V137, P113, DOI 10.1016/0042-6822(84)90014-X; RONCELLA S, 1993, LEUKEMIA LYMPHOMA, V9, P157, DOI 10.3109/10428199309148520; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SEABRIGHT MA, 1987, LANCET, V2, P971; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; SUGDEN B, 1979, J VIROL, V31, P590, DOI 10.1128/JVI.31.3.590-595.1979; TEO CG, 1987, P NATL ACAD SCI USA, V84, P8473, DOI 10.1073/pnas.84.23.8473; TOWBIN H, 1976, P NATL ACAD SCI USA, V76, P4350; TRIVEDI P, 1993, J GEN VIROL, V74, P1393, DOI 10.1099/0022-1317-74-7-1393; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	29	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					505	510						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630634				2022-12-17	WOS:A1995RN53000010
J	SMARDOVA, J; WALKER, A; MORRISON, LE; KABRUN, N; ENRIETTO, PJ				SMARDOVA, J; WALKER, A; MORRISON, LE; KABRUN, N; ENRIETTO, PJ			THE ROLE OF THE CARBOXY-TERMINUS OF V-REL IN TRANSFORMATION AND ACTIVATION OF ENDOGENOUS GENE-EXPRESSION	ONCOGENE			English	Article						V-REL; ONCOGENES; GENE EXPRESSION; TRANSFORMATION	NF-KAPPA-B; CHICKEN SPLEEN-CELLS; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; ONCOGENIC TRANSFORMATION; TRANSCRIPTION FACTORS; EMBRYO FIBROBLASTS; ESTROGEN-RECEPTOR; CELLULAR PROTEINS; HOMOLOGY DOMAIN	Proteins within the Rel/NF-kappa B transcription factor family can be divided into two functional domains, a homologous amino terminal region, the Rel Homology Domain, and a divergent carboxy terminal domain. The amino terminal sequences specify DNA binding, nuclear localization, and interaction with the I kappa B family of inhibitory proteins. The carboxy terminus of each protein functions as a transcriptional activation domain, however, precise definition of sequence requirements has been difficult. To further define these sequences, small 100 bp deletions were constructed throughout the carboxy terminus of v-Rel. Each resulting mutant was assayed for DNA binding, localization, protein complex formation, activation of endogenous gene expression and ability to transform bone marrow cells and fibroblasts. Surprisingly, deletion within the carboxy terminus had marginal effects on transforming potential. However, three separate regions were required for full activation of gene expression. Taken together, these results suggest that the carboxy terminus of v-Rel contains multiple sequences that participate in the activation of gene expression.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [R01 CA 51792, CA 09176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1987, CURRENT PROCOLS MOL; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GARSON K, 1990, ONCOGENE, V5, P1431; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1991, TRENDS GENET, V7, P307; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE J-I, 1991, P NATL ACAD SCI USA, V88, P3175; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1992, SEM DEV BIOL, V3, P15; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN J, 1992, ONCOGENE, V7, P1903; LEHN DA, 1993, DNA CELL BIOL, V12, P753, DOI 10.1089/dna.1993.12.753; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MACCABE JA, 1990, J EXPER ZOO, V257, P208; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; RUBEN SM, 1991, SCIENCE, V254, P11, DOI 10.1126/science.1925549; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992	60	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2017	2026						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761102				2022-12-17	WOS:A1995QZ92600016
J	CHUNG, SW; WONG, PMC				CHUNG, SW; WONG, PMC			THE BIOLOGY OF ABL DURING HEMATOPOIETIC STEM-CELL DIFFERENTIATION AND DEVELOPMENT	ONCOGENE			English	Review							MURINE LEUKEMIA-VIRUS; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ABELSON TYROSINE KINASE; IMMATURE LYMPHOID-CELLS; P210 BCR ABL; C-ABL; HEMATOPOIETIC-CELLS; V-ABL; PHILADELPHIA-CHROMOSOME		TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	CHUNG, SW (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT BIOCHEM, 3307 N BROAD ST, PHILADELPHIA, PA 19140 USA.				NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BELL JC, 1987, NATURE, V325, P552, DOI 10.1038/325552a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENNETT RL, 1992, DEVELOPMENT, V116, P953; BERGOLD PJ, 1987, VIROLOGY, V158, P320, DOI 10.1016/0042-6822(87)90204-2; BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; BESMER P, 1983, NATURE, V303, P825, DOI 10.1038/303825a0; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1986, BLOOD, V68, P1074; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1994, IN PRESS ONCOGENE, V9; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; DANIEL R, 1994, IN PRESS ONCOGENE; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; DYALLSMITH D, 1988, ONCOGENE RES, V2, P403; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; EVANS CA, 1993, CANCER RES, V53, P1735; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GISHIZKY ML, 1991, ONCOGENE, V6, P1299; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HERMINE O, 1991, BLOOD, V78, P2253; HUMPHRIES RK, 1988, EXP HEMATOL, V16, P774; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LEGROS GS, 1985, J IMMUNOL, V135, P4009; LOTEM J, 1991, BLOOD, V78, P953; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARK JK, 1990, SCIENCE, V248, P378; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PECH N, 1993, BLOOD, V82, P1502; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PREVOT BM, 1986, MOL CELL BIOL, V6, P4133; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RAMBALDI A, 1987, BLOOD, V69, P1409; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROVERA G, 1987, ONCOGENE, V1, P29; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCOTT KS, 1990, P NATL ACAD SCI USA, V87, P6502; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHORE SK, 1994, J BIOL CHEM, V269, P5413; SIRARD C, 1994, BLOOD, V83, P1575; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WONG PMC, 1987, EXP HEMATOL, V15, P280; WONG PMC, 1988, EXP HEMATOL, V16, P5; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	105	14	20	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1261	1268						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731675				2022-12-17	WOS:A1995QR65100001
J	YOON, HY; BOETTIGER, D				YOON, HY; BOETTIGER, D			EXPRESSION OF V-SRC ALTERS THE EXPRESSION OF MYOGENIC REGULATORY FACTOR GENES	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; CONTRACTILE PROTEIN-SYNTHESIS; MUSCLE-SPECIFIC GENES; DIFFERENTIATION PROGRAM; MYOBLAST DIFFERENTIATION; SKELETAL-MUSCLE; CELLS; MYOD1; FIBROBLASTS; ACTIVATION	Inactivation of v-src in transformed chicken myoblasts induced changes in expression of the myogenic regulatory factors (MRF's), MyoD, myogenin and Myf5. Both MyoD and Myf5 were expressed in the transformed cells. The inactivation of v-src by a temperature up-shift resulted in the loss of Myf5 expression, a transient increase in MyoD, followed by a rise in myogenin mRNA levels. The increase in transcripts for the later muscle proteins, myosin heavy and light chains, alpha-actin and troponin T followed the sequence of changes in MRF expression suggesting that their induction was the result of altered MRF expression. Thus, v-src appears to operate through effects on MRF's and not directly on the expression of the late muscle-specific proteins. When v-src was reactivated in mature myotubes by a temperature down-shift, the pattern of expression was quite different, the late muscle-specific transcripts decreased before the loss of myogenin transcripts and before the rise of Myf5 transcripts.	UNIV PENN,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NCI NIH HHS [CA 49866, CA 16502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049866, R01CA016502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ANESKIEVICH BJ, 1991, ONCOGENE, V6, P1381; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BISCHOFF R, 1968, J CELL BIOL, V36, P111, DOI 10.1083/jcb.36.1.111; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BRAN T, 1989, EMBO J, V8, P2617; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DEVLIN RB, 1978, CELL, V13, P599, DOI 10.1016/0092-8674(78)90211-8; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; GROSSI M, 1991, ONCOGENE, V6, P1767; HASTINGS KEM, 1985, J BIOL CHEM, V260, P3699; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MANGIACAPRA FJ, 1992, MOL ENDOCRINOL, V6, P2038, DOI 10.1210/me.6.12.2038; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OTT MO, 1991, DEVELOPMENT, V111, P1097; PAYETTE RF, 1988, DEV BIOL, V125, P341, DOI 10.1016/0012-1606(88)90217-5; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEST CM, 1983, CANCER RES, V43, P2042; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WYKE JA, 1973, VIROLOGY, V54, P152; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	46	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					801	807						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108122				2022-12-17	WOS:A1994MW55100015
J	LEE, MS; YANG, JH; SALEHI, Z; ARNSTEIN, P; CHEN, LS; JAY, G; RHIM, JS				LEE, MS; YANG, JH; SALEHI, Z; ARNSTEIN, P; CHEN, LS; JAY, G; RHIM, JS			NEOPLASTIC TRANSFORMATION OF A HUMAN KERATINOCYTE CELL-LINE BY THE V-FOS ONCOGENE	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; HUMAN EPIDERMAL-KERATINOCYTES; PROTO-ONCOGENE; TRANSCRIPTION; EXPRESSION; PRODUCT; ACID; DNA; CARCINOMA; LEUKEMIAS	To analyze the role of the fos oncogene in the growth of human epithelial cells, we have transfected a nontumorigenic human epidermal keratinocyte line (RHEK1) immortalized by the Ad12-SV40 hybrid virus with a plasmid carrying the v-fos gene together with plasmid pSV2-neo which confers resistance to neomycin. Individual neomycin-resistant clones were isolated and characterized with respect to morphological alteration. Of 16 independent clones analyzed, two appeared morphologically transformed and formed foci in culture. Only the two clones with a transformed phenotype were found by Southern blot hybridization analysis to contain the transfected v-fos gene. These clones formed colonies in soft agar and induced tumors when transplanted into nude mice. Analysis of fos specific mRNA and protein demonstrated that the transfected v-fos gene was expressed in these two clonal lines. These findings suggest that expression of the v-fos gene might facilitate the process of neoplastic transformation of human epithelial cells in culture. This appears to represent the first demonstration of the transforming potential of the v-fos gene in human cells.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; JEROME H HOLLAND LAB, VIROL LAB, ROCKVILLE, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jay, Gregory/C-6346-2013					BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1973, 24TH P S COLST RES S, V24, P353; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; GANTT R, 1987, CANCER RES, V47, P1390; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; KHARBANDA S, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P23; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEE CK, 1979, P SOC EXP BIOL MED, V162, P214, DOI 10.3181/00379727-162-40650; LEVY JA, 1978, J VIROL, V26, P11, DOI 10.1128/JVI.26.1.11-15.1978; LEVY JA, 1973, J NATL CANCER I, V51, P525; MAVILIO F, 1987, BLOOD, V69, P160; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; PINTO A, 1987, BLOOD, V70, P1450; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1989, ONCOGENE, V4, P1403; RHIM JS, 1981, P NATL ACAD SCI-BIOL, V78, P313, DOI 10.1073/pnas.78.1.313; RHIM JS, 1969, P SOC EXP BIOL MED, V132, P1091; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SKOUV J, 1986, CARCINOGENESIS, V7, P331, DOI 10.1093/carcin/7.2.331; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TERRIER P, 1988, BRIT J CANCER, V57, P43, DOI 10.1038/bjc.1988.6; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9	40	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					387	393						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426745				2022-12-17	WOS:A1993KN00600018
J	QUINLAN, MP				QUINLAN, MP			EXPRESSION OF ANTISENSE E1A IN 293 CELLS RESULTS IN ALTERED CELL MORPHOLOGIES AND CESSATION OF PROLIFERATION	ONCOGENE			English	Article							ADENOVIRUS-INDUCED ALTERATIONS; PRIMARY EPITHELIAL-CELLS; LONG TERMINAL REPEAT; MAMMARY-TUMOR VIRUS; CHROMOSOME-ABERRATIONS; GENE-EXPRESSION; MAMMALIAN-CELLS; E1A-12S PROTEIN; DNA FRAGMENTS; FRAGILE SITES	To determine whether continued E1A expression is required to maintain immortalization, 293 cells, a cell line that has been immortalized and transformed by adenovirus E1A and E1B, respectively, were transfected by an antisense E1A expression vector. In the presence of low serum, 293 cells underwent a transient, viable, nonproliferative phase wherein cells with altered morphologies were detected. However, only those clones which did not integrate the antisense sequences and exhibited a morphology similar to the original 293 cells were able to survive. High serum concentrations resulted in fewer clones, which rapidly discarded the antisense DNA. Similar experiments with an antisense CAT vector did not give rise to cells with either altered morphologies or growth rates. Furthermore, CAT antisense DNA was integrated into the 293 cell DNA. Hela cells, which were not immortalized or transformed by E1, were unaffected by the expression of antisense E1A and integrated the antisense DNA into genomic DNA. Consistently, the addition of synthetic antisense, but not sense oligonucleotides resulted in a transient inhibition of 293 cell DNA synthesis. These data demonstrate that even after extended periods of time in culture, cells immortalized by E1A still require E1A expression to activate the cell cycle and prevent them from senescing.			QUINLAN, MP (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163, USA.				NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER; NCI NIH HHS [CA50540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BELLETT AJD, 1982, CHROMOSOMA, V84, P571, DOI 10.1007/BF00292856; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DIPAOLO JA, 1983, JNCI, V70, P114; DURNAM D, 1986, CANCER CELL, V4, P349; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GORBUNOVA LV, 1982, MOL GEN GENET, V187, P473, DOI 10.1007/BF00332631; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; LEBEAU MM, 1986, BLOOD, V67, P849; LUKASH LL, 1985, J CELL SCI, V78, P97; MCDOUGALL JK, 1971, J GEN VIROL, V12, P43, DOI 10.1099/0022-1317-12-1-43; MIROSHNICHENKO OI, 1989, GENE, V84, P83, DOI 10.1016/0378-1119(89)90142-X; MURRAY JD, 1982, J VIROL, V44, P1072, DOI 10.1128/JVI.44.3.1072-1075.1982; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1986, CANCER CELL, V4, P327; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J., 1989, MOL CLONING LAB MANU; SIMON R, 1990, MOL CELL BIOL, V10, P5609, DOI 10.1128/MCB.10.11.5609; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; Stout J T, 1987, Methods Enzymol, V151, P519; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WEBER JM, 1990, J GEN VIROL, V71, P585, DOI 10.1099/0022-1317-71-3-585; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOUNG HA, 1977, J VIROL, V21, P139, DOI 10.1128/JVI.21.1.139-146.1977; YUNIS JJ, 1987, SOMAT CELL MOLEC GEN, V13, P397, DOI 10.1007/BF01534938	51	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					257	265						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426736				2022-12-17	WOS:A1993KN00600004
J	DUFORT, D; DROLET, M; NEPVEU, A				DUFORT, D; DROLET, M; NEPVEU, A			A PROTEIN-BINDING SITE FROM THE MURINE C-MYC PROMOTER CONTRIBUTES TO TRANSCRIPTIONAL BLOCK	ONCOGENE			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; RNA POLYMERASE-II; 3' END FORMATION; GENE-EXPRESSION; ANTITERMINATION PROTEIN; SNRNA PROMOTER; LAC PROMOTER; 1ST EXON; ELONGATION; TERMINATION	Recent studies have revealed that expression of several eukaryotic genes can be regulated at the level of transcription elongation. As a first step to elucidate the mechanism by which transcription elongation is modulated, several groups have identified sequences necessary for transcriptional block within the c-myc gene. These studies indicated that transcriptional block depends not only on sequences surrounding the sites of block, but also on sequences within the promoter: some deletions within the c-myc promoter eliminated transcriptional block and, with chimeric constructs, transcriptional block was observed when some heterologous promoters but not others were fused to the c-myc termination region. Using a chimeric construct containing the H-2K(b) major histocompatibility class gene promoter linked to the c-myc first exon, we show that transcriptional block is increased by the addition of a 25 bp DNA sequence from the c-myc promoter. Similar results are obtained whether this sequence is inserted upstream or downstream of the transcription initiation site. We further show that nuclear factors interact with this sequence in vitro. Interestingly, when a mutated version of this sequence was tested, we observed decreased nuclear factor binding in vitro as well as reduced transcriptional block in nuclear run-on transcription assays. These results suggest that interactions of protein factors with specific nucleotide sequences near the transcription initiation site can affect elongation of transcription at sites located further down stream.	MCGILL UNIV,DEPT ONCOL,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University			/AAB-8315-2020	Dufort, Daniel/0000-0002-6477-596X				ASSELIN C, 1989, ONCOGENE, V4, P549; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BESSE M, 1986, EMBO J, V5, P1377, DOI 10.1002/j.1460-2075.1986.tb04370.x; DEVEGVAR HEN, 1986, CELL, V47, P259; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	35	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					165	171						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423994				2022-12-17	WOS:A1993KN00500020
J	SAINTRUF, C; VIEGASPEQUIGNOT, E; ALFANI, E; CLEMENTI, M; DUTRILLAUX, B; CARLONI, G				SAINTRUF, C; VIEGASPEQUIGNOT, E; ALFANI, E; CLEMENTI, M; DUTRILLAUX, B; CARLONI, G			COAMPLIFICATION OF TRANSCRIPTIONALLY ACTIVE EPIDERMAL GROWTH-FACTOR RECEPTOR AND RIBOSOMAL GENES IN THE HUMAN HEPATOMA-CELL LINE LI7A	ONCOGENE			English	Article							HOMOGENEOUSLY STAINING REGIONS; BREAST-CANCER; SQUAMOUS-CELL; INVERTED DUPLICATION; ENHANCED EXPRESSION; ORGANIZER REGIONS; MAMMARY-CARCINOMA; HIGH-AFFINITY; SINGLE-COPY; A431 CELLS	A high level of expression of the functional product of the epidermal growth factor receptor (EGFR) gene was detected in the human hepatocarcinoma cell line Li7A and it was found to correlate with gene amplification. The karyotype was paratriploid, with 15 rearranged chromosomes, several of which contained abnormally banded regions (ABRs). The search for DNA sequences co-amplified with the EGFR gene, using the in-gel renaturation technique, allowed us to detect an amplified DNA band (La1) of about 30 kb. This DNA was used as a probe for in situ hybridization on chromosomes, to locate the amplified segment. In normal lymphocytes, the DNA of band La1 hybridized to chromosome regions in which repetitive DNAs are located, i.e. on juxtacentromeric regions, the site of alphoid and CCATT satellite DNA, and on the short arms of acrocentrics, the site of ribosomal RNA (RNR) genes. In Li7A cells, it hybridized to the same regions and, in addition, to several chromosome arms corresponding to ABRs. The same ABRs hybridized to EGFR and RNR probes, but neither Alu sequences nor various probes for other repetitive sequences were recognized. They also exhibited nucleolus organizer region staining characterizing functionally active (RNR) genes. It was concluded that transcriptionally active genes were co-amplified in the same ABRs, although they originated from different chromosomes, i.e. chromosome 7 for EGFR and acrocentrics for RNR genes.	INST CURIE,BIOL SECT,CNRS,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE; CNR,IST MED SPERIMENTALE,ROME,ITALY; IST SUPER SANITA,BIOL CELLULAIRE LAB,I-00161 ROME,ITALY; UNIV ANCONA,IST MICROBIOL,I-60100 ANCONA,ITALY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; Consiglio Nazionale delle Ricerche (CNR); Istituto Superiore di Sanita (ISS); Marche Polytechnic University			Clementi, Massimo/F-6646-2013	Clementi, Massimo/0000-0002-7461-5898				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BERTICS PJ, 1985, J BIOL CHEM, V260, P14643; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARLIN CR, 1988, MOL CELL BIOL, V8, P25, DOI 10.1128/MCB.8.1.25; CARLONI G, 1988, VIRAL HEPATITIS HEPA, P501; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CLEMENTI M, 1989, FEBS LETT, V249, P297, DOI 10.1016/0014-5793(89)80645-3; CORNEO G, 1970, J MOL BIOL, V48, P319, DOI 10.1016/0022-2836(70)90163-4; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; DUTRILLAUX B, 1981, PRATIQUE ANAL CHROMO, P7; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; FUKUMOTO M, 1988, P NATL ACAD SCI USA, V85, P6846, DOI 10.1073/pnas.85.18.6846; GIL GN, 1981, NATURE, V293, P305; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; HOLDEN JJA, 1985, CANCER GENET CYTOGEN, V14, P131, DOI 10.1016/0165-4608(85)90224-9; HUNTS J, 1985, JPN J CANCER RES, V76, P663; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KNOWLES AF, 1985, BIOCHEM BIOPH RES CO, V126, P8, DOI 10.1016/0006-291X(85)90564-9; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAVOLPE A, 1985, J MOL BIOL, V183, P213, DOI 10.1016/0022-2836(85)90214-1; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LOONEY JE, 1987, MOL CELL BIOL, V7, P569, DOI 10.1128/MCB.7.2.569; MADEN BEH, 1987, BIOCHEM J, V246, P519, DOI 10.1042/bj2460519; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MILLER OJ, 1979, CHROMOSOMA, V71, P183, DOI 10.1007/BF00292822; MILLER OJ, 1981, GENES CHROMOSOMES NE, P253; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; PASSANANTI C, 1987, EMBO J, V6, P1697, DOI 10.1002/j.1460-2075.1987.tb02420.x; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RIEHMAN RA, 1976, P NATL ACAD SCI USA, V73, P3589; Roninson I B, 1987, Methods Enzymol, V151, P332, DOI 10.1016/S0076-6879(87)51028-X; SAINTRUF C, 1990, GENE CHROMOSOME CANC, V2, P18, DOI 10.1002/gcc.2870020105; SAINTRUF C, 1991, CANCER GENET CYTOGEN, V52, P27, DOI 10.1016/0165-4608(91)90050-5; Sambrook J., 1989, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P666; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWARZACHER HG, 1983, HUM GENET, V63, P89, DOI 10.1007/BF00291525; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STURANI E, 1988, MOL CELL BIOL, V8, P1345, DOI 10.1128/MCB.8.3.1345; THEILLET C, 1990, ONCOGENE, V5, P147; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VIEGASPEQUIGNOT E, 1989, P NATL ACAD SCI USA, V86, P582, DOI 10.1073/pnas.86.2.582; VIEGASPEQUIGNOT E, 1990, CANCER GENET CYTOGEN, V49, P37, DOI 10.1016/0165-4608(90)90162-4; WAYE JS, 1987, MOL CELL BIOL, V7, P349, DOI 10.1128/MCB.7.1.349	56	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1557	1565						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321403				2022-12-17	WOS:A1992JE81300012
J	HOWARD, OMZ; DEAN, M; YOUNG, H; RAMSBURG, M; TURPIN, JA; MICHIEL, DF; KELVIN, DJ; LEE, L; FARRAR, WL				HOWARD, OMZ; DEAN, M; YOUNG, H; RAMSBURG, M; TURPIN, JA; MICHIEL, DF; KELVIN, DJ; LEE, L; FARRAR, WL			CHARACTERIZATION OF A CLASS-3 TYROSINE KINASE	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; CELL-LINES; EXPRESSION; GENE; IDENTIFICATION; ACTIVATION; SEQUENCE; P56LCK	In an effort to identify unique tyrosine kinases found in human leukemia cell lines, we utilized polymerase chain reaction (PCR) technology and degenerate oligonucleotide primers to produce a cDNA library of kinase catalytic domains found in the human monocytic cell line AML-193. This search yielded a member of the class 3 tyrosine kinases closely related to the murine kinase FD-22. Previous work has identified this kinase as JAK1. This class of tyrosine kinases is characterized by being ubiquitously expressed, lacking both a ligand-binding domain and a SH2 domain, while containing a second domain similar to a degenerate kinase domain. Our studies focused on the further characterization of this class 3 tyrosine kinase using Northern blot analysis to demonstrate an increase in steady-state mRNA by interferon-gamma in human monocytes. A human-hamster somatic cell hybrid panel and linkage mapping was used to assign JAK1 (aml-116) to human chromosome 1.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701; WALTER REED ARMY MED CTR,DEPT CELLULAR IMMUNOL,WASHINGTON,DC 20307	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	HOWARD, OMZ (corresponding author), NCI,PROGRAM RESOURCES INC DYNCORP,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21701, USA.		Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Howard, O M Zack/B-6117-2012; Young, Howard/A-6350-2008	Dean, Michael C/0000-0003-2234-0631; Howard, O M Zack/0000-0002-0505-7052; Young, Howard/0000-0002-3118-5111	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FISCHER T, 1990, J IMMUNOL, V145, P2914; GOLDBERG M, 1990, J CLIN INVEST, V85, P563, DOI 10.1172/JCI114473; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART PH, 1991, BLOOD, V77, P841; HOWARD OMZ, 1987, BIOCHEMISTRY-US, V26, P3565, DOI 10.1021/bi00386a047; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KALTER DC, 1991, J IMMUNOL, V146, P298; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANGE B, 1987, BLOOD, V70, P192; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; Maniatis T., 1982, MOL CLONING; MITELMAN F, 1990, CYTOGENET CELL GENET, V55, P358, DOI 10.1159/000133022; PAWSON T, 1988, ONCOGENE, V3, P491; THOMASSEN MJ, 1991, CANCER RES, V51, P857; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YI TL, 1989, ONCOGENE, V4, P1081; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801	28	14	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					895	900						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373877				2022-12-17	WOS:A1992HP64200008
J	LUDLOW, JW				LUDLOW, JW			SELECTIVE ABILITY OF S-PHASE CELL-EXTRACTS TO DEPHOSPHORYLATE SV40 LARGE T-ANTIGEN INVITRO	ONCOGENE			English	Note							SIMIAN-VIRUS 40; RETINOBLASTOMA SUSCEPTIBILITY GENE; DNA-REPLICATION INVITRO; LARGE TUMOR-ANTIGEN; PROTEIN PHOSPHATASE-2A; BINDING; PRODUCT; TRANSFORMATION; PHOSPHORYLATION; COMPLEX	Simian virus 40 (SV40) large tumor antigen (T) is an oncoprotein whose biological and biochemical functions appear to be modulated by phosphorylation. Recently, SV40 DNA replication in vitro has been shown to be activated by dephosphorylation involving the activity of a serine/threonine phosphoprotein phosphatase belonging to the type 2A class (PP2A) [Virshup, D.M., Kauffman, M.G. & Kelly, T.J. (1989) EMBO J., 8, 3891-3898]. To address the question of how specificity of PP2A activity towards T is regulated, an in vitro assay to study the process of T dephosphorylation was developed. Unlabeled extracts from cells enriched for various stages of the cell cycle were incubated with P-32-labeled, immunocomplexed T. Extracts from a population of cells enriched for S phase demonstrated a selective ability to dephosphorylate this labeled protein when compared with extracts prepared from G1- and M-phase cells. The time course of release from growth arrest demonstrated that this T-specific phosphatase activity occurred at the onset of host-cell DNA synthesis. In contrast, when using P-32-labeled phosphorylase a as the substrate, phosphatase activity appeared to be present throughout the cell cycle. The data presented here are consistent with the notion that PP2A activity towards T is regulated in a cell cycle-dependent manner.			LUDLOW, JW (corresponding author), UNIV ROCHESTER, CTR CANC, DIV TUMOR BIOL, BOX 704, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.							BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CHOU JY, 1975, J VIROL, V15, P145, DOI 10.1128/JVI.15.1.145-150.1975; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; GREENSPAN DS, 1981, P NATL ACAD SCI-BIOL, V78, P105, DOI 10.1073/pnas.78.1.105; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON R, 1990, J VIROL, V64, P2380, DOI 10.1128/JVI.64.5.2380-2383.1990; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAY P, 1976, EXP CELL RES, V100, P433, DOI 10.1016/0014-4827(76)90175-0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1991, J VIROL, V65, P2098, DOI 10.1128/JVI.65.4.2098-2101.1991; SIMMONS DT, 1984, J BIOL CHEM, V259, P8633; TEGTMEYER P, 1972, J VIROL, V10, P591, DOI 10.1128/JVI.10.4.591-598.1972; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TIJAN R, 1978, P NATL ACAD SCI USA, V75, P1279; VANROY F, 1983, J VIROL, V45, P315, DOI 10.1128/JVI.45.1.315-331.1983; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WALTER G, 1988, J VIROL, V62, P4760, DOI 10.1128/JVI.62.12.4760-4762.1988; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	38	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					1011	1014						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1315015				2022-12-17	WOS:A1992HP64200023
J	MAKELA, TP; SHIRAISHI, M; BORRELLO, MG; SEKIYA, T; ALITALO, K				MAKELA, TP; SHIRAISHI, M; BORRELLO, MG; SEKIYA, T; ALITALO, K			REARRANGEMENT AND CO-AMPLIFICATION OF L-MYC AND RLF IN PRIMARY LUNG-CANCER	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; N-MYC; CELL-LINES; GENE AMPLIFICATION; FAMILY ONCOGENES; TUMOR-CELLS; DNA; ACTIVATION; EXPRESSION; REPEATS	We have recently characterized a gene fusion and chimeric protein product formed by L-myc and part of a novel gene named rlf in two small-cell lung cancer (SCLC) cell lines. The rlf-L-myc fusion gene is formed by intrachromosomal rearrangements placing the regulatory region and (at least) the first exon of rlf upstream of the L-myc gene. In the characterized cases the fusion gene has also been involved in DNA amplification. Here we report on a similar in vivo rearrangement involving rlf and L-myc in a primary SCLC tumor. In addition, we have found co-amplification of L-myc and rlf without visible rearrangements in either gene in three other SCLC tumors, confirming the physical linkage of these loci.	UNIV HELSINKI,DEPT VIROL,CANC BIOL LAB,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,DEPT PATHOL,SF-00290 HELSINKI 29,FINLAND; NATL CANC CTR,RES INST,DIV ONCOGENE,CHUO KU,TOKYO 104,JAPAN; IST NAZL TUMORI,DIV EXPTL ONCOL A,I-20133 MILAN,ITALY	University of Helsinki; University of Helsinki; National Cancer Center - Japan; Fondazione IRCCS Istituto Nazionale Tumori Milan			Borrello, Maria Grazia/C-3161-2017; makela, tomi/B-3734-2009; Alitalo, Kari K/J-5013-2014	Borrello, Maria Grazia/0000-0002-6854-2848; makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BRENNAN J, 1991, CANCER RES, V51, P1708; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; GAZZERI S, 1991, CANCER RES, V51, P2566; HIRVONEN H, 1990, ONCOGENE, V5, P1787; HYIYAMA E, 1991, CANCER RES, V51, P1946; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; JOHNSON BE, 1988, CANCER RES, V48, P5163; KATO H, 1989, FEBS LETT, V250, P529, DOI 10.1016/0014-5793(89)80790-2; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NOGUCHI M, 1990, CANCER, V66, P2053, DOI 10.1002/1097-0142(19901115)66:10<2053::AID-CNCR2820661002>3.0.CO;2-K; SCHWAB M, 1986, MOL CELL BIOL, V6, P2800; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; TONIN PN, 1989, ONCOGENE, V4, P1117; YOKOTA J, 1988, ONCOGENE, V2, P607; ZEHNBAUER BA, 1988, MOL CELL BIOL, V8, P522, DOI 10.1128/MCB.8.2.522; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	29	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					405	409						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312699				2022-12-17	WOS:A1992HK00500002
J	SUGIYAMA, A; MIYAGI, Y; SHIRASAWA, Y; KUCHINO, Y				SUGIYAMA, A; MIYAGI, Y; SHIRASAWA, Y; KUCHINO, Y			DIFFERENT USAGE OF 2 POLYADENYLYLATION SIGNALS IN TRANSCRIPTION OF THE N-MYC GENE IN RAT-TUMOR CELLS	ONCOGENE			English	Article							CASEIN KINASE-II; DNA-BINDING PROTEINS; LARGE T-ANTIGEN; C-MYC; NUCLEOTIDE-SEQUENCE; ADENOVIRUS E1A; CODING REGION; EXPRESSION; ELEMENTS; FAMILY	The complete nucleotide sequence of a rat genomic DNA fragment of 6.9 kbp containing the entire N-myc gene was determined. A unique structural feature of the rat N-myc gene is the presence of two polyadenylation signals in the exon 3 region resulting in formation of two poly(A)+ N-myc mRNAs of 2.9 and 2.2 kb length. Elevated expression of the 2.9 kb mRNA, which was not due to gene amplification, was observed in normal rat tissues such as brain, adrenal and testis, and in rat tumor cells such as ascites hepatoma AH130, AH70Btc and AH7974 cells, and pituitary tumor GH3 cells. In contrast, expression of 2.2 kb mRNA, for which transcription was terminated at the upstream polyadenylation site, was observed only in GH3 cells.	NATL CANC CTR,RES INST,DIV BIOPHYS,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								ASSELIN C, 1989, ONCOGENE, V4, P549; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHELLAPPAN SP, 1990, P NATL ACAD SCI USA, V87, P5878, DOI 10.1073/pnas.87.15.5878; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORRAL M, 1988, EXP CELL RES, V174, P107, DOI 10.1016/0014-4827(88)90146-2; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FOUREL G, 1990, NUCLEIC ACIDS RES, V18, P4918, DOI 10.1093/nar/18.16.4918; HIRVONEN H, 1990, ONCOGENE, V5, P1787; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KATOH K, 1988, NUCLEIC ACIDS RES, V16, P3589, DOI 10.1093/nar/16.8.3589; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KUCHINO Y, 1990, GENETIC BASIS CARCIN, P239; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISEN PD, 1986, CANCER RES, V46, P6217; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; ROSEN N, 1986, CANCER RES, V46, P4139; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAWAI S, 1990, MOL CELL BIOL, V10, P2017, DOI 10.1128/MCB.10.5.2017; SCHWAB M, 1988, ONCOGENE HDB, P381; SHAW APW, 1988, ONCOGENE, V3, P143; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; WEISINGER G, 1988, ONCOGENE, V3, P635; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	43	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2027	2032						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719466				2022-12-17	WOS:A1991GX11900013
J	WANG, WP; QUICK, D; BALCERZAK, SP; NEEDLEMAN, SW; CHIU, IM				WANG, WP; QUICK, D; BALCERZAK, SP; NEEDLEMAN, SW; CHIU, IM			CLONING AND SEQUENCE-ANALYSIS OF THE HUMAN ACIDIC FIBROBLAST GROWTH-FACTOR GENE AND ITS PRESERVATION IN LEUKEMIA PATIENTS	ONCOGENE			English	Article							NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; FACTOR-I; FGF FAMILY; CELL; DNA; RECEPTOR; BINDING; EXPRESSION; REGION	Acidic fibroblast growth factor (aFGF), also known as heparin-binding growth factor 1, is a mitogen for a variety of mesoderm- and neuroectoderm-derived cells. Several different aFGF mRNA species resulting from alternative splicing have been reported. These results suggest that the gene structure and regulatory mechanism for gene expression of aFGF are complex. As a first step toward understanding aFGF gene structure, we have isolated nine overlapping genomic DNA clones spanning 54 kbp and determined the complete DNA sequences of all three coding exons. Comparison of the nucleotide sequences between the human and bovine DNA showed that the sequence similarity extended 2400 bp downstream from the coding region. Cloning of the aFGF gene allowed us to characterize this locus in acute nonlymphocytic leukemia (ANLL) patients. A fraction of ANLL patients (10-20%) have a deletion in the long arm of chromosome 5, whose distal breakpoint overlaps the aFGF locus. Therefore, a prospective cohort of eight ANLL patients was screened using three different repetitive sequence-free probes derived from the aFGF locus. Using beta-globin gene as a normalization probe for hybridizing band intensities, we conclude that there is no allelic loss or gross rearrangement within the 40 kbp stretch of the aFGF gene locus in ANLL patients with or without 5q - deletion. Consistent with this observation, the aFGF mRNA was not detected in the mononuclear cells derived from either an ANLL patient or a normal individual as judged by the reverse transcription and polymerase chain reaction. We also identified a DNA fragment, 10.7 kbp upstream from the first coding exon of human aFGF, whose sequence is conserved in both the primate and rodent genomes. Further characterization of this fragment is likely to provide insight into the significance of this high degree of conservation.	OHIO STATE UNIV,DAVIS MED RES CTR,MOLEC CELLULAR & DEV BIOL PROGRAM,480 W 9TH AVE,ROOM S2052,COLUMBUS,OH 43210; OHIO STATE UNIV,DAVIS MED RES CTR,DEPT INTERNAL MED,COLUMBUS,OH 43210; UNIV MARYLAND HOSP,BALTIMORE,MD 21201	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Maryland; University of Maryland Baltimore			Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [R01 CA45611, T32 CA09388, K04 CA01369] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611, K04CA001369] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, ONCOGENE, V5, P755; CHIU IM, 1990, TROPHIC FACTORS NERV, P57; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; CRUMLEY G, 1990, BIOCHEM BIOPH RES CO, V171, P7, DOI 10.1016/0006-291X(90)91348-V; CRUMLEY GR, 1989, GENE, V85, P489, DOI 10.1016/0378-1119(89)90443-5; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; HALL JA, 1990, J CELL BIOCHEM, V43, P17, DOI 10.1002/jcb.240430103; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUEBNER K, 1990, AM J HUM GENET, V46, P26; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAN M, 1988, J BIOL CHEM, V263, P11306; KANAS GS, 1985, J IMMUNOL, V134, P2995; KE YQ, 1990, BIOCHEM BIOPH RES CO, V171, P963, DOI 10.1016/0006-291X(90)90778-L; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LEBEAU MM, 1989, BLOOD, V73, P647; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MANE SM, 1990, GENE CHROMOSOME CANC, V2, P71, DOI 10.1002/gcc.2870020113; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; NIMER SD, 1987, BLOOD, V70, P1705; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROWLEY JD, 1985, CANCER PRINCIPLES PR, P67; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; VANDILLA MA, 1990, CYTOMETRY, V11, P208, DOI 10.1002/cyto.990110124; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YUNIS J J, 1989, Cancer Bulletin (Houston), V41, P283; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	63	14	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1521	1529						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1717925				2022-12-17	WOS:A1991GX27400005
J	DOZIER, C; ANSIEAU, S; FERREIRA, E; COLL, J; STEHELIN, D				DOZIER, C; ANSIEAU, S; FERREIRA, E; COLL, J; STEHELIN, D			AN ALTERNATIVELY SPLICED C-MIL/RAF MESSENGER-RNA IS PREDOMINANTLY EXPRESSED IN CHICKEN MUSCULAR TISSUES AND CONSERVED AMONG VERTEBRATE SPECIES	ONCOGENE			English	Note							ONCOGENE V-MIL; KINASE-ACTIVITY; RAF ONCOGENE; PROTEIN; PHOSPHORYLATION; ACTIVATION; GENE; SEQUENCE; RECEPTOR; IDENTIFICATION	The chicken c-mil gene produces two mRNA species generated by an alternative splicing mechanism. These two transcripts differ at least by the presence or absence of a 60 nucleotide exon (E7a) localized at the splice junction of c-mil exons 7 and 8. By using RNAase protection assays, we have analysed the pattern of expression of these two mRNA species in several chicken tissues. Here we report that the two c-mil mRNAs are differentially expressed in chicken tissues: the mRNA lacking E7a is detected in all tissues tested, while the mRNA containing E7a is detected only in the skeletal muscle, heart and brain. Sequences homologous to E7a have also been detected in DNAs from quail, mouse and human cells and their sequencing revealed that the alternative E7a is structurally preserved in these species. By PCR analyses performed on RNAs extracted from muscular tissues of these species, we also show that the alternative splicing mechanism described in chicken also occurs in these species.			DOZIER, C (corresponding author), INST PASTEUR,CNRS,UA 1160,INSERM,U186,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Ansieau, Stephane/I-6195-2016; DOZIER, Christine/P-1539-2014	ANSIEAU, Stephane/0000-0003-0989-2108				BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1984, VIROLOGY, V137, P217, DOI 10.1016/0042-6822(84)90028-X; KOENEN M, 1988, ONCOGENE, V2, P179; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PATCHINSKY T, 1986, MOL CELL BIOL, V6, P739; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; STORM SM, 1990, ONCOGENE, V5, P345; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809	25	14	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1307	1311						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886707				2022-12-17	WOS:A1991GX27200002
J	STENMAN, G; SAHLIN, P; MARK, J; LANDYS, D				STENMAN, G; SAHLIN, P; MARK, J; LANDYS, D			STRUCTURAL ALTERATIONS OF THE C-MOS LOCUS IN BENIGN PLEOMORPHIC ADENOMAS WITH CHROMOSOME-ABNORMALITIES OF 8Q12	ONCOGENE			English	Article								Recent mapping studies have assigned the human c-mos proto-oncogene to chromosome 8, bands q11-12. This region is frequently affected by chromosomal translocations in benign pleomorphic adenomas of the salivary glands. Using Southern blot analysis we report here that the c-mos gene and its flanking sequences are structurally altered in pleomorphic adenomas with chromosomal rearrangements of 8q12. Rearrangements were detected in two out of 23 tumors. Restriction fragment analysis indicated that the rearrangements were due to multiple, subtle mutations involving the c-mos open reading frame and its flanking sequences. There was no direct evidence of translocation of mos in any of the tumors. Control DNAs from the two patients showed a normal restriction pattern for all enzymes tested, indicating that the rearrangements are tumor specific. Collectively, our cytogenetic and molecular data suggest involvement of the c-mos gene in the pathogenesis of pleomorphic adenomas.	CENT HOSP SKOVDE, DEPT PATHOL, S-54185 SKOVDE, SWEDEN		STENMAN, G (corresponding author), GOTHENBURG UNIV, DEPT ORAL PATHOL, CYTOGENET LAB, S-40033 GOTHENBURG, SWEDEN.							BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BLAIR DG, 1984, CANCER CELL, V2, P281; BULLERDIEK J, 1989, CYTOGENET CELL GENET, V51, P973; BULLERDIEK J, 1989, CANCER, V64, P876, DOI 10.1002/1097-0142(19890815)64:4<876::AID-CNCR2820640419>3.0.CO;2-J; CAUBET JF, 1985, EMBO J, V4, P2245, DOI 10.1002/j.1460-2075.1985.tb03921.x; DALLAFAVERA R, 1987, RECENT ADV LEUKEMIA, P165; DIAZ MO, 1985, SCIENCE, V229, P767, DOI 10.1126/science.3860954; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GROFFEN J, 1989, PROG NUCLEIC ACID RE, V36, P281; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; KUFF EL, 1983, NATURE, V302, P547, DOI 10.1038/302547a0; LIDEREAU R, 1985, P NATL ACAD SCI USA, V82, P7068, DOI 10.1073/pnas.82.20.7068; MAGUIRE RT, 1983, P NATL ACAD SCI-BIOL, V80, P1947, DOI 10.1073/pnas.80.7.1947; MARK J, 1988, CANCER GENET CYTOGEN, V33, P229, DOI 10.1016/0165-4608(88)90033-7; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORRIS CM, 1989, HUM GENET, V81, P339, DOI 10.1007/BF00283687; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RENPING Z, 1991, IN PRESS SCIENCE; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SEIFERT G, 1986, DISEASES SALIVARY GL; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P184, DOI 10.1073/pnas.84.1.184; TESTA J R, 1988, Genomics, V3, P44, DOI 10.1016/0888-7543(88)90157-7; VANDEWOUDE GF, 1987, ADV VIRAL ONCOL, V6, P71; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	30	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1105	1108						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1677749				2022-12-17	WOS:A1991GV26000002
J	MARCELLUS, R; WHITFIELD, JF; RAPTIS, L				MARCELLUS, R; WHITFIELD, JF; RAPTIS, L			POLYOMA-VIRUS MIDDLE TUMOR-ANTIGEN STIMULATES MEMBRANE-ASSOCIATED PROTEIN-KINASE-C AT LOWER LEVELS THAN REQUIRED FOR PHOSPHATIDYLINOSITOL KINASE ACTIVATION AND NEOPLASTIC TRANSFORMATION	ONCOGENE			English	Article							T-ANTIGEN; TYROSINE KINASE; RAT-CELLS; PP60C-SRC; GENE; SRC; PRODUCT; DEPHOSPHORYLATION; PHOSPHORYLATION; FIBROBLASTS	Twelve independent rat F111 cell lines expressing the polyoma virus middle tumor antigen (mT) under control of the dexamethasone-regulatable MMTV-LTR promoter were assayed for levels of membrane-associated protein kinase C (PKC) activity. Low background levels of mT antigen expression (approximately 2%), although insufficient for transformation, triggered a dramatic increase in PKC activity. Under the same conditions, levels of the mT-associated phosphatidylinositol kinase activity were low, indicating that this kinase might be a factor limiting transformation in this cell system.	QUEENS UNIV, DEPT MICROBIOL & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA; NATL RES COUNCIL CANADA, INST BIOL SCI, CELL SYST SECT, OTTAWA K1A 0R6, ONTARIO, CANADA	Queens University - Canada; National Research Council Canada	RAPTIS, L (corresponding author), QUEENS UNIV, DEPT MICROBIOL & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA.							BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CHAKRAVARTHY BR, 1990, BIOCHEM BIOPH RES CO, V171, P1105, DOI 10.1016/0006-291X(90)90798-R; CHAKRAVARTHY BR, 1989, BIOCHEM BIOPH RES CO, V160, P340, DOI 10.1016/0006-291X(89)91661-6; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DOBROVOLNY MA, 1990, 6TH ANN M ONC FRED, P80; DOTTO GP, 1985, NATURE, V318, P472; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; DURKIN JP, 1990, CELL SIGNAL, V2, P285, DOI 10.1016/0898-6568(90)90056-G; DURKIN JP, 1990, IN PRESS CELLULAR SI; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MARSHALL CJ, 1989, INT J CANCER, P29; MATTHEWS JT, 1986, J VIROL, V58, P239, DOI 10.1128/JVI.58.2.239-246.1986; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V136, P995, DOI 10.1016/0006-291X(86)90431-6; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V140, P1106, DOI 10.1016/0006-291X(86)90749-7; RAPTIS L, 1988, BIOCHEM BIOPH RES CO, V154, P306, DOI 10.1016/0006-291X(88)90685-7; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RAPTIS L, 1989, J VIROL, V63, P753, DOI 10.1128/JVI.63.2.753-758.1989; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; WHITFIELD JF, 1990, CALCIUM CELL CYCLES; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	37	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1037	1040						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648699				2022-12-17	WOS:A1991GU62200020
J	CHIAO, PJ; KANNAN, P; YIM, SO; KRIZMAN, DB; WU, TA; GALLICK, GE; TAINSKY, MA				CHIAO, PJ; KANNAN, P; YIM, SO; KRIZMAN, DB; WU, TA; GALLICK, GE; TAINSKY, MA			SUSCEPTIBILITY TO RAS ONCOGENE TRANSFORMATION IS COREGULATED WITH SIGNAL TRANSDUCTION THROUGH GROWTH-FACTOR RECEPTORS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; SARCOMA-VIRUS; MOLECULAR-CLONING; CELL-LINE; ORNITHINE DECARBOXYLASE; NUCLEOTIDE-SEQUENCE; RIBONUCLEIC-ACID; CHINESE-HAMSTER; EGF RECEPTOR; GENE	The human teratocarcinoma cell line PA-1 was derived from culturing ascites fluid cells from a patient with an ovarian germ line tumor. We previously described a nonneoplastic variant cloned from the PA-1 human teratocarcinoma cell line, clone 6, which at passage 40 was resistant to transformation by activated ras oncogenes. However, these cells could be transformed by a plasmid containing both myc and ras. Another PA-1 cell variant, clone 1, isolated at passage 63 and used 50 passages later becomes tumorigenic in nude mice after transfection with an activated ras oncogene (Tainsky et al, Anticancer Res., 8, 899-914, 1988). We report here that the progression from ras resistance to ras susceptibility occurs in both clone 1 and clone 6 cells during 25 passages in culture. In the presence of epidermal growth factor, transforming growth factor-alpha, and basic fibroblast growth factor, the ras-transformable cells exhibit anchorage independent growth, whereas the ras-resistant cells can not be growth stimulated by these growth factors. Similarly, ornithine decarboxylase (ODC) activity was inducible in ras susceptible and ras transformed cells by these growth factors, but not in the ras resistant cells. These differences are not due to the level and activity of epidermal growth factor receptor or to the level of expression of 25 proto-oncogenes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	TAINSKY, MA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [R01CA042810] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42810] Funding Source: Medline; PHS HHS [09299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BOS JL, 1989, CANCER RES, V49, P4682; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLBURN NH, 1985, MOL CELL BIOL, V5, P890, DOI 10.1128/MCB.5.4.890; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FEDELE LA, 1982, J VIROL, V41, P489; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; FRIEND SH, 1986, NATURE, V323, P5643; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HIGHFIELD PE, 1980, J VIROL, V36, P271, DOI 10.1128/JVI.36.1.271-279.1980; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; KRIZMAN DB, 1990, SOMAT CELL MOLEC GEN, V16, P115; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; Maniatis T., 1982, MOL CLONING; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MILLER AD, 1984, CELL, V36, P51; MORIARITY DM, 1981, P NATL ACAD SCI-BIOL, V78, P2752, DOI 10.1073/pnas.78.5.2752; MORLA AO, 1986, P NATL ACAD SCI USA, V83, P8191, DOI 10.1073/pnas.83.21.8191; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAGER R, 1983, P NATL ACAD SCI-BIOL, V80, P7601, DOI 10.1073/pnas.80.24.7601; SAGER R, 1984, CANCER CELL, V2, P487; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; TAINSKY MA, 1988, ANTICANCER RES, V8, P899; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TREVILLYAN JM, 1983, BIOCHIM BIOPHYS ACTA, V762, P187, DOI 10.1016/0167-4889(83)90070-8; WATSON DK, 1983, P NATL ACAD SCI USA, V80, P4036; Williams-Ashman H G, 1972, Adv Enzyme Regul, V10, P225, DOI 10.1016/0065-2571(72)90016-7; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	55	14	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					713	720						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646984				2022-12-17	WOS:A1991GT82500005
J	JONES, RE; DEFEOJONES, D; MCAVOY, EM; VUOCOLO, GA; WEGRZYN, RJ; HASKELL, KM; OLIFF, A				JONES, RE; DEFEOJONES, D; MCAVOY, EM; VUOCOLO, GA; WEGRZYN, RJ; HASKELL, KM; OLIFF, A			MAMMALIAN-CELL LINES ENGINEERED TO IDENTIFY INHIBITORS OF SPECIFIC SIGNAL TRANSDUCTION PATHWAYS	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; SERUM-RESPONSE ELEMENT; PROTEIN KINASE-C; SWISS 3T3 CELLS; TRANSCRIPTION FACTOR; BIOLOGICAL-ACTIVITY; ENHANCER ELEMENTS; PHORBOL ESTERS; TUMOR-PROMOTER; RAS ONCOGENE	A variety of signal transduction pathways contribute to the regulation of transcription in mammalian cells. Several of these pathways ultimately rely upon the interaction of transcription factors with genetic sequences termed response elements in the promoter regions of some genes. The biochemical mechanisms that control the levels and state of activation of transcription factors are poorly understood. However, specific phosphorylation events mediated by protein kinase C, growth factor receptor-linked tyrosine kinases, and protein kinase A clearly participate in the regulation of these signal transduction pathways. To understand the relationship between activation and/or inhibition of these pathways and regulation of gene expression controlled by specific response elements, cell lines were prepared containing the TPA response element (TRE), serum response element (SRE), or cyclic AMP response element (CRE) fused to a gene encoding a secretable form of alkaline phosphatase (SEAP). These TRE-SEAP, SRE-SEAP, and CRE-SEAP cells exhibit dramatic increases in alkaline phosphatase (AP) activity following exposure to TPA, PDGF, or forskolin. Down regulation of protein kinase C or inhibition of tyrosine kinase activity blocked the stimulation of AP activity caused by TPA or PDGF. These cell lines can be used to characterize existing inhibitors, and to identify new agents that affect specific signal transduction pathways in mammalian cells.	MERCK SHARP & DOHME LTD,DEPT CANC RES,BLDG 16-101,W POINT,PA 19486	Merck & Company	OLIFF, A (corresponding author), MERCK SHARP & DOHME LTD,DEPT CANC RES,BLDG 16-101,W POINT,PA 19486, USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NISHIZUKA Y, 1984, NATURE, V308, P6893; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLIFF A, 1983, J VIROL, V48, P542, DOI 10.1128/JVI.48.2.542-546.1983; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; SAINSBURY JRC, 1987, LANCET, V1, P1398; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STRAATEN F, 1983, P NATL ACAD SCI USA, V80, P3183; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TJIAN R, 1987, SCIENCE, V238, P1386; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WHANG Y, 1987, J VIROL, V61, P1796, DOI 10.1128/JVI.61.6.1796-1807.1987; XIAO H, 1986, MOL CELL BIOL, V6, P3200, DOI 10.1128/MCB.6.9.3200	50	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					745	751						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1711189				2022-12-17	WOS:A1991GT82500009
J	STAPLETON, P; TAKAYAMA, Y; HARTSHORN, A; KALAIZIS, A; ROWE, PB; SYMONDS, G				STAPLETON, P; TAKAYAMA, Y; HARTSHORN, A; KALAIZIS, A; ROWE, PB; SYMONDS, G			TUMOR PROGRESSION FOLLOWING TRANSFORMATION OF MURINE MONOCYTES BY V-MYC - ACQUISITION OF IMMORTALIZATION AND TUMORIGENICITY	ONCOGENE			English	Article							C-FOS EXPRESSION; NUCLEOTIDE-SEQUENCE; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; MACROPHAGE DIFFERENTIATION; AUTOCRINE GROWTH; MOUSE MACROPHAGE; LEUKEMIA VIRUSES	Monocyte transformation by the v-myc oncogene has been used to study myelomonocytic tumor progression in vitro. Murine monocytes transformed by a recombinant retrovirus containing MC29 v-myc were found to exhibit a proliferative burst to day 28-40 post-infection. Thereafter growth slowed and cell number remained relatively static-to day 80-90 post-infection. During both the proliferative and quiescent periods, the cells were dependent on the myelomonocytic growth factor CSF-1 for growth and viability. Analysis of this transformation revealed that the initial transformants were polyclonal, non-immortal, and non-tumorigenic in syngeneic mice. At day 80-90 post infection, a fresh round of cellular proliferation occurred and, in contrast to the initial burst, growth was sustained allowing the establishment of cell lines. These lines were found to be monoclonal, immortal, growth factor independent and, in certain cases, tumorigenic in syngeneic mice. Associated with the establishment of growth factor independent cell lines was the constitutive synthesis of the myelomonocytic growth factor, CSF-1. Proto-oncogene screening of the initial transformants and the cell lines also revealed the expression of c-raf and the CSF-1 receptor, c-fms. Our results indicate that, following transformation by v-myc, monocytes can progress in vitro to become growth factor independent and immortal and that both monocyte transformation and immortalization can be dissociated from tumorigenicity.	CHILDRENS MED RES FDN,LEUKAEMIA RES & VIRAL PATHOL UNIT,POB 61,CAMPERDOWN,NSW 2050,AUSTRALIA; CHILDRENS MED RES FDN,DEV BIOL UNIT,CAMPERDOWN,NSW 2050,AUSTRALIA	Children's Medical Research Institute - Australia; Children's Medical Research Institute - Australia	SYMONDS, G (corresponding author), CHILDRENS MED RES FDN,LEUKAEMIA RES & VIRAL PATHOL UNIT,POB 61,CAMPERDOWN,NSW 2050,AUSTRALIA.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BISHOP JM, 1985, MOL BIOL TUMOR VIRUS, P249; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CALABRETTA B, 1987, MOL CELL BIOL, V7, P769, DOI 10.1128/MCB.7.2.769; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; Cleveland J L, 1988, Oncogene Res, V3, P357; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CORY S, 1987, ONCOGENE RES, V1, P61; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DEAN M, 1987, ONCOGENE RES, V1, P279; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DUESBERG PH, 1979, P NATL ACAD SCI USA, V76, P1633, DOI 10.1073/pnas.76.4.1633; FALK A, 1980, INT J CANCER, V26, P595, DOI 10.1002/ijc.2910260511; FRYKBERG L, 1987, ONCOGENE, V1, P415; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREEN SM, 1989, ONCOGENE, V4, P737; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HAYMAN MJ, 1983, CURR TOP MICROBIOL, V103, P109; HIGUCHI Y, 1988, ONCOGENE, V2, P515; HO MK, 1982, J IMMUNOL, V128, P1221; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; KAN NC, 1983, P NATL ACAD SCI-BIOL, V80, P6566, DOI 10.1073/pnas.80.21.6566; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KLEMENT V, 1977, METHOD VIROL, V6, P97; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1984, HEMOPOIETIC COLONIES; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; SARIBAN E, 1987, BLOOD, V69, P1437; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1981, J BIOL CHEM, V256, P3833; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STORM SM, 1990, ONCOGENE, V5, P345; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SYMONDS G, 1982, EMBO J, V1, P1343, DOI 10.1002/j.1460-2075.1982.tb01320.x; SYMONDS G, 1989, ONCOGENE, V4, P285; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VOGT M, 1989, ONCOGENE RES, V4, P19; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146	67	14	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					807	817						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1711191				2022-12-17	WOS:A1991GT82500017
J	PEACOCK, JW; MATLASHEWSKI, GJ; BENCHIMOL, S				PEACOCK, JW; MATLASHEWSKI, GJ; BENCHIMOL, S			SYNERGISM BETWEEN PAIRS OF IMMORTALIZING GENES IN TRANSFORMATION ASSAYS OF RAT EMBRYO FIBROBLASTS	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; LARGE T-ANTIGEN; HUMAN RETINOBLASTOMA GENE; ADENOVIRUS E1A PROTEINS; P53 GENE; PRIMARY-CELLS; CELLULAR P53; SV40-TRANSFORMED CELLS; HYDROPHOBIC REGION; COMPLEX-FORMATION	A number of cellular and viral genes encode proteins that play a role in the establishment of normal cells in culture. In addition, these genes cooperate with activated ras genes to induce cellular transformation. We show that ras-dependent transformation of rat embryo fibroblasts is more efficient when two establishment genes are used together compared with one alone. Both quantitative and qualitative differences in the efficiency of transformation were detected. The number of transformed foci generated was greater than the sum of the foci obtained with ras and each of the establishment genes used separately. In addition, the foci had a distinct morphology. Synergism was seen between the HPV-16 E7 gene and certain mutant alleles of the cellular p53 gene as well as between E7 and c-myc.	ONTARIO CANC INST,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; MCGILL UNIV,INST PARASITOL,ST ANNE BELLEVUE H9X 1C0,QUEBEC,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; McGill University				Benchimol, Samuel/0000-0003-3433-890X				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KELMAN Z, 1989, BLOOD, V74, P2318; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASHAL R, 1990, BLOOD, V75, P180; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MONTENARH M, 1986, FEBS LETT, V204, P51, DOI 10.1016/0014-5793(86)81386-2; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1987, ADV VIRAL ONCOL, P1; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOMPAYRAC LM, 1983, MOL CELL BIOL, V3, P290, DOI 10.1128/MCB.3.2.290; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	63	14	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1769	1774						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2178238				2022-12-17	WOS:A1990ET43600005
J	LAVECCHIO, JA; HAMER, PJ; NG, SC; TRIMPE, KL; CARNEY, WP				LAVECCHIO, JA; HAMER, PJ; NG, SC; TRIMPE, KL; CARNEY, WP			CHARACTERIZATION OF MONOCLONAL-ANTIBODIES SPECIFIC TO THE ACTIVATED RAS P21 WITH ASPARTIC-ACID AT POSITION-13	ONCOGENE			English	Article											LAVECCHIO, JA (corresponding author), DUPONT CO,DEPT MED PROD,ONCOGENE RES GRP,N BILLERICA,MA 01862, USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; CARNEY WP, 1986, P NATL ACAD SCI USA, V83, P7485, DOI 10.1073/pnas.83.19.7485; CARNEY WP, 1988, HUMAN TUMOR ANTIGENS, P53; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; GALFRE G, 1979, NATURE, V277, P131, DOI 10.1038/277131a0; GREENBERG PL, 1979, AM J MED, V66, P951, DOI 10.1016/0002-9343(79)90450-9; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; KAGAN A, 1979, METHOD HORM RADIOIMM, P327; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHUCHI N, 1987, J NATL CANCER I, V79, P109; PADUA RA, 1988, LEUKEMIA, V2, P503; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; PULLANO TG, 1989, ONCOGENE, V4, P1003; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RODENHUIS S, 1988, CANCER RES, V48, P5738; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TOKSOZ D, 1987, ONCOGENE, V1, P409; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; YUNIS JJ, 1989, ONCOGENE, V4, P609	35	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1173	1178						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2202949				2022-12-17	WOS:A1990DX36100009
J	KOCH, I; HOFSCHNEIDER, PH; LOTTSPEICH, F; ECKERSKORN, C; KOSHY, R				KOCH, I; HOFSCHNEIDER, PH; LOTTSPEICH, F; ECKERSKORN, C; KOSHY, R			TUMOR-RELATED EXPRESSION OF A TRANSLATION-ELONGATION FACTOR-LIKE PROTEIN	ONCOGENE			English	Article									MAX PLANCK INST BIOCHEM,DEPT VIRUS RES,W-8033 MARTINSRIED,GERMANY	Max Planck Society								ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; HARISIADIS L, 1978, NATURE, V274, P486, DOI 10.1038/274486a0; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; LENSTRA JA, 1986, EUR J BIOCHEM, V155, P475, DOI 10.1111/j.1432-1033.1986.tb09514.x; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MONTANDON PE, 1983, NUCLEIC ACIDS RES, V11, P5877, DOI 10.1093/nar/11.17.5877; MOON RC, 1977, NATURE, V267, P620, DOI 10.1038/267620a0; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; NAGATA S, 1983, P NATL ACAD SCI-BIOL, V80, P6192, DOI 10.1073/pnas.80.20.6192; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; RENNER I, 1988, THESIS U MUNICH; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; WERNER S, 1989, J CELL PHYSIOL, V141, P490, DOI 10.1002/jcp.1041410307	22	14	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					839	843						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2193292				2022-12-17	WOS:A1990DP55300009
J	BAUM, EZ; BEBERNITZ, GA				BAUM, EZ; BEBERNITZ, GA			K-RAS ONCOGENE EXPRESSION IN XENOPUS-LAEVIS	ONCOGENE			English	Note											BAUM, EZ (corresponding author), AMER CYANAMID CO,LEDERLE LABS,MOLEC BIOL SECT,PEARL RIVER,NY 10965, USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FURTH ME, 1987, ONCOGENE, V1, P47; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LEGUELLEC R, 1988, NUCLEIC ACIDS RES, V16, P10357; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MALLER JL, 1981, DEV BIOL, V85, P309, DOI 10.1016/0012-1606(81)90262-1; Maniatis T., 1982, MOL CLONING; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MECHALI M, 1988, BIOCHIMIE, V70, P895, DOI 10.1016/0300-9084(88)90230-1; MOREAU J, 1989, ONCOGENE, V4, P443; MULLER R, 1983, MOL CELL BIOL, V3, P1062; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NISHIKURA K, 1987, ONCOGENE RES, V1, P179; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SADLER SE, 1986, MOL CELL BIOL, V6, P719, DOI 10.1128/MCB.6.2.719; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SOUSSI T, 1987, ONCOGENE, V1, P71; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; STEELE RE, 1989, ONCOGENE RES, V4, P223; STTELE RE, 1989, J BIOL CHEM, V264, P10649; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907	37	14	15	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					763	767						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189109				2022-12-17	WOS:A1990DG37400018
J	BEREBBI, M; MARTIN, PM; BERTHOIS, Y; BERNARD, AM; BLANGY, D				BEREBBI, M; MARTIN, PM; BERTHOIS, Y; BERNARD, AM; BLANGY, D			ESTRADIOL DEPENDENCE OF THE SPECIFIC MAMMARY TISSUE TARGETING OF POLYOMA-VIRUS ONCOGENICITY IN NUDE-MICE	ONCOGENE			English	Article									CNRS,UPR 272,BP 8,F-94801 VILLEJUIF,FRANCE; JE CNRS,F-13009 MARSEILLE,FRANCE; CNRS,URA 1175,F-13326 MARSEILLE 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Berthois, Yolande/O-1168-2017	BERTHOIS, Yolande/0000-0001-9603-1626				ANDERSON TJ, 1982, BRIT J CANCER, V46, P376, DOI 10.1038/bjc.1982.213; BARTON MC, 1988, P NATL ACAD SCI USA, V85, P7119, DOI 10.1073/pnas.85.19.7119; BEREBBI M, 1988, ONCOGENE, V2, P149; BRESCIANI F, 1971, BASIC ACTIONS SEX ST, P130; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; Fried M, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 1, P45; HAWKINS RA, 1988, ENDOCRINE MANAGEMENT, P45; HENDERSON BE, 1988, CANCER RES, V48, P246; IQBAL MJ, 1987, BREAST NEWS INT 2, V2, P7; IQBAL MJ, 1986, BREAST NEWS INT 1, V2, P8; ISON EJ, 1981, AM J MED TECHNOL, V47, P38; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LEGOFF JM, 1988, J STEROID BIOCHEM, V31, P167, DOI 10.1016/0022-4731(88)90050-7; MARTIN PM, 1982, J STEROID BIOCHEM, V16, P215, DOI 10.1016/0022-4731(82)90170-4; MERKEL DE, 1988, ENDOCRIN MANAGEMENT, P84; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0	18	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					505	509						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970153				2022-12-17	WOS:A1990DB85300008
J	KOSKINEN, P; LEHVASLAIHO, H; MACDONALDBRAVO, H; ALITALO, K; BRAVO, R				KOSKINEN, P; LEHVASLAIHO, H; MACDONALDBRAVO, H; ALITALO, K; BRAVO, R			SIMILAR EARLY GENE RESPONSES TO LIGAND-ACTIVATED EGFR AND NEU TYROSINE KINASES IN NIH3T3 CELLS	ONCOGENE			English	Note									UNIV HELSINKI,DEPT PATHOL,SF-00290 HELSINKI 29,FINLAND; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Helsinki; European Molecular Biology Laboratory (EMBL)	KOSKINEN, P (corresponding author), UNIV HELSINKI,DEPT UROL,CANC BIOL LAB,HAARTMANINK 3,SF-00290 HELSINKI 29,FINLAND.		Koskinen, Päivi J/G-8939-2014; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1988, ONCOGENE HDB, P107; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; PANDIELLA A, 1989, ONCOGENE, V4, P1299; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	16	14	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					615	618						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970155				2022-12-17	WOS:A1990DB85300024
J	Park, SH; Fong, KW; Mong, E; Martin, MC; Schiltz, GE; Yu, JD				Park, Su H.; Fong, Ka-Wing; Mong, Ezinne; Martin, M. Cynthia; Schiltz, Gary E.; Yu, Jindan			Going beyond Polycomb: EZH2 functions in prostate cancer	ONCOGENE			English	Review							HISTONE METHYLTRANSFERASE ACTIVITY; GROUP PROTEIN EZH2; ZESTE HOMOLOG 2; GENE-EXPRESSION; PRC2 RECRUITMENT; SUPPRESSES METHYLATION; CONTEMPORARY INCIDENCE; REPRESSIVE COMPLEX-2; NUCLEOSOME-BINDING; LYSINE METHYLATION	The Polycomb group (PcG) protein Enhancer of Zeste Homolog 2 (EZH2) is one of the three core subunits of the Polycomb Repressive Complex 2 (PRC2). It harbors histone methyltransferase activity (MTase) that specifically catalyze histone 3 lysine 27 (H3K27) methylation on target gene promoters. As such, PRC2 are epigenetic silencers that play important roles in cellular identity and embryonic stem cell maintenance. In the past two decades, mounting evidence supports EZH2 mutations and/or over-expression in a wide array of hematological cancers and solid tumors, including prostate cancer. Further, EZH2 is among the most upregulated genes in neuroendocrine prostate cancers, which become abundant due to the clinical use of high-affinity androgen receptor pathway inhibitors. While numerous studies have reported epigenetic functions of EZH2 that inhibit tumor suppressor genes and promote tumorigenesis, discordance between EZH2 and H3K27 methylation has been reported. Further, enzymatic EZH2 inhibitors have shown limited efficacy in prostate cancer, warranting a more comprehensive understanding of EZH2 functions. Here we first review how canonical functions of EZH2 as a histone MTase are regulated and describe the various mechanisms of PRC2 recruitment to the chromatin. We further outline non-histone substrates of EZH2 and discuss post-translational modifications to EZH2 itself that may affect substrate preference. Lastly, we summarize non-canonical functions of EZH2, beyond its MTase activity and/or PRC2, as a transcriptional cofactor and discuss prospects of its therapeutic targeting in prostate cancer.	[Park, Su H.; Fong, Ka-Wing; Mong, Ezinne; Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Fong, Ka-Wing] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY USA; [Martin, M. Cynthia; Schiltz, Gary E.] Northwestern Univ, Dept Chem, Evanston, IL 60201 USA; [Schiltz, Gary E.] Northwestern Univ, Feinberg Sch Med, Dept Pharmacol, Chicago, IL 60611 USA; [Schiltz, Gary E.; Yu, Jindan] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; University of Kentucky; Northwestern University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Yu, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA.; Yu, JD (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Yu, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu			NIH/NCI [R01CA227918, T32CA09560, prostate SPORE P50CA180995]; Department of Defense [W81XWH-17-1-0405, W81XWH-17-1-0578]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense)	This work was supported in part by the NIH/NCI R01CA227918 (to JY), training grant T32CA09560 (to SP), prostate SPORE P50CA180995 (to JY), and Department of Defense grants W81XWH-17-1-0405 and W81XWH-17-1-0578 (to JY).	Aggarwal R, 2018, J CLIN ONCOL, V36, P2492, DOI 10.1200/JCO.2017.77.6880; Alanee S, 2015, ANTICANCER RES, V35, P4145; Aranda S, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500737; Ardehali MB, 2017, MOL CELL, V68, P872, DOI 10.1016/j.molcel.2017.10.025; Atchison L, 2003, EMBO J, V22, P1347, DOI 10.1093/emboj/cdg124; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Beltran M, 2016, GENOME RES, V26, P896, DOI 10.1101/gr.197632.115; Beringer M, 2016, MOL CELL, V64, P645, DOI 10.1016/j.molcel.2016.10.018; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Biggar KK, 2015, NAT REV MOL CELL BIO, V16, P5, DOI 10.1038/nrm3915; Blackledge NP, 2020, MOL CELL, V77, P857, DOI 10.1016/j.molcel.2019.12.001; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Boulay G, 2012, J BIOL CHEM, V287, P10509, DOI 10.1074/jbc.M111.320234; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Brien GL, 2012, NAT STRUCT MOL BIOL, V19, P1273, DOI 10.1038/nsmb.2449; Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao R, 2008, MOL CELL BIOL, V28, P1862, DOI 10.1128/MCB.01589-07; Caruso Lisa B, 2018, Oncotarget, V9, P10585, DOI 10.18632/oncotarget.24291; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chen BL, 2013, CELL CYCLE, V12, P112, DOI 10.4161/cc.23030; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Chen SM, 2018, MOL CELL, V69, P840, DOI 10.1016/j.molcel.2018.01.039; Chen XR, 2016, J PINEAL RES, V61, P208, DOI 10.1111/jpi.12341; Choi J, 2017, NAT STRUCT MOL BIOL, V24, P1039, DOI 10.1038/nsmb.3488; Ciavatta DJ, 2010, J CLIN INVEST, V120, P3209, DOI 10.1172/JCI40034; Clarke SG, 2013, TRENDS BIOCHEM SCI, V38, P243, DOI 10.1016/j.tibs.2013.02.004; Clermont PL, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0074-4; Conway E, 2018, MOL CELL, V70, P408, DOI 10.1016/j.molcel.2018.03.005; Cooper S, 2014, CELL REP, V7, P1456, DOI 10.1016/j.celrep.2014.04.012; Cromm PM, 2017, CELL CHEM BIOL, V24, P1181, DOI 10.1016/j.chembiol.2017.05.024; Cyrta J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19328-1; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Dardenne E, 2016, CANCER CELL, V30, P563, DOI 10.1016/j.ccell.2016.09.005; Fan WQ, 2010, EMBO J, V29, P4223, DOI 10.1038/emboj.2010.268; Ferrari KJ, 2014, MOL CELL, V53, P49, DOI 10.1016/j.molcel.2013.10.030; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Grijzenhout A, 2016, DEVELOPMENT, V143, P2716, DOI 10.1242/dev.123935; Gunawan M, 2015, NAT IMMUNOL, V16, P505, DOI 10.1038/ni.3125; Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884; Hauri S, 2016, CELL REP, V17, P583, DOI 10.1016/j.celrep.2016.08.096; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Hojfeldt JW, 2018, NAT STRUCT MOL BIOL, V25, P225, DOI 10.1038/s41594-018-0036-6; Holoch D, 2017, TRENDS BIOCHEM SCI, V42, P531, DOI 10.1016/j.tibs.2017.04.003; Hwang-Verslues WW, 2013, P NATL ACAD SCI USA, V110, P12331, DOI 10.1073/pnas.1222684110; Jain P, 2016, BIOESSAYS, V38, P446, DOI 10.1002/bies.201500162; Jermann P, 2014, P NATL ACAD SCI USA, V111, pE3415, DOI 10.1073/pnas.1400672111; Jiao LY, 2020, P NATL ACAD SCI USA, V117, P16992, DOI 10.1073/pnas.1914866117; Jiao LY, 2015, SCIENCE, V350, DOI 10.1126/science.aac4383; Justin N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11316; Kalb R, 2014, NAT STRUCT MOL BIOL, V21, P569, DOI 10.1038/nsmb.2833; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim J, 2018, CELL REP, V25, P2808, DOI 10.1016/j.celrep.2018.11.035; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Kim T, 2004, MOL CELL BIOL, V24, P10151, DOI 10.1128/MCB.24.23.10151-10160.2004; Kleb B, 2016, EPIGENETICS-US, V11, P184, DOI 10.1080/15592294.2016.1146851; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Kovalovsky D, 2008, NAT IMMUNOL, V9, P1055, DOI 10.1038/ni.1641; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kung PP, 2018, J MED CHEM, V61, P650, DOI 10.1021/acs.jmedchem.7b01375; Kuntz KW, 2016, J MED CHEM, V59, P1556, DOI 10.1021/acs.jmedchem.5b01501; Kurmasheva RT, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26218; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Laugesen A, 2019, MOL CELL, V74, P8, DOI 10.1016/j.molcel.2019.03.011; Lee CH, 2019, GENE DEV, V33, P1428, DOI 10.1101/gad.328773.119; Lee CH, 2018, MOL CELL, V70, P435, DOI 10.1016/j.molcel.2018.03.019; Lee CH, 2018, MOL CELL, V70, P422, DOI 10.1016/j.molcel.2018.03.020; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lee JK, 2016, CANCER CELL, V29, P536, DOI 10.1016/j.ccell.2016.03.001; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410; Li HJ, 2017, NATURE, V549, P287, DOI 10.1038/nature23881; Li J, 2017, ONCOGENE, V36, P2991, DOI 10.1038/onc.2016.453; Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08; Liefke R, 2016, MOL CELL, V64, P659, DOI 10.1016/j.molcel.2016.10.019; Liefke R, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.8; Long YC, 2020, NAT GENET, V52, P931, DOI 10.1038/s41588-020-0662-x; Lu HQ, 2016, AM J CANCER RES, V6, P2737; Luo J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09784-9; Lynch MD, 2012, EMBO J, V31, P317, DOI 10.1038/emboj.2011.399; Ma AQ, 2020, NAT CHEM BIOL, V16, P214, DOI 10.1038/s41589-019-0421-4; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Martin KA, 2015, MOL CELL BIOL, V35, P3934, DOI 10.1128/MCB.00635-15; Martin MC, 2020, J MED CHEM, V63, P15344, DOI 10.1021/acs.jmedchem.0c01344; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mendenhall EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001244; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Morishima S, 2019, BLOOD, V134, DOI 10.1182/blood-2019-125507; Moussa HF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09628-6; Mukhopadhyay NK, 2014, ONCOGENE, V33, P3235, DOI 10.1038/onc.2013.294; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1266, DOI 10.1038/nsmb.2435; Nalawansha DA, 2020, CELL CHEM BIOL, V27, P998, DOI 10.1016/j.chembiol.2020.07.020; Nekrasov M, 2005, EMBO REP, V6, P348, DOI 10.1038/sj.embor.7400376; Neri F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r91; Oksuz O, 2018, MOL CELL, V70, P1149, DOI 10.1016/j.molcel.2018.05.023; Paik WK, 2007, TRENDS BIOCHEM SCI, V32, P146, DOI 10.1016/j.tibs.2007.01.006; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Park SH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe2261; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Perino M, 2018, NAT GENET, V50, P1002, DOI 10.1038/s41588-018-0134-8; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pettersson Mariell, 2019, Drug Discov Today Technol, V31, P15, DOI 10.1016/j.ddtec.2019.01.002; Puca L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04495-z; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Riising EM, 2014, MOL CELL, V55, P347, DOI 10.1016/j.molcel.2014.06.005; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Riquelme E, 2016, CANCER RES, V76, P675, DOI 10.1158/0008-5472.CAN-15-1141; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rondinelli B, 2017, NAT CELL BIOL, V19, P1371, DOI 10.1038/ncb3626; Sanulli S, 2015, MOL CELL, V57, P769, DOI 10.1016/j.molcel.2014.12.020; Sarma K, 2008, MOL CELL BIOL, V28, P2718, DOI 10.1128/MCB.02017-07; Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Son J, 2013, GENE DEV, V27, P2663, DOI 10.1101/gad.225888.113; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Takaya T, 2008, J BIOL CHEM, V283, P9828, DOI 10.1074/jbc.M707391200; Tamburri S, 2020, MOL CELL, V77, P840, DOI 10.1016/j.molcel.2019.11.021; Tan HL, 2014, CLIN CANCER RES, V20, P890, DOI 10.1158/1078-0432.CCR-13-1982; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Taplin ME, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT094; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Vasanthakumar A, 2017, EMBO REP, V18, P619, DOI 10.15252/embr.201643237; Vaswani RG, 2016, J MED CHEM, V59, P9928, DOI 10.1021/acs.jmedchem.6b01315; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wang DJ, 2015, ONCOTARGET, V6, P41045, DOI 10.18632/oncotarget.5728; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Wang XY, 2019, GENE DEV, V33, P1416, DOI 10.1101/gad.328849.119; Wang XY, 2017, NAT STRUCT MOL BIOL, V24, P1028, DOI 10.1038/nsmb.3487; Wang ZX, 2002, BIOCHEM J, V368, P947, DOI 10.1042/BJ20020557; Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139; Wienken M, 2016, MOL CELL, V61, P68, DOI 10.1016/j.molcel.2015.12.008; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamaguchi H, 2018, ONCOGENE, V37, P208, DOI 10.1038/onc.2017.311; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zaffuto E, 2017, CLIN GENITOURIN CANC, V15, pE793, DOI 10.1016/j.clgc.2017.04.006; Zee BM, 2012, MOL CELL BIOL, V32, P2503, DOI 10.1128/MCB.06673-11; Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06177-2; Zhang Z, 2011, STEM CELLS, V29, P229, DOI 10.1002/stem.578	162	13	14	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5788	5798		10.1038/s41388-021-01982-4	http://dx.doi.org/10.1038/s41388-021-01982-4		AUG 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34349243	Green Accepted			2022-12-17	WOS:000681147100001
J	Jiang, Y; Wang, ZL; Ying, CT; Hu, JF; Zeng, T; Gao, L				Jiang, Yang; Wang, Zhenlin; Ying, Chenting; Hu, Jiangfeng; Zeng, Tao; Gao, Liang			FMR1/circCHAF1A/miR-211-5p/HOXC8 feedback loop regulates proliferation and tumorigenesis via MDM2-dependent p53 signaling in GSCs	ONCOGENE			English	Article							CIRCULAR RNAS; STEM-CELL; CANCER; PHOSPHORYLATION; ANGIOGENESIS; EXPRESSION; APOPTOSIS; CHAF1A; GROWTH	Glioma is the most common and fatal primary malignant brain tumor. Glioma stem cells (GSCs) may be an important factor in glioma cell proliferation, invasion, chemoradiotherapy tolerance, and recurrence. Therefore, discovering novel GSCs related circular RNAs (circRNAs) may finds out a prospective target for the treatment of glioma. A novel circRNA-CHAF1A (circCHAF1A) was first found in our study. CircCHAF1A was overexpressed in glioma and related to the low survival rate. Functionally, it was found that no matter in vitro or in vivo, circCHAF1A can facilitate the proliferation and tumorigenesis of TP53wt GSCs. Mechanistically, circCHAF1A upregulated transcription factor HOXC8 expression in GSCs through miR-211-5p sponging. Then, HOXC8 can transcriptionally upregulate MDM2 expression and inhibited the antitumor effect of p53. Furtherly, the RNA binding protein FMR1 can bind to and promoted the expression of circCHAF1A via maintaining its stability, while HOXC8 also transcribed the FMR1 expression to form a feedback loop, which may be involved in the malignant transformation of glioma. The novel feedback loop among FMR1, circCHAF1A, miR-211-5p, and HOXC8 in GSCs can facilitate the proliferation and tumorigenesis of glioma and GSCs. It also provided a helpful biomarker for diagnosis and prognostic evaluation of glioma and may be applied to molecular targeted therapy.	[Jiang, Yang; Zeng, Tao; Gao, Liang] Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai, Peoples R China; [Wang, Zhenlin; Ying, Chenting] Shanghai Jiao Tong Univ, Dept Surg, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China; [Hu, Jiangfeng] Shanghai Jiao Tong Univ, Dept Gastroenterol, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China	Tongji University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Gao, L (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Neurosurg, Sch Med, Shanghai, Peoples R China.	lianggaoh@126.com			National Natural Science Foundation of China [81900544]; Key disciplines-B neurosurgery of Shanghai Tenth People's Hospital [DS04! 02! 18014]; Shanghai Sailing Program [19YF1439000, 21YF1449900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key disciplines-B neurosurgery of Shanghai Tenth People's Hospital; Shanghai Sailing Program	We thank Zhitao Jing at the Department of Neurosurgery, The First Affiliated Hospital of China Medical University for molecular experimental technical support. This work was supported by the National Natural Science Foundation of China (81900544), Key disciplines-B neurosurgery of Shanghai Tenth People's Hospital (DS04! 02! 18014), and the Shanghai Sailing Program (No. 19YF1439000, No. 21YF1449900).	Arnold A, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00940-7; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110; Gong C, 2019, MOL CARCINOGEN, V58, P1863, DOI 10.1002/mc.23079; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; He JH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1120-1; He QR, 2018, MOL THER-NUCL ACIDS, V10, P331, DOI 10.1016/j.omtn.2017.12.014; He ZW, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1065-7; Hsu PJ, 2019, J BIOL CHEM, V294, P19889, DOI 10.1074/jbc.AC119.010078; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang TZ, 2017, CANCER CELL, V32, P840, DOI 10.1016/j.ccell.2017.11.005; Jiang Y, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01691-y; Jiang Y, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102651; Jiang Y, 2019, EBIOMEDICINE, V48, P36, DOI 10.1016/j.ebiom.2019.09.037; Jiang Y, 2018, EBIOMEDICINE, V37, P78, DOI 10.1016/j.ebiom.2018.10.053; Jiang Y, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0210-1; Kosti A, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02115-y; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034; Liang Tingyu, 2018, Chin Neurosurg J, V4, P24, DOI 10.1186/s41016-018-0132-9; Lin J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2474-4; Liu HL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0016-4; Liu TZ, 2017, EXP THER MED, V14, P4681, DOI 10.3892/etm.2017.5201; Liu XB, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01625-8; Luo Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01203-8; Lyu DB, 2017, RNA BIOL, V14, P1000, DOI 10.1080/15476286.2016.1227904; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Paz I, 2014, NUCLEIC ACIDS RES, V42, pW361, DOI 10.1093/nar/gku406; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Sadik A, 2020, CELL, V182, P1252, DOI 10.1016/j.cell.2020.07.038; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; Shao LQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1845-1; Shen LY, 2019, CANCER SCI, V110, P1735, DOI 10.1111/cas.13993; Sun JK, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1121-0; Suva ML, 2020, CANCER CELL, V37, P630, DOI 10.1016/j.ccell.2020.04.001; Wang ZL, 2021, ONCOGENE, V40, P1458, DOI 10.1038/s41388-020-01635-y; Wu PQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1771-2; Xia DD, 2017, BIOCHEM BIOPH RES CO, V486, P191, DOI 10.1016/j.bbrc.2017.03.026; Xing Z, 2016, ONCOTARGET, V7, P75394, DOI 10.18632/oncotarget.12215; Yang XS, 2018, ONCOGENE, V37, P6399, DOI 10.1038/s41388-018-0416-8; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zalfa F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.521; Zang JK, 2020, J NEUROSCI RES, V98, P87, DOI 10.1002/jnr.24356; Zeng Y, 2017, THERANOSTICS, V7, P3842, DOI 10.7150/thno.19764; Zhang J, 2019, INT J BIOCHEM CELL B, V114, DOI 10.1016/j.biocel.2019.06.005; Zhang J, 2017, J NEURO-ONCOL, V133, P553, DOI 10.1007/s11060-017-2464-2; Zhang LG, 2019, CANCER CELL, V36, P302, DOI 10.1016/j.ccell.2019.07.009; Zheng LX, 2018, EBIOMEDICINE, V38, P69, DOI 10.1016/j.ebiom.2018.11.009; Zhu ZL, 2019, THERANOSTICS, V9, P8294, DOI 10.7150/thno.36256	50	13	14	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4094	4110		10.1038/s41388-021-01833-2	http://dx.doi.org/10.1038/s41388-021-01833-2		MAY 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34017077				2022-12-17	WOS:000652439200005
J	Lv, Y; Wang, Y; Song, Y; Wang, SS; Cheng, KW; Zhang, ZQ; Yao, J; Zhou, LN; Ling, ZY; Cao, C				Lv, Yan; Wang, Yin; Song, Yu; Wang, Shu-Sheng; Cheng, Kai-wen; Zhang, Zhi-qing; Yao, Jin; Zhou, Li-na; Ling, Zhuo-yan; Cao, Cong			LncRNA PINK1-AS promotes G alpha i1-driven gastric cancer tumorigenesis by sponging microRNA-200a	ONCOGENE			English	Article							GROWTH-INHIBITION; NONCODING RNAS; METASTASIS; PROLIFERATION; CARCINOGENESIS; REQUIREMENT; STATISTICS; APOPTOSIS	Gastric cancer (GC) is one of the leading causes of human mortality around the world. We have previously shown that G alpha i1 (the inhibitory subunit 1 of the heterotrimeric guanine nucleotide-binding protein) recruitment to ligand-activated receptor tyrosine kinases (RTKs) is essential for signaling. Testing its role in GC cancer-promoting functions, we found that G alpha i1 is upregulated in human GC, correlating with poor overall survival. In established and primary human GC cells, G alpha i1 shRNA (small hairpin RNA) or knockout produced significant anti-GC cell activity, proliferation and migration was inhibited, and apoptosis was activated. Conversely, ectopic G alpha i1 overexpression promoted proliferation and migration of GC cells in vitro. By examining the tumor-suppressive miRNA microRNA-200a (miR-200a), we found that miR-200a directly silenced G alpha i1 to induce anti-GC cell activity. The expression of miR-200a was downregulated in human GC, correlating with upregulation of a novel miR-200a-targeting long non-coding RNA (LncRNA), PINK1 (PTEN Induced Kinase 1)-AS. RNA immunoprecipitation, RNA-pull down, and RNA fluorescence in situ hybridization assays confirmed that PINK1-AS directly binds to miR-200a. Silencing PINK1-AS in GC cells led to miR-200a accumulation, G alpha i1 downregulation, and inhibition of GC cell progression in vitro, whereas PINK1-AS upregulation produced the converse results. Significantly, anti-GC cell activity induced by PINK1-AS shRNA was ameliorated by the expression of miR-200a antisense or the 3MODIFIER LETTER PRIME-UTR (untranslated region)-depleted G alpha i1. In vivo, the growth of subcutaneous MGC-803 xenografts in nude mice was inhibited by PINK1-AS shRNA, but accelerated by PINK1-AS overexpression. Patient-derived GC xenograft growth in nude mice was largely inhibited after intratumoral injection of PINK1-AS shRNA lentivirus. In conclusion, PINK1-AS promotes G alpha i1-driven GC progression by sponging miR-200a.	[Lv, Yan; Cao, Cong] Soochow Univ, Affiliated Zhangjiagang Hosp, Ctr Translat Med, Suzhou, Peoples R China; [Wang, Yin; Cheng, Kai-wen; Zhang, Zhi-qing; Cao, Cong] Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China; [Wang, Yin; Cheng, Kai-wen; Zhang, Zhi-qing; Cao, Cong] Soochow Univ, Inst Neurosci, Suzhou, Peoples R China; [Song, Yu] Soochow Univ, Affiliated Zhangjiagang Hosp, Dept Oncol, Suzhou, Peoples R China; [Wang, Shu-Sheng] Soochow Univ, Affiliated Zhangjiagang Hosp, Dept Gen Surg, Suzhou, Peoples R China; [Yao, Jin] Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Peoples R China; [Zhou, Li-na] Jiangsu Univ, Affiliated Kunshan Hosp, Dept Radiotherapy & Oncol, Kunshan, Peoples R China; [Ling, Zhuo-yan] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou, Peoples R China; [Cao, Cong] Nanjing Med Univ, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, North Dist, Suzhou, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China; Nanjing Medical University; Jiangsu University; Soochow University - China; Nanjing Medical University	Cao, C (corresponding author), Soochow Univ, Affiliated Zhangjiagang Hosp, Ctr Translat Med, Suzhou, Peoples R China.; Cao, C (corresponding author), Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China.; Cao, C (corresponding author), Soochow Univ, Inst Neurosci, Suzhou, Peoples R China.; Yao, J (corresponding author), Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Peoples R China.; Zhou, LN (corresponding author), Jiangsu Univ, Affiliated Kunshan Hosp, Dept Radiotherapy & Oncol, Kunshan, Peoples R China.; Ling, ZY (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou, Peoples R China.; Cao, C (corresponding author), Nanjing Med Univ, Suzhou Municipal Hosp, Affiliated Suzhou Hosp, North Dist, Suzhou, Peoples R China.	dryaojin@yahoo.com; zhoulinaks@163.com; lingzhuoyan@126.com; caocong@suda.edu.cn	Zhou, Li/GSE-4531-2022		National Natural Science Foundation of China [81922025, 81802386, 81970823, 81974388, 81302195, 31371139, 81571282, 81771457, 81670878]; Natural Science Foundation of Jiangsu Province [BK20170060]; Priority Academic Program Development of Jiangsu Higher Education Institutions; Suzhou People's Livelihood Science and Technology project [sysd2018205]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Priority Academic Program Development of Jiangsu Higher Education Institutions; Suzhou People's Livelihood Science and Technology project	This work was generously supported by grants from the National Natural Science Foundation of China (81922025, 81802386, 81970823, 81974388, 81302195, 31371139, 81571282, 81771457, and 81670878), and the Natural Science Foundation of Jiangsu Province (BK20170060), a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, Suzhou People's Livelihood Science and Technology project (sysd2018205). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the paper.	Bai JY, 2021, THERANOSTICS, V11, P4894, DOI 10.7150/thno.56383; Bang YJ, 2010, LANCET, V376, P1302; Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118; Chen WZ, 2018, BIOCHEM BIOPH RES CO, V499, P913, DOI 10.1016/j.bbrc.2018.04.019; Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1985, DOI 10.1002/cncr.28002; Dan J, 2018, BIOMED PHARMACOTHER, V99, P931, DOI 10.1016/j.biopha.2018.01.164; Feng L, 2020, AGING-US, V12, P707, DOI 10.18632/aging.102651; Gu Y, 2015, FUTURE ONCOL, V11, P2427, DOI 10.2217/fon.15.175; Guo TS, 2018, CELL BIOL INT, V42, P506, DOI 10.1002/cbin.10924; Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197; He WM, 2019, ONCOGENE, V38, P4637, DOI 10.1038/s41388-019-0747-0; HEDNER C, 2016, ONCOGENE, V11; HUO X, 2017, WORLD J GASTROENTERO, V16; JI D, 2014, ASIAN PAC J CANCER P, V9; Li DD, 2020, MOL THER-NUCL ACIDS, V19, P109, DOI 10.1016/j.omtn.2019.11.003; Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913; Li PH, 2014, ASIAN PAC J CANCER P, V15, P10381, DOI 10.7314/APJCP.2014.15.23.10381; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Liu HT, 2018, CANCER RES, V78, P5877, DOI 10.1158/0008-5472.CAN-18-1011; Liu YY, 2018, ONCOGENE, V37, P2890, DOI 10.1038/s41388-018-0184-5; Ma LN, 2019, NUCLEIC ACIDS RES, V47, pD128, DOI 10.1093/nar/gky960; Marshall J, 2018, P NATL ACAD SCI USA, V115, pE3549, DOI 10.1073/pnas.1722493115; Mirzaei S, 2019, EUR J PHARMACOL, V857, DOI 10.1016/j.ejphar.2019.172426; Niu ZS, 2017, WORLD J GASTROENTERO, V23, P5860, DOI 10.3748/wjg.v23.i32.5860; Park CK, 2016, ONCOTARGET, V7, P72099, DOI 10.18632/oncotarget.12291; Peng WZ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0197-7; Qi P, 2015, INT J CANCER, V137, P1269, DOI 10.1002/ijc.29516; Satoh T, 2015, GASTRIC CANCER, V18, P824, DOI 10.1007/s10120-014-0420-9; Satoh T, 2014, J CLIN ONCOL, V32, P2039, DOI 10.1200/JCO.2013.53.6136; Shah MA, 2014, NAT REV CLIN ONCOL, V11, P438, DOI [10.1038/nrclinonc.2013.231-c2, 10.1038/nrclinonc.2013.231]; Shrestha S, 2014, CANCER MED-US, V3, P878, DOI 10.1002/cam4.246; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Sun J, 2018, THERANOSTICS, V8, P4695, DOI 10.7150/thno.26203; Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356; Sun M, 2016, HISTOL HISTOPATHOL, V31, P33, DOI 10.14670/HH-11-655; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Tan HD, 2020, THERANOSTICS, V10, P8880, DOI 10.7150/thno.47548; Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170; Wang WY, 2015, INT J CARDIOL, V181, P180, DOI 10.1016/j.ijcard.2014.10.148; Wei GH, 2017, EUR REV MED PHARMACO, V21, P3850; Wong H, 2013, THER ADV GASTROENTER, V6, P15, DOI 10.1177/1756283X12453636; Xie SS, 2020, CANCER LETT, V493, P55, DOI 10.1016/j.canlet.2020.06.022; Yang L, 2015, EXP CELL RES, V332, P47, DOI 10.1016/j.yexcr.2014.12.017; Yang X, 2015, CANCER LETT, V360, P119, DOI 10.1016/j.canlet.2015.02.035; YUAN L, 2020, HISTOL HISTOPATHOL, V19; ZHANG G, 2018, CANCER RES, V17; Zhang XH, 2019, AGING-US, V11, P11358, DOI 10.18632/aging.102533; Zhang YM, 2015, J INVEST DERMATOL, V135, P181, DOI 10.1038/jid.2014.326; Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z	51	13	13	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3826	3844		10.1038/s41388-021-01812-7	http://dx.doi.org/10.1038/s41388-021-01812-7		MAY 2021	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958720				2022-12-17	WOS:000648041500004
J	Kang, X; Li, WL; Liu, WX; Liang, H; Deng, JY; Wong, CC; Zhao, SN; Kang, W; To, KF; Chiu, PWY; Wang, GY; Yu, J; Ng, EKW				Kang, Xi; Li, Weilin; Liu, Weixin; Liang, Han; Deng, Jingyu; Wong, Chi Chun; Zhao, Sinan; Kang, Wei; To, Ka Fai; Chiu, Philip Wai Yan; Wang, Guiying; Yu, Jun; Ng, Enders Kwok Wai			LIMK1 promotes peritoneal metastasis of gastric cancer and is a therapeutic target	ONCOGENE			English	Article							ACTIVATION; KINASES	Peritoneal metastasis is a common form of metastasis among advanced gastric cancer patients. In this study, we reported the identification of LIM domain kinase 1 (LIMK1) as a promoter of gastric cancer peritoneal metastasis, and its potential to be a therapeutic target of dabrafenib (DAB). Using transcriptomic sequencing of paired gastric cancer peritoneal metastasis, primary tumors, and normal gastric tissues, we first unveiled that LIMK1 is selectively up-regulated in metastatic tumors. Increased LIMK1 in gastric cancer peritoneal metastasis was validated by immunohistochemistry analysis of an independent patient cohort. In vitro functional studies demonstrated that LIMK1 knockout or knockdown significantly inhibited cell migration and invasion of gastric cancer cells. LIMK1 knockout also abrogated peritoneal and liver metastases of gastric cancer cells in nude mice in vivo. Dabrafenib, a small molecule targeting LIMK1, was found to decrease cell migration and invasion of gastric cancer cells in vitro and abolish peritoneal and liver metastasis formation in vivo. Mechanistically, either LIMK1 knockout or Dabrafenib inhibited LIMK1 expression and phosphorylation of its downstream target cofilin. Taken together, our results demonstrated that LIMK1 functions as a metastasis promoter in gastric cancer by inhibiting LIMK1-p-cofilin and that Dabrafenib has the potential to serve as a novel treatment for gastric cancer peritoneal metastasis.	[Kang, Xi; Li, Weilin; Liu, Weixin; Wong, Chi Chun; Zhao, Sinan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China; [Kang, Xi; Li, Weilin; Liu, Weixin; Wong, Chi Chun; Zhao, Sinan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Kang, Xi; Wang, Guiying] Hebei Med Univ, Dept Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Li, Weilin; Chiu, Philip Wai Yan; Ng, Enders Kwok Wai] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China; [Liang, Han; Deng, Jingyu] Tianjin Med Univ Canc Hosp, Dept Gastroenterol, City Key Lab Tianjin Canc Ctr, Tianjin, Peoples R China; [Liang, Han; Deng, Jingyu] Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Zhao, Sinan] Hebei Med Univ, Dept Endocrinol, Hosp 2, Shijiazhuang, Hebei, Peoples R China; [Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Hebei Medical University; Chinese University of Hong Kong; Tianjin Medical University; Hebei Medical University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China.; Wang, GY (corresponding author), Hebei Med Univ, Dept Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China.; Ng, EKW (corresponding author), Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China.	wangguiyingtgzy@163.com; junyu@cuhk.edu.hk; endersng@surgery.cuhk.edu.hk	Li, Weilin/ABG-9032-2021; KANG, Wei/C-5451-2016; Chiu, Philip/ABB-1454-2020	KANG, Wei/0000-0002-4651-677X; Chiu, Philip/0000-0001-9292-112X; Wong, Chi Chun/0000-0003-1362-3541	National Natural Science Foundation of China (NSFC) [81772501, 81972576]; RGC-CRF Hong Kong [C7065-18G]; CUHK; Shenzhen Virtual University Park Support Scheme;  [MOST-2016YFC1303200]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); RGC-CRF Hong Kong; CUHK(Chinese University of Hong Kong); Shenzhen Virtual University Park Support Scheme; 	This project was supported by research funds from MOST-2016YFC1303200; National Natural Science Foundation of China (NSFC) (81772501, 81972576); RGC-CRF Hong Kong (C7065-18G); Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	[Anonymous], 2015, JINHUA WANG NG DABRA; Bell R, 2017, CURR MOL MED, V17, P200, DOI 10.2174/1566524017666170807144946; Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011; Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717; CHAN DYS, 2017, J GASTROINTEST SURG; Chen PX, 2014, ONCOL REP, V32, P2070, DOI 10.3892/or.2014.3461; COOLEN M, 2009, CURR OPIN NEUROBIOL; Dal Bo M, 2016, LEUKEMIA, V30, P2011, DOI 10.1038/leu.2016.88; Davidson B, 2014, HUM PATHOL, V45, P691, DOI 10.1016/j.humpath.2013.11.003; DEDRICK RL, 1978, CANCER TREAT REP, V62, P1; FIFE CM, 2014, BRIT J PHARMACOL; Fu JJ, 2018, PHYTOMEDICINE, V49, P23, DOI 10.1016/j.phymed.2018.06.009; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; GlaxoSmithKline, 2013, TAFINLAR DABRAFENIB; Gu Y, 2018, TRANSL ONCOL, V11, P1012, DOI 10.1016/j.tranon.2018.06.003; Henderson BW, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw9318; HOHMANN D, 2019, CELLS-BASEL; HSIEH SHK, 2006, J NEUROSCI; Ishizone S, 2006, CHEMOTHERAPY, V52, P301, DOI 10.1159/000096002; Kobayashi D, 2017, GASTRIC CANCER, V20, pS111, DOI 10.1007/s10120-016-0662-9; LEE SY, 2017, PHARM RES; LIM MK, 2007, EXP CELL RES; LING H, 2020, INT J ONCOL; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MASHIACHFARKASH E, 2012, ONCOTARGET; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; MENG Y, 2002, NEURON; PAGET S, 1989, CANCER METAST REV, V8, P98; Pierce A, 2008, EUR J CANCER, V44, P151, DOI 10.1016/j.ejca.2007.10.017; Pirini F, 2017, ONCOTARGET, V8, P38501, DOI 10.18632/oncotarget.16258; PUSZKIEL A, 2019, CLIN PHARMACOKINET; Rak, 2014, ONCOSCIENCE, DOI 10.18632/oncoscience.7; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001; SCHRATT GM, 2006, NATURE; SESHADRI RA, 2016, WORLD J GASTROENTERO; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; SU J, 2017, SCI REP-UK, V7; Sugarbaker Paul H, 2003, Semin Surg Oncol, V21, P233, DOI 10.1002/ssu.10042; SUN F, 2017, ONCOL LETT; Tang YY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0825-x; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; TURSUN B, 2005, GENE DEV; Wang Z, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957-019-1761-y; YU Q, 2018, BRIT J PHARMACOL; Zhou Y, 2013, ONCOL REP, V29, P394, DOI 10.3892/or.2012.2115	46	13	13	9	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3422	3433		10.1038/s41388-021-01656-1	http://dx.doi.org/10.1038/s41388-021-01656-1		APR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33883692	hybrid, Green Published			2022-12-17	WOS:000642072200001
J	Niu, GL; Hellmuth, I; Flisikowska, T; Pausch, H; Rieblinger, B; Carrapeiro, A; Schade, B; Bohm, B; Kappe, E; Fischer, K; Klinger, B; Steiger, K; Burgkart, R; Bourdon, JC; Saur, D; Kind, A; Schnieke, A; Flisikowski, K				Niu, Guanglin; Hellmuth, Isabel; Flisikowska, Tatiana; Pausch, Hubert; Rieblinger, Beate; Carrapeiro, Alexander; Schade, Benjamin; Boehm, Brigitte; Kappe, Eva; Fischer, Konrad; Klinger, Bernhard; Steiger, Katja; Burgkart, Reiner; Bourdon, Jean-Christophe; Saur, Dieter; Kind, Alexander; Schnieke, Angelika; Flisikowski, Krzysztof			Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA	ONCOGENE			English	Article							MUTANT P53; BREAST-CANCER; MESSENGER-RNA; DELTA-133P53; OSTEOSARCOMA; P63; P73; EXPRESSION; MUTATIONS; MOUSE	Recent years have seen an increasing number of genetically engineered pig models of human diseases including cancer. We previously generated pigs with a modified TP53 allele that carries a Cre-removable transcriptional stop signal in intron 1, and an oncogenic mutation TP53(R167H) (orthologous to human TP53(R175H)) in exon 5. Pigs with the unrecombined mutant allele (flTP53(R167H)) develop mainly osteosarcoma but also nephroblastomas and lymphomas. This observation suggested that TP53 gene dysfunction is itself the key initiator of bone tumorigenesis, but raises the question which aspects of the TP53 regulation lead to the development of such a narrow tumour spectrum. Molecular analysis of p53 revealed the presence of two internal TP53 promoters (Pint and P2) equivalent to those found in human. Consequently, both pig and human express TP53 isoforms. Data presented here strongly suggest that P2-driven expression of the mutant R167H-Delta 152p53 isoform (equivalent to the human R175H-Delta 160p53 isoform) and its circular counterpart circTP53 determine the tumour spectrum and play a critical role in the malignant transformation in flTP53(R167H) pigs. The detection of Delta 152p53 isoform mRNA in serum is indicative of tumorigenesis. Furthermore, we showed a tissue-specific p53-dependent deregulation of the p63 and p73 isoforms in these tumours. This study highlights important species-specific differences in the transcriptional regulation of TP53. Considering the similarities of TP53 regulation between pig and human, these observations provide useful pointers for further investigation into isoform function including the novel circTP53 in both the pig model and human patients.	[Niu, Guanglin; Hellmuth, Isabel; Flisikowska, Tatiana; Rieblinger, Beate; Carrapeiro, Alexander; Fischer, Konrad; Klinger, Bernhard; Kind, Alexander; Schnieke, Angelika; Flisikowski, Krzysztof] Tech Univ Munich, Chair Livestock Biotechnol, Munich, Germany; [Pausch, Hubert] Swiss Fed Inst Technol, Anim Genom, Zurich, Switzerland; [Schade, Benjamin; Boehm, Brigitte; Kappe, Eva] Bavarian Anim Hlth Serv, Dept Pathol, Poing, Germany; [Steiger, Katja] Tech Univ Munich, Inst Pathol, Sch Med, Munich, Germany; [Burgkart, Reiner] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Orthopad & Sportorthopad, Munich, Germany; [Bourdon, Jean-Christophe] Univ Dundee, Sch Med, Jacqui Wood Canc Ctr, Dundee, Scotland; [Saur, Dieter] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, Munich, Germany	Technical University of Munich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Technical University of Munich; Technical University of Munich; University of Dundee; Technical University of Munich	Flisikowski, K (corresponding author), Tech Univ Munich, Chair Livestock Biotechnol, Munich, Germany.	flisikowski@wzw.tum.de	JC, Bourdon/A-4439-2008; Pausch, Hubert/U-5934-2019; Saur, Dieter/O-8355-2015	JC, Bourdon/0000-0003-4623-9386; Pausch, Hubert/0000-0002-0501-6760; Saur, Dieter/0000-0001-5874-0210	German Research Foundation [SCHN 971/3-2, SFB 1321]; China Scholarship Council (CSC)	German Research Foundation(German Research Foundation (DFG)); China Scholarship Council (CSC)(China Scholarship Council)	This work was supported by the German Research Foundation grant nos. SCHN 971/3-2, SFB 1321 and China Scholarship Council (CSC). Open Access funding enabled and organized by Projekt DEAL.	Anbarasan T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246257; Avery-Kiejda KA, 2014, CARCINOGENESIS, V35, P586, DOI 10.1093/carcin/bgt411; Bernard H, 2013, ONCOGENE, V32, P2150, DOI 10.1038/onc.2012.242; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Blackburn J, 2016, MOL CARCINOGEN, V55, P1940, DOI 10.1002/mc.22441; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109; Campbell HG, 2012, CELL CYCLE, V11, P446, DOI 10.4161/cc.11.3.19054; Candeias MM, 2016, EMBO REP, V17, P1542, DOI 10.15252/embr.201541956; Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y; Chen S, 2008, CLIN EXP DERMATOL, V33, P634, DOI 10.1111/j.1365-2230.2008.02851.x; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Conforti F, 2012, AGING-US, V4, P202, DOI 10.18632/aging.100441; Denny SK, 2016, CELL, V166, P328, DOI 10.1016/j.cell.2016.05.052; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Durfee RA, 2016, RHEUMATOL THER, V3, P221, DOI 10.1007/s40744-016-0046-y; Fane M, 2017, INT J CANCER, V140, P2634, DOI 10.1002/ijc.30603; Flisikowska T, 2016, THERIOGENOLOGY, V86, P433, DOI 10.1016/j.theriogenology.2016.04.058; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fragou A, 2017, MOL MED REP, V15, P1455, DOI 10.3892/mmr.2017.6162; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gonfloni S, 2015, INT J DEV BIOL, V59, P87, DOI 10.1387/ijdb.150045sg; Guijarro MV, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00189; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hofstetter G, 2011, BRIT J CANCER, V105, P1593, DOI 10.1038/bjc.2011.433; Irwin MS, 2006, CANCER BIOL THER, V5, P804, DOI 10.4161/cbt.5.7.3023; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson JG, 2013, ONCOGENE, V32, P4325, DOI 10.1038/onc.2012.610; Joruiz SM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026039; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kalla D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020488; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee DS, 2014, STEM CELLS, V32, P2467, DOI 10.1002/stem.1733; Leuchs S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043323; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lucena-Araujo AR, 2015, BLOOD, V126, P2302, DOI 10.1182/blood-2015-01-623330; Marcel V, 2010, FEBS LETT, V584, P4463, DOI 10.1016/j.febslet.2010.10.005; Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320; Moll UM, 2003, CLIN CANCER RES, V9, P5437; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nutthasirikul N, 2013, INT J ONCOL, V42, P1181, DOI 10.3892/ijo.2013.1818; Ognjanovic S, 2012, CANCER-AM CANCER SOC, V118, P1387, DOI 10.1002/cncr.26390; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Poole LA, 2017, CRIT REV BIOCHEM MOL, V52, P696, DOI 10.1080/10409238.2017.1380597; Robertson N, 2020, EXPERT OPIN DRUG DIS, V15, P893, DOI 10.1080/17460441.2020.1757644; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rogalla S, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201904992; Saalfrank A, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.19; Seki M, 2017, NAT GENET, V49, P1274, DOI 10.1038/ng.3900; Seva J, 2001, VET REC, V148, P147, DOI 10.1136/vr.148.5.147; Sieren JC, 2014, J CLIN INVEST, V124, P4052, DOI 10.1172/JCI75447; Slatter TL, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.149; Slatter TL, 2011, BLOOD, V117, P5166, DOI 10.1182/blood-2010-11-321851; Stindt MH, 2015, ONCOGENE, V34, P4300, DOI 10.1038/onc.2014.359; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang J, 2019, P NATL ACAD SCI USA, V116, P24259, DOI 10.1073/pnas.1913919116; Zhang J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0719-3	59	13	13	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1896	1908		10.1038/s41388-021-01686-9	http://dx.doi.org/10.1038/s41388-021-01686-9		FEB 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33603167	Green Published, hybrid			2022-12-17	WOS:000619405600001
J	Yoon, H; Tang, CM; Banerjee, S; Yebra, M; Noh, S; Burgoyne, AM; Torre, JD; De Siena, M; Liu, MY; Klug, LR; Choi, YY; Hosseini, M; Delgado, AL; Wang, ZY; French, RP; Lowy, A; DeMatteo, RP; Heinrich, MC; Molinolo, AA; Gutkind, JS; Harismendy, O; Sicklick, JK				Yoon, Hyunho; Tang, Chih-Min; Banerjee, Sudeep; Yebra, Mayra; Noh, Sangkyu; Burgoyne, Adam M.; Torre, Jorge De la; Siena, Martina De; Liu, Mengyuan; Klug, Lillian R.; Choi, Yoon Young; Hosseini, Mojgan; Delgado, Antonio L.; Wang, Zhiyong; French, Randall P.; Lowy, Andrew; DeMatteo, Ronald P.; Heinrich, Michael C.; Molinolo, Alfredo A.; Gutkind, J. Silvio; Harismendy, Olivier; Sicklick, Jason K.			Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis	ONCOGENE			English	Article							IMATINIB MESYLATE; C-KIT; RECEPTOR; COMBINATION; ACTIVATION; MUTATIONS; MULTICENTER; INHIBITOR; KINASE; LIGAND	Targeted therapies for gastrointestinal stromal tumor (GIST) are modestly effective, but GIST cannot be cured with single agent tyrosine kinase inhibitors. In this study, we sought to identify new therapeutic targets in GIST by investigating the tumor microenvironment. Here, we identified a paracrine signaling network by which cancer-associated fibroblasts (CAFs) drive GIST growth and metastasis. Specifically, CAFs isolated from human tumors were found to produce high levels of platelet-derived growth factor C (PDGFC), which activated PDGFC-PDGFRA signal transduction in GIST cells that regulated the expression of SLUG, an epithelial-mesenchymal transition (EMT) transcription factor and downstream target of PDGFRA signaling. Together, this paracrine induce signal transduction cascade promoted tumor growth and metastasis in vivo. Moreover, in metastatic GIST patients, SLUG expression positively correlated with tumor size and mitotic index. Given that CAF paracrine signaling modulated GIST biology, we directly targeted CAFs with a dual PI3K/mTOR inhibitor, which synergized with imatinib to increase tumor cell killing and in vivo disease response. Taken together, we identified a previously unappreciated cellular target for GIST therapy in order to improve disease control and cure rates.	[Yoon, Hyunho; Tang, Chih-Min; Banerjee, Sudeep; Yebra, Mayra; Noh, Sangkyu; Burgoyne, Adam M.; Torre, Jorge De la; Siena, Martina De; Delgado, Antonio L.; French, Randall P.; Lowy, Andrew; Sicklick, Jason K.] Univ Calif San Diego, Dept Surg, Div Surg Oncol, Moores Canc Ctr, San Diego, CA 92103 USA; [Banerjee, Sudeep] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA; [Siena, Martina De] Fdn Policlin A Gemelli Catholic Univ Rome, Gastroenterol & Digest Endoscopy, Rome, Italy; [Liu, Mengyuan; DeMatteo, Ronald P.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Klug, Lillian R.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Klug, Lillian R.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Portland VA Hlth Care Syst, Knight Canc Inst, Portland, OR 97201 USA; [Choi, Yoon Young; Harismendy, Olivier] Univ Calif San Diego, Moores Canc Ctr, Div Biomed Informat, San Diego, CA 92103 USA; [Choi, Yoon Young] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea; [Hosseini, Mojgan; Molinolo, Alfredo A.] Univ Calif San Diego, Dept Pathol, Moores Canc Ctr, San Diego, CA 92103 USA; [Wang, Zhiyong; Gutkind, J. Silvio] Univ Calif San Diego, Dept Pharmacol, Moores Canc Ctr, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of Pennsylvania; Oregon Health & Science University; Oregon Health & Science University; University of California System; University of California San Diego; Yonsei University; Yonsei University Health System; University of California System; University of California San Diego; University of California System; University of California San Diego	Sicklick, JK (corresponding author), Univ Calif San Diego, Dept Surg, Div Surg Oncol, Moores Canc Ctr, San Diego, CA 92103 USA.	jsicklick@health.ucsd.edu	Gutkind, J. Silvio/J-1201-2016; Harismendy, Olivier/AAM-2072-2021; De Siena, Martina/AAB-8566-2022	Gutkind, J. Silvio/0000-0002-5150-4482; Harismendy, Olivier/0000-0002-8098-9888; De Siena, Martina/0000-0003-4913-7254; Heinrich, Michael/0000-0003-3790-0478	National Institutes of Health (NIH) [P30CA023100]; NIH [R01 CA226803, RO1 CA155620]; Food and Drug Administration [R01 FD006334]; Jonathan David Foundation; GIST Research Fund; GIST Cancer Research Fund; SDH Research Fund; VA Merit Review Grant [2l01BX000338-05]; Kristen Ann Carr Fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food and Drug Administration(United States Department of Health & Human Services); Jonathan David Foundation; GIST Research Fund; GIST Cancer Research Fund; SDH Research Fund; VA Merit Review Grant(US Department of Veterans Affairs); Kristen Ann Carr Fund	We thank T. Reya for her critical review of the manuscript. This work was supported in part by National Institutes of Health (NIH) grant nos. P30CA023100 (JKS, AM), as well as NIH grant (R01 CA226803) (RO1 CA155620) (AML), Food and Drug Administration (R01 FD006334, JKS), Jonathan David Foundation (JKS, MCH), GIST Research Fund (JKS), GIST Cancer Research Fund (MCH), SDH Research Fund (JKS), VA Merit Review Grant 2l01BX000338-05 (MCH), and Kristen Ann Carr Fund (JKS).	Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; [Anonymous], 2020, CANCER DISCOV, V10, P1438, DOI 10.1158/2159-8290.cd-rw2020-124; Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452; Boikos SA, 2016, JAMA ONCOL, V2, P922, DOI 10.1001/jamaoncol.2016.0256; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Corless CL, 2008, ANNU REV PATHOL-MECH, V3, P557, DOI 10.1146/annurev.pathmechdis.3.121806.151538; Corless CL, 2011, NAT REV CANCER, V11, P865, DOI 10.1038/nrc3143; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Dhillon S, 2020, DRUGS, V80, P1133, DOI 10.1007/s40265-020-01348-2; Dhillon S, 2020, DRUGS, V80, P433, DOI 10.1007/s40265-020-01275-2; Dolgin E, 2020, CANCER DISCOV, V10, P334, DOI 10.1158/2159-8290.CD-NB2020-002; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Edris B, 2013, P NATL ACAD SCI USA, V110, P3501, DOI 10.1073/pnas.1222893110; Ekpe-Adewuyi E, 2016, ONCOTARGET, V7, P83684, DOI 10.18632/oncotarget.13299; Floris G, 2013, CLIN CANCER RES, V19, P620, DOI 10.1158/1078-0432.CCR-12-2853; Goehrig D, 2019, GUT, V68, P693, DOI 10.1136/gutjnl-2018-317570; Grunewald S, 2021, CANCER DISCOV, V11, P108, DOI 10.1158/2159-8290.CD-20-0487; Hayashi Y, 2015, GASTROENTEROLOGY, V149, P420, DOI 10.1053/j.gastro.2015.04.006; Heinrich MC, 2020, LANCET ONCOL, V21, P935, DOI 10.1016/S1470-2045(20)30269-2; Hessmann E, 2018, GUT, V67, P497, DOI 10.1136/gutjnl-2016-311954; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Janku Filip, 2020, J Clin Oncol, V38, P3294, DOI 10.1200/JCO.20.00522; Joensuu H, 2015, J CLIN ONCOL, V33, P634, DOI 10.1200/JCO.2014.57.4970; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; McDermott U, 2009, CANCER RES, V69, P3937, DOI 10.1158/0008-5472.CAN-08-4327; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Pulkka OP, 2017, BRIT J CANCER, V116, P1195, DOI 10.1038/bjc.2017.82; Ray Katrina, 2020, Nat Rev Gastroenterol Hepatol, V17, P452, DOI 10.1038/s41575-020-0336-2; Ruffini F, 2017, ONCOTARGET, V8, P66833, DOI 10.18632/oncotarget.18706; Schoffski P, 2010, ANN ONCOL, V21, P1990, DOI 10.1093/annonc/mdq076; Shi E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1075-6; Sicklick JK, 2013, J GASTROINTEST SURG, V17, P1997, DOI 10.1007/s11605-013-2243-0; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Van Looy T, 2014, CLIN CANCER RES, V20, P6071, DOI 10.1158/1078-0432.CCR-14-1823; Vitiello GA, 2019, J CLIN INVEST, V129, P1863, DOI 10.1172/JCI124108; Wang LX, 2017, MED SCI MONITOR, V23, P3808, DOI 10.12659/MSM.906038; Wiley SZ, 2018, FASEB J, V32, P1170, DOI 10.1096/fj.201700834R; Zook P, 2017, CLIN CANCER RES, V23, P171, DOI 10.1158/1078-0432.CCR-16-0529	45	13	13	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1957	1973		10.1038/s41388-021-01685-w	http://dx.doi.org/10.1038/s41388-021-01685-w		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603171	hybrid, Green Published			2022-12-17	WOS:000619405600003
J	Lin, CC; Blessing, AM; Pulliam, TL; Shi, Y; Wilkenfeld, SR; Han, JJ; Murray, MM; Pham, AH; Duong, K; Brun, SN; Shaw, RJ; Ittmann, MM; Frigo, DE				Lin, Chenchu; Blessing, Alicia M.; Pulliam, Thomas L.; Shi, Yan; Wilkenfeld, Sandi R.; Han, Jenny J.; Murray, Mollianne M.; Pham, Alexander H.; Duong, Kevin; Brun, Sonja N.; Shaw, Reuben J.; Ittmann, Michael M.; Frigo, Daniel E.			Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling	ONCOGENE			English	Article							PROTEIN-KINASE KINASE; ANDROGEN RECEPTOR; CELL-GROWTH; TARGETING AUTOPHAGY; SURVIVAL MECHANISM; ULK1; AMPK; PHOSPHORYLATION; DEPRIVATION; AXIS	Previous work has suggested androgen receptor (AR) signaling mediates prostate cancer progression in part through the modulation of autophagy. However, clinical trials testing autophagy inhibition using chloroquine derivatives in men with castration-resistant prostate cancer (CRPC) have yet to yield promising results, potentially due to the side effects of this class of compounds. We hypothesized that identification of the upstream activators of autophagy in prostate cancer could highlight alternative, context-dependent targets for blocking this important cellular process during disease progression. Here, we used molecular, genetic, and pharmacological approaches to elucidate an AR-mediated autophagy cascade involving Ca2+/calmodulin-dependent protein kinase kinase 2 (CAMKK2; a kinase with a restricted expression profile), 5'-AMP-activated protein kinase (AMPK), and Unc-51 like autophagy activating kinase 1 (ULK1), but independent of canonical mechanistic target of rapamycin (mTOR) activity. Increased CAMKK2-AMPK-ULK1 signaling correlated with disease progression in genetic mouse models and patient tumor samples. Importantly, CAMKK2 disruption impaired tumor growth and prolonged survival in multiple CRPC preclinical mouse models. Similarly, an inhibitor of AMPK-ULK1 blocked autophagy, cell growth, and colony formation in prostate cancer cells. Collectively, our findings converge to demonstrate that AR can co-opt the CAMKK2-AMPK-ULK1 signaling cascade to promote prostate cancer by increasing autophagy. Thus, this pathway may represent an alternative autophagic target in CRPC.	[Lin, Chenchu; Pulliam, Thomas L.; Wilkenfeld, Sandi R.; Han, Jenny J.; Murray, Mollianne M.; Frigo, Daniel E.] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA; [Lin, Chenchu; Wilkenfeld, Sandi R.; Duong, Kevin] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Blessing, Alicia M.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Blessing, Alicia M.; Pulliam, Thomas L.; Shi, Yan; Pham, Alexander H.; Frigo, Daniel E.] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77004 USA; [Blessing, Alicia M.; Pulliam, Thomas L.; Frigo, Daniel E.] Univ Houston, Dept Biol & Biochem, Houston, TX 77004 USA; [Brun, Sonja N.; Shaw, Reuben J.] Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Ittmann, Michael M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX USA; [Ittmann, Michael M.] Dan L Duncan Canc Ctr, Houston, TX USA; [Ittmann, Michael M.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Frigo, Daniel E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Frigo, Daniel E.] Houston Methodist Res Inst, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Houston System; University of Houston; University of Houston System; University of Houston; Salk Institute; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; The Methodist Hospital System; The Methodist Hospital - Houston	Frigo, DE (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging, Houston, TX 77030 USA.; Frigo, DE (corresponding author), Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77004 USA.; Frigo, DE (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77004 USA.; Frigo, DE (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Frigo, DE (corresponding author), Houston Methodist Res Inst, Houston, TX 77030 USA.	frigo@mdanderson.org		Shi, Yan/0000-0003-4580-7556; Wilkenfeld, Sandi/0000-0002-4973-8941	National Institutes of Health [NIH R01CA184208]; American Cancer Society [RSG-16-084-01-TBE]; Antje Wuelfrath Gee and Harry Gee, Jr. Family Legacy Scholarship; Robert Hazelwood Graduate Fellowship for Cancer Research; CFP foundation; CCSG; NIH [P30CA016672]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Antje Wuelfrath Gee and Harry Gee, Jr. Family Legacy Scholarship; Robert Hazelwood Graduate Fellowship for Cancer Research; CFP foundation; CCSG; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Drs. Mondira Kundu, Christopher Counter and Nancy Weigel for plasmids and reagents, Kenneth Dunner, Jr. in the High Resolution Electron Microscopy Core Facility at MDACC for help with TEM, and Dr. Jeff Spencer for help with sgRNA design. This work was supported by grants from the National Institutes of Health (NIH R01CA184208 to DEF), American Cancer Society (RSG-16-084-01-TBE to DEF), an Institutional Research Grant (to DEF) and generous philanthropic contributions to The University of Texas MD Anderson Moon Shots Program (to DEF). This work was also supported by an Antje Wuelfrath Gee and Harry Gee, Jr. Family Legacy Scholarship, Robert Hazelwood Graduate Fellowship for Cancer Research (to CL) and MD Anderson Odyssey fellow supported by the CFP foundation (to AMB). Electron microscopy was performed by the CCSG-funded MDACC High Resolution Electron Microscopy Facility while histology was performed with the CCSG-funded MDACC Research Histology Core Laboratory, NIH grant P30CA016672.	Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Asquith CRM, 2018, MOLECULES, V23, DOI 10.3390/molecules23051221; Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bennett HL, 2013, BJU INT, V111, P672, DOI 10.1111/j.1464-410X.2012.11409.x; Berglund L, 2008, MOL CELL PROTEOMICS, V7, P2019, DOI 10.1074/mcp.R800013-MCP200; Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaturvedi AP, 2019, ADV EXP MED BIOL, V1210, P333, DOI 10.1007/978-3-030-32656-2_15; Chhipa RR, 2011, CELL SIGNAL, V23, P1466, DOI 10.1016/j.cellsig.2011.04.008; Comincini Sergio, 2018, J CANC METASTASIS TR, V4; Dadwal UC, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00335; Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104; Dite TA, 2018, J BIOL CHEM, V293, P8874, DOI 10.1074/jbc.RA118.003547; Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Frigo DE, 2011, CANCER RES, V71, P528, DOI 10.1158/0008-5472.CAN-10-2581; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Hardie DG, 2011, EMBO J, V30, P634, DOI 10.1038/emboj.2011.12; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Kaini RR, 2012, BIOCHEM BIOPH RES CO, V425, P150, DOI 10.1016/j.bbrc.2012.07.054; Karacosta LG, 2012, J BIOL CHEM, V287, P24832, DOI 10.1074/jbc.M112.370783; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Khan AS, 2017, NAT REV UROL, V14, P164, DOI 10.1038/nrurol.2016.272; Kim J, 2011, CELL CYCLE, V10, P1337, DOI 10.4161/cc.10.9.15291; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kranzbuhler B, 2019, PROSTATE, V79, P206, DOI 10.1002/pros.23725; Kukimoto-Niino M, 2011, J BIOL CHEM, V286, P22570, DOI 10.1074/jbc.M111.251710; Laker RC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00520-9; Lamoureux F, 2013, CLIN CANCER RES, V19, P833, DOI 10.1158/1078-0432.CCR-12-3114; Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049; Liu B, 2015, UROLOGY, V85, P1424, DOI 10.1016/j.urology.2015.03.006; Loffler AS, 2011, AUTOPHAGY, V7, P696, DOI 10.4161/auto.7.7.15451; Marcelo KL, 2016, TRENDS ENDOCRIN MET, V27, P706, DOI 10.1016/j.tem.2016.06.001; Martin KR, 2018, ISCIENCE, V8, P74, DOI 10.1016/j.isci.2018.09.012; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015; Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mortezavi A, 2019, WORLD J UROL, V37, P351, DOI 10.1007/s00345-018-2385-5; Munkley J, 2014, ONCOTARGET, V5, P131, DOI 10.18632/oncotarget.1405; Nguyen HG, 2014, ONCOGENE, V33, P4521, DOI 10.1038/onc.2014.25; Niture Suryakant, 2018, Oncotarget, V9, P26884, DOI 10.18632/oncotarget.25529; O'Byrne SN, 2020, MOLECULES, V25, DOI 10.3390/molecules25020325; Penfold L, 2018, CANCER RES, V78, P6747, DOI 10.1158/0008-5472.CAN-18-0585; Petherick KJ, 2015, J BIOL CHEM, V290, P11376, DOI [10.1074/jbc.A114.627778, 10.1074/jbc.C114.627778]; Price DJ, 2018, BIOORG MED CHEM LETT, V28, P1958, DOI 10.1016/j.bmcl.2018.03.034; Profeta GS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52795-1; Racioppi L, 2012, J BIOL CHEM, V287, P31658, DOI 10.1074/jbc.R112.356485; Santanam U, 2016, GENE DEV, V30, P399, DOI 10.1101/gad.274134.115; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Shat JJ, 2020, J CELL PHYSIOL, V235, P2129, DOI 10.1002/jcp.29117; Shi Y, 2013, MOL ENDOCRINOL, V27, P280, DOI 10.1210/me.2012-1260; Solitro AR, 2016, FUTURE MED CHEM, V8, P73, DOI 10.4155/fmc.15.166; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Tan Q, 2016, NEOPLASIA, V18, P347, DOI 10.1016/j.neo.2016.04.003; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tennakoon JB, 2014, ONCOGENE, V33, P5251, DOI 10.1038/onc.2013.463; Tian WL, 2015, FEBS LETT, V589, P1847, DOI 10.1016/j.febslet.2015.05.020; Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781; Wang L, 2016, EBIOMEDICINE, V7, P50, DOI 10.1016/j.ebiom.2016.03.022; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; White MA, 2018, ENDOCR-RELAT CANCER, V25, P453, DOI 10.1530/ERC-17-0051; Yang Y, 2020, CELL DEATH DIFFER, V27, P858, DOI 10.1038/s41418-019-0480-9; Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021; Zhang HY, 2017, J CLIN PATHOL, V70, P383, DOI 10.1136/jclinpath-2016-203926; Zhang Yun, 2019, Sichuan Da Xue Xue Bao Yi Xue Ban, V50, P323; Zhao F, 2016, ONCOTARGET, V7, P5366, DOI 10.18632/oncotarget.6783	81	13	13	5	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1690	1705		10.1038/s41388-021-01658-z	http://dx.doi.org/10.1038/s41388-021-01658-z		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33531625	Green Submitted, Green Accepted			2022-12-17	WOS:000613991700003
J	Kang, W; Zhang, JL; Huang, TT; Zhou, YH; Wong, CC; Chan, RCK; Dong, YJ; Wu, F; Zhang, B; Wu, WKK; Chan, MWY; Cheng, ASL; Yu, J; Wong, N; Lo, KW; To, KF				Kang, Wei; Zhang, Jinglin; Huang, Tingting; Zhou, Yuhang; Wong, Chi Chun; Chan, Ronald C. K.; Dong, Yujuan; Wu, Feng; Zhang, Bin; Wu, William K. K.; Chan, Michael W. Y.; Cheng, Alfred S. L.; Yu, Jun; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai			NOTCH3, a crucial target of miR-491-5p/miR-875-5p, promotes gastric carcinogenesis by upregulating PHLDB2 expression and activating Akt pathway	ONCOGENE			English	Article							GAMMA SECRETASE INHIBITOR; SIGNALING PATHWAY; MICRORNA EXPRESSION; PHASE-II; CANCER; RO4929097; GROWTH; TUMORIGENESIS; ONCOGENE; INVASION	Aberrant Notch activation has been implicated in multiple malignancies and the identification of NOTCH receptors and related pathways is critical for targeted therapy. In this study, we aim to delineate the most prominent dysregulated NOTCH receptor and comprehensively reveal its deregulation in gastric cancer (GC). In the four Notch members, NOTCH3 was found uniformly upregulated and associated with poor clinical outcomes in multiple GC datasets. siRNA-mediated NOTCH3 knockdown demonstrated antitumor effects by suppressing cell proliferation, inhibiting monolayer formation, and impairing cell invasion abilities. Its depletion also induced early and late apoptosis. NOTCH3 was confirmed to be a direct target of two tumor suppressor microRNAs (miRNAs), namely miR-491-5p and miR-875-5p. The activation of NOTCH3 is partly due to the silence of these two miRNAs. Through RNA-seq profiling and functional validation, PHLDB2 was identified as a potent functional downstream modulator for NOTCH3 in gastric carcinogenesis. PHLDB2 expression demonstrated a positive correlation with NOTCH3, but was negatively correlated with miR-491-5p. Akt-mTOR was revealed as the downstream signaling of PHLDB2. The NOTCH3-PHLDB2-Akt co-activation was found in 33.7% GC patients and the activation of this axis predicted poor clinical outcome. GC cells treated with siNOTCH3, siPHLDB2, miR-491-5p, miR-875-5p, were more sensitive to Cisplatin and 5-FU. Taken together, the NOTCH3-PHLDB2-Akt cascade plays oncogenic role in gastric carcinogenesis and serves as a therapeutic target. Our study provided insights into Notch-mediated underlying molecular mechanisms and implied translational potential.	[Kang, Wei; Zhang, Jinglin; Huang, Tingting; Zhou, Yuhang; Chan, Ronald C. K.; Wu, Feng; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China; [Kang, Wei; Zhang, Jinglin; Huang, Tingting; Zhou, Yuhang; Wong, Chi Chun; Dong, Yujuan; Yu, Jun; To, Ka Fai] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Kang, Wei; Zhang, Jinglin; Huang, Tingting; Zhou, Yuhang; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Zhang, Bin] Nanjing Univ, Med Sch, Dept Gastroenterol, Affiliated Drum Tower Hosp, Nanjing, Peoples R China; [Wu, William K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China; [Chan, Michael W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Nanjing University; Chinese University of Hong Kong; National Chung Cheng University; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China.; Kang, W (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China.; Kang, W (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	weikang@cuhk.edu.hk	Dong, Yujuan/AAS-3467-2021; huang, ting/GRR-3141-2022; Wu, William K.K./A-3277-2009; KANG, Wei/C-5451-2016	Wu, William K.K./0000-0002-5662-5240; KANG, Wei/0000-0002-4651-677X; Wong, Chi Chun/0000-0003-1362-3541	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2019.001]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK Direct Grant for Research from The Chinese University of Hong Kong	The manuscript is under support of Research Grants Council of the Hong Kong Special Administrative Region, China [Project No.: CUHK 14100019 and 14118518 (for GRF projects)], and CUHK Direct Grant for Research (2019.001) from The Chinese University of Hong Kong.	Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bauer L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044566; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Chen G, 2017, BIOCHEM BIOPH RES CO, V487, P90, DOI 10.1016/j.bbrc.2017.04.023; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Jesus-Acosta A, 2014, INVEST NEW DRUG, V32, P739, DOI 10.1007/s10637-014-0083-8; Denoyelle C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.389; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gong FC, 2016, AM J TRANSL RES, V8, P485; Guo LY, 2012, WORLD J GASTROENTERO, V18, P7262, DOI 10.3748/wjg.v18.i48.7262; He PY, 2017, ONCOL REP, V38, P3554, DOI 10.3892/or.2017.6037; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Hsu KW, 2012, CARCINOGENESIS, V33, P1459, DOI 10.1093/carcin/bgs165; Huang TT, 2015, ONCOTARGET, V6, P18012, DOI 10.18632/oncotarget.4000; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Ji DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085116; Kang H, 2012, HISTOPATHOLOGY, V61, P576, DOI 10.1111/j.1365-2559.2012.04274.x; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Kim SJ, 2016, ONCOGENE, V35, P251, DOI 10.1038/onc.2015.80; Kimura K, 2007, CANCER SCI, V98, P155, DOI 10.1111/j.1349-7006.2006.00369.x; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Liu LZ, 2007, CANCER RES, V67, P6325, DOI 10.1158/0008-5472.CAN-06-4261; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Luistro L, 2009, CANCER RES, V69, P7672, DOI 10.1158/0008-5472.CAN-09-1843; Mathe EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467; Molaei Fatemeh, 2018, Iranian Biomedical Journal, V22, P217, DOI 10.22034/ibj.22.4.217; Nair JS, 2013, ANTICANCER RES, V33, P1307; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Ozawa T, 2014, ANN SURG ONCOL, V21, P2650, DOI 10.1245/s10434-014-3659-9; Pasto A, 2014, CANCER RES, V74, P2106, DOI 10.1158/0008-5472.CAN-13-2022; Piazzi G, 2012, CELL CYCLE, V11, P4323, DOI 10.4161/cc.22388; Pine SR, 2008, DIS MARKERS, V24, P257, DOI 10.1155/2008/396281; Polkowski W, 1999, ANN SURG ONCOL, V6, P290, DOI 10.1007/s10434-999-0290-2; Qian CJ, 2015, MOL CELL BIOCHEM, V401, P165, DOI 10.1007/s11010-014-2304-z; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Serafin V, 2011, J PATHOL, V224, P448, DOI 10.1002/path.2895; Strosberg JR, 2012, EUR J CANCER, V48, P997, DOI 10.1016/j.ejca.2012.02.056; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Takebe N, 2014, PHARMACOL THERAPEUT, V141, P140, DOI 10.1016/j.pharmthera.2013.09.005; Tolcher AW, 2012, J CLIN ONCOL, V30, P2348, DOI 10.1200/JCO.2011.36.8282; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Wu WKK, 2010, CANCER LETT, V295, P144, DOI 10.1016/j.canlet.2010.04.025; Yeh TS, 2009, CANCER RES, V69, P5039, DOI 10.1158/0008-5472.CAN-08-4021; Yuan X, 2015, CANCER LETT, V369, P20, DOI 10.1016/j.canlet.2015.07.048; Zhang H, 2014, BRIT J CANCER, V110, P2283, DOI 10.1038/bjc.2014.135; Zhang TN, 2016, ONCOTARGET, V7, P42225, DOI 10.18632/oncotarget.9944; Zhao Q, 2015, ONCOL REP, V34, P979, DOI 10.3892/or.2015.4013; Zhou QOL, 2010, J BIOL CHEM, V285, P27581, DOI 10.1074/jbc.M110.146886	59	13	14	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1578	1594		10.1038/s41388-020-01579-3	http://dx.doi.org/10.1038/s41388-020-01579-3		JAN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33452458	hybrid, Green Published			2022-12-17	WOS:000607998600006
J	Liu, PI; Chang, AC; Lai, JL; Lin, TH; Tsai, CH; Chen, PC; Jiang, YJ; Lin, LW; Huang, WC; Yang, SF; Tang, CH				Liu, Po-, I; Chang, An-Chen; Lai, Jiun-Lin; Lin, Tien-Huang; Tsai, Chun-Hao; Chen, Po-Chun; Jiang, Ya-Jing; Lin, Liang-Wei; Huang, Wei-Chien; Yang, Shun-Fa; Tang, Chih-Hsin			Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases	ONCOGENE			English	Article							PROSTATE-CANCER; PLUS MELATONIN; CELLS; ANGIOGENESIS; CHEMOTHERAPY; METAANALYSIS; METABOLISM; MODULATION; MECHANISMS; STRATEGIES	Cancer-related bone erosion occurs frequently in bone metastasis and is associated with severe complications such as chronic bone pain, fractures, and lower survival rates. In recognition of the fact that the darkness hormone melatonin is capable of regulating bone homeostasis, we explored its therapeutic potential in bone metastasis. We found that melatonin directly reduces osteoclast differentiation, bone resorption activity and promotes apoptosis of mature osteoclasts. We also observed that melatonin inhibits RANKL production in lung and prostate cancer cells by downregulating the p38 MAPK pathway, which in turn prevents cancer-associated osteoclast differentiation. In lung and prostate bone metastasis models, twice-weekly melatonin treatment markedly reduced tumor volumes and numbers of osteolytic lesions. Melatonin also substantially lowered the numbers of TRAP-positive osteoclasts in tibia bone marrow and RANKL expression in tumor tissue. These findings show promise for melatonin in the treatment of bone metastases.	[Liu, Po-, I; Lai, Jiun-Lin; Jiang, Ya-Jing; Huang, Wei-Chien; Tang, Chih-Hsin] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Liu, Po-, I] Asia Univ Hosp, Dept Gen Thorac Surg, Taichung, Taiwan; [Chang, An-Chen; Chen, Po-Chun] Shin Kong Wu Ho Su Mem Hosp, Translat Med Ctr, Taipei, Taiwan; [Lin, Tien-Huang] Buddhist Tzu Chi Gen Hosp, Dept Urol, Taichung Branch, Taichung, Taiwan; [Lin, Tien-Huang] Tzu Chi Univ, Sch Postbaccalaureate Chinese Med, Hualien, Taiwan; [Tsai, Chun-Hao] China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan; [Tsai, Chun-Hao; Lin, Liang-Wei; Tang, Chih-Hsin] China Med Univ, Sch Med, Taichung, Taiwan; [Chen, Po-Chun] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Chen, Po-Chun; Tang, Chih-Hsin] Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung, Taiwan; [Yang, Shun-Fa] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Tang, Chih-Hsin] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan	China Medical University Taiwan; Shin Kong Wu Ho Su Memorial Hospital; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Tzu Chi University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan	Tang, CH (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Tang, CH (corresponding author), China Med Univ, Sch Med, Taichung, Taiwan.; Tang, CH (corresponding author), Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung, Taiwan.; Yang, SF (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Yang, SF (corresponding author), Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan.; Tang, CH (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.	ysf@csmu.edu.tw; chtang@mail.cmu.edu.tw	Yang, Shun-Fa/AAN-1519-2020; Chang, An-Chen/ABB-6915-2021; Huang, Wei-Chien/D-1740-2012	Yang, Shun-Fa/0000-0002-0365-7927; Chang, An-Chen/0000-0002-9544-9980; Huang, Wei-Chien/0000-0001-6467-8716	Taiwan's Ministry of Science and Technology [MOST 108-2320-B-039-026-, MOST 109-2320-B-341-002-]; China Medical University Hospital [DMR-110-102]; Shin Kong Wu Ho-Su Memorial Hospital [2020SKHBND001]; China Medical University under the Higher Education Sprout Project, Ministry of Education, Taiwan [CMRCCHM-3-1]; Asia University Hospital [10951002]; Chung Shan Medical University Hospital, Taiwan [CSH-2020-E-001-Y3]	Taiwan's Ministry of Science and Technology; China Medical University Hospital; Shin Kong Wu Ho-Su Memorial Hospital; China Medical University under the Higher Education Sprout Project, Ministry of Education, Taiwan; Asia University Hospital; Chung Shan Medical University Hospital, Taiwan	This study was supported by grants from Taiwan's Ministry of Science and Technology (MOST 108-2320-B-039-026-, MOST 109-2320-B-341-002-), China Medical University Hospital (DMR-110-102), Shin Kong Wu Ho-Su Memorial Hospital (2020SKHBND001), China Medical University under the Higher Education Sprout Project, Ministry of Education, Taiwan (CMRCCHM-3-1), Asia University Hospital (10951002) and Chung Shan Medical University Hospital, Taiwan (CSH-2020-E-001-Y3).	Anderson G, 2015, MULT SCLER RELAT DIS, V4, P112, DOI 10.1016/j.msard.2014.12.001; [Anonymous], 2018, Nat Rev Dis Primers, V4, P18002, DOI 10.1038/nrdp.2018.2; Arendt J, 2006, CHRONOBIOL INT, V23, P21, DOI 10.1080/07420520500464361; Ayoub MA, 2004, MOL PHARMACOL, V66, P312, DOI 10.1124/mol.104.000398; Bang J, 2012, RHEUMATOL INT, V32, P379, DOI 10.1007/s00296-010-1641-9; Benjamin Biju, 2016, Osteoporos Sarcopenia, V2, P77, DOI 10.1016/j.afos.2016.03.003; Bi HD, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00234; Boafo A, 2019, NAT SCI SLEEP, V11, P1, DOI 10.2147/NSS.S181365; Brown JE, 2005, JNCI-J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002; Chang AC, 2018, CANCER LETT, V426, P47, DOI 10.1016/j.canlet.2018.03.050; Chao CC, 2019, CLIN SCI, V133, P709, DOI 10.1042/CS20180945; Chen PC, 2013, CARCINOGENESIS, V34, P1669, DOI 10.1093/carcin/bgt103; Chen Q, 2002, INT IMMUNOPHARMACOL, V2, P1443, DOI 10.1016/S1567-5769(02)00088-7; Chin Hong, 2015, Fed Pract, V32, P24; Chuang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078022; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Cordoba-Moreno MO, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61652-5; Cutando A, 2014, ONCOL LETT, V7, P923, DOI 10.3892/ol.2014.1813; Dauchy RT, 2014, CANCER RES, V74, P4099, DOI 10.1158/0008-5472.CAN-13-3156; do Amaral FG, 2018, ARCH ENDOCRIN METAB, V62, P472, DOI 10.20945/2359-3997000000066; Farach-Carson MC, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00163; Fowler TW, 2015, J CELL SCI, V128, P683, DOI 10.1242/jcs.157834; Golan K, 2019, EXP HEMATOL, V78, P1, DOI 10.1016/j.exphem.2019.08.008; Golan K, 2018, CELL STEM CELL, V23, P572, DOI 10.1016/j.stem.2018.08.002; Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69; Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078-0432.CCR-06-1007; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; Han Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06304-x; Huang CC, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12560; Jahanban-Esfahlan R, 2018, BRIT J PHARMACOL, V175, P3230, DOI 10.1111/bph.13898; Jung B, 2006, CANCER RES, V66, P9789, DOI 10.1158/0008-5472.CAN-06-1776; Kim HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061142; Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12; Kim TK, 2013, FASEB J, V27, P2742, DOI 10.1096/fj.12-224691; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Leaw B, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00199; Lee HP, 2020, FOOD AGR IMMUNOL, V31, P193, DOI 10.1080/09540105.2020.1713055; Lee HP, 2019, FOOD AGR IMMUNOL, V30, P1033, DOI 10.1080/09540105.2019.1660623; Lee HP, 2019, J FUNCT FOODS, V52, P537, DOI 10.1016/j.jff.2018.11.040; Leja-Szpak A, 2018, PHARMACOL REP, V70, P1079, DOI 10.1016/j.pharep.2018.05.007; Li Y, 2017, ONCOTARGET, V8, P39896, DOI 10.18632/oncotarget.16379; LISSONI P, 1995, BRIT J CANCER, V71, P854, DOI 10.1038/bjc.1995.164; LISSONI P, 1994, TUMORI, V80, P464, DOI 10.1177/030089169408000611; Liu JB, 2016, ANNU REV PHARMACOL, V56, P361, DOI 10.1146/annurev-pharmtox-010814-124742; Liu JF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091491; Lopez-Canul M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102452; Lv JW, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12557; Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018-02236; Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321; Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465; Markus RP, 2018, BRIT J PHARMACOL, V175, P3239, DOI 10.1111/bph.14083; Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027; Menendez-Menendez J, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/3271948; Meng XT, 2018, MOL MED REP, V17, P7202, DOI 10.3892/mmr.2018.8729; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007; Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4; Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041; Rouach V, 2018, J BONE ONCOL, V12, P91, DOI 10.1016/j.jbo.2018.07.011; Schmid-Alliana A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010148; Seely D, 2012, INTEGR CANCER THER, V11, P293, DOI 10.1177/1534735411425484; Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182; Singh VA, 2014, SINGAP MED J, V55, P539, DOI 10.11622/smedj.2014138; Slominski AT, 2018, J INVEST DERMATOL, V138, P490, DOI 10.1016/j.jid.2017.10.025; Slominski AT, 2017, CELL MOL LIFE SCI, V74, P3913, DOI 10.1007/s00018-017-2617-7; Slominski AT, 2017, EXP DERMATOL, V26, P563, DOI 10.1111/exd.13208; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Palmer ACS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231379; Steger Guenther G, 2011, Ther Adv Med Oncol, V3, P233, DOI 10.1177/1758834011412656; Svensson E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016022; Tordjman S, 2017, CURR NEUROPHARMACOL, V15, P434, DOI 10.2174/1570159X14666161228122115; van Dam PA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092183; Wang B, 2019, J CELL PHYSIOL, V234, P1008, DOI 10.1002/jcp.27090; Wang MF, 2019, BIOCHEM PHARMACOL, V166, P23, DOI 10.1016/j.bcp.2019.05.005; Wang Y, 2018, ONCOTARGETS THER, V11, P7895, DOI 10.2147/OTT.S174100; Watanabe M, 2008, J OBSTET GYNAECOL RE, V34, P567, DOI 10.1111/j.1447-0756.2008.00818.x; Watkins LR, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060694; Wu MH, 2012, J CELL PHYSIOL, V227, P3016, DOI 10.1002/jcp.23043; Wutzl A, 2006, WIEN KLIN WOCHENSCHR, V118, P473, DOI 10.1007/s00508-006-0644-8; Yang YC, 2019, ENVIRON TOXICOL, V34, P203, DOI 10.1002/tox.22674	82	13	13	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1503	1515		10.1038/s41388-020-01613-4	http://dx.doi.org/10.1038/s41388-020-01613-4		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452455				2022-12-17	WOS:000607998600005
J	Bergin, CJ; Zouggar, A; Haebe, JR; Masibag, AN; Desrochers, FM; Reilley, SY; Agrawal, G; Benoit, YD				Bergin, Christopher J.; Zouggar, Aicha; Haebe, Joshua R.; Masibag, Angelique N.; Desrochers, Francois M.; Reilley, Simon Y.; Agrawal, Gautam; Benoit, Yannick D.			G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer	ONCOGENE			English	Article							STEM-CELLS; HISTONE H3; IDENTIFICATION; METHYLATION; METASTASIS; FEATURES	Colorectal tumors are hierarchically organized and governed by populations of self-renewing cancer stem cells, representing one of the deadliest types of cancers worldwide. Emergence of cancer stemness phenotype depends on epigenetic reprogramming, associated with profound transcriptional changes. As described for pluripotent reprogramming, epigenetic modifiers play a key role in cancer stem cells by establishing embryonic stem-like transcriptional programs, thus impacting the balance between self-renewal and differentiation. We identified overexpression of histone methyltransferase G9a as a risk factor for colorectal cancer, associated with shorter relapse-free survival. Moreover, using human transformed pluripotent cells as a surrogate model for cancer stem cells, we observed that G9a activity is essential for the maintenance of embryonic-like transcriptional signature promoting self-renewal, tumorigenicity, and undifferentiated state. Such a role was also applicable to colorectal cancer, where inhibitors of G9a histone methyltransferase function induced intestinal differentiation while restricting tumor-initiating activity in patient-derived colorectal tumor samples. Finally, by integrating transcriptome profiling with G9a/H3K9me2 loci co-occupancy, we identified the canonical Wnt pathway, epithelial-to-mesenchyme transition, and extracellular matrix organization as potential targets of such a chromatin regulation mechanism in colorectal cancer stem cells. Overall, our findings provide novel insights on the role of G9a as a driver of cancer stem cell phenotype, promoting self-renewal, tumorigenicity, and undifferentiated state.	[Bergin, Christopher J.; Zouggar, Aicha; Haebe, Joshua R.; Masibag, Angelique N.; Desrochers, Francois M.; Reilley, Simon Y.; Agrawal, Gautam; Benoit, Yannick D.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Benoit, YD (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada.	ybenoit@uottawa.ca		Bergin, Chris/0000-0003-3610-6184; Benoit, Yannick/0000-0002-6677-4020	Cancer Research Society [22778, 24039]; Ontario Ministry of Research, Innovation and Science [ER17-13-012]; CIHR [PJT-173541]; National Science and Engineering Research Council [RGPIN-2018-06521, DGECR-2018-00029]	Cancer Research Society; Ontario Ministry of Research, Innovation and Science; CIHR(Canadian Institutes of Health Research (CIHR)); National Science and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by grants from the Cancer Research Society (#22778 and #24039), the Ontario Ministry of Research, Innovation and Science (ER17-13-012), the CIHR (PJT-173541), and the National Science and Engineering Research Council (RGPIN-2018-06521 and DGECR-2018-00029).	Ardeljan D, 2017, CLIN CHEM, V63, P816, DOI 10.1373/clinchem.2016.257444; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Benoit YD, 2017, CELL CHEM BIOL, V24, P833, DOI 10.1016/j.chembiol.2017.05.026; Benoit YD, 2014, CLIN CANCER RES, V20, P5372, DOI 10.1158/1078-0432.CCR-13-2491; Bergin CJ, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060616; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Castro-Diaz N, 2014, GENE DEV, V28, P1397, DOI 10.1101/gad.241661.114; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353; Gifford CA, 2013, CELL, V153, P1149, DOI 10.1016/j.cell.2013.04.037; Grade M, 2007, CANCER RES, V67, P41, DOI 10.1158/0008-5472.CAN-06-1514; Jung G, 2020, NAT REV GASTRO HEPAT, V17, P111, DOI 10.1038/s41575-019-0230-y; Kato S, 2020, CANCER DISCOV, V10, P980, DOI 10.1158/2159-8290.CD-19-0532; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Lehnertz B, 2014, GENE DEV, V28, P317, DOI 10.1101/gad.236794.113; Lenstra DC, 2018, BIOORG MED CHEM LETT, V28, P1234, DOI 10.1016/j.bmcl.2018.02.043; Lima-Fernandes E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09309-4; Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159; Lu XY, 2014, NAT STRUCT MOL BIOL, V21, P423, DOI 10.1038/nsmb.2799; Luo CW, 2017, RADIOTHER ONCOL, V124, P395, DOI 10.1016/j.radonc.2017.03.002; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005; Nakazawa T, 2012, HUM PATHOL, V43, P834, DOI 10.1016/j.humpath.2011.07.009; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pangeni RP, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00879-5; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wainwright EN, 2017, TRENDS CANCER, V3, P372, DOI 10.1016/j.trecan.2017.04.004; Wang HJ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0147-5; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Werbowetski-Ogilvie TE, 2012, STEM CELLS, V30, P392, DOI 10.1002/stem.1017; Werbowetski-Ogilvie TE, 2009, NAT BIOTECHNOL, V27, P91, DOI 10.1038/nbt.1516; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Zhang T, 2016, CELL REP, V15, P77, DOI 10.1016/j.celrep.2016.03.007	43	13	13	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1191	1202		10.1038/s41388-020-01591-7	http://dx.doi.org/10.1038/s41388-020-01591-7		DEC 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323965	Green Published, hybrid			2022-12-17	WOS:000599126500012
J	Kwon, OJ; Zhang, L; Jia, DY; Xin, L				Kwon, Oh-Joon; Zhang, Li; Jia, Deyong; Xin, Li			Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells	ONCOGENE			English	Article							LINEAGE PLASTICITY; CANCER; MOUSE; METASTASIS; MODEL; EXPRESSION; RESISTANCE; PHENOTYPE; CARCINOMA; PATTERNS	Prostate adenocarcinoma undergoes neuroendocrine differentiation to acquire resistance toward antihormonal therapies. The underlying mechanisms have been investigated extensively, among which Sox2 has been shown to play a critical role. However, genetic evidence in mouse models for prostate cancer to support the crucial role of Sox2 is missing. The adult mouse prostate luminal cells contain both castration-resistant Sox2-expressing Sca-1(+) cells and castration-responsive Sca-1(-) cells. We show that both types of the luminal cell are susceptible to oncogenic transformation induced by loss of function of the tumor suppressor Pten. The tumors derived from the Sca-1(+) cells are castration resistant and are more inclined to develop castration-induced neuroendocrine differentiation. Genetic ablation of Sox2 suppresses neuroendocrine differentiation but does not impact the castration-resistant property. This study provides direct genetic evidence that Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation of Pten null prostate adenocarcinoma, corroborates that the lineage status of the prostate cancer cells is a determinant for its propensity to exhibit lineage plasticity, and supports that the intrinsic features of cell-of-origin for prostate cancers can dictate their clinical behaviors.	[Kwon, Oh-Joon; Zhang, Li; Jia, Deyong; Xin, Li] Univ Washington, Dept Urol, Seattle, WA 98109 USA; [Xin, Li] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Xin, L (corresponding author), Univ Washington, Dept Urol, Seattle, WA 98109 USA.; Xin, L (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.	xin18@uw.edu	Jia, Deyong/GSJ-0327-2022; Jia, Deyong/GQP-9611-2022	Jia, Deyong/0000-0003-2034-0363; Xin, Li/0000-0002-7138-0042; Kwon, Oh-Joon/0000-0001-9067-0240	 [R01CA190378]		This work is supported by R01CA190378 (LX).	Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Beltran H, 2019, CLIN CANCER RES, V25, P43, DOI 10.1158/1078-0432.CCR-18-1912; Berger A, 2019, J CLIN INVEST, V129, P3924, DOI 10.1172/JCI127961; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Crowell PD, 2019, CELL REP, V28, P1499, DOI 10.1016/j.celrep.2019.07.007; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; Fine SW, 2012, ADV ANAT PATHOL, V19, P204, DOI 10.1097/PAP.0b013e31825c6b92; Goldstein NS, 2002, AM J CLIN PATHOL, V117, P471, DOI 10.1309/G6PR-Y774-X738-FG2K; Guo WX, 2020, NAT GENET, V52, P908, DOI 10.1038/s41588-020-0642-1; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hsu EC, 2020, P NATL ACAD SCI USA, V117, P2032, DOI 10.1073/pnas.1905384117; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kwon OJ, 2020, ONCOGENE, V39, P7142, DOI 10.1038/s41388-020-01487-6; Kwon OJ, 2020, STEM CELLS, V38, P1479, DOI 10.1002/stem.3253; Kwon OJ, 2016, STEM CELLS, V34, P191, DOI 10.1002/stem.2217; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018; Lee AR, 2018, EBIOMEDICINE, V35, P167, DOI 10.1016/j.ebiom.2018.08.011; Lee TK, 2010, PATHOLOGY, V42, P319, DOI 10.3109/00313021003767314; Li HY, 2020, LAB INVEST, V100, P570, DOI 10.1038/s41374-019-0343-5; Lin D, 2014, CANCER RES, V74, P1272, DOI 10.1158/0008-5472.CAN-13-2921-T; Liu TT, 2016, CHINESE J CANCER RES, V28, P50, DOI 10.3978/j.issn.1000-9604.2016.02.02; Lovnicki J, 2020, J CLIN INVEST, V130, P5338, DOI 10.1172/JCI135373; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Masumori N, 2001, CANCER RES, V61, P2239; McAuley E, 2019, STEM CELLS, V37, P690, DOI 10.1002/stem.2987; Metz EP, 2019, J CELL PHYSIOL, V234, P19298, DOI 10.1002/jcp.28610; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Quintanal-Villalonga A, 2020, NAT REV CLIN ONCOL, V17, P360, DOI 10.1038/s41571-020-0340-z; Schaefer T, 2020, ONCOGENE, V39, P278, DOI 10.1038/s41388-019-0997-x; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang ZA, 2013, NAT CELL BIOL, V15, P274, DOI 10.1038/ncb2697; Wei X, 2019, CELL STEM CELL, V24, P753, DOI 10.1016/j.stem.2019.03.010; Won OJ, 2016, J CLIN INVEST, V126, P2626, DOI 10.1172/JCI84637; Xin L, 2019, ADV EXP MED BIOL, V1210, P67, DOI 10.1007/978-3-030-32656-2_4; Yu X, 2014, PROSTATE CANCER P D, V17, P301, DOI 10.1038/pcan.2014.29; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Zhang DX, 2018, STEM CELL REP, V10, P228, DOI 10.1016/j.stemcr.2017.11.016; Zhang L, 2012, TRANSGENIC RES, V21, P1117, DOI 10.1007/s11248-012-9598-y; Zhou ZX, 2007, CANCER RES, V67, P5683, DOI 10.1158/0008-5472.CAN-07-0768; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	45	13	13	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					203	214		10.1038/s41388-020-01526-2	http://dx.doi.org/10.1038/s41388-020-01526-2		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33110232	Green Accepted			2022-12-17	WOS:000582768100003
J	Li, HW; Zhao, LX; Lau, YS; Zhang, C; Han, RZ				Li, Haiwen; Zhao, Lixia; Lau, Yeh Siang; Zhang, Chen; Han, Renzhi			Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth	ONCOGENE			English	Article							MOUSE MODEL; CANCER; COLITIS; INACTIVATION; INFLAMMATION; GALECTINS; TISSUE; ROLES; STAT3; ROS	Colorectal cancer is the third leading cause of cancer-related deaths in the United States and the third most common cancer in men and women. Around 20% colon cancer cases are closely linked with colitis. Both environmental and genetic factors are thought to contribute to colon inflammation and tumor development. However, the genetic factors regulating colitis and colon tumorigenesis remain elusive. Since reactive oxygen species (ROS) is vitally involved in tissue inflammation and tumorigenesis, here we employed a genome-wide CRISPR knockout screening approach to systemically identify the genetic factors involved in the regulation of oxidative stress. Next generation sequencing (NGS) showed that over 600 gRNAs including the ones targeting LGALS2 were highly enriched in cells survived after sublethal H2O2 challenge. LGALS2 encodes the glycan-binding protein Galectin 2 (Gal2), which is predominantly expressed in the gastrointestinal tract and downregulated in human colon tumors. To examine the role of Gal2 in colitis, we employed the dextran sodium sulfate (DSS)-induced acute colitis model in mice with (WT) or without Lgals2 (Gal2-KO) and showed that Gal2 deficiency ameliorated DSS-induced colitis. We further demonstrated that Gal2-KO mice developed significantly larger tumors than WT mice using Azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced colorectal cancer model. We found that STAT3 phosphorylation was significantly increased in Gal2-deficient tumors as compared to those in WT mice. Gal2 overexpression decreased the proliferation of human colon tumor epithelial cells and blunted H2O2-induced STAT3 phosphorylation. Overall, our results demonstrate that Gal2 plays a suppressive role in colon tumor growth and highlights the therapeutic potential of Gal2 in colon cancer.	[Li, Haiwen; Zhao, Lixia; Lau, Yeh Siang; Zhang, Chen; Han, Renzhi] Ohio State Univ, Wexner Med Ctr, Biophys Grad Program, Davis Heart & Lung Res Inst,Biomed Sci Grad Progr, Columbus, OH 43210 USA; [Lau, Yeh Siang] Sunway Univ, Sch Healthcare & Med Sci, Bandar Sunway 47500, Selangor, Malaysia	University System of Ohio; Ohio State University; Sunway University	Han, RZ (corresponding author), Ohio State Univ, Wexner Med Ctr, Biophys Grad Program, Davis Heart & Lung Res Inst,Biomed Sci Grad Progr, Columbus, OH 43210 USA.	renzhi.han@osumc.edu		Han, Renzhi/0000-0002-8202-9186	US National Institutes of Health [R01 HL116546]; Parent Project Muscular Dystrophy award	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parent Project Muscular Dystrophy award	RH is supported by US National Institutes of Health Grant (R01 HL116546) and a Parent Project Muscular Dystrophy award. We thank Dr Chao Liu for assistance in bioinformatic analysis.	Akoumianakis I, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5055; Aran D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01027-z; Barrow H, 2011, CLIN CANCER RES, V17, P7035, DOI 10.1158/1078-0432.CCR-11-1462; Bi P, 2017, SCIENCE, V356, P323, DOI 10.1126/science.aam9361; Blaser H, 2016, TRENDS CELL BIOL, V26, P249, DOI 10.1016/j.tcb.2015.12.002; Califice S, 2004, ONCOGENE, V23, P7527, DOI 10.1038/sj.onc.1207997; Chen SD, 2015, CELL, V160, P1246, DOI 10.1016/j.cell.2015.02.038; COOPER HS, 1993, LAB INVEST, V69, P238; Diniz TC, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/171756; Dubreuil MM, 2020, CELL REP, V30, P1417, DOI 10.1016/j.celrep.2020.01.013; Fang BL, 2014, CANCERS, V6, P494, DOI 10.3390/cancers6010494; Francescone R, 2015, INFLAMM BOWEL DIS, V21, P409, DOI 10.1097/MIB.0000000000000236; Graham DB, 2020, NATURE, V578, P527, DOI 10.1038/s41586-020-2025-2; Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6; Guo JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007982; Han J, 2018, CELL REP, V23, P596, DOI 10.1016/j.celrep.2018.03.045; Hokama A, 2008, WORLD J GASTROENTERO, V14, P5133, DOI 10.3748/wjg.14.5133; Houessinon A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0526-2; Johannes L, 2018, J CELL SCI, V131, DOI 10.1242/jcs.208884; Jung JH, 2012, J GASTROENTEROL, V47, P37, DOI 10.1007/s00535-011-0463-1; Kalthoff S, 2010, J BIOL CHEM, V285, P5993, DOI 10.1074/jbc.M109.075770; Kennedy RJ, 2000, BRIT J SURG, V87, P1346, DOI 10.1046/j.1365-2168.2000.01615.x; Kim SW, 2013, CELL ONCOL, V36, P169, DOI 10.1007/s13402-013-0124-x; Kobayashi T, 2010, LEUKEMIA, V24, P843, DOI 10.1038/leu.2010.25; Langbein S, 2007, HISTOPATHOLOGY, V51, P681, DOI 10.1111/j.1365-2559.2007.02852.x; Li HW, 2019, FASEB J, V33, P2928, DOI 10.1096/fj.201801173R; Li Y, 2019, P NATL ACAD SCI USA, V116, P9527, DOI 10.1073/pnas.1900867116; Morgens DW, 2016, NAT BIOTECHNOL, V34, P634, DOI 10.1038/nbt.3567; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; Orr SL, 2013, GLYCOBIOLOGY, V23, P363, DOI 10.1093/glycob/cws150; Orsolic N, 2014, EUR J NUTR, V53, P1217, DOI 10.1007/s00394-013-0622-7; Paclik D, 2008, J MOL MED, V86, P1395, DOI 10.1007/s00109-007-0290-2; Park RJ, 2017, NAT GENET, V49, P193, DOI 10.1038/ng.3741; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Prasad S, 2017, CANCER LETT, V387, P95, DOI 10.1016/j.canlet.2016.03.042; Sakakura M, 2018, FEBS J, V285, P1129, DOI 10.1111/febs.14397; Satelli A, 2011, INT J CANCER, V129, P799, DOI 10.1002/ijc.25750; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shen YJ, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1137.1137; Srivastava J, 2016, MOL CARCINOGEN, V55, P1889, DOI 10.1002/mc.22438; Suzuki R, 2006, CARCINOGENESIS, V27, P162, DOI 10.1093/carcin/bgi205; Takaishi S, 2007, CANCER SCI, V98, P284, DOI 10.1111/j.1349-7006.2007.00392.x; Tamura M, 2016, J BIOCHEM, V160, P233, DOI 10.1093/jb/mvw029; Tamura M, 2015, BIOCHEM BIOPH RES CO, V457, P712, DOI 10.1016/j.bbrc.2015.01.055; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Tong Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034959; Xu J, 2018, J PATHOL CLIN RES, V4, P135, DOI 10.1002/cjp2.92; Xu J, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0069-z; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Yildirim C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124347; Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965	52	13	13	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					177	188		10.1038/s41388-020-01523-5	http://dx.doi.org/10.1038/s41388-020-01523-5		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33110234	Green Published, hybrid			2022-12-17	WOS:000582768100005
J	Leng, XJ; Wang, JF; An, N; Wang, X; Sun, YL; Chen, ZW				Leng, Xuejiao; Wang, Jianfeng; An, Na; Wang, Xue; Sun, Yile; Chen, Zhiwei			Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3	ONCOGENE			English	Article							UTX; CANCER; METHYLATION; ACTIVATION; EZH2; MUTATIONS; PATHWAY; GENES; H3	Aberrations in epigenetic modulation dysregulate transcription, playing a critical role in the developmental process of tumors, including lung cancer. Aberrant levels of the histone 3 lysine-27 demethylase KDM6A have been found in cancer and are either positively or negatively associated with tumorigenesis and prognosis. However, the clinical relevance and functional role of KDM6A in lung cancer is largely unknown. We found that KDM6A protein expression was higher in NSCLC tissues than in the corresponding paracancer tissues and that high KDM6A expression was associated with poor patient prognosis. Furthermore, KDM6A knockdown in NSCLC cell lines markedly inhibited the tumorigenic phenotype both in vitro and in vivo. Mechanistically, KDM6A colocalized and cooperated with KMT2B to reprogram the transcriptional network via regulating the cancer pathway, in which abnormal activation of the Wnt pathway is the dominant factor. Interestingly, in NSCLC cell lines, H3K4me3 but not H3K27me2/3 or H3K4me1/2 was markedly altered upon KDM6A or KMT2B knockdown, indicating that KDM6A may act independently of H3K27 demethylases in NSCLC. Taken together, these results indicated that KDM6A or KMT2B may be a prognostic biomarker and promising therapeutic target in NSCLC.	[Leng, Xuejiao; An, Na; Wang, Xue; Sun, Yile; Chen, Zhiwei] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai, Peoples R China; [Wang, Jianfeng] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, ZW (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai, Peoples R China.	drchenzhiwei@163.com		chen, zhiwei/0000-0002-6027-3575	National Natural Science Foundation of China [81572250]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by National Natural Science Foundation of China (Grant no. 81572250).	Ahuja N, 2016, ANNU REV MED, V67, P73, DOI 10.1146/annurev-med-111314-035900; Akiri G, 2009, ONCOGENE, V28, P2163, DOI 10.1038/onc.2009.82; Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Chen YC, 2018, COMPUT STRUCT BIOTEC, V16, P211, DOI 10.1016/j.csbj.2018.06.001; Cho Ju Hwan, 2017, Curr Pharmacol Rep, V3, P360; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Ezponda T, 2017, CELL REP, V21, P628, DOI 10.1016/j.celrep.2017.09.078; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Gridelli C, 2015, NAT REV DIS PRIMERS, V1, DOI [10.1038/nrdp.2015.9, 10.1038/nrdp.2015.48]; Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]; Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06; Jankowska AM, 2011, BLOOD, V118, P3932, DOI 10.1182/blood-2010-10-311019; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Li SH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010297; Li X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04769-6; Liao LL, 2015, CANCER GENET-NY, V208, P206, DOI 10.1016/j.cancergen.2015.02.008; Mansour AA, 2012, NATURE, V488, P409, DOI 10.1038/nature11272; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Ng L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080826; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Shpargel KB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002964; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Tang X, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0841-y; Toh TB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0596-9; Van der Meulen J, 2015, BLOOD, V125, P13, DOI 10.1182/blood-2014-05-577270; Van der Meulen J, 2014, EPIGENETICS-US, V9, P658, DOI 10.4161/epi.28298; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Wang CC, 2012, P NATL ACAD SCI USA, V109, P15324, DOI 10.1073/pnas.1204166109; Wang L, 2019, CANCER CELL, V35, P168, DOI 10.1016/j.ccell.2019.01.001; Xu BW, 2015, EXP HEMATOL, V43, P698, DOI 10.1016/j.exphem.2015.05.001; Zhang C, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0731-8	40	13	13	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6468	6479		10.1038/s41388-020-01449-y	http://dx.doi.org/10.1038/s41388-020-01449-y		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879445				2022-12-17	WOS:000565482600003
J	Liu, HP; Gruber, CW; Alewood, PF; Moller, A; Muttenthaler, M				Liu, Huiping; Gruber, Christian W.; Alewood, Paul F.; Moller, Andreas; Muttenthaler, Markus			The oxytocin receptor signalling system and breast cancer: a critical review	ONCOGENE			English	Review							PROTEIN-COUPLED RECEPTORS; MAMMARY-GLAND; GENE-EXPRESSION; CELL-GROWTH; PHYSICAL-EXERCISE; CARCINOMA CELLS; BLOOD-PRESSURE; RESEARCH TOOLS; REDUCED RISK; TUMOR-GROWTH	Breast cancer is making up one-quarter of all new female cancer cases diagnosed worldwide. Breast cancer surgeries, radiation therapies, cytotoxic chemotherapies and targeted therapies have made significant progress and play a dominant role in breast cancer patient management. However, many challenges remain, including resistance to systemic therapies, tumour recurrence and metastasis. The cyclic neuropeptide oxytocin (OT) elicits a plethora of biological responses via the oxytocin receptor (OTR) in both the central and peripheral nervous system, including social bonding, stress, maternal behaviour, sexual activity, uterus contraction, milk ejection and cancer. As a typical member of the G protein-coupled receptor family, OTR represents also an intriguing target for cancer therapy. There is emerging evidence that OTR plays a role in breast cancer development and progression, and several breast cancer cell lines express OTR. However, despite supporting evidence that OT lowers breast cancer risks, its mechanistic role in breast cancer development and the related signalling pathways are not fully understood. Here, we review the current knowledge of the OT/OTR signalling system in healthy breast tissue as well as in breast cancer, and discuss OTR as a potential therapeutic target for breast cancer management.	[Liu, Huiping; Alewood, Paul F.; Muttenthaler, Markus] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Gruber, Christian W.] Med Univ Vienna, Ctr Physiol & Pharmacol, A-1090 Vienna, Austria; [Moller, Andreas] QIMR Berghofer Med Res Inst, Tumour Microenvironm Lab, Herston, Qld 4006, Australia; [Muttenthaler, Markus] Univ Vienna, Fac Chem, Inst Biol Chem, A-1090 Vienna, Austria	University of Queensland; Medical University of Vienna; QIMR Berghofer Medical Research Institute; University of Vienna	Muttenthaler, M (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.; Muttenthaler, M (corresponding author), Univ Vienna, Fac Chem, Inst Biol Chem, A-1090 Vienna, Austria.	markus.muttenthaler@univie.ac.at	Muttenthaler, Markus/AAF-5944-2021; Liu, Huiping/C-3428-2018	Muttenthaler, Markus/0000-0003-1996-4646; Liu, Huiping/0000-0003-0317-9029; Gruber, Christian/0000-0001-6060-7048	European Research Council under the European Union [714366]; Australian Research Council [DP190101667]; Cancer Australia; Cancer Council Queensland [1146504]; National Breast Cancer Foundation Australia [IIRS-18-159]; Austrian Science Fund (FWF) [I3243, P32109]; Research Training Scholarship of The University of Queensland	European Research Council under the European Union(European Research Council (ERC)); Australian Research Council(Australian Research Council); Cancer Australia; Cancer Council Queensland(Cancer Council Queensland); National Breast Cancer Foundation Australia; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Research Training Scholarship of The University of Queensland	Funding supporting the studies are listed as follows: MM was supported by the European Research Council under the European Union's Horizon 2020 research and innovation program (714366) and by the Australian Research Council (DP190101667). MM, PFA and AM were supported by grants from Cancer Australia and Cancer Council Queensland (1146504). AM was supported by a grant from the National Breast Cancer Foundation Australia (IIRS-18-159). CWG has been supported by the Austrian Science Fund (FWF) through projects I3243 and P32109. HL is supported by the Research Training Scholarship of The University of Queensland.	Alizadeh AM, 2018, EXP PHYSIOL, V103, P222, DOI 10.1113/EP086463; Amico JA, 2002, ENDOCRINE, V18, P79, DOI 10.1385/ENDO:18:1:79; Benavente MA, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00119; Aoyagi T, 2009, KIDNEY INT, V76, P1035, DOI 10.1038/ki.2009.319; Ariana M, 2019, PERS MED, V16, P25, DOI 10.2217/pme-2018-0009; Bankir L, 2017, J INTERN MED, V282, P284, DOI 10.1111/joim.12645; Benavente MA, 2019, J COMP PATHOL, V170, P26, DOI 10.1016/j.jcpa.2019.05.005; BENSON GK, 1957, J ENDOCRINOL, V16, P189, DOI 10.1677/joe.0.0160189; Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0; BERNSTEIN L, 1994, J NATL CANCER I, V86, P1403, DOI 10.1093/jnci/86.18.1403; Berryhill GE, 2016, J DAIRY SCI, V99, P875, DOI 10.3168/jds.2015-10105; Biyikli NK, 2006, PEPTIDES, V27, P2249, DOI 10.1016/j.peptides.2006.03.029; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Breton C, 2001, J MOL ENDOCRINOL, V27, P175, DOI 10.1677/jme.0.0270175; Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178; Busnelli M, 2016, J MED CHEM, V59, P7152, DOI 10.1021/acs.jmedchem.6b00564; Busnelli M, 2012, J BIOL CHEM, V287, P3617, DOI 10.1074/jbc.M111.277178; Busnelli M, 2010, FERTIL STERIL, V94, P1869, DOI 10.1016/j.fertnstert.2009.10.064; Bussolati G, 1996, AM J PATHOL, V148, P1895; Bussolati G, 2001, CANCER RES, V61, P4393; CARMICHAEL MS, 1987, J CLIN ENDOCR METAB, V64, P27, DOI 10.1210/jcem-64-1-27; Cassoni P, 2006, INT J ONCOL, V28, P1263; Cassoni P, 2002, INT J ONCOL, V21, P375; Cassoni P, 2002, CANCER RES, V62, P2406; Cassoni P, 2001, ANN ONCOL, V12, pS37, DOI 10.1093/annonc/12.suppl_2.S37; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; CASSONI P, 1994, VIRCHOWS ARCH, V425, P467; Cassoni P, 1996, INT J CANCER, V66, P817, DOI 10.1002/(SICI)1097-0215(19960611)66:6<817::AID-IJC18>3.0.CO;2-#; Cassoni P, 1998, INT J CANCER, V77, P695, DOI 10.1002/(SICI)1097-0215(19980831)77:5<695::AID-IJC6>3.0.CO;2-Q; Cassoni P, 2000, J PATHOL, V190, P470, DOI 10.1002/(SICI)1096-9896(200003)190:4<470::AID-PATH550>3.0.CO;2-G; Cassoni P, 2006, MOL CANCER RES, V4, P351, DOI 10.1158/1541-7786.MCR-06-0024; Cavallaro G, 2007, EUR J PHARM BIOPHARM, V66, P182, DOI 10.1016/j.ejpb.2006.10.013; Chini B, 2003, BRIT J CANCER, V89, P930, DOI 10.1038/sj.bjc.6601189; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; Conti F, 2009, AM J PHYSIOL-ENDOC M, V296, pE532, DOI 10.1152/ajpendo.90590.2008; Copland JA, 1999, ENDOCRINOLOGY, V140, P2258, DOI 10.1210/en.140.5.2258; de Araujo AD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4165; de Jong TR, 2015, PSYCHONEUROENDOCRINO, V62, P381, DOI 10.1016/j.psyneuen.2015.08.027; De Silva M, 2010, CANCER EPIDEMIOL, V34, P267, DOI 10.1016/j.canep.2010.02.012; DEMBINSKI TC, 1985, CANCER RES, V45, P3083; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DHONDT G, 1977, PROSTAGLANDINS, V13, P1185, DOI 10.1016/0090-6980(77)90144-7; Di Giglio MG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41002; Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Duerrauer L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55675-w; Dutertre S, 2008, J BIOL CHEM, V283, P7100, DOI 10.1074/jbc.M706477200; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fay MJ, 1999, RES COMMUN MOL PATH, V103, P115; Friedenreich CM, 2011, RECENT RESULTS CANC, V188, P125, DOI 10.1007/978-3-642-10858-7_11; Garona J, 2016, CLIN EXP METASTAS, V33, P589, DOI 10.1007/s10585-016-9799-5; GAZIS D, 1978, P SOC EXP BIOL MED, V158, P663; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Gimpl G, 2008, EXPERT OPIN THER PAT, V18, P1239, DOI 10.1517/13543776.18.11.1239; Graf C, 2010, BREAST CARE, V5, P389, DOI 10.1159/000322650; Grotegut CA, 2011, AM J PHYSIOL-ENDOC M, V300, pE468, DOI 10.1152/ajpendo.00390.2010; Gruber CW, 2012, FUTURE MED CHEM, V4, P1791, DOI [10.4155/FMC.12.108, 10.4155/fmc.12.108]; Gruber CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032559; Guzzi F, 2002, ONCOGENE, V21, P1658, DOI 10.1038/sj.onc.1205219; Hassiotou F, 2013, CLIN ANAT, V26, P29, DOI 10.1002/ca.22165; Imanieh MH, 2014, EUR J PHARMACOL, V741, P112, DOI 10.1016/j.ejphar.2014.07.053; Iseri SO, 2005, J SURG RES, V126, P73, DOI 10.1016/j.jss.2005.01.021; Ito Y, 1996, ENDOCRINOLOGY, V137, P773, DOI 10.1210/en.137.2.773; Ivell R, 2001, EXP PHYSIOL, V86, P289, DOI 10.1113/eph8602185; Jean-Charles PY, 2017, J CARDIOVASC PHARM, V70, P142, DOI 10.1097/FJC.0000000000000482; Jurek B, 2018, PHYSIOL REV, V98, P1805, DOI 10.1152/physrev.00031.2017; Katritch V, 2012, TRENDS PHARMACOL SCI, V33, P17, DOI 10.1016/j.tips.2011.09.003; Keegan BP, 2006, BREAST CANCER RES TR, V95, P265, DOI 10.1007/s10549-005-9024-8; Khori V, 2018, PEPTIDES, V107, P54, DOI 10.1016/j.peptides.2018.07.007; KIMURA T, 1994, EUR J ENDOCRINOL, V131, P385, DOI 10.1530/eje.0.1310385; Klein BY, 2011, J CELL BIOCHEM, V112, P3216, DOI 10.1002/jcb.23243; Knols R, 2005, J CLIN ONCOL, V23, P3830, DOI 10.1200/JCO.2005.02.148; Koehbach J, 2013, P NATL ACAD SCI USA, V110, P21183, DOI 10.1073/pnas.1311183110; Koehbach J, 2013, BIOCHEM SOC T, V41, P197, DOI 10.1042/BST20120256; Kovtun O, 2015, J CELL SCI, V128, P1269, DOI 10.1242/jcs.167866; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; LANDGRAF R, 1982, ENDOKRINOLOGIE, V79, P281; LE MG, 1989, J CLIN EPIDEMIOL, V42, P1227, DOI 10.1016/0895-4356(89)90121-2; Lerman B, 2018, WORLD J CLIN ONCOL, V9, P74, DOI 10.5306/wjco.v9.i5.74; Li D, 2018, J ENDOCRINOL, V239, P121, DOI [10.1530/JOE-18-0356, 10.1530/joe-18-0356]; Li T, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00693; Macias H, 2012, WIRES DEV BIOL, V1, P533, DOI 10.1002/wdev.35; Manning M, 2012, J NEUROENDOCRINOL, V24, P609, DOI 10.1111/j.1365-2826.2012.02303.x; Manning M, 2008, PROG BRAIN RES, V170, P473, DOI 10.1016/S0079-6123(08)00437-8; Martinez JM, 1999, CLIN CHEM, V45, P1797; MCCANN SM, 1959, ENDOCRINOLOGY, V64, P870, DOI 10.1210/endo-64-6-870; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Morita T, 2004, INT J CANCER, V109, P525, DOI 10.1002/ijc.20017; MURRELL TGC, 1995, BREAST CANCER RES TR, V35, P225, DOI 10.1007/BF00668213; MUSTACCHI P, 1961, ARCH INTERN MED, V108, P639, DOI 10.1001/archinte.1961.03620100131018; Muttenthaler M, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan3398; Muttenthaler M, 2010, J MED CHEM, V53, P8585, DOI 10.1021/jm100989w; Nakano H, 2001, PFLUG ARCH EUR J PHY, V442, P57, DOI 10.1007/s004240100521; Nation DA, 2010, PSYCHOSOM MED, V72, P376, DOI 10.1097/PSY.0b013e3181d74c48; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; NISSENSON R, 1978, P NATL ACAD SCI USA, V75, P2044, DOI 10.1073/pnas.75.4.2044; OTA K, 1962, NATURE, V195, P77, DOI 10.1038/195077b0; Pandy-Szekeres G, 2018, NUCLEIC ACIDS RES, V46, pD440, DOI 10.1093/nar/gkx1109; Passoni I, 2016, J NEUROENDOCRINOL, V28, DOI 10.1111/jne.12363; Patel AV, 2003, CANCER CAUSE CONTROL, V14, P519, DOI 10.1023/A:1024895613663; PDQ Screening and Prevention Editorial Board, 2002, PDQ CANC INFORM SUMM; Pequeux C, 2004, ENDOCR-RELAT CANCER, V11, P871, DOI 10.1677/erc.1.00803; Petersson M, 2002, PEPTIDES, V23, P1121, DOI 10.1016/S0196-9781(02)00041-4; Petersson M, 2008, REGUL PEPTIDES, V150, P50, DOI 10.1016/j.regpep.2008.02.007; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Carrera-Gonzalez MP, 2011, TUMOR BIOL, V32, P543, DOI 10.1007/s13277-010-0149-y; Plested CP, 2001, EXP PHYSIOL, V86, P303, DOI 10.1113/eph8602187; Prevost M, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00001; Purwanto H, 2000, Gan To Kagaku Ryoho, V27 Suppl 2, P474; Renoir JM, 2013, BIOCHEM PHARMACOL, V85, P449, DOI 10.1016/j.bcp.2012.10.018; Reversi A, 2005, J BIOL CHEM, V280, P16311, DOI 10.1074/jbc.M409945200; Rimoldi V, 2003, ONCOGENE, V22, P6054, DOI 10.1038/sj.onc.1206612; Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002; Robinson VC, 2015, MED HYPOTHESES, V85, P976, DOI 10.1016/j.mehy.2015.09.002; Sanborn BM, 2005, J SOC GYNECOL INVEST, V12, P479, DOI 10.1016/j.jsgi.2005.07.002; Sapino A, 1998, ANTICANCER RES, V18, P2181; SAPINO A, 1993, ENDOCRINOLOGY, V133, P838, DOI 10.1210/en.133.2.838; Seyedabadi M, 2019, PHARMACOL THERAPEUT, V200, P148, DOI 10.1016/j.pharmthera.2019.05.006; Shukla AK, 2011, TRENDS BIOCHEM SCI, V36, P457, DOI 10.1016/j.tibs.2011.06.003; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Smith JS, 2018, NAT REV DRUG DISCOV, V17, P243, DOI 10.1038/nrd.2017.229; Smith MP, 2006, MOL ENDOCRINOL, V20, P379, DOI 10.1210/me.2005-0031; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; Strunecka A, 2009, FOLIA BIOL-PRAGUE, V55, P159; Sugawara Y, 2013, EUR J CANCER PREV, V22, P187, DOI 10.1097/CEJ.0b013e3283564610; Svennersten-Sjaunja K, 2005, DOMEST ANIM ENDOCRIN, V29, P241, DOI 10.1016/j.domaniend.2005.03.006; Szeto A, 2013, PSYCHONEUROENDOCRINO, V38, P685, DOI 10.1016/j.psyneuen.2012.08.009; Szeto A, 2008, AM J PHYSIOL-ENDOC M, V295, pE1495, DOI 10.1152/ajpendo.90718.2008; Tahara M, 2002, ENDOCRINOLOGY, V143, P920, DOI 10.1210/en.143.3.920; Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102; Takeda S, 1989, Nihon Naibunpi Gakkai Zasshi, V65, P182; Tang ZR, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101123; TAYLOR AH, 1990, CANCER RES, V50, P7882; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Uvnas-Moberg K, 1990, ACTA OBSTET GYN SCAN, V69, P301, DOI 10.3109/00016349009036151; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x; Vrachnis N, 2011, INT J ENDOCRINOL, V2011, DOI 10.1155/2011/350546; Wagner Kay-Uwe, 1997, Genes and Function, V1, P233; Wang P, 2015, J NEUROIMMUNOL, V289, P152, DOI 10.1016/j.jneuroim.2015.11.001; Wang YF, 2007, J NEUROSCI, V27, P1902, DOI 10.1523/JNEUROSCI.5346-06.2007; Wheatley M, 1997, BIOCHEM SOC T, V25, P1046, DOI 10.1042/bst0251046; Whittington K, 2007, PROSTATE, V67, P1132, DOI 10.1002/pros.20612; Xu H, 2017, ONCOTARGET, V8, P31215, DOI 10.18632/oncotarget.16107; Yip CH, 2014, FUTURE ONCOL, V10, P2293, DOI 10.2217/fon.14.110; YOKOYAMA AKIRA, 1959, ENDOCRINOL JAPON, V6, P268; Zhong M, 2003, ENDOCRINOLOGY, V144, P2947, DOI 10.1210/en.2002-221039; Zhou XB, 2007, MOL ENDOCRINOL, V21, P740, DOI 10.1210/me.2006-0220; Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043-2760(03)00080-8	153	13	14	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5917	5932		10.1038/s41388-020-01415-8	http://dx.doi.org/10.1038/s41388-020-01415-8		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32782397	Green Published, hybrid			2022-12-17	WOS:000558632600001
J	Bajaj, R; Kundu, ST; Grzeskowiak, CL; Fradette, JJ; Scott, KL; Creighton, CJ; Gibbons, DL				Bajaj, Rakhee; Kundu, Samrat T.; Grzeskowiak, Caitlin L.; Fradette, Jared J.; Scott, Kenneth L.; Creighton, Chad J.; Gibbons, Don L.			IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion	ONCOGENE			English	Article							LIGASE CBL-B; MIR-200 FAMILY; ORGANIZATION; TRAFFICKING; PATHWAY; TARGET; BREAST	Non-small cell lung cancer (NSCLC) is the deadliest form of cancer worldwide, due in part to its proclivity to metastasize. Identifying novel drivers of invasion and metastasis holds therapeutic potential for the disease. We conducted a gain-of-function invasion screen, which identified two separate hits, IMPAD1 and KDELR2, as robust, independent drivers of lung cancer invasion and metastasis. Given that IMPAD1 and KDELR2 are known to be localized to the ER-Golgi pathway, we studied their common mechanism of driving in vitro invasion and in vivo metastasis and demonstrated that they enhance Golgi-mediated function and secretion. Therapeutically inhibiting matrix metalloproteases (MMPs) suppressed both IMPAD1- and KDELR2-mediated invasion. The hits from this unbiased screen and the mechanistic validation highlight Golgi function as one of the key cellular features altered during invasion and metastasis.	[Bajaj, Rakhee; Kundu, Samrat T.; Fradette, Jared J.; Gibbons, Don L.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Grzeskowiak, Caitlin L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA; [Grzeskowiak, Caitlin L.; Scott, Kenneth L.; Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Med, Houston, TX 77030 USA; [Gibbons, Don L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Kundu, ST; Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	skundu@mdanderson.org; dlgibbon@mdanderson.org		Fradette, Jared/0000-0001-6712-2860; Kundu, Samrat/0000-0002-0117-6986; Bajaj, Rakhee/0000-0002-9990-1655	DoD CDMRP Lung cancer [W81XWH-12-16294]; NIH/NCI [K08 CA151651]; NIH [R37CA214609]; MD Anderson Physician-Scientist Program; Rexanna's Foundation for Fighting Lung Cancer; Jeane F. Shelby Scholarship Fund; generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program	DoD CDMRP Lung cancer; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson Physician-Scientist Program; Rexanna's Foundation for Fighting Lung Cancer; Jeane F. Shelby Scholarship Fund; generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program	This work was supported by the DoD CDMRP Lung cancer research award W81XWH-12-16294 (DLG and KLS), NIH/NCI K08 CA151651, NIH R37CA214609, the MD Anderson Physician-Scientist Program and Rexanna's Foundation for Fighting Lung Cancer (DLG). DLG is an R. Lee Clark Fellow of the University of Texas MD Anderson Cancer Center, supported by the Jeane F. Shelby Scholarship Fund. The work was also supported by the generous philanthropic contributions to The University of Texas MD Anderson Lung Cancer Moon Shots Program. We would like to thank the UTMDACC Department of Veterinary Medicine Facility.	Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; Bogdanov Alexey, 2017, F1000Res, V6, P10, DOI 10.12688/f1000research.10481.1; Brandizzi F, 2013, NAT REV MOL CELL BIO, V14, P382, DOI 10.1038/nrm3588; Cancino J, 2013, HISTOCHEM CELL BIOL, V140, P395, DOI 10.1007/s00418-013-1130-9; Capitani M, 2009, FEBS LETT, V583, P3863, DOI 10.1016/j.febslet.2009.10.053; Feizi A, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0021-4; Frederick JP, 2008, P NATL ACAD SCI USA, V105, P11605, DOI 10.1073/pnas.0801182105; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gibbons DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005401; Grzeskowiak CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04572-3; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Halberg N, 2016, CANCER CELL, V29, P339, DOI 10.1016/j.ccell.2016.02.013; HANDLER JS, 1989, ANNU REV PHYSIOL, V51, P729, DOI 10.1146/annurev.ph.51.030189.003501; Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046; Khajah MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193779; Kundu ST, 2016, ONCOGENE, V35, P173, DOI 10.1038/onc.2015.71; Kundu ST, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05013-x; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Martinotti S, 2020, METHODS MOL BIOL, V2109, P225, DOI 10.1007/7651_2019_259; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Ochieng JK, 2020, ONCOGENE; Pangon L, 2016, ONCOGENE, V35, P2834, DOI 10.1038/onc.2015.347; Paolino M, 2014, NATURE, V507, P508, DOI 10.1038/nature12998; Parris TZ, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.8; Plasterer C, 2019, G3-GENES GENOM GENET, V9, P1739, DOI 10.1534/g3.118.200873; Rodriguez-Boulan E, 2014, NAT REV MOL CELL BIO, V15, P225, DOI 10.1038/nrm3775; Ruggiero Carmen, 2018, Oncotarget, V9, P10228, DOI 10.18632/oncotarget.23421; Ruggiero C, 2015, ONCOTARGET, V6, P3375, DOI 10.18632/oncotarget.3270; Sbai O, 2008, MOL CELL NEUROSCI, V39, P549, DOI 10.1016/j.mcn.2008.08.004; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Sohaskey ML, 2008, DEVELOPMENT, V135, P2215, DOI 10.1242/dev.019950; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Tan XC, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax3772; Tan XC, 2017, J CLIN INVEST, V127, P117, DOI 10.1172/JCI88736; Tang CH, 2009, PROSTATE, V69, P1781, DOI 10.1002/pros.21029; Taylor A, 2016, J VIROL, V90, P4150, DOI 10.1128/JVI.03192-15; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Viotti C, 2016, METHODS MOL BIOL, V1459, P3, DOI 10.1007/978-1-4939-3804-9_1; Vissers LELM, 2011, AM J HUM GENET, V88, P608, DOI 10.1016/j.ajhg.2011.04.002; Wiersma VR, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00007; Wu XM, 2012, ONCOL REP, V27, P1488, DOI 10.3892/or.2012.1670; Xu L, 2017, NEOPLASIA, V19, P374, DOI 10.1016/j.neo.2017.01.011	45	13	13	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5979	5994		10.1038/s41388-020-01410-z	http://dx.doi.org/10.1038/s41388-020-01410-z		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32753652	Green Accepted			2022-12-17	WOS:000555747100001
J	Feng, H; Liu, J; Qiu, YY; Liu, Y; Saiyin, H; Liang, X; Zheng, F; Wang, Y; Jiang, DK; Wang, Y; Yu, L; Su, W; Shen, SQ; Wu, JX				Feng, Huan; Liu, Juan; Qiu, Yangyang; Liu, Yao; Saiyin, Hexig; Liang, Xiao; Zheng, Fen; Wang, Ying; Jiang, Deke; Wang, Ying; Yu, Long; Su, Wei; Shen, Suqin; Wu, Jiaxue			RNA-binding motif protein 43 (RBM43) suppresses hepatocellular carcinoma progression through modulation of cyclin B1 expression	ONCOGENE			English	Article							CELL-CYCLE; MESSENGER-RNA; PROLIFERATION; APOPTOSIS	RNA-binding proteins play key roles in the posttranscriptional regulation of mRNA during cancer progression. Here, we show that RNA-binding motif protein 43 (RBM43) is significantly downregulated in human tumors, and its low expression is correlated with poor prognosis in patients with HCC. Overexpression of RBM43 suppressed cell proliferation in culture and resulted in the growth arrest of tumor xenografts, whereas downregulating RBM43 played an opposite role. We have also demonstrated that overexpression or knockdown of RBM43 affects the cell-cycle progression of liver cancer cells. Mechanistically, RBM43 directly associated with the 3 ' UTR of Cyclin B1 mRNA and regulated its expression. Moreover, loss ofRbm43in mice promoted liver carcinogenesis and HCC development after diethylnitrosamine (DEN)-carbon tetrachloride (CCl4) treatment. Taken together, our data indicate that RBM43 is a tumor suppressor that controls the cell cycle through modulation of Cyclin B1 expression, providing evidence that RBM43 is particularly important in HCC.	[Feng, Huan; Liu, Juan; Qiu, Yangyang; Liu, Yao; Saiyin, Hexig; Liang, Xiao; Zheng, Fen; Wang, Ying; Yu, Long; Su, Wei; Shen, Suqin; Wu, Jiaxue] Fudan Univ, Zhongshan Hosp, State Key Lab Genet Engn, Shanghai, Peoples R China; [Feng, Huan; Liu, Juan; Qiu, Yangyang; Liu, Yao; Saiyin, Hexig; Liang, Xiao; Zheng, Fen; Wang, Ying; Yu, Long; Su, Wei; Shen, Suqin; Wu, Jiaxue] Fudan Univ, Sch Life Sci, Shanghai, Peoples R China; [Jiang, Deke] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China; [Jiang, Deke] Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Peoples R China; [Wang, Ying] Second Mil Med Univ, Changhai Hosp, Dept Oncol, Shanghai, Peoples R China	Fudan University; Fudan University; Southern Medical University - China; Southern Medical University - China; Naval Medical University	Shen, SQ; Wu, JX (corresponding author), Fudan Univ, Zhongshan Hosp, State Key Lab Genet Engn, Shanghai, Peoples R China.; Shen, SQ; Wu, JX (corresponding author), Fudan Univ, Sch Life Sci, Shanghai, Peoples R China.	shensq@fudan.edu.cn; jiaxue@fudan.edu.cn		Saiyin, Hexige/0000-0003-2993-6817; Jiang, Deke/0000-0002-7888-2344	National Natural Science Foundation of China [81702742, 81972712]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81702742 to SS and 81972712 to JW).	Aaltonen K, 2009, BRIT J CANCER, V100, P1055, DOI 10.1038/sj.bjc.6604874; Albertsen HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058257; Castello A, 2012, CELL, V149, P1393, DOI 10.1016/j.cell.2012.04.031; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Covini G, 1997, HEPATOLOGY, V25, P75; Dang H, 2017, CANCER CELL, V32, P101, DOI 10.1016/j.ccell.2017.06.002; Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007; Denicourt C, 2004, GENE DEV, V18, P851, DOI 10.1101/gad.1205304; Dong J, 2018, CLIN GASTROENTEROL H, V16, P1598, DOI 10.1016/j.cgh.2018.03.007; Egloff AM, 2005, ANN NY ACAD SCI, V1062, P29, DOI 10.1196/annals.1358.005; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813; Glisovic T, 2008, FEBS LETT, V582, P1977, DOI 10.1016/j.febslet.2008.03.004; Guan MJ, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0205-7; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130; Jiang DK, 2013, NAT GENET, V45, P72, DOI 10.1038/ng.2483; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Nakahata S, 2003, MECH DEVELOP, V120, P865, DOI 10.1016/S0925-4773(03)00160-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Sakurai T, 2016, ONCOGENE, V35, P5000, DOI 10.1038/onc.2016.35; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Takahashi K, 2018, BIOCHEM BIOPH RES CO, V503, P2778, DOI 10.1016/j.bbrc.2018.08.039; Van Assche E, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00141; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang Y, 2014, CANCER CELL, V26, P374, DOI 10.1016/j.ccr.2014.07.010; Wang ZQ, 2014, DEV CELL, V29, P217, DOI 10.1016/j.devcel.2014.03.012; Zhang H, 2019, J CELL PHYSIOL, V234, P619, DOI 10.1002/jcp.26816; Zhao LJ, 2019, NUCLEIC ACIDS RES, V47, P2011, DOI 10.1093/nar/gky1209	30	13	14	3	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5495	5506		10.1038/s41388-020-1380-7	http://dx.doi.org/10.1038/s41388-020-1380-7		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32632220				2022-12-17	WOS:000546748200001
J	Simoes, BM; Santiago-Gomez, A; Chiodo, C; Moreira, T; Conole, D; Lovell, S; Alferez, D; Eyre, R; Spence, K; Sarmiento-Castro, A; Kohler, B; Morisset, L; Lanzino, M; Ando, S; Marangoni, E; Sims, AH; Tate, EW; Howell, SJ; Clarke, RB				Simoes, Bruno M.; Santiago-Gomez, Angelica; Chiodo, Chiara; Moreira, Tiago; Conole, Daniel; Lovell, Scott; Alferez, Denis; Eyre, Rachel; Spence, Katherine; Sarmiento-Castro, Aida; Kohler, Bertram; Morisset, Ludivine; Lanzino, Marilena; Ando, Sebastiano; Marangoni, Elisabetta; Sims, Andrew H.; Tate, Edward W.; Howell, Sacha J.; Clarke, Robert B.			Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer	ONCOGENE			English	Article							PROMOTES TAMOXIFEN RESISTANCE; THERAPY; MAMMOSPHERE; PROGRESSION; ESTROGEN; TUMORS; GENE	Estrogen receptor (ER) positive breast cancer is frequently sensitive to endocrine therapy. Multiple mechanisms of endocrine therapy resistance have been identified, including cancer stem-like cell (CSC) activity. Here we investigate SFX-01, a stabilised formulation of sulforaphane (SFN), for its effects on breast CSC activity in ER+ preclinical models. SFX-01 reduced mammosphere formation efficiency (MFE) of ER+ primary and metastatic patient samples. Both tamoxifen and fulvestrant increased MFE and aldehyde dehydrogenase (ALDH) activity of patient-derived xenograft (PDX) tumors, which was reversed by combination with SFX-01. SFX-01 significantly reduced tumor-initiating cell frequency in secondary transplants and reduced the formation of spontaneous lung micrometastases by PDX tumors in mice. Mechanistically, we establish that both tamoxifen and fulvestrant induce STAT3 phosphorylation. SFX-01 suppressed phospho-STAT3 and SFN directly bound STAT3 in patient and PDX samples. Analysis of ALDH+ cells from endocrine-resistant patient samples revealed activation of STAT3 target genesMUC1andOSMR, which were inhibited by SFX-01 in patient samples. Increased expression of these genes after 3 months' endocrine treatment of ER+ patients (n = 68) predicted poor prognosis. Our data establish the importance of STAT3 signaling in CSC-mediated resistance to endocrine therapy and the potential of SFX-01 for improving clinical outcomes in ER+ breast cancer.	[Simoes, Bruno M.; Santiago-Gomez, Angelica; Chiodo, Chiara; Moreira, Tiago; Alferez, Denis; Eyre, Rachel; Spence, Katherine; Sarmiento-Castro, Aida; Kohler, Bertram; Howell, Sacha J.; Clarke, Robert B.] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Breast Biol Grp,Manchester Breast Ctr, Manchester, Lancs, England; [Chiodo, Chiara; Lanzino, Marilena; Ando, Sebastiano] Univ Calabria, Dept Pharm, Arcavacata Di Rende, Italy; [Conole, Daniel; Lovell, Scott; Tate, Edward W.] Imperial Coll, Mol Sci Res Hub, London, England; [Morisset, Ludivine; Marangoni, Elisabetta] PSL Res Univ, Inst Curie, Translat Res Dept, Paris, France; [Sims, Andrew H.] Univ Edinburgh, Appl Bioinformat Canc Grp, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland; [Howell, Sacha J.] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England	University of Manchester; University of Calabria; Imperial College London; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Edinburgh; Christie NHS Foundation Trust	Simoes, BM; Howell, SJ; Clarke, RB (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Breast Biol Grp,Manchester Breast Ctr, Manchester, Lancs, England.; Howell, SJ (corresponding author), Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England.	bruno.simoes@manchester.ac.uk; sacha.howell@christie.nhs.uk; robert.clarke@manchester.ac.uk	Simoes, Bruno/AAB-2582-2019; Marangoni, Elisabetta/GSO-3945-2022; Conole, Daniel/ABA-6423-2021; Clarke, Robert/AAA-3442-2021	Simoes, Bruno/0000-0003-1253-6657; Marangoni, Elisabetta/0000-0002-3337-6448; Conole, Daniel/0000-0002-3389-8377; Clarke, Robert/0000-0001-5407-3123; Santiago Gomez, Angelica/0000-0002-2946-2669; Tate, Edward/0000-0003-2213-5814; Moreira, Tiago/0000-0003-3817-7103	National Centre for the Replacement, Refinement and Reduction of Animals in Research [NC/T001267/1] Funding Source: Medline	National Centre for the Replacement, Refinement and Reduction of Animals in Research(UK Research & Innovation (UKRI)National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs))		Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158; Bui QT, 2017, CANCER LETT, V390, P115, DOI 10.1016/j.canlet.2017.01.014; Clarke JD, 2011, PHARM RES-DORDR, V28, P3171, DOI 10.1007/s11095-011-0500-z; Clulow JA, 2017, CHEM COMMUN, V53, P5182, DOI 10.1039/c6cc08797c; Cottu P, 2012, BREAST CANCER RES TR, V133, P595, DOI 10.1007/s10549-011-1815-5; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dagan IDFA, 2008, Stabilized sulforaphane, VWO2008091608A1, A61K 31/70 (2006.01) A61K 8/00 (2006.01) A61K 31/40 (2006.01, Patent No. 2008091608; Domenici G, 2019, ONCOGENE, V38, P3151, DOI 10.1038/s41388-018-0656-7; Dustin D, 2019, CANCER-AM CANCER SOC, V125, P3714, DOI 10.1002/cncr.32345; Eyre R, 2016, J MAMMARY GLAND BIOL, V21, P99, DOI 10.1007/s10911-016-9361-8; Franklin SJ, 2014, DRUG DEV IND PHARM, V40, P494, DOI 10.3109/03639045.2013.768634; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hong F, 2005, CHEM RES TOXICOL, V18, P1917, DOI 10.1021/tx0502138; HOWELL SJ, 2019, ANN ONCOL, V30, pv122, DOI DOI 10.1093/annonc/mdz242.036; Kettner NM, 2019, CLIN CANCER RES, V25, P3996, DOI 10.1158/1078-0432.CCR-18-3274; Kharbanda A, 2013, MOL CANCER RES, V11, P714, DOI 10.1158/1541-7786.MCR-12-0668; Li YY, 2010, CLIN CANCER RES, V16, P2580, DOI 10.1158/1078-0432.CCR-09-2937; Lin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082821; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Palmieri C, 2014, MOL CELL ENDOCRINOL, V382, P695, DOI 10.1016/j.mce.2013.08.001; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Parashar D, 2019, CELL REP, V29, P4389, DOI 10.1016/j.celrep.2019.11.085; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Pearce D.A., 2018, CONTINUOUS BIOMARKER, DOI [10.1101/208660, DOI 10.1101/208660]; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Sarmiento-Castro A, 2019, DORMANT SUBPOPULATIO, DOI [10.1101/821876, DOI 10.1101/821876]; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Simoes BM, 2015, CELL REP, V12, P1968, DOI 10.1016/j.celrep.2015.08.050; Simoes BM, 2011, BREAST CANCER RES TR, V129, P23, DOI 10.1007/s10549-010-1169-4; Tawara K, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0971-5; Tripathy D, 2017, CLIN CANCER RES, V23, P5658, DOI 10.1158/1078-0432.CCR-17-1819; Turnbull AK, 2015, J CLIN ONCOL, V33, P2270, DOI 10.1200/JCO.2014.57.8963; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wei W, 2014, STEM CELLS, V32, P2571, DOI 10.1002/stem.1752; West NR, 2014, ONCOGENE, V33, P1485, DOI 10.1038/onc.2013.105; West NR, 2012, ENDOCR-RELAT CANCER, V19, P181, DOI 10.1530/ERC-11-0326	42	13	13	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4896	4908		10.1038/s41388-020-1335-z	http://dx.doi.org/10.1038/s41388-020-1335-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32472077	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000541119400009
J	Shang, CW; Zhou, HY; Liu, W; Shen, T; Luo, Y; Huang, SL				Shang, Chaowei; Zhou, Hongyu; Liu, Wang; Shen, Tao; Luo, Yan; Huang, Shile			Iron chelation inhibits mTORC1 signaling involving activation of AMPK and REDD1/Bnip3 pathways	ONCOGENE			English	Article							PROTEIN-KINASE; ANTITUMOR-ACTIVITY; MAMMALIAN TARGET; UPSTREAM KINASE; PHOSPHATASE 2A; ENERGY-SENSOR; GENE-PRODUCTS; CELL-GROWTH; TGF-BETA; CANCER	The mammalian target of rapamycin (mTOR) functions as two complexes (mTORC1 and mTORC2), regulating cell growth and metabolism. Aberrant mTOR signaling occurs frequently in cancers, so mTOR has become an attractive target for cancer therapy. Iron chelators have emerged as promising anticancer agents. However, the mechanisms underlying the anticancer action of iron chelation are not fully understood. Particularly, reports on the effects of iron chelation on mTOR complexes are inconsistent or controversial. Here, we found that iron chelators consistently inhibited mTORC1 signaling, which was blocked by pretreatment with ferrous sulfate. Mechanistically, iron chelation-induced mTORC1 inhibition was not related to ROS induction, copper chelation, or PP2A activation. Instead, activation of AMPK pathway mainly and activation of both HIF-1/REDD1 and Bnip3 pathways partially contribute to iron chelation-induced mTORC1 inhibition. Our findings indicate that iron chelation inhibits mTORC1 via multiple pathways and iron is essential for mTORC1 activation.	[Shang, Chaowei; Zhou, Hongyu; Liu, Wang; Shen, Tao; Luo, Yan; Huang, Shile] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; [Shang, Chaowei; Shen, Tao; Huang, Shile] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Huang, SL (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.; Huang, SL (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Huang, Shile/I-1632-2019	Huang, Shile/0000-0002-3239-1072; Zhou, Hongyu/0000-0001-5852-3953	National Institutes of Health [CA115414]; American Cancer Society [RSG-08-135-01-CNE]; Feist-Weiller Cancer Center Idea Award; Carroll Feist Predoctoral Fellowship; Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center in Shreveport, LA	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Feist-Weiller Cancer Center Idea Award; Carroll Feist Predoctoral Fellowship; Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center in Shreveport, LA	We thank Michael N. Hall for reading the manuscript and helpful discussions, and Yu Jiang for generously providing Rheb-Q64L plasmid. This work was supported by the National Institutes of Health (CA115414; SH), American Cancer Society (RSG-08-135-01-CNE; SH), Feist-Weiller Cancer Center Idea Award (SH), and Carroll Feist Predoctoral Fellowship (CS and TS), Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center in Shreveport, LA.	Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Bystrom LM, 2015, FREE RADICAL BIO MED, V79, P337, DOI 10.1016/j.freeradbiomed.2014.04.035; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Coombs GS, 2012, ONCOGENE, V31, P213, DOI 10.1038/onc.2011.228; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; Dennis MD, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005103; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Dixon KM, 2013, BRIT J CANCER, V108, P409, DOI 10.1038/bjc.2012.582; DONFRANCESCO A, 1990, CANCER RES, V50, P4929; Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965; ESTROV Z, 1987, BLOOD, V69, P757; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Glick D, 2012, MOL CELL BIOL, V32, P2570, DOI 10.1128/MCB.00167-12; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Heberle AM, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970489; Huang X, 2003, MUTAT RES-FUND MOL M, V533, P153, DOI 10.1016/j.mrfmmm.2003.08.023; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; Kazyken D, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav3249; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kovacevic Z, 2013, ANTIOXID REDOX SIGN, V18, P874, DOI 10.1089/ars.2011.4273; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lane DJR, 2014, BBA-REV CANCER, V1845, P166, DOI 10.1016/j.bbcan.2014.01.005; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200; Lin A, 2014, ONCOGENE, V33, P3183, DOI 10.1038/onc.2013.273; Linden T, 2003, FASEB J, V17, P761, DOI 10.1096/fj.02-0586fje; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Lovejoy DB, 2011, CANCER RES, V71, P5871, DOI 10.1158/0008-5472.CAN-11-1218; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Ohyashiki JH, 2009, CANCER SCI, V100, P970, DOI 10.1111/j.1349-7006.2009.01131.x; Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]; Rao VA, 2009, CANCER RES, V69, P948, DOI 10.1158/0008-5472.CAN-08-1437; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen T, 2016, CURR PHARM DESIGN, V22, P4443, DOI 10.2174/1381612822666160530151209; Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757; Siddiqui N, 2015, BIOCHEM SOC T, V43, P763, DOI 10.1042/BST20150126; Singh M, 2011, APPL IMMUNOHISTO M M, V19, P417, DOI 10.1097/PAI.0b013e318209716e; Song S, 2011, CANCER RES, V71, P7628, DOI 10.1158/0008-5472.CAN-11-2745; Sowter HM, 2001, CANCER RES, V61, P6669; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; VAUGHN CB, 1987, CANCER INVEST, V5, P7, DOI 10.3109/07357908709020300; Voss M, 2011, CELL SIGNAL, V23, P114, DOI 10.1016/j.cellsig.2010.08.010; WANG GL, 1993, BLOOD, V82, P3610; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Watson A, 2016, CELL SIGNAL, V28, P412, DOI 10.1016/j.cellsig.2016.01.014; Whitnall M, 2006, P NATL ACAD SCI USA, V103, P14901, DOI 10.1073/pnas.0604979103; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Yu JS, 1998, J BIOCHEM, V124, P225, DOI 10.1093/oxfordjournals.jbchem.a022084; Yuan J, 2004, BLOOD, V104, P1450, DOI 10.1182/blood-2004-03-0868; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhou HY, 2016, BIOCHEM PHARMACOL, V116, P39, DOI 10.1016/j.bcp.2016.07.005; Zhou HY, 2014, ONCOTARGET, V5, P10140, DOI 10.18632/oncotarget.2471; Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255	76	13	13	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5201	5213		10.1038/s41388-020-1366-5	http://dx.doi.org/10.1038/s41388-020-1366-5		JUN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32541839	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000540391900001
J	Wu, PK; Hong, SK; Starenki, D; Oshima, K; Shao, H; Gestwicki, JE; Tsai, SS; Park, JI				Wu Pui-Kei; Hong, Seung-Keun; Starenki, Dmytro; Oshima, Kiyoko; Shao Hao; Gestwicki, Jason E.; Tsai, Susan; Park, Jong-In			Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability	ONCOGENE			English	Article							ADENINE-NUCLEOTIDE TRANSLOCASE; PANCREATIC-CANCER; TRANSITION PORE; UP-REGULATION; MKT-077; HSP70; P53; INHIBITOR; PROTEINS; BINDING	The mitochondrial HSP70 chaperone mortalin (HSPA9/GRP75) is often upregulated and mislocalized in MEK/ERK-deregulated tumors. Here, we show that mortalin depletion can selectively induce death of immortalized normal fibroblasts IMR90E1A when combined with K-Ras(G12V) expression, but not with wild-type K-Ras expression, and that K-Ras(G12V)-driven MEK/ERK activity is necessary for this lethality. This cell death was attenuated by knockdown or inhibition of adenine nucleotide translocase (ANT), cyclophilin D (CypD), or mitochondrial Ca2+ uniporter (MCU), which implicates a mitochondria-originated death mechanism. Indeed, mortalin depletion increased mitochondrial membrane permeability and induced cell death in KRAS-mutated human pancreatic ductal adenocarcinoma (PDAC) and colon cancer lines, which were attenuated by knockdown or inhibition of ANT, CypD, or MCU, and occurred independently of TP53 and p21(CIP1). Intriguingly, JG-98, an advanced MKT-077 derivative, phenocopied the lethal effects of mortalin depletion in K-Ras(G12V)-expressing IMR90E1A and KRAS-mutated tumor cell lines in vitro. Moreover, JG-231, a JG-98 analog with improved microsomal stability effectively suppressed the xenograft of MIA PaCa-2, a K-Ras(G12C)-expressing human PDAC line, in athymic nude mice. These data demonstrate that oncogenic KRAS activity sensitizes cells to the effects of mortalin depletion, suggesting that mortalin has potential as a selective therapeutic target for KRAS-mutated tumors.	[Wu Pui-Kei; Hong, Seung-Keun; Starenki, Dmytro; Park, Jong-In] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; [Oshima, Kiyoko] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Shao Hao; Gestwicki, Jason E.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Tsai, Susan] Med Coll Wisconsin, LaBahn Pancreat Canc Program, Milwaukee, WI 53226 USA; [Tsai, Susan] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Johns Hopkins University; University of California System; University of California San Francisco; Medical College of Wisconsin; Medical College of Wisconsin	Park, JI (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	jipark@mcw.edu	Oshima, Kiyoko/CAF-1543-2022	Park, Jong-In/0000-0001-7248-4735; Wu, Pui Kei/0000-0002-8734-2657	NIH/National Cancer Institute grant [R01CA138441]; NIH [R01NS059690]	NIH/National Cancer Institute grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH/National Cancer Institute grant (R01CA138441) to JP. Development of HSP70 modulators was funded by NIH R01NS059690 to JG.	Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Bonora M, 2015, ONCOGENE, V34, P1475, DOI 10.1038/onc.2014.96; Bonora M, 2019, TRENDS BIOCHEM SCI, V44, P559, DOI 10.1016/j.tibs.2019.04.009; BROEKEMEIER KM, 1994, MOL CELL BIOCHEM, V139, P33, DOI 10.1007/BF00944201; Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004; Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1; Chevrollier A, 2011, BBA-BIOENERGETICS, V1807, P562, DOI 10.1016/j.bbabio.2010.10.008; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Cui XL, 2017, HUM PATHOL, V64, P171, DOI 10.1016/j.humpath.2017.03.015; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI [10.1016/j.febslet.2007.05.039, 10.1016/j.febsiet.2007.05.039]; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; He JY, 2017, P NATL ACAD SCI USA, V114, P3409, DOI 10.1073/pnas.1702357114; Hong SK, 2018, CELL SIGNAL, V42, P11, DOI 10.1016/j.cellsig.2017.10.001; Hong SK, 2009, J BIOL CHEM, V284, P33006, DOI 10.1074/jbc.M109.012591; Hoshino A, 2019, NATURE, V575, P375, DOI 10.1038/s41586-019-1667-4; Humpton TJ, 2019, CANCER DISCOV, V9, P1268, DOI 10.1158/2159-8290.CD-18-1409; Hurst S, 2019, J BIOL CHEM, V294, P10807, DOI 10.1074/jbc.RA118.006443; Karkhanis M, 2015, CELL SIGNAL, V27, P479, DOI 10.1016/j.cellsig.2015.01.005; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; Kaul SC, 2007, EXP GERONTOL, V42, P263, DOI 10.1016/j.exger.2006.10.020; Khalil AA, 2011, BBA-REV CANCER, V1816, P89, DOI 10.1016/j.bbcan.2011.05.001; Kidger AM, 2018, PHARMACOL THERAPEUT, V187, P45, DOI 10.1016/j.pharmthera.2018.02.007; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Koya K, 1996, CANCER RES, V56, P538; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Leanza L, 2014, ONCOGENE, V33, P5569, DOI 10.1038/onc.2013.578; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Lu WJ, 2011, CELL DEATH DIFFER, V18, P1046, DOI 10.1038/cdd.2010.177; Maruta H, 1999, ANN NY ACAD SCI, V886, P283, DOI 10.1111/j.1749-6632.1999.tb09437.x; Miyata Y, 2013, ACS CHEM NEUROSCI, V4, P930, DOI 10.1021/cn300210g; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; Na Y, 2016, CANCER RES, V76, P2754, DOI 10.1158/0008-5472.CAN-15-2704; Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031; Neginskaya MA, 2019, CELL REP, V26, P11, DOI 10.1016/j.celrep.2018.12.033; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rousaki A, 2011, J MOL BIOL, V411, P614, DOI 10.1016/j.jmb.2011.06.003; Rozenberg P, 2013, INT J CANCER, V133, P514, DOI 10.1002/ijc.28029; Sale MJ, 2014, BIOCHEM SOC T, V42, P776, DOI 10.1042/BST20140129; Santo-Domingo J, 2007, BRIT J PHARMACOL, V151, P647, DOI 10.1038/sj.bjp.0707260; Shao H, 2018, J MED CHEM, V61, P6163, DOI 10.1021/acs.jmedchem.8b00583; Starenki D, 2015, ONCOGENE, V34, P4624, DOI 10.1038/onc.2014.392; Starenki D, 2013, J CLIN ENDOCR METAB, V98, P1529, DOI 10.1210/jc.2012-3671; SUN J, 2017, TUMOR BIOL, V39, DOI DOI 10.1177/1010428317695918; Utkina-Sosunova IV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062448; Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Wadhwa R, 2005, BIOCHEM J, V391, P185, DOI 10.1042/BJ20050861; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Wadhwa R, 2000, CANCER RES, V60, P6818; Wadhwa R, 2006, INT J CANCER, V118, P2973, DOI 10.1002/ijc.21773; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wu PK, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay1478; Wu PK, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00061-17; Wu PK, 2013, MOL CELL BIOL, V33, P4051, DOI 10.1128/MCB.00021-13; Xu M, 2019, GENE, V696, P63, DOI 10.1016/j.gene.2019.02.033; Yu M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125166; Yun CO, 2017, SCI REP-UK, V7, DOI 10.1038/srep42016	63	13	14	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4257	4270		10.1038/s41388-020-1285-5	http://dx.doi.org/10.1038/s41388-020-1285-5		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32291414	Green Submitted, Green Accepted			2022-12-17	WOS:000526237900001
J	Goto, Y; Ando, T; Izumi, H; Feng, XD; Arang, N; Gilardi, M; Wang, ZY; Ando, K; Gutkind, JS				Goto, Yusuke; Ando, Toshinori; Izumi, Hiroki; Feng, Xiaodong; Arang, Nadia; Gilardi, Mara; Wang, Zhiyong; Ando, Kazuyo; Gutkind, J. Silvio			Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK-YAP signaling axis	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; ANDROGEN RECEPTOR; VERTEPORFIN; PROGRESSION; ACTIVATION; EXPRESSION; THERAPY	Prostate cancer (PCa) innervation contributes to the progression of PCa. However, the precise impact of innervation on PCa cells is still poorly understood. By focusing on muscarinic receptors, which are activated by the nerve-derived neurotransmitter acetylcholine, we show that muscarinic receptors 1 and 3 (m1 and m3) are highly expressed in PCa clinical specimens compared with all other cancer types, and that amplification or gain of their corresponding encoding genes (CHRM1 and CHRM3, respectively) represent a worse prognostic factor for PCa progression free survival. Moreover, m1 and m3 gene gain or amplification is frequent in castration-resistant PCa (CRPC) compared with hormone-sensitive PCa (HSPC) specimens. This was reflected in HSPC-derived cells, which show aberrantly high expression of m1 and m3 under androgen deprivation mimicking castration and androgen receptor inhibition. We also show that pharmacological activation of m1 and m3 signaling is sufficient to induce the castration-resistant growth of PCa cells. Mechanistically, we found that m1 and m3 stimulation induces YAP activation through FAK, whose encoding gene, PTK2 is frequently amplified in CRPC cases. Pharmacological inhibition of FAK and knockdown of YAP abolished m1 and m3-induced castration-resistant growth of PCa cells. Our findings provide novel therapeutic opportunities for muscarinic-signal-driven CRPC progression by targeting the FAK-YAP signaling axis.	[Goto, Yusuke; Ando, Toshinori; Izumi, Hiroki; Feng, Xiaodong; Arang, Nadia; Gilardi, Mara; Wang, Zhiyong; Ando, Kazuyo; Gutkind, J. Silvio] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA; [Ando, Toshinori] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Feng, Xiaodong] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Peoples R China; [Ando, Kazuyo] Hiroshima Univ, Inst Biomed & Hlth Sci, Appl Life Sci, Dept Orthodont, Hiroshima, Japan	University of California System; University of California San Diego; Hiroshima University; Sichuan University; Hiroshima University	Gutkind, JS (corresponding author), Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA.	sgutkind@health.ucsd.edu	Gutkind, J. Silvio/J-1201-2016; Ando, Toshinori/AAG-4033-2021; Ando, Toshinori/AAA-6401-2021; Gilardi, Mara/AAP-4387-2020	Gutkind, J. Silvio/0000-0002-5150-4482; Ando, Toshinori/0000-0002-3141-8173; Ando, Toshinori/0000-0002-3141-8173; Arang, Nadia/0000-0002-8167-2188	JSPS Overseas Research Fellowships; Uehara Memorial Foundation Research Fellowship; 111 Project of MOE China [B14038]; National Natural Science Foundation China [81402230, 81672677]; FIRC-AIRC fellowship for abroad (Italian Foundation for cancer research);  [S10OD021831]	JSPS Overseas Research Fellowships; Uehara Memorial Foundation Research Fellowship(Uehara Memorial Foundation); 111 Project of MOE China; National Natural Science Foundation China(National Natural Science Foundation of China (NSFC)); FIRC-AIRC fellowship for abroad (Italian Foundation for cancer research); 	YG is supported by the JSPS Overseas Research Fellowships and the Uehara Memorial Foundation Research Fellowship. XF is supported by 111 Project of MOE (B14038) China, the National Natural Science Foundation (81402230, 81672677) China. MG is supported by FIRC-AIRC fellowship for abroad (Italian Foundation for cancer research). We thank La Jolla Institute Microscopy Core Facility for professional advice and guidance, in particular Zbigniew Mikulski. This work was supported by S10OD021831. YG initiated the study; YG and JSG designed the study and experiments; YG performed the genomic analyses; YG, TA, HI, NA, KA performed in vitro experiments, YG and MG performed immunofluorescence experiments, YG, NA and JSG prepared the manuscript, XF, ZW, NA and JSG provided advice and supervised the project. All authors discussed the results and reviewed the manuscript.	Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Baig AM, 2017, ANTI-CANCER DRUG, V28, P75, DOI 10.1097/CAD.0000000000000432; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Cao X, 2006, ONCOGENE, V25, P3719, DOI 10.1038/sj.onc.1209408; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chlenski A, 2001, PROSTATE, V47, P66; Crawford ED, 2015, J UROLOGY, V194, P1537, DOI 10.1016/j.juro.2015.06.106; Daaka Y., 2004, SCI STKE, V2004, pre2, DOI [10.1126/stke.2162004re2, DOI 10.1126/STKE.2162004RE2]; Drake JM, 2013, P NATL ACAD SCI USA, V110, pE4762, DOI 10.1073/pnas.1319948110; Feng XD, 2019, CANCER CELL, V35, P457, DOI 10.1016/j.ccell.2019.01.009; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gibault F, 2016, CURR MED CHEM, V23, P1171, DOI 10.2174/0929867323666160316125048; Grytli HH, 2014, EUR UROL, V65, P635, DOI 10.1016/j.eururo.2013.01.007; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Inoue A, 2019, CELL, V177, P1933, DOI 10.1016/j.cell.2019.04.044; Kaye JA, 2017, PHARMACOTHERAPY, V37, P673, DOI 10.1002/phar.1932; Konstantinou EK, 2017, SCI REP-UK, V7, DOI 10.1038/srep46581; Kuser-Abali G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9126; Lee WY, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.07.019; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Luthin GR, 1997, LIFE SCI, V60, P963, DOI 10.1016/S0024-3205(97)00035-0; Magnon C, 2013, SCIENCE, V341, P143, DOI 10.1126/science.1236361; Mauffrey P, 2019, NATURE, V569, P672, DOI 10.1038/s41586-019-1219-y; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Navone NM, 1997, CLIN CANCER RES, V3, P2493; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Patel N, 2011, PM&R, V3, P633, DOI 10.1016/j.pmrj.2011.04.024; Rayford W, 1997, PROSTATE, V30, P160, DOI 10.1002/(SICI)1097-0045(19970215)30:3<160::AID-PROS3>3.0.CO;2-Q; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Schultze A, 2010, EXPERT OPIN INV DRUG, V19, P777, DOI 10.1517/13543784.2010.489548; Schwartz S, 2015, CANCER CELL, V27, P109, DOI 10.1016/j.ccell.2014.11.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Slack-Davis JK, 2009, MOL CANCER THER, V8, P2470, DOI 10.1158/1535-7163.MCT-09-0262; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Wang NT, 2015, CLIN CANCER RES, V21, P4676, DOI 10.1158/1078-0432.CCR-14-3163; Wu V, 2019, J BIOL CHEM, V294, P11062, DOI 10.1074/jbc.REV119.005601; Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072; Zhang HB, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac5418; Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15	44	13	14	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4014	4027		10.1038/s41388-020-1272-x	http://dx.doi.org/10.1038/s41388-020-1272-x		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32205868	Green Accepted			2022-12-17	WOS:000521527500002
J	Olou, AA; King, RJ; Yu, F; Singh, PK				Olou, Appolinaire A.; King, Ryan J.; Yu, Fang; Singh, Pankaj K.			MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; CYTIDINE DEAMINASE; OXIDATIVE STRESS; GLUCOSE DEPRIVATION; GEMCITABINE RESISTANCE; TUMOR-CELLS; APOPTOSIS; ACTIVATION; CALCIUM	The Mucin 1 (MUC1) protein is overexpressed in various cancers and mediates chemotherapy resistance. However, the mechanism is not fully understood. Given that most chemotherapeutic drugs disrupt ER homeostasis as part of their toxicity, and MUC1 expression is regulated by proteins involved in ER homeostasis, we investigated the link between MUC1 and ER homeostasis. MUC1 knockdown in pancreatic cancer cells enhanced unfolded protein response (UPR) signaling and cell death upon ER stress induction. Transcriptomic analysis revealed alterations in the pyrimidine metabolic pathway and cytidine deaminase (CDA). ChIP and CDA activity assays showed that MUC1 occupied CDA gene promoter upon ER stress induction correlating with increased CDA expression and activity in MUC1-expressing cells as compared with MUC1 knockdown cells. Inhibition of either the CDA or pyrimidine metabolic pathway diminished survival in MUC1-expressing cancer cells upon ER stress induction. Metabolomic analysis demonstrated that MUC1-mediated CDA activity corresponded to deoxycytidine to deoxyuridine metabolic reprogramming upon ER stress induction. The resulting increase in deoxyuridine mitigated ER stress-induced cytotoxicity. In addition, given (1) the established roles of MUC1 in protecting cells against reactive oxygen species (ROS) insults, (2) ER stress-generated ROS further promote ER stress and (3) the emerging anti-oxidant property of deoxyuridine, we further investigated if MUC1 regulated ER stress by a deoxyuridine-mediated modulation of ROS levels. We observed that deoxyuridine could abrogate ROS-induced ER stress to promote cancer cell survival. Taken together, our findings demonstrate a novel MUC1-CDA axis of the adaptive UPR that provides survival advantage upon ER stress induction.	[Olou, Appolinaire A.; King, Ryan J.; Singh, Pankaj K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Yu, Fang; Singh, Pankaj K.] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA; [Singh, Pankaj K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Singh, Pankaj K.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Singh, Pankaj K.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Singh, PK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA.; Singh, PK (corresponding author), Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.	pankaj.singh@unmc.edu			National Institutes of Health (NCI) [R01 CA216853, CA163649, CA210439]; Specialized Programs of Research Excellence (SPORE, NCI) [2P50 CA127297]; NCI [P01 CA2117798]; Fred & Pamela Buffett Cancer Center Support Grant (NCI) [P30CA036727];  [R01CA216853-01]	National Institutes of Health (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Specialized Programs of Research Excellence (SPORE, NCI); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fred & Pamela Buffett Cancer Center Support Grant (NCI); 	This work was supported in part by funding from the National Institutes of Health (R01 CA216853, CA163649, CA210439, NCI) to PKS, the Specialized Programs of Research Excellence (SPORE, 2P50 CA127297, NCI) to PKS, P01 CA2117798 (NCI) to PKS, and a supplement to NIH grant (R01CA216853-01) to AAO. We would also like to acknowledge the Fred & Pamela Buffett Cancer Center Support Grant (P30CA036727, NCI) for supporting shared resources.	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Alejandro EU, 2015, CELL REP, V13, P2527, DOI 10.1016/j.celrep.2015.11.020; Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Castellvi A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39722-0; Chabosseau P, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1363; Chaika NV, 2012, P NATL ACAD SCI USA, V109, P13787, DOI 10.1073/pnas.1203339109; Chang QS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-64; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Chung SJ, 2005, J MED CHEM, V48, P658, DOI 10.1021/jm0496279; COHEN RM, 1971, J BIOL CHEM, V246, P7561; Denzel MS, 2014, CELL, V156, P1167, DOI 10.1016/j.cell.2014.01.061; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Dumartin L, 2017, ONCOGENE, V36, P3094, DOI 10.1038/onc.2016.459; Eletto D, 2014, J CELL SCI, V127, P3649, DOI 10.1242/jcs.153643; Fagone P, 2009, J LIPID RES, V50, pS311, DOI 10.1194/jlr.R800049-JLR200; Farooqi AA, 2015, TUMOR BIOL, V36, P5743, DOI 10.1007/s13277-015-3797-0; Feno S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9324018; Ferrer CM, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.961809; Gebregiworgis T, 2017, J PROTEOME RES, V16, P3536, DOI 10.1021/acs.jproteome.7b00246; Gemble S, 2016, J CELL SCI, V129, P3167, DOI 10.1242/jcs.187781; Goode G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176820; Guang W, 2009, INT J BIOCHEM CELL B, V41, P1354, DOI 10.1016/j.biocel.2008.12.004; Gunda V, 2017, CLIN CANCER RES, V23, P5881, DOI 10.1158/1078-0432.CCR-17-1151; Hauser J, 2008, P NATL ACAD SCI USA, V105, P1267, DOI 10.1073/pnas.0708220105; Hayakawa Y, 2011, P NATL ACAD SCI USA, V108, P780, DOI 10.1073/pnas.1011418108; Hiraki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep26643; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Ikonen E, 2008, NAT REV MOL CELL BIO, V9, P125, DOI 10.1038/nrm2336; Jing X, 2019, ONCOL REP, V41, P801, DOI 10.3892/or.2018.6887; Juin P, 1998, J BIOL CHEM, V273, P17559, DOI 10.1074/jbc.273.28.17559; Jun HS, 2010, BLOOD, V116, P2783, DOI 10.1182/blood-2009-12-258491; Kannan N, 2014, P NATL ACAD SCI USA, V111, P7789, DOI 10.1073/pnas.1403813111; Kriss CL, 2012, BLOOD, V120, P1027, DOI 10.1182/blood-2011-11-394346; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Lebrecht D, 2008, ARTHRITIS RHEUM-US, V58, P318, DOI 10.1002/art.23235; Lebrecht D, 2007, HEPATOLOGY, V45, P72, DOI 10.1002/hep.21490; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Li G, 2009, J CELL BIOL, V186, P783, DOI 10.1083/jcb.200904060; Vu LT, 2017, BIOSCI TRENDS, V11, P243, DOI 10.5582/bst.2017.01049; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70; Marini C, 2016, SCI REP-UK, V6, DOI 10.1038/srep25092; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Mehla K, 2014, BBA-REV CANCER, V1845, P126, DOI 10.1016/j.bbcan.2014.01.001; Menendez D, 2017, MOL CANCER RES, V15, P735, DOI 10.1158/1541-7786.MCR-17-0019; Nath S, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.16; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Norris AM, 2013, ONCOGENE, V32, P3867, DOI 10.1038/onc.2012.394; Oslowski CM, 2011, METHOD ENZYMOL, V490, P71, DOI 10.1016/B978-0-12-385114-7.00004-0; Rahn JJ, 2004, J BIOL CHEM, V279, P29386, DOI 10.1074/jbc.C400010200; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180; Rajabi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07850-0; Ren Z, 2017, TOXICOLOGY, V392, P11, DOI 10.1016/j.tox.2017.10.002; Ron D, 2004, J CELL BIOL, V167, P23, DOI 10.1083/jcb.200408117; Ruckemann K, 1998, J BIOL CHEM, V273, P21682, DOI 10.1074/jbc.273.34.21682; Serdjebi C, 2015, EXPERT OPIN DRUG MET, V11, P665, DOI 10.1517/17425255.2015.985648; Sharma AK, 2004, J BIOL CHEM, V279, P35564, DOI 10.1074/jbc.M401037200; Sharma S, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1651-1; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Song BB, 2008, J CLIN INVEST, V118, P3378, DOI 10.1172/JCI34587; Song M, 2018, NATURE, V562, P423, DOI 10.1038/s41586-018-0597-x; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084; STOLLER RG, 1978, BIOCHEM PHARMACOL, V27, P53, DOI 10.1016/0006-2952(78)90256-3; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tadros S, 2017, CANCER RES, V77, P5503, DOI 10.1158/0008-5472.CAN-16-3062; Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777; Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184110; Wang MX, 2018, CRIT REV ONCOL HEMAT, V127, P66, DOI 10.1016/j.critrevonc.2018.05.003; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357; Yamamori T, 2013, FEBS LETT, V587, P3348, DOI 10.1016/j.febslet.2013.08.030; Yamamoto M, 2019, CANCER RES, V79, P2031, DOI 10.1158/0008-5472.CAN-18-3259; Ye FG, 2015, CANCER RES, V75, P1504, DOI 10.1158/0008-5472.CAN-14-2341; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327; Zeng T, 2015, BIOCHEM BIOPH RES CO, V460, P530, DOI 10.1016/j.bbrc.2015.03.064; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	93	13	14	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3381	3395		10.1038/s41388-020-1225-4	http://dx.doi.org/10.1038/s41388-020-1225-4		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32103170	Green Accepted			2022-12-17	WOS:000516683200002
J	Li, JJ; Pu, TJ; Yin, LJ; Li, QL; Liao, CP; Wu, BJ				Li, Jingjing; Pu, Tianjie; Yin, Lijuan; Li, Qinlong; Liao, Chun-Peng; Wu, Boyang Jason			MAOA-mediated reprogramming of stromal fibroblasts promotes prostate tumorigenesis and cancer stemness	ONCOGENE			English	Article							MONOAMINE-OXIDASE; TUMOR PROGRESSION; SIGNALING PATHWAY; OXIDATIVE STRESS; CELLS; STAT3; INTERLEUKIN-6; INFLAMMATION; METASTASIS; MICROENVIRONMENT	The tumor microenvironment plays a critical role in prostate cancer (PC) development and progression. Inappropriate activation of the stroma potentiates the growth and transformation of epithelial tumor cells. Here, we show that upregulation of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, in stromal cells elevates production of reactive oxygen species, triggers an inflammatory response including activation of IL-6, and promotes tumorigenesis in vitro and in vivo. Mechanistically, MAOA enhances IL-6 transcription through direct Twist1 binding to a conserved E-box element at the IL-6 promoter. MAOA in stromal fibroblasts provides tumor cell growth advantages through paracrine IL-6/STAT3 signaling. Tissue microarray analysis revealed co-expression correlations between individual pairs of proteins of the stromal MAOA-induced Twist1/IL-6/STAT3 pathway in clinical specimens. Downstream of stromal MAOA, STAT3 also promotes cell stemness and transcriptionally activates expression of cancer stem cell marker CD44 in PC cells. MAOA inhibitor treatment effectively suppressed prostate tumor growth in mice in a stroma-specific targeted manner. Collectively, these findings characterize the contribution of MAOA to stromal activation in PC pathogenesis and provide a rationale for targeting MAOA in stromal cells to treat PC.	[Li, Jingjing; Pu, Tianjie; Wu, Boyang Jason] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, 205 E Spokane Falls Blvd,PBS 421, Spokane, WA 99202 USA; [Li, Jingjing] Shanghai Jiao Tong Univ, Sch Pharm, Lab Regener, Shanghai 200240, Peoples R China; [Pu, Tianjie; Yin, Lijuan] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu 610041, Sichuan, Peoples R China; [Yin, Lijuan] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA; [Li, Qinlong] Med Univ Air Force, Xijing Hosp, Dept Pathol, Xian 710032, Shaanxi, Peoples R China; [Liao, Chun-Peng] Univ Southern Calif, Keck Sch Med, Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90089 USA	Washington State University; Shanghai Jiao Tong University; Sichuan University; Cedars Sinai Medical Center; Air Force Military Medical University; University of Southern California	Wu, BJ (corresponding author), Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, 205 E Spokane Falls Blvd,PBS 421, Spokane, WA 99202 USA.	boyang.wu@wsu.edu	Li, Jing/GYU-5036-2022; Pu, Tianjie/AAE-9454-2022; Pu, Tianjie/AFD-8574-2022	Liao, Chun-Peng/0000-0001-8920-4322	Concern Foundation CONquer canCER Now Award; Department of Defense Prostate Cancer Research Program [W81XWH-15-1-0493]; NIH/NCI [R37CA233658]; WSU start-up fund	Concern Foundation CONquer canCER Now Award; Department of Defense Prostate Cancer Research Program(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WSU start-up fund	We thank Yang Li (University of Southern California), Yanping Wang (CSMC), and Yidi Xu (Washington State University) for technical help, Leland W.K. Chung (CSMC) for comprehensive support of this study, and Gary Mawyer for editorial assistance. This work was supported by a Concern Foundation CONquer canCER Now Award, the Department of Defense Prostate Cancer Research Program grant W81XWH-15-1-0493, the NIH/NCI grant R37CA233658, and the WSU start-up fund to B.J.W.	Acharya A, 2010, OXID MED CELL LONGEV, V3, P23, DOI 10.4161/oxim.3.1.10095; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Azevedo A, 2011, WORLD J CLIN ONCOL, V2, P384, DOI 10.5306/wjco.v2.i12.384; Barron DA, 2012, ENDOCR-RELAT CANCER, V19, pR187, DOI 10.1530/ERC-12-0085; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cheng N, 2011, JOVE-J VIS EXP, DOI 10.3791/2716; Culig Z, 2018, MOL CELL ENDOCRINOL, V462, P25, DOI 10.1016/j.mce.2017.03.012; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Dobrian Anca D, 2012, Front Endocrinol (Lausanne), V3, P108, DOI 10.3389/fendo.2012.00108; Dumont N, 2013, NEOPLASIA, V15, P249, DOI 10.1593/neo.121950; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Flamand V, 2010, J CANCER RES CLIN, V136, P1761, DOI 10.1007/s00432-010-0835-6; Franco OE, 2012, ADV PHARMACOL, V65, P267, DOI 10.1016/B978-0-12-397927-8.00009-9; Galoczova M, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0078-0; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Ishihara K, 2002, BBA-MOL CELL RES, V1592, P281, DOI 10.1016/S0167-4889(02)00321-X; Kawada M, 2006, CANCER RES, V66, P4419, DOI 10.1158/0008-5472.CAN-05-4239; Kumari N, 2016, TUMOR BIOL, V37, P11553, DOI 10.1007/s13277-016-5098-7; Policastro LL, 2013, ANTIOXID REDOX SIGN, V19, P854, DOI 10.1089/ars.2011.4367; Leach DA, 2017, CANCERS, V9, DOI 10.3390/cancers9010010; Lee JL, 2009, J CELL BIOL, V185, P949, DOI 10.1083/jcb.200812060; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Li Y, 2013, J BIOL CHEM, V288, P25007, DOI 10.1074/jbc.M113.450353; Lin L, 2016, INT J ONCOL, V49, P2265, DOI 10.3892/ijo.2016.3728; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mathy-Hartert M, 2008, OSTEOARTHR CARTILAGE, V16, P756, DOI 10.1016/j.joca.2007.10.009; Meng E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107142; Moreira MP, 2018, EXP CELL RES, V363, P283, DOI 10.1016/j.yexcr.2018.01.018; Olumi AF, 1999, CANCER RES, V59, P5002; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Sun XJ, 2010, IN VITRO CELL DEV-AN, V46, P538, DOI 10.1007/s11626-010-9309-z; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tanner MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016027; THALMANN GN, 1994, CANCER RES, V54, P2577; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103; Valencia T, 2014, CANCER CELL, V26, P121, DOI 10.1016/j.ccr.2014.05.004; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wassmann S, 2004, CIRC RES, V94, P534, DOI 10.1161/01.RES.0000115557.25127.8D; Wu JB, 2009, J BIOL CHEM, V284, P16723, DOI 10.1074/jbc.M901779200; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Wu JB, 2014, J CLIN INVEST, V124, P2891, DOI 10.1172/JCI70982; Yan YM, 2015, STEM CELL TRANSL MED, V4, P1033, DOI 10.5966/sctm.2015-0048; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang G, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/782581; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152; Zhu YZ, 2014, PROSTATE, V74, P1086, DOI 10.1002/pros.22819	56	13	13	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3305	3321		10.1038/s41388-020-1217-4	http://dx.doi.org/10.1038/s41388-020-1217-4		FEB 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32066880				2022-12-17	WOS:000514052700004
J	Yu, ZB; Feng, JB; Wang, W; Deng, ZY; Zhang, Y; Xiao, L; Wang, ZY; Liu, CH; Liu, Q; Chen, S; Wu, MH				Yu, Zhibin; Feng, Jianbo; Wang, Wei; Deng, Zhiyong; Zhang, Yan; Xiao, Lan; Wang, Zeyou; Liu, Changhong; Liu, Qing; Chen, Shuai; Wu, Minghua			The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically	ONCOGENE			English	Article							INTEGRATED GENOMIC ANALYSIS; TUMOR-SUPPRESSOR; C-MYC; MUTATION; REPRESSION; EXPRESSION; FAMILY; EGFR; IDH1; METHYLATION	The homeotic protein SIX3 is a transcription factor vital for neurogenesis and has a bivalent promoter. We previously showed that SIX3 can be transcriptionally silenced by DNA hypermethylation, functions as a tumor suppressor gene, and inhibits human glioblastoma transcriptionally. Here, we show that the activation of epidermal growth factor (EGFR) induces DNA methylation of SIX3 promoter through the MAPK pathway. ERK, when activated, binds with ZNF263, consequently abrogating the ubiquitination of ZNF263 and leading to its stabilization. ZNF263 binds to the core promoter region of SIX3 and recruits the KAP1/HATS/DNMT corepressor complex to induce transcriptional silencing of SIX3 through H3K27me3 and methylation of SIX3 promoter. Activation of the EGFR-ZNF263 signaling axis in phenotypically normal astrocytes or glioblastoma cells triggers or enhances tumorigenic activities, while elevated expression of the EGFR-ZNF263 signaling components in glioblastoma tissues is associated with poor prognosis of the patients. Together, our findings demonstrate that epigenetic silencing of SIX3 is controlled by a sophisticated and highly ordered oncogenic signaling pathway and therefore provide new insights into initiation and progression of glioblastoma.	[Yu, Zhibin; Feng, Jianbo; Deng, Zhiyong; Zhang, Yan; Liu, Changhong; Chen, Shuai; Wu, Minghua] Cent South Univ, Xiangya Med Sch, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Yu, Zhibin; Feng, Jianbo; Deng, Zhiyong; Zhang, Yan; Liu, Changhong; Chen, Shuai; Wu, Minghua] Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Yu, Zhibin; Feng, Jianbo; Zhang, Yan; Xiao, Lan; Liu, Changhong; Wu, Minghua] Cent South Univ, Sch Basic Med Sci, Canc Res Inst,Minist Hlth, Key Lab Carcinogenesis & Canc Invas,Minist Educ,K, Changsha 410078, Hunan, Peoples R China; [Yu, Zhibin; Feng, Jianbo] Shanghai Jiao Tong Univ, Yale Inst Immune Metab, Sch Med, Shanghai 200025, Peoples R China; [Wang, Wei] Jining Med Univ, Dept Pathol, Affiliated Hosp, Jining 272000, Shandong, Peoples R China; [Wang, Zeyou] Cent South Univ, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Liu, Qing] Cent South Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China	Central South University; Central South University; Central South University; Shanghai Jiao Tong University; Jining Medical University; Central South University; Central South University	Chen, S; Wu, MH (corresponding author), Cent South Univ, Xiangya Med Sch, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China.; Chen, S; Wu, MH (corresponding author), Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410013, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Sch Basic Med Sci, Canc Res Inst,Minist Hlth, Key Lab Carcinogenesis & Canc Invas,Minist Educ,K, Changsha 410078, Hunan, Peoples R China.	chenshuai16@139.com; wuminghua554@aliyun.com			National Natural Science Foundation of China [81874850, 81502185]; Graduate Student Research Innovation Project in Hunan Province [2019zzts084]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Graduate Student Research Innovation Project in Hunan Province	This work was supported by the National Natural Science Foundation of China (Grant No. 81874850, 81502185) and Graduate Student Research Innovation Project in Hunan Province (2019zzts084).	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Bierhoff H, 2014, MOL CELL, V54, P675, DOI 10.1016/j.molcel.2014.03.032; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Carl M, 2002, DEVELOPMENT, V129, P4057; Carlin D, 2012, DEVELOPMENT, V139, P2614, DOI 10.1242/dev.076018; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dingar D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05660-0; Ecco G, 2017, DEVELOPMENT, V144, P2719, DOI 10.1242/dev.132605; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Forloni M, 2016, CELL REP, V16, P457, DOI 10.1016/j.celrep.2016.05.087; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; Geng X, 2016, DEVELOPMENT, V143, P4462, DOI 10.1242/dev.132142; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Jeon Y, 2011, CELL, V146, P119, DOI 10.1016/j.cell.2011.06.026; Koh KH, 2016, METHODS MOL BIOL, V1366, P41, DOI 10.1007/978-1-4939-3127-9_5; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; Lengler J, 2001, BIOCHEM BIOPH RES CO, V287, P372, DOI 10.1006/bbrc.2001.5605; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lidke DS, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.064972; Lupo A, 2013, CURR GENOMICS, V14, P268, DOI 10.2174/13892029113149990002; Lv DG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01731-w; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasquier L, 2000, EUR J HUM GENET, V8, P797, DOI 10.1038/sj.ejhg.5200540; Pasquier L, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.023416; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Riso V, 2016, NUCLEIC ACIDS RES, V44, P8165, DOI 10.1093/nar/gkw505; Roy DM, 2014, PROTEIN CELL, V5, P265, DOI 10.1007/s13238-014-0031-6; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313; Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444; Stupp R, 2014, ANN ONCOL, V25, P93, DOI 10.1093/annonc/mdu050; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Thoresen SB, 2014, NAT CELL BIOL, V16, P547, DOI 10.1038/ncb2959; Tsai WB, 2012, CANCER RES, V72, P2622, DOI 10.1158/0008-5472.CAN-11-3605; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wajapeyee N, 2013, GENE DEV, V27, P2221, DOI 10.1101/gad.227413.113; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Yu ZB, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0483-2; Zhu CQC, 2002, DEVELOPMENT, V129, P2835; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106	54	13	14	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3163	3178		10.1038/s41388-020-1206-7	http://dx.doi.org/10.1038/s41388-020-1206-7		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32051553	Green Published, hybrid			2022-12-17	WOS:000513108700001
J	Kennedy, SP; O'Neill, M; Cunningham, D; Morris, PG; Toomey, S; Blanco-Aparicio, C; Martinez, S; Pastor, J; Eustace, AJ; Hennessy, BT				Kennedy, Sean P.; O'Neill, Michael; Cunningham, Darren; Morris, Patrick G.; Toomey, Sinead; Blanco-Aparicio, Carmen; Martinez, Sonia; Pastor, Joaquin; Eustace, Alex J.; Hennessy, Bryan T.			Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer	ONCOGENE			English	Article							PIM KINASE INHIBITOR; PROTEIN-KINASE; DUAL INHIBITION; PROSTATE-CANCER; THERAPY; PATHWAY; POTENT; CELLS; PHOSPHORYLATION; RESISTANCE	The proviral integration of Moloney virus (PIM) family of protein kinases are overexpressed in many haematological and solid tumours. PIM kinase expression is elevated in PI3K inhibitor-treated breast cancer samples, suggesting a major resistance pathway for PI3K inhibitors in breast cancer, potentially limiting their clinical utility. IBL-302 is a novel molecule that inhibits both PIM and PI3K/AKT/mTOR signalling. We thus evaluated the preclinical activity of IBL-302, in a range of breast cancer models. Our results demonstrate in vitro efficacy of IBL-302 in a range of breast cancer cell lines, including lines with acquired resistance to trastuzumab and lapatinib. IBL-302 demonstrated single-agent, anti-tumour efficacy in suppression of pAKT, pmTOR and pBAD in the SKBR-3, BT-474 and HCC-1954 HER2+/PIK3CA-mutated cell lines. We have also shown the in vivo single-agent efficacy of IBL-302 in the subcutaneous BT-474 and HCC-1954 xenograft model in BALB/c nude mice. The combination of trastuzumab and IBL-302 significantly increased the anti-proliferative effect in HER2+ breast cancer cell line, and matched trastuzumab-resistant line, relative to testing either drug alone. We thus believe that the novel PIM and PI3K/mTOR inhibitor, IBL-302, represents an exciting new potential treatment option for breast cancer, and that it should be considered for clinical investigation.	[Kennedy, Sean P.; Morris, Patrick G.; Toomey, Sinead; Hennessy, Bryan T.] Royal Coll Surgeons Ireland, Dept Mol Med, Med Oncol Grp, Smurfit Bldg Beaumont Hosp, Dublin, Ireland; [O'Neill, Michael; Cunningham, Darren] Inflect Biosci, Anglesea House, Dublin, Ireland; [Morris, Patrick G.; Hennessy, Bryan T.] Beaumont Hosp, Canc Clin Trials & Res Unit, Dublin, Ireland; [Blanco-Aparicio, Carmen; Martinez, Sonia; Pastor, Joaquin] Spanish Natl Canc Res Ctr CNIO, Expt Therapeut Programme, Madrid, Spain; [Eustace, Alex J.] Dublin City Univ, Natl Inst Cellular Biotechnol, Mol Therapeut Canc Ireland, Dublin, Ireland; [Hennessy, Bryan T.] Canc Trials Ireland, Innovat House,Old Finglas Rd, Dublin, Ireland	Royal College of Surgeons - Ireland; Centro Nacional de Investigaciones Oncologicas (CNIO); Dublin City University	Kennedy, SP (corresponding author), Royal Coll Surgeons Ireland, Dept Mol Med, Med Oncol Grp, Smurfit Bldg Beaumont Hosp, Dublin, Ireland.	Seanpkennedy@rcsi.ie	Fernandez, Joaquin Pastor/I-4567-2015; Gonzalez, Sonia Martinez/I-4616-2015; Blanco-Aparicio, Carmen/I-3162-2015	Fernandez, Joaquin Pastor/0000-0003-0553-8021; Gonzalez, Sonia Martinez/0000-0003-2230-7794; Blanco-Aparicio, Carmen/0000-0002-3249-6595; Hennessy, Bryan/0000-0002-7871-6477	North East Cancer Research & Education Trust; Enterprise Ireland [IV-2017-2125]; Fox family; Kerins family	North East Cancer Research & Education Trust; Enterprise Ireland; Fox family; Kerins family	We are very grateful to Stephen Madden for his valuable input and statistical analysis. This research was supported by the North East Cancer Research & Education Trust, Fox and Kerins families and Enterprise Ireland (Voucher ID: IV-2017-2125).	Aziz AUR, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8010007; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Beier UH, 2007, INT J ONCOL, V30, P1381; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Bian CN, 2018, ONCOL LETT, V15, P9655, DOI 10.3892/ol.2018.8587; Braso-Maristany F, 2016, NAT MED, V22, P1303, DOI 10.1038/nm.4198; Burger MT, 2015, J MED CHEM, V58, P8373, DOI 10.1021/acs.jmedchem.5b01275; Cen B, 2014, MOL CELL BIOL, V34, P2517, DOI 10.1128/MCB.00147-14; Cen B, 2013, CANCER RES, V73, P3402, DOI 10.1158/0008-5472.CAN-12-4619; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapuis N, 2010, CLIN CANCER RES, V16, P5424, DOI 10.1158/1078-0432.CCR-10-1102; Chen LS, 2009, BLOOD, V114, P4150, DOI 10.1182/blood-2009-03-212852; Cobb M, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-524; Cortes J, 2018, BRIT J CANCER, V118, P1425, DOI 10.1038/s41416-018-0082-1; Dakin LA, 2012, BIOORG MED CHEM LETT, V22, P4599, DOI 10.1016/j.bmcl.2012.05.098; Doshi KA, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-5332; Elster N, 2015, BREAST CANCER RES TR, V149, P373, DOI 10.1007/s10549-014-3239-5; Elster N, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918778297; Eustace AJ, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-53; Garcia PD, 2014, CLIN CANCER RES, V20, P1834, DOI 10.1158/1078-0432.CCR-13-2062; Haddach M, 2012, ACS MED CHEM LETT, V3, P135, DOI 10.1021/ml200259q; Herzog A, 2013, CLIN CANCER RES, V19, P3808, DOI 10.1158/1078-0432.CCR-12-2716; Hogan C, 2008, J BIOL CHEM, V283, P18012, DOI 10.1074/jbc.M709695200; Horiuchi D, 2016, NAT MED, V22, P1321, DOI 10.1038/nm.4213; Hua H, 2018, BIOMED PHARMACOTHER, V101, P115, DOI 10.1016/j.biopha.2018.02.031; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Isaac M, 2011, DRUG RESIST UPDATE, V14, P203, DOI 10.1016/j.drup.2011.04.002; Jin B, 2014, AGING CELL, V13, P879, DOI 10.1111/acel.12249; Keegan NM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.1036; Keeton EK, 2014, BLOOD, V123, P905, DOI 10.1182/blood-2013-04-495366; Koblish H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199108; Le XN, 2016, CANCER DISCOV, V6, P1134, DOI 10.1158/2159-8290.CD-16-0305; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu WT, 2016, CELL CYCLE, V15, P886, DOI 10.1080/15384101.2016.1152428; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Malinen M, 2013, MOL CELL ENDOCRINOL, V365, P270, DOI 10.1016/j.mce.2012.10.028; Mcdermott MSJ, 2017, INT J ONCOL, V50, P2221, DOI 10.3892/ijo.2017.3976; McDermott MSJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-157; Meja K, 2014, BRIT J HAEMATOL, V167, P69, DOI 10.1111/bjh.13013; Mohlin S, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810058; Moody SE, 2015, ONCOGENE, V34, P2061, DOI 10.1038/onc.2014.153; Moore G, 2017, J THORAC ONCOL, V12, pS527, DOI 10.1016/j.jtho.2016.11.649; Musiani D, 2014, J PROTEOME RES, V13, P4970, DOI 10.1021/pr500651n; Narlik-Grassow M, 2014, MED RES REV, V34, P136, DOI 10.1002/med.21284; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; Neil M, 2014, CANCER RES, V74, P4524; Paino T, 2017, CLIN CANCER RES, V23, P225, DOI 10.1158/1078-0432.CCR-16-0230; Rampal RK, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.634.634; Rebello Richard J., 2018, Advances in Biological Regulation, V67, P163, DOI 10.1016/j.jbior.2017.10.010; Reidy M, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.5713.5713; Roh M, 2003, CANCER RES, V63, P8079; Simioni C, 2014, ONCOTARGET, V5, P10034, DOI 10.18632/oncotarget.2490; Song JH, 2012, CANCER RES, V72, P294, DOI 10.1158/0008-5472.CAN-11-3240; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Tursynbay Y, 2016, BIOMED REP, V4, P140, DOI 10.3892/br.2015.561; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Warfel NA, 2015, PHARMACOL THERAPEUT, V151, P41, DOI 10.1016/j.pharmthera.2015.03.001; White E, 2003, GENE DEV, V17, P1813, DOI 10.1101/gad.1123103; Wong PM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9048; Xia ZP, 2009, J MED CHEM, V52, P74, DOI 10.1021/jm800937p; Yang J, 2017, ONCOGENE, V36, P4828, DOI 10.1038/onc.2017.96; Zhang F, 2009, CANCER BIOL THER, V8, P846, DOI 10.4161/cbt.8.9.8210; Zhang RX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16153-3; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zhao B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0348-9	65	13	13	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					3028	3040		10.1038/s41388-020-1202-y	http://dx.doi.org/10.1038/s41388-020-1202-y		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32042115	Green Published, hybrid			2022-12-17	WOS:000512528200002
J	Hsu, BE; Roy, J; Mouhanna, J; Rayes, RF; Ramsay, L; Tabaries, S; Annis, MG; Watson, IR; Spicer, JD; Costantino, S; Siegel, PM				Hsu, Brian E.; Roy, Joannie; Mouhanna, Jack; Rayes, Roni F.; Ramsay, LeeAnn; Tabaries, Sebastien; Annis, Matthew G.; Watson, Ian R.; Spicer, Jonathan D.; Costantino, Santiago; Siegel, Peter M.			C3a elicits unique migratory responses in immature low-density neutrophils	ONCOGENE			English	Article							PARTICLE TRACKING; CHEMOTAXIS; C5A; RECEPTOR; ANAPHYLATOXIN; ANTAGONIST; EXPRESSION; LEUKOCYTES; LTB4	Neutrophils represent the immune system's first line of defense and are rapidly recruited into inflamed tissue. In cancer associated inflammation, phenotypic heterogeneity has been ascribed to this cell type, whereby neutrophils can manifest anti- or pro-metastatic functions depending on the cellular/micro-environmental context. Here, we demonstrate that pro-metastatic immature low-density neutrophils (iLDNs) more efficiently accumulate in the livers of mice bearing metastatic lesions compared with anti-metastatic mature high-density neutrophils (HDNs). Transcriptomic analyses reveal enrichment of a migration signature in iLDNs relative to HDNs. We find that conditioned media derived from liver-metastatic breast cancer cells, but not lung-metastatic variants, specifically induces chemotaxis of iLDNs and not HDNs. Chemotactic responses are due to increased surface expression of C3aR in iLDNs relative to HDNs. In addition, we detect elevated secretion of cancer-cell derived C3a from liver-metastatic versus lung-metastatic breast cancer cells. Perturbation of C3a/C3aR signaling axis with either a small molecule inhibitor, SB290157, or reducing the levels of secreted C3a from liver-metastatic breast cancer cells by short hairpin RNAs, can abrogate the chemotactic response of iLDNs both in vitro and in vivo, respectively. Together, these data reveal novel mechanisms through which iLDNs prefentially accumulate in liver tissue harboring metastases in response to tumor-derived C3a secreted from the liver-aggressive 4T1 breast cancer cells.	[Hsu, Brian E.; Ramsay, LeeAnn; Tabaries, Sebastien; Annis, Matthew G.; Watson, Ian R.; Siegel, Peter M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Hsu, Brian E.; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; [Roy, Joannie; Costantino, Santiago] Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H1T 2M4, Canada; [Roy, Joannie; Costantino, Santiago] Univ Montreal, Inst Biomed Engn, Montreal, PQ H3C 3T5, Canada; [Mouhanna, Jack; Rayes, Roni F.; Spicer, Jonathan D.] McGill Univ, Ctr Hlth, Res Inst, Dept Surg, Montreal, PQ H4A 3J1, Canada; [Watson, Ian R.; Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; Universite de Montreal; Universite de Montreal; McGill University; McGill University	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.	peter.siegel@mcgill.ca	Costantino, Santiago/ABD-5472-2020	Costantino, Santiago/0000-0002-2454-2635; Watson, Ian/0000-0002-6025-3080; Rayes, Roni/0000-0001-7508-020X; Annis, Matthew/0000-0002-8776-004X	Cancer Research Society; Terry Fox Research Institute [242122]; Quebec Breast Cancer Foundation [242122]; NSERC; Genome Canada; FRQS; AATS; MGH foundation; Charlotte and Leo Karassik Foundation PhD Fellowship; Rolande and Marcel Gosselin Graduate Studentship	Cancer Research Society; Terry Fox Research Institute; Quebec Breast Cancer Foundation; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Genome Canada(Genome Canada); FRQS; AATS; MGH foundation; Charlotte and Leo Karassik Foundation PhD Fellowship; Rolande and Marcel Gosselin Graduate Studentship	We acknowledge the Goodman Cancer Research Centre histology core facility (McGill University) for routine histological services, the Cell Vision Core Facility (McGill University) for providing routine cell sorting service and the Genetics Perturbation Service for shRNAs (McGill University). We thank Anie Monast and Cynthia Lavoie for technical support and members of the Siegel laboratory for their thoughtful discussions and critical reading of the manuscript. This work was supported by an operating grant to P.M.S. from the Cancer Research Society and the Terry Fox Research Institute and Quebec Breast Cancer Foundation (Grant #: 242122). S.C. acknowledges funding support from NSERC and Genome Canada and salary awarded from FRQS. J.D.S acknowledges funding support from AATS, MGH foundation and FRQS. BEH acknowledges support from the Charlotte and Leo Karassik Foundation PhD Fellowship and the Rolande and Marcel Gosselin Graduate Studentship. PMS is a McGill University William Dawson Scholar.	Afonso PV, 2012, DEV CELL, V22, P1079, DOI 10.1016/j.devcel.2012.02.003; Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341; Banda NK, 2012, J IMMUNOL, V188, P1469, DOI 10.4049/jimmunol.1102310; Bautsch W, 2000, J IMMUNOL, V165, P5401, DOI 10.4049/jimmunol.165.10.5401; Brandau S, 2011, J LEUKOCYTE BIOL, V89, P311, DOI 10.1189/jlb.0310162; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Foxman EF, 1999, J CELL BIOL, V147, P577, DOI 10.1083/jcb.147.3.577; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Guglietta S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11037; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Heit Bryan, 2003, Sci STKE, V2003, pPL5, DOI 10.1126/stke.2003.170.pl5; Hsu BE, 2019, CELL REP, V27, P3902, DOI 10.1016/j.celrep.2019.05.091; Hutamekalin P, 2010, J PHARMACOL SCI, V112, P56, DOI 10.1254/jphs.09180FP; Jaqaman K, 2008, NAT METHODS, V5, P695, DOI 10.1038/nmeth.1237; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; KRAUSS AHP, 1994, J LEUKOCYTE BIOL, V55, P201, DOI 10.1002/jlb.55.2.201; Lammermann T, 2013, NATURE, V498, P371, DOI 10.1038/nature12175; Lim H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052666; Liu LH, 2010, DEV CELL, V19, P845, DOI 10.1016/j.devcel.2010.11.004; Lohman RJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00414-w; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Majumdar R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002336; MARDER SR, 1985, J IMMUNOL, V134, P3325; Mazzaferri J, 2015, BIOINFORMATICS, V31, P1279, DOI 10.1093/bioinformatics/btu793; Mishalian I, 2017, IMMUNOBIOLOGY, V222, P82, DOI 10.1016/j.imbio.2016.02.001; Mizutani N, 2009, J IMMUNOL, V183, P4039, DOI 10.4049/jimmunol.0901468; Mollnes TE, 2002, BLOOD, V100, P1869; NELSON RD, 1975, J IMMUNOL, V115, P1650; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; PALMBLAD J, 1981, BLOOD, V58, P658; Quell KM, 2017, J IMMUNOL, V199, P688, DOI 10.4049/jimmunol.1700318; Rink I, 2015, J IMMUNOL, V194, P5549, DOI 10.4049/jimmunol.1500148; Roy J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02993-6; Sadik CD, 2011, TRENDS IMMUNOL, V32, P452, DOI 10.1016/j.it.2011.06.008; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Saha P, 2017, J IMMUNOL, V198, P4293, DOI 10.4049/jimmunol.1700261; Saunders CA, 2019, METHOD CELL BIOL, V149, P31, DOI 10.1016/bs.mcb.2018.09.002; Subramanian BC, 2018, J CELL SCI, V131, DOI 10.1242/jcs.217422; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Tabaries S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0558-3; Takabayashi T, 1996, J IMMUNOL, V156, P3455; Talbot J, 2015, ARTHRITIS RHEUMATOL, V67, P1751, DOI 10.1002/art.39117; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wu MCL, 2013, P NATL ACAD SCI USA, V110, P9439, DOI 10.1073/pnas.1218815110	48	13	13	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2612	2623		10.1038/s41388-020-1169-8	http://dx.doi.org/10.1038/s41388-020-1169-8		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	32020055				2022-12-17	WOS:000511084200001
J	Castillo, L; Young, AIJ; Mawson, A; Schafranek, P; Steinmann, AM; Nessem, D; Parkin, A; Johns, A; Chou, A; Law, AMK; Lucas, MC; Murphy, KJ; Deng, N; Gallego-Ortega, D; Caldon, CE; Timpson, P; Pajic, M; Ormandy, CJ; Oakes, SR				Castillo, Lesley; Young, Adelaide I. J.; Mawson, Amanda; Schafranek, Pia; Steinmann, Angela M.; Nessem, Danielle; Parkin, Ashleigh; Johns, Amber; Chou, Angela; Law, Andrew M. K.; Lucas, Morghan C.; Murphy, Kendelle J.; Deng, Niantao; Gallego-Ortega, David; Caldon, Catherine E.; Timpson, Paul; Pajic, Marina; Ormandy, Christopher J.; Oakes, Samantha R.		Australian Pancreatic Canc Genome	MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma	ONCOGENE			English	Article							SRC; CANCER; SURVIVAL; FAMILY; EXPRESSION; INHIBITOR; MIGRATION; THERAPY; BCL-2	Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous with a highly unstable genome and provides few common therapeutic targets. We found that MCL1, Cofilin1 (CFL1) and SRC mRNA were highly expressed by a wide range of these cancers, suggesting that a strategy of dual MCL-1 and SRC inhibition might be efficacious for many patients. Immunohistochemistry revealed that MCL-1 protein was present at high levels in 94.7% of patients in a cohort of PDACs from Australian Pancreatic Genome Initiative (APGI). High MCL1 and Cofilin1 mRNA expression was also strongly predictive of poor outcome in the TCGA dataset and in the APGI cohort. In culture, MCL-1 antagonism reduced the level of the cytoskeletal remodeling protein Cofilin1 and phosphorylated SRC on the active Y416 residue, suggestive of reduced invasive capacity. The MCL-1 antagonist S63845 synergized with the SRC kinase inhibitor dasatinib to reduce cell viability and invasiveness through 3D-organotypic matrices. In preclinical murine models, this combination reduced primary tumor growth and liver metastasis of pancreatic cancer xenografts. These data suggest that MCL-1 antagonism, while reducing cell viability, may have an additional benefit in increasing the antimetastatic efficacy of dasatinib for the treatment of PDAC.	[Castillo, Lesley; Young, Adelaide I. J.; Mawson, Amanda; Schafranek, Pia; Steinmann, Angela M.; Nessem, Danielle; Parkin, Ashleigh; Johns, Amber; Law, Andrew M. K.; Lucas, Morghan C.; Murphy, Kendelle J.; Deng, Niantao; Gallego-Ortega, David; Caldon, Catherine E.; Timpson, Paul; Pajic, Marina; Ormandy, Christopher J.; Oakes, Samantha R.] Garvan Inst Med Res, Canc Res Div, 384 Victoria St, Darlinghurst, NSW 2010, Australia; [Castillo, Lesley; Young, Adelaide I. J.; Mawson, Amanda; Schafranek, Pia; Steinmann, Angela M.; Nessem, Danielle; Parkin, Ashleigh; Johns, Amber; Law, Andrew M. K.; Lucas, Morghan C.; Murphy, Kendelle J.; Deng, Niantao; Gallego-Ortega, David; Caldon, Catherine E.; Timpson, Paul; Pajic, Marina; Ormandy, Christopher J.; Oakes, Samantha R.] Kinghorn Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia; [Johns, Amber; Deng, Niantao; Gallego-Ortega, David; Caldon, Catherine E.; Timpson, Paul; Pajic, Marina; Ormandy, Christopher J.; Oakes, Samantha R.] UNSW Med, St Vincents Clin Sch, 384 Victoria St, Kensington, NSW 2052, Australia; [Chou, Angela] Univ Sydney, Camperdown, NSW 2006, Australia	Garvan Institute of Medical Research; University of Sydney	Oakes, SR (corresponding author), Garvan Inst Med Res, Canc Res Div, 384 Victoria St, Darlinghurst, NSW 2010, Australia.; Oakes, SR (corresponding author), Kinghorn Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia.; Oakes, SR (corresponding author), UNSW Med, St Vincents Clin Sch, 384 Victoria St, Kensington, NSW 2052, Australia.	s.oakes@garvan.org.au	Lucas, Morghan C/Y-6452-2019; Gallego-Ortega, David/AAK-9067-2020	Lucas, Morghan C/0000-0001-7654-9137; Gallego-Ortega, David/0000-0002-2347-7835; Herrmann, David/0000-0002-9514-7501; Deng, Niantao/0000-0001-9717-2236; Ormandy, Christopher/0000-0002-2504-7919; Murphy, Angela/0000-0002-8910-7626; Young, Adelaide/0000-0002-5714-0501; Timpson, Paul/0000-0002-5514-7080; Pereira, Brooke/0000-0003-3513-1214; Murphy, Kendelle/0000-0002-3234-3812; Pajic, Marina/0000-0002-3871-3829; Chou, Angela/0000-0001-9212-6927; Oakes, Samantha/0000-0003-1838-2310	Cancer Council NSW; NHMRC Australia; National Breast Cancer Foundation; Cancer Institute NSW; Len Ainsworth Pancreatic Cancer Fellowship; Avner Pancreatic Cancer Foundation; Sutton Motor Pancreatic cancer fund	Cancer Council NSW(Cancer Council New South Wales); NHMRC Australia(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation; Cancer Institute NSW; Len Ainsworth Pancreatic Cancer Fellowship; Avner Pancreatic Cancer Foundation; Sutton Motor Pancreatic cancer fund	This work was supported by grants from the Cancer Council NSW (SRO and CJO), NHMRC Australia (CJO, DGO, PT, MP, and SRO), National Breast Cancer Foundation (ND and CEC), Cancer Institute NSW (DGO, PT, MP), Sutton Motor Pancreatic cancer funding (PT), Len Ainsworth Pancreatic Cancer Fellowship (PT), Avner Pancreatic Cancer Foundation Grant (PT) as well as philanthropic support through the Mostyn Family Foundation (SRO) and Cue Clothing Co. (SRO), Estee Lauder Australia (SRO, DGO and CJO), RT Hall Trust (CJO). We thank Gillian Lehrbach for tissue culture support and Anaiis Zaratzian and Andrew Da Silva for histology services.	Abulwerdi F, 2014, MOL CANCER THER, V13, P565, DOI 10.1158/1535-7163.MCT-12-0767; Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; CARDIN DB, 2018, INVEST NEW DRUG, V36, P442, DOI DOI 10.1007/S10637-017-0519-Z; Chee CE, 2013, ONCOLOGIST, V18, P1091, DOI 10.1634/theoncologist.2013-0255; Chou A, 2018, GUT, V67, P2142, DOI 10.1136/gutjnl-2017-315144; Chowdry R.P., 2014, ONCOTARGET, P5, DOI [10.18632/oncotarget.7485, DOI 10.18632/ONCOTARGET.7485]; Creedon Helen, 2012, Critical Reviews in Oncogenesis, V17, P145; Donahue TR, 2012, CLIN CANCER RES, V18, P1352, DOI 10.1158/1078-0432.CCR-11-1539; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Evans TRJ, 2017, ANN ONCOL, V28, P354, DOI 10.1093/annonc/mdw607; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Goodwin CM, 2015, CELL DEATH DIFFER, V22, P2098, DOI 10.1038/cdd.2015.73; Johns AL, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0430-4; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Law AMK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15885-6; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Miyamoto Y, 1999, ONCOLOGY-BASEL, V56, P73, DOI 10.1159/000011933; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Opferman JT, 2016, FEBS J, V283, P2661, DOI 10.1111/febs.13472; Oser M, 2009, J CELL BIOCHEM, V108, P1252, DOI 10.1002/jcb.22372; Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036; Quinn BA, 2011, EXPERT OPIN INV DRUG, V20, P1397, DOI 10.1517/13543784.2011.609167; Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166; Renouf Daniel J, 2012, Invest New Drugs, V30, P779, DOI 10.1007/s10637-010-9611-3; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Timpson P, 2011, JOVE-J VIS EXP, DOI 10.3791/3089; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang JT, 2015, NEUROSCIENCE, V292, P90, DOI 10.1016/j.neuroscience.2015.02.025; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Young AIJ, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0781-6; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	40	13	13	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1821	1829		10.1038/s41388-019-1091-0	http://dx.doi.org/10.1038/s41388-019-1091-0			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31735913	Green Published, hybrid			2022-12-17	WOS:000514923000015
J	Dengler, MA; Teh, CE; Thijssen, R; Gangoda, L; Lan, P; Herold, MJ; Gray, DH; Kelly, GL; Roberts, AW; Adams, JM				Dengler, Michael A.; Teh, Charis E.; Thijssen, Rachel; Gangoda, Lahiru; Lan, Ping; Herold, Marco J.; Gray, Daniel H.; Kelly, Gemma L.; Roberts, Andrew W.; Adams, Jerry M.			Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma	ONCOGENE			English	Article							BRUTON TYROSINE KINASE; PHASE-I; BCL-2; VENETOCLAX; APOPTOSIS; EXPRESSION; CANCER; MICROENVIRONMENT; MUTATIONS; IBRUTINIB	Apoptosis-regulating BCL-2 family members, which can promote malignant transformation and resistance to therapy, have become prime therapeutic targets, as illustrated by the striking efficacy in certain lymphoid malignancies of the BCL-2-specific inhibitor venetoclax. In other lymphoid malignancies, however, such as the aggressive mantle cell lymphoma (MCL), cell survival might rely instead or also on BCL-2 relative MCL-1. We have explored MCL-1 as a target for killing MCL cells by both genetic and pharmacologic approaches. In several MCL cell lines, MCL-1 knockout with an inducible CRISPR/Cas9 system triggered spontaneous apoptosis. Accordingly, most MCL cell lines proved sensitive to the specific MCL-1 inhibitor S63845, and MCL-1 inhibition also proved efficacious in an MCL xenograft model. Furthermore, its killing efficacy rose on combination with venetoclax, the BCL-X-L-specific inhibitor A-1331852, or Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, which reduced pro-survival signals. We also tested the MCL-1 inhibitor in primary samples from 13 MCL patients, using CD40L-expressing feeder cells to model their microenvironmental support. Notably, all unstimulated primary MCL samples were very sensitive to S63845, but the CD40L stimulation attenuated their sensitivity. Mass cytometric analysis revealed that the stimulation likely conveyed protection by elevating BCL-X-L and MCL-1. Accordingly, sensitivity of the CD40L-stimulated cells to S63845 was substantially restored by co-treatment with venetoclax, the BCL-X-L-specific inhibitor or ibrutinib. Overall, our findings indicate that MCL-1 is very important for survival of MCL cells and that the MCL-1 inhibitor, both alone and together with ibrutinib, venetoclax or a BCL-X-L inhibitor, offers promise for novel improved MCL therapies.	[Dengler, Michael A.; Teh, Charis E.; Thijssen, Rachel; Gangoda, Lahiru; Lan, Ping; Herold, Marco J.; Gray, Daniel H.; Kelly, Gemma L.; Roberts, Andrew W.; Adams, Jerry M.] Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3052, Australia; [Dengler, Michael A.; Teh, Charis E.; Thijssen, Rachel; Gangoda, Lahiru; Lan, Ping; Herold, Marco J.; Gray, Daniel H.; Kelly, Gemma L.; Roberts, Andrew W.; Adams, Jerry M.] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia; [Lan, Ping] Jinan Univ, Inst Adv & Appl Chem Synth, Zhuhai 519070, Guangdong, Peoples R China	Walter & Eliza Hall Institute; University of Melbourne; Jinan University	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3052, Australia.; Adams, JM (corresponding author), Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia.	adams@wehi.edu.au	Dengler, Michael/AFR-3509-2022; Kelly, Gemma/AAG-6352-2020; Adams, Jerry M/E-1199-2013; Roberts, Andrew W/C-6736-2012; Herold, Marco J/C-8039-2013; Thijssen, Rachel/AAE-7599-2022; Gray, Daniel/A-3293-2013	Roberts, Andrew W/0000-0002-7341-5720; Herold, Marco J/0000-0001-7539-7581; Thijssen, Rachel/0000-0002-4493-306X; Adams, Jerry/0000-0002-4360-8628; Dengler, Michael/0000-0002-1693-1761; Gangoda, Lahiru/0000-0003-1931-6809; Gray, Daniel/0000-0002-8457-8242; Kelly, Gemma/0000-0002-6533-1201	Metro South Health; CASS Foundation Science Medicine Grant [SM/18/7801]; National Health and Medical Research Council (NHMRC) [1016701, 1079560]; SCOR from the Leukemia and Lymphoma Society [7015-18, 5467-18]; NHMRC [1089072, 1090236]; Victorian Cancer Agency Fellowship [MCRF 17028]; Cancer Council of Victoria [1146518, 1147328]; Leukaemia Foundation Australia grant; Australian Government Independent Research Institute Infrastructure Support Scheme [9000220]; Victorian State Government Operational Infrastructure Support Program	Metro South Health; CASS Foundation Science Medicine Grant; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); SCOR from the Leukemia and Lymphoma Society; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency Fellowship; Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Leukaemia Foundation Australia grant; Australian Government Independent Research Institute Infrastructure Support Scheme(Australian Government); Victorian State Government Operational Infrastructure Support Program	We thank Naomi Sprigg (Royal Melbourne Hospital) for assistance with fresh clinical samples, Leonie Gibson and Tania Tan for excellent technical assistance, and Connie Li Wai Suen for statistical advice. We would like to acknowledge the Metro South Health Cancer Collaborative Biobank, Brisbane for the provision of hematologic malignancy samples for this project. The Cancer Collaborative Biobank is supported by Metro South Health funding. This work was supported by a CASS Foundation Science & Medicine Grant SM/18/7801 (to MAD); program grant 1016701 (to JMA) and Practitioner Fellowship 1079560 (to AWR) from the National Health and Medical Research Council (NHMRC); SCOR grant 7015-18 (to JMA and AWR) and Fellowship 5467-18 (to RT) from the Leukemia and Lymphoma Society; NHMRC Fellowship 1089072 (to CET), NHMRC Fellowship 1090236 (to DHG), Victorian Cancer Agency Fellowship MCRF 17028 (to GLK), Cancer Council of Victoria Grants-in-Aid 1146518 (to DHG) and 1147328 (to GLK), Leukaemia Foundation Australia grant (to GLK), and operational infrastructure grants through the Australian Government Independent Research Institute Infrastructure Support Scheme (9000220) and the Victorian State Government Operational Infrastructure Support Program. This work was performed in part at the Materials Characterization and Fabrication Platform at the University of Melbourne and the Victorian Node of the Australian National Fabrication Facility.	Adams JM, 2018, CELL DEATH DIFFER, V25, P27, DOI 10.1038/cdd.2017.161; Agarwal R, 2019, NAT MED, V25, P119, DOI 10.1038/s41591-018-0243-z; Amin HM, 2003, ARCH PATHOL LAB MED, V127, P424; Anderson MA, 2016, BLOOD, V127, P3215, DOI 10.1182/blood-2016-01-688796; Arbour N, 2008, J NEUROSCI, V28, P6068, DOI 10.1523/JNEUROSCI.4940-07.2008; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110; Brennan MS, 2018, BLOOD, V132, P1573, DOI 10.1182/blood-2018-06-859405; Brien G, 2007, ONCOGENE, V26, P5828, DOI 10.1038/sj.onc.1210363; Burger JA, 2011, SEMIN CANCER BIOL, V21, P308, DOI 10.1016/j.semcancer.2011.09.006; Caenepeel S, 2018, CANCER DISCOV, V8, P1582, DOI 10.1158/2159-8290.CD-18-0387; Campo E, 2015, BLOOD, V125, P48, DOI 10.1182/blood-2014-05-521898; Camps J, 2006, LEUKEMIA RES, V30, P923, DOI 10.1016/j.leukres.2005.11.013; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chang BY, 2013, BLOOD, V122, P2412, DOI 10.1182/blood-2013-02-482125; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chiron D, 2016, BLOOD, V128, P2808, DOI 10.1182/blood-2016-06-720490; Chiron D, 2015, ONCOTARGET, V6, P8750, DOI 10.18632/oncotarget.3275; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Davids MS, 2017, J CLIN ONCOL, V35, P826, DOI 10.1200/JCO.2016.70.4320; Dengler MA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.552; Eyre TA, 2019, HAEMATOLOGICA, V104, pE68, DOI 10.3324/haematol.2018.198812; Fakhri B, 2017, THER ADV HEMATOL, V8, P223, DOI 10.1177/2040620717719616; Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149; Glaser SP, 2012, GENE DEV, V26, P120, DOI 10.1101/gad.182980.111; Gomez-Bougie P, 2018, BLOOD, V132, P2656, DOI 10.1182/blood-2018-03-836718; Gong JN, 2016, BLOOD, V128, P1834, DOI 10.1182/blood-2016-03-704908; Good Z, 2018, NAT MED, V24, P474, DOI 10.1038/nm.4505; Greaves G, 2019, CELL DEATH DIFFER, V26, P1037, DOI 10.1038/s41418-018-0183-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang S, 2018, P IEEE SEMICOND THER, P8; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Kurtova AV, 2009, BLOOD, V113, P4604, DOI 10.1182/blood-2008-10-185827; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Ma J, 2014, BRIT J HAEMATOL, V166, P849, DOI 10.1111/bjh.12974; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Montero J, 2018, CELL DEATH DIFFER, V25, P56, DOI 10.1038/cdd.2017.183; Moujalled DM, 2019, LEUKEMIA, V33, P905, DOI 10.1038/s41375-018-0261-3; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; PRICHARD MN, 1991, ANTIMICROB AGENTS CH, V35, P1060, DOI 10.1128/AAC.35.6.1060; Prukova D, 2019, CLIN CANCER RES, V25, P4455, DOI 10.1158/1078-0432.CCR-18-3275; Ramsey HE, 2018, CANCER DISCOV, V8, P1566, DOI 10.1158/2159-8290.CD-18-0140; Rauert-Wunderlich H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0157-6; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Rudolph C, 2004, CANCER GENET CYTOGEN, V153, P144, DOI 10.1016/j.cancergencyto.2004.01.006; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tam CS, 2018, NEW ENGL J MED, V378, P1211, DOI 10.1056/NEJMoa1715519; Teh TC, 2018, LEUKEMIA, V32, P303, DOI 10.1038/leu.2017.243; Thomas RL, 2013, GENE DEV, V27, P1365, DOI 10.1101/gad.215871.113; Tucker CA, 2006, LEUKEMIA RES, V30, P449, DOI 10.1016/j.leukres.2005.08.016; Vick B, 2009, HEPATOLOGY, V49, P627, DOI 10.1002/hep.22664; Vogler M, 2012, CELL DEATH DIFFER, V19, P67, DOI 10.1038/cdd.2011.158; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304	62	13	13	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					2009	2023		10.1038/s41388-019-1122-x	http://dx.doi.org/10.1038/s41388-019-1122-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772331				2022-12-17	WOS:000516579800014
J	Warren, NJH; Eastman, A				Warren, Nicholas J. H.; Eastman, Alan			Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage	ONCOGENE			English	Review							CYCLIN-DEPENDENT KINASES; STRAND BREAK REPAIR; CHK1 INHIBITOR; CELL-CYCLE; PHASE-I; REPLICATION STRESS; SYNTHETIC LETHALITY; DOSE-ESCALATION; CANCER-CELLS; GENOME INTEGRITY	Inhibition of the DNA damage response is an emerging strategy to treat cancer. Understanding how DNA damage response inhibitors cause cytotoxicity in cancer cells is crucial to their further clinical development. This review focuses on three different mechanisms of cell killing by checkpoint kinase I inhibitors (CHK1i). DNA damage induced by chemotherapy drugs, such as topoisomerase I inhibitors, results in S and G2 phase arrest. Addition of CHK1i promotes cell cycle progression before repair is completed resulting in mitotic catastrophe. Ribonucleotide reductase inhibitors such as gemcitabine also arrest cells in S phase by preventing dNTP synthesis. Addition of CHK1i re-activates the DNA helicase to unwind DNA, but in the absence of dNTPs, this leads to excessive single-strand DNA that exceeds the protective capacity of the single-strand-binding protein RPA. Unprotected DNA is subjected to nuclease cleavage, resulting in replication catastrophe. CHK1i alone also kills a subset of cell lines through MRE11 and MUS81-mediated DNA cleavage in S phase cells. The choice of mechanism depends on the activation state of CDK2. Low level activation of CDK2 mediates helicase activation, cell cycle progression, and both replication and mitotic catastrophe. In contrast, high CDK2 activity is required for sensitivity to CHK1i as monotherapy. This high CDK2 activity threshold usually occurs late in the cell cycle to prepare for mitosis, but in CHK1i-sensitive cells, high activity can be attained in early S phase, resulting in DNA cleavage and cell death. This sensitivity to CHK1i has previously been associated with endogenous replication stress, but the dependence on high CDK2 activity, as well as MRE11, contradicts this hypothesis. The major unresolved question is why some cell lines fail to restrain their high CDK2 activity and hence succumb to CHK1i in S phase. Resolving this question will facilitate stratification of patients for treatment with CHK1i as monotherapy.	[Warren, Nicholas J. H.; Eastman, Alan] Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03756 USA; [Eastman, Alan] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Eastman, A (corresponding author), Geisel Sch Med Dartmouth, Dept Mol & Syst Biol, Lebanon, NH 03756 USA.; Eastman, A (corresponding author), Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA.	Alan.R.Eastman@Dartmouth.edu		Warren, Nicholas/0000-0003-4640-2868	National Cancer Institute [CA117874]; Cancer Center Support Grant [CA23108]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant	The research of the authors has been supported by a grant from the National Cancer Institute (CA117874), and a Cancer Center Support Grant to the Norris Cotton Cancer Center (CA23108).	Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; Al-Ahmadie H, 2014, CANCER DISCOV, V4, P1014, DOI 10.1158/2159-8290.CD-14-0380; [Anonymous], 2019, J CLIN ONCOL S; Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Bahassi EM, 2008, ONCOGENE, V27, P3977, DOI 10.1038/onc.2008.17; Banerji U, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3095; Barnard D, 2016, INVEST NEW DRUG, V34, P49, DOI 10.1007/s10637-015-0310-y; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Betous R, 2012, GENE DEV, V26, P151, DOI 10.1101/gad.178459.111; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Brega N, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3062; Bremmer SC, 2012, J BIOL CHEM, V287, P1662, DOI 10.1074/jbc.M111.281105; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Brown JS, 2017, CANCER DISCOV, V7, P20, DOI 10.1158/2159-8290.CD-16-0860; Buis J, 2012, NAT STRUCT MOL BIOL, V19, P246, DOI 10.1038/nsmb.2212; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Carrassa L, 2011, CELL CYCLE, V10, P2121, DOI 10.4161/cc.10.13.16398; Cicenas J, 2014, CANCERS, V6, P2224, DOI 10.3390/cancers6042224; Coudreuse D, 2010, NATURE, V468, P1074, DOI 10.1038/nature09543; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; Daud AI, 2015, J CLIN ONCOL, V33, P1060, DOI 10.1200/JCO.2014.57.5027; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Del Nagro CJ, 2014, CELL CYCLE, V13, P303, DOI 10.4161/cc.27055; Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053; Duda H, 2016, DEV CELL, V39, P740, DOI 10.1016/j.devcel.2016.11.017; Dungrawala H, 2015, MOL CELL, V59, P998, DOI 10.1016/j.molcel.2015.07.030; Eastman A, 2017, ONCOTARGET, V8, P8854, DOI 10.18632/oncotarget.12673; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Forment JV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023517; Fugger K, 2015, CELL REP, V10, P1749, DOI 10.1016/j.celrep.2015.02.028; Fugger K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2395; Fukuda T, 2001, CANCER RES, V61, P23; Gadhikar MA, 2018, CANCER RES, V78, P781, DOI 10.1158/0008-5472.CAN-17-2802; Ge XQ, 2010, J CELL BIOL, V191, P1285, DOI 10.1083/jcb.201007074; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Godfrey M, 2017, MOL CELL, V65, P393, DOI 10.1016/j.molcel.2016.12.018; Gong CJ, 2016, BBA-GENE REGUL MECH, V1859, P612, DOI 10.1016/j.bbagrm.2016.02.012; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; He YJ, 2018, NATURE, V563, P522, DOI 10.1038/s41586-018-0670-5; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; Hong D, 2016, J CLIN ONCOL, V34, P1764, DOI 10.1200/JCO.2015.64.5788; Infante JR, 2017, CLIN CANCER RES, V23, P2423, DOI 10.1158/1078-0432.CCR-16-1782; Italiano A, 2018, ANN ONCOL, V29, P1304, DOI 10.1093/annonc/mdy076; Jorda R, 2018, J MED CHEM, V61, P9105, DOI 10.1021/acs.jmedchem.8b00049; Karp JE, 2012, CLIN CANCER RES, V18, P6723, DOI 10.1158/1078-0432.CCR-12-2442; Kim MK, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1231-z; Kohler C, 2016, CELL CYCLE, V15, P974, DOI 10.1080/15384101.2016.1152424; Koh SB, 2018, CANCER RES, V78, P3054, DOI 10.1158/0008-5472.CAN-17-3932; Koh SB, 2015, CANCER RES, V75, P3583, DOI 10.1158/0008-5472.CAN-14-3347; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kotsantis P, 2018, CANCER DISCOV, V8, P537, DOI 10.1158/2159-8290.CD-17-1461; Kumagai A, 2011, J CELL BIOL, V193, P995, DOI 10.1083/jcb.201102003; Kumagai A, 2010, CELL, V140, P349, DOI 10.1016/j.cell.2009.12.049; Kwok M, 2016, BLOOD, V127, P582, DOI 10.1182/blood-2015-05-644872; Lee Jeaho, 2016, [Journal of Creative Information Culture, 창의정보문화연구], V2, P1; Lemacon D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01180-5; Levesque AA, 2008, MOL CANCER THER, V7, P252, DOI 10.1158/1535-7163.MCT-07-2066; Lowery CD, 2019, CLIN CANCER RES, V25, P2278, DOI 10.1158/1078-0432.CCR-18-2728; Lu R, 2004, J BIOL CHEM, V279, P31164, DOI 10.1074/jbc.M404728200; Lu XY, 2009, J BIOL CHEM, V284, P35325, DOI 10.1074/jbc.M109.035949; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623; Mei L, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0733-6; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; Mohni KN, 2014, CANCER RES, V74, P2835, DOI 10.1158/0008-5472.CAN-13-3229; Montano R, 2017, ONCOTARGET, V8, P67754, DOI 10.18632/oncotarget.18834; Montano R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-604; Montano R, 2012, MOL CANCER THER, V11, P427, DOI 10.1158/1535-7163.MCT-11-0406; Nagel R, 2019, MOL CANCER THER, V18, P762, DOI 10.1158/1535-7163.MCT-18-0972; Parsels LA, 2016, CELL CYCLE, V15, P730, DOI 10.1080/15384101.2016.1148841; Pefani DE, 2014, NAT CELL BIOL, V16, P962, DOI 10.1038/ncb3035; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Pommier Y, 2013, ACS CHEM BIOL, V8, P82, DOI 10.1021/cb300648v; Powers BL, 2017, J CELL SCI, V130, P2673, DOI 10.1242/jcs.201012; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Rawlinson R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-483; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Rosell R, 2004, CLIN CANCER RES, V10, P1318, DOI 10.1158/1078-0432.CCR-03-0156; Sakurikar N, 2016, CELL CYCLE, V15, P1184, DOI 10.1080/15384101.2016.1160983; Sakurikar N, 2016, ONCOTARGET, V7, P1380, DOI 10.18632/oncotarget.6364; Saldivar JC, 2018, SCIENCE, V361, P806, DOI 10.1126/science.aap9346; Sausville E, 2014, CANCER CHEMOTH PHARM, V73, P539, DOI 10.1007/s00280-014-2380-5; Scagliotti G, 2016, INVEST NEW DRUG, V34, P625, DOI 10.1007/s10637-016-0368-1; Sen T, 2017, CANCER RES, V77, P3870, DOI 10.1158/0008-5472.CAN-16-3409; Seto T, 2013, CANCER CHEMOTH PHARM, V72, P619, DOI 10.1007/s00280-013-2234-6; Sorensen CS, 2010, CELL CYCLE, V9, P450, DOI 10.4161/cc.9.3.10513; Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062; Suhasini AN, 2013, MOL CELL BIOL, V33, P2212, DOI 10.1128/MCB.01256-12; Sultana R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057098; Swaffer MP, 2016, CELL, V167, P1750, DOI 10.1016/j.cell.2016.11.034; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Thompson R, 2013, BRIT J CLIN PHARMACO, V76, P358, DOI 10.1111/bcp.12139; Thompson R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044021; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Tomimatsu N, 2017, J BIOL CHEM, V292, P10779, DOI 10.1074/jbc.M116.772475; Ubhi T, 2019, CANCER RES, V79, P1730, DOI 10.1158/0008-5472.CAN-18-3631; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Walton MI, 2016, ONCOTARGET, V7, P2329, DOI 10.18632/oncotarget.4919; Warren NJH, 2019, ACS PHARMACOL TRANSL, V2, P168, DOI 10.1021/acsptsci.9b00001; Warren NJH, 2019, J BIOL CHEM, V294, P1763, DOI 10.1074/jbc.RA118.005231; Wehler T, 2017, LUNG CANCER, V108, P212, DOI 10.1016/j.lungcan.2017.03.001; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Wong PG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017533; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	115	13	14	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1389	1401		10.1038/s41388-019-1079-9	http://dx.doi.org/10.1038/s41388-019-1079-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659257	Green Accepted			2022-12-17	WOS:000513289600001
J	Moreno-Lama, L; Galindo-Campos, MA; Martinez, C; Comerma, L; Vazquez, I; Vernet-Tomas, M; Ampurdanes, C; Lutfi, N; Martin-Caballero, J; Dantzer, F; Quintela-Fandino, M; Ali, SO; Jimeno, J; Yelamos, J				Moreno-Lama, Lucia; Galindo-Campos, Miguel A.; Martinez, Carlos; Comerma, Laura; Vazquez, Ivonne; Vernet-Tomas, Maria; Ampurdanes, Coral; Lutfi, Nura; Martin-Caballero, Juan; Dantzer, Francoise; Quintela-Fandino, Miguel; Ali, Syed O.; Jimeno, Jaime; Yelamos, Jose			Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice	ONCOGENE			English	Article							CANCER; EXPRESSION; REVEALS	Poly(ADP-ribose)-polymerase (PARP)-1 and PARP-2 play an essential role in the DNA damage response. Based on this effect of PARP in the tumor cell itself, PARP inhibitors have emerged as new therapeutic tools both approved and in clinical trials. However, the interactome of multiple other cell types, particularly T cells, within the tumor microenvironment are known to either favor or limit tumorigenesis. Here, we bypassed the embryonic lethality of dually PARP-1/PARP-2-deficient mice by using a PARP-1-deficient mouse with a Cd4-promoter-driven deletion of PARP-2 in T cells to investigate the understudied role of these PARPs in the modulation of T cell responses against AT-3-induced breast tumors. We found that dual PARP-1/PARP-2-deficiency in T cells promotes tumor growth while single deficiency of each protein limited tumor progression. Analysis of tumor-infiltrating cells in dual PARP-1/PARP-2-deficiency host-mice revealed a global change in immunological profile and impaired recruitment and activation of T cells. Conversely, single PARP-1 and PARP-2-deficiency tends to produce an environment with an active and partially upregulated immune response. Our findings pinpoint opposite effects of single and dual PARP-1 and PARP-2-deficiency in modulating the antitumor response with an impact on tumor progression, and will have implications for the development of more selective PARP-centered therapies.	[Moreno-Lama, Lucia; Galindo-Campos, Miguel A.; Ampurdanes, Coral; Lutfi, Nura; Yelamos, Jose] Hosp del Mar Med Res Inst IMIM, Canc Res Program, Barcelona, Spain; [Martinez, Carlos] IMIB LAIB Arrixaca, Expt Pathol Unit, Murcia, Spain; [Comerma, Laura; Vazquez, Ivonne; Yelamos, Jose] Hosp del Mar, Dept Pathol, Barcelona, Spain; [Vernet-Tomas, Maria] Hosp del Mar Med Res Inst IMIM, Dept Obstet & Gynecol, Barcelona, Spain; [Martin-Caballero, Juan] Barcelona Biomed Res Pk PRBB, Barcelona, Spain; [Dantzer, Francoise] ESBS, Lab Excellence Medalis, Biotechnol & Cell Signaling, UMR7242 CNRS, Illkirch Graffenstaden, France; [Quintela-Fandino, Miguel] CNIO, Breast Canc Clin Res Unit, Madrid, Spain; [Ali, Syed O.] NHS, Oxford Univ Hosp, Oxford, England; [Jimeno, Jaime] Hosp Univ Marques Valdecilla, Dept Gen Surg, Breast Unit, Santander, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centro Nacional de Investigaciones Oncologicas (CNIO); Oxford University Hospitals NHS Foundation Trust; Hospital Universitario Marques de Valdecilla (HUMV)	Yelamos, J (corresponding author), Hosp del Mar Med Res Inst IMIM, Canc Res Program, Barcelona, Spain.; Yelamos, J (corresponding author), Hosp del Mar, Dept Pathol, Barcelona, Spain.	jyelamos@imim.es	Blesa, Laura Comerma/AAQ-9455-2020; Yelamos, Jose/N-2842-2016; Vernet-Tomas, Maria/AAE-6363-2021; Moreno Lama, Lucia/CAC-3410-2022; Martinez, Carlos M./E-4986-2016	Blesa, Laura Comerma/0000-0002-0249-4636; Moreno Lama, Lucia/0000-0003-3900-1388; Martinez, Carlos M./0000-0003-3307-1326; Dantzer, Francoise/0000-0003-0945-8483; Vazquez, Ivonne/0000-0002-5305-1560; Yelamos, Jose/0000-0003-1195-1496; Galindo Campos, Miguel Alejandro/0000-0002-0650-8660	Spanish Ministerio de Economia, Industria y Competitividad [SAF2017-83565-R]; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC); LABEX, Strasbourg University, CNRS [ANR-10-LABX-0034_Medalis]	Spanish Ministerio de Economia, Industria y Competitividad; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC); LABEX, Strasbourg University, CNRS	We thank Dr. Abrams Scott for giving us the AT-3 cell line, Mary Hensen for assistance with the AT-3 cell line, Gemma Torres-Sotodosos and Laura Regue for technical assistance, and Xavi Duran for statistical assistance. The Yelamos's lab is funded by the Spanish Ministerio de Economia, Industria y Competitividad (grant SAF2017-83565-R) and The Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC). The Dantzer's lab is supported by LABEX ANR-10-LABX-0034_Medalis, Strasbourg University, CNRS.	Ashworth A, 2018, NAT REV CLIN ONCOL, V15, P564, DOI 10.1038/s41571-018-0055-6; Badoual C, 2013, CANCER RES, V73, P128, DOI 10.1158/0008-5472.CAN-12-2606; Bai P, 2015, MOL CELL, V58, P947, DOI 10.1016/j.molcel.2015.01.034; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Bock FJ, 2015, MOL CELL, V58, P911, DOI 10.1016/j.molcel.2015.06.012; Broz ML, 2014, CANCER CELL, V26, P638, DOI 10.1016/j.ccell.2014.09.007; Cohen MS, 2018, NAT CHEM BIOL, V14, P236, DOI [10.1038/NCHEMBIO.2568, 10.1038/nchembio.2568]; Dantzer F, 2006, P NATL ACAD SCI USA, V103, P14854, DOI 10.1073/pnas.0604252103; Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Farres J, 2015, CELL DEATH DIFFER, V22, P1144, DOI 10.1038/cdd.2014.202; Farres J, 2013, BLOOD, V122, P44, DOI 10.1182/blood-2012-12-472845; Gibson BA, 2016, SCIENCE, V353, P45, DOI 10.1126/science.aaf7865; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Hui EF, 2017, SCIENCE, V355, P1428, DOI 10.1126/science.aaf1292; Lee KM, 2003, J IMMUNOL, V170, P4881, DOI 10.4049/jimmunol.170.10.4881; Luo XR, 2015, J BIOL CHEM, V290, P28675, DOI 10.1074/jbc.M115.661611; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martinez-Lostao L, 2015, CLIN CANCER RES, V21, P5047, DOI 10.1158/1078-0432.CCR-15-0685; Muntasell A, 2019, CLIN CANCER RES, V25, P1535, DOI 10.1158/1078-0432.CCR-18-2365; Navarro J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41962; Nicolas L, 2010, ONCOGENE, V29, P2877, DOI 10.1038/onc.2010.11; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Saenz L, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-171; Schalper KA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju435; Silva-Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568-019-0153-5; Simon S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1364828; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Stewart RA, 2018, CANCER RES, V78, P6717, DOI 10.1158/0008-5472.CAN-18-2652; Stewart TJ, 2007, J IMMUNOL, V179, P2851, DOI 10.4049/jimmunol.179.5.2851; Valdor R, 2008, MOL IMMUNOL, V45, P1863, DOI 10.1016/j.molimm.2007.10.044; Veglia F, 2017, CURR OPIN IMMUNOL, V45, P43, DOI 10.1016/j.coi.2017.01.002; Wahlberg E, 2012, NAT BIOTECHNOL, V30, P283, DOI 10.1038/nbt.2121; Wang BF, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-43; Yelamos J, 2006, EMBO J, V25, P4350, DOI 10.1038/sj.emboj.7601301; Yelamos J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1065370; Yelamos J, 2011, AM J CANCER RES, V1, P328; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Zhang P, 2013, BLOOD, V122, P2224, DOI 10.1182/blood-2013-05-503250	40	13	14	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2835	2843		10.1038/s41388-020-1175-x	http://dx.doi.org/10.1038/s41388-020-1175-x		JAN 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32001817				2022-12-17	WOS:000510328400003
J	McGinn, O; Ward, AV; Fettig, LM; Riley, D; Ivie, J; Paul, KV; Kabos, P; Finlay-Schultz, J; Sartorius, CA				McGinn, Olivia; Ward, Ashley, V; Fettig, Lynsey M.; Riley, Duncan; Ivie, Joshua; Paul, Kiran, V; Kabos, Peter; Finlay-Schultz, Jessica; Sartorius, Carol A.			Cytokeratin 5 alters beta-catenin dynamics in breast cancer cells	ONCOGENE			English	Article							NEGATIVE RESPONSE ELEMENTS; GROWTH-FACTOR RECEPTOR; STEM-CELLS; KERATIN 17; PROGESTERONE-RECEPTORS; EPITHELIAL PROGENITORS; ESTROGEN-RECEPTOR; MASS-SPECTROMETRY; RETINOIC ACID; CROSS-TALK	Estrogen receptor (ER) positive breast cancers often contain subpopulations of cells that express the intermediate filament protein cytokeratin 5 (CK5). CK5+ cells are enriched in cancer stem cell (CSC) properties, can be induced by progestins, and predict poor prognosis in ER+ breast cancer. We established through CK5 knockout and overexpression in ER+ breast cancer cell lines that CK5 is important for tumorsphere formation, prompting us to speculate that CK5 has regulatory activity in CSCs. To interrogate CK5 interacting proteins that may be functionally cooperative, we performed immunoprecipitation-mass spectrometry for CK5 in ER+ breast cancer cells. Focusing on proteins with signaling activity, we identified beta-catenin, a key transcription factor of the Wnt signaling pathway and cell adhesion molecule, as a CK5 interactor, which we confirmed by co-immunoprecipitation in several breast cancer models. We interrogated the dual functions of beta-catenin in relation to CK5. Knockout or knockdown of CK5 ablated beta-catenin transcriptional activity in response to progestins and Wnt stimuli. Conversely, CK5 induced by progestins or overexpression was sufficient to promote the loss of beta-catenin at the cell membrane and total E-cadherin loss. A breast cancer patient-derived xenograft showed similar loss of membrane beta-catenin and E-cadherin in CK5+ but not intratumoral CK5- cells and single-cell RNA sequencing found the top enriched pathways in the CK5+ cell cluster were cell junction remodeling and signaling. This report highlights that CK5 actively remodels cell morphology and that blockade of CK5-beta-catenin interaction may reverse the detrimental properties of CK5+ breast cancer cells.	[McGinn, Olivia; Ward, Ashley, V; Fettig, Lynsey M.; Riley, Duncan; Ivie, Joshua; Finlay-Schultz, Jessica; Sartorius, Carol A.] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA; [Paul, Kiran, V; Kabos, Peter] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Sartorius, CA (corresponding author), Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA.	Carol.Sartorius@cuanschutz.edu	; McGinn, Olivia/J-8337-2015	Riley, Duncan/0000-0003-1829-7116; Vinod Paul, Kiran/0000-0002-1212-4217; Finlay-Schultz, Jessica/0000-0002-7855-9870; McGinn, Olivia/0000-0003-0769-5581	National Institutes of Health [NIH F31 CA232456, NIH 2R01 CA140985]; Breast Cancer Research Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation	We thank the University of Colorado School of Medicine Biological Mass Spectrometry Facility and Advanced Light Microscopy Core for their assistance. This work was supported by National Institutes of Health grants NIH F31 CA232456 (OM), NIH 2R01 CA140985 (CAS), and the Breast Cancer Research Foundation (CAS).	Abdelrahman AE, 2017, ANN DIAGN PATHOL, V28, P43, DOI 10.1016/j.anndiagpath.2017.01.009; Axlund SD, 2013, HORM CANCER-US, V4, P36, DOI 10.1007/s12672-012-0127-5; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Boecker W, 2003, CELL PROLIFERAT, V36, P73, DOI 10.1046/j.1365-2184.36.s.1.7.x; Boudreau A, 2013, P NATL ACAD SCI USA, V110, pE3937, DOI 10.1073/pnas.1315022110; Brisken C, 2000, GENE DEV, V14, P650; Callipo L, 2010, ANAL BIOCHEM, V400, P195, DOI 10.1016/j.ab.2010.01.039; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Melo FDE, 2016, CANCERS, V8, DOI 10.3390/cancers8070060; DePianto D, 2010, NAT GENET, V42, P910, DOI 10.1038/ng.665; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Escobar-Hoyos LF, 2015, CANCER RES, V75, P3650, DOI 10.1158/0008-5472.CAN-15-0293; Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06; Farahani E, 2014, CARCINOGENESIS, V35, P747, DOI 10.1093/carcin/bgu045; Fettig LM, 2017, ONCOGENE, V36, P6074, DOI 10.1038/onc.2017.204; Finlay-Schultz J, 2017, CANCER RES, V77, P4934, DOI 10.1158/0008-5472.CAN-16-3541; Furthauer M, 2009, MOL ONCOL, V3, P339, DOI 10.1016/j.molonc.2009.05.006; Goodman CR, 2016, ONCOGENE, V35, P1373, DOI 10.1038/onc.2015.193; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hartwell KA, 2013, NAT CHEM BIOL, V9, P840, DOI [10.1038/NCHEMBIO.1367, 10.1038/nchembio.1367]; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Herrmann H, 2009, J CLIN INVEST, V119, P1772, DOI 10.1172/JCI38214; Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Howard S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023899; Jho SH, 2001, J BIOL CHEM, V276, P45914, DOI 10.1074/jbc.M103144200; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2012, BREAST CANCER RES TR, V135, P415, DOI 10.1007/s10549-012-2164-8; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Kam Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004580; Khanom R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161163; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kreplak L, 2004, EXP CELL RES, V301, P77, DOI 10.1016/j.yexcr.2004.08.021; Ku NO, 2004, J CELL BIOL, V166, P479, DOI 10.1083/jcb.200402051; Laakso M, 2006, CLIN CANCER RES, V12, P4185, DOI 10.1158/1078-0432.CCR-06-0353; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lindstrom LS, 2018, JNCI-J NATL CANCER I, V110, P726, DOI 10.1093/jnci/djx270; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557; Mikami T, 2015, VIRCHOWS ARCH, V466, P559, DOI 10.1007/s00428-015-1735-6; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830; Radoja N, 1997, J INVEST DERMATOL, V109, P566, DOI 10.1111/1523-1747.ep12337483; Roarty K, 2010, CURR OPIN PHARMACOL, V10, P643, DOI 10.1016/j.coph.2010.07.004; Sankar S, 2013, MOL CELL BIOL, V33, P4448, DOI 10.1128/MCB.00241-13; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Sato T, 2014, ONCOGENE, V33, P2215, DOI 10.1038/onc.2013.172; Searle BC, 2010, PROTEOMICS, V10, P1265, DOI 10.1002/pmic.200900437; Siitonen SMKJ, 1995, ANAT PATHOL, V105, P394; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; Sutton LM, 2010, AM J CLIN PATHOL, V134, P782, DOI 10.1309/AJCPRMD3ARUO5WPN; Toivola DM, 2010, TRENDS CELL BIOL, V20, P79, DOI 10.1016/j.tcb.2009.11.004; Truong TH, 2019, ENDOCRINOLOGY, V160, P430, DOI 10.1210/en.2018-00990; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155	71	13	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2478	2492		10.1038/s41388-020-1164-0	http://dx.doi.org/10.1038/s41388-020-1164-0		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988452	Green Accepted			2022-12-17	WOS:000509655100002
J	Chen, JB; Chou, FJ; Yeh, SY; Ou, ZY; Shyr, C; Huang, CP; Xiang, ZD; Sun, Y; Messing, E; Zu, XB; Chang, CS				Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Shyr, Chihrong; Huang, Chiping; Xiang, Zhendong; Sun, Yin; Messing, Edward; Zu, Xiongbing; Chang, Chawnshang			Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated G alpha i protein/MAPK/MMP9 intracellular signaling	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; ZINC TRANSPORTER; THERAPEUTIC TARGETS; HUMAN ZIP9; PROSTATE; METASTASIS; CALCIUM; STATES	While androgens may function via nuclear androgen receptor (nAR) to increase bladder cancer (BCa) progression, the impact of androgens on muscle invasive BCa, which contains nearly 80% nAR-negative cells, remains unclear. To dissect the androgens potential impacts on these nAR-negative muscle invasive BCa, we first found that the androgens, dihydrotestosterone (DHT) might function via a novel membrane AR (mAR-SLC39A9) to increase nAR-negative BCa cell migration and invasion. Mechanism dissection revealed that DHT/mAR-SLC39A9 might function by altering G(alpha i) protein-mediated MAPK/MMP9 intracellular signaling to increase nAR-negative BCa cell migration and invasion. Preclinical studies using multiple in vitro nAR-negative BCa cell lines and an in vivo mouse model all demonstrated that targeting this newly identified DHT/mAR-SLC39A9/G(alpha i)/MAPK/MMP9 signaling with small molecules mAR-SLC39A9-shRNA or G(alpha i)-shRNA, and not the classic antiandrogens including enzalutamide, bicalutamide, or hydroxyflutamide, could suppress nAR-negative BCa cell invasion. Results from human clinical samples surveys also indicated the positive correlation of this newly identified DHT/mAR signaling with BCa progression and prognosis. Together, these results suggest that androgens may not only function via the classic nAR to increase the nAR-positive BCa cell invasion, they may also function via this newly identified mAR-SLC39A9 to increase the nAR-negative/mAR-positive BCa cell invasion.	[Chen, Jinbo; Ou, Zhenyu; Zu, Xiongbing] Cent South Univ, Xiangya Hosp, Dept Urol, Changsha 410008, Peoples R China; [Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Xiang, Zhendong; Sun, Yin; Messing, Edward; Chang, Chawnshang] Univ Rochester, Dept Pathol, Med Inst, George Whipple Lab Canc Res, Rochester, NY 14627 USA; [Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Xiang, Zhendong; Sun, Yin; Messing, Edward; Chang, Chawnshang] Univ Rochester, Dept Urol, Med Inst, George Whipple Lab Canc Res, Rochester, NY USA; [Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Xiang, Zhendong; Sun, Yin; Messing, Edward; Chang, Chawnshang] Univ Rochester, Dept Radiat Oncol, Med Inst, George Whipple Lab Canc Res, Rochester, NY 14627 USA; [Chen, Jinbo; Chou, Fuju; Yeh, Shuyuan; Ou, Zhenyu; Xiang, Zhendong; Sun, Yin; Messing, Edward; Chang, Chawnshang] Univ Rochester, Wilmot Canc Ctr, Med Inst, Rochester, NY 14627 USA; [Shyr, Chihrong; Huang, Chiping; Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Dept Urol, Taichung 404, Taiwan; [Shyr, Chihrong; Huang, Chiping; Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Dept Med Technol, Taichung 404, Taiwan	Central South University; University of Rochester; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Zu, XB (corresponding author), Cent South Univ, Xiangya Hosp, Dept Urol, Changsha 410008, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Dept Pathol, Med Inst, George Whipple Lab Canc Res, Rochester, NY 14627 USA.; Chang, CS (corresponding author), Univ Rochester, Dept Radiat Oncol, Med Inst, George Whipple Lab Canc Res, Rochester, NY 14627 USA.; Chang, CS (corresponding author), Univ Rochester, Wilmot Canc Ctr, Med Inst, Rochester, NY 14627 USA.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Dept Urol, Taichung 404, Taiwan.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Dept Med Technol, Taichung 404, Taiwan.	whzuxb@163.com; chang@urmc.rochester.edu		Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477]; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]; National Natural Science Foundation of China [81572523]; Hunan Province Funds for Distinguished Young Scientists of China [2016JJ1026]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Province Funds for Distinguished Young Scientists of China	This work was supported by NIH grant (CA155477), in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002), the National Natural Science Foundation of China (81572523), and the Hunan Province Funds for Distinguished Young Scientists of China (2016JJ1026).	Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Berg AH, 2014, ENDOCRINOLOGY, V155, P4237, DOI 10.1210/en.2014-1198; Carneiro BA, 2015, CANCER TREAT REV, V41, P170, DOI 10.1016/j.ctrv.2014.11.003; Chang C, 2014, ONCOGENE, V33, P3225, DOI 10.1038/onc.2013.274; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; De Toni L, 2016, ENDOCRINOLOGY, V157, P4473, DOI 10.1210/en.2016-1312; Dobruch J, 2016, EUR UROL, V69, P300, DOI 10.1016/j.eururo.2015.08.037; Foradori CD, 2008, FRONT NEUROENDOCRIN, V29, P169, DOI 10.1016/j.yfrne.2007.10.005; Gao ZG, 2016, BIOCHEM PHARMACOL, V107, P59, DOI 10.1016/j.bcp.2016.03.003; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huang B, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0408-7; Ide H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174746; Izumi K, 2014, ONCOTARGET, V5, P12665, DOI 10.18632/oncotarget.2851; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Li P, 2017, CANCERS, V9, DOI 10.3390/cancers9020020; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Liu Q, 2015, J CELL BIOCHEM, V116, P1213, DOI 10.1002/jcb.25073; Milowsky MI, 2016, J CLIN ONCOL, V34, P1945, DOI 10.1200/JCO.2015.65.9797; Miyamoto H, 2012, CURR CANCER DRUG TAR, V12, P14, DOI 10.2174/156800912798888965; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Munnich N, 2016, BIOMETALS, V29, P995, DOI 10.1007/s10534-016-9971-z; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Ou ZY, 2015, ONCOTARGET, V6, P26065, DOI 10.18632/oncotarget.4569; Pi M, 2012, PROSTATE, V72, P399, DOI 10.1002/pros.21442; Pi M, 2010, J BIOL CHEM, V285, P39953, DOI 10.1074/jbc.M110.158063; Rosner W, 1999, STEROIDS, V64, P100, DOI 10.1016/S0039-128X(98)00108-1; Sen A, 2011, STEROIDS, V76, P822, DOI 10.1016/j.steroids.2011.02.016; Shiota M, 2015, ONCOTARGET, V6, P14710, DOI 10.18632/oncotarget.3817; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun YH, 2006, J ANDROL, V27, P671, DOI 10.2164/jandrol.106.000554; Tan WS, 2016, CANCER TREAT REV, V47, P22, DOI 10.1016/j.ctrv.2016.05.002; Tang XL, 2013, CANCER RES, V73, P6206, DOI 10.1158/0008-5472.CAN-13-1049; Thal DM, 2018, NATURE, V559, P45, DOI 10.1038/s41586-018-0259-z; Thomas P, 2018, GEN COMP ENDOCR, V257, P130, DOI 10.1016/j.ygcen.2017.04.016; Thomas P, 2017, MOL CELL ENDOCRINOL, V447, P23, DOI 10.1016/j.mce.2017.02.025; Thomas P, 2014, ENDOCRINOLOGY, V155, P4250, DOI 10.1210/en.2014-1201; Tuygun C, 2011, UROL ONCOL-SEMIN ORI, V29, P43, DOI 10.1016/j.urolonc.2009.01.033; Wang JL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0720-8	40	13	13	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					574	586		10.1038/s41388-019-0964-6	http://dx.doi.org/10.1038/s41388-019-0964-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31506605				2022-12-17	WOS:000509718300007
J	Feng, TT; Zhao, R; Sun, FF; Lu, QQ; Wang, XL; Hu, J; Wang, SG; Gao, L; Zhou, QQ; Xiong, XT; Dong, XS; Wang, L; Han, B				Feng, Tingting; Zhao, Ru; Sun, Feifei; Lu, Qiqi; Wang, Xueli; Hu, Jing; Wang, Shiguan; Gao, Lin; Zhou, Qianqian; Xiong, Xueting; Dong, Xuesen; Wang, Lin; Han, Bo			TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression	ONCOGENE			English	Article							CASTRATION; AR; PEROXIREDOXIN; THIOREDOXIN; DEGRADATION; ANTIOXIDANT; INVOLVEMENT; CARCINOMA; ESTROGEN; COMPLEX	Reactive oxygen species (ROS) and ROS-induced oxidative stress are associated with prostate cancer (PCa) development and castrate-resistant tumor progression. This is in part through the activation of the androgen receptor (AR) signaling. However, the molecular underpinning of ROS to activate AR remains poorly understood. Here, we report that the thioredoxin domain-containing 9 (TXNDC9) is an important regulator of ROS to trigger AR signaling. TXNDC9 expression is upregulated by ROS inducer, and increased TXNDC9 expression in patient tumors is associated with advanced clinical stages. TXNDC9 promotes PCa cell survival and proliferation. It is required for AR protein expression and AR transcriptional activity under oxidative stress conditions. Mechanistically, ROS inducers promote TXNDC9 to dissociate from PRDX1, but enhance a protein association with MDM2. Concurrently, PRDX1 enhances its association with AR. These protein interaction exchanges result in not only MDM2 protein degradation, but also PRDX1 mediated AR protein stabilization, and subsequent elevation of AR signaling. Blocking PRDX1 by its inhibitor, Conoidin A (CoA), suppresses AR signaling, PCa cell proliferation, and xenograft tumor growth even under androgen-deprived conditions. These tumor-suppressive effects of CoA were further strengthened when in combination with enzalutamide treatment. Together, these studies demonstrate that the TXNDC9-PRDX1 axis plays an important role for ROS to activate AR functions. It provides a proof-of-principle that co-targeting AR and PRDX1 may be more effective to control PCa growth.	[Feng, Tingting; Zhao, Ru; Sun, Feifei; Wang, Xueli; Hu, Jing; Gao, Lin; Zhou, Qianqian; Han, Bo] Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Peoples R China; [Feng, Tingting; Zhao, Ru; Sun, Feifei; Wang, Xueli; Hu, Jing; Gao, Lin; Zhou, Qianqian; Han, Bo] Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Peoples R China; [Lu, Qiqi; Wang, Shiguan; Wang, Lin] Shandong First Med Univ & Shandong Acad Med Sci, Res Ctr Med Biotechnol, Key Lab Rare & Uncommon Dis Shandong Prov, Jinan 250012, Peoples R China; [Wang, Xueli] Binzhou Cent Hosp, Dept Pathol, Binzhou 256610, Peoples R China; [Xiong, Xueting] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Dong, Xuesen] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada; [Han, Bo] Shandong Univ, Dept Pathol, Qilu Hosp, Jinan 250012, Peoples R China	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Toronto; University of British Columbia; Shandong University	Han, B (corresponding author), Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Peoples R China.; Han, B (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Peoples R China.; Wang, L (corresponding author), Shandong First Med Univ & Shandong Acad Med Sci, Res Ctr Med Biotechnol, Key Lab Rare & Uncommon Dis Shandong Prov, Jinan 250012, Peoples R China.; Han, B (corresponding author), Shandong Univ, Dept Pathol, Qilu Hosp, Jinan 250012, Peoples R China.	wanglin.83@163.com; boh@sdu.edu.cn	Zhou, Qianqian/GXG-4345-2022; Dong, Xuesen/AGF-9228-2022	Wang, Lin/0000-0002-0503-9727	National Key Research And Development Program of China [2018YFC0114703]; National Natural Science Foundation of China [81572544, 81772760, 81472417, 81672554]; Key Research and Development Project of Shandong [2016GSF201166]; Shandong Taishan Scholarship [tsqn20161076]	National Key Research And Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Project of Shandong; Shandong Taishan Scholarship	This work was supported by the National Key Research And Development Program of China (No. 2018YFC0114703), the National Natural Science Foundation of China (grant nos. 81572544, 81772760, 81472417, 81672554), The Key Research and Development Project of Shandong (grant no. 2016GSF201166), The Shandong Taishan Scholarship (grant no. tsqn20161076).	Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen DW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1150-4; Feng TT, 2016, ONCOTARGET, V7, P58381, DOI 10.18632/oncotarget.11126; Fizazi K, 2018, CLIN GENITOURIN CANC, V16, P332, DOI 10.1016/j.clgc.2018.07.017; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546; Groner AC, 2017, J CLIN INVEST, V127, P1126, DOI 10.1172/JCI88885; Guha P, 2017, ONCOTARGET, V8, P68191, DOI 10.18632/oncotarget.19277; Haraldsen JD, 2009, ORG BIOMOL CHEM, V7, P3040, DOI 10.1039/b901735f; Harashima K, 2005, INT J RADIAT BIOL, V81, P63, DOI 10.1080/09553000400029460; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Jacquot JP, 2002, BIOCHEM PHARMACOL, V64, P1065, DOI 10.1016/S0006-2952(02)01177-2; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Kakolyris S, 2001, CLIN CANCER RES, V7, P3087; Kumsta C, 2009, BIOCHEMISTRY-US, V48, P4666, DOI 10.1021/bi9003556; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu F, 2016, SCI REP-UK, V6, DOI 10.1038/srep21260; Liu G, 2010, CHEMMEDCHEM, V5, P41, DOI 10.1002/cmdc.200900391; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Nakka M, 2013, INT J BIOCHEM CELL B, V45, P763, DOI 10.1016/j.biocel.2012.12.012; Park SY, 2007, CANCER RES, V67, P9294, DOI 10.1158/0008-5472.CAN-07-0651; Parolia A, 2019, NATURE, V571, P413, DOI 10.1038/s41586-019-1347-4; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Samaranayake GJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01269-x; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Sharifi N, 2013, ENDOCRINOLOGY, V154, P4010, DOI 10.1210/en.2013-1466; Shiota M, 2010, ONCOGENE, V29, P237, DOI 10.1038/onc.2009.322; Shiota M, 2011, FREE RADICAL BIO MED, V51, P1320, DOI 10.1016/j.freeradbiomed.2011.07.011; Tam NNC, 2003, AM J PATHOL, V163, P2513, DOI 10.1016/S0002-9440(10)63606-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang L, 2015, ONCOGENE, V34, P4735, DOI 10.1038/onc.2014.401; Wang L, 2017, CANCER RES, V77, P5755, DOI 10.1158/0008-5472.CAN-17-0150; Xu BH, 2019, CELL RES, V29, P773, DOI 10.1038/s41422-019-0204-1; Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	42	13	15	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					356	367		10.1038/s41388-019-0991-3	http://dx.doi.org/10.1038/s41388-019-0991-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477836				2022-12-17	WOS:000507766400008
J	Li, B; Chen, YY; Wang, F; Guo, J; Fu, W; Li, M; Zheng, QC; Liu, Y; Fan, LL; Li, L; Xu, CR				Li, Bin; Chen, Yuyuan; Wang, Fei; Guo, Jun; Fu, Wen; Li, Min; Zheng, Qichang; Liu, Yong; Fan, Lingling; Li, Lei; Xu, Chuanrui			Bmi1 drives hepatocarcinogenesis by repressing the TGF beta 2/SMAD signalling axis	ONCOGENE			English	Article							CELL SELF-RENEWAL; TGF-BETA; C-MYC; IN-VIVO; H-RAS; GROWTH; RECEPTOR; PROTEIN; TUMORIGENESIS; ONCOPROTEIN	Bmi1 is overexpressed in one-third of hepatocellular carcinoma (HCC) patients and acts as an oncogene in hepatocarcinogenesis. However, the underlying mechanism is unclear. The role of TGF beta signalling in HCC is not well defined as well. Here, we report that TGF beta 2 is a target of Bmi1 in HCC and has a tumour-suppressing role. In Bmi1-knockout mouse livers and HCC cell lines, TGF beta 2/SMAD cascade proteins were upregulated. TGF beta 2 expression was inversely correlated with Bmi1 expression in human and mouse HCC tissues. In vitro, Bmi1 knockdown activated TGF beta 2/SMAD signalling and led to cell apoptosis via upregulation of p15 and p21. TGF beta 2 inhibition rescued the inhibitory effect of Bmi1 knockdown on HCC cell survival, proliferation, and cell-cycle progression. In vivo, restoration of TGF beta 2 expression blocked Bmi1/Ras-driven hepatocarcinogenesis in mice. Chromatin immunoprecipitation and luciferase reporter assays revealed that Bmi1 repressed TGF beta 2 expression by binding to its promoter as a co-factor of polycomb repressor complex 1. Our findings elucidate the molecular mechanism underlying hepatic Bmi1-driven carcinogenesis and highlight the importance of TGF beta 2 as a tumour suppressor in HCC development.	[Li, Bin; Chen, Yuyuan; Guo, Jun; Fu, Wen; Liu, Yong; Li, Lei; Xu, Chuanrui] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan 430030, Peoples R China; [Wang, Fei] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Wuhan 430030, Peoples R China; [Li, Min; Zheng, Qichang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan 430022, Peoples R China; [Fan, Lingling] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Stem Cell Ctr, Wuhan 430022, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Xu, CR (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan 430030, Peoples R China.	xcr@hust.edu.cn			National Science Foundation of China [81572723, 81872253]; Innovation Foundation of Higher Education of China [2016JCTD109]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Foundation of Higher Education of China	This study was supported by the National Science Foundation of China (81572723 and 81872253) and the Innovation Foundation of Higher Education of China (2016JCTD109).	Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Becker M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004230; Bentley ML, 2011, EMBO J, V30, P3285, DOI 10.1038/emboj.2011.243; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Chiba T, 2010, HEPATOLOGY, V52, P1111, DOI 10.1002/hep.23793; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Datta S, 2007, CANCER RES, V67, P10286, DOI 10.1158/0008-5472.CAN-07-1636; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Dhawan S, 2009, GENE DEV, V23, P906, DOI 10.1101/gad.1742609; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Dropmann A, 2016, ONCOTARGET, V7, P19499, DOI 10.18632/oncotarget.6967; Fan C, 2008, BBA-MOL BASIS DIS, V1782, P642, DOI 10.1016/j.bbadis.2008.08.009; Fan LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046472; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Goel HL, 2012, CANCER DISCOV, V2, P906, DOI 10.1158/2159-8290.CD-12-0085; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ho C, 2012, HEPATOLOGY, V55, P833, DOI 10.1002/hep.24736; Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229; Jiang Y, 2015, ONCOGENE, V34, P6079, DOI 10.1038/onc.2015.53; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009; Kim RH, 2010, EXP CELL RES, V316, P2600, DOI 10.1016/j.yexcr.2010.04.013; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Levy L, 2002, ANN NY ACAD SCI, V963, P21; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McGinty RK, 2014, NATURE, V514, P591, DOI 10.1038/nature13890; MITCHELL EJ, 1992, MOL BIOL CELL, V3, P1295, DOI 10.1091/mbc.3.11.1295; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; Oh S, 2013, CANCER GENE THER, V20, P94, DOI 10.1038/cgt.2012.90; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214; Qi SB, 2014, INT J MOL SCI, V15, P20004, DOI 10.3390/ijms151120004; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Rotzer D, 2001, EMBO J, V20, P480, DOI 10.1093/emboj/20.3.480; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171; Silva J, 2006, CLIN CANCER RES, V12, P6929, DOI 10.1158/1078-0432.CCR-06-0788; Tward AD, 2007, P NATL ACAD SCI USA, V104, P14771, DOI 10.1073/pnas.0706578104; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Wojtowicz JM, 2006, NAT PROTOC, V1, P1399, DOI 10.1038/nprot.2006.224; Xu CR, 2009, MOL CANCER RES, V7, P1937, DOI 10.1158/1541-7786.MCR-09-0333; Yang T, 2014, THERANOSTICS, V4, P1096, DOI 10.7150/thno.9423	56	13	13	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1063	1079		10.1038/s41388-019-1043-8	http://dx.doi.org/10.1038/s41388-019-1043-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31591477				2022-12-17	WOS:000511209700009
J	Weinberg, F; Griffin, R; Frohlich, M; Heining, C; Braun, S; Spohr, C; Iconomou, M; Hollek, V; Roring, M; Horak, P; Kreutzfeldt, S; Warsow, G; Hutter, B; Uhrig, S; Neumann, O; Reuss, D; Heiland, DH; von Kalle, C; Weichert, W; Stenzinger, A; Brors, B; Glimm, H; Frohling, S; Brummer, T				Weinberg, Florian; Griffin, Ricarda; Froehlich, Martina; Heining, Christoph; Braun, Sandra; Spohr, Corinna; Iconomou, Mary; Hollek, Viola; Roering, Michael; Horak, Peter; Kreutzfeldt, Simon; Warsow, Gregor; Hutter, Barbara; Uhrig, Sebastian; Neumann, Olaf; Reuss, David; Heiland, Dieter Henrik; von Kalle, Christof; Weichert, Wilko; Stenzinger, Albrecht; Brors, Benedikt; Glimm, Hanno; Froehling, Stefan; Brummer, Tilman			Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains	ONCOGENE			English	Article							RAF INHIBITOR RESISTANCE; B-RAF; TWEETY FAMILY; MAPK PATHWAY; TARGETED THERAPY; GENE FUSIONS; IN-VIVO; KINASE; CANCER; DIMERIZATION	Fusion proteins involving the BRAF serine/threonine kinase occur in many cancers. The oncogenic potential of BRAF fusions has been attributed to the loss of critical N-terminal domains that mediate BRAF autoinhibition. We used whole-exome and RNA sequencing in a patient with glioblastoma multiforme to identify a rearrangement between TTYH3, encoding a membrane-resident, calcium-activated chloride channel, and BRAF intron 1, resulting in a TTYH3-BRAF fusion protein that retained all features essential for BRAF autoinhibition. Accordingly, the BRAF moiety of the fusion protein alone, which represents full-length BRAF without the amino acids encoded by exon 1 (BRAF(Delta E1)), did not induce MEK/ERK phosphorylation or transformation. Likewise, neither the TTYH3 moiety of the fusion protein nor full-length TTYH3 provoked ERK pathway activity or transformation. In contrast, TTYH3-BRAF displayed increased MEK phosphorylation potential and transforming activity, which were caused by TTYH3-mediated tethering of near-full-length BRAF to the (endo)membrane system. Consistent with this mechanism, a synthetic approach, in which BRAF(Delta E1) was tethered to the membrane by fusing it to the cytoplasmic tail of CD8 also induced transformation. Furthermore, we demonstrate that TTYH3-BRAF signals largely independent of a functional RAS binding domain, but requires an intact BRAF dimer interface and activation loop phosphorylation sites. Cells expressing TTYH3-BRAF exhibited increased MEK/ERK signaling, which was blocked by clinically achievable concentrations of sorafenib, trametinib, and the paradox breaker PLX8394. These data provide the first example of a fully autoinhibited BRAF protein whose oncogenic potential is dictated by a distinct fusion partner and not by a structural change in BRAF itself.	[Weinberg, Florian; Griffin, Ricarda; Braun, Sandra; Spohr, Corinna; Iconomou, Mary; Hollek, Viola; Roering, Michael; Brummer, Tilman] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany; [Weinberg, Florian; Braun, Sandra] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany; [Froehlich, Martina; Hutter, Barbara; Uhrig, Sebastian; Brors, Benedikt] German Canc Res Ctr, Div Appl Bioinformat, Heidelberg, Germany; [Froehlich, Martina; Hutter, Barbara; Uhrig, Sebastian; Brors, Benedikt] Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Heining, Christoph; Glimm, Hanno] NCT Dresden, Dept Translat Med Oncol, Heidelberg, Germany; [Heining, Christoph; Horak, Peter; Kreutzfeldt, Simon; von Kalle, Christof; Glimm, Hanno; Froehling, Stefan; Brummer, Tilman] DKFZ, Heidelberg, Germany; [Heining, Christoph; Glimm, Hanno] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Heining, Christoph; Glimm, Hanno] German Canc Consortium DKTK, Dresden, Germany; [Spohr, Corinna] Univ Freiburg, Fac Biol, Freiburg, Germany; [Spohr, Corinna] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany; [Horak, Peter; Kreutzfeldt, Simon; Froehling, Stefan] NCT Heidelberg, Dept Translat Med Oncol, Heidelberg, Germany; [Horak, Peter; Kreutzfeldt, Simon; Neumann, Olaf; Reuss, David; Stenzinger, Albrecht; Brors, Benedikt; Froehling, Stefan] DKTK, Heidelberg, Germany; [Warsow, Gregor] DKFZ, Omics IT & Data Management Core Facil, Heidelberg, Germany; [Warsow, Gregor] DKFZ, Div Theoret Bioinformat, Heidelberg, Germany; [Uhrig, Sebastian] Heidelberg Univ, Fac Biosci, Heidelberg, Germany; [Neumann, Olaf; Stenzinger, Albrecht] Heidelberg Univ Hosp, Inst Pathol, Heidelberg, Germany; [Reuss, David] Heidelberg Univ Hosp, Inst Pathol, Dept Neuropathol, Heidelberg, Germany; [Reuss, David] German Canc Res Ctr, German Consortium Translat Canc Res DKTK, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Heiland, Dieter Henrik] Univ Freiburg, Fac Med, Med Ctr, Dept Neurosurg, Freiburg, Germany; [Heiland, Dieter Henrik] Univ Freiburg, Fac Med, Med Ctr, Translat NeuroOncol Res Grp, Freiburg, Germany; [von Kalle, Christof] NCT Heidelberg, Dept Translat Oncol, Heidelberg, Germany; [Weichert, Wilko] Tech Univ Munich, Inst Pathol, Munich, Germany; [Weichert, Wilko] DKTK, Munich, Germany; [Brummer, Tilman] Univ Freiburg, Comprehens Canc Ctr Freiburg, Freiburg, Germany; [Brummer, Tilman] DKTK Partner Site Freiburg, Heidelberg, Germany	University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Technical University of Munich; University of Freiburg	Brummer, T (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.; Frohling, S (corresponding author), NCT Heidelberg, Dept Translat Med Oncol, Heidelberg, Germany.; Frohling, S (corresponding author), DKTK, Heidelberg, Germany.; Brummer, T (corresponding author), Univ Freiburg, Comprehens Canc Ctr Freiburg, Freiburg, Germany.; Brummer, T (corresponding author), DKTK Partner Site Freiburg, Heidelberg, Germany.	stefan.froehling@nct-heidelberg.de; tilman.brummer@mol-med.uni-freiburg.de	Brors, Benedikt/E-5620-2013; Neumann, Olaf/GSO-3538-2022; Horak, Peter/ABC-1587-2021; Brummer, Tilman/AAA-9428-2020; Heiland, Dieter Henrik/ABE-8856-2020; Brummer, Tilman/B-6218-2016	Brors, Benedikt/0000-0001-5940-3101; Neumann, Olaf/0000-0003-2684-9187; Horak, Peter/0000-0003-4536-9306; Brummer, Tilman/0000-0003-4387-7905; Heiland, Dieter Henrik/0000-0002-9258-3033; Brummer, Tilman/0000-0003-4387-7905; Hollek, Viola/0000-0001-9768-5568; Griffin, Ricarda/0000-0003-1368-2832; von Kalle, Christof/0000-0001-9221-3297	German Research Foundation (DFG) [BR3662/4-1, SFB 850 B04, EXC 294 BIOSS]; DKFZ-Heidelberg Center for Personalized Oncology [021]; DFG	German Research Foundation (DFG)(German Research Foundation (DFG)); DKFZ-Heidelberg Center for Personalized Oncology; DFG(German Research Foundation (DFG))	This work was supported by the German Research Foundation (DFG) by BR3662/4-1, SFB 850 B04, and EXC 294 BIOSS to TB, and by grant 021 from the DKFZ-Heidelberg Center for Personalized Oncology to HG and SF, TB is the recipient of a Heisenberg Professorship from the DFG. CS is supported in part by the DFG-funded Spemann Graduate School of Biology and Medicine (SGBM, GSC 4). We thank the DKFZ-HIPO Sample Processing Laboratory, the DKFZ Genomics and Proteomics Core Facility, the Omics IT and Data Management Core Facility for technical support. We also thank D. Richter, K. Beck, K. Willmund, R. Eils, and P. Lichter for infrastructure and program development within DKFZ-HIPO.	Aoki Y, 2008, HUM MUTAT, V29, P992, DOI 10.1002/humu.20748; Behling F, 2019, CANCERS, V11, DOI 10.3390/cancers11060794; Bender S, 2016, NAT MED, V22, P1314, DOI 10.1038/nm.4204; Berghoff AS, 2014, CURR OPIN NEUROL, V27, P689, DOI 10.1097/WCO.0000000000000146; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Diedrich B, 2017, EMBO J, V36, P646, DOI 10.15252/embj.201694732; Eisenhardt AE, 2016, ONCOTARGET, V7, P26628, DOI 10.18632/oncotarget.8427; Eisenhardt AE, 2011, INT J CANCER, V129, P2297, DOI 10.1002/ijc.25893; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Fangusaro J, 2019, LANCET ONCOL, V20, P1011, DOI 10.1016/S1470-2045(19)30277-3; Fehrenbacher N, 2009, MOL ONCOL, V3, P297, DOI 10.1016/j.molonc.2009.06.004; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Galabova-Kovacs G, 2008, J CELL BIOL, V180, P947, DOI 10.1083/jcb.200709069; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Han YE, 2019, EXP NEUROBIOL, V28, P183, DOI 10.5607/en.2019.28.2.183; He YW, 2008, J BIOL CHEM, V283, P24000, DOI 10.1074/jbc.M803361200; He YW, 2008, BIOCHEM J, V412, P45, DOI 10.1042/BJ20071722; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; HENNECKE S, 1993, J BIOL CHEM, V268, P26607; Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5; Horak P, 2017, INT J CANCER, V141, P877, DOI 10.1002/ijc.30828; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Iodice L, 2001, J BIOL CHEM, V276, P28920, DOI 10.1074/jbc.M103558200; Isaacson AL, 2019, CSH MOL CASE STUD, V5, DOI 10.1101/mcs.a003848; Jain P, 2017, ONCOGENE, V36, P6348, DOI 10.1038/onc.2017.276; Jang JS, 2015, SCI REP-UK, V5, DOI 10.1038/srep09755; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jung E, 2017, J NEUROSCI, V37, P6837, DOI 10.1523/JNEUROSCI.3532-16.2017; Karajannis MA, 2014, NEURO-ONCOLOGY, V16, P1408, DOI 10.1093/neuonc/nou059; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; Kim HS, 2017, ONCOGENE, V36, P3334, DOI 10.1038/onc.2016.486; Kohler M, 2016, EMBO J, V35, P143, DOI 10.15252/embj.201592097; Kordes M, 2016, LEUKEMIA, V30, P937, DOI 10.1038/leu.2015.319; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; Lu HY, 2017, CANCER RES, V77, P3502, DOI 10.1158/0008-5472.CAN-16-2745; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masilamani AP, 2017, ONCOGENE, V36, P3562, DOI 10.1038/onc.2016.507; McEvoy CR, 2019, J CLIN INVEST, V129, P1940, DOI 10.1172/JCI123089; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Ng PKS, 2018, CANCER CELL, V33, P450, DOI 10.1016/j.ccell.2018.01.021; Nicolaides TP, 2011, CLIN CANCER RES, V17, P7595, DOI 10.1158/1078-0432.CCR-11-1456; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Phuchareon J, 2015, P NATL ACAD SCI USA, V112, pE3855, DOI 10.1073/pnas.1510733112; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Ramis G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038770; Ricklefs FL, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1588555; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Selt F, 2017, ONCOTARGET, V8, P11460, DOI 10.18632/oncotarget.14004; Selt F, 2016, BRAIN PATHOL, V26, P506, DOI 10.1111/bpa.12326; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Stefaniuk M, 2010, J NEUROCHEM, V115, P1183, DOI 10.1111/j.1471-4159.2010.07023.x; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Sun MH, 2010, P NATL ACAD SCI USA, V107, P15547, DOI 10.1073/pnas.1009652107; Suzuki M, 2004, J BIOL CHEM, V279, P22461, DOI 10.1074/jbc.M313813200; Terai K, 2006, EMBO J, V25, P3556, DOI 10.1038/sj.emboj.7601241; Terrell Elizabeth M., 2018, COLD SPRING HARB PER, V9, pa033746; Tien AC, 2012, DEVELOPMENT, V139, P2477, DOI 10.1242/dev.077214; Turski ML, 2016, MOL CANCER THER, V15, P533, DOI 10.1158/1535-7163.MCT-15-0643; Yao Z, 2019, NAT MED, V25, P284, DOI 10.1038/s41591-018-0274-5; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Yuan JM, 2018, ONCOGENE, V37, P5719, DOI 10.1038/s41388-018-0365-2; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982	80	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					814	832		10.1038/s41388-019-1021-1	http://dx.doi.org/10.1038/s41388-019-1021-1			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31558800				2022-12-17	WOS:000509197200006
J	Xu, CL; Wang, XR; Zhou, Y; Chen, FX; Wang, HW; Li, KN; Fan, HY; Tang, XM; Jiang, GJ; Zhang, J				Xu, Congling; Wang, Xinrui; Zhou, Yu; Chen, Fei Xavier; Wang, Haiwei; Li, Kening; Fan, Huiyong; Tang, Xiaomei; Jiang, Guojuan; Zhang, Ji			Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer	ONCOGENE			English	Article							CELL-DEATH; MEDIATED APOPTOSIS; UP-REGULATION; TUMOR-GROWTH; NRF2; P53; INHIBITION; ACTIVATION; SURVIVAL; BIOLOGY	Pancreatic cancer is a deadliest type of malignancy and lacks effective intervention. We here report a potential strategy for treatment of this malignancy by the combination of arsenic trioxide (ATO) and BET bromodomain inhibitor JQ1. These two agents synergistically modulate multistages of autophagy and thus induce apoptosis effectively in pancreatic cancer cells. Our genomic and biochemical data have demonstrated that crosstalks between ER stress and autophagy play crucial roles during ATO-induced apoptosis, in which NRF2 may stand at the crossroad between cell death and survival. This has been further strengthened by our finding that NRF2 depletion renders insensitive cells into sensitive ones in regard to ATO treatment-caused cell death. The knockdown of NRF2 and the addition of JQ1 result in similar molecular/cellular effects in promoting effective ATO-induced apoptosis in cells that are insensitive to ATO treatment alone. Thus, the combination of ATO and JQ1 may represent a new treatment strategy for pancreatic cancer.	[Xu, Congling; Wang, Xinrui; Li, Kening; Fan, Huiyong; Tang, Xiaomei; Jiang, Guojuan; Zhang, Ji] Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China; [Xu, Congling; Chen, Fei Xavier] Fudan Univ, Sch Basic Med Sci, Dept Syst Biol Med, Key Lab Mol Med,Shanghai Med Coll,Minist Educ, Shanghai 200032, Peoples R China; [Zhou, Yu] Civil Aviat Hosp Shanghai, Dept Orthoped, Shanghai, Peoples R China; [Wang, Haiwei] Fujian Med Univ, Fujian Prov Matern & Childrens Hosp, Fujian Key Lab Prenatal Diag & Birth Defect, Affiliated Hosp, Fuzhou 350001, Fujian, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Fudan University; Fujian Medical University	Zhang, J (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China.	Zj11222@rjh.com.cn	Wang, Xinrui/AAW-5405-2021	CHEN, FEI/0000-0002-7827-7988; Wang, Xinrui/0000-0002-7383-9128	National Natural Science Foundation [81370655]; Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University	This study is supported in part by the National Natural Science Foundation (no. 81370655), and by Distinguished Professorship (JZ) from Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University.	Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Antonucci L, 2015, P NATL ACAD SCI USA, V112, pE6166, DOI 10.1073/pnas.1519384112; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Du YZ, 2006, BLOOD, V107, P1582, DOI 10.1182/blood-2005-06-2318; Dunne RF, 2015, HEMATOL ONCOL CLIN N, V29, P595, DOI 10.1016/j.hoc.2015.04.003; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Garcia PL, 2016, ONCOGENE, V35, P833, DOI 10.1038/onc.2015.126; Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966; Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hussong M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.157; Iacobuzio-Donahue CA, 2014, NEW ENGL J MED, V370, P1352, DOI 10.1056/NEJMcibr1400189; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006; Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842; Langdon CG, 2017, MOL CANCER THER, V16, P1041, DOI 10.1158/1535-7163.MCT-16-0794; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Newman RA, 2007, INTEGR CANCER THER, V6, P354, DOI 10.1177/1534735407309623; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Piya S, 2017, AUTOPHAGY, V13, P214, DOI 10.1080/15548627.2016.1245263; Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sakamaki JI, 2017, MOL CELL, V66, P517, DOI 10.1016/j.molcel.2017.04.027; Shah P, 2017, MOLECULES, V22, DOI 10.3390/molecules22020194; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216; Wang KK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007538; Wen X, 2017, AUTOPHAGY, V13, P1801, DOI 10.1080/15548627.2017.1364334; Xia Y, 2013, EXP BIOL MED, V238, P932, DOI 10.1177/1535370213492689; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhang T. D., 1973, HEILONGJIANG MED J, P66; Zhang YX, 2011, ANTIOXID REDOX SIGN, V15, P2867, DOI 10.1089/ars.2010.3685	53	13	14	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7249	7265		10.1038/s41388-019-0930-3	http://dx.doi.org/10.1038/s41388-019-0930-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31420604				2022-12-17	WOS:000497989400005
J	Nitta, RT; Bolin, S; Luo, E; Solow-Codero, DE; Samghabadi, P; Purzner, T; Aujla, PS; Nwagbo, G; Cho, YJ; Li, G				Nitta, Ryan T.; Bolin, Sara; Luo, Emily; Solow-Codero, David E.; Samghabadi, Peyman; Purzner, Teresa; Aujla, Parvir S.; Nwagbo, Ginikachi; Cho, Yoon-Jae; Li, Gordon			Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide	ONCOGENE			English	Article							UNFAVORABLE PROGNOSTIC MARKER; BRAIN-TUMORS; CK2-ALPHA; CHEMOTHERAPY; EXPRESSION; SUBGROUPS; CARCINOMA; PATHWAYS; CHILDREN; TARGET	Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Since surviving patients experience severe neurocognitive disabilities, better and more effective treatments are needed to enhance their quality of life. Casein kinase 2 (CK2) is known to regulate cell growth and survival in multiple cancers; however, the role of CK2 in MB is currently being studied. In this study, we verified the importance of CK2 in MB tumorigenesis and discovered that inhibition of CK2 using the small molecule inhibitor, CX-4945, can sensitize MB cells to a well-known and tolerated chemotherapeutic, temozolomide (TMZ). To study the role of CK2 in MB we modulated CK2 expression in multiple MB cells. Exogenous expression of CK2 enhanced cell growth and tumor growth in mice, while depletion or inhibition of CK2 expression decreased MB tumorigenesis. Treatment with CX-4945 reduced MB growth and increased apoptosis. We conducted a high-throughput screen where 4000 small molecule compounds were analyzed to identify compounds that increased the anti-tumorigenic properties of CX-4945. TMZ was found to work synergistically with CX-4945 to decrease cell survival and increase apoptosis in MB cells. O-6-methylguanine-DNA methyltransferase (MGMT) activity is directly correlated to TMZ sensitivity. We found that loss of CK2 activity reduced beta-catenin expression, a known MGMT regulator, which in turn led to a decrease in MGMT expression and an increased sensitivity to TMZ. Our findings show that CK2 is important for MB maintenance and that treatment with CX-4945 can sensitize MB cells to TMZ treatment.	[Nitta, Ryan T.; Bolin, Sara; Luo, Emily; Aujla, Parvir S.; Nwagbo, Ginikachi; Li, Gordon] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Solow-Codero, David E.] Stanford Univ, Dept Chem & Syst Biol, High Throughput Biosci Ctr, Stanford, CA 94305 USA; [Samghabadi, Peyman] Stanford Univ, Dept Neuropathol, Stanford, CA 94305 USA; [Purzner, Teresa] Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; [Purzner, Teresa] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Cho, Yoon-Jae] Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Knight Canc Inst, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA	Stanford University; Stanford University; Stanford University; Stanford University; University of Toronto; Oregon Health & Science University	Nitta, RT (corresponding author), Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.	rnitta@stanford.edu		Li, Gordon/0000-0001-8372-0676; Bolin, Sara/0000-0003-2835-1518; Solow-Cordero, David/0000-0002-9886-5058	Stanford Cancer Institute Bioscience Screening Award; Swedish Childhood Cancer Foundation;  [NIH-KNS085333A]; NATIONAL CANCER INSTITUTE [P30CA124435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS085333] Funding Source: NIH RePORTER	Stanford Cancer Institute Bioscience Screening Award; Swedish Childhood Cancer Foundation(European Commission); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank Albert Wong and the Cell Sciences Imaging Facility (CSIF) at Stanford University for use of their equipment. This work was funded by generous donations of the Anatoly Machulskiy family, Keith Tsu and Carmelita Ko, Steven Sommer, and the Yatindra Singh family. This research was also funded by Stanford Cancer Institute Bioscience Screening Award and NIH-KNS085333A and SB was supported by the Swedish Childhood Cancer Foundation.	Aguilera D, 2013, CHILD NERV SYST, V29, P589, DOI 10.1007/s00381-012-2013-4; Akyuz C, 2012, CHILD NERV SYST, V28, P111, DOI 10.1007/s00381-011-1561-3; Bae JS, 2015, INT J CANCER, V136, P797, DOI 10.1002/ijc.29043; Berchtold NC, 2008, P NATL ACAD SCI USA, V105, P15605, DOI 10.1073/pnas.0806883105; BORAD MJ, 2017, J CLIN ONCOL S, V35; Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005; Chua MMJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188854; Chua MMJ, 2017, PHARMACEUTICALS-BASE, V10, DOI 10.3390/ph10010018; Dhall G, 2009, J CHILD NEUROL, V24, P1418, DOI 10.1177/0883073809341668; Faoro D, 2011, J NEURO-ONCOL, V103, P59, DOI 10.1007/s11060-010-0366-7; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Guo B, 2000, CLIN CANCER RES, V6, P718; Kim HS, 2014, FEBS J, V281, P851, DOI 10.1111/febs.12652; Kim JS, 2007, CLIN CANCER RES, V13, P1019, DOI 10.1158/1078-0432.CCR-06-1602; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lin K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018608; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Marschke RF, 2011, ASCO M ABSTRACTS S, V29, P3087, DOI DOI 10.1200/jco.2011.29.15_suppl.3087; Michaelis M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08202; Nitta RT, 2015, ONCOGENE, V34, P3688, DOI 10.1038/onc.2014.299; Nitta RT, 2011, ONCOGENE, V30, P234, DOI 10.1038/onc.2010.414; Nitta RT, 2013, J MOL GENET MED, V8, P1; Ortega CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115609; Othman RT, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-57; Packer RJ, 2006, J CLIN ONCOL, V24, P4202, DOI 10.1200/JCO.2006.06.4980; Purzner J, 2007, J NEUROSCI, V27, P6029, DOI 10.1523/JNEUROSCI.5441-06.2007; Purzner T, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aau5147; Rabjerg M, 2017, ONCOTARGET, V8, P1613, DOI 10.18632/oncotarget.13693; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; von Bueren AO, 2012, BRIT J CANCER, V107, P1399, DOI 10.1038/bjc.2012.403; Wickstrom M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9904; Zhang HX, 2015, ONCOTARGET, V6, P34800, DOI 10.18632/oncotarget.5470; Zheng Y, 2013, CLIN CANCER RES, V19, P6484, DOI 10.1158/1078-0432.CCR-13-0265	35	13	14	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6867	6879		10.1038/s41388-019-0927-y	http://dx.doi.org/10.1038/s41388-019-0927-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406250	Green Accepted, hybrid			2022-12-17	WOS:000490758200005
J	Wang, S; Wang, N; Yu, B; Cao, MX; Wang, YL; Guo, YQ; Zhang, YL; Zhang, P; Yu, X; Wang, SJ; Zeng, L; Liang, B; Li, X; Wu, YJ				Wang, Shuang; Wang, Ning; Yu, Bin; Cao, Mingxing; Wang, Yanlong; Guo, Yuqi; Zhang, Yanli; Zhang, Ping; Yu, Xiao; Wang, Shujing; Zeng, Li; Liang, Bin; Li, Xin; Wu, Yingjie			Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model	ONCOGENE			English	Article							CANCER CELLS; TRANSCRIPTIONAL REGULATION; GROWTH-FACTORS; I RECEPTOR; EXPRESSION; APOPTOSIS; BIM; PROGRESSION; RISK; FOXO	High circulating insulin-like growth factor-1 (IGF-1) levels increase the risk of prostate cancer. However, whether circulating IGF-1 levels directly aggravate prostate cancer remains elusive. In this study, we crossed a transgenic prostate adenocarcinoma mouse model, Hi-Myc mice, with a liver-specific IGF-1 transgenic mouse model (HIT) to increase their circulating IGF-1 levels to investigate the impact of the elevated circulating IGF-1 on prostate cancer development in vivo. The Hi-Myc/HIT mice had increased incidence and invasiveness of prostate cancer. IGF-1 elevation led to the accumulation of FOXO3A in the cytosol of prostate tumor cells and downregulation of its target gene Bien, which resulted in the apoptosis inhibition and prostate cancer overgrowth. The differential expressions of IGF-1R, FOXO3A, and BIM in the benign versus malignant prostate tissues supported a negative association between the FOXO3A/BIM axis and IGF-1R expression in human prostate adenocarcinoma. Our findings suggest that targeting the IGF-1/FOXO3A/BIM signaling axis could be an attractive strategy for prostate cancer prevention or treatment.	[Wang, Shuang; Wang, Ning; Yu, Bin; Cao, Mingxing; Zeng, Li; Wu, Yingjie] Dalian Med Univ, Inst Genome Engn Anim Models Human Dis, Dalian 116044, Liaoning, Peoples R China; [Wang, Shuang; Wang, Ning; Yu, Bin; Cao, Mingxing; Zeng, Li; Wu, Yingjie] Dalian Med Univ, Natl Ctr Genet Engn Anim Models Int Res, Dalian 116044, Liaoning, Peoples R China; [Wang, Shuang; Wang, Ning; Wu, Yingjie] Dalian Med Univ, Coll Integrat Med, Dalian 116044, Liaoning, Peoples R China; [Cao, Mingxing] Mudanjiang Normal Univ, Coll Life Sci & Technol, Mudanjiang 157011, Heilongjiang, Peoples R China; [Wang, Yanlong] Dalian Med Univ, Dalian Municipal Cent Hosp, Dept Urol Surg, Dalian 116033, Liaoning, Peoples R China; [Guo, Yuqi; Zhang, Yanli; Li, Xin; Wu, Yingjie] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA; [Zhang, Ping] Dalian Med Univ, Affiliated Hosp 2, Dept Endocrinol, Dalian 116027, Liaoning, Peoples R China; [Yu, Xiao] Dalian Med Univ, Dept Pathol, Dalian 116044, Liaoning, Peoples R China; [Wang, Shujing] Dalian Med Univ, Dept Biochem & Mol Biol, Dalian 116044, Liaoning, Peoples R China; [Liang, Bin] Chinese Acad Sci, Kunming Inst Zool, CAS Ctr Excellence Anim Evolut & Genet, Key Lab Anim Models & Human Dis Mech,Chinese Acad, Kunming 650223, Yunnan, Peoples R China; [Li, Xin] NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA; [Li, Xin] NYU, Langone Med Ctr, Perlmutter Canc Inst, New York, NY 10016 USA; [Wu, Yingjie] Icahn Sch Med Mt Sinai, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Dalian Medical University; Dalian Medical University; Dalian Medical University; Mudanjiang Normal University; Dalian Medical University; New York University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Chinese Academy of Sciences; Kunming Institute of Zoology; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; Icahn School of Medicine at Mount Sinai	Wu, YJ (corresponding author), Dalian Med Univ, Inst Genome Engn Anim Models Human Dis, Dalian 116044, Liaoning, Peoples R China.; Wu, YJ (corresponding author), Dalian Med Univ, Natl Ctr Genet Engn Anim Models Int Res, Dalian 116044, Liaoning, Peoples R China.; Wu, YJ (corresponding author), Dalian Med Univ, Coll Integrat Med, Dalian 116044, Liaoning, Peoples R China.; Li, X; Wu, YJ (corresponding author), NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA.; Liang, B (corresponding author), Chinese Acad Sci, Kunming Inst Zool, CAS Ctr Excellence Anim Evolut & Genet, Key Lab Anim Models & Human Dis Mech,Chinese Acad, Kunming 650223, Yunnan, Peoples R China.; Li, X (corresponding author), NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA.; Li, X (corresponding author), NYU, Langone Med Ctr, Perlmutter Canc Inst, New York, NY 10016 USA.; Wu, YJ (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA.	liangb@mail.kiz.ac.cn; xl15@nyu.edu; yingjiewu@dmu.edu.cn		Li, Xin/0000-0002-7414-5734	Nature Science Foundation of China (NSFC) [81471000, 31871163]; Ministry of Science and Technology [2014DFA32120]	Nature Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea)	This study was supported by the Nature Science Foundation of China (NSFC) No. 81471000, No. 31871163, and Ministry of Science and Technology (No. 2014DFA32120) to Yingjie Wu.	Ali TZ, 2008, AM J SURG PATHOL, V32, P1890, DOI 10.1097/PAS.0b013e31817ce994; Bonilla C, 2016, INT J CANCER, V139, P1520, DOI 10.1002/ijc.30206; Butler AA, 1998, CANCER RES, V58, P3021; Cannata D, 2010, ENDOCRINOLOGY, V151, P5751, DOI 10.1210/en.2010-0792; Cao Y, 2015, INT J CANCER, V136, P2418, DOI 10.1002/ijc.29295; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Das TP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.403; Dey P, 2014, ONCOGENE, V33, P4213, DOI 10.1038/onc.2013.384; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Grabowska MM, 2014, CANCER METAST REV, V33, P377, DOI 10.1007/s10555-013-9487-8; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross DN, 2009, CURR DIABETES REP, V9, P208, DOI 10.1007/s11892-009-0034-5; Imada K, 2017, PROSTATE, V77, P145, DOI 10.1002/pros.23254; Jin RJ, 2014, CANCER RES, V74, P2763, DOI 10.1158/0008-5472.CAN-13-2543; Kaplan-Lefko PJ, 2008, ONCOGENE, V27, P2868, DOI 10.1038/sj.onc.1210943; Le Roith Derek, 2003, Exp Diabesity Res, V4, P205, DOI 10.1155/EDR.2003.205; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Nandana S, 2010, PROSTATE, V70, P591, DOI 10.1002/pros.21093; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Osuka S, 2013, STEM CELLS, V31, P627, DOI 10.1002/stem.1328; Powell WC, 2003, CURR DRUG TARGETS, V4, P263, DOI 10.2174/1389450033491145; Rinner O, 2007, NAT BIOTECHNOL, V25, P345, DOI 10.1038/nbt1289; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sarwar S, 2017, PROSTATE CANCER, V2017, DOI 10.1155/2017/5687212; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shariat SF, 2000, UROLOGY, V56, P423, DOI 10.1016/S0090-4295(00)00648-8; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stan SD, 2008, CANCER RES, V68, P7661, DOI 10.1158/0008-5472.CAN-08-1510; Sun JJ, 2018, BBA-MOL BASIS DIS, V1864, P1873, DOI 10.1016/j.bbadis.2018.03.004; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Sutherland BW, 2008, CANCER RES, V68, P3495, DOI 10.1158/0008-5472.CAN-07-6531; Travis RC, 2016, CANCER RES, V76, P2288, DOI 10.1158/0008-5472.CAN-15-1551; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Weiss JM, 2007, INT J CANCER, V121, P2267, DOI 10.1002/ijc.22921; Wu YJ, 2009, ENDOCRINOLOGY, V150, P4395, DOI 10.1210/en.2009-0272; Wu YP, 2002, CANCER RES, V62, P1030; Yakar S, 2004, NOVART FDN SYMP, V262; Yakar S, 2004, NOVART FDN SYMP, V262, P9; Yakar Shoshana, 2004, Novartis Found Symp, V262, P3; Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200	45	13	13	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2019	38	36					6338	6353		10.1038/s41388-019-0880-9	http://dx.doi.org/10.1038/s41388-019-0880-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6EX	31312023				2022-12-17	WOS:000485776800002
J	Zhang, C; Stockwell, SR; Elbanna, M; Ketteler, R; Freeman, J; Al-Lazikani, B; Eccles, S; Brandon, AS; Raynaud, F; Hayes, A; Clarke, PA; Workman, P; Mittnacht, S				Zhang, Chi; Stockwell, Simon R.; Elbanna, May; Ketteler, Robin; Freeman, Jamie; Al-Lazikani, Bissan; Eccles, Suzanne; Brandon, Alexis De Haven; Raynaud, Florence; Hayes, Angela; Clarke, Paul A.; Workman, Paul; Mittnacht, Sibylle			Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; DEPENDENT KINASES; CANCER; COMBINATION; INHIBITION; PROTEIN; ARREST; PHOSPHORYLATION; MECHANISMS; RECEPTOR	Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prevalent in cancer; yet, inhibitors against these kinases are currently used only in restricted tumour contexts. The extent to which cancers depend on CDK4/6 and the mechanisms that may undermine such dependency are poorly understood. Here, we report that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion kinase (FAK) axis leads to CDK4/6-independent CDK2 activation, involving as critical mechanistic events loss of the CDKI p21(CIP1) and gain of its regulator, the ubiquitin ligase subunit SKP2. Combined inhibition of MET/FAK and CDK4/6 eliminates the proliferation capacity of cancer cells in culture, and enhances tumour growth inhibition in vivo. Activation of the MET/FAK axis is known to arise through cancer extrinsic and intrinsic cues. Our work predicts that such cues support cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases and identifies MET/FAK as a tractable route to broaden the utility of CDK4/6 inhibitor-based therapies in the clinic.	[Zhang, Chi; Stockwell, Simon R.; Elbanna, May; Mittnacht, Sibylle] UCL, UCL Canc Inst, London WC1E 6DD, England; [Zhang, Chi; Al-Lazikani, Bissan; Eccles, Suzanne; Brandon, Alexis De Haven; Raynaud, Florence; Hayes, Angela; Clarke, Paul A.; Workman, Paul] Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England; [Ketteler, Robin; Freeman, Jamie] UCL, MRC Lab Mol Cell Biol, London WC1E 6BT, England	University of London; University College London; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; MRC Laboratory Molecular Biology; University of London; University College London	Mittnacht, S (corresponding author), UCL, UCL Canc Inst, London WC1E 6DD, England.; Workman, P (corresponding author), Inst Canc Res, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England.	paul.workman@icr.ac.uk; s.mittnacht@cancer.ucl.ac.uk	Al-Lazikani, Bissan/AAG-4723-2022; Al-Lazikani, Bissan/AFK-6457-2022; Elbanna, May/ABC-3736-2021	Clarke, Paul/0000-0001-9342-1290; Al-Lazikani, Bissan/0000-0003-3367-2519; Raynaud, Florence/0000-0003-0957-6279; Zhang, Chi/0000-0002-9188-6307; Elbanna, May/0000-0002-9745-9066; Stockwell, Simon/0000-0002-3345-8945	Cancer Research UK [C309/A11566, C309/A8274, C309/A8992, C423/A1421, C423/A15043]; World Cancer Research Fund (WCRF) [12-1280]; Wellcome Trust [094885/Z/10/Z]	Cancer Research UK(Cancer Research UK); World Cancer Research Fund (WCRF)(World Cancer Research Fund International (WCRF)); Wellcome Trust(Wellcome TrustEuropean Commission)	The authors thank Nicky Evans for editorial help with writing this paper, and Albert Hallsworth, Melanie Valenti and Gary Box for assisting with the mouse work. We thank the Vogelstein laboratory for providing isogenic TP53<SUP>-/-</SUP> and TP53<SUP>WT</SUP> HCT116 human colorectal cancer cells. Financial support: The work was supported by grants from Cancer Research UK (ref. C309/A11566, ref. C309/A8274 and ref. C309/A8992 (PW), ref. C423/A1421 and ref. C423/A15043 (SM)) and the World Cancer Research Fund (WCRF) (ref. 12-1280). CZ was supported by a Wellcome Trust studentship (ref. 094885/Z/10/Z). PW is a Cancer Research UK Life Fellow. The funders had no role in the design of the study, the collection, analysis and interpretation of the data, the writing of the paper or the decision to submit the paper for publication.	Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Bilgin B, 2017, CURR MED RES OPIN, V33, P1559, DOI 10.1080/03007995.2017.1348344; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Blagg J, 2017, CANCER CELL, V32, P9, DOI 10.1016/j.ccell.2017.06.005; Bond M, 2004, J BIOL CHEM, V279, P37304, DOI 10.1074/jbc.M404307200; Bryant P, 2006, MOL CELL BIOL, V26, P4201, DOI 10.1128/MCB.01612-05; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Engels B, 2012, SEMIN CANCER BIOL, V22, P41, DOI 10.1016/j.semcancer.2011.12.008; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Franco J, 2014, ONCOTARGET, V5, P6512, DOI 10.18632/oncotarget.2270; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gentile A, 2008, CANCER METAST REV, V27, P85, DOI 10.1007/s10555-007-9107-6; Goel S, 2016, CANCER CELL, V29, P255, DOI 10.1016/j.ccell.2016.02.006; Golubovskaya VM, 2014, FRONT BIOSCI-LANDMRK, V19, P687, DOI 10.2741/4236; Gu JM, 2004, MOL BIOL CELL, V15, P3320, DOI 10.1091/mbc.E04-03-0227; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Huang G, 2014, ANTI-CANCER AGENT ME, V14, P9, DOI 10.2174/18715206113139990141; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 2017, TRENDS CANCER, V3, P39, DOI 10.1016/j.trecan.2016.11.006; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Leontieva OV, 2013, CELL CYCLE, V12, P3063, DOI 10.4161/cc.26130; Lv PC, 2018, EXPERT OPIN THER PAT, V28, P139, DOI 10.1080/13543776.2018.1414183; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Matsumoto K, 2006, INT J CANCER, V119, P477, DOI 10.1002/ijc.21808; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Richardson E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031627; Rocca A, 2017, THER ADV MED ONCOL, V9, P83, DOI 10.1177/1758834016677961; Roy-Luzarraga M, 2016, CLIN CANCER RES, V22, P3718, DOI 10.1158/1078-0432.CCR-14-2021; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Schettini F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00608; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 2000, CANCER RES, V60, P3689; Shibue T, 2013, CANCER CELL, V24, P481, DOI 10.1016/j.ccr.2013.08.012; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Verschuren EW, 2007, DEV CELL, V12, P169, DOI 10.1016/j.devcel.2007.01.015; Wang L, 2007, BLOOD, V110, P2075, DOI 10.1182/blood-2007-02-071266; Whittaker SR, 2017, PHARMACOL THERAPEUT, V173, P83, DOI 10.1016/j.pharmthera.2017.02.008; Ye F, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S8-S3; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; 1988, LAB ANIM UK, V22, P195	52	13	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5905	5920		10.1038/s41388-019-0850-2	http://dx.doi.org/10.1038/s41388-019-0850-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31296956	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000482739300005
J	Zhu, SM; Soutto, M; Chen, Z; Piazuelo, MB; Washington, MK; Belkhiri, A; Zaika, A; Peng, DF; El, WERA				Zhu, Shoumin; Soutto, Mohammed; Chen, Zheng; Piazuelo, M. Blanca; Washington, M. Kay; Belkhiri, Abbes; Zaika, Alexander; Peng, Dunfa; El-Rifai, Wael			Activation of IGF1R by DARPP-32 promotes STAT3 signaling in gastric cancer cells	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; NEGATIVE REGULATION; INSULIN; EXPRESSION; INFLAMMATION; BLOCKADE; PATHWAY; GENE; OVEREXPRESSION	Dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32), is frequently overexpressed in early stages of gastric cancers. We utilized in vitro assays, 3D gastric gland organoid cultures, mouse models, and human tissue samples to investigate the biological and molecular impact of DARPP-32 on activation of IGF1R and STAT3 signaling and gastric tumorigenesis. DARPP-32 enhanced phosphorylation of IGF1R (Y1135), a step that was critical for STAT3 phosphorylation at Y705, nuclear localization, and transcription activation. By using proximity ligation and co-immunoprecipitation assays, we found that IGF1R and DARPP-32 co-existed in the same protein complex. Binding of DARPP-32 to IGF1R promoted IGF1R phosphorylation with subsequent activation of downstream SRC and STAT3. Analysis of gastric tissues from the TFF1 knockout (KO) mouse model of gastric neoplasia, demonstrated phosphorylation of STAT3 in the early stages of gastric tumorigenesis. By crossing the TFF1 KO mice with DARPP-32 (DP) knockout (KO) mice, that have normal stomach, we obtained double knockout (TFF1 KO/DP KO). The gastric mucosa from the double KO mice did not show phosphorylation of IGF1R or STAT3. In addition, the TFF1 KO/DP KO mice had a significant delay in developing neoplastic gastric lesions. Analysis of human gastric cancer tissue microarrays, showed high levels of DARPP-32 and positive immunostaining for nuclear STAT3 in cancer tissues, as compared to non-cancer histologically normal tissues. In summary, the DARPP-32-IGF1R signaling axis plays a key role in regulating the STAT3 signaling, a critical step in gastric tumorigenesis.	[Zhu, Shoumin; Soutto, Mohammed; Chen, Zheng; Zaika, Alexander; Peng, Dunfa; El-Rifai, Wael] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Soutto, Mohammed; Chen, Zheng; Zaika, Alexander; El-Rifai, Wael] Miami Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA; [Zaika, Alexander; Peng, Dunfa; El-Rifai, Wael] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Piazuelo, M. Blanca] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Washington, M. Kay] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Belkhiri, Abbes] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA	University of Miami; University of Miami; Vanderbilt University; Vanderbilt University; Vanderbilt University	El, WERA (corresponding author), Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA.; El, WERA (corresponding author), Miami Healthcare Syst, Dept Vet Affairs, Miami, FL 33125 USA.; El, WERA (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.	wxe45@miami.edu			U.S. National Institutes of Health [R01CA93999]; U.S. Department of Veterans affairs [I01BX001179, 1IK6BX003787]; NATIONAL CANCER INSTITUTE [R01CA138833, R01CA093999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002115, I01BX001179, IK6BX003787] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Veterans affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by the U.S. National Institutes of Health (R01CA93999), Research Career Scientist award (1IK6BX003787), and a merit award (I01BX001179) from the U.S. Department of Veterans affairs (W. El-Rifai). The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Veterans Affairs, National Institutes of Health, or the University of Miami.	Adachi Y, 2014, TUMOR BIOL, V35, P973, DOI 10.1007/s13277-013-1131-2; Adachi Y, 2009, CARCINOGENESIS, V30, P1305, DOI 10.1093/carcin/bgp134; Ahn JH, 2015, MOL HUM REPROD, V21, P792, DOI 10.1093/molehr/gav039; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Cafferkey C, 2016, EXPERT OPIN INV DRUG, V25, P1023, DOI 10.1080/13543784.2016.1195807; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Chen Z, 2017, GENE CHROMOSOME CANC, V56, P535, DOI 10.1002/gcc.22456; Chen Z, 2016, GUT, V65, P925, DOI 10.1136/gutjnl-2014-308416; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; El-Rifai W, 2002, CANCER RES, V62, P4061; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Ge J, 2015, MOL MED REP, V11, P633, DOI 10.3892/mmr.2014.2746; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Gryko M, 2014, POL J PATHOL, V65, P135, DOI 10.5114/PJP.2014.42678; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li CJ, 2013, J CANCER RES THER, V9, pS67, DOI 10.4103/0973-1482.119100; Li SL, 2015, TUMOR BIOL, V36, P4519, DOI 10.1007/s13277-015-3096-9; Ma YF, 2016, CLIN CANCER RES, V22, P1767, DOI 10.1158/1078-0432.CCR-15-1677; Menting JG, 2015, STRUCTURE, V23, P1271, DOI 10.1016/j.str.2015.04.016; Mitchell TJ, 2005, IMMUNOLOGY, V114, P301, DOI 10.1111/j.1365-2567.2005.02091.x; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Numata K, 2016, J CANCER RES CLIN, V142, P415, DOI 10.1007/s00432-015-2039-6; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Soutto M, 2011, J CLIN INVEST, V121, P1753, DOI 10.1172/JCI43922; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vangamudi B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-240; Wang MSJ, 2005, INT J CLIN PRACT, V59, P58, DOI 10.1111/j.1742-1241.2004.00305.x; Werner H, 2012, ONCOGENE, V31, P2703, DOI 10.1038/onc.2011.447; Yadav A, 2005, J BIOL CHEM, V280, P31830, DOI 10.1074/jbc.M501316200; Yoshimura A, 2003, CURR OPIN IMMUNOL, V15, P704, DOI 10.1016/j.coi.2003.09.004; Yoshimura A, 2005, ARTHRITIS RES THER, V7, P100, DOI 10.1186/ar1741; Zhao GB, 2016, ONCOL REP, V35, P1787, DOI 10.3892/or.2016.4544; Zhou JD, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0386-9; Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	41	13	14	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5805	5816		10.1038/s41388-019-0843-1	http://dx.doi.org/10.1038/s41388-019-0843-1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31235784	Green Accepted			2022-12-17	WOS:000480752800005
J	Kim, AR; Choi, KW				Kim, Ah-Ram; Choi, Kwang-Wook			TRiC/CCT chaperonins are essential for organ growth by interacting with insulin/TOR signaling in Drosophila	ONCOGENE			English	Article							EUKARYOTIC CHAPERONIN; CELLULAR GROWTH; CCT CHAPERONIN; IN-VIVO; COMPLEX; PROTEINS; BIOGENESIS; ACTIVATION; EXPRESSION; AUTOPHAGY	Organ size is regulated by intercellular signaling for cell growth and proliferation. The TOR pathway mediates a key signaling mechanism for controlling cell size and number in organ growth. Chaperonin containing TCP-1 (CCT) is a complex that assists protein folding and function, but its role in animal development is largely unknown. Here we show that the CCT complex is required for organ growth by interacting with the TOR pathway in Drosophila. Reduction of CCT4 results in growth defects by affecting both cell size and proliferation. Loss of CCT4 causes preferential cell death anterior to the morphogenetic furrow in the eye disc and within wing pouch in the wing disc. Depletion of any CCT subunit in the eye disc results in headless phenotype. Overgrowth by active TOR signaling is suppressed by CCT RNAi. The CCT complex physically interacts with TOR signaling components including TOR, Rheb, and S6K. Loss of CCT leads to decreased phosphorylation of S6K and S6 while increasing phosphorylation of Akt. Insulin/TOR signaling is also necessary and sufficient for promoting CCT complex transcription. Our data provide evidence that the CCT complex regulates organ growth by directly interacting with the TOR signaling pathway.	[Kim, Ah-Ram; Choi, Kwang-Wook] Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 305701, South Korea; [Kim, Ah-Ram] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA	Korea Advanced Institute of Science & Technology (KAIST); Harvard University; Harvard Medical School	Choi, KW (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 305701, South Korea.	kchoi100@kaist.ac.kr	Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065; Kim, Ah-Ram/0000-0001-9597-6759	National Research Foundation of Korea - Ministry of Education, Science & Technology, Republic of Korea [NRF-2014K1A1A2042982, NRF-2017R1A2B3007516]	National Research Foundation of Korea - Ministry of Education, Science & Technology, Republic of Korea	We are grateful to Kyungok Cho, Jongkyeong Chung, Aurelio Teleman, Gabor Juhasz, Norbert Perrimon, the Bloomington Drosophila Stock Center, the National Institute of Genetics, the the Vienna Drosophila Resource Center, the Kyoto Stock Center, the Drosophila Genomics Resource Center, and the Developmental Studies Hybridoma Bank for reagents and fly stocks. We also thank Jean Jung for commenting on the manuscript. This research was supported by grants (NRF-2014K1A1A2042982 and NRF-2017R1A2B3007516) of the National Research Foundation of Korea funded by the Ministry of Education, Science & Technology, Republic of Korea.	Abe Y, 2009, J BIOL CHEM, V284, P14939, DOI 10.1074/jbc.M900097200; Antonova SV, 2018, NAT STRUCT MOL BIOL, V25, P1119, DOI 10.1038/s41594-018-0156-z; Bassiouni R, 2016, CLIN CANCER RES, V22, P4366, DOI 10.1158/1078-0432.CCR-15-2502; Bateman JR, 2006, GENETICS, V173, P769, DOI 10.1534/genetics.106.056945; Berger J, 2018, CELL REP, V22, P313, DOI 10.1016/j.celrep.2017.12.069; Boudiaf-Benmammar C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060895; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hodeify R, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau1935; Housden BE, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab3729; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; Hu YH, 2013, G3-GENES GENOM GENET, V3, P1607, DOI 10.1534/g3.113.007021; Jaeger K, 2019, APOPTOSIS, V24, P62, DOI 10.1007/s10495-018-1505-4; Jeong JY, 2012, APPL ENVIRON MICROB, V78, P5440, DOI 10.1128/AEM.00844-12; Kaisari S, 2017, P NATL ACAD SCI USA, V114, P956, DOI 10.1073/pnas.1620451114; Karim FD, 1998, DEVELOPMENT, V125, P1; Kim W, 2017, DEV CELL, V42, P363, DOI 10.1016/j.devcel.2017.07.020; Kockel L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000990; Le TP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11501; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Liu XQ, 2005, MOL CELL BIOL, V25, P4993, DOI 10.1128/MCB.25.12.4993-5010.2005; Liu YG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.460; Lundin VF, 2008, DEV BIOL, V313, P320, DOI 10.1016/j.ydbio.2007.10.022; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Nagy P, 2014, AUTOPHAGY, V10, P453, DOI 10.4161/auto.27442; Noormohammadi A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13649; Pavel M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13821; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Raineri E, 2010, BIOINFORMATICS, V26, P1685, DOI 10.1093/bioinformatics/btq287; Ramadan N, 2007, NAT PROTOC, V2, P2245, DOI 10.1038/nprot.2007.250; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Roh SH, 2015, INT J MOL SCI, V16, P26706, DOI 10.3390/ijms161125975; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Seo S, 2010, P NATL ACAD SCI USA, V107, P1488, DOI 10.1073/pnas.0910268107; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stoldt V, 1996, YEAST, V12, P523, DOI 10.1002/(SICI)1097-0061(199605)12:6<523::AID-YEA962>3.3.CO;2-3; Stowers RS, 1999, GENETICS, V152, P1631; Svanstrom A, 2016, CELL STRESS CHAPERON, V21, P55, DOI 10.1007/s12192-015-0637-5; Tang HW, 2018, CELL METAB, V27, P1040, DOI 10.1016/j.cmet.2018.02.023; Trinidad AG, 2013, MOL CELL, V50, P805, DOI 10.1016/j.molcel.2013.05.002; Tsokanos FF, 2016, EMBO J, V35, P1058, DOI 10.15252/embj.201593118; Vinayagam A, 2016, CELL REP, V16, P3062, DOI 10.1016/j.celrep.2016.08.029; Wells CA, 2006, J BIOL CHEM, V281, P20221, DOI 10.1074/jbc.M602409200; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Yam AY, 2008, NAT STRUCT MOL BIOL, V15, P1255, DOI 10.1038/nsmb.1515; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	51	13	13	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4739	4754		10.1038/s41388-019-0754-1	http://dx.doi.org/10.1038/s41388-019-0754-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30792539	Green Published, hybrid			2022-12-17	WOS:000471160500007
J	Nakayama, R; Ueno, Y; Ueda, K; Honda, T				Nakayama, Ryota; Ueno, Yumiko; Ueda, Keiji; Honda, Tomoyuki			Latent infection with Kaposi's sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1	ONCOGENE			English	Article							PRIMARY EFFUSION LYMPHOMA; HUMAN L1 ELEMENT; KAPPA-B PATHWAY; DNA-SEQUENCES; ENDOTHELIAL ICAM-1; ACTIVATION; EXPRESSION; CANCER; GENE; VFLIP	Kaposi's sarcoma (KS)-associated herpesvirus (KSHV), a gamma-2 herpesvirus, is the causative agent of KS, primary effusion lymphoma (PEL), and a plasma cell variant of multicentric Castleman's disease. Although KSHV latency is detected in KS-related tumors, oncogenic pathways activated by KSHV latent infection are not fully understood. Here, we found that retrotransposition of long interspersed element-1 (L1), a retrotransposon in the human genome, was enhanced in PEL cells. Among the KSHV latent genes, viral FLICE-inhibitory protein (vFLIP) enhanced L1 retrotransposition in an NF-kappa B-dependent manner. Intracellular cell adhesion molecule-1 (ICAM-1), an NF-kappa B target, regulated the vFLIP-mediated enhancement of L1 retrotransposition. Furthermore, ICAM-1 downregulated the expression of Moloney leukemia virus 10 (MOV10), an L1 restriction factor. Knockdown of ICAM-1 or overexpression of MOV10 relieved the vFLIP-mediated enhancement of L1 retrotransposition. Collectively, during KSHV latency, vFLIP upregulates ICAM-1 in an NF-kappa B-dependent manner, which, in turn, downregulates MOV10 expression and thereby enhances L1 retrotransposition. Because active L1 retrotransposition can lead to genomic instability, which is commonly found in KS and PEL, activation of L1 retrotransposition during KSHV latency may accelerate oncogenic processes through enhancing genomic instability. Our results suggest that L1 retrotransposition may be a novel target for impeding tumor development in KSHV-infected patients.	[Nakayama, Ryota; Ueno, Yumiko; Ueda, Keiji; Honda, Tomoyuki] Osaka Univ, Dept Microbiol & Immunol, Div Virol, Grad Sch Med, Osaka, Japan	Osaka University	Honda, T (corresponding author), Osaka Univ, Dept Microbiol & Immunol, Div Virol, Grad Sch Med, Osaka, Japan.	thonda@virus.med.osaka-u.ac.jp			MEXT/JSPS KAKENHI [15K08496, 18H02664, 18K19449]; Takeda Science Foundation; Senri Life Science Foundation; Suzuken Memorial Foundation; Shimizu Foundation for Immunology and Neuroscience; NOVARTIS Foundation (Japan) for the Promotion of Science	MEXT/JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Senri Life Science Foundation; Suzuken Memorial Foundation; Shimizu Foundation for Immunology and Neuroscience; NOVARTIS Foundation (Japan) for the Promotion of Science(Novartis)	This study was supported in part by the MEXT/JSPS KAKENHI Grant Numbers 15K08496, 18H02664, and 18K19449 (T.H.), and grants from the Takeda Science Foundation, Senri Life Science Foundation, Suzuken Memorial Foundation, The Shimizu Foundation for Immunology and Neuroscience Grant for 2015, and The NOVARTIS Foundation (Japan) for the Promotion of Science (T.H.).	Adamson P, 1999, J IMMUNOL, V162, P2964; Bagneris C, 2008, MOL CELL, V30, P620, DOI 10.1016/j.molcel.2008.04.029; Beck CR, 2010, CELL, V141, P1159, DOI 10.1016/j.cell.2010.05.021; Belancio VP, 2009, GENOME MED, V1, DOI 10.1186/gm97; Boshoff C, 2001, ANNU REV MED, V52, P453, DOI 10.1146/annurev.med.52.1.453; BOVI PD, 1986, CANCER RES, V46, P6333; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Burns KH, 2012, CELL, V149, P740, DOI 10.1016/j.cell.2012.04.019; Burwinkel B, 1998, J MOL BIOL, V277, P513, DOI 10.1006/jmbi.1998.1641; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chen JM, 2005, HUM GENET, V117, P411, DOI 10.1007/s00439-005-1321-0; Choi J, 2018, NUCLEIC ACIDS RES, V46, P1912, DOI 10.1093/nar/gkx1312; Coscoy L, 2007, NAT REV IMMUNOL, V7, P391, DOI 10.1038/nri2076; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248; Dai LX, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-18; Delabesse E, 1997, J CLIN PATHOL, V50, P664, DOI 10.1136/jcp.50.8.664; Denli AM, 2015, CELL, V163, P583, DOI 10.1016/j.cell.2015.09.025; Ding D, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003065; Dittmer DP, 2016, J CLIN INVEST, V126, P3165, DOI 10.1172/JCI84418; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DUPIN N, 1995, NEW ENGL J MED, V333, P798; Dupuy AJ, 2009, CANCER RES, V69, P8150, DOI 10.1158/0008-5472.CAN-09-1135; Ehrlich ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091359; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Gaidano G, 1997, HUM PATHOL, V28, P748, DOI 10.1016/S0046-8177(97)90187-8; Ganem D, 2010, J CLIN INVEST, V120, P939, DOI 10.1172/JCI40567; Gill PS, 1998, P NATL ACAD SCI USA, V95, P8257, DOI 10.1073/pnas.95.14.8257; Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022; Goodier JL, 2016, MOBILE DNA-UK, V7, DOI 10.1186/s13100-016-0070-z; Goodier JL, 2014, MOBILE DNA-UK, V5, DOI 10.1186/1759-8753-5-11; Goodier JL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002941; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hancks DC, 2012, CURR OPIN GENET DEV, V22, P191, DOI 10.1016/j.gde.2012.02.006; Holland J, 1997, J BIOL CHEM, V272, P9108; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; Honda T, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02537; Honda T, 2016, FRONT CHEM, V4, DOI 10.3389/fchem.2016.00021; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kinomoto M, 2007, NUCLEIC ACIDS RES, V35, P2955, DOI 10.1093/nar/gkm181; Lau CC, 2014, CANCER CELL, V25, P335, DOI 10.1016/j.ccr.2014.01.030; Lawson C, 2009, PHARMACOL REP, V61, P22, DOI 10.1016/S1734-1140(09)70004-0; Li XY, 2013, J BIOL CHEM, V288, P21148, DOI 10.1074/jbc.M113.465856; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Mesri EA, 2014, CELL HOST MICROBE, V15, P266, DOI 10.1016/j.chom.2014.02.011; MIKI Y, 1992, CANCER RES, V52, P643; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MOOSLEHNER K, 1991, MOL CELL BIOL, V11, P886, DOI 10.1128/MCB.11.2.886; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Nishikawa Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103243; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Punj V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037498; Rad R, 2010, SCIENCE, V330, P1104, DOI 10.1126/science.1193004; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Scott EC, 2016, GENOME RES, V26, P745, DOI 10.1101/gr.201814.115; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032; Singer T, 2010, TRENDS NEUROSCI, V33, P345, DOI 10.1016/j.tins.2010.04.001; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staudt Michelle R., 2003, Current Drug Targets - Infectious Disorders, V3, P129, DOI 10.2174/1568005033481150; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Xie Y, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1076	70	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4340	4351		10.1038/s41388-019-0726-5	http://dx.doi.org/10.1038/s41388-019-0726-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30770900				2022-12-17	WOS:000469339100010
J	Zhao, YF; Qiao, SP; Hou, XL; Tian, H; Deng, S; Ye, KR; Nie, YZ; Chen, XB; Yan, HJ; Tian, WM				Zhao, Yufang; Qiao, Shupei; Hou, Xiaolu; Tian, Hui; Deng, Shuai; Ye, Kangruo; Nie, Yongzhan; Chen, Xiongbiao; Yan, Hongji; Tian, Weiming			Bioengineered tumor microenvironments with naked mole rats high-molecular-weight hyaluronan induces apoptosis in breast cancer cells	ONCOGENE			English	Article							CD44; RESISTANCE; HAS2; P53; INVASION; GROWTH	The naked mole rat (nmr) is cancer resistant due to the abundant production of extremely high-molecular-weight hyaluronan (EHMW-HA). However, whether EHMW-HA has similar anti-cancer effects in mice and humans remains to be determined. The present study used breast cancer cells to clarify the effect of EHMW-HA on breast cancer. First, the overexpression of nmrHas2 in 4T1 and BT549 cell lines in both two-dimensional (2D) and three-dimensional (3D) models to mimic tumor microenvironment was established. The 4T1/BT549-nmrHas2 cells could secrete EHMW-HA (with a molecular weight of up to 6 MDa), which was similar to that found in the naked mole rat. Second, EHMW-HA altering tumor microenvironment in both 2D monolayers and 3D spheroids significantly enhanced apoptosis, inhibiting the proliferation of 4T1 and BT549 cells. The prominent anticancer effects of EHMW-HA on the cancer-cell apoptosis phenotype were further confirmed by inhibiting tumor formation in nude mice. Finally, EHMW-HA significantly induced higher p53 protein expression, which enhanced pro-apoptotic proteins p21 and Bax in breast cancer cells; this is in contrast with the triggering of hypersensitivity of the naked mole rat cells to early contact inhibition (ECI). These results have important implications for the design of therapeutic approaches based on the application of EHMW-HA.	[Zhao, Yufang; Qiao, Shupei; Hou, Xiaolu; Tian, Hui; Deng, Shuai; Ye, Kangruo; Tian, Weiming] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Heilongjiang, Peoples R China; [Zhao, Yufang] Harbin Inst Technol, Res Ctr Basic Space Sci, Space Environm Stimulat & Res Interface, Harbin 150080, Heilongjiang, Peoples R China; [Nie, Yongzhan] Fourth Mil Med Univ, State Key Lab Canc Biol, Harbin 150080, Heilongjiang, Peoples R China; [Nie, Yongzhan] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Harbin 150080, Heilongjiang, Peoples R China; [Chen, Xiongbiao] Univ Saskatchewan, Dept Mech Engn, Saskatoon, SK S7N 5A2, Canada; [Yan, Hongji] AlbaNova Univ Ctr, Sch Engn Sci Chem Biotechnol & Hlth, KTHRoyal Inst Technol, Dept Chem,Div Glycosci, S-10691 Stockholm, Sweden	Harbin Institute of Technology; Harbin Institute of Technology; Air Force Military Medical University; Air Force Military Medical University; University of Saskatchewan; Royal Institute of Technology	Tian, WM (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Heilongjiang, Peoples R China.	tianweiming@hit.edu.cn	Yan, Hongji/AAL-7040-2021	Chen, Xiongbiao (Daniel)/0000-0002-4716-549X; DENG, Shuai/0000-0001-7622-2097; /0000-0001-7257-5522; Tian, Weiming/0000-0003-4958-4118	National Natural Science Foundation of China [51773050, 81770923]; Opening Foundation of the State Key Laboratory of Cancer Biology [CBSKL201106]; Heilongjiang Postdoctoral Fund [LBH-Z18068]; China Postdoctoral Science Foundation [2018M641837]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Opening Foundation of the State Key Laboratory of Cancer Biology; Heilongjiang Postdoctoral Fund; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This research was supported by the National Natural Science Foundation of China (Grant No.: 51773050 and 81770923), the Opening Foundation of the State Key Laboratory of Cancer Biology (CBSKL201106), and the author was supported by the Heilongjiang Postdoctoral Fund (No. LBH-Z18068) and a general financial grant from the China Postdoctoral Science Foundation (No. 2018M641837).	Beasley KL, 2009, FACIAL PLAST SURG, V25, P86, DOI 10.1055/s-0029-1220647; Bernert B, 2011, J BIOL CHEM, V286, P42349, DOI 10.1074/jbc.M111.278598; Brown TJ, 2008, CURR PHARM BIOTECHNO, V9, P253, DOI 10.2174/138920108785161514; Carvalho MP, 2016, CARBOHYD POLYM, V150, P139, DOI 10.1016/j.carbpol.2016.05.005; COOPER EH, 1988, BRIT J CANCER, V58, P668, DOI 10.1038/bjc.1988.283; Fuchs K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.364; Gao F, 2008, CLIN INVEST MED, V31, pE106, DOI 10.25011/cim.v31i3.3467; Gao F, 2010, MATRIX BIOL, V29, P107, DOI 10.1016/j.matbio.2009.11.002; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GILLI R, 1994, CARBOHYD RES, V263, P315, DOI 10.1016/0008-6215(94)00147-2; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Goldsworthy TL, 1996, MUTAT RES-REV GENET, V365, P71, DOI 10.1016/S0165-1110(96)90013-5; Heldin P, 2013, J BIOCHEM, V154, P395, DOI 10.1093/jb/mvt085; Huang Z, 2014, INFLAMM CELL SIGNAL, V1; Karbownik MS, 2013, PHARMACOL REP, V65, P1056, DOI 10.1016/S1734-1140(13)71465-8; Kultti Anne, 2012, Cancers (Basel), V4, P873, DOI 10.3390/cancers4030873; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1995, ANN RHEUM DIS, V54, P429, DOI 10.1136/ard.54.5.429; Lee YJ, 2016, ACTA PHARMACOL SIN, V37, P664, DOI 10.1038/aps.2015.151; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Louderbough JMV, 2011, MOL CANCER RES, V9, P1573, DOI 10.1158/1541-7786.MCR-11-0156; Masters KS, 2005, BIOMATERIALS, V26, P2517, DOI 10.1016/j.biomaterials.2004.07.018; Mirzayans R, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/170325; Miyawaki S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11471; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nikitovic D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/929531; Okuda H, 2012, CANCER RES, V72, P537, DOI 10.1158/0008-5472.CAN-11-1678; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Park TJ, 2017, SCIENCE, V356, P305, DOI 10.1126/science.aab3896; Rayahin JE, 2015, ACS BIOMATER SCI ENG, V1, P481, DOI 10.1021/acsbiomaterials.5b00181; Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142-9612(98)00107-0; Seluanov A, 2018, NAT REV CANCER, V18, P433, DOI 10.1038/s41568-018-0004-9; Seluanov A, 2009, P NATL ACAD SCI USA, V106, P19352, DOI 10.1073/pnas.0905252106; Song YK, 2002, AM J PATHOL, V160, P1069, DOI 10.1016/S0002-9440(10)64927-9; Thanos CD, 2016, NOVEL IMMUNOTHERAPEU, P249; Tian X, 2015, P NATL ACAD SCI USA, V112, P1053, DOI 10.1073/pnas.1418203112; Tian X, 2013, NATURE, V499, P346, DOI 10.1038/nature12234; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Wu M, 2015, FASEB J, V29, P1290, DOI 10.1096/fj.14-259978; Yang CX, 2012, J BIOL CHEM, V287, P43094, DOI 10.1074/jbc.M112.349209; Zhao Y, 2018, P NATL ACAD SCI USA, V115, P1801, DOI 10.1073/pnas.1721160115; Zhao YF, 2017, ACS APPL MATER INTER, V9, P9327, DOI 10.1021/acsami.6b15187	43	13	14	1	72	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4297	4309		10.1038/s41388-019-0719-4	http://dx.doi.org/10.1038/s41388-019-0719-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30700830				2022-12-17	WOS:000469339100007
J	Somers, K; Wen, VW; Middlemiss, SMC; Osborne, B; Forgham, H; Jung, M; Karsa, M; Clifton, M; Bongers, A; Gao, JX; Mayoh, C; Raoufi-Rad, N; Kusnadi, EP; Hannan, KM; Scott, DA; Kwek, A; Liu, B; Flemming, C; Chudakova, DA; Pandher, R; Failes, TW; Lim, J; Angeli, A; Osterman, AL; Imamura, T; Kees, UR; Supuran, CT; Pearson, RB; Hannan, RD; Davis, TP; McCarroll, J; Kavallaris, M; Turner, N; Gudkov, AV; Haber, M; Norris, MD; Henderson, MJ				Somers, Klaartje; Wen, Victoria W.; Middlemiss, Shiloh M. C.; Osborne, Brenna; Forgham, Helen; Jung, MoonSun; Karsa, Mawar; Clifton, Molly; Bongers, Angelika; Gao, Jixuan; Mayoh, Chelsea; Raoufi-Rad, Newsha; Kusnadi, Eric P.; Hannan, Kate M.; Scott, David A.; Kwek, Alan; Liu, Bing; Flemming, Claudia; Chudakova, Daria A.; Pandher, Ruby; Failes, Tim W.; Lim, James; Angeli, Andrea; Osterman, Andrei L.; Imamura, Toshihiko; Kees, Ursula R.; Supuran, Claudiu T.; Pearson, Richard B.; Hannan, Ross D.; Davis, Thomas P.; McCarroll, Joshua; Kavallaris, Maria; Turner, Nigel; Gudkov, Andrei V.; Haber, Michelle; Norris, Murray D.; Henderson, Michelle J.			A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction	ONCOGENE			English	Article							TARGETING MITOCHONDRIA; THERAPEUTIC STRATEGY; CARBONIC-ANHYDRASES; OXIDATIVE STRESS; MEIS1; CANCER; INHIBITION; EXPRESSION; METABOLISM; TRANSLOCATIONS	Survival rates for pediatric patients suffering from mixed lineage leukemia (MLL)-rearranged leukemia remain below 50% and more targeted, less toxic therapies are urgently needed. A screening method optimized to discover cytotoxic compounds selective for MLL-rearranged leukemia identified CCI-006 as a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways. CCI-006 inhibited mitochondrial respiration and induced mitochondrial membrane depolarization and apoptosis in a subset (7/11, 64%) of MLL-rearranged leukemia cell lines within a few hours of treatment. The unresponsive MLL-rearranged leukemia cells did not undergo mitochondrial membrane depolarization or apoptosis despite a similar attenuation of mitochondrial respiration by the compound. In comparison to the sensitive cells, the unresponsive MLL-rearranged leukemia cells were characterized by a more glycolytic metabolic phenotype, exemplified by a more pronounced sensitivity to glycolysis inhibitors and elevated HIF1 alpha expression. Silencing of HIF1 alpha expression sensitized an intrinsically unresponsive MLL-rearranged leukemia cell to CCI-006, indicating that this pathway plays a role in determining sensitivity to the compound. In addition, unresponsive MLL-rearranged leukemia cells expressed increased levels of MEIS1, an important leukemogenic MLL target gene that plays a role in regulating metabolic phenotype through HIF1 alpha. MEIS1 expression was also variable in a pediatric MLL-rearranged ALL patient dataset, highlighting the existence of a previously undescribed metabolic variability in MLL-rearranged leukemia that may contribute to the heterogeneity of the disease. This study thus identified a novel small molecule that rapidly kills MLL-rearranged leukemia cells by targeting a metabolic vulnerability in a subset of low HIF1 alpha/low MEIS1-expressing MLL-rearranged leukemia cells.	[Somers, Klaartje; Wen, Victoria W.; Middlemiss, Shiloh M. C.; Forgham, Helen; Jung, MoonSun; Karsa, Mawar; Clifton, Molly; Bongers, Angelika; Gao, Jixuan; Mayoh, Chelsea; Raoufi-Rad, Newsha; Kwek, Alan; Liu, Bing; Flemming, Claudia; Chudakova, Daria A.; Pandher, Ruby; Failes, Tim W.; Lim, James; McCarroll, Joshua; Kavallaris, Maria; Haber, Michelle; Norris, Murray D.; Henderson, Michelle J.] UNSW, Childrens Canc Inst, Lowy Canc Res Ctr, Randwick, NSW, Australia; [Osborne, Brenna; Turner, Nigel] UNSW, Sch Med Sci, Mitochondrial Bioenerget Lab, Randwick, NSW, Australia; [Forgham, Helen; McCarroll, Joshua; Kavallaris, Maria] UNSW Australia, Australian Ctr NanoMed, ARC Ctr Excellence Convergent Bionano Sci & Techn, Sydney, NSW, Australia; [Kusnadi, Eric P.; Pearson, Richard B.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Hannan, Kate M.; Hannan, Ross D.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia; [Scott, David A.; Osterman, Andrei L.] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA 92037 USA; [Failes, Tim W.] UNSW, ACRF Drug Discovery Ctr, Childrens Canc Inst, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Angeli, Andrea; Supuran, Claudiu T.] Univ Florence, Neurofarba Dept, Florence, Italy; [Imamura, Toshihiko] Kyoto Prefectural Univ Med, Dept Pediat, Kyoto, Japan; [Kees, Ursula R.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Davis, Thomas P.] Monash Univ, ARC Ctr Excellence Convergent Bionano Sci & Techn, Monash Inst Pharmaceut Sci, Clayton, Vic, Australia; [Davis, Thomas P.] Univ Warrick, Dept Chem, Coventry, W Midlands, England; [Gudkov, Andrei V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Gudkov, Andrei V.] Oncotartis Inc, Buffalo, NY USA; [Norris, Murray D.] UNSW Ctr Childhood Canc Res, Sydney, NSW, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Peter Maccallum Cancer Center; Australian National University; John Curtin School of Medical Research; Sanford Burnham Prebys Medical Discovery Institute; Children's Cancer Institute; University of New South Wales Sydney; University of Florence; Kyoto Prefectural University of Medicine; Telethon Kids Institute; University of Western Australia; Monash University; University of Warwick; Roswell Park Cancer Institute	Henderson, MJ (corresponding author), UNSW, Childrens Canc Inst, Lowy Canc Res Ctr, Randwick, NSW, Australia.	mhenderson@ccia.unsw.edu.au	Osborne, Brenna/F-5950-2018; Chudakova, Daria/ABB-3032-2020; Mayoh, Chelsea/AAE-7349-2021; McCarroll, Joshua/E-8481-2010; Turner, Nigel/H-7176-2013; Davis, Thomas/B-6395-2008	Osborne, Brenna/0000-0002-0197-3010; Mayoh, Chelsea/0000-0002-6398-3046; McCarroll, Joshua/0000-0001-8807-3623; Turner, Nigel/0000-0002-0119-9328; Davis, Thomas/0000-0003-2581-4986; Gao, Jixuan/0000-0002-2209-3143; Forgham, Helen/0000-0002-6871-3213; Hannan, Katherine/0000-0003-4186-8167; Scott, David/0000-0002-8668-2449; Haber, Michelle/0000-0003-2036-8817; Kavallaris, Maria/0000-0003-2309-898X; Supuran, Claudiu/0000-0003-4262-0323; Karsa, Mawar/0000-0001-9682-1118; angeli, andrea/0000-0002-1470-7192	NHMRC; Leukemia Foundation; NSW Cancer Council; Cancer Institute NSW; Tenix Foundation; ISG Foundation; Children's Leukemia & Cancer Research Foundation, Perth; NCI Cancer Center Support Grant [P30 CA30199]; Anthony Rothe Memorial Trust; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Leukemia Foundation; NSW Cancer Council(Cancer Council New South Wales); Cancer Institute NSW; Tenix Foundation; ISG Foundation; Children's Leukemia & Cancer Research Foundation, Perth; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Anthony Rothe Memorial Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by NHMRC, Leukemia Foundation, Anthony Rothe Memorial Trust, NSW Cancer Council, Cancer Institute NSW, Tenix Foundation, ISG Foundation and the Children's Leukemia & Cancer Research Foundation, Perth. Metabolic analysis was performed at the Cancer Metabolism Core, SBP Medical Discovery Institute, with assistance from Olga Zagnitko and support of NCI Cancer Center Support Grant P30 CA30199.	Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x; Arechederra RL, 2013, BIOORGAN MED CHEM, V21, P1544, DOI 10.1016/j.bmc.2012.06.053; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bao XR, 2016, ELIFE, V5, DOI 10.7554/eLife.10575; BLISS CI, 1956, BACTERIOL REV, V20, P243, DOI 10.1128/MMBR.20.4.243-258.1956; Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7; Caudell D, 2007, CANCER RES, V67, P8022, DOI 10.1158/0008-5472.CAN-06-3749; Chen L, 2013, LEUKEMIA, V27, P813, DOI 10.1038/leu.2012.327; Chen LL, 2016, ONCOTARGET, V7, P25208, DOI 10.18632/oncotarget.8199; Cole A, 2015, CANCER CELL, V27, P864, DOI 10.1016/j.ccell.2015.05.004; Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644; Driessen EMC, 2016, LEUKEMIA, V30, P1184, DOI 10.1038/leu.2015.246; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hulbert AJ, 2006, J COMP PHYSIOL B, V176, P93, DOI 10.1007/s00360-005-0025-z; Hulleman E, 2009, BLOOD, V113, P2014, DOI 10.1182/blood-2008-05-157842; Jhas B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058367; Kees UR, 2003, MOL CANCER THER, V2, P671; Klaus CR, 2014, J PHARMACOL EXP THER, V350, P646, DOI 10.1124/jpet.114.214577; Kocabas F, 2012, BLOOD, V120, P4963, DOI 10.1182/blood-2012-05-432260; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kuhn A, 2016, ONCOTARGET, V7, P35341, DOI 10.18632/oncotarget.9241; Kumar AR, 2009, BLOOD, V113, P1756, DOI 10.1182/blood-2008-06-163287; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lee EA, 2015, CANCER RES, V75, P2478, DOI 10.1158/0008-5472.CAN-14-2676; MacArthur DG, 2008, HUM MOL GENET, V17, P1076, DOI 10.1093/hmg/ddm380; Marin-Hernandez A, 2009, MINI-REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610; Marschalek R, 2016, ANN LAB MED, V36, P85, DOI 10.3343/alm.2016.36.2.85; Orlovsky K, 2011, P NATL ACAD SCI USA, V108, P7956, DOI 10.1073/pnas.1103154108; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Quiros PM, 2017, J CELL BIOL, V216, P2027, DOI 10.1083/jcb.201702058; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roychoudhury J, 2015, BLOOD, V125, P2544, DOI 10.1182/blood-2014-09-599258; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Shah GN, 2013, J PHARMACOL EXP THER, V344, P637, DOI 10.1124/jpet.112.201400; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Somers K, 2016, ONCOTARGET, V7, P46067, DOI 10.18632/oncotarget.10022; Sriskanthadevan S, 2015, BLOOD, V125, P2120, DOI 10.1182/blood-2014-08-594408; Stam RW, 2010, BLOOD, V115, P2835, DOI 10.1182/blood-2009-07-233049; Stein EM, 2018, BLOOD, V131, P2661, DOI 10.1182/blood-2017-12-818948; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Teo J, 2016, BIOMACROMOLECULES, V17, P2337, DOI 10.1021/acs.biomac.6b00185; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Trentin L, 2009, EUR J HAEMATOL, V83, P406, DOI 10.1111/j.1600-0609.2009.01305.x; Turner N, 2007, DIABETES, V56, P2085, DOI 10.2337/db07-0093; Unnisa Z, 2012, BLOOD, V120, P4973, DOI 10.1182/blood-2012-06-435800; van der Linden MH, 2009, BLOOD, V114, P3764, DOI 10.1182/blood-2009-02-204214; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867	55	13	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3824	3842		10.1038/s41388-018-0666-5	http://dx.doi.org/10.1038/s41388-018-0666-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670779	Green Published, hybrid			2022-12-17	WOS:000468035600005
J	Kim, I; Shin, SH; Lee, JE; Park, JW				Kim, Iljin; Shin, Seung-Hyun; Lee, Jae Eun; Park, Jong-Wan			Oxygen sensor FIH inhibits HACE1-dependent ubiquitination of Rac1 to enhance metastatic potential in breast cancer cells	ONCOGENE			English	Article							ANKYRIN REPEAT DOMAIN; INDUCIBLE FACTOR FIH; ASPARAGINYL HYDROXYLATION; LIGASE HACE1; TRANSCRIPTIONAL ACTIVITY; PROTEIN INTERACTIONS; DUCTAL CARCINOMA; HYPOXIA; TUMOR; UBIQUITYLATION	Oxygen is an indispensable element for cell survival and maintenance. Eukaryotic cells are equipped with a series of signaling pathways that cope with hypoxia. The dioxygenase factor inhibiting HIF (FIH) is an oxygen sensor that regulates the transcriptional activity of hypoxia-inducible factor (HIF) through asparaginyl hydroxylation. Given that HACE1 was detected as an FIH-interacting protein in a previous proteomics study, we tested whether the E3 ubiquitin ligase HACE1 is a substrate for FIH. FIH interacted with HACE1, in cells and in vitro, and was determined to hydroxylate HACE1 at the N191 residue within the ankyrin repeat domain. Hydroxylation disrupted the physical association between HACE1 and its representative target, Rac1. Under hypoxic conditions, HACE1 is less hydroxylated due to the inactivation of FIH, and subsequently functions to ubiquitinate the active form of Rac1, leading to the proteasomal degradation of Rac1. Since Rac1 stimulates cell movement, HACE1 inhibits cell migration and invasion in breast cancer by removing active Rac1. Such an effect of HACE1 is reinforced under hypoxia because HACE1 escapes from FIH-mediated hydroxylation. In clinical datasets, HACE1 downregulation is associated with poor outcomes in patients with breast cancer. Taken together, FIH is likely to act as an oxygen sensor that determines oxygen-dependent cancer progression.	[Kim, Iljin; Shin, Seung-Hyun; Lee, Jae Eun; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehak Ro, Seoul, South Korea; [Kim, Iljin; Shin, Seung-Hyun; Lee, Jae Eun; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Hypox Dis Inst, Canc Res Inst & Ischem, 103 Daehak Ro, Seoul, South Korea; [Shin, Seung-Hyun; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Dept Pharmacol, 103 Daehak Ro, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, 103 Daehak Ro, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Hypox Dis Inst, Canc Res Inst & Ischem, 103 Daehak Ro, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 103 Daehak Ro, Seoul, South Korea.	parkjw@snu.ac.kr		Park, Jong-Wan/0000-0003-4676-5191; Lee, Judy/0000-0001-9862-3502	National Research Foundation of Korea [2017R1A4A1015015]	National Research Foundation of Korea(National Research Foundation of Korea)	This study was supported by a grant from the National Research Foundation of Korea (2017R1A4A1015015; to J.W.P).	Andrio E, 2017, SCI REP-UK, V7, DOI 10.1038/srep44779; Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Berndsen CE, 2014, NAT STRUCT MOL BIOL, V21, P301, DOI 10.1038/nsmb.2780; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brunner AL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-5-r71; Castillo-Lluva S, 2013, ONCOGENE, V32, P1735, DOI 10.1038/onc.2012.189; Chun YS, 2000, BIOCHEM BIOPH RES CO, V268, P652, DOI 10.1006/bbrc.2000.2180; Cockman ME, 2006, P NATL ACAD SCI USA, V103, P14767, DOI 10.1073/pnas.0606877103; Cockman ME, 2009, ANN NY ACAD SCI, V1177, P9, DOI 10.1111/j.1749-6632.2009.05042.x; Cockman ME, 2009, MOL CELL PROTEOMICS, V8, P535, DOI 10.1074/mcp.M800340-MCP200; Coleman ML, 2007, J BIOL CHEM, V282, P24027, DOI 10.1074/jbc.M704102200; Daugaard M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3180; Ferguson JE, 2007, MOL CELL BIOL, V27, P6407, DOI 10.1128/MCB.00511-07; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Goka ET, 2015, ONCOGENE, V34, P5395, DOI 10.1038/onc.2014.468; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hewitson KS, 2008, J BIOL CHEM, V283, P25971, DOI 10.1074/jbc.M804999200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hordijk PL, 2006, CIRC RES, V98, P453, DOI 10.1161/01.RES.0000204727.46710.5e; Hyseni A, 2011, CELL ONCOL, V34, P565, DOI 10.1007/s13402-011-0053-5; Janke K, 2013, J CELL SCI, V126, P2629, DOI 10.1242/jcs.117564; Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085; Karttunen S, 2015, J CELL SCI, V128, P225, DOI 10.1242/jcs.158451; Kretschmer C, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-15; Lachance V, 2014, J CELL SCI, V127, P111, DOI 10.1242/jcs.132944; Lancaster DE, 2004, BIOCHEM SOC T, V32, P943, DOI 10.1042/BST0320943; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lee GY, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0089-y; Lee SD, 2016, CANCER LETT, V373, P138, DOI 10.1016/j.canlet.2016.01.031; Lesurf R, 2016, CELL REP, V16, P1166, DOI 10.1016/j.celrep.2016.06.051; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Liu ZZ, 2014, CANCER CELL, V26, P106, DOI 10.1016/j.ccr.2014.05.015; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Masson N, 2012, EMBO REP, V13, P251, DOI 10.1038/embor.2012.9; Palicharla VR, 2015, CELL SIGNAL, V27, P2355, DOI 10.1016/j.cellsig.2015.09.001; PETTERSEN EO, 1986, CANCER RES, V46, P4346; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rodriguez J, 2016, CELL REP, V14, P2745, DOI 10.1016/j.celrep.2016.02.043; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scholz CC, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002347; Semenza GL, 2007, J MOL MED-JMM, V85, P1293, DOI 10.1007/s00109-007-0285-z; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036; So JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109517; Tan EY, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1838; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Tortola L, 2016, CELL REP, V16, P3414, DOI 10.1016/j.celrep.2016.08.072; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wilkins SE, 2016, CHEMMEDCHEM, V11, P773, DOI 10.1002/cmdc.201600012; Yan M, 2009, BRIT J CANCER, V101, P1168, DOI 10.1038/sj.bjc.6605287; Yang M, 2011, FEBS J, V278, P1086, DOI 10.1111/j.1742-4658.2011.08022.x; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621; Zhang LY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4430; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P18147, DOI 10.1073/pnas.0408260101; 2003, J BIOL CHEM, V278, P1802, DOI DOI 10.1074/JBC.C200644200; 2001, GENE DEV, V15, P2675	57	13	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3651	3666		10.1038/s41388-019-0676-y	http://dx.doi.org/10.1038/s41388-019-0676-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30659265				2022-12-17	WOS:000467379600007
J	Mann, J; Githaka, JM; Buckland, TW; Yang, N; Montpetit, R; Patel, N; Li, L; Baksh, S; Godbout, R; Lemieux, H; Goping, IS				Mann, Jasdeep; Githaka, John Maringa; Buckland, Timothy W.; Yang, Ning; Montpetit, Rachel; Patel, Namrata; Li, Lei; Baksh, Shairaz; Godbout, Roseline; Lemieux, Helene; Goping, Ing Swie			Non-canonical BAD activity regulates breast cancer cell and tumor growth via 14-3-3 binding and mitochondrial metabolism	ONCOGENE			English	Article							DEATH AGONIST BAD; PROAPOPTOTIC BAD; BH3 DOMAIN; PHOSPHORYLATION; SURVIVAL; PROTEIN; EXPRESSION; RESPIRATION; INACTIVATE; GLYCOLYSIS	The Bcl-2-associated death promoter BAD is a prognostic indicator for good clinical outcome of breast cancer patients; however, whether BAD affects breast cancer biology is unknown. Here we showed that BAD increased cell growth in breast cancer cells through two distinct mechanisms. Phosphorylation of BAD at S118 increased S99 phosphorylation, 14-3-3 binding and AKT activation to promote growth and survival. Through a second, more prominent pathway, BAD stimulated mitochondrial oxygen consumption in a novel manner that was downstream of substrate entry into the mitochondria. BAD stimulated complex I activity that facilitated enhanced cell growth and sensitized cells to apoptosis in response to complex I blockade. We propose that this dependence on oxidative metabolism generated large but nonaggressive cancers. This model identifies a non-canonical role for BAD and reconciles BAD-mediated tumor growth with favorable outcomes in BAD-high breast cancer patients.	[Mann, Jasdeep; Githaka, John Maringa; Buckland, Timothy W.; Yang, Ning; Montpetit, Rachel; Patel, Namrata; Baksh, Shairaz; Goping, Ing Swie] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; [Li, Lei; Baksh, Shairaz; Godbout, Roseline; Goping, Ing Swie] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada; [Baksh, Shairaz] Univ Alberta, Dept Pediat, Edmonton, AB T6G 2H7, Canada; [Lemieux, Helene] Univ Alberta, Dept Med, Edmonton, AB T6G 2H7, Canada; [Lemieux, Helene] Univ Alberta, Fac St Jean, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta	Goping, IS (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.; Goping, IS (corresponding author), Univ Alberta, Dept Oncol, Edmonton, AB T6G 2H7, Canada.	igoping@ualberta.ca	Baksh, Shairaz/GRX-2106-2022; Buckland, Timothy/AAV-9022-2021; Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265; lemieux, Helene/0000-0002-8864-6062	Women and Children's Health Research Institute; Canadian Breast Cancer Foundation; Alberta Cancer Foundation	Women and Children's Health Research Institute; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Alberta Cancer Foundation	We thank Dr. Bernard Lemire (University of Alberta), Dr. Thomas Simmen (University of Alberta), and Dr. Manijeh Pasdar (University of Alberta) for their generous gift of reagents. Additionally, we acknowledge all Goping lab members for the meaningful discussions and contributions to this work. This work was supported by operating grants from the Women and Children's Health Research Institute, Canadian Breast Cancer Foundation and Alberta Cancer Foundation to ISG.	Adachi M, 2002, CELL DEATH DIFFER, V9, P1240, DOI 10.1038/sj.cdd.4401097; Adams LD, 2004, CURR PROTOC MOL BIOL; Al-Bazz YO, 2009, EUR J CANCER, V45, P694, DOI 10.1016/j.ejca.2008.11.044; Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856; Cannings E, 2007, BREAST CANCER RES TR, V102, P173, DOI 10.1007/s10549-006-9323-8; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Craik AC, 2010, ONCOGENE, V29, P5381, DOI 10.1038/onc.2010.272; Czernick M, 2009, BIOCHEM BIOPH RES CO, V379, P145, DOI 10.1016/j.bbrc.2008.12.025; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; FALOONA GR, 1969, BIOCHEMISTRY-US, V8, P4497, DOI 10.1021/bi00839a041; Fouque A, 2016, CELL DEATH DIFFER, V23, P1702, DOI 10.1038/cdd.2016.61; Gimenez-Cassina A, 2014, CELL METAB, V19, P272, DOI 10.1016/j.cmet.2013.12.001; Gimenez-Cassina A, 2012, NEURON, V74, P719, DOI 10.1016/j.neuron.2012.03.032; Gnaiger E, 2000, P NATL ACAD SCI USA, V97, P11080, DOI 10.1073/pnas.97.20.11080; Gnaiger E, 1995, J BIOENERG BIOMEMBR, V27, P583, DOI 10.1007/BF02111656; GOPING IS, 1995, FEBS LETT, V373, P45; Grun D, 2016, ONCOGENE, V35, P4379, DOI 10.1038/onc.2015.507; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; John S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017674; Joshi S, 2015, CELL REP, V13, P1895, DOI 10.1016/j.celrep.2015.10.059; Lee KH, 2008, ONCOL RES, V17, P23, DOI 10.3727/096504008784046072; Lee KH, 2010, ONCOL RES, V19, P67, DOI 10.3727/096504010X12864748215043; Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001; Marchion DC, 2011, CLIN CANCER RES, V17, P6356, DOI 10.1158/1078-0432.CCR-11-0735; Martinez-Reyes I, 2016, MOL CELL, V61, P199, DOI 10.1016/j.molcel.2015.12.002; Maslyar DJ, 2001, ONCOGENE, V20, P5087, DOI 10.1038/sj.onc.1204662; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Osundiji MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028016; Pandya V, 2016, ONCOTARGET, V7, P33272, DOI 10.18632/oncotarget.8924; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sinicrope FA, 2008, CLIN CANCER RES, V14, P4128, DOI 10.1158/1078-0432.CCR-07-5160; Smith AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006224; Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170; Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yang J, 2010, J THEOR BIOL, V266, P231, DOI 10.1016/j.jtbi.2010.06.009; YANG N, 2017, CELL DEATH DIS, V8; Yu YY, 2015, INT J CLIN EXP PATHO, V8, P13075; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; 1999, J BIOL CHEM, V274, P3485; 2001, MOL PHARM, V60, P1325	56	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3325	3339		10.1038/s41388-018-0673-6	http://dx.doi.org/10.1038/s41388-018-0673-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30635657	Green Published, hybrid			2022-12-17	WOS:000466610000001
J	Zhu, JR; Wu, GY; Ke, ZF; Cao, LX; Tang, ML; Li, ZW; Li, QJ; Zhou, JH; Tan, ZY; Song, LB; Li, J				Zhu, Jinrong; Wu, Geyan; Ke, Zunfu; Cao, Lixue; Tang, Miaoling; Li, Ziwen; Li, Qiaojia; Zhou, Junhao; Tan, Zhanyao; Song, Libing; Li, Jun			Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma	ONCOGENE			English	Article							NF-KAPPA-B; ACTININ 4 ACTN4; CANCER PROGRESSION; PROGNOSTIC MARKER; C PROMOTES; ALPHA; GROWTH; ENHANCER; SUBUNIT	Tumor-associated lymphangiogenesis has attracted increasing attention because of its potential contribution to lymph node metastasis. However, the molecular mechanisms underlying lymphangiogenesis in cancer remains elusive. In the current study, we demonstrate that tripartite motif-containing 3 (TRIM3) directly interacts with and induces E3 ligase-dependent proteasomal turnover of importin alpha 3 and alpha-Actinin-4 (ACTN4), which controls nuclear factor kappa B (NF-kappa B) activity at a well-ordered level. Heterozygous deletion-mediated TRIM3 downregulation led to NF-kappa B constitutive activation through disruption of the NF-kappa B-I kappa B-alpha negative feedback loop and enhancement of the p65 DNA-binding affinity and transcriptional activity via promoting symmetrical dimethylarginine modification of NF-kappa B/p65 at Arg30 and Arg35, which consequently promoted lymphatic metastasis of esophageal squamous cell carcinoma (ESCC) cells. Treatment with Tecfidera, a medication used to treat multiple sclerosis, restored the negative feedback inhibition of NF-kappa B by reducing the NF-kappa B/ACTN4 interaction and decreasing symmetrically dimethylated NF-kappa B levels, resulting in inhibition of ESCC lymphatic metastasis both in vitro and in vivo. Taken together, our results uncover a novel mechanism for constitutive NF-kappa B activation in cancer and may represent an attractive strategy to treat ESCC lymphatic metastasis.	[Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Li, Ziwen; Li, Qiaojia; Zhou, Junhao; Tan, Zhanyao; Li, Jun] Sun Yat Sen Univ, Key Lab Liver Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China; [Zhu, Jinrong; Tang, Miaoling; Li, Jun] Sun Yat Sen Univ, Dept Biochem, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China; [Wu, Geyan; Song, Libing] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Ke, Zunfu] Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 1, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Li, J (corresponding author), Sun Yat Sen Univ, Key Lab Liver Dis Guangdong Prov, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.; Li, J (corresponding author), Sun Yat Sen Univ, Dept Biochem, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn	wu, ge/ABE-3285-2020; Cao, Lixue/AAM-9316-2020; Song, LB/AAL-1968-2020	Cao, Lixue/0000-0002-0486-6587; 	Natural Science Foundation of China [81830082, 91740119, 91529301, 81621004, 91740118, 81773106, 81530082]; Guangzhou Science and Technology Plan Projects [201803010098]; Natural Science Foundation of Guangdong Province [2018B030311009, 2016A030308002]; Fundamental Research Funds for the Central Universities [17ykjc02]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Science and Technology Plan Projects; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by Natural Science Foundation of China (No. 81830082, 91740119, 91529301, 81621004, 91740118, 81773106 and 81530082); Guangzhou Science and Technology Plan Projects (201803010098); Natural Science Foundation of Guangdong Province (2018B030311009 and 2016A030308002); The Fundamental Research Funds for the Central Universities [No. 17ykjc02].	Agarwal N, 2013, ONCOGENE, V32, P462, DOI 10.1038/onc.2012.69; Aksenova V, 2013, ONCOTARGET, V4, P362, DOI 10.18632/oncotarget.901; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; An HT, 2014, J BIOL CHEM, V289, P4969, DOI 10.1074/jbc.M113.515395; [Anonymous], 2011, Nat Rev Drug Discov, V10, P404, DOI 10.1038/nrd3465; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Boulay JL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-71; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Chakraborty S, 2006, J BIOL CHEM, V281, P35070, DOI 10.1074/jbc.M602474200; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; Diaz GM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26519-w; Dieterich LC, 2016, ADV DRUG DELIVER REV, V99, P148, DOI 10.1016/j.addr.2015.12.011; El-Husseini AE, 2001, GENOMICS, V71, P363, DOI 10.1006/geno.2000.6452; Feng YK, 2011, EUR J CANCER, V47, P2353, DOI 10.1016/j.ejca.2011.05.006; Girard C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1998; He W, 2018, J CLIN INVEST, V128, P861, DOI 10.1172/JCI96218; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hirakawa S, 2011, J DERMATOL SCI, V61, P85, DOI 10.1016/j.jdermsci.2010.11.020; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Karpanen T, 2001, CANCER RES, V61, P1786; Kastrati I, 2016, J BIOL CHEM, V291, P3639, DOI 10.1074/jbc.M115.679704; Khurana S, 2012, J BIOL CHEM, V287, P35418, DOI 10.1074/jbc.M112.401364; Khurana S, 2011, J BIOL CHEM, V286, P1850, DOI 10.1074/jbc.M110.162107; Kumagai Y, 2018, DIS ESOPHAGUS, V31, P1, DOI DOI 10.1093/DOTE/DOY052/5036207; Lam CT, 2002, CANCER LETT, V178, P75, DOI 10.1016/S0304-3835(01)00814-X; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Lin C, 2015, ONCOGENE, V34, P332, DOI 10.1038/onc.2013.559; Liu PF, 2011, CYTOKINE, V55, P8, DOI 10.1016/j.cyto.2011.03.008; Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008-5472.CAN-15-1022; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Moskaluk CA, 1998, CANCER, V83, P232, DOI 10.1002/(SICI)1097-0142(19980715)83:2<232::AID-CNCR5>3.3.CO;2-G; Mukherjee S, 2016, CANCER RES, V76, P2443, DOI 10.1158/0008-5472.CAN-15-2299; Nicolay JP, 2016, BLOOD, V128, P805, DOI 10.1182/blood-2016-01-694117; Peng HY, 2012, J BIOL CHEM, V287, P28017, DOI 10.1074/jbc.M112.383380; Ribatti D, 2018, CURR OPIN IMMUNOL, V53, P161, DOI 10.1016/j.coi.2018.04.027; Saad RS, 2009, AM J CLIN PATHOL, V131, P92, DOI 10.1309/AJCPKWUQSIPVG90H; Schoppmann SF, 2013, SURGERY, V153, P526, DOI 10.1016/j.surg.2012.10.007; Schreiber J, 2015, J CELL BIOL, V211, P569, DOI 10.1083/jcb.201506048; Smith MD, 2018, EUR J IMMUNOL, V48, P380, DOI 10.1002/eji.201747277; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Su CH, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-85; Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110; Yan Q, 2005, MOL BIOL CELL, V16, P2470, DOI 10.1091/mbc.E04-11-1014; Zhao X, 2017, J BIOL CHEM, V292, P1637, DOI 10.1074/jbc.M116.755546; Zhao X, 2015, J BIOL CHEM, V290, P338, DOI 10.1074/jbc.M114.597260	48	13	13	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2736	2749		10.1038/s41388-018-0621-5	http://dx.doi.org/10.1038/s41388-018-0621-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542119				2022-12-17	WOS:000464121600005
J	Liu, BY; Yi, JJ; Yan, X; Liu, L; Lou, XL; Zhang, ZY; Qi, H; Wang, Z; Zou, JH; Zhu, WG; Gu, W; Luo, JY				Liu, Boya; Yi, Jingjie; Yan, Xin; Liu, Lu; Lou, Xinlin; Zhang, Zeyuan; Qi, Hao; Wang, Zhe; Zou, Junhua; Zhu, Wei-Guo; Gu, Wei; Luo, Jianyuan			MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner	ONCOGENE			English	Article							WERNER-SYNDROME PROTEIN; DNA-DAMAGE; TARGETS WRN; P53 PATHWAY; S-PHASE; MDM2; HELICASE; PHOSPHORYLATION; E3; PRODUCT	MDM2 (Murine double minute 2) acts as a key repressor for p53-mediated tumor-suppressor functions, which includes cellular senescence. We found that MDM2 can promote cellular senescence by modulating WRN stability. Werner syndrome (WS), caused by mutations of the WRN gene, is an autosomal recessive disease, which is characterized by premature aging. Loss of WRN function induces cellular senescence in human cancer cells. Here, we found that MDM2 acts as an E3 ligase for WRN protein. MDM2 interacts with WRN both in vivo and in vitro. MDM2 induces ubiquitination of WRN and dramatically downregulates the levels of WRN protein in human cells. During DNA damage response, WRN is translocated to the nucleoplasm to facilitate its DNA repair functions; however, it is degraded by the MDM2-mediated ubiquitination pathway. Moreover, the senescent phenotype induced by DNA damage reagents, such as Etoposide, is at least in part mediated by MDM2-dependent WRN degradation as it can be significantly attenuated by ectopic expression of WRN. These results show that MDM2 is critically involved in regulating WRN function via ubiquitin-dependent degradation and reveal an unexpected role of MDM2 in promoting cellular senescence through a p53-independent manner.	[Liu, Boya; Yan, Xin; Liu, Lu; Lou, Xinlin; Zhang, Zeyuan; Qi, Hao; Wang, Zhe; Zou, Junhua; Luo, Jianyuan] Peking Univ, Hlth Sci Ctr, Dept Med Genet, 38 Xueyuan Rd, Beijing 100191, Peoples R China; [Yi, Jingjie; Gu, Wei] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Zhu, Wei-Guo] Shenzhen Univ, Sch Med, Dept Biochem & Mol Biol, Shenzhen, Peoples R China	Peking University; Columbia University; Shenzhen University	Luo, JY (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Med Genet, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	luojianyuan@bjmu.edu.cn	Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914; Yang, Xin/0000-0003-0222-5839; Zhu, Wei-Guo/0000-0001-8385-6581	National Natural Science Foundation of China [81270427, 81471405, 81671389, 81720108027, 81321003]; National Research Program of National Natural Science Foundation of China China [2013CB530801]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Research Program of National Natural Science Foundation of China China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (81270427, 81471405, 81671389, 81720108027 and 81321003) and from National Research Program of National Natural Science Foundation of China China (973 Program, 2013CB530801).	Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Bernstein KA, 2010, ANNU REV GENET, V44, P393, DOI 10.1146/annurev-genet-102209-163602; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; Croteau DL, 2014, ANNU REV BIOCHEM, V83, P519, DOI 10.1146/annurev-biochem-060713-035428; Ghosh A, 2009, J BIOL CHEM, V284, P31074, DOI 10.1074/jbc.M109.027532; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kusumoto R, 2007, MECH AGEING DEV, V128, P50, DOI 10.1016/j.mad.2006.11.010; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Li K, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0012286, 10.1371/journal.pone.0010341]; Mikawa T, 2014, J CELL BIOL, V204, P729, DOI 10.1083/jcb.201306149; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muftuoglu M, 2008, HUM GENET, V124, P369, DOI 10.1007/s00439-008-0562-0; Muftuoglu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001918; Palermo V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12880; Pichierri P, 2003, ONCOGENE, V22, P1491, DOI 10.1038/sj.onc.1206169; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Shamanna RA, 2016, ONCOTARGET, V7, P13269, DOI 10.18632/oncotarget.7906; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sidorova JM, 2008, CELL CYCLE, V7, P796, DOI 10.4161/cc.7.6.5566; Su FT, 2016, ONCOTARGET, V7, P46, DOI 10.18632/oncotarget.6659; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tollini LA, 2014, CANCER CELL, V26, P235, DOI 10.1016/j.ccr.2014.06.006; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	41	13	13	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2501	2515		10.1038/s41388-018-0605-5	http://dx.doi.org/10.1038/s41388-018-0605-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532073				2022-12-17	WOS:000463335200005
J	Zhang, JX; Tan, P; Guo, L; Gong, J; Ma, JJ; Li, J; Lee, M; Fang, SH; Jing, J; Johnson, G; Sun, DQ; Cao, WM; Dashwood, R; Han, L; Zhou, YB; Dong, WG; Huang, Y				Zhang, Jixiang; Tan, Peng; Guo, Lei; Gong, Jing; Ma, Jingjing; Li, Jia; Lee, Minjung; Fang, Shaohai; Jing, Ji; Johnson, Gavin; Sun, Deqiang; Cao, Wen-ming; Dashwood, Roderick; Han, Leng; Zhou, Yubin; Dong, Wei-Guo; Huang, Yun			p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance	ONCOGENE			English	Article							DNA-DAMAGE; STEM-CELLS; P53; 5-HYDROXYMETHYLCYTOSINE; 5-METHYLCYTOSINE; ANTICANCER; MUTATIONS; MOUSE; REPLICATION; METHYLATION	Tumor cells with p53 inactivation frequently exhibit chemotherapy resistance, which poses a long-standing challenge to cancer treatment. Here we unveiled a previously unrecognized role of TET2 in mediating p53-loss induced chemotherapy resistance in colon cancer. Deletion of TET2 in p53-null colon cancer cells enhanced DNA damage and restored chemotherapy sensitivity. By taking a two-pronged approach that combined pharmacological inhibition with genetic depletion, we discovered that p53 destabilized TET2 at the protein level by promoting its autophagic degradation. At the molecular level, we further revealed a physical association between TET2 and p53 that facilitated the nucleoplasmic shuttling of TET2, as well as its recruitment to the autophagosome for degradation. Our study has unveiled a functional interplay between TET2 and p53 during anti-cancer therapy. Our findings establish the rationale for targeting TET2 to overcome chemotherapy resistance associated with mutant p53 tumors.	[Zhang, Jixiang; Guo, Lei; Li, Jia; Lee, Minjung; Fang, Shaohai; Johnson, Gavin; Sun, Deqiang; Dashwood, Roderick; Huang, Yun] Texas A&M Univ, Ctr Epigenet & Dis Prevent, Inst Biosci & Technol, Houston, TX 77030 USA; [Zhang, Jixiang; Ma, Jingjing; Dong, Wei-Guo] Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China; [Tan, Peng; Guo, Lei; Jing, Ji; Zhou, Yubin] Texas A&M Univ, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA; [Gong, Jing; Han, Leng] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Cao, Wen-ming] Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou 310022, Zhejiang, Peoples R China; [Dashwood, Roderick; Huang, Yun] Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA; [Zhou, Yubin] Texas A&M Univ, Coll Med, Dept Med Physiol, Temple, TX 76504 USA	Texas A&M University System; Wuhan University; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston; Zhejiang Cancer Hospital; Texas A&M University System; Texas A&M University College Station; Texas A&M University System	Huang, Y (corresponding author), Texas A&M Univ, Ctr Epigenet & Dis Prevent, Inst Biosci & Technol, Houston, TX 77030 USA.; Dong, WG (corresponding author), Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.; Zhou, YB (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA.; Huang, Y (corresponding author), Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA.; Zhou, YB (corresponding author), Texas A&M Univ, Coll Med, Dept Med Physiol, Temple, TX 76504 USA.	yzhou@ibt.tamhsc.edu; dwg@whu.edu.cn; yun.huang@ibt.tamhsc.edu	Tan, Peng/HGD-6812-2022; Dashwood, Roderick/AAF-2025-2020; Han, Leng/HCH-3491-2022; Zhou, Yubin/D-4748-2011; Tan, Peng/ABD-8190-2020	Han, Leng/0000-0002-7380-2640; Zhou, Yubin/0000-0001-7962-0517; sun, deqiang/0000-0002-5806-7289; Fang, Shaohai/0000-0003-3940-9586; Tan, Peng/0000-0001-6992-9000; Cao, Wen-Ming/0000-0002-5644-3156	Cancer Prevention and Research Institute of Texas [RR140053, RP170660, RR150085]; American Heart Association [16IRG27250155]; John S. Dunn Foundation; Center for Translational Environmental Health Research (CTEHR); National Institute of Health [R01HL134780, R01GM112003]; Welch Foundation [BE-1913]; American Cancer Society [RSG-18-043-01-LIB, RSG-16-215-01-TBE]; Texas AM University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL134780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM112003] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas; American Heart Association(American Heart Association); John S. Dunn Foundation; Center for Translational Environmental Health Research (CTEHR); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); American Cancer Society(American Cancer Society); Texas AM University; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from Cancer Prevention and Research Institute of Texas (RR140053 to YH, to RP170660 to YZ, RR150085 to LH), the Innovation Award from American Heart Association (16IRG27250155 to YH), the John S. Dunn Foundation Collaborative Research Award (to YH), the Center for Translational Environmental Health Research (CTEHR) Seed Grant to YH, the National Institute of Health grants (R01HL134780 to YH, R01GM112003 to YZ), the Welch Foundation (BE-1913 to YZ), the American Cancer Society (RSG-18-043-01-LIB to YH, RSG-16-215-01-TBE to YZ), and by an allocation from the Texas A&M University start-up funds (YH).	Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; An J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10071; Bejar R, 2012, J CLIN ONCOL, V30, P3376, DOI 10.1200/JCO.2011.40.7379; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Dou ZX, 2015, NATURE, V527, P105, DOI 10.1038/nature15548; Dunkern TR, 2003, DNA REPAIR, V2, P49, DOI 10.1016/S1568-7864(02)00185-4; Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019; Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P4841, DOI 10.1093/nar/gks155; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hientz K, 2017, ONCOTARGET, V8, P8921, DOI 10.18632/oncotarget.13475; Huang Y, 2014, TRENDS GENET, V30, P464, DOI 10.1016/j.tig.2014.07.005; Inoue A, 2011, SCIENCE, V334, P194, DOI 10.1126/science.1212483; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jiang DW, 2017, EMBO REP, V18, P781, DOI 10.15252/embr.201643179; Kafer GR, 2016, CELL REP, V14, P1283, DOI 10.1016/j.celrep.2016.01.035; Ko M, 2013, NATURE, V497, P122, DOI 10.1038/nature12052; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lemonnier F, 2012, BLOOD, V120, P1466, DOI 10.1182/blood-2012-02-408542; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nakagawa T, 2015, MOL CELL, V57, P247, DOI 10.1016/j.molcel.2014.12.002; Papaemmanuil E, 2011, NEW ENGL J MED, V365, P1384, DOI 10.1056/NEJMoa1103283; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Shetzer Y, 2014, CARCINOGENESIS, V35, P1196, DOI 10.1093/carcin/bgu073; Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tefferi A, 2009, LEUKEMIA, V23, P1343, DOI 10.1038/leu.2009.59; Thienpont B, 2016, NATURE, V537, P63, DOI 10.1038/nature19081; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wang Y, 2014, CELL REP, V6, P278, DOI 10.1016/j.celrep.2013.12.031; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Zhang YW, 2017, MOL CELL, V65, P323, DOI 10.1016/j.molcel.2016.12.013	44	13	14	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1905	1919		10.1038/s41388-018-0524-5	http://dx.doi.org/10.1038/s41388-018-0524-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390073	Green Accepted			2022-12-17	WOS:000461164400009
J	Kheimar, A; Trimpert, J; Groenke, N; Kaufer, BB				Kheimar, Ahmed; Trimpert, Jakob; Groenke, Nicole; Kaufer, Benedikt B.			Overexpression of cellular telomerase RNA enhances virus-induced cancer formation	ONCOGENE			English	Article							MAREKS-DISEASE VIRUS; CELLS; MYC; IDENTIFICATION; RECOMBINATION; EXPRESSION; PROTEINS; SUBUNIT; GENES	The telomerase RNA subunit (TR) is overexpressed in many tumors; however, the contribution of TR in cancer formation remains elusive. The most frequent clinically diagnosed cancer in the animal kingdom is caused by the highly oncogenic herpesvirus Marek's disease virus (MDV). MDV encodes a TR (vTR) that plays an important role in virus-induced tumorigenesis and shares 88% sequence identity with its cellular homologue. To determine if the cellular TR possesses pro-oncogenic activity, we replaced vTR with the cellular homologue in the virus genome. Insertion of cellular TR resulted in a strong overexpression in virus infected cells, while virus replication was not affected. Strikingly, cellular TR promoted tumor formation as efficient as vTR, while tumorigenesis was severely impaired in the absence of vTR. Our data provide the first evidence that overexpression of cellular TR can contribute to tumor formation in vivo using this natural virus-host model for herpesvirus-induced oncogenesis.	[Kheimar, Ahmed; Trimpert, Jakob; Groenke, Nicole; Kaufer, Benedikt B.] Free Univ Berlin, Inst Virol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany; [Kheimar, Ahmed] Sohag Univ, Fac Vet Med, Dept Poultry Dis, Sohag 82424, Egypt	Free University of Berlin; Egyptian Knowledge Bank (EKB); Sohag University	Kaufer, BB (corresponding author), Free Univ Berlin, Inst Virol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany.	b.kaufer@fu-berlin.de	Kheimar, Ahmed M./AAB-4022-2021; Kaufer, Benedikt B./AAZ-8216-2020; Kheimar, Ahmed/AAM-7694-2021	Kaufer, Benedikt B./0000-0003-1328-2695; Kheimar, Ahmed/0000-0001-8121-8981; Trimpert, Jakob/0000-0003-1616-0810; Groenke, Nicole/0000-0002-6927-3774	DFG [KA 3492/3-1]; Ministry of High Education Egypt (MOHE); Studienstiftung des deutschen Volkes	DFG(German Research Foundation (DFG)); Ministry of High Education Egypt (MOHE); Studienstiftung des deutschen Volkes	DFG grant (KA 3492/3-1), Ministry of High Education Egypt (MOHE), and Studienstiftung des deutschen Volkes.	Akincilar SC, 2015, FEBS LETT, V589, P974, DOI 10.1016/j.febslet.2015.02.035; Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Autexier C, 2006, ANNU REV BIOCHEM, V75, P493, DOI 10.1146/annurev.biochem.75.103004.142412; Baena-Del Valle JA, 2018, J PATHOL, V244, P11, DOI 10.1002/path.4980; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Chbab N, 2010, VET RES, V41, DOI 10.1051/vetres/2010026; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Collins K, 2008, MECH AGEING DEV, V129, P91, DOI 10.1016/j.mad.2007.10.008; Engel AT, 2012, J VIROL, V86, P8536, DOI 10.1128/JVI.00556-12; Fragnet L, 2005, J BIOL CHEM, V280, P23502, DOI 10.1074/jbc.M501163200; Fragnet L, 2003, J VIROL, V77, P5985, DOI 10.1128/JVI.77.10.5985-5996.2003; Gazzaniga FS, 2014, BLOOD, V124, P3675, DOI 10.1182/blood-2014-06-582254; Ghosh A, 2012, NAT CELL BIOL, V14, P1270, DOI 10.1038/ncb2621; Jarosinski K, 2007, P NATL ACAD SCI USA, V104, P20025, DOI 10.1073/pnas.0706295104; Jarosinski KW, 2007, J VIROL, V81, P10575, DOI 10.1128/JVI.01065-07; Jarosinski KW, 2005, J VIROL, V79, P11647, DOI 10.1128/JVI.79.18.11647-11659.2005; Kaufer BB, 2011, J EXP MED, V208, P605, DOI 10.1084/jem.20101402; Kaufer BB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001073; Khattar E, 2016, J CLIN INVEST, V126, P4045, DOI 10.1172/JCI86042; Kheimar A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18638-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Le SY, 2000, MOL BIOL CELL, V11, P999, DOI 10.1091/mbc.11.3.999; Li L, 2014, EUR J GYNAECOL ONCOL, V35, P289; Martin-Rivera L, 2001, J BIOL CHEM, V276, P5856, DOI 10.1074/jbc.M008419200; Mason M, 2011, CURR OPIN STRUC BIOL, V21, P92, DOI 10.1016/j.sbi.2010.11.005; Murre C, 2007, IMMUNITY, V26, P751, DOI 10.1016/j.immuni.2007.06.001; Nowak T, 2006, ONCOL REP, V16, P301; Osterrieder N, 2006, NAT REV MICROBIOL, V4, P283, DOI 10.1038/nrmicro1382; Penzo M, 2015, ONCOTARGET, V6, P21755, DOI 10.18632/oncotarget.4580; Rao SY, 2016, CANCER RES, V76, P3387, DOI 10.1158/0008-5472.CAN-15-2698; Rao SY, 2012, BLOOD, V120, P3764, DOI 10.1182/blood-2012-03-415349; Rumin Wen JL, 2006, CHINESE J CLIN ONCOL, V3, P326; Schumacher D, 2005, J VIROL, V79, P3987, DOI 10.1128/JVI.79.7.3987-3997.2005; Shkreli M, 2007, J VIROL, V81, P4848, DOI 10.1128/JVI.02530-06; Tischer BK, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/472537; Tischer BK, 2010, METHODS MOL BIOL, V634, P421, DOI 10.1007/978-1-60761-652-8_30; Tischer BK, 2006, BIOTECHNIQUES, V40, P191, DOI 10.2144/000112096; Trapp S, 2006, J EXP MED, V203, P1307, DOI 10.1084/jem.20052240; Wyatt HDM, 2010, NUCLEIC ACIDS RES, V38, P5609, DOI 10.1093/nar/gkq370	41	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1778	1786		10.1038/s41388-018-0544-1	http://dx.doi.org/10.1038/s41388-018-0544-1			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30846849				2022-12-17	WOS:000460423800015
J	Lee, SY; Park, JH; Jeong, S; Kim, BY; Kang, YK; Xu, Y; Chung, SK				Lee, Seo-Young; Park, Jung-Hyun; Jeong, Sangkyun; Kim, Bu-Yeo; Kang, Yong-Kook; Xu, Yang; Chung, Sun-Ku			K120R mutation inactivates p53 by creating an aberrant splice site leading to nonsense-mediated mRNA decay	ONCOGENE			English	Article							CELL-CYCLE ARREST; ACETYLATION; APOPTOSIS; ACTIVATION; SURVIVAL; CANCERS; PREDICT; TP53; GENE	The point mutation that substitutes lysine with arginine at position 120 of human p53 has been characterized as a missense mutation. The K120R mutation renders the p53 protein disabled for acetylation and, as a result, defective for apoptotic function, which provides a mechanistic link between the missense mutation and tumorigenesis. However, we noticed the failures of tumorigenesis in mice with the mutation, and of the related studies to notice that it has arbitrarily reflected in amino acid change through a sequence modification (AGA) of the original tumor mutation (AGG) by codon degeneracy. Unlike this modified version, we also discovered a novel splicing site the original mutation, TP53 c.359A>G, may induce. Using a human induced pluripotent stem cell line that was engineered to be homozygous for the original mutation, we here identified that the accidental splicing site generates a defective transcript variant with a frame-shifted premature termination codon which is subjected to nonsense-mediated mRNA decay. The authentic splicing still occurs but in extremely low amounts. Taken together, this mutation causes depletion of cellular p53 via defective mRNA, suggesting a new link to tumorigenesis.	[Lee, Seo-Young; Park, Jung-Hyun; Jeong, Sangkyun; Kim, Bu-Yeo; Chung, Sun-Ku] Korea Inst Oriental Med, Div Clin Med, 1672 Yuseong Daero, Daejeon 34054, South Korea; [Kang, Yong-Kook] Korea Res Inst Biosci & Biotechnol, Dev & Differentiat Res Ctr, 125 Gwahak Ro, Daejeon 34141, South Korea; [Kang, Yong-Kook] Korea Univ Sci & Technol, Dept Funct Genom, Daejeon, South Korea; [Xu, Yang] Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA	Korea Institute of Oriental Medicine (KIOM); Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Science & Technology (UST); University of California System; University of California San Diego	Chung, SK (corresponding author), Korea Inst Oriental Med, Div Clin Med, 1672 Yuseong Daero, Daejeon 34054, South Korea.	skchung@kiom.re.kr		Xu, Yang/0000-0001-5574-921X	National Research Foundation of Korea [NRF-2013M3A9B4076487]; Korea Institute of Oriental Medicine Grants [K18131]	National Research Foundation of Korea(National Research Foundation of Korea); Korea Institute of Oriental Medicine Grants	We thank B-J. Park, K-S. Chae, and I. Horikawa for comments on the manuscript and Y-D. Kim for technical assistance. This research was supported in part by the National Research Foundation of Korea Grants (NRF-2013M3A9B4076487) and Korea Institute of Oriental Medicine Grants (K18131).	Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Chung SK, 2007, GASTROENTEROLOGY, V132, P2459, DOI 10.1053/j.gastro.2007.04.024; Deissler H, 2004, ONCOL REP, V11, P1281; Franks TM, 2010, CELL, V143, P938, DOI 10.1016/j.cell.2010.11.043; Gong L, 2018, ONCOGENE, V37, P2150, DOI 10.1038/s41388-017-0117-8; Hashimoto T, 1999, CANCER RES, V59, P5572; Hayes VM, 1999, BRAIN PATHOL, V9, P463, DOI 10.1111/j.1750-3639.1999.tb00535.x; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim BY, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.43; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lee SY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2725670; Leitao MM, 2004, GYNECOL ONCOL, V93, P301, DOI 10.1016/j.ygyno.2004.01.043; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liebermann DA, 2007, CELL CYCLE, V6, P166, DOI 10.4161/cc.6.2.3789; Liu NS, 2013, CANCER RES, V73, P3749, DOI 10.1158/0008-5472.CAN-12-3684; Liu XF, 2016, EMBO REP, V17, P349, DOI 10.15252/embr.201540505; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; MEYERS FJ, 1993, J NATL CANCER I, V85, P1856, DOI 10.1093/jnci/85.22.1856; Monteith JA, 2016, MOL ONCOL, V10, P1207, DOI 10.1016/j.molonc.2016.05.007; Shinmen N, 2009, FEBS LETT, V583, P1916, DOI 10.1016/j.febslet.2009.04.041; Song H, 2010, CELL STEM CELL, V6, P80, DOI 10.1016/j.stem.2009.11.016; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang J, 2000, J MICROBIOL METH, V39, P121, DOI 10.1016/S0167-7012(99)00107-4; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Yu H, 2009, GENOMICS, V94, P355, DOI 10.1016/j.ygeno.2009.08.004; Yun T, 2016, J BIOL CHEM, V291, P7386, DOI 10.1074/jbc.M115.706341	28	13	14	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1597	1610		10.1038/s41388-018-0542-3	http://dx.doi.org/10.1038/s41388-018-0542-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348990				2022-12-17	WOS:000460423800002
J	Leong, TL; Gayevskiy, V; Steinfort, DP; De Massy, MR; Gonzalez-Rajal, A; Marini, KD; Stone, E; Chin, V; Havryk, A; Plit, M; Irving, LB; Jennings, BR; McCloy, RA; Jayasekara, WSN; Alamgeer, M; Boolell, V; Field, A; Russell, PA; Kumar, B; Gough, DJ; Szczepny, A; Ganju, V; Rossello, FJ; Cain, JE; Papenfuss, AT; Asselin-Labat, ML; Cowley, MJ; Watkins, DN				Leong, Tracy L.; Gayevskiy, Velimir; Steinfort, Daniel P.; De Massy, Marc R.; Gonzalez-Rajal, Alvaro; Marini, Kieren D.; Stone, Emily; Chin, Venessa; Havryk, Adrian; Plit, Marshall; Irving, Louis B.; Jennings, Barton R.; McCloy, Rachael A.; Jayasekara, W. Samantha N.; Alamgeer, Muhammad; Boolell, Vishal; Field, Andrew; Russell, Prudence A.; Kumar, Beena; Gough, Daniel J.; Szczepny, Anette; Ganju, Vinod; Rossello, Fernando J.; Cain, Jason E.; Papenfuss, Anthony T.; Asselin-Labat, Marie-Liesse; Cowley, Mark J.; Watkins, D. Neil			Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer	ONCOGENE			English	Article							INTRATUMOR HETEROGENEITY; MUTATIONAL SIGNATURES; FRAMEWORK; CANCERIZATION; HYPERMUTATION; EPIDEMIOLOGY; EVOLUTIONARY; LANDSCAPE; PROFILES; SMOKING	Our understanding of genomic heterogeneity in lung cancer is largely based on the analysis of early-stage surgical specimens. Here we used endoscopic sampling of paired primary and intrathoracic metastatic tumors from 11 lung cancer patients to map genomic heterogeneity inoperable lung cancer with deep whole-genome sequencing. Intra-patient heterogeneity in driver or targetable mutations was predominantly in the form of copy number gain. Private mutation signatures, including patterns consistent with defects in homologous recombination, were highly variable both within and between patients. Irrespective of histotype, we observed a smaller than expected number of private mutations, suggesting that ancestral clones accumulated large mutation burdens immediately prior to metastasis. Single-region whole-genome sequencing of from 20 patients showed that tumors in ever-smokers with the strongest tobacco signatures were associated with germline variants in genes implicated in the repair of cigarette-induced DNA damage. Our results suggest that lung cancer precursors in ever-smokers accumulate large numbers of mutations prior to the formation of frank malignancy followed by rapid metastatic spread. In advanced lung cancer, germline variants in DNA repair genes may interact with the airway environment to influence the pattern of founder mutations, whereas similar interactions with the tumor microenvironment may play a role in the acquisition of mutations following metastasis.	[Leong, Tracy L.; Asselin-Labat, Marie-Liesse] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3050, Australia; [Leong, Tracy L.; Steinfort, Daniel P.; Irving, Louis B.; Asselin-Labat, Marie-Liesse] Univ Melbourne, Dept Med Biol, Parkville, Vic 3050, Australia; [Gayevskiy, Velimir; De Massy, Marc R.; Cowley, Mark J.] Garvan Inst Med Res, Kinghorn Ctr Clin Genom, Darlinghurst, NSW 2010, Australia; [Steinfort, Daniel P.; Irving, Louis B.] Royal Melbourne Hosp, Dept Resp Med, Parkville, Vic 3050, Australia; [Gonzalez-Rajal, Alvaro; Chin, Venessa; McCloy, Rachael A.; Watkins, D. Neil] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia; [Marini, Kieren D.; Stone, Emily; Jayasekara, W. Samantha N.; Alamgeer, Muhammad; Boolell, Vishal; Gough, Daniel J.; Szczepny, Anette; Ganju, Vinod; Cain, Jason E.] Hudson Inst Med Res, Clayton, Vic 3168, Australia; [Stone, Emily; Havryk, Adrian; Plit, Marshall; Watkins, D. Neil] St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW 2010, Australia; [Chin, Venessa; Havryk, Adrian; Plit, Marshall; Field, Andrew; Cowley, Mark J.; Watkins, D. Neil] UNSW Sydney, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia; [Chin, Venessa; Watkins, D. Neil] St Vincents Hosp, Dept Med Oncol, Darlinghurst, NSW 2010, Australia; [Jennings, Barton R.] Monash Hlth, Dept Resp & Sleep Med, Clayton, Vic 3168, Australia; [Field, Andrew] St Vincents Hosp, Dept Pathol, Sydney, NSW 2010, Australia; [Russell, Prudence A.] St Vincents Hosp Melbourne, Dept Pathol, Fitzroy, Vic 3000, Australia; [Kumar, Beena] Monash Hlth, Dept Pathol, Clayton, Vic 3168, Australia; [Gough, Daniel J.; Ganju, Vinod; Cain, Jason E.] Monash Univ, Dept Mol & Translat Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Rossello, Fernando J.] Monash Univ, Dept Anat & Dev Biol, Fac Med Nursing & Hlth Sci, Clayton, Vic 3168, Australia; [Rossello, Fernando J.] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic 3168, Australia; [Papenfuss, Anthony T.] Peter MacCallum Canc Ctr, Computat Canc Biol Program, Melbourne, Vic 3000, Australia; [Papenfuss, Anthony T.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia; [Papenfuss, Anthony T.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia; [Cowley, Mark J.] Childrens Canc Inst, Kensington, NSW 2750, Australia	Walter & Eliza Hall Institute; University of Melbourne; Garvan Institute of Medical Research; Royal Melbourne Hospital; Garvan Institute of Medical Research; Hudson Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; St Vincent's Hospital Melbourne; Monash University; Monash University; Australian Regenerative Medicine Institute; Monash University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Walter & Eliza Hall Institute; Children's Cancer Institute	Asselin-Labat, ML (corresponding author), Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3050, Australia.; Asselin-Labat, ML (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic 3050, Australia.; Cowley, MJ (corresponding author), Garvan Inst Med Res, Kinghorn Ctr Clin Genom, Darlinghurst, NSW 2010, Australia.; Watkins, DN (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW 2010, Australia.; Watkins, DN (corresponding author), St Vincents Hosp, Dept Thorac Med, Darlinghurst, NSW 2010, Australia.; Cowley, MJ; Watkins, DN (corresponding author), UNSW Sydney, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia.; Watkins, DN (corresponding author), St Vincents Hosp, Dept Med Oncol, Darlinghurst, NSW 2010, Australia.; Cowley, MJ (corresponding author), Childrens Canc Inst, Kensington, NSW 2750, Australia.	labat@wehi.edu.au; m.cowley@garvan.org.au; dr.neil.watkins@gmail.com	Rossello, Fernando/B-1208-2015; Steinfort, Daniel/AAO-6898-2020; Gonzalez-Rajal, Alvaro/ABA-6874-2020; Stone, Emily/GZL-2451-2022; Stone, Emily/AAP-1249-2021; Papenfuss, Anthony T/C-6297-2008; Alamgeer, Muhammad/AAM-4784-2021	Rossello, Fernando/0000-0003-3885-8777; Steinfort, Daniel/0000-0002-8998-2949; Gonzalez-Rajal, Alvaro/0000-0002-9230-0339; Stone, Emily/0000-0001-9021-8449; Papenfuss, Anthony T/0000-0002-1102-8506; Watkins, Neil/0000-0001-8218-4920; Cowley, Mark/0000-0002-9519-5714; Chin, Venessa/0000-0002-4630-4451; Gough, Daniel/0000-0001-5725-8668; McCloy, Rachael/0000-0001-7791-4044; Gough, Daniel/0000-0001-6479-1735; Robert de Massy, Marc/0000-0002-3048-1680	Victorian Cancer Agency [TS10-01]; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; Baxter Charitable Foundation; St Vincent's Clinic Foundation; Tour de Cure; Australian Government NHMRC IRIISS; Victorian State Government Operational Infrastructure Support; Australian Cancer Therapeutics CRC; Australian Cancer Research Foundation; NHMRC Career Development Fellowship [GNT1063914]; Victoria Cancer Agency Mid-Career Fellowship [MCRF17014]; Viertel Foundation Senior Medical Researcher Fellowship; Cancer Institute NSW Early Career Fellowship [13ECF/1-46]; NSW Health Early-Mid-Career Fellowship; Kinghorn Foundation; NHMRC Senior Research Fellowship [GNT546107]	Victorian Cancer Agency; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; Baxter Charitable Foundation; St Vincent's Clinic Foundation; Tour de Cure; Australian Government NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government Operational Infrastructure Support; Australian Cancer Therapeutics CRC; Australian Cancer Research Foundation; NHMRC Career Development Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Victoria Cancer Agency Mid-Career Fellowship; Viertel Foundation Senior Medical Researcher Fellowship; Cancer Institute NSW Early Career Fellowship; NSW Health Early-Mid-Career Fellowship; Kinghorn Foundation; NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the Victorian Cancer Agency, (TS10-01), the Petre Foundation, the Victorian Government's Operational Infrastructure Support Program, the Baxter Charitable Foundation, the St Vincent's Clinic Foundation, Tour de Cure, the Australian Government NHMRC IRIISS, the Victorian State Government Operational Infrastructure Support, the Australian Cancer Therapeutics CRC (TLL), the Australian Cancer Research Foundation, an NHMRC Career Development Fellowship (GNT1063914, DJG), a Victoria Cancer Agency Mid-Career Fellowship (MCRF17014, JEC), a Viertel Foundation Senior Medical Researcher Fellowship (M-LA-L), a Cancer Institute NSW Early Career Fellowship (13ECF/1-46) and NSW Health Early-Mid-Career Fellowship (MJC), the Kinghorn Foundation (MJC, VG), and an NHMRC Senior Research Fellowship (GNT546107, DNW). We thank the Victorian Cancer Biobank for technical support.	Adamo P, 2016, ONCOGENE, V35, P403, DOI 10.1038/onc.2015.109; Alexandrov LB, 2016, SCIENCE, V354, P618, DOI 10.1126/science.aag0299; Alioto TS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10001; Amirouchene-Angelozzi N, 2017, CANCER DISCOV, V7, P805, DOI 10.1158/2159-8290.CD-17-0343; Bakhoum SF, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a029611; Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Cardarella S, 2013, AM J RESP CRIT CARE, V188, P770, DOI 10.1164/rccm.201305-0843PP; Chansky K, 2017, J THORAC ONCOL, V12, P1109, DOI 10.1016/j.jtho.2017.04.011; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710; Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gayevskiy V, 2019, BIOINFORMATICS, V35, P122, DOI 10.1093/bioinformatics/bty540; Gehring JS, 2015, BIOINFORMATICS, V31, P3673, DOI 10.1093/bioinformatics/btv408; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Gonzalez-Perez A, 2013, NAT METHODS, V10, P1081, DOI [10.1038/NMETH.2642, 10.1038/nmeth.2642]; Grainge CL, 2013, CHEST, V144, P1906, DOI 10.1378/chest.12-1944; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Houghton AM, 2013, NAT REV CANCER, V13, P233, DOI 10.1038/nrc3477; Jakubek Y, 2016, CANCER RES, V76, P3676, DOI 10.1158/0008-5472.CAN-15-3064; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jin XR, 2017, ONCOTARGET, V8, P23130, DOI 10.18632/oncotarget.15506; Kadara H, 2016, CANCER PREV RES, V9, P518, DOI 10.1158/1940-6207.CAPR-15-0400; Kadara Humam, 2012, Proc Am Thorac Soc, V9, P38, DOI 10.1513/pats.201201-004MS; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Leong TL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106862; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Maley CC, 2017, NAT REV CANCER, V17, P605, DOI 10.1038/nrc.2017.69; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Meienberg J, 2016, HUM GENET, V135, P359, DOI 10.1007/s00439-015-1631-9; Nahar R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02584-z; Reiter JG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14114; Samet JM, 2009, CLIN CANCER RES, V15, P5626, DOI 10.1158/1078-0432.CCR-09-0376; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Shields PG, 2002, ONCOGENE, V21, P6870, DOI 10.1038/sj.onc.1205832; Shugay M, 2013, BIOINFORMATICS, V29, P2539, DOI 10.1093/bioinformatics/btt445; TheGeneOntologyConsortium, 2017, Nucleic Acids Res, V45, pD331, DOI 10.1093/nar/gkw1108; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Um SW, 2016, CANCER RES, V76, P6568, DOI 10.1158/0008-5472.CAN-16-0873; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wiencke JK, 2002, ONCOGENE, V21, P7376, DOI 10.1038/sj.onc.1205799; Wu XF, 2004, ONCOGENE, V23, P6500, DOI 10.1038/sj.onc.1207811; Yu AM, 2016, ONCOTARGET, V7, P28624, DOI 10.18632/oncotarget.8721; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930	52	13	13	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1661	1675		10.1038/s41388-018-0536-1	http://dx.doi.org/10.1038/s41388-018-0536-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30348992	Green Published, hybrid			2022-12-17	WOS:000460423800007
J	Lin, YP; Wu, JI; Tseng, CW; Chen, HJ; Wang, LH				Lin, Yi-Pei; Wu, Jun-I; Tseng, Chien-Wei; Chen, Huei-Jane; Wang, Lu-Hai			Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation	ONCOGENE			English	Article							PROTEIN-KINASE-C; SIGNALING PATHWAYS; CELL-MIGRATION; ANGIOTENSIN-II; GAP-JUNCTIONS; EXPRESSION; INVASION; CONNEXIN-43; GROWTH; RECEPTOR	Most lung cancer patients are diagnosed late with metastasis, which is the major cause of cancer-related death and recurrent tumors that often exhibit chemoresistance. In the present study, we initially identified gap junction beta-4 protein (Gjb4) to be overexpressed in highly metastatic cancer cells selected by their enhanced binding to serum components. Overexpression or knockdown of Gjb4 increased or decreased lung metastasis of syngeneic mice, respectively. We found that Gjb4 expression was higher in lung tumors than normal tissues (p = 0.0026), and Gjb4 levels in blood buffy coat samples showed significant performance in diagnosing stage I-III (p = 0.002814) and stage IV (p < 0.0001) lung cancer. Moreover, high Gjb4 expression levels were correlated with poor prognosis (p = 1.4e-4) and recurrence (p = 1.9e-12). Using syngeneic mouse model, we observed that Gjb4 was able to promote tumor growth. High molecular weight serum fraction containing the major growth factor component IGF1 was able to induce Gjb4 via PKC pathway. Gjb4 activated Src signaling via MET, and overexpression of Gjb4 enhanced sphere-forming ability and anchorage-independent growth, which were reversed by inhibition of Src. In addition, we demonstrated that Gjb4-mediated Src activation enhanced chemoresistance of cancer cells toward gemcitabine and etoposide. The combination of Gjb4 knockdown, gemcitabine, and dasatinib further enhanced the inhibition of cancer cell viability. Together, our study has identified Gjb4 as a potential novel diagnostic and prognostic biomarker for lung cancer. Targeting Gjb4 may be exploited as a modality for improving lung cancer therapy.	[Lin, Yi-Pei; Wu, Jun-I; Tseng, Chien-Wei; Chen, Huei-Jane; Wang, Lu-Hai] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Lin, Yi-Pei; Wang, Lu-Hai] Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei, Taiwan; [Wu, Jun-I; Wang, Lu-Hai] Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan; [Tseng, Chien-Wei] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University; National Central University; China Medical University Taiwan	Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan.; Wang, LH (corresponding author), Natl Taiwan Univ, Inst Mol & Cellular Biol, Taipei, Taiwan.; Wang, LH (corresponding author), Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan.; Wang, LH (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.	lu-hai.wang@nhri.org.tw			National Health Research Institutes, Taiwan [06A1-MGPP09-014]; Ministry of Education, Taiwan [CMRC-CHM-7]; Ministry of Science and Technology, Taiwan [MOST 104-2320-B-039-055-MY3, MOST 104-2320-B-039-054-MY3, MOST 106-2320-B-039-059-]	National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); Ministry of Education, Taiwan(Ministry of Education, Taiwan); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the National Health Research Institutes, Taiwan (06A1-MGPP09-014), the Ministry of Education, Taiwan (CMRC-CHM-7), and the Ministry of Science and Technology, Taiwan (MOST 104-2320-B-039-055-MY3, MOST 104-2320-B-039-054-MY3 and MOST 106-2320-B-039-059-). We thank Core Laboratory of Microarray, Cell Sorting, Pathology, Confocal Microscopy as well as Proteomics and chemistry of National Health Research Institutes (NHRI) for experiments involving exon array analysis, cell sorting, H&E staining, Immunohistochemistry, confocal microscopy and mass spectrometry, respectively. We thank Dr. Yi Rong Chen of IMGM, NHRI, Taiwan for the gift of H1650 human lung cancer cell line. We also thank Dr. Chin Fu Hsiao of Division of Biostatistics and Bioinformatics of NHRI, Taiwan for the clinical samples from lung cancer tissue bank. We thank Dr. Sheng-Chieh Lin for the assistance of manuscript preparation.	Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Banerjee Debarshi, 2016, Int J Cell Biol, V2016, P9025905, DOI 10.1155/2016/9025905; Bausch-Fluck D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121314; Beattie J, 2006, BIOCHEM J, V395, P1, DOI 10.1042/BJ20060086; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Chu CH, 2008, J ENDOCRINOL, V197, P381, DOI 10.1677/JOE-07-0619; Common JEA, 2005, J INVEST DERMATOL, V125, P920, DOI 10.1111/j.0022-202X.2005.23919.x; Dorey K, 2010, DEVELOPMENT, V137, P3731, DOI 10.1242/dev.037689; Duggan MA, 2016, AM J SURG PATHOL, V40, pE94, DOI 10.1097/PAS.0000000000000749; Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20; Ezumi K, 2008, CLIN CANCER RES, V14, P677, DOI 10.1158/1078-0432.CCR-07-1184; Feliciano P., 2012, NAT GENET, V44, P840; Ganapathy V, 2015, J CONTROL RELEASE, V219, P215, DOI 10.1016/j.jconrel.2015.09.042; Gavalas NG, 2013, INT J MOL SCI, V14, P15885, DOI 10.3390/ijms140815885; Geimonen E, 1996, J BIOL CHEM, V271, P23667, DOI 10.1074/jbc.271.39.23667; George TJ, 2014, ONCOLOGIST, V19, P211, DOI 10.1634/theoncologist.2013-0410; Gielen PR, 2013, NEUROPHARMACOLOGY, V75, P539, DOI 10.1016/j.neuropharm.2013.05.002; Giuffrida ML, 2010, REV NEUROSCIENCE, V21, P83; Gonzalez-Sanchez A, 2016, ONCOTARGET, V7, P49819, DOI 10.18632/oncotarget.10454; Guan PP, 2015, ONCOTARGET, V6, P9140, DOI 10.18632/oncotarget.3274; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Han YH, 2009, ONCOL REP, V22, P215, DOI 10.3892/or_00000427; Hedberg KK, 2000, EXP CELL RES, V257, P67, DOI 10.1006/excr.2000.4873; Huang GY, 2015, CELL MOL LIFE SCI, V72, P1741, DOI 10.1007/s00018-015-1833-2; Huang LM, 2014, ONCOTARGETS THER, V7, DOI 10.2147/OTT.S67251; Jaraiz-Rodriguez M, 2017, STEM CELL REP, V9, P451, DOI 10.1016/j.stemcr.2017.06.007; Jia GH, 2007, J SURG RES, V142, P137, DOI 10.1016/j.jss.2006.11.007; Kalemkerian GP, 2016, LANCET ONCOL, V17, P1033, DOI 10.1016/S1470-2045(16)30160-7; Kloverpris S, 2013, BIOCHEM J, V449, P209, DOI 10.1042/BJ20120801; Kotini M, 2015, DEV BIOL, V401, P143, DOI 10.1016/j.ydbio.2014.12.023; Kyo N, 2008, ONCOL REP, V19, P627; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Leto SM, 2014, J MOL MED, V92, P709, DOI 10.1007/s00109-014-1161-2; Li X, 2012, NEOPLASMA, V59, P500, DOI 10.4149/neo_2012_064; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Lin KT, 2012, CANCER RES, V72, P3000, DOI 10.1158/0008-5472.CAN-11-2502; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LONGATI P, 1994, ONCOGENE, V9, P49; Lopez-Bigas N, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9023; Losa D, 2011, EXPERT OPIN THER TAR, V15, P989, DOI 10.1517/14728222.2011.584875; Manegold Christian, 2004, Expert Rev Anticancer Ther, V4, P345, DOI 10.1586/14737140.4.3.345; Matta C, 2014, CELL SIGNAL, V26, P979, DOI 10.1016/j.cellsig.2014.01.011; Mese G, 2007, J INVEST DERMATOL, V127, P2516, DOI 10.1038/sj.jid.5700770; Miyata T, 2015, PERS MED U, V4, P40, DOI [10.1016/j.pmu.2015.03.007, DOI 10.1016/J.PMU.2015.03.007]; Montuenga Luis M, 2009, Eur J Cancer, V45 Suppl 1, P377, DOI 10.1016/S0959-8049(09)70055-3; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Munoz JL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.111; Murphy SF, 2016, CANCER RES, V76, P139, DOI 10.1158/0008-5472.CAN-15-1286; Naoi Y, 2007, BREAST CANCER RES TR, V106, P11, DOI 10.1007/s10549-006-9465-8; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Popper HH, 2016, CANCER METAST REV, V35, P75, DOI 10.1007/s10555-016-9618-0; Reck M, 2005, LUNG CANCER-J IASLC, V48, P409, DOI 10.1016/j.lungcan.2004.11.013; Roskoski R, 2015, PHARMACOL RES, V94, P9, DOI 10.1016/j.phrs.2015.01.003; Shigyo M, 2015, SCI REP-UK, V5, DOI 10.1038/srep12055; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Spray DC, 1998, CIRC RES, V83, P679, DOI 10.1161/01.RES.83.6.679; Steinberg M, 2007, CLIN THER, V29, P2289, DOI 10.1016/j.clinthera.2007.11.005; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; TAPPER H, 1995, J CELL PHYSIOL, V163, P137, DOI 10.1002/jcp.1041630116; Teleki I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112541; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Touyz RM, 2000, PHARMACOL REV, V52, P639; Tung SL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.25; Uramoto H, 2014, TRANSL LUNG CANCER R, V3, P242, DOI 10.3978/j.issn.2218-6751.2013.12.05; van Oosterwijk JG, 2013, BRIT J CANCER, V109, P1214, DOI 10.1038/bjc.2013.451; Wan YT, 2017, EXP THER MED, V13, P3067, DOI 10.3892/etm.2017.4356; Wang SY, 2009, METHODS MOL BIOL, V568, P151, DOI 10.1007/978-1-59745-280-9_9; Yeh YM, 2013, INT J CANCER, V133, P867, DOI 10.1002/ijc.28086; Zaghloul M., 2015, TROP MED SURG, V3, pe122, DOI [10.4172/2329-9088.1000 e122, DOI 10.4172/2329-9088.1000E122]; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhang W, 2003, J NEUROSURG, V99, P1039, DOI 10.3171/jns.2003.99.6.1039; Zhao JH, 2016, PHARMACOL THERAPEUT, V160, P145, DOI 10.1016/j.pharmthera.2016.02.008	74	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					822	837		10.1038/s41388-018-0471-1	http://dx.doi.org/10.1038/s41388-018-0471-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177841				2022-12-17	WOS:000458006300005
J	Lau, BW; Huh, K; Madero-Marroquin, R; De Marchi, F; Lim, Y; Wang, QJ; Lobo, F; Marchionni, L; Smith, DB; DeZern, A; Levis, MJ; Aplan, PD; Matsui, W; Gondek, LP				Lau, Bonnie W.; Huh, Kyounghee; Madero-Marroquin, Rafael; De Marchi, Federico; Lim, Yiting; Wang, Qiuju; Lobo, Francisco; Marchionni, Luigi; Smith, Douglas B.; DeZern, Amy; Levis, Mark J.; Aplan, Peter D.; Matsui, William; Gondek, Lukasz P.			Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; STEM-CELLS; TRANSCRIPTION FACTOR; PATHWAY ACTIVATION; SIGNALING PATHWAYS; SCORING SYSTEM; HUMAN HOMOLOG; EARLY DEATH; PREDICTION; EVOLUTION	Myelodysplastic syndromes (MDSs) are stem cell disorders with risk of transformation to acute myeloid leukemia (AML). Gene expression profiling reveals transcriptional expression of GLI1, of Hedgehog (Hh) signaling, in poor-risk MDS/AML. Using a murine model of MDS we demonstrated that constitutive Hh/Gli1 activation accelerated leukemic transformation and decreased overall survival. Hh/Gli1 activation resulted in clonal expansion of phenotypically defined granulocyte macrophage progenitors (GMPs) and acquisition of self-renewal potential in a non-self-renewing progenitor compartment. Transcriptome analysis of GMPs revealed enrichment in gene signatures of self-renewal pathways, operating via direct Gli1 activation. Using human cell lines we demonstrated that in addition to canonical Hh signaling, GLI1 is activated in a Smoothened-independent manner. GLI1 knockdown or inhibition with GANT61 resulted in decreased proliferation and clonogenic potential. Our data suggest that GLI1 activation is frequent in MDS during disease progression and inhibition of GLI1 is an attractive therapeutic target for a subset of patients.	[Lau, Bonnie W.; Huh, Kyounghee; Madero-Marroquin, Rafael; De Marchi, Federico; Lim, Yiting; Wang, Qiuju; Lobo, Francisco; Marchionni, Luigi; Smith, Douglas B.; DeZern, Amy; Levis, Mark J.; Gondek, Lukasz P.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; [Lim, Yiting] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Lobo, Francisco] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Biol Geral, Belo Horizonte, MG, Brazil; [Aplan, Peter D.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Matsui, William] Univ Texas Austin, Dell Med Sch, LIVESTRONG Canc Inst, Austin, TX 78712 USA	Johns Hopkins University; Johns Hopkins Medicine; Fred Hutchinson Cancer Center; Universidade Federal de Minas Gerais; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Austin	Gondek, LP (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.; Matsui, W (corresponding author), Univ Texas Austin, Dell Med Sch, LIVESTRONG Canc Inst, Austin, TX 78712 USA.	matsuwi@jhmi.edu; lgondek1@jhmi.edu	Marchionni, Luigi/S-6774-2017; Lobo, Francisco Pereira/AAG-3118-2021	Marchionni, Luigi/0000-0002-7336-8071; Lobo, Francisco Pereira/0000-0002-9671-9313	National Institute of Health [K08 HL136894]; Edward P. Evans Foundation; Sidney Kimmel Comprehensive Cancer Center Core Facilities [P30 CA006973]; NATIONAL CANCER INSTITUTE [P30CA006973, K24CA198315, ZIABC010983] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL136894] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Edward P. Evans Foundation; Sidney Kimmel Comprehensive Cancer Center Core Facilities; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We would like to acknowledge Dr. David Huso, previously an Associate Professor in the Department of Molecular and Comparative Pathobiology at Johns Hopkins, for preparing the histology slides; and Dr. Hao Zhang, Research Associate in the Department of Molecular Microbiology and Immunology at Johns Hopkins, for helping to sort the murine bone marrow for cell subpopulations. This work was supported by grants from the National Institute of Health (K08 HL136894) (LPG) and Edward P. Evans Foundation (LPG). Flow cytometry and microarray analysis was performed with the support of the Sidney Kimmel Comprehensive Cancer Center Core Facilities (P30 CA006973).	Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Brechbiel J, 2014, CANCER TREAT REV, V40, P750, DOI 10.1016/j.ctrv.2014.02.003; Chaudhry P, 2017, BLOOD, V129, P3465, DOI 10.1182/blood-2016-05-718585; CORTES JE, 2016, BLOOD, V128; Dagklis A, 2016, BLOOD, V128, P2642, DOI 10.1182/blood-2016-03-703454; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Fenaux P, 2011, BLOOD, V118, P3765, DOI 10.1182/blood-2011-01-330126; Gao J, 2009, CELL STEM CELL, V4, P548, DOI 10.1016/j.stem.2009.03.015; Gerstung M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6901; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jiang Y, 2009, BLOOD, V113, P1315, DOI 10.1182/blood-2008-06-163246; Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008-5472.CAN-10-2993; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Joo J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007608; Kang HJ, 2015, KOREAN J RADIOL, V16, P1068, DOI 10.3348/kjr.2015.16.5.1068; Kobune M, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.36; Krug U, 2010, LANCET, V376, P2000, DOI 10.1016/S0140-6736(10)62105-8; LANCET JE, 2016, BLOOD, V128; Lim Y, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac9303; Lin YW, 2005, BLOOD, V106, P287, DOI 10.1182/blood-2004-12-4794; Liu Z, 2014, ONCOGENE, V33, P65, DOI 10.1038/onc.2012.544; Long B, 2016, CELL PHYSIOL BIOCHEM, V38, P1288, DOI 10.1159/000443075; Makishima H, 2017, NAT GENET, V49, P204, DOI 10.1038/ng.3742; Malcovati L, 2007, J CLIN ONCOL, V25, P3503, DOI 10.1200/JCO.2006.08.5696; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Martinelli G, 2015, LANCET HAEMATOL, V2, pE339, DOI 10.1016/S2352-3026(15)00096-4; McMillan R, 2012, CLIN CANCER RES, V18, P4883, DOI 10.1158/1078-0432.CCR-11-2509; Meggendorfer M, 2015, HAEMATOLOGICA, V100, pE487, DOI 10.3324/haematol.2015.127985; Merchant A, 2010, BLOOD, V115, P2391, DOI 10.1182/blood-2009-09-241703; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Ringuette R, 2016, DEV BIOL, V411, P85, DOI 10.1016/j.ydbio.2016.01.006; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Seto M, 2009, MOL CARCINOGEN, V48, P703, DOI 10.1002/mc.20516; Tefferi A, 2015, AM J HEMATOL, V90, P831, DOI 10.1002/ajh.24102; Tefferi A, 2009, NEW ENGL J MED, V361, P1872, DOI 10.1056/NEJMra0902908; Torchia EC, 2007, MOL CELL BIOL, V27, P7918, DOI 10.1128/MCB.00099-07; Walter RB, 2011, J CLIN ONCOL, V29, P4417, DOI 10.1200/JCO.2011.35.7525; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wellbrock J, 2015, CLIN CANCER RES, V21, P2388, DOI 10.1158/1078-0432.CCR-14-1059; Xavier-Ferrucio JM, 2015, HAEMATOLOGICA, V100, pE491, DOI 10.3324/haematol.2015.124040; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zou JX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136843; Zou JX, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/957502; Zwerner JP, 2008, ONCOGENE, V27, P3282, DOI 10.1038/sj.onc.1210991	51	13	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					687	698		10.1038/s41388-018-0431-9	http://dx.doi.org/10.1038/s41388-018-0431-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171262	Green Accepted			2022-12-17	WOS:000457300300006
J	Patel, Y; Soni, M; Awgulewitsch, A; Kern, MJ; Liu, S; Shah, N; Singh, UP; Chen, H				Patel, Y.; Soni, M.; Awgulewitsch, A.; Kern, M. J.; Liu, S.; Shah, N.; Singh, U. P.; Chen, H.			Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis	ONCOGENE			English	Article							STEM-CELLS; BREAST-CANCER; GLAND; MAINTENANCE; QUIESCENT	Although it has been demonstrated that transformed progenitor cell population can contribute to tumor initiation, factors contributing to this malignant transformation are poorly known. Using in vitro and xenograft-based models, previous studies demonstrated that miR-489 acts as a tumor suppressor miRNA by targeting various oncogenic pathways. It has been demonstrated that miR-489 directly targets HER2 and inhibits the HER2 signaling pathway; however, its role in mammary gland development and HER2-induced tumor initiation hasn't been studied. To dissect the role of miR-489, we sorted different populations of mammary epithelial cells and determined that miR-489 was highly expressed in mammary stem cells. MMTV-miR-489 mice that overexpressed miR-489 in mammary epithelial cells were developed and these mice exhibited an inhibition of mammary gland development in early ages with a specific impact on highly proliferative cells. Double transgenic MMTV-Her2-miR489 mice were then generated to observe how miR-489 overexpression affects HER2-induced tumorigenesis. miR-489 overexpression delayed HER2-induced tumor initiation significantly. Moreover, miR-489 overexpression inhibited tumor growth and lung metastasis. miR-489 overexpression reduced mammary progenitor cell population significantly in preneoplastic mammary glands of MMTV-Her2 mice which showed a putative transformed population in HER2-induced tumorigenesis. The miR-489 overexpression reduced CD49f(hi)CD61(hi) populations in tumors that have stem-like properties, and miR-489 overexpression altered the HER2 signaling pathway in mammary tumors. Altogether, these data indicate that the inhibition of HER2-induced tumorigenesis by miR-489 overexpression was due to altering progenitor cell populations while decreasing tumor growth and metastasis via influencing tumor promoting genes DEK and SHP2.	[Patel, Y.; Soni, M.; Liu, S.; Shah, N.; Chen, H.] Univ South Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Patel, Y.; Soni, M.; Liu, S.; Shah, N.; Chen, H.] Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA; [Awgulewitsch, A.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Awgulewitsch, A.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Transgen & Genome Editing Core, Charleston, SC 29425 USA; [Kern, M. J.] Med Univ South Carolina, Gene Funct Core, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA; [Singh, U. P.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Chen, H (corresponding author), Univ South Carolina, Dept Biol Sci, Columbia, SC 29208 USA.; Chen, H (corresponding author), Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA.	hchen@biol.sc.edu	chen, hexin/F-1714-2011	Chen, Hexin/0000-0001-9300-0859; Singh, Udai/0000-0002-7048-4325	NIH [4R01 CA178386-04, 4P30 GM103342-05]; USC ASPIRE-1 grant; USC SPARC graduate research grant; NATIONAL CANCER INSTITUTE [R01CA178386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103342] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USC ASPIRE-1 grant; USC SPARC graduate research grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank the Gene Function and Transgenic and Genome Editing (TGE) Cores of the Medical University of South Carolina (MUSC) for their assistance with the generation of transgenic MMTV-miR-489 mice. This work was supported by the NIH grants (4R01 CA178386-04 and 4P30 GM103342-05) and the USC ASPIRE-1 grant to H.C., and the USC SPARC graduate research grant to M.S.	Boras-Granic K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0487-6; Cai S, 2017, CELL STEM CELL, V20, P247, DOI 10.1016/j.stem.2016.11.007; Celia-Terrassa T, 2017, NAT CELL BIOL, V19, P711, DOI 10.1038/ncb3533; Chang THT, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3593; Chen H, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0754-0; Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743; Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834; Cho Andrew, 2009, Curr Protoc Cell Biol, VChapter 19, DOI 10.1002/0471143030.cb1911s42; Elsarraj HS, 2013, J CELL SCI, V126, P2446, DOI 10.1242/jcs.119214; Fu NY, 2017, NAT CELL BIOL, V19, P164, DOI 10.1038/ncb3471; Greene SB, 2010, J CELL SCI, V123, P606, DOI 10.1242/jcs.056812; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Jiang L, 2014, FEBS LETT, V588, P2009, DOI 10.1016/j.febslet.2014.04.024; Ke J, 2015, ONCOTARGET, V6, P3709, DOI 10.18632/oncotarget.2888; Kikkawa N, 2010, BRIT J CANCER, V103, P877, DOI 10.1038/sj.bjc.6605811; Kim JC, 2016, CANCER RES, V76, P6424, DOI 10.1158/0008-5472.CAN-16-1571; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Martinez-Ruiz H, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf5402; Patel Y, 2016, ONCOTARGET, V7, P18295, DOI 10.18632/oncotarget.7577; Phua YW, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0593-0; Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017; Rodriguez-Barrueco R, 2017, GENE DEV, V31, P553, DOI 10.1101/gad.292318.116; Soady KJ, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0539-6; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2009, J PATHOL, V217, P229, DOI 10.1002/path.2457; Tiede BJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008035; Vaillant F, 2007, STEM CELL REV, V3, P114, DOI 10.1007/s12015-007-0018-2; Vinnedge LMP, 2015, ONCOGENE, V34, P2325, DOI 10.1038/onc.2014.173; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Yallowitz AR, 2014, CELL DEATH DIFFER, V21, P645, DOI 10.1038/cdd.2013.199; Yoo KH, 2014, DEV BIOL, V395, P245, DOI 10.1016/j.ydbio.2014.09.012; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	34	13	13	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					445	453		10.1038/s41388-018-0439-1	http://dx.doi.org/10.1038/s41388-018-0439-1			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30104710	Green Accepted			2022-12-17	WOS:000455851200010
J	Willems, E; Dedobbeleer, M; Digregorio, M; Lombard, A; Goffart, N; Lumapat, PN; Lambert, J; Van den Ackerveken, P; Szpakowska, M; Chevigne, A; Scholtes, F; Rogister, B				Willems, Estelle; Dedobbeleer, Matthias; Digregorio, Marina; Lombard, Arnaud; Goffart, Nicolas; Lumapat, Paul Noel; Lambert, Jeremy; Van den Ackerveken, Priscilla; Szpakowska, Martyna; Chevigne, Andy; Scholtes, Felix; Rogister, Bernard			Aurora A plays a dual role in migration and survival of human glioblastoma cells according to the CXCL12 concentration	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; STEM-LIKE CELLS; SUBVENTRICULAR ZONES; INITIATING CELLS; A KINASE; RADIOTHERAPY; INHIBITION; PROLIFERATION; TEMOZOLOMIDE; ACTIVATION	Primary glioblastoma is the most frequent human brain tumor in adults and is generally fatal due to tumor recurrence. We previously demonstrated that glioblastoma-initiating cells invade the subventricular zones and promote their radio-resistance in response to the local release of the CXCL12 chemokine. In this work, we show that the mitotic Aurora A kinase (AurA) is activated through the CXCL12-CXCR4 pathway in an ERK1/2-dependent manner. Moreover, the CXCL12-ERK1/2 signaling induces the expression of Ajuba, the main cofactor of AurA, which allows the auto-phosphorylation of AurA. We show that AurA contributes to glioblastoma cell survival, radio-resistance, self-renewal, and proliferation regardless of the exogenous stimulation with CXCL12. On the other hand, AurA triggers the CXCL12-mediated migration of glioblastoma cells in vitro as well as the invasion of the subventricular zone in xenograft experiments. Moreover, AurA regulates cytoskeletal proteins (i.e., Actin and Vimentin) and favors the pro-migratory activity of the Rho-GTPase CDC42 in response to CXCL12. Altogether, these results show that AurA, a well-known kinase of the mitotic machinery, may play alternative roles in human glioblastoma according to the CXCL12 concentration.	[Willems, Estelle; Dedobbeleer, Matthias; Digregorio, Marina; Lombard, Arnaud; Goffart, Nicolas; Lumapat, Paul Noel; Lambert, Jeremy; Van den Ackerveken, Priscilla; Scholtes, Felix; Rogister, Bernard] Univ Liege, Lab Nervous Syst Dis & Therapy, GIGA Neurosci, Liege, Belgium; [Lombard, Arnaud; Lambert, Jeremy; Scholtes, Felix] CHU Liege, Dept Neurosurg, Liege, Belgium; [Szpakowska, Martyna; Chevigne, Andy] Luxembourg Inst Hlth, Immunopharmacol & Interact, Dept Infect & Immun, Esch Sur Alzette, Luxembourg; [Rogister, Bernard] CHU Liege, Dept Neurol, Liege, Belgium	University of Liege; University of Liege; Luxembourg Institute of Health; University of Liege	Rogister, B (corresponding author), Univ Liege, Lab Nervous Syst Dis & Therapy, GIGA Neurosci, Liege, Belgium.; Rogister, B (corresponding author), CHU Liege, Dept Neurol, Liege, Belgium.	Bernard.Rogister@uliege.be	Rogister, Bernard/AAJ-9591-2020; Lombard, Arnaud/AAG-1624-2021	Szpakowska, Martyna/0000-0002-5659-8377; Chevigne, Andy/0000-0003-4768-6743; Van Den Ackerveken, Priscilla/0000-0001-5913-6293; Digregorio, Marina/0000-0002-5317-7788; Lombard, Arnaud/0000-0002-7789-0801	National Fund for Scientific Research (F.N.R.S.), Special Funds of the University of Liege; Televie sub-organization, Special Funds of the University of Liege; Anti-Cancer Center near the University of Liege Grant; Leon Fredericq Grant; Erasmus Mundus Joint Doctorate in nanomedicine and pharmaceutical innovation (NANOFAR); European Erasmus Mundus; Luxembourg Institute of Health (LIH) MESR; Luxembourg National Research Fund "Fonds National de la Recherche - Aides a la Formation-Recherche" (FNR)	National Fund for Scientific Research (F.N.R.S.), Special Funds of the University of Liege; Televie sub-organization, Special Funds of the University of Liege; Anti-Cancer Center near the University of Liege Grant; Leon Fredericq Grant; Erasmus Mundus Joint Doctorate in nanomedicine and pharmaceutical innovation (NANOFAR); European Erasmus Mundus; Luxembourg Institute of Health (LIH) MESR; Luxembourg National Research Fund "Fonds National de la Recherche - Aides a la Formation-Recherche" (FNR)	The National Fund for Scientific Research (F.N.R.S.) and the Televie sub-organization, the Special Funds of the University of Liege; an Anti-Cancer Center near the University of Liege and Leon Fredericq Grants; Erasmus Mundus Joint Doctorate in nanomedicine and pharmaceutical innovation (NANOFAR), European Erasmus Mundus (Paul Noel Lumapat), the Luxembourg Institute of Health (LIH) MESR, the Luxembourg National Research Fund "Fonds National de la Recherche - Aides a la Formation-Recherche" (FNR) (Martyna Szpakowska and Andy Chevigne).	Adeberg S, 2014, INT J RADIAT ONCOL, V90, P886, DOI 10.1016/j.ijrobp.2014.07.027; Bai MR, 2014, GENE, V543, P133, DOI 10.1016/j.gene.2014.03.048; Chan W, 2002, EUR J CELL BIOL, V81, P692, DOI 10.1078/0171-9335-00281; Chevigne A, 2014, BBA-MOL CELL RES, V1843, P1031, DOI 10.1016/j.bbamcr.2014.01.017; Cuddapah VA, 2014, NAT REV NEUROSCI, V15, P455, DOI 10.1038/nrn3765; Edalat L, 2016, ONCOTARGET, V7, P14259, DOI 10.18632/oncotarget.7423; Fogh BS, 2014, J HISTOCHEM CYTOCHEM, V62, P172, DOI 10.1369/0022155413517701; Gatti M, 2013, TOXICOLOGY, V314, P209, DOI 10.1016/j.tox.2013.10.003; Goffart N, 2017, NEURO-ONCOLOGY, V19, P66, DOI 10.1093/neuonc/now136; Goffart N, 2015, NEURO-ONCOLOGY, V17, P81, DOI 10.1093/neuonc/nou144; Hochegger H, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120185; Hong X, 2014, CANCER CHEMOTH PHARM, V73, P983, DOI 10.1007/s00280-014-2430-z; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; Kalatskaya I, 2009, MOL PHARMACOL, V75, P1240, DOI 10.1124/mol.108.053389; Kroonen J, 2011, INT J CANCER, V129, P574, DOI 10.1002/ijc.25709; Lehman NL, 2012, CELL CYCLE, V11, P489, DOI 10.4161/cc.11.3.18996; Li N, 2015, MOL CANCER THER, V14, P419, DOI 10.1158/1535-7163.MCT-14-0526; Li S, 2015, J BIOL CHEM, V290, P17546, DOI 10.1074/jbc.M115.652453; Liu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059750; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Llaguno SRA, 2016, BRIT J CANCER, V115, P1445, DOI 10.1038/bjc.2016.354; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Mannino M, 2014, STEM CELL RES, V13, P135, DOI 10.1016/j.scr.2014.05.001; Mistry AM, 2017, J NEURO-ONCOL, V131, P125, DOI 10.1007/s11060-016-2278-7; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; Odemis V, 2012, GLIA, V60, P372, DOI 10.1002/glia.22271; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Samaras V, 2009, PATHOL RES PRACT, V205, P765, DOI 10.1016/j.prp.2009.06.011; Singh SK, 2003, CANCER RES, V63, P5821; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun HZ, 2014, BBA-MOL CELL RES, V1843, P934, DOI 10.1016/j.bbamcr.2014.01.019; Ullmann U, 2007, MOL HUM REPROD, V13, P21, DOI 10.1093/molehr/gal091; Van Brocklyn JR, 2014, CANCER RES, V74, P5364, DOI 10.1158/0008-5472.CAN-14-0386; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Willems E, 2017, TARGET ONCOL, V12, P11, DOI 10.1007/s11523-016-0457-2; Wu MH, 2008, J CELL BIOCHEM, V103, P245, DOI 10.1002/jcb.21400; Wurth R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00144; Xia ZB, 2013, MOL CANCER RES, V11, P1101, DOI 10.1158/1541-7786.MCR-13-0044; Zorba A, 2014, ELIFE, V3, DOI 10.7554/eLife.02667	44	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					73	87		10.1038/s41388-018-0437-3	http://dx.doi.org/10.1038/s41388-018-0437-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082913	Green Published, hybrid			2022-12-17	WOS:000454775900006
J	Kaverina, NV; Kadagidze, ZG; Borovjagin, AV; Karseladze, AI; Kim, CK; Lesniak, MS; Miska, J; Zhang, P; Baryshnikova, MA; Xiao, T; Ornelles, D; Cobbs, C; Khramtsov, A; Ulasov, IV				Kaverina, Natalya, V; Kadagidze, Zaira G.; Borovjagin, Anton, V; Karseladze, Apollon, I; Kim, Chung Kwon; Lesniak, Maciej S.; Miska, Jason; Zhang, Peng; Baryshnikova, Maria A.; Xiao, Ting; Ornelles, David; Cobbs, Charles; Khramtsov, Andrey; Ulasov, Ilya, V			Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX	ONCOGENE			English	Article							NORMAL HUMAN FIBROBLASTS; MALIGNANT GLIOMA; BECLIN 1; SECRETORY PHENOTYPE; PROTEIN EXPRESSION; HUMAN GLIOBLASTOMA; APOPTOSIS; SENESCENCE; DEATH; P53	Autophagy is an evolutionarily conserved process regulating cellular homeostasis via digestion of dysfunctional proteins and whole cellular organelles by mechanisms, involving their enclosure into double-membrane vacuoles that are subsequently fused to lysosomes. Glioma stem cells utilize autophagy as a main mechanism of cell survival and stress response. Most recently, we and others demonstrated induction of autophagy in gliomas in response to treatment with chemical drugs, such as temozolomide (TMZ) or oncolytic adenoviruses (Ads). As autophagy has been implicated in the mechanism of Ad-mediated cell killing, autophagy deficiency in some glioma tumors could be the reason for their resistance to oncolysis. Despite the observed connection, the exact relationship between autophagy-activating cell signaling and adenoviral infection remains unclear. Here, we report that inhibition of autophagy in target glioma cells induces their resistance to killing by oncolytic agent CRAd-S-5/3. Furthermore, we found that downregulation of autophagy inducer Beclin-1 inhibits replication-competent Ad-induced oncolysis of human glioma by suppressing cell proliferation and inducing premature senescence. To overcome the autophagy-deficient state of such glioma cells and restore their susceptibility to oncolytic Ad-infection, we propose treating glioma tumors with an anticancer drug tamoxifen (TAM) as a means to induce apoptosis in Ad-targeted cancer cells via upregulation of BAX/PUMA genes. In agreement with the above hypothesis, our data suggest that TAM improves susceptibility of Beclin-1-deficient glioma cells to CRAd-S-5/3 oncolysis by means of activating autophagy and pro-apoptotic signaling pathways in the target cancer cells.	[Kaverina, Natalya, V; Kadagidze, Zaira G.; Karseladze, Apollon, I] RAMN, NN Blokhin Natl Med Res Ctr Oncol, Kashirskoe Shosse 23, Moscow 115478, Russia; [Kaverina, Natalya, V; Baryshnikova, Maria A.] RAMN, Inst Expt Diagnost & Biotherapy, NN Blokhin Natl Med Res Ctr Oncol, Kashirskoe Shosse 23, Moscow 115478, Russia; [Borovjagin, Anton, V] Univ Alabama Birmingham, Inst Oral Hlth Res, Birmingham Sch Dent, Birmingham, AL 35205 USA; [Kim, Chung Kwon] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst Suwon, Suwon 440746, South Korea; [Lesniak, Maciej S.; Miska, Jason; Zhang, Peng; Xiao, Ting; Ulasov, Ilya, V] Northwestern Univ, Northwestern Brain Tumor Inst, Chicago, IL 60611 USA; [Ornelles, David] Wake Forest Sch Med, Dept Microbiol & Immunol, Salem, NC 27101 USA; [Cobbs, Charles] Swedish Neurosci Inst, Seattle, WA 98104 USA; [Khramtsov, Andrey] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol & Lab Med, Chicago, IL 60611 USA; [Ulasov, Ilya, V] Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia	University of Alabama System; University of Alabama Birmingham; Sungkyunkwan University (SKKU); Northwestern University; Swedish Medical Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Sechenov First Moscow State Medical University	Ulasov, IV (corresponding author), Northwestern Univ, Northwestern Brain Tumor Inst, Chicago, IL 60611 USA.; Ulasov, IV (corresponding author), Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia.	ulasov75@yahoo.com	Ulasov, Ilya/A-2352-2014; Khramtsov, Andrey I/H-8701-2018	Ulasov, Ilya/0000-0002-0818-0363; Khramtsov, Andrey I/0000-0001-6301-4619	Russian Fund of Fundamental Research (Russia) [11 411.0008700. 13.082, 13 411. 1008799.13.120]	Russian Fund of Fundamental Research (Russia)	This research was supported by Russian Fund of Fundamental Research (number 11 411.0008700. 13.082 and number 13 411. 1008799.13.120 Russia, MAB) and private donors. We are grateful to Dr. Cobbs for providing patient-derived tumor cells and to Dr. Cobbs's laboratory personnel for their support and technical assistance with experiments.	Abbadie C, 2017, CELL MOL LIFE SCI, V74, P4471, DOI 10.1007/s00018-017-2587-9; Alers S, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-7; Caino MC, 2009, APOPTOSIS, V14, P392, DOI 10.1007/s10495-009-0316-z; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Criollo A, 2009, CELL CYCLE, V8, P2319, DOI 10.4161/cc.8.15.9153; Culmsee C, 2003, J NEUROSCI, V23, P8586; Fernandez-Cuesta L, 2011, INT J CANCER, V128, P1813, DOI 10.1002/ijc.25512; Fimia GM, 2011, AUTOPHAGY, V7, P115, DOI 10.4161/auto.7.1.14071; Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33; Giatromanolaki A, 2014, CANCER BIOL THER, V15, P1468, DOI 10.4161/15384047.2014.955719; GRAHAM FL, 1987, J GEN VIROL, V68, P937, DOI 10.1099/0022-1317-68-3-937; Hothi P, 2012, ONCOTARGET, V3, P1124; Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051; Ito H, 2005, INT J ONCOL, V26, P1401; Jiang H, 2011, J VIROL, V85, P4720, DOI 10.1128/JVI.02032-10; Jiang H, 2009, CURR GENE THER, V9, P422, DOI 10.2174/156652309789753356; Joshi A, 2016, CELL DEATH DIFFER, V23, P216, DOI 10.1038/cdd.2015.88; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kang HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023367; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kumar M, 2014, AM J RESP CELL MOL, V51, P323, DOI 10.1165/rcmb.2013-0382PS; Lasry A, 2015, TRENDS IMMUNOL, V36, P217, DOI 10.1016/j.it.2015.02.009; Lefranc F, 2009, ADV TECH STAND NEURO, V34, P3, DOI 10.1007/978-3-211-78741-0_1; Lefranc Florence, 2006, Neurosurg Focus, V20, pE7, DOI 10.3171/foc.2006.20.4.4; Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637; Liu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059750; Maciel-Baron LA, 2016, AGE, V38, DOI 10.1007/s11357-016-9886-1; Mirochnik Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031052; Pei L, 2014, J NEUROSCI, V34, P6546, DOI 10.1523/JNEUROSCI.5119-13.2014; Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227; Piya S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029467; Ro SH, 2013, AUTOPHAGY, V9, P2103, DOI 10.4161/auto.26563; Salminen A, 2013, AGEING RES REV, V12, P520, DOI 10.1016/j.arr.2012.11.004; Sasaki T, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004409; Schilbach K, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1014760; Shukla S, 2014, J BIOL CHEM, V289, P22306, DOI 10.1074/jbc.M114.567032; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Tepper CG, 2000, EXP CELL RES, V260, P9, DOI 10.1006/excr.2000.4990; Thomas MA, 2009, J VIROL, V83, P2406, DOI 10.1128/JVI.01972-08; Tripathi R, 2014, J CELL MOL MED, V18, P2275, DOI 10.1111/jcmm.12386; Tyler MA, 2009, AUTOPHAGY, V5, P856, DOI 10.4161/auto.8792; Ulasov IV, 2009, BRIT J CANCER, V100, P1154, DOI 10.1038/sj.bjc.6604969; Ulasov IV, 2015, ONCOTARGET, V6, P3977, DOI 10.18632/oncotarget.2897; Vater CA, 1996, ONCOGENE, V13, P739; Villalonga-Planells R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018588; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Zhang M, 2016, EUR REV MED PHARMACO, V20, P3152	49	13	14	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6069	6082		10.1038/s41388-018-0395-9	http://dx.doi.org/10.1038/s41388-018-0395-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29991800				2022-12-17	WOS:000450175900005
J	Cui, YH; Kim, H; Lee, M; Yi, JM; Kim, RK; Uddin, N; Yoo, KC; Kang, JH; Choi, MY; Cha, HJ; Kwon, OS; Bae, IH; Kim, MJ; Kaushik, N; Lee, SJ				Cui, Yan-Hong; Kim, Hyeonmi; Lee, Minyoung; Yi, Joo Mi; Kim, Rae-Kwon; Uddin, Nizam; Yoo, Ki-Chun; Kang, Jae Hyeok; Choi, Mi-Young; Cha, Hyuk-Jin; Kwon, Ok-Seon; Bae, In-Hwa; Kim, Min-Jung; Kaushik, Neha; Lee, Su-Jae			FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; F-BOX PROTEINS; GENE FAMILY; CELL; EXPRESSION; SURVIVAL; PHOSPHORYLATION; METASTASIS; MICRORNAS; MIGRATION	Understanding the molecular mechanisms that underlie the aggressive behavior and relapse of breast cancer may help in the development of novel therapeutic interventions. CUB-domain-containing protein 1 (CDCP1), a transmembrane adaptor protein, is highly maintained and required in the context of cellular metastatic potential in triple-negative breast cancer (TNBC). For this reason, gene expression levels of CDCP1 have been considered as a prognostic marker in TNBC. However, not rarely, transcript levels of genes do not reflect always the levels of proteins, due to the post-transcriptional regulation. Here we show that miR-17/20a control the FBXL14 E3 ligase, establishing FBXL14 as an upstream regulator of the CDCP1 pathway. FBXL14 acts as an novel interaction partner of CDCP1, and facilitates its ubiquitination and proteasomal degradation with an enhanced capacity to suppress CDCP1 protein stability that eventually prevents CDCP1 target genes involved in breast cancer metastasis. Our findings first time uncovers the regulatory mechanism of CDCP-1 protein stabilization, more predictable criteria than gene expression levels for prognosis of breast cancer patients.	[Cui, Yan-Hong; Kim, Hyeonmi; Kim, Rae-Kwon; Uddin, Nizam; Yoo, Ki-Chun; Kang, Jae Hyeok; Choi, Mi-Young; Kaushik, Neha; Lee, Su-Jae] Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea; [Lee, Minyoung] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 01812, South Korea; [Yi, Joo Mi] Dongnam Inst Radiol & Med Sci, Res Inst, Busan, South Korea; [Cha, Hyuk-Jin; Kwon, Ok-Seon] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Bae, In-Hwa] Korea Inst Radiol & Med Sci, Div Basic Radiat Biosci, Seoul, South Korea; [Kim, Min-Jung] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul, South Korea	Hanyang University; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Seoul National University (SNU); Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences	Kaushik, N; Lee, SJ (corresponding author), Hanyang Univ, Res Inst Nat Sci, Dept Life Sci, Seoul 04763, South Korea.	neha.bioplasma@gmail.com; sj0420@hanyang.ac.kr	Kaushik, Neha/AAL-8177-2020; Cha, Hyuk-Jin/AAB-8508-2020; Cui, Yanhong/ABB-1148-2021; Kaushik, Neha/AAY-5982-2020	Cha, Hyuk-Jin/0000-0001-9277-2662; Cui, Yanhong/0000-0002-4169-6521; Kaushik, Neha/0000-0001-8671-6779; Ud Din, Nizam/0000-0002-9845-3109	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program [NRF-2016R1E1A1A01942075, NRF-2015M2A2A7A01044998]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program	This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program NRF-2016R1E1A1A01942075 and NRF-2015M2A2A7A01044998.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Alajati A, 2015, CELL REP, V11, P564, DOI 10.1016/j.celrep.2015.03.044; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brock M, 2011, J BIOL CHEM, V286, P40142, DOI 10.1074/jbc.M111.251793; Brock M, 2009, CIRC RES, V104, P1184, DOI 10.1161/CIRCRESAHA.109.197491; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Cao MQ, 2016, TUMOR BIOL, V37, P1651, DOI 10.1007/s13277-015-3527-7; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Chen CL, 2010, J CELL SCI, V123, P2901, DOI 10.1242/jcs.069765; Chou CT, 2015, ANN SURG ONCOL, V22, P4335, DOI 10.1245/s10434-015-4505-4; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Cui YH, 2015, ONCOGENE, V34, P5372, DOI 10.1038/onc.2014.466; Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Diaz VM, 2016, SEMIN CANCER BIOL, V36, P71, DOI 10.1016/j.semcancer.2015.10.003; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Heo JH, 2016, SEMIN CANCER BIOL, V36, P33, DOI 10.1016/j.semcancer.2015.09.015; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Labidi-Galy SI, 2015, ONCOGENE, V34, P299, DOI 10.1038/onc.2013.562; Law ME, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0741-1; Liu R, 2009, J BIOL CHEM, V284, P16791, DOI 10.1074/jbc.M808919200; Mazzucotelli E, 2006, CURR GENOMICS, V7, P509, DOI 10.2174/138920206779315728; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415; Shostak K, 2014, NAT COMMUN, V287, P9792; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Sun Y, 2001, ANTIOXID REDOX SIGN, V3, P635, DOI 10.1089/15230860152542989; Turdo F, 2016, ONCOTARGET, V7, P69649, DOI 10.18632/oncotarget.11935; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Wright HJ, 2016, ONCOGENE, V35, P4762, DOI 10.1038/onc.2016.7; Wright HJ, 2017, P NATL ACAD SCI USA, V114, pE6556, DOI 10.1073/pnas.1703791114; Yi JM, 2013, CLIN CANCER RES, V19, P6544, DOI 10.1158/1078-0432.CCR-12-3224; Zhu HQ, 2014, AM J PATHOL, V184, P2828, DOI 10.1016/j.ajpath.2014.06.024	43	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2018	37	43					5794	5809		10.1038/s41388-018-0372-3	http://dx.doi.org/10.1038/s41388-018-0372-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY1KL	29973690				2022-12-17	WOS:000448288200007
J	Di Modugno, F; Spada, S; Palermo, B; Visca, P; Iapicca, P; Di Carlo, A; Antoniani, B; Sperduti, I; Di Benedetto, A; Terrenato, I; Mottolese, M; Gandolfi, F; Facciolo, F; Chen, EI; Schwartz, MA; Santoni, A; Bissell, MJ; Nistico, P				Di Modugno, Francesca; Spada, Sheila; Palermo, Belinda; Visca, Paolo; Iapicca, Pierluigi; Di Carlo, Anna; Antoniani, Barbara; Sperduti, Isabella; Di Benedetto, Anna; Terrenato, Irene; Mottolese, Marcella; Gandolfi, Francesco; Facciolo, Francesco; Chen, Emily I.; Schwartz, Martin A.; Santoni, Angela; Bissell, Mina J.; Nistico, Paola			hMENA isoforms impact NSCLC patient outcome through fibronectin/beta 1 integrin axis	ONCOGENE			English	Article							BREAST-CANCER CELLS; EXTRACELLULAR-MATRIX; BETA(1) INTEGRIN; LUNG-CANCER; ACTIN DYNAMICS; BARBED END; TRANSENDOTHELIAL MIGRATION; 3-DIMENSIONAL CULTURE; ENA/VASP PROTEINS; SRF ACTIVITY	We demonstrated previously that the splicing of the actin regulator, hMENA, generates two alternatively expressed isoforms, hMENA(11a) and hMENA Delta v6, which have opposite functions in cell invasiveness. Their mechanisms of action have remained unclear. Here we report two major findings: (i) hMENA regulates beta 1 integrin expression. This was shown by depleting total hMENA, which led to loss of nuclear expression of serum response factor (SRF)-coactivator myocardin-related transcription factor 1 (MRTF-A), leading to an increase in the G-actin/F-actin ratio crucial for MRTF-A localization. This in turn inhibited SRF activity and the expression of its target gene beta 1 integrin. (ii) hMENA(11a) reduces and hMENA Delta v6 increases beta 1 integrin activation and signaling. Moreover, exogenous expression of hMENA(11a) in hMENA Delta v6-positive cancer cells dramatically reduces secretion of extracellular matrix (ECM) components, including beta 1 integrin ligands and metalloproteinases. On the other hand, overexpression of the pro-invasive hMENA.v6 increases fibronectin production. In primary tumors high hMENA(11a) correlates with low stromal fibronectin and a favorable clinical outcome of early node-negative non-small-cell lung cancer patients. These data provide new insights into the roles of hMENA(11a) and hMENA Delta v6 in the druggable beta 1 integrin-ECM signaling axis and allow stratification of patient risk, guiding their clinical management.	[Di Modugno, Francesca; Spada, Sheila; Palermo, Belinda; Iapicca, Pierluigi; Di Carlo, Anna; Nistico, Paola] IRCCS Regina Elena Natl Canc Inst, Tumor Immunol & Immunotherapy Unit, Rome, Italy; [Spada, Sheila; Santoni, Angela] Univ Sapienza, Dept Mol Med, Rome, Italy; [Visca, Paolo; Antoniani, Barbara; Di Benedetto, Anna; Mottolese, Marcella] IRCCS Regina Elena Natl Canc Inst, Pathol Lab, Rome, Italy; [Sperduti, Isabella; Terrenato, Irene] IRCCS Regina Elena Natl Canc Inst, Biostat Sci Direct, Rome, Italy; [Gandolfi, Francesco] Univ Sapienza, Dept Phys, Rome, Italy; [Facciolo, Francesco] IRCCS Regina Elena Natl Canc Inst, Thorac Surg Unit, Rome, Italy; [Chen, Emily I.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Pharmacol, New York, NY USA; [Schwartz, Martin A.] Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Internal Med, New Haven, CT 06511 USA; [Schwartz, Martin A.] Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Cell Biol, New Haven, CT 06511 USA; [Schwartz, Martin A.] Yale Sch Med, Yale Cardiovasc Res Ctr, Dept Biomed Engn, New Haven, CT 06511 USA; [Bissell, Mina J.] Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	Sapienza University Rome; Sapienza University Rome; Columbia University; Yale University; Yale University; Yale University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Nistico, P (corresponding author), IRCCS Regina Elena Natl Canc Inst, Tumor Immunol & Immunotherapy Unit, Rome, Italy.	paola.nistico@ifo.gov.it	Di Carlo, Anna/AAY-4368-2021; Terrenato, Irene/B-1308-2017; Sperduti, Isabella/K-8902-2016; Spada, Sheila/AAN-1520-2020; Di Modugno, Francesca/ABH-9406-2020; Nistico, Paola/B-2862-2018	Di Carlo, Anna/0000-0002-6037-6160; Terrenato, Irene/0000-0002-0187-9323; Sperduti, Isabella/0000-0001-5115-3099; Di Modugno, Francesca/0000-0003-1427-1883; Facciolo, Francesco/0000-0002-7137-8946; iapicca, pierluigi/0000-0002-7995-2391; Di Benedetto, Anna/0000-0002-9853-8671; Palermo, Belinda/0000-0001-6293-0113; Nistico, Paola/0000-0003-4409-2261	Italian Association for Cancer Research AIRC: 5x1000 [12182, IG 15224]; NCI [R37CA064786, U54CA143836]; Department of Defense Breast Cancer Research Program [W81XWH0810736]; Breast Cancer Research Foundation; NIH [RO1 GM47214]; NATIONAL CANCER INSTITUTE [R37CA064786, R01CA064786, U54CA143836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER	Italian Association for Cancer Research AIRC: 5x1000(Fondazione AIRC per la ricerca sul cancro); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense Breast Cancer Research Program(United States Department of Defense); Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	PN is supported by the Italian Association for Cancer Research AIRC: 5x1000, 12182, and IG 15224. M.J.B. is supported by the NCI (awards R37CA064786 and U54CA143836-Bay Area Physical Sciences Oncology Center), the Department of Defense Breast Cancer Research Program (award W81XWH0810736), and by a grant from the Breast Cancer Research Foundation. MAS is supported by NIH, RO1 GM47214.	AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; Bae YK, 2013, HUM PATHOL, V44, P2028, DOI 10.1016/j.humpath.2013.03.006; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Bear JE, 2009, J CELL SCI, V122, P1947, DOI 10.1242/jcs.038125; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Bria E, 2014, ONCOTARGET, V5, P11054, DOI 10.18632/oncotarget.2609; Caccavari F, 2010, CELL ADHES MIGR, V4, P124, DOI 10.4161/cam.4.1.10976; Di Modugno F, 2006, CLIN CANCER RES, V12, P1470, DOI 10.1158/1078-0432.CCR-05-2027; Di Modugno F, 2004, INT J CANCER, V109, P909, DOI 10.1002/ijc.20094; Di Modugno F, 2007, CANCER RES, V67, P2657, DOI 10.1158/0008-5472.CAN-06-1997; Modugno F, 2018, P NATL ACAD SCI USA, V115, P3132, DOI 10.1073/pnas.1715998115; Di Modugno F, 2012, P NATL ACAD SCI USA, V109, P19280, DOI 10.1073/pnas.1214394109; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gertler F, 2011, TRENDS CELL BIOL, V21, P81, DOI 10.1016/j.tcb.2010.10.001; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Han JY, 2003, LUNG CANCER-J IASLC, V41, P65, DOI 10.1016/S0169-5002(03)00146-6; Hansen SD, 2010, J CELL BIOL, V191, P571, DOI 10.1083/jcb.201003014; HOWLETT AR, 1995, J CELL SCI, V108, P1945; Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; Krause M, 2003, ANNU REV CELL DEV BI, V19, P541, DOI 10.1146/annurev.cellbio.19.050103.103356; Kuhnel K, 2004, P NATL ACAD SCI USA, V101, P17027, DOI 10.1073/pnas.0403069101; Li J, 2017, P NATL ACAD SCI USA, V114, P4685, DOI 10.1073/pnas.1704171114; Margadant C, 2011, CURR OPIN CELL BIOL, V23, P607, DOI 10.1016/j.ceb.2011.08.005; Melchionna R, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1221556; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Nam JM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3454; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; Nistico P, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0459-x; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Oudin MJ, 2016, CANCER DISCOV, V6, P516, DOI 10.1158/2159-8290.CD-15-1183; Park CC, 2008, CANCER RES, V68, P4398, DOI 10.1158/0008-5472.CAN-07-6390; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169; Rotty JD, 2015, DEV CELL, V32, P54, DOI 10.1016/j.devcel.2014.10.026; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Shibue T, 2013, CANCER CELL, V24, P481, DOI 10.1016/j.ccr.2013.08.012; Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev-cellbio-100109-104020; Su Y, 2016, P NATL ACAD SCI USA, V113, pE3872, DOI 10.1073/pnas.1605074113; Trono P, 2016, ONCOGENE, V35, P887, DOI 10.1038/onc.2015.143; Vidaki M, 2017, NEURON, V95, P608, DOI 10.1016/j.neuron.2017.06.048; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Worth DC, 2010, J CELL BIOL, V189, P369, DOI 10.1083/jcb.200912014; Xu R, 2009, CANCER METAST REV, V28, P167, DOI 10.1007/s10555-008-9178-z; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0	56	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5605	5617		10.1038/s41388-018-0364-3	http://dx.doi.org/10.1038/s41388-018-0364-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29907768	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000447619100002
J	Yang, H; Xu, M; Lu, F; Zhang, QN; Feng, YQ; Yang, CS; Li, N; Jia, XD				Yang, Hui; Xu, Miao; Lu, Fang; Zhang, Qiannan; Feng, Yongquan; Yang, Chung S.; Li, Ning; Jia, Xudong			Tocopherols inhibit esophageal carcinogenesis through attenuating NF-kappa B activation and CXCR3-mediated inflammation	ONCOGENE			English	Article							NUTRITION INTERVENTION TRIALS; VITAMIN-E; GAMMA-TOCOPHEROL; CANCER PREVENTION; PROSTATE-CANCER; COLON CARCINOGENESIS; ALPHA-TOCOPHEROL; DELTA-TOCOPHEROL; SELENIUM; PROMOTES	Esophageal cancer is one of the common causes of cancer mortality in the world. The predominant histological subtype, esophageal squamous cell carcinoma (ESCC), often results in poor prognosis due to the lack of effective approaches for the early diagnosis and treatment, highlighting the need for preventive intervention against this disease. Here we report that dietary tocopherols significantly prevents esophageal carcinogenesis by inhibiting the activation of NF-kappa B and the subsequent interaction of chemokine CXCL9/10/11 with their receptor CXCR3 in ESCC induced by N-nitrosomethylbenzylamine (NMBA) in murine models. Dietary supplementation with 0.15% alpha-tocopherol (alpha-T), d-tocopherol (delta-T), or gamma-tocopherol rich mixture (gamma-TmT) markedly suppressed the production of pro-inflammatory cytokines, as well as the induction of CXCR3+ effector T cells (CD4+ Th1 and CD8+ CTLs) infiltration, especially at the early stage of carcinogenesis. In experiments in vivo and in vitro, these events were tightly correlated with the blockade of NF-kappa B activation. Our results show that tocopherols decrease carcinogenesis through inhibiting NF-kappa B and CXCR3 signaling, as well as related inflammation in early premalignant lesions. This pathway may offer a novel target for chemoprevention of esophageal cancer.	[Yang, Hui; Zhang, Qiannan; Feng, Yongquan; Li, Ning; Jia, Xudong] Natl Ctr Food Safety Risk Assessment, Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing, Peoples R China; [Xu, Miao] Sichuan Univ, West China Sch Publ Hlth, Chengdu, Sichuan, Peoples R China; [Lu, Fang] Beijing Agr Univ, Beijing, Peoples R China; [Yang, Chung S.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ USA	Sichuan University; Beijing University of Agriculture; Rutgers State University New Brunswick	Yang, H; Jia, XD (corresponding author), Natl Ctr Food Safety Risk Assessment, Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing, Peoples R China.	yanghui@cfsa.net.cn; jiaxudong@cfsa.net.cn	Yang, Hui/AAK-8492-2020	Yang, Hui/0000-0002-6025-338X	National Natural Science Foundation of China [81402679]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a grant from the National Natural Science Foundation of China (no. 81402679).	Arnold M, 2015, GUT, V64, P381, DOI 10.1136/gutjnl-2014-308124; Bak MJ, 2017, CANCER PREV RES, V10, P188, DOI [10.1158/1940-6207.CAPR-16-0223, 10.1158/1940-6207.capr-16-0223]; Billottet C, 2013, BBA-REV CANCER, V1836, P287, DOI 10.1016/j.bbcan.2013.08.002; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen JX, 2017, MOL CARCINOGEN, V56, P172, DOI 10.1002/mc.22481; Chen JX, 2016, CANCER LETT, V371, P71, DOI 10.1016/j.canlet.2015.11.010; Clark-Lewis I, 2003, J BIOL CHEM, V278, P289, DOI 10.1074/jbc.M209470200; Das Gupta S, 2015, CANCER PREV RES, V8, P807, DOI 10.1158/1940-6207.CAPR-15-0154; Dietrich M, 2006, J AM COLL NUTR, V25, P292, DOI 10.1080/07315724.2006.10719538; Eitenmiller T, 2004, VITAMIN E FOOD CHEM; Fong LYY, 1999, CANCER LETT, V143, P63, DOI 10.1016/S0304-3835(99)00191-3; Gaziano JM, 2009, JAMA-J AM MED ASSOC, V301, P52, DOI 10.1001/jama.2008.862; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Guan F, 2012, CANCER PREV RES, V5, P644, DOI 10.1158/1940-6207.CAPR-11-0521; Hannelien V, 2012, BBA-REV CANCER, V1825, P117, DOI 10.1016/j.bbcan.2011.10.008; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; IARC, 2012, SECT CANC INF; Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437; Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56; Lee JH, 2012, CANCER RES, V72, P3175, DOI 10.1158/0008-5472.CAN-12-0481; Li GX, 2011, CANCER PREV RES, V4, P404, DOI 10.1158/1940-6207.CAPR-10-0130; Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864; Lunardi S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1027473; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Malyak M, 1998, J IMMUNOL, V161, P1997; Malyak M, 1998, J IMMUNOL, V161, P2004; Maresso KC, 2015, CA-CANCER J CLIN, V65, P345, DOI 10.3322/caac.21287; Mark SD, 2000, J NATL CANCER I, V92, P1753, DOI 10.1093/jnci/92.21.1753; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Mulligan AM, 2013, CLIN CANCER RES, V19, P336, DOI 10.1158/1078-0432.CCR-11-3314; Patterson TA, 2006, NAT BIOTECHNOL, V24, P1140, DOI 10.1038/nbt1242; Perez S, 2017, FREE RADICAL BIO MED, V104, P75, DOI 10.1016/j.freeradbiomed.2016.12.048; Qiao YL, 2009, JNCI-J NATL CANCER I, V101, P507, DOI 10.1093/jnci/djp037; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Smolarek AK, 2012, CANCER PREV RES, V5, P1310, DOI 10.1158/1940-6207.CAPR-12-0263; Stoner GD, 2006, NUTR CANCER, V54, P33, DOI 10.1207/s15327914nc5401_5; Taylor PR, 2003, J NATL CANCER I, V95, P1414, DOI 10.1093/jnci/djg044; TAYLOR PR, 1994, CANCER RES, V54, pS2029; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; Wang H, 2016, MOL CARCINOGEN, V55, P1728, DOI 10.1002/mc.22422; Wingender E, 2008, BRIEF BIOINFORM, V9, P326, DOI 10.1093/bib/bbn016; Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483; Yang CS, 2016, MOL NUTR FOOD RES, V60, P1239, DOI 10.1002/mnfr.201500766; Yang CS, 2012, CANCER PREV RES, V5, P701, DOI 10.1158/1940-6207.CAPR-12-0045; Yang H, 2012, INT J CANCER, V131, P1517, DOI 10.1002/ijc.27423; Yang H, 2011, CARCINOGENESIS, V32, P381, DOI 10.1093/carcin/bgq279; Zhou HF, 2016, BIOMED PHARMACOTHER, V82, P479, DOI 10.1016/j.biopha.2016.04.069; Zipin-Roitman A, 2007, CANCER RES, V67, P3396, DOI 10.1158/0008-5472.CAN-06-3087	53	13	13	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3909	3923		10.1038/s41388-018-0246-8	http://dx.doi.org/10.1038/s41388-018-0246-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662196				2022-12-17	WOS:000439101300001
J	Shi, C; Pan, BQ; Shi, F; Xie, ZH; Jiang, YY; Shang, L; Zhang, Y; Xu, X; Cai, Y; Hao, JJ; Wang, MR				Shi, Chao; Pan, Bei-Qing; Shi, Feng; Xie, Zhi-Hui; Jiang, Yan-Yi; Shang, Li; Zhang, Yu; Xu, Xin; Cai, Yan; Hao, Jia-Jie; Wang, Ming-Rong			Sequestosome 1 protects esophageal squamous carcinoma cells from apoptosis via stabilizing SKP2 under serum starvation condition	ONCOGENE			English	Article							CANCER-CELLS; LUNG-CANCER; PB1 DOMAIN; PROSTATE-CANCER; AUTOPHAGY; P62; KINASE; DEGRADATION; P62/SQSTM1; ACTIVATION	Esophageal squamous cell carcinoma (ESCC) is one of the malignancies in digestive system, with a low 5-year survival rate. We previously revealed that Sequestosome 1 (SQSTM1/p62) protein levels were upregulated in ESCC tissues. However, it is unclear about the function of p62 and the underlying mechanism. Here, we used immunofluorescence and immunohistochemistry to investigate the expression of p62 in ESCC. Western blotting, quantitative RT-PCR, colony formation assay, flow cytometry, immunoprecipitation and xenograft tumor assay were used to analyze the role of p62 in vitro and vivo. Here, we showed that p62 serves as a regulator of cell apoptosis under serum starvation condition in ESCC cells. Through activating the protein kinase C iota (PKCiota)-S-phase kinase-associated protein 2 (SKP2) signaling pathway, p62 enhances cell apoptosis resistance and colony formation in vitro and tumor growth in mouse models. Through interaction with the domains PB1, p62 upregulated the expression of PKCiota and then depressed the ubiquitin-mediated proteasomal degradation of SKP2. p62-silencing combined with a PKCiota inhibitor ATM significantly enhanced cell apoptosis and inhibited cell survival. Immunohistochemical analysis revealed a positive association between the expression of p62 and SKP2 in primary ESCC tissues. And importantly, p62 presented a markedly cytoplasmic translocation in cancerous cells, including in 16 (30.76%) tumors at stage T1, as compared with its nuclear location in normal esophageal epithelial cells. In summary, p62 plays an anti-apoptotic role in ESCC cells via stabilizing SKP2 under serum starvation condition. These data suggest that p62 might be an early biomarker and a candidate therapeutic target of ESCC.	[Shi, Chao; Pan, Bei-Qing; Shi, Feng; Xie, Zhi-Hui; Jiang, Yan-Yi; Shang, Li; Zhang, Yu; Xu, Xin; Cai, Yan; Hao, Jia-Jie; Wang, Ming-Rong] Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Shi, Chao; Pan, Bei-Qing; Shi, Feng; Xie, Zhi-Hui; Jiang, Yan-Yi; Shang, Li; Zhang, Yu; Xu, Xin; Cai, Yan; Hao, Jia-Jie; Wang, Ming-Rong] Chinese Acad Med Sci, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Hao, JJ; Wang, MR (corresponding author), Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Hao, JJ; Wang, MR (corresponding author), Chinese Acad Med Sci, Beijing 100021, Peoples R China.	hjj8173@126.com; wangmr2015@126.com	; Zhang, Yu/G-2453-2011	WANG, Ming-Rong/0000-0002-8767-9356; Zhang, Yu/0000-0003-1375-1594	National Natural Science Foundation of China [31571420, 81520108023]; Beijing Natural Science Foundation [7151008]; CAMS Innovation Fund for Medical Sciences [CIFMS2016-I2M-1-001/3-007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); CAMS Innovation Fund for Medical Sciences	This work was supported by National Natural Science Foundation of China (31571420 and 81520108023). Beijing Natural Science Foundation (7151008) and CAMS Innovation Fund for Medical Sciences (CIFMS2016-I2M-1-001/3-007).	Burdelski C, 2015, CLIN CANCER RES, V21, P3471, DOI 10.1158/1078-0432.CCR-14-0620; Burke RM, 2015, ANTIOXID REDOX SIGN, V22, P1243, DOI 10.1089/ars.2014.6182; Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226; Duran A, 2016, CANCER CELL, V30, P595, DOI 10.1016/j.ccell.2016.09.004; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; He PX, 2014, ACTA PHARMACOL SIN, V35, P1055, DOI 10.1038/aps.2014.47; Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x; Inui T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074398; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kopsiaftis S, 2016, MOL CANCER RES, V14, P1182, DOI 10.1158/1541-7786.MCR-16-0111; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Lu SH, 2000, MUTAT RES-REV MUTAT, V462, P343, DOI 10.1016/S1383-5742(00)00023-5; Lu W, 2017, ONCOGENE, V36, P1364, DOI 10.1038/onc.2016.300; Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222; Ma CQ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.91; Mansfield AS, 2013, ANTI-CANCER DRUG, V24, P1079, DOI 10.1097/CAD.0000000000000009; Marjuki H, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-134; Mohamed A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00070; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nakamura K, 2010, J BIOL CHEM, V285, P2077, DOI 10.1074/jbc.M109.065102; Nakano T, 2004, ACTA NEUROPATHOL, V107, P359, DOI 10.1007/s00401-004-0821-7; Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Ren J, 2014, SCI CHINA LIFE SCI, V57, P69, DOI 10.1007/s11427-013-4592-z; Scharf VF, 2014, ANTI-CANCER DRUG, V25, P332, DOI 10.1097/CAD.0000000000000061; Wang BS, 2014, MOL CARCINOGEN, V53, P514, DOI 10.1002/mc.22003; Wang XC, 2009, MOL CANCER RES, V7, P12, DOI 10.1158/1541-7786.MCR-08-0092; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Xie WY, 2015, EXP CELL RES, V339, P270, DOI 10.1016/j.yexcr.2015.11.005; Xu DZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7641; Yamada SI, 2016, PATHOL ONCOL RES, V22, P625, DOI 10.1007/s12253-016-0049-6; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang MZ, 2014, DIABETES, V63, P2063, DOI 10.2337/db13-1279; Zhao ZM, 2017, ANTI-CANCER DRUG, V28, P187, DOI 10.1097/CAD.0000000000000451	36	13	16	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3260	3274		10.1038/s41388-018-0217-0	http://dx.doi.org/10.1038/s41388-018-0217-0			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551772				2022-12-17	WOS:000435526600006
J	Cong, B; Ohsawa, S; Igaki, T				Cong, Bojie; Ohsawa, Shizue; Igaki, Tatsushi			JNK and Yorkie drive tumor progression by generating polyploid giant cells in Drosophila	ONCOGENE			English	Article							SIGNALING PATHWAY; SUPPRESSOR GENES; APOPTOSIS; PROLIFERATION; OVERGROWTH; BREAST; CANCER; RAS; DEGRADATION; AUTOPHAGY	Epithelial cancer tissues often possess polyploid giant cells, which are thought to be highly oncogenic. However, the mechanisms by which polyploid giant cells are generated in tumor tissues and how such cells contribute to tumor progression remain elusive. We previously noticed in Drosophila imaginal epithelium that cells mutant for the endocytic gene rab5 exhibit enlarged nuclei. Here we find that mutations in endocytic 'neoplastic tumor-suppressor' genes, such as rab5, vps25, erupted, or avalanche result in generation of polyploid giant cells. Genetic analyses on rab5-defective cells reveal that cooperative activation of JNK and Yorkie generates polyploid giant cells via endoreplication. Mechanistically, Yorkie-mediated upregulation of Diap1 cooperates with JNK to downregulate the G2/M cyclin CycB, thereby inducing endoreplication. Interestingly, malignant tumors induced by Ras activation and cell polarity defect also consist of polyploid giant cells, which are generated by JNK and Yorkie-mediated downregulation of CycB. Strikingly, elimination of polyploid giant cells from such malignant tumors by blocking endoreplication strongly suppressed tumor growth and metastatic behavior. Our observations suggest that JNK and Yorkie, two oncogenic proteins activated in many types of human cancers, cooperatively drive tumor progression by generating oncogenic polyploid giant cells.	[Cong, Bojie; Ohsawa, Shizue; Igaki, Tatsushi] Kyoto Univ, Grad Sch Biostudies, Lab Genet, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan	Kyoto University	Igaki, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Lab Genet, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	igaki@lif.kyoto-u.ac.jp		Igaki, Tatsushi/0000-0001-5839-9526	MEXT/JSPS KAKENHI [26114002, 16K14606, 16H02505, 15H05862, 26711013, 17H03673]; Naito Foundation; Takeda Science Foundation; Japan Foundation for Applied Enzymology; Japan Agency for Medical Research and Development; Ichikawa International Scholarship Foundation	MEXT/JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Naito Foundation(Naito Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Japan Foundation for Applied Enzymology; Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Ichikawa International Scholarship Foundation	We thank Masato Enomoto, Yukari Sando, Yuya Sanaki, Kiichiro Taniguchi, and Masatoshi Yamamoto for discussions, and K. Sawada, K. Baba and Y. Senda for technical assistance. We also thank Leonie Quinn, Masayuki Miura, Takashi Adachi-Yamada, the Bloomington Stock Center, the Drosophila Genomics and Genetic Resources (DGGR), and the FlyORF for fly stocks. This work was supported in part by grants from the MEXT/JSPS KAKENHI (Grant Number 26114002, 16K14606, 16H02505, 15H05862, 26711013, and 17H03673) to S.O. and T.I., the Naito Foundation to T.I., the Takeda Science Foundation to S.O. and T.I., the Japan Foundation for Applied Enzymology to S.O., and Japan Agency for Medical Research and Development (Project for Elucidating and Controlling Mechanisms of Aging and Longevity) to T.I. B.C. was supported in part by Ichikawa International Scholarship Foundation. This work was supported in part by grants from the MEXT/JSPS KAKENHI (Grant Numbers 26114002, 16K14606, 16H02505, 15H05862, 26711013, and 17H03673), the Naito Foundation, the Takeda Science Foundation, the Japan Foundation for Applied Enzymology, and Japan Agency for Medical Research and Development (Project for Elucidating and Controlling Mechanisms of Aging and Longevity) to T.I. B.C. was supported in part by Ichikawa International Scholarship Foundation.	Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Davidson B, 2006, GYNECOL ONCOL, V102, P453, DOI 10.1016/j.ygyno.2006.01.034; Davoli T, 2011, ANNU REV CELL DEV BI, V27, P585, DOI 10.1146/annurev-cellbio-092910-154234; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Fox DT, 2013, DEVELOPMENT, V140, P3, DOI 10.1242/dev.080531; FRIERSON HF, 1991, AM J SURG PATHOL, V15, P358, DOI 10.1097/00000478-199104000-00004; Giebel B, 2006, CURR BIOL, V16, pR91, DOI 10.1016/j.cub.2006.01.022; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Gong FR, 2015, ONCOTARGET, V6, P18469, DOI 10.18632/oncotarget.4063; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Gutierrez GJ, 2010, J BIOL CHEM, V285, P14217, DOI 10.1074/jbc.M110.121848; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Herz HM, 2006, DEVELOPMENT, V133, P1871, DOI 10.1242/dev.02356; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lindqvist A, 2010, J CELL BIOL, V189, P197, DOI 10.1083/jcb.201003032; Maugeri-Sacca M, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.12; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; Mohd-Sarip A, 2012, SCIENCE, V336, P744, DOI 10.1126/science.1215927; Nakamura M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6264; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Robinson BS, 2011, CELL CYCLE, V10, P4110, DOI 10.4161/cc.10.23.18243; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Shabbeer S, 2013, ONCOGENE, V32, P5005, DOI 10.1038/onc.2012.522; Takino K, 2014, DEV BIOL, V395, P19, DOI 10.1016/j.ydbio.2014.09.003; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Wang H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.138; Xu DB, 2009, FLY, V3, P78, DOI 10.4161/fly.3.1.7800; XU T, 1993, DEVELOPMENT, V117, P1223; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhang SH, 2017, CANCER CELL, V31, P669, DOI 10.1016/j.ccell.2017.04.004	35	13	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3088	3097		10.1038/s41388-018-0201-8	http://dx.doi.org/10.1038/s41388-018-0201-8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29535423				2022-12-17	WOS:000434641400004
J	Ehedego, H; Mohs, A; Jansen, B; Hiththetiya, K; Sicinski, P; Liedtke, C; Trautwein, C				Ehedego, Haksier; Mohs, Antje; Jansen, Bettina; Hiththetiya, Kanishka; Sicinski, Piotr; Liedtke, Christian; Trautwein, Christian			Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; RNA INTERFERENCE; CELL-CYCLE; MICE; PROLIFERATION; EXPRESSION; DELETION; CANCER; PHOSPHORYLATION; ENDOREPLICATION	Chronic liver injury triggers liver fibrosis and hepatocellular carcinoma (HCC), the third leading cause of cancer-related mortality. Cyclin E1 (CcnE1, formerly designated Cyclin E) is a regulatory subunit of the Cyclin-dependent kinase 2 (CDK2). It is overexpressed in approximately 70% of human HCCs correlating with poor prognosis, while the relevance of its orthologue Cyclin E2 (CcnE2) is unclear. Hepatocyte-specific deletion of NF-kappa-B essential modulator (NEMO Delta hepa) leads to chronic hepatitis, liver fibrosis, and HCC as well as CcnE upregulation. To this end, we generated NEMO Delta hepa/CcnE1(-/-) and NEMO Delta hepa/CcnE2(-/-) double knockout mice and investigated age-dependent liver disease progression in these animals. Deletion of CcnE1 in NEMO Delta hepa mice decreased basal liver damage and reduced spontaneous liver inflammation in young mice. In contrast, loss of CcnE2 did not affect liver injury in NEMO Delta hepa livers pointing to a unique, non-redundant function of CcnE1 in chronic hepatitis. Accordingly, basal compensatory hepatocyte proliferation in NEMO Delta hepa mice was reduced by concomitant ablation of CcnE1, but not after loss of CcnE2. In aged NEMO.hepa mice, loss of CcnE1 resulted in significant reduction of liver tumorigenesis, while deletion of CcnE2 had no effect on HCC formation. CcnE1, but not its orthologue CcnE2, substantially contributes to hepatic inflammatory response, liver disease progression, and hepatocarcinogenesis in NEMO Delta hepa mice.	[Ehedego, Haksier; Mohs, Antje; Jansen, Bettina; Liedtke, Christian; Trautwein, Christian] Univ Hosp RWTH Aachen, Dept Internal Med 3, Aachen, Germany; [Hiththetiya, Kanishka] Univ Hosp Bonn, Inst Pathol, Bonn, Germany; [Sicinski, Piotr] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA USA; [Sicinski, Piotr] Harvard Med Sch, Dept Genet, Boston, MA USA	RWTH Aachen University; RWTH Aachen University Hospital; University of Bonn; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Trautwein, C (corresponding author), Univ Hosp RWTH Aachen, Dept Internal Med 3, Aachen, Germany.	ctrautwein@ukaachen.de	Liedtke, Christian/DTV-1874-2022	Liedtke, Christian/0000-0003-4681-7887; Mohs, Antje/0000-0001-5937-0696	German Cancer Foundation (Deutsche Krebshilfe) [107682, SFB TRR/57]; Interdisciplinary Centre for Clinical Research (IZKF Aachen) within the Faculty of Medicine; RWTH Aachen; NATIONAL CANCER INSTITUTE [R01CA202634] Funding Source: NIH RePORTER	German Cancer Foundation (Deutsche Krebshilfe)(Deutsche Krebshilfe); Interdisciplinary Centre for Clinical Research (IZKF Aachen) within the Faculty of Medicine; RWTH Aachen; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant of the German Cancer Foundation (Deutsche Krebshilfe) Grant Nr. 107682, the SFB TRR/57 and the Interdisciplinary Centre for Clinical Research (IZKF Aachen) within the Faculty of Medicine; RWTH Aachen.	Aigelsreiter A, 2012, HUM PATHOL, V43, P1012, DOI 10.1016/j.humpath.2011.08.009; Bangen JM, 2017, HEPATOLOGY, V66, P1242, DOI 10.1002/hep.29275; Beraza N, 2009, J EXP MED, V206, P1727, DOI 10.1084/jem.20082152; Bisteau X, 2014, CANCERS, V6, P79, DOI 10.3390/cancers6010079; Chuma M, 2003, HEPATOLOGY, V37, P198, DOI 10.1053/jhep.2003.50022; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Ehedego H, 2015, CANCER RES, V75, P1144, DOI 10.1158/0008-5472.CAN-14-1356; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Geng Y, 2001, P NATL ACAD SCI USA, V98, P13138, DOI 10.1073/pnas.231487798; Geng Y, 2007, MOL CELL, V25, P127, DOI 10.1016/j.molcel.2006.11.029; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hu W, 2014, HEPATOLOGY, V59, P651, DOI 10.1002/hep.26584; Jung YJ, 2001, CANCER LETT, V168, P57, DOI 10.1016/S0304-3835(01)00403-7; Li KY, 2003, CANCER RES, V63, P3593; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Malato Y, 2012, GASTROENTEROLOGY, V143, P1597, DOI 10.1053/j.gastro.2012.08.030; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Nevzorova YA, 2012, HEPATOLOGY, V56, P1140, DOI 10.1002/hep.25736; Nevzorova YA, 2009, GASTROENTEROLOGY, V137, P691, DOI 10.1053/j.gastro.2009.05.003; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pok S, 2013, J GASTROEN HEPATOL, V28, P1545, DOI 10.1111/jgh.12216	23	13	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3329	3339		10.1038/s41388-018-0181-8	http://dx.doi.org/10.1038/s41388-018-0181-8			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29551768	Green Accepted			2022-12-17	WOS:000436411300001
J	Ozes, AR; Pulliam, N; Ertosun, MG; Yilmaz, O; Tang, J; Copuroglu, E; Matei, D; Ozes, ON; Nephew, KP				Ozes, Ali R.; Pulliam, Nick; Ertosun, Mustafa G.; Yilmaz, Ozlem; Tang, Jessica; Copuroglu, Ece; Matei, Daniela; Ozes, Osman N.; Nephew, Kenneth P.			Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity	ONCOGENE			English	Article							OVARIAN-CANCER CELLS; ZESTE HOMOLOG 2; PKA PHOSPHORYLATES; PROSTATE-CANCER; TARGETING EZH2; STEM-CELLS; IN-VITRO; PROLIFERATION; COMPLEX; GENE	Polycomb repressive complex 2 (PRC2) member enhancer of zeste homolog 2 (EZH2) trimethylates histone H3 lysine 27 (H3K27me3), alters chromatin structure and contributes to epigenetic regulation of gene expression in normal and disease processes. Phosphorylation of EZH2 augmented EZH2 oncogenic activity in cancer but observations have been limited to threonine 350 (T350) and serine 21 (S21) residues by cyclin-dependent kinase 1 and protein kinase B, respectively. In addition, phosphorylation of the evolutionarily conserved T372 motif of EZH2 by p38 resulted in EZH2 interaction with Ying Yang 1 and promoted muscle stem cell differentiation. In the present study, we used epithelial ovarian cancer (OC) cells as a model to demonstrate that phosphorylation of EZH2 at T372 by protein kinase A (PKA) induced a dominant-negative EZH2 phenotype, inhibited OC cell proliferation and migration in vitro and decreased ovarian xenograft tumor growth in vivo. Phosphorylation of T372 by PKA enhanced the interaction between EZH2 and signal transducer and activator of transcription 3 (STAT3), and STAT3 binding to pT372-EZH2 reduced cellular levels of pSTAT3 and downregulated interleukin 6 receptor expression in OC. Furthermore, PKA-mediated pT372-EZH2 decreased ATP levels and altered mitochondrial gene expression, resulting in mitochondrial dysfunction and reduced OC cell growth. These findings demonstrate that PKA-mediated T372 phosphorylation reduces oncogenic EZH2 activity and reveal a novel role for pT372 in regulating EZH2 in OC and possibly other cancers.	[Ozes, Ali R.; Pulliam, Nick; Nephew, Kenneth P.] Indiana Univ, Mol & Cellular Biochem Dept, Bloomington, IN 47405 USA; [Ozes, Ali R.; Pulliam, Nick; Tang, Jessica; Nephew, Kenneth P.] Indiana Univ, Sch Med Med Sci, Bloomington, IN 47405 USA; [Ertosun, Mustafa G.; Yilmaz, Ozlem; Copuroglu, Ece; Ozes, Osman N.] Akdeniz Univ, Dept Med Biol & Genet, Antalya, Turkey; [Matei, Daniela] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA; [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Akdeniz University; Northwestern University; Feinberg School of Medicine; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Nephew, KP (corresponding author), Indiana Univ, Mol & Cellular Biochem Dept, Bloomington, IN 47405 USA.; Nephew, KP (corresponding author), Indiana Univ, Sch Med Med Sci, Bloomington, IN 47405 USA.; Ozes, ON (corresponding author), Akdeniz Univ, Dept Med Biol & Genet, Antalya, Turkey.; Nephew, KP (corresponding author), Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.; Nephew, KP (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.	oozes@akdeniz.edu.tr; knephew@indiana.edu	Copuroglu, F.Ece/AAG-1925-2020	Matei, Daniela/0000-0003-2169-5035	National Cancer Institute [CA13001, CA182832]; V Foundation for Cancer Research Translational Grant; Walther Cancer Foundation (Indianapolis, IN); Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University); NATIONAL CANCER INSTITUTE [R01CA182832] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); V Foundation for Cancer Research Translational Grant; Walther Cancer Foundation (Indianapolis, IN); Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Fang Fang and Jay Pilrose for assistance with animal studies, Dr. Scott Michaels, Dr. Doug Rusch and Aaron Buechlein (Center for Genomics and Bioinformatics, Indiana University) for RNA-seq data analysis, Dr. Haojie Huang for EZH2-pGEX-4T-1 vectors (University of Minnesota) and Dr. Jian Jian (UC Davis) for PGL2-3 x -SIEGAS STAT3 reporter plasmid. We thank Dr. Heather O'Hagan and Dr. Peter Hollenorst (Medical Sciences, Indiana University School of Medicine) for critically reading the manuscript and offering valuable suggestions. This work was made possible by funding from the National Cancer Institute (Awards CA13001 and CA182832), The V Foundation for Cancer Research Translational Grant, Walther Cancer Foundation (Indianapolis, IN) and the Doane and Eunice Dahl Wright Fellowship (Medical Sciences Program, Indiana University).	Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575; Baba A, 2011, NAT CELL BIOL, V13, P668, DOI 10.1038/ncb2228; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Cardenas H, 2016, ONCOTARGET, V7, P84453, DOI 10.18632/oncotarget.11497; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chen S, 2013, J IMMUNOL, V191, P2614, DOI 10.4049/jimmunol.1203143; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; Copeland RA, 2013, ONCOGENE, V32, P939, DOI 10.1038/onc.2012.552; de Vries NA, 2015, CELL REP, V10, P383, DOI 10.1016/j.celrep.2014.12.028; Djouder N, 2010, EMBO J, V29, P469, DOI 10.1038/emboj.2009.339; Feliciello A, 2005, CELL SIGNAL, V17, P279, DOI 10.1016/j.cellsig.2004.09.009; Garcia-Bermudez J, 2015, CELL REP, V12, P2143, DOI 10.1016/j.celrep.2015.08.052; Garipov A, 2013, MOL CANCER RES, V11, P360, DOI 10.1158/1541-7786.MCR-12-0661; Gibaja V, 2016, ONCOGENE, V35, P558, DOI 10.1038/onc.2015.114; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398; Liu T, 2014, TUMOR BIOL, V35, P7239, DOI 10.1007/s13277-014-1950-9; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Ozes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75; Ozes AR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00966-3; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Papa S, 2012, FEBS LETT, V586, P568, DOI 10.1016/j.febslet.2011.09.019; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95; Wang YN, 2014, CANCER RES, V74, P4922, DOI 10.1158/0008-5472.CAN-14-1022; Wee ZN, 2014, CELL REP, V8, P204, DOI 10.1016/j.celrep.2014.05.045; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamamoto Y, 2016, J PATHOL, V238, P519, DOI 10.1002/path.4649	42	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3589	3600		10.1038/s41388-018-0218-z	http://dx.doi.org/10.1038/s41388-018-0218-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29576612	Green Accepted, Green Submitted			2022-12-17	WOS:000436412500009
J	Stanicka, J; Rieger, L; O'Shea, S; Cox, O; Coleman, M; O'Flanagan, C; Addario, B; McCabe, N; Kennedy, R; O'Connor, R				Stanicka, Joanna; Rieger, Leonie; O'Shea, Sandra; Cox, Orla; Coleman, Michael; O'Flanagan, Ciara; Addario, Barbara; McCabe, Nuala; Kennedy, Richard; O'Connor, Rosemary			FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion	ONCOGENE			English	Article							BREAST-CANCER; CORTACTIN PHOSPHORYLATION; CARCINOMA-CELLS; IGF-1 RECEPTOR; RESISTANCE; PROTEIN; SRC; METASTASIS; EXPRESSION; MIGRATION	IGF-1 receptor (IGF-1R) and integrin cooperative signaling promotes cancer cell survival, proliferation, and motility, but whether this influences cancer progression and therapy responses is largely unknown. Here we investigated the non-receptor tyrosine adhesion kinase FES-related (FER), following its identification as a potential mediator of sensitivity to IGF-1R kinase inhibition in a functional siRNA screen. We found that FER and the IGF-1R co-locate in cells and can be coimmunoprecipitated. Ectopic FER expression strongly enhanced IGF-1R expression and phosphorylation on tyrosines 950 and 1131. FER phosphorylated these sites in an IGF-1R kinase-independent manner and also enhanced IGF-1-mediated phosphorylation of SHC, and activation of either AKT or MAPK-signaling pathways in different cells. The IGF-1R, beta 1 Integrin, FER, and its substrate cortactin were all observed to co-locate in cell adhesion complexes, the disruption of which reduced IGF-1R expression and activity. High FER expression correlates with phosphorylation of SHC in breast cancer cell lines and with a poor prognosis in patient cohorts. FER and SHC phosphorylation and IGF-1R expression could be suppressed with a known anaplastic lymphoma kinase inhibitor (AP26113) that shows high specificity for FER kinase. Overall, we conclude that FER enhances IGF-1R expression, phosphorylation, and signaling to promote cooperative growth and adhesion signaling that may facilitate cancer progression.	[Stanicka, Joanna; Rieger, Leonie; O'Shea, Sandra; Cox, Orla; Coleman, Michael; O'Flanagan, Ciara; Addario, Barbara; O'Connor, Rosemary] Univ Coll Cork, Sch Biochem & Cell Biol, Cell Biol Lab, Cork, Ireland; [McCabe, Nuala; Kennedy, Richard] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [McCabe, Nuala; Kennedy, Richard] Queens Univ Belfast, Almac Diagnost, Belfast, Antrim, North Ireland	University College Cork; Queens University Belfast; Queens University Belfast	O'Connor, R (corresponding author), Univ Coll Cork, Sch Biochem & Cell Biol, Cell Biol Lab, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014; Coleman, Michael/AAM-4725-2021	O'Connor, Rosemary/0000-0002-0687-3422; Coleman, Michael/0000-0002-6914-848X; Rieger, Leonie/0000-0003-3263-801X	Science Foundation Ireland [11/PI/1139]; European Union FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) Program [251480]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); European Union FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) Program	This work was funded by a Science Foundation Ireland Principal Investigator award 11/PI/1139, and the European Union FP7 Marie Curie Industry-Academia Partnerships and Pathways (IAPP) Program 251480 BiomarkerIGF.	Ahn J, 2013, MOL CANCER RES, V11, P952, DOI 10.1158/1541-7786.MCR-13-0003-T; Andersson S, 2009, BIOCHEM BIOPH RES CO, V387, P36, DOI 10.1016/j.bbrc.2009.06.088; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Cao H, 2005, NAT CELL BIOL, V7, P483, DOI 10.1038/ncb1246; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cox OT, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00106; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; Deevi RK, 2014, NEOPLASIA, V16, P422, DOI 10.1016/j.neo.2014.04.006; Fan G, 2014, FASEB J, V28; Farabaugh SM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00059; Goel HL, 2005, CANCER RES, V65, P6692, DOI 10.1158/0008-5472.CAN-04-4315; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Guo CH, 2011, P NATL ACAD SCI USA, V108, P7968, DOI 10.1073/pnas.1105369108; Hellwig S, 2012, CHEM BIOL, V19, P529, DOI 10.1016/j.chembiol.2012.01.020; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Itoh T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000393; Ivanova IA, 2013, ONCOGENE, V32, P5582, DOI 10.1038/onc.2013.277; Ivaska J, 2011, ANNU REV CELL DEV BI, V27, P291, DOI 10.1146/annurev-cellbio-092910-154017; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; King H, 2014, CANCER TREAT REV, V40, P1096, DOI 10.1016/j.ctrv.2014.07.004; Kostler WJ, 2006, J CANCER RES CLIN, V132, P9, DOI 10.1007/s00432-005-0038-8; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Lennartsson J, 2013, J BIOL CHEM, V288, P15736, DOI 10.1074/jbc.M113.476424; Li HM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0576-5; Liu BA, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-27; Malaguarnera R, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00010; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; Min HY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0392-3; Muellner MK, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145664; Muharram G, 2014, DEV CELL, V29, P421, DOI 10.1016/j.devcel.2014.03.024; Niepel M, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004379; O'Flanagan CH, 2016, ONCOTARGET, V7, P56826, DOI 10.18632/oncotarget.10862; Oneyama C, 2016, ONCOGENE, V35, P501, DOI 10.1038/onc.2015.110; Osorio FG, 2016, NAT MED, V22, P91, DOI 10.1038/nm.4013; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sangrar W, 2015, ONCOGENE, V34, P4109, DOI 10.1038/onc.2014.340; Shen MR, 2006, CARCINOGENESIS, V27, P962, DOI 10.1093/carcin/bgi336; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Taliaferro-Smith L, 2015, ONCOTARGET, V6, P4757, DOI 10.18632/oncotarget.3023; van Rossum AGSH, 2005, BREAST CANCER RES, V7, P235, DOI 10.1186/bcr1316; Vistein R, 2014, TRAFFIC, V15, P1195, DOI 10.1111/tra.12202; Voisset E, 2010, LEUKEMIA, V24, P721, DOI 10.1038/leu.2009.301; Wu RF, 2016, MOL CELL BIOL, V36, P2824, DOI 10.1128/MCB.00194-16; Yoneyama T, 2012, MOL BIOL CELL, V23, P771, DOI 10.1091/mbc.E11-06-0517; Zhang S, 2016, CLIN CANCER RES, V22, P5527, DOI 10.1158/1078-0432.CCR-16-0569; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zheng DH, 2010, MOL CARCINOGEN, V49, P200, DOI 10.1002/mc.20590	50	13	14	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3131	3150		10.1038/s41388-017-0113-z	http://dx.doi.org/10.1038/s41388-017-0113-z			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540831	Green Submitted			2022-12-17	WOS:000434641400007
J	Meder, L; Konig, K; Dietlein, F; Macheleidt, I; Florin, A; Ercanoglu, MS; Rommerscheidt-Fuss, U; Koker, M; Schon, G; Odenthal, M; Klein, F; Buttner, R; Schulte, JH; Heukamp, LC; Ullrich, RT				Meder, Lydia; Koenig, Katharina; Dietlein, Felix; Macheleidt, Iris; Florin, Alexandra; Ercanoglu, Meryem S.; Rommerscheidt-Fuss, Ursula; Koker, Mirjam; Schoen, Gisela; Odenthal, Margarete; Klein, Florian; Buettner, Reinhard; Schulte, Johannes H.; Heukamp, Lukas C.; Ullrich, Roland T.			LIN28B enhanced tumorigenesis in an autochthonous KRAS(G12V)-driven lung carcinoma mouse model	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER PATIENTS; K-RAS; MULTIPLE MECHANISMS; CELL-PROLIFERATION; PANCREATIC-CANCER; DOWN-REGULATION; KRAS MUTATIONS; BREAST-CANCER; SELF-RENEWAL	LIN28B is a RNA-binding protein regulating predominantly let-7 microRNAs with essential functions in inflammation, wound healing, embryonic stem cells, and cancer. LIN28B expression is associated with tumor initiation, progression, resistance, and poor outcome in several solid cancers, including lung cancer. However, the functional role of LIN28B, especially in non-small cell lung adenocarcinomas, remains elusive. Here, we investigated the effects of LIN28B expression on lung tumorigenesis using LIN28B transgenic overexpression in an autochthonous KRAS(G12V)-driven mouse model. We found that LIN28B overexpression significantly increased the number of CD44+/CD326+ tumor cells, upregulated VEGF-A and miR-21 and promoted tumor angiogenesis and epithelial-to-mesenchymal transition (EMT) accompanied by enhanced AKT phosphorylation and nuclear translocation of c-MYC. Moreover, LIN28B accelerated tumor initiation and enhanced proliferation which led to a shortened overall survival. In addition, we analyzed lung adenocarcinomas of the Cancer Genome Atlas (TCGA) and found LIN28B expression in 24% of KRAS-mutated cases, which underscore the relevance of our model.	[Meder, Lydia; Koker, Mirjam; Schoen, Gisela; Ullrich, Roland T.] Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany; [Meder, Lydia; Koker, Mirjam; Schoen, Gisela; Odenthal, Margarete; Buettner, Reinhard; Ullrich, Roland T.] Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany; [Koenig, Katharina] Lab Dr Quade & Kollegen GmbH, Aachener Str 338, D-50933 Cologne, Germany; [Dietlein, Felix] Dana Faber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Dietlein, Felix] Broad Inst MIT & Havard, Canc Program, Cambridge, MA 02142 USA; [Macheleidt, Iris; Florin, Alexandra; Rommerscheidt-Fuss, Ursula; Odenthal, Margarete; Buettner, Reinhard] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany; [Ercanoglu, Meryem S.; Klein, Florian] Univ Cologne, Lab Expt Immunol, Inst Virol, Robert Koch Str 21, D-50931 Cologne, Germany; [Buettner, Reinhard] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Kerpener Str 62, D-50937 Cologne, Germany; [Schulte, Johannes H.] Charite Univ Med Berlin, Dept Pediat Oncol Hematol, Augustenburger Pl 1, D-13353 Berlin, Germany; [Schulte, Johannes H.] German Canc Consortium DKTK Berlin, Berlin, Germany; [Schulte, Johannes H.] BIH, Berlin, Germany; [Schulte, Johannes H.] Deutsch Krebsforschungszentrum Heidelberg DKFZ, Heidelberg, Germany; [Heukamp, Lukas C.] New Oncol, Gottfried Hagen Str 20, D-51105 Cologne, Germany; [Heukamp, Lukas C.] Inst Hematopathol Hamburg, Fangdieckstr 75a, Hamburg, Germany	University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Cologne; University of Cologne; University of Cologne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Helmholtz Association; German Cancer Research Center (DKFZ)	Meder, L (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany.; Meder, L (corresponding author), Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany.	lydia.meder@uk-koeln.de	Schulte, Johannes H./V-2474-2018; Heukamp, Lukas/G-9967-2012	Heukamp, Lukas/0000-0002-3388-3482; Schulte, Johannes Hubertus/0000-0003-0671-1201; Meder, Lydia/0000-0002-9547-5812	Deutsche Forschungsgemeinschaft (DFG) [UL379/1-1]; German Research Foundation [SFB832]; Thyssen foundation [10.16.1.028MN]; Nachwuchsforschungsgruppen-NRW [1411ng005]; German ministry of science and education (BMBF) as part of the e:Med initiative [01ZX11307E, 017X1303B]; Center for Molecular Medicine Cologne (CMMC)	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Research Foundation(German Research Foundation (DFG)); Thyssen foundation; Nachwuchsforschungsgruppen-NRW; German ministry of science and education (BMBF) as part of the e:Med initiative; Center for Molecular Medicine Cologne (CMMC)	This work was supported by the Deutsche Forschungsgemeinschaft (DFG) (Grant No.: UL379/1-1 to RTU), by the German Research Foundation (SFB832, Z2 and TP6 to RTU; Z1 and TP5 to LCH and RB), by the Thyssen foundation (Grant No.: 10.16.1.028MN to RTU), by the Nachwuchsforschungsgruppen-NRW (Grant No.: 1411ng005 to RTU), by the German ministry of science and education (BMBF) as part of the e:Med initiative (Grant No.: 01ZX11307E and 017X1303B to JHS) and by the Center for Molecular Medicine Cologne (CMMC) (to RB and MO).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alam M, 2015, MOL CANCER RES, V13, P449, DOI 10.1158/1541-7786.MCR-14-0363; Balzeau J, 2017, FRONT GENET, V8, P1, DOI 10.3389/fgene.2017.00031; Bauml J, 2013, CLIN LUNG CANCER, V14, P581, DOI 10.1016/j.cllc.2013.05.002; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cao J, 2016, MOL MED REP, V13, P75, DOI 10.3892/mmr.2015.4568; Chien CS, 2015, CANCER RES, V75, P2553, DOI 10.1158/0008-5472.CAN-14-2215; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cufii S, 2013, SCI REP-UK, V3, P1, DOI 10.1038/srep02459; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Feng C, 2012, CELL CYCLE, V11, P2486, DOI 10.4161/cc.20893; Fennell DA, 2016, CANCER TREAT REV, V44, P42, DOI 10.1016/j.ctrv.2016.01.003; Hamano R, 2012, BRIT J CANCER, V106, P1415, DOI 10.1038/bjc.2012.90; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Hu HB, 2016, LUNG CANCER, V97, P87, DOI 10.1016/j.lungcan.2016.04.017; Hu Q, 2014, INT J CLIN EXP PATHO, V7, P5083; Kasinski AL, 2012, CANCER RES, V72, P5576, DOI 10.1158/0008-5472.CAN-12-2001; Kent OA, 2013, ONCOGENE, V32, P2576, DOI 10.1038/onc.2012.266; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Konig K, 2015, J THORAC ONCOL, V10, P1049, DOI 10.1097/JTO.0000000000000570; Konig K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057996; Kugel S, 2016, CELL, V165, P1401, DOI 10.1016/j.cell.2016.04.033; Landskroner-Eiger S, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006643; Lee YS, 2016, ONCOGENE, V35, P827, DOI 10.1038/onc.2015.153; Li C, 2016, ONCOTARGET, V7, P66989, DOI 10.18632/oncotarget.11888; Li CG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107276; Li Y, 2014, CANCER LETT, V355, P130, DOI 10.1016/j.canlet.2014.09.007; Liu CH, 2017, INT J ONCOL, V50, P1109, DOI 10.3892/ijo.2017.3876; Manier S, 2017, LEUKEMIA, V31, P853, DOI 10.1038/leu.2016.296; Mellema WW, 2013, J THORAC ONCOL, V8, P1190, DOI 10.1097/JTO.0b013e318298764e; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Morizane R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04578; Nguyen LH, 2014, CANCER CELL, V26, P248, DOI 10.1016/j.ccr.2014.06.018; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Pagliuca A, 2013, ONCOGENE, V32, P4806, DOI 10.1038/onc.2012.495; Powers JT, 2016, NATURE, V535, P246, DOI 10.1038/nature18632; Qiu JL, 2012, CHIN J CANCER, V31, P223, DOI 10.5732/cjc.011.10426; Qu X, 2014, J INVEST DERMATOL, V134, P159, DOI 10.1038/jid.2013.281; Ragusa M, 2014, AM J CLIN ONCOL-CANC, V37, P343, DOI 10.1097/COC.0b013e31827a7e7a; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sato H, 2017, SCI REP-UK, V7, DOI 10.1038/srep40847; Shao YB, 2015, AM J CANCER RES, V5, P2643; Sonobe M, 2012, ANN SURG ONCOL, V19, pS347, DOI 10.1245/s10434-011-1799-8; Stahlhut C, 2015, CELL CYCLE, V14, P2171, DOI 10.1080/15384101.2014.1003008; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang TZ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0402-5; Watanabe S, 2009, AM J PATHOL, V174, P854, DOI 10.2353/ajpath.2009.080523; Wefers AK, 2017, CEREBELLUM, V16, P122, DOI 10.1007/s12311-016-0774-0; Wilbert ML, 2012, MOL CELL, V48, P195, DOI 10.1016/j.molcel.2012.08.004; Wu TF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083869; Wu ZH, 2016, TUMOR BIOL, V37, P7245, DOI 10.1007/s13277-015-4604-7; Yu YJ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0372-7; Zhang J, 2016, CELL STEM CELL, V19, P66, DOI 10.1016/j.stem.2016.05.009; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050; Zhang Z, 2017, CANCER GENE THER, V24, P83, DOI 10.1038/cgt.2017.1; Zhou JB, 2017, MOL CANCER RES, V15, P294, DOI 10.1158/1541-7786.MCR-16-0275-T; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033; Zipeto MA, 2016, CELL STEM CELL, V19, P177, DOI 10.1016/j.stem.2016.05.004	60	13	13	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2746	2756		10.1038/s41388-018-0158-7	http://dx.doi.org/10.1038/s41388-018-0158-7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29503447				2022-12-17	WOS:000432545100010
J	Wang, H; Bei, L; Shah, CA; Huang, WQ; Platanias, LC; Eklund, EA				Wang, Hao; Bei, Ling; Shah, Chirag A.; Huang, Weiqi; Platanias, Leonidas C.; Eklund, Elizabeth A.			The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; BONE-MARROW-CELLS; GENE-EXPRESSION; ACTIVATES TRANSCRIPTION; ENCODING GP91(PHOX); PROGENITOR CELLS; HOX EXPRESSION; DNA-BINDING; IN-VITRO; DIFFERENTIATION	Chromosomal translocations involving the MLL1 gene characterize a poor prognosis subset of acute myeloid leukemia (AML), referred to as 11q23-AML. Transcription of the HOXA9 and HOXA10 genes is enhanced in hematopoietic stem and progenitor cells in these leukemias. We previously found the ARIH2 gene was repressed by HoxA9 in myeloid progenitors, but activated by HoxA10 during granulopoiesis. ARIH2 encodes the Triad1 protein, an anti-proliferative E3 ubiquitin ligase. In the current study, we investigate the role of Triad1 in leukemogenesis induced by an MLL1 fusion protein (Mll-Ell). We found Mll-Ell increased expression of HoxA9, HoxA10, and Triad1 because HoxA9 represses only one of two ARIH2 cis elements that are activated by HoxA10. Although Triad1 antagonized the generally pro-proliferative effects of the Mll-Ell oncoprotein, we found blocking HoxA9 and HoxA10 phosphorylation shifted the balance to ARIH2 repression in Mll-Ell(+) cells. We investigated the significance of these in vitro results in a murine bone marrow transplant model. We found Triad1 knockdown significantly shortened the latency to development of AML in mice transplanted with Mll-Ell-transduced bone marrow. And, Triad1 expression fell during the prolonged AML latency period in mice transplanted with bone marrow expressing Mll-Ell alone. Our studies identify Triad1 as a leukemia suppressor in 11q23-AML. This suggests defining relevant Triad1 substrates may indicate novel therapeutic targets in this disease.	[Wang, Hao; Bei, Ling; Shah, Chirag A.; Huang, Weiqi; Platanias, Leonidas C.; Eklund, Elizabeth A.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Bei, Ling; Shah, Chirag A.; Platanias, Leonidas C.; Eklund, Elizabeth A.] Jesse Brown Vet Adm Med Ctr, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Eklund, EA (corresponding author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.; Eklund, EA (corresponding author), Jesse Brown Vet Adm Med Ctr, Chicago, IL 60612 USA.	e-eklund@northwestern.edu		Wang, Hao/0000-0003-2131-0377	NIH [HL87717]; Robert H. Lurie Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R01CA195642] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087717] Funding Source: NIH RePORTER; Veterans Affairs [I01BX004635] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert H. Lurie Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)	NIH grant HL87717, a VA Merit Review, the Mander Foundation, and the Director's Research Fund of the Robert H. Lurie Comprehensive Cancer Center (to EAE).	ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Bei L, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.49; Bei L, 2007, J BIOL CHEM, V282, P16846, DOI 10.1074/jbc.M609744200; Bei L, 2011, J BIOL CHEM, V286, P19047, DOI 10.1074/jbc.M110.213983; Bjornsson JM, 2001, BLOOD, V98, P3301, DOI 10.1182/blood.V98.12.3301; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Compendia Biosciences, ONC 4 4; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Eklund E. A., 2011, Critical Reviews in Oncogenesis, V16, P65; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Eklund EA, 2000, J BIOL CHEM, V39, P36878; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; LARRICK JW, 1980, J IMMUNOL, V125, P6; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; Li ZJ, 2009, CANCER RES, V69, P1109, DOI 10.1158/0008-5472.CAN-08-3381; Lin AE, 2013, NAT IMMUNOL, V14, P27, DOI 10.1038/ni.2478; Lindsey S, 2005, J IMMUNOL, V175, P5269, DOI 10.4049/jimmunol.175.8.5269; Lindsey S, 2007, J BIOL CHEM, V282, P2237, DOI 10.1074/jbc.M608642200; Marteijn JAF, 2005, BLOOD, V106, P4114, DOI 10.1182/blood-2005-04-1450; Nabinger SC, 2013, LEUKEMIA, V27, P398, DOI 10.1038/leu.2012.308; Oberley MJ, 2003, METHOD ENZYMOL, V371, P577; Roche J, 2004, LEUKEMIA, V18, P1059, DOI 10.1038/sj.leu.2403366; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shah CA, 2013, J BIOL CHEM, V288, P32490, DOI 10.1074/jbc.M113.496109; Shah CA, 2012, J BIOL CHEM, V287, P18230, DOI 10.1074/jbc.M111.328401; Shah CA, 2011, J BIOL CHEM, V286, P3161, DOI 10.1074/jbc.M110.183251; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Van der Reijden BA, 1999, PROTEIN SCI, V8, P1557, DOI 10.1110/ps.8.7.1557; Wang H, 2007, J BIOL CHEM, V282, P16164, DOI 10.1074/jbc.M610556200; Wang H, 2015, J IMMUNOL, V194, P5375, DOI 10.4049/jimmunol.1401909; Wang H, 2011, J BIOL CHEM, V286, P16832, DOI 10.1074/jbc.M110.213975; Wang H, 2009, J BIOL CHEM, V284, P2549, DOI 10.1074/jbc.M804704200; Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894	38	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2532	2544		10.1038/s41388-018-0131-5	http://dx.doi.org/10.1038/s41388-018-0131-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29459712	Green Published, hybrid			2022-12-17	WOS:000431873400006
J	Lahusen, TJ; Kim, SJ; Miao, K; Huang, ZB; Xu, XL; Deng, CX				Lahusen, Tyler J.; Kim, Seung-Jin; Miao, Kai; Huang, Zebin; Xu, Xiaoling; Deng, Chu-Xia			BRCA1 function in the intra-S checkpoint is activated by acetylation via a pCAF/SIRT1 axis	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-CYCLE; HISTONE ACETYLTRANSFERASES; TRANSCRIPTIONAL REGULATION; PHASE CHECKPOINT; TUMOR-SUPPRESSOR; BREAST-CANCER; SIRT1; CHK1; PHOSPHORYLATION	Breast cancer associated gene 1 (BRCA1) function has been shown to be regulated by phosphorylation but the role of acetylation has not been determined. Therefore, we tested whether BRCA1 can be acetylated by the acetyltransferases P300/CBP-associated factor (pCAF), GCN5, and p300. p300 exhibited the highest level of BRCA1 acetylation; however, there was also a decrease in the total level of BRCA1. Therefore, we focused on pCAF and GCN5 because they both acetylated BRCA1 without affecting BRCA1 expression. Further analysis indicated that the acetylated form of BRCA1 is deacetylated by wild-type (WT) SIRT1, but not deacetylase mutant SIRT1, suggesting that SIRT1 is a specific deacetylase of BRCA1. We demonstrated that lysine 830 of BRCA1 is a preferential acetylation site by pCAF and tested its function in embryonic stem (ES) cells by changing lysine 830 to arginine using a transcription activator-like effector nuclease (TALEN) system. After exposure to DNA damage-inducing UV radiation, the viability of BRCA1 K830R mutant cells is greater than the WT ES cells. Further analysis using additional cell lines indicated that the BRCA1 K830R mutation impairs the intra-S checkpoint. Also, checkpoint kinase 1 (CHK1) phosphorylation was less in K830R cells as compared with WT cells after UV exposure. These data suggest that acetylation of BRCA1 on lysine 830 activates BRCA1 function at the intra-S checkpoint after DNA damage.	[Lahusen, Tyler J.; Kim, Seung-Jin; Deng, Chu-Xia] NIDDK, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA; [Miao, Kai; Huang, Zebin; Xu, Xiaoling; Deng, Chu-Xia] Univ Macau, Fac Hlth Sci, Macau, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Macau	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.; Deng, CX (corresponding author), Univ Macau, Fac Hlth Sci, Macau, Peoples R China.	cxdeng@umac.mo			Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA; Chair Professor Grant by University of Macau, Macau SAR, China [CPG2017-00026-FHS]; Macao Science and Technology Development Fund grants [065/2015/A2, 094/2015/A3]	Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA; Chair Professor Grant by University of Macau, Macau SAR, China; Macao Science and Technology Development Fund grants	We thank Dr. Zhen Xiao for BRCA1 acetylation analysis and the members of the Deng laboratory for helpful discussion. This work was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA, and by the Chair Professor Grant (CPG2017-00026-FHS), granted to C.D. by University of Macau, Macau SAR, China; Macao Science and Technology Development Fund grants (065/2015/A2 and 094/2015/A3), granted to C.D.	Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Di LJ, 2010, NAT STRUCT MOL BIOL, V17, P1406, DOI 10.1038/nsmb.1941; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Han MK, 2008, CELL STEM CELL, V2, P241, DOI 10.1016/j.stem.2008.01.002; Kim HB, 2015, INT J BIOL SCI, V11, P923, DOI 10.7150/ijbs.10896; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Luo JY, 2016, INT J BIOL SCI, V12, P1500, DOI 10.7150/ijbs.16176; Masuda T, 2016, INT J BIOL SCI, V12, P133, DOI 10.7150/ijbs.14242; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nielsen FC, 2016, NAT REV CANCER, V16, P599, DOI 10.1038/nrc.2016.72; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park EY, 2016, INT J BIOL SCI, V12, P1555, DOI 10.7150/ijbs.13833; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wang RH, 2014, INT J BIOL SCI, V10, P1193, DOI 10.7150/ijbs.11066; Warmerdam DO, 2013, J CELL SCI, V126, P1923, DOI 10.1242/jcs.118265; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zheng HP, 2017, SCI REP-UK, V7, DOI 10.1038/srep43517	30	13	13	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2343	2350		10.1038/s41388-018-0127-1	http://dx.doi.org/10.1038/s41388-018-0127-1			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29440709				2022-12-17	WOS:000431100200010
J	Szczepny, A; Carey, K; McKenzie, L; Jayasekara, WSN; Rossello, F; Gonzalez-Rajal, A; Mccaw, AS; Popovski, D; Wang, D; Sadler, AJ; Mahar, A; Russell, PA; Wright, G; McCloy, RA; Garama, DJ; Gough, DJ; Baylin, SB; Burgess, A; Cain, JE; Watkins, DN				Szczepny, Anette; Carey, Kirstyn; McKenzie, Lisa; Jayasekara, W. Samantha N.; Rossello, Fernando; Gonzalez-Rajal, Alvaro; Mccaw, Andrew S.; Popovski, Dean; Wang, Die; Sadler, Anthony J.; Mahar, Annabelle; Russell, Prudence A.; Wright, Gavin; McCloy, Rachael A.; Garama, Daniel J.; Gough, Daniel J.; Baylin, Stephen B.; Burgess, Andrew; Cain, Jason E.; Watkins, D. Neil			The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; DIRECT TARGET GENE; CANCER 1 HIC1; DNA-DAMAGE; BREAST-CANCER; LUNG ADENOCARCINOMA; DRIVES PROGRESSION; MI-2/NURD COMPLEX; P53; INSTABILITY	Hypermethylated-in-Cancer 1 (Hic1) is a tumor suppressor gene frequently inactivated by epigenetic silencing and loss-of-heterozygosity in a broad range of cancers. Loss of HIC1, a sequence-specific zinc finger transcriptional repressor, results in deregulation of genes that promote a malignant phenotype in a lineage-specific manner. In particular, upregulation of the HIC1 target gene SIRT1, a histone deacetylase, can promote tumor growth by inactivating TP53. An alternate line of evidence suggests that HIC1 can promote the repair of DNA double strand breaks through an interaction with MTA1, a component of the nucleosome remodeling and deacetylase (NuRD) complex. Using a conditional knockout mouse model of tumor initiation, we now show that inactivation of Hic1 results in cell cycle arrest, premature senescence, chromosomal instability and spontaneous transformation in vitro. This phenocopies the effects of deleting Brca1, a component of the homologous recombination DNA repair pathway, in mouse embryonic fibroblasts. These effects did not appear to be mediated by deregulation of Hic1 target gene expression or loss of Tp53 function, and rather support a role for Hic1 in maintaining genome integrity during sustained replicative stress. Loss of Hic1 function also cooperated with activation of oncogenic KRas in the adult airway epithelium of mice, resulting in the formation of highly pleomorphic adenocarcinomas with a micropapillary phenotype in vivo. These results suggest that loss of Hic1 expression in the early stages of tumor formation may contribute to malignant transformation through the acquisition of chromosomal instability.	[Szczepny, Anette; Carey, Kirstyn; McKenzie, Lisa; Jayasekara, W. Samantha N.; Mccaw, Andrew S.; Popovski, Dean; Wang, Die; Sadler, Anthony J.; Garama, Daniel J.; Gough, Daniel J.; Cain, Jason E.] Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia; [Szczepny, Anette; Carey, Kirstyn; McKenzie, Lisa; Popovski, Dean; Wang, Die; Sadler, Anthony J.; Garama, Daniel J.; Gough, Daniel J.] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Mol & Translat Sci, Clayton, Vic, Australia; [Rossello, Fernando] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Rossello, Fernando] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic, Australia; [Gonzalez-Rajal, Alvaro; Burgess, Andrew; Watkins, D. Neil] Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia; [Mahar, Annabelle] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Russell, Prudence A.] St Vincents Hosp Melbourne, Dept Pathol, Fitzroy, Vic, Australia; [Wright, Gavin] St Vincents Hosp Melbourne, Dept Surg, Fitzroy, Vic, Australia; [Baylin, Stephen B.] Johns Hopkins, Sidney Kimmel Canc Ctr, Baltimore, MD USA; [Watkins, D. Neil] UNSW Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Watkins, D. Neil] St Vincents Hosp, Dept Thorac Med, Sydney, NSW, Australia	Hudson Institute of Medical Research; Monash University; Monash University; Australian Regenerative Medicine Institute; Monash University; Garvan Institute of Medical Research; University of Sydney; St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; Johns Hopkins University; University of New South Wales Sydney; St Vincents Hospital Sydney	Cain, JE (corresponding author), Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia.; Watkins, DN (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia.; Watkins, DN (corresponding author), UNSW Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia.; Watkins, DN (corresponding author), St Vincents Hosp, Dept Thorac Med, Sydney, NSW, Australia.	jason.cain@hudson.org.au; n.watkins@garvan.org.au	Rossello, Fernando/B-1208-2015; Gonzalez-Rajal, Alvaro/ABA-6874-2020; sadler, anthony/ABA-5572-2020; Burgess, Andrew/H-3339-2019; Wang, Die/H-8860-2017	Rossello, Fernando/0000-0003-3885-8777; Gonzalez-Rajal, Alvaro/0000-0002-9230-0339; sadler, anthony/0000-0002-7970-8030; Burgess, Andrew/0000-0003-4536-9226; Wang, Die/0000-0001-7628-7309; Gough, Daniel/0000-0001-6479-1735; Gough, Daniel/0000-0001-5725-8668; McKenzie, Lisa/0000-0002-1432-6496; Carey, Kirstyn/0000-0003-4743-2700; McCloy, Rachael/0000-0001-7791-4044	National Health and Medical Research Council (NHMRC) of Australia [GNT10838550]; Victorian Cancer Agency [TS10-01]; National Institutes of Health [NCI-RO1 NS054085]; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC [GNT1063914]; Cancer Institute NSW Fellowship [10/FRL/3-02]; Patricia Helen Guest Fellowship; National Health and Medical Research Council of Australia [GNT1063914, GNT1083855]; National Breast Cancer Foundation [IIRS-18-103] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054085] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Petre Foundation; Victorian Government's Operational Infrastructure Support Program; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW Fellowship; Patricia Helen Guest Fellowship; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (Project Grant GNT10838550, The Victorian Cancer Agency (TS10-01), The National Institutes of Health (NCI-RO1 NS054085), The Petre Foundation, and the Victorian Government's Operational Infrastructure Support Program. Dr Gough is supported by an NHMRC Career Development Fellowship (GNT1063914). Dr Burgess is supported by Cancer Institute NSW Fellowship (10/FRL/3-02) and a Patricia Helen Guest Fellowship. The contents of this manuscript are solely the responsibility of the participating institutions and individual authors, and do not reflect the views of these funding agencies. We thank Dr Dominique LePrince for the gift of the Hic1-FLAG expression vector. National Health and Medical Research Council of Australia (GNT1083855): J.E.C., D.N.W.; (GNT1063914): D.J.G. National Institutes of Health (NINDS RO1 NS054085): D.N.W., S.B.B. The Petre Foundation: D.N.W. Cancer Institute of NSW Fellowship (10/FRL/3-02) and the Patricia Helen Guest Fellowship: A.B.	Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x; Badea TC, 2003, J NEUROSCI, V23, P2314; Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Briggs KJ, 2008, CANCER RES, V68, P8654, DOI 10.1158/0008-5472.CAN-08-1904; Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908; Britschgi C, 2008, BRIT J HAEMATOL, V141, P179, DOI 10.1111/j.1365-2141.2008.06992.x; Cain Jason E., 2013, Sarcoma, V2013, P608964, DOI 10.1155/2013/608964; Caldon CE, 2013, CELL CYCLE, V12, P606, DOI 10.4161/cc.23512; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Cheng GC, 2014, CANCER RES, V74, P862, DOI 10.1158/0008-5472.CAN-13-2420; Cohen SM, 2010, NUCLEIC ACIDS RES, V38, P6906, DOI 10.1093/nar/gkq559; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Dehennaut V, 2013, J BIOL CHEM, V288, P10254, DOI 10.1074/jbc.M112.421610; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Evers B, 2006, ONCOGENE, V25, P5885, DOI 10.1038/sj.onc.1209871; Foveau B, 2012, J BIOL CHEM, V287, P5366, DOI 10.1074/jbc.M111.329466; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Ganem NJ, 2012, J CELL BIOL, V199, P871, DOI 10.1083/jcb.201210040; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Guarente L, 2011, COLD SH Q B, V76, P81, DOI 10.1101/sqb.2011.76.010629; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Heng HH, 2013, CANCER METAST REV, V32, P325, DOI 10.1007/s10555-013-9427-7; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janeckova L, 2015, MOL CANCER RES, V13, P1139, DOI 10.1158/1541-7786.MCR-15-0033; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Leibiger C, 2013, J HISTOCHEM CYTOCHEM, V61, P306, DOI 10.1369/0022155413476868; Li DQ, 2010, CELL CYCLE, V9, P2071, DOI 10.4161/cc.9.11.11735; Li P, 2015, ONCOTARGET, V6, P38151, DOI 10.18632/oncotarget.5832; Lin YM, 2013, CELL CYCLE, V12, P2266, DOI 10.4161/cc.25365; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Melki JR, 1999, CANCER RES, V59, P3730; Mermoud JE, 2011, CELL CYCLE, V10, P4017, DOI 10.4161/cc.10.23.18558; Mohammad HP, 2011, ONCOGENE, V30, P2659, DOI 10.1038/onc.2010.633; Nagy A, 2008, CSH PROTOC, P2014; Paget S, 2017, ONCOTARGET, V8, P2916, DOI 10.18632/oncotarget.13807; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Pinte S, 2004, ONCOGENE, V23, P4023, DOI 10.1038/sj.onc.1207504; Prakash R, 2015, COLD SPRING HARB PER, V7; Rood BR, 2002, CANCER RES, V62, P3794; Russell PA, 2013, J THORAC ONCOL, V8, P461, DOI 10.1097/JTO.0b013e3182828fb8; Sims JK, 2011, MOL BIOL CELL, V22, P3094, DOI 10.1091/mbc.E11-03-0258; Stephen JK, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0005-3; Stevens JB, 2013, CANCER METAST REV, V32, P391, DOI 10.1007/s10555-013-9428-6; Sun Hong, 2007, V383, P303, DOI 10.1007/978-1-59745-335-6_19; Szczepny A, 2017, ONCOGENE, V23, P2314; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Thomas A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6282; Tseng RC, 2009, NEOPLASIA, V11, P763, DOI 10.1593/neo.09470; Ung M, 2016, CLIN LUNG CANCER, V17, P391, DOI 10.1016/j.cllc.2016.03.001; Valenta T, 2006, EMBO J, V25, P2326, DOI 10.1038/sj.emboj.7601147; Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350; Van Rechem C, 2009, BIOCHEM BIOPH RES CO, V385, P586, DOI 10.1016/j.bbrc.2009.05.115; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wallace MD, 2014, ONCOGENE, V33, P3688, DOI 10.1038/onc.2013.339; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12	71	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1939	1948		10.1038/s41388-017-0022-1	http://dx.doi.org/10.1038/s41388-017-0022-1			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29367758	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000429303300010
J	Idoux-Gillet, Y; Nassour, M; Lakis, E; Bonini, F; Theillet, C; Du Manoir, S; Savagner, P				Idoux-Gillet, Y.; Nassour, M.; Lakis, E.; Bonini, F.; Theillet, C.; Du Manoir, S.; Savagner, P.			Slug/Pcad pathway controls epithelial cell dynamics in mammary gland and breast carcinoma	ONCOGENE			English	Article							CADHERIN ADHESION MOLECULES; TRANSCRIPTION FACTOR SLUG; PANCREATIC-CANCER CELLS; REPRESSES E-CADHERIN; RHO-FAMILY GTPASES; P-CADHERIN; STEM-CELL; MESENCHYMAL TRANSITIONS; PROMOTES MOTILITY; GENE-EXPRESSION	Mammary gland morphogenesis results from the coordination of proliferation, cohort migration, apoptosis and stem/progenitor cell dynamics. We showed earlier that the transcription repressor Slug is involved in these functions during mammary tubulogenesis. Slug is expressed by a subpopulation of basal epithelial cells, co-expressed with P-cadherin (Pcad). Slug-knockout mammary glands showed excessive branching, similarly to Pcad-knockout. Here, we found that Slug unexpectedly binds and activates Pcad promoter through E-boxes, inducing Pcad expression. We determined that Pcad can mediate several functions of Slug: Pcad promoted clonal mammosphere growth, basal epithelial differentiation, cell-cell dissociation and cell migration, rescuing Slug depletion. Pcad also promoted cell migration in isolated cells, in association with Src activation, focal adhesion reorganization and cell polarization. Pcad, similarly to Slug, was required for in vitro 3D tubulogenesis. Therefore, Pcad appears to be responsible for epithelial-mesenchymal transition-linked plasticity in mammary epithelial cells. In addition, we found that genes from the Slug/Pcad pathway components were co-expressed and specifically correlated in human breast carcinomas subtypes, carrying pathophysiological significance.	[Idoux-Gillet, Y.; Nassour, M.; Lakis, E.; Bonini, F.; Theillet, C.; Du Manoir, S.; Savagner, P.] Univ Montpellier, Inst Reg Canc Montpellier ICM, IRCM, Inserm,U1194, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Savagner, P (corresponding author), Univ Montpellier, Inst Rech Cancerol Montpellier, Inst Reg Canc Montpellier ICM, F-34298 Montpellier 5, France.	Pierre.Savagner@icm.unicancer.fr	Idoux-Gillet, Ysia/ABH-3112-2020; du manoir, stan p/O-8677-2017; Theillet, Charles/O-7634-2018; Savagner, Pierre/AAD-9357-2020	du manoir, stan p/0000-0002-2200-2651; Lakis, Emile/0000-0001-8629-1862; Savagner, Pierre/0000-0002-8287-2229; Theillet, Charles/0000-0001-5555-2759; Idoux-Gillet, Ysia/0000-0002-0436-1968	Fondation de France [E 2009 006685]; Ligue Nationale contre le Cancer; Ligue Regionale contre le Cancer (Languedoc-Roussillon and Ardeche); Aide a la Recherche en Partenariat avec Entreprises (ARPE-Languedoc-Roussillon); Ligue Regionale (Ardeche); Nationale contre le Cancer for Y Idoux-Gillet and Association pour la Recherche sur le Cancer for M Nassour	Fondation de France(Fondation de France); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Ligue Regionale contre le Cancer (Languedoc-Roussillon and Ardeche); Aide a la Recherche en Partenariat avec Entreprises (ARPE-Languedoc-Roussillon); Ligue Regionale (Ardeche); Nationale contre le Cancer for Y Idoux-Gillet and Association pour la Recherche sur le Cancer for M Nassour	Financial support was provided by the Fondation de France (no. E 2009 006685), the Ligue Nationale contre le Cancer, the Ligue Regionale contre le Cancer (Languedoc-Roussillon and Ardeche) and Aide a la Recherche en Partenariat avec Entreprises (ARPE-Languedoc-Roussillon). In addition, the authors gratefully acknowledge support from the Ligue Regionale (Ardeche) and Nationale contre le Cancer for Y Idoux-Gillet and Association pour la Recherche sur le Cancer for M Nassour. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We are grateful to L Larue for plasmid vector Ecad, Professor M Takeichi for Pcad vector, Marisa M Faraldo and Marie-Ange Deugnier for Luciferase gene reporter and constructive discussions.	Albergaria A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055749; Albergaria A, 2011, INT J DEV BIOL, V55, P811, DOI 10.1387/ijdb.113382aa; Albergaria A, 2010, HUM MOL GENET, V19, P2554, DOI 10.1093/hmg/ddq134; Annicotte JS, 2003, MOL CELL BIOL, V23, P6713, DOI 10.1128/MCB.23.19.6713-6724.2003; Arnoux V, 2008, MOL BIOL CELL, V19, P4738, DOI 10.1091/mbc.E07-10-1078; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Bernardes N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069023; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; Deugnier MA, 2006, DEV BIOL, V293, P414, DOI 10.1016/j.ydbio.2006.02.007; Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Faraldo MM, 2007, FEBS LETT, V581, P831, DOI 10.1016/j.febslet.2007.01.053; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hajra KM, 2002, CANCER RES, V62, P1613; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HIRAI Y, 1989, DEVELOPMENT, V105, P271; Nguyen-Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109; Ko SY, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-170; Kumper S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011801; Kurley SJ, 2012, DEVELOPMENT, V139, P1754, DOI 10.1242/dev.072769; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; MEDINA D, 1986, J NATL CANCER I, V76, P1143; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nassour M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053498; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; Onodera T, 2010, SCIENCE, V329, P562, DOI 10.1126/science.1191880; Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704; Paredes J, 2012, BBA-REV CANCER, V1826, P297, DOI 10.1016/j.bbcan.2012.05.002; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Plutoni C, 2016, J CELL BIOL, V212, P199, DOI 10.1083/jcb.201505105; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025; Rakshit S, 2012, P NATL ACAD SCI USA, V109, P18815, DOI 10.1073/pnas.1208349109; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Rembold M, 2014, GENE DEV, V28, P167, DOI 10.1101/gad.230953.113; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Ribeiro AS, 2010, ONCOGENE, V29, P392, DOI 10.1038/onc.2009.338; Ribeiro AS, 2013, J PATHOL, V229, P705, DOI 10.1002/path.4143; Sarrio D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-74; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2015, CURR TOP DEV BIOL, V112, P273, DOI 10.1016/bs.ctdb.2014.11.021; Shields MA, 2012, J BIOL CHEM, V287, P6218, DOI 10.1074/jbc.M111.308940; Shimomura Y, 2008, DEVELOPMENT, V135, P743, DOI 10.1242/dev.006718; Stefansson IM, 2004, J CLIN ONCOL, V22, P1242, DOI 10.1200/JCO.2004.09.034; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; TanakaMatakatsu M, 1996, DEVELOPMENT, V122, P3697; Tang Y, 2016, NAT CELL BIOL, V18, P917, DOI 10.1038/ncb3394; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Thuault S, 2013, ONCOGENE, V32, P1876, DOI 10.1038/onc.2012.217; Turashvili G, 2011, MODERN PATHOL, V24, P64, DOI 10.1038/modpathol.2010.189; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Uygur B, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-139; Vieira AF, 2014, ONCOTARGET, V5, P679, DOI 10.18632/oncotarget.1459; Vieira AF, 2012, STEM CELLS, V30, P854, DOI 10.1002/stem.1075; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897	68	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2018	37	5					578	588		10.1038/onc.2017.355	http://dx.doi.org/10.1038/onc.2017.355			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FU4GT	28991231				2022-12-17	WOS:000423812200004
J	Ferrara, M; Sessa, G; Fiore, M; Bernard, F; Asteriti, IA; Cundari, E; Colotti, G; Ferla, S; Desideri, M; Buglioni, S; Trisciuoglio, D; Del Bufalo, D; Brancale, A; Degrassi, F				Ferrara, M.; Sessa, G.; Fiore, M.; Bernard, F.; Asteriti, I. A.; Cundari, E.; Colotti, G.; Ferla, S.; Desideri, M.; Buglioni, S.; Trisciuoglio, D.; Del Bufalo, D.; Brancale, A.; Degrassi, F.			Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization	ONCOGENE			English	Article							NDC80 COMPLEX; BINDING-SITE; SPINDLE; HEC1; ATTACHMENT; DYNAMICS; INSTABILITY; CATASTROPHE; ANEUPLOIDY; STABILITY	Highly expressed in cancer protein 1 (Hec1) is a subunit of the kinetochore (KT)-associated Ndc80 complex, which ensures proper segregation of sister chromatids at mitosis by mediating the interaction between KTs and microtubules (MTs). HEC1 mRNA and protein are highly expressed in many malignancies as part of a signature of chromosome instability. These properties render Hec1 a promising molecular target for developing therapeutic drugs that exert their anticancer activities by producing massive chromosome aneuploidy. A virtual screening study aimed at identifying small molecules able to bind at the Hec1-MT interaction domain identified one positive hit compound and two analogs of the hit with high cytotoxic, pro-apoptotic and anti-mitotic activities. The most cytotoxic analog (SM15) was shown to produce chromosome segregation defects in cancer cells by inhibiting the correction of erroneous KT-MT interactions. Live cell imaging of treated cells demonstrated that mitotic arrest and segregation abnormalities lead to cell death through mitotic catastrophe and that cell death occurred also from interphase. Importantly, SM15 was shown to be more effective in inducing apoptotic cell death in cancer cells as compared to normal ones and effectively reduced tumor growth in a mouse xenograft model. Mechanistically, cold-induced MT depolymerization experiments demonstrated a hyper-stabilization of both mitotic and interphase MTs. Molecular dynamics simulations corroborate this finding by showing that SM15 can bind the MT surface independently from Hec1 and acts as a stabilizer of both MTs and KT-MT interactions. Overall, our studies represent a clear proof of principle that MT-Hec1-interacting compounds may represent novel powerful anticancer agents.	[Ferrara, M.; Sessa, G.; Fiore, M.; Bernard, F.; Asteriti, I. A.; Cundari, E.; Colotti, G.; Trisciuoglio, D.; Degrassi, F.] CNR, Inst Mol Biol & Pathol, Natl Res Council, Via Apuli 4, I-00185 Rome, Italy; [Ferla, S.; Brancale, A.] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Redwood Bldg,King Edward 7 Ave, Cardiff CF10 3XF, S Glam, Wales; [Desideri, M.; Buglioni, S.; Trisciuoglio, D.; Del Bufalo, D.] Regina Elena Inst Canc Res, Adv Diagnost & Technol Innovat Dept, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Cardiff University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Degrassi, F (corresponding author), CNR, Inst Mol Biol & Pathol, Natl Res Council, Via Apuli 4, I-00185 Rome, Italy.; Brancale, A (corresponding author), Cardiff Univ, Sch Pharm & Pharmaceut Sci, Redwood Bldg,King Edward 7 Ave, Cardiff CF10 3XF, S Glam, Wales.	brancalea@cf.ac.uk; francesca.degrassi@uniroma1.it	Colotti, Gianni/D-2015-2010; Colotti, Gianni/AAG-4918-2019; Del Bufalo, Donatella/K-8673-2016; Brancale, Andrea/N-9445-2014; trisciuoglio, daniela/AAL-4002-2021; Del Bufalo, Donatella/AAC-1594-2021; Ferla, Salvatore/F-7976-2016	Colotti, Gianni/0000-0002-9913-0635; Del Bufalo, Donatella/0000-0002-3148-6096; Brancale, Andrea/0000-0002-9728-3419; Del Bufalo, Donatella/0000-0002-3148-6096; buglioni, simonetta/0000-0002-5066-1523; Ferla, Salvatore/0000-0002-5918-9237	Life Science Research Net-work Wales through the Welsh Government's Ser Cymru program [NRNPGSep14008]; Italian Association for Cancer Research [IG 18560]; FIRC fellowship [18313]	Life Science Research Net-work Wales through the Welsh Government's Ser Cymru program; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); FIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	Live cell imaging experiments were performed at the Nikon Reference Centre, IBPM CNR. The authors thank G Guarguaglini and P Lavia for advice and support with live cell analysis, L Lanzetti, W Malorni and C Rinaldo for cell lines and reagents. AB acknowledges the support of the Life Science Research Net-work Wales grant no. NRNPGSep14008, an initiative funded through the Welsh Government's Ser Cymru program. Work in the laboratory of DDB is supported by grants from the Italian Association for Cancer Research (IG 18560). IAA is supported by a FIRC fellowship (18313).	Alushin GM, 2010, NATURE, V467, P805, DOI 10.1038/nature09423; [Anonymous], 2016, SCHROD REL 2016 1 MA; [Anonymous], 2015, MOL OP ENV MOE 2015; Avdoshina V, 2016, J NEUROCHEM, V137, P287, DOI 10.1111/jnc.13557; Bakhoum SF, 2012, J CLIN INVEST, V122, P1138, DOI 10.1172/JCI59954; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Ciferri C, 2008, CELL, V133, P427, DOI 10.1016/j.cell.2008.03.020; Cimini D, 2005, TRENDS CELL BIOL, V15, P442, DOI 10.1016/j.tcb.2005.06.008; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2012, CURR OPIN CELL BIOL, V24, P48, DOI 10.1016/j.ceb.2011.11.003; Ferretti C, 2010, CELL CYCLE, V9, P4174, DOI 10.4161/cc.9.20.13457; Galimberti F, 2010, CLIN CANCER RES, V16, P109, DOI 10.1158/1078-0432.CCR-09-2151; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Hayama S, 2006, CANCER RES, V66, P10339, DOI 10.1158/0008-5472.CAN-06-2137; Janssen A, 2013, ONCOGENE, V32, P4459, DOI 10.1038/onc.2012.576; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kaneko N, 2009, BIOCHEM BIOPH RES CO, V390, P1235, DOI 10.1016/j.bbrc.2009.10.127; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; Magnani M, 2009, FEBS J, V276, P2701, DOI 10.1111/j.1742-4658.2009.06994.x; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Mattiuzzo M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016307; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; Musacchio A, 2015, CURR BIOL, V25, pR1002, DOI 10.1016/j.cub.2015.08.051; Orticello M, 2015, ONCOGENE, V34, P3325, DOI 10.1038/onc.2014.265; Sundin LJR, 2011, MOL BIOL CELL, V22, P759, DOI 10.1091/mbc.E10-08-0671; Tooley JG, 2011, MOL BIOL CELL, V22, P1217, DOI 10.1091/mbc.E10-07-0626; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Wei RR, 2007, NAT STRUCT MOL BIOL, V14, P54, DOI 10.1038/nsmb1186; Wilson-Kubalek EM, 2008, J CELL BIOL, V182, P1055, DOI 10.1083/jcb.200804170	33	13	13	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					231	240		10.1038/onc.2017.320	http://dx.doi.org/10.1038/onc.2017.320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925395	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000422631700009
J	Larmonie, NSD; Arentsen-Peters, TCJM; Obulkasim, A; Valerio, D; Sonneveld, E; Danen-van Oorschot, AA; de Haas, V; Reinhardt, D; Zimmermann, M; Trka, J; Baruchel, A; Pieters, R; van den Heuvel-Eibrink, MM; Zwaan, CM; Fornerod, M				Larmonie, N. S. D.; Arentsen-Peters, T. C. J. M.; Obulkasim, A.; Valerio, D.; Sonneveld, E.; Danen-van Oorschot, A. A.; de Haas, V.; Reinhardt, D.; Zimmermann, M.; Trka, J.; Baruchel, A.; Pieters, R.; van den Heuvel-Eibrink, M. M.; Zwaan, C. M.; Fornerod, M.			MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; EXPRESSION; MUTATIONS; CELLS; MAINTENANCE; RESISTANCE; CHILDREN; PATTERNS; PROGRAMS	In acute myeloid leukemia (AML), specific genomic aberrations induce aberrant methylation, thus directly influencing the transcriptional programing of leukemic cells. Therefore, therapies targeting epigenetic processes are advocated as a promising therapeutic tool for AML treatment. However, to develop new therapies, a comprehensive understanding of the mechanism(s) driving the epigenetic changes as a result of acquired genetic abnormalities is necessary. This understanding is still lacking. In this study, we performed genome-wide CpG-island methylation profiling on pediatric AML samples. Six differentially methylated genomic regions within two genes, discriminating inv(16)(p13;q22) from non-inv(16) pediatric AML samples, were identified. All six regions had a hypomethylated phenotype in inv(16) AML samples, and this was most prominent at the regions encompassing the meningioma (disrupted in balanced translocation) 1 (MN1) oncogene. MN1 expression primarily correlated with the methylation level of the 3' end of the MN1 exon-1 locus. Decitabine treatment of different cell lines showed that induced loss of methylation at the MN1 locus can result in an increase of MN1 expression, indicating that MN1 expression is coregulated by DNA methylation. To investigate this methylation-associated mechanism, we determined the expression of DNA methyltransferases in inv(16) AML. We found that DNMT3B expression was significantly lower in inv(16) samples. Furthermore, DNMT3B expression correlated negatively with MN1 expression in pediatric AML samples. Importantly, depletion of DNMT3B impaired remethylation efficiency of the MN1 exon-1 locus in AML cells after decitabine exposure. These findings identify DNMT3B as an important coregulator of MN1 methylation. Taken together, this study shows that the methylation level of the MN1 exon-1 locus regulates MN1 expression levels in inv(16) pediatric AML. This methylation level is dependent on DNMT3B, thus suggesting a role for DNMT3B in leukemogenesis in inv(16) AML, through MN1 methylation regulation.	[Larmonie, N. S. D.; Arentsen-Peters, T. C. J. M.; Obulkasim, A.; Valerio, D.; Danen-van Oorschot, A. A.; Zwaan, C. M.; Fornerod, M.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands; [Sonneveld, E.; de Haas, V.] DCOG, The Hague, Netherlands; [Reinhardt, D.; Zimmermann, M.] Med High Sch, Dept Pediat Oncol Hematol, Hannover, Germany; [Trka, J.] Charles Univ Prague, Med Sch 2, Pediat Hematol Oncol, Prague, Czech Republic; [Baruchel, A.] CHU Paris, Hop Robert Debre, Paris, France; [Pieters, R.; van den Heuvel-Eibrink, M. M.] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Dutch Childhood Oncology Group; Charles University Prague; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Fornerod, M (corresponding author), Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	m.fornerod@erasmusmc.nl	Reinhardt, Dirk/N-7003-2016; Trka, Jan/Y-4820-2019	Reinhardt, Dirk/0000-0002-7027-4483; Fornerod, Maarten/0000-0002-6166-3030	Children Cancer Free Foundation (KIKA) [64]	Children Cancer Free Foundation (KIKA)	We acknowledge L Verboon, NJ Basheer and JM Boer for technical support and advice. This project was supported by grants from the Children Cancer Free Foundation (KIKA), project no. 64, entitled: Aberrant signal transduction profiling in pediatric AML.	Alvarez S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012197; Alvarez-Errico D, 2015, NAT REV IMMUNOL, V15, P7, DOI 10.1038/nri3777; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Balgobind BV, 2008, BLOOD, V111, P4322, DOI 10.1182/blood-2007-06-095075; Balgobind BV, 2011, HAEMATOL-HEMATOL J, V96, P221, DOI 10.3324/haematol.2010.029660; Bernt KM, 2011, HEMATOL-AM SOC HEMAT, P354, DOI 10.1182/asheducation-2011.1.354; Bullinger L, 2010, CANCER CELL, V17, P1, DOI 10.1016/j.ccr.2009.12.033; Carella C, 2007, LEUKEMIA, V21, P1679, DOI 10.1038/sj.leu.2404778; Chang HM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1909; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chowdhury B, 2015, SCI REP-UK, V5, DOI 10.1038/srep09281; Coombes KR, 2009, CLASSES METHODS CLAS; Creutzig U, 2012, BLOOD, V120, P3187, DOI 10.1182/blood-2012-03-362608; Deneberg S, 2011, BLOOD, V118, P5573, DOI 10.1182/blood-2011-01-332353; Duymich CE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11453; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; FOA P, 1982, CELL TISSUE KINET, V15, P399, DOI 10.1111/j.1365-2184.1982.tb01057.x; Gaidzik VI, 2012, J CLIN ONCOL, V30, P1350, DOI 10.1200/JCO.2011.39.2886; Grosveld GC, 2007, BLOOD CELL MOL DIS, V39, P336, DOI 10.1016/j.bcmd.2007.06.009; Heuser M, 2007, BLOOD, V110, P1639, DOI 10.1182/blood-2007-03-080523; Heuser M, 2006, BLOOD, V108, P3898, DOI 10.1182/blood-2006-04-014845; Hlady RA, 2012, J CLIN INVEST, V122, P163, DOI 10.1172/JCI57292; Hollink IHIM, 2009, BLOOD, V113, P5951, DOI 10.1182/blood-2008-09-177949; Im AP, 2014, LEUKEMIA, V28, P1774, DOI 10.1038/leu.2014.124; Inaba H, 2008, CANCER, V113, P522, DOI 10.1002/cncr.23581; KASPERS GJL, 1994, BRIT J CANCER, V70, P1047, DOI 10.1038/bjc.1994.446; Kastl L, 2010, INT J ONCOL, V36, P1235, DOI 10.3892/ijo_00000607; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294; Larmonie NSD, 2014, GENES IMMUN, V15, P72, DOI 10.1038/gene.2013.63; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Mandoli A, 2014, LEUKEMIA, V28, P770, DOI 10.1038/leu.2013.257; Mitschka S, 2015, SCI REP-UK, V5, DOI 10.1038/srep11126; Moore AS, 2013, LEUKEMIA, V27, P1451, DOI 10.1038/leu.2013.106; Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112; Qu XY, 2015, EPIGENETICS-US, V10, P526, DOI 10.1080/15592294.2015.1048060; R Core Team, 2013, LANG ENV STAT COMP; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Saied MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033213; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stumpel DJPM, 2009, BLOOD, V114, P5490, DOI 10.1182/blood-2009-06-227660; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Van Vlierberghe P, 2006, BLOOD, V108, P3520, DOI 10.1182/blood-2006-04-019927; Walton EL, 2011, EPIGENETICS-US, V6, P1373, DOI 10.4161/epi.6.11.17978; Wilop S, 2011, BRIT J HAEMATOL, V155, P65, DOI 10.1111/j.1365-2141.2011.08801.x; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; Wunderlich M, 2006, BLOOD, V108, P1690, DOI 10.1182/blood-2005-12-012773; Yan Pearlly S, 2002, Methods Mol Biol, V200, P87; Zwaan CM, 2015, J CLIN ONCOL, V33, P2949, DOI 10.1200/JCO.2015.62.8289	53	13	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					107	115		10.1038/onc.2017.293	http://dx.doi.org/10.1038/onc.2017.293			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28892045				2022-12-17	WOS:000422625000011
J	Leclerc, J; Ballotti, R; Bertolotto, C				Leclerc, J.; Ballotti, R.; Bertolotto, C.			Pathways from senescence to melanoma: focus on MITF sumoylation	ONCOGENE			English	Review							ONCOGENE-INDUCED SENESCENCE; MICROPHTHALMIA TRANSCRIPTION FACTOR; DNA-DAMAGE RESPONSE; CELLULAR SENESCENCE; BETA-CATENIN; GERMLINE MUTATION; BRAF MUTATIONS; TUMOR-SUPPRESSOR; ULTRAVIOLET-RADIATION; MELANOCYTIC NEVUS	Cutaneous melanoma is a deadly skin cancer that originates from melanocytes. The development of cutaneous melanoma involves a complex interaction between environmental factors, mainly ultraviolet radiation from sunlight, and genetic alterations. Melanoma can also occur from a pre-existing nevus, a benign lesion formed from melanocytes harboring oncogenic mutations that trigger proliferative arrest and senescence entry. Senescence is a potent barrier against tumor progression. As such, the acquisition of mutations that suppress senescence and promote cell division is mandatory for cancer development. This topic appears central to melanoma development because, in humans, several somatic and germline mutations are related to the control of cellular senescence and proliferative activity. Consequently, primary melanoma can be viewed as a paradigm of senescence evasion. In support of this notion, a sumoylation-defective germline mutation in microphthalmia-associated transcription factor (MITF), a master regulator of melanocyte homeostasis, is associated with the development of melanoma. Interestingly, this MITF variant has also been recently reported to negatively impact the program of senescence. This article reviews the genetic alterations that have been shown to be involved in melanoma and that alter the process of senescence to favor melanoma development. Then, the transcription factor MITF and its sumoylation-defective mutant are described. How sumoylation misregulation can change MITF activity and impact the process of senescence is discussed. Finally, the contribution of such information to the development of anti-malignant melanoma strategies is evaluated.	[Leclerc, J.; Ballotti, R.; Bertolotto, C.] INSERM, U1065 Equipe 1, Equipe Labelisee ARC 2016, C3M, Ave St Antoine Ginestiere, F-06204 Nice, France; [Leclerc, J.; Ballotti, R.; Bertolotto, C.] Univ Cote Azur, INSERM, C3M, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Bertolotto, C (corresponding author), INSERM, U1065 Equipe 1, Equipe Labelisee ARC 2016, C3M, Ave St Antoine Ginestiere, F-06204 Nice, France.	bertolot@unice.fr	Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013; Bertolotto-Ballotti, Corine/O-2155-2016	Bertolotto, Corine/0000-0001-6971-7753; Leclerc, Justine/0000-0003-3793-458X; BALLOTTI, Robert/0000-0002-7322-4908	INCa [INCa_10573, INCa_2013-070, ANR-13-BSV1-0025-01]; La ville de Nice	INCa(Institut National du Cancer (INCA) France); La ville de Nice	We are very grateful to Dr I Davidson (IGBMC, Strasbourg) for the analysis of the ChIP-sequencing data set by the MEME program and his helpful discussion. This work was funded by INCa grants INCa_10573 to CB and INCa_2013-070 to RB and ANR-13-BSV1-0025-01 to RB and from La ville de Nice.	Abdallah P, 2009, NAT CELL BIOL, V11, P988, DOI 10.1038/ncb1911; Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Andreou AM, 2010, ADV EXP MED BIOL, V694, P160; Andreou Artemisia M., 2009, Biotechnology Journal, V4, P1740, DOI 10.1002/biot.200900219; Aoude LG, 2015, PIGM CELL MELANOMA R, V28, P148, DOI 10.1111/pcmr.12333; Arafeh R, 2015, NAT GENET, V47, P1408, DOI 10.1038/ng.3427; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bastian BC, 2003, AM J DERMATOPATH, V25, P83, DOI 10.1097/00000372-200302000-00019; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Basu S, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026302; Bataille V, 2007, CANCER EPIDEM BIOMAR, V16, P1499, DOI 10.1158/1055-9965.EPI-07-0152; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bedogni B, 2006, CELL CYCLE, V5, P1258, DOI 10.4161/cc.5.12.2810; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bennett DC, 2016, PIGM CELL MELANOMA R, V29, P122, DOI 10.1111/pcmr.12422; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bonet C, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw340; Bossis G, 2014, CELL REP, V7, P1815, DOI 10.1016/j.celrep.2014.05.016; Box NF, 2001, AM J HUM GENET, V69, P765, DOI 10.1086/323412; Cao JX, 2013, MOL CELL, V51, P409, DOI 10.1016/j.molcel.2013.08.010; Carbone M, 2013, NAT REV CANCER, V13, P153, DOI 10.1038/nrc3459; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348; Conde-Perez A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9093; Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Davis MJ, 2013, P NATL ACAD SCI USA, V110, P912, DOI 10.1073/pnas.1220895110; de- Paillerets BB, 2013, EUR J CELL BIOL, V93, P71; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Demenais F, 2010, JNCI-J NATL CANCER I, V102, P1568, DOI 10.1093/jnci/djq363; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116; Fung C, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12062; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Ghiorzo P, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12047; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Haferkamp S, 2008, AGING CELL, V7, P733, DOI 10.1111/j.1474-9726.2008.00422.x; Haferkamp S, 2013, J INVEST DERMATOL, V133, P1601, DOI 10.1038/jid.2013.6; Haferkamp S, 2009, AGING-US, V1, P542, DOI 10.18632/aging.100051; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Jafri M, 2015, CANCER DISCOV, V5, P723, DOI 10.1158/2159-8290.CD-14-1096; Jarrett SG, 2015, J INVEST DERMATOL, V135, P3086, DOI 10.1038/jid.2015.280; Jhappan C, 2003, ONCOGENE, V22, P3099, DOI 10.1038/sj.onc.1206450; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kirkland JL, 2015, EXP GERONTOL, V68, P19, DOI 10.1016/j.exger.2014.10.012; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Kumar A, 2015, COMPUT STRUCT BIOTEC, V13, P204, DOI 10.1016/j.csbj.2015.03.001; Larribere L, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12369; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Levy C, 2003, MOL CELL BIOL, V23, P9073, DOI 10.1128/MCB.23.24.9073-9080.2003; Li A, 2012, J INVEST DERMATOL, V132, P2610, DOI 10.1038/jid.2012.186; Liu Y, 2013, EMBO MOL MED, V5, P149, DOI 10.1002/emmm.201201378; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; Machesky LM, 2012, PIGM CELL MELANOMA R, V25, P762, DOI 10.1111/pcmr.12004; MacKenzie Ross AD, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12060; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mannava S, 2012, ONCOGENE, V31, P1484, DOI 10.1038/onc.2011.339; McNeal AS, 2015, CANCER DISCOV, V5, P1072, DOI 10.1158/2159-8290.CD-15-0196; Meierjohann S, 2014, EUR J CELL BIOL, V93, P36, DOI 10.1016/j.ejcb.2013.11.005; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miller AJ, 2005, J BIOL CHEM, V280, P146, DOI 10.1074/jbc.M411757200; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Murakami H, 2005, PIGM CELL RES, V18, P265, DOI 10.1111/j.1600-0749.2005.00234.x; Neumann AA, 2002, NAT REV CANCER, V2, P879, DOI 10.1038/nrc929; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Olumi AF, 1999, CANCER RES, V59, P5002; Pandiani C, 2017, GENE DEV, V31, P724, DOI 10.1101/gad.296962.117; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Potrony M, 2016, JAMA DERMATOL, V152, P405, DOI 10.1001/jamadermatol.2015.4356; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robles-Espinoza CD, 2015, MOL CANCER RES, V13, P211, DOI 10.1158/1541-7786.MCR-14-0305; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Scurr LL, 2017, ADV EXP MED BIOL, V963, P215, DOI 10.1007/978-3-319-50044-7_13; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Seeler JS, 2017, NAT REV CANCER, V17, P184, DOI 10.1038/nrc.2016.143; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sonnenblick A, 2004, MOL CELL BIOL, V24, P10584, DOI 10.1128/MCB.24.24.10584-10592.2004; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Sturm RA, 2014, J INVEST DERMATOL, V134, P141, DOI 10.1038/jid.2013.272; Suram A, 2012, EMBO J, V31, P2839, DOI 10.1038/emboj.2012.132; Sviderskaya EV, 2003, J NATL CANCER I, V95, P723, DOI 10.1093/jnci/95.10.723; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Swope V, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12252; te Poele RH, 2002, CANCER RES, V62, P1876; Tentori L, 2013, TRENDS PHARMACOL SCI, V34, P656, DOI 10.1016/j.tips.2013.10.003; Terzian T, 2010, PIGM CELL MELANOMA R, V23, P781, DOI 10.1111/j.1755-148X.2010.00773.x; Tran S, 2013, AGING-US, V5, P98, DOI 10.18632/aging.100537; Tran Sieu L, 2013, Methods Mol Biol, V965, P313, DOI 10.1007/978-1-62703-239-1_21; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Walrath JC, 2010, ADV CANCER RES, V106, P113, DOI 10.1016/S0065-230X(10)06004-5; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Xue Y, 2011, AM J PHYSIOL-HEART C, V300, pH2169, DOI 10.1152/ajpheart.00970.2010; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Yu B, 2015, P NATL ACAD SCI USA, V112, pE1724, DOI 10.1073/pnas.1415569112; Zhang YQ, 2008, J CELL BIOL, V182, P35, DOI 10.1083/jcb.200712124; Zhao R, 2016, EBIOMEDICINE, V8, P30, DOI 10.1016/j.ebiom.2016.04.017; Zhu ST, 2009, P NATL ACAD SCI USA, V106, P17025, DOI 10.1073/pnas.0909292106; Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	150	13	13	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6659	6667		10.1038/onc.2017.292	http://dx.doi.org/10.1038/onc.2017.292			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28825724	Green Submitted			2022-12-17	WOS:000416780800001
J	Ramadoss, S; Sen, S; Ramachandran, I; Roy, S; Chaudhuri, G; Farias-Eisner, R				Ramadoss, S.; Sen, S.; Ramachandran, I.; Roy, S.; Chaudhuri, G.; Farias-Eisner, R.			Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance	ONCOGENE			English	Correction															Carl and Roberta Deutsch Foundation; NIH/NCI [U54CA143930]	Carl and Roberta Deutsch Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge The Carl and Roberta Deutsch Foundation (PI: Farias-Eisner), Kelly Day, and NIH/NCI U54CA143930 Grant (PI: Farias-Eisner) for their financial support. We thank Professor Oliver Dorigo, Stanford University Medical Center, for the generous gift of cisplatin-resistant ovarian cancer cell lines. We thank Dr Xiangming Ding, UCLA Clinical Microarray Core, for the statistical assistance.	Ramadoss S, 2017, ONCOGENE, V36, P1537, DOI 10.1038/onc.2016.320	1	13	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6508	6508		10.1038/onc.2017.331	http://dx.doi.org/10.1038/onc.2017.331			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28925393	Green Published, hybrid			2022-12-17	WOS:000415622900014
J	Szymiczek, A; Carbone, M; Pastorino, S; Napolitano, A; Tanji, M; Minaai, M; Pagano, I; Mason, JM; Pass, HI; Bray, MR; Mak, TW; Yang, H				Szymiczek, A.; Carbone, M.; Pastorino, S.; Napolitano, A.; Tanji, M.; Minaai, M.; Pagano, I.; Mason, J. M.; Pass, H. I.; Bray, M. R.; Mak, T. W.; Yang, H.			Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma	ONCOGENE			English	Article							PLEURAL MESOTHELIOMA; CHROMOSOMAL INSTABILITY; ASBESTOS EXPOSURE; CANCER; BAP1; PROTEIN; ANEUPLOIDY; MUTATIONS; CFI-402257; MURINE	Malignant mesothelioma (MM) is an aggressive malignancy, highly resistant to current medical and surgical therapies, whose tumor cells characteristically show a high level of aneuploidy and genomic instability. We tested our hypothesis that targeting chromosomal instability in MM would improve response to therapy. Thr/Tyr kinase (TTK)/monopolar spindle 1 kinase (Mps-1) is a kinase of the spindle assembly checkpoint that controls cell division and cell fate. CFI-402257 is a novel, selective inhibitor of Mps-1 with antineoplastic activity. We found that CFI-402257 suppresses MM growth. We found that Mps-1 is overexpressed in MM and that its expression correlates with poor patients' outcome. In vitro, CFI-402257-mediated inhibition of Mps-1 resulted in abrogation of the mitotic checkpoint, premature progression through mitosis, marked aneuploidy and mitotic catastrophe. In vivo, CFI-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent, and more so when used in combination with cisplatin+pemetrexed, the current standard of care. Our preclinical findings indicate that CFI-402257 is a promising novel therapeutic agent to improve the efficacy of the current chemotherapeutic regimens for MM patients.	[Szymiczek, A.; Carbone, M.; Pastorino, S.; Napolitano, A.; Tanji, M.; Minaai, M.; Pagano, I.; Yang, H.] Univ Hawaii Manoa, Univ Hawaii, Ctr Canc, Thorac Oncol Program, Honolulu, HI 96822 USA; [Mason, J. M.; Bray, M. R.; Mak, T. W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, MaRS Ctr, TMDT East Tower, Toronto, ON, Canada; [Pass, H. I.] NYU, Langone Med Ctr, Dept Cardiothorac Surg, New York, NY USA	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; New York University; NYU Langone Medical Center	Carbone, M (corresponding author), Univ Hawaii Manoa, Univ Hawaii, Ctr Canc, 701 Ilalo St,Room 437, Honolulu, HI 96813 USA.; Yang, H (corresponding author), Univ Hawaii, Canc Biol Program, Ctr Canc, 701 Ilalo St,Room 439, Honolulu, HI 96813 USA.	mcarbone@cc.hawaii.edu; hyang@cc.hawaii.edu	Napolitano, Andrea/I-3146-2019	Napolitano, Andrea/0000-0002-7509-1555; Bray, Mark/0000-0003-4609-6127; Pass, Harvey/0000-0003-3222-3471	NCI-R01 [CA198138, CA160715]; University of Hawai'i Foundation; NATIONAL CANCER INSTITUTE [R01CA198138, P30CA071789, R01CA160715] Funding Source: NIH RePORTER	NCI-R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Hawai'i Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the NCI-R01 CA198138 to MC; by the NCI-R01 CA160715 to HY; and by the University of Hawai'i Foundation, which received an unrestricted gift to support MM research from Honeywell International Inc., to MC; and from United-4-a-Cure, to MC and HY CFI-402257 was synthesized and provided by our collaborators and co-authors at the Campbell Family Institute for Breast Cancer Research, Toronto, Canada.	Bononi A, 2017, CELL DEATH DIFFER, V24, P1694, DOI 10.1038/cdd.2017.95; Bononi A, 2017, NATURE, V546, P549, DOI 10.1038/nature22798; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Carbone M, 2000, J CELL BIOCHEM, V76, P189, DOI 10.1002/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J; Carbone M, 2016, J THORAC ONCOL, V11, P1246, DOI 10.1016/j.jtho.2016.04.028; Carbone M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005633; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Colombo R, 2010, CANCER RES, V70, P10255, DOI 10.1158/0008-5472.CAN-10-2101; Comertpay S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0301-3; Daniel J, 2011, P NATL ACAD SCI USA, V108, P5384, DOI 10.1073/pnas.1007645108; Delgermaa V, 2011, B WORLD HEALTH ORGAN, V89, P716, DOI 10.2471/BLT.11.086678; Fisk HA, 2004, CELL CYCLE, V3, P439; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gazdar Adi F, 2003, Clin Lung Cancer, V5, P177, DOI 10.3816/CLC.2003.n.031; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Guo GW, 2015, CANCER RES, V75, P264, DOI 10.1158/0008-5472.CAN-14-1008; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; Hao JQ, 2008, CHINESE MED J-PEKING, V121, P602, DOI 10.1097/00029330-200804010-00006; Henley SJ, 2013, INT J OCCUP ENV HEAL, V19, P1, DOI 10.1179/2049396712Y.0000000016; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; ISOBE H, 1994, INT J CANCER, V57, P581, DOI 10.1002/ijc.2910570423; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jean D, 2011, AM J PATHOL, V178, P881, DOI 10.1016/j.ajpath.2010.10.039; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Jemaa M, 2013, CELL DEATH DIFFER, V20, P1532, DOI 10.1038/cdd.2013.105; Ji ZJ, 2015, SCIENCE, V348, P1260, DOI 10.1126/science.aaa4029; Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kwiatkowski N, 2010, NAT CHEM BIOL, V6, P359, DOI 10.1038/nchembio.345; Ling YG, 2014, BIOCHEM BIOPH RES CO, V450, P1690, DOI 10.1016/j.bbrc.2014.07.071; Liu XD, 2012, ANNU REV BIOCHEM, V81, P561, DOI 10.1146/annurev-biochem-061611-090435; Liu Y, 2016, ACS MED CHEM LETT, V7, P671, DOI 10.1021/acsmedchemlett.5b00485; Lo Iacono M, 2015, J THORAC ONCOL, V10, P492, DOI 10.1097/JTO.0000000000000436; Mason JM, 2017, P NATL ACAD SCI USA, V114, P3127, DOI 10.1073/pnas.1700234114; Meyerhoff RR, 2015, J SURG RES, V196, P23, DOI 10.1016/j.jss.2015.01.043; Mezzapelle R, 2016, SCI REP-UK, V6, DOI 10.1038/srep22850; Napolitano A, 2016, ONCOGENE, V35, P1996, DOI 10.1038/onc.2015.243; Napolitano A, 2016, CLIN CANCER RES, V22, P3087, DOI 10.1158/1078-0432.CCR-15-1130; Nasu M, 2015, J THORAC ONCOL, V10, P565, DOI 10.1097/JTO.0000000000000471; Nijenhuis W, 2013, J CELL BIOL, V201, P217, DOI 10.1083/jcb.201210033; Ostroff RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046091; Singhi AD, 2016, MODERN PATHOL, V29, P14, DOI 10.1038/modpathol.2015.121; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; TAGUCHI T, 1993, CANCER RES, V53, P4349; Taniguchi T, 2007, CANCER SCI, V98, P438, DOI 10.1111/j.1349-7006.2006.00386.x; Tardif KD, 2011, MOL CANCER THER, V10, P2267, DOI 10.1158/1535-7163.MCT-11-0453; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Ugurluer G, 2016, ANTICANCER RES, V36, P2331; van Jaarsveld RH, 2016, TRENDS CANCER, V2, P561, DOI 10.1016/j.trecan.2016.09.003; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Yang HN, 2006, P NATL ACAD SCI USA, V103, P10397, DOI 10.1073/pnas.0604008103; Yoshikawa Y, 2016, P NATL ACAD SCI USA, V113, P13432, DOI 10.1073/pnas.1612074113; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104	58	13	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6501	6507		10.1038/onc.2017.266	http://dx.doi.org/10.1038/onc.2017.266			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759042	Green Accepted			2022-12-17	WOS:000415622900013
J	Yang, N; Leung, EH; Liu, C; Li, L; Eguether, T; Yao, XJJ; Jones, EC; Norris, DA; Liu, A; Clark, RA; Roop, DR; Pazour, GJ; Shroyer, KR; Chen, J				Yang, N.; Leung, EL-H; Liu, C.; Li, L.; Eguether, T.; Yao, X-J Jun; Jones, E. C.; Norris, D. A.; Liu, A.; Clark, R. A.; Roop, D. R.; Pazour, G. J.; Shroyer, K. R.; Chen, J.			INTU is essential for oncogenic Hh signaling through regulating primary cilia formation in basal cell carcinoma	ONCOGENE			English	Article							HEDGEHOG PATHWAY; HAIR FOLLICLE; VERTEBRATE DEVELOPMENT; EMBRYONIC-DEVELOPMENT; HUMAN HOMOLOG; STEM-CELLS; POLARITY; MOUSE; DIFFERENTIATION; CILIOGENESIS	Inturned (INTU), a cilia and planar polarity effector, performs prominent ciliogenic functions during morphogenesis, such as in the skin. INTU is expressed in adult tissues but its role in tissue maintenance is unknown. Here, we report that the expression of the INTU gene is aberrantly elevated in human basal cell carcinoma (BCC), coinciding with increased primary cilia formation and activated hedgehog (Hh) signaling. Disrupting Intu in an oncogenic mutant Smo (SmoM2)-driven BCC mouse model prevented the formation of BCC through suppressing primary cilia formation and Hh signaling, suggesting that Intu performs a permissive role during BCC formation. INTU is essential for intraflagellar transport A complex assembly during ciliogenesis. To further determine whether Intu is directly involved in the activation of Hh signaling downstream of ciliogenesis, we examined the Hh signaling pathway in mouse embryonic fibroblasts, which readily responds to the Hh pathway activation. Depleting Intu blocked Smo agonist-induced Hh pathway activation, whereas the expression of Gli2 Delta N, a constitutively active Gli2, restored Hh pathway activation in Intu-deficient cells, suggesting that INTU functions upstream of Gli2 activation. In contrast, overexpressing Intu did not promote ciliogenesis or Hh signaling. Taken together, data obtained from this study suggest that INTU is indispensable during BCC tumorigenesis and that its aberrant upregulation is likely a prerequisite for primary cilia formation during Hh-dependent tumorigenesis.	[Yang, N.; Liu, C.; Shroyer, K. R.; Chen, J.] SUNY Stony Brook, Dept Pathol, Basic Sci Tower,Level 9,Room 151, Stony Brook, NY 11794 USA; [Leung, EL-H; Yao, X-J Jun; Chen, J.] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Li, L.] Beijing Union Med Coll Hosp, Dept Dermatol, Beijing, Peoples R China; [Eguether, T.; Pazour, G. J.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA; [Jones, E. C.; Clark, R. A.; Chen, J.] SUNY Stony Brook, Dept Dermatol, Basic Sci Tower,Level 9,Room 151, Stony Brook, NY 11794 USA; [Norris, D. A.; Roop, D. R.] Univ Colorado Denver, Charles C Gates Ctr Regenerat Med, Aurora, CO USA; [Liu, A.] Penn State Univ, Dept Biol, Eberly Coll Sci, University Pk, PA 16802 USA; [Roop, D. R.] Univ Colorado Denver, Dept Dermatol, Aurora, CO USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Macau University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; University of Massachusetts System; University of Massachusetts Worcester; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Chen, J (corresponding author), SUNY Stony Brook, Dept Pathol, Sch Med, Basic Sci Tower,Level 9,Room 151, Stony Brook, NY 11794 USA.	jiang.chen@stonybrook.edu	Eguether, Thibaut/AAZ-5403-2020	Eguether, Thibaut/0000-0003-1891-9253; Liu, Aimin/0000-0003-0099-0879	Research Histology Core Laboratory of the Department of Pathology; Cancer Center of Stony Brook University; NIH [AR061485, AR060388, CA052607]; PKD foundation [02YI08A]; SDRC of University of Colorado Denver (NIH) [AR057212]; REACH program of Stony Brook University (NIH) [U01HL127522]; REACH program of Stony Brook University (NYS Department of Economic Development) [C140151]; NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL127522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057212, R01AR060388, R01AR061485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060992] Funding Source: NIH RePORTER	Research Histology Core Laboratory of the Department of Pathology; Cancer Center of Stony Brook University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PKD foundation; SDRC of University of Colorado Denver (NIH); REACH program of Stony Brook University (NIH); REACH program of Stony Brook University (NYS Department of Economic Development); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Stephanie Burke and Mallory Korman for histology assistance. This study is supported by the Research Histology Core Laboratory of the Department of Pathology, the Cancer Center of Stony Brook University, and research grants from NIH (AR061485 to JC; AR060388 and CA052607 to DRR), a Young Investigator Career Development Award from the PKD foundation (02YI08A to AL), a Pilot and Feasibility Award from the SDRC of University of Colorado Denver (NIH, AR057212), and the REACH program of Stony Brook University (NIH, U01HL127522 and the NYS Department of Economic Development, C140151).	Aszterbaum M, 1999, J INVEST DERM SYMP P, V4, P41, DOI 10.1038/sj.jidsp.5640179; Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002; Atwood SX, 2012, J CELL BIOL, V199, P193, DOI 10.1083/jcb.201207140; Basset-Seguin N, 2015, MOL CANCER THER, V14, P633, DOI 10.1158/1535-7163.MCT-14-0703; Chang R, 2015, DEV DYNAM, V244, P736, DOI 10.1002/dvdy.24272; Cui C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001720; Dai D, 2013, CELL DEATH DIFFER, V20, P130, DOI 10.1038/cdd.2012.104; Dai D, 2011, J INVEST DERMATOL, V131, P302, DOI 10.1038/jid.2010.306; DeRouen MC, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-112; Eggenschwiler JT, 2007, ANNU REV CELL DEV BI, V23, P345, DOI 10.1146/annurev.cellbio.23.090506.123249; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Grachtchouk M, 2011, J CLIN INVEST, V121, P1768, DOI 10.1172/JCI46307; Gray RS, 2009, NAT CELL BIOL, V11, P1225, DOI 10.1038/ncb1966; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Heydeck W, 2011, DEV DYNAM, V240, P1938, DOI 10.1002/dvdy.22696; Heydeck W, 2009, DEV DYNAM, V238, P3035, DOI 10.1002/dvdy.22130; Infante P, 2015, TRENDS PHARMACOL SCI, V36, P547, DOI 10.1016/j.tips.2015.05.006; Kim DJ, 2014, J CLIN ONCOL, V32, P745, DOI 10.1200/JCO.2013.49.9525; Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027; Metcalfe C, 2011, CANCER RES, V71, P5057, DOI 10.1158/0008-5472.CAN-11-0923; Oh EC, 2012, DEVELOPMENT, V139, P443, DOI 10.1242/dev.050054; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park TJ, 2006, NAT GENET, V38, P303, DOI 10.1038/ng1753; Park WJ, 1996, DEVELOPMENT, V122, P961; Peterson SC, 2015, CELL STEM CELL, V16, P400, DOI 10.1016/j.stem.2015.02.006; Pricl S, 2015, MOL ONCOL, V9, P389, DOI 10.1016/j.molonc.2014.09.003; Sanchez-Danes A, 2016, NATURE, V536, P298, DOI 10.1038/nature19069; Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534; Toriyama M, 2016, NAT GENET, V48, P648, DOI 10.1038/ng.3558; Villumsen BH, 2013, EMBO J, V32, P3029, DOI 10.1038/emboj.2013.223; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Wong SY, 2014, J INVEST DERMATOL, V134, pE18, DOI 10.1038/skinbio.2014.4; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yasuda Masahito, 2013, Methods Mol Biol, V989, P143, DOI 10.1007/978-1-62703-330-5_12; Youssef KK, 2012, NAT CELL BIOL, V14, P1282, DOI 10.1038/ncb2628; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zeng HQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015900; Zeng HQ, 2010, DEV BIOL, V339, P418, DOI 10.1016/j.ydbio.2010.01.003; Zhang ZC, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0028817, 10.1371/journal.pone.0024608]; Zilber Y, 2013, MOL BIOL CELL, V24, P555, DOI 10.1091/mbc.E12-06-0437	45	13	14	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4997	5005		10.1038/onc.2017.117	http://dx.doi.org/10.1038/onc.2017.117			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459465	Green Accepted			2022-12-17	WOS:000408768800005
J	Hendrick, E; Peixoto, P; Blomme, A; Polese, C; Matheus, N; Cimino, J; Frere, A; Mouithys-Mickalad, A; Serteyn, D; Bettendorff, L; Elmoualij, B; De Tullio, P; Eppe, G; Dequiedt, F; Castronovo, V; Mottet, D				Hendrick, E.; Peixoto, P.; Blomme, A.; Polese, C.; Matheus, N.; Cimino, J.; Frere, A.; Mouithys-Mickalad, A.; Serteyn, D.; Bettendorff, L.; Elmoualij, B.; De Tullio, P.; Eppe, G.; Dequiedt, F.; Castronovo, V.; Mottet, D.			Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; HUMAN CANCER-CELLS; ALZHEIMERS-DISEASE; IRON; PROLIFERATION; CHEMOTHERAPY; EXPRESSION; CISPLATIN; AUTOPHAGY; ANGIOGENESIS	The US FDA approval of broad-spectrum histone deacetylase (HDAC) inhibitors has firmly laid the cancer community to explore HDAC inhibition as a therapeutic approach for cancer treatment. Hitting one HDAC member could yield clinical benefit but this required a complete understanding of the functions of the different HDAC members. Here we explored the consequences of specific HDAC5 inhibition in cancer cells. We demonstrated that HDAC5 inhibition induces an iron-dependent reactive oxygen species (ROS) production, ultimately leading to apoptotic cell death as well as mechanisms of mitochondria quality control (mitophagy and mitobiogenesis). Interestingly, adaptation of HDAC5-depleted cells to oxidative stress passes through reprogramming of metabolic pathways towards glucose and glutamine. Therefore, interference with both glucose and glutamine supply in HDAC5-inhibited cancer cells significantly increases apoptotic cell death and reduces tumour growth in vivo; providing insight into a valuable clinical strategy combining the selective inhibition of HDAC5 with various inhibitors of metabolism as a new therapy to kill cancer cells.	[Hendrick, E.; Polese, C.; Matheus, N.; Frere, A.; Dequiedt, F.; Mottet, D.] Univ Liege, GIGA Mol Biol Dis, Prot Signalisat & Interact PSI Lab, Liege, Belgium; [Peixoto, P.; Blomme, A.; Castronovo, V.] Univ Liege, GIGA Canc, MRL, Liege, Belgium; [Cimino, J.] Univ Liege, Lab Tumor & Dev Biol LBTD, GIGA Canc, Liege, Belgium; [Frere, A.] Univ Liege, Lab Pharmaceut Technol & Biopharm LTPB, CIRM, Liege, Belgium; [Mouithys-Mickalad, A.; Serteyn, D.] Univ Liege, CORD, Inst Chem, Liege, Belgium; [Bettendorff, L.] Univ Liege, Lab Pathol Aging & Epilepsy, GIGA Signal Neurosci, Liege, Belgium; [Elmoualij, B.] Univ Liege, Dept Human Histol CRPP, Liege, Belgium; [De Tullio, P.] Univ Liege, Med Chem Dept, Drug Res Ctr, CIRM, Liege, Belgium; [Eppe, G.] Univ Liege, Chem Dept, CART LSM, Inorgan Analyt Chem, Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Mottet, D (corresponding author), Univ Liege, Prot Signalisat & Interact Lab, GIGA, GIGA Bldg,B34,2, B-4000 Liege, Belgium.	dmottet@ulg.ac.be	De Tullio, Pascal/ABE-5585-2021; Blomme, Arnaud/AAM-1440-2020; Blomme, Arnaud/AGO-7915-2022	Blomme, Arnaud/0000-0003-4183-8726; Eppe, Gauthier/0000-0002-4821-3115; Peixoto, Paul/0000-0001-6302-7823; Dequiedt, Franck/0000-0003-1234-7477	National Fund for Scientific Research (FNRS) (Belgium); TELEVIE; Centre Anti-Cancereux; Fonds Leon Fredericq and Fonds Speciaux de Recherche pres de l'Universite de Liege	National Fund for Scientific Research (FNRS) (Belgium)(Fonds de la Recherche Scientifique - FNRS); TELEVIE; Centre Anti-Cancereux; Fonds Leon Fredericq and Fonds Speciaux de Recherche pres de l'Universite de Liege	The authors thank the GIGA 'Cell Imaging and Flow Cytometry', the GIGA 'Transciptomic ' as well as the GIGA 'Animal' core facility for technical assistance. This work was supported by grants from the National Fund for Scientific Research (FNRS) (Belgium), TELEVIE, the Centre Anti-Cancereux, Fonds Leon Fredericq and Fonds Speciaux de Recherche pres de l'Universite de Liege. PP and JC are FNRS-TELEVIE Post Doc. DM is a Research Associate. P DT is Senior Research Associate and LB is Research Director at the National Fund for Scientific Research (FNRS). CP, EH and AB are FNRS-TELEVIE fellows. NM is FRIA fellow.	Agis-Balboa RC, 2013, J ALZHEIMERS DIS, V33, P35, DOI 10.3233/JAD-2012-121009; Ahrens TD, 2016, LAB INVEST, V96, P307, DOI 10.1038/labinvest.2015.148; Allen EL, 2016, CELL REP, V17, P876, DOI 10.1016/j.celrep.2016.09.052; Altamura S, 2009, J ALZHEIMERS DIS, V16, P879, DOI 10.3233/JAD-2009-1010; Arriaga JM, 2014, MOL CANCER THER, V13, P1369, DOI 10.1158/1535-7163.MCT-13-0944; Baliga R, 1998, KIDNEY INT, V53, P394, DOI 10.1046/j.1523-1755.1998.00767.x; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Buranrat B, 2015, ONCOL REP, V34, P2790, DOI 10.3892/or.2015.4250; Ceusters JD, 2013, MITOCHONDRION, V13, P410, DOI 10.1016/j.mito.2012.12.004; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chekhun VF, 2013, INT J ONCOL, V43, P1481, DOI 10.3892/ijo.2013.2063; Cheng T, 2015, DRUG TODAY, V51, P491, DOI 10.1358/dot.2015.51.8.2362311; Deby-Dupont G, 2005, BIOCHEM BIOPH RES CO, V333, P21, DOI 10.1016/j.bbrc.2005.05.073; Di Domenico F, 2015, EXPERT REV NEUROTHER, V15, P19, DOI 10.1586/14737175.2015.955853; Fan J, 2014, TUMOR BIOL, V35, P11523, DOI 10.1007/s13277-014-2358-2; Gammoh N, 2012, AUTOPHAGY, V8, P1521, DOI 10.4161/auto.21151; Gangolf M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013616; Gaude E, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-10; Grunblatt E, 2011, J NEURAL TRANSM, V118, P371, DOI 10.1007/s00702-010-0426-3; Harris IS, 2015, NATURE, V527, P170, DOI 10.1038/nature15644; He P, 2015, INT J CLIN EXP MED, V8, P6510; Held NM, 2015, BIOESSAYS, V37, P867, DOI 10.1002/bies.201500013; Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85; Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156; Lenaz G, 2010, BBA-BIOENERGETICS, V1797, P633, DOI 10.1016/j.bbabio.2010.01.025; Liu JQ, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-015-0753-0; Liu Q, 2014, MOL MED REP, V10, P2045, DOI 10.3892/mmr.2014.2395; Ma PA, 2017, NANO LETT, V17, P928, DOI 10.1021/acs.nanolett.6b04269; Mailloux RJ, 2011, FREE RADICAL BIO MED, V51, P1106, DOI 10.1016/j.freeradbiomed.2011.06.022; Margalit O, 2012, INT J CANCER, V131, pE562, DOI 10.1002/ijc.26441; McCord MC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00077; McDermott J, 2014, DRUG TODAY, V50, P337, DOI 10.1358/dot.2014.50.5.2138703; Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371; Mottet D, 2008, CLIN EXP METASTAS, V25, P183, DOI 10.1007/s10585-007-9131-5; Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377; Nebbioso A, 2012, MOL ONCOL, V6, P657, DOI 10.1016/j.molonc.2012.09.004; Patel D, 2016, J BIOL CHEM, V291, P9322, DOI 10.1074/jbc.M115.710145; Peixoto P, 2012, CELL DEATH DIFFER, V19, P1239, DOI 10.1038/cdd.2012.3; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Qiu TZ, 2013, FUTURE ONCOL, V9, P255, DOI [10.2217/fon.12.173, 10.2217/FON.12.173]; Rangwala S, 2012, FUTURE MED CHEM, V4, P471, DOI [10.4155/FMC.12.6, 10.4155/fmc.12.6]; Ratnikov B, 2015, ONCOTARGET, V6, P7379, DOI 10.18632/oncotarget.3132; Sag CM, 2014, J MOL CELL CARDIOL, V73, P103, DOI 10.1016/j.yjmcc.2014.02.002; Sawas A, 2015, THER ADV HEMATOL, V6, P202, DOI 10.1177/2040620715592567; Shpyleva SI, 2011, BREAST CANCER RES TR, V126, P63, DOI 10.1007/s10549-010-0849-4; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI [10.2217/fon.11.2, 10.2217/FON.11.2]; Urbich C, 2009, BLOOD, V113, P5669, DOI 10.1182/blood-2009-01-196485; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Zhang L, 2015, FREE RADICAL BIO MED, V89, P452, DOI 10.1016/j.freeradbiomed.2015.08.030; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zhu X, 2007, CELL MOL LIFE SCI, V64, P2202, DOI 10.1007/s00018-007-7218-4	52	13	14	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4859	4874		10.1038/onc.2017.103	http://dx.doi.org/10.1038/onc.2017.103			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28414307	Green Published			2022-12-17	WOS:000408234400004
J	Lu, W; Cheng, F; Yan, W; Li, X; Yao, X; Song, W; Liu, M; Shen, X; Jiang, H; Chen, J; Li, J; Huang, J				Lu, W.; Cheng, F.; Yan, W.; Li, X.; Yao, X.; Song, W.; Liu, M.; Shen, X.; Jiang, H.; Chen, J.; Li, J.; Huang, J.			Selective targeting p53(WT) lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA	ONCOGENE			English	Article							CYCLOPHILIN-A; ACQUIRED-RESISTANCE; ISOMERASE ACTIVITY; COMPLEX PROMOTES; CYCLOSPORINE-A; MUTANT P53; CISPLATIN; BINDING; SUPPRESSION; ACTIVATION	TP53 plays essential roles in tumor initiation and progression, and is frequently mutated in cancer. However, pharmacological stabilization and reactivation of p53 have not been actively explored for targeted cancer therapies. Herein, we identify a novel Cyclophilin A (CypA) small molecule inhibitor (HL001) that induces non-small cell lung cancer (NSCLC) cell cycle arrest and apoptosis via restoring p53 expression. We find that HL001 stabilizes p53 through inhibiting the MDM2-mediated p53 ubiquitination. Further mechanistic studies reveal that the downregulation of G3BP1 and the induction of reactive oxygen species and DNA damage by HL001 contribute to p53 stabilization. Surprisingly, HL001 selectively suppresses tumor growth in p53 wildtype NSCLC harboring Arg72 homozygous alleles (p53-72R) through disrupting interaction between MDM2 and p53-72R in a CypA-dependent manner. Moreover, combining HL001 with cisplatin synergistically enhance tumor regression in orthotopic NSCLC mouse model. Collectively, this study demonstrates that pharmacologic inhibition of CypA offers a potential therapeutic strategy via specific activation of p53-72R in NSCLC.	[Lu, W.; Yan, W.; Li, X.; Yao, X.; Shen, X.; Jiang, H.; Li, J.; Huang, J.] East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, Shanghai 200237, Peoples R China; [Lu, W.; Liu, M.] East China Univ Sci & Technol, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai, Peoples R China; [Lu, W.; Liu, M.] East China Univ Sci & Technol, Sch Life Sci, Shanghai, Peoples R China; [Cheng, F.] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Cheng, F.] Collaborat Innovat Ctr Biotherapy, Chengdu, Sichuan, Peoples R China; [Song, W.; Chen, J.] Vanderbilt Univ, Sch Med, Vet Affairs Med Ctr, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Shen, X.; Jiang, H.] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res, Shanghai, Peoples R China; [Chen, J.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Chen, J.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; [Chen, J.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Cheng, F.] Harvard Med Sch, Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA USA; [Cheng, F.] Northeastern Univ, Ctr Complex Networks Res, Boston, MA 02115 USA	East China University of Science & Technology; East China University of Science & Technology; East China University of Science & Technology; Sichuan University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northeastern University	Li, J; Huang, J (corresponding author), East China Univ Sci & Technol, Shanghai Key Lab New Drug Design, Sch Pharm, Shanghai 200237, Peoples R China.	jianli@ecust.edu.cn; huangjin@ecust.edu.cn		Chen, Jin/0000-0002-5557-2079; Cheng, Feixiong/0000-0002-1736-2847; XUE, YAO/0000-0002-1806-7372; huang, jin/0000-0002-0698-1693	National Natural Science Foundation of China [21222211, 31371485, 81402482, 91313303, 81573020]; CAS Key Laboratory of Receptor Research; Shanghai Committee of Science and Technology [14ZR1411100, 15431902000]; China Postdoctoral Science Foundation [2014M551361, 2015T80415]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAS Key Laboratory of Receptor Research; Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We are grateful to Mr Lianbiao Cheng, Miss Jiaqian Pu and Miss Ningning Dong (all from Jin Huang lab) for material and intellectual help with the design and execution of some of these experiments. The authors thank Professor Jose M Cuezva (Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid, Madrid, Spain) for providing G3BP1 plasmid; Professor Xiangshi Tan (Department of Chemistry, Fudan University, Shanghai, China) for providing the pMAL-c2x-derived MBPHT-Cherry2 vector; Professor Yi Yang (Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China) for providing H23, H838, H1703 and H2126 lung cancer cell lines. The work is supported by the National Natural Science Foundation of China (21222211, 31371485, 81402482, 91313303 and 81573020), CAS Key Laboratory of Receptor Research, the Shanghai Committee of Science and Technology (14ZR1411100 and 15431902000), China Postdoctoral Science Foundation Grant (2014M551361 and 2015T80415).	Abraham S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8286; Arnedos M, 2015, NAT REV CLIN ONCOL, V12, P693, DOI 10.1038/nrclinonc.2015.123; Bai JPF, 2013, ANNU REV PHARMACOL, V53, P451, DOI 10.1146/annurev-pharmtox-011112-140248; Baum N, 2009, ONCOGENE, V28, P3915, DOI 10.1038/onc.2009.248; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Bonfils C, 2010, BIOCHEM BIOPH RES CO, V393, P325, DOI 10.1016/j.bbrc.2010.01.135; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Cheng FX, 2017, TRENDS IMMUNOL, V38, P77, DOI 10.1016/j.it.2016.11.007; Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759; Choudhury R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4078; Cohen P, 2013, ACS CHEM BIOL, V8, P96, DOI 10.1021/cb300610s; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Hamilton G, 2014, CURR CANCER DRUG TAR, V14, P46, DOI 10.2174/15680096113136660109; Hong F, 2002, FASEB J, V16, P1633, DOI 10.1096/fj.02-0060fje; Howard BA, 2005, CANCER RES, V65, P8853, DOI 10.1158/0008-5472.CAN-05-1219; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Klein DK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6800; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Leroy B, 2014, HUM MUTAT, V35, P756, DOI 10.1002/humu.22556; Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366; Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; MUTCH DG, 1992, GYNECOL ONCOL, V47, P28, DOI 10.1016/0090-8258(92)90070-Y; Ni SS, 2009, J MED CHEM, V52, P5295, DOI 10.1021/jm9008295; Nigro P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.410; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Puente XS, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-15; Rajagopalan S, 2009, J BIOL CHEM, V284, P21728, DOI 10.1074/jbc.M109.006429; Rosell R, 2013, LANCET, V382, P720, DOI 10.1016/S0140-6736(13)61715-8; Shim JH, 2010, CANCER PREV RES, V3, P670, DOI 10.1158/1940-6207.CAPR-09-0185; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Yang HR, 2007, BIOCHEM BIOPH RES CO, V361, P763, DOI 10.1016/j.bbrc.2007.07.085; Zhu D, 2015, NAT MED, V21, P572, DOI 10.1038/nm.3867; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	44	13	13	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4719	4731		10.1038/onc.2017.41	http://dx.doi.org/10.1038/onc.2017.41			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394340	hybrid, Green Published			2022-12-17	WOS:000407702400005
J	Di Giacomo, V; Tian, TV; Mas, A; Pecoraro, M; Batlle-Morera, L; Noya, L; Martin-Caballero, J; Ruberte, J; Keyes, WM				Di Giacomo, V.; Tian, T. V.; Mas, A.; Pecoraro, M.; Batlle-Morera, L.; Noya, L.; Martin-Caballero, J.; Ruberte, J.; Keyes, W. M.			Delta Np63 alpha promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82	ONCOGENE			English	Article							PROGENITOR CELLS; SUPPRESSOR GENE; P53 HOMOLOG; STEM-CELLS; P63; PROLIFERATION; SURVIVAL; PC3; COMMITMENT; EXPRESSION	Delta Np63 alpha is a critical mediator of epithelial development and stem cell function in a variety of tissues including the skin and breast, while overexpression of Delta Np63 alpha acts as an oncogene to drive tumor formation and cancer stem cell properties in squamous cell carcinoma. However, with regards to the prostate, while Delta Np63 alpha is expressed in the basal stem cells of the mature gland, during adenocarcinoma development, its expression is lost and its absence is used to clinically diagnose the malignant state. Surprisingly, here we identify a sub-population of bone metastatic prostate cancer cells in the PC3 cell line that express Delta Np63 alpha. Interestingly, we discovered that Delta Np63 alpha favors adhesion and stem-like growth of these cells in the bone microenvironment. In addition, we show that these properties require expression of the target gene CD82. Together, this work uncovers a population of bone metastatic prostate cancer cells that express Delta Np63 alpha, and provides important information about the mechanisms of bone metastatic colonization. Finally, we identify metastasis-promoting properties for the tetraspanin family member CD82.	[Di Giacomo, V.; Tian, T. V.; Mas, A.; Pecoraro, M.; Batlle-Morera, L.; Keyes, W. M.] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Gene Regulat Stem Cells & Canc Program, Barcelona, Spain; [Di Giacomo, V.; Tian, T. V.; Mas, A.; Pecoraro, M.; Batlle-Morera, L.; Keyes, W. M.] UPF, Barcelona, Spain; [Noya, L.] Univ Autonoma Barcelona, Dept Anim Hlth & Anat, Barcelona, Spain; [Noya, L.] Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, Barcelona, Spain; [Martin-Caballero, J.] PRBB, Unidad Anim Lab, Barcelona, Spain; [Keyes, W. M.] Univ Strasbourg, Inserm U964, CNRS UMR7104,Dev & Stem Cells program, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; [Di Giacomo, V.] ZeClinics, Barcelona, Spain; [Pecoraro, M.] Max Planck Inst Biochem, Dept Prote & Signal Transduct, Martinsried, Germany	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Autonomous University of Barcelona; Autonomous University of Barcelona; Pompeu Fabra University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society	Keyes, WM (corresponding author), Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Carrer Dr Aiguader 88, Barcelona 08003, Spain.	bill.keyes@crg.eu	Ruberte, Jesus/AAS-9240-2021; TIAN, TIAN/O-1726-2015	RUBERTE, JESUS/0000-0003-1540-1432; BATLLE MORERA, LAURA/0000-0002-6924-9002; TIAN, TIAN/0000-0002-9906-0980	La Caixa; Spanish Ministry; Ministerio de Economia y Competitividad [SAF2010-18829, SAF2013-49082-P]; Marie Curie International Reintegration Grant [PIRG5-GA-2009-248262]	La Caixa(La Caixa Foundation); Spanish Ministry(Spanish Government); Ministerio de Economia y Competitividad(Spanish Government); Marie Curie International Reintegration Grant(European Commission)	We thank Roger Gomis and Marc Guiu for help with tumor imaging analysis, Jason Doles for help in the short hairpin design and the CRG Bioinformatics facility for assistance with microarray and sequencing data analysis. VDG was supported by a fellowship from 'La Caixa', and MP with an F. P. I. fellowship from the Spanish Ministry. This work was funded by Grants SAF2010-18829 (WMK) and SAF2013-49082-P (WMK) from the Ministerio de Economia y Competitividad and a Marie Curie International Reintegration Grant PIRG5-GA-2009-248262 (WMK).	Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Burchert A, 1999, BRIT J HAEMATOL, V107, P494, DOI 10.1046/j.1365-2141.1999.01741.x; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Chae YS, 2012, FEBS LETT, V586, P1128, DOI 10.1016/j.febslet.2012.03.021; Crum CP, 2010, ANNU REV PATHOL-MECH, V5, P349, DOI 10.1146/annurev-pathol-121808-102117; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Doherty RE, 2011, BIOCHEM BIOPH RES CO, V414, P801, DOI 10.1016/j.bbrc.2011.10.010; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ferone G, 2015, CELL TISSUE RES, V360, P513, DOI 10.1007/s00441-014-2108-1; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Grisanzio C, 2008, J CELL BIOCHEM, V103, P1354, DOI 10.1002/jcb.21555; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384; Larochelle A, 2012, BLOOD, V119, P1848, DOI 10.1182/blood-2011-08-371583; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Lee HA, 2011, CELL PHYSIOL BIOCHEM, V27, P575, DOI 10.1159/000329979; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Litvinov IV, 2006, PROSTATE, V66, P1329, DOI 10.1002/pros.20483; Liu QX, 2013, CANCER RES, V73, P3297, DOI 10.1158/0008-5472.CAN-12-3970; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mulholland DJ, 2009, CANCER RES, V69, P8555, DOI 10.1158/0008-5472.CAN-08-4673; Nishioka C, 2013, INT J CANCER, V132, P2006, DOI 10.1002/ijc.27904; Olsen JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062547; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Park SI, 2010, CURR PROTOC PHARM, V51, P14, DOI [DOI 10.1002/0471141755.PH1415S51, 10.1002/0471141755.ph1415s51]; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Signoretti S, 2005, P NATL ACAD SCI USA, V102, P11355, DOI 10.1073/pnas.0500165102; Termini CM, 2014, MOL BIOL CELL, V25, P1560, DOI 10.1091/mbc.E13-11-0660; Tien JCY, 2013, CANCER RES, V73, P3997, DOI 10.1158/0008-5472.CAN-12-3929; Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002; Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Valkenburg KC, 2011, PROSTATE CANCER, V2011, DOI 10.1155/2011/895238; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.239; Wu N, 2012, J BIOL CHEM, V287, P5627, DOI 10.1074/jbc.M111.328120; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang KX, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-319	49	13	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4381	4392		10.1038/onc.2017.42	http://dx.doi.org/10.1038/onc.2017.42			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368419	Green Published, hybrid			2022-12-17	WOS:000406806000001
J	Wang, SA; Wang, YC; Chuang, YP; Huang, YH; Su, WC; Chang, WC; Hung, JJ				Wang, S-A; Wang, Y-C; Chuang, Y-P; Huang, Y-H; Su, W-C; Chang, W-C; Hung, J-J			EGF-mediated inhibition of ubiquitin-specific peptidase 24 expression has a crucial role in tumorigenesis	ONCOGENE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; LUNG-CARCINOMA; CELL-CYCLE; CANCER; BAX; DISEASE; ASSOCIATION; APOPTOSIS; USP24; USP40	In this study, several cancer-related proteins (Bax, p300, E2F4 and securin) have been proven to be substrates of ubiquitin-specific peptidase 24 (USP24), and relevance has been shown between USP24 and its substrates in samples from clinical lung cancer patients. Silencing USP24 increases the cancer formation by inhibiting cellular apoptosis and increasing cellular proliferation. Epidermal growth factor ( EGF) treatment, and the Kras(G12D) and EGFR(L858R) mutations decrease USP24 protein stability via EGF- or CDK1-mediated phosphorylation at Ser1616, Ser2047 and Ser2604. Knockdown of USP24 decreases Bax and p300 levels, and reduces Ku70 acetylation, thereby preventing cancer cell apoptosis. In addition, knockdown of USP24 increases cell cycle progression by enhancing the G1-S transition and metaphase-anaphase transition. The molecular mechanism involves a decrease in the USP24 level, which reduces the expression of E2F4 and its partner TFDP1, and thus increases the G1/S transition. In conclusion, the USP24 level was decreased during the early stage of cancer and the mitotic stage of the cell cycle to regulate its substrates p300, Bax, E2F4 and securin, resulting in decreased cell apoptosis and increased cell cycle progression and, thus, cancer formation.	[Wang, S-A; Huang, Y-H; Hung, J-J] Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan, Taiwan; [Wang, S-A; Hung, J-J] Natl Cheng Kung Univ, Dept Biotechnol & Bioind Sci, Coll Biosci & Biotechnol, Tainan, Taiwan; [Wang, Y-C; Hung, J-J] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan, Taiwan; [Chuang, Y-P] Natl Cheng Kung Univ, Dept Pharmacol, Tainan, Taiwan; [Su, W-C] Natl Cheng Kung Univ, Dept Internal Med, Coll Med & Hosp, Tainan, Taiwan; [Chang, W-C] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan; [Chang, W-C; Hung, J-J] Taipei Med Univ, PhD Program Neural Regenerat Med, Taipei, Taiwan; [Hung, J-J] Natl Cheng Kung Univ, Ctr Infect Dis & Signal Transduct, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; Taipei Medical University; National Cheng Kung University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw		Wang, Shao-an/0000-0002-5473-4195; Su, Wu-Chou/0000-0003-2953-4105; Wang, Yi-Chang/0000-0001-9346-5234	Ministry of Science and Technology, Taiwan [104-2923-B-038-002-MY3, 103-2320-B-006-035-MY3, 103-2321-B-006-023]; Taiwan Protein Project [MOST105-0210-01-12-01]; National Cheng Kung University Hospital [DOH105-TD-PB-111-NSC101]; Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Taiwan Protein Project; National Cheng Kung University Hospital; Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital	We are grateful for the support from the Tissue Bank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. We would also like to acknowledge the TCGA Research Network for providing mRNA sequencing data. This work was supported by the grants (104-2923-B-038-002-MY3, 103-2320-B-006-035-MY3 and 103-2321-B-006-023) obtained from the Ministry of Science and Technology, Taiwan. This work was also supported by the Taiwan Protein Project (MOST105-0210-01-12-01). This work was also supported by the grants DOH105-TD-PB-111-NSC101 obtained from National Cheng Kung University Hospital.	Amsel AD, 2008, P NATL ACAD SCI USA, V105, P5117, DOI 10.1073/pnas.0706700105; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Blons H, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-25; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Garg AV, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003699; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Heideker J, 2015, BIOCHEM J, V465, P1, DOI 10.1042/BJ20140496; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Li YH, 2006, HUM MUTAT, V27, P1017, DOI 10.1002/humu.20382; Liu CC, 2014, NUCLEIC ACIDS RES, V42, P9543, DOI 10.1093/nar/gku675; Lukas J, 2004, NATURE, V432, P564, DOI 10.1038/432564a; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; SUN JZ, 1995, CANCER RES, V55, P4243; Takahashi Y, 2000, GENE DEV, V14, P804; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang YC, 2016, ONCOGENE, V35, P3669, DOI 10.1038/onc.2015.432; Wang YQ, 2015, AUTOPHAGY, V11, P595, DOI 10.1080/15548627.2015.1034408; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu YR, 2010, CLIN CHIM ACTA, V411, P955, DOI 10.1016/j.cca.2010.03.013; Zhang YH, 1997, GENOMICS, V39, P95, DOI 10.1006/geno.1996.4473; Zhao B, 2012, EUR NEUROL, V68, P181, DOI 10.1159/000339641; Zhao GY, 2015, TUMOR BIOL, V36, P1721, DOI 10.1007/s13277-014-2773-4	26	13	15	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2930	2945		10.1038/onc.2016.445	http://dx.doi.org/10.1038/onc.2016.445			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27991932	hybrid, Green Published			2022-12-17	WOS:000402000400002
J	Dimitrova, N; Nagaraj, AB; Razi, A; Singh, S; Kamalakaran, S; Banerjee, N; Joseph, P; Mankovich, A; Mittal, P; DiFeo, A; Varadan, V				Dimitrova, N.; Nagaraj, A. B.; Razi, A.; Singh, S.; Kamalakaran, S.; Banerjee, N.; Joseph, P.; Mankovich, A.; Mittal, P.; Difeo, A.; Varadan, V.			InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer	ONCOGENE			English	Article							REVEALS; PHOSPHORYLATION; SENSITIVITY; PATHWAYS; BINDING; TARGET; ALPHA; FOXM1	Characterizing the complex interplay of cellular processes in cancer would enable the discovery of key mechanisms underlying its development and progression. Published approaches to decipher driver mechanisms do not explicitly model tissue-specific changes in pathway networks and the regulatory disruptions related to genomic aberrations in cancers. We therefore developed InFlo, a novel systems biology approach for characterizing complex biological processes using a unique multidimensional framework integrating transcriptomic, genomic and/or epigenomic profiles for any given cancer sample. We show that InFlo robustly characterizes tissue-specific differences in activities of signalling networks on a genome scale using unique probabilistic models of molecular interactions on a per-sample basis. Using large-scale multi-omics cancer datasets, we show that InFlo exhibits higher sensitivity and specificity in detecting pathway networks associated with specific disease states when compared to published pathway network modelling approaches. Furthermore, InFlo's ability to infer the activity of unmeasured signalling network components was also validated using orthogonal gene expression signatures. We then evaluated multi-omics profiles of primary high-grade serous ovarian cancer tumours (N = 357) to delineate mechanisms underlying resistance to frontline platinumbased chemotherapy. InFlo was the only algorithm to identify hyperactivation of the cAMP-CREB1 axis as a key mechanism associated with resistance to platinum-based therapy, a finding that we subsequently experimentally validated. We confirmed that inhibition of CREB1 phosphorylation potently sensitized resistant cells to platinum therapy and was effective in killing ovarian cancer stem cells that contribute to both platinum-resistance and tumour recurrence. Thus, we propose InFlo to be a scalable and widely applicable and robust integrative network modelling framework for the discovery of evidence-based biomarkers and therapeutic targets.	[Dimitrova, N.; Kamalakaran, S.; Banerjee, N.; Mankovich, A.] Philips Res North Amer, Dept Clin Informat Solut & Serv, Briarcliff Manor, NY USA; [Nagaraj, A. B.; Razi, A.; Singh, S.; Joseph, P.; Difeo, A.; Varadan, V.] Case Western Reserve Univ, Case Comprehens Canc Ctr, 2103 Cornell Rd,WRB 3125, Cleveland, OH 44106 USA; [Mittal, P.] Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA	Philips; Philips Research; Case Western Reserve University; Princeton University	DiFeo, A; Varadan, V (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, 2103 Cornell Rd,WRB 3125, Cleveland, OH 44106 USA.	analisa.difeo@case.edu; vinay.varadan@case.edu	Varadan, Vinay/AAC-2520-2020; Singh, Salendra/AAG-8574-2019; Nagaraj, Anil Belur/V-7779-2019	Singh, Salendra/0000-0002-4903-9868; DiFeo, Analisa/0000-0001-8319-6763	PHS award: Career Development Program of Case GI SPORE [P50 CA150964]; PHS award: Career Development Program in Computational Genomic Epidemiology of Cancer [R25T CA094186]; Philips Healthcare; Rosalie and Morton Cohen Family Memorial Genomics Fund of University Hospitals; Ohio Cancer Research award; VelaSano Bike for Cure Funds; Norma I and Al G Geller Endowment in Ovarian Cancer Research (Analisa DiFeo); NATIONAL CANCER INSTITUTE [P50CA150964, R25CA094186] Funding Source: NIH RePORTER	PHS award: Career Development Program of Case GI SPORE; PHS award: Career Development Program in Computational Genomic Epidemiology of Cancer; Philips Healthcare; Rosalie and Morton Cohen Family Memorial Genomics Fund of University Hospitals; Ohio Cancer Research award; VelaSano Bike for Cure Funds; Norma I and Al G Geller Endowment in Ovarian Cancer Research (Analisa DiFeo); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported, in part, by PHS awards: Career Development Program of Case GI SPORE (P50 CA150964) award to Vinay Varadan; Career Development Program in Computational Genomic Epidemiology of Cancer (R25T CA094186) award to Vinay Varadan In addition, this research was supported, in part, by research funding from Philips Healthcare to Vinay Varadan: the Rosalie and Morton Cohen Family Memorial Genomics Fund of University Hospitals to Vinay Varadan: Ohio Cancer Research award to Vinay Varadan: VelaSano Bike for Cure Funds award to Analisa DiFeo and Vinay Varadan: and the Norma I and Al G Geller Endowment in Ovarian Cancer Research (Analisa DiFeo).	Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Benedetti V, 2008, MOL CANCER THER, V7, P679, DOI 10.1158/1535-7163.MCT-07-0450; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Efroni S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000425; Figueroa JD, 2010, BREAST CANCER RES TR, V121, P727, DOI 10.1007/s10549-009-0590-z; Greenblum SI, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-133; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kuroda T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065158; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu JS., 2001, MONTE CARLO STRATEGI, DOI DOI 10.1007/978-0-387-76371-2; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Mutation C, 2015, NAT METHODS, V12, P615, DOI DOI 10.1038/NMETH.3440; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Varadan V, 2012, IEEE SIGNAL PROC MAG, V29, P35, DOI 10.1109/MSP.2011.943037; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Wessels LFA, 2005, BIOINFORMATICS, V21, P3755, DOI 10.1093/bioinformatics/bti429; Xie Y, 2014, MOL MED REP, V10, P2346, DOI 10.3892/mmr.2014.2490; Yang S, 2009, ANESTH ANALG, V108, P964, DOI 10.1213/ane.0b013e318192442c; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	27	13	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2472	2482		10.1038/onc.2016.398	http://dx.doi.org/10.1038/onc.2016.398			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27819677	hybrid, Green Published			2022-12-17	WOS:000400268900012
J	Agaesse, G; Barbollat-Boutrand, L; Sulpice, E; Bhajun, R; El Kharbili, M; Berthier-Vergnes, O; Degoul, F; de la Fouchardiere, A; Berger, E; Voeltzel, T; Lamartine, J; Gidrol, X; Masse, I				Agaesse, G.; Barbollat-Boutrand, L.; Sulpice, E.; Bhajun, R.; El Kharbili, M.; Berthier-Vergnes, O.; Degoul, F.; de la Fouchardiere, A.; Berger, E.; Voeltzel, T.; Lamartine, J.; Gidrol, X.; Masse, I.			A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion	ONCOGENE			English	Article							MEDIATOR COMPLEX; CELL-PROLIFERATION; TRANSCRIPTIONAL REGULATION; HEPATOCELLULAR-CARCINOMA; TETRASPANIN CO-029; OVARIAN-CANCER; GROWTH; MED19; METASTASIS; EXPRESSION	Melanoma is the deadliest form of skin cancer owing to its proclivity to metastasise, and recently developed therapies have not yielded the expected results, because almost all patients relapse. Therefore, understanding the molecular mechanisms that underlie early invasion by melanoma cells is crucial to improving patient survival. We have previously shown that, whereas the Tetraspanin 8 protein (Tspan8) is undetectable in normal skin and benign lesions, its expression arises with the progression of melanoma and is sufficient to increase cell invasiveness. Therefore, to identify Tspan8 transcriptional regulators that could explain the onset of Tspan8 expression, thereby conferring an invasive phenotype, we performed an innovative RNA interference-based screen, which, for the first time, identified several Tspan8 repressors and activators, such as GSK3 beta, PTEN, IQGAP1, TPT1 and LCMR1. LCMR1 is a recently identified protein that is overexpressed in numerous carcinomas; its expression and role, however, had not previously been studied in melanoma. The present study identified Tspan8 as the first LCMR1 target that could explain its function in carcinogenesis. LCMR1 modulation was sufficient to positively regulate endogenous Tspan8 expression, with concomitant in vitro phenotypic changes such as loss of melanoma cell-matrix adherence and increase in invasion, and Tspan8 expression promoted tumourigenicity in vivo. Moreover, LCMR1 and Tspan8 overexpression were shown to correlate in melanoma lesions, and both proteins could be downregulated in vitro by vemurafenib. In conclusion, this study highlights the importance of Tspan8 and its regulators in the control of early melanoma invasion and suggests that they may be promising new therapeutic targets downstream of the RAF-MEK-ERK signalling pathway.	[Agaesse, G.; Barbollat-Boutrand, L.; El Kharbili, M.; Berthier-Vergnes, O.; Lamartine, J.; Masse, I.] Univ Lyon, Lyon, France; [Agaesse, G.; Barbollat-Boutrand, L.; El Kharbili, M.; Berthier-Vergnes, O.; Lamartine, J.; Masse, I.] Univ Lyon 1, Lyon, France; [Agaesse, G.; Barbollat-Boutrand, L.; El Kharbili, M.; Berthier-Vergnes, O.; Lamartine, J.; Masse, I.] CNRS, Ctr Genet & Physiol Mol & Cellulaires, UMR5534, Villeurbanne, France; [Sulpice, E.; Bhajun, R.; Gidrol, X.] Univ Grenoble Alpes, Grenoble, France; [Sulpice, E.; Bhajun, R.; Gidrol, X.] CEA, BIG BGE, Biom, Grenoble, France; [Sulpice, E.; Bhajun, R.; Gidrol, X.] INSERM, BGE, Grenoble, France; [Degoul, F.] Univ Auvergne, Clermont Univ, Imagerie Mol & Therapie Vectorisee, Clermont Ferrand, France; INSERM, U 990, Clermont Ferrand, France; [de la Fouchardiere, A.] Ctr Leon Berard, Dept Biopathol, Lyon, France; [Berger, E.] Univ Lyon, INRA 1397, INSA, Lab CarMeN,INSERM 1060, Lyon, France; [Voeltzel, T.] Univ Lyon 1, Inserm U1052, CNRS UMR5286, Ctr Rech Cancerol Lyon, Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard	Masse, I (corresponding author), Univ Lyon 1, Ctr Genet & Physiol Mol & Cellulaires, CNRS, UMR5534, Batiment Mendel 2eme Etage,16 Rue Dubois, F-69622 Villeurbanne, France.	ingrid.masse@univ-lyon1.fr	de la Fouchardiere, Arnaud/I-2807-2019; DEGOUL, Francoise/Q-4745-2019; DEGOUL, Francoise/L-4856-2015	de la Fouchardiere, Arnaud/0000-0003-2251-8241; DEGOUL, Francoise/0000-0002-0206-3350; DEGOUL, Francoise/0000-0002-0206-3350; Voeltzel, Thibault/0000-0001-7099-8716; Sulpice, Eric/0000-0001-7695-0561; Lamartine, Jerome/0000-0003-2322-1618; Gidrol, Xavier/0000-0002-4233-3749; MASSE, Ingrid/0000-0003-3193-970X	French Society for Dermatological Research (SRD); La Ligue Contre le Cancer (Comite Ardeche); association 'Vaincre le Melanome'; Roche Company	French Society for Dermatological Research (SRD); La Ligue Contre le Cancer (Comite Ardeche); association 'Vaincre le Melanome'; Roche Company	We thank Elise Malandain for technical assistance and Cyril Py for immunohistochemical processing, Stephanie Combe and Patricia Obeid for RNAi screening, Alain Geloen for adhesion assays, and Tiffany Witkowski and Janine Papon for experiments on mice. This work was supported by a grant from the French Society for Dermatological Research (SRD) and a grant from La Ligue Contre le Cancer (Comite Ardeche) and a grant from the association 'Vaincre le Melanome'. We acknowledge the Roche Company for financial support for manuscript writing and publication.	Ailane N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00364; Allen BL, 2015, NAT REV MOL CELL BIO, V16, P155, DOI 10.1038/nrm3951; Berthier-Vergnes O, 2011, BRIT J CANCER, V104, P155, DOI 10.1038/sj.bjc.6605994; BERTHIERVERGNES O, 1993, LANCET, V341, P1292, DOI 10.1016/0140-6736(93)91205-Z; Byers Hugh Randolph, 1992, Journal of Dermatology (Tokyo), V19, P847; Chen LA, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-18; Cochran AJ, 1999, HUM PATHOL, V30, P556, DOI 10.1016/S0046-8177(99)90201-0; Colombino M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.136; Conde-Perez A, 2012, FUTURE ONCOL, V8, P1109, DOI [10.2217/fon.12.106, 10.2217/FON.12.106]; Cui XG, 2011, BMB REP, V44, P547, DOI 10.5483/BMBRep.2011.44.8.547; Ding XF, 2012, GENE, V504, P262, DOI 10.1016/j.gene.2012.04.033; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Gesierich S, 2006, CANCER RES, V66, P7083, DOI 10.1158/0008-5472.CAN-06-0391; Greco C, 2010, CANCER RES, V70, P7674, DOI 10.1158/0008-5472.CAN-09-4482; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Ishimura N, 2003, CANCER LETT, V199, P169, DOI 10.1016/S0304-3835(03)00384-7; Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165; Ji-Fu E, 2012, MOL BIOL REP, V39, P3675, DOI 10.1007/s11033-011-1142-2; John JK, 2012, J INVEST DERMATOL, V132, P2818, DOI 10.1038/jid.2012.237; Kanetaka K, 2001, J HEPATOL, V35, P637, DOI 10.1016/S0168-8278(01)00183-0; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kubic JD, 2012, MOL CANCER RES, V10, P1065, DOI 10.1158/1541-7786.MCR-11-0387; Le Naour F, 2006, MOL CELL PROTEOMICS, V5, P845, DOI 10.1074/mcp.M500330-MCP200; LeNaour F, 1996, ONCOGENE, V13, P481; Li LH, 2011, CANCER CHEMOTH PHARM, V68, P207, DOI 10.1007/s00280-010-1468-9; Li XH, 2011, CANCER BIOTHER RADIO, V26, P495, DOI 10.1089/cbr.2010.0863; Liu YT, 2012, MOL MED REP, V6, P1050, DOI 10.3892/mmr.2012.1065; Lu Z., 2015, MATH PROBLEM ENG, V2015, P1, DOI DOI 10.3389/FPSYG.2015; Mekky RY, 2015, J INFECTION, V70, P78, DOI 10.1016/j.jinf.2014.08.013; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Nazarenko I, 2010, CANCER RES, V70, P1668, DOI 10.1158/0008-5472.CAN-09-2470; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Park CS, 2016, ONCOGENE, V35, P4540, DOI 10.1038/onc.2015.520; Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118; Plaschka C, 2015, NATURE, V518, P376, DOI 10.1038/nature14229; Saalbach A, 2005, ONCOGENE, V24, P4710, DOI 10.1038/sj.onc.1208559; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Spagnolo F, 2014, ONCOTARGET, V5, P10206, DOI 10.18632/oncotarget.2602; Sun M, 2011, MOL CELL BIOCHEM, V355, P27, DOI 10.1007/s11010-011-0835-0; Tikhmyanova N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022102; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Wang TJ, 2011, ONCOL RES, V19, P193, DOI 10.3727/096504011X12970940207760; Wei LS, 2015, INT J CLIN EXP MED, V8, P8599; Wen H, 2013, ANN DIAGN PATHOL, V17, P259, DOI 10.1016/j.anndiagpath.2012.11.004; Xu YQ, 2012, PROG NEUROBIOL, V97, P1, DOI 10.1016/j.pneurobio.2012.02.002; Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004; Yu WX, 2014, EUR J CANCER, V50, P1125, DOI 10.1016/j.ejca.2014.01.030; Yue SJ, 2015, ONCOTARGET, V6, P2366, DOI 10.18632/oncotarget.2958; Zhang H, 2012, UROL ONCOL-SEMIN ORI, V30, P920, DOI 10.1016/j.urolonc.2010.10.003; Zhou Z, 2008, CLIN EXP METASTAS, V25, P537, DOI 10.1007/s10585-008-9168-0; Zhu LJ, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-116; Zou SW, 2011, ACTA PHARMACOL SIN, V32, P354, DOI 10.1038/aps.2010.223	55	13	13	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					446	457		10.1038/onc.2016.219	http://dx.doi.org/10.1038/onc.2016.219			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27375018				2022-12-17	WOS:000394166700002
J	Yang, M; Lewinska, M; Fan, X; Zhu, J; Yuan, ZM				Yang, M.; Lewinska, M.; Fan, X.; Zhu, J.; Yuan, Z-M			PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis	ONCOGENE			English	Article							PROTEIN-KINASE B/AKT; TERMINAL SH3 DOMAIN; PROLINE-RICH MOTIFS; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-SURVIVAL; CRYSTAL-STRUCTURE; RAS; GRB2; SUBUNIT; SRC	Chromosomal focal amplifications often cause an increase in gene copy number, contributing to the pathogenesis of cancer. PRR14 overexpression is associated with recurrent locus amplification in lung cancer, and it correlates with a poor prognosis. We show that increased PRR14 expression promoted and reduced PRR14 expression impeded lung cancer cell proliferation. Interestingly, PRR14 cells were markedly enlarged in size and exhibited an elevated activity of the PI3-kinase/Akt/mTOR pathway, which was associated with a heightened sensitivity to the inhibitors of PI3K and mammalian target of rapamycin (mTOR). Biochemical analysis revealed that PRR14, as a proline-rich protein, binds to the Src homology 3 (SH3) domains of GRB2 resulting in PI3K activation. Significantly, two cancer patient-derived PRR14 mutants displayed considerably augmented GRB2-binding and an enhanced ability of promoting cell proliferation. Together with the in vivo data demonstrating a strong tumor-promoting activity of PRR14 and the mutants, our work uncovered this proline-rich protein as a novel activator of the PI3K pathway that promoted tumorigenesis in lung cancer.	[Yang, M.; Lewinska, M.; Fan, X.; Zhu, J.; Yuan, Z-M] Harvard TH Chan Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Sch Publ Hlth, Dept Genet & Complex Dis, 655 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Lewinska, Monika/N-9919-2017	Lewinska, Monika/0000-0002-5275-992X; yang, mei/0000-0001-9574-2282	Morningside Foundation; Zhu Fund; National Cancer Institute at the National Institutes of Health [R01CA085679, RO1CA167814, RO1CA125144]; NATIONAL CANCER INSTITUTE [R01CA085679, R01CA125144, R01CA167814, R01CA183074] Funding Source: NIH RePORTER	Morningside Foundation; Zhu Fund; National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to current and former members of the Yuan laboratory for support, advice and helpful discussions. We thank Dr Brendan Manning for reagents. This work was supported in part by the Morningside Foundation, the Zhu Fund and grants from the National Cancer Institute at the National Institutes of Health (R01CA085679, RO1CA167814 and RO1CA125144).	Ball LJ, 2005, ANGEW CHEM INT EDIT, V44, P2852, DOI 10.1002/anie.200400618; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Brognard J, 2001, CANCER RES, V61, P3986; Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Castellano E, 2010, CURR TOP MICROBIOL, V346, P143, DOI 10.1007/82_2010_56; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng HY, 2014, LUNG CANCER MANAG, V3, P67, DOI 10.2217/LMT.13.72; DALY RJ, 1994, ONCOGENE, V9, P2723; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GURUPRASAD L, 1995, J MOL BIOL, V248, P856, DOI 10.1006/jmbi.1995.0266; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Job B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015145; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin XB, 2001, LANGENBECK ARCH SURG, V386, P293, DOI 10.1007/s004230100203; Liu AX, 1998, CANCER RES, V58, P2973; Lysek DA, 2004, BIOCHEMISTRY-US, V43, P10393, DOI 10.1021/bi0494828; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; Massion PP, 2004, AM J RESP CRIT CARE, V170, P1088, DOI 10.1164/rccm.200404-487OC; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541; Poleshko A, 2013, CELL REP, V5, P292, DOI 10.1016/j.celrep.2013.09.024; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Shen XC, 2010, J BIOL CHEM, V285, P29416, DOI 10.1074/jbc.M110.155325; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Spoerke JM, 2012, CLIN CANCER RES, V18, P6771, DOI 10.1158/1078-0432.CCR-12-2347; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420; Wissmueller S, 2011, PROTEINS, V79, P2365, DOI 10.1002/prot.23068; Yang XL, 2011, CELL RES, V21, P715, DOI 10.1038/cr.2011.63; YANG YS, 1994, EMBO J, V13, P1270, DOI 10.1002/j.1460-2075.1994.tb06379.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	13	15	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5527	5538		10.1038/onc.2016.93	http://dx.doi.org/10.1038/onc.2016.93			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27041574	Green Accepted			2022-12-17	WOS:000386998200007
J	Zhang, S; Matsunaga, S; Lin, YF; Sishc, B; Shang, Z; Sui, J; Shih, HY; Zhao, Y; Foreman, O; Story, MD; Chen, DJ; Chen, BPC				Zhang, S.; Matsunaga, S.; Lin, Y-F; Sishc, B.; Shang, Z.; Sui, J.; Shih, H-Y; Zhao, Y.; Foreman, O.; Story, M. D.; Chen, D. J.; Chen, B. P. C.			Spontaneous tumor development in bone marrow-rescued DNA-PKcs(3A/3A) mice due to dysfunction of telomere leading strand deprotection	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; HUMAN SOMATIC-CELLS; DNA-PKCS; CATALYTIC SUBUNIT; BREAK REPAIR; DYSKERATOSIS-CONGENITA; CANCER-CELLS; AUTOPHOSPHORYLATION; OVERHANG; DAMAGE	Phosphorylation of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) at the Thr2609 cluster is essential for its complete function in DNA repair and tissue stem cell homeostasis. This phenomenon is demonstrated by congenital bone marrow failure occurring in DNA-PKcs(3A/3A) mutant mice, which require bone marrow transplantation (BMT) to prevent early mortality. Surprisingly, an increased incidence of spontaneous tumors, especially skin cancer, was observed in adult BMT-rescued DNA-PKcs(3A/3A) mice. Upon further investigation, we found that spontaneous yH2AX foci occurred in DNA-PKcs(3A/3A) skin biopsies and primary keratinocytes and that these foci overlapped with telomeres during mitosis, indicating impairment of telomere replication and maturation. Consistently, we observed significantly elevated frequencies of telomere fusion events in DNA-PKcs3A/3A cells as compared with wild-type and DNA-PKcs-knockout cells. In addition, a previously identified DNA-PKcs Thr2609Pro mutation, found in breast cancer, also induces a similar impairment of telomere leading-end maturation. Taken together, our current analyses indicate that the functional DNA-PKcs T2609 cluster is required to facilitate telomere leading strand maturation and prevention of genomic instability and cancer development.	[Zhang, S.; Matsunaga, S.; Lin, Y-F; Sishc, B.; Shang, Z.; Sui, J.; Shih, H-Y; Story, M. D.; Chen, D. J.; Chen, B. P. C.] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, 2201 Inwood Rd,Room NC7-206, Dallas, TX 75390 USA; [Zhang, S.] Sichuan Canc Hosp, Dept Radiat Oncol, Chengdu 610041, Peoples R China; [Matsunaga, S.] Tottori Univ, Dept Pathophysiol & Therapeut Sci, Div Mol Pharmacol, Yonago, Tottori, Japan; [Zhao, Y.] Sun Yat Sen Univ, Sch Life Sci, Cooperat Innovat Ctr High Performance Comp, Key Lab Gene Engn,Minist Educ, Guangzhou, Guangdong, Peoples R China; [Foreman, O.] Jackson Lab, Sacramento, CA USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Tottori University; Sun Yat Sen University; Jackson Laboratory	Zhang, S; Chen, BPC (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, 2201 Inwood Rd,Room NC7-206, Dallas, TX 75390 USA.; Zhang, S (corresponding author), Sichuan Canc Hosp, Dept Radiat Oncol, Chengdu 610041, Peoples R China.	zhangsc65@hotmail.com; benjamin.chen@utsouthwestern.edu	Story, Michael/AAX-2864-2021; Sishc, Brock James/ABE-4487-2021; Sui, Jiang-Dong/AAU-6005-2021	Story, Michael/0000-0001-6522-4169; 	National Institutes of Health [CA166677]; Cancer Prevention Research Institute of Texas [RP110465]; NATIONAL CANCER INSTITUTE [R01CA166677] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health (CA166677) and the Cancer Prevention Research Institute of Texas (RP110465) to BPC. We thank Dr Titia de Lange for kindly providing anti-TRF1 antibody, and Dr Damiana Chiavolini for critical reading and editing of the manuscript.	Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bombarde O, 2010, EMBO J, V29, P1573, DOI 10.1038/emboj.2010.49; Chai WH, 2006, MOL CELL, V21, P427, DOI 10.1016/j.molcel.2005.12.004; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200; Chow TT, 2012, GENE DEV, V26, P1167, DOI 10.1101/gad.187211.112; Convery E, 2005, P NATL ACAD SCI USA, V102, P1345, DOI 10.1073/pnas.0406466102; Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Giunta S, 2010, J CELL BIOL, V190, P197, DOI 10.1083/jcb.200911156; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Hammel M, 2010, J BIOL CHEM, V285, P1414, DOI 10.1074/jbc.M109.065615; Hayashi MT, 2012, NAT STRUCT MOL BIOL, V19, P387, DOI 10.1038/nsmb.2245; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Heijink AM, 2013, MUTAT RES-FUND MOL M, V750, P45, DOI 10.1016/j.mrfmmm.2013.07.003; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Hsu FM, 2012, TRANSL CANCER RES, V1, P22, DOI 10.3978/j.issn.2218-676X.2012.04.01; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Ishii-Ohba H, 2007, MUTAT RES-FUND MOL M, V619, P124, DOI 10.1016/j.mrfmmm.2007.02.028; Jiang WX, 2015, MOL CELL, V58, P172, DOI 10.1016/j.molcel.2015.02.024; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Khadka P, 2014, BIOCHEM J, V463, P19, DOI 10.1042/BJ20131395; Kirwan M, 2008, CLIN GENET, V73, P103, DOI 10.1111/j.1399-0004.2007.00923.x; Laud PR, 2005, GENE DEV, V19, P2560, DOI 10.1101/gad.1321305; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Meek K, 2007, MOL CELL BIOL, V27, P3881, DOI 10.1128/MCB.02366-06; Mikkola HKA, 2006, DEVELOPMENT, V133, P3733, DOI 10.1242/dev.02568; Mirchandani KD, 2006, EXP CELL RES, V312, P2647, DOI 10.1016/j.yexcr.2006.06.014; Nishio N, 2010, INT J HEMATOL, V92, P419, DOI 10.1007/s12185-010-0695-5; Orthwein A, 2014, SCIENCE, V344, P189, DOI 10.1126/science.1248024; Poon Steven S S, 2001, Curr Protoc Cell Biol, VChapter 18, DOI 10.1002/0471143030.cb1804s12; Potts PR, 2007, NAT STRUCT MOL BIOL, V14, P581, DOI 10.1038/nsmb1259; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Ruis BL, 2008, MOL CELL BIOL, V28, P6182, DOI 10.1128/MCB.00355-08; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Sui JD, 2015, NUCLEIC ACIDS RES, V43, P5971, DOI 10.1093/nar/gkv539; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Wang XS, 2008, CANCER RES, V68, P971, DOI 10.1158/0008-5472.CAN-07-6272; Wang YB, 2009, P NATL ACAD SCI USA, V106, P12430, DOI 10.1073/pnas.0903362106; Williams ES, 2009, CANCER RES, V69, P2100, DOI 10.1158/0008-5472.CAN-08-2854; Wu P, 2010, MOL CELL, V39, P606, DOI 10.1016/j.molcel.2010.06.031; Yajima H, 2006, MOL CELL BIOL, V26, P7520, DOI 10.1128/MCB.00048-06; YU H, 1993, BLOOD, V81, P373; Zhang SC, 2011, J CELL BIOL, V193, P295, DOI 10.1083/jcb.201009074; Zhao Y, 2009, CELL, V138, P463, DOI 10.1016/j.cell.2009.05.026	49	13	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3909	3918		10.1038/onc.2015.459	http://dx.doi.org/10.1038/onc.2015.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26616856	Green Accepted			2022-12-17	WOS:000381013100003
J	Saran, S; Tran, DDH; Ewald, F; Koch, A; Hoffmann, A; Koch, M; Nashan, B; Tamura, T				Saran, S.; Tran, D. D. H.; Ewald, F.; Koch, A.; Hoffmann, A.; Koch, M.; Nashan, B.; Tamura, T.			Depletion of three combined THOC5 mRNA export protein target genes synergistically induces human hepatocellular carcinoma cell death	ONCOGENE			English	Article							INTERACTING PROTEIN; TREX COMPLEX; FMIP; TRANSCRIPTION; CONTRIBUTES; KINASES; MEMBER	Hepatocellular carcinoma (HCC) is a frequent form of cancer with a poor prognosis and with limited possibilities of medical intervention. It has been shown that over 100 putative driver genes are associated with multiple recurrently altered pathways in HCC, suggesting that multiple pathways will need to be inhibited for any therapeutic method. mRNA processing is regulated by a complex RNA-protein network that is essential for the maintenance of homeostasis. THOC5, a member of mRNA export complex, has a role in less than 1% of mRNA processing, and is required for cell growth and differentiation, but not for cell survival in normal fibroblasts, hepatocytes and macrophages. In this report, we show that 50% depletion of THOC5 in human HCC cell lines Huh7 and HepG2 induced apoptosis. Transcriptome analysis using THOC5-depleted cells revealed that 396 genes, such as transmembrane BAX inhibitor motif containing 4 (TMBIM4), transmembrane emp24-like trafficking protein 10 (Tmed10) and D-tyrosyl-tRNA deacylase 2 (Dtd2) genes were downregulated in both cell lines. The depletion of one of these THOC5 target genes in Huh7 or HepG2 did not significantly induce cell death, suggesting that these may be fine tuners for HCC cell survival. However, the depletion of a combination of these genes synergistically increased the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling)-positive HCC. It must be noted that the depletion of these genes did not induce cell death in the hepatocyte cell line, THLE-2 cells. THOC5 expression was enhanced in 78% of cytological differentiation grading G2 and G3 tumor in primary HCC. Furthermore, the expression of a putative glycoprotein, Tmed10, is correlated to THOC5 expression level in primary HCCs, suggesting that this protein may be a novel biomarker for HCC. These data imply that the suppression of the multiple THOC5 target genes may represent a novel strategy for HCC therapy.	[Saran, S.; Tran, D. D. H.; Koch, A.; Tamura, T.] Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany; [Ewald, F.; Koch, M.; Nashan, B.] Univ Med Ctr Eppendorf, Dept Hepatobiliary & Transplant Surg, Hamburg, Germany; [Hoffmann, A.] Hannover Med Sch, Klin Orthopadie, OE8893, Hannover, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	Tamura.Teruko@MH-Hannover.de	Tran, Doan Duy Hai/AGU-7573-2022; Hoffmann, Andrea/AAG-4488-2020; Koch, Martina/AAJ-6611-2020; Nashan, Björn/H-9087-2019	Tran, Doan Duy Hai/0000-0003-2392-0259; Hoffmann, Andrea/0000-0003-2318-8985; Nashan, Björn/0000-0001-7587-9935	Deutsche Krebshilfe [111153]; DFG [Ta-111/13-1]; PhD program Molecular Medicine; Leistungsorientierte Mittelvergabe	Deutsche Krebshilfe(Deutsche Krebshilfe); DFG(German Research Foundation (DFG)); PhD program Molecular Medicine; Leistungsorientierte Mittelvergabe	We thank C Bruce Boschek for critically reading the manuscript and Iris Albers and Annika Hamm for technical assistance. SS and DDHT contributed equally to this work. This research was supported by Deutsche Krebshilfe (111153), DFG Ta-111/13-1, and PhD program Molecular Medicine and Leistungsorientierte Mittelvergabe with Frauenfaktor from MHH.	Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Corkery DP, 2015, NUCLEUS-PHILA, V6, P279, DOI 10.1080/19491034.2015.1062194; Tran DDH, 2014, NUCLEIC ACIDS RES, V42, P12249, DOI 10.1093/nar/gku911; Ferrin G, 2015, HEPATIC MED-EVID RES, V7, P1, DOI 10.2147/HMER.S50161; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Griaud F, 2013, LEUKEMIA, V27, P932, DOI 10.1038/leu.2012.283; Gubser C, 2007, PLOS PATHOG, V3, P246, DOI 10.1371/journal.ppat.0030017; Guria A, 2011, RNA, V17, P1048, DOI 10.1261/rna.2607011; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Jimeno Sonia, 2010, Journal of Biology (London), V8, P6, DOI 10.1186/jbiol217; Koch A, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0073-7; Maguire SL, 2015, J PATHOL, V235, P571, DOI 10.1002/path.4483; Mancini A, 2007, ONCOGENE, V26, P1020, DOI 10.1038/sj.onc.1209853; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; Mancini A, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-1; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Panagopoulos I, 2014, INT J ONCOL, V45, P1829, DOI 10.3892/ijo.2014.2605; Pierce A, 2008, BRIT J HAEMATOL, V141, P641, DOI 10.1111/j.1365-2141.2008.07090.x; Rehwinkel J, 2004, NAT STRUCT MOL BIOL, V11, P558, DOI 10.1038/nsmb759; Saran S, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-51; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Tran DDH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.409; Tran DDH, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-3; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236	27	13	14	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3872	3879		10.1038/onc.2015.433	http://dx.doi.org/10.1038/onc.2015.433			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26549021				2022-12-17	WOS:000380753200012
J	Parsel, SM; Grandis, JR; Thomas, SM				Parsel, S. M.; Grandis, J. R.; Thomas, S. M.			Nucleic acid targeting: towards personalized therapy for head and neck cancer	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; HERPES-SIMPLEX-VIRUS; P53 GENE-TRANSFER; SMALL INTERFERING RNA; MULTICENTER PHASE-II; FACTOR-KAPPA-B; IN-VIVO; RECURRENT HEAD; GLUCOSYLATED POLYETHYLENIMINE	In light of a detailed characterization of genetic aberrations in cancer, nucleic acid targeting represents an attractive therapeutic approach with significant translational potential. Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer deaths worldwide with stagnant 5-year survival rates. Advances in conventional treatment have done little to improve survival and combined chemoradiation is associated with significant adverse effects. Recent reports have characterized the genetic alterations in HNSCC and demonstrated that mutations confer resistance to conventional and molecular targeted therapies. The ability to use specific nucleic acid sequences to inhibit cancer-associated genes including non-druggable targets facilitates personalized medicine approaches with less adverse effects. Additionally, advances in drug delivery mechanisms have increased the transfection efficiency aiding in greater therapeutic responses. Given these advances, the stage has been set to translate the information garnered from genomic studies into personalized treatment strategies. Genes involved in the tumor protein 53 and epidermal growth factor receptor pathways have been extensively investigated and many promising preclinical studies have shown tumor inhibition through genetic modulation. We, and others, have demonstrated that targeting oncogene expression with gene therapy approaches is feasible in patients. Other methods such as RNA interference have proven to be effective and are potential candidates for clinical studies. This review summarizes the major advances in sequence-specific gene modulation in the preclinical setting and in clinical trials in head and neck cancer patients.	[Parsel, S. M.; Thomas, S. M.] Univ Kansas, Med Ctr, Dept Otolaryngol, Kansas City, KS 66103 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Thomas, S. M.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA; [Thomas, S. M.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Thomas, SM (corresponding author), Univ Kansas, Med Ctr, 3901 Rainbow Blvd,3020A Wahl Hall East, Kansas City, KS 66160 USA.	sthomas7@kumc.edu	Thomas, Sufi Mary/AFR-1642-2022; Parsel, Sean Michael/AAZ-4251-2020; Thomas, Sufi/O-1487-2018; Parsel, Sean Michael/G-1228-2013	Thomas, Sufi Mary/0000-0001-5370-0842; Parsel, Sean Michael/0000-0003-0821-7784; Thomas, Sufi/0000-0001-5370-0842; Parsel, Sean Michael/0000-0003-0821-7784	Department of Otolaryngology, University of Kansas Medical Center; University of Kansas Cancer Center's CCSG [1-P30-CA168524-02]; Kansas Intellectual and Developmental Disabilities Center [NICHD HD00258]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002528] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA097190, P30CA168524] Funding Source: NIH RePORTER	Department of Otolaryngology, University of Kansas Medical Center; University of Kansas Cancer Center's CCSG; Kansas Intellectual and Developmental Disabilities Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hinrich Staecker, Department of Otolaryngology, University of Kansas Medical Center, Kansas City, KS and Dr Stefan Rothenberg, K-State University, Manhattan, KS for critical review of the manuscript. We also thank Mr Phil Shafer for the artwork. We apologize to authors whose work was not cited due to space constraints. Department of Otolaryngology, University of Kansas Medical Center and University of Kansas Cancer Center's CCSG (1-P30-CA168524-02), and the Kansas Intellectual and Developmental Disabilities Center (NICHD HD00258) were the funding sources.	Accardi R, 2008, WORLD CANC REPORT 20, P30; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blackwell JL, 1999, ARCH OTOLARYNGOL, V125, P856, DOI 10.1001/archotol.125.8.856; Boehm AL, 2008, MOL PHARMACOL, V73, P1632, DOI 10.1124/mol.107.044636; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Carson AR, 2012, CANCER RES, V72, P6191, DOI 10.1158/0008-5472.CAN-11-4079; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; Chang EH, 1997, ARCH OTOLARYNGOL, V123, P507; Chen SM, 2008, CANCER BIOL THER, V7, P734, DOI 10.4161/cbt.7.5.5722; Chen WH, 2015, CANCER LETT, V359, P65, DOI 10.1016/j.canlet.2014.12.052; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Cohen EEW, 2004, J CLIN ONCOL, V22, P1743, DOI 10.1200/JCO.2004.06.147; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; Deng Y, 2014, GENE, V538, P217, DOI 10.1016/j.gene.2013.12.019; Dobrossy L, 2005, CANCER METAST REV, V24, P9, DOI 10.1007/s10555-005-5044-4; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dolivet G, 2002, CANCER GENE THER, V9, P708, DOI 10.1038/sj.cgt.7700485; Duan JM, 2007, MOL CANCER THER, V6, P37, DOI 10.1158/1535-7163.MCT-05-0285; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Ferris RL, 2007, CLIN CANCER RES, V13, P5663, DOI 10.1158/1078-0432.CCR-07-1544; Fujimoto Y, 2006, ACTA OTO-LARYNGOL, V126, P1115, DOI 10.1080/00016480600702100; Ganly I, 2000, CLIN CANCER RES, V6, P798; Garber K, 2006, J NATL CANCER I, V98, P298, DOI 10.1093/jnci/djj111; Gleich LL, 1998, ARCH OTOLARYNGOL, V124, P1097, DOI 10.1001/archotol.124.10.1097; Gleich LL, 2001, ARCH OTOLARYNGOL, V127, P775; Graff JR, 2007, J CLIN INVEST, V117, P2638, DOI 10.1172/JCI32044; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Guttmann DM, 2013, INT J RADIAT ONCOL, V87, P168, DOI 10.1016/j.ijrobp.2013.05.028; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; Hazar-Rethinam M, 2015, CLIN CANCER RES, V21, P417, DOI 10.1158/1078-0432.CCR-14-1962; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; Heise CC, 1999, CANCER RES, V59, P2623; Hong DS, 2011, CLIN CANCER RES, V17, P6582, DOI 10.1158/1078-0432.CCR-11-0430; Hsin CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113129; Hu JCC, 2006, CLIN CANCER RES, V12, P6737, DOI 10.1158/1078-0432.CCR-06-0759; Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706; Jing NJ, 2006, MOL CANCER THER, V5, P279, DOI 10.1158/1535-7163.MCT-05-0302; Kanazawa T, 2003, GENE THER, V10, P51, DOI 10.1038/sj.gt.3301837; Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6; Kawakami K, 2001, CANCER RES, V61, P6194; Kedmi R, 2010, BIOMATERIALS, V31, P6867, DOI 10.1016/j.biomaterials.2010.05.027; Kindt N, 2014, J CANCER RES CLIN, V140, P937, DOI 10.1007/s00432-014-1648-9; Klein JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081819; Konopka K, 2006, CELL MOL BIOL LETT, V11, P171, DOI 10.2478/s11658-006-0015-5; Kothari V, 2012, ANTICANCER RES, V32, P121; Lai SY, 2009, J CLIN ONCOL, V27, P1235, DOI 10.1200/JCO.2008.17.8251; Lalonde ES, 2002, HEAD NECK-J SCI SPEC, V24, P1038, DOI 10.1002/hed.10148; Lamont JP, 2000, ANN SURG ONCOL, V7, P588, DOI 10.1007/BF02725338; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Li DQ, 1999, CLIN CANCER RES, V5, P1551; Li MF, 2002, CLIN CANCER RES, V8, P3570; Li Y, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-16; Liu Dan, 2006, Ai Zheng, V25, P11; LIU TJ, 1995, CANCER RES, V55, P3117; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Lun MY, 2005, ANN CLIN LAB SCI, V35, P251; Mace ATM, 2007, ACTA OTO-LARYNGOL, V127, P880, DOI 10.1080/00016480601075381; Mace ATM, 2008, HEAD NECK-J SCI SPEC, V30, P1045, DOI 10.1002/hed.20840; Mansoori B, 2014, ADV PHARM BULL, V4, P313, DOI 10.5681/apb.2014.046; Masuelli L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-122; Matsui M, 2009, CANCER RES, V69, P2523, DOI 10.1158/0008-5472.CAN-08-2793; Mazumdar A, 2009, HEAD NECK-J SCI SPEC, V31, P625, DOI 10.1002/hed.21007; Michaluart P, 2008, CANCER GENE THER, V15, P676, DOI 10.1038/cgt.2008.35; Morris JC, 2000, MOL THER, V1, P56, DOI 10.1006/mthe.1999.0014; Ndoye A, 2004, INT J ONCOL, V25, P1575; Nemunaitis J, 2009, CLIN CANCER RES, V15, P7719, DOI 10.1158/1078-0432.CCR-09-1044; Nozawa H, 2006, CANCER SCI, V97, P1115, DOI 10.1111/j.1349-7006.2006.00287.x; Okunaga S, 2015, CANCER GENE THER, V22, P163, DOI 10.1038/cgt.2015.3; OMALLEY BW, 1995, CANCER RES, V55, P1080; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Park IK, 2005, ARCH PHARM RES, V28, P1302, DOI 10.1007/BF02978216; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Rahman MA, 2012, J CONTROL RELEASE, V159, P384, DOI 10.1016/j.jconrel.2012.01.045; Rao DD, 2009, ADV DRUG DELIVER REV, V61, P746, DOI 10.1016/j.addr.2009.04.004; Ren H, 2015, MED ONCOL, V32, P1; Saba NF, 2015, ORAL ONCOL, V51, P112, DOI 10.1016/j.oraloncology.2014.11.002; Sahu B, 2009, J ORG CHEM, V74, P1509, DOI 10.1021/jo802211n; Seiwert TY, 2013, ANN ONCOL, V24, P769, DOI 10.1093/annonc/mds523; Sen M, 2012, CANCER DISCOV, V2, P694, DOI 10.1158/2159-8290.CD-12-0191; Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675; Shimizu S, 2008, INT J CANCER, V123, P1816, DOI 10.1002/ijc.23710; Shin EJ, 2007, LARYNGOSCOPE, V117, P210, DOI 10.1097/01.mlg.0000246194.66295.d8; Skinner HD, 2012, CLIN CANCER RES, V18, P290, DOI 10.1158/1078-0432.CCR-11-2260; Smith NB, 2003, ULTRASOUND MED BIOL, V29, P311, DOI 10.1016/S0301-5629(02)00706-8; Sobral LM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-32; Sok JC, 2006, CLIN CANCER RES, V12, P5064, DOI 10.1158/1078-0432.CCR-06-0913; Sorace AG, 2014, ULTRASOUND MED BIOL, V40, P755, DOI 10.1016/j.ultrasmedbio.2013.11.002; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sugano M, 2012, INT J PHARMACEUT, V422, P332, DOI 10.1016/j.ijpharm.2011.11.001; Suzuki R, 2007, J CONTROL RELEASE, V117, P130, DOI 10.1016/j.jconrel.2006.09.008; Tassone P, 2013, ORAL ONCOL, V49, P733, DOI 10.1016/j.oraloncology.2013.03.447; Thomas SM, 2003, CANCER GENE THER, V10, P518, DOI 10.1038/sj.cgt.7700567; Thomas SM, 2013, ACS CHEM BIOL, V8, P345, DOI 10.1021/cb3003946; Thomas SM, 2008, MOL PHARMACOL, V73, P627, DOI 10.1124/mol.107.041160; Tousignant JD, 2000, HUM GENE THER, V11, P2493, DOI 10.1089/10430340050207984; van den Broek GB, 2007, CLIN CANCER RES, V13, P4386, DOI 10.1158/1078-0432.CCR-06-2817; Vannucci L, 2013, NEW MICROBIOL, V36, P1; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Villaret D, 2002, HEAD NECK-J SCI SPEC, V24, P661, DOI 10.1002/hed.10107; Wang Y, 2008, CANCER BIOL THER, V7, P896, DOI 10.4161/cbt.7.6.5910; Wang YD, 2013, TECHNOL CANCER RES T, V12, P525, DOI 10.7785/tcrt.2012.500343; Xu L, 2002, MOL CANCER THER, V1, P337; Xu L, 2001, MOL MED, V7, P723, DOI 10.1007/BF03401962; Xu LA, 1999, HUM GENE THER, V10, P2941, DOI 10.1089/10430349950016357; Yoo GH, 2009, ARCH OTOLARYNGOL, V135, P869, DOI 10.1001/archoto.2009.122; Yuen AR, 1999, CLIN CANCER RES, V5, P3357; Zaoui K, 2012, CANCER GENE THER, V19, P181, DOI 10.1038/cgt.2011.75; Zeng Qing, 2002, J Exp Ther Oncol, V2, P174, DOI 10.1046/j.1359-4117.2002.01033.x; Zhang QZ, 2004, INT J CANCER, V111, P849, DOI 10.1002/ijc.20334	114	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 23	2016	35	25					3217	3226		10.1038/onc.2015.424	http://dx.doi.org/10.1038/onc.2015.424			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP2GN	26592450	Bronze, Green Accepted, Green Submitted			2022-12-17	WOS:000378306400001
J	Felli, N; Errico, MC; Pedini, F; Petrini, M; Puglisi, R; Bellenghi, M; Boe, A; Felicetti, F; Mattia, G; De Feo, A; Bottero, L; Tripodo, C; Care, A				Felli, N.; Errico, M. C.; Pedini, F.; Petrini, M.; Puglisi, R.; Bellenghi, M.; Boe, A.; Felicetti, F.; Mattia, G.; De Feo, A.; Bottero, L.; Tripodo, C.; Care, A.			AP2 alpha controls the dynamic balance between miR-126&126*and miR-221&222 during melanoma progression	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; AP-2 TRANSCRIPTION FACTOR; CUTANEOUS MELANOMA; GROWTH-FACTOR; METASTATIC MELANOMA; TERMINAL FRAGMENT; CANCER-CELLS; TUMOR-GROWTH; MIR-126; METHYLATION	Accumulating evidences have shown the association between aberrantly expressed microRNAs (miRs) and cancer, where these small regulatory RNAs appear to dictate the cell fate by regulating all the main biological processes. We demonstrated the responsibility of the circuitry connecting the oncomiR-221&222 with the tumor suppressors miR-126&126* in melanoma development and progression. According to the inverse correlation between endogenous miR-221&222 and miR-126&126*, respectively increasing or decreasing with malignancy, their enforced expression or silencing was sufficient for a reciprocal regulation. In line with the opposite roles of these miRs, protein analyses confirmed the reverse expression pattern of miR-126&126*-targeted genes that were induced by miR-221&222. Looking for a central player in this complex network, we revealed the dual regulation of AP2 alpha, on one side directly targeted by miR-221&222 and on the other a transcriptional activator of miR-126&126*. We showed the chance of restoring miR-126&126* expression in metastatic melanoma to reduce the amount of mature intracellular heparin-binding EGF like growth factor, thus preventing promyelocytic leukemia zinc finger delocalization and maintaining its repression on miR-221&222 promoter. Thus, the low-residual quantity of these two miRs assures the release of AP2 alpha expression, which in turn binds to and induces miR-126&126* transcription. All together these results point to an unbalanced ratio functional to melanoma malignancy between these two couples of miRs. During progression this balance gradually moves from miR-126&126* toward miR-221&222. This circuitry, besides confirming the central role of AP2 alpha in orchestrating melanoma development and/or progression, further displays the significance of these miRs in cancer and the option of utilizing them for novel therapeutics.	[Felli, N.; Errico, M. C.; Pedini, F.; Petrini, M.; Puglisi, R.; Bellenghi, M.; Boe, A.; Felicetti, F.; Mattia, G.; Bottero, L.; Care, A.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy; [Tripodo, C.] Univ Palermo, Dept Hlth Sci, Palermo, Italy	Istituto Superiore di Sanita (ISS); University of Palermo	Care, A (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	alessandra.care@iss.it	Errico, Maria Cristina/K-3971-2016; Tripodo, Claudio/AAB-6004-2022; De Feo, Alessandra/ABI-1458-2020; Puglisi, Rossella/M-7120-2017; Mattia, Gianfranco/K-5194-2016; Pedini, Francesca/N-5677-2017; Boe, Alessandra/AAA-2653-2019; De Feo, Alessandra/C-7030-2019; Felicetti, Federica/N-7077-2017; Bellenghi, Maria/AHE-8886-2022; Tripodo, Claudio/O-4536-2016; Care, Alessandra/H-5090-2016; Felli, Nadia/G-2088-2012	Errico, Maria Cristina/0000-0003-3014-2643; Tripodo, Claudio/0000-0002-0821-6231; De Feo, Alessandra/0000-0002-9805-1361; Puglisi, Rossella/0000-0003-1680-1032; Mattia, Gianfranco/0000-0001-7047-6360; Pedini, Francesca/0000-0002-3454-6162; Boe, Alessandra/0000-0002-8888-7501; De Feo, Alessandra/0000-0002-9805-1361; Felicetti, Federica/0000-0003-4628-0696; Tripodo, Claudio/0000-0002-0821-6231; Care, Alessandra/0000-0003-4106-3342; Bellenghi, Maria/0000-0002-1156-5950; Felli, Nadia/0000-0001-6763-3361; petrini, marina/0000-0003-4891-3389	Italian Ministry of Health [RF-2010-2310494]; Italian Association for Cancer Research [AIRC IG13247]	Italian Ministry of Health(Ministry of Health, Italy); Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Italian Ministry of Health (RF-2010-2310494) and the Italian Association for Cancer Research (AIRC IG13247) to AC.	Aftab MN, 2014, ARCH BIOCHEM BIOPHYS, V563, P60, DOI 10.1016/j.abb.2014.07.022; Alcazar O, 2012, INT J CANCER, V131, P18, DOI 10.1002/ijc.26320; Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Braeuer RR, 2011, SEMIN CANCER BIOL, V21, P83, DOI 10.1016/j.semcancer.2010.12.007; Dai X, 2015, ADV DRUG DELIVER REV, V81, P184, DOI 10.1016/j.addr.2014.09.010; Das Thakur M, 2013, CANCER RES, V73, P6106, DOI 10.1158/0008-5472.CAN-13-1633; Du CL, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0259-1; Ebrahimi F, 2014, EXP MOL PATHOL, V96, P98, DOI 10.1016/j.yexmp.2013.12.004; Eggermont AMM, 2014, LANCET, V383, P816, DOI 10.1016/S0140-6736(13)60802-8; Errico MC, 2013, INT J CANCER, V133, P879, DOI 10.1002/ijc.28097; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Felli N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056824; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170; Hallberg AR, 2014, EPIGENETICS-US, V9, P1641, DOI 10.4161/15592294.2014.988062; Igoucheva O, 2009, BIOCHEM BIOPH RES CO, V379, P790, DOI 10.1016/j.bbrc.2008.12.152; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jonckheere N, 2009, BRIT J CANCER, V101, P637, DOI 10.1038/sj.bjc.6605190; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Kivisaari AK, 2010, BRIT J DERMATOL, V163, P726, DOI 10.1111/j.1365-2133.2010.09924.x; Kwong LN, 2014, ONCOGENE, V33, P1, DOI 10.1038/onc.2013.34; Le Bras A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012156; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Little EG, 2012, DERMATOL CLIN, V30, P355, DOI 10.1016/j.det.2012.04.001; Liu RH, 2015, CLIN CANCER RES, V21, P854, DOI 10.1158/1078-0432.CCR-14-1740; Mattia G, 2011, PIGM CELL MELANOMA R, V24, P953, DOI 10.1111/j.1755-148X.2011.00881.x; Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198; Melnikova VO, 2008, CANCER BIOL THER, V7, P997, DOI 10.4161/cbt.7.7.6535; Menzies AM, 2014, LANCET ONCOL, V15, pE371, DOI 10.1016/S1470-2045(14)70072-5; Mobley AK, 2012, CANCER METAST REV, V31, P621, DOI 10.1007/s10555-012-9358-8; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; Ozeki K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056770; Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098; Sun YQ, 2010, BIOCHEM BIOPH RES CO, V391, P1483, DOI 10.1016/j.bbrc.2009.12.098; Toki F, 2005, J CELL PHYSIOL, V202, P839, DOI 10.1002/jcp.20175; Wang J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003785; Xu M, 2013, AM J PATHOL, V182, P84, DOI 10.1016/j.ajpath.2012.09.018; Yang XL, 2014, MOL MED REP, V10, P125, DOI 10.3892/mmr.2014.2171; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690	41	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3016	3026		10.1038/onc.2015.357	http://dx.doi.org/10.1038/onc.2015.357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434590	Green Published, hybrid			2022-12-17	WOS:000377474500007
J	Weekes, D; Kashima, TG; Zandueta, C; Perurena, N; Thomas, DP; Sunters, A; Vuillier, C; Bozec, A; El-Emir, E; Miletich, I; Patino-Garcia, A; Lecanda, F; Grigoriadis, AE				Weekes, D.; Kashima, T. G.; Zandueta, C.; Perurena, N.; Thomas, D. P.; Sunters, A.; Vuillier, C.; Bozec, A.; El-Emir, E.; Miletich, I.; Patino-Garcia, A.; Lecanda, F.; Grigoriadis, A. E.			Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1 (vol 35, pg 2852, 2016)	ONCOGENE			English	Correction													Bozec, Aline/M-6942-2015; Patiño-Garcia, Ana/I-4299-2012	Bozec, Aline/0000-0001-8174-2118; Patiño-Garcia, Ana/0000-0002-4066-8203; Weekes, Daniel/0000-0001-8083-7617; Zandueta Pascual, Carolina/0000-0002-7931-8649				Weekes D, 2016, ONCOGENE, V35, P2852, DOI 10.1038/onc.2015.344	1	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2948	2948		10.1038/onc.2015.420	http://dx.doi.org/10.1038/onc.2015.420			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	27251742	Bronze			2022-12-17	WOS:000377473700014
J	Kim, J; Liu, Y; Qiu, M; Xu, Y				Kim, J.; Liu, Y.; Qiu, M.; Xu, Y.			Pluripotency factor Nanog is tumorigenic by deregulating DNA damage response in somatic cells	ONCOGENE			English	Article							CYCLE ARREST; P53; ACTIVATION; EXPRESSION; INVASION; ATM	The pluripotency gene Nanog is not expressed in normal adult tissues but is overexpressed in some human cancers. However, the tumorigenic roles of Nanog remain unclear. The ectopic expression of Nanog is not sufficient to induce spontaneous tumors in mice but can promote metastasis of established tumors by activating the expression of metastatic genes. The expression of Nanog in mouse skin activates tumor suppressor p53, leading to the differentiation of epidermal stem cells. In the absence of p53, Nanog induces spontaneous squamous cell carcinoma, identifying a novel role of Nanog in tumorigenesis. Therefore, the induction of p53 and differentiation in Nanog-expressing skin suppresses the tumorigenic activities of Nanog, which include the induction of DNA double-stranded break damage. Notably, Nanog interacts with the KRAB-associated protein 1 (KAP1) and inhibits its sumoylation activity, impairing KAP1-mediated chromatin remodeling, which is important for efficiently activating DNA damage response. In summary, Nanog is an oncogene with multiple roles in promoting tumorigenesis and metastasis.	[Kim, J.; Liu, Y.; Xu, Y.] Southern Med Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China; [Kim, J.; Qiu, M.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA	Southern Medical University - China; University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X	Chinese Ministry of Science and Technology [2012CB966900, 2013ZX10002008002]; CIRM [RC1-00148]	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); CIRM(California Institute for Regenerative Medicine)	We thank Dr Manando Nakasaki for help with skin analysis, Dr Colin Jamora for providing K14-cre transgenic mice, and the UCSD Cancer Center Histology Core for help with the histological analysis. This work was supported by grants from Chinese Ministry of Science and Technology (2012CB966900 and 2013ZX10002008002) and CIRM (RC1-00148).	Badeaux MA, 2013, CELL CYCLE, V12, P2395, DOI 10.4161/cc.25402; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chiu SJ, 2009, CHEM-BIOL INTERACT, V182, P173, DOI 10.1016/j.cbi.2009.08.019; Costa Y, 2013, NATURE, V495, P370, DOI 10.1038/nature11925; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Falk M, 2008, BBA-MOL CELL RES, V1783, P2398, DOI 10.1016/j.bbamcr.2008.07.010; Fischedick G, 2014, STEM CELL RES, V13, P300, DOI 10.1016/j.scr.2014.08.001; Gandarillas A, 2012, CELL CYCLE, V11, P4507, DOI 10.4161/cc.22529; Goodarzi AA, 2011, NAT STRUCT MOL BIOL, V18, P831, DOI 10.1038/nsmb.2077; Han JH, 2012, CANCER LETT, V321, P80, DOI 10.1016/j.canlet.2012.02.021; Ho BT, 2012, J BIOL CHEM, V287, P18656, DOI 10.1074/jbc.M111.322883; Ivanov AV, 2007, MOL CELL, V28, P823, DOI 10.1016/j.molcel.2007.11.012; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kim J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.87; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI13563; Lin YL, 2011, MOL CELL BIOCHEM, V351, P109, DOI 10.1007/s11010-011-0717-5; Liu DP, 2010, NAT CELL BIOL, V12, P993, DOI 10.1038/ncb2100; Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moretto-Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Noh KH, 2012, J CLIN INVEST, V122, P4077, DOI 10.1172/JCI64057; Piazzolla D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5226; Piestun D, 2006, BIOCHEM BIOPH RES CO, V343, P279, DOI 10.1016/j.bbrc.2006.02.152; Santaliz-Ruiz LEIV, 2014, INT J CANCER, V135, P2741, DOI 10.1002/ijc.28690; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Siu MKY, 2013, ONCOGENE, V32, P3500, DOI 10.1038/onc.2012.363; Sun C, 2013, INT J BIOCHEM CELL B, V45, P1099, DOI 10.1016/j.biocel.2013.02.017; Takata H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075622; Theunissen TW, 2011, PHILOS T R SOC B, V366, P2222, DOI 10.1098/rstb.2011.0003; Thomson JA, 1998, CURR TOP DEV BIOL, V38, P133; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135	36	13	13	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1334	1340		10.1038/onc.2015.205	http://dx.doi.org/10.1038/onc.2015.205			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26073077				2022-12-17	WOS:000371763100014
J	Lau, E; Sedy, J; Sander, C; Shaw, MA; Feng, Y; Scortegagna, M; Claps, G; Robinson, S; Cheng, P; Srivas, R; Soonthornvacharin, S; Ideker, T; Bosenberg, M; Gonzalez, R; Robinson, W; Chanda, SK; Ware, C; Dummer, R; Hoon, D; Kirkwood, JM; Ronai, ZA				Lau, E.; Sedy, J.; Sander, C.; Shaw, M. A.; Feng, Y.; Scortegagna, M.; Claps, G.; Robinson, S.; Cheng, P.; Srivas, R.; Soonthornvacharin, S.; Ideker, T.; Bosenberg, M.; Gonzalez, R.; Robinson, W.; Chanda, S. K.; Ware, C.; Dummer, R.; Hoon, D.; Kirkwood, J. M.; Ronai, Z. A.			Transcriptional repression of IFN beta 1 by ATF2 confers melanoma resistance to therapy	ONCOGENE			English	Article							METASTATIC MELANOMA; INTERFERON-BETA; RAF INHIBITION; IFN-BETA; KAPPA-B; CELLS; BIOCHEMOTHERAPY; EXPRESSION; INDUCTION; CANCER	The resistance of melanoma to current treatment modalities represents a major obstacle for durable therapeutic response, and thus the elucidation of mechanisms of resistance is urgently needed. The crucial functions of activating transcription factor-2 (ATF2) in the development and therapeutic resistance of melanoma have been previously reported, although the precise underlying mechanisms remain unclear. Here, we report a protein kinase C-epsilon (PKC epsilon)- and ATF2-mediated mechanism that facilitates resistance by transcriptionally repressing the expression of interferon-beta 1 (IFN beta 1) and downstream type-I IFN signaling that is otherwise induced upon exposure to chemotherapy. Treatment of early-stage melanomas expressing low levels of PKC epsilon with chemotherapies relieves ATF2-mediated transcriptional repression of IFN beta 1, resulting in impaired S-phase progression, a senescence-like phenotype and increased cell death. This response is lost in late-stage metastatic melanomas expressing high levels of PKC epsilon. Notably, nuclear ATF2 and low expression of IFN beta 1 in melanoma tumor samples correlates with poor patient responsiveness to biochemotherapy or neoadjuvant IFN-alpha 2a. Conversely, cytosolic ATF2 and induction of IFN beta 1 coincides with therapeutic responsiveness. Collectively, we identify an IFN beta 1-dependent, cell-autonomous mechanism that contributes to the therapeutic resistance of melanoma via the PKC epsilon-ATF2 regulatory axis.	[Lau, E.; Sedy, J.; Feng, Y.; Scortegagna, M.; Claps, G.; Soonthornvacharin, S.; Chanda, S. K.; Ware, C.; Ronai, Z. A.] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA 92037 USA; [Sander, C.; Kirkwood, J. M.] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA USA; [Shaw, M. A.; Hoon, D.] John Wayne Canc Inst, Santa Monica, CA USA; [Robinson, S.; Gonzalez, R.; Robinson, W.] Univ Colorado, Div Med Oncol, Aurora, CO USA; [Cheng, P.; Dummer, R.] Univ Zurich, Dept Dermatol, Zurich, Switzerland; [Srivas, R.] Stanford Univ, Sch Med, Dept Genet, Palo Alto, CA 94304 USA; [Ideker, T.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Bosenberg, M.] Yale Univ, Sch Med, New Haven, CT USA	Sanford Burnham Prebys Medical Discovery Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; John Wayne Cancer Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Zurich; Stanford University; University of California System; University of California San Diego; Yale University	Lau, E (corresponding author), Sanford Burnham Med Res Inst, Ctr Canc, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.	elau@sbmri.org; ronai@sbmri.org	gonzález, rene/W-2081-2019; Cheng, Phil/AAN-8567-2021; Hoon, Dave SB/C-7146-2018; Claps, Giuseppina/G-6180-2018	Cheng, Phil/0000-0003-2940-006X; Hoon, Dave SB/0000-0003-1915-3683; Srivas, Rohith/0000-0001-9495-9949; Claps, Giuseppina/0000-0002-3064-0063; Sedy, John/0000-0002-6428-1054; RONAI, ZEEV/0000-0002-3859-0400; Ideker, Trey/0000-0002-1708-8454; Robinson, William/0000-0003-1875-9691	NCI [CA128814, CA179170, CA164679, CA177322, CA121973]; Hervey Family Non-endowment Fund at The San Diego Foundation; Melanoma Research Foundation;  [CA172705];  [CA121949]; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA164679, P01CA128814, K99CA172705, R01CA179170, P50CA121973, P01CA177322, T32CA121949, R01CA172017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048073] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Hervey Family Non-endowment Fund at The San Diego Foundation; Melanoma Research Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Serge Fuchs (UPENN) and members of the Ronai laboratory for crucial scientific discussions and critical reading of this manuscript. Additional thanks to Mitch Levesque and Valerie Amann for their assistance in providing patient samples from the Department of Dermatology, University of Zurich. We are grateful to Jian-Liang Li of the SBMRI Bioinformatics Core, as well as the SBMRI Flow Cytometry and Histology Core, for technical support. Support from NCI P01 (CA128814), R01 (CA179170), Hervey Family Non-endowment Fund at The San Diego Foundation and a Melanoma Research Foundation grant to ZAR are gratefully acknowledged. Support from NCI Grants R01 (CA164679) and P01 (CA177322) to CW and P50 SPORE (CA121973) to JMK is also gratefully acknowledged. EL has been supported by K99 (CA172705) and T32 (CA121949) Grants.	Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Bhoumik A, 2004, P NATL ACAD SCI USA, V101, P4222, DOI 10.1073/pnas.0400195101; Eiro N, 2014, J IMMUNOTHER, V37, P366, DOI 10.1097/CJI.0000000000000045; Gajewski TF, 2012, CANCER IMMUNOL IMMUN, V61, P1343, DOI 10.1007/s00262-012-1305-6; Garbe C, 2011, ONCOLOGIST, V16, P5, DOI 10.1634/theoncologist.2010-0190; Haferkamp S, 2013, J INVEST DERMATOL, V133, P1601, DOI 10.1038/jid.2013.6; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Ives NJ, 2007, J CLIN ONCOL, V25, P5426, DOI 10.1200/JCO.2007.12.0253; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Koyanagi K, 2005, J CLIN ONCOL, V23, P8057, DOI 10.1200/JCO.2005.02.0958; Koyanagi K, 2010, CLIN CANCER RES, V16, P2402, DOI 10.1158/1078-0432.CCR-10-0037; Lau E, 2012, CELL, V148, P543, DOI 10.1016/j.cell.2012.01.016; Maeda S, 2014, J BIOL CHEM, V289, P23786, DOI 10.1074/jbc.M114.551879; Malmgaard L, 2002, J VIROL, V76, P4520, DOI 10.1128/JVI.76.9.4520-4525.2002; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Pencheva N, 2014, CELL, V156, P986, DOI 10.1016/j.cell.2014.01.038; Rao RD, 2006, CANCER, V106, P375, DOI 10.1002/cncr.21611; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rubin Krista M, 2013, Semin Oncol Nurs, V29, P195, DOI 10.1016/j.soncn.2013.06.005; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Ryu H, 2014, CANCER LETT, V352, P220, DOI 10.1016/j.canlet.2014.06.018; Schuchter LM, 2004, J CLIN ONCOL, V22, P7, DOI 10.1200/JCO.2004.10.907; Snijders AM, 2014, ONCOTARGET, V5, P4011, DOI 10.18632/oncotarget.2148; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Testori A, 2009, ANN ONCOL, V20, P22, DOI 10.1093/annonc/mdp257; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Varsano T, 2013, CLIN CANCER RES, V19, P2710, DOI 10.1158/1078-0432.CCR-12-2689; Wang JM, 2010, J IMMUNOL, V185, P1720, DOI 10.4049/jimmunol.1000114; Yue CY, 2015, INT J CANCER, V136, P117, DOI 10.1002/ijc.29004	35	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5739	5748		10.1038/onc.2015.22	http://dx.doi.org/10.1038/onc.2015.22			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25728676	Green Accepted			2022-12-17	WOS:000364594600006
J	Ryland, KE; Svoboda, LK; Vesely, ED; McIntyre, JC; Zhang, L; Martens, JR; Lawlor, ER				Ryland, K. E.; Svoboda, L. K.; Vesely, E. D.; McIntyre, J. C.; Zhang, L.; Martens, J. R.; Lawlor, E. R.			Polycomb-dependent repression of the potassium channel-encoding gene KCNA5 promotes cancer cell survival under conditions of stress	ONCOGENE			English	Article							STEM-CELLS; DIFFERENTIAL EXPRESSION; GROUP PROTEINS; ION CHANNELS; K+ CHANNELS; KV1.5; APOPTOSIS; HYPOXIA; BMI-1; METABOLISM	Relapse after clinical remission remains a leading cause of cancer-associated death. Although the mechanisms of tumor relapse are complex, the ability of cancer cells to survive physiological stress is a prerequisite for recurrence. Ewing sarcoma (ES) and neuroblastoma (NB) are aggressive cancers that frequently relapse after initial remission. In addition, both tumors overexpress the polycomb group (PcG) proteins BMI-1 and EZH2, which contribute to tumorigenicity. We have discovered that ES and NB resist hypoxic stress-induced death and that survival depends on PcG function. Epigenetic repression of developmental programs is the most well-established cancer-associated function of PcG proteins. However, we noted that voltage-gated potassium (Kv) channel genes are also targets of PcG regulation in stem cells. Given the role of potassium in regulating apoptosis, we reasoned that repression of Kv channel genes might have a role in cancer cell survival. Here we describe our novel finding that PcG-dependent repression of the Kv1.5 channel gene KCNA5 contributes to cancer cell survival under conditions of stress. We show that survival of cancer cells in stress is dependent upon suppression of Kv1.5 channel function. The KCNA5 promoter is marked in cancer cells with PcG-dependent chromatin repressive modifications that increase in hypoxia. Genetic and pharmacological inhibition of BMI-1 and EZH2, respectively, restore KCNA5 expression, which sensitizes cells to stress-induced death. In addition, ectopic expression of the Kv1.5 channel induces apoptotic cell death under conditions of hypoxia. These findings identify a novel role for PcG proteins in promoting cancer cell survival via repression of KCNA5.	[Ryland, K. E.; Vesely, E. D.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; [Ryland, K. E.; Svoboda, L. K.; Lawlor, E. R.] Univ Michigan, Translat Oncol Program, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [McIntyre, J. C.; Zhang, L.; Martens, J. R.] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Lawlor, E. R.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; State University System of Florida; University of Florida; University of Michigan System; University of Michigan	Martens, JR (corresponding author), Univ Florida, Coll Med, Dept Pharmacol & Therapeut, POB 100267, Gainesville, FL 32610 USA.	martensj@ufl.edu; elawlor@med.umich.edu			CureSearch Children's Oncology Group; Nick Currey Fund; National Institutes of Health [1R01 CA134604, R01HL070973, AACR-SU2C IRG-1309]; Pharmacological Sciences Training Program [T32 GM007767]; UM Cancer Biology Training grant [5T32 CA009676-20]; NATIONAL CANCER INSTITUTE [T32CA009676, R01CA134604] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	CureSearch Children's Oncology Group; Nick Currey Fund; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmacological Sciences Training Program; UM Cancer Biology Training grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of the Lawlor and Martens labs for helpful discussion. This research was supported by grants from the CureSearch Children's Oncology Group and Nick Currey Fund, the National Institutes of Health grants 1R01 CA134604 (to ERL), R01HL070973 (to JRM), AACR-SU2C IRG-1309 (to ERL), Pharmacological Sciences Training Program T32 GM007767 (to KER) and UM Cancer Biology Training grant 5T32 CA009676-20 (to LKS).	Archer SL, 2008, AM J PHYSIOL-HEART C, V294, pH570, DOI 10.1152/ajpheart.01324.2007; Arvind S, 2012, BRIT J NEUROSURG, V26, P16, DOI 10.3109/02688697.2011.583365; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bielanska J, 2009, CURR CANCER DRUG TAR, V9, P904, DOI 10.2174/156800909790192400; Bielanska J, 2012, CANCER INVEST, V30, P203, DOI 10.3109/07357907.2012.654872; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Burg ED, 2006, J MEMBRANE BIOL, V209, P3, DOI 10.1007/s00232-005-0838-4; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; Caouette D, 2003, N-S ARCH PHARMACOL, V368, P479, DOI 10.1007/s00210-003-0834-0; Cooper A, 2011, CLIN CANCER RES, V17, P56, DOI 10.1158/1078-0432.CCR-10-1417; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Fedida D, 1995, AM J PHYSIOL-CELL PH, V494, P377; Felipe A, 2012, CURR MED CHEM, V19, P661, DOI 10.2174/092986712798992048; Fiske JL, 2006, CANCER METAST REV, V25, P493, DOI 10.1007/s10555-006-9017-z; Fraser SP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0105; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gutman GA, 2003, PHARMACOL REV, V55, P583, DOI 10.1124/pr.55.4.9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heshe D, 2011, CANCER CHEMOTH PHARM, V67, P647, DOI 10.1007/s00280-010-1361-6; Huang X, 2014, J CELL BIOL, V206, P151, DOI 10.1083/jcb.201404136; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772; Karki P, 2007, CELL DEATH DIFFER, V14, P2068, DOI 10.1038/sj.cdd.4402221; Lang F, 2012, COMPR PHYSIOL, V2, P2037, DOI 10.1002/cphy.c110046; Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006; Lawlor ER, 2002, ONCOGENE, V21, P307, DOI 10.1038/sj.onc.1205053; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McEwen DP, 2007, J BIOL CHEM, V282, P29612, DOI 10.1074/jbc.M704402200; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; MILLER C, 2000, GENOME BIOL, V1, P4; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Pardo LA, 2014, NAT REV CANCER, V14, P39, DOI 10.1038/nrc3635; Platoshyn O, 2006, AM J PHYSIOL-CELL PH, V290, pC907, DOI 10.1152/ajpcell.00028.2005; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049; Schumacher SM, 2010, HEART RHYTHM, V7, P1309, DOI 10.1016/j.hrthm.2010.02.017; Schumacher SM, 2009, CIRC RES, V104, P1390, DOI 10.1161/CIRCRESAHA.108.192773; Semenza GL, 2013, ONCOGENE, V32, P4057, DOI 10.1038/onc.2012.578; Shieh CC, 2000, PHARMACOL REV, V52, P557; Stapels M, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000502; Stump GL, 2005, J PHARMACOL EXP THER, V315, P1362, DOI 10.1124/jpet.105.092197; Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010; Urrego D, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0094; Vallejo-Gracia A, 2013, J LEUKOCYTE BIOL, V94, P779, DOI 10.1189/jlb.0213094; VanWagoner DR, 1997, CIRC RES, V80, P772; von Levetzow C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019305; Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961; WANG ZG, 1993, CIRC RES, V73, P276, DOI 10.1161/01.RES.73.2.276; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135	59	13	13	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4591	4600		10.1038/onc.2014.384	http://dx.doi.org/10.1038/onc.2014.384			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435365	Green Accepted			2022-12-17	WOS:000360189300005
J	Santonico, E; Mattioni, A; Panni, S; Belleudi, F; Mattei, M; Torrisi, MR; Cesareni, G; Castagnoli, L				Santonico, E.; Mattioni, A.; Panni, S.; Belleudi, F.; Mattei, M.; Torrisi, M. R.; Cesareni, G.; Castagnoli, L.			RNF11 is a GGA protein cargo and acts as a molecular adaptor for GGA3 ubiquitination mediated by Itch	ONCOGENE			English	Article							TRANS-GOLGI NETWORK; EAR HOMOLOGY DOMAIN; VHS DOMAINS; PROXIMITY LIGATION; GAMMA-ADAPTIN; MEMBRANE-TRANSPORT; FINGER PROTEIN; BETA-SECRETASE; SORTING-SIGNAL; MET RECEPTOR	Ring finger protein 11 (RNF11) is a RING (really interesting new gene)-H2 E3 ligase that is overexpressed in several human tumor tissues. The mature protein, which is anchored to membranes via a double acylation, localizes to early endosome and recycling compartments. Apart from its subcellular localization, additional lines of evidence implicate RNF11 in the mechanisms underlying vesicle traffic. Here we identify two acidic-cluster dileucine (Ac-LL) motifs, which are recognized by the VHS domains of Golgi-localized, gamma adaptin era-containing, ADP-ribosylation factor-binding protein (GGA) adaptors, as the molecular determinants governing RNF11 sorting at the trans-Golgi network and its internalization from the plasma membrane. We also show that RNF11 recruits itch to drive the ubiquitination of GGA3. This function is experimentally detectable only in cells overexpressing an RNF11 variant that is inactivated in the RING domain, indicating that RNF11 recruits GGA3 and controls its ubiquitination by regulating itch activity. Accordingly, our data demonstrate the involvement of itch in regulating GGA3 stability. Indeed, we observe that the endogenous levels of GGA3 are increased in cells knocked down for itch and endogenous GGA3 is hyperubiquitinated in an itch-dependent manner in a cell line expressing catalytically inactive RNF11. Our data are consistent with a model whereby the RING E3 ligase RNF11 is a novel GGA cargo actively participating in regulating the ubiquitination of the GGA protein family. The results that we are presenting put RNF11 at the center of a finally regulated system where it acts both as an adaptor and a modulator of itch-mediated control of ubiquitination events underlying membrane traffic.	[Santonico, E.; Mattioni, A.; Mattei, M.; Cesareni, G.; Castagnoli, L.] Univ Roma Tor Vergata, Dept Mol Biol, I-00133 Rome, Italy; [Panni, S.] Univ Calabria, Dept Cell Biol, I-87036 Cosenza, Italy; [Belleudi, F.; Torrisi, M. R.] Univ Roma La Sapienza, Dept Clin & Mol Med, Inst Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; [Torrisi, M. R.] Azienda Osped S Andrea, Rome, Italy; [Cesareni, G.] IRCCS Fdn S Lucia, Rome, Italy	University of Rome Tor Vergata; University of Calabria; Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Santa Lucia	Santonico, E (corresponding author), Univ Roma Tor Vergata, Dept Mol Biol, Via Ric Sci, I-00133 Rome, Italy.	Elena.Santonico@uniroma2.it	Santonico, Elena/ABB-8919-2020; Cesareni, Gianni/AAW-1382-2020; Mattei, Maurizio/AAC-1303-2019	Santonico, Elena/0000-0002-3897-8990; Mattei, Maurizio/0000-0002-0814-8873; panni, simona/0000-0002-7500-4028; Castagnoli, Luisa/0000-0001-5283-8671	MIUR; AIRC-Associazione Italiana per la Ricerca sul Cancro, Italy [IG 10272]	MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC-Associazione Italiana per la Ricerca sul Cancro, Italy(Fondazione AIRC per la ricerca sul cancro)	We would like to thank Dr Elena Romano and Dr Palma Mattioli of the Centre of Advanced Microscopy (CAM) of Tor Vergata University for their skillful assistance in the use of the facility. We thank Juan Bonifacino (National Institutes of Health, Bethesda, MD, USA) for the generous gifts of myc-GGA1, GGA2 and GGA3 expression vectors and Marino Zerial (Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany) for providing the GFP constructs for Rab4, Rab5, Rab7 and Rab11. A special thanks to Natalia Speranzini for generating stable cell lines and to Gemma Biondo, Anita Palma and Daniela Posca for technical support. This work was partially supported by grants from MIUR and from AIRC-Associazione Italiana per la Ricerca sul Cancro (IG 10272), Italy.	[Anonymous], 2003, BIOCH BIOPHYS ACTA, V1639, P104; Azmi P, 2005, EUR J CANCER, V41, P2549, DOI 10.1016/j.ejca.2005.08.020; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 2003, NAT REV MOL CELL BIO, V4, P409, DOI 10.1038/nrm1099; Boucher R, 2008, HISTOCHEM CELL BIOL, V130, P315, DOI 10.1007/s00418-008-0436-5; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Burger A, 2006, NEOPLASIA, V8, P689, DOI 10.1593/neo.06469; Chen C, 2008, OBES REV, V9, P1, DOI 10.1111/j.1467-789X.2007.00429.x; Clague MJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002422; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Doray B, 2012, TRAFFIC, V13, P1315, DOI 10.1111/j.1600-0854.2012.01396.x; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Ghosh P, 2004, EUR J CELL BIOL, V83, P257, DOI 10.1078/0171-9335-00374; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hoppe T, 2005, TRENDS BIOCHEM SCI, V30, P183, DOI 10.1016/j.tibs.2005.02.004; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Kostaras E, 2013, ONCOGENE, V32, P5220, DOI 10.1038/onc.2012.554; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Mattera R, 2011, J BIOL CHEM, V286, P2022, DOI 10.1074/jbc.M110.197178; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Oberst A, 2007, P NATL ACAD SCI USA, V104, P11280, DOI 10.1073/pnas.0701773104; Pak Y, 2006, J CELL BIOL, V175, P631, DOI 10.1083/jcb.200603001; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Santonico E, 2010, ONCOGENE, V29, P5604, DOI 10.1038/onc.2010.294; Santonico Elena, 2007, BMC Biochemistry, V8, P29, DOI 10.1186/1471-2091-8-29; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Seki N, 1999, BBA-GENE STRUCT EXPR, V1489, P421, DOI 10.1016/S0167-4781(99)00190-6; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; Soderberg O, 2008, METHODS, V45, P227, DOI 10.1016/j.ymeth.2008.06.014; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; van Wijk SJL, 2010, FASEB J, V24, P981, DOI 10.1096/fj.09-136259; Weibrecht I, 2010, EXPERT REV PROTEOMIC, V7, P401, DOI 10.1586/EPR.10.10; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	50	13	14	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3377	3390		10.1038/onc.2014.256	http://dx.doi.org/10.1038/onc.2014.256			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25195858				2022-12-17	WOS:000356871700004
J	Stodden, GR; Lindberg, ME; King, ML; Paquet, M; MacLean, JA; Mann, JL; DeMayo, FJ; Lydon, JP; Hayashi, K				Stodden, G. R.; Lindberg, M. E.; King, M. L.; Paquet, M.; MacLean, J. A.; Mann, J. L.; DeMayo, F. J.; Lydon, J. P.; Hayashi, K.			Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironment	ONCOGENE			English	Article							E-CADHERIN EXPRESSION; DIFFERENT HISTOLOGIC TYPES; UTERINE SEROUS CARCINOMA; NF-KAPPA-B; ENDOMETRIAL CARCINOMA; HUMAN BREAST; MICROARRAY ANALYSIS; CANCER DEVELOPMENT; GASTRIC-CARCINOMA; ADHESION	Type II endometrial carcinomas (ECs) are estrogen independent, poorly differentiated tumors that behave in an aggressive manner. As TP53 mutation and CDH1 inactivation occur in 80% of human endometrial type II carcinomas, we hypothesized that mouse uteri lacking both Trp53 and Cdh1 would exhibit a phenotype indicative of neoplastic transformation. Mice with conditional ablation of Cdh1 and Trp53 (Cdh1(d/d)Trp53(d/d)) clearly demonstrate architectural features characteristic of type II ECs, including focal areas of papillary differentiation, protruding cytoplasm into the lumen (hobnailing) and severe nuclear atypia at 6 months of age. Further, Cdh1(d/d)Trp53(d/d) tumors in 12-month-old mice were highly aggressive, and metastasized to nearby and distant organs within the peritoneal cavity, such as abdominal lymph nodes, mesentery and peri-intestinal adipose tissues, demonstrating that tumorigenesis in this model proceeds through the universally recognized morphological intermediates associated with type II endometrial neoplasia. We also observed abundant cell proliferation and complex angiogenesis in the uteri of Cdh1(d/d)Trp53(d/d) mice. Our microarray analysis found that most of the genes differentially regulated in the uteri of Cdh1(d/d)Trp53(d/d) mice were involved in inflammatory responses. CD163 and Arg1, markers for tumor-associated macrophages, were also detected and increased in the uteri of Cdh1(d/d)Trp53(d/d) mice, suggesting that an inflammatory tumor microenvironment with immune cell recruitment is augmenting tumor development in Cdh1(d/d)Trp53(d/d) uteri. Further, inflammatory mediators secreted from CDH1-negative, TP53 mutant endometrial cancer cells induced normal macrophages to express inflammatory-related genes through activation of nuclear factor-kappa B signaling. These results indicate that absence of CDH1 and TP53 in endometrial cells initiates chronic inflammation, promotes tumor microenvironment development following the recruitment of macrophages and promotes aggressive ECs.	[Stodden, G. R.; Lindberg, M. E.; King, M. L.; MacLean, J. A.; Hayashi, K.] So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; [Paquet, M.] Univ Montreal St Hyacinthe, Dept Pathol & Microbiol, Quebec City, PQ, Canada; [Mann, J. L.] So Illinois Univ, Sch Med, Dept Pathol, Springfield, IL USA; [DeMayo, F. J.; Lydon, J. P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Baylor College of Medicine	Hayashi, K (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, 1135 Lincoln Dr, Carbondale, IL 62901 USA.	khayashi@siumed.edu	DeMayo, Francesco/C-6255-2019; Paquet, Marilene/L-3414-2019	DeMayo, Francesco/0000-0002-9480-7336; Paquet, Marilene/0000-0002-3562-4636; Hayashi, Kanako/0000-0002-5028-799X	NIH/NCI [R15CA179214]; ACS-IL [139038]; NIH/NICHD [R15HD065584, U54HD007495]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD065584] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R15CA179214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES103311] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS-IL; NIH/NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Jenny Zadeh at the University of Illinois at Urbana-Champaign Biotechnology Center for microarray analysis. This work was supported by NIH/NCI R15CA179214 and ACS-IL 139038 (to KH), NIH/NICHD R15HD065584 (to JAM) and NIH/NICHD U54HD007495 (to FJD and JPL).	Acharya S, 2005, LANCET ONCOL, V6, P961, DOI 10.1016/S1470-2045(05)70463-0; Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; AMBROS RA, 1995, HUM PATHOL, V26, P1260, DOI 10.1016/0046-8177(95)90203-1; Bansal N, 2009, CANCER CONTROL, V16, P8, DOI 10.1177/107327480901600102; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Boussadia O, 2002, MECH DEVELOP, V115, P53, DOI 10.1016/S0925-4773(02)00090-4; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; De Marzo AM, 1999, UROLOGY, V53, P707, DOI 10.1016/S0090-4295(98)00577-9; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Derksen PWB, 2011, DIS MODEL MECH, V4, P347, DOI 10.1242/dmm.006395; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Franco HL, 2008, SEMIN CELL DEV BIOL, V19, P178, DOI 10.1016/j.semcdb.2007.12.001; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Goff BA, 2005, GYNECOL ONCOL, V98, P341, DOI 10.1016/j.ygyno.2005.07.006; GRAFF JR, 1995, CANCER RES, V55, P5195; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hermani Alexander, 2006, Exp Cell Res, V312, P184, DOI 10.1016/j.yexcr.2005.10.013; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Holcomb K, 2002, OBSTET GYNECOL, V100, P1290, DOI 10.1016/S0029-7844(02)02391-8; Horn LC, 2007, ANN DIAGN PATHOL, V11, P297, DOI 10.1016/j.anndiagpath.2007.05.002; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huszar M, 2010, J PATHOL, V220, P551, DOI 10.1002/path.2673; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim JJ, 2013, ENDOCR REV, V34, P130, DOI 10.1210/er.2012-1043; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kim TH, 2010, ONCOGENE, V29, P3770, DOI 10.1038/onc.2010.126; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Koyuncuoglu M, 2012, GYNECOL ONCOL, V125, P208, DOI 10.1016/j.ygyno.2011.12.433; Kuhn E, 2012, JNCI-J NATL CANCER I, V104, P1503, DOI 10.1093/jnci/djs345; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Lax SF, 2004, VIRCHOWS ARCH, V444, P213, DOI 10.1007/s00428-003-0947-3; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Lin EY, 2004, BRIT J CANCER, V90, P2053, DOI 10.1038/sj.bjc.6601705; Lindberg ME, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.109462; Llobet D, 2009, J CLIN PATHOL, V62, P777, DOI 10.1136/jcp.2008.056101; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Marchetti A, 2005, EUR J GYNAECOL ONCOL, V26, P479; Maxwell GL, 2005, CLIN CANCER RES, V11, P4056, DOI 10.1158/1078-0432.CCR-04-2001; Mazieres J, 2013, LUNG CANCER, V82, P231, DOI 10.1016/j.lungcan.2013.07.016; Medvedev AE, 1999, J BIOL CHEM, V274, P9342, DOI 10.1074/jbc.274.14.9342; MOLL R, 1993, AM J PATHOL, V143, P1731; Moon A, 2008, MOL CANCER RES, V6, P1544, DOI 10.1158/1541-7786.MCR-08-0189; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Raes G, 2005, J IMMUNOL, V174, P6561, DOI 10.4049/jimmunol.174.11.6561; Reardon SN, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.112.098871; Reed JR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2246; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Riethmuller G, 2001, SEMIN CANCER BIOL, V11, P307, DOI 10.1006/scbi.2001.0386; Risinger JI, 2003, CANCER RES, V63, P6; Samarnthai N, 2010, OBSTET GYNECOL INT, V2010, DOI 10.1155/2010/162363; Santin AD, 2005, BRIT J CANCER, V92, P1561, DOI 10.1038/sj.bjc.6602480; Scotton CJ, 2005, J IMMUNOL, V174, P834, DOI 10.4049/jimmunol.174.2.834; Shaco-Levy R, 2008, ACTA OBSTET GYN SCAN, V87, P868, DOI 10.1080/00016340802253775; SHERMAN ME, 1992, AM J SURG PATHOL, V16, P600, DOI 10.1097/00000478-199206000-00008; Shimada S, 2012, GUT, V61, P344, DOI 10.1136/gutjnl-2011-300050; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Soong R, 1996, BRIT J CANCER, V74, P562, DOI 10.1038/bjc.1996.401; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Wu Y, 2009, CELL CYCLE, V8, P3267, DOI 10.4161/cc.8.20.9699; Wu ZY, 2005, WORLD J GASTROENTERO, V11, P3139, DOI 10.3748/wjg.v11.i20.3139; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	86	13	14	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2471	2482		10.1038/onc.2014.193	http://dx.doi.org/10.1038/onc.2014.193			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998851	Green Accepted			2022-12-17	WOS:000354190400006
J	Sun, Y; Kaneko, S; Li, XK; Li, X				Sun, Y.; Kaneko, S.; Li, X. K.; Li, X.			The PI3K/Akt signal hyperactivates Eya1 via the SUMOylation pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER CELL-LINES; EYES ABSENT PROTEINS; BREAST-CANCER; CONJUGATING ENZYME; TRANSCRIPTIONAL REPRESSION; TUMOR-CELLS; GENE; PHOSPHATASE; EXPRESSION	Eyes absent 1 (Eya1) is a conserved critical regulator of organ-specific stem cells. Ectopic Eya1 activities, however, promote transformation of mammary epithelial cells. Signals that instigate Eya1 oncogenic activities remain to be determined. Here, we show that Akt1 kinase physically interacts with Eya1 and phosphorylates a conserved consensus site of the Akt kinase. PI3K/Akt signaling enhances Eya1 transcription activity, which largely attributes to the phosphorylation-induced reduction of Eya1 SUMOylation. Indeed, SUMOylation inhibits Eya1 transcription activity; and pharmacologic and genetic activation of PI3K/Akt robustly reduces Eya1 SUMOylation. Wild-type but not Akt phosphorylation site mutant Eya1 variant rescues the cell migratory phenotype of EYA1-silenced breast cancer cells, highlighting the importance of Eya1 phosphorylation. Furthermore, knockdown EYA1 sensitizes breast cancer cells to the PI3K/Akt1 inhibitor and irradiation treatments. Thus, the PI3K/Akt signal pathway activates Eya1. These findings further suggest that regulation of SUMOylation by PI3K/Akt signaling is likely an important aspect of tumorigenesis.	[Sun, Y.; Kaneko, S.; Li, X.] Boston Childrens Hosp, Urol Dis Res Ctr, Boston, MA 02115 USA; [Sun, Y.; Kaneko, S.; Li, X.] Harvard Univ, Sch Med, Dept Surg, Boston, MA USA; [Sun, Y.; Kaneko, S.; Li, X.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA; [Li, X. K.] Wenzhou Med Coll, Sch Pharmaceut Sci, Wenzhou, Peoples R China	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Wenzhou Medical University	Li, XK (corresponding author), Boston Childrens Hosp, Urol Dis Res Ctr, 300 Longwood Ave, Boston, MA 02115 USA.	sean.li@childrens.harvard.edu		Sun, Ye/0000-0002-7674-9056	NIH/NIDCR [1R01DE019823]; NIH/NIDDK [R01DK916451, P50DK65298]; AHA [13GRNT16950006]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065298, R01DK091645] Funding Source: NIH RePORTER	NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); AHA(American Heart Association); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank S Morley for suggestions and critical reading of the manuscript. We thank I Teng, CS Guo, XJ Shi, ZF Chai and K Pelton for technical supports. We are grateful to R Adam, G Gill, J Brugge, C Kuperwasser for providing reagents, cell lines and helpful discussion. This work was supported by grant from NIH/NIDCR (1R01DE019823, XL), NIH/NIDDK (R01DK916451 and P50DK65298, XL) and AHA (13GRNT16950006, XL).	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Alkuraya FS, 2006, SCIENCE, V313, P1751, DOI 10.1126/science.1128406; Bawa-Khalfe T, 2012, P NATL ACAD SCI USA, V109, P17466, DOI 10.1073/pnas.1209378109; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Dunnebier T, 2010, BREAST CANCER RES TR, V121, P185, DOI 10.1007/s10549-009-0530-y; Dunnebier T, 2009, INT J CANCER, V125, P596, DOI 10.1002/ijc.24286; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Guo CS, 2011, J CLIN INVEST, V121, P1585, DOI 10.1172/JCI44630; Jian OY, 2009, MOL CELL, V34, P145, DOI 10.1016/j.molcel.2009.03.013; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Li R, 2013, CANCER RES, V73, P5742, DOI 10.1158/0008-5472.CAN-13-0538; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Machon O, 2000, MECH DEVELOP, V97, P3, DOI 10.1016/S0925-4773(00)00402-0; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Moschos SJ, 2010, HUM PATHOL, V41, P1286, DOI 10.1016/j.humpath.2010.02.007; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Okabe Y, 2009, NATURE, V460, P520, DOI 10.1038/nature08138; Pandey RN, 2010, ONCOGENE, V29, P3715, DOI 10.1038/onc.2010.122; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sajithlal G, 2005, DEV BIOL, V284, P323, DOI 10.1016/j.ydbio.2005.05.029; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Synowiec E, 2010, MUTAT RES-FUND MOL M, V694, P31, DOI 10.1016/j.mrfmmm.2010.09.002; Tadjuidje E, 2013, CELL MOL LIFE SCI, V70, P1897, DOI 10.1007/s00018-012-1144-9; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Torbett NE, 2008, BIOCHEM J, V415, P97, DOI 10.1042/BJ20080639; Wu KM, 2013, CANCER RES, V73, P4488, DOI 10.1158/0008-5472.CAN-12-4078; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang XJ, 2006, MOL CELL, V23, P779, DOI 10.1016/j.molcel.2006.08.009; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	49	13	15	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2527	2537		10.1038/onc.2014.179	http://dx.doi.org/10.1038/onc.2014.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24954506	Green Accepted, Green Submitted			2022-12-17	WOS:000354190400011
J	Robichaux, JP; Hallett, RM; Fuseler, JW; Hassell, JA; Ramsdell, AF				Robichaux, J. P.; Hallett, R. M.; Fuseler, J. W.; Hassell, J. A.; Ramsdell, A. F.			Mammary glands exhibit molecular laterality and undergo left-right asymmetric ductal epithelial growth in MMTV-cNeu mice	ONCOGENE			English	Article							MESSENGER-RNA EXPRESSION; BREAST-CANCER PATIENTS; NEOADJUVANT CHEMOTHERAPY; CANDIDATE BIOMARKERS; KINASE-1 PLK1; RESISTANCE; CELLS; STATHMIN; SURVIVIN; FOXM1	Significant left-right (L-R) differences in tumor incidence and disease outcome occur for cancers of paired organs, including the breasts; however, the basis for this laterality is unknown. Here, we show that despite their morphologic symmetry, left versus right mammary glands in wild-type mice have baseline differences in gene expression that are L-R independently regulated during pubertal development, including genes that regulate luminal progenitor cell renewal, luminal cell differentiation, mammary tumorigenesis, tamoxifen sensitivity and chemotherapeutic resistance. In MMTV-cNeu(Tg/Tg) mice, which model HER2/Neu-amplified breast cancer, baseline L-R differences in mammary gene expression are amplified, sustained or inverted in a gene-specific manner and the mammary ductal epithelium undergoes L-R asymmetric growth and patterning. Comparative genomic analysis of mouse L-R mammary gene expression profiles with gene expression profiles of human breast tumors revealed significant linkage between right-sided gene expression and decreased breast cancer patient survival. Collectively, these findings are the first to demonstrate that mammary glands are lateralized organs, and, moreover, that mammary glands have L-R differential susceptibility to HER2/Neu oncogene-mediated effects on ductal epithelial growth and differentiation. We propose that intrinsic molecular laterality may have a role in L-R asymmetric breast tumor incidence and, furthermore, that interplay between the L-R molecular landscape and oncogene activity may contribute to the differential disease progression and patient outcome that are associated with tumor situs.	[Robichaux, J. P.; Ramsdell, A. F.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA; [Robichaux, J. P.; Ramsdell, A. F.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Hallett, R. M.; Hassell, J. A.] McMaster Univ, Ctr Funct Genom, Dept Biochem Biomed Sci, Hamilton, ON, Canada; [Fuseler, J. W.; Ramsdell, A. F.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29208 USA; [Ramsdell, A. F.] Univ S Carolina, Coll Arts & Sci, Program Womens & Gender Studies, Columbia, SC 29208 USA	Medical University of South Carolina; Medical University of South Carolina; McMaster University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Ramsdell, AF (corresponding author), Univ S Carolina, Sch Med, Dept Cell Biol & Anat, 6439 Garners Ferry Rd,Bldg 1,RM C-36, Columbia, SC 29208 USA.	ramsdell@musc.edu		Ramsdell, Ann F/0000-0003-2469-7079; Robichaux, Jacqulyne/0000-0001-8812-7054	National Institutes of Health [K02HL086737, R21HD068993]; Cancer Center Support Grant [P30CA138313]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD068993] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA138313] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL086737] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Scott Argraves, Dr Jeremey Barth and Mr Victor Fresco of the MUSC Proteogenomics Facility for performing the DNA microarray and Dr Caroline Alexander and Dr Elizabeth Yeh for helpful discussion. This work was supported by National Institutes of Health K02HL086737 (AFR), R21HD068993 (AFR) and conducted in facilities supported, in part, by Cancer Center Support Grant P30CA138313 to the Hollings Cancer Center, MUSC.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Baquero MT, 2012, CANCER-AM CANCER SOC, V118, P4660, DOI 10.1002/cncr.27453; Biro FM, 2013, J ADOLESCENT HEALTH, V52, pS15, DOI 10.1016/j.jadohealth.2012.09.019; Boudreau A, 2013, P NATL ACAD SCI USA, V110, pE3937, DOI 10.1073/pnas.1315022110; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Brill B, 2008, LAB ANIM-UK, V42, P104, DOI 10.1258/la.2007.06003e; Cao XC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056735; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Carr JR, 2012, CELL REP, V1, P715, DOI 10.1016/j.celrep.2012.05.005; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Cheng Y, 2014, MOL CANCER THER, V13, P675, DOI 10.1158/1535-7163.MCT-13-0416; Chintapalli VR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032577; Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943; Colas E, 2011, INT J CANCER, V129, P2435, DOI 10.1002/ijc.25901; Dalgin GS, 2008, J UROLOGY, V180, P1126, DOI 10.1016/j.juro.2008.04.137; de Wit M, 2014, J PROTEOMICS, V99, P26, DOI 10.1016/j.jprot.2014.01.001; DELAHUNT B, 1994, UROLOGY, V43, P300, DOI 10.1016/0090-4295(94)90070-1; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Eccles SA, 2011, INT J DEV BIOL, V55, P685, DOI 10.1387/ijdb.113396se; El Hajj P, 2013, BRIT J CANCER, V108, P1641, DOI 10.1038/bjc.2013.115; Falkenius J, 2013, MELANOMA RES, V23, P452, DOI 10.1097/CMR.0000000000000027; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fatima N, 2013, ASIAN PAC J CANCER P, V14, P43, DOI 10.7314/APJCP.2013.14.1.43; Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131; Fenton SE, 2012, ANNU REV PHARMACOL, V52, P455, DOI 10.1146/annurev-pharmtox-010611-134659; Flanagan JM, 2013, ANN ONCOL, V24, P2813, DOI 10.1093/annonc/mdt370; Fuseler JW, 2014, ANTICANCER RES, V34, P1171; Gakiopoulou H, 2007, BRIT J CANCER, V97, P1124, DOI 10.1038/sj.bjc.6603992; Gasnereau I, 2012, AM J PATHOL, V180, P131, DOI 10.1016/j.ajpath.2011.09.040; Gheibi A, 2012, Adv Biomed Res, V1, P80, DOI 10.4103/2277-9175.102990; Golding JP, 2004, GENE EXPR PATTERNS, V5, P3, DOI 10.1016/j.modgep.2004.08.004; Golding JP, 2004, DEV DYNAM, V231, P795, DOI 10.1002/dvdy.20176; Hallett RM, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-16; Hallett RM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00227; Han ZX, 2013, CANCER BIOTHER RADIO, V28, P398, DOI 10.1089/cbr.2012.1323; HARTVEIT F, 1984, ONCOLOGY, V41, P149, DOI 10.1159/000225812; Hatzis C, JAMA, V305, P1873; Hsu I, 2014, CARCINOGENESIS, V35, P651, DOI 10.1093/carcin/bgt348; Hu KJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3107; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Hwang JE, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-431; Imai K, 2011, BRIT J CANCER, V104, P300, DOI 10.1038/sj.bjc.6606052; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Journe F, 2011, BRIT J CANCER, V105, P1726, DOI 10.1038/bjc.2011.451; Kaneko N, 2013, BIOL PHARM BULL, V36, P1921, DOI 10.1248/bpb.b13-00515; King SI, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3136; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Li A, 2013, ONCOL REP, V29, P535, DOI 10.3892/or.2012.2144; Li WJ, 2013, MOL BIOL REP, V40, P6143, DOI 10.1007/s11033-013-2725-x; Lindsay J, 2008, CTS-CLIN TRANSL SCI, V1, P107, DOI 10.1111/j.1752-8062.2008.00041.x; Liu WJ, 2012, MOL MED REP, V6, P607, DOI 10.3892/mmr.2012.966; Maire V, 2013, CANCER RES, V73, P813, DOI 10.1158/0008-5472.CAN-12-2633; Maynadier M, 2012, MOL CELL ENDOCRINOL, V364, P126, DOI 10.1016/j.mce.2012.08.016; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Meng XL, 2012, GENET TEST MOL BIOMA, V16, P689, DOI 10.1089/gtmb.2011.0298; Miceli C, 2013, CANCER GENE THER, V20, P298, DOI 10.1038/cgt.2013.21; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Mobasheri A, 2014, J MAMMARY GLAND BIOL, V19, P91, DOI 10.1007/s10911-013-9312-6; Mohanan S, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/895343; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; Pasini A, 2012, TRANSL ONCOL, V5, P461, DOI 10.1593/tlo.12256; Petrarca CR, 2011, CLIN BREAST CANCER, V11, P129, DOI 10.1016/j.clbc.2011.03.002; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Roychoudhuri R, 2006, CANCER CAUSE CONTROL, V17, P655, DOI 10.1007/s10552-005-0615-9; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Su D, 2009, CANCER-AM CANCER SOC, V115, P2453, DOI 10.1002/cncr.24282; Teh MT, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00146; Valladares-Ayerbes M, 2010, CANCER EPIDEM BIOMAR, V19, P1432, DOI 10.1158/1055-9965.EPI-10-0123; Veltmaat JM, 2006, DEVELOPMENT, V133, P2325, DOI 10.1242/dev.02394; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wang QP, 2013, INT J BIOCHEM CELL B, V45, P2036, DOI 10.1016/j.biocel.2013.06.026; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang ZW, 2010, BBA-REV CANCER, V1806, P258, DOI 10.1016/j.bbcan.2010.06.001; Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439; Wierer M, 2013, CELL REP, V3, P2021, DOI 10.1016/j.celrep.2013.05.024; Wilting J, 2011, CURR MED CHEM, V18, P5519, DOI 10.2174/092986711798347252; Yamashita J, 2012, ACTA DERM-VENEREOL, V92, P593, DOI 10.2340/00015555-1416; Yoruk O, 2009, INT J NEUROSCI, V119, P815, DOI 10.1080/00207450802329639; Zhang EY, 2013, J PROTEOME RES, V12, P2805, DOI 10.1021/pr4001527; Zhang M, TARGET ONCOL; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047; Zhao YC, 2014, MOL MED REP, V9, P614, DOI 10.3892/mmr.2013.1842; Zou J, 2013, CELL CYCLE, V12, P14; Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217	87	13	14	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					2003	2010		10.1038/onc.2014.149	http://dx.doi.org/10.1038/onc.2014.149			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24909172	Green Accepted			2022-12-17	WOS:000352725600014
J	Yang, J; Kalogerou, M; Samsel, PA; Zhang, Y; Griffiths, DFR; Gallacher, J; Sampson, JR; Shen, MH				Yang, J.; Kalogerou, M.; Samsel, P. A.; Zhang, Y.; Griffiths, D. F. R.; Gallacher, J.; Sampson, J. R.; Shen, M. H.			Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; INSULIN-RESISTANCE; MAMMALIAN TARGET; MTOR; ACTIVATION; REVEALS; KINASE; IDENTIFICATION; LETHALITY; SUBSTRATE	Tuberous sclerosis (TSC) is an inherited syndrome in which tumours in multiple organs are characterised by activation of mammalian target of rapamycin complex 1 (mTORC1). Previous work suggests that mTORC1 activation is associated with feedback inhibition of Akt, a substrate of mTORC2. This could limit TSC-associated tumour growth but lead to paradoxical promotion of tumour cell survival upon treatment with mTOR inhibitors. However, Akt/mTOR signalling has not been fully investigated in TSC-associated tumours and it has been uncertain whether mTOR inhibition can prevent TSC-associated renal tumourigenesis. In this study, we investigated Akt/mTOR signalling in renal tumours using a Tsc2(+/-) mouse model and tested whether mTOR inhibition could prevent renal tumourigenesis. We found that all renal lesions including cysts, adenomas and carcinomas exhibited activation of both Akt and mTORC1 as evidenced by increased protein expression and phosphorylation of Akt and mTOR and their downstream targets. Protein kinase Ca was also highly expressed and phosphorylated in these lesions, consistent with activation of mTORC2. Surprisingly, IRS proteins were highly expressed, in contrast to a striking decrease seen in cultured Tsc2(-/-) mouse embryonic fibroblasts, suggesting one mechanism through which loss of feedback inhibition of Akt may occur in mTORC1 hyperactivated Tsc-associated tumours. Long-term treatment with rapamycin reduced both Akt and mTORC1 activity in normal kidney tissues and blocked the development of all types of renal lesions. In conclusion, in contrast to previous studies, we found that Akt signalling is not inhibited in Tsc-associated renal lesions and that by partially inhibiting the Akt/mTOR pathway, rapamycin is highly effective in preventing Tsc-associated tumours.	[Yang, J.; Kalogerou, M.; Samsel, P. A.; Zhang, Y.; Sampson, J. R.; Shen, M. H.] Cardiff Univ, Sch Med, Inst Canc & Genet, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales; [Griffiths, D. F. R.] Cardiff Univ, Sch Med, Inst Canc & Genet, Sect Pathol, Cardiff CF14 4XN, S Glam, Wales; [Gallacher, J.] Cardiff Univ, Sch Med, Dept Primary Care & Publ Hlth, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Shen, MH (corresponding author), Cardiff Univ, Sch Med, Inst Canc & Genet, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales.	Sampson@cf.ac.uk; shenmh@cf.ac.uk			Wales Gene Park, UK; Tuberous Sclerosis Association, UK	Wales Gene Park, UK; Tuberous Sclerosis Association, UK	We thank Dr David Kwiatkowski for providing the Tsc2<SUP>+/-</SUP> mouse model. This project was supported by the Wales Gene Park, UK and the Tuberous Sclerosis Association, UK.	Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj.cdd.4400978; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hasumi Y, 2009, P NATL ACAD SCI USA, V106, P18722, DOI 10.1073/pnas.0908853106; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Johannessen CM, 2008, CURR BIOL, V18, P56, DOI 10.1016/j.cub.2007.11.066; Kalogerou M, 2012, EUR J RADIOL, V81, P2069, DOI 10.1016/j.ejrad.2011.06.054; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamming DW, 2012, SCIENCE, V335, P1638, DOI 10.1126/science.1215135; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; NELLIST M, 1993, CELL, V75, P1305; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38; Proud CG, 2011, BIOCHEM SOC T, V39, P431, DOI 10.1042/BST0390431; Russell RC, 2011, DEVELOPMENT, V138, P3343, DOI 10.1242/dev.058230; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wilson C, 2005, HUM MOL GENET, V14, P1839, DOI 10.1093/hmg/ddi190; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Xu XS, 2012, J BIOL CHEM, V287, P40758, DOI 10.1074/jbc.M112.405209; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984	38	13	13	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					922	931		10.1038/onc.2014.17	http://dx.doi.org/10.1038/onc.2014.17			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24632604	Green Accepted			2022-12-17	WOS:000349472000012
J	Sun, J; Mohlin, S; Lundby, A; Kazi, JU; Hellman, U; Pahlman, S; Olsen, JV; Ronnstrand, L				Sun, J.; Mohlin, S.; Lundby, A.; Kazi, J. U.; Hellman, U.; Pahlman, S.; Olsen, J. V.; Ronnstrand, L.			The PI3-kinase isoform p110 delta is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner	ONCOGENE			English	Article						c-Kit; c-Kit/D816V; PI3-kinase; p110 delta; phosphorylation; cell transformation	ACUTE MYELOID-LEUKEMIA; PHOSPHOINOSITIDE 3-KINASE; GENE-MUTATIONS; AGGRESSIVE MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS; TYROSINE KINASE; BREAST-CANCER; ACTIVATION; DASATINIB; GROWTH	PI3-kinase has a crucial role in transformation mediated by the oncogenic c-Kit mutant D816V. In this study, we demonstrate that the c-Kit/D816V-mediated cell survival is dependent on an intact direct binding of PI3-kinase to c-Kit. However, mutation of this binding site had little effect on the PI3-kinase activity in the cells, suggesting that c-Kit/D816V-mediated cell survival is dependent on PI3-kinase but not its kinase activity. Furthermore, inhibition of the lipid kinase activity of PI3-kinase led only to a slight inhibition of cell survival. Knockdown of the predominant PI3-kinase isoform p110 delta in c-Kit/D816V-expressing Ba/F3 cells led to reduced cell transformation both in vitro and in vivo without affecting the overall PI3-kinase activity. This suggests that p110 delta has a lipid-kinaseindependent role in c-Kit/D816V-mediated cell transformation. We furthermore demonstrate that p110 delta is phosphorylated at residues Y524 and S1039 and that phosphorylation requires an intact binding site for PI3-kinase in c-Kit/D816V. Overexpression of p110 delta carrying the Y523F and S1038A mutations significantly reduced c-Kit/D816V-mediated cell survival and proliferation. Taken together, our results demonstrate an important lipid-kinase-independent role of p110 delta in c-Kit/D816V-mediated cell transformation. This furthermore suggests that p110 delta could be a potential diagnostic factor and selective therapeutic target for c-Kit/D816V-expressing malignancies.	[Sun, J.; Kazi, J. U.; Ronnstrand, L.] Lund Univ, Skane Univ Hosp, Dept Lab Med, Expt Clin Chem, Malmo, Sweden; [Mohlin, S.; Pahlman, S.] Lund Univ, Skane Univ Hosp, CREATE Hlth, Dept Lab Med,Ctr Mol Pathol, Malmo, Sweden; [Lundby, A.; Olsen, J. V.] Univ Copenhagen, Fac Hlth Sci, Dept Prote, Novo Nordisk Fdn Ctr Prot Res, Copenhagen, Denmark; [Hellman, U.] Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; University of Copenhagen; Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Lund Univ, Dept Lab Med, Expt Clin Chem, Bldg 404 C3, SE-22381 Lund, Sweden.	Lars.Ronnstrand@med.lu.se	Lundby, Alicia/H-3322-2013; Olsen, Jesper/ABH-4638-2020; Kazi, Julhash U./D-9190-2011	Olsen, Jesper/0000-0002-4747-4938; Kazi, Julhash U./0000-0002-0719-5336; Ronnstrand, Lars/0000-0003-1275-5809; Lundby, Alicia/0000-0002-1612-6041; Mohlin, Sofie/0000-0002-2458-3963	Swedish Cancer Society; Swedish Research Council; Strategic Cancer Research Program at Lund University; BioCARE; ALF governmental clinical grant; Stiftelsen Olle Engkvist Byggmastare; Alfred Osterlund Foundation; Gunnar Nilsson Cancer Society; MAS Cancer Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Strategic Cancer Research Program at Lund University; BioCARE; ALF governmental clinical grant; Stiftelsen Olle Engkvist Byggmastare(Swedish Research Council); Alfred Osterlund Foundation; Gunnar Nilsson Cancer Society; MAS Cancer Foundation	This research was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Strategic Cancer Research Program at Lund University, BioCARE, ALF governmental clinical grant, Stiftelsen Olle Engkvist Byggmastare, Alfred Osterlund Foundation, Gunnar Nilsson Cancer Society and MAS Cancer Foundation.	Aichberger KJ, 2008, EUR J CLIN INVEST, V38, P869, DOI 10.1111/j.1365-2362.2008.02036.x; Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; Boissel N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188; Boller D, 2008, CLIN CANCER RES, V14, P1172, DOI 10.1158/1078-0432.CCR-07-0737; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Cohen SM, 2012, AM J SURG, V204, P895, DOI 10.1016/j.amjsurg.2012.07.027; Corless CL, 2011, NAT REV CANCER, V11, P865, DOI 10.1038/nrc3143; Cornillet-Lefebvre P, 2006, LEUKEMIA, V20, P374, DOI 10.1038/sj.leu.2404054; Cox J, 2009, NAT PROTOC, V4, P698, DOI 10.1038/nprot.2009.36; Czupalla C, 2003, J BIOL CHEM, V278, P11536, DOI 10.1074/jbc.M210351200; Eickholt BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000869; Hantschel O, 2008, LEUKEMIA LYMPHOMA, V49, P615, DOI 10.1080/10428190801896103; Harir N, 2008, BLOOD, V112, P2463, DOI 10.1182/blood-2007-09-115477; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Hongyo T, 2000, CANCER RES, V60, P2345; Jia SD, 2009, CURR OPIN CELL BIOL, V21, P199, DOI 10.1016/j.ceb.2008.12.007; Lennartsson J, 2012, PHYSIOL REV, V92, P1619, DOI 10.1152/physrev.00046.2011; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Lundby A, 2011, METHODS MOL BIOL, V753, P143, DOI 10.1007/978-1-61779-148-2_10; Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039; Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200; Nijenhuis CM, 2013, CANCER TREAT REV, V39, P305, DOI 10.1016/j.ctrv.2012.10.006; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Ogita S, 2011, TARGET ONCOL, V6, P103, DOI 10.1007/s11523-011-0176-7; Olsen JV, 2009, MOL CELL PROTEOMICS, V8, P2759, DOI 10.1074/mcp.M900375-MCP200; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Pardanani A, 2012, AM J HEMATOL, V87, P402, DOI 10.1002/ajh.23134; Sadrzadeh H, 2011, DISCOV MED, V12, P481; Sakuma Y, 2004, CANCER SCI, V95, P716, DOI 10.1111/j.1349-7006.2004.tb03251.x; Sawyer C, 2003, CANCER RES, V63, P1667; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Sun JM, 2008, J BIOL CHEM, V283, P27444, DOI 10.1074/jbc.M709703200; Sun JM, 2009, J BIOL CHEM, V284, P11039, DOI 10.1074/jbc.M808058200; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Verstovsek S, 2008, CLIN CANCER RES, V14, P3906, DOI 10.1158/1078-0432.CCR-08-0366	43	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5360	5369		10.1038/onc.2013.479	http://dx.doi.org/10.1038/onc.2013.479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24213578	Green Submitted			2022-12-17	WOS:000345120600006
J	O'Leary, KA; Rugowski, DE; Sullivan, R; Schuler, LA				O'Leary, K. A.; Rugowski, D. E.; Sullivan, R.; Schuler, L. A.			Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas	ONCOGENE			English	Article						p53; breast cancer; prolactin; AP-1	BREAST-CANCER CELLS; TO-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR GENE; TRANSCRIPTION FACTOR; GLAND DEVELOPMENT; MATRIX METALLOPROTEINASES; GROWTH-FACTOR; EXPRESSION; TUMORIGENESIS; AP-1	TP53 is one of the most commonly mutated genes in cancer. In breast cancer, it is mutated in about 40% of primary clinical tumors and is associated with poor survival. The mammotrophic hormone, prolactin (PRL), and/or its receptor are also expressed in many breast cancers, and accumulating epidemiologic data link PRL to breast cancer development and progression. Like TP53 mutations, evidence for PRL activity is evident across several molecular cancer subtypes, and elevated PRL expression and loss of p53 have been observed in some of the same clinical tumors. In order to examine the interaction of these factors, we used genetically modified mouse models of mammary-specific p53 loss and local overexpression of PRL. We demonstrated that mammary PRL decreased the latency of tumors in the absence of p53, and increased the proportion of triple-negative claudin-low carcinomas, which display similarities to human clinical metaplastic carcinomas. Moreover, PRL/p53(-/-) carcinomas displayed higher rates of proliferation and more aggressive behavior. Transcripts associated with cell cycle progression, invasion and stromal reactivity were differentially expressed in carcinomas that developed in the presence of elevated PRL. PRL/p53(-/-) carcinomas also exhibited selectively altered expression of activating protein-1 components, including higher levels of c-Jun and FosL1, which can drive transcription of many of these genes and the epithelial-mesenchymal transition. The ability of PRL to promote claudin-low carcinomas demonstrates that PRL can influence this subset of triple-negative breast cancers, which may have been obscured by the relative infrequency of this cancer subtype. Our findings suggest novel therapeutic approaches, and provide a preclinical model to develop possible agents.	[O'Leary, K. A.; Rugowski, D. E.; Schuler, L. A.] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; [Sullivan, R.; Schuler, L. A.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu			CDMRP [W81XWH-06-1-0647]; NIH [R01CA157675]; Department of Comparative Biosciences (LAS); UWCCC Core Grant [P30 CA014520]; NATIONAL CANCER INSTITUTE [R01CA157675, P30CA014520] Funding Source: NIH RePORTER	CDMRP(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Comparative Biosciences (LAS); UWCCC Core Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate the assistance of William Mulligan and Craig Barcus with the collagen imaging. This work was supported in part by CDMRP W81XWH-06-1-0647 (KAO), NIH R01CA157675 and funds from the Department of Comparative Biosciences (LAS) and UWCCC Core Grant P30 CA014520 (RS).	Ameyar-Zazoua M, 2005, ONCOGENE, V24, P2298, DOI 10.1038/sj.onc.1208424; Arendt LM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2819; Arendt LM, 2009, J ENDOCRINOL, V203, P99, DOI 10.1677/JOE-09-0221; Arendt LM, 2009, AM J PATHOL, V174, P1065, DOI 10.2353/ajpath.2009.080719; Asher JM, 2012, AM J PATHOL, V181, P294, DOI 10.1016/j.ajpath.2012.03.041; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Barcus CE, 2013, J BIOL CHEM, V288, P12722, DOI 10.1074/jbc.M112.447631; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; Bhatavdekar JM, 2000, EUR J SURG ONCOL, V26, P540, DOI 10.1053/ejso.2000.0943; Bhatavdekar JM, 2000, ANN SURG ONCOL, V7, P305, DOI 10.1007/s10434-000-0305-5; BHATAVDEKAR JM, 1990, CANCER, V65, P2028, DOI 10.1002/1097-0142(19900501)65:9&lt;2028::AID-CNCR2820650924&gt;3.0.CO;2-9; Camarillo IG, 2001, J ENDOCRINOL, V171, P85, DOI 10.1677/joe.0.1710085; Cardiff RD, 2010, J MAMMARY GLAND BIOL, V15, P225, DOI 10.1007/s10911-010-9184-y; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607; Clevenger CV, 1997, J MAMMARY GLAND BIOL, V2, P59, DOI 10.1023/A:1026325630359; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Donehower LA, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001081; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gass S, 2003, J MAMMARY GLAND BIOL, V8, P269, DOI 10.1023/B:JOMG.0000010029.85796.63; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; GINSBURG E, 1995, CANCER RES, V55, P2591; Gutzman JH, 2007, ONCOGENE, V26, P6341, DOI 10.1038/sj.onc.1210454; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Hasen NS, 2010, CANCER PREV RES, V3, P620, DOI 10.1158/1940-6207.CAPR-09-0225; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; HOLTKAMP W, 1984, INT J CANCER, V34, P323, DOI 10.1002/ijc.2910340307; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Howell SJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2129; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson JG, 2013, ONCOGENE, V32, P4325, DOI 10.1038/onc.2012.610; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kohrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-188; Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681; Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723; McHale K, 2008, MODERN PATHOL, V21, P565, DOI 10.1038/modpathol.2008.7; Medina D, 2005, CANCER RES, V65, P3493, DOI 10.1158/0008.5472.CAN-04-3869; Medina D, 2003, CANCER RES, V63, P1067; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Meng JP, 2004, CANCER RES, V64, P5677, DOI 10.1158/0008-5472.CAN-04-1019; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; MONTES GS, 1991, MEM I OSWALDO CRUZ, V86, P1; Mujagic Z, 2004, CROAT MED J, V45, P176; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; Oakes SR, 2007, ONCOGENE, V26, P543, DOI 10.1038/sj.onc.1209838; Oakes SR, 2008, J MAMMARY GLAND BIOL, V13, P13, DOI 10.1007/s10911-008-9069-5; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Ridgeway AG, 2006, ONCOGENE, V25, P3518, DOI 10.1038/sj.onc.1209391; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Sakamoto K, 2010, ONCOGENE, V29, P5359, DOI 10.1038/onc.2010.274; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Sharpless NE, 2002, CANCER RES, V62, P2761; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Shen Q, 2006, DEV BIOL, V295, P589, DOI 10.1016/j.ydbio.2006.03.042; Shen Q, 2008, CANCER PREV RES, V1, P45, DOI 10.1158/1940-6207.CAPR-08-0034; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Swaminathan G, 2008, J MAMMARY GLAND BIOL, V13, P81, DOI 10.1007/s10911-008-9068-6; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tworoger SS, 2008, J MAMMARY GLAND BIOL, V13, P41, DOI 10.1007/s10911-008-9063-y; Vleugel MM, 2006, HUM PATHOL, V37, P668, DOI 10.1016/j.humpath.2006.01.022; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001; Zhang SL, 2003, ONCOGENE, V22, P2285, DOI 10.1038/sj.onc.1206257; Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59	78	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3075	3082		10.1038/onc.2013.278	http://dx.doi.org/10.1038/onc.2013.278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23873024	Green Accepted			2022-12-17	WOS:000337232200014
J	Armacki, M; Joodi, G; Nimmagadda, SC; de Kimpe, L; Pusapati, GV; Vandoninck, S; Van Lint, J; Illing, A; Seufferlein, T				Armacki, M.; Joodi, G.; Nimmagadda, S. C.; de Kimpe, L.; Pusapati, G. V.; Vandoninck, S.; Van Lint, J.; Illing, A.; Seufferlein, T.			A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis	ONCOGENE			English	Article						PKD2; CIB1; angiogenesis; carcinogenesis	FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; CIB1; PHOSPHORYLATION; INVASION; D2; ACTIVATION; INHIBITION; EXPORT; IDENTIFICATION	Protein kinase D2 (PKD2) is a member of the PKD family of serine/threonine kinases, a subfamily of the CAMK super-family. PKDs have a critical role in cell motility, migration and invasion of cancer cells. Expression of PKD isoforms is deregulated in various tumours and PKDs, in particular PKD2, have been implicated in the regulation of tumour angiogenesis. In order to further elucidate the role of PKD2 in tumours, we investigated the signalling context of this kinase by performing an extensive substrate screen by in vitro expression cloning (IVEC). We identified a novel splice variant of calcium and integrin-binding protein 1, termed CIB1a, as a potential substrate of PKD2. CIB1 is a widely expressed protein that has been implicated in angiogenesis, cell migration and proliferation, all important hallmarks of cancer, and CIB1a was found to be highly expressed in various cancer cell lines. We identify Ser(118) as the major PKD2 phosphorylation site in CIB1a and show that PKD2 interacts with CIB1a via its alanine and proline-rich domain. Furthermore, we confirm that CIB1a is indeed a substrate of PKD2 also in intact cells using a phosphorylation-specific antibody against CIB1a-Ser(118). Functional analysis of PKD2-mediated CIB1a phosphorylation revealed that on phosphorylation, CIB1a mediates tumour cell invasion, tumour growth and angiogenesis by mediating PKD-induced vascular endothelial growth factor secretion by the tumour cells. Thus, CIB1a is a novel mediator of PKD2-driven carcinogenesis and a potentially interesting therapeutic target.	[Armacki, M.; Illing, A.; Seufferlein, T.] Univ Ulm, Dept Internal Med 1, D-89081 Baden Baden, Germany; [Armacki, M.; Joodi, G.; Nimmagadda, S. C.; Seufferlein, T.] Univ Halle Wittenberg, Dept Internal Med 1, D-06108 Halle, Saale, Germany; [de Kimpe, L.] Univ Amsterdam, AMC, Amsterdam, Netherlands; [de Kimpe, L.; Vandoninck, S.; Van Lint, J.] Katholieke Univ Leuven, Fac Med, Dept Cellular & Mol Med, Louvain, Belgium; [Pusapati, G. V.] Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA	Ulm University; Martin Luther University Halle Wittenberg; University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven; Stanford University	Seufferlein, T (corresponding author), Univ Ulm, Dept Internal Med 1, Albert Einstein Allee 23, D-89081 Ulm, Germany.	Thomas.seufferlein@uniklinik-ulm.de	Van Lint, Johan/P-9073-2019; Seufferlein, Thomas TW/P-7147-2018	Pusapati, Ganesh/0000-0002-1406-2566; Van Lint, Johan/0000-0002-0275-571X; Joodi, Golsa/0000-0002-6371-433X	German Federal Ministry of Education and Research (BMBF) [PKB-01GS08209-4]; German Cancer Aid [109373]; Research Programme of the Research Foundation-Flanders (FWO);  [G.0612.07]	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Cancer Aid(Deutsche Krebshilfe); Research Programme of the Research Foundation-Flanders (FWO)(FWO); 	This project was funded in part by the German Federal Ministry of Education and Research (BMBF) grant no. PKB-01GS08209-4 and the German Cancer Aid grant no. 109373 (both to TS) and in part by the Research Programme of the Research Foundation-Flanders (FWO) (PhD fellowship to LDK and grant G.0612.07 to JVL). We thank Holger Reim and Claudia Ruhland for expert technical assistance.	Albini A, 2004, INT J DEV BIOL, V48, P563, DOI 10.1387/ijdb.041822aa; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 1998, Pathol Oncol Res, V4, P230; Auer A, 2005, MOL BIOL CELL, V16, P4375, DOI 10.1091/mbc.E05-03-0251; Azoitei N, 2011, NEURO-ONCOLOGY, V13, P710, DOI 10.1093/neuonc/nor084; Azoitei N, 2010, GUT, V59, P1316, DOI 10.1136/gut.2009.206813; Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Bard F, 2006, ANNU REV CELL DEV BI, V22, P439, DOI 10.1146/annurev.cellbio.21.012704.133126; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Cells J., 1998, CELL BIOL LAB HDB; Chen J, 2008, CANCER RES, V68, P3844, DOI 10.1158/0008-5472.CAN-07-5156; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Eiseler T, 2007, FEBS LETT, V581, P4279, DOI 10.1016/j.febslet.2007.07.079; Eiseler T, 2009, NAT CELL BIOL, V11, P545, DOI 10.1038/ncb1861; Engling A, 2002, J CELL SCI, V115, P3619, DOI 10.1242/jcs.00036; Evans IM, 2008, CELL SIGNAL, V20, P1375, DOI 10.1016/j.cellsig.2008.03.002; Evans IM, 2011, IUBMB LIFE, V63, P258, DOI 10.1002/iub.456; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Gao ZH, 2000, BIOCHEM BIOPH RES CO, V268, P562, DOI 10.1006/bbrc.2000.2168; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guha S, 2010, BIOCHEM PHARMACOL, V80, P1946, DOI 10.1016/j.bcp.2010.07.002; Ha CH, 2008, J BIOL CHEM, V283, P14590, DOI 10.1074/jbc.M800264200; Haataja L, 2002, J BIOL CHEM, V277, P8321, DOI 10.1074/jbc.M105363200; Hao Q, 2009, J BIOL CHEM, V284, P799, DOI 10.1074/jbc.M807546200; Hollenbach AD, 2002, BBA-GENE STRUCT EXPR, V1574, P321, DOI 10.1016/S0167-4781(02)00230-0; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Jackson LN, 2006, BIOCHEM BIOPH RES CO, V348, P945, DOI 10.1016/j.bbrc.2006.07.142; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Lacal PM, 2005, INT J ONCOL, V27, P1625; Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090; Malhotra V, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005280; Mihailovic T, 2004, CANCER RES, V64, P8939, DOI 10.1158/0008-5472.CAN-04-0981; Naik MU, 2011, J CELL BIOCHEM, V112, P3289, DOI 10.1002/jcb.23255; Naik MU, 2011, INT J CANCER, V128, P587, DOI 10.1002/ijc.25388; Naik MU, 2003, BLOOD, V102, P3629, DOI 10.1182/blood-2003-05-1703; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Norrby K, 2006, J CELL MOL MED, V10, P588, DOI 10.1111/j.1582-4934.2006.tb00423.x; Obenauer John C, 2004, Methods Mol Biol, V261, P445; Peterburs P, 2009, CANCER RES, V69, P5634, DOI 10.1158/0008-5472.CAN-09-0718; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Pusapati GV, 2010, MOL BIOL CELL, V21, P1011, DOI 10.1091/mbc.E09-09-0814; Qazi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020348; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Rozengurt E, 2011, PHYSIOLOGY, V26, P23, DOI 10.1152/physiol.00037.2010; Ruifrok AC, 1997, ANAL QUANT CYTOL, V19, P107; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Vempati P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011860; Vogler M, 2005, ONCOGENE, V24, P7190, DOI 10.1038/sj.onc.1208876; von Blume J, 2007, EMBO J, V26, P4619, DOI 10.1038/sj.emboj.7601891; White C, 2006, J BIOL CHEM, V281, P20825, DOI 10.1074/jbc.M602175200; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Yuan W, 2006, MOL CELL BIOL, V26, P8507, DOI 10.1128/MCB.01488-06; Yuan WP, 2006, J CELL BIOL, V172, P169, DOI 10.1083/jcb.200505131; Zayed MA, 2007, CIRC RES, V101, P1185, DOI 10.1161/CIRCRESAHA.107.157586; Zayed MA, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-17; Zhang C, 2004, METHODS, V33, P144, DOI 10.1016/j.ymeth.2003.11.004	66	13	19	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1167	1180		10.1038/onc.2013.43	http://dx.doi.org/10.1038/onc.2013.43			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23503467				2022-12-17	WOS:000331933800010
J	Meyer, DS; Aceto, N; Sausgruber, N; Brinkhaus, H; Muller, U; Pallen, CJ; Bentires-Alj, M				Meyer, D. S.; Aceto, N.; Sausgruber, N.; Brinkhaus, H.; Mueller, U.; Pallen, C. J.; Bentires-Alj, M.			Tyrosine phosphatase PTP alpha contributes to HER2-evoked breast tumor initiation and maintenance	ONCOGENE			English	Article						phosphatases; breast cancer; HER2	CANCER CELL-LINES; EPITHELIAL-CELLS; MAMMARY-TUMORS; IN-VITRO; SRC; 1B; ACTIVATION; IDENTIFICATION; TRANSFORMATION; KINASES	Protein tyrosine phosphatase alpha (PTP alpha/PTPRA) was shown previously to be overexpressed in human primary breast cancers, and to suppress apoptosis in estrogen receptor-negative breast cancer cells in vitro. However, it is not known whether PTP alpha is important for mammary tumor initiation, maintenance and/or progression. We have used a combination of three-dimensional cultures, a transgenic mouse model of breast cancer lacking PTP alpha as well as xenografts of human breast cancer cell lines to address these questions. We found that PTP alpha knockdown after overt tumor development reduced the growth of HER2-positive human breast cancer cell lines, and that this effect was accompanied by a reduction in AKT phosphorylation. However, PTP alpha knockdown did not affect invasiveness of HER2-positive human breast cancer cells grown in three-dimensional cultures. Moreover, in MMTV-NeuNT/PTP alpha(-/-) mice, PTP alpha ablation did not affect NeuNT-evoked tumor onset or metastasis but decreased the number of tumors per mouse. Thus, we demonstrate that PTP alpha contributes to both HER2/Neu-mediated mammary tumor initiation and maintenance. Our results suggest that inhibition of PTP alpha can have a beneficial effect on HER2-positive breast cancers, but that inhibition of additional targets is needed to block breast tumorigenesis.	[Meyer, D. S.; Aceto, N.; Sausgruber, N.; Brinkhaus, H.; Mueller, U.; Bentires-Alj, M.] Friedrich Miescher Inst Biomed Res FMI, Basel, Switzerland; [Pallen, C. J.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; [Pallen, C. J.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 1M9, Canada	Friedrich Miescher Institute for Biomedical Research; University of British Columbia; Child & Family Research Institute; University of British Columbia	Bentires-Alj, M (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	bentires@fmi.ch	Mohamed, Bentires-Alj/F-4484-2015; Aceto, Nicola/O-2484-2014	Mohamed, Bentires-Alj/0000-0001-6344-1127; Pallen, Catherine/0000-0002-3576-5295; Aceto, Nicola/0000-0001-9579-6918	Novartis Research Foundation; European Research Council (ERC starting grant) [243211-PTPsBDC]; Swiss Cancer League; Krebsliga Beider Basel	Novartis Research Foundation; European Research Council (ERC starting grant)(European Research Council (ERC)); Swiss Cancer League; Krebsliga Beider Basel	We thank members of the Bentires-Alj laboratory for advice and discussions. Research in the laboratory of MBA is supported by the Novartis Research Foundation, the European Research Council (ERC starting grant 243211-PTPsBDC), the Swiss Cancer League and the Krebsliga Beider Basel.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Arias-Romero LE, 2009, CANCER RES, V69, P4582, DOI 10.1158/0008-5472.CAN-08-4001; Balavenkatraman KK, 2011, MOL CANCER RES, V9, P1377, DOI 10.1158/1541-7786.MCR-11-0198; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Lin G, 2011, GENE DEV, V25, P1412, DOI 10.1101/gad.2018911; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Perou CM, 2011, COLD SPRING HARB PER, V3; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Yip SC, 2010, TRENDS BIOCHEM SCI, V35, P442, DOI 10.1016/j.tibs.2010.03.004; Zheng X, 2008, INT J CANCER, V122, P1999, DOI 10.1002/ijc.23321; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	20	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					398	402		10.1038/onc.2012.585	http://dx.doi.org/10.1038/onc.2012.585			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318421				2022-12-17	WOS:000330214000014
J	Ling, LS; Voskas, D; Woodgett, JR				Ling, L. S.; Voskas, D.; Woodgett, J. R.			Activation of PDK-1 maintains mouse embryonic stem cell self-renewal in a PKB-dependent manner	ONCOGENE			English	Article						PDK-1; GSK-3; embryonic stem cell; pluripotency	PROTEIN-KINASE-B; BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASES; INSULIN; PLURIPOTENCY; PHOSPHORYLATION; INHIBITION; GROWTH; AKT; PROLIFERATION	The phosphatidylinositol 30 kinase (PI3K) pathway is involved in many cellular processes including cell proliferation, survival and glucose transport, and is implicated in various disease states, such as cancer and diabetes. Although there have been numerous studies dissecting the role of PI3K signaling in different cell types and disease models, the mechanism by which PI3K signaling regulates embryonic stem (ES) cell fate remains unclear. It is believed that in addition to proliferation and tumorigenesis, PI3K activity may also be important for ES cell self-renewal. Paling et al. reported that the inhibition of PI3K led to a reduction in the ability of leukemia inhibitory factor to maintain self-renewal, causing cells to differentiate. Studies in our lab have revealed that ES cells completely lacking glycogen synthase kinase-3 (GSK-3) remain undifferentiated compared with wild-type ES cells. GSK-3 is negatively regulated by PI3K, suggesting that PI3K may have a vital role in maintaining pluripotency in ES cells through GSK-3. By using a modified Flp recombinase system, we expressed activated alleles of 3-phosphoinositide-dependent protein kinase-1 and protein kinase B to create stable, isogenic ES cell lines to further study the role of the PI3K signaling pathway in stem cell fate determination. In vitro characterization of the transgenic cell lines revealed a strong tendency toward the maintenance of pluripotency, and this phenotype was found to be independent of canonical Wnt signal transduction. In summary, PI3K signaling is sufficient to maintain the self-renewal and survival of stem cells. As this pathway is frequently mutationally activated in cancers, its effect on suppressing differentiation may contribute to its oncogenicity.	[Ling, L. S.; Woodgett, J. R.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Ling, L. S.; Voskas, D.; Woodgett, J. R.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Woodgett, JR (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave,Room 982, Toronto, ON M5G 1X5, Canada.	woodgett@lunenfeld.ca	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NSERC Canada Graduate Scholarship; Heart and Stroke Foundation of Canada Fellowship; CIHR [FRN 12858]	NSERC Canada Graduate Scholarship(Natural Sciences and Engineering Research Council of Canada (NSERC)); Heart and Stroke Foundation of Canada Fellowship(Heart & Stroke Foundation of Canada); CIHR(Canadian Institutes of Health Research (CIHR))	We thank Brad Doble for generously sharing reagents and protocols, Malgosia Kownacka for providing feeder cells, Mike Parsons and Elizabeth Rubie for technical expertise and advice, and Eric Ho and Satish Patel for troubleshooting and helpful discussions. LSL was supported by a NSERC Canada Graduate Scholarship and DV was supported by a Heart and Stroke Foundation of Canada Fellowship. These studies were funded by a CIHR operating grant (FRN 12858).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Gu DY, 2007, FEBS LETT, V581, P382, DOI 10.1016/j.febslet.2006.12.043; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Ishibe S, 2006, MOL CELL BIOL, V26, P9232, DOI 10.1128/MCB.01312-06; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kingham E, 2009, J CELL SCI, V122, P2311, DOI 10.1242/jcs.046557; Kobielak K, 2007, P NATL ACAD SCI USA, V104, P10063, DOI 10.1073/pnas.0703004104; Lianguzova MS, 2007, CELL BIOL INT, V31, P330, DOI 10.1016/j.cellbi.2007.01.019; Lin YJ, 2012, MOL CELL, V48, P627, DOI 10.1016/j.molcel.2012.08.030; Logie L, 2007, DIABETES, V56, P2218, DOI 10.2337/db07-0343; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692; Niwa H, 2009, NATURE, V460, P118, DOI 10.1038/nature08113; Orlando L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030234; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2005, MOL CELL BIOL, V25, P2347, DOI 10.1128/MCB.25.6.2347-2363.2005; Storm MP, 2009, STEM CELLS, V27, P764, DOI 10.1002/stem.3; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi K, 2005, BIOCHEM SOC T, V33, P1522, DOI 10.1042/BST0331522; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307; Wu G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004926; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	40	13	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5397	5408		10.1038/onc.2013.44	http://dx.doi.org/10.1038/onc.2013.44			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23455320	Green Published, hybrid			2022-12-17	WOS:000327177600003
J	Skeen, VR; Collard, TJ; Southern, SL; Greenhough, A; Hague, A; Townsend, PA; Paraskeva, C; Williams, AC				Skeen, V. R.; Collard, T. J.; Southern, S. L.; Greenhough, A.; Hague, A.; Townsend, P. A.; Paraskeva, C.; Williams, A. C.			BAG-1 suppresses expression of the key regulatory cytokine transforming growth factor beta (TGF-beta 1) in colorectal tumour cells	ONCOGENE			English	Article						BAG-1; TGF-beta 1; colorectal cancer; adenoma; transcriptional repression	HUMAN COLONIC ADENOMA; NF-KAPPA-B; TGF-BETA; GLUCOCORTICOID-RECEPTOR; GENE-EXPRESSION; IN-VIVO; PROGRESSION; INHIBITION; ISOFORMS; BUTYRATE	As colorectal cancer remains the second highest cause of cancer-related deaths in much of the industrialised world, identifying novel strategies to prevent colorectal tumour development remains an important challenge. BAG-1 is a multi-functional protein, the expression of which is up-regulated at relatively early stages in colorectal tumorigenesis. Importantly, BAG-1 is thought to enhance colorectal tumour progression through promoting tumour cell survival. Here, we report for the first time a novel role for BAG-1, establishing it as a suppressor of transforming growth factor beta (TGF-beta 1) expression in colorectal tumour cells. Microarray analysis first highlighted the possibility that BAG-1 may regulate TGF-beta 1 expression, a key cytokine in normal colonic tissue homoeostasis. Q-RT-PCR and ELISA demonstrated TGFB1 mRNA and protein expression to be significantly increased when BAG1 levels were reduced by small interfering RNA; additionally, induction of BAG-1L caused suppression of TGFB1 mRNA in colorectal tumour cells. Using reporter and chromatin immunoprecipitation assays, a direct association of BAG-1 with the TGFB1 gene regulatory region was identified. Immunohistochemistry and Weiser fraction data indicated that the levels of BAG-1 and TGF-beta 1 are inversely correlated in the normal colonic epithelium in vivo, consistent with a role for BAG-1-mediated repression of TGF-beta 1 production. In vitro studies showed that the change in TGF-beta 1 production following manipulation of BAG-1 is functionally relevant; through induction of anchorage-independent growth in TGF-beta 1-dependent normal rat kidney fibroblasts and regulation of SMAD2 phosphorylation in TGF-beta 1-sensitive adenoma cells. Taken together, this study identifies the anti-apoptotic protein BAG-1 as a suppressor of the inhibitory growth factor TGF-beta 1, suggesting that high expression of BAG-1 can impact on a number of the hallmarks of cancer, of potential importance in promoting the early stages of colorectal tumorigenesis. Establishing BAG-1 as a repressor of TGF-beta 1 has important biological implications, and highlights a new role for BAG-1 in colorectal tumorigenesis.	[Skeen, V. R.; Collard, T. J.; Southern, S. L.; Greenhough, A.; Paraskeva, C.; Williams, A. C.] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England; [Hague, A.] Univ Bristol, Sch Oral & Dent Sci, Bristol BS8 1TD, Avon, England; [Townsend, P. A.] Univ Southampton, Southampton Gen Hosp, Sch Med, Southampton, Hants, England	University of Bristol; University of Bristol; University of Southampton	Williams, AC (corresponding author), Univ Bristol, Sch Cellular & Mol Med, Med Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England.	PATownsend@soton.ac.uk; Ann.C.Williams@bristol.ac.uk	Greenhough, Alexander/J-9308-2012; Townsend, Paul/AAF-8234-2020; Greenhough, Alexander/Y-6728-2019	Greenhough, Alexander/0000-0002-8306-811X; Greenhough, Alexander/0000-0002-8306-811X; Townsend, Paul/0000-0001-8956-9508; Williams, Ann/0000-0002-6009-7137	Cancer Research UK programme grant; Citrina Foundation; John James Bristol Foundation; CORE; Cancer Research UK [11975] Funding Source: researchfish	Cancer Research UK programme grant(Cancer Research UK); Citrina Foundation; John James Bristol Foundation; CORE(Luxembourg National Research Fund); Cancer Research UK(Cancer Research UK)	This work was funded by a Cancer Research UK programme grant, the Citrina Foundation, CORE and by the John James Bristol Foundation. We thank members of the CP group for useful discussion.	Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P798; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; Barnes JD, 2005, APOPTOSIS, V10, P301, DOI 10.1007/s10495-005-0804-8; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Clemo NK, 2008, CARCINOGENESIS, V29, P849, DOI 10.1093/carcin/bgn004; Cutress RI, 2003, ONCOGENE, V22, P4973, DOI 10.1038/sj.onc.1206688; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; Gehring U, 2009, INT J MOL SCI, V10, P906, DOI 10.3390/ijms10030906; Hague A, 1997, GASTROENTEROLOGY, V112, P1036, DOI 10.1053/gast.1997.v112.agast971036; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hong W, 2008, J MOL BIOL, V384, P22, DOI 10.1016/j.jmb.2008.09.010; Hong W, 2009, FEBS LETT, V583, P2451, DOI 10.1016/j.febslet.2009.07.010; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kikuchi R, 2002, BRIT J CANCER, V87, P1136, DOI 10.1038/sj.bjc.6600579; KIM SJ, 1989, J BIOL CHEM, V264, P402; Lampropoulos P, 2012, CANCER LETT, V314, P1, DOI 10.1016/j.canlet.2011.09.041; Lee KY, 2006, J IMMUNOL, V176, P603, DOI 10.4049/jimmunol.176.1.603; MANNING AM, 1991, ONCOGENE, V6, P1471; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; MULDER KM, 1988, BIOCHEM BIOPH RES CO, V150, P711, DOI 10.1016/0006-291X(88)90449-4; Myant K, 2011, EXP CELL RES, V317, P2725, DOI 10.1016/j.yexcr.2011.08.001; Niyaz Y, 2001, J CELL SCI, V114, P1839; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PARASKEVA C, 1989, CANCER RES, V49, P1282; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Picon A, 1998, CANCER EPIDEM BIOMAR, V7, P497; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sharp Adam, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007537; Sharp A, 2009, FEBS LETT, V583, P3405, DOI 10.1016/j.febslet.2009.09.047; Sharp A, 2009, J PHARMACOL EXP THER, V331, P680, DOI 10.1124/jpet.109.153601; Shatkina L, 2003, MOL CELL BIOL, V23, P7189, DOI 10.1128/MCB.23.20.7189-7197.2003; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Skeen VR, 2012, CURR PHARM DESIGN, V18, P3874; Smartt HJM, 2012, GUT, V61, P1306, DOI 10.1136/gutjnl-2011-300817; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Takayama S, 1998, CANCER RES, V58, P3116; Townsend PA, 2005, INT J BIOCHEM CELL B, V37, P251, DOI 10.1016/j.biocel.2004.03.016; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; WANG G, 1992, EXP CELL RES, V198, P27, DOI 10.1016/0014-4827(92)90144-W; Wang XH, 2009, BRIT J CANCER, V100, P1347, DOI 10.1038/sj.bjc.6604985; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; Xu WQ, 2007, EXP MOL PATHOL, V82, P284, DOI 10.1016/j.yexmp.2006.10.011; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zhang XY, 2011, MOL CELL BIOL, V31, P5037, DOI 10.1128/MCB.06297-11; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	53	13	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4490	4499		10.1038/onc.2012.480	http://dx.doi.org/10.1038/onc.2012.480			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108401	Green Accepted			2022-12-17	WOS:000324831300004
J	Xuan, C; Wang, Q; Han, X; Duan, Y; Li, L; Shi, L; Wang, Y; Shan, L; Yao, Z; Shang, Y				Xuan, C.; Wang, Q.; Han, X.; Duan, Y.; Li, L.; Shi, L.; Wang, Y.; Shan, L.; Yao, Z.; Shang, Y.			RBB, a novel transcription repressor, represses the transcription of HDM2 oncogene	ONCOGENE			English	Article						MDM2; p53; RBB; transcription repressor; NuRD complex	PROTEIN INTERACTION MOTIF; ACUTE PROMYELOCYTIC LEUKEMIA; POZ-DOMAIN; TUMOR-SUPPRESSOR; DOWN-REGULATION; MDM2 GENE; P53; COREPRESSOR; EXPRESSION; PROMOTES	The p53 tumor suppressor is important in many aspects of cell biology. Tight regulation of p53 is thus imperative for maintaining cell homeostasis and preventing tumorigenesis. The stabilization and activity of p53 is primarily regulated by MDM2, which is encoded for by HDM2. However, how the expression and activity of MDM2 is regulated remains largely unknown. Here, we report a novel BTB and BEN domains-containing protein, RBB. We demonstrated that RBB is a novel transcriptional repressor binding specific DNA motif via a homodimer and interacting with the nucleosome remodeling and deacetylase (NuRD) complex. Genome wide transcription target analysis by ChIP sequencing revealed that RBB represses the transcription of a series of functionally important genes including HDM2. We showed that RBB recruits the NuRD complex to the internal promoter of HDM2 and inhibits the expression of MDM2 protein, leading to subsequent stabilization of tumor suppressor p53. Significantly, we showed that RBB suppresses cell proliferation and sensitizes cells to DNA damage-induced apoptosis. Our data indicate that RBB is a novel transcriptional repressor and an important regulator of p53 pathway.	[Xuan, C.; Wang, Q.; Duan, Y.; Li, L.; Shi, L.; Wang, Y.; Shan, L.; Yao, Z.; Shang, Y.] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Tianjin 300070, Peoples R China; [Wang, Q.; Yao, Z.] Tianjin Med Univ, Dept Immunol, Tianjin 300070, Peoples R China; [Han, X.] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Key Lab Carcinogenesis & Translat Res, Beijing 100871, Peoples R China	Tianjin Medical University; Tianjin Medical University; Peking University	Xuan, C (corresponding author), Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.	chenghaoxuan@bjmu.edu.cn; yshang@hsc.pku.edu.cn	duan, yang/GZA-6440-2022; Han, Xiao/A-1109-2017	Han, Xiao/0000-0002-5395-4022; Han, Xiao/0000-0002-6024-6286	National Natural Science Foundation of China [81000876, 81130048, 30921062]; Ministry of Science and Technology of China [2011CB504204]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by grants (81000876, 81130048 and 30921062 to YS) from the National Natural Science Foundation of China and grants (973 Program: 2011CB504204 to YS) from the Ministry of Science and Technology of China.	Abhiman S, 2008, BIOINFORMATICS, V24, P458, DOI 10.1093/bioinformatics/btn007; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brooks CL, 2004, CELL CYCLE, V3, P895; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; Grochola LF, 2010, PANCREAS, V39, P76, DOI 10.1097/MPA.0b013e3181b9f105; Grzenda A, 2009, BBA-GENE REGUL MECH, V1789, P443, DOI 10.1016/j.bbagrm.2009.05.007; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Huynh KD, 2000, GENE DEV, V14, P1810; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jung CR, 2010, J CLIN INVEST, V120, P4493, DOI 10.1172/JCI42674; JUVEN T, 1993, ONCOGENE, V8, P3411; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Xuan C, 2008, CELL MICROBIOL, V10, P31, DOI 10.1111/j.1462-5822.2007.01011.x; Xuan CH, 2007, J BIOL CHEM, V282, P28800, DOI 10.1074/jbc.M702823200; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334	52	13	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2013	32	32					3711	3721		10.1038/onc.2012.386	http://dx.doi.org/10.1038/onc.2012.386			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22926524				2022-12-17	WOS:000322904400006
J	Maicas, M; Vazquez, I; Vicente, C; Garcia-Sanchez, MA; Marcotegui, N; Urquiza, L; Calasanz, MJ; Odero, MD				Maicas, M.; Vazquez, I.; Vicente, C.; Garcia-Sanchez, M. A.; Marcotegui, N.; Urquiza, L.; Calasanz, M. J.; Odero, M. D.			Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription	ONCOGENE			English	Article						EVI1; promoter; AML; RUNX1; ELK1	POINT MUTATIONS; ETS FAMILY; EXPRESSION; DIFFERENTIATION; ONCOGENE; CELLS; PHOSPHORYLATION; ACTIVATION; GATA-1; DOMAIN	The EVI1 gene (3q26) codes for a transcription factor with important roles in normal hematopoiesis and leukemogenesis. High expression of EVI1 is a negative prognostic indicator of survival in acute myeloid leukemia (AML) irrespective of the presence of 3q26 rearrangements. However, the only known mechanisms that lead to EVI1 overexpression are 3q aberrations, and the MLL-ENL oncoprotein, which activates the transcription of EVI1 in hematopoietic stem cells. Our aim was to characterize the functional promoter region of EVI1, and to identify transcription factors involved in the regulation of this gene. Generation of seven truncated constructs and luciferase reporter assays allowed us to determine a 318-bp region as the minimal promoter region of EVI1. Site-directed mutagenesis and chromatin immunoprecipitation (ChIP) assays identified RUNX1 and ELK1 as putative transcription factors of EVI1. Furthermore, knockdown of RUNX1 and ELK1 led to EVI1 downregulation, and their overexpression to upregulation of EVI1. Interestingly, in a series of patient samples with AML at diagnosis, we found a significant positive correlation between EVI1 and RUNX1 at protein level. Moreover, we identified one of the roles of RUNX1 in the activation of EVI1 during megakaryocytic differentiation. EVI1 knockdown significantly inhibited the expression of megakaryocytic markers after treating K562 cells with TPA, as happens when knocking down RUNX1. In conclusion, we define the minimal promoter region of EVI1 and demonstrate that RUNX1 and ELK1, two proteins with essential functions in hematopoiesis, regulate EVI1 in AML. Furthermore, our results show that one of the mechanisms by which RUNX1 regulates the transcription of EVI1 is by acetylation of the histone H3 on its promoter region. This study opens new directions to further understand the mechanisms of EVI1 overexpressing leukemias. Oncogene (2013) 32, 2069-2078; doi:10.1038/onc.2012.222; published online 11 June 2012	[Maicas, M.; Vazquez, I.; Vicente, C.; Garcia-Sanchez, M. A.; Marcotegui, N.; Urquiza, L.; Odero, M. D.] Univ Navarra, CIMA, Div Oncol, Genet Lab, Pamplona 31008, Spain; [Maicas, M.; Calasanz, M. J.; Odero, M. D.] Univ Navarra, Dept Genet, Pamplona 31008, Spain	University of Navarra; University of Navarra	Odero, MD (corresponding author), Univ Navarra, CIMA, Div Oncol, Genet Lab, C Pio 12,55, Pamplona 31008, Spain.	modero@unav.es	Calasanz, MJ/R-5813-2016; Vicente, Carmen/AAA-7098-2021; Maicas, Miren/A-9836-2017; Garcia-Sanchez, Asuncion/AAE-8611-2019; Vázquez, Iria/AAD-4092-2020; Odero/ABG-9860-2020	Calasanz, MJ/0000-0002-0374-3008; Vicente, Carmen/0000-0002-3363-3459; Maicas, Miren/0000-0003-1404-5552; Garcia-Sanchez, Asuncion/0000-0002-9655-4918; Vázquez, Iria/0000-0003-0027-6384; Odero/0000-0002-8858-2054	Ministerio Educacion y Ciencia [AP2007-03879]; Ministerio Ciencia e Innovacion [PI081687]; Departamento Salud del Gobierno de Navarra [14/2008]; ISCIII-RTICC [RD06/0020/0078]; Fundacion para la Investigacion Medica Aplicada y UTE (Spain)	Ministerio Educacion y Ciencia(Spanish Government); Ministerio Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Departamento Salud del Gobierno de Navarra; ISCIII-RTICC(Instituto de Salud Carlos III); Fundacion para la Investigacion Medica Aplicada y UTE (Spain)	We thank Dr Hipskind (Hannover Medical School, Germany) for the plasmid pCDNA3-ELK1, Dr Zhang (Department of Molecular and Experimental Medicine, La Jolla, CA, USA) for the plasmid pFlagCMV2-AML1B (Addgene plasmid 12504), and Dr Arenas and Dr Guruceaga (Department of Proteomics, Genomics and Bioinformatics, CIMA) for technical support. This work was supported by Ministerio Educacion y Ciencia (AP2007-03879), Ministerio Ciencia e Innovacion (PI081687), Departamento Salud del Gobierno de Navarra (14/2008), ISCIII-RTICC (RD06/0020/0078) and Fundacion para la Investigacion Medica Aplicada y UTE (Spain).	Arai S, 2011, BLOOD, V117, P6304, DOI 10.1182/blood-2009-07-234310; Aytekin M, 2005, GENE, V356, P160, DOI 10.1016/j.gene.2005.04.032; Biggs JR, 2006, MOL CELL BIOL, V26, P7420, DOI 10.1128/MCB.00597-06; Bingemann SC, 2009, FEBS J, V276, P6810, DOI 10.1111/j.1742-4658.2009.07398.x; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Fernandez-Alvarez A, 2010, J BIOL CHEM, V285, P11765, DOI 10.1074/jbc.M109.067447; Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001; Gaidzik VI, 2011, J CLIN ONCOL, V29, P1364, DOI 10.1200/JCO.2010.30.7926; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Goldfarb AN, 2009, J CELL BIOCHEM, V107, P377, DOI 10.1002/jcb.22142; Goyama S, 2008, CELL STEM CELL, V3, P207, DOI 10.1016/j.stem.2008.06.002; Groschel S, 2010, J CLIN ONCOL, V28, P2101, DOI 10.1200/JCO.2009.26.0646; Haas K, 2008, GENE CHROMOSOME CANC, V47, P288, DOI 10.1002/gcc.20532; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Laricchia-Robbio L, 2006, MOL CELL BIOL, V26, P7658, DOI 10.1128/MCB.00363-06; Laricchia-Robbio L, 2009, CANCER RES, V69, P1633, DOI 10.1158/0008-5472.CAN-08-2562; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; Nucifora G, 2006, GENE, V368, P1, DOI 10.1016/j.gene.2005.09.020; Oakford PC, 2010, LEUKEMIA RES, V34, P1203, DOI 10.1016/j.leukres.2010.03.029; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pencovich N, 2011, BLOOD, V117, pE1, DOI 10.1182/blood-2010-07-295113; Senyuk V, 2007, CANCER RES, V67, P5658, DOI 10.1158/0008-5472.CAN-06-3962; Shimizu S, 2002, BIOCHEM BIOPH RES CO, V292, P609, DOI 10.1006/bbrc.2002.6693; Terui K, 2000, TOHOKU J EXP MED, V192, P259, DOI 10.1620/tjem.192.259; Vazquez I, 2011, HAEMATOL-HEMATOL J, V96, P1448, DOI 10.3324/haematol.2011.040535; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wieser R, 2007, GENE, V396, P346, DOI 10.1016/j.gene.2007.04.012; Yasar D, 2010, CANCER GENET CYTOGEN, V197, P122, DOI 10.1016/j.cancergencyto.2009.11.018; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679; Zhang L, 2003, J BIOL CHEM, V278, P33097, DOI 10.1074/jbc.M303972200	35	13	13	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2069	2078		10.1038/onc.2012.222	http://dx.doi.org/10.1038/onc.2012.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22689058				2022-12-17	WOS:000317919900008
J	Hennigan, RF; Moon, CA; Parysek, LM; Monk, KR; Morfini, G; Berth, S; Brady, S; Ratner, N				Hennigan, R. F.; Moon, C. A.; Parysek, L. M.; Monk, K. R.; Morfini, G.; Berth, S.; Brady, S.; Ratner, N.			The NF2 tumor suppressor regulates microtubule-based vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway	ONCOGENE			English	Article						merlin; NF2; Rac; trafficking; exocytosis	FAST AXONAL-TRANSPORT; MEDIATES CONTACT INHIBITION; HUMAN SCHWANNOMA CELLS; NEUROFIBROMATOSIS TYPE-2; PLASMA-MEMBRANE; P21-ACTIVATED KINASE; SIGNALING PATHWAY; ERM PROTEINS; MERLIN; RECEPTOR	Neurofibromatosis type 2 patients develop schwannomas, meningiomas and ependymomas resulting from mutations in the tumor suppressor gene, NF2, encoding a membrane-cytoskeleton adapter protein called merlin. Merlin regulates contact inhibition of growth and controls the availability of growth factor receptors at the cell surface. We tested if microtubule-based vesicular trafficking might be a mechanism by which merlin acts. We found that schwannoma cells, containing merlin mutations and constitutive activation of the Rho/Rac family of GTPases, had decreased intracellular vesicular trafficking relative to normal human Schwann cells. In Nf2-/- mouse Schwann (SC4) cells, re-expression of merlin as well as inhibition of Rac or its effector kinases, MLK and p38(SAPK), each increased the velocity of Rab6 positive exocytic vesicles. Conversely, an activated Rac mutant decreased Rab6 vesicle velocity. Vesicle motility assays in isolated squid axoplasm further demonstrated that both mutant merlin and active Rac specifically reduce anterograde microtubule-based transport of vesicles dependent upon the activity of p38(SAPK) kinase. Taken together, our data suggest loss of merlin results in the Rac-dependent decrease of anterograde trafficking of exocytic vesicles, representing a possible mechanism controlling the concentration of growth factor receptors at the cell surface. Oncogene (2013) 32, 1135-1143; doi:10.1038/onc.2012.135; published online 23 April 2012	[Hennigan, R. F.; Moon, C. A.; Ratner, N.] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Parysek, L. M.] Univ Cincinnati, Sch Med, Dept Cell & Canc Biol, Cincinnati, OH USA; [Monk, K. R.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Morfini, G.; Berth, S.; Brady, S.] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL USA; [Morfini, G.; Berth, S.; Brady, S.; Ratner, N.] Marine Biol Lab, Woods Hole, MA 02543 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Washington University (WUSTL); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Marine Biological Laboratory - Woods Hole	Hennigan, RF (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, 240 Albert Sabin Way, Cincinnati, OH 45229 USA.	Robert.Hennigan@cchmc.org	Morfini, Gerardo/AAP-8070-2021	Morfini, Gerardo/0000-0001-6059-5518; RATNER, NANCY/0000-0001-5030-9354	NIH [R01 CA118032, R01 NS23868]; MBL research fellowships; NATIONAL CANCER INSTITUTE [R01CA118032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023868] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MBL research fellowships; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH R01 CA118032 (to NR), and MBL research fellowships (to NR and GM), NIH R01 NS23868 (to SIB). We thank Atira Dudley Hardiman for assistance with growth and transfection of human cells, Jamie M Walker for expert technical assistance and Dr Yi Zheng for critical reading of the manuscript.	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Ammoun S, 2011, NAT REV NEUROL, V7, P392, DOI 10.1038/nrneurol.2011.82; Avruch J, 2007, BBA-MOL CELL RES, V1773, P1150, DOI 10.1016/j.bbamcr.2006.11.006; Bensenor LB, 2010, P NATL ACAD SCI USA, V107, P7311, DOI 10.1073/pnas.0907389107; Best A, 1996, J BIOL CHEM, V271, P3756; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bosco DA, 2010, NAT NEUROSCI, V13, P1396, DOI 10.1038/nn.2660; Bosco EE, 2010, ONCOGENE, V29, P2540, DOI 10.1038/onc.2010.20; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cole BK, 2008, MOL CELL BIOL, V28, P1274, DOI 10.1128/MCB.01139-07; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Edelstein A., 2010, COMPUTER CONTROL MIC; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gerst JE, 1999, CELL MOL LIFE SCI, V55, P707, DOI 10.1007/s000180050328; Giovannini M, 2000, GENE DEV, V14, P1617; Grigoriev I, 2007, DEV CELL, V13, P305, DOI 10.1016/j.devcel.2007.06.010; Hennigan RF, 2010, MOL CELL BIOL, V30, P54, DOI 10.1128/MCB.00248-09; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2009, ONCOGENE, V28, P854, DOI 10.1038/onc.2008.427; Lerdrup M, 2006, J CELL SCI, V119, P85, DOI 10.1242/jcs.02707; Lerdrup M, 2007, MOL BIOL CELL, V18, P3656, DOI 10.1091/mbc.e07-01-0025; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; MACCOLLIN M, 1993, JAMA-J AM MED ASSOC, V270, P2316, DOI 10.1001/jama.270.19.2316; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; McClatchey AI, 2009, TRENDS CELL BIOL, V19, P198, DOI 10.1016/j.tcb.2009.02.006; Morfini G, 2006, NAT NEUROSCI, V9, P907, DOI 10.1038/nn1717; Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009; Morfini GA, 2009, NAT NEUROSCI, V12, P864, DOI 10.1038/nn.2346; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2007, HUM MOL GENET, V16, P1742, DOI 10.1093/hmg/ddm122; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTKOWSKI JL, 1995, NAT MED, V1, P80, DOI 10.1038/nm0195-80; Sampo B, 2003, NEURON, V37, P611, DOI 10.1016/S0896-6273(03)00058-8; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Woodcock SA, 2010, CURR BIOL, V20, P669, DOI 10.1016/j.cub.2010.02.033; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	54	13	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2013	32	9					1135	1143		10.1038/onc.2012.135	http://dx.doi.org/10.1038/onc.2012.135			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525268	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000316428800007
J	Archibald, KM; Kulbe, H; Kwong, J; Chakravarty, P; Temple, J; Chaplin, T; Flak, MB; McNeish, IA; Deen, S; Brenton, JD; Young, BD; Balkwill, F				Archibald, K. M.; Kulbe, H.; Kwong, J.; Chakravarty, P.; Temple, J.; Chaplin, T.; Flak, M. B.; McNeish, I. A.; Deen, S.; Brenton, J. D.; Young, B. D.; Balkwill, F.			Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium	ONCOGENE			English	Article						CXCR4; CXCL12; malignant transformation; high-grade serous ovarian cancer; p53	DNA COPY NUMBER; SEROUS CARCINOMA; GENOMIC ANALYSES; CANCER-CELLS; LOW-GRADE; EXPRESSION; P53; MUTATIONS; BREAST; CXCL12	Early genetic events in the development of high-grade serous ovarian cancer (HGSOC) may define the molecular basis of the profound structural and numerical instability of chromosomes in this disease. To discover candidate genetic changes we sequentially passaged cells from a karyotypically normal hTERT immortalised human ovarian surface epithelial line (IOSE25) resulting in the spontaneous formation of colonies in soft agar. Cell lines transformed ovarian surface epithelium 1 and 4 (TOSE 1 and 4) established from these colonies had an abnormal karyotype and altered morphology, but were not tumourigenic in immunodeficient mice. TOSE cells showed loss of heterozygosity (LOH) at TP53, increased nuclear p53 immunoreactivity and altered expression profile of p53 target genes. The parental IOSE25 cells contained a missense, heterozygous R175H mutation in TP53, whereas TOSE cells had LOH at the TP53 locus with a new R273H mutation at the previous wild-type TP53 allele. Cytogenetic and array CGH analysis of TOSE cells also revealed a focal genomic amplification of CXCR4, a chemokine receptor commonly expressed by HGSOC cells. TOSE cells had increased functional CXCR4 protein and its abrogation reduced epidermal growth factor receptor (EGFR) expression, as well as colony size and number. The CXCR4 ligand, CXCL12, was epigenetically silenced in TOSE cells and its forced expression increased TOSE colony size. TOSE cells had other cytogenetic changes typical of those seen in HGSOC ovarian cancer cell lines and biopsies. In addition, enrichment of CXCR4 pathway in expression profiles from HGSOC correlated with enrichment of a mutated TP53 gene expression signature and of EGFR pathway genes. Our data suggest that mutations in TP53 and amplification of the CXCR4 gene locus may be early events in the development of HGSOC, and associated with chromosomal instability. Oncogene (2012) 31, 4987-4995; doi:10.1038/onc.2011.653; published online 23 January 2012	[Balkwill, F.] Queen Mary Univ London, Barts Canc Inst, Ctr Canc & Inflammat, London EC1M 6BQ, England; [Archibald, K. M.; Kulbe, H.; Balkwill, F.] Queen Mary Univ London, Barts Canc Inst, Ctr Canc & Inflammat, London EC1M 6BQ, England; [Kwong, J.] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Chakravarty, P.] Bioinformat & Biostat Serv, London, England; [Temple, J.; Brenton, J. D.] Cambridge Res Inst, Li Ka Shing Ctr, Canc Res UK, Funct Genom Ovarian Canc Lab, Cambridge, England; [Flak, M. B.; McNeish, I. A.] Queen Mary Univ London, Ctr Mol Oncol, Barts Canc Inst, London EC1M 6BQ, England; [Deen, S.] Univ Nottingham Hosp, Dept Histopathol, Nottingham NG7 2UH, England; [Chaplin, T.; Young, B. D.] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Chinese University of Hong Kong; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of London; Queen Mary University London; University of Nottingham; University of London; Queen Mary University London	Balkwill, F (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Canc & Inflammat, Charterhouse Sq, London EC1M 6BQ, England.	f.balkwill@qmul.ac.uk	Flak, Magdalena B/M-7106-2016; Brenton, James D/B-3174-2008; Kwong, Joseph/H-2368-2013; Flak, Magdalena/AAG-5272-2020	Flak, Magdalena B/0000-0002-8238-9835; Brenton, James D/0000-0002-5738-6683; Kwong, Joseph/0000-0002-3380-6882; Flak, Magdalena/0000-0002-8238-9835; chakravarty, probir/0000-0003-1146-8824; McNeish, Iain/0000-0002-9387-7586; Balkwill, Frances/0000-0002-5587-9759	Cancer Research UK; Association for International Cancer Research; HEFCE; Cancer Research UK [15601] Funding Source: researchfish; Medical Research Council [G0601891] Funding Source: researchfish; MRC [G0601891] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Association for International Cancer Research; HEFCE(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Nitzan Rosenfeld and Davina Gale for their expert advice and analysis for the TP53 quantification. We also thank Debra Lillington for karyotyping TOSE cells, and the Genome Centre at Barts and the London School of Medicine and Dentistry for microsatellite analysis. This work was supported by Cancer Research UK, the Association for International Cancer Research and HEFCE.	Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Ansieau S, 2008, CELL CYCLE, V7, P3659, DOI 10.4161/cc.7.23.7049; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernardini MQ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-237; Cooke SL, 2010, ONCOGENE, V29, P4905, DOI 10.1038/onc.2010.245; Dimova I, 2009, TUMORI, V95, P357; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Farley J, 2008, CELL RES, V18, P538, DOI 10.1038/cr.2008.52; Flak MB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-175; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138; Kajiyama H, 2008, INT J CANCER, V122, P91, DOI 10.1002/ijc.23083; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Katoh M, 2010, INT J ONCOL, V36, P415, DOI 10.3892/ijo_00000514; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kulbe H, 2005, CANCER RES, V65, P10355, DOI 10.1158/0008-5472.CAN-05-0957; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Kuo KT, 2009, CANCER RES, V69, P4036, DOI 10.1158/0008-5472.CAN-08-3913; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Li NF, 2007, CELL PROLIFERAT, V40, P780, DOI 10.1111/j.1365-2184.2007.00462.x; Maia AT, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2458; Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275; Mehta SA, 2007, ONCOGENE, V26, P3329, DOI 10.1038/sj.onc.1210120; Micci F, 2010, J ONCOL, V2010, DOI 10.1155/2010/646340; Nakayama K, 2007, INT J CANCER, V120, P2613, DOI 10.1002/ijc.22609; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Roh HJ, 2000, CANCER RES, V60, P6496; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stoczynska-Fidelus E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-243; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Team RDC, 2008, R FDN STAT COMP; TESTA JR, 1994, CANCER RES, V54, P2778; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751; Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505; Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024	55	13	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					4987	4995		10.1038/onc.2011.653	http://dx.doi.org/10.1038/onc.2011.653			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22266861	Green Accepted			2022-12-17	WOS:000311888600003
J	Lago, CU; Nowinski, SM; Rundhaug, JE; Pfeiffer, ME; Kiguchi, K; Hirasaka, K; Yang, X; Abramson, EM; Bratton, SB; Rho, O; Colavitti, R; Kenaston, MA; Nikawa, T; Trempus, C; DiGiovanni, J; Fischer, SM; Mills, EM				Lago, C. U.; Nowinski, S. M.; Rundhaug, J. E.; Pfeiffer, M. E.; Kiguchi, K.; Hirasaka, K.; Yang, X.; Abramson, E. M.; Bratton, S. B.; Rho, O.; Colavitti, R.; Kenaston, M. A.; Nikawa, T.; Trempus, C.; DiGiovanni, J.; Fischer, S. M.; Mills, E. M.			Mitochondrial respiratory uncoupling promotes keratinocyte differentiation and blocks skin carcinogenesis	ONCOGENE			English	Article						mitochondria; uncoupling proteins; skin; carcinogenesis; differentiation	STEM-CELLS; HAIR FOLLICLE; SKELETAL-MUSCLE; CANCER; EXPRESSION; MUTATIONS; METABOLISM; ACTIVATION; INDUCTION; CARCINOMA	Decreased mitochondrial oxidative metabolism is a hallmark bioenergetic characteristic of malignancy that may have an adaptive role in carcinogenesis. By stimulating proton leak, mitochondrial uncoupling proteins (UCP1-3) increase mitochondrial respiration and may thereby oppose cancer development. To test this idea, we generated a mouse model that expresses an epidermal-targeted keratin-5-UCP3 (K5-UCP3) transgene and exhibits significantly increased cutaneous mitochondrial respiration compared with wild type (FVB/N). Remarkably, we observed that mitochondrial uncoupling drove keratinocyte/epidermal differentiation both in vitro and in vivo. This increase in epidermal differentiation corresponded to the loss of markers of the quiescent bulge stem cell population, and an increase in epidermal turnover measured using a bromodeoxyuridine (BrdU)-based transit assay. Interestingly, these changes in K5-UCP3 skin were associated with a nearly complete resistance to chemically-mediated multistage skin carcinogenesis. These data suggest that targeting mitochondrial respiration is a promising novel avenue for cancer prevention and treatment.	[Lago, C. U.; Abramson, E. M.; Bratton, S. B.; Mills, E. M.] Univ Texas Austin, Coll Pharm, Div Pharmacol & Toxicol, Inst Cellular & Mol Biol, Austin, TX 78712 USA; [Lago, C. U.] NHLBI, Ctr Mol Med, NIH, Bethesda, MD 20892 USA; [Rundhaug, J. E.; Fischer, S. M.] Univ Texas MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX USA; [Yang, X.] Fudan Univ, Shanghai 200433, Peoples R China; [Colavitti, R.] Stanford Univ, Div Radiat & Canc Biol, Stanford, CA 94305 USA; [Nikawa, T.] Univ Tokushima, Inst Hlth Biosci, Dept Nutr Physiol, Tokushima 770, Japan; [Trempus, C.] NIEHS, Matrix Biol Grp, Lab Resp Biol, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Austin; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; UTMD Anderson Cancer Center; Fudan University; Stanford University; Tokushima University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Mills, EM (corresponding author), Univ Texas Austin, Coll Pharm, Div Pharmacol & Toxicol, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	ted_mills@mail.utexas.edu	Rundhaug, Joyce E/E-9114-2011; Hirasaka, Katsuya/AAJ-7371-2021; Hirasaka, Katsuya/J-5283-2019	Rundhaug, Joyce E/0000-0002-2481-6317; Hirasaka, Katsuya/0000-0003-2645-8450; Nowinski, Sara/0000-0002-4744-6101	National Institutes of Health [DK089224, T32ES07247]; NATIONAL CANCER INSTITUTE [R01CA129521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK089224, R01DK089224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007247] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [24700753] Funding Source: KAKEN	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	EMM was supported by the National Institutes of Health grant # DK089224. SMN was supported by the National Institutes of Health Toxicology Training grant T32ES07247.	Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Derdak Z, 2006, CARCINOGENESIS, V27, P956, DOI 10.1093/carcin/bgi335; Derdak Z, 2008, CANCER RES, V68, P2813, DOI 10.1158/0008-5472.CAN-08-0053; Faurschou A, 2007, EXP DERMATOL, V16, P485, DOI 10.1111/j.1600-0625.2007.00551.x; Gates AC, 2007, CELL METAB, V6, P497, DOI 10.1016/j.cmet.2007.10.010; Guigal N, 2002, J BIOL CHEM, V277, P47407, DOI 10.1074/jbc.M208048200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; MacAskill AF, 2010, EUR J NEUROSCI, V32, P231, DOI 10.1111/j.1460-9568.2010.07345.x; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mills EM, 2002, J BIOL CHEM, V277, P27385, DOI 10.1074/jbc.M111860200; Mori S, 2008, J INVEST DERMATOL, V128, P1894, DOI 10.1038/jid.2008.20; Morris RJ, 2000, CANCER RES, V60, P226; NICHOLLS DG, 1984, BIOCHEM SOC T, V12, P388, DOI 10.1042/bst0120388; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Oakes SA, 2007, P NATL ACAD SCI USA, V104, P15171, DOI 10.1073/pnas.0707798104; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Rundhaug JE, 1997, MOL CARCINOGEN, V20, P125, DOI 10.1002/(SICI)1098-2744(199709)20:1<125::AID-MC14>3.3.CO;2-A; Sayeed A, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.30; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shakya A, 2009, NAT CELL BIOL, V11, P320, DOI 10.1038/ncb1840; Tamiji S, 2005, J INVEST DERMATOL, V125, P647, DOI 10.1111/j.0022-202X.2005.23885.x; Trempus CS, 2007, CANCER RES, V67, P4173, DOI 10.1158/0008-5472.CAN-06-3128; Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wu WY, 2004, METH MOL B, V289, P79; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	42	13	13	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4725	4731		10.1038/onc.2011.630	http://dx.doi.org/10.1038/onc.2011.630			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22266853	Green Accepted			2022-12-17	WOS:000310724400008
J	Fransson, S; Uv, A; Eriksson, H; Andersson, MK; Wettergren, Y; Bergo, M; Ejeskar, K				Fransson, S.; Uv, A.; Eriksson, H.; Andersson, M. K.; Wettergren, Y.; Bergo, M.; Ejeskar, K.			p37 delta is a new isoform of PI3K p110 delta that increases cell proliferation and is overexpressed in tumors	ONCOGENE			English	Article						p110 delta; p37 delta; p85; RAS; ovarian cancer; colorectal cancer	P85 REGULATORY SUBUNIT; PHOSPHOINOSITIDE 3-KINASE; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3'-KINASE; NEUROBLASTOMA TUMORS; COLORECTAL-CANCER; CLASS IPI3K; KEY ROLE; MUCOSA; METABOLISM	The phosphatidylinositol 3-kinases (PI3Ks) regulate cell growth, proliferation and survival, and are frequently affected in human cancer. PI3K is composed of a catalytic subunit, p110, and a regulatory subunit, p85. The PI3K catalytic subunit p110 delta is encoded by PIK3CD and contains p85- and RAS-binding domains, and a kinase domain. Here we present an alternatively spliced PIK3CD transcript encoding a previously unknown protein, p37 delta, and demonstrate that this protein is expressed in human ovarian and colorectal tumors. p37 delta retains the p85-binding domain and a fraction of the RAS-binding domain, lacks the catalytic domain, and has a unique carboxyl-terminal region. In contrast to p110 delta, which stabilizes p85, p37 delta promoted p85 sequestering. Despite the truncated RAS-binding domain, p37 delta bound to RAS and we found a strong positive correlation between the protein levels of p37 delta and RAS. Overexpressing p37 delta, but not p110 delta, increased the proliferation and invasive properties of HEK-293 cells and mouse embryonic fibroblasts. Cells overexpressing p37 delta showed a quicker phosphorylation response of AKT and ERK1/2 following serum stimulation. Ubiquitous expression of human p37 delta in the fruit fly increased body size, DNA content and phosphorylated ERK1/2 levels. Thus, p37 delta appears to be a new tumor-specific isoform of p110 delta with growth-promoting properties. Oncogene (2012) 31, 3277-3286; doi: 10.1038/onc.2011.492; published online 24 October 2011	[Fransson, S.; Uv, A.; Eriksson, H.; Ejeskar, K.] Univ Gothenburg, Sahlgrenska Canc Ctr, Dept Med & Clin Genet, SE-40530 Gothenburg, Sweden; [Andersson, M. K.] Univ Gothenburg, Sahlgrenska Canc Ctr, Dept Pathol, SE-40530 Gothenburg, Sweden; [Wettergren, Y.] Univ Gothenburg, Dept Gen Surg, SE-40530 Gothenburg, Sweden; [Bergo, M.] Univ Gothenburg, Sahlgrenska Canc Ctr, Dept Med, SE-40530 Gothenburg, Sweden; [Ejeskar, K.] Univ Skovde, Sch Life Sci, Skovde, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Skovde	Ejeskar, K (corresponding author), Univ Gothenburg, Sahlgrenska Canc Ctr, Dept Med & Clin Genet, Box 425, SE-40530 Gothenburg, Sweden.	katarina.ejeskar@gu.se		Fransson, Susanne/0000-0002-9713-3074; Ejeskar, Katarina/0000-0001-8962-0860	Swedish Cancer Society [100405]; Swedish Children's Cancer Fund; Gunvor and Ivan Svensson's Foundation; Ake Wiberg's Foundation; Sahlgrenska University Hospital Foundation; Assar Gabrielsson Foundation; Mary Beves Stiftelse for Barncancerforskning; Frimurare Barnhusdirektionen; ALF Grants, County of Vastergotland	Swedish Cancer Society(Swedish Cancer Society); Swedish Children's Cancer Fund; Gunvor and Ivan Svensson's Foundation; Ake Wiberg's Foundation; Sahlgrenska University Hospital Foundation; Assar Gabrielsson Foundation; Mary Beves Stiftelse for Barncancerforskning; Frimurare Barnhusdirektionen; ALF Grants, County of Vastergotland	We thank the Genomics Core Facility for access to the ABI PRISM7900HT System, Magnus Pettersson, Maria Yhr and Grissel Faura for technical assistance. This work was supported by grants from the Swedish Cancer Society (K Ejeskar and 100405), the Swedish Children's Cancer Fund, Gunvor and Ivan Svensson's Foundation, Ake Wiberg's Foundation, the Sahlgrenska University Hospital Foundation, the Assar Gabrielsson Foundation, Mary Beves Stiftelse for Barncancerforskning, Frimurare Barnhusdirektionen and ALF Grants, County of Vastergotland.	Bilancio A, 2006, BLOOD, V107, P642, DOI 10.1182/blood-2005-07-3041; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Caren H, 2007, BRIT J CANCER, V97, P1416, DOI 10.1038/sj.bjc.6604032; Chagpar RB, 2010, P NATL ACAD SCI USA, V107, P5471, DOI 10.1073/pnas.0908899107; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Ciraolo E, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1161577; Denley A, 2008, ONCOGENE, V27, P2561, DOI 10.1038/sj.onc.1210918; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Foukas LC, 2010, P NATL ACAD SCI USA, V107, P11381, DOI 10.1073/pnas.0906461107; Fransson S, 2007, GENE CHROMOSOME CANC, V46, P45, DOI 10.1002/gcc.20387; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kok K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005145; Luo J, 2005, J CELL BIOL, V170, P455, DOI 10.1083/jcb.200503088; Odin E, 2003, CLIN CANCER RES, V9, P6012; Patton DT, 2007, BIOCHEM SOC T, V35, P167, DOI 10.1042/BST0350167; Philp AJ, 2001, CANCER RES, V61, P7426; Polley ACJ, 2006, CANCER RES, V66, P6553, DOI 10.1158/0008-5472.CAN-06-0534; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Sawyer C, 2003, CANCER RES, V63, P1667; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Taniguchi CM, 2010, CANCER RES, V70, P5305, DOI 10.1158/0008-5472.CAN-09-3399; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vogt PK, 2009, CURR OPIN GENET DEV, V19, P12, DOI 10.1016/j.gde.2008.11.011; Wettergren Y, 2008, MOL MED, V14, P412, DOI 10.2119/2007-00096.Wettergren; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244	29	13	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3277	3286		10.1038/onc.2011.492	http://dx.doi.org/10.1038/onc.2011.492			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22020336				2022-12-17	WOS:000306113400007
J	Hauser, S; Ulrich, T; Wurster, S; Schmitt, K; Reichert, N; Gaubatz, S				Hauser, S.; Ulrich, T.; Wurster, S.; Schmitt, K.; Reichert, N.; Gaubatz, S.			Loss of LIN9, a member of the DREAM complex, cooperates with SV40 large T antigen to induce genomic instability and anchorage-independent growth	ONCOGENE			English	Article						DREAM complex; senescence; genomic instability; mitosis	SPINDLE-ASSEMBLY CHECKPOINT; PRB-RELATED PROTEINS; B-MYB; MEDIATED TRANSFORMATION; G(2)/M GENES; IN-VIVO; SIMIAN-VIRUS-40; EXPRESSION; ANEUPLOIDY; P107	The DREAM complex is an important regulator of mitotic gene expression during the cell cycle. Here we report that inactivation of LIN9, a subunit of DREAM, results in premature senescence, which can be overcome by the SV40 large T (LT) antigen. Together with the observation that p16(INK4a) and p21(Waf1) are upregulated upon loss of LIN9, these results indicate that senescence is triggered by the pRB and p53 tumor suppressor pathways. We also find that LIN9-null cells that escape senescence are chromosomally instable because of compromised mitotic fidelity. SV40 LT-expressing cells that adapt to the loss of LIN9 can grow anchorage-independently in soft agar, a hallmark of oncogenic transformation. Taken together, these results suggest an important role of mitotic gene regulation in the maintenance of genomic stability and tumor suppression. Oncogene (2012) 31, 1859-1868; doi: 10.1038/onc.2011.364; published online 22 August 2011	[Hauser, S.; Ulrich, T.; Wurster, S.; Schmitt, K.; Reichert, N.; Gaubatz, S.] Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Bavaria, Germany	University of Wurzburg	Gaubatz, S (corresponding author), Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Bavaria, Germany.	stefan.gaubatz@biozentrum.uni-wuerzburg.de		Wurster, Sebastian/0000-0002-7784-7256; Gaubatz, Stefan/0000-0001-8751-4191	DFG [575/6-1, TR17-B1]	DFG(German Research Foundation (DFG))	We thank all members of the laboratory for their suggestions and critical reading of the manuscript. We also thank Michael Schmid and Claus Steinlein for their advice and help with karyotype analysis. This work was supported by grants from the DFG (575/6-1 and TR17-B1) to SG.	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; Cimini D, 2005, TRENDS CELL BIOL, V15, P442, DOI 10.1016/j.tcb.2005.06.008; Cotsiki M, 2004, P NATL ACAD SCI USA, V101, P947, DOI 10.1073/pnas.0308006100; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gagrica S, 2004, EMBO J, V23, P4627, DOI 10.1038/sj.emboj.7600470; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Knight AS, 2009, ONCOGENE, V28, P1737, DOI 10.1038/onc.2009.22; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Maehara K, 2010, MOL CELL BIOL, V30, P2090, DOI 10.1128/MCB.01318-09; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Reichert N, 2010, MOL CELL BIOL, V30, P2896, DOI 10.1128/MCB.00028-10; Schliekelman M, 2009, CANCER RES, V69, P45, DOI 10.1158/0008-5472.CAN-07-6330; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Song J, 2010, ONCOGENE, V29, P1976, DOI 10.1038/onc.2009.485; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Ye XF, 2007, MOL CELL BIOL, V27, P2452, DOI 10.1128/MCB.01592-06; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800	28	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	14					1859	1868		10.1038/onc.2011.364	http://dx.doi.org/10.1038/onc.2011.364			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860417				2022-12-17	WOS:000302785200011
J	Sriram, G; Reichman, C; Tunceroglu, A; Kaushal, N; Saleh, T; Machida, K; Mayer, B; Ge, Q; Li, J; Hornbeck, P; Kalodimos, CG; Birge, RB				Sriram, G.; Reichman, C.; Tunceroglu, A.; Kaushal, N.; Saleh, T.; Machida, K.; Mayer, B.; Ge, Q.; Li, J.; Hornbeck, P.; Kalodimos, C. G.; Birge, R. B.			Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation	ONCOGENE			English	Article						Crk tyrosine phosphorylation; SH2 domains; Abl transactivation	ADAPTER PROTEIN CRK; BREAST-CANCER CELLS; C-ABL; SIGNALING PROTEIN; MALIGNANT FEATURE; STRUCTURAL BASIS; FACTOR C3G; GROWTH; ACTIVATION; BINDING	Here, we report the identification and characterization of a novel tyrosine phosphorylation site in the carboxyterminal Src Homology 3 (SH3) (SH3C) domain of the Crk adaptor protein. Y251 is located in the highly conserved RT loop structure of the SH3C, a region of Crk involved in the allosteric regulation of the Abl kinase. Exploiting kinase assays to show that Y251 is phosphorylated by Abl in vitro, we generated affinity-purified antisera against phosphorylated Y251 in Crk and showed that Abl induces phosphorylation at Y251 in vivo, and that the kinetics of phosphorylation at Y251 and the negative regulatory Y221 site in vitro are similar. Y251 on endogenous Crk was robustly phosphorylated in chronic myelogenous leukemia cell lines and in A431 and MDA-MB-468 cells stimulated with epidermal growth factor. Using streptavidin-biotin pull downs and unbiased high-throughput Src Homology 2 (SH2) profiling approaches, we found that a pY251 phospho-peptide binds specifically to a subset of SH2 domains, including Abl and Arg SH2, and that binding of pY251 to Abl SH2 induces transactivation of Abl 1b. Finally, the Y251F Crk mutant significantly abrogates Abl transactivation in vitro and in vivo. These studies point to a yet unrealized positive regulatory role resulting from tyrosine phosphorylation of Crk, and identify a novel mechanism by which an adaptor protein activates a non-receptor tyrosine kinase by SH2 domain displacement. Oncogene (2011) 30, 4645-4655; doi:10.1038/onc.2011.170; published online 23 May 2011	[Sriram, G.; Reichman, C.; Tunceroglu, A.; Kaushal, N.; Birge, R. B.] UMDNJ New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ USA; [Saleh, T.; Kalodimos, C. G.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ USA; [Machida, K.; Mayer, B.] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet Mol Med, Farmington, CT USA; [Ge, Q.; Li, J.; Hornbeck, P.] Cell Signaling Technol, Danvers, MA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Connecticut	Birge, RB (corresponding author), Univ Med & Dent New Jersey, Sch Med, Dept Biochem & Mol Biol, MSB E647,185 S Orange Ave, Newark, NJ 07103 USA.	birgera@umdnj.edu	Hornbeck, Peter V/K-2226-2017; Kalodimos, Charalampos/Q-9846-2018; Saleh, Tamjeed/M-8698-2016	Hornbeck, Peter V/0000-0002-1126-5149; Kalodimos, Charalampos/0000-0001-6354-2796; Saleh, Tamjeed/0000-0002-7539-7300	NIH [RO1GM080308]; NJCCR [08-1093-CCR-EO]; NATIONAL CANCER INSTITUTE [R01CA082258, R01CA165077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055760, R01GM080308] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NJCCR; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was in part supported by the NIH grant RO1GM080308 to CK and RBB, as well as NJCCR pre-doctoral fellowship 08-1093-CCR-EO to AT. We thank Leszek Kotula, Eric Haura and Khanh Nguyen for helpful discussion, and Neil Devoe for critical comments on the MS.	Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Birge RB, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-13; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Dubielecka PM, 2010, FEBS LETT, V584, P3279, DOI 10.1016/j.febslet.2010.06.029; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Fathers KE, 2010, AM J PATHOL, V176, P446, DOI 10.2353/ajpath.2010.090383; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Johnson KJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007439; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Linghu H, 2006, ONCOGENE, V25, P3547, DOI 10.1038/sj.onc.1209398; Machida K, 2007, MOL CELL, V26, P899, DOI 10.1016/j.molcel.2007.05.031; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Matsumoto T, 2000, BIOCHEM BIOPH RES CO, V270, P28, DOI 10.1006/bbrc.2000.2374; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Muralidharan V, 2006, BIOCHEMISTRY-US, V45, P8874, DOI 10.1021/bi060590z; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Park TJ, 2006, MOL CELL BIOL, V26, P6272, DOI 10.1128/MCB.00472-06; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Reichman C, 2005, ONCOGENE, V24, P8187, DOI 10.1038/sj.onc.1208988; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sarkar P, 2007, MOL CELL, V25, P413, DOI 10.1016/j.molcel.2007.01.004; Sarkar P, 2011, NAT CHEM BIOL, V7, P51, DOI 10.1038/NCHEMBIO.494; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sorokin A, 1998, ONCOGENE, V16, P2425, DOI 10.1038/sj.onc.1201781; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Wang L, 2007, BIOCHEM BIOPH RES CO, V362, P976, DOI 10.1016/j.bbrc.2007.08.106; Xiong XL, 2008, BBA-MOL CELL RES, V1783, P737, DOI 10.1016/j.bbamcr.2008.01.028; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvara A, 2001, ONCOGENE, V20, P951, DOI 10.1038/sj.onc.1204173	51	13	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	46					4645	4655		10.1038/onc.2011.170	http://dx.doi.org/10.1038/onc.2011.170			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21602891	Green Accepted			2022-12-17	WOS:000297252100004
J	Andorfer, P; Rotheneder, H				Andorfer, P.; Rotheneder, H.			EAPP: Gatekeeper at the crossroad of apoptosis and p21-mediated cell-cycle arrest	ONCOGENE			English	Article						EAPP; p21; apoptosis; DNA damage; cell-cycle arrest	DEPENDENT KINASE INHIBITOR; S-PHASE ENTRY; DNA-REPLICATION; P53-MEDIATED APOPTOSIS; HISTONE DEACETYLASE-1; TRANSCRIPTION FACTORS; MULTIDRUG-RESISTANCE; TUMOR SUPPRESSION; P21; P53	We previously identified and characterized E2F-associated phospho-protein (EAPP), a nuclear phosphoprotein that interacts with the activating members of the E2F transcription factor family. EAPP levels are frequently elevated in transformed human cells. To examine the biological relevance of EAPP, we studied its properties in stressed and unstressed cells. Overexpression of EAPP in U2OS cells increased the fraction of G1 cells and lead to heightened resistance against DNA damage-or E2F1-induced apoptosis in a p21-dependent manner. EAPP itself becomes upregulated in confluent cells and after DNA damage and stimulates the expression of p21 independently of p53. It binds to the p21 promoter and seems to be required for the assembly of the transcription initiation complex. RNAi-mediated knockdown of EAPP expression brought about increased sensitivity towards DNA damage and resulted in apoptosis even in the absence of stress. Our results indicate that the level of EAPP is critical for cellular homeostasis. Too much of it results in G1 arrest and resistance to apoptosis, which, paradoxically, might favor cellular transformation. Too little EAPP seems to retard the expression not only of the p21 gene, but also of a number of other genes and ultimately results in apoptosis. Oncogene (2011) 30, 2679-2690; doi:10.1038/onc.2010.639; published online 24 January 2011	[Andorfer, P.; Rotheneder, H.] Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Rotheneder, H (corresponding author), Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	Johann.Rotheneder@meduniwien.ac.at			Austrian FWF [P18417]; Herzfelder'sche Familienstiftung	Austrian FWF(Austrian Science Fund (FWF)); Herzfelder'sche Familienstiftung	We are grateful to H Nomura, BH Park, A Ashworth, and N Heintz for expression vectors. We thank Christian Seiser for helpful discussions and the histone antibodies, Erhard Wintersberger and Christian Seiser for critically reading this manuscript, Ingrid Mudrak and Egon Ogris for help with the generation of the monoclonal EAPP antibody, and Thomas Sauer for assistance with the FACS analysis. This work was supported by the Austrian FWF (Grant P18417) and by the Herzfelder'sche Familienstiftung.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Baptiste-Okoh N, 2008, CELL CYCLE, V7, P1133, DOI 10.4161/cc.7.9.5805; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN K, 2010, MOL PHARM; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Goda K, 2009, CURR CANCER DRUG TAR, V9, P281, DOI 10.2174/156800909788166493; GOUBIN F, 1995, ONCOGENE, V10, P2281; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; Gutmann DAP, 2010, TRENDS BIOCHEM SCI, V35, P36, DOI 10.1016/j.tibs.2009.07.009; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Janicke RU, 2007, CELL CYCLE, V6, P407; Karakas B, 2007, CANCER BIOL THER, V6, P1025, DOI 10.4161/cbt.6.7.4202; Kawasaki T, 1996, INT J CANCER, V68, P501, DOI 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Kornberg RD, 2007, P NATL ACAD SCI USA, V104, P12955, DOI 10.1073/pnas.0704138104; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Li AG, 2007, MOL CELL, V28, P408, DOI 10.1016/j.molcel.2007.09.006; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Novy M, 2005, MOL BIOL CELL, V16, P2181, DOI 10.1091/mbc.E04-11-0975; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Perucca P, 2009, CELL CYCLE, V8, P105, DOI 10.4161/cc.8.1.7507; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Rozan LM, 2007, CELL DEATH DIFFER, V14, P3, DOI 10.1038/sj.cdd.4402058; Schwarzmayr L, 2008, INT J BIOCHEM CELL B, V40, P2845, DOI 10.1016/j.biocel.2008.06.001; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sikorski TW, 2009, CURR OPIN CELL BIOL, V21, P344, DOI 10.1016/j.ceb.2009.03.006; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101	51	13	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	23					2679	2690		10.1038/onc.2010.639	http://dx.doi.org/10.1038/onc.2010.639			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778CV	21258403	Green Published, hybrid			2022-12-17	WOS:000291677800008
J	Copeland, E; Balgobin, S; Lee, CM; Rozakis-Adcock, M				Copeland, E.; Balgobin, S.; Lee, C. M.; Rozakis-Adcock, M.			hTID-1 defines a novel regulator of c-Met Receptor signaling in renal cell carcinomas	ONCOGENE			English	Article						hTid-1; molecular chaperones; c-Met receptor tyrosine kinase; renal cell carcinoma; cell migration	DROSOPHILA TUMOR-SUPPRESSOR; HUMAN DNAJ PROTEIN; HEPATOCYTE GROWTH-FACTOR; HUMAN HOMOLOG; MOLECULAR CHAPERONES; MAMMALIAN HOMOLOG; MET/HGF RECEPTOR; TYROSINE KINASE; IMAGINAL-DISCS; GENE-PRODUCT	The c-Met receptor tyrosine kinase (MetR) is frequently overexpressed and constitutively phosphorylated in a number of human malignancies. Activation of the receptor by its ligand, hepatocyte growth factor (HGF), leads to increased cell proliferation, motility, survival and disruption of adherens junctions. In this study, we show that hTid-1, a DNAJ/Hsp40 chaperone, represents a novel modulator of the MetR signaling pathway. hTid-1 is a co-chaperone of the Hsp70 family of proteins, and has been shown to regulate a number of cellular signaling proteins including several involved in tumorigenic and apoptotic pathways. In this study we demonstrate that hTid-1 binds to unphosphorylated MetR and becomes dissociated from the receptor upon HGF stimulation. Overexpression of the short form of hTid-1 (hTid-1(S)) in 786-0 renal clear cell carcinomas (RCCs) enhances MetR kinase activity leading to an increase in HGF-mediated cell migration with no discernible effect on cell proliferation. By contrast, knockdown of hTid-1 markedly impairs both the onset and amplitude of MetR phosphorylation in response to HGF without altering receptor protein levels. hTid-1-depleted cells display defective migratory properties, coincident with inhibition of ERK/MAP kinase and STAT3 pathways. Taken together, our findings denote hTid-1(S) as an essential regulatory component of MetR signaling. We propose that the binding of hTid-1(S) to MetR may stabilize the receptor in a ligand-competent state and this stabilizing function may influence conformational changes that take place during the catalytic cycle that promote kinase activation. Given the prevalence of HGF/MetR pathway activation in human cancers, targeted inhibition of hTid-1 may be a useful therapeutic in the management of MetR-dependent malignancies. Oncogene (2011) 30, 2252-2263; doi:10.1038/onc.2010.601; published online 17 January 2011	[Rozakis-Adcock, M.] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Rozakis-Adcock, M (corresponding author), Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Med Sci Bldg,1 Kings Coll Circle,Room 6238A, Toronto, ON M5S 1A8, Canada.	maria.rozakis@utoronto.ca			National Cancer Institure of Canada; Ontario Graduate Scholarship; Canadian Institutes of Health Research	National Cancer Institure of Canada; Ontario Graduate Scholarship(Ontario Graduate Scholarship); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by a grant from the National Cancer Institure of Canada (to MRA). ER was supported by an Ontario Graduate Scholarship and CML by a Canadian Institutes of Health Research Master's Award. We thank Kevin Conway for assistance with immunofluorescence microscopy.	Ahn BY, 2010, ONCOGENE, V29, P1155, DOI 10.1038/onc.2009.413; Bae MK, 2005, CANCER RES, V65, P2520, DOI 10.1158/0008-5472.CAN-03-2735; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen CY, 2009, J PATHOL, V219, P347, DOI 10.1002/path.2604; Cheng H, 2005, MOL CELL BIOL, V25, P44, DOI 10.1128/MCB.25.1.44-59.2005; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Edwards KM, 2004, ONCOGENE, V23, P8419, DOI 10.1038/sj.onc.1207732; FERRACINI R, 1995, ONCOGENE, V10, P739; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hov H, 2004, CLIN CANCER RES, V10, P6686, DOI 10.1158/1078-0432.CCR-04-0874; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; Koga F, 2007, CELL CYCLE, V6, P1393, DOI 10.4161/cc.6.11.4296; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kurzik-Dumke U, 2007, CELL SIGNAL, V19, P1973, DOI 10.1016/j.cellsig.2007.05.008; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Lesko E, 2007, ANTI-CANCER DRUG, V18, P1173, DOI 10.1097/CAD.0b013e3282ef532d; Linnoila J, 2008, NEURON, V60, P625, DOI 10.1016/j.neuron.2008.09.025; Liu HY, 2005, J BIOL CHEM, V280, P19461, DOI 10.1074/jbc.M500313200; Maulik G, 2002, CLIN CANCER RES, V8, P620; Nakaigawa N, 2006, CANCER RES, V66, P3699, DOI 10.1158/0008-5472.CAN-05-0617; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peruzzi B, 2006, P NATL ACAD SCI USA, V103, P14531, DOI 10.1073/pnas.0606850103; Peruzzi B, 2006, CELL CYCLE, V5, P2839, DOI 10.4161/cc.5.24.3581; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Qian J, 2010, GASTROENTEROLOGY, V138, P1418, DOI 10.1053/j.gastro.2009.10.044; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Sangwan V, 2008, J BIOL CHEM, V283, P34374, DOI 10.1074/jbc.M805916200; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schaaf CP, 2004, FASEB J, V18, P267, DOI 10.1096/fj.04-1558fje; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Trentin GA, 2004, FEBS LETT, V578, P323, DOI 10.1016/j.febslet.2004.11.034; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Wakabayashi Y, 2007, NATURE, V445, P761, DOI 10.1038/nature05489; WALL D, 1994, J BIOL CHEM, V269, P5446; Webb CP, 2000, CANCER RES, V60, P342; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; Zia MK, 2007, INT J MOL MED, V20, P605	51	13	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2252	2263		10.1038/onc.2010.601	http://dx.doi.org/10.1038/onc.2010.601			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242965	Green Published, hybrid			2022-12-17	WOS:000290514600008
J	Hsu, CC; Chiang, CW; Cheng, HC; Chang, WT; Chou, CY; Tsai, HW; Lee, CT; Wu, ZH; Lee, TY; Chao, A; Chow, NH; Ho, CL				Hsu, C-C; Chiang, C-W; Cheng, H-C; Chang, W-T; Chou, C-Y; Tsai, H-W; Lee, C-T; Wu, Z-H; Lee, T-Y; Chao, A.; Chow, N-H; Ho, C-L			Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach	ONCOGENE			English	Article						oncofetal genes; expressed sequence tags; LRRC16B	LEUCINE-RICH REPEAT; ALPHA-FETOPROTEIN; TUMOR-MARKERS; FLIGHTLESS I; STEM-CELLS; PROTEIN; WNT; EXPRESSION; GROWTH; BETA	Oncofetal genes are expressed in embryos or fetuses, are downregulated or undetectable in adult tissues, and then re-expressed in tumors. Known oncofetal genes, such as AFP, GCB, FGF18, IMP-1 and SOX1, often have important clinical applications or pivotal biological functions. To find new oncofetal-like genes, we used the public information of expressed sequence tags to systematically analyze gene expression patterns and identified a novel oncofetal-like gene, LRRC16B. It increased the proliferation, anchorage-independent growth and tumorigenesis of transformed cells in xenografts, possibly through its effects on cyclin B1 protein levels. These findings exemplify the feasibility of using bioinformatics to find new oncofetal-like genes and suggest that more genes with important functional roles will be uncovered in the candidate gene list. Oncogene (2011) 30, 654-667; doi:10.1038/onc.2010.451; published online 22 November 2010	[Chou, C-Y; Tsai, H-W; Chow, N-H; Ho, C-L] Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan 70428, Taiwan; [Hsu, C-C; Chiang, C-W; Cheng, H-C; Chang, W-T; Lee, T-Y; Chow, N-H; Ho, C-L] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chiang, C-W; Wu, Z-H; Chow, N-H; Ho, C-L] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan 70101, Taiwan; [Chou, C-Y] Natl Cheng Kung Univ Hosp, Dept Obstet & Gynecol, Tainan 70428, Taiwan; [Chao, A.] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Dept Ophthalmol, Tao Yuan, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; Chang Gung Memorial Hospital; Chang Gung University	Ho, CL (corresponding author), Natl Cheng Kung Univ Hosp, Dept Pathol, 138 Sheng Li Rd, Tainan 70428, Taiwan.	clh9@mail.ncku.edu.tw			National Science Council, Taiwan [NSC-95-2320-B-006-057-MY2]; Department of Health, Taiwan [DOH99-TD-C-111-003]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Department of Health, Taiwan	This was supported by Grant NSC-95-2320-B-006-057-MY2 from the National Science Council, Taiwan, and Grant DOH99-TD-C-111-003 from the Department of Health, Taiwan. There is no competing financial interest in relation to this work.	Adachi-Yamada T, 2005, MOL CELL BIOL, V25, P3140, DOI 10.1128/MCB.25.8.3140-3150.2005; ALEXANDER P, 1970, MEDICINA, V30, P176; Aouacheria A, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-94; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; BERGSTRAND CG, 1956, SCAND J CLIN LAB INV, V8, P174, DOI 10.3109/00365515609049266; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Campagne F, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-481; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Cleynen I, 2007, MOL CANCER RES, V5, P363, DOI 10.1158/1541-7786.MCR-06-0331; Colantuoni C, 2000, J NEUROSCI RES, V59, P1, DOI 10.1002/(SICI)1097-4547(20000101)59:1<1::AID-JNR1>3.0.CO;2-2; Cowin AJ, 2007, J PATHOL, V211, P572, DOI 10.1002/path.2143; Dao DY, 2007, ANN NY ACAD SCI, V1116, P82, DOI 10.1196/annals.1402.082; Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987; Eisenmann KM, 2007, CURR BIOL, V17, P579, DOI 10.1016/j.cub.2007.03.024; Esteve P, 2006, CURR OPIN NEUROBIOL, V16, P13, DOI 10.1016/j.conb.2006.01.001; FARGHALY SA, 1992, GYNECOL OBSTET INVES, V34, P65, DOI 10.1159/000292728; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Gabory A, 2006, CYTOGENET GENOME RES, V113, P188, DOI 10.1159/000090831; Garcia-Barcelo MM, 2007, ANN HUM GENET, V71, P746, DOI 10.1111/j.1469-1809.2007.00384.x; Gilboa E, 1999, CANCER IMMUNOL IMMUN, V48, P382, DOI 10.1007/s002620050590; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Grozdanov PN, 2006, LAB INVEST, V86, P1272, DOI 10.1038/labinvest.3700479; Hishinuma M, 2006, HISTOPATHOLOGY, V49, P479, DOI 10.1111/j.1365-2559.2006.02522.x; Hossain MS, 2008, ONCOGENE, V27, P6075, DOI 10.1038/onc.2008.200; Imamura F, 2006, J COMP NEUROL, V495, P754, DOI 10.1002/cne.20896; Kato T, 2007, CLIN CANCER RES, V13, P434, DOI 10.1158/1078-0432.CCR-06-1297; Katoh M, 2007, STEM CELL REV, V3, P30, DOI 10.1007/s12015-007-0006-6; Katoh M, 2007, INT J MOL MED, V19, P197; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kopecki Z, 2008, INT J BIOCHEM CELL B, V40, P1415, DOI 10.1016/j.biocel.2007.04.011; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; Liu CI, 2005, DEV BIOL, V285, P238, DOI 10.1016/j.ydbio.2005.05.045; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; MCNAMEE D, 1995, LANCET, V345, P1169, DOI 10.1016/S0140-6736(95)90998-2; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Niemann H, 2007, THERIOGENOLOGY, V68, pS165, DOI 10.1016/j.theriogenology.2007.05.041; Park TJ, 2009, EXP CELL RES, V315, P3152, DOI 10.1016/j.yexcr.2009.07.009; Qiao M, 2007, CANCER RES, V67, P5293, DOI 10.1158/0008-5472.CAN-07-0877; Sarandakou A, 2007, CRIT REV CL LAB SCI, V44, P151, DOI 10.1080/10408360601003143; Shimokawa T, 2003, CANCER RES, V63, P6116; Sugimori M, 2008, DEVELOPMENT, V135, P1271, DOI 10.1242/dev.015370; TROJAN J, 1995, MOL REPROD DEV, V42, P369, DOI 10.1002/mrd.1080420402; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang R, 2010, BIOL CELL, V102, P173, DOI 10.1042/BC20090091; Xu L, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-275	48	13	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					654	667		10.1038/onc.2010.451	http://dx.doi.org/10.1038/onc.2010.451			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	21102520	Bronze			2022-12-17	WOS:000287192000003
J	Beilke, S; Oswald, F; Genze, F; Wirth, T; Adler, G; Wagner, M				Beilke, S.; Oswald, F.; Genze, F.; Wirth, T.; Adler, G.; Wagner, M.			The zinc-finger protein KCMF1 is overexpressed during pancreatic cancer development and downregulation of KCMF1 inhibits pancreatic cancer development in mice	ONCOGENE			English	Article						cancer; pancreas; KCMF1; gene trap mice; mouse model; tumor progression	TRANSFORMING-GROWTH-FACTOR; EWINGS-SARCOMA; FACTOR-ALPHA; CYCLIN D1; IN-VIVO; CELLS; MOUSE; EXPRESSION; ADENOCARCINOMA; TUMORIGENESIS	Potassium channel modulatory factor 1 (KCMF1) was found upregulated in a differential screen in the metaplastic epithelium in the pancreas of transforming growth factor (TGF)-alpha transgenic mice. Expression analysis indicated broad overexpression in human cancer tissues. Therefore, we investigated the hypothesis that KCMF1 promotes metaplastic changes and tumor development. KCMF1 represents an evolutionarily highly conserved protein with a 95% identity between human and zebrafish. KCMF1 is expressed during embryonic development and in the majority of adult tissues investigated. Upregulation of nuclear KCMF1 expression is evident in preneoplastic lesions and in several epithelial malignancies, such as pancreatic cancer in mice and humans. In cell culture and in the chicken chorioallantoic membrane model, KCMF1 enhances proliferation, migration and invasion of HEK-293 and Panc1 cells. In crossbreeding experiments, KCMF1-knockdown gene trap mice showed a reduced number and size of premalignant lesions and absence of pancreatic cancer formation in TGF-alpha transgenic mice. This effect is related to the decreased expression of G1 to S cell-cycle regulators such as cyclin D and cyclin-dependent kinase (CDK) 4. Our data support the hypothesis that KCMF1 mediates pro-oncogenic functions in vitro and in vivo and downregulation of KCMF1 results in the inhibition of pancreatic cancer formation in mice. These effects are mediated through downregulation of cell-cycle control genes such as cyclin D and CDK4. Oncogene (2010) 29, 4058-4067; doi:10.1038/onc.2010.156; published online 17 May 2010	[Beilke, S.; Oswald, F.; Adler, G.; Wagner, M.] Univ Hosp Ulm, Dept Internal Med 1, Ctr Internal Med, D-89083 Ulm, Baden Wuerttemb, Germany; [Genze, F.] Univ Ulm, Inst Pharmacol Nat Prod, Ulm, Germany; [Wirth, T.] Univ Ulm, Dept Physiol Chem, Ulm, Germany	Ulm University; Ulm University; Ulm University	Wagner, M (corresponding author), Univ Hosp Ulm, Dept Internal Med 1, Ctr Internal Med, Albert Einstein Allee 23, D-89083 Ulm, Baden Wuerttemb, Germany.	martin.wagner@uni-ulm.de	Oswald, Franz/AAO-9584-2020; Wirth, Thomas/X-7172-2019		Deutsche Forschungsgemeinschaft [SFB518: A10, A18, B23]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Jessica Wegele and Uschi Mohnle for excellent technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft (SFB518: A10 to MW, A18 to FO and B23 to TW). We thank all the participating members of the SFB518 for helpful discussions, advices and materials.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; CALDAS C, 1994, CANCER RES, V54, P3568; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; de Alava E, 2007, CLIN TRANSL ONCOL, V9, P130, DOI 10.1007/s12094-007-0027-2; Ghaneh P, 2006, BEST PRACT RES CL GA, V20, P383, DOI 10.1016/j.bpg.2005.11.008; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Hahn SA, 1996, CANCER RES, V56, P490; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jang JH, 2004, FEBS LETT, V578, P21, DOI 10.1016/j.febslet.2004.10.071; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Khasawneh J, 2009, P NATL ACAD SCI USA, V106, P3354, DOI 10.1073/pnas.0802864106; Kreppel M, 2006, ONCOGENE, V25, P2795, DOI 10.1038/sj.onc.1209300; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; Li ZX, 2003, BIOCHEM BIOPH RES CO, V306, P623, DOI 10.1016/S0006-291X(03)00875-1; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mendez J, 2009, CRIT REV BIOCHEM MOL, V44, P343, DOI 10.1080/10409230903232618; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032; Nakhai LA, 2007, EVID-BASED COMPL ALT, V4, P43, DOI 10.1093/ecam/nel051; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tosh D, 2002, NAT REV MOL CELL BIO, V3, P187, DOI 10.1038/nrm761; Wagner M, 1998, GASTROENTEROLOGY, V115, P1254, DOI 10.1016/S0016-5085(98)70098-8; Wagner M, 1998, GASTROENTEROLOGY, V114, P798, DOI 10.1016/S0016-5085(98)70594-3; Wagner M, 2002, GASTROENTEROLOGY, V122, P1898, DOI 10.1053/gast.2002.33594; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; Yamamoto M, 2006, MOL CARCINOGEN, V45, P901, DOI 10.1002/mc.20204	33	13	16	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4058	4067		10.1038/onc.2010.156	http://dx.doi.org/10.1038/onc.2010.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473331				2022-12-17	WOS:000279892400006
J	Dong, F; Soubeyrand, S; Hache, RJG				Dong, F.; Soubeyrand, S.; Hache, R. J. G.			Activation of PARP-1 in response to bleomycin depends on the Ku antigen and protein phosphatase 5	ONCOGENE			English	Article						Ku antigen; PARP-1; protein phosphatase 5; DNA repair; bleomycin	DOUBLE-STRAND BREAKS; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE-1; SERINE/THREONINE PHOSPHATASE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; KINASE-C; IN-VITRO; PHOSPHORYLATION; IDENTIFICATION	Poly (ADP-ribose) polymerase-1 (PARP-1) has an important role in the cellular response to a broad spectrum of DNA lesions. PARP-1 is strongly activated in response to double-stranded DNA breaks (DSBs), yet its contribution to the DSB response is poorly understood. Here we used bleomycin, a radiomimetic that generates DSBs with high specificity to focus on the response of PARP-1 to DSBs. We report that the induction of PARP-1 activity by bleomycin depends on the Ku antigen, a nonhomologous-DNA-End-Joining factor and protein phosphatase 5 (PP5). PARP-1 activation in response to bleomycin was reduced over 10-fold in Ku-deficient cells, whereas its activation in response to U. V. was unaffected. PARP-1 activation was rescued by reexpression of Ku, but was refractory to manipulation of DNA-dependent protein kinase or ATM. Similarly, PARP-1 activation subsequent to bleomycin was reduced 2-fold on ablation of PP5 and was increased 5-fold when PP5 was overexpressed. PP5 seemed to act directly on PARP-1, as its basal phosphorylation was reduced on overexpression of PP5, and PP5 dephosphorylated PARP-1 in vitro. These results highlight the functional importance of Ku antigen and PP5 for PARP-1 activity subsequent to DSBs. Oncogene (2010) 29, 2093-2103; doi: 10.1038/onc.2009.492; published online 25 January 2010	[Dong, F.; Soubeyrand, S.; Hache, R. J. G.] Ottawa Hlth Res Inst, Ottawa, ON, Canada; [Hache, R. J. G.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Hache, R. J. G.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Hache, RJG (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr, Calgary, AB T2N 1N4, Canada.	rjhache@ucalgary.ca		soubeyrand, sebastien/0000-0002-9317-301X	Canadian Institutes of Health Research [CIHR MT 13412]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We are very grateful to Dr V Schreiber and Dr G de Murcia for providing the PARP-deficient and control mouse fibroblasts. We would also like to thank Dr Y Shiloh for providing us with the ATM-restored and AT fibroblast cell lines (PEBS-YZ5 and PEBS, respectively). Finally, we are grateful to L Pope for her logistical support. This work was funded by an operating grant from the Canadian Institutes of Health Research (CIHR MT 13412) to RJGH. RJGH was a University of Ottawa Health Research Chair.	Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Audebert M, 2006, J MOL BIOL, V356, P257, DOI 10.1016/j.jmb.2005.11.028; BAUER PI, 1992, BIOCHEM BIOPH RES CO, V187, P730, DOI 10.1016/0006-291X(92)91256-P; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; CANTONI O, 1986, BIOCHIM BIOPHYS ACTA, V867, P135, DOI 10.1016/0167-4781(86)90073-4; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; Cole A, 1975, Basic Life Sci, V5B, P665; Douglas P, 2005, DNA REPAIR, V4, P1006, DOI 10.1016/j.dnarep.2005.05.003; Errami A, 1996, MOL CELL BIOL, V16, P1519; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Giffin W, 1995, DNA CELL BIOL, V14, P1025, DOI 10.1089/dna.1995.14.1025; Golden TA, 2003, METHOD ENZYMOL, V366, P372; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grote J, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-48; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Hossain MB, 2009, J BIOL CHEM, V284, P8612, DOI 10.1074/jbc.M807198200; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Idogawa M, 2007, CANCER RES, V67, P911, DOI 10.1158/0008-5472.CAN-06-2360; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kang Y, 2009, J BIOL CHEM, V284, P9845, DOI 10.1074/jbc.M809272200; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Lis JT, 2006, CELL, V125, P1225, DOI 10.1016/j.cell.2006.06.016; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Meyer-Ficca ML, 2005, INT J BIOCHEM CELL B, V37, P920, DOI 10.1016/j.biocel.2004.09.011; Midorikawa R, 2006, CELL, V125, P371, DOI 10.1016/j.cell.2006.02.039; Mitsuhashi S, 2001, BIOCHEM BIOPH RES CO, V287, P328, DOI 10.1006/bbrc.2001.5596; OGATA N, 1981, J BIOL CHEM, V256, P4135; OKAYAMA H, 1977, J BIOL CHEM, V252, P7000; Perrault R, 2004, J CELL BIOCHEM, V92, P781, DOI 10.1002/jcb.20104; Pion E, 2005, BIOCHEMISTRY-US, V44, P14670, DOI 10.1021/bi050755o; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Postow L, 2008, J CELL BIOL, V182, P467, DOI 10.1083/jcb.200802146; POVIRK LF, 1989, BIOCHEMISTRY-US, V28, P5808, DOI 10.1021/bi00440a016; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Rivera-Calzada A, 2007, EMBO REP, V8, P56, DOI 10.1038/sj.embor.7400847; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Schild-Poulter C, 2003, CANCER RES, V63, P7197; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; TANAKA Y, 1987, BIOCHEM BIOPH RES CO, V148, P709, DOI 10.1016/0006-291X(87)90934-X; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/s0079-6603(08)60611-x; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Yin H, 2006, J BIOL CHEM, V281, P11496, DOI 10.1074/jbc.M511138200; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	55	13	14	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2093	2103		10.1038/onc.2009.492	http://dx.doi.org/10.1038/onc.2009.492			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101203				2022-12-17	WOS:000276402800008
J	Kohler, EM; Brauburger, K; Behrens, J; Schneikert, J				Kohler, E. M.; Brauburger, K.; Behrens, J.; Schneikert, J.			Contribution of the 15 amino acid repeats of truncated APC to beta-catenin degradation and selection of APC mutations in colorectal tumours from FAP patients	ONCOGENE			English	Article						adenomatous polyposis coli; APC; beta-catenin; colon cancer; mutation	ADENOMATOUS POLYPOSIS-COLI; SOMATIC MUTATIONS; DESTRUCTION COMPLEX; SUPPRESSOR PROTEIN; CLUSTER REGION; FUNCTIONAL INTERACTION; CRYSTAL-STRUCTURE; STEM-CELLS; IN-VIVO; GENE	The adenomatous polyposis coli (APC) protein is a negative regulator of the mitogenic transcription factor beta-catenin by stimulating its proteasomal degradation. This involves several APC domains, including the binding sites for axin/conductin, the recently described beta-Catenin Inhibitory Domain (CID) and the third 20 amino acid repeat (20R3) that is a beta-catenin-binding site. The four 15 amino acid repeats (15R) and the 20R1 are also beta-catenin-binding sites, but their role in beta-catenin degradation has remained unclear. We show here that binding of beta-catenin to the 15R of APC is necessary and sufficient to target beta-catenin for degradation whereas binding to the 20R1 is neither necessary nor sufficient. The first 15R displays the highest affinity for beta-catenin in the 15R-20R1 module. Biallelic mutations of the APC gene lead to colon cancer in familial adenomatous polyposis coli (FAP) and result in the synthesis of truncated products lacking domains involved in beta-catenin degradation but still having a minimal length. The analysis of the distribution of truncating mutations along the APC sequence in colorectal tumours from FAP patients revealed that the first 15R is one target of the positive selection of mutations that lead to tumour development. Oncogene (2010) 29, 1663-1671; doi:10.1038/onc.2009.447; published online 7 December 2009	[Kohler, E. M.; Brauburger, K.; Behrens, J.; Schneikert, J.] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, D-91054 Erlangen, Bayern, Germany	University of Erlangen Nuremberg	Schneikert, J (corresponding author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Gluckstr 6, D-91054 Erlangen, Bayern, Germany.	jschneik@molmed.uni-erlangen.de		Wenzel, Eva Maria/0000-0002-5561-3344	Interdisziplinares Zentrum fur Klinische Forschung (IZKF); Sander Stiftung	Interdisziplinares Zentrum fur Klinische Forschung (IZKF); Sander Stiftung	We thank G Daum for technical, and A Doebler for secretarial assistances. We thank also I Wacker for critical reading of the paper. This work was supported by grants from the Interdisziplinares Zentrum fur Klinische Forschung (IZKF) and the Sander Stiftung to JB.	Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Clarke AR, 2006, ONCOGENE, V25, P7512, DOI 10.1038/sj.onc.1210065; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; Ferrarese A, 2007, BIOCHEMISTRY-US, V46, P11902, DOI 10.1021/bi701674z; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; Gupta PK, 1997, CANCER RES, V57, P1188; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Hong Y, 2007, MUTAT RES-FUND MOL M, V614, P48, DOI 10.1016/j.mrfmmm.2006.06.006; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kohler EM, 2008, HUM MOL GENET, V17, P1978, DOI 10.1093/hmg/ddn095; Kohler EM, 2009, HUM MOL GENET, V18, P213, DOI 10.1093/hmg/ddn338; Kotiligam D, 2008, HISTOL HISTOPATHOL, V23, P117, DOI 10.14670/HH-23.117; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Latchford A, 2007, HUM MOL GENET, V16, P78, DOI 10.1093/hmg/ddl442; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2006, J MOL BIOL, V360, P133, DOI 10.1016/j.jmb.2006.04.064; McCartney BM, 2008, CURR OPIN CELL BIOL, V20, P186, DOI 10.1016/j.ceb.2008.02.001; Menendez M, 2008, GASTROENTEROLOGY, V134, P56, DOI 10.1053/j.gastro.2007.10.009; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyaki M, 2008, INT J CANCER, V122, P2491, DOI 10.1002/ijc.23390; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke I, 2006, NAT REV CANCER, V6, P967, DOI 10.1038/nrc2010; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; Peterson-Nedry W, 2008, DEV BIOL, V320, P226, DOI 10.1016/j.ydbio.2008.05.521; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Pollard P, 2009, GASTROENTEROLOGY, V136, P2204, DOI 10.1053/j.gastro.2009.02.058; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Schneikert J, 2006, INT J CANCER, V119, P74, DOI 10.1002/ijc.21826; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Taketo MM, 2006, ONCOGENE, V25, P7522, DOI 10.1038/sj.onc.1210058; Tickenbrock L, 2003, J MOL BIOL, V327, P359, DOI 10.1016/S0022-2836(03)00144-X; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603	58	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1663	1671		10.1038/onc.2009.447	http://dx.doi.org/10.1038/onc.2009.447			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966865				2022-12-17	WOS:000275694700011
J	Dean, JL; McClendon, AK; Stengel, KR; Knudsen, ES				Dean, J. L.; McClendon, A. K.; Stengel, K. R.; Knudsen, E. S.			Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context	ONCOGENE			English	Article						retinoblastoma tumor suppressor (RB); Ras; c-Myc; chemotherapeutics; cell cycle checkpoints	PRB-DEFICIENT EPIDERMIS; CYCLE CONTROL; RETINOBLASTOMA PROTEIN; C-MYC; SKIN CARCINOGENESIS; INDUCED APOPTOSIS; RAS; CANCER; P53; FIBROBLASTS	The retinoblastoma tumor suppressor, RB, is a key regulator of cellular proliferation that is functionally inactivated at high frequency in human cancer. Although RB has been extensively studied with regard to tumor etiology, loss of tumor-suppressor function often occurs relatively late in tumor progression. Therefore, inactivation of RB could have a profound impact on the behavior of tumors driven by discrete oncogenes. Here, collaboration between Ras or c-Myc deregulation and RB functional state was investigated in a model of conditional genetic deletion to decipher the effects related to disease progression. These studies showed that RB loss had a robust impact on mitogen dependence, anchorage dependence and overall survival, which was significantly modified by oncogene activation. Specifically, RB deficiency predisposed c-Myc-expressing cells to cell death and reduced overall tumorigenic proliferation. In contrast, RB deficiency exacerbated the tumorigenic behavior of Ras-transformed cells in both the model system and human tumor cell lines. As these tumors exhibited highly aggressive behavior, the possibility of exploiting the intrinsic sensitivity to cell death with RB loss was evaluated. Particularly, although Ras-transformed, RB-deficient cells bypassed the G1-checkpoint elicited by pharmacological activation of the p53 pathway, they were also highly sensitized to cell death. Altogether, these data suggest that the impact of RB deletion is dependent on the oncogene milieu, and can directly contribute to transformed phenotypes and response to therapeutic intervention.	[Dean, J. L.; McClendon, A. K.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Dean, J. L.; McClendon, A. K.; Knudsen, E. S.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Stengel, K. R.] Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Cincinnati, OH USA	Jefferson University; Jefferson University; University of Cincinnati	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB Room 1002,233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org		Stengel, Kristy/0000-0002-8330-5744				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alkarain A, 2004, BREAST CANCER RES, V6, P13, DOI 10.1186/bcr722; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; BOS JL, 1989, CANCER RES, V49, P4682; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; DeGregori J, 2006, MOL CELL BIOL, V26, P1165, DOI 10.1128/MCB.26.4.1165-1169.2006; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FILMUS J, 1994, ONCOGENE, V9, P3627; Groth A, 2000, J BIOL CHEM, V275, P27473; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Kharitonova MA, 2007, CELL BIOL INT, V31, P220, DOI 10.1016/j.cellbi.2006.10.008; Kitagawa M, 2008, ONCOGENE, V27, P5303, DOI 10.1038/onc.2008.164; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacPherson D, 2007, EMBO J, V26, P784, DOI 10.1038/sj.emboj.7601515; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Marino S, 2000, GENE DEV, V14, P994; Markey MP, 2007, ONCOGENE, V26, P6307, DOI 10.1038/sj.onc.1210450; Markey MP, 2002, CANCER RES, V62, P6587; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; Miyamoto H, 1996, J UROLOGY, V155, P1444, DOI 10.1016/S0022-5347(01)66304-3; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Rogoff HA, 2004, CELL CYCLE, V3, P845; Ruiz S, 2005, CANCER RES, V65, P9678, DOI 10.1158/0008-5472.CAN-05-1853; Santos M, 2008, MOL CARCINOGEN, V47, P815, DOI 10.1002/mc.20426; Seeley SL, 2007, CANCER LETT, V245, P205, DOI 10.1016/j.canlet.2006.01.028; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Stengel KR, 2008, CELL CYCLE, V7, DOI 10.4161/cc.7.8.5737; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Williams JP, 2006, MOL CELL BIOL, V26, P1170, DOI 10.1128/MCB.26.4.1170-1182.2006; Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	54	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					68	80		10.1038/onc.2009.313	http://dx.doi.org/10.1038/onc.2009.313			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802012				2022-12-17	WOS:000273373500007
J	Gaidarenko, O; Xu, Y				Gaidarenko, O.; Xu, Y.			Transcription activity is required for p53-dependent tumor suppression	ONCOGENE			English	Article						p53; transcription activity; tumor suppression; metastasis	EMBRYONIC STEM-CELLS; LI-FRAUMENI-SYNDROME; MOUSE MODEL; DNA-DAMAGE; P53 GAIN; APOPTOSIS; CANCER; MICE; PHOSPHORYLATION; ACTIVATION	As a transcription factor, the critical tumor suppressor, p53, directly regulates the transcription of hundreds of genes, leading to cell-cycle arrest, apoptosis, cellular senescence and differentiation. Although it has been assumed that p53 transcription activity is critical for tumor suppression, this assumption has been increasingly contested by recent findings of transcription-independent roles of p53 in apoptosis as well as findings that none of the mutant mice lacking important p53 transcription targets are cancer prone. On the basis of previous findings that p53 transcription activity is abolished in p53(QS) (Leu25Trp26 to Gln25Ser26) knock-in mouse cells after DNA damage, to determine the importance of transcription activity of p53 in tumor suppression, we generated knock-in mice that can conditionally express p53QS protein in a Cre-dependent manner. By breeding the knock-in mice with Lck-Cre transgenic mice that specifically express Cre in thymocytes, we show that p53-dependent suppression of thymic lymphomas is abolished in thymocytes expressing high levels of p53QS protein. In addition, p53QS protein is accumulated in some of the thymic tumors. Therefore, p53 transcription activity induced by DNA damage is required for tumor suppression. Together with the findings that the disruption of various p53-dependent functions individually fails to promote cancer, our findings indicate that various transcription-dependent functions of p53 must collaborate to efficiently suppress tumorigenesis. Oncogene (2009) 28, 4397-4401; doi: 10.1038/onc.2009.290; published online 21 September 2009	[Gaidarenko, O.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.du		Xu, Yang/0000-0001-5574-921X; Gaidarenko, Olga/0000-0002-3259-3352	NIH [R01 CA94254]; NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank T Lin and C Chao for their help in constructing the p53QS mice. This work was supported by a NIH grant (R01 CA94254) to YX.	BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Inlay M, 2002, NAT IMMUNOL, V3, P463, DOI 10.1038/ni790; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Xu Y, 2005, CELL CYCLE, V4, P363, DOI 10.4161/cc.4.3.1529	28	13	13	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4397	4401		10.1038/onc.2009.290	http://dx.doi.org/10.1038/onc.2009.290			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19767771	Green Accepted			2022-12-17	WOS:000272876400008
J	Yuan, J; Yang, BMP; Zhong, ZH; Shats, I; Milyavsky, M; Rotter, V; Lock, RB; Reddel, RR; MacKenzie, KL				Yuan, J.; Yang, B. M-P; Zhong, Z-H; Shats, I.; Milyavsky, M.; Rotter, V.; Lock, R. B.; Reddel, R. R.; MacKenzie, K. L.			Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase	ONCOGENE			English	Article						survivin; telomerase; apoptosis; immortalization; fibroblasts	ANTI-APOPTOSIS GENE; MALIGNANT-TRANSFORMATION; SPINDLE CHECKPOINT; CELL-DIVISION; CORD BLOOD; CANCER; INACTIVATION; INHIBITOR; GROWTH; EXPRESSION	These investigations demonstrate that expression of the inhibitor of apoptosis family member, survivin, is dramatically increased during immortalization of nontransformed human fibroblasts that were transduced with telomerase reverse transcriptase (hTERT). Expression of survivin in immortalized fibroblasts peaked during G(2)/M phase of the cell cycle. However, the upregulation of survivin was dissociated from the rate of proliferation and proportion of G(2)/M cells. Depletion of survivin from immortal flbroblasts increased sensitivity to stress-induced apoptosis and resulted in an accumulation of cells with 4N DNA content. Conversely, overexpression of survivin in mortal. broblasts conferred resistance to apoptosis. In contrast, very low levels of survivin in proliferating parental. broblasts had no bearing on sensitivity to apoptosis. The upregulation of survivin did not appear to be a direct consequence of hTERT transduction. However, repression of hTERT resulted in the rapid downregulation of survivin in telomerase-immortalized. broblasts and tumor cell lines, but not in cells immortalized via an Alternative Lengthening of Telomeres mechanism. These results have important therapeutic implications, as telomerase and survivin are both broadly expressed in human cancers. Selection during the immortalization process for cells expressing high levels of survivin may account for the abundance of survivin in diverse tumor types. Oncogene (2009) 28, 2678-2689; doi: 10.1038/onc.2009.136; published online 1 June 2009	[MacKenzie, K. L.] Sydney Childrens Hosp, Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia; [Yuan, J.; Yang, B. M-P; Lock, R. B.; MacKenzie, K. L.] Univ New S Wales, Fac Med, Sydney, NSW, Australia; [Zhong, Z-H; Reddel, R. R.] Childrens Med Res Inst, Westmead, NSW, Australia; [Zhong, Z-H; Reddel, R. R.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Shats, I.; Milyavsky, M.; Rotter, V.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Children's Cancer Institute; University of New South Wales Sydney; Children's Medical Research Institute - Australia; University of Sydney; Weizmann Institute of Science	MacKenzie, KL (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Australia Med Res, Level 1,High St,POB 81, Randwick, NSW 2031, Australia.	k.mackenzie@unsw.edu.au	Reddel, Roger R/A-6635-2014; MacKenzie, Karen/N-5849-2019; Shats, Igor/AAD-8775-2019; Mackenzie, Karen/F-1310-2011; Lock, Richard/G-4253-2013; Milyavsky, Michael/E-8306-2011	Reddel, Roger R/0000-0002-6302-6107; Shats, Igor/0000-0001-6449-5979; Lock, Richard/0000-0002-3436-9071; MacKenzie, Karen/0000-0003-2996-1617				Adida C, 1998, AM J PATHOL, V152, P43; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Arora V, 2007, J BIOL CHEM, V282, P26202, DOI 10.1074/jbc.M700776200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; Colnaghi R, 2006, J BIOL CHEM, V281, P33450, DOI 10.1074/jbc.C600164200; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Fukuda S, 2001, BLOOD, V98, P2091, DOI 10.1182/blood.V98.7.2091; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Milyavsky M, 2003, CANCER RES, V63, P7147; Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Pennati M, 2007, CARCINOGENESIS, V28, P1133, DOI 10.1093/carcin/bgm047; Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Schuller CE, 2007, LEUKEMIA, V21, P983, DOI 10.1038/sj.leu.2404631; Stewart SA, 2006, ANNU REV CELL DEV BI, V22, P531, DOI 10.1146/annurev.cellbio.22.010305.104518; Taylor LM, 2004, J BIOL CHEM, V279, P43634, DOI 10.1074/jbc.M402388200; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verhagen AM, 2001, GENOME BIOL, V2; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Wang ZX, 2005, CANCER RES, V65, P8224, DOI 10.1158/0008-5472.CAN-05-0303; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2008, CANCER RES, V68, P3086; Wen VW, 2006, CANCER RES, V66, P10691, DOI 10.1158/0008-5472.CAN-06-0979; Wright WE, 1996, DEV GENET, V18, P173; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yang J, 2008, ONCOGENE, V27, P5326, DOI 10.1038/onc.2008.165; Zhang M, 2006, J EXP CLIN CANC RES, V25, P391	47	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2678	2689		10.1038/onc.2009.136	http://dx.doi.org/10.1038/onc.2009.136			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483728				2022-12-17	WOS:000268211200006
J	Connors, SK; Balusu, R; Kundu, CN; Jaiswal, AS; Gairola, CG; Narayan, S				Connors, S. K.; Balusu, R.; Kundu, C. N.; Jaiswal, A. S.; Gairola, C. G.; Narayan, S.			C/EBP beta-mediated transcriptional regulation of bcl-xl gene expression in human breast epithelial cells in response to cigarette smoke condensate	ONCOGENE			English	Article						cigarette smoke condensate; bcl-xl; C/EBP beta; gene regulation; breast carcinogenesis	MOUSE MAMMARY-GLAND; CANCER-CELLS; TOBACCO-SMOKE; NULL ASSOCIATION; ACTIVE SMOKING; PROTEIN; APOPTOSIS; BCL-X(L); RISK; OVEREXPRESSION	In earlier studies, we have shown that cigarette smoke condensate (CSC), a surrogate for cigarette smoke, is capable of transforming the spontaneously immortalized human breast epithelial cell line, MCF10A. These transformed cells displayed upregulation of the antiapoptotic gene, bcl-xl. Upregulation of this gene may impede the apoptotic pathway and allow the accumulation of DNA damage that can lead to cell transformation and carcinogenesis. In the present study, we have determined the mechanism of CSC-mediated transcriptional upregulation of bcl-xl gene expression in MCF10A cells. We cloned the human bcl-xl promoter (pBcl-xLP) and identified putative transcription factor binding sites. Sequential deletion constructs that removed the putative cis-elements were constructed and transfected into MCF10A cells to determine the CSC-responsive cis-element(s) on the pBcl-xLP. Gel-shift, super-shift and chromatin immunoprecipitation analysis confirmed that CCAAT/enhancer-binding protein (C/EBP beta) specifically bound to a C/EBP-binding site on the pBcl-xLP in vitro and in vivo. Additionally, overexpression of C/EBP beta-LAP2 stimulated pBcl-xLP activity and Bcl-xL protein levels, which mimicked the conditions of CSC treatment. Our results indicate that C/EBP beta regulates bcl-xl gene expression in MCF10A cells in response to CSC treatment; therefore, making it a potential target for chemotherapeutic intervention of cigarette smoke-induced breast carcinogenesis.	[Connors, S. K.; Balusu, R.; Kundu, C. N.; Jaiswal, A. S.; Narayan, S.] Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32610 USA; [Connors, S. K.; Balusu, R.; Kundu, C. N.; Jaiswal, A. S.; Narayan, S.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Gairola, C. G.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Kentucky	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, Canc & Genet Res Complex,Room 255,POB 103633,1376, Gainesville, FL 32610 USA.	snarayan@ufl.edu		Kundu, Chanakya/0000-0003-0297-1030	NCI-NIH [CA-100247]; Flight Attendant Medical Research Institute; University Florida Shands Cancer Center; NATIONAL CANCER INSTITUTE [R01CA100247] Funding Source: NIH RePORTER	NCI-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Flight Attendant Medical Research Institute; University Florida Shands Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michael Kilberg from the University of Florida for the gift of the C/EBP beta overexpression constructs. The financial support for these studies was provided by the Grants from NCI-NIH (CA-100247) and Flight Attendant Medical Research Institute to Satya Narayan, and T32-Training Grant in Cancer Biology from University Florida Shands Cancer Center to Shahnjayla K Connors.	Bennett WP, 1999, JNCI-J NATL CANCER I, V91, P2009, DOI 10.1093/jnci/91.23.2009; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bundy L, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-43; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431; Espana L, 2004, BREAST CANCER RES TR, V87, P33, DOI 10.1023/B:BREA.0000041579.51902.89; Feng G, 2001, CANCER RES, V61, P7999; Fernandez Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628; Fink AK, 2003, CANCER CAUSE CONTROL, V14, P497, DOI 10.1023/A:1024922824237; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; HSU TC, 1991, MUTAT RES, V259, P67, DOI 10.1016/0165-1218(91)90110-8; Jaiswal AS, 2006, CARCINOGENESIS, V27, P252, DOI 10.1093/carcin/bgi225; Johnson KC, 2005, INT J CANCER, V117, P619, DOI 10.1002/ijc.21150; KUMAR R, 1990, ONCOGENE, V5, P1271; Kundu CN, 2007, ONCOGENE, V26, P1428, DOI 10.1038/sj.onc.1209925; Lash TL, 2002, BREAST CANCER RES TR, V75, P181, DOI 10.1023/A:1019625102365; Mendez O, 2005, CLIN EXP METASTAS, V22, P297, DOI 10.1007/s10585-005-8751-x; Mendez O, 2001, BREAST CANCER RES TR, V65, P171, DOI 10.1023/A:1006490622103; Mendez O, 2006, CARCINOGENESIS, V27, P1169, DOI 10.1093/carcin/bgi363; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Nagata C, 2006, JPN J CLIN ONCOL, V36, P387, DOI 10.1093/jjco/hyl031; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Olopade OI, 1997, CANCER J SCI AM, V3, P230; PERERA FP, 1995, CANCER EPIDEM BIOMAR, V4, P233; PETRAKIS NL, 1978, SCIENCE, V199, P303, DOI 10.1126/science.619458; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Rubio N, 2001, LAB INVEST, V81, P725, DOI 10.1038/labinvest.3780281; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SOULE HD, 1990, CANCER RES, V50, P6075; Stabbert R, 2003, J APPL TOXICOL, V23, P329, DOI 10.1002/jat.924; TAIT L, 1990, CANCER RES, V50, P6087; WELLS AJ, 2000, J WOMENS CANC, V2, P55; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428; [No title captured]; [No title captured]	51	13	13	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					921	932		10.1038/onc.2008.429	http://dx.doi.org/10.1038/onc.2008.429			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19043455	Green Accepted			2022-12-17	WOS:000263320000014
J	Parisi, T; Bronson, RT; Lees, JA				Parisi, T.; Bronson, R. T.; Lees, J. A.			Inhibition of pituitary tumors in Rb mutant chimeras through E2f4 loss reveals a key suppressive role for the pRB/E2F pathway in urothelium and ganglionic carcinogenesis	ONCOGENE			English	Article						E2f4; Rb; neuroendocrine tumors; urothelial cancer	CELLULAR PROLIFERATION; FAMILY PROTEINS; G(1) CONTROL; MICE; CANCER; PRB; IMMORTALIZATION; TUMORIGENESIS; CARCINOMA; GENES	The retinoblastoma protein pRB suppresses tumorigenesis largely through regulation of the E2F transcription factors. E2F4, the most abundant E2F protein, is thought to act in cooperation with pRB to restrain cell proliferation. In this study, we analyse how loss of E2f4 affects the tumorigenicity of pRB-deficient tissues. As Rb-/-; E2f4(-/-) germline mice die in utero, we generated Rb-/-; E2f4(-/-) chimeric animals to allow examination of adult tumor phenotypes. We found that loss of E2f4 had a differential effect on known Rb-associated neuroendocrine tumors. It did not affect thyroid and adrenal glands tumors but partially suppressed lung neuroendocrine hyperplasia. The most striking effect was in the pituitary where E2F4 loss delayed the development, and reduced the incidence, of Rb mutant tumors. This tumor suppression increased the longevity of the Rb-/-; E2f4(-/-) chimeric animals allowing us to identify novel tumor types. We observed ganglionic neuroendocrine neoplasms, lesions not associated earlier with mutation of either Rb or E2f4. Moreover, a subset of the Rb-/-; E2f4(-/-) chimeras developed either low- or high-grade carcinomas in the urothelium transitional epithelium supporting a key role for Rb in bladder cancer.	[Parisi, T.; Lees, J. A.] MIT, David H Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA 02139 USA; [Bronson, R. T.] Tufts Cummings Sch Vet Med, Dept Pathol, North Grafton, MA USA	Massachusetts Institute of Technology (MIT)	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, Dept Biol, 77 Mass Ave,E17-517B, Cambridge, MA 02139 USA.	jalees@mit.edu			NIH [CA121921]; NATIONAL CANCER INSTITUTE [R01CA121921] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the CCR Transgenic Facility, in particular to John M Mkandawire and Peimin Qu, for technical help, and to Alicia Caron in the Histology Facility. We are also thankful to SR Frank and P White for critical reading of the paper and helpful discussion. This project was supported by NIH grants to JAL (CA121921). JAL is a Ludwig Scholar.	CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dinney CPN, 2004, CANCER CELL, V6, P111, DOI 10.1016/j.ccr.2004.08.002; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Huber K, 2006, DEV BIOL, V298, P335, DOI 10.1016/j.ydbio.2006.07.010; Humbert PO, 2000, GENE DEV, V14, P690; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Parisi T, 2007, MOL CELL BIOL, V27, P2283, DOI 10.1128/MCB.01854-06; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Schulz WA, 2006, INT J CANCER, V119, P1513, DOI 10.1002/ijc.21852; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wikenheiser-Brokamp KA, 2006, CELL MOL LIFE SCI, V63, P767, DOI 10.1007/s00018-005-5487-3; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zhang ZT, 1999, CANCER RES, V59, P3512; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	32	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					500	508		10.1038/onc.2008.406	http://dx.doi.org/10.1038/onc.2008.406			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997819	Green Accepted			2022-12-17	WOS:000262866500004
J	Suzuki, T; Tsuzuku, J; Kawakami, K; Miyasaka, T; Yamamoto, T				Suzuki, T.; Tsuzuku, J.; Kawakami, K.; Miyasaka, T.; Yamamoto, T.			Proteasome-mediated degradation of Tob is pivotal for triggering UV-induced apoptosis	ONCOGENE			English	Article						Tob; apoptosis; DNA damage; proteasome	DNA-DAMAGE; CYTOCHROME-C; CANCER-CELLS; MICE LACKING; CASPASE 9; P53; REPAIR; TRANSCRIPTION; FIBROBLASTS; ACTIVATION	Eukaryotic cells respond to genotoxic stress by inducing cell growth arrest or apoptosis. Although the p53 tumor suppressor largely contributes to the response by regulating antiproliferative or pro-apoptotic genes, some genotoxic stresses including ultraviolet (UV) light induce apoptosis even in the absence of p53. The molecular mechanisms by which cells respond to UV in the p53-independent manner remain to be established. Here, we show that UV-induced stress promotes proteasome-dependent degradation of Tob, triggering an apoptotic signal. We found that Tob with either short deletion or a tag sequence at the C terminus was resistant to UV-induced degradation. Introduction of the degradation-resistant Tob impaired UV-induced apoptosis. Reciprocally, suppression of Tob by small interfering RNA (siRNA) resulted in frequent induction of apoptosis irrespective of the presence of functional p53 even at UV doses that do not promote Tob degradation. Finally, tob-deficient (tob(-/-)) mice and primary embryonic fibroblasts (MEFs) from tob(-/-) mice exhibit increased sensitivity to UV irradiation. Thus, proteasomal clearance of Tob provides a novel p53-independent pathway for UV-induced apoptosis.	[Suzuki, T.; Tsuzuku, J.; Kawakami, K.; Miyasaka, T.; Yamamoto, T.] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Oncol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Seiji Takeuchi (University of Fukui, Japan) for technical advice about UV irradiation of animals, and Dr Robert Whittier (Institute of Medical Science, Tokyo, Japan) and Dr Marius Sudol (Weis Center for Research, Danville, PA, USA) for comments on the paper. We also thank members of our laboratory for scientific comments and valuable discussions. This study was supported by a grant for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Dornetshuber R, 2007, CHEM RES TOXICOL, V20, P465, DOI 10.1021/tx600259t; El-Mahdy MA, 2000, MUTAT RES-DNA REPAIR, V459, P135, DOI 10.1016/S0921-8777(99)00066-X; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hiramatsu Y, 2006, CANCER RES, V66, P8477, DOI 10.1158/0008-5472.CAN-06-1603; Kondo T, 2004, J BIOL CHEM, V279, P27315, DOI 10.1074/jbc.M314023200; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; LATONEN L, 2006, BIOCHIM BIOPHYS ACTA, V1755, P71; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Matsuda S, 1996, ONCOGENE, V12, P705; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Naik E, 2007, J CELL BIOL, V176, P415, DOI 10.1083/jcb.200608070; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Saldeen J, 2003, MOL CELL BIOCHEM, V243, P113, DOI 10.1023/A:1021651811345; Sasajima H, 2002, EUR J BIOCHEM, V269, P3596, DOI 10.1046/j.1432-1033.2002.03052.x; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Tomicic MT, 2005, APOPTOSIS, V10, P1295, DOI 10.1007/s10495-005-1392-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang SY, 2006, J BIOL CHEM, V281, P34810, DOI 10.1074/jbc.M607484200; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhao Y, 2008, ONCOGENE, V27, P1, DOI 10.1038/sj.onc.1210625; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	38	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					401	411		10.1038/onc.2008.387	http://dx.doi.org/10.1038/onc.2008.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18850001				2022-12-17	WOS:000262550300008
J	Sripathy, SP; Chaplin, LJ; Gaikwad, NW; Rogan, EG; Montano, MM				Sripathy, S. P.; Chaplin, L. J.; Gaikwad, N. W.; Rogan, E. G.; Montano, M. M.			hPMC2 is required for recruiting an ER beta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen	ONCOGENE			English	Article						PARP-1; ER beta-dependent transcription; antioxidative enzymes; tamoxifen; breast cancer	ESTROGEN-RECEPTOR-BETA; QUINONE REDUCTASE GENE; BREAST-CANCER; FUNCTIONAL IMPLICATIONS; C-FOS; ALPHA; ACTIVATION; EXPRESSION; ENZYMES; ELEMENT	In the presence of ER beta, trans-hydroxytamoxifen (TOT) protects cells against 17 beta-estradiol(E-2)-induced oxidative DNA damage (ODD) and this correlates with increased expression of the antioxidative enzyme quinone reductase (QR). Here, we investigate the molecular mechanism responsible for ER beta-mediated protection against ODD. We observe constitutive interaction between ERb and the novelprote in hPMC2. Using a combination of breast epithelial cell lines that are either positive or negative for ER alpha, we demonstrate TOT-dependent recruitment of both ERb and hPMC2 to the EpRE (electrophile response element)- regulated antioxidative enzyme QR. We further demonstrate TOT-dependent corecruitment of the coactivators Nrf2, PARP-1 (poly (ADP-ribose) polymerase 1) and topoisomerase II beta, both in the presence and absence of ER alpha. However, absence of either ER beta or hPMC2 results in nonrecruitment of PARP-1 and topoisomerase IIb, loss of antioxidative enzyme induction and attenuated protection against ODD by TOT even in the presence of Nrf2 and ERa. These findings indicate minor role for Nrf2 and ER alpha in TOT-dependent antioxidative gene regulation. However, downregulation of PARP-1 attenuates TOT-dependent antioxidative gene induction. We conclude that ER beta and hPMC2 are required for TOT-dependent recruitment of coactivators such as PARP-1 to the EpRE resulting in the induction of antioxidative enzymes and subsequent protection against ODD.	[Sripathy, S. P.; Chaplin, L. J.; Montano, M. M.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Gaikwad, N. W.; Rogan, E. G.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA	Case Western Reserve University; University of Nebraska System; University of Nebraska Medical Center	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, 2901 Adelbert Rd,W305, Cleveland, OH 44106 USA.	mxm126@case.edu			NIH [CA92440, CA130066]; NATIONAL CANCER INSTITUTE [R01CA092440, R03CA130066] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grants (CA92440 and CA130066) to MMM.	Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx700191p; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CAVALIERI E, 2006, BIOCH BIOPHYS ACTA; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Fabian C, 2007, CANCER EPIDEM BIOMAR, V16, P2210, DOI 10.1158/1055-9965.EPI-06-1065; Gaikwad NW, 2007, FREE RADICAL BIO MED, V43, P1289, DOI 10.1016/j.freeradbiomed.2007.07.021; Gruvberger-Saal SK, 2007, CLIN CANCER RES, V13, P1987, DOI 10.1158/1078-0432.CCR-06-1823; Jordan VC, 2007, CANCER EPIDEM BIOMAR, V16, P2207, DOI 10.1158/1055-9965.EPI-07-0629; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Li KM, 2004, CARCINOGENESIS, V25, P289, DOI 10.1093/carcin/bgg191; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Lis JT, 2006, CELL, V125, P1225, DOI 10.1016/j.cell.2006.06.016; Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140; Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281; Menzel HJ, 2004, BRIT J CANCER, V90, P1989, DOI 10.1038/sj.bjc.6601779; Montano MM, 2007, ONCOGENE, V26, P3587, DOI 10.1038/sj.onc.1210144; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Oestergaard MZ, 2006, BRIT J CANCER, V95, P525, DOI 10.1038/sj.bjc.6603272; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAKODA LC, 2007, BREAST CANC RES TREA; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Speirs V, 2007, J PATHOL, V211, P499, DOI 10.1002/path.2130; Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8; TEW KD, 1994, CANCER RES, V54, P4313; Udler M, 2007, J CLIN ONCOL, V25, P3015, DOI 10.1200/JCO.2006.10.0099; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h	37	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	49					6376	6384		10.1038/onc.2008.235	http://dx.doi.org/10.1038/onc.2008.235			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18663360	Green Accepted			2022-12-17	WOS:000260263400007
J	Zhu, S; Bjorge, JD; Cheng, HC; Fujita, DJ				Zhu, S.; Bjorge, J. D.; Cheng, H. C.; Fujita, D. J.			Decreased CHK protein levels are associated with Src activation in colon cancer cells	ONCOGENE			English	Article						cHK; src; colon cancer	HOMOLOGOUS KINASE CHK; LYN TYROSINE KINASE; COLORECTAL-CANCER; BREAST-CANCER; GENETIC PATHWAYS; FOCAL ADHESIONS; CSK; EXPRESSION; FAMILY; BRAIN	Src activation has been associated with colon cancers but the mechanism underlying Src activation is largely unknown. Csk-homologous kinase (CHK) can inhibit the kinase activity of certain Src kinase family members in vitro by phosphorylating the C-terminal tyrosine and by a non-catalytic mechanism. CHK was previously reported to be expressed primarily in brain and hematopoietic cells. We report herein that CHK is also expressed in normal colon cell lines. Furthermore, CHK protein levels are significantly decreased in various colon cancer cell lines and the decrease correlates with the increased specific activity of Src in these cell lines, while the level of the other Src inhibitory kinase, C-terminal Src kinase, is not significantly changed. CHK is also expressed in normal colon tissues but its expression level is decreased in colon cancer tissues collected from the same patients. Immuno- fluorescence microscopy shows that CHK colocalizes with Src in normal colon FHC cells. Overexpression of CHK in colon cancer cells results in inactivation of Src without phosphorylating Y530 at its C-terminus. In addition, CHK suppresses anchorage-independent cell growth and cell invasion of colon cancer cells. These results reveal a potentially important role for CHK in Src activation and tumorigenicity in colon cancer cells.	[Zhu, S.; Bjorge, J. D.; Fujita, D. J.] Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; [Zhu, S.; Bjorge, J. D.; Fujita, D. J.] Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; [Cheng, H. C.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Parkville, Vic 3052, Australia	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Melbourne	Fujita, DJ (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	dfujita@ucalgary.ca	Zhu, Shudong/A-1741-2011	Cheng, Heung-Chin/0000-0002-4965-7148				AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Chong YP, 2004, J BIOL CHEM, V279, P20752, DOI 10.1074/jbc.M309865200; Chong YP, 2006, J BIOL CHEM, V281, P32988, DOI 10.1074/jbc.M602951200; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; ERSHLER MA, 1995, FEBS LETT, V375, P50, DOI 10.1016/0014-5793(95)01154-7; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Hirao A, 1998, J BIOL CHEM, V273, P10004, DOI 10.1074/jbc.273.16.10004; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Isozumi T, 1997, ACTA NEUROPATHOL, V93, P438, DOI 10.1007/s004010050637; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kim S, 2002, J BIOL CHEM, V277, P36465, DOI 10.1074/jbc.M206018200; Kim SO, 2004, CANCER-AM CANCER SOC, V101, P1018, DOI 10.1002/cncr.20442; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KRUEGER JG, 1980, P NATL ACAD SCI-BIOL, V77, P4142, DOI 10.1073/pnas.77.7.4142; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; Levin Victor A, 2004, Cancer Treat Res, V119, P89; Nakayama Y, 2005, EXP CELL RES, V304, P570, DOI 10.1016/j.yexcr.2004.11.027; SAKANO S, 1994, ONCOGENE, V9, P1155; Samokhvalov I, 1997, BIOCHEM MOL BIOL INT, V43, P115; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Trubert CL, 1997, EUR J HISTOCHEM, V41, P169; WATANABE N, 1995, JPN J CLIN ONCOL, V25, P5; Yamaguchi N, 2001, J CELL SCI, V114, P1631; ZHU S, 2007, IN PRESS CANC RES, V67; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	41	13	15	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2027	2034		10.1038/sj.onc.1210838	http://dx.doi.org/10.1038/sj.onc.1210838			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17934522				2022-12-17	WOS:000254359100007
J	Banerjee, S; Brooks, WS; Crawford, DF				Banerjee, S.; Brooks, W. S.; Crawford, D. F.			Inactivation of the ubiquitin conjugating enzyme UBE2Q2 causes a prophase arrest and enhanced apoptosis in response to microtubule inhibiting agents	ONCOGENE			English	Article						UBE2Q2; checkpoint; mitosis; microtubule; inhibiting agents (MIAs); apoptosis; antephase	MITOTIC STRESS CHECKPOINT; CELL-CYCLE; KAPPA-B; SPINDLE CHECKPOINT; CHFR; DELAYS; DEGRADATION; EXPRESSION; METAPHASE; GENE	A putative ubiquitin conjugating enzyme known as UBE2Q2 was previously identified in a microarray screen for mitotic regulatory proteins. UBE2Q2 is very similar to another human protein, UBE2Q1 and orthologs from other higher eukaryotic species. In these studies, we demonstrate that UBE2Q2 can covalently bind ubiquitin on the active site cysteine in vitro and show that inhibition of this protein in vivo causes an early mitotic arrest and increased cytotoxicity when cells are treated with microtubule inhibiting agents (MIAs). Changes in cell cycle progression and viability are not observed in the absence of MIA treatment, indicating that UBE2Q2 is involved in the response to MIAs rather than performing a more general function in mitosis. Inhibition of the UBE2Q2 protein causes cells to undergo a prolonged prophase arrest suggesting that UBE2Q2 normally functions to antagonize an early mitotic checkpoint. Furthermore, UBE2Q2 inhibition sensitizes cells to the cytotoxic effects of MIAs through caspase-mediated apoptosis that is correlated with PARP-1 cleavage. These data provide insights into the cellular response to MIAs and demonstrate that inhibition of UBE2Q2 protein function may be useful in the treatment of malignancies.	Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Crawford, DF (corresponding author), Univ Alabama, Dept Pediat & Cell Biol, 1600 7th Ave S,ACC 512, Birmingham, AL 35233 USA.	dfc@uab.edu			NCI NIH HHS [5K08CA86941-5] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA086941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Baker DJ, 2005, CURR OPIN CELL BIOL, V17, P583, DOI 10.1016/j.ceb.2005.09.011; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; CHEN C, 1987, MOL CELL BIOL, V7, P27; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; Gu HD, 2003, P NATL ACAD SCI USA, V100, P8963, DOI 10.1073/pnas.1533420100; Huang Y, 2004, MOL CANCER THER, V3, P271; Koh DW, 2005, PHARMACOL RES, V52, P5, DOI 10.1016/j.phrs.2005.02.011; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Liu Q, 2006, INVEST OPHTH VIS SCI, V47, P1302, DOI 10.1167/iovs.05-0935; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; Melner MH, 2004, BIOL REPROD, V70, P406, DOI 10.1095/biolreprod.103.020719; Melner MH, 2006, BIOL REPROD, V75, P395, DOI 10.1095/biolreprod.106.051458; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Pallardy M, 1999, METHODS, V19, P36, DOI 10.1006/meth.1999.0825; Pati D, 1999, MOL CELL BIOL, V19, P5001; PINKERTON CR, 1988, CANCER CHEMOTH PHARM, V22, P271, DOI 10.1007/BF00273423; Pray TR, 2002, DRUG RESIST UPDATE, V5, P249, DOI 10.1016/S1368-7646(02)00121-8; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Schulze E, 2003, BIOCHEM BIOPH RES CO, V305, P691, DOI 10.1016/S0006-291X(03)00824-6; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Seghatoleslam A, 2006, BIOCHEM BIOPH RES CO, V339, P422, DOI 10.1016/j.bbrc.2005.11.026; Skerra A, 1999, BIOMOL ENG, V16, P79, DOI 10.1016/S1050-3862(99)00033-9; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; WEISSMAN AM, 2001, NAT REV MOL CELL BIO, V21, P3445; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	40	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6509	6517		10.1038/sj.onc.1210471	http://dx.doi.org/10.1038/sj.onc.1210471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471241				2022-12-17	WOS:000249919800004
J	Johnson, C; Marriott, SJ; Levy, LS				Johnson, C.; Marriott, S. J.; Levy, L. S.			Overexpression of p101 activates PI3K gamma signaling in T cells and contributes to cell survival	ONCOGENE			English	Article						phosphatidylinositol-3-kinase-gamma; retrovirus integration site; lymphoma; apoptosis	G-BETA-GAMMA; PHOSPHOINOSITIDE 3-KINASE; REGULATORY SUBUNIT; FREQUENT INACTIVATION; CANCER; PIK3CA; P110-GAMMA; P110-DELTA; EXPRESSION; MUTATIONS	p101, the regulatory subunit of phosphatidylinositol--3-kinase- gamma (PI3KC gamma), was recently reported as a common site of retroviral insertion in T-cell lymphomas induced in mice by MoFe2-MuLV, a unique recombinant gammaretrovirus. The common interruption of p101 by retroviral integration suggests that the locus encodes an oncogene whose altered expression is related to the induction of T-cell malignancy. To examine a possible role in the malignant process, p101 was overexpressed in human T-cell lines Molt-4 and Jurkat. Transient overexpression of p101 induced apoptosis in recipient cells; however, stable expression could be established in cells that expressed moderate levels of p101. Constitutive p101 overexpression in those cells conferred significant protection against ultraviolet-induced apoptosis. Protection against apoptotic induction was attributed to p101-mediated activation of the Akt pathway. Constitutive overexpression of p101 enhanced the activity of p110 gamma and further sensitized it to activation upon stimulation of G protein-coupled receptor. These findings are the first to implicate altered expression of p101 in malignancy, specifically in T-cell lymphoma. The findings further provide insight into the regulation of p110 gamma, indicating that the stoichiometry of p110 gamma and p101 are important in regulating PI3K gamma signaling.	Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Tualne Canc Ctr, New Orleans, LA 70112 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Interdepartmental Program Cell & Mol Biol, Houston, TX 77030 USA	Tulane University; Tulane University; Baylor College of Medicine; Baylor College of Medicine	Levy, LS (corresponding author), Tulane Univ, Sch Med, Dept Microbiol & Immunol, 1430 Tulane Ave SL-38, New Orleans, LA 70112 USA.	llevy@tulane.edu			NATIONAL CANCER INSTITUTE [R01CA083823] Funding Source: NIH RePORTER; NCI NIH HHS [CA83823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbdelMageed AB, 1997, CANCER GENE THER, V4, P199; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cairns P, 1997, CANCER RES, V57, P4997; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hickey FB, 2006, J BIOL CHEM, V281, P2441, DOI 10.1074/jbc.M511173200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Johnson C, 2005, J VIROL, V79, P57, DOI 10.1128/JVI.79.1.57-66.2005; Jucker M, 2002, LEUKEMIA, V16, P894, DOI 10.1038/sj.leu.2402484; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Voigt P, 2006, J BIOL CHEM, V281, P9977, DOI 10.1074/jbc.M512502200; Voigt P, 2005, J BIOL CHEM, V280, P5121, DOI 10.1074/jbc.M413104200; Woenckhaus J, 2002, J PATHOL, V198, P335, DOI 10.1002/path.1207	31	13	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7049	7057		10.1038/sj.onc.1210504	http://dx.doi.org/10.1038/sj.onc.1210504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486067	Bronze			2022-12-17	WOS:000250412200010
J	Clarke, AR; Jones, N; Pryde, F; Adachi, Y; Sansom, OJ				Clarke, A. R.; Jones, N.; Pryde, F.; Adachi, Y.; Sansom, O. J.			53BP1 deficiency in intestinal enterocytes does not alter the immediate response to ionizing radiation, but leads to increased nuclear area consistent with polyploidy	ONCOGENE			English	Article						polyploidy; 53BP1; mice; apoptosis; DNA damage; p53	DNA-DAMAGE CHECKPOINT; TUMOR-SUPPRESSOR; GENOMIC INSTABILITY; GAMMA-IRRADIATION; PROTEIN 53BP1; P53; ACTIVATION; APOPTOSIS; MICE; TUMORIGENESIS	The p53-binding protein 53BP1 has been implicated in the DNA damage response and genomic instability. Previous reports have highlighted these roles in vivo in haematopoietic lineages. To investigate the importance of 53BP1 to the DNA damage response in epithelial cells in vivo, we have investigated the role of 53BP1 in mediating apoptosis and proliferation within the murine small intestine following gamma-irradiation. 53BP1 deficiency does not affect the immediate response to gamma-irradiation with normal levels of apoptosis, proliferation and p53 and p21 accumulation. However, 48 h post-gamma-irradiation there was a significant accumulation of cells with much larger nuclei marked by p53 and p21 accumulation. These data reflect increases in polyploidy observed 53BP1 -/- deficient fibroblasts following gamma-irradiation. At 72 h post-irradiation both the 4N and 8N populations were significantly increased in 53BP1 -/- MEFS. Taken together, these results show that following in vivo exposure to gamma-irradiation, 53BP1 is dispensable for signalling apoptosis and cell-cycle arrest in the intestinal epithelium. However, it is important for prevention of genomic instability within this epithelial cell population.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland; Univ Cardiff Wales, Cardiff Sch Biosci, Inst Cell Biol, Cardiff, Wales	Beatson Institute; University of Edinburgh; Cardiff University	Sansom, OJ (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Sansom, Owen J./0000-0001-9540-3010; Adachi, Yasuhisa/0000-0003-4197-092X; Clarke, Alan/0000-0002-4281-426X	MRC [G0301154] Funding Source: UKRI; Medical Research Council [G0301154] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Finke D, 2001, CURR OPIN GENET DEV, V11, P561, DOI 10.1016/S0959-437X(00)00233-1; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Marshman E, 2001, J PATHOL, V195, P285; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Motohashi Y, 2004, NUTR METAB CARDIOVAS, V14, P6, DOI 10.1016/S0939-4753(04)80041-3; Pryde F, 2005, J CELL SCI, V118, P2043, DOI 10.1242/jcs.02336; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Senger P, 2004, PROG PART NUCL PHYS, V53, P1, DOI 10.1016/j.ppnp.2004.02.005; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shigeta T, 1999, CANCER RES, V59, P2602; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Ward IM, 2005, MOL CELL BIOL, V25, P10079, DOI 10.1128/MCB.25.22.10079-10086.2005; Ward IM, 2004, J CELL BIOL, V165, P459, DOI 10.1083/jcb.200403021	32	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6349	6355		10.1038/sj.onc.1210457	http://dx.doi.org/10.1038/sj.onc.1210457			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452983				2022-12-17	WOS:000249583300011
J	Mazzieri, R; Furlan, F; D'Alessio, S; Zonari, E; Talotta, F; Verde, P; Blasi, F				Mazzieri, R.; Furlan, F.; D'Alessio, S.; Zonari, E.; Talotta, F.; Verde, P.; Blasi, F.			A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts	ONCOGENE			English	Article						urokinase receptor; cell proliferation; Ras; E1A; Ink4a	CELL-SURFACE RECEPTOR; TUMOR-GROWTH; CANCER; PROLIFERATION; METASTASIS; INHIBITION; INVASION; AP-1; ANTAGONISTS; CARCINOMA	In addition to its role in invasion and metastasis of several tumors, the multifunctional urokinase receptor uPAR ( urokinase plasminogen activator receptor) is directly involved in the growth of several cancer cells in vitro and in vivo. We have compared growth rate and oncogenic transformation in wild-type (wt) or uPAR(-/-) mouse embryonic fibroblasts (MEFs). Surprisingly, uPAR(-/-) MEFs grew faster than wt MEFs. This agreed with elevated levels of cell cycle mediators like extracellular signal-regulated protein kinase, p38, AP1 and Cyclin D1. Infection with a uPAR retrovirus reverted the effect, decreasing the growth rate. When MEFs were transformed with H-Ras(V12) and E1A oncogenes, the efficiency of transformation in uPAR(-/-) MEFs was higher than in wt. UPAR(-/-) MEFs grew faster at low serum, produced more colonies in agar and produced tumors in vivo in nude mice with a lower latency period. The properties of the heterozygous uPAR(-/-) MEFs were always intermediate. We conclude therefore that in MEFs uPAR concentration controls cell proliferation and the transforming activity of some oncogenes.	IFOM, FIRC, Inst Mol Oncol, Washington, DC 20016 USA; Univ Vita Salute San Raffaele, Dept Mol Biol & Funct Gen, Milan, Italy	Vita-Salute San Raffaele University	Blasi, F (corresponding author), IFOM, FIRC, Inst Mol Oncol, Via Adamello 16, Washington, DC 20016 USA.	francesco.blasi@ifom-ieo-campus.it	Mazzieri, Roberta/C-9773-2015; Zonari, Erika/K-9638-2016; Danese, Silvio/ABH-9571-2020	Mazzieri, Roberta/0000-0002-5172-0927; Zonari, Erika/0000-0002-7915-3995; Danese, Silvio/0000-0001-7341-1351; Blasi, Francesco/0000-0001-9406-1784				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Lakka SS, 2001, CLIN CANCER RES, V7, P1087; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mazzieri R, 2006, MOL BIOL CELL, V17, P367, DOI 10.1091/mbc.E05-07-0635; Mazzieri R, 2005, THROMB HAEMOSTASIS, V93, P641, DOI 10.1160/TH05-01-0021; Min HY, 1996, CANCER RES, V56, P2428; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; Reuning U, 1998, INT J ONCOL, V13, P893; Selleri C, 2005, BLOOD, V105, P2198, DOI 10.1182/blood-2004-06-2424; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9	38	13	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					725	732		10.1038/sj.onc.1209833	http://dx.doi.org/10.1038/sj.onc.1209833			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878153				2022-12-17	WOS:000243902200009
J	Martinelli, S; Kostylina, G; Niggli, V; Baumann, C; Fey, MF; Wendel, HG; Lowe, SW; Yousefi, S; Simon, HU				Martinelli, S.; Kostylina, G.; Niggli, V.; Baumann, C.; Fey, M. F.; Wendel, H-G; Lowe, S. W.; Yousefi, S.; Simon, H-U			Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils	ONCOGENE			English	Article						apoptosis; cancer; chemotherapy; myelosuppression; neutrophils; survivin	CANCER-CELLS; INDUCED APOPTOSIS; ACTIVATION; PATHWAY; GENE; AKT; TRANSCRIPTION; INHIBITION; CYCLE; DEATH	Myelosuppression is the most common unwanted side effect associated with the administration of anticancer drugs, and infections remain a common cause of death in chemotherapy-treated patients. Several mechanisms of the cytotoxicity of these drugs have been proposed and may synergistically operate in a given cell. Survivin expression has been associated with cancer, but recent reports suggest that this molecule is also expressed in several immature and mature hematopoietic cells. Here, we provide evidence that treatment of immature neutrophils with anticancer drugs reduced endogenous survivin levels causing apoptosis. The anticancer drugs did not directly target survivin, instead they blocked the activity of phosphatidylinositol-3-OH kinase, which regulated survivin expression and apoptosis in these cells. Strikingly, and in contrast to other cells, this pathway did not involve the serine/threonine kinase c-akt/PKB. Moreover, in combination with anticancer drug therapy, rapamycin did not induce increased myelosuppression in an experimental lymphoma mouse model. These data suggest that drugs that block either c-akt/PKB or signaling molecules located distal to c-akt/PKB may preferentially induce apoptosis of cancer cells as they exhibit no cytotoxicity for immature neutrophils.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Bern, Dept Pathol, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Inst Med Oncol, CH-3010 Bern, Switzerland; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of Bern; University of Bern; University of Bern; University Hospital of Bern; Cold Spring Harbor Laboratory	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Yousefi, Shida/L-9689-2016; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-5079-2020; Simon, Hans-Uwe/AAU-7410-2020	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736				Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Belyanskaya LL, 2005, INT J CANCER, V117, P755, DOI 10.1002/ijc.21242; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Bruno A, 2005, J IMMUNOL, V174, P8090, DOI 10.4049/jimmunol.174.12.8090; BURERING BM, 1995, NATURE, V376, P599; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Conus S, 2005, J ALLERGY CLIN IMMUN, V116, P1228, DOI 10.1016/j.jaci.2005.09.003; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dale D, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00326-9; Daly C, 2004, GENE DEV, V18, P1060, DOI 10.1101/gad.1189704; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fukuda S, 2004, BLOOD, V103, P120, DOI 10.1182/blood-2003-05-1756; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Herr I, 2000, ONCOGENE, V19, P4255, DOI 10.1038/sj.onc.1203776; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Martinelli S, 2004, J BIOL CHEM, V279, P44123, DOI 10.1074/jbc.M405883200; McCormick F, 2004, NATURE, V428, P267, DOI 10.1038/428267a; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Murphy BM, 2003, J EXP MED, V197, P625, DOI 10.1084/jem.20021862; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scheel-Toellner D, 2002, EUR J IMMUNOL, V32, P486, DOI 10.1002/1521-4141(200202)32:2<486::AID-IMMU486>3.0.CO;2-U; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Straka C, 2004, BLOOD, V104, P1989, DOI 10.1182/blood-2004-02-0628; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Uruno A, 2005, CIRCULATION, V112, P727, DOI 10.1161/CIRCULATIONAHA.104.500959; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wang Shulin, 2004, Cancer Treat Res, V119, P175; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zangemeister-Wittke U, 2004, CELL CYCLE, V3, P1121	48	13	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6915	6923		10.1038/sj.onc.1209692	http://dx.doi.org/10.1038/sj.onc.1209692			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715127				2022-12-17	WOS:000241732300002
J	Scatton, O; Chiappini, F; Riou, P; Marconi, A; Saffroy, R; Bralet, MP; Azoulay, D; Boucheix, C; Debuire, B; Uzan, G; Lemoine, A				Scatton, O.; Chiappini, F.; Riou, P.; Marconi, A.; Saffroy, R.; Bralet, M. -P.; Azoulay, D.; Boucheix, C.; Debuire, B.; Uzan, G.; Lemoine, A.			Fate and characterization of circulating tumor cells in a NOD/SCID mouse model of human hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; liver cancer; circulating cells; metastasis; mouse model	FETOPROTEIN MESSENGER-RNA; BONE-MARROW-CELLS; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; HEMATOGENOUS DISSEMINATION; MOLECULAR SIGNATURE; COLORECTAL-CANCER; LIVER RESECTION; GASTRIC-CANCER; LUNG-CANCER	There is much debate about the way in which epithelial tumors metastasize. It has been proposed that the bone marrow (BM) acts as a tumor cell reservoir. We injected human hepatocellular carcinoma (HCC) cells (Mahlavu cell line) into the livers, circulation or BM of NOD/SCID mice and circulating tumor cells were quantified. When injected under the Glisson capsule, a primary tumor developed and continuously yielded circulating tumor cells. Liver tumor removal led to a very low level of Mahlavu cells both in blood and BM 30 days later. When Mahlavu cells (cultured or from BM of primary mice femurs) were intravenously injected into mice, the number of cells in the bloodstream (BS) steadily decreased, whereas the BM was not significantly colonized. When Mahlavu cells were directly injected into one femur, the controlateral femur was not colonized. Microscopic analysis and a sensitive PCR assay (< 1 Mahlavu cell/nuclear cells) both failed to detect human tumor cells in other organs regardless of injection route. In conclusion, our model strongly supports the hypothesis that HCCs continuously release cells into the BS. However, in sharp contrast with the current hypothesis, the BM is not specifically colonized by tumor cells but could store them at a very low level.	Hop Univ Paul Brousse, INSERM, U602, Serv Biochim & Biol Mol,Assistance Publ Hop Paris, F-94804 Villejuif, France; Hop Univ Paul Brousse, Ctr Hepatobiliaire, EA 35 41, Assistance Publ Hop Paris, F-94804 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Lemoine, A (corresponding author), Hop Univ Paul Brousse, INSERM, U602, Serv Biochim & Biol Mol,Assistance Publ Hop Paris, 14 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.	antoinette.lemoine@pbr.ap-hop-paris.fr	Chiappini, Franck/AAB-9894-2021; Uzan, Georges/M-8199-2018; Azoulay, Daniel/Q-7887-2018	Uzan, Georges/0000-0002-0178-5386; Boucheix, Claude/0000-0003-4184-7008; SAFFROY, RAPHAEL/0000-0002-9878-3669				Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Braun S, 2001, J CLIN ONCOL, V19, P368, DOI 10.1200/JCO.2001.19.2.368; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chiappini F, 2004, LAB INVEST, V84, P908, DOI 10.1038/labinvest.3700113; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; DIOGUARDI N, 1992, J HEPATOL, V14, P401; Esumi T, 2003, TRANSPLANTATION, V76, P1543, DOI 10.1097/01.TP.0000081945.23698.5D; Fukutomi M, 2001, EUR J GASTROEN HEPAT, V13, P1083, DOI 10.1097/00042737-200109000-00015; Gerber B, 2001, J CLIN ONCOL, V19, P960, DOI 10.1200/JCO.2001.19.4.960; Goodison S, 2003, CLIN CANCER RES, V9, P3808; Greene AK, 2003, J INVEST SURG, V16, P99, DOI 10.1080/08941930390194424; Gross-Goupil M, 2003, ANN SURG, V238, P241, DOI 10.1097/01.sla.0000080959.95226.be; Guller U, 2002, ANN SURG, V236, P768, DOI 10.1097/00000658-200212000-00009; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Ishikawa H, 2004, GUT, V53, P884, DOI 10.1136/gut.2003.026047; Kienle P, 2000, ARCH SURG-CHICAGO, V135, P213, DOI 10.1001/archsurg.135.2.213; Kushida T, 2001, BLOOD, V97, P3292, DOI 10.1182/blood.V97.10.3292; Lemoine A, 1997, ANN SURG, V226, P43, DOI 10.1097/00000658-199707000-00006; Li QG, 2004, WORLD J GASTROENTERO, V10, P903; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Liu Yang, 2003, Hepatobiliary Pancreat Dis Int, V2, P414; Louha M, 1999, HEPATOLOGY, V29, P879, DOI 10.1002/hep.510290348; Majno PE, 1997, ANN SURG, V226, P688, DOI 10.1097/00000658-199712000-00006; Marx J, 2004, SCIENCE, V306, P1455; MATSUMURA M, 1994, HEPATOLOGY, V20, P1418, DOI 10.1002/hep.1840200607; Minata M, 2001, J GASTROEN HEPATOL, V16, P445, DOI 10.1046/j.1440-1746.2001.02461.x; Osaki T, 2002, J CLIN ONCOL, V20, P2930, DOI 10.1200/JCO.2002.11.011; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; Poon RTP, 2002, ANN SURG, V235, P373, DOI 10.1097/00000658-200203000-00009; Qin LX, 2002, WORLD J GASTROENTERO, V8, P193; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Sell S, 2002, SEMIN CELL DEV BIOL, V13, P419, DOI 10.1016/S1084952102001295; Soeth E, 1997, CANCER RES, V57, P3106; Solakoglu O, 2002, P NATL ACAD SCI USA, V99, P2246, DOI 10.1073/pnas.042372199; Tsavellas G, 2001, BRIT J SURG, V88, P1307, DOI 10.1046/j.0007-1323.2001.01863.x; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Woelfle U, 2003, CANCER RES, V63, P5679	44	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4067	4075		10.1038/sj.onc.1209430	http://dx.doi.org/10.1038/sj.onc.1209430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491122				2022-12-17	WOS:000238802400007
J	Chung, J; Roberts, AM; Chow, J; Coady-Osberg, N; Ohh, M				Chung, J.; Roberts, A. M.; Chow, J.; Coady-Osberg, N.; Ohh, M.			Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway	ONCOGENE			English	Article						VHL; ECV; e3; HIF; homotypic association	HIPPEL-LINDAU PROTEIN; SUPPRESSOR PROTEIN; GERMLINE DELETION; COMPLEX; MUTATIONS; HYDROXYLATION; CORRELATE; DISEASE; BINDING; LIGASE	The von Hippel-Lindau (VHL) tumour suppressor gene encodes a substrate-specifying component of an E3 ubiquitin ligase that targets hypoxia-inducible factor (HIF) alpha subunits for degradation under normoxia. The VHL protein is composed of an N-terminal HIF alpha-binding ss domain and a C-terminal alpha domain, which is necessary and sufficient for the formation of the E3 multiprotein enzyme. A large number of disease-causing mutations in either the alpha or ss domain renders HIF alpha stable irrespective of oxygen tension, leading to the upregulation of numerous HIF-target genes, such as GLUT1 and VEGF. Here, we show that VHL forms a self-associated complex in vivo, but not in vitro, and demonstrate that coexpression of two different VHL missense mutants - one in the a domain and the other in the ss domain - restores HIF-mediated gene expression profile. These findings indicate that VHL homotypic complexes can function in vivo in a complementary fashion to target HIF alpha for ubiquitinmediated proteolysis, and potentially explain why VHL-associated tumours witha missense mutation-carrying VHL allele is almost invariably accompanied by a second VHL allele harbouring a gross truncation or deletion.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med Genet, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Ohh, M (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Med Sci Bldg,Room 6303,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca						Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Bradley JF, 1999, AM J MED GENET, V87, P163, DOI 10.1002/(SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO;2-A; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KONDO K, 2002, CANCER CELL, V1, P211; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Vortmeyer A, 2002, ONCOGENE, V21, P1167, DOI 10.1038/sj.onc.1205121; Wait SD, 2004, ANN NEUROL, V55, P236, DOI 10.1002/ana.10807	17	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3079	3083		10.1038/sj.onc.1209328	http://dx.doi.org/10.1038/sj.onc.1209328			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407835	Bronze			2022-12-17	WOS:000237950800013
J	Basrawala, Z; Alimirah, F; Xin, H; Mohideen, N; Campbell, SC; Flanigan, RC; Choubey, D				Basrawala, Z; Alimirah, F; Xin, H; Mohideen, N; Campbell, SC; Flanigan, RC; Choubey, D			Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells	ONCOGENE			English	Article						prostate; androgen receptor; interferons; stromal cells	CANCER-CELLS; CELLULAR SENESCENCE; IN-VITRO; EXPRESSION; PROGRESSION; MECHANISMS; INDUCTION; DISEASE; IFI-16; GENES	Proliferation of normal and malignant prostate epithelium is regulated by androgen stimulation via both the androgen receptor (AR)-positive stromal and epithelial cells. However, it is not known how AR expression is regulated in human prostate cells. We report that treatment of normal human prostate stromal cells (PrSCs) with type I IFN ( alpha or beta), but not type II IFN ( gamma), resulted in increased levels of AR protein. The maximal increase in AR protein levels was dependent on the dose and the duration of the IFN-alpha treatment. We found that the increase in AR protein levels was independent of de novo transcription and protein synthesis. Interestingly, the IFN-alpha treatment of PrSCs resulted in considerable nuclear accumulation of AR, stimulation of AR-mediated transcription of reporter genes, and retardation of cell proliferation. Furthermore, treatment of normal human prostate epithelial cells with IFNs ( alpha, beta or gamma) also resulted in increased levels of AR protein. Together, our observations identify the androgen receptor as an IFN-regulated protein in normal human prostate stromal and epithelial cells and predict that IFN-induced levels of AR in prostate cells contribute to the regulation of androgen signaling.	Loyola Univ Chicago, Edward Hines Jr VA Hosp, Hines, IL 60141 USA; Loyola Univ Chicago, Dept Radiat Oncol, Hines, IL USA; Loyola Univ Chicago, Dept Urol, Hines, IL USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; Loyola University Chicago	Choubey, D (corresponding author), Loyola Univ Chicago, Edward Hines Jr VA Hosp, 5th Ave,Roosevelt Rd,Bldg 1,MC 114B, Hines, IL 60141 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008					Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Agoulnik IU, 2003, J BIOL CHEM, V278, P31136, DOI 10.1074/jbc.M305153200; Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Caraglia M, 2005, J CELL PHYSIOL, V202, P323, DOI 10.1002/jcp.20137; CHANG C, 1989, J STEROID BIOCHEM, V34, P311; Chlenski A, 2001, PROSTATE, V47, P66; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Condon MS, 1999, IN VIVO, V13, P61; Garraway LA, 2003, PROSTATE, V55, P206, DOI 10.1002/pros.10244; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Henshall SM, 2001, CANCER RES, V61, P423; Janssen M, 2000, PROSTATE, V43, P20, DOI 10.1002/(SICI)1097-0045(20000401)43:1<20::AID-PROS4>3.0.CO;2-6; Kominsky SL, 2000, CANCER RES, V60, P3904; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Litvinov IV, 2004, PROSTATE, V61, P299, DOI 10.1002/pros.20187; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nelson William G, 2004, J Urol, V172, pS6, DOI 10.1097/01.ju.0000142058.99614.ff; Olapade-Alaopa EO, 1999, CLIN CANCER RES, V5, P569; Ricciardelli C, 2005, PROSTATE, V63, P19, DOI 10.1002/pros.20154; ROY AK, 1995, CRIT REV EUKAR GENE, V5, P157, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.30; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; SICA G, 1994, UROL RES, V22, P33, DOI 10.1007/BF00431546; Smyth MJ, 2004, IMMUNOL REV, V202, P275, DOI 10.1111/j.0105-2896.2004.00199.x; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Untergasser G, 2002, CANCER RES, V62, P6255; Xin H, 2004, ONCOGENE, V23, P6209, DOI 10.1038/sj.onc.1207836; Xin H, 2003, ONCOGENE, V22, P4831, DOI 10.1038/sj.onc.1206754; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	32	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2812	2817		10.1038/sj.onc.1209304	http://dx.doi.org/10.1038/sj.onc.1209304			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16331249				2022-12-17	WOS:000237272900013
J	Gartel, AL				Gartel, AL			A new mode of transcriptional repression by c-myc: methylation	ONCOGENE			English	Editorial Material							GROWTH ARREST; DNA; METHYLTRANSFERASES; RECRUITMENT; ASSOCIATION; MECHANISMS; EXPRESSION; MIZ-1; GENES		Univ Illinois, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, Chicago, IL 60612 USA.	agartel@uic.edu						Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Vaque JP, 2005, J BIOL CHEM, V280, P1112, DOI 10.1074/jbc.M409503200; Ziegelbauer J, 2004, P NATL ACAD SCI USA, V101, P458, DOI 10.1073/pnas.0307562100	14	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	14					1989	1990		10.1038/sj.onc.1209101	http://dx.doi.org/10.1038/sj.onc.1209101			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16170342				2022-12-17	WOS:000236359700001
J	Russell, JL; Weaks, RL; Berton, TR; Johnson, DG				Russell, JL; Weaks, RL; Berton, TR; Johnson, DG			E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway	ONCOGENE			English	Article						E2F; p53; p21; p19ARF	TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; TUMOR-SUPPRESSOR; DNA-DAMAGE; MOUSE SKIN; P53-DEPENDENT APOPTOSIS; E2F-1-INDUCED APOPTOSIS; P53-MEDIATED APOPTOSIS; DEREGULATED EXPRESSION; TRANSGENIC MODEL	The E2F1 transcription factor, which is deregulated in most human cancers by mutations in the p16-cyclin D-Rb pathway, has both oncogenic and tumor-suppressive properties. This is dramatically illustrated by the phenotype of an E2F1 transgenic mouse model that spontaneously develops tumors in the skin and other epithelial tissues but is resistant to papilloma formation when subjected to a two-stage carcinogenesis protocol. Here, this E2F1 transgenic model was used to further explore the tumor-suppressive property of E2F1. Transgenic expression of E2F1 was found to inhibit ras-driven skin carcinogenesis at the promotion stage independent of the type of promoting agent used. E2F1 transgenic epidermis displayed increased expression of p19(ARF), p53, and p21(Cip1). Inactivation of either p53 or Arf in E2F1 transgenic mice restored sensitivity to two-stage skin carcinogenesis. While Arf inactivation impaired tumor suppression and p21 induction by E2F1, it did not reduce the level of apoptosis observed in E2F1 transgenic mice. Based on these findings, we propose that E2F1 suppresses ras-driven skin carcinogenesis through a nonapoptotic mechanism involving ARF and p53.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.	djohnson@mdanderson.org		Johnson, David/0000-0002-6223-1790	NCI NIH HHS [CA 09480, CA 79648, CA 16672] Funding Source: Medline; NIEHS NIH HHS [ES 07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079648, T32CA009480, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; FISCHER SM, 1987, CARCINOGENESIS, V8, P421, DOI 10.1093/carcin/8.3.421; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lin WC, 2001, GENE DEV, V15, P1833; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mitchell DL, 1999, CANCER RES, V59, P2875; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Powers JT, 2004, MOL CANCER RES, V2, P203; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Rounbehler RJ, 2001, ONCOGENE, V20, P5341, DOI 10.1038/sj.onc.1204691; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CANCER RES, V60, P3689; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vorburger SA, 2002, ONCOGENE, V21, P6278, DOI 10.1038/sj.onc.1205761; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wang DW, 2001, MOL CARCINOGEN, V31, P90, DOI 10.1002/mc.1044; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					867	876		10.1038/sj.onc.1209120	http://dx.doi.org/10.1038/sj.onc.1209120			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16205640				2022-12-17	WOS:000235212700006
J	Roberts, A; Mishra, L				Roberts, A; Mishra, L			Role of TGF-beta in stem cells and cancer	ONCOGENE			English	Editorial Material									Georgetown Univ, Washington, DC 20007 USA; DVAMC, Washington, DC 20007 USA; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Georgetown Univ, Lab GI Dev Biol, Dept Surg, Washington, DC USA; Georgetown Univ, Lombardi Canc Ctr, Washington, DC USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University; Georgetown University	Mishra, L (corresponding author), Georgetown Univ, Med Dent Bldg,NW 210-12 3900 Reservoir Rd,NW, Washington, DC 20007 USA.	Lopamishra@yahoo.com							0	13	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5667	5667		10.1038/sj.onc.1208915	http://dx.doi.org/10.1038/sj.onc.1208915			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ					2022-12-17	WOS:000231452800001
J	Suzuki, J; Sukezane, T; Akagi, T; Georgescu, MM; Ohtani, M; Inoue, H; Jat, PS; Goff, SP; Hanafusa, H; Shishido, T				Suzuki, J; Sukezane, T; Akagi, T; Georgescu, MM; Ohtani, M; Inoue, H; Jat, PS; Goff, SP; Hanafusa, H; Shishido, T			Loss of c-abl facilitates anchorage-independent growth of p53- and RB-deficient primary mouse embryonic fibroblasts	ONCOGENE			English	Article						anchorage-independent growth; SV40 T antigen; c-Abl; p53; RB	CHRONIC MYELOGENOUS LEUKEMIA; LARGE TUMOR-ANTIGEN; T-ANTIGEN; TYROSINE KINASE; CELL-TRANSFORMATION; PHOSPHORYLATION; METHYLATION; MICE; P53; SUPPRESSOR	The c-abl tyrosine kinase is the proto-oncogene of the v-abl oncogene of the Abelson murine leukemia virus. Although mutational variants of c-Abl can exhibit gain of function and can produce a transformed phenotype, the function of c-Abl in transformation remained unclear. Here, we report that the loss of c-abl facilitates transformation. c-abl-knockout mouse embryonic fibroblasts (MEFs) immortalized by SV40 T antigen acquired anchorage-independent growth, and by constructing mutational variants of T antigen we showed that binding of large T antigen to p53 and RB was necessary to induce anchorage-independent growth. Although c-abl/p53 double-knockout MEFs did not undergo anchorage-independent growth, those expressing human papilloma virus 16 E7, which mainly inactivates RB, did. Our results show that the loss of c-abl facilitates anchorage-independent growth in the context of p53 and RB deficiency, and suggest that loss of function of c-abl facilitates some types of transformation.	Nara Inst Sci & Technol, Oncol Mol Lab, Nara 6300101, Japan; Osaka Biosci Inst, Oncol Mol Lab, Osaka 5650874, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Shiga Univ Med Sci, Sch Med, Dept Microbiol, Shiga 5202192, Japan; Ludwig Inst Canc Res, London W1W 7BS, England; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Nara Institute of Science & Technology; Osaka University; University of Texas System; UTMD Anderson Cancer Center; Shiga University of Medical Science; Ludwig Institute for Cancer Research; Columbia University	Shishido, T (corresponding author), Nara Inst Sci & Technol, Oncol Mol Lab, 8916-5 Takayama, Nara 6300101, Japan.	shishid@bs.naist.jp	Georgescu, Maria-Magdalena/AAJ-6359-2020; Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547; Shishido, Tomoyuki/0000-0002-8944-2088				ABELSON HT, 1970, CANCER RES, V30, P2213; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Asimakopoulos FA, 1999, BLOOD, V94, P1141, DOI 10.1182/blood.V94.3.1141.415a35d_1141_1142; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hardin JD, 1996, ONCOGENE, V12, P2669; Issa JPJ, 1999, BLOOD, V93, P2075, DOI 10.1182/blood.V93.6.2075.406k29_2075_2080; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Miyoshi-Akiyama T, 2001, ONCOGENE, V20, P4058, DOI 10.1038/sj.onc.1204528; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JM, 2002, FRONT BIOSCI, V7, pD31; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; Whang YE, 2000, P NATL ACAD SCI USA, V97, P5486, DOI 10.1073/pnas.97.10.5486; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	44	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8527	8534		10.1038/sj.onc.1207894	http://dx.doi.org/10.1038/sj.onc.1207894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378021				2022-12-17	WOS:000224870700013
J	van Haaften, G; Plasterk, RHA; Tijsterman, M				van Haaften, G; Plasterk, RHA; Tijsterman, M			Genomic instability and cancer: scanning the Caenorhabditis elegans genome for tumor suppressors	ONCOGENE			English	Article						genomic instability; RNAi; mutator genes; C. elegans; DNA damage; DNA repair; carcinogenesis	DNA-DAMAGE RESPONSE; C-ELEGANS; SACCHAROMYCES-CEREVISIAE; RNA INTERFERENCE; MISMATCH-REPAIR; CHECKPOINT PROTEIN; WIDE SCREEN; GENES; TRANSPOSON; MUTATIONS	Maintaining the stability of the genome is critical to normal cell growth and development. The early notion that cancer is the result of mutations in genes controlling cellular growth implied that gene or genome integrity is vital to the prevention of oncogenesis, and many genes and pathways that prevent genomic deterioration have been identified over the past decades. Recent progress in reverse genetic approaches, principally RNA interference, now allows the systematic analysis of gene function on a genomic scale in an animal system. Here, we discuss genomic approaches in the model organism Caenorhabditis elegans, aimed to identify genes and genetic networks that contribute to genome stability and are thus potentially involved in human carcinogenesis.	Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Tijsterman, M (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	tijsterman@niob.knaw.nl	Tijsterman, Marcel/H-5663-2018; van Haaften, Gijs/G-7832-2012	Tijsterman, Marcel/0000-0001-8465-9002; van Haaften, Gijs/0000-0003-3033-0329				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; Anderson P, 1995, METHOD CELL BIOL, V48, P31; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Boulton SJ, 2004, CURR BIOL, V14, P33, DOI 10.1016/j.cub.2003.11.029; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Carr AM, 2002, DNA REPAIR, V1, P983, DOI 10.1016/S1568-7864(02)00165-9; Chang M, 2002, P NATL ACAD SCI USA, V99, P16934, DOI 10.1073/pnas.262669299; Cheung I, 2002, NAT GENET, V31, P405, DOI [10.1038/ng928, 10.1038/417405a]; Colaiacovo MP, 2002, GENETICS, V162, P113; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; CUPPLES CG, 1990, GENETICS, V125, P275; Degtyareva NP, 2002, P NATL ACAD SCI USA, V99, P2158, DOI 10.1073/pnas.032671599; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; GREENWALD IS, 1980, GENETICS, V96, P147; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanway D, 2002, P NATL ACAD SCI USA, V99, P10605, DOI 10.1073/pnas.152264899; HARTMAN PS, 1982, MOL GEN GENET, V187, P116, DOI 10.1007/BF00384393; HENDERSON ST, 1993, GENETICS, V134, P57; HODGKIN J, 1979, GENETICS, V91, P67; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kelly KO, 2000, GENETICS, V156, P617; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KIFF JE, 1988, NATURE, V331, P631, DOI 10.1038/331631a0; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LINK CD, 1988, DEVELOPMENT, V103, P485; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; MEYER BJ, 1997, C ELEGANS, V2, P209; Miller JH, 1998, MUTAT RES-DNA REPAIR, V409, P99, DOI 10.1016/S0921-8777(98)00049-4; Muller A, 2002, CANCER INVEST, V20, P102, DOI 10.1081/CNV-120000371; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; Plasterk Ronald H.A., 1997, Cold Spring Harbor Monograph Series, V33, P97; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Stergiou L, 2004, CELL DEATH DIFFER, V11, P21, DOI 10.1038/sj.cdd.4401340; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tijsterman M, 2002, GENETICS, V161, P651; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; VANHAAFTEN G, 2004, IN PRESS P NATL ACAD; Vastenhouw NL, 2004, TRENDS GENET, V20, P314, DOI 10.1016/j.tig.2004.04.011; Vastenhouw NL, 2003, CURR BIOL, V13, P1311, DOI 10.1016/s0960-9822(03)00539-6; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	63	13	14	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8366	8375		10.1038/sj.onc.1208011	http://dx.doi.org/10.1038/sj.onc.1208011			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517018				2022-12-17	WOS:000224815900007
J	Gartel, AL; Radhakrishnan, SK; Serfas, MS; Kwon, YH; Tyner, AL				Gartel, AL; Radhakrishnan, SK; Serfas, MS; Kwon, YH; Tyner, AL			A novel p21(WAF1/CIP1) transcript is highly dependent on p53 for its basal expression in mouse tissues	ONCOGENE			English	Article						p21; p53; alternate transcript	KINASE INHIBITOR; CELL-CYCLE; GENE; P21; ARREST; CLONING; WAF1	p21(WAF1/CIP1) is an important transcriptional target of p53 and it plays a critical role in growth arrest after DNA damage. Here, we report the identification of a novel alternate mouse p21 transcript that is conserved in evolution. It differs from the classical p21(WAF1/CIP1) transcript in the first exon, which is located at approximately 2.8 kb upstream of transcriptional start site of p21(WAF1/CIP1) and is sandwiched between two p53 binding sites. This novel p21 transcript is present in most mouse tissues with highest levels of expression in the spleen. In contrast to the classical p21(WAF1/CIP1) transcript, this new transcript is highly dependent on p53 for its basal expression, as evidenced by its absence in nearly all of p53(-/-) mouse tissues. This transcript is also absent at nonpermissive temperature in a 10-1 mouse cell line lacking endogenous p53 and harboring temperature-sensitive p53 mutant. However, this novel transcript is induced to appreciable levels in the presence of high p53 activity at the permissive temperature. Our data suggest that p53-dependent induction of p21 may be an additive effect conferred by individual increases in the alternate and classical p21 transcripts.	Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, 840 S Wood St, Chicago, IL 60612 USA.	atyner@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498; Tyner, Angela/0000-0001-7448-8625	NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NCI NIH HHS [CA91146-01A1] Funding Source: Medline; NIDDK NIH HHS [DK56283, R01 DK056283-05, R01 DK056283] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Couronne O, 2003, GENOME RES, V13, P73, DOI 10.1101/gr.762503; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hogga I, 2002, DEVELOPMENT, V129, P4915; HUPPI K, 1994, ONCOGENE, V9, P3017; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAO L, 1995, CANCER RES, V55, P2995; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; QUELLE DE, 1995, CELL, V83, P993; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Tsubari M, 1997, CANCER RES, V57, P2966; Wang XD, 2004, NAT GENET, V36, P231, DOI 10.1038/ng1301; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	23	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8154	8157		10.1038/sj.onc.1207820	http://dx.doi.org/10.1038/sj.onc.1207820			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361845				2022-12-17	WOS:000224692500013
J	Damiola, F; Keime, C; Gonin-Giraud, S; Dazy, B; Gandrillon, O				Damiola, F; Keime, C; Gonin-Giraud, S; Dazy, B; Gandrillon, O			Global transcription analysis of immature avian erythrocytic progenitors: from self-renewal to differentiation	ONCOGENE			English	Article						self-renewal; differentiation; SAGE; erythroid progenitors	STEM-CELLS; GENE-EXPRESSION; SERIAL ANALYSIS; GLUCOCORTICOID-RECEPTOR; CANCER; ADULT; SAGE; PHOSPHORYLATION; CANDIDATE; INDUCE	The molecular mechanisms regulating the cell fate decision between self-renewal and differentiation/apoptosis in stem and progenitor cells are poorly understood. Here, we report the first comprehensive identification of genes potentially involved in the switch from self-renewal toward differentiation of primary, non-immortalized erythroid avian progenitor cells (T2EC cells). We used the Serial Analysis of Gene Expression ( SAGE) technique in order to identify and quantify the genome fraction functionally active in a self-renewing versus a differentiating cell population. We generated two SAGE libraries and sequenced a total of 37 589 tags, thereby obtaining the first transcriptional pro. le characterization of a chicken cell. Tag identification was performed using a new relational database (Identitag) developed in the laboratory, which allowed a highly satisfactory level of identification. Among 123 differentially expressed genes, 11 were investigated further and for nine of them the differential expression was subsequently confirmed by real-time PCR. The comparison of tag abundance between the two libraries revealed that only a small fraction of transcripts was differentially expressed. The analysis of their functions argue against a prominent role for a master switch in T2EC cells decision-making, but are in favor of a critical role for coordinated small variations in a relatively small number of genes that can lead to essential cellular identity changes.	Univ Lyon 1, CNRS,UMR 5534, Ctr Genet Mol & Cellulaire, Equipe Signalisat & Ident Cellulaires, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Damiola, F (corresponding author), Univ Lyon 1, CNRS,UMR 5534, Ctr Genet Mol & Cellulaire, Equipe Signalisat & Ident Cellulaires, Bat Gregore Mendel,16 Rue Dubois, F-69622 Villeurbanne, France.	Damiola@cgmc.univ-lyon1.fr; Keime@cgmc.univ-lyon1.fr; Gonin@cgmc.univ-lyon1.fr; Dazy@cgmc.univ-lyon1.fr; Gandrillon@cgmc.univ-lyon1.fr		Damiola, Francesca/0000-0002-0238-1252; KEIME, Celine/0000-0001-7604-3814				ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Antica M, 1997, IMMUNOL LETT, V55, P47, DOI 10.1016/S0165-2478(96)02682-X; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; Becquet C, 2002, GENOME BIOL, V3; Boheler KR, 2003, TRENDS BIOTECHNOL, V21, P55, DOI 10.1016/S0167-7799(02)00031-8; Cao A, 2002, PEDIATR RES, V51, P415, DOI 10.1203/00006450-200204000-00003; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; Dazy S, 2003, ONCOGENE, V22, P9205, DOI 10.1038/sj.onc.1207049; Detmer K, 2000, BLOOD CELL MOL DIS, V26, P360, DOI 10.1006/bcmd.2000.0318; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Fortunel NO, 2003, SCIENCE, V302, P393; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; Gandrillon O, 1998, ONCOGENE, V16, P563, DOI 10.1038/sj.onc.1201550; Heller S, 1998, P NATL ACAD SCI USA, V95, P11400, DOI 10.1073/pnas.95.19.11400; HINSSEN H, 1987, J CELL BIOL, V105, P1425, DOI 10.1083/jcb.105.3.1425; Ito CY, 2003, BLOOD, V101, P517, DOI 10.1182/blood-2002-06-1918; Ivanova NB, 2003, SCIENCE, V302; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; KEIME C, 2004, UNPUB; Keith WN, 2004, ONCOGENE, V23, P5092, DOI 10.1038/sj.onc.1207762; Kolbus A, 2003, BLOOD, V102, P3136, DOI 10.1182/blood-2003-03-0923; Man MZ, 2000, BIOINFORMATICS, V16, P953, DOI 10.1093/bioinformatics/16.11.953; Margulies EH, 2000, BIOINFORMATICS, V16, P650, DOI 10.1093/bioinformatics/16.7.650; Marone M, 2002, LEUKEMIA, V16, P94, DOI 10.1038/sj.leu.2402334; Matsumura F, 2001, CELL STRUCT FUNCT, V26, P639, DOI 10.1247/csf.26.639; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piquemal D, 2002, GENOMICS, V80, P361, DOI 10.1006/geno.2002.6836; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roessler E, 1999, HUM GENET, V105, P489, DOI 10.1007/s004390051135; Terskikh AV, 2003, BLOOD, V102, P94, DOI 10.1182/blood-2002-08-2509; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vinogradov AE, 1998, CYTOMETRY, V31, P100, DOI 10.1002/(SICI)1097-0320(19980201)31:2<100::AID-CYTO5>3.0.CO;2-Q; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhou GL, 2001, P NATL ACAD SCI USA, V98, P13966, DOI 10.1073/pnas.241526198	44	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7628	7643		10.1038/sj.onc.1208061	http://dx.doi.org/10.1038/sj.onc.1208061			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15378009				2022-12-17	WOS:000224306700004
J	Yoder, MC				Yoder, MC			Generation of HSCs in the embryo and assays to detect them	ONCOGENE			English	Review						stem cells; embryonic; transplantation; in utero	HEMATOPOIETIC STEM-CELLS; YOLK-SAC; MOUSE EMBRYO; AORTA; ENGRAFTMENT; CIRCULATION; PRECURSORS; EMERGENCE; REGION; BLOOD	The precise temporal and spatial emergence of hematopoietic stem cells (HSC) in the murine embryo has been somewhat controversial largely due to differences in the assays utilized to demonstrate HSC repopulating ability. One strategy is to determine where and when one can first detect HSC that engraft upon transplantation into lethally irradiated adult mice. However, knowing that the primary sites and patterns of hematopoiesis change during ontogeny, an alternative strategy is to select transplantation models where the recipient subjects more closely mirror the stage of development of the donor cells. In this regard, perhaps the most relevant assay to determine the presence of HSC activity in the early embryo is to transplant the donor cells in utero into recipient embryos. Other recipient models that may permit engraftment of embryonic cells include the use of submyeloablated or genetically HSC deficient newborn mice. Additional informative strategies have included co-culturing embryonic tissues that appear to lack HSC activity, with stromal cells derived from different developmental sites of hematopoiesis to induce HSC emergence, followed by transplantation as a means to determine which embryonic tissues possess HSC potential. This review will highlight some of the various transplantation assays used to identify HSC from embryonic tissues.	Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Yoder, MC (corresponding author), Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, 1044 W Wlanut St,R4-402E, Indianapolis, IN 46202 USA.	myoder@iupui.edu						Cumano A, 2001, IMMUNITY, V15, P477, DOI 10.1016/S1074-7613(01)00190-X; de Bruijn MFTR, 2002, IMMUNITY, V16, P673, DOI 10.1016/S1074-7613(02)00313-8; Godin I, 1999, J EXP MED, V190, P43, DOI 10.1084/jem.190.1.43; JOHNSON SA, IN PRESS DEV HEMATOP; Kumaravelu P, 2002, DEVELOPMENT, V129, P4891; Matsuoka S, 2001, BLOOD, V98, P6, DOI 10.1182/blood.V98.1.6; McGrath KE, 2003, BLOOD, V101, P1669, DOI 10.1182/blood-2002-08-2531; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; North TE, 2002, IMMUNITY, V16, P661, DOI 10.1016/S1074-7613(02)00296-0; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; Palis J, 1999, DEVELOPMENT, V126, P5073; Palis J, 2001, EXP HEMATOL, V29, P927, DOI 10.1016/S0301-472X(01)00669-5; Palis J, 2001, P NATL ACAD SCI USA, V98, P4528, DOI 10.1073/pnas.071002398; Ramshaw H S, 1995, Biol Blood Marrow Transplant, V1, P74; Rao SS, 1997, EXP HEMATOL, V25, P114; STEWART FM, 1993, BLOOD, V81, P2566; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; Weissman I, 1978, DIFFERENTIATION NORM, V5, P33; Xu MJ, 1998, BLOOD, V92, P2032, DOI 10.1182/blood.V92.6.2032.418k29_2032_2040; Yoder MC, 1997, BLOOD, V89, P2176, DOI 10.1182/blood.V89.6.2176; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6	21	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2004	23	43					7161	7163		10.1038/sj.onc.1207931	http://dx.doi.org/10.1038/sj.onc.1207931			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378076				2022-12-17	WOS:000223998800002
J	Zhang, YJ; Yang, HY; Zhang, XC; Yang, HL; Tsai, ML; Lee, MH				Zhang, YJ; Yang, HY; Zhang, XC; Yang, HL; Tsai, ML; Lee, MH			Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth	ONCOGENE			English	Article						ARF; HER2; p27; Akt	DEPENDENT KINASE INHIBITOR; CELL-CYCLE PROGRESSION; TAXOL-INDUCED APOPTOSIS; P14(ARF) GENE-TRANSFER; HUMAN-BREAST-CANCER; CYTOPLASMIC LOCALIZATION; P53-DEPENDENT APOPTOSIS; MAMMALIAN-CELLS; STABILIZES P53; S-PHASE	HER2/neu, a receptor tyrosine kinase oncogene, promotes mitogenic growth and antiapoptotic activity in cancer cells. Strong expression of HER2/neu in cancers has been associated with poor prognosis. Alternative reading frame protein (ARF), a tumor suppressor protein encoded by a gene located in the Ink4a/ARF gene locus, is frequently inactivated in human cancers. Little is known about the tumor suppressor role of ARF in HER2/neuoverexpressing cancers. Here, we applied the ARF gene as a tumor-suppressive agent for HER2/neu-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system. W e found that ARF antagonized protein kinase B (PKB)/Akt-mediated p27(Kip1) phosphorylation and increased p27 stability in HER2/neu-overexpressing cells. ARF expression also led to decreased levels of Cul1 and Skp2, two proteins involved in p27 degradation. W e also found that ARF caused apoptosis in HER2/neu-overexpressing cells, and sensitized cells to apoptosis induced by the chemotherapeutic agents taxol and 2-methoxyestradiol. Most significantly for clinical application, we found that ARF inhibited HER2/neu-mediated cell growth, transformation, and tumorigenesis. These findings indicate that modulation of ARF activity may be a useful therapeutic intervention in HER2-overexpressing cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA; Univ Texas, Grad Sch Biomed Sci, Program Genes & Dev, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System	Lee, MH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.	mhlee@notes.mdacc.tmc.edu		Lee, Mong-Hong/0000-0001-8675-8215	NCI NIH HHS [R01CA (089266)] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2003, CANCER RES, V63, P3395; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deng XY, 2002, BIOCHEM BIOPH RES CO, V296, P792, DOI 10.1016/S0006-291X(02)00948-8; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Katner AL, 2002, J UROLOGY, V168, P766, DOI 10.1016/S0022-5347(05)64742-8; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; MILLER SJ, 1995, ONCOL REP, V2, P497; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Saadatmandi N, 2002, CANCER GENE THER, V9, P830, DOI 10.1038/sj.cgt.7700505; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Tango Y, 2002, HUM GENE THER, V13, P1373, DOI 10.1089/104303402760128595; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Uhrbom L, 2002, CANCER RES, V62, P5551; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; You MJ, 2002, P NATL ACAD SCI USA, V99, P1455, DOI 10.1073/pnas.022632099; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YW, 2001, ONCOGENE, V20, P4138, DOI 10.1038/sj.onc.1204563; Zhang YW, 2003, CANCER RES, V63, P1623; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7132	7143		10.1038/sj.onc.1207918	http://dx.doi.org/10.1038/sj.onc.1207918			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273726	Bronze			2022-12-17	WOS:000223885100014
J	Ozawa, H; Ashizawa, S; Naito, M; Yanagihara, M; Ohnishi, N; Maeda, T; Matsuda, Y; Jo, Y; Higashi, H; Kakita, A; Hatakeyama, M				Ozawa, H; Ashizawa, S; Naito, M; Yanagihara, M; Ohnishi, N; Maeda, T; Matsuda, Y; Jo, Y; Higashi, H; Kakita, A; Hatakeyama, M			Paired-like homeodomain protein ESXR1 possesses a cleavable C-terminal region that inhibits cyclin degradation	ONCOGENE			English	Article						ESXR1; cyclin; paired-like homeodomain; processing; M-phase arrest	MITOSIS UNTIL; DNA-BINDING; KINASE; PHOSPHORYLATION; PROTEOLYSIS; CELLS; G1; PROGRESSION; ACTIVATION; ONSET	The eukaryotic cell cycle is regulated by sequential activation and inactivation of cyclin-cyclin-dependent kinase (Cdk) complexes. In this work, we screened human cDNAs that can rescue yeast Saccharomyces cerevisiae from lethality caused by ectopic expression of human cyclin E and isolated a cDNA encoding ESXR1, a paired-like homeodomain-containing protein with a unique C-terminal proline-rich repeat region. In adult tissues, ESXR1 is primarily expressed in the testis. We demonstrate that ESXR1 prevents degradation of ubiquitinated cyclins in human cells. Accordingly, elevation of ESXR1 level results in accumulation of cyclin A and cyclin B1 and thereby provokes M-phase arrest. In human cells, the 65-kDa full-length ESXR1 protein is capable of proteolytically processing into N-terminal 45-kDa and C-terminal 20-kDa fragments. The C-terminal fragment, containing a proline-rich repeat region, is localized to the cytoplasm and displays the ability to inhibit cyclin degradation. In contrast, the N-terminal fragment, containing a paired-like homeodomain, is localized exclusively in the nucleus, suggesting that it plays a role in transcription. Our results indicate that proteolytic processing of ESXR1 plays a role in concerted regulation of the cell cycle and transcription in human cells.	Hokkaido Univ, Grad Sch Sci, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600815, Japan; Kitasato Univ, Sch Med, Dept Surg, Sagamihara, Kanagawa 2288555, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Lab Supramol Struct, Tokyo 1130032, Japan; Hokkaido Univ, Ctr Adv Sci & Technol, Lab Anim Cytogenet, Sapporo, Hokkaido 0600810, Japan; Kawasaki Med Sch, Dept Urol, Kurashiki, Okayama 7010192, Japan	Hokkaido University; Hokkaido University; Kitasato University; University of Tokyo; Hokkaido University; Kawasaki Medical School	Hatakeyama, M (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Mol Oncol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Maeda, Tatsuya/L-5540-2019; Higashi, Hideaki/F-6872-2012; OHNISHI, Naomi/F-6914-2012	OHNISHI, Naomi/0000-0002-2382-3152				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Branford WW, 1997, MECH DEVELOP, V65, P87, DOI 10.1016/S0925-4773(97)00058-0; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Fohn LE, 2001, GENOMICS, V74, P105, DOI 10.1006/geno.2001.6532; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAUMANN M, 1993, ONCOGENE, V8, P2275; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Sette C, 1999, J BIOL CHEM, V274, P33571, DOI 10.1074/jbc.274.47.33571; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Su TT, 2001, CURR BIOL, V11, pR467, DOI 10.1016/S0960-9822(01)00283-4; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yan YT, 2000, MOL CELL BIOL, V20, P661, DOI 10.1128/MCB.20.2.661-671.2000	32	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6590	6602		10.1038/sj.onc.1207884	http://dx.doi.org/10.1038/sj.onc.1207884			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235584				2022-12-17	WOS:000223530800006
J	Politi, K; Kljuic, A; Szabolcs, M; Fisher, P; Ludwig, T; Efstratiadis, A				Politi, K; Kljuic, A; Szabolcs, M; Fisher, P; Ludwig, T; Efstratiadis, A			'Designer' tumors in mice	ONCOGENE			English	Article						breast cancer; sarcoma; animal models of cancer; gene expression profiling	MIDDLE-T-ONCOGENE; AMINO-TERMINAL DOMAIN; TRANSGENIC MICE; MESSENGER-RNA; SINGLE-COPY; K-RAS; EXPRESSION; VIRUS; ACTIN; MOUSE	We have developed and tested successfully a general method based on Cre-mediated recombination that can be used for ubiquitous or tissue-specific expression of protein products, including tumor-inducing oncoproteins. Depending on the specificity of a chosen promoter driving cre expression, tumors develop by design in bitransgenic mouse progeny derived by crossing Cre-producing mice with partners carrying a dormant oncogenic transgene (targeted into the 3' noncoding region of the cytoplasmic beta-actin locus) that becomes functional after excision of a 'floxed' DNA segment. To provide proof-of-principle, we have used as models transgenes encoding the polyomavirus middle T antigen (PVMT) and the T antigens of the SV40 early region (SVER). Cre-dependent activation of widespread SVER expression resulted in hyperplasias or invasive tumors affecting particular visceral smooth muscles, whereas Cre-dependent, mammary gland-specific expression of PVMT-induced adenocarcinomas, according to plan. Unexpectedly, we also encountered spontaneous (Cre-independent) oncogene expression occurring as a rare event, which simulates the initiation of sporadic tumors and leads to PVMT-induced hemangiomas and mammary carcinomas or SVER-induced disseminated sarcomas, thus, revealing particular tissue susceptibilities to the actions of these oncoproteins.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Efstratiadis, A (corresponding author), Columbia Univ, Dept Genet & Dev, Berrie Med Sci Pavil,1150 St Nicholas Ave, New York, NY 10032 USA.	arg@cancercenter.columbia.edu	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585	NATIONAL CANCER INSTITUTE [P01CA075553, T32CA009503, P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75553, P01 CA97403, T32 CA09503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1992, PROG CLIN BIOL RES, V376, P1; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; Berns A, 2001, NATURE, V410, P1043, DOI 10.1038/35074238; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; DARBY I, 1990, LAB INVEST, V63, P21; Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037; Dorer DR, 1997, TRANSGENIC RES, V6, P3, DOI 10.1023/A:1018460413680; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; Eyden B, 2001, ULTRASTRUCT PATHOL, V25, P39, DOI 10.1080/019131201300004672; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hollies CR, 2001, EUR J HUM GENET, V9, P143, DOI 10.1038/sj.ejhg.5200590; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; POLITI K, 2004, IN PRESS AM J PATHOL, V164; Ratineau C, 2000, GASTROENTEROLOGY, V119, P1305, DOI 10.1053/gast.2000.19278; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Wallace H, 2000, NUCLEIC ACIDS RES, V28, P1455, DOI 10.1093/nar/28.6.1455; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WILLIAMS RL, 1988, CELL, V52, P121; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x	34	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1558	1565		10.1038/sj.onc.1207275	http://dx.doi.org/10.1038/sj.onc.1207275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14661057				2022-12-17	WOS:000189219500009
J	Davies, ML; Roberts, GT; Spiller, DG; Wakeman, JA				Davies, ML; Roberts, GT; Spiller, DG; Wakeman, JA			Density-dependent location and interactions of truncated APC and beta-catenin	ONCOGENE			English	Article						adenomatous polyposis coli; beta-catenin; cell density; E-cadherin; tumour progression	TUMOR-SUPPRESSOR; E-CADHERIN; NUCLEAR EXPORT; SUBCELLULAR-LOCALIZATION; CYCLIN D1; TARGET; IDENTIFICATION; MUTATIONS; GENES; TRANSACTIVATION	Adenomatous polyposis coli (APC) is a multifunctional tumour suppressor protein, central to development and the mature organism. It is mutated in most cases of colorectal cancer, rendering it ineffective in mediating beta-catenin degradation. We show that localization of full-length APC in colon carcinoma and noncancer cell lines is independent of cell density. However, the location of truncated APC is a function of cell density and in high-density cells truncated APC is predominantly not nuclear. Although the distribution of truncated APC and beta-catenin is closely linked in subconfluent SW480 cells, at high cell density they are not colocalized. We postulated that in this cell line this could be due to an increase in beta-catenin bound to E-cadherin with formation of adherens junctions at high cell density. However, while in coimmunoprecipitation assays we observe an increase in binding between beta-catenin and E-cadherin and a corresponding decrease in binding between beta-catenin and APC at high cell density, we did not observe a strict colocalization of beta-catenin and E-cadherin at the membrane of all cells.	Univ Wales Bangor, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	Bangor University; University of Liverpool	Wakeman, JA (corresponding author), Univ Wales Bangor, Sch Biol Sci, Deiniol Rd, Bangor LL57 2UW, Gwynedd, Wales.	j.a.wakeman@bangor.ac.uk	Spiller, David G/I-3645-2012	Spiller, David Geoffrey/0000-0003-2502-6787; Wakeman, Jane/0000-0002-7561-634X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Allan V, 2001, NAT CELL BIOL, V3, pE226, DOI 10.1038/ncb1001-e226; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brocardo MG, 2001, BIOCHEM BIOPH RES CO, V284, P982, DOI 10.1006/bbrc.2001.5066; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, EMBO REP, V1, P519; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orsulic S, 1999, J CELL SCI, V112, P1237; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	37	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1412	1419		10.1038/sj.onc.1207266	http://dx.doi.org/10.1038/sj.onc.1207266			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647421				2022-12-17	WOS:000189035800008
J	Lionneton, F; Lelievre, E; Baillat, D; Stehelin, D; Soncin, F				Lionneton, F; Lelievre, E; Baillat, D; Stehelin, D; Soncin, F			Characterization and functional analysis of the p42Ets-1 variant of the mouse Ets-1 transcription factor	ONCOGENE			English	Article						Ets-1; endothelium; VE-cadherin; gene promoter	DNA-BINDING MOTIF; CHICK-EMBRYO; MURINE ETS-1; PROTEIN INTERACTIONS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; C-ETS-1; PROMOTER; DOMAIN; PHOSPHORYLATION	We have identified the mouse exon VII splice variant of the Ets-1 transcription factor. The variant is expressed in all cell lines which express ets-1, at lower levels, it is also expressed in the mouse embryo in vivo. The corresponding protein, p42Ets-1, is a transcription factor as it is able to bind to specific DNA sequences and to transactivate a bona. de ETS reporter vector. A comparison of optimal DNA-binding sites shows that p42Ets-1 binds to more various DNA sequences than p51Ets-1; p42Ets-1 recognizes the same optimal consensus sequence as p51Ets-1, but also many variations of it, mainly at base -1, which is located just prior to the GGAA/T core sequence. The binding differences were quantified by surface plasmon resonance analyses and the protein region responsible for the differences in DNA sequence recognition located in the Val(280)-Glu(302) fragment, which is encoded by exon VII. The specific DNA-binding properties of each isoform translates into clear differences in activity, p42Ets-1 transactivates the natural VE-cadherin gene promoter through both ETS-binding site (EBS)2 and EBS4 whereas p51Ets-1 is mainly active on EBS4. Altogether, our data suggest that p42Ets-1 acts as a distinct transcription factor from p51Ets-1.	Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS)	Soncin, F (corresponding author), Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59021 Lille, France.		SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673; Lelievre, Etienne/0000-0003-0452-1578				Anderson MK, 1999, DEVELOPMENT, V126, P3131; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Castellano R, 2002, J BIOL CHEM, V277, P42841, DOI 10.1074/jbc.M207689200; Cowley DO, 2000, GENE DEV, V14, P366; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1991, ONCOGENE, V6, P2249; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Garvie CW, 2002, J BIOL CHEM, V277, P45529, DOI 10.1074/jbc.M206327200; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; JORCYK CL, 1991, ONCOGENE, V6, P523; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Lelievre E, 2002, J BIOL CHEM, V277, P25143, DOI 10.1074/jbc.M201628200; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Lionneton F, 2001, PROTEIN EXPRES PURIF, V21, P492, DOI 10.1006/prep.2001.1405; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; QUEVA C, 1993, ONCOGENE, V8, P2511; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAYGALLET D, 1995, ONCOGENE, V11, P303; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	53	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9156	9164		10.1038/sj.onc.1207241	http://dx.doi.org/10.1038/sj.onc.1207241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668797				2022-12-17	WOS:000187149100006
J	Aoyagi, M; Higashino, F; Yasuda, M; Takahashi, A; Sawada, Y; Totsuka, Y; Kohgo, T; Sano, H; Kobayashi, M; Shindoh, M				Aoyagi, M; Higashino, F; Yasuda, M; Takahashi, A; Sawada, Y; Totsuka, Y; Kohgo, T; Sano, H; Kobayashi, M; Shindoh, M			Nuclear export of adenovirus E4orf6 protein is necessary for its ability to antagonize apoptotic activity of BH3-only proteins	ONCOGENE			English	Article						E4orf6; adenovirus; nuclear export; BH-3 only protein; BNIP3; Bik	BCL-2 FAMILY; EARLY REGION-4; PERMEABILITY TRANSITION; 55-KILODALTON PROTEIN; DNA-REPLICATION; TUMOR-ANTIGEN; BH3 DOMAIN; CELL-DEATH; P53; GENE	The adenovirus E4orf6 is a viral oncoprotein known to cooperate with the E1A gene product in transforming primary murine cells. It has been shown to inhibit the apoptotic activities of p53 and p73 through direct binding to these proteins. Here, we demonstrate that the adenovirus E4orf6 protein inhibits apoptosis mediated by BNIP3 and Bik, which are BH3-only proteins of the Bcl-2 family. This activity was not mediated by p53 and p73 because E4orf6 had the same effect on the apoptosis in Saos-2 cells that do not express p53-related genes. It was also ascertained that E4orf6 could change the mitochondrial localization of BNIP3 and Bik. A mutant lacking the nuclear export signal of E4orf6 failed to inhibit apoptosis and to translocate BNIP3 protein from the mitochondria. Moreover, it was also established that E4orf6 was able to interact with BNIP3 and Bik. In BNIP3 protein, the region required for the interaction included the transmembrane domain, which is required for the localization of BNIP3 to the mitochondria. These results suggest that E4orf6 is exported from the nucleus to the cytoplasm, enabling it to interact with BH3-only proteins, eventually leading to the inhibition of apoptotic activity.	Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Kita Ku, Sapporo, Hokkaido 0608586, Japan; Hokkaido Univ, Grad Sch Dent Med, Dept Oral Hlth Sci, Kita Ku, Sapporo, Hokkaido 0608586, Japan; Hokkaido Inst Publ Hlth, Dept Biol, Sapporo, Hokkaido 0600819, Japan; Hokkaido Univ, Sch Med, Inst Med Genet, Div Canc Pathobiol, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Higashino, F (corresponding author), Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Kita Ku, N13,W7, Sapporo, Hokkaido 0608586, Japan.	fhigashi@den.hokudai.ac.jp	Higashino, Fumihiro/F-8510-2012; Sano, Hidehiko/A-4802-2012; Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823; Takahashi, Akiko/0000-0003-1904-7645				BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Fischer N, 1999, FEBS LETT, V447, P311, DOI 10.1016/S0014-5793(99)00313-0; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MIYASHITA T, 1995, CELL, V80, P293; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	43	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6919	6927		10.1038/sj.onc.1206743	http://dx.doi.org/10.1038/sj.onc.1206743			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534539				2022-12-17	WOS:000185843400013
J	Hornstein, I; Mortin, MA; Katzav, S				Hornstein, I; Mortin, MA; Katzav, S			DroVav, the Drosophila melanogaster homologue of the mammalian Vav proteins, serves as a signal transducer protein in the Rac and DER pathways	ONCOGENE			English	Article						Vav; Rac; cytoskeleton; RNAi; Drosophila	T-CELL-RECEPTOR; NUCLEOTIDE EXCHANGE FACTOR; CYTOSKELETAL REORGANIZATION; GDP/GTP EXCHANGE; SH2 DOMAIN; ACTIVATION; FAMILY; EGF; JNK; RHO	Mammalian Vav signal transducer proteins couple receptor tyrosine kinase signals to the activation of the Rho/Rac GTPases, leading to cell differentiation and/or proliferation. The unique and complex structure of mammalian Vav proteins is preserved in the Drosophila melanogaster homologue, DroVav. We demonstrate that DroVav functions as a guanine-nucleotide exchange factor (GEF) for DRac. Drosophila cells overexpressing wildtype (wt) DroVav exhibited a normal morphology. However, overexpression of a truncated DroVav mutant ( that functions as an oncogene when expressed in NIH3T3 cells) results in striking changes in the actin cytoskeleton, resembling those usually visible following Rac activation. Dominant-negative DRac abrogated these morphological changes, suggesting that the effect of the truncated DroVav mutant is mediated by activation of DRac. In Drosophila cells, we find that stimulation of the Drosophila EGF receptor (DER) increases tyrosine phosphorylation of DroVav, which in turn associates with tyrosine-phosphorylated DER. In addition, the following results imply that DroVav participates in downstream DER signalling, such as ERK phosphorylation: ( a) overexpression of DroVav induces ERK phosphorylation; and (b) 'knockout' of DroVav by RNA interference blocks ERK phosphorylation induced by DER stimulation. Unlike mammalian Vav proteins, DroVav was not found to induce Jnk phosphorylation under the experimental circumstances tested in fly cells. The se results establish the role of DroVav as a signal transducer that participates in receptor tyrosine kinase pathways and functions as a GEF for the small RhoGTPase, DRac.	Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Katzav, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91120 Jerusalem, Israel.	katzav@cc.huji.ac.il	Mortin, Mark A/B-4251-2008					Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BOURBON HM, 2000, MECH DEVELOP, V110, P71; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Carthew RW, 2001, CURR OPIN CELL BIOL, V13, P244, DOI 10.1016/S0955-0674(00)00204-0; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dekel I, 2000, FEBS LETT, V472, P99, DOI 10.1016/S0014-5793(00)01413-7; del Pozo MA, 2003, J IMMUNOL, V170, P41, DOI 10.4049/jimmunol.170.1.41; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Golembo M, 1999, GENE DEV, V13, P158, DOI 10.1101/gad.13.2.158; Golembo M, 1996, DEVELOPMENT, V122, P223; Groysman M, 2002, J BIOL CHEM, V277, P50121, DOI 10.1074/jbc.M204299200; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; HORNSTEIN I, 2003, IN PRESS CELL SIGNAL; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; KATZAV S, 1995, ONCOGENE, V11, P1079; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kranewitter WJ, 1999, FEBS LETT, V455, P123, DOI 10.1016/S0014-5793(99)00857-1; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Luschnig S, 2000, MOL CELL, V5, P231, DOI 10.1016/S1097-2765(00)80419-0; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Moller A, 2001, J BIOL CHEM, V276, P20022, DOI 10.1074/jbc.M011139200; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; Rebay I, 2002, DEV BIOL, V251, P1, DOI 10.1006/dbio.2002.0806; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; Rivera J, 2001, INT ARCH ALLERGY IMM, V124, P137, DOI 10.1159/000053692; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schuebel KE, 1996, ONCOGENE, V13, P363; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Settleman J, 2001, DEV CELL, V1, P321, DOI 10.1016/S1534-5807(01)00053-3; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Sotillos S, 2000, DEVELOPMENT, V127, P5427; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WU J, 1995, MOL CELL BIOL, V15, P4337; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	75	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6774	6784		10.1038/sj.onc.1207027	http://dx.doi.org/10.1038/sj.onc.1207027			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555990				2022-12-17	WOS:000185799300012
J	Jing, Y; Xia, LJ; Lu, M; Waxman, S				Jing, Y; Xia, LJ; Lu, M; Waxman, S			The cleavage product Delta PML-RAR alpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells	ONCOGENE			English	Article						acute promyelocytic leukemia; PML-RAR alpha; all-trans retinoic acid	RESISTANT NB4 CELLS; PML/RAR-ALPHA; HISTONE DEACETYLASE; IN-VITRO; PROTEASOME PATHWAY; ARSENIC TRIOXIDE; NUCLEAR-BODIES; FUSION PROTEIN; CHIMERIC GENE; NEW-YORK	PML-RARalpha protein, the leukemogenic product of t(15,17) in acute promyelocytic leukemia, is cleaved into a truncated form termed DeltaPML-RARalpha during all-trans retinoic acid (ATRA)-induced differentiation of NB4 cells. DeltaPML-RARalpha is not formed in ATRA differentiation resistant NB4 subclones. As2O3 inhibits DeltaPML-RARalpha formation and differentiation-induction when given in combination with ATRA. Treatment with hexamethylene bisacetamide (HMBA) combined with ATRA enhances ATRA-induced differentiation in ATRA-insensitive NB4-CI and arsenic-resistant NB4/As cells, and is associated with stabilization of PML-RARalpha protein and increased DeltaPML-RARalpha formation. Unlike forced expression of PML-RARalpha, forced DPML-RARalpha expression based on an estimated deletion of the N-terminal PML portion does not repress RARE-tk-luc reporter activity mediated by endogenous retinoic acid receptors. The cleavage of PML-RARalpha is blocked by RARalpha antagonist Ro-41-5253 and cycloheximide and therefore requires a RARalpha transactivation-dependent pathway. Proteasome inhibitor MG-132 and caspase inhibitor Z-VAD-FMK do not block ATRA-induced PML-RARalpha cleavage and differentiation. These data suggest that (a) ATRA treatment induces PML-RARalpha cleavage by induction of unknown enzymes independent of proteasome- and caspase-mediated pathways; (b) DeltaPML-RARalpha might function differently from both PML-RARalpha and RARalpha; (c) failure to cleave PML-RARalpha and form DeltaPML-RARalpha after ATRA treatment may contribute to ATRA resistance in APL cells.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Jing, Y (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Box 1178,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [CA93533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CASTAIGNE S, 1990, BLOOD, V76, P1704; Castaigne Sylvie, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P515; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DEGOS L, 1990, LANCET, V336, P1440, DOI 10.1016/0140-6736(90)93135-C; DELVA L, 1993, BLOOD, V82, P2175; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Duprez E, 1996, ONCOGENE, V12, P2451; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; FRANKEL SR, 1994, ANN INTERN MED, V120, P278, DOI 10.7326/0003-4819-120-4-199402150-00004; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Idres N, 2001, CANCER RES, V61, P700; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Jing YK, 2002, BLOOD, V100, P1008, DOI 10.1182/blood.V100.3.1008; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LANOTTE M, 1991, BLOOD, V77, P1080; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; Nervi C, 1998, BLOOD, V92, P2244; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; Takayama N, 2001, EXP HEMATOL, V29, P864, DOI 10.1016/S0301-472X(01)00651-8; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, LEUKEMIA, V8, pS33; Yoshida H, 1996, CANCER RES, V56, P2945; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	48	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4083	4091		10.1038/sj.onc.1206568	http://dx.doi.org/10.1038/sj.onc.1206568			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821942				2022-12-17	WOS:000183707600011
J	Laiho, P; Hienonen, T; Karhu, A; Lipton, L; Aalto, Y; Thomas, HJW; Birkenkamp-Demtroder, K; Hodgson, S; Salovaara, R; Mecklin, JP; Jarvinen, H; Knuutila, S; Halford, S; Orntoft, TF; Tomlinson, I; Launonen, V; Houlston, R; Aaltonen, LA				Laiho, P; Hienonen, T; Karhu, A; Lipton, L; Aalto, Y; Thomas, HJW; Birkenkamp-Demtroder, K; Hodgson, S; Salovaara, R; Mecklin, JP; Jarvinen, H; Knuutila, S; Halford, S; Orntoft, TF; Tomlinson, I; Launonen, V; Houlston, R; Aaltonen, LA			Genome-wide allelotyping of 104 Finnish colorectal cancers reveals an excess of allelic imbalance in chromosome 20q in familial cases	ONCOGENE			English	Article						colorectal cancer; familial; hereditary; allelic imbalance; loss of heterozygosity	HERITABLE FACTORS; HETEROZYGOSITY; HYBRIDIZATION; GAINS; SUSCEPTIBILITY; CARCINOMAS; LOSSES; SWEDEN; GENES	We have allelotyped a series of 104 Finnish colorectal cancers (CRCs) using 372 polymorphic markers spaced, on average, at 10 cM intervals, and have made a comparison of the differences in the frequency of allelic imbalance (AI) between familial and sporadic cases. Differences in the frequency of allelic imbalance (loss of heterozygosity or amplification) at a number of loci were detected and these were evaluated through analysis of additional series of cancers using specific markers. The most consistent difference was observed at chromosome 20q13.1-13.3 characterized by a two fold difference between familial and nonfamilial disease in a total of 99 familial and 186 sporadic Finnish cases. This difference was not observed in a UK set of 67 familial and 96 sporadic CRCs. The genome-wide effort resulted in a large data set giving clues to the location of putative CRC predisposition genes in the genome. The approach provides an alternative strategy for detecting cancer predisposition genes solely reliant on the molecular analysis of single cases obviating the requirement to collect multiple samples from families.	Univ Helsinki, Biomedicum, Dept Med Genet, FIN-00014 Helsinki, Finland; Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; St Marks Hosp, Cancres Res UK, Colorectal Unit, Harrow HA1 3UJ, Middx, England; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00029 Helsinki, Finland; Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8200 Aarhus, N Skejby, Denmark; Guys Hosp, Dept Clin Genet, Canc Res UK, London SE1 9RT, England; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Cent Hosp Jyvaskyla, Dept Surg, FIN-40620 Jyvaskyla, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00029 Helsinki, Finland; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland	University of Helsinki; Cancer Research UK; Imperial College London; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aarhus University; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of Helsinki; Central Finland Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of London; Institute of Cancer Research - UK; University of Helsinki; Helsinki University Central Hospital	Aaltonen, LA (corresponding author), Univ Helsinki, Biomedicum, Dept Med Genet, POB 63, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Mecklin, Jukka-Pekka/AAC-9650-2019; Birkenkamp-Demtröder, Karin/C-1981-2017; Aaltonen, Lauri/A-5375-2010; Mecklin, Jukka-Pekka/AAB-5378-2020; Birkenkamp-Demtröder, Karin/AAN-1764-2021	Aaltonen, Lauri/0000-0001-6839-4286; Mecklin, Jukka-Pekka/0000-0003-4895-2249; Birkenkamp-Demtröder, Karin/0000-0001-8057-6277; Karhu, Auli/0000-0002-7927-0796; Houlston, Richard/0000-0002-5268-0242				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Aust DE, 2000, HUM PATHOL, V31, P109, DOI 10.1016/S0046-8177(00)80206-3; Bonaiti-Pellie C, 1999, EUR J CANCER PREV, V8, pS27; BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655; Canzian F, 1996, CANCER RES, V56, P3331; CUZICK J, 1999, METABOLIC POLYMORPHI, P109; De Angelis PM, 1999, BRIT J CANCER, V80, P526; De Angelis PM, 2001, INT J COLORECTAL DIS, V16, P38, DOI 10.1007/s003840000275; Dong C, 2001, INT J CANCER, V93, P155, DOI 10.1002/ijc.1317; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; Ginzinger DG, 2000, CANCER RES, V60, P5405; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; Lewis CM, 1996, CANCER RES, V56, P1382; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; Mertens F, 1997, CANCER RES, V57, P2765; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Peto J, 2001, EUR J CANCER, V37, pS88; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Teh BT, 1998, AM J HUM GENET, V63, P1544, DOI 10.1086/302097; THORLACIUS S, 1991, ANTICANCER RES, V11, P1501; Tomlinson I, 1999, GASTROENTEROLOGY, V116, P789, DOI 10.1016/S0016-5085(99)70061-2; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Weber TK, 1999, CYTOGENET CELL GENET, V86, P142, DOI 10.1159/000015368	27	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2206	2214		10.1038/sj.onc.1206294	http://dx.doi.org/10.1038/sj.onc.1206294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687022				2022-12-17	WOS:000182066900014
J	Gohda, J; Nomura, Y; Suzuki, H; Arai, H; Akiyama, T; Inoue, J				Gohda, J; Nomura, Y; Suzuki, H; Arai, H; Akiyama, T; Inoue, J			Elimination of the vertebrate Escherichia coli Ras-like protein homologue leads to cell cycle arrest at G1 phase and apoptosis	ONCOGENE			English	Article						apoptosis; KH domain; GTP-binding protein; RNA-binding protein	GTP-BINDING PROTEIN; 16S RIBOSOMAL-RNA; FRAGILE-X SYNDROME; STREPTOCOCCUS-PNEUMONIAE; CYTOCHROME-C; ERA GTPASE; KH DOMAIN; GENE; DISRUPTION; FAMILY	Homologues of the Escherichia coli (E. colt) Ras-like protein (ERA), a GTP-binding protein with RNA binding activity, have recently been found in various species, including human, mouse, and Antirrhinum majus. Depletion of prokaryotic ERA blocks cell division without affecting chromosome segregation. However, the physiological function of eukaryotic ERA is largely unknown. We have performed a genetic analysis of chicken ERA (GdERA) in DT40 cells. Depletion of GdERA diminished the growth rate of the cells, accompanied by an accumulation of apoptotic cells. The analysis of cell cycle indicates that the elimination of GdERA caused arrest at G1 phase, but not at M phase, which highlights the distinct role of vertebrate ERA in the cell cycle progression compared to prokaryotic ERA. Furthermore, human ERA (HsERA) rescued the phenotype of GdERA-deficient cells, whereas a mutant of HsERA deprived of RNA-binding activity did not. These data suggest that vertebrate ERA regulates the G1 phase progression via an as yet unknown molecular mechanism, which involves RNA recognition by ERA.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Inoue, J (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Akiyama, Taishin/0000-0002-0341-6154				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; Akiyama T, 2001, GENES CELLS, V6, P987, DOI 10.1046/j.1365-2443.2001.00480.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Britton RA, 2000, GENOMICS, V67, P78, DOI 10.1006/geno.2000.6243; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; GOLLOP N, 1991, J BACTERIOL, V173, P2265, DOI 10.1128/JB.173.7.2265-2270.1991; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hang JQ, 2001, EUR J BIOCHEM, V268, P5570, DOI 10.1046/j.1432-1033.2001.02493.x; INADA T, 1989, J BACTERIOL, V171, P5017, DOI 10.1128/jb.171.9.5017-5024.1989; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lahti JM, 1999, METHODS, V17, P305, DOI 10.1006/meth.1999.0744; LERNER CG, 1991, MOL MICROBIOL, V5, P951, DOI 10.1111/j.1365-2958.1991.tb00770.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Meier TI, 2000, MICROBIOL-UK, V146, P1071, DOI 10.1099/00221287-146-5-1071; Meier TI, 1999, J BACTERIOL, V181, P5242, DOI 10.1128/JB.181.17.5242-5249.1999; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Sayed A, 1999, BIOCHEM BIOPH RES CO, V264, P51, DOI 10.1006/bbrc.1999.1471; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1	25	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1340	1348		10.1038/sj.onc.1206287	http://dx.doi.org/10.1038/sj.onc.1206287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618759				2022-12-17	WOS:000181360900008
J	Crowder, C; Kopantzev, E; Williams, K; Lengel, C; Miki, T; Rudikoff, S				Crowder, C; Kopantzev, E; Williams, K; Lengel, C; Miki, T; Rudikoff, S			An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth	ONCOGENE			English	Article						Ras; mutation; transformation; growth factor independence	GUANINE-NUCLEOTIDE-BINDING; N-RAS; K-RAS; ACTIVATING MUTATIONS; STRUCTURAL DIFFERENCES; TRANSDUCTION PATHWAY; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR-3; LIVER-TUMORS; PRODUCT P21	Multiple myeloma (MM) is an incurable plasma cell malignancy. To investigate biochemical lesions associated,with MM, we constructed an expression cDNA library from the OPM-2 human myeloma line. A highly transforming H-Ras mutant was identified by transfection analysis using NIH 3T3 cells. DNA sequencing demonstrated a single-point mutation at position 117 located in the guanine nucleotide-binding site resulting in a lysine-to-glutamic acid substitution. This mutant, H-Ras (K117E), was found to be constitutively activated in terms of GTP binding. We compared the biological effects of H-Ras (K117E) and H-Ras (G12V) in 32D murine hematopoietic progenitor cells. Whereas both Ras proteins are constitutively activated, 32D cells expressing H-Ras (G12V) are still dependent on IL-3 for survival and proliferation while cells carrying H-Ras (K117E) become IL-3 independent. Similar experiments conducted with the B9 line, an IL-6-dependent hybridoma, also demonstrated that B9/H-Ras (KI17E) became IL-6-independent. Expression of H-Ras (K117E) in the human IL-6-dependent ANBL-6 myeloma line resulted in enhanced proliferation at suboptimal concentrations of IL-6. These observations suggest that H-Ras mutations at the binding site for the GTP nucleotide ring structure may also represent activating lesions and have additional biological effects when compared to previously described Ras mutants.	NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA; NCI, Mol Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Lab Cellular & Mol Biol, NIH, Bethesda, MD 20892 USA.	rudikoff@helix.nih.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNA CH, 1994, CARCINOGENESIS, V15, P2255, DOI 10.1093/carcin/15.10.2255; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BERGUI L, 1989, J EXP MED, V170, P613, DOI 10.1084/jem.170.2.613; Bezieau S, 2001, HUM MUTAT, V18, P212, DOI 10.1002/humu.1177; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; BOS JL, 1987, BLOOD, V69, P1237; Chesi M, 2000, ANN ONCOL, V11, P131, DOI 10.1023/A:1008300325610; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; Cool RH, 1999, MOL CELL BIOL, V19, P6297; CORRADINI P, 1994, LEUKEMIA LYMPHOMA, V15, P17, DOI 10.3109/10428199409051673; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DIAMANT M, 1994, J IMMUNOL METHODS, V173, P229, DOI 10.1016/0022-1759(94)90301-8; Drach J, 2000, J CANCER RES CLIN, V126, P441, DOI 10.1007/s004320050011; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; FREUND GG, 1993, J IMMUNOL, V151, P1811; Ge NL, 2000, BLOOD, V96, P2856; GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; Ho PJ, 2001, BLOOD, V97, P490, DOI 10.1182/blood.V97.2.490; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kalakonda N, 2001, BLOOD, V98, P1555, DOI 10.1182/blood.V98.5.1555; Kastrinakis NG, 2000, ANN ONCOL, V11, P1217, DOI 10.1023/A:1008331714186; KATAGIRI S, 1985, INT J CANCER, V36, P241, DOI 10.1002/ijc.2910360217; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273, DOI 10.1016/S0889-8588(18)30344-7; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Lattanzio G, 1997, AM J PATHOL, V151, P689; LIDA S, 1997, NAT GENET, V17, P226; LIOTTA LA, 1988, J NATL CANCER I, V80, P468, DOI 10.1093/jnci/80.7.468; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; Liu Q, 2001, EXP HEMATOL, V29, P962, DOI 10.1016/S0301-472X(01)00677-4; MATOZAKI S, 1991, Kobe Journal of Medical Sciences, V37, P35; MIKI T, 1995, METHOD ENZYMOL, V254, P196; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rawat R, 2000, BLOOD, V96, P3514; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; STANLEY LA, 1994, CARCINOGENESIS, V15, P1125, DOI 10.1093/carcin/15.6.1125; TAKAHASHI M, 1994, HEMATOL ONCOL, V12, P53, DOI 10.1002/hon.2900120202; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TSUCHIYA H, 1988, BLOOD, V72, P796; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832	56	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					649	659		10.1038/sj.onc.1206180	http://dx.doi.org/10.1038/sj.onc.1206180			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569357				2022-12-17	WOS:000180642100002
J	Furuta, S; Miura, K; Copeland, T; Shang, WH; Oshima, A; Kamata, T				Furuta, S; Miura, K; Copeland, T; Shang, WH; Oshima, A; Kamata, T			Light Chain 3 associates with a Sos1 guanine nucleotide exchange factor: its significance in the Sos1-mediated Rac1 signaling leading to membrane ruffling	ONCOGENE			English	Article						Sos1; Rac1; light chain 3	PROTEIN; BINDING; RAS; AUTOPHAGOSOME; ACTIVATION; DOMAIN; YEAST; MSOS1	A 19 kDa protein was identified to associate with the Dbl oncogene homology domain of Sos1 (Sos-DH) and was purified from rat brains by GST-Sos-DH affinity chromatography. Peptide sequencing revealed that the protein is identical to light chain 3 (LC3), a microtubule-associated protein. LC3 coimmunoprecipitated with Sos1, and GST-LC3 was capable of forming complexes with Sos1 in in vitro GST-pull down assay. Furthermore, LC3 was colocalized with Sos1 in cells, as determined by immunohistochemistry. While Sos1 stimulated the guanine nucleotide exchange reaction on Rac1, LC3 suppressed the ability of Sos1 to activate Rac1 in in vitro experiments using COS cell lysates. Consistent with this, overexpression of LC3 decreased the level of active GTP-bound Rac1 in COS cells. Sos1 expression induced membrane ruffling, a downstream target for Rac1, but LC3 expression inhibited this biological effect of Sos1. These findings suggest that LC3 interacts with Sos1 and thereby negatively regulates the Sos1-dependent Rac1 activation leading to membrane ruffling.	Shinshu Univ, Sch Med, Dept Biochem & Mol Biol, Matsumoto, Nagano 3908621, Japan; NCI, Frederick Canc Res & Dev Ctr, IRSP, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Wlodawers Program Struct Biol, Frederick, MD 21702 USA	Shinshu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Biochem & Mol Biol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.							Downward J, 1996, CANCER SURV, V27, P87; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; MANN SS, 1994, J BIOL CHEM, V269, P11492; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; VAN AL, 1997, GENE DEV, V11, P2295; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	15	13	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7060	7066		10.1038/sj.onc.1205790	http://dx.doi.org/10.1038/sj.onc.1205790			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370828				2022-12-17	WOS:000178424900009
J	Chou, AH; Howard, BD				Chou, AH; Howard, BD			Inhibition by Wnt-1 or Wnt-3a of nerve growth factor-induced differentiation of PC12 cells is reversed by bisindolylmaleimide-I but not by several other PKC inhibitors	ONCOGENE			English	Article						bisindolylmaleimide-I; protein kinase C; signaling	PROTEIN-KINASE-C; GLYCOGEN-SYNTHASE KINASE-3; SIGNALING PATHWAY; PHEOCHROMOCYTOMA CELLS; INT-1 PROTOONCOGENE; COLON-CARCINOMA; ACTIVATION; MOUSE; EXPRESSION; POTENT	Wnt-1 and Wnt-3a exhibit redundancy in neural crest development. We have found that they do not produce the same effects on PC12 cells, which were obtained from the adrenal medulla, a neural crest derivative. However, both Wnt-1 or Wnt-3a inhibit nerve growth factor (NGF)-induced neurite outgrowth. The inhibition is reversed by the protein kinase C (PKC) inhibitor, bisindolylmaleimide-I, but it did not reverse Wnt-l-induced activation of the canonical Writ pathway. The Wnt-1 inhibitory effect was not reversed by several other PKC inhibitors, by phorbol ester-induced down-regulation of PKC, or by pertussis toxin, which is known to inhibit another Writ signaling pathway, the Wnt/Ca2+ pathway. We suggest that bisindolylmaleimide-I acts by affecting either a pathway downstream from Lef-1/Tcf in the canonical pathway or a Writ signaling pathway other than the canonical pathway. In either case, the bisindolylmaleimide-I sensitivity of this pathway should aid in its identification.	Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Howard, BD (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, Sch Med, Los Angeles, CA 90095 USA.							ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; BITLER CM, 1986, J NEUROCHEM, V47, P1286; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; BURSTEIN DE, 1982, BRAIN RES, V247, P115, DOI 10.1016/0006-8993(82)91033-2; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chou AH, 2000, MOL BRAIN RES, V77, P232, DOI 10.1016/S0169-328X(00)00058-9; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; EDREICHEPSTEIN A, 1998, GROWTH FACTORS, V15, P149; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Ito Y, 1997, J NEUROCHEM, V69, P729; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Liu T, 1999, J BIOL CHEM, V274, P33539, DOI 10.1074/jbc.274.47.33539; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; Sambrook J, 1989, MOL CLONING LAB MANU; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRACHTE GJ, 1995, AM J PHYSIOL-CELL PH, V268, pC978, DOI 10.1152/ajpcell.1995.268.4.C978; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; XIE RP, 1995, DEV BRAIN RES, V87, P77, DOI 10.1016/0165-3806(95)00061-H; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377	35	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6348	6355		10.1038/sj.onc.1205791	http://dx.doi.org/10.1038/sj.onc.1205791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214275				2022-12-17	WOS:000177829000011
J	Ratcliffe, KE; Tao, Q; Yavuz, B; Stoletov, KV; Spring, SC; Terman, BI				Ratcliffe, KE; Tao, Q; Yavuz, B; Stoletov, KV; Spring, SC; Terman, BI			Sck is expressed in endothelial cells and participates in vascular endothelial growth factor-induced signaling	ONCOGENE			English	Article						VEGF; KDR; Shc; Sck; angiogenesis	FACTOR RECEPTOR KDR; PHOSPHOTYROSINE INTERACTION DOMAIN; TYROSINE KINASE; PERMEABILITY FACTOR; ADAPTER PROTEIN; SH2 DOMAINS; FOCAL ADHESIONS; DNA-SYNTHESIS; TUMOR-GROWTH; IN-VIVO	Sek, a member of the She family of cell signaling proteins, has only been studied in neuronal cells, though previous studies have demonstrated its expression in tissues other than brain. Using RT-PCR and RNase protection assays, we detected Sek mRNA expression in endothelial cells, and Sek protein was detected by Western blotting using polyclonal and monoclonal antibodies targeting the Sek CH1 domain. Immunohistochemistry protocols demonstrate that Sck is expressed in KDR and PECAM positive cells found in the mouse retina, mouse heart and human umbilical chord. Treatment of human umbilical vein endothelial (HUVE) cells with vascular endothelial growth factor (VEGF) leads to the recruitment of Sck to the KDR VEGF receptor and an enhanced Sek tyrosine phosphorylation. Sek is recruited to KDR tyrosine 1175, as coimmunoprecipitation of KDR and Sek is not observed in VEGF-treated porcine aortic endothelial cells expressing a receptor mutated at this autophosphorylation site. The Sek and She SH2 domains, and not the PTB domain, mediates its interactions with KDR, as recombinant Sek SH2 domain binds to a tyrosine phosphorylated KDR 1175-derived synthetic peptide, but not to a peptide synthesized without tyrosine phosphate. Recombinant PLCgamma, SH2 domain also interacts with the phosphotyrosine 1175 containing peptide. VEGF-induced MAPK activation is dependent upon PLCgamma activity, and chimeric proteins consisting of the She or Sek SH2 domains fused with a cellular internalization sequence attenuated this activation. Taken together, these results demonstrate that Sck is expressed in vascular endothelial cells, and participates in VEGF-induced signal transduction.	Albert Einstein Coll Med, Div Cardiol, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Terman, BI (corresponding author), Albert Einstein Coll Med, Div Cardiol, Dept Med, Forchheimer 715,1300 Morris Pk Ave, Bronx, NY 10461 USA.	Terman@aecom.yu.edu		Stoletov, Konstantin/0000-0002-7384-2917	NCI NIH HHS [R01 CA86289-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kojima T, 2001, BIOCHEM BIOPH RES CO, V284, P1039, DOI 10.1006/bbrc.2001.5080; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lai KMV, 2000, GENE DEV, V14, P1132; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEER J, 1995, LAB INVEST, V72, P638; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yoshiji H, 1996, CANCER RES, V56, P2013; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6307	6316		10.1038/sj.onc.1205781	http://dx.doi.org/10.1038/sj.onc.1205781			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214271				2022-12-17	WOS:000177829000007
J	Larmonier, N; Billerey, C; Rebe, C; Parcellier, A; Moutet, M; Fromentin, A; Kroemer, G; Garrido, C; Solary, E; Martin, F; Bonnotte, B				Larmonier, N; Billerey, C; Rebe, C; Parcellier, A; Moutet, M; Fromentin, A; Kroemer, G; Garrido, C; Solary, E; Martin, F; Bonnotte, B			An atypical caspase-independent death pathway for an immunogenic cancer cell line	ONCOGENE			English	Article						apoptosis; necrosis; caspase-independent; z-VAD; tumor immunology	DENDRITIC CELLS; NUCLEAR TRANSLOCATION; APOPTOTIC CELLS; ACTIVATED DNASE; ANTIGEN; BCL-2; INHIBITION; EXPRESSION; MATURATION; FORM	REGb cell line, a highly immunogenic tumor cell variant isolated from a rat colon cancer, yields regressive tumors when injected into syngeneic hosts. We previously demonstrated that REGb tumor immunogenicity was related to the capacity of releasing dead cells in vivo. Also, in vitro, REGb cell monolayers release dead cells, especially when cultured in serum-free medium. In the current study, we show that the release of dead cells results from an atypical death process associating features of necrosis and apoptosis. In spite of features considered as hallmarks of caspase-dependent apoptosis, including chromatin fragmentation and DNA oligonucleosomal cleavage, caspases are not activated and caspase inhibitors are ineffective to prevent REGb cell death. In contrast with a number of other types of cell death, the spontaneous death of REGb cells in culture depends on de novo protein synthesis as this death is blocked by low doses of the mRNA translation inhibitor cycloheximide. This unusual mode of cell death that associates necrotic and apoptotic features could provide optimal conditions for triggering a specific immune response.	Fac Med & Pharm Dijon, INSERM U517, IFR 100, F-21079 Dijon, France; Inst Gustave Roussy, CNRS UMR 1599, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Gustave Roussy	Bonnotte, B (corresponding author), Fac Med & Pharm Dijon, INSERM U517, IFR 100, 7 Blvd Jeanne Arc, F-21079 Dijon, France.		Kroemer, Guido/AAY-9859-2020; Garrido, Carolina/GWM-5557-2022; Garrido, carmen/G-1633-2018; KROEMER, Guido/B-4263-2013; Bonnotte, Bernard/ABA-2525-2021; REBE, Cédric/AAD-4316-2019	Garrido, carmen/0000-0003-1368-1493; KROEMER, Guido/0000-0002-9334-4405; Bonnotte, Bernard/0000-0002-1098-4598; REBE, Cédric/0000-0001-8831-145X; Solary, Eric/0000-0002-8629-1341				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Belmokhtar CA, 2000, EXP CELL RES, V254, P99, DOI 10.1006/excr.1999.4737; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; Bonnotte B, 1998, J IMMUNOL, V161, P1433; Bonnotte B, 2000, J IMMUNOL, V164, P1995, DOI 10.4049/jimmunol.164.4.1995; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; Chen DX, 2000, J BIOL CHEM, V275, P38508, DOI 10.1074/jbc.M003906200; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Famulski KS, 1999, CELL DEATH DIFFER, V6, P281, DOI 10.1038/sj.cdd.4400495; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Rovere P, 1998, J IMMUNOL, V161, P4467; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Shaif-Muthana M, 2000, CANCER RES, V60, P6441; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Torriglia A, 2000, ANN NY ACAD SCI, V926, P192; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956	25	13	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6091	6100		10.1038/sj.onc.1205738	http://dx.doi.org/10.1038/sj.onc.1205738			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203121				2022-12-17	WOS:000177671300012
J	Fang, WZ; Mori, T; Cobrinik, D				Fang, WZ; Mori, T; Cobrinik, D			Regulation of PML-dependent transcriptional repression by pRB and low penetrance pRB mutants	ONCOGENE			English	Article						pRB; PML; Mad; transcriptional repression; senescence	ACUTE PROMYELOCYTIC LEUKEMIA; CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; RAR-ALPHA; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; GROWTH-SUPPRESSOR; TUMOR-CELLS; PREMATURE SENESCENCE; ONCOGENIC RAS	The retinoblastoma protein (pRB) is thought to suppress tumorigenesis, in part, through interactions with E2F transcription factors. However, certain low penetrance pRB mutants substantially reduce tumor incidence despite having a minimal ability to bind E2F. These low penetrance mutants retain the ability to induce a senescence-like state, suggesting that they may suppress tumorigenesis through a senescence-associated process. Here, we identify a novel pRB function that is associated with senescence and which is retained by non-EN binding low penetrance pRB mutants. It was found that pRB and these mutants substantially increased the production of PML nuclear bodies (NBs). In keeping with the role of PML in transcriptional repression, pRB also promoted PML-dependent transcriptional repression by the c-Myc antagonist Mad1. In a series of pRB-p130 chimeric proteins, the ability to increase NB production correlated with the ability to induce a senescence-like phenotype. However, neither NB formation nor PML function were required for pRB to induce the senescence-like response. Together, these observations indicate that a pRB-induced increase in PML NB formation is coordinated with, but separable from, the pRB-induced senescence program. The data further suggest that PML may contribute to an E2F-independent tumor suppressor function of pRB.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Cobrinik, D (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	dc197@columbia.edu			NCI NIH HHS [P30CA 13696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gottifredi V, 2001, TRENDS CELL BIOL, V11, P184, DOI 10.1016/S0962-8924(01)01983-3; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harbour JW, 2001, CURR TOP MICROBIOL, V254, P137; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Jiang WQ, 1997, CELL GROWTH DIFFER, V8, P513; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2001, J BIOL CHEM, V276, P43491, DOI 10.1074/jbc.C100532200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KRATZKE RA, 1994, ONCOGENE, V9, P1321; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Otterson GA, 1999, AM J HUM GENET, V65, P1040, DOI 10.1086/302581; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Zhang P, 2000, INT J CANCER, V85, P599, DOI 10.1002/(SICI)1097-0215(20000301)85:5<599::AID-IJC1>3.0.CO;2-#; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	55	13	14	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5557	5565		10.1038/sj.onc.1205666	http://dx.doi.org/10.1038/sj.onc.1205666			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165854				2022-12-17	WOS:000177442000005
J	Nakamura, S; Roth, JA; Mukhopadhyay, T				Nakamura, S; Roth, JA; Mukhopadhyay, T			Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells	ONCOGENE			English	Article						MDM2; p53; E6	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; P53-MEDIATED APOPTOSIS; STABILIZES P53; ONCOPROTEIN; PROMOTES; UBIQUITINATION; ASSOCIATION; ONCOGENE; TARGETS	We have recently shown that lysine mutations in p53's putative C-terminal acetylation sites result in increased stability and cytoplasmic distribution of the p53 protein in a human lung cancer cell line. In the present study, we showed that when lysine residues 372, 373, 381, and 382 of p53 were substituted with alanine, the resulting A4 protein was resistant to MDM2-mediated proteosomal degradation but was highly sensitive to human papillomavirus E6-mediated proteolysis. When A4 and wildtype p53 were transfected into MDM2-overexpressing MCF-7 cells, A4 significantly reduced colony formation in vitro, when compared with wild-type p53. Our results suggest that A4 exerts a growth-inhibitory effect more efficiently than wild-type p53 does in cell lines that overexpress MDM2 and may therefore be a better therapeutic tool than wild-type p53 for certain cancers in which MDM2 is amplified or overexpressed.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd,Box 445, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P01CA078778, P50CA070907, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA-70907, P01 CA 78778-01A1, 2P50-CA 70970-04, P50-CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Buschmann T, 2001, J BIOL CHEM, V276, P13852, DOI 10.1074/jbc.M007955200; Chen JD, 1996, MOL CELL BIOL, V16, P2445; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meng RD, 1998, CLIN CANCER RES, V4, P251; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; NAKAMURA S, 2002, IN PRESS ONCOGENE; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; REIHSAUS E, 1990, ONCOGENE, V5, P137; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas M, 1996, ONCOGENE, V13, P265; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	39	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2605	2610		10.1038/sj.onc.1205343	http://dx.doi.org/10.1038/sj.onc.1205343			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971195				2022-12-17	WOS:000174918400017
J	Nakamura, S; Gomyo, Y; Roth, JA; Mukhopadhyay, T				Nakamura, S; Gomyo, Y; Roth, JA; Mukhopadhyay, T			C-terminus of p53 is required for G(2) arrest	ONCOGENE			English	Article						p53; p21; G(2) arrest	DNA-DAMAGE; CELL-CYCLE; PHOSPHORYLATION; INHIBITION; APOPTOSIS; CANCER; MDM2; CHECKPOINTS; ACETYLATION; EXPRESSION	Mutation of four lysine residues in the p53 C-terminal domain inhibits MDM2-dependent ubiquitination of p53 and alters its subcellular distribution. This implies that modification (such as acetylation and phosphorylation) of amino acid residues in p53 C-terminal domain, regulate the biological functions of p53. In this study, we demonstrated that p53 with lysine residues 372, 373, 381, and 382 mutated to alanine (the A4 mutant) retained the transactivation activity of wild-type p53, although the transactivation activity of p21 promoter by the A4 mutant was slightly reduced. The inducible expression of wild-type p53 and the A4 mutant in H1299 cells caused growth inhibition due to cell-cycle arrest. Consistent with previous studies, the expression of wild-type p53 elicited G(1) and G(2) arrests. However, the cells expressing the A4 mutant underwent G(1) arrest but not G(2) arrest. Cyclin B1-associated kinase activity was reduced in cells expressing wild-type p53 but not A4, when the cells underwent G(2) arrest. This suggests that modification of the p53 C-terminal domain might inhibit p53-mediated G(2) arrest. In other words, p53 requires an intact C-terminus to induce G(2) arrest.	Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Dept Thorac & Cardiovasc Surg, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.	tmukhopa@mail.mdanderson.org			NCI NIH HHS [2P50 CA70970-04, P50-CA70907, P01 CA78778-01A1, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, P01CA078778, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; STEWART N, 1995, ONCOGENE, V10, P109; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	31	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2102	2107		10.1038/sj.onc.1205251	http://dx.doi.org/10.1038/sj.onc.1205251			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960383				2022-12-17	WOS:000174827000017
J	Baldassarre, G; Bruni, P; Boccia, A; Salvatore, G; Melillo, RM; Motti, ML; Napolitano, M; Belletti, B; Fusco, A; Santoro, M; Viglietto, G				Baldassarre, G; Bruni, P; Boccia, A; Salvatore, G; Melillo, RM; Motti, ML; Napolitano, M; Belletti, B; Fusco, A; Santoro, M; Viglietto, G			Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1)	ONCOGENE			English	Article						GDNF; RET; p27; embryonal carcinoma	EMBRYONAL CARCINOMA-CELLS; NEURONAL DIFFERENTIATION; RETINOIC ACID; TYROSINE KINASE; NTERA-2 CELLS; GROWTH-FACTOR; PC12 CELLS; ACTIVATION; RECEPTOR; SURVIVAL	Growth factors of the glial cell line-derived neurotrophic factor (GDNF) family control the differentiation of neuronal cells of the central and peripheral nervous systems. Intracellular signalling of these growth factors is, at least in part, mediated by activation of the RET receptor tyrosine kinase. Here, we demonstrate that GDNF triggering inhibits the proliferation of the embryonal carcinoma cell line NT2/Dl. This antiproliferative effect is accompanied by down-regulation of the SSEA-3 antigen, a marker typical of undifferentiated NT2/D1 cells. We show that these effects are mediated by activation of RET signalling. The block of RET by a kinase-deficient dominant negative mutant impairs GDNF-dependent growth inhibition, whereas the adoptive expression of a constitutively active RET, the RET-MEN2A oncogene, promotes effects similar to those exerted by GDNF. We show that RET signalling increases the expression of the cyclin-dependent kinase inhibitor P27(kip1) in NT2/Dl cells. Both DNA synthesis inhibition and SSEA-3 down-regulation are prevented if p27(kip1) expression is blocked by an antisense construct, which demonstrates that RET-triggered effects are mediated by p27(kip1).	Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Ist Nazl Tumori, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, BIOGEM, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II	Viglietto, G (corresponding author), Univ Naples Federico II, CNR, Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	gvigliet@tin.it	Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019; melillo, rosa marina/O-5255-2015; napolitano, maria/K-1615-2016	Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275; napolitano, maria/0000-0002-8996-3297				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Billon N, 1996, ONCOGENE, V13, P2047; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; CALIFANO D, 1995, ONCOGENE, V11, P107; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; De Vita G, 2000, CANCER RES, V60, P3916; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE VMY, 1986, J NEUROSCI, V6, P514; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyazono M, 1996, J COMP NEUROL, V376, P603, DOI 10.1002/(SICI)1096-9861(19961223)376:4<603::AID-CNE8>3.0.CO;2-5; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Rose GM, 1999, AGE, V22, P1, DOI 10.1007/s11357-999-0001-8; SAMBROOK J, 1989, MOL CLONINB LAB MANU; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; YAN GZ, 1995, J NEUROSCI, V15, P6200	38	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1739	1749		10.1038/sj.onc.1205226	http://dx.doi.org/10.1038/sj.onc.1205226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896605				2022-12-17	WOS:000174214200012
J	Yi, KS; Chung, JH; Lee, YH; Chung, HG; Kim, IJ; Suh, BC; Kim, E; Cocco, L; Ryu, SH; Suh, PG				Yi, KS; Chung, JH; Lee, YH; Chung, HG; Kim, IJ; Suh, BC; Kim, E; Cocco, L; Ryu, SH; Suh, PG			Inhibition of the EGF-induced activation of phospholipase C-gamma 1 by a single chain antibody fragment	ONCOGENE			English	Article						PLC-gamma 1; single chain antibody (scFv); EGF	C ISOZYMES; INTRACELLULAR EXPRESSION; TYROSINE RESIDUES; ELEVATED CONTENT; SCFV FRAGMENT; DNA-SYNTHESIS; SH3 DOMAIN; GROWTH; RECEPTOR; CELLS	Phospholipase C-gamma (PLC-gamma1) is known to play an essential role in various cellular responses, such as proliferation and tumorigenesis, and PLC-gamma1 -specific inhibitors are commonly employed to investigate the mechanism of the PLC-gamma1-mediated signaling pathway. In this study, we developed a single chain antibody fragment (scFv) as a blocker for PLC-gamma1 mediated signaling. scFv, designated F7-scFv, specifically bound to PLC-gammal with high affinity (K-d= 1.9 x 10(-8) M) in vitro. F7-scFv also bound to PLC-gamma1 in vivo and altered the distribution pattern of PLC-gamma1 from the cytoplasm to the intracellular aggregates, where F7-scFv was localized. Moreover, F7-scFv interrupted the EGF-induced translocation of PLC-gamma1 from the cytosol to the membrane ruffle and attenuated EGF-induced inositol phosphates generation and intracellular calcium mobilization. These results indicate that F7-scFv blocks EGF-induced PLC-gamma1 activation by causing sequestering of PLC-gamma1 into intracellular aggregates, and may therefore be useful in studies of the PLC-gamma1-mediated signaling pathway.	Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 7907840, Kyungbuk, South Korea; Seoul Natl Univ, Coll Med, Dept Biochem, Seoul 110799, South Korea; Yeungnam Univ, Coll Med, Dept Biochem, Kyongsan 712749, South Korea; Dongguk Univ, Coll Med, Dept Microbiol, Kyungju 780140, South Korea; Univ Bologna, Cellular Signaling Lab, Dept Anat Sci, I-40126 Bologna, Italy	Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); Yeungnam University; Dongguk University; University of Bologna	Suh, PG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 7907840, Kyungbuk, South Korea.		Kim, In-San/D-3956-2017; Chung, Junho/J-2792-2012; Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Bae SS, 2000, FASEB J, V14, P1083, DOI 10.1096/fasebj.14.9.1083; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; Cardinale A, 1998, FEBS LETT, V439, P197, DOI 10.1016/S0014-5793(98)01369-6; Cattaneo A, 1999, TRENDS BIOTECHNOL, V17, P115, DOI 10.1016/S0167-7799(98)01268-2; Chang JS, 1997, CANCER RES, V57, P5465; Cochet O, 1998, CANCER RES, V58, P1170; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kabat EA, 1991, SEQUENCES PROTEINS I; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCCAFFERTY J, 1996, ANTIBODY ENG PRACTIC; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Nebigil CG, 1997, BIOCHEMISTRY-US, V36, P15949, DOI 10.1021/bi971721m; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; PARK JG, 1994, CANCER RES, V54, P2240; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; SUH PG, 1988, J BIOL CHEM, V263, P14497; Tsumoto K, 1998, J IMMUNOL METHODS, V219, P119, DOI 10.1016/S0022-1759(98)00127-6; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; Yi K, 1999, HYBRIDOMA, V18, P243, DOI 10.1089/027245799315899	42	13	13	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7954	7964		10.1038/sj.onc.1204959	http://dx.doi.org/10.1038/sj.onc.1204959			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753678				2022-12-17	WOS:000172288700004
J	Cassinat, B; Chomienne, C				Cassinat, B; Chomienne, C			Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management	ONCOGENE			English	Article						APL blasts; differentiation; granulopoiesis; retinoids; RARa gene rearrangements	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML-RAR-ALPHA; INDUCED GRANULOCYTIC DIFFERENTIATION; COLONY-STIMULATING FACTOR; HISTONE DEACETYLASE; MYELOID-LEUKEMIA; RECEPTOR-ALPHA; CELLS; GENE	In recent years, discovery of the in vitro and in giro differentiation of APL blasts by all-trans retinoic acid (ATRA) has modified the therapeutic approach of APL and lead to important advances in understanding the biology of APL. Since it became apparent that differentiation therapy of APL with ATRA was indeed a true model of targetted therapy, evidencing the molecular targets of retinoic acid efficacy became crucial. These molecular targets are closely related to the biological features of APL cells, some of which are well-known and have contributed to the morphological and cytogenetic definition of the leukemia, others have just been defined or re-discovered in the light of a better understanding of molecular controls of cell growth and differentiation. The aims of characterizing the biological features of APL cells should allow a better management of APL therapy and the identification of potential markers for differentiation therapies in other leukemias or solid tumors.	Hop St Louis, Inst Hematol, Lab Biol Cellulaire Hematopoiet, INSERM E 00 03, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chomienne, C (corresponding author), Hop St Louis, Inst Hematol, Lab Biol Cellulaire Hematopoiet, INSERM E 00 03, 1 Ave Claude Vellefaux, F-75010 Paris, France.		CASSINAT, BRUNO/N-2752-2017	CASSINAT, BRUNO/0000-0002-6514-3905; CHOMIENNE, Christine/0000-0001-5513-5752				AGADIR A, 1995, J CLIN ONCOL, V13, P2517, DOI 10.1200/JCO.1995.13.10.2517; AGADIR A, 1995, BIOCHEM BIOPH RES CO, V213, P112, DOI 10.1006/bbrc.1995.2105; Allford S, 1999, BRIT J HAEMATOL, V105, P198; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Belaaouaj A, 1999, MAMM GENOME, V10, P210; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Calabresse C, 1995, LEUKEMIA, V9, P2049; Cassinat B, 1998, BLOOD, V92, p596A; CASSINAT B, 2001, IN PRESS BLOOD; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANG KS, 1992, BLOOD, V79, P1802; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; CHOMIENNE C, 1990, BLOOD, V76, P1710; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Da Silva N, 2000, Hematol J, V1, P316, DOI 10.1038/sj.thj.6200047; De Botton S, 1998, BLOOD, V92, P2712, DOI 10.1182/blood.V92.8.2712.420k03_2712_2718; de Botton S, 2000, BRIT J HAEMATOL, V111, P801, DOI 10.1046/j.1365-2141.2000.02442.x; DEGENTILE A, 1994, LEUKEMIA, V8, P1758; DELVA L, 1993, BLOOD, V82, P2175; Delva L, 1999, MOL CELL BIOL, V19, P7158; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; DOMBRET H, 1993, LEUKEMIA, V7, P2; Douer D, 2001, BLOOD, V97, P73, DOI 10.1182/blood.V97.1.73; DUBOIS C, 1994, LEUKEMIA, V8, P1750; DUBOIS C, 1994, BLOOD, V83, P3264; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Exner M, 2000, CYTOMETRY, V42, P106, DOI 10.1002/(SICI)1097-0320(20000415)42:2<106::AID-CYTO3>3.0.CO;2-S; Fenaux P, 1999, BLOOD, V94, P1192, DOI 10.1182/blood.V94.4.1192.416k07_1192_1200; Ferrara F, 2000, J CLIN ONCOL, V18, P1295, DOI 10.1200/JCO.2000.18.6.1295; Foley R, 2001, AM J HEMATOL, V67, P34, DOI 10.1002/ajh.1073; GALLAGHER RE, 1995, BLOOD, V86, P1540, DOI 10.1182/blood.V86.4.1540.bloodjournal8641540; Garattini E, 1996, LEUKEMIA LYMPHOMA, V23, P493, DOI 10.3109/10428199609054858; GJERTSEN MK, 1995, LANCET, V346, P1399, DOI 10.1016/S0140-6736(95)92408-6; GRIGNANI F, 1994, BLOOD, V83, P10; Grimwade D, 2000, BLOOD, V96, P1297; Guglielmi C, 1998, BRIT J HAEMATOL, V102, P1035, DOI 10.1046/j.1365-2141.1998.00871.x; GUIDEZ F, 1994, LEUKEMIA, V8, P312; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hsu HC, 1999, EUR J HAEMATOL, V63, P11; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; JURCIC JG, 1995, LEUKEMIA, V9, P244; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Miyauchi J, 1997, BLOOD, V90, P803, DOI 10.1182/blood.V90.2.803.803_803_813; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; MUINDI J, 1992, BLOOD, V79, P299; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; Neame PB, 1997, AM J HEMATOL, V56, P131, DOI 10.1002/(SICI)1096-8652(199711)56:3<131::AID-AJH1>3.0.CO;2-Z; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Novick S, 1999, BLOOD, V94, p61A; PAIETTA E, 1994, LEUKEMIA, V8, P1108; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; Pollock JL, 2000, BLOOD, V96, p827A; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; Sainty D, 2000, BLOOD, V96, P1287; Seale J, 1996, LEUKEMIA, V10, P95; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Slack JL, 1997, J CLIN ONCOL, V15, P1786, DOI 10.1200/JCO.1997.15.5.1786; Slack JL, 1998, BLOOD, V91, P3347, DOI 10.1182/blood.V91.9.3347.3347_3347_3356; Thomas X, 2000, LEUKEMIA, V14, P1006, DOI 10.1038/sj.leu.2401800; TOSI P, 1994, LEUKEMIA LYMPHOMA, V14, P503, DOI 10.3109/10428199409049711; Wang ZG, 1998, SCIENCE, V279, P1547; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	83	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7154	7160		10.1038/sj.onc.1204761	http://dx.doi.org/10.1038/sj.onc.1204761			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704844				2022-12-17	WOS:000171891900004
J	Barton, MC; Crowe, AJ				Barton, MC; Crowe, AJ			Chromatin alteration, transcription and replication: What's the opening line to the story?	ONCOGENE			English	Review						chromatin; replication; transcription; polymerase; remodeling	RNA-POLYMERASE-II; CHROMOSOMAL DNA-REPLICATION; BETA-GLOBIN LOCUS; HISTONE ACETYLATION; REMODELING COMPLEX; INTERGENIC TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; TRANSCRIBING POLYMERASE; NUCLEOSOME STRUCTURE; ACTIVATION DOMAIN	Polymerase accessibility to chromatin is a limiting step in both RNA and DNA synthesis. Unwinding DNA and nucleosomes during polymerase complex binding and processing likely requires priming by chromatin restructuring. The initiating step in these processes remains an area of speculation, This review focuses on the physical handling of chromatin during transcription and replication, the fate of nucleosomes assembled on DNA during unwinding and processing the chromatin substrate, and how these alterations in chromatin structure may affect gene expression, Transcription or replication may alter chromatin structure during synthesis, enabling regulatory factor binding and, potentially, future rounds of transcription. As chromatin remodeling and transcription factor binding augment transcription and replication, and are themselves increased by these processes, a temporal model of structural alterations and gene activation is built that mag be more circular than linear.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Texas System; UTMD Anderson Cancer Center; University of Washington; University of Washington Seattle	Barton, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.			Barton, Michelle/0000-0002-4042-1374				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BARTON MC, 1994, GENE DEV, V8, P2453, DOI 10.1101/gad.8.20.2453; BASTOS RN, 1977, CELL, V11, P641, DOI 10.1016/0092-8674(77)90081-2; Bednar J, 1999, MOL CELL, V4, P377, DOI 10.1016/S1097-2765(00)80339-1; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Brown SA, 1997, GENE DEV, V11, P3116, DOI 10.1101/gad.11.23.3116; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Crowe AJ, 2000, MOL CELL BIOL, V20, P4169, DOI 10.1128/MCB.20.11.4169-4180.2000; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; Flanagan JF, 1999, NUCLEIC ACIDS RES, V27, P2022, DOI 10.1093/nar/27.9.2022; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; GROUDINE M, 1981, CELL, V24, P393, DOI 10.1016/0092-8674(81)90329-9; Groudine M, 1989, Prog Clin Biol Res, V316A, P15; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; IMAIZUMI T, 1973, P NATL ACAD SCI USA, V70, P1122, DOI 10.1073/pnas.70.4.1122; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kershnar E, 1998, J BIOL CHEM, V273, P34444, DOI 10.1074/jbc.273.51.34444; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kodadek T, 1998, TRENDS BIOCHEM SCI, V23, P79, DOI 10.1016/S0968-0004(97)01165-1; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Li R, 1999, J BIOL CHEM, V274, P30310, DOI 10.1074/jbc.274.42.30310; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; Litt MD, 1997, J BIOL CHEM, V272, P14921, DOI 10.1074/jbc.272.23.14921; LUCCHINI R, 1995, NATURE, V374, P276, DOI 10.1038/374276a0; Muller M, 2000, MOL CELL, V5, P767, DOI 10.1016/S1097-2765(00)80317-2; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Travers A, 1999, P NATL ACAD SCI USA, V96, P13634, DOI 10.1073/pnas.96.24.13634; Venturi CB, 2000, MOL CELL BIOL, V20, P6435, DOI 10.1128/MCB.20.17.6435-6448.2000; Verreault A, 2000, GENE DEV, V14, P1430; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; WOLFFE AP, 1991, J CELL SCI, V99, P201; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	67	13	13	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3094	3099		10.1038/sj.onc.1204334	http://dx.doi.org/10.1038/sj.onc.1204334			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420725				2022-12-17	WOS:000169308500013
J	Prasher, JM; Elenitoba-Johnson, KSJ; Kelley, LL				Prasher, JM; Elenitoba-Johnson, KSJ; Kelley, LL			Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia	ONCOGENE			English	Article						p53; erythroleukemia; Friend virus	VIRUS-INDUCED ERYTHROLEUKEMIA; MURINE LEUKEMIA-VIRUS; MULV-INDUCED-ERYTHROLEUKEMIAS; TRANSGENIC MICE DEVELOP; ERYTHROPOIETIN RECEPTOR; F-MULV; CELL-DEATH; GENE; GROWTH; ONCOGENE	A role for p53 in the in vivo progression of Friend virus-induced erythroleukemia has been suggested but not clearly defined, We developed a Friend virus-sensitive, p53-deficient mouse model to directly address the role of p53 in Friend erythroleukemia. When infected with the polycythemia-inducing strain of Friend virus (FVP), p53 null mice exhibited accelerated progression to erythroleukemia and accelerated death following diagnosis when compared to wild type mice. Confirmation that p53 mutations were required for disease progression was provided by sequence analysis of p53 transcripts in leukemic wild type and heterozygous mice. All transcripts evaluated had point mutations, deletions or insertions in the p53 gene. The ability to grow tumor colonies in vitro and derive cell lines was enhanced in FVP-infected p53 null animals, Although PU.1 oncogene overexpression is a common mutation observed in cell lines derived from Friend virus-infected p53 wild type mice, it was not a universal finding in cell lines derived from p53 null animals. Our data conclusively demonstrate that loss of p53 function is a requirement for progression of Friend erythroleukemia in vivo. Further, the data demonstrate that erythroleukemias arising in Friend virus-infected p53 null mice are biologically and genetically distinct from those that occur in wild type animals, suggesting that the temporal order of PU.1 and p53 mutations is an important parameter in the pathogenesis of leukemic development. Oncogene (2001) 20, 3946-2955.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Huntsman Canc Inst, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Kelley, LL (corresponding author), Univ Utah, Dept Med, Div Hematol, SOM 4C416, Salt Lake City, UT 84102 USA.	linda.kelley@hsc.utah.edu		Elenitoba-Johnson, Kojo/0000-0002-1082-1545	NCI NIH HHS [CA83984-01] Funding Source: Medline; NIDDK NIH HHS [P50DK49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA083984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Hainaut P, 2000, ADV CANCER RES, V77, P81; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Koury MJ, 1997, BLOOD, V90, P4054, DOI 10.1182/blood.V90.10.4054; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; MUNROE DG, 1988, ONCOGENE, V2, P621; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHIBUYA T, 1982, CELL, V31, P483, DOI 10.1016/0092-8674(82)90141-6; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SOUSSI T, 2001, ANN NY ACAD SCI, P121; TAMBOURIN PE, 1973, BRIT J HAEMATOL, V24, P511, DOI 10.1111/j.1365-2141.1973.tb01677.x; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2946	2955		10.1038/sj.onc.1204395	http://dx.doi.org/10.1038/sj.onc.1204395			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420707				2022-12-17	WOS:000168901800010
J	Paggi, MG; Bonetto, F; Severino, A; Baldi, A; Battista, T; Bucci, F; Felsani, A; Lombardi, D; Giordano, A				Paggi, MG; Bonetto, F; Severino, A; Baldi, A; Battista, T; Bucci, F; Felsani, A; Lombardi, D; Giordano, A			The retinoblastoma-related Rb2/p130 gene is an effector downstream of AP-2 during neural differentiation	ONCOGENE			English	Article						AP-2; Rb2/p130; differentiation; NGF; PC12	TRANSCRIPTION FACTOR AP-2; NERVE GROWTH-FACTOR; PC12 CELLS; NEUROBLASTOMA-DIFFERENTIATION; EXPRESSION; PROTEINS; FAMILY; P107; P130; PROMOTER	Rb2/p130, a member of the Retinoblastoma family of growth and tumour suppressor genes, is extensively implicated in the control of cell cycle and differentiation. The minimal promoter region of Rb2/p130 in T98G human glioblastoma cells was identified and its analysis revealed the presence of a KER1 palindromic sequence able to bind the transcription factor AP-2, a regulatory protein that plays a crucial role in ectodermal differentiation, This KER1 site interacted in vitro with AP-2, and AP-2 overexpression increased Rb2/p130 transcription and translation, We also found that rat PC12 pheochromocytoma cells, when induced to differentiate by NGF, displayed an increase of AP-2 protein levels and of Rb2/p130 transcription and protein levels, AP-2-transfected PC12 cells displayed enhanced transcription and translation of Rb2/p130 and of the cdk inhibitor p21(WAF1/CIP1), a gene known to be under the control of AP-2, but unable by itself to elicit PC12 differentiation. Overexpression of either AP-2 or Rb2/p130 elicited per se cell differentiation in the absence of NGF, while coexpression of AP-IB, a negative regulator of AP-2 transcriptional activity, inhibited only AP-2-induced differentiation, Altogether, these results indicate that Rb2/p130 is a critical effector of AP-2 in sustaining ectodermal differentiation.	Regina Elena Canc Inst, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, I-00158 Rome, Italy; CNR, Ist Tecnol Biomed, I-00137 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; Jefferson University	Paggi, MG (corresponding author), Regina Elena Canc Inst, Ctr Expt Res, Lab Cell Metab & Pharmacokinet, Via Messi Doro 156, I-00158 Rome, Italy.		Severino, Anna/S-3417-2019; Giordano, Antonio/F-1927-2010; Felsani, Armando/D-1784-2010; Baldi, Alfonso/ABG-2397-2021; Paggi, Marco G./K-3494-2018	Severino, Anna/0000-0002-6276-7747; Giordano, Antonio/0000-0002-5959-016X; Felsani, Armando/0000-0001-8851-6295; Baldi, Alfonso/0000-0002-8693-3842	NCI NIH HHS [R01 CA 60999-01A1] Funding Source: Medline; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BENNETT GS, 1985, DEV BIOL, V107, P94, DOI 10.1016/0012-1606(85)90379-3; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Fajas L, 2000, FEBS LETT, V471, P29, DOI 10.1016/S0014-5793(00)01363-6; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTELLI F, 1994, ONCOGENE, V9, P3579; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLOPADE OI, 1992, CANCER RES, V52, P2523; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; PHILIPP J, 1994, DEV BIOL, V165, P602, DOI 10.1006/dbio.1994.1279; Puri PL, 1998, CANCER RES, V58, P1325; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STEINMAN RA, 1994, ONCOGENE, V9, P3389; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; Wu F, 1998, NUCLEIC ACIDS RES, V26, P4837, DOI 10.1093/nar/26.21.4837; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	53	13	14	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2570	2578		10.1038/sj.onc.1204356	http://dx.doi.org/10.1038/sj.onc.1204356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420667				2022-12-17	WOS:000168652500008
J	Liu, ML; Shibata, MA; Von Lintig, FC; Wang, WL; Cassenaer, S; Boss, GR; Green, JE				Liu, ML; Shibata, MA; Von Lintig, FC; Wang, WL; Cassenaer, S; Boss, GR; Green, JE			Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice	ONCOGENE			English	Article						Ki-ras; mammary gland tumor; transgenic mice	GROWTH IN-VITRO; MOUSE; GENE; EXPRESSION; CARCINOMA; ADENOCARCINOMA; IDENTIFICATION; AMPLIFICATION; SUPPRESSION; APOPTOSIS	We have previously demonstrated that amplification and overexpression of the Ki-ras gene is associated with mammary tumor progression in C3(1)/SV40Tag transgenic mice (Liu Et al,, 1998), To further evaluate the functional significance of the Ki-vas proto-oncogene in mammary cancer development, in vivo studies were conducted to examine the effect of Ki-vas gene dosage on tumor progression. The lack of one normal Ki-vas allele C3(1)/SV40Tag transgenic mice resulted in significantly delayed mammary intraepithelial neoplasia (MIN) formation as well as in a decreased number of mammary gland carcinomas, However, despite the retardation of tumor development by reduced Ki-ras gene dosage, overall survival was only modestly affected. This appears to be due to several factors including significant mammary tumor growth associated with Ki-ras gene amplification and over-expression that occurs during the advanced stage of oncogenesis in mice carrying either one or two normal Ki-ras alleles, The retardation of tumor progression due to the haploid loss of Ki-ras did not appear to be related to accelerated apoptosis, or a reduced rate of cell proliferation at the tumor stages examined. These data strongly suggest that the gene dosage of Ki-vas affects tumor promotion at an early stage of mammary tumor progression in this SV40 Tag-induced model of mammary oncogenesis.	NCI, Lab Cell Regulat & Carcinogenesis, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Div Basic Sci, NIH, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Boss, Gerry/0000-0002-9758-8714				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FILMUS JE, 1985, CANCER RES, V45, P4468; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GARCIA I, 1989, CANCER RES, V49, P6675; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GRAHAM KA, 1985, CANCER RES, V45, P2201; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Maroulakou IG, 1999, ONCOGENE, V18, P5435, DOI 10.1038/sj.onc.1202926; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; Sills RC, 1999, IARC SCI PUBL, P55; TANAKA T, 1986, CANCER RES, V46, P1465; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	24	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2044	2049		10.1038/sj.onc.1204280	http://dx.doi.org/10.1038/sj.onc.1204280			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360188				2022-12-17	WOS:000168043800012
J	O'Connor, RJ; Schaley, JE; Feeney, G; Hearing, P				O'Connor, RJ; Schaley, JE; Feeney, G; Hearing, P			The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters	ONCOGENE			English	Article						E2F; p107; p130; DNA binding; transcription repression	ADENOVIRUS E4-6/7 PROTEIN; CELLULAR TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; HISTONE DEACETYLASE; DEREGULATED EXPRESSION; COMPLEX-FORMATION; RNA-POLYMERASE; CYCLE; INDUCTION	E2F transcription factors are key players in the regulation of proliferation, apoptosis, and differentiation in mammalian cells. E2Fs are negatively regulated by members of the retinoblastoma protein family, Rb, p107 and p130, During adenovirus infection, viral proteins are expressed that displace Rb family members from E2Fs and recruit E2F complexes to viral and cellular promoter regions. This recruitment of E2F involves the induction of stable E2F binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters and induces both viral and cellular gene expression. The cellular p107 tumor suppressor also displays such regulation of E2F DNA binding activity. p107 induces stable E2F-4/DP binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters. The induction of E2F DNA binding by p107 minimally requires the sequences in p107 that mediate E2F interaction. The related tumor suppressor, p130, also effects this function. p107 levels increase substantially as cells progress through S phase. p107 induction of E2F DNA binding was observed primarily in S phase cells coincident with the increase in p107 protein levels. The results of promoter activity assays directly correlate the induction of E2F DNA binding by p107 with effective transcriptional repression. These results support a model in which p107 and p130 induce the stable binding of E2F complexes to promoters that drive expression of critical regulatory proteins such as E2F-1, Since p107 and p130 bind histone deacetylase complexes (HDACs) which repress promoter activity, p107-E2F and p130-E2F would stably recruit repressor complexes to effect efficient promoter repression.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hearing, P (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Guy CT, 1996, MOL CELL BIOL, V16, P685; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OCONNOR RJ, 1991, NUCLEIC ACIDS RES, V19, P6579, DOI 10.1093/nar/19.23.6579; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Schaley J, 2000, J VIROL, V74, P2084, DOI 10.1128/JVI.74.5.2084-2093.2000; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	13	13	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1882	1891		10.1038/sj.onc.1204278	http://dx.doi.org/10.1038/sj.onc.1204278			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313936				2022-12-17	WOS:000167908400009
J	Sugibayashi, R; Shimizu, T; Suzuki, T; Yamamoto, N; Hamada, H; Takeda, K				Sugibayashi, R; Shimizu, T; Suzuki, T; Yamamoto, N; Hamada, H; Takeda, K			Upregulation of p21(WAF1/CIP1) leads to morphologic changes and esterase activity in TPA-mediated differentiation of human prostate cancer cell line TSU-Pr1	ONCOGENE			English	Article						prostate cancer; TSU-Prl; differentiation; TPA; p21(WAF1/CIF1)	PROTEIN-KINASE-C; LEUKEMIA-CELLS; DOWN-REGULATION; PHORBOL ESTERS; CYCLE ARREST; MAP KINASE; EXPRESSION; GROWTH; P21; INHIBITOR	We reported previously that human prostate cancer cell line TSU-Pr1 can differentiate into microglia-like cells by 12-O-tetra-decanoylphorbol-13-acetate (TPA) treatment. In this study, we identified a signal transduction pathway involved in TPA-induced TSU-Pr1 cell differentiation and investigated the mechanism of growth arrest that accompanies this differentiation. TPA-induced differentiation and growth arrest of TSU-Pr1 cells were inhibited by treatment with Protein kinase C (PKC) inhibitor GF109203X and mitogen-activated protein (MAP) kinase inhibitor PD98059, Treatment of TSU-Pr1 cells with TPA for 15 min or longer resulted in translocation of PKC alpha, PKC gamma, and PKC epsilon from cytosolic to membrane fraction. Our results suggest that TPA-induced TSU-Pr1 cell differentiation is associated with activation of MAP kinase and PKC alpha, PKC gamma, and PKC epsilon, The mechanism of growth arrest in TSU-Pr1 cells that underwent TPA-induced differentiation were examined for factors in the signaling pathway downstream of MAP kinase that control the cell cycle. Upregulation of p21(WAF1/CIP1) cyclin-dependent kinase inhibitor protein was observed in a manner dependent on PKC or MAP kinase, Moreover, adenovirus-mediated overexpression of recombinant p21(WAF1/CP1) in TSU-Pr1 cells result in growth arrest, morphological change to microglia-like cells, and increased alpha -naphthyl acetate esterase activity, all of which are associated with cellular differentiation. Thus, our results indicate that p21(WAF1/CIP1) mediates TPA-induced growth arrest and differentiation of TSU-Pr1 cells.	Sci Univ Tokyo, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, Tokyo 1620826, Japan; Sapporo Med Univ, Dept Mol Med, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Tokyo University of Science; Sapporo Medical University	Takeda, K (corresponding author), Sci Univ Tokyo, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, 12 Ichigaya Funagawara Machi, Tokyo 1620826, Japan.							Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Barboule N, 1999, FEBS LETT, V444, P32, DOI 10.1016/S0014-5793(99)00022-8; BARENDSEN N, 1990, LEUKEMIA RES, V14, P467, DOI 10.1016/0145-2126(90)90034-7; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; BOUCHE M, 1995, CELL GROWTH DIFFER, V6, P845; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen J, 1996, ONCOGENE, V13, P1395; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Frey MR, 1997, J BIOL CHEM, V272, P9424; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall MC, 2000, J UROLOGY, V163, P1033, DOI 10.1016/S0022-5347(05)67877-9; HEIKKILA J, 1993, BIOCHEM BIOPH RES CO, V197, P1185, DOI 10.1006/bbrc.1993.2602; HEIKKILA JE, 1989, J CELL PHYSIOL, V140, P593, DOI 10.1002/jcp.1041400326; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUPPI K, 1994, ONCOGENE, V9, P3017; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; Itayasu T, 1998, ANTICANCER RES, V18, P113; JIANG HP, 1994, ONCOGENE, V9, P3397; Joshi US, 1998, PANCREAS, V16, P107, DOI 10.1097/00006676-199803000-00001; Joshi US, 1998, CANCER GENE THER, V5, P183; Kagawa S, 1999, CELL DEATH DIFFER, V6, P765, DOI 10.1038/sj.cdd.4400549; Kiley S C, 1994, Trends Cell Biol, V4, P223, DOI 10.1016/0962-8924(94)90146-5; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Liu J, 2000, J BIOL CHEM, V275, P11846, DOI 10.1074/jbc.275.16.11846; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McShea A, 2000, J BIOL CHEM, V275, P23181, DOI 10.1074/jbc.M001772200; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V264, P457, DOI 10.1006/bbrc.1999.1516; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIKAWA M, 1986, LIFE SCI, V39, P1101, DOI 10.1016/0024-3205(86)90202-X; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Takahashi N, 2000, PROSTATE, V44, P328, DOI 10.1002/1097-0045(20000901)44:4<328::AID-PROS10>3.0.CO;2-8; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang ZL, 1998, EXP CELL RES, V244, P105, DOI 10.1006/excr.1998.4191; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; YAMAUCHI Y, 1989, BRIT J CANCER, V60, P15, DOI 10.1038/bjc.1989.211; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	59	13	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1220	1228		10.1038/sj.onc.1204206	http://dx.doi.org/10.1038/sj.onc.1204206			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313866				2022-12-17	WOS:000167570100009
J	Gross, AW; Ren, RB				Gross, AW; Ren, RB			Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells	ONCOGENE			English	Article						Bcr-Abl; v-Abl; CML; ALL; myeloid cells	CHRONIC MYELOGENOUS LEUKEMIA; DNA-BINDING ACTIVITY; MOUSE BONE-MARROW; MYELOPROLIFERATIVE DISEASE; TRANSGENIC MICE; CONSTITUTIVE ACTIVATION; BCR/ABL; ONCOGENE; P210; DISTINCT	The Bcr-Abl/p210 fusion protein plays a primary role in the pathogenesis of chronic myelogenous leukemia (CML), Abelson murine leukemia virus, which encodes v-Abl/p160, induces a pre-B cell leukemia/lymphoma in mice. It has been unclear whether the apparent specificity of these two abl oncogenes for myeloid versus lymphoid neoplasms is due to specific intrinsic properties of these Abl oncoproteins, or due to the properties of the target cells expressing them. We have recently shown that expression of Bcr-Abl in bone marrow cells by retroviral transduction efficiently induces a myeloproliferative disorder in mice resembling human CML, In this study, we compared Ber-Abl/p210 and v-Abl/p160 in this mouse CML model. We found that early in the course of disease, both Bcr-Abl/p210 and v-Abl/p160 expanded early immature hematopoietic cells. Later Bcr-Abl/p210 selectively expanded myeloid cells while v-Abl/p160 primarily induced the rapid in vivo expansion of B lymphoblastic cells, along with a minor population of myeloid cells. In vitro, Bcr-Abl/p210 induced more growth of myeloid colonies from S-fluorouracil treated bone marrow than v-Abl/p160. These results, obtained under equal bone marrow transduction/transplantation conditions, indicate that Bcr-Abl/p210 has a greater intrinsic capacity than v-Abl/pl60 to induce the neoplastic growth of myeloid cells. In addition, we found that cultured cells expressing Bcr-Abl/p210 had more activated STAT5 than cells that expressed v-Abl/p160. This suggests that activation of STAT5 might be one part of the mechanism of abl oncogene disease specificity.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, Waltham, MA 02254 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, MS029, Waltham, MA 02254 USA.				NCI NIH HHS [CA68008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Coligan J.E., 1996, CURRENT PROTOCOLS IM; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Gross AW, 1999, MOL CELL BIOL, V19, P6918; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; Kieslinger M, 2000, GENE DEV, V14, P232; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; Shuai K, 1996, ONCOGENE, V13, P247; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Verfaillie CM, 1997, J LAB CLIN MED, V129, P584, DOI 10.1016/S0022-2143(97)90192-X; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	37	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6286	6296		10.1038/sj.onc.1204023	http://dx.doi.org/10.1038/sj.onc.1204023			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175343				2022-12-17	WOS:000166210500012
J	Kitamura, E; Su, GF; Sossey-Alaoui, K; Malaj, E; Lewis, J; Pan, HQ; Hawthorn, L; Roe, B; Cowell, JK				Kitamura, E; Su, GF; Sossey-Alaoui, K; Malaj, E; Lewis, J; Pan, HQ; Hawthorn, L; Roe, B; Cowell, JK			A transcription map of the minimally deleted region from 13q14 in B-cell chronic lymphocytic leukemia as defined by large scale sequencing of the 650 kb critical region	ONCOGENE			English	Article						B-CLL; genomic sequence; transcript map; 13q14; gene annotation	CHROMOSOME-ABNORMALITIES; D13S25 LOCUS; L1 ELEMENT; GENE; INSERTION; TRANSLOCATION; BREAKPOINT; PROTEINS; CLONING; CONTIG	Extensive analysis of tumors has demonstrated homozygous and heterozygous deletions in chromosome region 13q14.3 in B-cell chronic lymphocytic leukemia (B-CLL), suggesting the site of a tumor suppressor gene. Since previous searches for this gene have not yielded any viable candidates, we now present the sequence of the BACs which span the minimally deleted approximately 650 kb region between markers D13S319 and D13S25, This sequence has allowed us to create the definitive transcription map for the region which reveals 93 ESTs and 12 Unigene clusters in this region. Using gene prediction programs, a further 19 potential genes are also identified. The genes show an asymmetrical distribution throughout the region with most of them clustering at the extreme ends. This sequencing effort provides for the definitive structure of the B-CLL deletion region and the identification of the vast majority of the potential candidate genes. Of all the genes identified, only three have homologies to known genes: two LL repeat genes and rabbit epididymal protein 52, This 13q14.3 sequence provides the final substrate from which to characterize the B-CLL tumor suppressor gene.	Cleveland Clin Fdn, Ctr Mol Genet, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	Cleveland Clinic Foundation; University of Oklahoma System; University of Oklahoma - Norman	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Pan, Huaqin/0000-0002-7166-108X; Cowell, John/0000-0002-2079-5950; Hawthorn, Lesleyann/0000-0001-8179-0937; Koculi, Eda/0000-0001-9477-555X	NATIONAL CANCER INSTITUTE [R01CA074190] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001604, R01HG000313] Funding Source: NIH RePORTER; NCI NIH HHS [CA74190] Funding Source: Medline; NHGRI NIH HHS [HG00313, HG01604] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bezieau S, 1998, GENOMICS, V52, P369, DOI 10.1006/geno.1998.5464; BIENZ N, 1993, BRIT J HAEMATOL, V85, P819, DOI 10.1111/j.1365-2141.1993.tb03233.x; Bodenteich A, 1993, AUTOMATED DNA SEQUEN, P42; BouygeMoreau I, 1997, GENOMICS, V46, P183, DOI 10.1006/geno.1997.5008; Brandon CI, 1999, THERIOGENOLOGY, V52, P863, DOI 10.1016/S0093-691X(99)00178-8; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHAPMAN RM, 1994, ONCOGENE, V9, P1289; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; ESCUDIER SM, 1993, BLOOD, V81, P2702; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hawthorn L, 1995, GENOMICS, V30, P425, DOI 10.1006/geno.1995.1260; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; Hawthorn LA, 1998, ANN HUM GENET, V62, P401, DOI 10.1046/j.1469-1809.1998.6250401.x; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; IULIUSSON G, 1988, CANCER, V62, P500; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KILLIAN GJ, 1993, BIOL REPROD, V49, P1202, DOI 10.1095/biolreprod49.6.1202; Kooy R F, 1994, Eur J Hum Genet, V2, P228; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; PITTMAN S, 1983, CANCER GENET CYTOGEN, V9, P355, DOI 10.1016/0165-4608(83)90084-5; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; ROE BA, 1996, DNA ISOLATION SEQUEN; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; XU Y, 1994, 2 INT C INT SYST MOL	38	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5772	5780		10.1038/sj.onc.1203978	http://dx.doi.org/10.1038/sj.onc.1203978			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126364				2022-12-17	WOS:000165477700009
J	Chang, YC; Nakajima, H; Illenye, S; Lee, YS; Honjo, N; Makiyama, T; Fujiwara, I; Mizuta, N; Sawai, K; Saida, K; Mitsui, Y; Heintz, NH; Magae, J				Chang, YC; Nakajima, H; Illenye, S; Lee, YS; Honjo, N; Makiyama, T; Fujiwara, I; Mizuta, N; Sawai, K; Saida, K; Mitsui, Y; Heintz, NH; Magae, J			Caspase-dependent apoptosis by ectopic expression of E2F-4	ONCOGENE			English	Article						E2F; apoptosis; cell cycle	S-PHASE ENTRY; DIHYDROFOLATE-REDUCTASE GENE; CELL-CYCLE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; TUMOR-SUPPRESSOR; SUBCELLULAR-LOCALIZATION; FAMILY PROTEINS; DNA-SYNTHESIS	E2F is a family of transcription factors which regulates cell cycle and apoptosis of mammalian cells. E2F-1-3 localize in the nucleus, and preferentially bind pRb, while E2F-4 and 5 have no nuclear localization signal and preferentially bind p107/p130. E2F-6 suppresses the transcriptional activity of other E2F proteins. DP-1 and 2 are heterodimeric partners of each E2F protein. Using tetracycline-responsive promoters, here we compared the effects of ectopic expression of E2F-1, DP-I and E2F-4 on cell cycle progression and apoptosis in Chinese hamster cell lines, We found that E2F-4, as well as DP-I and E2F-1, induced growth arrest and caspase-dependent apoptosis, E2F-4 did not have a marked effect on cell cycle progression, while E2P-1 induced DNA synthesis of resting cells and DP-1 arrested cells in G1, Ectopic expression of E2F-4 did not activate E2F-dependent transcription. Our results suggest that expression of E2F-4 at elevated levels induces growth arrest and apoptosis of mammalian cells through a mechanism distinct from E2F-1 and DP-1.	Inst Res & Innovat, Kashiwa, Chiba 2770861, Japan; Univ Vermont, Coll Med, Dept Pathol, S Burlington, VT 05403 USA; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Kyoto Prefectural Univ Med, Dept Surg 2, Kamikyo Ku, Kyoto 602, Japan	University of Vermont; National Institute of Advanced Industrial Science & Technology (AIST); Kyoto Prefectural University of Medicine	Magae, J (corresponding author), Inst Res & Innovat, 1201 Takada, Kashiwa, Chiba 2770861, Japan.				NIGMS NIH HHS [GM54726] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054726] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BARGOU RC, 1996, J EXP MED, V183, P3; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; delaLuna S, 1996, J CELL SCI, V109, P2443; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Huang DY, 1996, J BIOL CHEM, V271, P1218, DOI 10.1074/jbc.271.2.1218; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Magae J, 1996, J CELL SCI, V109, P1717; Magae J, 1997, ONCOGENE, V15, P759, DOI 10.1038/sj.onc.1201251; Magae J, 1999, ONCOGENE, V18, P593, DOI 10.1038/sj.onc.1202345; MILBRANDT JD, 1981, P NATL ACAD SCI USA, V78, P6042; Muller H, 1997, MOL CELL BIOL, V17, P5508; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHULL S, 1991, J BIOL CHEM, V266, P24398; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells J, 1996, MOL CELL BIOL, V16, P634; Wells JM, 1997, J BIOL CHEM, V272, P4483, DOI 10.1074/jbc.272.7.4483; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	49	13	13	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4713	4720		10.1038/sj.onc.1203833	http://dx.doi.org/10.1038/sj.onc.1203833			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032021				2022-12-17	WOS:000089528800005
J	Shimizu, T; Awai, N; Takeda, K				Shimizu, T; Awai, N; Takeda, K			Complex regulation of CDKs and G1 arrest during the granulocytic differentiation of human myeloblastic leukemia ML-1 cells	ONCOGENE			English	Article						leukemia; differentiation; CDK; p27; p18	DEPENDENT KINASE INHIBITOR; RETINOIC ACID; CYCLE ARREST; MYELOID-LEUKEMIA; P21; P27(KIP1); INDUCTION; P18(INK4C); MEDIATOR; CLONING	We previously reported that all-trans retinoic acid (ATRA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) synergistically induced granulocytic differentiation in human myeloblastic leukemia ML-1 cells. The combination of these agents also suppressed DNA-synthesis. In the present study, we investigated the suppression of cyclin dependent kinase (CDK) activities resulting in G1 arrest in differentiated ML-1 cells. We show that treatment of ML-1 cells with ATRA plus GM-CSF results in G1 arrest and suppression of CDK activities, Protein levels of the G1 CDKs were essentially unchanged during this time, However, we observed an increase in CDK2-bound p27 and CDK4-bound pig, and a decrease in CDK6-bound cyclin D3, These results suggest that complex regulation of CDKs play a key role in Ct arrest of ML-l after treatment with ATRA and GM-CSF, We also showed that an increase in CDK2-bound p27 and CDK4-bound p18 are caused by treatment with ATRA and a decrease in CDK6-bound cyclin D3 is induced synergistically by treatment with both reagents. Furthermore, we propose that the changes in binding of p18 and cyclin D3 to CDKs are due to changes at the protein expression level and that the increase in p27 binding to CDK2 is due to a novel mechanism.	Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, Tokyo 1620826, Japan	Tokyo University of Science	Takeda, K (corresponding author), Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Hyg Chem, Shinjuku Ku, 12 Ichigaya Funagawara Machi, Tokyo 1620826, Japan.							Asiedu C, 1997, BLOOD, V90, P3430, DOI 10.1182/blood.V90.9.3430; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oka Y, 1997, ANTICANCER RES, V17, P1951; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Saito Y, 1999, ANTICANCER RES, V19, P1069; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu T, 1999, LEUKEMIA RES, V23, P901, DOI 10.1016/S0145-2126(99)00106-X; Singh SP, 1998, CANCER RES, V58, P1730; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sueoka N, 1999, CANCER RES, V59, P3838; TAKEDA K, 1982, CANCER RES, V42, P5152; TAKEDA K, 1986, NATURE, V323, P338, DOI 10.1038/323338a0; TAKEI M, 1984, BIOCHEM BIOPH RES CO, V124, P100, DOI 10.1016/0006-291X(84)90922-7; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang QM, 1996, CANCER RES, V56, P264; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	47	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2000	19	40					4640	4646		10.1038/sj.onc.1203821	http://dx.doi.org/10.1038/sj.onc.1203821			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030153				2022-12-17	WOS:000089438200010
J	Nowak, R; Sikora, K; Pietas, A; Skoneczna, I; Chrapusta, SJ				Nowak, R; Sikora, K; Pietas, A; Skoneczna, I; Chrapusta, SJ			Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors	ONCOGENE			English	Article						testicular germ cell tumors; telomerase; telomeric length; tumor pathogenesis	BRAIN-TUMORS; CANCER; PATHOGENESIS; MAINTENANCE; EXPRESSION; CARCINOMA; CISPLATIN; TISSUES	Telomere maintenance plays an important role in cell proliferation and tumor survival. Human male germ cells, which carry long telomeres and express telomerase, give rise to a highly heterogeneous group of malignant tumors. We compared telomeric length and telomerase activity between two major histological types of primary testicular germ cell tumors. Fifteen out of 16 seminoma samples revealed telomeric restriction fragment (TRF) length below 13 kb; the remaining seminoma showed a major TRF fraction of 18 kb and a distinct minor fraction of above 23 kb length. In contrast, all 13 samples from nonseminomas showed TRF length greater than or equal to 23 kb, which is similar to that reported in human sperm. Nine out of 11 seminoma specimens and six out of seven nonseminomas studied showed moderate to high telomerase activity, the only telomerase-negative non-seminoma being pure mature teratoma. These results indicate to a major difference in telomeric length between seminomas and nonseminomas, which is apparently unrelated to the presence of telomerase activity, and suggest a germline-like homeostasis of telomeric length is preserved in human nonseminomas.	Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Mol Biol, PL-02781 Warsaw, Poland; Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Pathol, PL-02781 Warsaw, Poland; Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Urol Oncol, PL-02781 Warsaw, Poland; Polish Acad Sci, Med Res Ctr, Lab Expt Pharmacol, PL-02106 Warsaw, Poland	Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Polish Academy of Sciences	Nowak, R (corresponding author), Maria Sklodowska Curie Mem Ctr & Inst Oncol, Dept Mol Biol, 5 Roentgena St, PL-02781 Warsaw, Poland.		Chrapusta, Stanisław/GLS-1363-2022; Chrapusta, Stanisław/AAA-3076-2020	Chrapusta, Stanislaw Jonatan/0000-0001-5219-8993				Albanell J, 1999, J NATL CANCER I, V91, P1321, DOI 10.1093/jnci/91.15.1321; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bacchetti S, 1996, CANCER SURV, V28, P197; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Burger AM, 1997, BRIT J CANCER, V75, P516, DOI 10.1038/bjc.1997.90; de Lange T, 1998, CANCER J SCI AM, V4, pS22; Delgado R, 1999, CANCER, V86, P1802, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1802::AID-CNCR23>3.3.CO;2-G; Engelhardt M, 1997, CLIN CANCER RES, V3, P1849; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hiraga S, 1998, CANCER RES, V58, P2117; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; KLEIN H, 1993, TEACH SOCIOL, V21, P1, DOI 10.2307/1318846; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Lutzker SG, 1998, MOL MED TODAY, V4, P404, DOI 10.1016/S1357-4310(98)01329-X; MOSTOFI FK, 1998, WHO INT HISTOLOGICAL, V16, P1; Nowak R, 1997, ONCOL REP, V4, P1099; Nowak R, 1998, CANCER J SCI AM, V4, P148; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oliver R T, 1999, Curr Opin Oncol, V11, P236; Sambrook J., 1989, MOL CLONING, pA1; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; Sano K, 1999, J NEUROSURG, V90, P258, DOI 10.3171/jns.1999.90.2.0258; Sano T, 1998, BRIT J CANCER, V77, P1633, DOI 10.1038/bjc.1998.267; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Skakkebaek NE, 1998, APMIS, V106, P3, DOI 10.1111/j.1699-0463.1998.tb01314.x; Soder AI, 1998, ONCOGENE, V16, P979, DOI 10.1038/sj.onc.1201620; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weng NP, 1997, IMMUNOL REV, V160, P43, DOI 10.1111/j.1600-065X.1997.tb01026.x; Wright WE, 1996, DEV GENET, V18, P173; Yasumoto S, 1996, ONCOGENE, V13, P433; Youngren K, 1998, HUM GENET, V102, P640, DOI 10.1007/s004390050755	40	13	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4075	4078		10.1038/sj.onc.1203746	http://dx.doi.org/10.1038/sj.onc.1203746			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962566				2022-12-17	WOS:000088825300015
J	del Arroyo, AG; Gil-Lamagniere, C; Lazaro, I; de Marco, MC; Layunta, I; Silva, A				del Arroyo, AG; Gil-Lamagniere, C; Lazaro, I; de Marco, MC; Layunta, I; Silva, A			Involvement of p53 and interleukin 3 in the up-regulation of CD95 (APO-1/Fas) by X-ray irradiation	ONCOGENE			English	Article						apoptosis; CD95 (Fas/Apo-1); IL-3; p53; X-ray irradiation	DRUG-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; BONE-MARROW CELLS; WILD-TYPE P53; RECEPTOR/LIGAND SYSTEM; DEATH DOMAIN; DIFFERENTIAL EXPRESSION; NEUROBLASTOMA-CELLS; ANTICANCER DRUGS; PERIPHERAL-BLOOD	Interleukin 3-dependent hone marrow and Ba/F3 cells present constitutive Fas expression. A dose dependent increase in Fas surface expression was induced in these cells by X-ray irradiation. Using primary cell cultures and established cell lines derived from p53-null mice (p53(-/-)), we demonstrated that the increase in Fas expression upon X-ray irradiation is dependent on the presence of at least one wild-type p53 allele. Fas induction by X-ray irradiation was negatively modulated by IL-3; an earlier Fas induction was observed in the absence of IL-3 or at low IL-3 concentrations. However, IL-3 withdrawal in non-irradiated cells did not induce an increase in Fas expression. X-ray irradiation of Ba/F3 cells induced the expression of functional Fas receptors. Therefore, in IL-3-dependent cells, IL-3 regulates the rate of Fas expression, which is correlated with the degree of apoptosis observed in X-irradiated cells. Finally, we demonstrate that IL-3 controls the degree of Fas expression induced by irradiation through a p53-mediated pathway.	CSIC, Ctr Invest Biol, Dept Immunol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Silva, A (corresponding author), CSIC, Ctr Invest Biol, Dept Immunol, Velazquez 144, E-28006 Madrid, Spain.		Gil-Lamaignere, Cristina/A-3866-2013					Akagi T, 1998, LEUKEMIA LYMPHOMA, V28, P483, DOI 10.3109/10428199809058355; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Booker JK, 1998, J IMMUNOL, V161, P4536; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; IWAI K, 1994, BLOOD, V84, P1201; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Li T, 1996, CELL GROWTH DIFFER, V7, P107; MARVEL J, 1994, ONCOGENE, V9, P1117; MATSUE H, 1995, ARCH DERMATOL RES, V287, P315, DOI 10.1007/BF01105085; MIYASHITA T, 1995, CELL, V80, P293; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MULLNER EW, 1997, IMMUNOLOGY METHODS M; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Ruiz-Ruiz MD, 1999, CELL DEATH DIFFER, V6, P271, DOI 10.1038/sj.cdd.4400490; SATA M, 1988, NAT MED, V4, P415; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Silva A, 1997, BLOOD, V89, P2717, DOI 10.1182/blood.V89.8.2717; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TAMURA T, 1995, ONCOGENE, V11, P1939; WARASUKAMA H, 1988, EUR J IMMUNOL, V18, P97; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	49	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3647	3655		10.1038/sj.onc.1203662	http://dx.doi.org/10.1038/sj.onc.1203662			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951571				2022-12-17	WOS:000088568300011
J	Jiang, JG; Gao, B; Zarnegar, R				Jiang, JG; Gao, B; Zarnegar, R			The concerted regulatory functions of the transcription factors nuclear factor-1 and upstream stimulatory factor on a composite element in the promoter of the hepatocyte growth factor gene	ONCOGENE			English	Article						hepatocyte growth factor; NF1; USF; promoter; partial hepatectomy; transcription	FACTOR SCATTER-FACTOR; MAJOR LATE PROMOTER; USF FAMILY; EXPRESSION; PROTEINS; REGION; RECEPTOR; LIVER; DNA; BINDS	Hepatocyte growth factor (HGF) is an important multifunctional cytokine whose gene expression is regulated mainly at the transcriptional level, Previous studies using transgenic mice as well as in vitro analyses showed that a potential regulatory element(s) exists between -260 to -230 bp in the upstream region of the HGF gene promoter. In the present study, me have discovered that this region is a composite site through which members of the nuclear factor 1 (NF1) and upstream stimulatory factor (USF) families bind to and regulate HGF gene transcription. Gel mobility shift and supershift assays revealed that USF and NF1 have high binding affinity for this region and that the binding sites of the two different transcription factor families overlap. Functional studies showed that NF1 suppresses HGF gene promoter activity and that USF has an activating function, We found that the NF1/X and NF1/Red1 isoforms strongly suppressed HGF promoter activity while the NF1/L variant had no obvious effects. USF1, but not USF2, of the USF family stimulated HGF gene promoter activity, More interestingly, during liver regeneration after partial hepatectomy, a process which activates the HGF gene, we noted that the binding activity of USF to the HGF promoter element increased while that of NF1 decreased. These data provide insight into the molecular mechanisms that govern HGF gene transcription.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Virginia Commonwealth University	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.		Jiang, Jie-Gen/K-3845-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES 06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAVAMUDAN B, 1993, BIOCHEM BIOPH RES CO, V195, P346, DOI 10.1006/bbrc.1993.2050; Bell AW, 1998, J BIOL CHEM, V273, P6900, DOI 10.1074/jbc.273.12.6900; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Gao B, 1998, J BIOL CHEM, V273, P31784, DOI 10.1074/jbc.273.48.31784; Gao B, 1996, MOL CELL BIOL, V16, P5997; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; LIU YH, 1994, J BIOL CHEM, V269, P4152; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Sirito Mario, 1992, Gene Expression, V2, P231; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	26	13	14	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2786	2790		10.1038/sj.onc.1203581	http://dx.doi.org/10.1038/sj.onc.1203581			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851080				2022-12-17	WOS:000087318500008
J	Lin, YC; Peng, JM; Wang, WB				Lin, YC; Peng, JM; Wang, WB			The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene	ONCOGENE			English	Article						simian virus 40 (SV40); small t antigen; T/t-common; HER-2/neu; tumor suppressor	E1A GENE-PRODUCTS; SV40 SMALL-T; OVARIAN-CANCER CELLS; SMALL TUMOR-ANTIGEN; RNA-POLYMERASE-II; NEU ONCOGENE; TRANSCRIPTIONAL REPRESSION; PROTEIN PHOSPHATASE-2A; MOLECULAR-CLONING; BREAST-CANCER	Overexpression of HER-2/neu (also known as c-erbB-2) proto-oncogene frequently occurs in many different types of human cancers, including ovarian carcinoma, and is known to enhance tumor metastasis and chemoresistance. Previous studies showed that inhibition of HER-2/neu expression by various agents, such as adenovirus E1A and simian virus 40 large T, can lead to suppression of tumorigenicity of HER-2/neu-overexpressing cancer cells. Here we report that T/t-common, which contains the N-terminal common domain of simian, virus 40 large T and small t antigens, could specifically repress the HER-2/neu promoter. When the coding sequence of T/t-common was stably transfected into the HER-2/neu-overexpressing human ovarian carcinoma SK-OV-3 cells, the expression of HER-2/neu was dramatically reduced by the expression of Tit-common. Accordingly the tumorigenic potential of these T/t-common-expressing clones, including the ability to grow anchorage-independently and the ability to induce tumor in nu/nu mice, was also drastically suppressed. Furthermore, when T/t-common was transiently cotransfected with the activated genomic neu into NIH3T3 cells, the transforming activity of the latter was suppressed by Tit-common in soft-agarose microcolony formation assays. Taken together, these data suggest that Tit-common may act as a transformation suppressor of the HER-2/neu oncogene.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei, Taiwan	National Taiwan University	Wang, WB (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, No 1,Jen Ai Rd,1st Sect, Taipei, Taiwan.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BERCHUCK A, 1990, CANCER RES, V50, P4087; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HARLOW E, 1988, ANTIBODES LAB MANUAL; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; Hung MC, 1999, SEMIN ONCOL, V26, P51; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kao MC, 1998, ONCOGENE, V16, P547, DOI 10.1038/sj.onc.1201513; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1051; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Porras A, 1996, J VIROL, V70, P6902; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; RUBIN H, 1982, CELL, V30, P469, DOI 10.1016/0092-8674(82)90244-6; Rushton JJ, 1997, J VIROL, V71, P5620, DOI 10.1128/JVI.71.7.5620-5623.1997; Sambrook J, 1989, MOL CLONING LAB MANU; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STOKER M, 1968, NATURE, V218, P234, DOI 10.1038/218234a0; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Tevethia MJ, 1997, J VIROL, V71, P8157, DOI 10.1128/JVI.71.11.8157-8166.1997; Tooze J, 1981, MOL BIOL TUMOR VIRUS; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG WB, 1994, J VIROL, V68, P6180, DOI 10.1128/JVI.68.10.6180-6187.1994; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P1947	59	13	13	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2704	2713		10.1038/sj.onc.1203582	http://dx.doi.org/10.1038/sj.onc.1203582			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851070				2022-12-17	WOS:000087193000006
J	Alevizopoulos, K; Sanchez, B; Amati, B				Alevizopoulos, K; Sanchez, B; Amati, B			Conserved region 2 of adenovirus E1A has a function distinct from pRb binding required to prevent cell cycle arrest by p16(INK4a) or p27(Kip1)	ONCOGENE			English	Article						E1A; p27; p16; pRb; E2F	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR PROTEIN; S-PHASE ENTRY; HISTONE DEACETYLASE; GROWTH SUPPRESSION; REPRESS TRANSCRIPTION; NEGATIVE MODULATION; FAMILY PROTEINS; DROSOPHILA CTBP	Ectopic expression of the CDK inhibitors (CKIs) p16(INK4a) and p27(Kip1) in Rat1 fibroblasts induces dephosphorylation and activation of Retinoblastoma-family proteins (pRb, p107 and p130), their association with E2F proteins, and cell cycle arrest in G1, The growth-inhibitory action of p16, in particular, is believed to be mediated essentially via pRb activation. The 12S E1A protein of human Adenovirus 5 associates with pRb-family proteins via residues in its Conserved Regions (CR) 1 and 2, in particular through the motif LXCXE in CR2. These interactions are required for E1A to prevent G1 arrest upon co-expression of CKIs, We show here that mutating either of two conserved motifs adjacent to LXCXE in CR2, GFP and SDDEDEE, also impairs the ability of E1A to overcome G1 arrest by p16 or p27, Strikingly, however, these mutations affect neither the association of E1A with pRb, p07 and p130, nor its ability to derepress E2F-1 transcriptional activity in transient transfection assays. One of the E1A mutants, however, is defective in derepressing several endogenous E2F target genes in the presence of p16 or p27, Thus, CR2 possesses an essential function besides pRb-binding, We speculate that this function might be required for the full derepression of E2F-regulated genes in their natural chromatin context.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Amati, B (corresponding author), Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland.		Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BARBEAU D, 1994, ONCOGENE, V9, P359; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckner R, 1996, BIOL CHEM, V377, P685; EGAN C, 1989, ONCOGENE, V4, P383; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Geng Y, 1996, ONCOGENE, V12, P1173; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NEVINS JR, 1992, SCIENCE, V258, P424; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Putzer BM, 1997, J VIROL, V71, P9538; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUELLE DE, 1995, ONCOGENE, V11, P635; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Whalen SG, 1996, J VIROL, V70, P5373, DOI 10.1128/JVI.70.8.5373-5383.1996; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	76	13	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2067	2074		10.1038/sj.onc.1203534	http://dx.doi.org/10.1038/sj.onc.1203534			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803468				2022-12-17	WOS:000086613200011
J	Schroter, M; Peli, J; Hahne, M; Tschopp, J; Reichmann, E				Schroter, M; Peli, J; Hahne, M; Tschopp, J; Reichmann, E			Fas-dependent tissue turnover is implicated in tumor cell clearance	ONCOGENE			English	Article						tumorigenesis; Fas-signaling; caspase activity; apoptosis; immune response; tissue turnover	LIGAND EXPRESSION; INDUCED APOPTOSIS; IMMUNE ESCAPE; DEATH FACTOR; CD95; INHIBITION; CASPASE-8; MICE	The apoptosis-inducing Fas receptor has been shown to be down-regulated in various types of tumors, while its ligand (FasL) appears to be frequently up-regulated. Here we provide evidence that there is a strong selective pressure in vivo against Fas-expressing, tumorigenic NIH3T3 cells, favoring survival, proliferation and eventually tumor formation by Fas-negative tells. Importantly, re-expression of Fas in these cells results in either the complete abolishment of tumor development, or in a significant extenuation of the latency period of tumor outgrowth. In addition, we found that environmental conditions which prevail during tumorigenesis, such as limiting amounts of survival factors and the lack of cell adhesion, are markedly sensitizing tumor cells to Fas-mediated suicide. Our data suggest that in addition to T cell-mediated immune responses, mechanisms of Fas-dependent tissue turnover are also centrally implicated in tumor cell clearance.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne	Reichmann, E (corresponding author), Swiss Inst Expt Canc Res, Chem Boveresses 155, CH-1066 Epalinges, Switzerland.							Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Butler LM, 1998, BRIT J CANCER, V77, P1454, DOI 10.1038/bjc.1998.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Faris M, 1998, J IMMUNOL, V160, P134; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Lebel M, 1996, ONCOGENE, V12, P1127; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; ROBERTSON MJ, 1995, LEUKEMIA LYMPHOMA, V17, P51, DOI 10.3109/10428199509051703; Shinoura N, 1999, CANCER RES, V59, P4119; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ungefroren H, 1998, CANCER RES, V58, P1741; Walker PR, 1997, J IMMUNOL, V158, P4521; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	27	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1794	1800		10.1038/sj.onc.1203499	http://dx.doi.org/10.1038/sj.onc.1203499			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777213				2022-12-17	WOS:000086292500007
J	Epinat, JC; Kazandjian, D; Harkness, DD; Petros, S; Dave, J; White, DW; Gilmore, TD				Epinat, JC; Kazandjian, D; Harkness, DD; Petros, S; Dave, J; White, DW; Gilmore, TD			Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein	ONCOGENE			English	Article						v-Rel; retroviral oncogene; transcription factor; malignant transformation; NF-kappa B; envelope sequences	VIRUS STRAIN-T; C-REL; KAPPA-B; HOMOLOGY DOMAIN; AMINO-ACIDS; TRANSCRIPTION; ACTIVATION; TRANSFORMATION; PROTEIN; EXPRESSION	The retroviral oncoprotein v-Rel is a member of the Rel/NF-kappa B family of transcription factors. v-Rel has multiple changes as compared to the proto-oncoprotein c-Rel, and these changes render v-Rel highly oncogenic in avian lymphoid cells, Previous results have shown that three mutant residues in the eleven helper virus-derived Envelope (Env) amino acids (aa) at the N-terminus of v-Rel are required for its full oncogenicity. In this report, we show that these mutant Env aa also enable sequences in the N-terminal half of v-Rel to activate transcription in yeast and chicken cells, under conditions where the analogous sequences from c-Rel either do not or only weakly activate transcription. Removal of the Env aa from v-Rel or site-directed mutations that revert the three mutant residues to the residues present in the Rev-A helper virus Env protein abolish this transactivation ability of v-Rel, Addition of mutant Env aa onto c-Rel is not sufficient to fully restore the transactivation function; other sequences in the N-terminal half of v-Rel are needed for full transactivating ability, A C terminally-truncated form of NF-kappa B p100 (p85), produced in HUT-78 human leukemic cells, also activates transcription in yeast, under conditions where the normal p52 and p100 proteins do not. Furthermore, transcriptional activation by p85 in yeast is likely to occur through N-terminal sequences, Taken together, these results are consistent with a model in which transactivation by N-terminal Rel Homology (RH) domain sequences in oncogenic Rel family proteins is influenced by sequences outside the RH domain.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BHAT GV, 1990, ONCOGENE, V5, P625; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen CL, 1999, MOL CELL BIOL, V19, P307; Curristin SM, 1997, J VIROL, V71, P5972, DOI 10.1128/JVI.71.8.5972-5981.1997; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HRDLICKOVA R, 1994, J VIROL, V68, P2371; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MOSIALOS G, 1993, ONCOGENE, V8, P721; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, ONCOGENE, V8, P2501; SMARDOVA J, 1995, ONCOGENE, V10, P2017; THAKUR S, 1994, ONCOGENE, V9, P2335; Wang Y, 1999, GENE, V234, P403, DOI 10.1016/S0378-1119(99)00168-7; Whitford GM, 1996, MONOGR ORAL SCI, V16, P1; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; Xu X, 1997, ONCOGENE, V14, P1521, DOI 10.1038/sj.onc.1200985	36	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					599	607		10.1038/sj.onc.1203376	http://dx.doi.org/10.1038/sj.onc.1203376			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698504				2022-12-17	WOS:000085192000001
J	Gryz, EA; Meakin, SO				Gryz, EA; Meakin, SO			Acidic substitution of the activation loop tyrosines in TrkA supports nerve growth factor-independent cell survival and neuronal differentiation	ONCOGENE			English	Article						nerve growth factor; TrkA; tyrosine kinase receptor; kinase activation; activation loop; neurotrophins	MAP KINASE KINASE; FACTOR-I RECEPTOR; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MAMMALIAN-CELLS; PC12 CELLS; NEURITE OUTGROWTH; CRYSTAL-STRUCTURE; BINDING-SITES	TrkA is the receptor tyrosine kinase (RTK) for nerve growth factor (NGF) and stimulates NGF-dependent cell survival and differentiation in primary neurons. TrkA expression in neuronal tumors also supports NGF-dependent differentiation of neuroblastomas and apoptosis of medulloblastomas. Phosphorylation of the activation loop tyrosines in RTK's are essential to activation as well as allosteric changes that facilitate substrate interaction and phosphorylation. Acidic amino acid substitution of the activation loop tyrosines in TrkA, Tyr(683)Tyr(684), was performed to mimic the negative charges normally induced by ligand activation and receptor phosphorylation. A total of eight independent mutants containing single or double substitutions were generated for comparison. Herein, we demonstrate that acidic substitution of the activation loop tyrosines is sufficient to induce allosteric changes required for constitutive TrkA kinase activity as well as phosphorylation of TrkA signaling proteins such as Shc, PLC gamma-1, FRS-2 and erk1/2. The strongest constitutively active TrkA mutants, GluAsp and AspGlu, support NGF-independent neuritogenesis and cell survival to levels approximately 65 and 80-100%, respectively, of NGF-activated wild type TrkA. Thus, constitutively active TrkA may provide a useful strategy in future therapeutic approaches to limit the development and progression of neuronal tumors.	John P Robarts Res Inst, Neurodegenerat Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Neurodegenerat Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.		Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; Goldsmith BA, 1997, J NEUROCHEM, V69, P1014; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GREEN SH, 1986, J BIOL CHEM, V261, P5316; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LONGATI P, 1994, ONCOGENE, V9, P49; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; McCarty JH, 1998, ONCOGENE, V16, P1691, DOI 10.1038/sj.onc.1201688; Meakin SO, 1997, J NEUROCHEM, V69, P954; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1991, P NATL ACAD SCI USA, V88, P5862, DOI 10.1073/pnas.88.13.5862; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Muragaki Y, 1997, J NEUROSCI, V17, P530; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POLUHA W, 1995, ONCOGENE, V10, P185; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Raffioni S, 1998, J BIOL CHEM, V273, P35250, DOI 10.1074/jbc.273.52.35250; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHILLING P, 1991, J HYPERTENS, V9, P3; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Webster MK, 1996, MOL CELL BIOL, V16, P4081; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG B, 1991, J BIOL CHEM, V266, P990	56	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					417	430		10.1038/sj.onc.1203330	http://dx.doi.org/10.1038/sj.onc.1203330			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656690				2022-12-17	WOS:000084873700013
J	Martinez, LA; Chen, Y; Pavone, A; Fischer, SM; Conti, CJ				Martinez, LA; Chen, Y; Pavone, A; Fischer, SM; Conti, CJ			Deregulated expression of cyclin D1 overrides antimitogenic signals	ONCOGENE			English	Article						cell cycle; cyclin D1; keratinocytes; transforming growth factor beta 1	MOUSE SKIN CARCINOGENESIS; EPITHELIAL-CELL LINE; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; RETINOBLASTOMA PROTEIN; GROWTH-INHIBITION; BREAST-CANCER; ECTOPIC EXPRESSION; P27(KIP1) PROTEIN; DEPENDENT KINASES	Several types of epithelial neoplasms exhibit high expression of transforming growth factor beta 1 (TGF(beta)-1), indicating that they have acquired tolerance to this normally growth inhibitory cytokine, Since cyclin D1 is expressed at high levels in murine skin tumors coincident with high levels of TGF(beta)-1 expression, we hypothesized that cyclin D1 may override TGF(beta)-1 induced growth arrest, We observed that in primary murine keratinocytes treated with TGF(beta)-1, cyclin D1 is quickly suppressed at both the mRNA and protein level. Since changes in other cell cycle proteins occur at a later time during TGF,-1 treatment, the early suppression of cyclin D1 suggests that this gene is a critical target for TGF(beta)-1 growth suppression, Using primary keratinocytes from transgenic mice that overexpress cyclin D1 (K5-D1 mice), we observed partial resistance to TGF(beta)-1 growth inhibition. This resistance involves changes in the cyclin/ cdk/inhibitor complexes rather than differences in expression of the TGF(beta) receptors or signaling. Comparison of cdk associated kinase activity between wild-type and K5-D1 cells shows differential regulation, We conclude that deregulated cyclin D1 and subsequent alterations in cell cycle machinery provides keratinocytes the ability to at least partially override growth inhibitory signals.	Univ Texas, MD Andersn Canc Res Ctr, Pk Res Div, Smithville, TX 78957 USA; Med Univ S Carolina, Hollings Canc Ctr, Ctr Mol & Struct Biol, Charleston, SC 29425 USA	University of Texas System; UTMD Anderson Cancer Center; Medical University of South Carolina	Conti, CJ (corresponding author), Univ Texas, MD Andersn Canc Res Ctr, Pk Res Div, Pk Rd 1-C, Smithville, TX 78957 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042157, R01CA034443] Funding Source: NIH RePORTER; NCI NIH HHS [CA42157, CA34443, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; Arber N, 1996, ONCOGENE, V12, P1903; BIANCHI AB, 1993, ONCOGENE, V8, P1127; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Ciaparrone M, 1998, CANCER RES, V58, P114; Doki Y, 1997, CARCINOGENESIS, V18, P1139, DOI 10.1093/carcin/18.6.1139; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; Fowlis DJ, 1996, CELL GROWTH DIFFER, V7, P679; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; JIANG W, 1993, ONCOGENE, V8, P3447; KO TC, 1995, ONCOGENE, V10, P177; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PATAMALAI B, 1994, MOL CARCINOGEN, V9, P220, DOI 10.1002/mc.2940090406; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rundhaug JE, 1997, MOL CARCINOGEN, V19, P122, DOI 10.1002/(SICI)1098-2744(199707)19:2<122::AID-MC7>3.0.CO;2-H; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; Sgambato A, 1997, CLIN CANCER RES, V3, P1879; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572	40	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					315	322		10.1038/sj.onc.1203301	http://dx.doi.org/10.1038/sj.onc.1203301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645011				2022-12-17	WOS:000084844400018
J	Tchou, WW; Yie, TA; Tan, TH; Rom, WN; Tchou-Wong, KM				Tchou, WW; Yie, TA; Tan, TH; Rom, WN; Tchou-Wong, KM			Role of c-Jun N-terminal kinase 1 (JNK1) in cell cycle checkpoint activated by the protease inhibitor N-acetyl-leucinyl-leucinyl-norleucinal	ONCOGENE			English	Article						JNK; LLnL; cell cycle arrest	SPINDLE ASSEMBLY CHECKPOINT; MAP KINASE; INDUCED APOPTOSIS; GAMMA-RADIATION; MAMMALIAN-CELLS; ARREST; PATHWAY; REQUIREMENT; DEGRADATION; INDUCTION	The cysteine protease inhibitor N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) inhibited the growth of the Calu-1 lung carcinoma cells and induced a prolonged cell cycle arrest in the S phase, c-Jun N-terminal kinases (JNKs) participate in cellular responses to mitogenic stimuli, environmental stresses, and apoptotic signals but its role in cell cycle checkpoint control has not been elucidated. In this report, me examined the role of JNK in LLnL-induced S phase checkpoint by overexpression of a dominant-negative mutant of JNK1 (JNK1-APF) in Calu-1 cells. Expression of high levels of JNK1-APF blocked the growth-inhibitory effects of LLnL and abrogated S phase arrest induced by LLnL. These results support the role of JNK in the activation of cell cycle checkpoint induced by LLnL.	NYU, Med Ctr, Div Hematol & Oncol, New York, NY 10016 USA; NYU, Med Ctr, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU, Med Ctr, Dept Environm Med, New York, NY 10016 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	New York University; New York University; New York University; New York University; New York University; Baylor College of Medicine	Tchou-Wong, KM (corresponding author), NYU, Med Ctr, Div Hematol & Oncol, 550 1st Ave,MSB 147, New York, NY 10016 USA.		Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Rom, William/0000-0002-8793-7028	NHLBI NIH HHS [R01 HL59832] Funding Source: Medline; NIAID NIH HHS [R01 AI38649] Funding Source: Medline; PHS HHS [M0100096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Patel R, 1998, J CELL SCI, V111, P2247; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	32	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6974	6980		10.1038/sj.onc.1203195	http://dx.doi.org/10.1038/sj.onc.1203195			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597296				2022-12-17	WOS:000083901900002
J	Mori, A; Higashi, H; Hoshikawa, Y; Imamura, M; Asaka, M; Hatakeyama, M				Mori, A; Higashi, H; Hoshikawa, Y; Imamura, M; Asaka, M; Hatakeyama, M			Granulocytic differentiation of myeloid progenitor cells by p130, the retinoblastoma tumor suppressor homologue	ONCOGENE			English	Article						p130; pRB; granulocytic differentiation; 32Dc13 cell; E1A	DEPENDENT KINASE-ACTIVITY; ADENOVIRUS E1A PROTEINS; PRB-RELATED P130; HUMAN CYCLIN-A; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INACTIVATION; GROWTH SUPPRESSION; CELLULAR PROTEIN; P107 PROTEIN	The retinoblastoma protein (pRB) and the related pocket proteins, p107 and p130, play crucial roles in mammalian cell cycle control. Recent studies indicate that these pocket proteins are also involved in cellular differentiation processes. We demonstrate in this work that the pRB-related p130 selectively accumulates during the in vitro differentiation of the myeloid progenitor cell, 32Dc13, into granulocyte in response to granulocyte-colony stimulating factor (G-CSF). This G-CSF-dependent granulocytic differentiation is blocked by the adenovirus E1A oncoprotein, which binds to and inactivates the pRB family of pocket proteins including p130. Furthermore, enforced overexpression of p130 but not PRE inhibits the myeloid cell proliferation that is concomitantly associated with granulocytic differentiation morphologically characterized by nuclear segmentation. However, simple G1-cell cycle al rest induced by cytokine deprivation or ectopic overexpression of the p27 cyclin-dependent kinase inhibitor, or inhibition of E2F activities by dominant negative DP-1 is not sufficient to trigger granulocytic differentiation. The differentiation-promoting activity of p130 in myeloid cells requires both the pocket domain and the spacer domain. Our results indicate that the pRB-related p130 plays a critical role in myeloid cell differentiation and suggest that coupling of cell cycle exit with the cellular differentiation program may be specifically achieved by p130.	Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan; Hokkaido Univ, Sch Med, Dept Hematol & Oncol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Dept Internal Med 3, Sapporo, Hokkaido 0608638, Japan	Japanese Foundation for Cancer Research; Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.		Asaka, Masahiro/A-5948-2012; Higashi, Hideaki/F-6872-2012					BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOULUKOS KE, 1993, ONCOGENE, V8, P237; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GIORDANO A, 1991, ONCOGENE, V6, P481; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; TAM SW, 1994, ONCOGENE, V9, P2663; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	77	13	13	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6209	6221		10.1038/sj.onc.1203044	http://dx.doi.org/10.1038/sj.onc.1203044			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597219				2022-12-17	WOS:000083934100004
J	Chin, L				Chin, L			Modeling malignant melanoma in mice: pathogenesis and maintenance	ONCOGENE			English	Article						melanoma; RAS; tumor maintenance; mouse model	ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; CELL-CYCLE ARREST; INK4A LOCUS; P53-DEPENDENT APOPTOSIS; CUTANEOUS MELANOMAS; MELANOCYTIC LESIONS; FAMILIAL MELANOMA; FACTOR EXPRESSION; P53		Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Chin, L (corresponding author), Harvard Univ, Sch Med, Dept Dermatol, 44 Binney St,M413, Boston, MA 02115 USA.							Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BARNHILL RL, 1993, DERMATOLOGY GEN MED, P1078; Bastian BC, 1998, CANCER RES, V58, P2170; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BENNETT DC, 1993, INT REV CYTOL, V146, P191, DOI 10.1016/S0074-7696(08)60383-6; BERKELHAMMER J, 1987, CANCER RES, V47, P1251; Boni R, 1998, MELANOMA RES, V8, P300; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; DEWIT PEJ, 1992, J INVEST DERMATOL, V99, P168, DOI 10.1111/1523-1747.ep12616793; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DOHERTY PC, 1994, CIBA F SYMP, V187, P245; ELLIS DL, 1992, J AM ACAD DERMATOL, V27, P539, DOI 10.1016/0190-9622(92)70219-6; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Guldberg P, 1997, CANCER RES, V57, P3660; HALABAN R, 1988, ONCOGENE RES, V3, P177; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; HERLYN M, 1993, MOL CELLULAR BIOL ME, P107; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JAFARI M, 1995, J CANCER RES CLIN, V121, P23, DOI 10.1007/BF01202725; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KOPROWSKI H, 1985, SOMAT CELL MOLEC GEN, V11, P297, DOI 10.1007/BF01534687; LEDOUARIN N, 1998, NEURAL CREST, P1; Mazure NM, 1996, CANCER RES, V56, P3436; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NESBIT M, 1999, IN PRESS ONCOGENE; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Rigel DS, 1996, J AM ACAD DERMATOL, V35, P1012, DOI 10.1016/S0190-9622(96)90139-5; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; RODECK U, 1991, CANCER METAST REV, V10, P89, DOI 10.1007/BF00049407; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SAENZSANTAMARIA M, 1995, AM J DERMATOPATH, V17, P344; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shih Ie-Ming, 1994, In Vivo (Attiki), V8, P113; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Teng DHF, 1997, CANCER RES, V57, P5221; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; TRENT JM, 1991, CANCER METAST REV, V10, P103, DOI 10.1007/BF00049408; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; WANG Y, 1993, JPN J HUM GENET, V38, P399, DOI 10.1007/BF01907986; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	65	13	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5304	5310		10.1038/sj.onc.1203106	http://dx.doi.org/10.1038/sj.onc.1203106			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498882				2022-12-17	WOS:000082808400008
J	Ibanez-Tallon, I; Caretti, G; Blasi, F; Crippa, MP				Ibanez-Tallon, I; Caretti, G; Blasi, F; Crippa, MP			In vivo analysis of the state of the human uPA enhancer following stimulation by TPA	ONCOGENE			English	Article						urokinase; enhancer; transcription; DNase I; hypersensitivity; in vivo footprinting	PLASMINOGEN-ACTIVATOR GENE; UROKINASE GENE; TRANSCRIPTION FACTORS; PHORBOL-ESTER; PROMOTER; CELLS; AP-1; COOPERATION; EXPRESSION; INDUCTION	We have analysed in vivo the -2.0 kb enhancer of the human urokinase-type plasminogen activator (uPA) gene in HepG2 cells, in which gene expression can be induced by phorbol esters, The results reveal that, within the regulatory region, the enhancer, the silencer and the minimal promoter become hypersensitive to deoxyribonuclease I (DNase I) upon induction of transcription, The hypersensitivity of the enhancer can be reversed after removal of the inducer. In vivo footprinting analysis indicates that all the cis-acting elements of the enhancer, previously identified in vitro, are occupied in vivo upon 12-O-tetradecanoyl-phorbol-13-acetate (TPA) stimulation of HepG2 cells, Micrococcal nuclease (MNase) cleavage of this region fails to reveal discrete nucleosomal boundaries in vivo in close proximity of the enhancer, either before or after stimulation. Furthermore, this region does not lose its nucleosomal configuration after TPA induction of transcription. An approximately 600 bp long region around the enhancer becomes more, but not fully, accessible to restriction endonucleases upon stimulation. A time-course experiment shows that this accessibility reaches a plateau after a Ih TPA treatment suggesting the persistent presence of nucleosomes, These results indicate that TPA induces the binding of transcription factors to the uPA enhancer without chromatin remodelling of this region.	Hosp San Raffaele, DIBIT, Mol Genet Lab, I-20132 Milan, Italy; Univ Milan, Dept Genet & Microbial Biol, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan	Crippa, MP (corresponding author), Hosp San Raffaele, DIBIT, Mol Genet Lab, Via Olgettina 58, I-20132 Milan, Italy.		crippa, massimo/J-6514-2016	crippa, massimo/0000-0003-3214-9670; Blasi, Francesco/0000-0001-9406-1784				Ausubel FM, 1994, CURRENT PROTOCOLS MO; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; BESSER D, 1996, FIBRINOLYSIS, V10, P214; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DECESARE D, 1995, ONCOGENE, V11, P365; DeCesare D, 1996, ONCOGENE, V13, P2551; Guerrini L, 1996, FEBS LETT, V393, P69, DOI 10.1016/0014-5793(96)00854-X; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE JS, 1994, NUCLEIC ACIDS RES, V22, P569, DOI 10.1093/nar/22.4.569; Li GY, 1998, GENE, V209, P139, DOI 10.1016/S0378-1119(98)00039-0; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; Quivy JP, 1996, J MOL BIOL, V256, P249, DOI 10.1006/jmbi.1996.0083; Quivy JP, 1997, METHODS, V11, P171, DOI 10.1006/meth.1996.0403; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WINTER H, 1990, DIFFERENTIATION, V43, P105, DOI 10.1111/j.1432-0436.1990.tb00436.x	27	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2836	2845		10.1038/sj.onc.1202644	http://dx.doi.org/10.1038/sj.onc.1202644			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362254				2022-12-17	WOS:000080125100006
J	Ferrer, M; Lopez-Borges, S; Lazo, PA				Ferrer, M; Lopez-Borges, S; Lazo, PA			Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines	ONCOGENE			English	Article						Burkitt lymphoma; TSG101; aberrant splicing; protein isoform; tumor susceptibility gene; cancer; gene expression	HUMAN BREAST-CANCER; FHIT GENE; LUNG-CANCER; SUPPRESSOR; ONCOPROTEIN-18; CARCINOMAS; 3P14.2	The tumor susceptibility gene, TSG101, has been identified as a candidate tumor suppressor gene. We have examined the expression of TSG101 in Burkitt lymphoma cell lines. Several aberrant messages were detected in all cell lines. Aberrant splice donor sites are located within exon 1 at positions 132, 154, 172 and 284. Splice accepters are located at positions 847 and 1054 within exon 5. The aberrant messages are coexpressed with a normal message and could be the result of additional splicing reactions of the mature message that behaves as an intermediate. The normal message codes for 46 kDa protein (TSG101A). One aberrant message joins in frame nucleotides 283-1055 and codes for a protein isoform of 17 kDa (TSG101B), as demonstrated by in vitro translation assays. The TSG101B isoform lacks the leucine zipper near the C-terminus, a transcriptional repressor domain, and retains most of the N-terminal region which has homology to E2 ubiquitin regulatory enzymes and the CROC-1 transcriptional regulator. The TSG101B isoform was detected in sixteen out of twenty-two (72%) BL cell lines, but not in normal lymphoid populations. The presence of two TSG101 isoforms with different dimerization potential opens up a new level of regulation of the TSG101 proteins possibly affecting cell cycle regulation.	Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Genet & Med Mol, Majadahonda 28220, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain	Instituto de Salud Carlos III; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Genet & Med Mol, Majadahonda 28220, Spain.		Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; EHLINHENRIKSSON B, 1987, INT J CANCER, V39, P211, DOI 10.1002/ijc.2910390215; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FEDUCHI E, 1994, INT J CANCER, V58, P855; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Hayashi S, 1997, CANCER RES, V57, P1981; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lee MP, 1997, CANCER RES, V57, P3131; LI L, 1996, CELL, V85, P315; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; LINPM, 1998, BR J HAEMATOL, V102, P753; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; Oh Y, 1998, ONCOGENE, V17, P1141, DOI 10.1038/sj.onc.1202029; Ponting CP, 1997, J MOL MED-JMM, V75, P467; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RODOFSKY ML, 1997, GENE, V195, P141; ROOS G, 1993, LEUKEMIA, V7, P1538; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Thomson TM, 1998, FEBS LETT, V423, P49, DOI 10.1016/S0014-5793(98)00060-X; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1997, CANCER RES, V57, P4225; Zimonjic DB, 1997, CANCER RES, V57, P1166	33	13	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2253	2259		10.1038/sj.onc.1202551	http://dx.doi.org/10.1038/sj.onc.1202551			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327071				2022-12-17	WOS:000079525100009
J	Sun, SC; Maggirwar, SB; Harhaj, EW; Uhlik, M				Sun, SC; Maggirwar, SB; Harhaj, EW; Uhlik, M			Binding of c-Rel to STAT5 target sequences in HTLV-I-transformed T cells	ONCOGENE			English	Article						HTLV-I; c-Rel; STAT; T-cell transformation; NF-kappa B	NF-KAPPA-B; VIRUS TYPE-I; LEUKEMIA-LYMPHOMA VIRUS; LONG TERMINAL REPEAT; JAK-3 JANUS KINASE; TAX PROTEIN; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE ACTIVATION; SIGNAL; PHOSPHORYLATION	The type I human T-cell leukemia virus (HTLV-I) induces abnormal growth and subsequent transformation of T cells, which is associated with the development of an acute T-cell malignancy termed adult T-cell leukemia, A characteristic of HTLV-I-transformed T cells is the constitutive nuclear expression of NF-kappa B/Rel family of transcription factors, which appears to be essential for the growth of these transformed cells. Although NF-kappa B/Rel factors are known to induce the expression of T-cell growth factor interleukin (IL)-2, it is unclear how they participate in the IL-2-independent growth of HTLV-1-transformed cells, In this study, we show that certain NF-kappa B/Rel members, predominantly c-Rel, interact with enhancer sequences for STAT5, a key transcription factor mediating IL-2-induced T-cell proliferation. Reporter gene assays reveal that the binding of c-Rel to the STAT5 site present in the Fc gamma 1 gene leads to potent transactivation of this enhancer. Binding of c-Rel to the Fc gamma R1 STAT site also occurs in human peripheral blood T cells immortalized with HTLV-I in vitro and is correlated with enhanced levels of proliferation of these cells. These results raise the possibility that NF-kappa B/Rel may participate in the growth control of HTLV-I-transformed T cells by regulating genes driven by both kappa B and certain STAT enhancers.	Penn State Univ, Coll Med, Hershey Med Ctr, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Hershey Med Ctr, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.				NCI NIH HHS [1 R01 CA68471-03, 5 T32 CA 6039-5] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GAZDAR AF, 1980, BLOOD, V55, P409; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOEFFLER HP, 1984, BLOOD, V64, P482; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERL S, 1984, BLOOD, V64, P967; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYOSHI I, 1981, GANN, V72, P978; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	52	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1401	1409		10.1038/sj.onc.1202430	http://dx.doi.org/10.1038/sj.onc.1202430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050877				2022-12-17	WOS:000078651600002
J	Koreth, J; Bakkenist, CJ; Larin, Z; Hunt, NCA; James, MR; McGee, JO				Koreth, J; Bakkenist, CJ; Larin, Z; Hunt, NCA; James, MR; McGee, JO			11q23.1 and 11q25-qter YACs suppress tumour growth in vivo	ONCOGENE			English	Article						tumour suppressor gene; YAC functional complementation; chromosome 11q; cancer; A9 cells	BREAST-CANCER; OVARIAN-CANCER; ATAXIA-TELANGIECTASIA; CERVICAL-CARCINOMA; MALIGNANT-MELANOMA; CHROMOSOME 11Q23; HUMAN GENE; HETEROZYGOSITY; REGION; CELLS	Frequent allelic deletion at chromosome 11q22-q23.1 has been described in breast cancer and a number of other malignancies, suggesting putative tumour suppressor gene(s) within the similar to 8 Mb deleted region. In addition, we recently described another locus, at the 11q25-qter region, frequently deleted in breast cancer, suggesting additional tumour suppressor gene(s) in this similar to 2 Mb deleted region. An 11q YAC contig was accessed and three YACs, one containing the candidate gene A TM at 11q23.1, and two contiguous YACs (overlapping for similar to 400-600kb) overlying most of the 11q25 deleted region, were retrofitted with a G418 resistance marker and transfected into murine A9 fibrosarcoma cells, Selected A9 transfectant clones (and control untransfected and 'irrelevant' alphoid YAC transfectant A9 clones) were assayed for in vivo tumorigenicity in athymic female Balb c-nu/nu mice. All the 11q YAC transfectant clones demonstrated significant tumour suppression compared to the control untransfected and 'irrelevant' YAC transfected A9 cells. These results define two discrete tumour suppressor loci on chromosome 11q by functional complementation, one to a similar to 1.2 Mb region on 11q23.1 (containing the ATM locus) and another to a similar to 400-600 kb subterminal region on 11q25-qter.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Wellcome Trust Ctr Human Genet, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	McGee, JO (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Pathol & Bacteriol, Oxford OX3 9DU, England.		Monaco, Zoia L/C-5762-2011					Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Baffa R, 1996, CANCER RES, V56, P268; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; CARTER SL, 1994, CANCER RES, V54, P6270; Davis M, 1996, CANCER RES, V56, P741; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; EASTON DF, 1994, INT J RADIAT BIOL, V66, P6270; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GABRA H, 1995, BRIT J CANCER, V72, P367, DOI 10.1038/bjc.1995.340; Gioeli D, 1997, CANCER RES, V57, P1157; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; HIRST MC, 1991, NUCLEIC ACIDS RES, V19, P3283, DOI 10.1093/nar/19.12.3283; Horikawa I, 1995, CANCER GENET CYTOGEN, V85, P97, DOI 10.1016/0165-4608(95)00147-6; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; IIZUKA M, GENES CHROMOSOMES CA, V13, P40; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; KORETH J, 1998, IN PRESS J PATHOL; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; LARIN Z, 1995, PULSED FIELD GEL ELE, P139; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; Phillips KK, 1996, CANCER RES, V56, P1222; RASIO D, 1995, CANCER RES, V55, P3988; Robertson G, 1996, CANCER RES, V56, P4487; Savitsky K, 1996, GENOMICS, V33, P199, DOI 10.1006/geno.1996.0184; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; Stilgenbauer S, 1996, P NATL ACAD SCI USA, V93, P11837, DOI 10.1073/pnas.93.21.11837; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Todd MC, 1996, ONCOGENE, V13, P2387; Tomlinson IPM, 1996, J CLIN PATHOL, V49, P386, DOI 10.1136/jcp.49.5.386; VANHEYNINGEN V, 1995, CYTOGENET CELL GENET, V69, P128, DOI 10.1159/000133953; Vorechovsky I, 1996, CANCER RES, V56, P2726; WINQVIST R, 1995, CANCER RES, V55, P2660; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	46	13	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1157	1164		10.1038/sj.onc.1202372	http://dx.doi.org/10.1038/sj.onc.1202372			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022121				2022-12-17	WOS:000078510700004
J	Rapp, L; Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ				Rapp, L; Liu, Y; Hong, YH; Androphy, EJ; Chen, JJ			The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis	ONCOGENE			English	Article						BPV-1 E6; TNF; cytolysis; apoptosis; p53; arachidonic acid	CYTOSOLIC PHOSPHOLIPASE A(2); CALCIUM-BINDING PROTEIN; OPEN READING FRAME; P53 FUNCTION; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GENE; ARACHIDONIC-ACID; ENDOPLASMIC-RETICULUM; MUTATIONAL ANALYSIS; VIRUS DNA	Expression of viral proteins may result in susceptibility of cells to the cytotoxic effect of Tumor Necrosis Factor Alpha (TNF), While murine C127 cells containing the bovine papillomavirus type 1 (BPV-1) genome were reported to exhibit increased TNF sensitivity, the gene(s) responsible was not identified. The BPV-1 E6 oncoprotein induces tumorigenic transformation of murine C127 cells and stimulates transcription when targeted to a promoter. BPV-1 E6 was introduced into C127 cells (PBE6) by retroviral infection and stable clones were isolated. These cells showed increased apoptosis in response to TNF, as measured by several criteria. TNF-induced apoptosis in PBE6 cells was accompanied by increased release of arachidonic acid, indicating that phospholipase A, was activated. We also provide evidence that BPV-1 E6 mediated-sensitization of cells to TNF-induced apoptosis can ocur in the absence of p53.	New England Med Ctr, Dept Dermatol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Chen, JJ (corresponding author), New England Med Ctr, Dept Dermatol, 750 Washington St,Box 166, Boston, MA 02111 USA.			Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R01CA073558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007562] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73558] Funding Source: Medline; NIAMS NIH HHS [T32 AR 07562] Funding Source: Medline; PHS HHS [F32] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; Bergqvist A, 1997, J VIROL, V71, P276, DOI 10.1128/JVI.71.1.276-283.1997; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chen JJ, 1997, VIROLOGY, V236, P30, DOI 10.1006/viro.1997.8725; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEURKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DODDS D, 1995, J NEUROCHEM, V64, P2339; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; FAN SJ, 1995, CANCER RES, V55, P1649; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; Hawkins DS, 1996, CANCER RES, V56, P892; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KERR JFR, 1992, APOPTOSIS MOL BASIS, P5; Krajcsi P, 1996, J VIROL, V70, P4904, DOI 10.1128/JVI.70.8.4904-4913.1996; KULL FC, 1981, CANCER RES, V41, P4885; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LASTER SM, 1988, J IMMUNOL, V141, P2629; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ned R, 1997, J VIROL, V71, P4866, DOI 10.1128/JVI.71.6.4866-4870.1997; OSTROVE JM, 1979, P SOC EXP BIOL MED, V160, P354; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; QUI ZH, 1998, J BIOL CHEM, V273, P8203; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Steller MA, 1996, CANCER RES, V56, P5087; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thomas M, 1996, ONCOGENE, V13, P265; Thorne TE, 1996, J VIROL, V70, P8502, DOI 10.1128/JVI.70.12.8502-8507.1996; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TSANG NM, 1995, ONCOGENE, V10, P2403; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; VOUSDEN KH, 1989, J VIROL, V63, P2340, DOI 10.1128/JVI.63.5.2340-2342.1989; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WEIS K, 1994, J BIOL CHEM, V269, P19142; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026; ZURHAUSEN H, 1996, BIOCHIM BIOPHYS ACTA, V1288, pF55; [No title captured]	70	13	13	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					607	615		10.1038/sj.onc.1202373	http://dx.doi.org/10.1038/sj.onc.1202373			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989810				2022-12-17	WOS:000078394400005
J	Julius, MA; Rai, SD; Kitajewski, J				Julius, MA; Rai, SD; Kitajewski, J			Chimeric Wnt proteins define the amino-terminus of Wnt-1 as a transformation-specific determinant	ONCOGENE			English	Article						Wnt; chimera; transformation; beta-catenin	MAMMARY EPITHELIAL-CELLS; POLARITY GENE ARMADILLO; PROTO-ONCOGENE INT-1; XENOPUS EMBRYOS; BETA-CATENIN; WINGLESS GENE; DROSOPHILA; FAMILY; EXPRESSION; LINE	Wnt-1 induces morphological transformation of C57MG mammary epithelial cells and accumulation of cytosolic beta-catenin whereas Wnt-5a has no effect. To identify regions within the 370 amino acid Wnt-1 protein required for these functions we tested eleven chimeric genes that contained variable amounts of Wnt-1;Ind Wnt-5a sequence. Transformation and beta-catenin regulation in C57MG cells is controlled by amino acids that lie within 186 residues of the amino terminus of Wnt-1. Small substitutions between residues 186 and 292 reduced Wnt-1 activity. Replacement of the carboxy terminal 79 amino acids of Wnt-1 by Wnt-5a did not affect function. These results were supported by transient expression assays in 293 cells wherein beta-catenin accumulated in the cytoplasm in response to ectopic Wnt-1 expression. Un 293 cells, a larger region of the amino-terminus of Wnt-1 was found to be required for beta-catenin regulation. Nonfunctional chimeras that contained at least 99 amino terminal Wnt-1 residues inhibited Wnt-1 stimulation of 293 cells. One of these chimeras inhibited both Wnt-1 and Wnt-3 activity suggesting that Wnt-1 and Wnt-3 interact with a common signaling component.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA	Columbia University; Columbia University	Kitajewski, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.							BEJSOVEC A, 1995, GENETICS, V139, P309; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Binari RC, 1997, DEVELOPMENT, V124, P2623; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BROWN AMC, 1995, RETROVIRAL VECTORS, V4, P113; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; Dale TC, 1998, BIOCHEM J, V329, P209; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Fagotto F, 1997, DEVELOPMENT, V124, P453; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Haerry TE, 1997, DEVELOPMENT, V124, P3055; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JASIN M, 1992, P NATL ACAD SCI USA, V89, P10681, DOI 10.1073/pnas.89.22.10681; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Klymkowsky MW, 1997, BIOESSAYS, V19, P537, DOI 10.1002/bies.950190702; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MOON RT, 1993, DEVELOPMENT, V119, P97; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; Schryver B, 1996, ONCOGENE, V13, P333; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	61	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					149	156		10.1038/sj.onc.1202268	http://dx.doi.org/10.1038/sj.onc.1202268			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926929				2022-12-17	WOS:000078166000016
J	Matsuguchi, T; Kraft, AS				Matsuguchi, T; Kraft, AS			Regulation of myeloid cell growth by distinct effectors of Ras	ONCOGENE			English	Article						ras; cell growth; myeloid cells; apoptosis; kip1	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; INDEPENDENT PATHWAYS; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; TRANSFORMATION; AKT; P27(KIP1)	To examine the biochemical pathways by which activated Ha-Ras(G12V) (Ha-RasV12) induces factor-independent growth of myeloid cells, Ha-Ras effector loop mutations, including Y40C, T35S, and E37G, were analysed in a mouse factor-dependent myeloid cell line, WT19. Expression of a single effector loop mutant, Ha-Ras(G12V, Y40C) (Ha-RasV12C40), inhibited factor-withdrawal apoptosis, suggesting that activation of the phosphatidylinositol 3'-kinase (Pl3K) pathway is essential to prevent cell death. Neither Ha-Ras (G12V, T35S) (Ha-RasV12S35), which activates the Ran signaling pathway, nor Ha-Ras(G12V, E37G) (Ha-RasV12G37), which stimulates the RalGDS pathway, did not have significant effects on factor-withdrawal apoptosis of myeloid cells. Although Ha-RasV12C40 inhibited apoptosis, it did not stimulate entry into the cell cycle. Cell lines containing the combination of Ha-RasV12G37 and Ha-RasV12C40 were capable of factor-independent cell growth, while expression of the other combinations of the Ha-Ras effector mutants were not. The combined expression of Bcl-2 and Ha-RasV12G37 was not sufficient to stimulate factor independent growth, suggesting that Ha-RasV12C40 activates additional signals, besides blocking apoptosis, which are critical for factor-independent growth of myeloid cells. In factor-starved myeloid cells, inducible expression of Ha-RasV12G37 results in decreased level of p27(Kip1) protein, a cyclin-dependent kinase inhibitor (CKI). These data suggest that the factor-independent growth of myeloid cells requires the activation of at least two pathways, one inhibiting factor-withdrawal apoptosis, and another causing cell cycle progression.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NIDDK NIH HHS [DK44741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murai H, 1997, J BIOL CHEM, V272, P10483; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	50	13	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2701	2709		10.1038/sj.onc.1202201	http://dx.doi.org/10.1038/sj.onc.1202201			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840934				2022-12-17	WOS:000077146700003
J	Cowell, JK; Bia, B				Cowell, JK; Bia, B			A novel missense mutation in patients from a retinoblastoma pedigree showing only mild expression of the tumor phenotype	ONCOGENE			English	Article						retinoblastoma; missense mutation; incomplete penetrance; SSCP	ONCOGENIC POINT MUTATIONS; GERM-LINE MUTATIONS; RB1 GENE; HEREDITARY RETINOBLASTOMA; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; MECHANISMS; SPECTRUM; IDENTIFICATION; SITES	We have used single strand conformation polymorphism analysis to study the 27 exons of the RB1 gene in individuals from a family showing 'mild' expression of the retinoblastoma phenotype. In this family affected individuals developed unilateral tumors and, as a result of linkage analysis, unaffected mutation carriers were also identified within the pedigree. A single band shift using SSCP was identified in exon 21 which resulted in a missense mutation converting a cys-->arg at nucleotide position 28 in the exon. The mutation destroyed an NdeI restriction enzyme site. Analysis of all family members demonstrated that the missense mutation co-segregated with patients with tumors or who, as a result of linkage analysis had been predicted to carry the predisposing mutation. These observations point to another region of the RBI gene where mutations only modify the function of the gene and raise important questions for genetic counseling in families with these distinctive phenotypes.	Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cowell, JK (corresponding author), Cleveland Clin Fdn, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950				BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell JK, 1996, ONCOGENE, V12, P431; Cowell JK, 1996, EUR J CANCER, V32A, P1749, DOI 10.1016/0959-8049(96)00201-8; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; LIU ZX, 1995, GENE CHROMOSOME CANC, V14, P277, DOI 10.1002/gcc.2870140406; Lohmann DR, 1996, AM J HUM GENET, V58, P940; LOHMANN DR, 1994, HUM MOL GENET, V3, P2187, DOI 10.1093/hmg/3.12.2187; MACKLIN MT, 1960, AM J HUM GENET, V12, P1; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; ONADIM ZO, 1990, ARCH DIS CHILD-FETAL, V65, P651, DOI 10.1136/adc.65.7_Spec_No.651; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	29	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3211	3213		10.1038/sj.onc.1201833	http://dx.doi.org/10.1038/sj.onc.1201833			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671401				2022-12-17	WOS:000074261300015
J	Gandrillon, O; Samarut, J				Gandrillon, O; Samarut, J			Role of the different RAR isoforms in controlling the erythrocytic differentiation sequence. Interference with the v-erbA and p135(gap-myb-ets) nuclear oncogenes	ONCOGENE			English	Article						nuclear hormone receptors; erythroleukemia; viral transformation	RETINOIC ACID RECEPTORS; AVIAN ERYTHROBLASTOSIS VIRUS; ETS FUSION ONCOPROTEIN; LEUKEMIA-VIRUS; TRANSCRIPTIONAL ACTIVATION; PROGENITOR CELLS; THYROID-HORMONE; MYELOID CELLS; TARGET-CELLS; SELF-RENEWAL	Little is known as to how the nuclear oncogenes v-erbA and p135(gag-myb-ets) do transform cells. The elucidation of their molecular mechanisms of action requires the identification of relevant target genes. We analysed the possibility for the RAR beta gene to represent such a target gene. We first show that the RAR beta gene induction is a specific and direct process, requiring the continous presence of retinoids and under the control of the RAR alpha isoform exclusively. We then show that the expression of either the v-erbA or the p135(gag-myb-ets) oncogene is not sufficient to block the RAR beta gene induction. We confirmed the loss of RARE gene response in certain cell lines but we discarded the possibility that this lass might represent a necessary step for cell lines immortalization. We further show that the RAR alpha isoform activation is necessary and sufficient to induce the growth inhibition and the differentiation stimulation characteristic for the commitment-inducing ability of retinoids in chicken erythrocytic progenitor cells. We therefore propose a model showing that RAR alpha but not RAR beta is the key mediator for commitment to differentiation and that it should control two different set of genes whose expression is differentially affected by the v-erbA and the p135(gag-myb-ets) oncogenes.	Ecole Normale Super Lyon, Dept Biol Mol & Cellulaire, F-69364 Lyon 7, France	Ecole Normale Superieure de Lyon (ENS de LYON)	Gandrillon, O (corresponding author), Ecole Normale Super Lyon, Dept Biol Mol & Cellulaire, 46 Allee Italie, F-69364 Lyon 7, France.		Samarut, Jacques/AAD-2587-2019					ALMOUSTAFA AE, 1994, CELL GROWTH DIFFER, V5, P863; APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; Botling J, 1996, CELL GROWTH DIFFER, V7, P1239; CassarMalek I, 1997, ONCOGENE, V14, P1099, DOI 10.1038/sj.onc.1200928; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1995, INT J ONCOL, V6, P215; Geisen C, 1997, CANCER RES, V57, P1460; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HERMANN T, 1993, ONCOGENE, V8, P55; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168; KRAUT N, 1995, ONCOGENE, V10, P1027; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; Mills KJ, 1996, CELL GROWTH DIFFER, V7, P327; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Rascle A, 1996, MOL CELL BIOL, V16, P6338; REICHERT U, 1993, MOL BIOL THERAPEUTIC, V5, P117; Rogers MB, 1996, CELL GROWTH DIFFER, V7, P115; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Rusten LS, 1996, BLOOD, V87, P1728; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; WOODS C, 1995, ENDOCRINOLOGY, V136, P85, DOI 10.1210/en.136.1.85; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	51	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					563	574		10.1038/sj.onc.1201550	http://dx.doi.org/10.1038/sj.onc.1201550			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482102				2022-12-17	WOS:000071816600001
J	Girard, L; Jolicoeur, P				Girard, L; Jolicoeur, P			A full-length Notch1 allele is dispensable for transformation associated with a provirally activated truncated Notch1 allele in Moloney MuLV-infected MMTVD/myc transgenic mice	ONCOGENE			English	Article						Notch1; transgenic mice; targeted mutagenesis; retrovirus; MuLV	DROSOPHILA NOTCH; INSERTIONAL MUTAGENESIS; HUMAN HOMOLOG; C-ELEGANS; GENE; RECEPTOR; MYOGENESIS; NEOPLASMS; LIN-12; DOMAIN	The Notch1 gene was previously found to be targetted by provirus insertion in a high proportion of T-cell lymphomas arising in Moloney MuLV-inoculated MMTVD/myc transgenic mice, Proviral activation of Notch1 was associated with overexpression of truncated Notch1, deleted of the sequences coding for the extracellular domain, The high levels of truncated Notch1 RNA and proteins in these tumors are thought to be involved in the oncogenic transformation, However, in addition to these truncated RNA and proteins, high level expression of full-length Notch1 RNA and proteins was also observed in several tumors, suggesting that they could also contribute to the transformation process, To test this hypothesis, me used a genetic approach and studied MMTVD/myc transgenic mice in which one of the Notch1 alleles was mutated by targeted mutagenesis (Notch(+/-) mice). Heterozygote (Notch1(+/-)) and wild-type (Notch1(+/+)) transgenic mice were inoculated with Moloney MuLV and the frequency of Notch1 rearrangements was compared between both groups. Notch1 was rearranged at similar frequencies in both groups, indicating that the full-length Notch1 allele is dispensable in tumors harboring an activated Notch1 allele.	Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Christensen S, 1996, DEVELOPMENT, V122, P1373; CONLON RA, 1995, DEVELOPMENT, V121, P1533; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; HANNA Z, 1993, ONCOGENE, V8, P1661; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; NYE JS, 1994, DEVELOPMENT, V120, P2421; PAQUETTE Y, 1992, MOL CELL BIOL, V12, P3522, DOI 10.1128/MCB.12.8.3522; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8	24	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					517	522		10.1038/sj.onc.1201562	http://dx.doi.org/10.1038/sj.onc.1201562			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484841	Green Submitted			2022-12-17	WOS:000071739400010
J	Morris, SW; Naeve, C; Mathew, P; Kirstein, MN; Cui, XL; Witte, DP				Morris, SW; Naeve, C; Mathew, P; Kirstein, MN; Cui, XL; Witte, DP			ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) (vol 14, pg 2175, 1997)	ONCOGENE			English	Correction, Addition																		Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062	1	13	13	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2883	2883						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803					2022-12-17	WOS:A1997YJ80300015
J	Hess, RD; Brandner, G				Hess, RD; Brandner, G			DNA-damage-inducible p53 activity in SV40-transformed cells	ONCOGENE			English	Article						p53 function; SV40 transformation; large SV40 tumour antigen; DNA damage response; SV40 T antigen; p21WAF1	LARGE-T-ANTIGEN; WILD-TYPE P53; NUCLEAR ACCUMULATION; CANCER CELLS; PROTEIN; FIBROBLASTS; EXPRESSION; APOPTOSIS; INDUCTION; AGENTS	The biological state of the tumour suppressor proteins Rb and p53 is altered in papillomavirus-and SV40-transformed cells, due to interaction with the DNA tumour virus oncogene proteins E6/E7 and the tumour (T) antigen, Thus, the DNA damage response function of p53, a crucial feature of the tumour suppressor p53, might be considered as inactive, To investigate this subject, C57SV and VLM, two SV40-transformed murine cell lines enharboring constitutively high nuclear p53 and SV40 large T antigen levels, were treated with mitomycin C, Mitomycin C is known for its activity to elicit DNA damage, followed by nuclear accumulation of biologically active p53, Surprisingly, the nuclear p53 level significantly increased in mitomycin-C-treated C57SV cells and to a lesser degree in VLM cells. In addition, expression of p21WAF1 protein was induced in C57SV and VLM cells, This indicates a possible DNA-damage-elicited p53 activation, Finally, nuclear extracts of mitomycin-C-treated C57SV and VLM cells, but not of untreated cells, exhibited PAb421-enhanced specific DNA-binding activity of p53, as proven by gel shift analysis, Thus, DNA damage induced essential biological functions typical for wild-type p53 in the SV40-transformed cell lines examined so far.			Hess, RD (corresponding author), UNIV FREIBURG,INST MED MIKROBIOL & HYG,DEPT VIROL,POB 820,D-79008 FREIBURG,GERMANY.							ALBERTS B, 1994, MOL BIOL CELL, P1284; BUTZ K, 1995, ONCOGENE, V10, P927; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; FRITSCHE M, 1993, ONCOGENE, V8, P307; FRITSCHE M, 1991, J CANCER RES CLIN, V117, P30; GOLDBERG YP, 1992, J CELL BIOCHEM, V49, P74, DOI 10.1002/jcb.240490113; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; JANSON W, 1997, IN PRESS ONCOGENE; JOHN B, 1995, THESIS FREIBURG GERM; KASTAN MB, 1991, CANCER RES, V51, P6304; KNOBLICH J, 1993, THESIS FREIBURG GERM; KNOWLES BB, 1979, J IMMUNOL, V122, P1798; Lenahan MK, 1996, ONCOGENE, V12, P1847; LONG SB, 1995, ANTICANCER RES, V15, P1375; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mukhopadhyay T, 1996, INT J ONCOL, V9, P405; Plaumann B, 1996, ONCOGENE, V13, P1605; SCHOEFFEL A, 1988, VIROLOGY, V166, P245, DOI 10.1016/0042-6822(88)90166-3; SIEGEL J, 1995, ONCOGENE, V11, P1363; Spitkovsky D, 1996, ONCOGENE, V13, P1027; TAHARA H, 1995, ONCOGENE, V10, P835; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wu GS, 1996, CLIN CANCER RES, V2, P623; ZARLING JM, 1973, J NATL CANCER I, V50, P137, DOI 10.1093/jnci/50.1.137; Zeng YX, 1996, ONCOGENE, V12, P1557	28	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2501	2504		10.1038/sj.onc.1201404	http://dx.doi.org/10.1038/sj.onc.1201404			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395246				2022-12-17	WOS:A1997YE96300012
J	LeBrun, DP; Matthews, BP; Feldman, BJ; Cleary, ML				LeBrun, DP; Matthews, BP; Feldman, BJ; Cleary, ML			The chimeric oncoproteins E2A-PBX1 and E2A-HLF are concentrated within spherical nuclear domains	ONCOGENE			English	Article						leukemia; E2A-PBX1; E2A-HLF; transcription factors; translocations	ACUTE LYMPHOBLASTIC-LEUKEMIA; COOPERATIVE DNA-BINDING; PRE-B; TRANSCRIPTIONAL ACTIVATOR; HOMEODOMAIN PROTEIN; PBX1 HOMEODOMAIN; MESSENGER-RNA; HOX PROTEINS; E2A GENE; FUSION	Oncogenic mutation of nuclear transcription factors often is associated with altered patterns of subcellular localization that may be of functional importance, The leukemogenic transcription factor gene E2A-PBX1 is created through fusion of the genes E2A and PBX1 as a result of t(1;19) in acute lymphoblastic leukemia, We evaluated subcellular localization patterns of E2A-PBX1 protein in transfected cells using immunofluorescence. Full-length E2A-PBX1 was exclusively nuclear and was concentrated in spherical domains denoted chimeric-E2A oncoprotein domains (CODs), In contrast, nuclear fluorescence for wild-type E2A or PBX1 proteins was diffuse, Enhanced concentrations of RNA polymerase II within many CODs and the requirement for an E2A-encoded activation domain suggested transcriptional relevance, However, in situ co-detection of nascent transcripts labeled with bromouridine failed to confirm altered transcriptional activity in relation to CODs, CODs also failed to co-localize with other proteins known to occupy functional nuclear compartments, including the transcription factor PML, the spliceosome-associated protein SC-35 and the adenovirus replication factor DBP, or with foci of DNA replication, Co-transfection of Hoxb7, a homeodomain protein capable of enhancing DNA binding by PBX1, impaired COD formation, suggesting that CODs contain E2A-PBX1 protein not associated with DNA, We conclude that, as a 'gain of function' phenomenon requiring protein elements from both E2A and PBX1, COD formation may be relevant to the biology of E2A-PBX1 in leukemogenesis.	STANFORD UNIV,MED CTR,DEPT PATHOL,EXPT ONCOL LAB,STANFORD,CA 94305	Stanford University	LeBrun, DP (corresponding author), QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA.				NCI NIH HHS [CA42971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BERENDES P, 1995, LEUKEMIA, V9, P1321; BOROWITZ M, 1992, NEOPLASTIC HEMATOPAT, P1295; BRIDGE E, 1995, J VIROL, V69, P281, DOI 10.1128/JVI.69.1.281-290.1995; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARROLL AJ, 1984, BLOOD, V63, P721; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CLEARY ML, 1992, CANCER SURV, V15, P89; CRIST WM, 1990, BLOOD, V76, P117; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FORNEROD M, 1995, ONCOGENE, V10, P1739; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, BLOOD, V83, P2970, DOI 10.1182/blood.V83.10.2970.2970; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; Inukai T., 1996, Blood, V88, p552A; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; PUI CH, 1990, BLOOD, V76, P1449; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1984, BIOL CELL, V51, P109, DOI 10.1111/j.1768-322X.1984.tb00289.x; SPECTOR DL, 1987, ONCOGENE, V1, P5; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; TISCHLER AS, 1992, J HISTOCHEM CYTOCHEM, V40, P1043, DOI 10.1177/40.7.1351491; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERHEIJEN R, 1986, J CELL SCI, V86, P173; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247	51	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2059	2067		10.1038/sj.onc.1201367	http://dx.doi.org/10.1038/sj.onc.1201367			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366523				2022-12-17	WOS:A1997YC28400007
J	Flajolet, M; Gegonne, A; Ghysdael, J; Tiollais, P; Buendia, MA; Fourel, G				Flajolet, M; Gegonne, A; Ghysdael, J; Tiollais, P; Buendia, MA; Fourel, G			Cellular and viral trans-acting factors modulate N-myc2 promoter activity in woodchuck liver tumors	ONCOGENE			English	Article						N-myc2; woodchucks; IL-6	INTERLEUKIN-6 RESPONSE ELEMENT; HEPATITIS-VIRUS; HEPADNAVIRUS INSERTION; MYC; EXPRESSION; ACTIVATION; PROTEIN; FAMILY; CELLS; GENE	Activation of the N-myc2 oncogene by integration of woodchuck hepatitis virus (WHV) DNA is a central event in woodchuck liver oncogenesis, In this study, we have evaluated the influence of several cellular and viral tr ans-acting factors and mediators of inflammation on N-myc2 promoter activity in hepatoma cell lines, Ets oncoproteins, including Ets1, Ets2 and PEA3 efficiently activated a chimeric N-myc2 promoter/luciferase reporter gene, By electrophoretic mobility shift assays, we show that Ets1 and Ets2 proteins can efficiently bind two consensus Ets sites located within a 59 bp sequence upstream of the N-myc2 transcription start site, Site-directed mutagenesis of these Ets-binding motifs abolished transactivation of the N-myc2 promoter by Ets proteins, Addition of interleukin-6 (IL-6) induced a weak but reproducible activation of the N-myc2 promoter, while IL-1 was ineffective, We further show that the N-myc2 promoter can be transactivated by the hepadnavirus X protein, and that distal promoter sequences are required for both IL-6 and X responsiveness, Similar effects of these factors were observed in the context of the N-myc2 promoter activated by WHV cis-regulatory elements, In view of the high-level expression of the N-myc2 oncogene in most woodchuck liver tumors, the Ets oncoproteins, inflammation-associated cytokine IL-6 and the viral X transactivator might play important roles in hepadnavirus-associated tumorigenesis.	CTR UNIV ORSAY, CNRS URA 1443, F-91405 ORSAY, FRANCE	UDICE-French Research Universities; Universite Paris Saclay	Flajolet, M (corresponding author), INST PASTEUR, INSERM U163, UNITE RECOMBINAISON & EXPRESS GENET, F-75724 PARIS, FRANCE.		GHYSDAEL, Jacques/F-3377-2013					BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FLAJOLET M, 1997, IN PRESS VIRAL HEPAT; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; Fourel G, 1996, J VIROL, V70, P8571, DOI 10.1128/JVI.70.12.8571-8583.1996; FOUREL G, 1994, LIVER GENE EXPRESSIO, P297; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; POLI V, 1994, LIVER GENE EXPRESSIO, P131; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; STEMMER WPC, 1992, BIOTECHNIQUES, V13, P214; TOSHKOV I, 1990, J CANCER RES CLIN, V116, P581, DOI 10.1007/BF01637078; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; Ueda K, 1996, J VIROL, V70, P4714, DOI 10.1128/JVI.70.7.4714-4723.1996; Ueda K, 1996, VIROLOGY, V217, P413, DOI 10.1006/viro.1996.0133; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; YANG D, 1993, CANCER RES, V53, P2020; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	41	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1103	1110		10.1038/sj.onc.1201257	http://dx.doi.org/10.1038/sj.onc.1201257			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285565				2022-12-17	WOS:A1997XT16100012
J	Feitelson, MA; Ranganathan, PN; Clayton, MM; Zhang, SM				Feitelson, MA; Ranganathan, PN; Clayton, MM; Zhang, SM			Partial characterization of the woodchuck tumor suppressor, p53, and its interaction with woodchuck hepatitis virus X antigen in hepatocarcinogenesis	ONCOGENE			English	Article						woodchuck hepatitis virus; p53; X-antigen; hepatocarcinogenesis	HUMAN HEPATOCELLULAR CARCINOMAS; TATA-BINDING PROTEIN; B-VIRUS; C-MYC; TRANSCRIPTIONAL ACTIVITY; CARRIER PATIENTS; DNA INTEGRATION; TRANSGENIC MICE; LIVER-CANCER; HBX PROTEIN	Full length cDNAs for p53 were made by reverse transcription-polymerase chain reaction of total RNA from two normal woodchuck livers. Two randomly chosen clones from each liver were sequenced and shown to be identical. This sequence revealed 80% or more identity with p53 sequences from human, monkey, and mouse. The cDNA was translated into a similar to 55 kD protein in vitro that was immunoprecipitated by antibodies to p53. Cotranslation of woodchuck p53 with woodchuck hepatitis virus X antigen, followed by immunoprecipitation suggested X/p53 complex formation. Similar complexes were also immunoprecipitated from extracts of infected liver, but not from uninfected liver. The finding of X/p53 complexes in vivo and in vitro in the woodchuck hepadnavirus system, combined with analogous data with hepatitis B, suggests a common mechanism by which these viruses contribute to hepatocellular transformation.			Feitelson, MA (corresponding author), THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107, USA.				NCI NIH HHS [CA48656] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048656, R01CA048656] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; FEITELSON MA, 1990, GASTROENTEROLOGY, V98, P1071, DOI 10.1016/0016-5085(90)90035-Y; FEITELSON MA, 1990, VIROLOGY, V177, P357, DOI 10.1016/0042-6822(90)90491-9; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEITELSON MA, 1993, J HEPATOL, V17, pS24, DOI 10.1016/S0168-8278(05)80420-9; FEITELSON MA, 1990, VIROLOGY, V177, P367, DOI 10.1016/0042-6822(90)90492-A; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hansen RS, 1996, ONCOGENE, V13, P995; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; LEE HS, 1988, HEPATOLOGY, V8, P1116, DOI 10.1002/hep.1840080524; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NATOLI G, 1994, ONCOGENE, V9, P2837; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RIVKINA MB, 1994, CANCER RES, V54, P5430; ROBINSON WS, 1994, ANNU REV MED, V45, P297; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SU Q, 1994, HEPATOLOGY, V19, P788; SUMMERS J, 1981, HEPATOLOGY, V1, P179, DOI 10.1002/hep.1840010215; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WANG J, 1992, ONCOGENE, V7, P1653; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; ZAHM P, 1988, ONCOGENE, V3, P169; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	57	13	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					327	336		10.1038/sj.onc.1201203	http://dx.doi.org/10.1038/sj.onc.1201203			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233767				2022-12-17	WOS:A1997XK99900009
J	Vedrenne, J; Assier, E; Pereno, R; BouzinbaSegard, H; Azzarone, B; Jasmin, C; Charron, D; Krief, P				Vedrenne, J; Assier, E; Pereno, R; BouzinbaSegard, H; Azzarone, B; Jasmin, C; Charron, D; Krief, P			Inhibitor (IK) of IFN-gamma induced HLA class II antigens expression also inhibits HLA class II constitutive expression in the human Raji B cell line	ONCOGENE			English	Article						MHC class II; IK; CIITA; IFN-gamma	BARE LYMPHOCYTE SYNDROME; DEFICIENT COMBINED IMMUNODEFICIENCY; TRANSACTIVATOR GENE CIITA; MONOCLONAL-ANTIBODIES; TRANSCRIPTION; SEQUENCES; CLONING	The expression of major histocompatibility complex (MHC) class II antigens is constitutive in professional antigen presenting cells (APCs) but can also be induced by interferon-gamma (IFN-gamma) on the majority of the non professional APCs (e.g. fibroblasts). We have recently characterised a new factor called IK which is an efficient inhibitor of IFN-gamma induction of MHC class II antigens expression. Here, we demonstrate a novel role for IK in MHC class II expression since over-expression of this protein by stable transfection into human B cells led to a total disappearance of constitutive MHC class II mRNA expression. The class II transactivator (CIITA) is necessary for both constitutive and IFN-gamma induced MHC class II expressions. Examination of CIITA mRNA in IK stably transfected clones revealed a marked reduction of CIITA mRNA transcription. Taken together these results demonstrate that the IK protein plays a keg role in the constitutive expression of MHC class II antigens and that inhibition induced by IK is upstream of CIITA in this regulatory pathway.	HOP PAUL BROUSSE,INSERM U268,F-94807 VILLEJUIF,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vedrenne, J (corresponding author), INSERM U396,INST BIOMED CORDELIERS,15 RUE ECOLE MED,F-75006 PARIS,FRANCE.		Azzarone, Bruno/AAH-9251-2019; Krief, Patricia/M-6073-2014	Azzarone, Bruno/0000-0002-5962-3849; Krief, Patricia/0000-0001-5106-466X; Assier, Eric/0000-0001-8366-1645				ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BROWN JA, 1995, IMMUNOGENETICS, V43, P88; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEPREVAL C, 1988, NEW ENGL J MED, V318, P1295, DOI 10.1056/NEJM198805193182003; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Griscelli C, 1989, Immunodefic Rev, V1, P135; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KRIEF P, 1994, ONCOGENE, V9, P3449; KRIEF P, 1987, EUR J IMMUNOL, V17, P1021, DOI 10.1002/eji.1830170719; MACH B, 1994, IMMUNOL REV, V138, P207, DOI 10.1111/j.1600-065X.1994.tb00853.x; PERROT JY, 1986, SCAND J IMMUNOL, V23, P623, DOI 10.1111/j.1365-3083.1986.tb01997.x; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEED JL, 1987, P NATL ACAD SCI USA, V84, P3305; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P410; TOURAINE JL, 1985, EXP HEMATOL, V13, P86; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9	26	13	15	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1453	1461		10.1038/sj.onc.1200971	http://dx.doi.org/10.1038/sj.onc.1200971			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136989				2022-12-17	WOS:A1997WT58400008
J	Gelderloos, JA; Anderson, SM				Gelderloos, JA; Anderson, SM			Over-expression of protein tyrosine phosphatase 1 (PTP1) alters IL-3-dependent growth and tyrosine phosphorylation	ONCOGENE			English	Article						IL-3; signal transduction; protein tyrosine phosphatase; tyrosine kinase	COLONY-STIMULATING FACTOR; RECEPTOR-LIKE PROTEIN; MYELOID CELL-LINES; GM-CSF RECEPTOR; INTERLEUKIN-3 RECEPTOR; SIGNAL-TRANSDUCTION; KINASE PP56LCK; HUMAN-PLACENTA; BETA-SUBUNIT; STEEL FACTOR	Interleukin-3 (IL-3) is a hematopoietic growth factor receptor which stimulates the proliferation of multilineage progenitor cells, It is known that IL-3 stimulates tyrosine phosphorylation while transducing a mitogenic signal. The signal transduction pathways activated by the IL-3 receptor, however, are not fully understood, In this study a protein tyrosine phosphatase has been overexpressed in the IL-3 dependent, murine myeloid progenitor cell line, 32D c13 in order to test whether altering the levels of tyrosine phosphorylation would change IL-3 stimulated proliferation, These cells were transfected with a metal-inducible expression vector containing a rat cDNA encoding PTP1. A low basal level of rat PTP1 message and protein was detected in cells transfected with the PTP1 vector, and zinc treatment resulted in a three- to fourfold increase in the amount of PTP1 message, protein and catalytic activity, Over-expression of PTP1 resulted in a two- to threefold decrease in IL-3 stimulated proliferation, Cells over-expressing PTP1 also exhibited decreased levels of tyrosine phosphorylation; phosphorylation of the IL-3 receptor beta subunit and the She protein were both dramatically decreased, Thus, PTP1 over-expression negatively modulated IL-3 signal transduction. To identify potential substrates of PTP1, 32D c13 cells were transfected with a catalytically inactive PTP1 mutant, PTP1(C/S). Three tyrosine-phosphorylated proteins of MW 140, 79 and 69 k coprecipitated with PTP1(C/S). We believe that the 140 kDa protein represents the beta subunit of the IL-3 receptor, In addition, a GST-fusion protein containing active PTP1 dephosphorylated the beta-subunit in an in vitro assay, By immunofluorescent microscopy over-expressed PTP1(C/S) co-localized largely with calnexin, an endoplasmic reticulum-associated protein, Immunofluorescent microscopy also indicated that PTP1(C/S) and the beta subunit co-localized at discrete sites at the plasma membrane and around a cytoplasmic organelle where most of the beta subunit was located, These observations suggest PTP1 over-expression may downregulate the growth response to IL-3 through dephosphorylation of the IL-3 receptor, perhaps in an intracellular compartment, thereby inhibiting propagation of the IL-3 mitogenic signal.	SUNY STONY BROOK, PROGRAM MOL & CELLULAR BIOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								ANDERSON SM, 1995, J IMMUNOL, V155, P1660; BROWNSHIMER S, 1992, CANCER RES, V52, P478; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CIRCIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ERWIN JL, 1992, ONCOGENE, V7, P1101; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; IHLE JN, 1982, J IMMUNOL, V129, P1377; IHLE JN, 1982, IMMUNOL REV, V63, P5, DOI 10.1111/j.1600-065X.1982.tb00409.x; ISCOVE NN, 1982, J CELL PHYSIOL, P65; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAMPS MP, 1988, ONCOGENE, V2, P305; KANAKURA Y, 1990, BLOOD, V76, P706; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; OKUDA K, 1992, BLOOD, V79, P2880; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RAINES MA, 1992, BLOOD, V79, P3350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1983, EXP HEMATOL, V11, P667; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOJO A, 1987, EXP CELL RES, V171, P16, DOI 10.1016/0014-4827(87)90247-3; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TORIGOE T, 1992, BLOOD, V80, P617; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	64	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2367	2378						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957078				2022-12-17	WOS:A1996VX10800009
J	Mayo, LD; Berberich, SJ				Mayo, LD; Berberich, SJ			Wild-type p53 protein is unable to activate the mdm-2 gene during F9 cell differentiation	ONCOGENE			English	Article						mdm-2; p53; F9 cellular differentiation	DNA-BINDING; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TUMOR-SUPPRESSOR; EXPRESSION; SEQUENCE; ONCOGENE; CYCLE; CHECKPOINT; GROWTH	In this study, we set out to assess whether the p53 protein affects mdm-2 gene expression as F9 embryonal carcinoma cells differentiate into parietal endoderm cells. It was previously reported that F9 cells possess abundant levels of wild-type p53 and upon induction to differentiate, p53 mRNA and protein levels decrease (Oren et at, 1982; Deny et al., 1985). We demonstrate that while p53 mRNA and protein levels decrease as F9 cells differentiate, mdm-2 mRNA and protein expression remains constitutive. Using RNA primer extension assays, we determined that the mdm-2 mRNA expression is not directed by p53 in either F9 embryonal (undifferentiated) or parietal endoderm (differentiated) cells. However, p53 protein does stimulate mdm-2 mRNA expression in response to u.v. irradiation. The inability of p53 to transactivate mdm-2 in undamaged F9 cells was not the result of latent pools as p53 sequence specific DNA binding activity was observed using electrophoretic mobility shift assays. Our results suggest that, in F9 cells, the p53:Mdm-2 autoregulatory loop is confined to pathways governing DNA damage.	WRIGHT STATE UNIV,DEPT BIOCHEM & MOL BIOL,DAYTON,OH 45435	Wright State University Dayton								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BERBERICH S, 1994, ONCOGENE, V9, P1469; BERBERICH S, 1992, ONCOGENE, V7, P775; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHUANG SE, 1994, BIOTECHNIQUES, V17, P634; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P4279; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1994, ONCOGENE, V9, P3321; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Shaw P, 1996, ONCOGENE, V12, P921; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	41	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2315	2321						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957072				2022-12-17	WOS:A1996VX10800003
J	DavidPfeuty, T; NouvianDooghe, Y				DavidPfeuty, T; NouvianDooghe, Y			Human cyclin B1 is targeted to the nucleus in G(1) phase prior to its accumulation in the cytoplasm	ONCOGENE			English	Article						cell-cycle regulation; cyclin B1; cyclin A; transformation	CDK-ACTIVATING KINASE; ROUS-SARCOMA VIRUS; HUMAN WEE1 KINASE; SEA-URCHIN EGGS; FISSION YEAST; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; DNA-REPLICATION; PROTEIN-KINASE; S-PHASE	The immunolocalisation patterns of cyclin B1 have been investigated in various tumour-derived and untransformed human cells, using one polyclonal (B7/B8) and tao different monoclonal anti-human cyclin B1 antibodies, GNS1 and GNS11. In actively dividing cell populations, GNS11 reveals uniquely a cytoplasmic pool of cyclin B1 that rapidly increases after the onset of S phase; yet, B7/B8 and GNS1 detect, besides this cytoplasmic cyclin B1 population, a moderate but clear nuclear concentration of the protein in cells that have not yet entered S phase. As for confluent populations of untransformed and tumour cells, they become enriched in G(1)- and G(2)-arrested cells that characteristically display a discreet nuclear or an intense cytoplasmic GNS1 immunostaining respectively. Altogether, our immunofluorescence data conjugated with the results of a detailed biochemical analysis suggest that human cyclin B1 would exist in situ as two distinguishable molecular entities differentially susceptible to in vitro degradation and exhibiting different timing, kinetics and site of accumulation during the cell cycle: one form (recognized by the polyclonal and GNS1 antibodies but apparently not by GNS11) starts to build up inside the nucleus prior to entry in S phase and the other (in which both the GNS11 and GNS1 epitopes are readily accessible) emerges and accumulates in the cytoplasm beyond the G(1)/S boundary.			DavidPfeuty, T (corresponding author), CTR UNIV ORSAY, INST CURIE, SECT RECH, BATIMENT 110, F-91405 ORSAY, FRANCE.							AFLA CE, 1990, NATURE, V347, P680; ALFA CE, 1989, J CELL SCI, P9; BAILLY E, 1992, J CELL SCI, V101, P529; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BALDIN V, 1995, J CELL SCI, V108, P2425; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; DARBON JM, 1994, ONCOGENE, V9, P3127; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GENEVIEREGARRIGUES AM, 1995, J CELL SCI, V108, P2693; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1988, CELL, V54, P739; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1995, EMBO J, V14, P2760, DOI 10.1002/j.1460-2075.1995.tb07276.x; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARIDOR G, 1993, J CELL SCI, V106, P535; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STARGER JM, 1978, J CELL BIOL, V78, P93, DOI 10.1083/jcb.78.1.93; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	56	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1447	1460						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875983				2022-12-17	WOS:A1996VL38400010
J	Pedley, J; Ablett, EM; Pettit, A; Meyer, J; Dunn, IS; Sturm, RA; Parsons, PG				Pedley, J; Ablett, EM; Pettit, A; Meyer, J; Dunn, IS; Sturm, RA; Parsons, PG			Inhibition of retinoblastoma protein translation by UVB in human melanocytic cells and reduced cell cycle arrest following repeated irradiation	ONCOGENE			English	Article						UVB; melanocytes; retinoblastoma gene product; translation; cycle arrest	GENE-PRODUCT; BILATERAL RETINOBLASTOMA; CUTANEOUS MELANOMA; PHOSPHORYLATION; DIFFERENTIATION; RADIATION; RB; EXPRESSION; IDENTIFICATION; TRANSCRIPTION	In human melanocytes and a human melanoma cell line (MM96L), the level of the retinoblastoma gene product (pRB) detected by Western blotting transiently decreased to 55% and 70% of controls respectively 9-12 h after a noncytostatic exposure (75 Jm(-2)) to UVB (280-315 mm) and to 2% and 14% 48 h after a cytostatic exposure (300 Jm(-2)). The pRB levels in fibroblasts and HeLa showed minimal loss, and under some conditions increased compared with unirradiated cells. Equitoxic doses of gamma radiation, cisplatin or the antimetabolite deoxyinosine had little effect on pRB levels. UVC (254 mn) was less inhibitory compared with equitoxic UVB. No loss of PRB mRNA was found in MM96L after UVB, nor was PRB protein stability significantly affected. Synthesis of new pRB in h MM96L 24 h after UVB was 16% of controls, suggesting that loss of pRB results from a UVB-specific inhibition of translation. Compared with HeLa cells and fibroblasts, MM96L cells exhibited reduced cycle arrest if irradiated when pRB was depleted by a previous WE exposure. These results suggest a mechanism whereby down-regulation of pRB translation by UVB may play a role in genesis of melanoma.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND LABS,HERSTON,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT PATHOL,BRISBANE,QLD 4072,AUSTRALIA; UNIV QUEENSLAND,CTR MOL & CELL BIOL,BRISBANE,QLD 4072,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland			Parsons, Peter G/H-8163-2015; Pettit, Allison/O-4462-2019; Sturm, Richard A/C-9943-2009	Parsons, Peter G/0000-0002-0473-3346; Pettit, Allison/0000-0003-4707-7892; Sturm, Richard A/0000-0003-1301-0294				ABDELMALEK Z, 1994, PIGM CELL RES, V7, P326, DOI 10.1111/j.1600-0749.1994.tb00635.x; ALBERT LS, 1990, J AM ACAD DERMATOL, V23, P1001, DOI 10.1016/0190-9622(90)70322-9; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P251, DOI 10.1002/gcc.2870090405; AUSUBEL FM, 1989, CURRENT RPOTOCOLS MO; BARKER D, 1995, CANCER RES, V55, P4041; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COFFER PJ, 1995, ONCOGENE, V11, P561; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GALLIE BL, 1990, LAB INVEST, V62, P394; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROVITZ M, 1993, NEW STATESMAN SOC, V6, P24; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHANNA KK, 1995, ONCOGENE, V11, P609; KLEINSZANTO AJP, 1994, CANCER RES, V54, P4569; KRANENBURG O, 1995, ONCOGENE, V10, P87; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEVY R, 1993, PRESSE MED, V22, P878; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MEDRANO EE, 1995, CANCER RES, V55, P4047; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MUNCASTER MM, 1992, CANCER RES, V52, P654; PARSONS PG, 1985, PHOTOCHEM PHOTOBIOL, V42, P287, DOI 10.1111/j.1751-1097.1985.tb08944.x; POLLOCK PM, 1995, ONCOGENE, V11, P663; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROSENSTEIN BS, 1995, PHOTOCHEM PHOTOBIOL, V61, P142, DOI 10.1111/j.1751-1097.1995.tb03952.x; SAUNDERS BM, 1989, BRIT J CANCER, V60, P358; SCHWARTZ E, 1995, J INVEST DERMATOL, V105, P65, DOI 10.1111/1523-1747.ep12312576; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; TANG A, 1989, ONCOGENE, V4, P401; YAVUZER U, 1995, ONCOGENE, V10, P123; YEN A, 1992, EUR J CELL BIOL, V57, P210; YEN A, 1992, IN VITRO CELL DEV-AN, V28A, P669; ZACHSENHAUS E, 1993, MOL CELL BIOL, V13, P4588	51	13	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1335	1342						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808708				2022-12-17	WOS:A1996VJ20200025
J	Vairapandi, M; Duker, NJ				Vairapandi, M; Duker, NJ			Partial purification and characterization of human 5-methylcytosine-DNA glycosylase	ONCOGENE			English	Article						5-methylcytosine; DNA; demethylation; glycosylase; apyrimidinic site	TRANSIENT DNA DEMETHYLATION; DEOXYRIBONUCLEIC-ACID; APYRIMIDINIC SITES; ENZYMATIC REMOVAL; NUCLEAR EXTRACTS; MAMMALIAN-CELLS; CHICKEN EMBRYOS; EXCISION-REPAIR; METHYLATION; CYTOSINE	The molecular mechanisms by which DNA 5-methylcytosine content is modulated are incompletely understood, Reduction of DNA 5-methylcytosine content has been correlated with the transition from hyperplasia to adenoma in the genesis of human adenocarcinoma of the colon, 5-methylcytosine-DNA glycosylase removes 5-methylcytosine from DNA as a free base, but its involvement in this process is unknown, The 5-methylcytosine-DNA glycosylase activity in HeLa nuclear extracts has been partially purified, with a 460-fold enrichment, and characterized, This activity is specific for 5-methylcytosine at CpG sites in fully methylated DNA; hemimethylated DNA is not a significant substrate, DIVA containing unmethylated cytosines is not cleaved by the enzyme, There is an absolute requirement for Mg2+ ions for the activity, which is inhibited by EDTA, This 5-methylcytosine-DNA glycosylase activity could be involved in carcinogenesis, transcription, replication, differentiation and development through resultant DNA hypomethylation following enzymatic removal of 5-methylcytosine from DNA.	TEMPLE UNIV,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19122; TEMPLE UNIV,SCH MED,FES INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19122	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; CELEWICZ L, 1992, PHOTOCHEM PHOTOBIOL, V55, P823, DOI 10.1111/j.1751-1097.1992.tb08530.x; DUKER NJ, 1995, BIOCH LIF SCI ADV, V14, P1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GENTIL A, 1992, J MOL BIOL, V227, P981, DOI 10.1016/0022-2836(92)90513-J; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JOST JP, 1994, J BIOL CHEM, V269, P10040; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; JOST JP, 1993, DNA METHYLATION MOL; KUYKENDALL JR, 1989, CANCER LETT, V47, P149, DOI 10.1016/0304-3835(89)90191-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; Mazin A. L., 1993, Molekulyarnaya Biologiya (Moscow), V27, P160; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NYCE J, 1991, SOMAT CELL MOLEC GEN, V17, P543, DOI 10.1007/BF01233619; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; Sambrook J, 1989, MOL CLONING LAB MANU; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; STEINBERG RA, 1995, NUCLEIC ACIDS RES, V23, P1621, DOI 10.1093/nar/23.9.1621; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; VAIRAPANDI M, 1994, MUTAT RES-DNA REPAIR, V315, P85, DOI 10.1016/0921-8777(94)90009-4; VOLPE P, 1993, FEBS LETT, V329, P233, DOI 10.1016/0014-5793(93)80228-M; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WEISS RB, 1989, BIOCHEMISTRY-US, V28, P1488, DOI 10.1021/bi00430a010; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	34	13	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					933	938						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806682				2022-12-17	WOS:A1996VG76600006
J	Tarunina, M; Grimaldi, M; Ruaro, E; Pavlenko, M; Schneider, C; Jenkins, JR				Tarunina, M; Grimaldi, M; Ruaro, E; Pavlenko, M; Schneider, C; Jenkins, JR			Selective loss of endogenous p21(waf1/cip1) induction underlies the G(1) checkpoint defect of monomeric p53 proteins	ONCOGENE			English	Article						p53; oligomerisation; G(1) checkpoint; p21(waf1/cip1); induction; apoptosis	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL NUCLEAR ANTIGEN; DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TRANS-ACTIVATION; GENE; APOPTOSIS; TRANSFORMATION	Wild-type p53 protein displays a spectrum of activities including the ability to suppress transformed cell growth, to direct apoptotic cell death and to mediate G(1) checkpoint in response to cellular DNA damage. Earlier work showed that a self-association defective p53 protein retained transformation suppressor activity in rat embryo fibroblast based assays, but that monomerisation of tumour mutant p53 proteins resulted in loss of dominant transforming activity. In order to acquire a more detailed understanding of the biological consequences attendant on disruption of p53:p53 association we have carried out a study of the wild-type-like activities that are retained by monomeric p53 proteins and which are associated with the suppression of transformation. Here we show that monomeric p53 proteins are G(1) checkpoint defective. Although able to stimulate transcription via a p53 DNA binding motif from the p21(waf1/cip1) gene promoter in episome based assays these p53 proteins are unable to transactivate the chromosomal p21(waf1/cip1) gene and are sensitive both to degeneracy of consensus binding site and to half site spacing. Monomeric p53 proteins fail to trigger apoptosis in a BRK cell line transformed with E7 and ras. However, they retain wild type transformation suppressor activity in BRK cell based transformation assays. Our results indicate that p21(waf1/cip1) induction and all related p53 dependent G(1) checkpoint activities are dispensable for the p53 directed suppression of transformed cell growth, and that such transformation suppression by monomeric p53 proteins may occur in the absence of an apoptotic response.	MARIE CURIE RES INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND; LAB NAZL CONSORZIO INTERUNIV BIOTECNOL,I-34012 TRIESTE,ITALY; RUSSIAN ACAD SCI,INST CYTOL,ST PETERSBURG 194064,RUSSIA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HIRANO Y, 1995, ONCOGENE, V10, P1879; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI YJ, 1995, ONCOGENE, V10, P599; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sambrook J, 1989, MOL CLONING LAB MANU; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; TARUNINA M, 1993, CHALL MOD MED, V1, P221; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; YOUDALE T, 1975, J CELL PHYSIOL, V86, P495, DOI 10.1002/jcp.1040860306; ZAKUT R, 1995, ONCOGENE, V11, P393; ZHANG W, 1994, ONCOGENE, V9, P2513	68	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					589	598						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760300				2022-12-17	WOS:A1996VB32800016
J	Jacob, ANK; Kandpal, G; Kandpal, RP				Jacob, ANK; Kandpal, G; Kandpal, RP			Isolation of expressed sequences that include a gene for familial breast cancer (BRCA2) and other novel transcripts from a five megabase region on chromosome 13q12	ONCOGENE			English	Article						cDNA selection; familial breast cancer; BRCA2; chromosome 13q12; gene expression; positional cloning	ATAXIA-TELANGIECTASIA; PROTEIN; MUTATION; SELECTION; LINKAGE	A proportion of familial breast cancer has recently been shown by genetic linkage analysis to map to chromosome 13q12 (Wooster ct al., 1994), This locus contains a tumor suppressor gene BRCA2, mutations in which lead to tumorigenesis, Genetic alterations at this locus have also been shown in pancreatic adenocarcinoma and in hepatocellular carcinoma, In an effort to isolate the BRCA2 gene, we have cloned 73 non overlapping cDNAs from a set of nine YACs spanning 6 cM interval on chromosome 13q12 by using a direct cDNA selection method, One of the selected cDNAs corresponds to a region of the 3' portion of BRCA2 mRNA, the sequence of which was published recently (Wooster ct al., 1995), Northern analysis of BRCA2 transcripts from a variety of cell lines showed altered sizes of the mRNA in a breast cancer cell line (MCF7) and a prostate carcinoma cell line (DU145), Furthermore, BRCA2 transcript was present in cDNA libraries from total fetus as well as adult human tissues, Fifteen unique cDNA fragments encode genes/ESTs that are already known, of which only two have been mapped to this region, The other 12 cDNAs include genes for RPL6/mRNA for TAX REB 107, elongation factor-1 delta, 26S protease S4 regulatory subunit, small cytoplasmic 7SL RNA, a full length open reading frame (ORFU), brain thiol specific antioxidant protein, ribosomal protein, L35, and lipoxygenase activating protein, Six cDNAs represent human homologs of genes known in other species, namely, mouse HSPE71, Rat RhoGAP protein, S cerevisiae leucyl tRNA synthetase and S cerevisiae chromosome II ORF YBLO44W. The remaining 52 cDNAs showed either weak similarity or no similarity to sequences in the nucleotide data base and hence mould represent novel genes, The plausible functions of some of these genes based on their sequence similarity to other known genes is discussed.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006182] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC06182] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENOTHMANE K, 1995, AM J HUM GENET, V57, P732; BIRCH JM, 1994, CANCER RES, V54, P1298; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS N, 1995, ONCOGENE, V10, P1673; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEO S, 1992, GENOMICS, V13, P201, DOI 10.1016/0888-7543(92)90221-D; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; GUILFORD P, 1994, NAT GENET, V6, P24, DOI 10.1038/ng0194-24; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; IWAYA K, 1995, LAB INVEST, V72, P707; JACOB ANK, 1995, ONCOGENE, V11, P981; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; JUNG M, 1994, CANCER RES, V54, P2541; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MCKUSICK VA, 1992, MENDELIAN GENETICS M, V1; MCKUSICK VA, 1992, MENDELIAN GENETICS M, V2; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIMORI K, 1995, CANCER, V75, P1446, DOI 10.1002/1097-0142(19950315)75:6+<1446::AID-CNCR2820751509>3.0.CO;2-P; MORALES J, 1992, NUCLEIC ACIDS RES, V20, P4091, DOI 10.1093/nar/20.15.4091; MORII N, 1993, J BIOL CHEM, V268, P27160; MORITA T, 1993, AIDS RES HUM RETROV, V9, P115, DOI 10.1089/aid.1993.9.115; OHTA K, 1994, J MOL ENDOCRINOL, V12, P85, DOI 10.1677/jme.0.0120085; OSBORNELAWRENCE S, 1995, GENOMICS, V25, P248, DOI 10.1016/0888-7543(95)80132-6; PAHL P, 1995, GENOMICS, V26, P602, DOI 10.1016/0888-7543(95)80183-M; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RIDLEY AJ, 1994, J CELL SCI, P127; Sambrook J., 1989, MOL CLONING; SCHUTTE M, 1995, CANCER RES, V55, P4570; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAKAHASHI S, 1994, AM J CLIN PATHOL, V101, P519; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WASHINGTON SS, 1995, CYTOGENET CELL GENET, V70, P2; WOOSTER R, 1992, NAT GENET, V2, P132, DOI 10.1038/ng1092-132; WOOSTER R, 1993, HUM GENET, V92, P91, DOI 10.1007/BF00216153; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	53	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					213	221						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700550				2022-12-17	WOS:A1996UX31900025
J	Casciano, I; Marchi, JVM; Muresu, R; Volpi, EV; Rozzo, C; Opdenakker, G; Romani, M				Casciano, I; Marchi, JVM; Muresu, R; Volpi, EV; Rozzo, C; Opdenakker, G; Romani, M			Molecular and genetic studies on the region of translocation and duplication in the neuroblastoma cell line NGP at the 1p36.13-p36.32 chromosomal site	ONCOGENE			English	Article						neuroblastoma; reciprocal translocation; duplication; antioncogenes; chromosome 1	INSITU HYBRIDIZATION; BREAST-CANCER; SHORT ARM; HETEROZYGOSITY; PCR; INTEGRATION; DELETION; 1P	Cytogenic and molecular studies suggest that chromosome 1p might contain oncosuppressor genes involved in the pathogenesis of neuroblastoma and other adult tumors, The isolation of these genes by the 'positional cloning' approach will be facilitated by the characterization of cell lines with well defined chromosomal aberrations, In the present report we provide molecular data on the NGP neuroblastoma cell line which contains a reciprocal t(1;15) translocation, Two regions, possibly hosting oncosuppressor genes, have been identified: one is distal to the ENO1 locus, the other one is comprised between PND and A12M2 and corresponds to that of a constitutional t(1;17) translocation described in a neuroblastoma patient, Genetic data also suggest that the NGP cell line, despite the presence of two chromosomes 1, might be hemizygous for the subtelomeric 1p region.	IST,IST NAZL RIC CANC,LAB POPULAT GENET,ALGHERO,ITALY; CNR,IST GENET MOL,ALGHERO,ITALY; CATHOLIC UNIV LEUVEN,REGA INST,B-3000 LOUVAIN,BELGIUM	University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); KU Leuven			Opdenakker, Ghislain/Q-3130-2017; Rozzo, Carla M/C-4300-2015; Opdenakker, Ghislain/V-8562-2019	Opdenakker, Ghislain/0000-0003-1714-2294; Rozzo, Carla M/0000-0001-6581-2227; Opdenakker, Ghislain/0000-0003-1714-2294; Volpi, Emanuela/0000-0002-2422-9104; casciano, ida/0000-0003-1776-670X				AMLER LC, 1995, ONCOGENE, V10, P1095; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALDINI A, 1992, GENOMICS, V14, P181, DOI 10.1016/S0888-7543(05)80303-9; BALDINI A, 1991, GENOMICS, V9, P770, DOI 10.1016/0888-7543(91)90374-N; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEAMBROSIS A, 1992, CANCER GENET CYTOGEN, V60, P1, DOI 10.1016/0165-4608(92)90223-U; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAUREYS G, 1995, ONCOGENE, V10, P1087; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; MARS WM, 1991, CANCER DETECT PREV, V15, P145; MURESU R, 1995, GENE CHROMOSOME CANC, V13, P66, DOI 10.1002/gcc.2870130111; NOBILE C, 1994, MAMM GENOME, V5, P566, DOI 10.1007/BF00354931; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; ROMANI M, 1993, GENE, V135, P153, DOI 10.1016/0378-1119(93)90060-G; ROMANI M, 1994, CYTOGENET CELL GENET, V67, P37, DOI 10.1159/000133793; ROMANI M, 1996, IN PRESS J NEURO ONC; SAVALYEVA L, 1994, AM J HUM GENET, V55, P334; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SIMON D, 1991, ONCOGENE, V6, P765; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WHITE PS, 1993, GENE CHROMOSOME CANC, V7, P102, DOI 10.1002/gcc.2870070207; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	35	13	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2101	2108						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668335				2022-12-17	WOS:A1996UP28300008
J	Tian, MX; Martin, GS				Tian, MX; Martin, GS			Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation	ONCOGENE			English	Article						Src; SH2 domain; phosphotyrosine; transformation	TYROSINE-PHOSPHORYLATED PEPTIDES; ROUS-SARCOMA VIRUS; SIGNAL-TRANSDUCTION; HOMOLOGY REGION-2; KINASE-ACTIVITY; C-SRC; MUTAGENESIS; INSERTION; MUTATIONS; MUTANTS	The SH2 domain of v-Src binds phosphotyrosyl-proteins in vivo and in vitro. The function of this domain is necessary for transformation of Rat-2 cells and for morphologically wild-type transformation of chicken embryo fibroblasts (CEF). The phosphate group of phosphotyrosine interacts directly with a conserved arginine residue in the FLVRES motif of the SH2 domain, R175 in v-Src. To examine the role of phosphotyrosine binding in transformation by v-Src, we have characterized the effects of R175 mutations on the transforming ability of v-Src and on the interaction of the v-Src SH2 domain with phosphotyrosyl-proteins. The R175H mutation, and to a lesser extent the R175K mutation, reduced but did not eliminate the binding of phosphotyrosyl-proteins to the v-Src SH2 domain. However neither mutation affected transformation of CEF or Rat-2 cells by v-Src and neither mutation resulted in major changes in the level or pattern of protein-tyrosine phosphorylation in transformed CEF. In contrast, the R175E mutant of v-Src induced fusiform transformation of CEF and failed to transform Rat-2 cells; the mutant SH2 domain was insoluble when expressed in bacteria, suggesting that the R175E mutation disrupts the structure of the v-Src SH2 domain. We conclude that, although the Arg residue in the FLVRES motif is invariant in most if not all SH2 domains, at position 175 in the v-Src SH2 domain residues other than arginine can support the binding of phosphotyrosyl-proteins, albeit at reduced levels. Furthermore under the expression conditions normally used, that is when v-Src is expressed under the-control of a retroviral LTR, the reduced binding of phosphotyrosyl-proteins is compatible with wild-type transformation.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R37CA017542, R01CA017542] Funding Source: NIH RePORTER; NCI NIH HHS [CA17542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOEUF H, 1995, ONCOGENE, V10, P433; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LIEBL EC, 1993, VIROLOGY, V195, P265, DOI 10.1006/viro.1993.1371; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					727	734						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632894				2022-12-17	WOS:A1996TW68600003
J	ELKIND, NB; GOLDFINGER, N; ROTTER, V				ELKIND, NB; GOLDFINGER, N; ROTTER, V			SPOT-1, A NOVEL NLS-BINDING PROTEIN THAT INTERACTS WITH P53 THROUGH A DOMAIN ENCODED BY P(CA)(N) REPEATS	ONCOGENE			English	Article						NLS; P(CA)(N) REPEATS; P53; EXPRESSION LIBRARY	NUCLEAR-LOCALIZATION SIGNALS; WILD-TYPE P53; NF-KAPPA-B; CELL-CYCLE; LOCATION SIGNAL; CYTOPLASMIC RETENTION; KARYOPHILIC PROTEINS; COLORECTAL-CANCER; ESCHERICHIA-COLI; HUMAN-DISEASE	Nuclear Localization Signals (NLS) have been found to mediate the import of proteins into the nucleus. Proteins interacting directly with NLS control the subcellular localization of nucleophillic proteins. The p53 protein is spatially regulated throughout the cell cycle and this regulation has been shown to be dependent on the presence of its NLS sequences. We identified three novel cDNA clones that were isolated from an expression library because they encode polypeptides that bind a synthetic peptide containing the major NLS of p53 (NLS I). These clones were found to share a common domain encoded by p(CA)(n) repeats; a simple sequence length polymorphism (SSLP). This is the first report where p(CA)(n) repeats mere found to encode protein. One cDNA clone encodes a fun length, 16 kDa protein, designated spot-1, that is represented in cells predominantly as oligomers. spot-1 interacts with the NLS I of p53 through its p(CA)(n) repeat. Cell fractionation and immunofluorescence analysis demonstrated that spot-1 is a nuclear protein which, in fibroblasts, co-localizes with p53.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DANG CV, 1989, J BIOL CHEM, V264, P18019; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HARPER JW, 1993, CELL, V75, P805; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; LACASSE EC, 1993, ENDOCRINOLOGY, V132, P1017, DOI 10.1210/en.132.3.1017; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LI RH, 1992, EXP CELL RES, V202, P355, DOI 10.1016/0014-4827(92)90085-M; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEIER UT, 1992, CELL, V70, P127; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PANDEY S, 1991, BIOCHIM BIOPHYS ACTA, V1063, P81, DOI 10.1016/0005-2736(91)90356-D; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382; ZERRAHN J, 1992, ONCOGENE, V7, P1371	86	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					841	851						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675445				2022-12-17	WOS:A1995RU79800004
J	COOK, JL; RE, R; GIARDINA, JF; FONTENOT, FE; CHENG, DY; ALAM, J				COOK, JL; RE, R; GIARDINA, JF; FONTENOT, FE; CHENG, DY; ALAM, J			DISTANCE CONSTRAINTS AND STEREOSPECIFIC ALIGNMENT REQUIREMENTS CHARACTERISTIC OF P53 DNA-BINDING CONSENSUS SEQUENCE HOMOLOGIES	ONCOGENE			English	Article						P53; TRANSCRIPTIONAL REGULATION; STEM CELL; LEUKEMIA GENE; CONSENSUS SEQUENCE	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVITY; REPORTER GENE; PROTEIN; PROMOTER; EXPRESSION; MUTATIONS; MUTANTS; SITES; MODULATION	We present evidence in favor of the position that some mutant p53 proteins retain the ability to trans-activate downstream genes through p53 DNA-binding consensus sequence (CS) homologies. We tested one cell line possessing high levels of mutant p53 and found that this mutant p53 is highly active in trans-activating one CS homology, moderately active in trans-activating a second sequence and inactive in modulating a third sequence. We tested a second cell line, also possessing high levels of mutant p53 and found the same pattern of activation. In addition we find that inter-motif distance [represented by N in RRRCWWGYYY(N)RRRCWWGYYY] is very important in determining the relative binding affinity of a given CS homology for wild-type or mutant p53. Our studies suggest that stereospecific alignment of the DNA-binding motifs within the CS may favor binding of wildtype p53 while misalignment may favor binding of mutant p53. Furthermore, we find that the maximum distances at which p53 DNA-binding CS homologies are functionally active vary for different sequences. Introduction of as few as 200 bp between one CS homology and the downstream TATA box can eliminate a 45-fold p53-mediated trans-activation. We present evidence that the composition of the DNA which flanks a p53 DNA-binding consensus sequence may also modulate trans-activation.			COOK, JL (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DIV RES,1516 JEFFERSON HIGHWAY,NEW ORLEANS,LA 70121, USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X				ALAM J, 1992, J BIOL CHEM, V267, P21894; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BARBEE RW, 1993, BIOCHEM BIOPH RES CO, V190, P70, DOI 10.1006/bbrc.1993.1012; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MIYASHITA T, 1994, CANCER RES, V54, P3131; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RIVAS CI, 1992, BLOOD, V79, P1982; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	49	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					723	733						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651736				2022-12-17	WOS:A1995RQ46900014
J	SLACK, RS; CRAIG, J; COSTA, S; MCBURNEY, MW				SLACK, RS; CRAIG, J; COSTA, S; MCBURNEY, MW			ADENOVIRUS 5 E1A INDUCED-DIFFERENTIATION OF P19 EMBRYONAL CARCINOMA-CELLS REQUIRES BINDING TO P300	ONCOGENE			English	Article						E1A MUTATIONS; ENDODERM; RETINOIC ACID; RETINOBLASTOMA PROTEIN	F9 TERATOCARCINOMA CELLS; REGION 1A PROTEINS; MOUSE PGK-1 GENE; MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; DNA-SYNTHESIS; TRANSFORMATION; POLYPEPTIDES; EXPRESSION; REPRESSION	We transfected P19 embryonal carcinoma (EC) cells with genes encoding the adenovirus 5 E1A products. Expression of either the 12S or 13S transcripts yielded P19 cells either incapable of proliferating or able to proliferate but having lost the characteristics of the EC cell parent. The proliferating clones of E1A expressing P19 cells were incapable of differentiating in response to retinoic acid or dimethyl sulfoxide, no longer expressed the SSEA-1 surface antigen characteristic of EC cells, and did express cytokeratin 55, a marker of epithelial tissues. We used a number of 12S E1A constructs carrying deletions in the first exon and found that the effects on P19 cell growth and differentiated properties were lost with alterations affecting either the N terminal 25 amino acids or the CR1 region of the E1A protein. Both regions are required to bind the cellular p300 protein that we showed is present in P19 cells. We conclude that binding of E1A to the p300 protein in P19 cells results in the loss of EC cell characteristics.	UNIV OTTAWA, DEPT MED, OTTAWA, ON K1H 8M5, CANADA	University of Ottawa				Slack, Ruth/0000-0002-1552-2835				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BOCCO JL, 1993, ONCOGENE, V8, P2977; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DYSON N, 1992, CANCER SURV, V12, P161; EAGEN C, 1988, MOL CELL BIOL, V8, P3955; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARRIS JF, 1984, J IMMUNOL, V132, P2502; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELMSA TN, 1988, VIROLOGY, V163, P494; JELMSA TN, 1989, VIROLOGY, V171, P120; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCBURNEY MW, 1994, UNPUB; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SLACK RS, 1993, ONCOGENE, V8, P1585; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	43	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					19	25						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824272				2022-12-17	WOS:A1995QA98000003
J	DESEPULVEDA, P; PEYRIERAS, N; PANTHIER, JJ				DESEPULVEDA, P; PEYRIERAS, N; PANTHIER, JJ			INSTABILITY AT THE W/C-KIT LOCUS IN MICE - ANALYSIS OF MELANOCYTE CELL-LINES DERIVED FROM REVERSION SPOTS	ONCOGENE			English	Article							W-MUTANT MICE; C-KIT; MITOTIC RECOMBINATION; MOUSE MELANOCYTES; RECEPTOR KINASE; NEURAL CREST; HOUSE MOUSE; MUTATIONS; EXPRESSION; GENE	Mutations at the mouse W/c-kit locus have pleiotropic defects including impaired development of the melanocyte lineage. We have characterized the molecular basis of the W-ei mutation. We show here that W-ei is the result of a missense mutation in the ATP binding site domain of c-kit proto-oncogene which affects the tyrosine kinase function of the receptor. As a result, few melanoblasts survive during embryogenesis in heterozygous W-ei/+ foetuses. Therefore the adult skin is partly devoid of differentiated pigmented cells giving rise to a mottled coat colour phenotype. However, three per cent of W-ei/+mice exhibit spots of wild-type pigmentation on the coat which is otherwise of mutant phenotype. Such areas are known as phenotypic reversions. To dissect the molecular events responsible for the phenotypic instability of the W-ei mutation, we have isolated pure cultures of continuously proliferating melanocytes from two independent reversion spots. These melanocyte lines, designated W-ei-R1 and W-ei-R2, were shown to exhibit none of the characteristics associated with transformed melanocytes. We have used a polymorphic restriction site generated by the W-ei mutation to show that both melanocyte lines are still heterozygous at the W focus. Furthermore, W-ei-R1 and W-ei-R2 melanocytes express both the mutated and the wild-type c-kit RNA. These results indicate that the somatic mutation events responsible for reversion spots are not necessarily associated with loss of heterozygosity at the W/c-kit locus. Together with previous data, this points to the fact that several mechanisms account for the coat colour reversion phenotype.	ECOLE NATL VET, INRA, URA GENET MOLEC, F-94704 MAISONS ALFORT, FRANCE; CNRS MARSEILLE LUMINY, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			PANTHIER, Jean-Jacques/I-4366-2014; De sepulveda, paulo/K-6043-2015	PANTHIER, Jean-Jacques/0000-0002-7966-0663; De sepulveda, paulo/0000-0001-8295-5414; Peyrieras, Nadine/0000-0002-4905-6414				BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; DUBREUIL P, 1990, ANN NY ACAD SCI, V599, P58; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; EICHE A, 1984, HEREDITAS, V101, P273; EICHE A, 1982, HEREDITAS, V97, P316; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; GEISSLER EN, 1981, GENETICS, V97, P337; GOKKEL E, 1992, ONCOGENE, V7, P1423; Green MC., 1989, GENETIC VARIANTS STR, P12; GUENET JL, 1979, J HERED, V70, P9, DOI 10.1093/oxfordjournals.jhered.a109202; HALABAN R, 1984, IN VITRO CELL DEV B, V20, P447; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HUSZAR D, 1991, DEVELOPMENT, V112, P131; IWAMOTO T, 1992, EXP CELL RES, V200, P410, DOI 10.1016/0014-4827(92)90189-F; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; LARUE L, 1992, P NATL ACAD SCI USA, V89, P7816, DOI 10.1073/pnas.89.16.7816; LARUE L, 1993, ONCOGENE, V8, P523; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1974, ANNU REV GENET, V8, P411, DOI 10.1146/annurev.ge.08.120174.002211; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; MINTZ B, 1970, 25TH S INT SOC CELL, P15; MOTRO B, 1991, DEVELOPMENT, V113, P1207; MURPHY M, 1992, DEV BIOL, V153, P396, DOI 10.1016/0012-1606(92)90124-Y; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PANTHIER JJ, 1990, GENETICS, V125, P175; PANTHIER JJ, 1991, BIOESSAYS, V13, P351, DOI 10.1002/bies.950130709; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; Sambrook J., 1989, MOL CLONING LAB MANU; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TSUJIMURA T, 1993, BLOOD, V81, P2530; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	46	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2655	2661						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	7520149				2022-12-17	WOS:A1994PC05400026
J	CHACKALAPARAMPIL, I; BAGRODIA, S; SHALLOWAY, D				CHACKALAPARAMPIL, I; BAGRODIA, S; SHALLOWAY, D			TYROSINE DEPHOSPHORYLATION OF PP60(C-SRC) IS STIMULATED BY A SERINE/THREONINE PHOSPHATASE INHIBITOR	ONCOGENE			English	Article							PROTEIN-KINASE-C; XENOPUS-LAEVIS OOCYTES; OKADAIC ACID; CELL-CYCLE; TUMOR PROMOTERS; AUTOPHOSPHORYLATION SITE; OVEREXPRESSED PP60C-SRC; NEGATIVE REGULATOR; SPONGE TOXIN; H1 KINASE	Incubation of NIH3T3-derived c-src overexpressor cells with okadaic acid, a specific serine/threonine phosphatase inhibitor, stimulates pp60(c-src) kinase activity about 2-3-fold. Activation is blocked if cells are simultaneously treated with orthovanadate, a tyrosine phosphatase inhibitor. Furthermore, okadaic acid treatment induces a small decrease in Tyr 527 phosphorylation of wild-type pp60(c-src) and a large decrease in Tyr 527 phosphorylation of kinase-defective pp60(c-src)(lys 295--> Arg). These results suggest that the activation is mediated by okadaic acid-induced changes in tyrosine phosphorylation of pp60(c-src) involving 'cross-over' from serine/threonine to tyrosine signal transduction pathways. Stimulation of pp60(c-src) activity and Tyr 527 dephosphorylation do not require changes in serine/threonine phosphorylation of pp60(c-src), suggesting that these changes result from modulation of an upstream Tyr 527 phosphatase or kinase which is itself regulated by altered serine/threonine phosphorylation. Since okadaic acid induces a pseudo-mitotic phenotype in rodent cells (K. Yamashita, H. Yasuda, J. Pines, K. Yasumoto, H. Nishitani, M. Ohtsubo, T. Hunter, T. Sugimura and T. Nishimoto, EMBO J., 9: 4331-4338, 1990), it is possible that these phenomena are induced by a biochemical mechanism similar to that which causes transient tyrosine dephosphorylation of pp60(c-src) during mitosis.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NATIONAL CANCER INSTITUTE [R01CA008964, R01CA047333, R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [CA08964, CA32317, CA47333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRACONI S, 1992, BIOCHEM J, V286, P851, DOI 10.1042/bj2860851; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GAVIN AC, 1991, EXP CELL RES, V192, P75, DOI 10.1016/0014-4827(91)90159-R; GOPALAKRISHNA R, 1992, BIOCHEM BIOPH RES CO, V189, P950, DOI 10.1016/0006-291X(92)92296-A; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HAYSTEAD TAJ, 1990, EUR J BIOCHEM, V187, P199, DOI 10.1111/j.1432-1033.1990.tb15295.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; HIROTA Y, 1988, MOL CELL BIOL, V8, P1826, DOI 10.1128/MCB.8.4.1826; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; HUNTER T, 1992, CIBA F SYMP, V170, P1; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAECH S, 1993, ONCOGENE, V8, P575; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; RIME H, 1990, DEV BIOL, V141, P115, DOI 10.1016/0012-1606(90)90106-S; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERNBERG DW, 1993, EMBO J, V12, P323, DOI 10.1002/j.1460-2075.1993.tb05660.x; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	73	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					1947	1955						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7516061				2022-12-17	WOS:A1994NR68500019
J	LANDESMAN, Y; BRINGOLD, F; KIMCHI, A				LANDESMAN, Y; BRINGOLD, F; KIMCHI, A			P53 UNDERGOES EPITOPIC CHANGES IN-VITRO BY SODIUM-VANADATE	ONCOGENE			English	Note							TUMOR-SUPPRESSOR PROTEIN; KERATINOCYTE CELL-LINE; VIRUS-40 T-ANTIGEN; BINDING-SITE; WILD-TYPE; MUTANT; KINASE; GENE; PHOSPHORYLATION; SEQUENCE	p53 has at least two conformations that differ in their immunoreactivity. They consist of the functional tumor suppressor form, characteristic of the wild type p53 and the mutant form, generated by changes in the primary amino acid sequence of the protein. It has been previously shown that the wild type p53 protein also acquires the mutant conformation upon certain changes in growth conditions. Here we report that similar epitopic changes can be induced in crude cell lysate by addition of vanadate anions at 1 mm final concentration. A panel of anti p53 antibodies was used to discriminate between the different immunoreactive forms of wild type p53 in SV80 fibroblasts. It was found that addition of sodium vanadate to the lysis buffer converted part of p53 molecules into a mutant conformation that is recognized by the PAb 240 monoclonal antibodies. The effect of vanadate on p53 conformation was prominent even if it was added to the cell lysates after 15 min of preincubation at 37-degrees-C. This further excluded its possible role as phosphatase inhibitor in the system and suggested a direct interaction with the p53 protein itself. Based on these data we recommend to avoid using sodium vanadate as a phosphatase inhibitor in experiments where in vivo conformational changes of wild type p53 are studied.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; GERMAN CANC RES CTR,DIV DIFFERENTIAT & CARCINOGENESIS IN VITRO 0240,D-69120 HEIDELBERG,GERMANY	Weizmann Institute of Science; Helmholtz Association; German Cancer Research Center (DKFZ)								BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1993, P53 GROWTH CONTROL N; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HIRATSUKA T, 1990, J BIOL CHEM, V265, P18791; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANDESMAN Y, 1992, ONCOGENE, V7, P1661; LANE PD, 1991, CURR OPIN CELL BIOL, V2, P581; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MONTENARH M, 1992, Critical Reviews in Oncogenesis, V3, P233; NECHAY BR, 1986, FASEB J, V45, P123; OREN M, 1991, BIOCH MOL ASPECTS SE, P373; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; TRACEY AS, 1986, P NATL ACAD SCI USA, V83, P609, DOI 10.1073/pnas.83.3.609; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1241	1245						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510864				2022-12-17	WOS:A1994NC04800029
J	SEITE, P; HILLION, J; DAGAY, MF; BERGER, R; LARSEN, CJ				SEITE, P; HILLION, J; DAGAY, MF; BERGER, R; LARSEN, CJ			BCL2 COMPLEX REARRANGEMENT IN FOLLICULAR LYMPHOMA - TRANSLOCATION MBR J(H) AND DELETION IN THE VCR REGION OF THE SAME BCL2 ALLELE	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; VARIANT T(2-18) TRANSLOCATION; BREAKPOINT-CLUSTER REGION; LIGHT CHAIN GENE; B-CELL LYMPHOMA; CHROMOSOMAL TRANSLOCATION; T(14-18) TRANSLOCATION; MALIGNANT-LYMPHOMAS; EXPRESSION; TRANSCRIPTS	Two rearrangements affecting the same allele of the BCL2 gene were characterized by molecular analysis of an untreated follicular lymphoma. The first rearrangement interested the major breakpoint region (mbr) on chromosome 18 and a J(H) segment on chromosome 14. The other one was located at the 5' end of the BCL2 gene, in the so called variant cluster region (vcr), and consisted of a series of deletions that removed part of a DNA region where initiation of transcription normally occurs. Interestingly, both rearrangements involved the same BCL2 allele. The simultaneous presence of mbr (or mcr) translocations and of minor rearrangements in vcr has been previously suggested by restriction map analysis in a significant number of follicular lymphomas. The significance of these abnormalities on the oncogenic process is discussed.	INST GENET MOLEC,INSERM,U301,27 RUE J DODU,F-75010 PARIS,FRANCE; HOP ST LOUIS,ANAT PATHOL LAB,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite				Seite, Paule/0000-0002-7809-7610				ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1990, ONCOGENE, V5, P1653; AMAKAWA R, 1991, BLOOD, V77, P1970; AVENTIN A, 1990, BRIT J HAEMATOL, V74, P367, DOI 10.1111/j.1365-2141.1990.tb02599.x; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; DEJONG D, 1989, J EXP MED, V169, P613, DOI 10.1084/jem.169.3.613; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GAULARD P, 1992, AM J PATHOL, V140, P1089; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HILLION J, 1991, ONCOGENE, V6, P169; JONVEAUX P, 1992, BRIT J HAEMATOL, V81, P620, DOI 10.1111/j.1365-2141.1992.tb03006.x; KIEM HP, 1990, ONCOGENE, V5, P1815; KONISHI H, 1990, CANCER RES, V50, P2698; LARSEN CJ, 1990, NOUV REV FR HEMATOL, V32, P401; LARSEN CJ, 1993, NOUV REV FR HEMATOL, V35, P37; LEROUX D, 1991, GENE CHROMOSOME CANC, V3, P205, DOI 10.1002/gcc.2870030306; LEROUX D, 1990, BRIT J HAEMATOL, V75, P290, DOI 10.1111/j.1365-2141.1990.tb02669.x; LIMPENS J, 1991, ONCOGENE, V6, P2271; MIKRAKI V, 1991, GENE CHROMOSOME CANC, V3, P117, DOI 10.1002/gcc.2870030206; OSADA H, 1989, JPN J CANCER RES, V80, P711, DOI 10.1111/j.1349-7006.1989.tb01702.x; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PRICE CGA, 1991, LEUKEMIA, V5, P548; RIMOKH R, 1993, BLOOD, V81, P136; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEITE P, 1993, GENE CHROMOSOME CANC, V6, P39, DOI 10.1002/gcc.2870060108; SEITE P, 1993, LEUKEMIA, V7, P410; SETO M, 1991, JPN J CANCER RES, V82, P65, DOI 10.1111/j.1349-7006.1991.tb01747.x; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TASHIRO S, 1992, ONCOGENE, V7, P573; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; ZELENETZ AD, 1991, BLOOD, V78, P1552; 1991, GUIDELINES CANCER CY	41	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3073	3080						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414508				2022-12-17	WOS:A1993MC09300023
J	FIORETOS, T; HEISTERKAMP, N; GROFFEN, J; BENJES, S; MORRIS, C				FIORETOS, T; HEISTERKAMP, N; GROFFEN, J; BENJES, S; MORRIS, C			CRK PROTOONCOGENE MAPS TO HUMAN-CHROMOSOME BAND 17P13	ONCOGENE			English	Note							BREAST-CANCER; GENE; P53; INVOLVEMENT; ALLELOTYPE; SH2	A genomic DNA fragment, isolated from a human phage library using a chicken crk cDNA probe, was shown to derive from the human CRK locus. We have used fluorescent in situ hybridization (FISH) to map CRK distal in chromosome band 17p13, a region which demonstrates frequent deletion or loss of heterozygosity in a wide range of human cancers.	CHRISTCHURCH HOSP,CHRISTCHURCH SCH MED,DEPT PATHOL,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND; CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGN SECT,LOS ANGELES,CA 90027	Christchurch Hospital New Zealand; University of Otago; Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Fioretos, Thoas/0000-0002-3235-6154	NCI NIH HHS [CA47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA047456, R01CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COGEN PH, 1992, AM J HUM GENET, V50, P584; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; FUJIMORI M, 1991, CANCER RES, V51, P89; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MATSUDA M, 1992, MOL CELL BIOL, V12, P3842; MATSUMURA K, 1992, CANCER RES, V52, P3474; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; NISHIDA N, 1993, CANCER RES, V53, P368; PRESTI JC, 1991, CANCER RES, V51, P5405; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; TENHOEVE J, 1993, IN PRESS ONCOGENE; TSAO SW, 1991, ANTICANCER RES, V11, P1975; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B	21	13	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2853	2855						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378094				2022-12-17	WOS:A1993LX34300029
J	BUSAM, KJ; GEISER, AG; ROBERTS, AB; SPORN, MB				BUSAM, KJ; GEISER, AG; ROBERTS, AB; SPORN, MB			SYNERGISTIC INCREASE OF PHORBOL ESTER-INDUCED C-FOS MESSENGER-RNA EXPRESSION BY RETINOIC ACID THROUGH STABILIZATION OF THE C-FOS MESSAGE	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION; GROWTH-FACTORS; POSTTRANSCRIPTIONAL REGULATION; COLLAGENASE PRODUCTION; HOMEOBOX GENES; TRANSCRIPTION; INHIBITION; AP-1	Retinoic acid (RA) has been shown to be able to antagonize or synergize with phorbol 12-myristate 13-acetate (PMA). In contrast to its antagonistic effects on PMA-dependent gene expression, no molecular target or mechanism of synergism has been characterized yet. We now report, that RA synergistically enhances the induction of c-fos, but not c-jun mRNA by PMA in cells whose growth was stimulated by RA alone. The responding cells were hybrids of tumor cell lines whose growth and PMA-dependent c-fos mRNA expression remained unaffected by RA. The increase in PMA-dependent c-fos expression required pretreatment of cells with RA for at least 2 - 4 h and was achieved at doses as low as 10(-10) M. Nuclear run-on experiments and transient transfection assays using a chimeric reporter gene construct with sequences from the c-fos promoter indicated that RA did not affect PMA-dependent c-fos transcription. Instead, RA stabilized the c-fos message after induction by PMA as assessed by measuring the half-life of c-fos mRNA in actinomycin D-treated cells. This post-transcriptional regulation provides a mechanism whereby RA can synergistically enhance gene expression by PMA.			BUSAM, KJ (corresponding author), NCI, CHEMOPREVENT LAB, BETHESDA, MD 20892 USA.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BRINCKERHOFF CE, 1980, NEW ENGL J MED, V303, P432, DOI 10.1056/NEJM198008213030805; BRINCKERHOFF CE, 1983, SCIENCE, V221, P756, DOI 10.1126/science.6308759; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DICKER P, 1979, BIOCHEM BIOPH RES CO, V91, P1203, DOI 10.1016/0006-291X(79)91195-1; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEISER AG, 1989, CANCER RES, V49, P1572; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JETTEN AM, 1983, CANCER RES, V43, P68; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MILLER WH, 1990, ONCOGENE, V5, P511; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; RADZIOCH D, 1991, MOL CELL BIOL, V11, P2718, DOI 10.1128/MCB.11.5.2718; REPRESA J, 1990, DEVELOPMENT, V110, P1081; ROBERTS AB, 1984, RETINOIDS, V2, P209; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHRODER EW, 1980, CANCER RES, V40, P3089; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1989, Molecular Reproduction and Development, V1, P107, DOI 10.1002/mrd.1080010205; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; YANGYEN HF, 1991, NEW BIOL, V3, P1206	38	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2267	2273						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336949				2022-12-17	WOS:A1993LP17100029
J	METIVIER, C; PIU, F; PFARR, CM; YANIV, M; LOISEAU, L; CASTELLAZZI, M				METIVIER, C; PIU, F; PFARR, CM; YANIV, M; LOISEAU, L; CASTELLAZZI, M			IN-VITRO TRANSFORMING CAPACITIES OF MOUSE C-JUN-JUND CHIMERIC GENES	ONCOGENE			English	Note							TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; ONCOGENE JUN; V-JUN; FOS; AP-1; PHOSPHORYLATION; DOMAIN; CELLS; DNA	Among the murine Jun family of transcription factors, c-Jun and JunD are closely-related proteins with similar dimerization, DNA binding and transactivating properties. However, when expressed from a self-replicating retroviral RCAS vector, c-jun, but not junD, transforms chick embryo fibroblasts. We attempted to map the regions of c-jun which are important for transformation by constructing hybrids between c-jun and junD. Using common restriction sites, we prepared six different chimeric molecules. All of these c-jun:junD hybrids code for transactivators of AP1-containing promoters. An N-terminal segment of 79 amino acids of c-Jun converts JunD into a strong transforming protein, while other segments of c-Jun contribute to a lesser extent. Contrary to what has been reported with rat embryo fibroblasts, a c-Jun derivative with serines substituted by alanines in positions 63 and 73 still transforms CEFs efficiently.	ECOLE NORMALE SUPER, CNRS,UMR49,BIOL MOLEC & CELLULAIRE LAB, 46 ALLEE ITALIE, F-69364 LYON 07, FRANCE; INST PASTEUR, DEPT BIOTECHNOL,CNRS,URA 1644, UNITE VIRUS ONCOGENES, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite			Pfarr, Curt/HHD-1410-2022					ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERGER I, 1991, ONCOGENE, V6, P561; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1991, ONCOGENE, V6, P1623; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1990, New Biologist, V2, P126; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANG-YEN H-F, 1990, New Biologist, V2, P351	38	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2311	2315						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336952				2022-12-17	WOS:A1993LP17100036
J	SCHMIEG, FI; SIMMONS, DT				SCHMIEG, FI; SIMMONS, DT			P53 MUTANTS WITH CHANGES IN CONSERVED REGION-II - 3 CLASSES WITH DIFFERING ANTIBODY REACTIVITY, SV40-T ANTIGEN-BINDING AND ABILITY TO INHIBIT TRANSFORMATION OF RAT-CELLS	ONCOGENE			English	Article							LARGE T-ANTIGEN; WILD-TYPE P53; TUMOR SUPPRESSOR GENE; NONSPECIFIC DNA-BINDING; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODY; ACTIVATING MUTATIONS; RESPONSIVE ELEMENT; PROTEINS BIND; ONCOGENE	The wild-type p53 gene is able to inhibit the ability of a number of oncogenes to induce transformation, but this inhibition is frequently lost when the p53 gene undergoes mutation. In this study, we generated mutated mouse p53 proteins containing conservative amino acid substitutions at residues 127 to 138 and at 140. The mutant proteins fell into three distinct classes. Class I proteins reacted well with PAb246 (246+), poorly with PAb240 (240-), bound to SV40 T antigen (T+), and inhibited the transformation of rat embryo fibroblasts by adenovirus E1a and activated ras. Class II proteins were 246-, 240+, T-, and failed to inhibit transformation. Class III proteins were 246+, 240-, but T-, and varied in their ability to inhibit transformation. The existence and properties of the Class III proteins suggest that the residues mutated in this class are important for binding to T antigen. They also lead us to conclude that the maintenance of an apparent wild-type structure is not sufficient for p53 to inhibit transformation and that the loss of T antigen binding does not necessarily result in loss of transformation inhibition. We propose the existence of a third activity important for the ability of p53 to inhibit transformation.			SCHMIEG, FI (corresponding author), UNIV DELAWARE,SCH LIFE & HLTH SCI,NEWARK,DE 19716, USA.				NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER; NCI NIH HHS [CA55234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CASEY G, 1991, ONCOGENE, V6, P1791; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEDCALF EA, 1992, ONCOGENE, V7, P71; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; RITTLING SR, 1992, ONCOGENE, V7, P935; RUGGERI B, 1991, CANCER RES, V51, P6615; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; SOUSSI T, 1987, ONCOGENE, V1, P71; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2043	2050						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393158				2022-12-17	WOS:A1993LP17100003
J	BOEHM, T				BOEHM, T			ANALYSIS OF MULTIGENE FAMILIES BY DNA FINGERPRINTING OF CONSERVED DOMAINS - DIRECTED CLONING OF TISSUE-SPECIFIC PROTEIN TYROSINE PHOSPHATASES	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; NERVOUS-SYSTEM AXONS; KINASES; IDENTIFICATION; EXPRESSION; RHOMBOTIN; HOMOLOGY; GENES	Little is known about the number of mouse protein tyrosine phosphatases (PTPs) and their developmental and tissue-specific expression patterns. A new procedure based on fingerprinting of amplified catalytic domains detects expression of at least 20 different mouse PTPs during development. The majority of these PTPs show developmentally regulated expression patterns; some display a unique tissue specificity. Diagnostic fragments detected in the fingerprint analysis are used here as specific probes to directly clone two previously unknown ubiquitously expressed PTPs and PTP1C, a protein tyrosine phosphatase highly expressed in thymus RNA. The fingerprinting procedure is also applicable to the analysis of protein tyrosine kinases and may also be used to study the expression pattern of other multigene families.			BOEHM, T (corresponding author), UNIV FREIBURG,DEPT MED 1,MOLEC MED GRP,HUGSTETTER STR 55,W-7800 FREIBURG,GERMANY.							BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KREUGER NX, 1992, EMBO J, V89, P7417; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NISHI M, 1990, FEBS LETT, V271, P178, DOI 10.1016/0014-5793(90)80400-D; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI TL, 1991, BLOOD, V78, P2222	26	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1385	1390						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479755				2022-12-17	WOS:A1993KY32800033
J	ALEXANDROPOULOS, K; QURESHI, SA; FOSTER, DA				ALEXANDROPOULOS, K; QURESHI, SA; FOSTER, DA			HA-RAS FUNCTIONS DOWNSTREAM FROM PROTEIN-KINASE-C IN V-FPS-INDUCED GENE-EXPRESSION MEDIATED BY TPA RESPONSE ELEMENTS	ONCOGENE			English	Note							PHOSPHOLIPASE-D; TYROSINE KINASES; BINDING-PROTEIN; ONCOGENIC RAS; 3T3 CELLS; ACTIVATION; SRC; HYDROLYSIS; PHOSPHATIDYLCHOLINE; TRANSFORMATION	v-Fps activates promoters under the control of the 12-O-tetradecanoyl phorbol 13-acetate (TPA) response element (TRE). The induction of TRE-mediated transcription by v-Fps was sensitive to a dominant-negative mutant of Ha-Ras. An activated derivative of Ha-Ras, v-Ha-Ras, also activated TRE-mediated transcription. v-Fps-induced TRE-mediated gene expression was sensitive to depleting cells of protein kinase C (PKC), whereas v-Ha-Ras-induced TRE-mediated transcription was insensitive to PKC depletion, suggesting that Ha-Ras functions downstream from PKC in v-Fps-induced TRE-mediated gene expression. Consistent with this hypothesis, the induction of TRE-mediated gene expression by phorbol esters that activate PKC directly was blocked by the dominant-negative Ha-Ras mutant. Thus, v-Fps-induced activation of TRE-mediated gene expression is via an intracellular signaling mechanism that is dependent upon both PKC and Ha-Ras and Ha-Ras functions downstream from PKC.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PK AVE, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)					NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; ALEXANDROPOULOS K, 1991, J BIOL CHEM, V266, P15583; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JDH, 1989, ONCOGENE, V4, P27; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	46	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					803	807						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437865				2022-12-17	WOS:A1993KN00800035
J	BAGNIS, C; COSSET, FL; SAMARUT, J; MOSCOVICI, G; MOSCOVICI, C				BAGNIS, C; COSSET, FL; SAMARUT, J; MOSCOVICI, G; MOSCOVICI, C			LEUKEMOGENICITY OF V-MYB-TRANSFORMED MONOBLASTS CELLS CAN BE MODULATED BY NORMAL BONE-MARROW ENVIRONMENT	ONCOGENE			English	Article							MEDIATED GENE-TRANSFER; CHICKEN OPTIC TECTUM; BETA-GALACTOSIDASE; RECOMBINANT RETROVIRUS; MYELOMONOCYTIC CELLS; LINEAGE ANALYSIS; C-MYB; EXPRESSION; ONCOGENE; DIFFERENTIATION	The avian myeloblastosis virus (AMV) causes monoblastic leukemia in the chick. Two non-producer clones of AMV-transformed monoblasts, BM2/C3A and BM2L/A2B5, have been described (see Bottazzi et al., this issue). They differ in their growth requirements and in their ability to induce leukemia when injected into the chick embryo. We first genetically tagged these clones by retroviral infection with a vector expressing the bacterial lacZ gene. Then, we injected the lacZ-positive cells via the chorioaltantoic vein into chick embryos. With BM2L/A2B5 cells, the bone marrow of the injected birds was rapidly invaded by lacZ-positive cells. In addition, these cells rapidly overgrew cultures of bone marrow cells derived from injected animals. Conversely, the growth of BM2/C3A was inhibited in the injected animals and only a few blue cells, with the morphology of macrophages, were detected in cultures of bone marrow cells. We developed an in vitro assay to mimic in vitro the differential growth of BM2/C3A and BM2L/A2B5 observed in vivo. These data strongly suggest that BM2/C3A cells retain their ability to differentiate into macrophages in the normal bone marrow environment and that BM2L/A2B5 cells differ from BMC/C3A in the loss of this capacity.	UNIV LYON 1,INST CHIM & BIOL MOLEC & CELLULAIRE,CNRS,UA 92,F-69622 VILLEURBANNE,FRANCE; VET ADM MED CTR,TUMOR VIROL LAB,GAINESVILLE,FL 32602	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BAGNIS, C (corresponding author), ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 13,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Samarut, Jacques/AAD-2587-2019	Cosset, Francois-Loic/0000-0001-8842-3726				BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; COSSET FL, 1991, J VIROL, V65, P3388, DOI 10.1128/JVI.65.6.3388-3394.1991; CRAIG RW, 1984, CANCER RES, V44, P442; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; ELFOULY MH, 1989, MOL CARCINOGEN, V2, P131, DOI 10.1002/mc.2940020305; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MACGREEGOR JM, 1989, GENE EXPRESSION IN V; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MANIATIS T, 1983, MOL CLONING; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI C, 1982, CONTINUOUS LINES AMV; MOSCOVICI C, 1982, ADV VIRAL ONCOLOGY T; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; SAMARUT J, 1980, J CELL PHYSIOL, V105, P553, DOI 10.1002/jcp.1041050320; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; STRAIR RK, 1990, NUCLEIC ACIDS RES, V18, P4759, DOI 10.1093/nar/18.16.4759; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P3014, DOI 10.1073/pnas.85.9.3014	32	13	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					737	743						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437857				2022-12-17	WOS:A1993KN00800026
J	GUILHOT, C; BENCHAIBI, M; FLECHON, JE; SAMARUT, J				GUILHOT, C; BENCHAIBI, M; FLECHON, JE; SAMARUT, J			THE 12S-ADENOVIRAL E1A-PROTEIN IMMORTALIZES AVIAN CELLS AND INTERACTS WITH THE AVIAN RB-PRODUCT	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEINS; LARGE TUMOR-ANTIGEN; REGION 1A PROTEINS; EPITHELIAL-CELLS; GENE-PRODUCT; GROWTH; LINE; ESTABLISHMENT; ASSOCIATION; ONCOGENE	Quail cells were immortalized for the first time by using retroviruses expressing the 12S adenoviral E1A gene. In these cells, interaction between the 12S E1A product and the quail RB protein was shown, suggesting that the 12S adenoviral E1A product works in avian cells through similar biochemical pathways as in mammalian cells by interacting and inactivating host cellular proteins, including the RB product. These results confirm that the RB product exhibits a universal function among higher vertebrates in controlling cellular growth and tumor progression.	ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE; INRA,UNITE BIOL CELLULAIRE & MICROSCOPIE ELECTR,F-78350 JOUY EN JOSAS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; INRAE; UDICE-French Research Universities; Universite Paris Saclay			Samarut, Jacques/AAD-2587-2019					BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, J CELL PHYSL S, V1, P195; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; EMAMI S, 1989, P NATL ACAD SCI USA, V86, P3194, DOI 10.1073/pnas.86.9.3194; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIEHLE RD, 1990, ONCOGENE, V5, P787	29	13	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					619	624						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437845				2022-12-17	WOS:A1993KN00800012
J	SAVOYSKY, E; SUZUKI, M; SIMBULAN, C; TAMAI, K; OHUCHI, T; AKIYAMA, T; YOSHIDA, S				SAVOYSKY, E; SUZUKI, M; SIMBULAN, C; TAMAI, K; OHUCHI, T; AKIYAMA, T; YOSHIDA, S			IMMUNOPURIFIED RB PROTEIN INHIBITS SV40-T ANTIGEN-DEPENDENT STIMULATION OF DNA-POLYMERASE ALPHA	ONCOGENE			English	Article							LARGE T-ANTIGEN; SIMIAN VIRUS-40 ORIGIN; REPLICATION INVITRO; CALF THYMUS; RETINOBLASTOMA GENE; PURIFIED PROTEINS; STRAND SYNTHESIS; INITIATION; PRIMASE; COMPLEX	It has been shown that purified SV40 large T antigen (Tag) forms a complex with both human and calf thymus DNA polymerase alpha and stimulates its activity. Furthermore, Tag has also been found to complex with purified human Rb protein. Here, we show the effect of Rb protein on the stimulation of DNA polymerase alpha by Tag, in an in vitro system using either purified human or calf thymus DNA polymerase alpha and either primed single-stranded M13 DNA or calf thymus-activated DNA. Both human and calf thymus enzymes were dose-dependently stimulated several fold by Tag. The stimulation was also observed in the coupled reaction of primase and polymerase alpha, using unprimed single-stranded M13 DNA. These stimulatory effects were, however, completely abolished by preincubating Tag with an equimolar amount of Rb protein. primase activity of DNA polymerase alpha-primase complex was also stimulated by Tag, and this stimulation was abolished by the presence of Rb protein. In contrast, free primase was not affected by either Tag or Rb protein. Kinetic analysis revealed that in the presence of Tag the apparent K(m) for the template of either human or calf DNA polymerase alpha was decreased by approximately 2.5-fold and the V(max) was increased twofold, whereas Tag complexed with Rb protein did not affect the K(m) or the V(max). These results suggest a competition between Rb protein and DNA polymerase alpha for binding to Tag, which may be a key step for the initiation of SV40 DNA replication.	NAGOYA UNIV,SCH MED,DIS MECH & CONTROL RES INST,CANC CELL BIOL LAB,SHOWA KU,NAGOYA,AICHI 466,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,OSAKA,JAPAN	Nagoya University; Osaka University			Suzuki, Motoshi/I-7246-2014; Tamai, Katsuyuki/F-4743-2013	Suzuki, Motoshi/0000-0003-0682-5006; Tamai, Katsuyuki/0000-0003-4094-3911; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342				BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; SAVOYSKY E, 1992, BIOCHEM BIOPH RES CO, V187, P697, DOI 10.1016/0006-291X(92)91251-K; SHIODA M, 1991, BIOCHEMISTRY-US, V30, P11403, DOI 10.1021/bi00112a006; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SOPRANO KJ, 1983, VIROLOGY, V109, P127; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; UZVOLGYI E, 1991, CELL GROWTH DIFFER, V2, P297; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; YOSHIDA S, 1981, BIOCHIM BIOPHYS ACTA, V654, P194, DOI 10.1016/0005-2787(81)90172-6; YOSHIDA S, 1983, BIOCHIM BIOPHYS ACTA, V741, P348, DOI 10.1016/0167-4781(83)90155-0	32	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					319	325						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381219				2022-12-17	WOS:A1993KN00600010
J	PANTERNE, B; HATZFELD, J; BLANCHARD, JM; LEVESQUE, JP; BERTHIER, R; GINSBOURG, M; HATZFELD, A				PANTERNE, B; HATZFELD, J; BLANCHARD, JM; LEVESQUE, JP; BERTHIER, R; GINSBOURG, M; HATZFELD, A			C-FOS MESSENGER-RNA CONSTITUTIVE EXPRESSION BY MATURE HUMAN MEGAKARYOCYTES	ONCOGENE			English	Note							INSITU HYBRIDIZATION; GENE-EXPRESSION; HUMAN-MONOCYTES; PROTO-ONCOGENE; 3T3 CELLS; GROWTH; TRANSCRIPTION; MACROPHAGES; PROTOONCOGENE; GRANULOCYTES	By in situ hybridization with a c-fos probe, we have shown that human bone marrow megakaryocytes cultured in the presence of 20% aplastic anemia plasma constitutively express c-fos mRNA. At day 0, megakaryocytes are mostly immature and only 3% of them are labeled. The number of labeled cells reached 23% after 12 days of culture. Interleukin 3 (IL-3) and IL-6 added together at day 10 further increased this number to 31% 2 days later. Mature labeled megakaryocytes were more numerous and more strongly labeled than immature ones. These results suggest that c-fos could play a role in megakaryocytic terminal differentiation, either in the polyploidization or in the thrombopoietic function unique to these cells.	HOP PAUL BROUSSE,ICIG,BIOL CELLULAIRE & MOLEC FACTEURS CROISSANCE LAB,CNRS,F-94804 VILLEJUIF,FRANCE; CEN,DEPT HEMATOL,F-38041 GRENOBLE,FRANCE; UNIV MONTPELLIER 2,BIOCHIM LAB,CNRS,UA 1191,F-34060 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,BIOL MOLEC LAB,CNRS,UA 1191,F-34060 MONTPELLIER,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Levesque, Jean-Pierre/C-5426-2011; HATZFELD, Antoinette/I-2341-2013; HATZFELD, Jacques A/I-2346-2013	Levesque, Jean-Pierre/0000-0002-7299-6025; HATZFELD, Antoinette/0000-0002-9147-533X; HATZFELD, Jacques A/0000-0002-3468-6659				ANGERER LM, 1987, METHOD ENZYMOL, V152, P649; BERNAUDIN JF, 1988, J IMMUNOL, V140, P3822; BERTHIER R, 1987, EXP HEMATOL, V15, P750; CAUBET JF, 1989, BLOOD, V74, P947; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COLLART MA, 1987, J IMMUNOL, V139, P949; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; DEBILI N, 1991, BLOOD, V77, P2326; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hayhoe FG, 1982, COLOUR ATLAS HAEMATO; KREIPE H, 1987, J HISTOCHEM CYTOCHEM, V35, P837, DOI 10.1177/35.8.3298425; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE J, 1987, BLOOD, V69, P1542; MCCUNE JM, 1990, SCIENCE, V217, P864; MESSNER HA, 1987, P NATL ACAD SCI USA, V84, P6765, DOI 10.1073/pnas.84.19.6765; MESSNER HA, 1984, METHODS HEMATOLOGY, V2, P73; SARIBAN E, 1988, MOL CELL BIOL, V8, P340, DOI 10.1128/MCB.8.1.340	22	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2341	2344						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437157				2022-12-17	WOS:A1992JW66500029
J	FUJITAYOSHIGAKI, J; YOKOYAMA, S; SHINDOOKADA, N; NISHIMURA, S				FUJITAYOSHIGAKI, J; YOKOYAMA, S; SHINDOOKADA, N; NISHIMURA, S			AZATYROSINE INHIBITS NEURITE OUTGROWTH OF PC12 CELLS INDUCED BY ONCOGENIC RAS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; H-RAS; DIFFERENTIATION; PHOSPHORYLATION; MICROINJECTION; EXPRESSION; MOUSE; P21; ANTIBODY	An antibiotic, azatyrosine [L-beta-(5-hydroxy-2-pyridyl) alanine], specifically converts ras-, raf- or c-erbB2 (neu)-transformed NIH3T3 cells to apparently normal phenotype. The reversion induced by azatyrosine is permanent, and the phenotype of the revertant cells does not change even after prolonged culture in the absence of azatyrosine [N. Shindo-Okada, O. Manabe, H. Nagahara & S. Nishimura (1989). Mol. Carcinogen., 2, 159-167]. In the present study, we found that neurite outgrowth of PC12 cells induced by expression of either the ras or raf oncogenes was inhibited by addition of azatyrosine to the medium. Azatyrosine also inhibited neurite outgrowth induced by microinjection of oncogenic Ras protein into PC12 cells. The dose dependency was much the same for the two systems, inhibition of neurite outgrowth of PC12 cells and reversion of the transformed NIH3T3 cells. Microinjection of azatyrosine into the cells was as effective as addition to the medium, indicating that the target of azatyrosine is intracellular. In contrast, neurite outgrowth induced by nerve growth factor, which has been shown to be mediated by normal Ras [N. Hagag, S. Halegouna & M. Viola (1986). Nature, 319, 680-682], was found to be resistant to azatyrosine. Azatyrosine also showed no effect on neurite outgrowth induced by a membrane-permeant cyclic AMP analog through another pathway. These findings suggest that azatyrosine sensitivity is the result of abnormal signal transduction by oncogenic Ras. It was shown that azatyrosine also inhibited differentiation-associated growth arrest of PC12 cells induced by oncogenic Ras. In Ras-induced neurite outgrowth, the azatyrosine-sensitive process was found to be completed in the first 6-9 h, and is probably essential for the commitment of PC12 cells to differentiation rather than to growth.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; NATL CANC CTR,RES INST,CHUO KU,TOKYO 104,JAPAN	University of Tokyo; University of Tokyo; National Cancer Center - Japan			Yoshigaki, Junko/AAE-6702-2020; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; INOUYE S, 1975, CHEM PHARM BULL, V23, P2669; IZAWA M, 1992, IN PRESS CANCER RES; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MIURA K, 1986, JPN J CANCER RES, V77, P45; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SHIROUZU M, 1992, ONCOGENE, V7, P475; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	33	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2019	2024						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328988				2022-12-17	WOS:A1992JP42400016
J	MERCOLA, D; CARPENTER, PM; GROVERBARDWICK, A; MERCOLA, M				MERCOLA, D; CARPENTER, PM; GROVERBARDWICK, A; MERCOLA, M			RAPID, COMPLETE AND REVERSIBLE TRANSFORMATION BY V-SIS PRECEDES IRREVERSIBLE TRANSFORMATION	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; HUMAN-TUMOR CELLS; FACTOR A-CHAIN; GROWTH-FACTOR; HUMAN-FIBROBLASTS; B-CHAIN; C-FOS; AUTOCRINE STIMULATION; PDGF RECEPTORS; ANTISENSE RNA	v-sis is the oncogene of simian sarcoma virus, but whether tumor growth is maintained by v-sis expression alone or requires additional changes is unknown. To distinguish these possibilities we studied a model of reversible transformation including tumorigenicity using NIH3T3 cells bearing a metallothionein promoter-v-sis construction. Cells subcultured from 10 out of 18 tumors from athymic mice, all < 0.1 g and less-than-or-equal-to 21 days in age, reverted to a normal phenotype but exhibited transformation upon addition of zinc as judged by morphology, growth rate, saturation density and anchorage independence of growth. Thus, activation of v-sis alone is sufficient for initiation and early autocrine-based growth of tumors. However, the cells from the remaining and predominantly larger, 0.5 +/- 0.7 g, tumors did not revert and exhibited zinc-independent transformation as judged by the same criteria. Southern analysis and examination of the regulation of v-sis product expression in cells derived from these tumors showed no change in zinc-dependent and reversible regulation of v-sis sequences. These results suggest that subsequent tumor growth strongly favors acquisition of additional irreversible change(s) in the tumor cell genome at high frequency (44%). Thus an earl event of a multistep process stimulated by v-sis-dependent transformation best accounts for the sum of results.	UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; DEPT VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA; HARVARD UNIV, DEPT PHYSIOL, BOSTON, MA 02115 USA	University of California System; University of California San Diego; Harvard University	MERCOLA, D (corresponding author), UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA 49963] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049963] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BISHOP JM, 1982, MOL BIOL TUMOR VIR 3; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CAVENEE W, 1988, RECESSIVE ONCOGENES; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DER CJ, 1988, ONCOGENE, V3, P105; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FAVERA RD, 1981, NATURE, V292, P31; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRY DG, 1988, MUTAT RES, V199, P341, DOI 10.1016/0027-5107(88)90213-8; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GRAVES D, 1984, P NATL ACAD SCI USA, V83, P4636; GROVER A, 1985, J BIOL CHEM, V260, P2252; GROVERBARDWICK A, 1991, BIOTECHNOLOGY CELL R, V4, P227; HAMMER RE, 1984, NATURE, V311, P65, DOI 10.1038/311065a0; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUANG SS, 1988, J BIOL CHEM, V263, P12608; IGARASHI H, 1987, ONCOGENE, V1, P79; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KELLY JD, 1985, EMBO J, V4, P3399, DOI 10.1002/j.1460-2075.1985.tb04096.x; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEKUTH M, 1990, BIOCHIM BIOPHYS ACTA, V103, P1; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MERCOLA D, 1989, BIOCHEM BIOPH RES CO, V147, P854; MERCOLA D, 1991, GENE REGULATION ANTI, P329; MERCOLA D, 1991, PROSPECTS APPLICATIO, P83; MERCOLA D, 1992, 1991 OST RES C; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; NOWELL PC, 1986, CANCER RES, V46, P2203; OSNOBE MH, 1991, ONCOGENE, V6, P1531; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PECH M, 1989, P NATL ACAD SCI USA, V86, P2693, DOI 10.1073/pnas.86.8.2693; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBBINS K, 1988, SCIENCE, V241, P1346; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; SUKUMAR S, 1989, CURR TOP MICROBIOL, V148, P93; VANDENBERG S, 1991, MOL CARCINOGEN, V4, P460, DOI 10.1002/mc.2940040609; VERSNEL MA, 1988, ONCOGENE, V2, P601; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WU JX, 1990, ONCOGENE, V5, P989; [No title captured]	59	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1793	1803						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501889				2022-12-17	WOS:A1992JJ37600016
J	LINK, DC; GUTKIND, SJ; ROBBINS, KC; LEY, TJ				LINK, DC; GUTKIND, SJ; ROBBINS, KC; LEY, TJ			CHARACTERIZATION OF THE 5' UNTRANSLATED REGION OF THE HUMAN C-FGR GENE AND IDENTIFICATION OF THE MAJOR MYELOMONOCYTIC C-FGR PROMOTER	ONCOGENE			English	Article							NF-KAPPA-B; PROTO-ONCOGENE; MESSENGER-RNA; CELL-LINES; EXPRESSION; PROTOONCOGENE; VIRUS; DIFFERENTIATION; TRANSCRIPTS; ACTIVATION	In this study, we have characterized the 5' region of the human c-fgr proto-oncogene and identified the major myelomonocytic c-fgr promoter. Seven distinct 5' untranslated exons were identified and localized to a region extending 13 kb upstream from the first coding exon. Two major promoters were identified, one utilized exclusively in Epstein-Barr virus (EBV)-infected B-lymphocyte cell lines, and the other functional only in myelomonocytic cells. Differential promoter utilization and alternative splicing of the 5' untranslated exons give rise to at least six distinct c-fgr mRNA species that differ only in their 5' untranslated regions. Two major mRNAs were identified, c-fgr A and c-fgr 4; these two mRNAs were detected exclusively in EBV-infected B-lymphocyte cell lines and myelomonocytic cells respectively. We have previously demonstrated that c-fgr is transcriptionally activated in U937 cells treated with either 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or cycloheximide (CHX). We now show that a DNA fragment extending from -772 to +97 (with respect to the transcription initiation site upstream from exon M4) is responsive to TPA but not CHX treatment in U937 cells. These results suggest that TPA and CHX induce c-fgr mRNA accumulation by different mechanisms.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT GENET,ST LOUIS,MO 63110; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038682, R37DK038682, R56DK038682] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49712] Funding Source: Medline; NIDDK NIH HHS [DK 38682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICKELL PM, 1988, BRIT J CANCER, V58, P704, DOI 10.1038/bjc.1988.294; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; FAHEY JL, 1971, ANN NY ACAD SCI, V190, P221, DOI 10.1111/j.1749-6632.1971.tb13537.x; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; INOUE K, 1987, ONCOGENE, V1, P301; INOUE K, 1990, MOL CELL BIOL, V10, P1789, DOI 10.1128/MCB.10.4.1789; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KLEIN C, 1988, INT J CANCER, V42, P29, DOI 10.1002/ijc.2910420107; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; PATEL M, 1990, ONCOGENE, V5, P201; PERKINS SL, 1991, IN PRESS J LEUKOCYTE; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RASHEED S, 1982, VIROLOGY, V117, P238, DOI 10.1016/0042-6822(82)90522-0; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TRONICK SR, 1985, P NATL ACAD SCI USA, V82, P6595, DOI 10.1073/pnas.82.19.6595; ULRICH MJ, 1990, BLOOD, V75, P990; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	31	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					877	884						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373875				2022-12-17	WOS:A1992HP64200006
J	PERRAUD, F; YOSHIMURA, K; LOUIS, B; DALEMANS, W; ALIHADJI, D; SCHULTZ, H; CLAUDEPIERRE, MC; CHARTIER, C; DANEL, C; BELLOCQ, JP; CRYSTAL, RG; LECOCQ, JP; PAVIRANI, A				PERRAUD, F; YOSHIMURA, K; LOUIS, B; DALEMANS, W; ALIHADJI, D; SCHULTZ, H; CLAUDEPIERRE, MC; CHARTIER, C; DANEL, C; BELLOCQ, JP; CRYSTAL, RG; LECOCQ, JP; PAVIRANI, A			THE PROMOTER OF THE HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE DIRECTING SV40 T-ANTIGEN EXPRESSION INDUCES MALIGNANT PROLIFERATION OF EPENDYMAL CELLS IN TRANSGENIC MICE	ONCOGENE			English	Note							IDENTIFICATION; MUTATIONS; PROTEIN; TUMORS; LINES; DEFECT	Transgenic mice bearing a human cystic fibrosis transmembrane conductance regulator (CFTR) promoter-SV40 T antigen fusion transgene were generated in order to localize in vivo the potential oncogenesis linked to the tissue-specific activity of the promoter for the CFTR gene. Surprisingly, the only site of tumors resulting from expression of the reporter onc gene was ependymal cells lining the brain ventricles. SV40 T antigen expression in these cells led to a consistent pathology in the first weeks of age: ependymoma and consequent hydrocephaly. Tumor-derived cell lines were established, characterized and shown to originate from SV40 T antigen-induced ependymoma. No pathological alterations were found in other organs, such as lungs and pancreas, in which cystic fibrosis is pathologically manifest in humans. Such transgenic mice and derived cell lines may represent valid models for analysing (1) the role of SV40 T antigen in ependymoma formation and (2) CFTR function in ependymal cells.	TRANSGENE SA,DEPT ANIM SYST,11 RUE MOLSHEIM,F-67082 STRASBOURG,FRANCE; NHLBI,PULM BRANCH,BETHESDA,MD 20892; HOP HAUTE PIERRE,SERV ANAT PATHOL GEN,F-67200 STRASBOURG,FRANCE	Transgene SA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); CHU Strasbourg								ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARAKI M, 1983, ARCH HISTOL JAPON, V46, P191, DOI 10.1679/aohc.46.191; BABINET C, 1989, GENOME, V31, P938, DOI 10.1139/g89-165; BECKER LE, 1983, HUM PATHOL, V14, P538, DOI 10.1016/S0046-8177(83)80006-9; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BRUNI JE, 1985, BRAIN RES REV, V9, P1, DOI 10.1016/0165-0173(85)90016-5; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DALEMANS W, 1990, BIOLOGICALS, V18, P191, DOI 10.1016/1045-1056(90)90006-L; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Flint S. J, 1981, DNA TUMOR VIRUSES; GABRION J, 1988, NEUROSCIENCE, V24, P993, DOI 10.1016/0306-4522(88)90082-6; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Hogan B., 1986, MANIPULATING MOUSE E; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LEVITAN IB, 1989, SCIENCE, V244, P1423, DOI 10.1126/science.2544028; MANTHORPE CM, 1977, BRAIN RES, V134, P407, DOI 10.1016/0006-8993(77)90818-6; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PAVIRANI A, 1989, BIO-TECHNOL, V7, P1049; PERRAUD F, 1991, EXP CELL RES, V195, P59, DOI 10.1016/0014-4827(91)90500-T; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROESSMANN U, 1980, BRAIN RES, V200, P13, DOI 10.1016/0006-8993(80)91090-2; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WHITE MB, 1990, NATURE, V344, P665, DOI 10.1038/344665a0; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	46	13	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					993	997						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373882				2022-12-17	WOS:A1992HP64200020
J	MOSNER, J; DEPPERT, W				MOSNER, J; DEPPERT, W			CONFORMATIONAL-ANALYSIS OF P53 IN RESTING AND CONCANAVALIN A-STIMULATED MOUSE LYMPHOCYTES	ONCOGENE			English	Article							CELL-CYCLE CONTROL; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; MUTANT P53; NORMAL 3T3; PROTEIN; EXPRESSION; MUTATIONS; ANTIGENS; CANCER	We report that p53 in resting and concanavalin A-stimulated Balb/c mouse lymphocytes cannot be distinguished on the basis of different reactivity with various epitope-specific monoclonal antibodies, regardless of whether the lymphocytes are stimulated with concanavalin A in the presence or absence of serum. Our results thus question the 'conformational hypothesis' put forward by Milner [Milner, J. (1991). Curr. Op. Cell Biol., 3, 282-286], according to which wild-type p53, depending on its conformational status, can act as a negative or a positive growth regulator.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	Heinrich Pette Institute; University of Hamburg								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BOYUM A, 1968, SCAND J CLIN LAB INV, V97, P76; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DEPPERT W, 1990, ONCOGENE, V5, P1701; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS AL, 1990, J PATHOL, V162, P5, DOI 10.1002/path.1711620103; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, ONCOGENE, V5, P1683; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; STEINMEYER K, 1990, ONCOGENE, V5, P1691; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	22	13	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					661	666						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565465				2022-12-17	WOS:A1992HQ68200007
J	KOCHEL, T; RICE, NR				KOCHEL, T; RICE, NR			V-REL- AND C-REL- PROTEIN COMPLEXES BIND TO THE NF-KAPPA-B SITE INVITRO	ONCOGENE			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; TRANSFORMED LYMPHOID-CELLS; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATOR; ONCOGENE ENCODES; GENE; DNA; FIBROBLASTS; EXPRESSION; NUCLEAR	Previous work by others has revealed homology between the rel oncogene and the transcription factor NF-kappa-B. Further, in vitro-translated v-rel protein and c-rel protein are able to bind to an oligonucleotide containing the kappa-B binding site. Unlike the in vitro-translated product, cellular Rel protein exists in high molecular weight complexes with several other proteins. In this report we show that immunopurified cellular complexes containing the v-rel protein and/or the c-rel protein are also able to bind to an oligonucleotide containing the kappa-B site. These cellular complexes are heterogeneous in size, and all sizes appeared to have binding activity. UV cross-linking demonstrated that the Rel proteins themselves were bound to the DNA. Thus it is likely that the Rel proteins play a direct role in transcriptional regulation.	NCI,FREDERICK CANC RES & DEV CTR,MOLECUL VIROL & CARCINOGENESIS LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; GRUMONT RJ, 1990, CELL GROWTH DIFFER, V1, P345; GRUMONT RJ, 1990, ONCOGENE RES, V5, P245; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MORRISON LE, 1989, ONCOGENE, V4, P677; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1988, ONCOGENE HDB, P495; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	39	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					567	572						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549370				2022-12-17	WOS:A1992HK00500025
J	AGUILARCORDOVA, E; STRANGE, R; YOUNG, LJT; BILLY, HT; GUMERLOCK, PH; CARDIFF, RD				AGUILARCORDOVA, E; STRANGE, R; YOUNG, LJT; BILLY, HT; GUMERLOCK, PH; CARDIFF, RD			VIRAL HA-RAS MEDIATED MAMMARY-TUMOR PROGRESSION	ONCOGENE			English	Article							MOUSE SKIN CARCINOGENESIS; TRANSGENIC MICE; EPITHELIAL-CELLS; ENZYMATIC AMPLIFICATION; MOLECULAR-BIOLOGY; HARVEY; TISSUE; VIRUS; GENE; DNA	An immortal mammary epithelial cell line, Comma 1D, and primary cultures of mammary epithelial cells were used to examine the effects of vHa-ras on mammary tumor development. In culture, Comma 1D and primary cells were morphologically indistinguishable. Infection with a replication defective vHa-ras retroviral vector (psi-ras) did not alter their in vitro phenotype. Uninfected Comma 1D cells implanted into gland-cleared mammary fat pads gave rise to dysplastic outgrowths, while implants of primary cells gave rise to normal gland structures. After psi-ras infection, implants of Comma 1D cells progressed to adenocarcinomas and those of primary cells resulted in initiated dysplastic outgrowths. High level infection of either cell type with replication competent HaMSV (psi-ras plus helper virus) resulted in in vitro transformation and undifferentiated in vivo tumors. Thus, in vivo analysis was necessary to detect the observed correlation between tumorigenic stage and level of infection. In this system, expression of vHa-ras was vital but not sufficient for mammary tumor initiation and progression, which resulted from an accumulation of events that did not need to occur in a specific order.	UNIV CALIF DAVIS,SCH MED,DEPT PATHOL,DAVIS,CA 95616; UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT INTERNAL MED,DIV HEMATOL ONCOL,SACRAMENTO,CA 95817	University of California System; University of California Davis; University of California System; University of California Davis								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ASCH BB, 1986, CANCER RES, V46, P1255; ASHLEY RL, 1980, CANCER RES, V40, P4232; BALL RK, 1988, MOL ENDOCRINOL, V2, P133, DOI 10.1210/mend-2-2-133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; COHEN JC, 1979, J VIROL, V32, P483, DOI 10.1128/JVI.32.2.483-496.1979; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; EDWARDS PAW, 1988, ONCOGENE, V2, P402; EHMANN UK, 1987, JNCI-J NATL CANCER I, V78, P751; EHMANN UK, 1984, J CELL BIOL, V98, P1026, DOI 10.1083/jcb.98.3.1026; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HENNINGS H, 1985, J NATL CANCER I, V74, P735; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KAWABE TT, 1986, LAB MED, V17, P143, DOI 10.1093/labmed/17.3.143; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO Y, 1986, AM J PATHOL, V125, P431; SINN E, 1987, CELL, V49, P466; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRANGE R, 1989, ONCOGENE, V4, P309; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	32	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1601	1607						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923527				2022-12-17	WOS:A1991GX27400015
J	GILL, S; STRATTON, MR; PATTERSON, H; SPURR, NK; FISHER, C; GUSTERSON, BA; COOPER, CS				GILL, S; STRATTON, MR; PATTERSON, H; SPURR, NK; FISHER, C; GUSTERSON, BA; COOPER, CS			DETECTION OF TRANSFORMING GENES BY TRANSFECTION OF DNA FROM PRIMARY SOFT-TISSUE TUMORS	ONCOGENE			English	Note							SARCOMA CELL-LINES; STRUCTURAL ALTERATIONS; HUMAN-TUMORS; ONCOGENE; IDENTIFICATION; SEQUENCES; RAS	A series of adult soft-tissue tumours were screened for the presence of activated oncogenes by transfecting tumour DNA into NIH3T3 mouse fibroblasts. In these studies an activated K-ras gene that contained a mutation at the second position of codon 12 (GGT --> GAT) was found in a leiomyosarcoma. In addition, following transfection of DNA from a liposarcoma, we identified an activated gene that failed to hybridize to probes prepared from 10 known human oncogenes (K-ras, H-ras, N-ras, ret, met, trk, mas, dbl, raf and hst) that have previously been detected in DNA transfection experiments. BamHI-BamHI fragments of this activated gene of 3.5 and 8.5 kb were cloned from NIH3T3 secondary transfectants using a probe that detects the human alu family of highly repetitive DNA sequences. Repeat-free subclones of these BamHI fragments were used to map this gene to human chromosome 19 (p13.2-q13.3). Our studies also demonstrate that a subclone from one of the BamHI fragments detects a 3.0 kb transcript in primary and secondary transfectants.	IMPERIAL CANC RES FUND,POTTERS BAR EN6 3LD,HERTS,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,LONDON SW3 6JJ,ENGLAND; INST CANC RES,CELL BIOL & EXPTL PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	GILL, S (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		gusterson, barry a/D-3752-2009					BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER CS, 1991, CARCINOGENESIS, V12, P155, DOI 10.1093/carcin/12.2.155; COOPER CS, 1989, CHEM CARCINOGENESIS, V2, P319; Enzinger RM., 2011, SOFT TISSUE TUMORS, P1178; EVA A, 1987, ONCOGENE, V1, P355; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HALL A, 1989, CHEM CARCINOGENESIS, V2, P271; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARTINZANCA D, 1986, NATURE, V328, P527; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; STRATTON MR, 1989, CANCER RES, V49, P6324; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	23	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1651	1656						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923531				2022-12-17	WOS:A1991GX27400021
J	SZPIRER, C; SZPIRER, J; RIVIERE, M; INGVARSSON, S; VENNSTROM, B; ISLAM, MQ; LEVAN, G				SZPIRER, C; SZPIRER, J; RIVIERE, M; INGVARSSON, S; VENNSTROM, B; ISLAM, MQ; LEVAN, G			CHROMOSOMAL ASSIGNMENT OF 5 CANCER-ASSOCIATED RAT GENES - 2 THYROID-HORMONE RECEPTOR (ERBA) GENES, 2 ERBB GENES AND THE RETINOBLASTOMA GENE	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; AVIAN ERYTHROBLASTOSIS VIRUS; SOMATIC-CELL HYBRIDIZATION; C-ERBA; NEU ONCOGENE; LUNG-CANCER; MALIGNANT MESOTHELIOMA; DNA-SEQUENCE; AMPLIFICATION	Using a panel of somatic cell hybrids that segregate rat chromosomes, the localization of five cancer-related rat genes was determined: (i) two thyroid receptor genes, THRA1/ERBA1 and THRB/ERBA2 on chromosomes 10 and 15 respectively, (ii) two ERBB genes, namely the epidermal growth factor gene (EGFR, also called ERBB1) and the ERBB2 gene (also designated neu) on chromosomes 14 and 10 respectively, and (iii) the retinoblastoma gene, RB1, on chromosome 15. The THRA1/ERBA1 and ERBB2/neu genes are thus included in a synteny group, conserved on rat chromosomes 10 and human chromosome arm 17q.	KAROLINSKA INST,DEPT MOLEC BIOL,S-10401 STOCKHOLM 60,SWEDEN; GOTHENBURG UNIV,DEPT GENET,S-40033 GOTHENBURG,SWEDEN	Karolinska Institutet; University of Gothenburg	SZPIRER, C (corresponding author), UNIV LIBRE BRUXELLES,DEPT BIOL MOLEC,RUE CHEVAUX 67,B-1640 RHODE ST GENESE,BELGIUM.		Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOUIZAR Z, 1989, CANCER RES, V49, P5199; BUCHBERG AM, 1989, GENETICS, V122, P153; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOBROVIC A, 1988, CANCER RES, V48, P682; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EHLEN T, 1990, ONCOGENE, V5, P219; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; FULCHIGNONILATAUD MC, 1990, CYTOGENET CELL GENET, V53, P172, DOI 10.1159/000132922; GEORGE DL, 1981, HUM GENET, V57, P138; GILL TJ, 1989, SCIENCE, V245, P269, DOI 10.1126/science.2665079; HAAG MM, 1984, CANCER RES, V44, P784; HAYMAN MJ, 1986, TRENDS GENET, V2, P260, DOI 10.1016/0168-9525(86)90259-3; HEIMER S, 1987, CANCER CYTOGENETICS; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; JACKSONGRUSBY LL, 1988, ENDOCRINOLOGY, V122, P2462, DOI 10.1210/endo-122-6-2462; KANOTANAKA K, 1982, INT J CANCER, V30, P495, DOI 10.1002/ijc.2910300417; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KNUDSON AG, 1976, NEW ENGL J MED, V295, P1120, DOI 10.1056/NEJM197611112952007; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOVI J, 1978, JNCI-J NATL CANCER I, V61, P495; LALLEY PA, 1989, CYTOGENET CELL GENET, V51, P503, DOI 10.1159/000132806; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEVAN G, 1975, HEREDITAS, V79, P161; Levan G., 1990, Genetic maps: locus of complex genomes.; LEVAN G, 1974, HEREDITAS, V77, P263; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LIBBUS BL, 1988, CANCER RES, V48, P6455; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MATTEI MG, 1991, IN PRESS GENOMICS, V10; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MITELMAN F, 1971, HEREDITAS-GENETISK A, V69, P155; MITELMAN F, 1986, CANCER GENET CYTOGEN, V22, P95, DOI 10.1016/0165-4608(86)90168-8; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NADEAU JH, 1990, GENETIC VARIANTS STR, P506; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; POPESCU NC, 1988, CANCER RES, V48, P142; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEARLE AG, 1989, ANN HUM GENET, V53, P89, DOI 10.1111/j.1469-1809.1989.tb01777.x; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHEER D, 1985, ANN HUM GENET, V49, P167, DOI 10.1111/j.1469-1809.1985.tb01690.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STONE JC, 1989, GENOMICS, V5, P70, DOI 10.1016/0888-7543(89)90088-8; SUGIYAMA T, 1978, J NATL CANCER I, V60, P153, DOI 10.1093/jnci/60.1.153; SZPIRER C, 1989, CYTOGENET CELL GENET, V50, P23, DOI 10.1159/000132712; SZPIRER C, 1988, CURR TOP MICROBIOL, V137, P33; SZPIRER J, 1984, CYTOGENET CELL GENET, V38, P142, DOI 10.1159/000132047; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WIENER F, 1982, INT J CANCER, V29, P431, DOI 10.1002/ijc.2910290412; YAMAMOTO T, 1986, CANCER RES, V46, P414; YANGFENG TL, 1985, CYTOGENET CELL GENET, V40, P784; YOKOTA J, 1988, ONCOGENE, V2, P283; YOSHIDA MC, 1978, CYTOGENET CELL GENET, V22, P606, DOI 10.1159/000131034; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	79	13	13	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1319	1324						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679528				2022-12-17	WOS:A1991GX27200004
J	MEIJER, I; VANDAM, H; BOOT, AJM; BOS, JL; ZANTEMA, A; VANDEREB, AJ				MEIJER, I; VANDAM, H; BOOT, AJM; BOS, JL; ZANTEMA, A; VANDEREB, AJ			CO-REGULATED EXPRESSION OF JUNB AND MHC CLASS-I GENES IN ADENOVIRUS-TRANSFORMED CELLS	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR FAMILY; DNA-BINDING; RAT-CELLS; E1A GENE; FUNCTIONAL DOMAINS; PROTEIN; PROMOTER; AP-1; FOS	The expression of the junB gene parallels the expression of the MHC class I genes in Adenovirus (Ad) transformed cells. In Ad12E1-transformed primary BRK cells both genes are transcriptionally repressed only when the 13S product of Ad12E1A is present. This indicates that repression of MHC class I and junB genes is a function of conserved region 3 (CR3) of the Ad12E1A protein. In Ad5-transformed BRK cells expression of these genes is unchanged. In established NRK cells, however, introduction of Ad12E1A does not cause repression of the MHC class I and junB genes, but in these cells Ad5E1A increases the expression of both MHC class I and junB. Using mutant Ad5E1A genes, it is shown that this activation is mediated by CR1. Introduction of a functional junB gene under the control of a heterologous promoter in Ad12E1-transformed BRK cells causes no increase in MHC class I expression. This demonstrates that the down-regulation of junB is not directly responsible for class I repression, but rather that both genes are coregulated by the Ad12E1 region.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	VANDEREB, AJ (corresponding author), LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS.			van Dam, Hans/0000-0002-8307-4325				ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERNARDS R, 1987, TRENDS GENET, V3, P298, DOI 10.1016/0168-9525(87)90272-1; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLARK L, 1988, GENE DEV, V2, P991, DOI 10.1101/gad.2.8.991; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JOCHEMSEN AG, 1984, EMBO J, V3, P2923, DOI 10.1002/j.1460-2075.1984.tb02233.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MEIJER I, 1989, J VIROL, V63, P4039, DOI 10.1128/JVI.63.9.4039-4042.1989; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TIMMERS HTM, 1990, THESIS U LEIDEN; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VOGT PK, 1990, IN PRESS ADV CANCER; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	40	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					911	916						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906158				2022-12-17	WOS:A1991GU62200004
J	NIELSCH, U; FOGNANI, C; BABISS, LE				NIELSCH, U; FOGNANI, C; BABISS, LE			ADENOVIRUS E1A-P105(RB) PROTEIN INTERACTIONS PLAY A DIRECT ROLE IN THE INITIATION BUT NOT THE MAINTENANCE OF THE RODENT CELL TRANSFORMED PHENOTYPE	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; REGION 1A PROTEINS; LARGE T-ANTIGEN; TYPE-5 ADENOVIRUS; E1A GENE; EXPRESSION; BINDING; PRODUCTS; DNA; POLYPEPTIDES	The morphological transformation of rodent fibroblast cells by adenovirus requires expression of the viral E1A and E1B genes. Recent studies have suggested that one function of the E1A proteins is to interact with and inactivate specific cellular proteins (anti-oncoproteins) that maintain regulated cell growth. One candidate cellular protein that may be influenced by its interaction with the E1A oncoproteins is the retinoblastoma (Rb) susceptibility gene product. In this report we show that over-expressing the human Rb protein in two rodent fibroblast cell lines leads to a significant reduction in the frequency of focus-formation following adenovirus infection. Therefore, Rb-E1A protein interactions play an important role in the initiation of cellular transformation by adenovirus. Using cell lines which are conditionally transformed by adenovirus mutants which fail to express the E1A 289R protein, we show that the process leading to a loss of the maintenance of the transformed cell phenotype is not associated with changes in the levels of E1A-Rb protein complexes. These observations suggest distinct roles of Rb-E1A interactions in initiating and maintaining the transformed cell phenotype. Finally, in contrast to results with the SV40 large T Ag, we find that E1A protein expression has no affect on cellular Rb gene expression in both virus-infected and virus-transformed cell lines.	ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,BOX 279,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University	BABISS, LE (corresponding author), ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,BOX 279,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R29CA048707] Funding Source: NIH RePORTER; NCI NIH HHS [CA48707-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Ginsberg HS, 1984, ADENOVIRUSES; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; HEARING P, 1983, CELL, V33, P292; HERBST RS, 1988, J VIROL, V62, P4634, DOI 10.1128/JVI.62.12.4634-4643.1988; HO YS, 1982, VIROLOGY, V122, P109, DOI 10.1016/0042-6822(82)90381-6; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORITSUKA T, 1989, ONCOGENE RES, V5, P155; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	30	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1031	1036						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	2067843				2022-12-17	WOS:A1991GU62200019
J	HEWLETT, IK; GEYER, SJ; HAWTHORNE, CA; RUTA, M; EPSTEIN, JS				HEWLETT, IK; GEYER, SJ; HAWTHORNE, CA; RUTA, M; EPSTEIN, JS			KINETICS OF EARLY HIV-1 GENE-EXPRESSION IN INFECTED H9-CELLS ASSESSED BY PCR	ONCOGENE			English	Note							HUMAN IMMUNODEFICIENCY VIRUS; POLYMERASE CHAIN-REACTION; RNA; AMPLIFICATION; DNA; CELLS	The time course of viral gene expression in H9 cells acutely infected with HIV-1 was analysed by the polymerase chain reaction (PCR). Virus-specific sequences were first detected in genomic DNA of H9 cells 1-2h after infection. RNA for the regulatory genes such as the tat and nef appeared 2-3h post-infection and RNA for the gag and env at 3 h. The results demonstrate that viral DNA synthesis occurs rapidly after infection of target cells followed by synthesis of viral RNA. Cell-associated reverse transcriptase activity increased after 24 h, while culture supernatant enzyme activity increased later, between 1-5 days. The delay in virus release after rapid integration and transcriptional activity suggests the involvement of additional factors, perhaps both cellular and viral, that control the formation and budding of mature virions.			HEWLETT, IK (corresponding author), US FDA,DIV TRANSFUS SCI,RETROVIROL LAB,BETHESDA,MD 20892, USA.			Epstein, Jay/0000-0003-2293-9062				CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GEYER SJ, 1989, 5TH INT C AIDS INT A, P636; GOTTLINGER HG, 1990, 6TH INT C AIDS; HART C, 1988, LANCET, V2, P596; HEWLETT IK, 1989, ONCOGENE, V4, P1149; HEWLETT IK, 1988, J CLIN IMMUNOASSAY, V11, P161; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; Maniatis T., 1984, MOL CLONING; MURAKAWA GJ, 1988, DNA-J MOLEC CELL BIO, V7, P287, DOI 10.1089/dna.1988.7.287; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617	15	13	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					491	493						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1707154				2022-12-17	WOS:A1991FT34400023
J	PUNYAMMALEE, B; CRABEEL, M; DELANNOY, C; PERBAL, B; GLANSDORFF, N				PUNYAMMALEE, B; CRABEEL, M; DELANNOY, C; PERBAL, B; GLANSDORFF, N			2 C-MYB PROTEINS DIFFERING BY THEIR AMINOTERMINI EXHIBIT DIFFERENT TRANSCRIPTIONAL TRANSACTIVATION ACTIVITIES - YEAST REPORTER-EFFECTOR SYSTEM	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; DNA-BINDING ACTIVITY; GENE V-MYB; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; SACCHAROMYCES-CEREVISIAE; TRANSFORMING GENE; MESSENGER-RNA; CHICKEN DNA; PLASMACYTOID LYMPHOSARCOMAS	We assayed in the yeast S. cerevisiae the transcriptional transactivation activity of the c-myb products encoded by a normal thymus cDNA and of an aminoterminally truncated version of it (minus 58 amino acids) corresponding to the cDNAs isolated from lymphoma and leukemia cells from different origins. Both proto-oncogene products were expressed under the control of the galactose inducible GAL10 promoter. The reporter system used to monitor the transactivation potential of the myb products consisted of a CYCl-lacZ gene fusion in which the UAS(cyc) signals were replaced by one or multiple copies of the myb recognition element (mRE). As shown by Northern blot analyses and by primer extension experiments both c-myb products increase the level of beta-galactosidase transcription. Interestingly, the c-myb product corresponding to lymphoma cDNAs stimulates transcription four to five times more efficiently than does the normal thymic c-myb product.	VRIJE UNIV BRUSSELS,COOVI,CERIA,RES INST,1 E GRYSONLAAN,B-1070 BRUSSELS,BELGIUM; UNIV PARIS 06,F-75230 PARIS 05,FRANCE; CTR UNIV ORSAY,INST CURIE,F-91405 ORSAY,FRANCE	Vrije Universiteit Brussel; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay								BADING H, 1987, ONCOGENE, V1, P395; BALUDA MA, 1983, FOLIA BIOL-PRAGUE, V29, P18; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BERGMAN DG, 1980, J VIROL, V40, P450; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; Broach J. R., 1983, EXPT MANIPULATION GE, P83; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1988, ONCOGENE, V2, P545; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; MA J, 1987, CELL, V51, P13; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MCMAHON J, 1988, ONCOGENE, V3, P717; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; Miller J.H., 1972, EXPT MOL GENETICS; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PELLICI PG, 1986, SCIENCE, V224, P1117; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; Perbal B., 1988, PRACTICAL GUIDE MOL; RAMOS F, 1979, EUR J BIOCHEM, V94, P409, DOI 10.1111/j.1432-1033.1979.tb12908.x; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SPRAGUE J, 1983, J VIROL, V45, P773, DOI 10.1128/JVI.45.2.773-781.1983; SSAMBROOK J, 1988, MOL CLONING LABORATO; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEINSTEIN Y, 1987, J VIROL, V61, P2339, DOI 10.1128/JVI.61.7.2339-2343.1987; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	63	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					11	19						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992438				2022-12-17	WOS:A1991EY03900002
J	CLASSON, M; HENRIKSSON, M; KLEIN, G; SUMEGI, J				CLASSON, M; HENRIKSSON, M; KLEIN, G; SUMEGI, J			THE EFFECT OF MYC PROTEINS ON SV40 REPLICATION IN HUMAN LYMPHOID-CELLS	ONCOGENE			English	Article											CLASSON, M (corresponding author), KAROLINSKA INST, DEPT TUMOR BIOL, S-10401 STOCKHOLM 60, SWEDEN.		Henriksson, Marie Arsenian/F-5010-2015		NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1 CA14054-14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BROOKS BJ, 1986, ADV VIRAL ONCOL, V7, P155; CAVALIERI F, 1988, ONCOGENE, V2, P289; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; EVAN GI, 1988, CURR TOP MICROBIOL, V141, P189; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; HAMMARSKJOLD ML, 1986, GENE, V43, P41, DOI 10.1016/0378-1119(86)90006-5; HENRIKSSON M, 1988, CURR TOP MICROBIOL, V141, P202; HENRIKSSON M, 1988, ONCOGENE, V3, P587; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; INGVARSSON S, 1987, SOMAT CELL MOLEC GEN, V13, P335, DOI 10.1007/BF01534927; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; MARGOLSKEE RF, 1984, J VIROL, V49, P386, DOI 10.1128/JVI.49.2.386-393.1984; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MENEZES J, 1975, BIOMEDICINE, V22, P276; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9585, DOI 10.1073/pnas.85.24.9585; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; TEGTMEYER P, 1972, J VIROL, V10, P591, DOI 10.1128/JVI.10.4.591-598.1972; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	52	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1990	5	9					1371	1376						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2170898				2022-12-17	WOS:A1990EC24100014
J	IWAHANA, H; ORITA, M; KANAZAWA, H; HAYASHI, K; SEKIYA, T				IWAHANA, H; ORITA, M; KANAZAWA, H; HAYASHI, K; SEKIYA, T			A NEW RFLP IN INTRON-1 OF THE HUMAN C-HA-RAS1 GENE AND ITS CLOSE RELATIONSHIP WITH THE VARIABLE TANDEM REPEATS IN THE REGION 3' TO THE GENE	ONCOGENE			English	Article									NATL CANC CTR,RES INST,DIV ONCOGENE,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CECCHERININELLI L, 1987, BRIT J CANCER, V56, P1, DOI 10.1038/bjc.1987.143; COHEN JB, 1987, J CELL PHYSL S, V5, P75; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; HAYWARD NK, 1988, HUM GENET, V78, P115, DOI 10.1007/BF00278178; HEIGHWAY J, 1986, BRIT J CANCER, V53, P453, DOI 10.1038/bjc.1986.72; KASPERCZYK A, 1989, AM J HUM GENET, V45, P689; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LEE JH, 1989, CANCER RES, V49, P1220; LIDEREAU R, 1986, JNCI-J NATL CANCER I, V77, P697, DOI 10.1093/jnci/77.3.697; MACKAY J, 1988, LANCET, V2, P1384; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SANGER F, 1981, SCIENCE, V214, P1305; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SPANDIDOS DA, 1987, FEBS LETT, V218, P41, DOI 10.1016/0014-5793(87)81014-1; SUTHERLAND C, 1986, BRIT J CANCER, V54, P787, DOI 10.1038/bjc.1986.241; THEILLET C, 1986, CANCER RES, V46, P4776; THEIN SL, 1986, NATURE, V321, P84, DOI 10.1038/321084a0; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WYLLIE FS, 1988, BRIT J CANCER, V57, P135, DOI 10.1038/bjc.1988.28; YOSHIMOTO K, 1989, CANCER RES, V49, P2716	28	13	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1049	1053						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1973828				2022-12-17	WOS:A1990DP41500014
J	WAGNER, S; KNIPPERS, R				WAGNER, S; KNIPPERS, R			AN SV40 LARGE T-ANTIGEN BINDING-SITE IN THE CELLULAR GENOME IS PART OF A CIS-ACTING TRANSCRIPTIONAL ELEMENT	ONCOGENE			English	Article											WAGNER, S (corresponding author), UNIV CONSTANCE,FAK BIOL,W-7750 CONSTANCE,GERMANY.							BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BURGER C, 1983, VIROLOGY, V126, P19, DOI 10.1016/0042-6822(83)90459-2; CONRAD SE, 1982, MOL CELL BIOL, V2, P949, DOI 10.1128/MCB.2.8.949; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORA S, 1989, J VIROL, V63, P2820, DOI 10.1128/JVI.63.6.2820-2828.1989; Fordis C M, 1987, Methods Enzymol, V151, P382; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GALLO GJ, 1988, MOL CELL BIOL, V8, P1648, DOI 10.1128/MCB.8.4.1648; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRUSS C, 1988, VIROLOGY, V167, P349, DOI 10.1016/S0042-6822(88)90095-5; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HUBER B, 1985, VIROLOGY, V146, P188, DOI 10.1016/0042-6822(85)90003-0; JENKINS JR, 1988, ONCOGENE HDB; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; LANE DP, 1985, PROC R SOC SER B-BIO, V226, P25, DOI 10.1098/rspb.1985.0077; Maniatis T., 1982, MOL CLONING; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; POLLWEIN P, 1987, NUCLEIC ACIDS RES, V15, P9741, DOI 10.1093/nar/15.23.9741; PULM W, 1985, MOL CELL BIOL, V5, P295; RIO D, 1980, P NATL ACAD SCI-BIOL, V77, P5706, DOI 10.1073/pnas.77.10.5706; ROBBINS PD, 1986, MOL CELL BIOL, V6, P1283, DOI 10.1128/MCB.6.4.1283; RYDER K, 1985, CELL, V42, P539, DOI 10.1016/0092-8674(85)90111-4; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHEFFNER M, 1989, NUCLEIC ACIDS RES, V17, P93, DOI 10.1093/nar/17.1.93; SCHORPP M, 1988, J MOL BIOL, V199, P83, DOI 10.1016/0022-2836(88)90380-4; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1987, BIOCHIM BIOPHYS ACTA, V910, P1, DOI 10.1016/0167-4781(87)90088-1; TOOZE J, 1982, MOL BIOL TUMOR VIRUS, V2; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	37	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					353	359						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2156208				2022-12-17	WOS:A1990CW41500013
J	LAVIALLE, C				LAVIALLE, C			CORRECTION	ONCOGENE			English	Correction, Addition													Lavialle, Christian/O-2329-2019					CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; LAVIALLE C, 1988, ONCOGENE, V3, P335; LEIBOVITZ A, 1979, J NATL CANCER I, V63, P635, DOI 10.1093/jnci/63.3.635; SUAREZ HG, 1987, ONCOGENE RES, V1, P201	5	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					245	245						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029					2022-12-17	WOS:A1990CU02900013
J	QUINLAN, MP				QUINLAN, MP			THE AD5 12S GROWTH-FACTOR INDUCES F9 CELL-PROLIFERATION AND DIFFERENTIATION	ONCOGENE			English	Note									COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOX NW, 1984, DEV BIOL, V103, P263, DOI 10.1016/0012-1606(84)90028-9; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HARLAND R, 1988, TRENDS GENET, V4, P62, DOI 10.1016/0168-9525(88)90041-8; Hogan B. L. M, 1983, CANCER SURV, V2, P115; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KNOWLES BB, 1980, NATURE, V288, P615, DOI 10.1038/288615a0; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1986, CANCER CELL, V4, P327; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOLTER D, 1979, DEV BIOL, V70, P515, DOI 10.1016/0012-1606(79)90043-5; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAUB M, 1984, METHODS SERUM FREE C, V2; TOGARI A, 1985, J NEUROSCI, V5, P307; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	23	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1051	1055						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2569707				2022-12-17	WOS:A1989AJ29700017
J	ROVERA, G; REICHARD, BA; HUDSON, S; BITTENBENDER, S; YAMADA, M; TOURNAY, O; PREISLER, HD				ROVERA, G; REICHARD, BA; HUDSON, S; BITTENBENDER, S; YAMADA, M; TOURNAY, O; PREISLER, HD			POINT MUTATIONS IN BOTH TRANSFORMING AND NON-TRANSFORMING CODONS OF THE N-RAS PROTO-ONCOGENE OF PH+ LEUKEMIAS	ONCOGENE			English	Article									UNIV CINCINNATI,BARRETT CANC CTR,CINCINNATI,OH 45221; UNIV CINCINNATI,DIV HEMATOL ONCOL,CINCINNATI,OH 45221	University of Cincinnati; University of Cincinnati	ROVERA, G (corresponding author), WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA 10816, CA 41285, CA 47983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047983, P01CA041285] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P548; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; COLLINS SJ, 1989, BLOOD, V73, P1028; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HIRAI H, 1987, BIOCHEM BIOPH RES CO, V147, P108, DOI 10.1016/S0006-291X(87)80093-1; HIRAI H, 1985, BLOOD, V66, P1371; JANSSEN JVG, 1987, P NATL ACAD SCI USA, V86, P9228; JANSSEN JWG, 1987, NUCLEIC ACIDS RES, V15, P5669, DOI 10.1093/nar/15.14.5669; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEMAISTRE A, 1989, BLOOD, V73, P889; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; Maniatis T., 1982, MOL CLONING; MAVILIO F, 1988, ONCOGENE, V4, P301; MURRAY M, 1987, CELL, V33, P749; NEEDLEMAN SW, 1986, BLOOD, V67, P753; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; PREISLER HD, 1988, CANCER GENET CYTOGEN, V32, P133, DOI 10.1016/0165-4608(88)90320-2; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SELIGER H, 1986, CHEM SCRIPTA, V26, P569; SHIH TY, 1979, P NATL ACAD SCI USA, V176, P5714	29	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					867	872						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666907				2022-12-17	WOS:A1989AE58400008
J	SMITH, KT; CAMPO, MS				SMITH, KT; CAMPO, MS			AMPLIFICATION OF SPECIFIC DNA-SEQUENCES IN C127 MOUSE CELLS TRANSFORMED BY BOVINE PAPILLOMAVIRUS TYPE-4	ONCOGENE			English	Article											SMITH, KT (corresponding author), BEATSON INST CANC RES,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; AMTMANN E, 1985, EXP CELL RES, V161, P541, DOI 10.1016/0014-4827(85)90109-0; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CAMPO MS, 1985, EMBO J, V4, P1819, DOI 10.1002/j.1460-2075.1985.tb03856.x; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0; HEILBRONN R, 1985, INT J CANCER, V36, P85, DOI 10.1002/ijc.2910360114; LEHN H, 1985, P NATL ACAD SCI USA, V82, P5540, DOI 10.1073/pnas.82.16.5540; MACNAB JCM, 1987, J GEN VIROL, V68, P2525, DOI 10.1099/0022-1317-68-10-2525; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; OCADIZ R, 1987, CANCER RES, V47, P4173; RIOU G, 1988, ONCOGENE, V3, P329; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0	15	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					409	413						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2541389				2022-12-17	WOS:A1989U567700003
J	AMSON, RB; MARCELLE, C; TELERMAN, A				AMSON, RB; MARCELLE, C; TELERMAN, A			IDENTIFICATION OF A 130 KDA BCR RELATED GENE-PRODUCT	ONCOGENE			English	Article									FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,CAMPUS ERASME,BLDG C,ROUTE LENNIK 808,B-1070 BRUSSELS,BELGIUM; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Weizmann Institute of Science								BARTRAM CR, 1985, EMBO J, V4, P683, DOI 10.1002/j.1460-2075.1985.tb03683.x; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BUDARF M, 1988, Genomics, V3, P168, DOI 10.1016/0888-7543(88)90149-8; CANAANI E, 1984, LANCET, V1, P593; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GREENBERG ME, 1983, CELL, V33, P767, DOI 10.1016/0092-8674(83)90019-3; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LIFSHITZ B, 1988, ONCOGENE, V2, P113; NALDINI L, 1986, MOL CELL BIOL, V6, P1803, DOI 10.1128/MCB.6.5.1803; NOWELL PC, 1960, SCIENCE, V132, P1497; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263	29	13	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					243	247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2494632				2022-12-17	WOS:A1989U567500017
J	BRADY, G; WILLIAMS, RL; NORDSTROM, K; VENNSTROM, B; ISCOVE, NN				BRADY, G; WILLIAMS, RL; NORDSTROM, K; VENNSTROM, B; ISCOVE, NN			A SELECTABLE TEMPERATURE-SENSITIVE V-SRC MOLONEY RETROVIRUS	ONCOGENE			English	Article									EUROPEAN MOLEC BIOL LAB, D-6900 HEIDELBERG, FED REP GER; KAROLINSKA INST, CMB, S-10401 STOCKHOLM 60, SWEDEN	European Molecular Biology Laboratory (EMBL); Karolinska Institutet	BRADY, G (corresponding author), ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA.							ANDERSON SM, 1987, VIROLOGY, V160, P263, DOI 10.1016/0042-6822(87)90070-5; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BOULTER CA, 1988, ONCOGENE, V2, P207; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GRAF T, 1973, VIROLOGY, V56, P369, DOI 10.1016/0042-6822(73)90314-0; GRAF T, 1976, VIROLOGY, V72, P283, DOI 10.1016/0042-6822(76)90332-9; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; WATSON JD, 1987, J IMMUNOL, V139, P123; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	19	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1988	3	6					687	689						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2485257				2022-12-17	WOS:A1988R646000010
J	IGUCHIARIGA, SMM; OKAZAKI, T; ITANI, T; ARIGA, H				IGUCHIARIGA, SMM; OKAZAKI, T; ITANI, T; ARIGA, H			CLONING OF THE P53-DEPENDENT ORIGIN OF CELLULAR DNA-REPLICATION	ONCOGENE			English	Article									UNIV TOKYO,INST MED SCI,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				ARIGA H, 1984, MOL CELL BIOL, V4, P1476, DOI 10.1128/MCB.4.8.1476; ARIGA H, 1987, MOL CELL BIOL, V7, P1; ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FAVERA R D, 1982, Nature (London), V299, P61, DOI 10.1038/299061a0; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; ITANI T, 1987, GENE, V56, P267; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; PAPABADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P484; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					509	515						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2978868				2022-12-17	WOS:A1988R516300004
J	MAHADEVAN, LC; HEATH, JK; LEICHTFRIED, FE; CUMMING, DVE; HIRST, EMA; FOULKES, JG				MAHADEVAN, LC; HEATH, JK; LEICHTFRIED, FE; CUMMING, DVE; HIRST, EMA; FOULKES, JG			RAPID APPEARANCE OF NOVEL PHOSPHOPROTEINS IN THE NUCLEI OF MITOGEN-STIMULATED FIBROBLASTS	ONCOGENE			English	Article									NATL INST MED RES,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND; NATL INST MED RES,CELL SURFACE INTERACT LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research; MRC National Institute for Medical Research								AARONSON RP, 1975, P NATL ACAD SCI USA, V72, P1007, DOI 10.1073/pnas.72.3.1007; BELL JC, 1987, NATURE, V235, P552; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BERRIDGE MJ, 1986, ONCOGENES GROWTH CON, P147; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BRAVO R, 1986, ONCOGENES GROWTH CON, P253; CIRILLO DM, 1986, MOL CELL BIOL, V6, P4641, DOI 10.1128/MCB.6.12.4641; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DOWNES CP, 1985, MOL ASPECTS CELLULAR, V4, P3; EVERED D, 1986, CIBA F S; FOULKES JG, 1985, MOL ASPECTS CELL REG, V4, P217; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HEATH JK, 1986, EMBO J, V5, P1809, DOI 10.1002/j.1460-2075.1986.tb04430.x; HEATH JK, 1984, EMBO J, V3, P2957, DOI 10.1002/j.1460-2075.1984.tb02240.x; HEATH JK, 1987, TERATOCARCINOMAS EMB; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1986, ONCOGENES GROWTH CON, P138; ISACKE CM, 1986, EMBO J, V5, P2889, DOI 10.1002/j.1460-2075.1986.tb04584.x; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MCKEON FD, 1984, CELL, V36, P83, DOI 10.1016/0092-8674(84)90076-X; MOOLENAAR WH, 1986, ONCOGENES GROWTH CON, P170; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARKER PJ, 1986, ONCOGENES GROWTH CON, P154; POUYSSEGUR J, 1985, CANCER CELL, V3, P409; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; THOMAS G, 1986, ONCOGENES GROWTH CON, P177; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; USHIRO H, 1980, J BIOL CHEM, V255, P8363	41	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					249	257						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3353115				2022-12-17	WOS:A1988M593100007
J	BASTIEN, C; FEUNTEUN, J				BASTIEN, C; FEUNTEUN, J			THE HAMSTER POLYOMAVIRUS TRANSFORMING PROPERTIES	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy			Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				ACHESON NH, 1978, P NATL ACAD SCI USA, V75, P4754, DOI 10.1073/pnas.75.10.4754; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DELMAS V, 1985, EMBO J, V4, P1279, DOI 10.1002/j.1460-2075.1985.tb03773.x; GRAFFI A, 1970, COMP LEUK RES BIBLIO, V36, P293; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; MENEGUZZI G, 1984, EMBO J, V3, P365, DOI 10.1002/j.1460-2075.1984.tb01813.x; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZOUZIAS D, 1977, J VIROL, V24, P142, DOI 10.1128/JVI.24.1.142-150.1977	14	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					129	135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285292				2022-12-17	WOS:A1988M086000005
J	SAKSELA, K				SAKSELA, K			EXPRESSION OF THE L-MYC GENE IS UNDER POSITIVE CONTROL BY SHORT-LIVED PROTEINS	ONCOGENE			English	Article											SAKSELA, K (corresponding author), UNIV HELSINKI,DEPT VIROL,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND.							ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERGH J, 1984, LAB INVEST, V51, P307; BERGH J, 1985, AM J CLIN PATHOL, V84, P1; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CARNEY DN, 1985, CANCER RES, V45, P2913; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNA K, 1987, IN PRESS AM J CLIN P; GAZDAR AF, 1985, CANCER RES, V45, P2924; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GROSSO LE, 1985, CANCER RES, V45, P847; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MINNA JD, 1986, COLD SPRING HARB SYM, V51, P843, DOI 10.1101/SQB.1986.051.01.098; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISEN PD, 1986, CANCER RES, V46, P6217; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RADICE PA, 1982, CANCER-AM CANCER SOC, V50, P2894, DOI 10.1002/1097-0142(19821215)50:12<2894::AID-CNCR2820501232>3.0.CO;2-G; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SAKSELA K, 1986, J CELL BIOCHEM, V31, P297, DOI 10.1002/jcb.240310407; SAKSELA K, 1985, CANCER RES, V45, P1823; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	50	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					291	296						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	2838780				2022-12-17	WOS:A1987J970500009
J	Bischoff, P; Trinks, A; Obermayer, B; Pett, JP; Wiederspahn, J; Uhlitz, F; Liang, XZ; Lehmann, A; Jurmeister, P; Elsner, A; Dziodzio, T; Ruckert, JC; Neudecker, J; Falk, C; Beule, D; Sers, C; Morkel, M; Horst, D; Bluthgen, N; Klauschen, F				Bischoff, Philip; Trinks, Alexandra; Obermayer, Benedikt; Pett, Jan Patrick; Wiederspahn, Jennifer; Uhlitz, Florian; Liang, Xizi; Lehmann, Annika; Jurmeister, Philipp; Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens; Falk, Christine; Beule, Dieter; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick			Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma	ONCOGENE			English	Article							TO-MACROPHAGE DIFFERENTIATION; INTERNATIONAL ASSOCIATION; GENE-EXPRESSION; CLASSIFICATION; SIGNATURES; DENSITY	Recent developments in immuno-oncology demonstrate that not only cancer cells, but also the tumor microenvironment can guide precision medicine. A comprehensive and in-depth characterization of the tumor microenvironment is challenging since its cell populations are diverse and can be important even if scarce. To identify clinically relevant microenvironmental and cancer features, we applied single-cell RNA sequencing to ten human lung adenocarcinomas and ten normal control tissues. Our analyses revealed heterogeneous carcinoma cell transcriptomes reflecting histological grade and oncogenic pathway activities, and two distinct microenvironmental patterns. The immune-activated (CPE)-E-2 microenvironment was composed of cancer-associated myofibroblasts, proinflammatory monocyte-derived macrophages, plasmacytoid dendritic cells and exhausted CD8+ T cells, and was prognostically unfavorable. In contrast, the inert (NMC)-M-3 microenvironment was characterized by normal-like myofibroblasts, non-inflammatory monocyte-derived macrophages, NK cells, myeloid dendritic cells and conventional T cells, and was associated with a favorable prognosis. Microenvironmental marker genes and signatures identified in single-cell profiles had progonostic value in bulk tumor profiles. In summary, single-cell RNA profiling of lung adenocarcinoma provides additional prognostic information based on the microenvironment, and may help to predict therapy response and to reveal possible target cell populations for future therapeutic approaches.	[Bischoff, Philip; Trinks, Alexandra; Wiederspahn, Jennifer; Liang, Xizi; Lehmann, Annika; Jurmeister, Philipp; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Bischoff, Philip; Trinks, Alexandra; Wiederspahn, Jennifer; Liang, Xizi; Lehmann, Annika; Jurmeister, Philipp; Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick] Free Univ Berlin, Berlin, Germany; [Bischoff, Philip; Trinks, Alexandra; Wiederspahn, Jennifer; Liang, Xizi; Lehmann, Annika; Jurmeister, Philipp; Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick] Humboldt Univ, Berlin, Germany; [Bischoff, Philip; Trinks, Alexandra; Jurmeister, Philipp; Dziodzio, Tomasz; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany; [Obermayer, Benedikt; Pett, Jan Patrick; Beule, Dieter] Charite Univ Med Berlin, Core Unit Bioinformat CUBI, Berlin Inst Hlth, Berlin, Germany; [Wiederspahn, Jennifer; Uhlitz, Florian; Bluethgen, Nils] Humboldt Univ, IRI Life Sci, Berlin, Germany; [Uhlitz, Florian; Jurmeister, Philipp; Sers, Christine; Morkel, Markus; Horst, David; Bluethgen, Nils; Klauschen, Frederick] German Canc Res Ctr, German Canc Consortium DKTK Partner Site Berlin, Heidelberg, Germany; [Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens] Charite Univ Med Berlin, Dept Surg, Campus Charite Mitte, Berlin, Germany; [Elsner, Aron; Dziodzio, Tomasz; Rueckert, Jens-Carsten; Neudecker, Jens] Charite Univ Med Berlin, Dept Surg, Campus Virchow Klinikum, Berlin, Germany; [Falk, Christine] Hannover Med Sch, Inst Transplant Immunol, Hannover, Germany; [Falk, Christine] German Ctr Infect Dis DZIF, TTU IICH Hannover Braunschweig Site, Braunschweig, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School; German Center for Infection Research	Bischoff, P (corresponding author), Charite Univ Med Berlin, Inst Pathol, Berlin, Germany.; Bischoff, P (corresponding author), Free Univ Berlin, Berlin, Germany.; Bischoff, P (corresponding author), Humboldt Univ, Berlin, Germany.; Bischoff, P (corresponding author), Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany.	philip.bischoff@charite.de	Sers, Christine/B-5438-2010; Klauschen, Frederick/C-5637-2015; Bischoff, Philip/HHC-2955-2022	Klauschen, Frederick/0000-0002-9131-2389; Morkel, Markus/0000-0002-2553-9999; Lehmann, Annika/0000-0001-9424-5882; Bischoff, Philip/0000-0002-4442-7116; Beule, Dieter/0000-0002-3284-0632; Trinks, Alexandra/0000-0001-9983-1506; von Schlichting, Jennifer/0000-0003-0117-9754; Obermayer, Benedikt/0000-0002-9116-630X; Dziodzio, Tomasz/0000-0002-3337-4573; Sers, christine/0000-0002-6219-1514	Berlin Institute of Health; German Cancer Consortium DKTK; German Research Foundation DFG [RTG2424 CompCancer]; Einstein Foundation/Stiftung Charite; Charite-Universitatsmedizin Berlin; Projekt DEAL	Berlin Institute of Health; German Cancer Consortium DKTK; German Research Foundation DFG(German Research Foundation (DFG)); Einstein Foundation/Stiftung Charite; Charite-Universitatsmedizin Berlin; Projekt DEAL	The work was in part funded by the Berlin Institute of Health (to PB, PJ, DH, MM, CS, and NB), the German Cancer Consortium DKTK (to MM and NB), the German Research Foundation DFG (RTG2424 CompCancer to NB) and the Einstein Foundation/Stiftung Charite (to NB). PB is participant in the BIH-Charite Junior Clinician Scientist Program funded by the Charite-Universitatsmedizin Berlin and the Berlin Institute of Health. PJ is participant in the BIH-Charite Digital Clinician Scientist Program funded by the Charite-Universitatsmedizin Berlin and the Berlin Institute of Health and the German Research Foundation (DFG). Open Access funding enabled and organized by Projekt DEAL.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Braga FAV, 2019, NAT MED, V25, P1153, DOI 10.1038/s41591-019-0468-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Conway EM, 2016, AM J RESP CRIT CARE, V193, P116, DOI 10.1164/rccm.201508-1545CI; Donnem T, 2015, CLIN CANCER RES, V21, P2635, DOI 10.1158/1078-0432.CCR-14-1905; Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x; Franklin RA, 2016, TRENDS CANCER, V2, P20, DOI 10.1016/j.trecan.2015.11.004; Gao Y, 2018, INT J CANCER, V143, P931, DOI 10.1002/ijc.31357; Geng YT, 2015, CELL PHYSIOL BIOCHEM, V37, P1560, DOI 10.1159/000438523; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Habermann AC, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1972; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1874-1; Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Holland CH, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1949-z; House IG, 2020, CLIN CANCER RES, V26, P487, DOI 10.1158/1078-0432.CCR-19-1868; Huang JB, 2020, CANCER SCI, V111, P1876, DOI 10.1111/cas.14390; Inoue C, 2019, VIRCHOWS ARCH, V475, P181, DOI 10.1007/s00428-019-02587-9; Ito M, 2012, CHEST, V142, P151, DOI 10.1378/chest.11-2458; Jiang WQ, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622509; Jiang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.162; Kim N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16164-1; Koucky V, 2019, CANCERS, V11, DOI 10.3390/cancers11040470; Kubouchi Y, 2018, HISTOPATHOLOGY, V72, P490, DOI 10.1111/his.13390; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin JR, 2018, ELIFE, V7, DOI 10.7554/eLife.31657; Lin ZY, 2019, J CANCER, V10, P211, DOI 10.7150/jca.26444; Liu YY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10992; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Memon H, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.116713; Mohrherr J, 2019, INT J CANCER, V145, P3376, DOI 10.1002/ijc.32624; Molina-Romero C, 2017, HUM PATHOL, V66, P188, DOI 10.1016/j.humpath.2017.06.002; Moreira AL, 2020, J THORAC ONCOL, V15, P1599, DOI 10.1016/j.jtho.2020.06.001; Niemira M, 2020, CANCERS, V12, DOI 10.3390/cancers12010037; Ojlert AK, 2019, MOL ONCOL, V13, P1166, DOI 10.1002/1878-0261.12475; Okazaki T, 2018, J THORAC ONCOL, V13, pS523, DOI 10.1016/j.jtho.2018.08.712; Parra ER, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0368-0; Patel AJ, 2020, CANCER IMMUNOL IMMUN, V69, P325, DOI 10.1007/s00262-019-02461-2; Peng H, PROFILING TUMOR IMMU, V2021, DOI 10.1101/2021.05.28.446005; Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9; Qu Y, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107873; Rajewsky N, 2020, NATURE, V587, P377, DOI 10.1038/s41586-020-2715-9; Schalper KA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju435; Schubert M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02391-6; Shi JL, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.01.82; Sholl LM, 2020, J THORAC ONCOL, V15, P1409, DOI 10.1016/j.jtho.2020.05.019; Solberg R, 2015, BIOL CHEM, V396, P71, DOI 10.1515/hsz-2014-0172; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Stahl PL, 2016, SCIENCE, V353, P78, DOI 10.1126/science.aaf2403; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/NMETH.4380, 10.1038/nmeth.4380]; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Tam SY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00486; Tan AC, 2020, THORAC CANCER, V11, P511, DOI 10.1111/1759-7714.13328; Tao Y, 2020, FUTURE ONCOL, V16, P1825, DOI 10.2217/fon-2019-0829; Tata PR, 2017, DEVELOPMENT, V144, P755, DOI 10.1242/dev.143784; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Travaglini KJ, 2020, NATURE, V587, DOI 10.1038/s41586-020-2922-4; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Wakelee HA, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.07.2983; Wrangle JM, 2018, LANCET ONCOL, V19, P694, DOI 10.1016/S1470-2045(18)30148-7; Xu NZ, 2019, J HISTOCHEM CYTOCHEM, V67, P453, DOI 10.1369/0022155419829050; Yang HR, 2019, MOL THER-ONCOLYTICS, V14, P82, DOI 10.1016/j.omto.2019.03.012; Yoshida GJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01611-0; Zhang S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01242	76	12	12	7	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6748	6758		10.1038/s41388-021-02054-3	http://dx.doi.org/10.1038/s41388-021-02054-3		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34663877	hybrid, Green Submitted, Green Accepted, Green Published			2022-12-17	WOS:000708355700001
J	Wang, BK; Zhang, W; Zhang, G; Kwong, L; Lu, HZ; Tan, JF; Sadek, N; Xiao, M; Zhang, J; Labrie, M; Randell, S; Beroard, A; Sugarman, E; Rebecca, VW; Wei, Z; Lu, YL; Mills, GB; Field, J; Villanueva, J; Xu, XW; Herlyn, M; Guo, W				Wang, Beike; Zhang, Wei; Zhang, Gao; Kwong, Lawrence; Lu, Hezhe; Tan, Jiufeng; Sadek, Norah; Xiao, Min; Zhang, Jie; Labrie, Marilyne; Randell, Sergio; Beroard, Aurelie; Sugarman, Eric; Rebecca, Vito W.; Wei, Zhi; Lu, Yiling; Mills, Gordon B.; Field, Jeffrey; Villanueva, Jessie; Xu, Xiaowei; Herlyn, Meenhard; Guo, Wei			Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma	ONCOGENE			English	Article							GENE COPY NUMBER; MAMMALIAN TARGET; PHASE-II; ADAPTIVE RESISTANCE; PROTEIN EXPRESSION; CONFER RESISTANCE; RAPAMYCIN MTOR; MAPK PATHWAY; CANCER; AKT	Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient strategy to treat melanoma harboring BRAF-mutation. The development of acquired resistance is inevitable due to the signaling pathway rewiring. Combining western blotting, immunohistochemistry, and reverse phase protein array (RPPA), we aim to understanding the role of the mTORC1 signaling pathway, a center node of intracellular signaling network, in mediating drug resistance of BRAF-mutant melanoma to the combination of BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) therapy. The mTORC1 signaling pathway is initially suppressed by BRAFi and MEKi combination in melanoma but rebounds overtime after tumors acquire resistance to the combination therapy (CR) as assayed in cultured cells and PDX models. In vitro experiments showed that a subset of CR melanoma cells was sensitive to mTORC1 inhibition. The mTOR inhibitors, rapamycin and NVP-BEZ235, induced cell cycle arrest and apoptosis in CR cell lines. As a proof-of-principle, we demonstrated that rapamycin and NVP-BEZ235 treatment reduced tumor growth in CR xenograft models. Mechanistically, AKT or ERK contributes to the activation of mTORC1 in CR cells, depending on PTEN status of these cells. Our study reveals that mTOR activation is essential for drug resistance of melanoma to MAPK inhibitors, and provides insight into the rewiring of the signaling networks in CR melanoma.	[Wang, Beike; Zhang, Wei; Guo, Wei] Univ Penn, Sch Arts & Sci, Dept Biol, Philadelphia, PA 19104 USA; [Zhang, Gao; Tan, Jiufeng; Sadek, Norah; Xiao, Min; Randell, Sergio; Beroard, Aurelie; Sugarman, Eric; Rebecca, Vito W.; Villanueva, Jessie; Herlyn, Meenhard] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program & Melanoma Res, 3601 Spruce St, Philadelphia, PA 19104 USA; [Kwong, Lawrence] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Lu, Hezhe] Mt Sinai Hosp, Ctr Syst Biol, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Zhang, Jie; Wei, Zhi] New Jersey Inst Technol, Dept Comp Sci, Newark, NJ 07102 USA; [Labrie, Marilyne; Mills, Gordon B.] Oregon Hlth & Sci Univ, Sch Med, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Labrie, Marilyne; Mills, Gordon B.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Lu, Yiling] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Div Canc Med, Houston, TX 77030 USA; [Field, Jeffrey] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA; [Xu, Xiaowei] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Zhang, Gao] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA; [Zhang, Gao] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	University of Pennsylvania; The Wistar Institute; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; New Jersey Institute of Technology; Oregon Health & Science University; Oregon Health & Science University; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Duke University; Duke University	Guo, W (corresponding author), Univ Penn, Sch Arts & Sci, Dept Biol, Philadelphia, PA 19104 USA.; Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program & Melanoma Res, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org; guowei@sas.upenn.edu		Labrie, Marilyne/0000-0003-3957-5533	NIH [R35GM141832, P01 CA114046, P50 CA174523, U54 CA224070]; DoD PRCRP [WX1XWH-16-1-0119 [CA150619]]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD PRCRP	This work was supported by NIH R35GM141832, P01 CA114046, P50 CA174523, U54 CA224070, DoD PRCRP WX1XWH-16-1-0119 [CA150619], and a kind gift from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation to MH and GBM.	Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Ali M, 2017, BMB REP, V50, P601, DOI 10.5483/BMBRep.2017.50.12.206; Amaral T, 2017, EUR J CANCER, V73, P93, DOI 10.1016/j.ejca.2016.12.012; Atefi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028973; Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012; Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572; Carlo MI, 2016, ONCOLOGIST, V21, P787, DOI 10.1634/theoncologist.2016-0145; Corcoran RB, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005753; Corcoran RB, 2011, ONCOTARGET, V2, P336; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng W, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2011.00950.x; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; El Zaoui I, 2019, INVEST OPHTH VIS SCI, V60, P2764, DOI 10.1167/iovs.18-26508; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Fazio N, 2016, ANTICANCER RES, V36, P713; Gopal YNV, 2014, CANCER RES, V74, P7037, DOI 10.1158/0008-5472.CAN-14-1392; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Iadevaia V, 2012, BIOCHEM SOC T, V40, P168, DOI 10.1042/BST20110682; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; John T, 2009, ONCOGENE, V28, pS14, DOI 10.1038/onc.2009.197; Kappelmann-Fenzl M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1821-9; Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363; Krepler C, 2017, CELL REP, V21, P1953, DOI 10.1016/j.celrep.2017.10.021; Krepler C, 2016, CLIN CANCER RES, V22, P1592, DOI 10.1158/1078-0432.CCR-15-1762; Kumar SM, 2005, AM J PATHOL, V166, P823, DOI 10.1016/S0002-9440(10)62303-6; Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178; Kwong LN, 2015, J CLIN INVEST, V125, P1459, DOI 10.1172/JCI78954; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Libutti S, 2015, NEUROENDOCRINOLOGY, V102, P131; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694; LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018; Lu HZ, 2017, NATURE, V550, P133, DOI 10.1038/nature24040; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Menzies AM, 2014, LANCET ONCOL, V15, pE371, DOI 10.1016/S1470-2045(14)70072-5; Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Penna I, 2016, ONCOTARGET, V7, P3947, DOI 10.18632/oncotarget.6600; Pongas G, 2016, ONCOLOGIST, V21, P1033, DOI 10.1634/theoncologist.2016-0243; Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; Romano G, 2018, CANCER DISCOV, V8, P556, DOI 10.1158/2159-8290.CD-17-0745; Salazar R, 2015, J CLIN ONCOL, V33, P4102; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shi HB, 2014, CANCER DISCOV, V4, P69, DOI 10.1158/2159-8290.CD-13-0279; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Silva JM, 2014, MOL CANCER RES, V12, P447, DOI 10.1158/1541-7786.MCR-13-0224-T; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Subbiah V, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00189; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Sweetlove M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00135; Teh JLF, 2018, CANCER DISCOV, V8, P568, DOI 10.1158/2159-8290.CD-17-0699; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wang J, 2015, PIGM CELL MELANOMA R, V28, P572, DOI 10.1111/pcmr.12390; Welsh SJ, 2016, EUR J CANCER, V62, P76, DOI 10.1016/j.ejca.2016.04.005; Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zuo Q, 2018, ONCOGENE, V37, P3275, DOI 10.1038/s41388-018-0205-4	87	12	12	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5590	5599		10.1038/s41388-021-01911-5	http://dx.doi.org/10.1038/s41388-021-01911-5		JUL 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34304249	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000677232000002
J	Brahma, MK; Gilglioni, EH; Zhou, L; Trepo, E; Chen, PY; Gurzov, EN				Brahma, Manoja K.; Gilglioni, Eduardo H.; Zhou, Lang; Trepo, Eric; Chen, Pengyu; Gurzov, Esteban N.			Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges	ONCOGENE			English	Review							NONALCOHOLIC FATTY LIVER; PROTEIN-TYROSINE PHOSPHATASES; NITRIC-OXIDE SYNTHASE; BCL-2 FAMILY PROTEINS; NF-KAPPA-B; CO-DELIVERY; MITOCHONDRIAL-FUNCTION; REVERSIBLE OXIDATION; INSULIN SENSITIVITY; NLRP3 INFLAMMASOME	Obesity affects more than 650 million individuals worldwide and is a well-established risk factor for the development of hepatocellular carcinoma (HCC). Oxidative stress can be considered as a bona fide tumor promoter, contributing to the initiation and progression of liver cancer. Indeed, one of the key events involved in HCC progression is excessive levels of reactive oxygen species (ROS) resulting from the fatty acid influx and chronic inflammation. This review provides insights into the different intracellular sources of obesity-induced ROS and molecular mechanisms responsible for hepatic tumorigenesis. In addition, we highlight recent findings pointing to the role of the dysregulated activity of BCL-2 proteins and protein tyrosine phosphatases (PTPs) in the generation of hepatic oxidative stress and ROS-mediated dysfunctional signaling, respectively. Finally, we discuss the potential and challenges of novel nanotechnology strategies to prevent ROS formation in obesity-associated HCC.	[Brahma, Manoja K.; Gilglioni, Eduardo H.; Gurzov, Esteban N.] Univ Libre Bruxelles, Signal Transduct & Metab Lab, Lab Gastroenterol Expt & Endotools, Brussels, Belgium; [Zhou, Lang; Chen, Pengyu] Auburn Univ, Mat Res & Educ Ctr, Auburn, AL 36849 USA; [Trepo, Eric] Univ Libre Bruxelles, Dept Gastroenterol Hepatopancreatol & Digest Onco, CUB Hop Erasme, Brussels, Belgium; [Trepo, Eric] Univ Libre Bruxelles, Lab Expt Gastroenterol, Brussels, Belgium	Universite Libre de Bruxelles; Auburn University System; Auburn University; Universite Libre de Bruxelles; Universite Libre de Bruxelles	Gurzov, EN (corresponding author), Univ Libre Bruxelles, Signal Transduct & Metab Lab, Lab Gastroenterol Expt & Endotools, Brussels, Belgium.	esteban.gurzov@ulb.be	Trépo, Eric/ABD-9339-2021	BRAHMA, MANOJA/0000-0003-3191-0720; Gilglioni, Eduardo Hideo/0000-0001-5137-4051	Fonds National de la Recherche Scientifique (FNRS)-MIS grant [33650793]; FNRS-WELBIO grant [35112672]; FNRS-CDR grant [35275350]; European Research Council (ERC) Consolidator grant METAPTPs [GA817940]; JDRF Career Development Award [CDA-2019-758-A-N]; National Science Foundation grant [CBET-1943302]; National Institutes of Health grant [R35GM133795]	Fonds National de la Recherche Scientifique (FNRS)-MIS grant(Fonds de la Recherche Scientifique - FNRS); FNRS-WELBIO grant(Fonds de la Recherche Scientifique - FNRSWELBIO); FNRS-CDR grant; European Research Council (ERC) Consolidator grant METAPTPs(European Research Council (ERC)); JDRF Career Development Award(Juvenile Diabetes Research Foundation); National Science Foundation grant(National Science Foundation (NSF)); National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Pu Chun Ke for critical reading of the manuscript. This work was supported by Fonds National de la Recherche Scientifique (FNRS)-MIS grant (33650793), FNRS-WELBIO grant (35112672), FNRS-CDR grant (35275350), European Research Council (ERC) Consolidator grant METAPTPs (GA817940), a JDRF Career Development Award (CDA-2019-758-A-N), National Science Foundation grant (CBET-1943302) and National Institutes of Health grant (R35GM133795). E.T. and E.N.G. are Research Associates of the FNRS, Belgium.	Al-Serri A, 2012, J HEPATOL, V56, P448, DOI 10.1016/j.jhep.2011.05.029; Anstee QM, 2019, NAT REV GASTRO HEPAT, V16, P411, DOI 10.1038/s41575-019-0145-7; Baffy G, 2018, ADV EXP MED BIOL, V1061, P63, DOI 10.1007/978-981-10-8684-7_6; Bartneck Matthias, 2014, Hepatobiliary Surg Nutr, V3, P364, DOI 10.3978/j.issn.2304-3881.2014.11.02; Bedoui S, 2020, NAT REV MOL CELL BIO, V21, P678, DOI 10.1038/s41580-020-0270-8; Bellanti F, 2017, FREE RADICAL BIO MED, V111, P173, DOI 10.1016/j.freeradbiomed.2017.01.023; Bessone F, 2019, CELL MOL LIFE SCI, V76, P99, DOI 10.1007/s00018-018-2947-0; Bettaieb A, 2015, GASTROENTEROLOGY, V149, P468, DOI 10.1053/j.gastro.2015.04.009; Bhattacharya S, 2008, BIOORG MED CHEM LETT, V18, P5856, DOI 10.1016/j.bmcl.2008.06.029; Bian XL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14420; Boivin B, 2008, P NATL ACAD SCI USA, V105, P9959, DOI 10.1073/pnas.0804336105; Bourebaba L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051294; Broadfield LA, 2021, CANCER RES, V81, P1988, DOI 10.1158/0008-5472.CAN-20-1954; Brown KE, 2001, AM J PATHOL, V159, P2081, DOI 10.1016/S0002-9440(10)63059-3; Cao N, 2011, BIOMATERIALS, V32, P2222, DOI 10.1016/j.biomaterials.2010.11.061; Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851; Cheng HW, 2018, MAT SCI ENG C-MATER, V83, P210, DOI 10.1016/j.msec.2017.08.075; Cho CY, 2006, CELL METAB, V3, P367, DOI 10.1016/j.cmet.2006.03.006; D'Hollander A, 2017, BIOMATERIALS, V123, P15, DOI 10.1016/j.biomaterials.2017.01.007; Dai Q, 2014, ANGEW CHEM INT EDIT, V53, P5093, DOI 10.1002/anie.201309464; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Derdak Z, 2013, J HEPATOL, V58, P785, DOI 10.1016/j.jhep.2012.11.042; Dubois MJ, 2006, NAT MED, V12, P549, DOI 10.1038/nm1397; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Emdin CA, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008629; Fares R, 2015, LIVER INT, V35, P1574, DOI 10.1111/liv.12707; Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401; Fransen M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061126; Fukushima A, 2010, DIABETES, V59, P1906, DOI 10.2337/db09-1365; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Glick D, 2012, MOL CELL BIOL, V32, P2570, DOI 10.1128/MCB.00167-12; Goh GBB, 2016, DIGEST DIS SCI, V61, P1226, DOI 10.1007/s10620-016-4095-4; Grohmann M, 2018, CELL, V175, P1289, DOI 10.1016/j.cell.2018.09.053; Gross A, 2017, CELL DEATH DIFFER, V24, P1348, DOI 10.1038/cdd.2017.22; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Guri Y, 2017, CANCER CELL, V32, P807, DOI 10.1016/j.ccell.2017.11.011; Gurzov EN, 2015, TRENDS ENDOCRIN MET, V26, P30, DOI 10.1016/j.tem.2014.10.004; Gurzov EN, 2014, CELL METAB, V20, P85, DOI 10.1016/j.cmet.2014.05.011; Haque A, 2011, CELL, V147, P185, DOI 10.1016/j.cell.2011.08.036; Hsu MF, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101658; Huang YD, 2018, CANCERS, V10, DOI 10.3390/cancers10030082; Huang YQ, 2019, THERANOSTICS, V9, P4391, DOI 10.7150/thno.32462; Husseini UK, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4752-4; Kale J, 2018, CELL DEATH DIFFER, V25, P65, DOI 10.1038/cdd.2017.186; Kanda T, 2018, WORLD J GASTROENTERO, V24, P2661, DOI 10.3748/wjg.v24.i25.2661; Ke PC, 2017, ACS NANO, V11, P11773, DOI 10.1021/acsnano.7b08008; Kelkar SS, 2011, BIOCONJUGATE CHEM, V22, P1879, DOI 10.1021/bc200151q; Khan AA, 2016, BIOMED PHARMACOTHER, V81, P394, DOI 10.1016/j.biopha.2016.04.033; Kim J, 2021, J CONTROL RELEASE, V330, P920, DOI 10.1016/j.jconrel.2020.10.065; Kim M, 2017, CURR PHARM DESIGN, V23, P4226, DOI [10.2174/1381612823666170710145019, 10.2174/1381612823666170616082125]; Kim TH, 2016, ENDOCR-RELAT CANCER, V23, P813, DOI 10.1530/ERC-16-0219; Koliaki C, 2015, CELL METAB, V21, P739, DOI 10.1016/j.cmet.2015.04.004; Krishnan N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02252-2; Kumar M, 2014, CANCER RES, V74, P3271, DOI 10.1158/0008-5472.CAN-13-2015; Kumar P, 2022, ARCH PHYSIOL BIOCHEM, V128, P836, DOI 10.1080/13813455.2020.1733024; Lally JSV, 2019, CELL METAB, V29, P174, DOI 10.1016/j.cmet.2018.08.020; Lee S, 2017, ONCOTARGET, V8, P63370, DOI 10.18632/oncotarget.18812; Li DC, 2004, CANCER SCI, V95, P644, DOI 10.1111/j.1349-7006.2004.tb03323.x; Li XY, 2020, NUCLEIC ACIDS RES, V48, P8255, DOI 10.1093/nar/gkaa615; Liang S, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00017; Lismont C, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00035; Litwak SA, 2017, DIABETES, V66, P2973, DOI 10.2337/db17-0348; Liu DP, 2011, ANTIOXID REDOX SIGN, V15, P1669, DOI 10.1089/ars.2010.3644; Liu MX, 2018, ONCOGENE, V37, P1637, DOI 10.1038/s41388-017-0070-6; Liu MC, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00677-4; Llovet JM, 2021, NAT REV GASTRO HEPAT, V18, P293, DOI 10.1038/s41575-020-00395-0; Loh K, 2009, CELL METAB, V10, P260, DOI 10.1016/j.cmet.2009.08.009; Lou YW, 2008, FEBS J, V275, P69, DOI 10.1111/j.1742-4658.2007.06173.x; Loughran PA, 2005, P NATL ACAD SCI USA, V102, P13837, DOI 10.1073/pnas.0503926102; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Marquardt JU, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01421; Masarone M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9547613; Matsuo K, 2010, J BIOL CHEM, V285, P39750, DOI 10.1074/jbc.M110.153734; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Merino D, 2018, CANCER CELL, V34, P879, DOI 10.1016/j.ccell.2018.11.004; Mobasher MA, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.150; Nahon P, 2009, HEPATOLOGY, V50, P1484, DOI 10.1002/hep.23187; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Nakajima W., 2016, INTEGR CANC SCI THER, V3, P437, DOI [10.15761/icst.1000184, DOI 10.15761/ICST.1000184]; Ning Q, 2019, ACS APPL MATER INTER, V11, P10578, DOI 10.1021/acsami.9b00634; Nisha R, 2021, MOL PHARMACEUT, V18, P1102, DOI 10.1021/acs.molpharmaceut.0c01024; Nishida N, 2016, J GASTROEN HEPATOL, V31, P1646, DOI 10.1111/jgh.13318; Nishino T, 2008, FEBS J, V275, P3278, DOI 10.1111/j.1742-4658.2008.06489.x; Ostman A, 2011, J BIOCHEM, V150, P345, DOI 10.1093/jb/mvr104; Ramalho RM, 2006, EUR J GASTROEN HEPAT, V18, P21, DOI 10.1097/00042737-200601000-00005; Raza Sana, 2019, Hepatoma Res, V5, P42, DOI 10.20517/2394-5079.2019.014; Schneider J, 2018, CHEM RES TOXICOL, V31, P447, DOI 10.1021/acs.chemrestox.7b00329; Scotcher J, 2011, J AM SOC MASS SPECTR, V22, P888, DOI 10.1007/s13361-011-0088-x; Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3; Sparacino-Watkins CE, 2014, J BIOL CHEM, V289, P10345, DOI 10.1074/jbc.M114.555177; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Stolz DB, 2002, HEPATOLOGY, V36, P81, DOI 10.1053/jhep.2002.33716; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Sunny NE, 2017, TRENDS ENDOCRIN MET, V28, P250, DOI 10.1016/j.tem.2016.11.006; Susnow N, 2009, SEMIN CANCER BIOL, V19, P42, DOI 10.1016/j.semcancer.2008.12.002; Tanaka T, 1997, HEPATOLOGY, V26, P283, DOI 10.1002/hep.510260205; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tao JY, 2021, HEPATOLOGY, V74, P741, DOI 10.1002/hep.31730; Tian GX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00004; Tiganis T, 2011, TRENDS PHARMACOL SCI, V32, P82, DOI 10.1016/j.tips.2010.11.006; Tomita K, 2012, J HEPATOL, V57, P837, DOI 10.1016/j.jhep.2012.05.013; Tummala KS, 2014, CANCER CELL, V26, P826, DOI 10.1016/j.ccell.2014.10.002; Wali JA, 2018, CELL DEATH DIFFER, V25, P217, DOI 10.1038/cdd.2017.168; Wang B, 2010, J HEPATOL, V53, P508, DOI 10.1016/j.jhep.2010.03.026; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Wen YK, 2021, CELL MOL IMMUNOL, V18, P45, DOI 10.1038/s41423-020-00558-8; Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025; Wree A, 2014, HEPATOLOGY, V59, P898, DOI 10.1002/hep.26592; Xu E, 2012, DIABETES, V61, P1949, DOI 10.2337/db11-1502; Ye Z, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201706600; Yoboue ED, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0033-4; Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109; Yu M, 2018, ARTIF CELL NANOMED B, V46, P323, DOI 10.1080/21691401.2017.1307215; Zhang H, 2015, INT J NANOMED, V10, P1909, DOI 10.2147/IJN.S77125; Zhou Y., 2019, J NANOMATERIALS, V2019, P1	119	12	12	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5155	5167		10.1038/s41388-021-01950-y	http://dx.doi.org/10.1038/s41388-021-01950-y		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34290399	Green Accepted			2022-12-17	WOS:000677857200002
J	Prokakis, E; Dyas, A; Grun, R; Fritzsche, S; Bedi, U; Kazerouni, ZB; Kosinsky, RL; Johnsen, SA; Wegwitz, F				Prokakis, Evangelos; Dyas, Anna; Gruen, Regina; Fritzsche, Sonja; Bedi, Upasana; Kazerouni, Zahra B.; Kosinsky, Robyn L.; Johnsen, Steven A.; Wegwitz, Florian			USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; CANCER CELLS; RESISTANCE; SAGA; ACTIVATION; APOPTOSIS; UBIQUITINATION; TRANSCRIPTION; DEGRADATION; SENSITIVITY	The Ubiquitin-Specific Protease 22 (USP22) is a deubiquitinating subunit of the mammalian SAGA transcriptional co-activating complex. USP22 was identified as a member of the so-called "death-from-cancer" signature predicting therapy failure in cancer patients. However, the importance and functional role of USP22 in different types and subtypes of cancer remain largely unknown. In the present study, we leveraged human cell lines and genetic mouse models to investigate the role of USP22 in HER2-driven breast cancer (HER2(+)-BC) and demonstrate for the first time that USP22 is required for the tumorigenic properties in murine and human HER2(+)-BC models. To get insight into the underlying mechanisms, we performed transcriptome-wide gene expression analyses and identified the Unfolded Protein Response (UPR) as a pathway deregulated upon USP22 loss. The UPR is normally induced upon extrinsic or intrinsic stresses that can promote cell survival and recovery if shortly activated or programmed cell death if activated for an extended period. Strikingly, we found that USP22 actively suppresses UPR induction in HER2(+)-BC cells by stabilizing the major endoplasmic reticulum (ER) chaperone HSPA5. Consistently, loss of USP22 renders tumor cells more sensitive to apoptosis and significantly increases the efficiency of therapies targeting the ER folding capacity. Together, our data suggest that therapeutic strategies targeting USP22 activity may sensitize tumor cells to UPR induction and could provide a novel, effective approach to treat HER2(+)-BC.	[Prokakis, Evangelos; Dyas, Anna; Gruen, Regina; Fritzsche, Sonja; Kazerouni, Zahra B.; Kosinsky, Robyn L.; Johnsen, Steven A.; Wegwitz, Florian] Univ Med Ctr Gottingen, Dept Gen Visceral & Pediat Surg, Gottingen, Germany; [Dyas, Anna] Univ Cambridge, Hutchison MRC Res Ctr, MRC Canc Unit, Box 197,Cambridge Biomed Campus, Cambridge CB2 0XZ, England; [Fritzsche, Sonja; Wegwitz, Florian] Univ Med Ctr Gottingen, Dept Gynecol & Obstet, Gottingen, Germany; [Bedi, Upasana] Jawaharlal Nehru Univ, Chromatin Remodeling Lab, Sch Life Sci, New Delhi 110067, India; [Kosinsky, Robyn L.; Johnsen, Steven A.] Mayo Clin, Gene Regulatory Mech & Mol Epigenet Lab, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA	University of Cambridge; University of Gottingen; Jawaharlal Nehru University, New Delhi; Mayo Clinic	Johnsen, SA; Wegwitz, F (corresponding author), Univ Med Ctr Gottingen, Dept Gen Visceral & Pediat Surg, Gottingen, Germany.; Wegwitz, F (corresponding author), Univ Med Ctr Gottingen, Dept Gynecol & Obstet, Gottingen, Germany.; Johnsen, SA (corresponding author), Mayo Clin, Gene Regulatory Mech & Mol Epigenet Lab, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA.	johnsen.steven@mayo.edu; fwegwit@gwdg.de	Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Wegwitz, Florian/0000-0003-0750-6998; Fritzsche, Sonja/0000-0003-3335-3534; Prokakis, Dr. rer. nat. Evangelos/0000-0001-9297-1821	Deutsche Krebshilfe [111600]	Deutsche Krebshilfe(Deutsche Krebshilfe)	We would like to thank S. Bolte, N. Molitor and the staff of the European Neuroscience Institute Gottingen for assistance in the animal handling administration, F. Alves (Translational Molecular Imaging, Max Planck Institute for Experimental Medicine, Gottingen) for access to the IncuCyte (R) Live Cell Analysis System (Sartorius AG). Also, we would especially like to thank Xin Wang and Ana Patricia Kutschat for providing precious feedback to this work. Moreover, we would like to thank the TCGA Research Network for the free access of patient-derived mRNA-seq and survival data (https://www.cancer.gov/tcga).In addition, we would like to thank Dr. Wiebke Mobius (Max Planck Institute of Experimental Medicine Electron Microscopy Core Unit Dept. of Neurogenetics, Gottingen) for her technical support. This work was supported by funding from the Deutsche Krebshilfe to S.A.J. (111600).	Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006; Atanassov BS, 2016, MOL CELL, V62, P558, DOI 10.1016/j.molcel.2016.03.030; Bailly C, 2019, BIOCHEM PHARMACOL, V163, P269, DOI 10.1016/j.bcp.2019.02.038; Baumann J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2611-8; Brooks AC, 2014, J MOL CELL CARDIOL, V76, P138, DOI 10.1016/j.yjmcc.2014.08.011; Cai Z, 2020, J EXP MED, V217, DOI 10.1084/jem.20191174; Casas C, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00177; Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Chen X, 2011, J CELL BIOL, V192, P825, DOI 10.1083/jcb.201008090; Darini C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10138-8; Dittrich A, 2014, J MAMMARY GLAND BIOL, V19, P253, DOI 10.1007/s10911-014-9329-5; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Gao YY, 2014, FEBS LETT, V588, P878, DOI 10.1016/j.febslet.2014.02.016; Gennaro VJ, 2018, P NATL ACAD SCI USA, V115, pE9298, DOI 10.1073/pnas.1807704115; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Harbeck N, 2018, CURR OPIN OBSTET GYN, V30, P55, DOI 10.1097/GCO.0000000000000431; Hayner JN, 2018, BBA-GENE REGUL MECH, V1861, P72, DOI 10.1016/j.bbagrm.2018.01.002; Helmlinger D, 2017, TRENDS BIOCHEM SCI, V42, P850, DOI 10.1016/j.tibs.2017.09.001; Huang X, 2019, CANCER IMMUNOL RES, V7, P1580, DOI 10.1158/2326-6066.CIR-18-0910; Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022; Ishizawa J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac4380; Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598; Jeusset LMP, 2017, CANCERS, V9, DOI 10.3390/cancers9120167; Kim D, 2017, J CELL PHYSIOL, V232, P3664, DOI 10.1002/jcp.25841; Komurov K, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.25; Kopp MC, 2019, NAT STRUCT MOL BIOL, V26, P1053, DOI 10.1038/s41594-019-0324-9; Kosinsky RL, 2015, ONCOTARGET, V6, P37906, DOI 10.18632/oncotarget.5412; Kosinsky RL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2141-9; Kosinsky RL, 2020, CELL DEATH DIFFER, V27, P1328, DOI 10.1038/s41418-019-0420-8; Koutelou E, 2010, CURR OPIN CELL BIOL, V22, P374, DOI 10.1016/j.ceb.2010.03.005; Kumler I, 2014, CANCER TREAT REV, V40, P259, DOI 10.1016/j.ctrv.2013.09.002; Lang G, 2011, MOL CELL BIOL, V31, P3734, DOI 10.1128/MCB.05231-11; Lim C, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1137-y; Lin ZH, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.28; Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024; Ling SB, 2017, MOL ONCOL, V11, P682, DOI 10.1002/1878-0261.12067; Liu XL, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03435-y; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Martin-Perez R, 2014, CANCER RES, V74, P1766, DOI 10.1158/0008-5472.CAN-13-1747; McCann JJ, 2020, CANCER RES, V80, P430, DOI 10.1158/0008-5472.CAN-19-1033; McConkey DJ, 2017, BIOCHEM BIOPH RES CO, V482, P450, DOI 10.1016/j.bbrc.2016.11.047; Melo-Cardenas J, 2018, BLOOD, V132, P423, DOI 10.1182/blood-2017-10-811760; Millet A, 2016, J MED CHEM, V59, P8276, DOI 10.1021/acs.jmedchem.6b00547; Mishra VK, 2017, NUCLEIC ACIDS RES, V45, P6334, DOI 10.1093/nar/gkx212; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Ruggiero C, 2018, MOL CELL ENDOCRINOL, V474, P57, DOI 10.1016/j.mce.2018.02.010; Schoenhacker-Alte B, 2017, CANCER LETT, V404, P79, DOI 10.1016/j.canlet.2017.07.009; Shubin AV, 2016, ONCOTARGET, V7, P55863, DOI 10.18632/oncotarget.10150; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Wang L, 2014, EPIGENOMICS-UK, V6, P329, DOI [10.2217/EPI.14.22, 10.2217/epi.14.22]; Wang SL, 2020, CELL DEATH DIFFER, V27, P3131, DOI 10.1038/s41418-020-0568-2; Wang Y, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00612-y; Wienken M, 2016, MOL CELL, V61, P68, DOI 10.1016/j.molcel.2015.12.008; Xiao HB, 2015, BIOCHEM BIOPH RES CO, V460, P703, DOI 10.1016/j.bbrc.2015.03.093; Xu XW, 2017, CLIN CANCER RES, V23, P5123, DOI 10.1158/1078-0432.CCR-16-2191; Yang GH, 2000, TOXICOL APPL PHARM, V162, P207, DOI 10.1006/taap.1999.8842; Yao XL, 2020, AM J CANCER RES, V10, P838; Zhang HJ, 2018, CANCER LETT, V433, P186, DOI 10.1016/j.canlet.2018.07.002; Zhang J, 2017, ONCOTARGET, V8, P24728, DOI 10.18632/oncotarget.15798; Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679; Zhang T., 2020, EMBO MOL MED, V12, P1; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhang YX, 2011, J CANCER RES CLIN, V137, P1245, DOI 10.1007/s00432-011-0998-9; Zhou AD, 2016, NAT CELL BIOL, V18, P954, DOI 10.1038/ncb3396	69	12	12	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4004	4018		10.1038/s41388-021-01814-5	http://dx.doi.org/10.1038/s41388-021-01814-5		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	34007022	hybrid, Green Published			2022-12-17	WOS:000651700100001
J	Hutchinson, SA; Websdale, A; Cioccoloni, G; Roberg-Larsen, H; Lianto, P; Kim, B; Rose, A; Soteriou, C; Pramanik, A; Wastall, LM; Williams, BJ; Henn, MA; Chen, JJ; Ma, LQ; Moore, JB; Nelson, E; Hughes, TA; Thorne, JL				Hutchinson, Samantha A.; Websdale, Alex; Cioccoloni, Giorgia; Roberg-Larsen, Hanne; Lianto, Priscilia; Kim, Baek; Rose, Ailsa; Soteriou, Chrysa; Pramanik, Arindam; Wastall, Laura M.; Williams, Bethany J.; Henn, Madeline A.; Chen, Joy J.; Ma, Liqian; Moore, J. Bernadette; Nelson, Erik; Hughes, Thomas A.; Thorne, James L.			Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer	ONCOGENE			English	Article								Triple negative breast cancer (TNBC) is challenging to treat successfully because targeted therapies do not exist. Instead, systemic therapy is typically restricted to cytotoxic chemotherapy, which fails more often in patients with elevated circulating cholesterol. Liver x receptors are ligand-dependent transcription factors that are homeostatic regulators of cholesterol, and are linked to regulation of broad-affinity xenobiotic transporter activity in non-tumor tissues. We show that LXR ligands confer chemotherapy resistance in TNBC cell lines and xenografts, and that LXRalpha is necessary and sufficient to mediate this resistance. Furthermore, in TNBC patients who had cancer recurrences, LXRalpha and ligands were independent markers of poor prognosis and correlated with P-glycoprotein expression. However, in patients who survived their disease, LXRalpha signaling and P-glycoprotein were decoupled. These data reveal a novel chemotherapy resistance mechanism in this poor prognosis subtype of breast cancer. We conclude that systemic chemotherapy failure in some TNBC patients is caused by co-opting the LXRalpha:P-glycoprotein axis, a pathway highly targetable by therapies that are already used for prevention and treatment of other diseases.	[Hutchinson, Samantha A.; Websdale, Alex; Cioccoloni, Giorgia; Lianto, Priscilia; Soteriou, Chrysa; Moore, J. Bernadette; Thorne, James L.] Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England; [Hutchinson, Samantha A.] Inst Canc Res, London, England; [Roberg-Larsen, Hanne] Univ Oslo, Dept Chem, Oslo, Norway; [Kim, Baek; Wastall, Laura M.; Williams, Bethany J.] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England; [Rose, Ailsa; Pramanik, Arindam; Hughes, Thomas A.] Univ Leeds, Sch Med, Leeds, W Yorkshire, England; [Henn, Madeline A.; Chen, Joy J.; Ma, Liqian; Nelson, Erik] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL USA; [Nelson, Erik] Univ Illinois, Canc Ctr Illinois, Urbana, IL USA; [Nelson, Erik] Univ Illinois, Div Nutr Sci, Urbana, IL USA; [Nelson, Erik] Univ Illinois, Canc Ctr, Chicago, IL USA; [Nelson, Erik] Univ Illinois, Carl R Woese Inst Genom Biol, Anticanc Discovery Pets People Theme, Urbana, IL USA; [Hughes, Thomas A.; Thorne, James L.] Univ Leeds, Fac Med & Hlth, Leeds Breast Canc Res Grp, Leeds, W Yorkshire, England	University of Leeds; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oslo; University of Leeds; University of Leeds; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign; University of Leeds	Thorne, JL (corresponding author), Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England.; Hughes, TA (corresponding author), Univ Leeds, Sch Med, Leeds, W Yorkshire, England.; Hughes, TA; Thorne, JL (corresponding author), Univ Leeds, Fac Med & Hlth, Leeds Breast Canc Res Grp, Leeds, W Yorkshire, England.	t.hughes@leeds.ac.uk; j.l.thorne@leeds.ac.uk	Pramanik, Arindam/AAD-1192-2019; Hughes, Thomas A/O-8031-2015; Nelson, Erik/B-5158-2013	Pramanik, Arindam/0000-0002-5827-6267; Hughes, Thomas A/0000-0003-1169-3386; Ma, Liqian/0000-0002-0264-9263; Moore, J Bernadette/0000-0003-4750-1550; Kim, Baek/0000-0001-9759-7533; Hutchinson, Samantha/0000-0003-4780-2441; Nelson, Erik/0000-0002-8887-1905; Soteriou, Chrysa/0000-0002-2808-1215; Chen, Joy/0000-0002-3703-4787	Breast Cancer Action [3T57/9R17-02]; Breast Cancer UK [PO-180309]; University of Leeds School of Food Science and Nutrition; British Endocrine Society; National Cancer Institute of the National Institutes of Health [R01CA234025]; School of Food Science and Nutrition; Leeds Doctoral Scholarships	Breast Cancer Action; Breast Cancer UK; University of Leeds School of Food Science and Nutrition; British Endocrine Society; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); School of Food Science and Nutrition; Leeds Doctoral Scholarships	GC was supported by a grant funding from Breast Cancer Action (3T57/9R17-02). The human metabolite data collection and analysis, immunohistochemistry, and antibody validation performed by AW was supported by a grant from Breast Cancer UK (PO-180309) and by the University of Leeds School of Food Science and Nutrition. The British Endocrine Society provided an equipment award (NOV2016) allowing the development of the high throughput chemotherapy efflux assay. SAH, CS, and PL were supported with Leeds Doctoral Scholarships and School of Food Science and Nutrition consumables support. ERN was supported by the National Cancer Institute of the National Institutes of Health (R01CA234025).	Baek AE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00910-z; Bagegni NA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222358; Bauriaud-Mallet M, 2019, J STEROID BIOCHEM, V192, DOI 10.1016/j.jsbmb.2019.105390; Brennan SF, 2017, CRIT REV FOOD SCI, V57, P1999, DOI 10.1080/10408398.2012.724481; Chlebowski RT, 2006, JNCI-J NATL CANCER I, V98, P1767, DOI 10.1093/jnci/djj494; CLARE K, 1995, ATHEROSCLEROSIS, V118, P67, DOI 10.1016/0021-9150(95)05594-M; Dalenc F, 2017, J STEROID BIOCHEM, V169, P210, DOI 10.1016/j.jsbmb.2016.06.010; Das S, 2013, J BIOL CHEM, V288, P11824, DOI 10.1074/jbc.M112.432302; De Cicco P, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071514; Dias IHK, 2018, REDOX BIOL, V16, P139, DOI 10.1016/j.redox.2018.02.014; dos Santos CR, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-132; Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493; ElAli A, 2012, BRAIN PATHOL, V22, P175, DOI 10.1111/j.1750-3639.2011.00517.x; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Guillemot-Legris O, 2016, SCI REP-UK, V6, DOI 10.1038/srep19694; Hutchinson SA, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112618; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang L, 2019, J ONCOL, V2019, DOI 10.1155/2019/7479518; Kim B, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1625-y; Kim BJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0068422, 10.1371/journal.pone.0057460]; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liu BL, 2017, BREAST CANCER RES TR, V164, P1, DOI 10.1007/s10549-017-4246-0; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Nguyen VTM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10044; Poirot M, 2018, BIOCHEM PHARMACOL, V153, P75, DOI 10.1016/j.bcp.2018.01.046; Saint-Pol J, 2013, BRAIN RES, V1517, P1, DOI 10.1016/j.brainres.2013.04.008; Shahoei SH, 2019, ENDOCRINOLOGY, V160, P1573, DOI 10.1210/en.2019-00025; Sozen E, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8520746; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Tavazoie MF, 2018, CELL, V172, P825, DOI 10.1016/j.cell.2017.12.026; Thorne JL, 2020, P NUTR SOC, V79, P367, DOI 10.1017/S0029665120000099; Thorne JL, 2018, BBA-GENE REGUL MECH, V1861, P996, DOI 10.1016/j.bbagrm.2018.08.005; Toledo E, 2015, JAMA INTERN MED, V175, P1752, DOI 10.1001/jamainternmed.2015.4838; Wouters E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01811; Wu Q, 2013, CELL REP, V5, P637, DOI 10.1016/j.celrep.2013.10.006; Xia LY, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01907-7; Yang MY, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8030167	37	12	12	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2872	2883		10.1038/s41388-021-01720-w	http://dx.doi.org/10.1038/s41388-021-01720-w		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742124	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000630675000004
J	Ma, SQ; Zhang, L; Ren, Y; Dai, W; Chen, TQ; Luo, LP; Zeng, J; Mi, K; Lang, JY; Cao, BR				Ma, Shiqi; Zhang, Lu; Ren, Yuan; Dai, Wei; Chen, Tingqing; Luo, Liping; Zeng, Juan; Mi, Kun; Lang, Jinyi; Cao, Bangrong			Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer	ONCOGENE			English	Article								Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective against non-small cell lung cancer (NSCLC) with EGFR-activating mutations. The mechanisms underlying EGFR-TKI resistance are not fully understood. This study aimed to analyze the effects of seven EGFR ligands on EGFR-TKI sensitivity in NSCLC cells and patients. Cells with EGFR E746-A750del mutation were treated with recombinant EGFR ligands, and analyzed for cell viability, proliferation, and apoptosis. shRNA knockdown of endogenous Epiregulin (EREG) or overexpression of exogenous EREG and immunofluorescence experiments were carried out. Public gene expression datasets were used for tumor microenvironment and clinical assessment. Among the EGFR ligands, EREG significantly diminished cellular sensitivity to TKIs and was associated with decreased response to erlotinib in NSCLC patients. EREG induced AKT phosphorylation and attenuated TKI-induced cellular apoptosis in an ErbB2-dependent manner. EREG induced the formation of the EGFR/ErbB2 heterodimer regardless of gefitinib treatment. However, overexpression or knockdown of EREG in cancer cells had little impact on TKI sensitivity. Single-cell RNA sequencing data revealed that EREG was predominantly expressed in macrophages in the tumor microenvironment. In addition, EREG-enriched macrophage conditional medium induced EGFR-TKI resistance. These findings shed new light on the mechanism underlying EGFR-TKI resistance, and suggest macrophage-produced intratumoral EREG as a novel regulator and biomarker for EGFR-TKI therapy in NSCLC.	[Ma, Shiqi; Zhang, Lu; Ren, Yuan; Chen, Tingqing; Luo, Liping; Zeng, Juan; Mi, Kun; Lang, Jinyi; Cao, Bangrong] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Radiat Oncol Key Lab Sichuan Prov, Chengdu, Peoples R China; [Dai, Wei] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Thorac Surg, Chengdu, Peoples R China; [Cao, Bangrong] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Biobank, Chengdu, Peoples R China	University of Electronic Science & Technology of China; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China	Lang, JY; Cao, BR (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Radiat Oncol Key Lab Sichuan Prov, Chengdu, Peoples R China.; Cao, BR (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Biobank, Chengdu, Peoples R China.	langjy610@163.com; caobangrong@uestc.edu.cn		lang, jinyi/0000-0002-5406-8671; Luo, Liping/0000-0002-2673-9749	National Natural Science Foundation of China [81602731]; Science and Technology Department of Sichuan Province [2019YJ0573, 2020YJ0453]; Innovation Program of Sichuan Medical Association Science for Youth [Q18009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Sichuan Province; Innovation Program of Sichuan Medical Association Science for Youth	This work was supported by the National Natural Science Foundation of China (Grant No. 81602731), the Science and Technology Department of Sichuan Province (Grant Nos. 2019YJ0573 and 2020YJ0453), and the Innovation Program of Sichuan Medical Association Science for Youth (Grant No. Q18009).	Bauer AK, 2017, MOL CARCINOGEN, V56, P94, DOI 10.1002/mc.22475; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chen JC, 2016, PHYSIOL REV, V96, P1025, DOI 10.1152/physrev.00030.2015; De Luca A, 2008, J CELL PHYSIOL, V214, P559, DOI 10.1002/jcp.21260; Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Hsu CC, 2020, J THORAC ONCOL, V15, P50, DOI 10.1016/j.jtho.2019.09.006; Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008-5472.CAN-05-1556; Kakiuchi S, 2004, HUM MOL GENET, V13, P3029, DOI 10.1093/hmg/ddh331; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Kim TM, 2015, J THORAC ONCOL, V10, P1736, DOI 10.1097/JTO.0000000000000688; Lim B, 2020, CANCER CELL, V37, P456, DOI 10.1016/j.ccell.2020.03.008; Massip-Copiz M, 2018, J CELL BIOCHEM, V119, P2911, DOI 10.1002/jcb.26483; Mok T, 2016, LUNG CANCER, V98, P1, DOI 10.1016/j.lungcan.2016.04.023; Nagano T, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110212; Ono T, 2020, INVEST NEW DRUG, V38, P885, DOI 10.1007/s10637-020-00919-0; Poole JA, 2020, AM J PHYSIOL-LUNG C, V318, pL180, DOI 10.1152/ajplung.00039.2019; Recondo G, 2018, NAT REV CLIN ONCOL, V15, P694, DOI 10.1038/s41571-018-0081-4; Riese DJ, 2014, SEMIN CELL DEV BIOL, V28, P49, DOI 10.1016/j.semcdb.2014.03.005; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Santoni-Rugiu E, 2019, CANCERS, V11, DOI 10.3390/cancers11070923; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sunaga N, 2015, LUNG CANCER-TARGETS, V6, P91, DOI 10.2147/LCTT.S60427; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Vlaicu P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-197; Vollebergh MA, 2010, J THORAC ONCOL, V5, P1939, DOI 10.1097/JTO.0b013e3181f77a39; Wang YJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1277-x; Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703; Zhang J, 2008, CANCER PREV RES, V1, P201, DOI 10.1158/1940-6207.CAPR-08-0014; Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009	30	12	12	2	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2596	2609		10.1038/s41388-021-01734-4	http://dx.doi.org/10.1038/s41388-021-01734-4		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33750895				2022-12-17	WOS:000626816500002
J	Butti, R; Nimma, R; Kundu, G; Bulbule, A; Kumar, TVS; Gunasekaran, VP; Tomar, D; Kumar, D; Mane, A; Gill, SS; Patil, T; Weber, GF; Kundu, GC				Butti, Ramesh; Nimma, Ramakrishna; Kundu, Gautam; Bulbule, Anuradha; Kumar, Totakura V. S.; Gunasekaran, Vinoth Prasanna; Tomar, Deepti; Kumar, Dhiraj; Mane, Anupama; Gill, Satyajit S.; Patil, Tushar; Weber, Georg F.; Kundu, Gopal C.			Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression	ONCOGENE			English	Article								Tumor-stroma interactions are important determinants for the disease course in cancer. While stromal influence has been known to often play a tumor-promoting role, incomplete mechanistic insight into this phenomenon has prevented its therapeutic targeting. Stromal fibroblasts can be activated by tumor cells to differentiate into cancer-associated fibroblasts (CAFs), that exhibit the traits of myofibroblasts, and in turn, they increase cancer aggressiveness. Here, we report the crosstalk between the cancer cells and stromal fibroblasts that leads to tumor progression. The process is initiated by secretion of a chemokine like protein, osteopontin (OPN) from the cancer cells that differentiates the fibroblasts to myofibroblasts. Tumor-derived OPN achieves this transition by engaging CD44 and alpha v beta 3 integrins on the fibroblast surface, which mediates signaling via Akt and ERK to induce Twist1-dependent gene expression. The OPN-driven CAFs then secrete CXCL12, which in turn triggers epithelial to mesenchymal transition (EMT) in the tumor cells. OPN, produced by the cancer cells, and CXCL12, secreted by activated fibroblasts, are necessary and sufficient to perpetuate the crosstalk. Knocking out OPN in carcinogen-induced mammary tumors or knocking down OPN in cancer cells and fibroblast co-implanted xenografts abrogates myofibroblast differentiation, Twist1, and CXCL12 expression. OPN expression is correlated with CAF-specific gene signature as shown by breast tumor tissue microarray consisting of 100 patient specimens. Bioinformatics analyses have confirmed that the expression of OPN is significantly correlated with the expression of myofibroblast-specific markers as demonstrated in human breast carcinoma dataset of 2509 patients. Our findings describe OPN and CXCL12 act as compelling targets to curb the tumor-promoting features of the stromal components and further suggested that OPN-regulated CXCL12 network might act as potential therapeutic target for the management of CAF-mediated breast cancer progression.	[Butti, Ramesh; Nimma, Ramakrishna; Bulbule, Anuradha; Kumar, Totakura V. S.; Gunasekaran, Vinoth Prasanna; Tomar, Deepti; Kundu, Gopal C.] Natl Ctr Cell Sci, Pune, Maharashtra, India; [Kundu, Gautam] NIA, Baltimore, MD 21224 USA; [Mane, Anupama; Gill, Satyajit S.] Jehangir Hosp, Pune, Maharashtra, India; [Patil, Tushar] Yashwantrao Chavan Mem Hosp, Pune, Maharashtra, India; [Weber, Georg F.] Univ Cincinnati, Cincinnati, OH USA; [Kundu, Gopal C.] KIIT Deemed Univ, Inst Eminence, Sch Biotechnol, Bhubaneswar, Odisha, India; [Kundu, Gopal C.] KIIT Deemed Univ, Inst Eminence, Kalinga Inst Med Sci KIMS, Bhubaneswar, Odisha, India; [Kumar, Dhiraj] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Ohio; University of Cincinnati; Kalinga Institute of Industrial Technology (KIIT); Kalinga Institute of Industrial Technology (KIIT); University of Texas System; UTMD Anderson Cancer Center	Kundu, GC (corresponding author), Natl Ctr Cell Sci, Pune, Maharashtra, India.; Kundu, GC (corresponding author), KIIT Deemed Univ, Inst Eminence, Sch Biotechnol, Bhubaneswar, Odisha, India.; Kundu, GC (corresponding author), KIIT Deemed Univ, Inst Eminence, Kalinga Inst Med Sci KIMS, Bhubaneswar, Odisha, India.	gopalc.kundu@kiit.ac.in	Butti, Ramesh/ABF-7762-2021; Kumar, Dhiraj/AAJ-6305-2020	Kumar, Dhiraj/0000-0002-6085-5911; Gunasekaran, Vinoth prasanna/0000-0001-5610-0770	National Centre for Cell Science, Pune, India; Council of Scientific and Industrial Research (CSIR), Govt. of India; Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India; Intramural Research Program of the NIH, National Institute of Ageing	National Centre for Cell Science, Pune, India; Council of Scientific and Industrial Research (CSIR), Govt. of India(Council of Scientific & Industrial Research (CSIR) - India); Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India; Intramural Research Program of the NIH, National Institute of Ageing	This work was primarily supported by National Centre for Cell Science, Pune, India (to GCK). RB, RN, and DT were supported by Council of Scientific and Industrial Research (CSIR), Govt. of India. VPG is supported by Science and Engineering Research Board (SERB), Department of Science and Technology (DST), Govt. of India. This research was supported in part by the Intramural Research Program of the NIH, National Institute of Ageing.	Avgustinova A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10305; Bandopadhyay M, 2014, EXPERT OPIN THER TAR, V18, P883, DOI 10.1517/14728222.2014.925447; Belev B, 2012, PERIOD BIOL, V114, P511; Bossung V, 2010, CURR OPIN OBSTET GYN, V22, P79, DOI 10.1097/GCO.0b013e328334e462; Bremnes RM, 2011, J THORAC ONCOL, V6, P209, DOI 10.1097/JTO.0b013e3181f8a1bd; Butti R, 2015, MULTITARGETED APPROA, P113; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Cao HM, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090985; Castello LM, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4049098; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chakraborty G, 2008, J CELL MOL MED, V12, P2305, DOI 10.1111/j.1582-4934.2008.00263.x; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Das S, 2013, J BIOL CHEM, V288, P11824, DOI 10.1074/jbc.M112.432302; Dine J, 2017, ASIA-PAC J ONCOL NUR, V4, P127, DOI 10.4103/apjon.apjon_4_17; Dong CY, 2014, STEM CELLS, V32, P3173, DOI 10.1002/stem.1803; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Graessmann M, 2007, ONCOGENE, V26, P2840, DOI 10.1038/sj.onc.1210096; Hellerstedt BA, 2002, CA-CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154; Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181; Johnson GA, 2003, BIOL REPROD, V69, P1458, DOI 10.1095/biolreprod.103.020651; Kale S, 2014, ONCOGENE, V33, P2295, DOI 10.1038/onc.2013.184; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Klement JD, 2018, J CLIN INVEST, V128, P5549, DOI 10.1172/JCI123360; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kothari AN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040039; Kumar D, 2016, J INVEST DERMATOL, V136, P2462, DOI 10.1016/j.jid.2016.07.024; Kumar S, 2012, CURR MOL MED, V12, P952, DOI 10.2174/156652412802480826; Kumar V, 2010, CANCER RES, V70, P10381, DOI 10.1158/0008-5472.CAN-10-1470; Kuo PC, 2015, J AM COLL SURGEONS, V221, P642; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Lenga Y, 2008, CIRC RES, V102, P319, DOI 10.1161/CIRCRESAHA.107.160408; Madar S, 2013, TRENDS MOL MED, V19, P447, DOI 10.1016/j.molmed.2013.05.004; Martin MA, 2005, STEM CELLS DEV, V14, P493, DOI 10.1089/scd.2005.14.493; McCarthy JB, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00048; Mi ZY, 2011, CARCINOGENESIS, V32, P477, DOI 10.1093/carcin/bgr009; Mikheeva SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-194; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Ng L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126219; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pang H, 2011, CANCER BIOTHER RADIO, V26, P165, DOI 10.1089/cbr.2010.0838; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005; Pio GM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177640; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Rasanen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032; Ray P, 2015, ONCOGENE, V34, P2043, DOI 10.1038/onc.2014.157; Sangaletti S, 2014, CANCER RES, V74, P4706, DOI 10.1158/0008-5472.CAN-13-3334; Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990; Sung CO, 2011, AM J PATHOL, V179, P1827, DOI 10.1016/j.ajpath.2011.06.032; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Xu K, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0674-8; Xu YY, 2015, MOL CLIN ONCOL, V3, P357, DOI 10.3892/mco.2014.480; Zhang RH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023831	58	12	12	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2002	2017		10.1038/s41388-021-01663-2	http://dx.doi.org/10.1038/s41388-021-01663-2		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603163				2022-12-17	WOS:000619433100004
J	Xiong, YY; Ju, LG; Yuan, LS; Chen, L; Wang, G; Xu, HM; Peng, TC; Luo, YW; Xiao, Y; Wang, XH				Xiong, Yaoyi; Ju, Lingao; Yuan, Lushun; Chen, Liang; Wang, Gang; Xu, Huimin; Peng, Tianchen; Luo, Yongwen; Xiao, Yu; Wang, Xinghuan			KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer	ONCOGENE			English	Article							PI3K/AKT PATHWAY; THERAPY; TARGET	KNSTRN is a component of the mitotic spindle, which was rarely investigated in tumorigenesis. AKT plays an essential role in tumorigenesis by modulating the phosphorylation of various substrates. The activation of AKT is regulated by PTEN and PIP3. Here, we prove KNSTRN is positively correlated with malignancy of bladder cancer and KNSTRN activates AKT phosphorylation at Thr308 and Ser473. More importantly, our study reveals that both KNSTRN and PTEN interact with PH domain of AKT at cell membrane. The amount of KNSTRN interacted with AKT is negatively related to PTEN. Furthermore, PIP3 pull-down assay proves that KNSTRN promoted AKT movement to PIP3. These data suggest KNSTRN may activate AKT phosphorylation by promoting AKT movement to PIP3 and alleviating PTEN suppression. Based on the activation of AKT phosphorylation, our study demonstrates that KNSTRN promotes bladder cancer metastasis and gemcitabine resistance in vitro and in vivo. Meanwhile, the effect of KNSTRN on tumorigenesis and gemcitabine resistance could be restored by AKT specific inhibitor MK2206 or AKT overexpression. In conclusion, we identify an oncogene KNSTRN that promotes tumorigenesis and gemcitabine resistance by activating AKT phosphorylation and may serve as a therapeutic target in bladder cancer.	[Xiong, Yaoyi; Chen, Liang; Xu, Huimin; Peng, Tianchen; Luo, Yongwen; Xiao, Yu; Wang, Xinghuan] Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan, Peoples R China; [Ju, Lingao; Wang, Gang; Xiao, Yu] Wuhan Univ, Zhongnan Hosp, Dept Biol Repositories, Wuhan, Peoples R China; [Ju, Lingao; Wang, Gang; Xiao, Yu] Human Genet Resource Preservat Ctr Hubei Prov, Wuhan, Peoples R China; [Ju, Lingao; Wang, Gang; Xiao, Yu; Wang, Xinghuan] Chinese Acad Med Sci, Res Ctr Wuhan Infect Dis & Canc, Wuhan, Peoples R China; [Yuan, Lushun] Leiden Univ Med Ctr, Dept Internal Med, Div Nephrol, Leiden, Netherlands; [Chen, Liang] Natl Inst Environm Hlth Sci, Signal Transduct Lab, Durham, NC USA; [Xiao, Yu] Wuhan Univ, Zhongnan Hosp, Lab Precis Med, Wuhan, Peoples R China; [Wang, Xinghuan] Wuhan Univ, Med Res Inst, Wuhan, Peoples R China	Wuhan University; Wuhan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Leiden University; Leiden University Medical Center (LUMC); Wuhan University; Wuhan University	Xiao, Y; Wang, XH (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Urol, Wuhan, Peoples R China.; Xiao, Y (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Biol Repositories, Wuhan, Peoples R China.; Xiao, Y (corresponding author), Human Genet Resource Preservat Ctr Hubei Prov, Wuhan, Peoples R China.; Xiao, Y; Wang, XH (corresponding author), Chinese Acad Med Sci, Res Ctr Wuhan Infect Dis & Canc, Wuhan, Peoples R China.; Xiao, Y (corresponding author), Wuhan Univ, Zhongnan Hosp, Lab Precis Med, Wuhan, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Med Res Inst, Wuhan, Peoples R China.	yu.xiao@whu.edu.cn; wangxinghuan@whu.edu.cn	Xiao, Yu/AGA-4786-2022; Ju, Lingao/ADP-8482-2022	Xiao, Yu/0000-0003-1377-9685; Ju, Lingao/0000-0003-0813-3628	Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor) from National Health Commission of China [ZLYNXM202006]; National Natural Science Foundation of China [81772730, 31900902, 81902603]	Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor) from National Health Commission of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors wish to acknowledge thank Dr Xiaoling Li from NIEHS for critical editing during the preparation of this paper. The excellent technical assistance of Ms Yayun Fang and Ms Danni Shan is gratefully acknowledged. We would like to acknowledge the the TCGA databases for free use. This work was supported by the Improvement Project for Theranostic ability on Difficulty miscellaneous disease (Tumor) from National Health Commission of China (ZLYNXM202006) and National Natural Science Foundation of China to XW (81772730), LJ (31900902) and GW (81902603).	Albers P, 2011, ANN ONCOL, V22, P288, DOI 10.1093/annonc/mdq398; Bergman AM, 2002, DRUG RESIST UPDATE, V5, P19, DOI 10.1016/S1368-7646(02)00002-X; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao DL, 2019, CANCER RES, V79, P2604, DOI 10.1158/0008-5472.CAN-18-3842; Choo Z, 2016, ONCOTARGET, V7, P34229, DOI 10.18632/oncotarget.8748; Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daizumoto K, 2018, CANCER RES, V78, P2233, DOI 10.1158/0008-5472.CAN-17-2528; Delaloge S, 2017, LANCET ONCOL, V18, P1293, DOI 10.1016/S1470-2045(17)30514-4; Dunsch AK, 2011, J CELL BIOL, V192, P959, DOI 10.1083/jcb.201008023; Friese A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11407; Gao X, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2530-0; Houede N, 2015, PHARMACOL THERAPEUT, V145, P1, DOI 10.1016/j.pharmthera.2014.06.004; Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040; Kern DM, 2017, ELIFE, V6, DOI 10.7554/eLife.26866; Kern DM, 2016, J CELL BIOL, V213, P315, DOI 10.1083/jcb.201510117; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee CS, 2014, NAT GENET, V46, P1060, DOI 10.1038/ng.3091; Li WJ, 2019, CELL DEATH DIFFER, V26, P1379, DOI 10.1038/s41418-018-0211-7; Liu BL, 2019, ONCOL REP, V41, P2168, DOI 10.3892/or.2019.7019; LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; Miyamoto DT, 2018, LANCET ONCOL, V19, pE683, DOI 10.1016/S1470-2045(18)30693-4; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Qin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep38791; Shelley MD, 2012, BJU INT, V109, P496, DOI 10.1111/j.1464-410X.2011.10880.x; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toker A, 2015, CANCER CELL, V28, P143, DOI 10.1016/j.ccell.2015.07.010; van der Vos KE, 2011, ANTIOXID REDOX SIGN, V14, P579, DOI 10.1089/ars.2010.3419; van Rhijn BWG, 2009, EUR UROL, V56, P430, DOI 10.1016/j.eururo.2009.06.028; Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1; Webb AE, 2014, TRENDS BIOCHEM SCI, V39, P159, DOI 10.1016/j.tibs.2014.02.003; Wong K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08081-1; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang PZ, 2017, NAT MED, V23, P1055, DOI 10.1038/nm.4379	41	12	12	4	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1595	1608		10.1038/s41388-020-01634-z	http://dx.doi.org/10.1038/s41388-020-01634-z		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33452459				2022-12-17	WOS:000607998600008
J	Kuo, TC; Wu, MH; Yang, SH; Chen, ST; Hsu, TW; Jhuang, JY; Liao, YY; Tien, YW; Huang, MC				Kuo, Ting-Chun; Wu, Ming-Hsun; Yang, Shih-Hung; Chen, Syue-Ting; Hsu, Tzu-Wen; Jhuang, Jie-Yang; Liao, Ying-Yu; Tien, Yu-Wen; Huang, Min-Chuan			C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin alpha(v)	ONCOGENE			English	Article							CANCER-CELLS; GLYCOSYLATION; ADHESION; FAK	Pancreatic adenocarcinoma (PDAC) is a leading cause of cancer-related death. Altered glycosylation contributes to tumor progression and chemoresistance in many cancers. C1GALT1 is the key enzyme controlling the elongation of GalNAc-type O-glycosylation. Here we showed that C1GALT1 was overexpressed in 85% (107/126) of PDAC tumors compared with adjacent non-tumor tissues. High expression of C1GALT1 was associated with poor disease-free and overall survival (n = 99). C1GALT1 knockdown using siRNA suppressed cell viability, migration, and invasion as well as increased gemcitabine sensitivity in PDAC cells. In contrast, C1GALT1 overexpression enhanced cell migration and invasion. In subcutaneous and pancreatic orthotopic injection models, C1GALT1 knockdown decreased tumor growth and metastasis of PDAC cells in NOD/SCID mice. Mechanistically, C1GALT1 knockdown dramatically suppressed cell-extracellular matrix (ECM) adhesion, which was associated with decreased phosphorylation of FAK at Y397/Y925 and changes in O-glycans on integrins including the beta(1), alpha(v), and alpha(5) subunits. Using functional blocking antibodies, we identified integrin alpha(v) as a critical factor in C1GALT1-mediated invasiveness of PDAC cells. In conclusion, this study not only reveals that C1GALT1 could be a potential therapeutic target for PDAC but also provides novel insights into the role of O-glycosylation in the alpha subunits of integrins.	[Kuo, Ting-Chun; Chen, Syue-Ting; Hsu, Tzu-Wen; Liao, Ying-Yu; Huang, Min-Chuan] Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan; [Kuo, Ting-Chun; Wu, Ming-Hsun; Tien, Yu-Wen] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Kuo, Ting-Chun] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan; [Yang, Shih-Hung] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [Jhuang, Jie-Yang] Mackay Mem Hosp, Dept Pathol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Mackay Memorial Hospital	Huang, MC (corresponding author), Natl Taiwan Univ, Grad Inst Anat & Cell Biol, Coll Med, Taipei, Taiwan.; Tien, YW (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.	ywtien5106@ntu.edu.tw; mchuang@ntu.edu.tw	wu, larry/AAV-5282-2021	wu, larry/0000-0002-8811-9203; HUANG, MIN-CHUAN/0000-0002-0704-3447; TIEN, YU-WEN/0000-0002-9126-2705; KUO, TING-CHUN/0000-0003-1960-1423	National Taiwan University Hospital [105-N3200, 106-N3608, 107-N3965, 109-O02]; Ministry of Science and Technology, Taiwan [107-2314-B-002-233-MY3, 108-2320-B-002 -064 -MY3, 106-2321-B-002-034]	National Taiwan University Hospital(National Taiwan University); Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by National Taiwan University Hospital (105-N3200, 106-N3608, 107-N3965, and 109-O02 to Dr TCK) and Ministry of Science and Technology, Taiwan (107-2314-B-002-233-MY3 to Dr TCK, 108-2320-B-002 -064 -MY3 to Dr MCH, and 106-2321-B-002-034 to Dr YWT). In addition, we are grateful to Dr WH Lee (Genomics Research Center, Academia Sinica, Taiwan) for providing human PDAC and HPaSteC cell lines. We thank Dr Kelvin K. Tsai (National Health Research Institutes, Taiwan) for providing human HPDE cells. And we thank Dr CL Hsu and Dr YT Huang (Department of Medical Research, National Taiwan University Hospital, Taiwan) as well as Ms Chun-Chi Chen (Graduate Institute of Anatomy and Cell Biology, National Taiwan University, Taiwan) for their technical support during the study.	Adorno-Cruz V, 2019, GENES DIS, V6, P16, DOI 10.1016/j.gendis.2018.12.003; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Chen CH, 2016, GYNECOL ONCOL, V140, P131, DOI 10.1016/j.ygyno.2015.11.025; Chen ST, 2018, ONCOGENE, V37, P6041, DOI 10.1038/s41388-018-0403-0; Chia J, 2016, BBA-GEN SUBJECTS, V1860, P1623, DOI 10.1016/j.bbagen.2016.03.008; Chou CH, 2017, INT J GYNECOL CANCER, V27, P863, DOI 10.1097/IGC.0000000000000965; Chou CH, 2015, ONCOTARGET, V6, P6123, DOI 10.18632/oncotarget.3045; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; El-Brolosy MA, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006780; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Guan JL, 2010, IUBMB LIFE, V62, P268, DOI 10.1002/iub.303; Hakamada K, 2019, ANN GASTROENT SURG, V3, P120, DOI 10.1002/ags3.12244; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Hatley RJD, 2018, ANGEW CHEM INT EDIT, V57, P3298, DOI 10.1002/anie.201707948; Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815; Kang R, 2011, AUTOPHAGY, V7, P442, DOI 10.4161/auto.7.4.14681; Klein AP, 2004, CANCER RES, V64, P2634, DOI 10.1158/0008-5472.CAN-03-3823; Lee PC, 2020, ONCOGENE, V39, P2724, DOI 10.1038/s41388-020-1178-7; Lin MC, 2018, ONCOGENE, V37, P5780, DOI 10.1038/s41388-018-0375-0; Liu C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092743; Magalhaes A, 2017, CANCER CELL, V31, P733, DOI 10.1016/j.ccell.2017.05.012; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Saitoh M, 2018, J BIOCHEM, V164, P257, DOI 10.1093/jb/mvy047; Tsai CH, 2016, CANCER RES, V76, P5756, DOI 10.1158/0008-5472.CAN-16-0641; Weis SM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006478; Wu YM, 2013, CANCER RES, V73, P5580, DOI 10.1158/0008-5472.CAN-13-0869; Zhang CY, 2018, J CANCER, V9, P2666, DOI 10.7150/jca.25252	29	12	12	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1242	1254		10.1038/s41388-020-01594-4	http://dx.doi.org/10.1038/s41388-020-01594-4		JAN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420364	Green Published, hybrid			2022-12-17	WOS:000607346000012
J	Yang, Y; Ma, YD; Gao, HB; Peng, TS; Shi, HJ; Tang, YX; Li, H; Chen, L; Hu, KS; Han, AJ				Yang, Yang; Ma, Yuedong; Gao, Huabin; Peng, Tingsheng; Shi, Huijuan; Tang, Yunxiang; Li, Hui; Chen, Lin; Hu, Kaishun; Han, Anjia			A novel HDGF-ALCAM axis promotes the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway	ONCOGENE			English	Article							CELL-ADHESION MOLECULE; GROWTH-FACTOR; ACTIN POLYMERIZATION; CDC42 GTPASES; RHO; RAC; MIGRATION; CANCER; DOMAIN; ACTIVATION	Ewing sarcoma (ES) is a type of highly aggressive pediatric tumor in bones and soft tissues and its metastatic spread remains the most powerful predictor of poor outcome. We previously identified that the transcription factor hepatoma-derived growth factor (HDGF) promotes ES tumorigenesis. However, the mechanisms underlying ES metastasis remain unclear. Here, we show that HDGF drives ES metastasis in vitro and in vivo, and HDGF reduces metastasis-free survival (MFS) in two independent large cohorts of human ES patients. Integrative analyses of HDGF ChIP-seq and gene expression profiling in ES cells reveal that HDGF regulates multiple metastasis-associated genes, among which activated leukocyte cell adhesion molecule (ALCAM) emerges as a major HDGF target and a novel metastasis-suppressor in ES. HDGF down-regulates ALCAM, induces expression and activation of the downstream effectors Rho-GTPase Rac1 and Cdc42, and promotes actin cytoskeleton remodeling and cell-matrix adhesion. In addition, repression of ALCAM and activation of Rac1 and Cdc42 are required for the pro-metastatic functions of HDGF in vitro. Moreover, analyses in murine models with ES tumor orthotopic implantation and experimental metastasis, as well as in human ES samples, demonstrate the associations among HDGF, ALCAM, and GTPases expression levels. Furthermore, high HDGF/low ALCAM expression define a subgroup of patients harboring the worst MFS. These findings suggest that the HDGF/ALCAM/GTPases axis represents a promising therapeutic target for limiting ES metastasis.	[Yang, Yang; Gao, Huabin; Peng, Tingsheng; Shi, Huijuan; Tang, Yunxiang; Li, Hui; Chen, Lin; Han, Anjia] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Peoples R China; [Ma, Yuedong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou 510080, Peoples R China; [Hu, Kaishun] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Med Res Ctr, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Han, AJ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Peoples R China.; Hu, KS (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Med Res Ctr, Guangzhou 510120, Peoples R China.	huksh3@mail.sysu.edu.cn; hananjia@mail.sysu.edu.cn		Chen, Lin/0000-0002-7552-8673; Hu, Kaishun/0000-0003-2157-6239	National Nature Science Foundation in China [81772862, 81402413, 81402000]; Fundamental Research Funds for the Sun Yat-sen Universities [16ykpy42]	National Nature Science Foundation in China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Sun Yat-sen Universities	This work was supported by grants from the National Nature Science Foundation in China (81772862 and 81402413 to YY, and 81402000 to HL) and from the Fundamental Research Funds for the Sun Yat-sen Universities (16ykpy42 to YY).	Anderson S, 2016, P NATL ACAD SCI USA, V113, pE5481, DOI 10.1073/pnas.1610994113; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Bar-Shavit R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081320; Cotterill SJ, 2000, J CLIN ONCOL, V18, P3108, DOI 10.1200/JCO.2000.18.17.3108; Everett AD, 2001, J BIOL CHEM, V276, P37564, DOI 10.1074/jbc.M105109200; Franzetti GA, 2017, ONCOGENE, V36, P3505, DOI 10.1038/onc.2016.498; Granowetter L, 2009, J CLIN ONCOL, V27, P2536, DOI 10.1200/JCO.2008.19.1478; Jansen S, 2018, PHARMACOL THERAPEUT, V183, P1, DOI 10.1016/j.pharmthera.2017.09.002; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kijima N, 2012, NEURO-ONCOLOGY, V14, P1254, DOI 10.1093/neuonc/nor202; Kishima Y, 2002, J BIOL CHEM, V277, P10315, DOI 10.1074/jbc.M111122200; Kung ML, 2012, BIOCHEM BIOPH RES CO, V425, P169, DOI 10.1016/j.bbrc.2012.07.060; Lunter PC, 2005, CANCER RES, V65, P8801, DOI 10.1158/0008-5472.CAN-05-0378; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Maldonado MD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00201; Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619; Mao JS, 2008, CANCER SCI, V99, P2120, DOI 10.1111/j.1349-7006.2008.00928.x; Masedunskas A, 2006, FEBS LETT, V580, P2637, DOI 10.1016/j.febslet.2006.04.013; Mendoza-Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343; Moreau V, 1998, FEBS LETT, V427, P353, DOI 10.1016/S0014-5793(98)00443-8; NAKAMURA H, 1994, J BIOL CHEM, V269, P25143; Nameki N, 2005, PROTEIN SCI, V14, P756, DOI 10.1110/ps.04975305; Nelissen JMDT, 2000, MOL BIOL CELL, V11, P2057, DOI 10.1091/mbc.11.6.2057; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Penna E, 2013, CANCER RES, V73, P4098, DOI 10.1158/0008-5472.CAN-12-3686; Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009; Satterfield L, 2017, INT J CANCER, V141, P2062, DOI 10.1002/ijc.30909; Savola S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-17; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Swart GWM, 2002, EUR J CELL BIOL, V81, P313, DOI 10.1078/0171-9335-00256; van Kempen LCLT, 2004, J INVEST DERMATOL, V122, P1293, DOI 10.1111/j.0022-202X.2004.22531.x; van Kilsdonk JWJ, 2008, CANCER RES, V68, P3671, DOI 10.1158/0008-5472.CAN-07-5767; Wang CH, 2011, BIOCHEM J, V433, P127, DOI 10.1042/BJ20100589; Wei YP, 2020, HEPATOLOGY, V71, P130, DOI 10.1002/hep.30795; Woldu SL, 2018, NAT REV UROL, V15, P83, DOI 10.1038/nrurol.2017.184; Yang J, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-101; Yang J, 2009, J MOL BIOL, V386, P938, DOI 10.1016/j.jmb.2008.12.080; Yang Y, 2014, J CLIN PATHOL, V67, DOI 10.1136/jclinpath-2013-201705; Yang Y, 2013, J PATHOL, V231, P323, DOI 10.1002/path.4241; Yao HH, 2011, J NEUROSCI, V31, P5942, DOI 10.1523/JNEUROSCI.5618-10.2011; Zhang Z, 2014, ONCOGENE, V33, P3374, DOI 10.1038/onc.2013.337	44	12	11	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					731	745		10.1038/s41388-020-01485-8	http://dx.doi.org/10.1038/s41388-020-01485-8		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33239755				2022-12-17	WOS:000592629300002
J	Zhang, QY; Zhou, W; Yu, S; Ju, YJ; To, SKY; Wong, AST; Jiao, YF; Poon, TCW; Tam, KY; Lee, LTO				Zhang, Qingyu; Zhou, Wei; Yu, Shan; Ju, Yaojun; To, Sally Kit Yan; Wong, Alice Sze Tsai; Jiao, Yufei; Poon, Terence Chuen Wai; Tam, Kin Yip; Lee, Leo Tsz On			Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation	ONCOGENE			English	Article							FATTY-ACID OXIDATION; TYROSINE KINASE; BREAST-CANCER; C-SRC; ACTIVATION; INHIBITION; STRESS; CELLS; ACSL1; LINKS	As a result of the hostile microenvironment, metabolic alterations are required to enable the malignant growth of cancer cells. To understand metabolic reprogramming during metastasis, we conducted shotgun proteomic analysis of highly metastatic (HM) and non-metastatic (NM) ovarian cancer cells. The results suggest that the genes involved in fatty-acid (FA) metabolism are upregulated, with consequent increases of phospholipids with relatively short FA chains (myristic acid, MA) in HM cells. Among the upregulated proteins, ACSL1 expression could convert the lipid profile of NM cells to that similar of HM cells and make them highly aggressive. Importantly, we demonstrated that ACSL1 activates the AMP-activated protein kinase and Src pathways via protein myristoylation and finally enhances FA beta oxidation. Patient samples and tissue microarray data also suggested that omentum metastatic tumours have higher ACSL1 expression than primary tumours and a strong association with poor clinical outcome. Overall, our data reveal that ACSL1 enhances cancer metastasis by regulating FA metabolism and myristoylation.	[Zhang, Qingyu; Yu, Shan; Lee, Leo Tsz On] Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macau, Peoples R China; [Zhang, Qingyu] Guangdong Med Univ, Affiliated Hosp, Dept Obstet & Gynaecol, Zhanjiang 524001, Guangdong, Peoples R China; [Zhou, Wei] China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing 210009, Peoples R China; [Ju, Yaojun; Poon, Terence Chuen Wai; Tam, Kin Yip] Univ Macau, Fac Hlth Sci, Prote Metabol & Drug Dev Core, Taipa, Macau, Peoples R China; [To, Sally Kit Yan; Wong, Alice Sze Tsai] Univ Hong Kong, Sch Biol Sci, Pokfulam Rd, Hong Kong, Peoples R China; [Jiao, Yufei] Harbin Med Univ, Affiliated Hosp 2, Dept Pathol, Harbin 150001, Peoples R China; [Lee, Leo Tsz On] Univ Macau, Fac Hlth Sci, Ctr Reprod Dev & Aging, Taipa, Macau, Peoples R China	University of Macau; Guangdong Medical University; China Pharmaceutical University; University of Macau; University of Hong Kong; Harbin Medical University; University of Macau	Lee, LTO (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Taipa, Macau, Peoples R China.; Lee, LTO (corresponding author), Univ Macau, Fac Hlth Sci, Ctr Reprod Dev & Aging, Taipa, Macau, Peoples R China.	LTOLee@um.edu.mo	Tam, Kin/A-7812-2011; Wong, Alice/AFJ-4595-2022; Lee, Leo T.O./AAB-1581-2021	Tam, Kin/0000-0001-5507-8524; Wong, Alice/0000-0002-0676-6475; 	Science and Technology Development Fund, Macau SAR [0016/2020/A1]; University of Macau [MYRG2019-00075-FHS]; Hong Kong Research Grant Council [GRF17105919]	Science and Technology Development Fund, Macau SAR; University of Macau; Hong Kong Research Grant Council(Hong Kong Research Grants Council)	This work and LTOL were funded by The Science and Technology Development Fund, Macau SAR (File no. 0016/2020/A1) and University of Macau (File. no. MYRG2019-00075-FHS). ASTW was supported by Hong Kong Research Grant Council grant GRF17105919. We acknowledge the Animal Research Core Facility from University of Macau for their support in the animal experiments.	Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949; Anbalagan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033017; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Cui M, 2014, BIOCHEM BIOPH RES CO, V444, P270, DOI 10.1016/j.bbrc.2014.01.051; Das U, 2012, CURR CANCER DRUG TAR, V12, P667, DOI 10.2174/156800912801784857; Deng L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1201-x; Dian C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14847-3; Dirat B, 2010, ENDOCR DEV, V19, P45, DOI 10.1159/000316896; Fullerton MD, 2013, NAT MED, V19, P1649, DOI 10.1038/nm.3372; Jeon Sang-Min, 2012, Cell Logist, V2, P197; Kim S, 2017, CANCER RES, V77, P6950, DOI 10.1158/0008-5472.CAN-17-0981; Kim S, 2017, J BIOL CHEM, V292, P18422, DOI [10.1074/jbc.M117.798827, 10.1074/jbc.m117.798827]; Liang JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8926; Lobo S, 2009, J BIOL CHEM, V284, P18347, DOI 10.1074/jbc.M109.017244; Lopez-Mejia IC, 2017, MOL CELL, V68, P336, DOI 10.1016/j.molcel.2017.09.034; Mizrachy-Schwartz S, 2011, J BIOL CHEM, V286, P15268, DOI 10.1074/jbc.M110.211813; Oakhill JS, 2010, P NATL ACAD SCI USA, V107, P19237, DOI 10.1073/pnas.1009705107; Park JH, 2016, CELL REP, V14, P2154, DOI 10.1016/j.celrep.2016.02.004; Patwardhan P, 2010, MOL CELL BIOL, V30, P4094, DOI 10.1128/MCB.00246-10; Pengetnze Y, 2003, BIOCHEM BIOPH RES CO, V309, P377, DOI 10.1016/j.bbrc.2003.08.012; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Resh MD, 2013, CURR BIOL, V23, pR431, DOI 10.1016/j.cub.2013.04.024; Sanchez-Martinez R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11612-3; Sulejmani Essilvo, 2018, Oncoscience, V5, P3, DOI 10.18632/oncoscience.391; Tang Y, 2018, ONCOL LETT, V16, P1390, DOI 10.3892/ol.2018.8843; Thinon E, 2016, ACS CHEM BIOL, V11, P2165, DOI 10.1021/acschembio.6b00371; Thinon E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5919; To SKY, 2017, ONCOGENE, V36, P5927, DOI 10.1038/onc.2017.185; Tryfonopoulos D, 2011, ANN ONCOL, V22, P2234, DOI 10.1093/annonc/mdq757; Tucker SL, 2014, CLIN CANCER RES, V20, P3280, DOI 10.1158/1078-0432.CCR-14-0445; Udenwobele DI, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00751; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Wang Y, 2017, BIOCHEM BIOPH RES CO, V484, P565, DOI 10.1016/j.bbrc.2017.01.126; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Yen MC, 2017, ONCOL REP, V37, P3253, DOI 10.3892/or.2017.5610; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	38	12	13	4	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					97	111		10.1038/s41388-020-01516-4	http://dx.doi.org/10.1038/s41388-020-01516-4		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33082557				2022-12-17	WOS:000582339900002
J	Chen, H; Libring, S; Ruddraraju, KV; Miao, JM; Solorio, L; Zhang, ZY; Wendt, MK				Chen, Hao; Libring, Sarah; Ruddraraju, Kasi Viswanatharaju; Miao, Jinmin; Solorio, Luis; Zhang, Zhong-Yin; Wendt, Michael K.			SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHATASE; ANTITUMOR IMMUNITY; KINASE INHIBITOR; ACTIVATION; CELLS; NERATINIB; PHOSPHORYLATION; MECHANISM; SUBSETS	Metastatic breast cancer (MBC) is an extremely recalcitrant disease capable of bypassing current targeted therapies via engagement of several growth promoting pathways. SH2 containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase known to facilitate growth and survival signaling downstream of numerous receptor inputs. Herein, we used inducible genetic depletion and two distinct pharmacological inhibitors to investigate the therapeutic potential of targeting SHP2 in MBC. Cells that acquired resistance to the ErbB kinase inhibitor, neratinib, displayed increased phosphorylation of SHP2 at the Y542 activation site. In addition, higher levels of SHP2 phosphorylation, but not expression, were associated with decreased survival of breast cancer patients. Pharmacological inhibition of SHP2 activity blocked ERK1/2 and AKT signaling generated from exogenous stimulation with FGF2, PDGF, and hGF and readily prevented MBC cell growth induced by these factors. SHP2 was also phosphorylated upon engagement of the extracellular matrix (ECM) via focal adhesion kinase. Consistent with the potential of SHP2-targeted compounds as therapeutic agents, the growth inhibitory property of SHP2 blockade was enhanced in ECM-rich 3D culture environments. In vivo blockade of SHP2 in the adjuvant setting decreased pulmonary metastasis and extended the survival of systemic tumor-bearing mice. Finally, inhibition of SHP2 in combination with FGFR-targeted kinase inhibitors synergistically blocked the growth of MBC cells. Overall, our findings support the conclusion that SHP2 constitutes a shared signaling node allowing MBC cells to simultaneously engage a diversity of growth and survival pathways, including those derived from the ECM.	[Chen, Hao; Ruddraraju, Kasi Viswanatharaju; Miao, Jinmin; Zhang, Zhong-Yin; Wendt, Michael K.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Libring, Sarah; Solorio, Luis] Purdue Univ, Dept Biomed Engn, W Lafayette, IN 47907 USA; [Solorio, Luis; Zhang, Zhong-Yin; Wendt, Michael K.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Wendt, MK (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.; Wendt, MK (corresponding author), Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.	mwendt@purdue.edu	Ruddraraju, Kasi Viswanatharaju/D-2384-2016; Miao, Jinmin/AAU-8461-2021	Ruddraraju, Kasi Viswanatharaju/0000-0002-5614-720X; Chen, Hao/0000-0002-2070-5062; Wendt, Mike/0000-0002-3665-7413; Libring, Sarah/0000-0001-8336-5862	National Cancer Institute [R01CA207751, RO1CA207288]; Metavivor Foundation Translation Research Award; American Cancer Society Research Scholar Grant [RSG-CSM-130259]; SIRG Graduate Research Assistantships Award [P30CA023168]; Purdue University Center for Cancer Research	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Metavivor Foundation Translation Research Award; American Cancer Society Research Scholar Grant(American Cancer Society); SIRG Graduate Research Assistantships Award; Purdue University Center for Cancer Research	This work was supported by National Cancer Institute (R01CA207751), Metavivor Foundation Translation Research Award, and American Cancer Society Research Scholar Grant (RSG-CSM-130259) to MKW and National Cancer Institute (RO1CA207288) to ZYZ. We gratefully acknowledge the SIRG Graduate Research Assistantships Award (P30CA023168) and the support from the Purdue University Center for Cancer Research. We thank Dr. Jill E. Hutchcroft, Dr. Wen-Hung Wang, and Flow Cytometry and Cell Separation Core Facility at Bindley Bioscience Center, Purdue University for technical support. We also thank Saeed Salehin Akhand, Hang Lin, Juan Sebastian Paez and other members at Wendt Lab for technical support.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Ahmed TA, 2019, CELL REP, V26, P65, DOI 10.1016/j.celrep.2018.12.013; Alexander PB, 2017, J BIOL CHEM, V292, P748, DOI 10.1074/jbc.M116.754960; ALI R, 2018, CELL DEATH DIS, V9, P1, DOI DOI 10.1038/s41419-017-0012-9; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Brown WS, 2016, ONCOTARGET, V7, P83424, DOI 10.18632/oncotarget.13117; Brown WS, 2016, MOL CANCER THER, V15, P2096, DOI 10.1158/1535-7163.MCT-16-0136; Bunda S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9859; Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Fedele C, 2018, CANCER DISCOV, V8, P1237, DOI 10.1158/2159-8290.CD-18-0444; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hanker AB, 2017, CANCER DISCOV, V7, P575, DOI 10.1158/2159-8290.CD-16-1431; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Koyama T, 2008, J BIOL CHEM, V283, P24234, DOI 10.1074/jbc.M803907200; Lan LX, 2015, EMBO J, V34, P1493, DOI 10.15252/embj.201489004; Li DM, 2011, BREAST CANCER RES TR, V128, P7, DOI 10.1007/s10549-011-1499-x; Liu W, 2017, LEUKEMIA, V31, P1415, DOI 10.1038/leu.2016.326; Mariotto AB, 2017, CANCER EPIDEM BIOMAR, V26, P809, DOI [10.1158/1055-9965.EPI-16-0889, 10.1158/1055-9965.epi-16-0889]; Martin M, 2017, LANCET ONCOL, V18, P1688, DOI 10.1016/S1470-2045(17)30717-9; Minuti G, 2012, BRIT J CANCER, V107, P793, DOI 10.1038/bjc.2012.335; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Palakurthi S, 2019, CANCER IMMUNOL RES, V7, P1457, DOI 10.1158/2326-6066.CIR-18-0595; Pulaski BA, 2000, CURR PROTOC IMMUNOL, V39, P20; Ran H, 2016, CANCER CELL, V30, P194, DOI 10.1016/j.ccell.2016.07.010; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Shinde A, 2018, MOL CANCER RES, V16, P1579, DOI 10.1158/1541-7786.MCR-18-0151; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Sun J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3037; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wei T., 2017, STATISTICIAN, V56, pe24; Wendt MK, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3623; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360; Ye TH, 2014, BREAST CANCER RES TR, V143, P435, DOI 10.1007/s10549-013-2829-y; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Zeng LF, 2014, J MED CHEM, V57, P6594, DOI 10.1021/jm5006176; Zhang RY, 2016, ONCOTARGET, V7, P73817, DOI 10.18632/oncotarget.12074; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhao H, 2019, ONCOGENE, V38, P2275, DOI 10.1038/s41388-018-0574-8; Zhao MX, 2019, ACTA PHARM SIN B, V9, P304, DOI 10.1016/j.apsb.2018.08.009; Zhou B, 2014, MOL CANCER RES, V12, P143, DOI 10.1158/1541-7786.MCR-13-0184	53	12	12	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7166	7180		10.1038/s41388-020-01488-5	http://dx.doi.org/10.1038/s41388-020-01488-5		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33033382	hybrid, Green Published			2022-12-17	WOS:000576873200001
J	Vernier, M; McGuirk, S; Dufour, CR; Wan, LXY; Audet-Walsh, E; St-Pierre, J; Giguere, V				Vernier, Mathieu; McGuirk, Shawn; Dufour, Catherine R.; Wan, Liangxinyi; Audet-Walsh, Etienne; St-Pierre, Julie; Giguere, Vincent			Inhibition of DNMT1 and ERR alpha crosstalk suppresses breast cancer via derepression ofIRF4	ONCOGENE			English	Article							ESTROGEN-RELATED RECEPTORS; ONE-CARBON METABOLISM; DNA METHYLATION; TUMOR-SUPPRESSOR; ADIPOSE-TISSUE; GENES; TARGET; DECITABINE; SERINE; CONVERSION	DNA methylation is implicated in the acquisition of malignant phenotypes, and the use of epigenetic modulating drugs is a promising anti-cancer therapeutic strategy. 5-aza-2'deoxycytidine (decitabine, 5-azadC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor with proven effectiveness against hematological malignancies and more recently triple-negative breast cancer (BC). Herein, genetic or pharmacological studies uncovered a hitherto unknown feedforward molecular link between DNMT1 and the estrogen related receptor alpha (ERR alpha), a key transcriptional regulator of cellular metabolism. Mechanistically, DNMT1 promotes ERR alpha stability which in turn couples DNMT1 transcription with that of the methionine cycle and S-adenosylmethionine synthesis to drive DNA methylation. In vitro and in vivo investigation using a pre-clinical mouse model of BC demonstrated a clear therapeutic advantage for combined administration of the ERR alpha inhibitor C29 with 5-azadC. A large-scale bisulfite genomic sequencing analysis revealed specific methylation perturbations fostering the discovery that reversal of promoter hypermethylation and consequently derepression of the tumor suppressor gene,IRF4, is a factor underlying the observed BC suppressive effects. This work thus uncovers a critical role of ERR alpha in the crosstalk between transcriptional control of metabolism and epigenetics and illustrates the potential for targeting ERR alpha in combination with DNMT inhibitors for BC treatment and other epigenetics-driven malignancies.	[Vernier, Mathieu; McGuirk, Shawn; Dufour, Catherine R.; Wan, Liangxinyi; Audet-Walsh, Etienne; St-Pierre, Julie; Giguere, Vincent] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Med, Montreal, PQ H3G 1Y6, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Audet-Walsh, Etienne] Univ Laval, Dept Med Mol, Fac Med, Ctr Rech,CHU Quebec, Quebec City, PQ G1V 4G2, Canada; [St-Pierre, Julie] Univ Ottawa, Ottawa Inst Syst Biol, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	McGill University; McGill University; McGill University; McGill University; Laval University; University of Ottawa	Vernier, M; Giguere, V (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Med, Montreal, PQ H3G 1Y6, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Oncol, Montreal, PQ H3G 1Y6, Canada.	mathieu.vernier@mail.mcgill.ca; vincent.giguere@mcgill.ca	St-Pierre, Julie/AGB-3651-2022	St-Pierre, Julie/0000-0002-2815-7099; Vernier, Mathieu/0000-0001-9356-7353; Giguere, Vincent/0000-0001-9567-3694; Dufour, Catherine Rosa/0000-0001-7324-3458	Terry Fox Research Institute Program Project Team Grant on Oncometabolism; Canadian Institutes of Health Research (CIHR); CIHR [MOP-106603]; Vanier Canada Graduate Scholarship-CIHR; CIHR	Terry Fox Research Institute Program Project Team Grant on Oncometabolism; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); Vanier Canada Graduate Scholarship-CIHR(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR))	We acknowledge contributions from the Metabolomics Core Facility (MCF) of the GCRC, as well as technical assistance from Dr. Daina Avizonis, Mariana De Sa Tavares Russo, Gaelle Bridon, and Luc Choiniere. We thank all members of the V.G. laboratory for discussions, Xiaojing Li for technical assistance and Dr. David J. Papadopoli for guidance with metabolic studies. This work was supported by a Terry Fox Research Institute Program Project Team Grant on Oncometabolism (VG and JS-P), a Foundation Grant from the Canadian Institutes of Health Research (CIHR) to VG, and an operating grant from CIHR to JS-P (MOP-106603). MV was a recipient of a post-doctoral fellowship from CIHR. SM was supported by a Vanier Canada Graduate Scholarship-CIHR. EAW was a recipient of a post-doctoral fellowship from CIHR.	Acquaviva J, 2008, BLOOD, V112, P3798, DOI 10.1182/blood-2007-10-117838; Ariazi EA, 2002, CANCER RES, V62, P6510; Audet-Walsh E, 2016, CELL REP, V14, P920, DOI 10.1016/j.celrep.2015.12.086; Audet-Walsh E, 2015, ACTA PHARMACOL SIN, V36, P51, DOI 10.1038/aps.2014.121; Barcena C, 2018, CELL REP, V24, P2392, DOI 10.1016/j.celrep.2018.07.089; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Bauerle MR, 2015, J BIOL CHEM, V290, P3995, DOI 10.1074/jbc.R114.607044; Cao S, 2017, CANCER RES, V77, P4185, DOI 10.1158/0008-5472.CAN-17-0262; Castellano-Castillo D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010087; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073; Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44; de la Rosa J, 2017, NAT GENET, V49, P730, DOI 10.1038/ng.3817; Deblois G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12156; Deblois G, 2013, NAT REV CANCER, V13, P27, DOI 10.1038/nrc3396; Deblois G, 2009, CANCER RES, V69, P6149, DOI 10.1158/0008-5472.CAN-09-1251; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Farlik M, 2016, CELL STEM CELL, V19, P808, DOI 10.1016/j.stem.2016.10.019; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Heimes AS, 2017, J CANCER RES CLIN, V143, P1123, DOI 10.1007/s00432-017-2377-7; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200; Huss L, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1169-1; Issa Jean-Pierre, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS24, DOI 10.1038/ncponc0355; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jeon H, 2016, ONCOTARGET, V7, P67223, DOI 10.18632/oncotarget.11615; Komninou D, 2006, NUTR CANCER, V54, P202, DOI 10.1207/s15327914nc5402_6; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lambert SA, 2018, CELL, V175, P598, DOI 10.1016/j.cell.2018.09.045; Lee BC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4592; Li Y, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0316-3; Lindqvist BM, 2014, EPIGENETICS-US, V9, P1149, DOI 10.4161/epi.29632; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Luo CY, 2018, SCIENCE, V361, P1336, DOI 10.1126/science.aat6806; Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014; Martin EM, 2018, ANNU REV PUBL HEALTH, V39, P309, DOI 10.1146/annurev-publhealth-040617-014629; McGuirk S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-22; Mehrmohamadi M, 2014, CELL REP, V9, P1507, DOI 10.1016/j.celrep.2014.10.026; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; Phan NLC, 2016, ONCOTARGETS THER, V9, DOI 10.2147/OTT.S96291; Nilsson E, 2014, DIABETES, V63, P2962, DOI 10.2337/db13-1459; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Park S, 2019, CELL REP, V27, P3587, DOI 10.1016/j.celrep.2019.05.066; Patch RJ, 2011, J MED CHEM, V54, P788, DOI 10.1021/jm101063h; Putiri EL, 2011, CLIN EPIGENETICS, V2, P299, DOI 10.1007/s13148-010-0017-z; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Sanchez-Mut JV, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.214; Sanderson SM, 2019, NAT REV CANCER, V19, P625, DOI 10.1038/s41568-019-0187-8; Schade B, 2009, J BIOL CHEM, V284, P19018, DOI 10.1074/jbc.M109.018937; Shaffer AL, 2009, CLIN CANCER RES, V15, P2954, DOI 10.1158/1078-0432.CCR-08-1845; Shlomi T, 2014, ANAL CHEM, V86, P1583, DOI 10.1021/ac4032093; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Vernier M, 2020, GENE DEV, V34, P544, DOI 10.1101/gad.330746.119; Yu J, 2018, J CLIN INVEST, V128, P2376, DOI 10.1172/JCI97924; Zdzisinska B, 2017, ARCH IMMUNOL THER EX, V65, P21, DOI 10.1007/s00005-016-0406-x	62	12	12	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6406	6420		10.1038/s41388-020-01438-1	http://dx.doi.org/10.1038/s41388-020-01438-1		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32855526	hybrid, Green Published			2022-12-17	WOS:000565020000002
J	Chen, J; Dang, YZ; Feng, WB; Qiao, CY; Liu, DF; Zhang, TY; Wang, YJ; Tian, D; Fan, DM; Nie, YZ; Wu, KC; Xia, LM				Chen, Jie; Dang, Yunzhi; Feng, Weibo; Qiao, Chenyang; Liu, Danfei; Zhang, Tongyue; Wang, Yijun; Tian, Dean; Fan, Daiming; Nie, Yongzhan; Wu, Kaichun; Xia, Limin			SOX18 promotes gastric cancer metastasis through transactivating MCAM and CCL7	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; CARCINOMA; PROLIFERATION; EXPRESSION; INVASION; CHEMOKINES; MOLECULE; MELANOMA; CELLS	The therapeutic strategies for advanced gastric cancer (GC) remain unsatisfying and limited. Therefore, it is still imperative to fully elucidate the mechanisms underlying GC metastasis. Here, we report a novel role of SRY-box transcription factor 18 (SOX18), a member of the SOX family, in promoting GC metastasis. The elevated expression of SOX18 was positively correlated with distant metastasis, higher AJCC stage, and poor prognosis in human GC. SOX18 expression was an independent and significant risk factor for the recurrence and survival in GC patients. Up-regulation of SOX18 promoted GC invasion and metastasis, whereas down-regulation of SOX18 decreased GC invasion and metastasis. Melanoma cell adhesion molecule (MCAM) and C-C motif chemokine ligand 7 (CCL7) are direct transcriptional targets of SOX18. Knockdown of MCAM and CCL7 significantly decreased SOX18-mediated GC invasion and metastasis, while the stable overexpression of MCAM and CCL7 reversed the decrease in cell invasion and metastasis that was induced by the inhibition of SOX18. A mechanistic investigation indicated that the upregulation of SOX18 that was mediated by the CCL7-CCR1 pathway relied on the ERK/ELK1 pathway. SOX18 knockdown significantly reduced CCL7-enhanced GC invasion and metastasis. Furthermore, BX471, a specific CCR1 inhibitor, significantly reduced the SOX18-mediated GC invasion and metastasis. In human GC tissues, SOX18 expression was positively correlated with CCL7 and MCAM expression, and patients with positive coexpression of SOX18/CCL7 or SOX18/MCAM had the worst prognosis. In conclusion, we defined a CCL7-CCR1-SOX18 positive feedback loop that played a pivotal role in GC metastasis, and targeting this pathway may be a promising therapeutic option for the clinical management of GC.	[Chen, Jie; Liu, Danfei; Zhang, Tongyue; Wang, Yijun; Tian, Dean; Xia, Limin] Huazhong Univ Sci & Technol, Dept Gastroenterol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Peoples R China; [Chen, Jie; Dang, Yunzhi; Feng, Weibo; Qiao, Chenyang; Fan, Daiming; Nie, Yongzhan; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Chen, Jie; Dang, Yunzhi; Feng, Weibo; Qiao, Chenyang; Fan, Daiming; Nie, Yongzhan; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China	Huazhong University of Science & Technology; Air Force Military Medical University; Air Force Military Medical University	Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Dept Gastroenterol, Inst Liver & Gastrointestinal Dis, Tongji Hosp,Tongji Med Coll, Wuhan 430030, Peoples R China.; Xia, LM (corresponding author), Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian 710032, Peoples R China.; Xia, LM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China.	xialimin@tjh.tjmu.edu.cn	Wang, Yijun/GXW-1763-2022		National Key Research and Development Program of China [2018YFC1312103]; National Natural Science Foundation of China [81972237, 81772623]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Research was supported by grants from the National Key Research and Development Program of China 2018YFC1312103 (L.X.), National Natural Science Foundation of China No. 81972237 (L.X.), and No. 81772623 (L.X.).	Barbarani G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39926-4; Bie LY, 2019, ARTIF CELL NANOMED B, V47, P3180, DOI 10.1080/21691401.2019.1646751; Chang WJ, 2014, WORLD J GASTROENTERO, V20, P4586, DOI 10.3748/wjg.v20.i16.4586; Chen G, 2012, J BIOL CHEM, V287, P12132, DOI 10.1074/jbc.M111.302299; Chen L, 2015, CANCER RES, V75, P3832, DOI 10.1158/0008-5472.CAN-14-3690; Cheng JW, 2014, CYTOKINE, V69, P277, DOI 10.1016/j.cyto.2014.06.007; Dang YN, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109430; Du F, 2020, ONCOGENE, V39, P3522, DOI 10.1038/s41388-020-1233-4; Du F, 2019, CANCER LETT, V452, P103, DOI 10.1016/j.canlet.2019.03.035; Duong T, 2012, CANCER RES, V72, P3105, DOI 10.1158/0008-5472.CAN-11-4026; Fontaine F, 2017, CELL CHEM BIOL, V24, P346, DOI 10.1016/j.chembiol.2017.01.003; Gladue RP, 2010, CURR TOP MED CHEM, V10, P1268; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Higashijima Y, 2020, SEMIN CANCER BIOL, V67, P39, DOI 10.1016/j.semcancer.2019.09.008; Hwang TL, 2012, WORLD J GASTROENTERO, V18, P1249, DOI 10.3748/wjg.v18.i11.1249; Jethon A, 2015, INT J ONCOL, V46, P123, DOI 10.3892/ijo.2014.2698; Julian LM, 2017, CURR OPIN GENET DEV, V46, P24, DOI 10.1016/j.gde.2017.06.005; Jung DW, 2010, INT J CANCER, V127, P332, DOI 10.1002/ijc.25060; Kasza A, 2013, BBA-GENE REGUL MECH, V1829, P1026, DOI 10.1016/j.bbagrm.2013.05.004; Kitamura T, 2010, P NATL ACAD SCI USA, V107, P13063, DOI 10.1073/pnas.1002372107; Klaus M, 2016, NUCLEIC ACIDS RES, V44, P3922, DOI 10.1093/nar/gkw130; Kumar P, 2020, SEMIN CANCER BIOL, V67, P105, DOI 10.1016/j.semcancer.2019.06.016; Kuzuhara T, 2007, J CANCER RES CLIN, V133, P287, DOI 10.1007/s00432-006-0169-6; Lee HJ, 2014, WORLD J GASTROENTERO, V20, P1681, DOI 10.3748/wjg.v20.i7.1681; Lee YS, 2016, ONCOTARGET, V7, P36842, DOI 10.18632/oncotarget.9209; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Levin AA, 2019, NEW ENGL J MED, V380, P57, DOI 10.1056/NEJMra1705346; Liang M, 2000, J BIOL CHEM, V275, P19000, DOI 10.1074/jbc.M001222200; Liu YY, 2018, PEERJ, V6, DOI 10.7717/peerj.4928; Man CH, 2015, BLOOD, V125, P3928, DOI 10.1182/blood-2014-06-580993; Miao ZH, 2018, ONCOTARGETS THER, V11, P8481, DOI 10.2147/OTT.S178916; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Overman J, 2017, ELIFE, V6, DOI 10.7554/eLife.21221; Pei XH, 2014, BIOCHEM BIOPH RES CO, V446, P322, DOI 10.1016/j.bbrc.2014.02.109; Pula B, 2014, ANTICANCER RES, V34, P4029; Qin YR, 2011, CLIN CANCER RES, V17, P46, DOI 10.1158/1078-0432.CCR-10-1155; Santos JC, 2016, CANCER RES, V76, P6735, DOI 10.1158/0008-5472.CAN-16-1120; SERS C, 1994, CANCER RES, V54, P5689; Tan DS, 2020, SEMIN CANCER BIOL, V67, P65, DOI 10.1016/j.semcancer.2019.08.008; Thrumurthy SG, 2015, NAT REV CLIN ONCOL, V12, P676, DOI 10.1038/nrclinonc.2015.132; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang D, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0461-2; Wang GM, 2015, ONCOL REP, V34, P1121, DOI 10.3892/or.2015.4112; Wang J, 2016, ONCOGENE, V35, P1692, DOI 10.1038/onc.2015.234; Wang L, 2019, FASEB J, V33, P254, DOI 10.1096/fj.201701453RR; Wang ZQ, 2013, CANCER LETT, V330, P150, DOI 10.1016/j.canlet.2012.11.049; Wu GJ, 2001, GENE, V279, P17, DOI 10.1016/S0378-1119(01)00736-3; You JX, 2019, ONCOTARGETS THER, V12, P2465, DOI 10.2147/OTT.S197087; Zeng QQ, 2012, P NATL ACAD SCI USA, V109, P1127, DOI 10.1073/pnas.1111053108; Zhang JX, 2016, ONCOL REP, V35, P3721, DOI 10.3892/or.2016.4746; Zhang Y, 2009, CANCER LETT, V277, P29, DOI 10.1016/j.canlet.2008.11.014; Zhou HL, 2019, ONCOL LETT, V18, P599, DOI 10.3892/ol.2019.10387; Zhu Y, 2018, CANCER SCI, V109, P710, DOI 10.1111/cas.13487	55	12	12	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5536	5552		10.1038/s41388-020-1378-1	http://dx.doi.org/10.1038/s41388-020-1378-1		JUL 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32616889				2022-12-17	WOS:000545059900002
J	El Jamal, SM; Alamodi, A; Wahl, RU; Grada, Z; Shareef, MA; Hassan, SY; Murad, F; Hassan, SL; Santourlidis, S; Gomez, CR; Haikel, Y; Megahed, M; Hassan, M				Jamal, Siraj M. El; Alamodi, Abdulhadi; Wahl, Renate U.; Grada, Zakaria; Shareef, Mohammad Abrar; Hassan, Sofie-Yasmin; Murad, Fadi; Hassan, Sarah-Lilly; Santourlidis, Simeon; Gomez, Christian R.; Haikel, Youssef; Megahed, Mosaad; Hassan, Mohamed			Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways	ONCOGENE			English	Article							KINASE C-YES; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; ELEVATED EXPRESSION; INDUCED APOPTOSIS; THERAPEUTIC TARGET; PHASE-III; ACTIVATION; MULTICENTER; INHIBITOR	Melanoma stem cells (MSCs) are characterized by their unique cell surface proteins and aberrant signaling pathways. These stemness properties are either in a causal or consequential relationship to melanoma progression, treatment resistance and recurrence. The functional analysis of CD133(+)and CD133(-)cells in vitro and in vivo revealed that melanoma progression and treatment resistance are the consequences of CD133 signal to PI3K pathway. CD133 signal to PI3K pathway drives two downstream pathways, the PI3K/Akt/MDM2 and the PI3K/Akt/MKP-1 pathways. Activation of PI3K/Akt/MDM2 pathway results in the destabilization of p53 protein, while the activation of PI3K/Akt/MKP-1 pathway results in the inhibition of mitogen-activated protein kinases (MAPKs) JNK and p38. Activation of both pathways leads to the inhibition of fotemustine-induced apoptosis. Thus, the disruption of CD133 signal to PI3K pathway is essential to overcome Melanoma resistance to fotemustine. The pre-clinical verification of in vitro data using xenograft mouse model of MSCs confirmed the clinical relevance of CD133 signal as a therapeutic target for melanoma treatment. In conclusion, our study provides an insight into the mechanisms regulating MSCs growth and chemo-resistance and suggested a clinically relevant approach for melanoma treatment.	[Jamal, Siraj M. El] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Alamodi, Abdulhadi] Jackson State Univ, Sch Publ Hlth, Jackson, MS USA; [Wahl, Renate U.; Hassan, Sofie-Yasmin; Hassan, Sarah-Lilly; Megahed, Mosaad] Univ Hosp Aachen, Clin Dermatol, Aachen, Germany; [Grada, Zakaria] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; [Shareef, Mohammad Abrar] Eastern Maine Med Ctr, Dept Internal Med, Bangor, ME USA; [Murad, Fadi] Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Santourlidis, Simeon] Heinrich Heine Univ Duesseldorf, Inst Transplantat Diagnost & Cell Therapeut, Epigenet Core Lab, Med Fac, Dusseldorf, Germany; [Gomez, Christian R.] Univ Mississippi, Med Ctr, Dept Pathol, Jackson, MS 39216 USA; [Haikel, Youssef; Hassan, Mohamed] INSERM, Strasbourg, France; [Haikel, Youssef] Univ Strasbourg, Dept Operat Dent & Endodont, Dent Fac, Strasbourg, France; [Hassan, Mohamed] Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA	Icahn School of Medicine at Mount Sinai; Jackson State University; RWTH Aachen University; RWTH Aachen University Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Eastern Maine Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Heinrich Heine University Dusseldorf; University of Mississippi; University of Mississippi Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tulane University	Hassan, M (corresponding author), INSERM, Strasbourg, France.; Hassan, M (corresponding author), Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA.	dr.hassan@gmx.de	Jamal, Siraj M El/J-2603-2013; Hassan, Mohamed/AHE-7565-2022; Jamal, Siraj El/AAJ-1728-2021	Jamal, Siraj M El/0000-0001-6299-1071; Jamal, Siraj El/0000-0001-6299-1071; Santourlidis, Simeon/0000-0002-0743-5336	German Research Foundation [HA 5081/3-1]; L' Alsace contre le cancer, France; German cancer research foundation [10-2202-Ha 1]	German Research Foundation(German Research Foundation (DFG)); L' Alsace contre le cancer, France; German cancer research foundation	This work was supported by grants from German Research Foundation (HA 5081/3-1), from L' Alsace contre le cancer, France, German cancer research foundation (10-2202-Ha 1) to MH.	Assouline SE, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.71; Aveic S, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0341-2; Bagrodia S, 2012, PIGM CELL MELANOMA R, V25, P819, DOI 10.1111/pcmr.12007; Beasley GM, 2015, ANN SURG ONCOL, V22, P287, DOI 10.1245/s10434-014-3887-z; Bright R, 2017, J IMMUNOTHER, V40, P21, DOI 10.1097/CJI.0000000000000149; de Polo A, 2017, J MOL CELL BIOL, V9, P154, DOI 10.1093/jmcb/mjw045; Desvignes C, 2017, MELANOMA RES, V27, P281, DOI 10.1097/CMR.0000000000000350; Dong CY, 2016, ONCOTARGET, V7, P8850, DOI 10.18632/oncotarget.7091; Easty DJ, 2011, PIGM CELL MELANOMA R, V24, P446, DOI 10.1111/j.1755-148X.2011.00836.x; El Jamal SM, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0023-4; El-Khattouti A, 2016, J CELL MOL MED, V20, P266, DOI 10.1111/jcmm.12718; El-Khattouti A, 2015, CANCER LETT, V357, P83, DOI 10.1016/j.canlet.2014.10.043; El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034; El-Khattouti A, 2014, CANCER LETT, V343, P123, DOI 10.1016/j.canlet.2013.09.024; Fenouille N, 2011, ONCOGENE, V30, P4887, DOI 10.1038/onc.2011.198; Fujii Y, 2018, INTERNAL MED, V57, P1173, DOI 10.2169/internalmedicine.8910-17; Ganesh S, 2018, MOL CANCER THER, V17, P544, DOI 10.1158/1535-7163.MCT-17-0605; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Gen Y, 2013, CANCER SCI, V104, P810, DOI 10.1111/cas.12155; del Alba AG, 2017, CRIT REV ONCOL HEMAT, V113, P171, DOI 10.1016/j.critrevonc.2017.03.010; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; Hassan M, 2016, J CELL BIOCHEM, V117, P1308, DOI 10.1002/jcb.25419; Hays JL, 2003, J BIOL CHEM, V278, P27456, DOI 10.1074/jbc.M210648200; Ichimura K, 2000, CANCER RES, V60, P417; Jang JW, 2017, LIFE SCI, V184, P25, DOI 10.1016/j.lfs.2017.07.008; Jazirehi AR, 2014, AM J CLIN EXP IMMUNO, V3, P43; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022; Kakavand H, 2017, MODERN PATHOL, V30, P1666, DOI 10.1038/modpathol.2017.89; Kaufmann R, 2005, J CLIN ONCOL, V23, P9001, DOI 10.1200/JCO.2005.01.1551; Kawaguchi K, 2018, ONCOTARGET, V9, P915, DOI [10.18632/oncotarget.24996, 10.18632/oncotarget.23185]; Ko A, 2018, MOL CELLS, V41, P381, DOI 10.14348/molcells.2018.0100; Ko HM, 2018, BIOCHEM BIOPH RES CO, V495, P1214, DOI 10.1016/j.bbrc.2017.11.143; Kumar D, 2016, J INVEST DERMATOL, V136, P2462, DOI 10.1016/j.jid.2016.07.024; Lee J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695534; Lee WR, 2016, MOL CARCINOGEN, V55, P1542, DOI 10.1002/mc.22407; Li H, 2018, ACTA PHARMACOL SIN, V39, P1787, DOI 10.1038/s41401-018-0034-6; Li ZH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006436; Liu FR, 2018, ONCOL REP, V39, P1523, DOI 10.3892/or.2018.6188; Liu MX, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.114.117754; LOGANZO F, 1993, ONCOGENE, V8, P2637; Ma LJ, 2016, TUMOR BIOL, V37, P12889, DOI 10.1007/s13277-016-5209-5; Maio M, 2018, LANCET ONCOL, V19, P510, DOI 10.1016/S1470-2045(18)30106-2; Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; Meng Y, 2018, EUR J HEALTH ECON, V19, P1163, DOI 10.1007/s10198-018-0964-4; Michaelis M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.129; Munugalavadla V, 2007, BLOOD, V110, P1612, DOI 10.1182/blood-2006-10-053058; Nadel G, 2018, CELL PHYSIOL BIOCHEM, V50, P121, DOI 10.1159/000493963; Nikolic N, 2015, ARCH ORAL BIOL, V60, P1662, DOI 10.1016/j.archoralbio.2015.08.011; Oo AKK, 2018, TRANSL ONCOL, V11, P653, DOI 10.1016/j.tranon.2018.03.001; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037; Pulluri B, 2017, PHARMACOL RES, V123, P95, DOI 10.1016/j.phrs.2017.07.006; Roesch A, 2016, EUR J CANCER, V59, P109, DOI 10.1016/j.ejca.2016.02.023; Schadendorf D, 2015, EUR J CANCER, V51, P833, DOI 10.1016/j.ejca.2015.03.004; Segrelles C, 2014, STEM CELLS, V32, P1917, DOI 10.1002/stem.1669; Selimovic D, 2013, CELL SIGNAL, V25, P308, DOI 10.1016/j.cellsig.2012.10.004; Selimovic D, 2012, J CELL MOL MED, V16, P349, DOI 10.1111/j.1582-4934.2011.01304.x; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sun HY, 2011, EXP BIOL MED, V236, P352, DOI 10.1258/ebm.2010.010106; Tanaka K, 2009, P JPN ACAD B-PHYS, V85, P12, DOI [10.2183/pjab.85.12, 10.2183/pjab/85.12]; van den Hurk K, 2012, BBA-REV CANCER, V1826, P89, DOI 10.1016/j.bbcan.2012.03.011; Verstraete K, 2012, NAT REV CANCER, V12, P753, DOI 10.1038/nrc3371; Wang Haibin, 2018, Oncotarget, V9, P35512, DOI 10.18632/oncotarget.26283; Wang YH, 2018, J PATHOL, V246, P508, DOI 10.1002/path.5164; Wang Z, 2018, CELL SIGNAL, V52, P137, DOI 10.1016/j.cellsig.2018.09.007; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Yadav V, 2012, J BIOL CHEM, V287, P28087, DOI 10.1074/jbc.M112.377218; Yang H, 2017, ONCOGENE, V36, P3842, DOI 10.1038/onc.2016.526; Yao DY, 2013, HUM PATHOL, V44, P844, DOI 10.1016/j.humpath.2012.08.009; Yoshimoto N, 2017, METHODS MOL BIOL, V1487, P35, DOI 10.1007/978-1-4939-6424-6_3; Zhao Y, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0288-x	74	12	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5468	5478		10.1038/s41388-020-1373-6	http://dx.doi.org/10.1038/s41388-020-1373-6		JUL 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32616888				2022-12-17	WOS:000545059900001
J	Aubry, A; Pearson, JD; Huang, K; Livne-Bar, I; Ahmad, M; Jagadeesan, M; Khetan, V; Ketela, T; Brown, KR; Yu, T; Lu, SY; Wrana, JL; Moffat, J; Bremner, R				Aubry, Arthur; Pearson, Joel D.; Huang, Katherine; Livne-Bar, Izhar; Ahmad, Mohammad; Jagadeesan, Madhavan; Khetan, Vikas; Ketela, Troy; Brown, Kevin R.; Yu, Tao; Lu, Suying; Wrana, Jeffrey L.; Moffat, Jason; Bremner, Rod			Functional genomics identifies new synergistic therapies for retinoblastoma	ONCOGENE			English	Article							DNA-REPAIR; TUMOR-SUPPRESSOR; INTRAVITREAL CHEMOTHERAPY; HOMOLOGOUS RECOMBINATION; BRCA1 INTERACTS; RB INACTIVATION; VITREOUS SEEDS; CELL-DEATH; PATHWAY; PROTEIN	Local intravitreal or intra-arterial chemotherapy has improved therapeutic success for the pediatric cancer retinoblastoma (RB), but toxicity remains a major caveat. RB initiates primarily withRB1loss or, rarely,MYCNamplification, but the critical downstream networks are incompletely understood. We set out to uncover perturbed molecular hubs, identify synergistic drug combinations to target these vulnerabilities, and expose and overcome drug resistance. We applied dynamic transcriptomic analysis to identify network hubs perturbed in RB versus normal fetal retina, and performed in vivo RNAi screens inRB1(null)andRB1(wt);MYCN(amp)orthotopic xenografts to pinpoint essential hubs. We employed in vitro and in vivo studies to validate hits, define mechanism, develop new therapeutic modalities, and understand drug resistance. We identified BRCA1 and RAD51 as essential for RB cell survival. Their oncogenic activity was independent of BRCA1 functions in centrosome, heterochromatin, or ROS regulation, and instead linked to DNA repair. RAD51 depletion or inhibition with the small molecule inhibitor, B02, killed RB cells in a Chk1/Chk2/p53-dependent manner. B02 further synergized with clinically relevant topotecan (TPT) to engage this pathway, activating p53-BAX mediated killing of RB but not human retinal progenitor cells. Paradoxically, a B02/TPT-resistant tumor exhibited more DNA damage than sensitive RB cells. Resistance reflected dominance of the p53-p21 axis, which mediated cell cycle arrest instead of death. Deleting p21 or applying the BCL2/BCL2L1 inhibitor Navitoclax re-engaged the p53-BAX axis, and synergized with B02, TPT or both to override resistance. These data expose new synergistic therapies to trigger p53-induced killing in diverse RB subtypes.	[Aubry, Arthur; Pearson, Joel D.; Huang, Katherine; Ahmad, Mohammad; Yu, Tao; Lu, Suying; Wrana, Jeffrey L.; Bremner, Rod] Sinai Hlth, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Aubry, Arthur; Pearson, Joel D.; Bremner, Rod] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Pearson, Joel D.; Livne-Bar, Izhar; Bremner, Rod] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada; [Livne-Bar, Izhar] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada; [Jagadeesan, Madhavan] Sankara Nethralaya, Vis Res Fdn, Chennai, Tamil Nadu, India; [Khetan, Vikas] Sankara Nethralaya, Dept Vitroretina & Ocular Oncol, Chennai, Tamil Nadu, India; [Ketela, Troy; Brown, Kevin R.; Moffat, Jason] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [Wrana, Jeffrey L.; Moffat, Jason] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Jagadeesan, Madhavan] Dualhelix Genet Diagnost, Chennai, Tamil Nadu, India	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; Krembil Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Bremner, R (corresponding author), Sinai Hlth, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.; Bremner, R (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	bremner@lunenfeld.ca	Bremner, Rod/I-6490-2012; Moffat, Jason/AAC-1110-2020; Pearson, Joel/AFK-9248-2022	Bremner, Rod/0000-0001-9184-7212; Moffat, Jason/0000-0002-5663-8586; Aubry, Arthur/0000-0002-4344-1194; Khetan, Vikas/0000-0003-4396-9877	Canadian Institutes for Health Research (CIHR) [153128]; Cancer Research Society; Krembil Foundation	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Krembil Foundation	This work was funded by grants to RB from the Canadian Institutes for Health Research (CIHR) Grant #153128, The Cancer Research Society, and the Krembil Foundation.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abramson DH, 2015, JAMA OPHTHALMOL, V133, P1341, DOI 10.1001/jamaophthalmol.2015.3108; Anderson SN, 2007, J BIOMOL SCREEN, V12, P938, DOI 10.1177/1087057107306130; Aubry A, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0237-8; Banerjee R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5527; Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Camp DA, 2019, J AAPOS, V23, P241, DOI 10.1016/j.jaapos.2019.03.002; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chu WK, 2016, P NATL ACAD SCI USA, V113, P14396, DOI 10.1073/pnas.1617427113; Clairmont CS, 2020, NAT CELL BIOL, V22, P87, DOI 10.1038/s41556-019-0442-y; Cook R, 2015, CELL REP, V10, P2006, DOI 10.1016/j.celrep.2015.02.059; Corella AN, 2020, CLIN CANCER RES, V26, P1667, DOI 10.1158/1078-0432.CCR-19-0775; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; De Francesco S, 2015, INT OPHTHALMOL, V35, P887, DOI 10.1007/s10792-015-0129-8; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dimaras H, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.21; Dizin E, 2006, J BIOL CHEM, V281, P24236, DOI 10.1074/jbc.M602176200; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Elison JR, 2006, ARCH OPHTHALMOL-CHIC, V124, P1269, DOI 10.1001/archopht.124.9.1269; Etemadmoghadam D, 2013, P NATL ACAD SCI USA, V110, P19489, DOI 10.1073/pnas.1314302110; FITZSIMMONS J, 1994, EARLY HUM DEV, V38, P121, DOI 10.1016/0378-3782(94)90223-2; Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149; Francis JH, 2017, OPHTHALMOLOGY, V124, P1548, DOI 10.1016/j.ophtha.2017.04.010; Francis JH, 2015, OPHTHALMOLOGY, V122, P1173, DOI 10.1016/j.ophtha.2015.01.017; Garsed DW, 2018, CLIN CANCER RES, V24, P569, DOI 10.1158/1078-0432.CCR-17-1621; Gavande NS, 2016, PHARMACOL THERAPEUT, V160, P65, DOI 10.1016/j.pharmthera.2016.02.003; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Huang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100993; Huang F, 2011, ACS CHEM BIOL, V6, P628, DOI 10.1021/cb100428c; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Knudsen ES, 2006, CURR MOL MED, V6, P749; Landreville S, 2010, CURR EYE RES, V35, P435, DOI 10.3109/02713680903509428; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2002, CANCER RES, V62, P301; Laurie NA, 2007, CURR CANCER DRUG TAR, V7, P689, DOI 10.2174/156800907782418266; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lemaitre S, 2020, CLIN EXP OPHTHALMOL, V48, P500, DOI 10.1111/ceo.13711; Liang TY, 2020, INT J OPHTHALMOL-CHI, V13, P257, DOI 10.18240/ijo.2020.02.09; Liu JC, 2018, CELL REP, V23, P112, DOI 10.1016/j.celrep.2018.03.039; Lochmann TL, 2018, CLIN CANCER RES, V24, P360, DOI 10.1158/1078-0432.CCR-17-1606; Maclay T, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-363; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Marshall AE, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00105-19; MIYASHITA T, 1995, CELL, V80, P293; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Munier FL, 2012, BRIT J OPHTHALMOL, V96, P1078, DOI 10.1136/bjophthalmol-2011-301450; Nam C, 2010, HISTOL HISTOPATHOL, V25, P485, DOI 10.14670/HH-25.485; Oser MG, 2019, CANCER DISCOV, V9, P230, DOI 10.1158/2159-8290.CD-18-0389; Pajovic S, 2011, INVEST OPHTH VIS SCI, V52, P7618, DOI 10.1167/iovs.11-7989; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Qi DL, 2017, ONCOGENE, V36, P1760, DOI 10.1038/onc.2016.350; Rasmussen RD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13398; Rudin CM, 2012, CLIN CANCER RES, V18, P3163, DOI 10.1158/1078-0432.CCR-11-3090; Rushlow DE, 2013, LANCET ONCOL, V14, P327, DOI 10.1016/S1470-2045(13)70045-7; Sangwan M, 2012, ONCOGENE, V31, P5019, DOI 10.1038/onc.2011.654; Schuster A, 2019, TRENDS BIOTECHNOL, V37, P38, DOI 10.1016/j.tibtech.2018.08.002; Shepard T.H., 1975, GROWTH DEV HUMAN EMB; Shields CL, 2014, JAMA OPHTHALMOL, V132, P319, DOI 10.1001/jamaophthalmol.2013.7666; Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104; Suvarna V, 2019, EUR J PHARMACOL, V862, DOI 10.1016/j.ejphar.2019.172655; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522; Thangavel C, 2014, CLIN CANCER RES, V20, P5468, DOI 10.1158/1078-0432.CCR-14-0326; To KH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-69; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Tsui JY, 2008, INVEST OPHTH VIS SCI, V49, P490, DOI 10.1167/iovs.07-0653; Velez-Cruz R, 2016, GENE DEV, V30, P2500, DOI 10.1101/gad.288282.116; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Yang Y, 2013, INT J MOL MED, V32, P137, DOI 10.3892/ijmm.2013.1374; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371	81	12	12	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5338	5357		10.1038/s41388-020-1372-7	http://dx.doi.org/10.1038/s41388-020-1372-7		JUN 2020	20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32572160	hybrid, Green Published			2022-12-17	WOS:000542723000002
J	Chao, HH; Karagounis, IV; Thomas, C; Francois, NB; Facciabene, A; Koumenis, C; Maity, A				Chao, Hann-Hsiang; Karagounis, Ilias, V; Thomas, Christoforos; Francois, Noeulle B.; Facciabene, Andrea; Koumenis, Constantinos; Maity, Amit			Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation	ONCOGENE			English	Article							INTERFERON REGULATORY FACTOR-3; CYTOSOLIC DNA SENSOR; KINASE INHIBITOR; MITOTIC ENTRY; STING PATHWAY; S-PHASE; CHECKPOINT; CELLS; PEMBROLIZUMAB; CANCER	We explore a novel strategy of activating immune signaling through increased micronuclei formation utilizing a cell cycle checkpoint inhibitor to drive cell cycle progression following ionizing radiation. The Chk1/2 inhibitor AZD7762 is used to abrogate radiation therapy (RT)-induced G2/M cell cycle arrest in multiple cell lines and, we find that this therapeutic combination promotes increased micronuclei formation in vitro and subsequently drives increased type I interferon signaling and cytotoxic T-cell activation. In vivo studies using B16-F10 melanoma cancer cells implanted in C57/BL6 mice demonstrate improved rates of tumor control at the abscopal (unirradiated) site, located outside of the radiation field, only in the AZD7762 + RT group, with a corresponding reduction in mean tumor volume, increase in the CD8 T-cell population, and immune activated gene signaling. Our results demonstrate that targeted inhibition of cell cycle checkpoint activation following ionizing radiation drives increased production of immunogenic micronuclei, leading to systemic tumor response with potential future clinical benefit.	[Chao, Hann-Hsiang; Karagounis, Ilias, V; Thomas, Christoforos; Francois, Noeulle B.; Facciabene, Andrea; Koumenis, Constantinos; Maity, Amit] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Chao, Hann-Hsiang] McGuire VA Med Ctr, Dept Radiat Oncol, Richmond, VA USA	University of Pennsylvania; Hunter Holmes McGuire Veterinary Affairs Medical Center	Maity, A (corresponding author), Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.	Amit.Maity@uphs.upenn.edu	Karagounis, Ilias V/A-6497-2013	Karagounis, Ilias V/0000-0003-1642-1996; Maity, Amit/0000-0001-7151-2845; Koumenis, Costas/0000-0001-5945-4726	NIH/NCI grant [1R01CA182747]; University of Pennsylvania Radiation Oncology Resident Research Award	NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pennsylvania Radiation Oncology Resident Research Award	This study was supported by NIH/NCI grant (1R01CA182747 (PI: AM, CK) and the University of Pennsylvania Radiation Oncology Resident Research Award (to H-HC). The authors thank Roger Greenberg group for contribution of cGAS constructs.	Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen Q, 2016, NAT IMMUNOL, V17, P1142, DOI 10.1038/ni.3558; Cuneo KC, 2019, J CLIN ONCOL, V37, P2643, DOI 10.1200/JCO.19.00730; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Dillon MT, 2017, MOL CANCER THER, V16, P25, DOI 10.1158/1535-7163.MCT-16-0239; Diner EJ, 2013, CELL REP, V3, P1355, DOI 10.1016/j.celrep.2013.05.009; Dou ZX, 2017, NATURE, V550, P402, DOI 10.1038/nature24050; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Guzi TJ, 2011, MOL CANCER THER, V10, P591, DOI 10.1158/1535-7163.MCT-10-0928; Hamilton DH, 2014, CANCER RES, V74, P2510, DOI 10.1158/0008-5472.CAN-13-1894; Harding SM, 2017, NATURE, V548, P466, DOI 10.1038/nature23470; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; KASTAN MB, 1991, CANCER RES, V51, P6304; Lu Hsu-Fung, 2007, Cancer Genomics & Proteomics, V4, P93; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Maity A, 2018, BRIT J CANCER, V119, P1200, DOI 10.1038/s41416-018-0281-9; Melms JC, 2020, CANCER RES, V80, P798, DOI 10.1158/0008-5472.CAN-19-2330; Moran DM, 2008, ONCOGENE, V27, P5567, DOI 10.1038/onc.2008.172; Morgan MA, 2010, CANCER RES, V70, P4972, DOI 10.1158/0008-5472.CAN-09-3573; Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824; Reck M, 2018, IMMUNOTHERAPY-UK, V10, P93, DOI 10.2217/imt-2017-0121; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Schoonen PM, 2019, MOL ONCOL, V13, P2422, DOI 10.1002/1878-0261.12573; Shaverdian N, 2017, LANCET ONCOL, V18, P895, DOI 10.1016/S1470-2045(17)30380-7; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Tao YG, 2009, CELL CYCLE, V8, P3172, DOI 10.4161/cc.8.19.9729; Thomas C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3358; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Vendetti FP, 2018, J CLIN INVEST, V128, P3926, DOI 10.1172/JCI96519; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Woo SR, 2015, TRENDS IMMUNOL, V36, P250, DOI 10.1016/j.it.2015.02.003; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zeng L, 2017, MOL CANCER THER, V16, P591, DOI 10.1158/1535-7163.MCT-16-0352; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	45	12	13	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4344	4357		10.1038/s41388-020-1300-x	http://dx.doi.org/10.1038/s41388-020-1300-x		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32335582	Green Accepted			2022-12-17	WOS:000528824400001
J	Uka, R; Britschgi, C; Krattli, A; Matter, C; Mihic, D; Okoniewski, MJ; Gualandi, M; Stupp, R; Cinelli, P; Dummer, R; Levesque, MP; Shakhova, O				Uka, Rexhep; Britschgi, Christian; Krattli, Anja; Matter, Claudia; Mihic, Daniela; Okoniewski, Michal J.; Gualandi, Marco; Stupp, Roger; Cinelli, Paolo; Dummer, Reinhard; Levesque, Mitchell P.; Shakhova, Olga			Temporal activation of WNT/beta-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth	ONCOGENE			English	Article							BETA-CATENIN; TRANSCRIPTION FACTOR; CUTANEOUS MELANOMA; MITF; CELL; PROGRESSION; IPILIMUMAB; IDENTIFICATION; MONOTHERAPY; VEMURAFENIB	Despite advances in the systemic treatment of patients with metastatic melanoma using immune checkpoint and tyrosine kinase inhibitors (TKI), the majority of stage IV melanoma patients eventually succumb to the disease. We have previously identified the transcription factor Sox10 as a crucial player in melanoma, yet the underlying molecular mechanisms mediating Sox10-dependent tumorigenesis remain largely uncharacterized. Here, we show that MEK and RAF inhibitors do not suppress levels of SOX10 protein in patient-derived cells in vitro, as well as in melanoma patients in vivo. In a search for pharmacological inhibitors of SOX10, we performed a mass spectrometry-based screen in human melanoma cells. Subsequent analysis revealed that SOX10 directly interacts with beta-catenin, which is a key mediator of canonical Wnt/beta-catenin signaling. We demonstrate that inhibitors of glycogen synthase kinase 3 alpha/beta (GSK3 alpha/beta) efficiently abrogate SOX10 protein in human melanoma cells in vitro and in melanoma mouse models in vivo. The mechanism of action of GSK3-mediated SOX10 suppression is transcription-independent and relies on the presence of a proteasome degradable form of beta-catenin. Taken together, we provide evidence that activation of canonical Wnt signaling has a profound effect on melanoma growth and is able to counteract Sox10-dependent melanoma maintenance both in vitro and in vivo.	[Uka, Rexhep; Britschgi, Christian; Krattli, Anja; Matter, Claudia; Gualandi, Marco; Stupp, Roger; Shakhova, Olga] Univ Zurich, Univ Hosp Zurich, Dept Med Oncol & Hematol, Wagistr 14, CH-8952 Schlieren, Switzerland; [Mihic, Daniela] Univ Zurich, Univ Hosp Zurich, Dept Surg Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland; [Okoniewski, Michal J.] Swiss Fed Inst Technol, Sci IT Serv ETH Zurich, Weinbergstr 11, CH-8092 Zurich, Switzerland; [Cinelli, Paolo] Univ Zurich, Univ Zurich Hosp, Dept Trauma Surg, Sternwartstr 1, CH-8091 Zurich, Switzerland; [Dummer, Reinhard; Levesque, Mitchell P.] Univ Zurich, Univ Zurich Hosp, Dept Dermatol, Wagistrasse 14, CH-8952 Schlieren, Switzerland; [Stupp, Roger] Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol, Chicago, IL 60611 USA; [Stupp, Roger] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Lou & Jean Malnati Brain Tumor Inst, Chicago, IL 60611 USA	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Shakhova, O (corresponding author), Univ Zurich, Univ Hosp Zurich, Dept Med Oncol & Hematol, Wagistr 14, CH-8952 Schlieren, Switzerland.	olga.shakhova@usz.ch		Britschgi, Christian/0000-0001-8831-1564	Oncosuisse; Promedica UBS Stiftung; Krebsliga Zurich; Novartis Research Foundation	Oncosuisse; Promedica UBS Stiftung; Krebsliga Zurich; Novartis Research Foundation	This work was supported by Oncosuisse, Promedica UBS Stiftung, Krebsliga Zurich, and Novartis Research Foundation to OS. We thank A. Serra-Roma, C-L Yang, O. Engeler for helpful suggestions and scientific discussions. We thank Dr Lorenza Penengo (Institute of Molecular Cancer Research University of Zurich) for technical support and suggestions. We thank Dr Jelena Kuhn-Georgijevic from Functional Genomic Center Zurich for her support in RNA sequencing. We thank Dr Daniel Zingg from Institute of Anatomy University of Zurich for kindly providing with Mel888 and Mel501 human melanoma cell lines. We thank Axel Zani and Redi Leraj for helping drawing the cartoons. We thank Cindy Lee for helpful discussion and critically reading of the manuscript. Finally, we would like to thank the University Research Priority Program (URPP) in translational cancer research biobank for the melanoma cell lines that were generated from surplus biopsy material from consenting patients at the University of Zurich Hospital (EK.647/800).	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156; Atkinson JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125028; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Bastidas F, 2004, DEV DYNAM, V229, P109, DOI 10.1002/dvdy.10486; Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274; Biechele TL, 2010, CHEM BIOL, V17, P1177, DOI 10.1016/j.chembiol.2010.08.012; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; Dummer R, 2015, ANN ONCOL, V26, pV126, DOI 10.1093/annonc/mdv297; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Grob JJ, 2015, LANCET ONCOL, V16, P1389, DOI 10.1016/S1470-2045(15)00087-X; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kaur A, 2016, BRIT J CANCER, V115, P1273, DOI 10.1038/bjc.2016.332; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Leung AW, 2016, DEVELOPMENT, V143, P398, DOI 10.1242/dev.130849; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Long GV, 2018, J CLIN ONCOL, V36, P667, DOI 10.1200/JCO.2017.74.1025; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maelandsmo GM, 2003, CLIN CANCER RES, V9, P3383; Nonaka D, 2008, AM J SURG PATHOL, V32, P1291, DOI 10.1097/PAS.0b013e3181658c14; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Rehberg S, 2002, MOL CELL BIOL, V22, P5826, DOI 10.1128/MCB.22.16.5826-5834.2002; Reifenberger J, 2002, INT J CANCER, V100, P549, DOI 10.1002/ijc.10512; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Tacha D, 2015, ARCH PATHOL LAB MED, V139, P530, DOI 10.5858/arpa.2014-0077-OA; Vasilescu J, 2004, PROTEOMICS, V4, P3845, DOI 10.1002/pmic.200400856; Webster MR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004114; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhou DJ, 2014, TUMOR BIOL, V35, P9935, DOI 10.1007/s13277-014-1893-1; Zimmerman ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069593	52	12	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4132	4154		10.1038/s41388-020-1267-7	http://dx.doi.org/10.1038/s41388-020-1267-7		APR 2020	23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32238882	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000522804800002
J	He, JC; McLaughlin, RP; van der Beek, L; Canisius, S; Wessels, L; Smid, M; Martens, JWM; Foekens, JA; Zhang, YH; van de Water, B				He, Jichao; McLaughlin, Ronan P.; van der Beek, Lambert; Canisius, Sander; Wessels, Lodewyk; Smid, Marcel; Martens, John W. M.; Foekens, John A.; Zhang, Yinghui; van de Water, Bob			Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; COPY NUMBER VARIATION; SURVIVAL; MYC; LANDSCAPE; IMPACT; REGION	The genetically heterogeneous triple-negative breast cancer (TNBC) continues to be an intractable disease, due to lack of effective targeted therapies. Gene amplification is a major event in tumorigenesis. Genes with amplification-dependent expression are being explored as therapeutic targets for cancer treatment. In this study, we have applied Analytical Multi-scale Identification of Recurring Events analysis and transcript quantification in the TNBC genome across 222 TNBC tumors and identified 138 candidate genes with positive correlation in copy number gain (CNG) and gene expression. siRNA-based loss-of-function screen of the candidate genes has validated EGFR, MYC, ASAP1, IRF2BP2, and CCT5 genes as drivers promoting proliferation in different TNBC cells. MYC, ASAP1, IRF2BP2, and CCT5 display frequent CNG and concurrent expression over 2173 breast cancer tumors (cBioPortal dataset). More frequently are MYC and ASAP1 amplified in TNBC tumors (>30%, n = 320). In particular, high expression of ASAP1, the ADP-ribosylation factor GTPase-activating protein, is significantly related to poor metastatic relapse-free survival of TNBC patients (n = 257, bc-GenExMiner). Furthermore, we have revealed that silencing of ASAP1 modulates numerous cytokine and apoptosis signaling components, such as IL1B, TRAF1, AIFM2, and MAP3K11 that are clinically relevant to survival outcomes of TNBC patients. ASAP1 has been reported to promote invasion and metastasis in various cancer cells. Our findings that ASAP1 is an amplification-dependent TNBC driver gene promoting TNBC cell proliferation, functioning upstream apoptosis components, and correlating to clinical outcomes of TNBC patients, support ASAP1 as a potential actionable target for TNBC treatment.	[He, Jichao; McLaughlin, Ronan P.; van der Beek, Lambert; Zhang, Yinghui; van de Water, Bob] Leiden Univ, Div Drug Discovery & Safety, Leiden Acad Ctr Drug Res, NL-2300 RA Leiden, Netherlands; [Canisius, Sander; Wessels, Lodewyk] Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; [Smid, Marcel; Martens, John W. M.; Foekens, John A.] Erasmus MC, Dept Med Oncol & Canc Genom Netherlands, Erasmus MC Canc Inst, NL-3000 CA Rotterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	van de Water, B (corresponding author), Leiden Univ, Div Drug Discovery & Safety, Leiden Acad Ctr Drug Res, NL-2300 RA Leiden, Netherlands.	b.water@lacdr.leidenuniv.nl		Zhang, Yinghui/0000-0003-1635-0278; Martens, John/0000-0002-3428-3366	ERC Advanced grant Triple-BC [322737]; China Scholarship Council	ERC Advanced grant Triple-BC; China Scholarship Council(China Scholarship Council)	This work was supported by the ERC Advanced grant Triple-BC (grant no. 322737). JH was financially supported by the China Scholarship Council.	Andreopoulou E, 2017, BREAST CARE, V12, P21, DOI 10.1159/000455821; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Chaignat E, 2011, GENOME RES, V21, P106, DOI 10.1101/gr.112748.110; Chiu AM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29992-5; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941; Fallah Y, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030053; Gamazon ER, 2015, BRIEF FUNCT GENOMICS, V14, P352, DOI 10.1093/bfgp/elv017; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; He JC, 2019, BREAST CANCER RES TR, V178, P263, DOI 10.1007/s10549-019-05380-z; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; Hou T, 2014, INT J CLIN EXP PATHO, V7, P280; Jandu H, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2071-1; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Jolly C, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1476-3; Kim MH, 2013, J CLIN INVEST, V123, P3211, DOI 10.1172/JCI65521; Kim Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13027-2; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krepischi ACV, 2012, EUR J CANCER, V48, pS134, DOI 10.1016/S0959-8049(12)71222-4; Kwok HF, 2015, AM J CANCER RES, V5, P52; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liang L, 2016, ONCOGENE, V35, P1475, DOI 10.1038/onc.2015.209; Lin D, 2008, CANCER RES, V68, P4352, DOI 10.1158/0008-5472.CAN-07-5237; Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02-01-0018; Long J, 2018, AM J CANCER RES, V8, P778; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Muller T, 2010, ONCOGENE, V29, P2393, DOI 10.1038/onc.2010.6; Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Rimawi MF, 2013, J CLIN ONCOL, V31, P1726, DOI 10.1200/JCO.2012.44.8027; Riquelme E, 2014, J THORAC ONCOL, V9, P998, DOI 10.1097/JTO.0000000000000202; Robertson AG, 2018, CANCER CELL, V33, P151, DOI 10.1016/j.ccell.2017.12.013; Sabe H, 2009, TRAFFIC, V10, P982, DOI 10.1111/j.1600-0854.2009.00917.x; Sandhu V, 2016, CANCER RES, V76, P5092, DOI 10.1158/0008-5472.CAN-16-0658; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Schaub FX, 2018, CELL SYST, V6, P282, DOI 10.1016/j.cels.2018.03.003; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shi YQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0850-9; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678; van Dyk E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12159; van Dyk E, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt155; Ventura Elisa, 2018, Oncoscience, V5, P278, DOI 10.18632/oncoscience.467; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang K, 2013, HEPATOLOGY, V58, P706, DOI 10.1002/hep.26402; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Weisman PS, 2016, MODERN PATHOL, V29, P476, DOI 10.1038/modpathol.2016.39; Zhang T, 2018, ONCOL LETT, V15, P4432, DOI 10.3892/ol.2018.7834; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883; Zhao ZM, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5290-4; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	54	12	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4118	4131		10.1038/s41388-020-1279-3	http://dx.doi.org/10.1038/s41388-020-1279-3		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32235890	hybrid, Green Published			2022-12-17	WOS:000522606000002
J	Chandrashekar, DS; Chakravarthi, BVSK; Robinson, AD; Anderson, JC; Agarwal, S; Balasubramanya, SAH; Eich, ML; Bajpai, AK; Davuluri, S; Guru, MS; Guru, AS; Naik, G; Della Manna, DL; Acharya, KK; Carskadon, S; Manne, U; Crossman, DK; Ferguson, JE; Grizzle, WE; Palanisamy, N; Willey, CD; Crowley, MR; Netto, GJ; Yang, ES; Varambally, S; Sonpavde, G				Chandrashekar, Darshan S.; Chakravarthi, Balabhadrapatruni V. S. K.; Robinson, Alyncia D.; Anderson, Joshua C.; Agarwal, Sumit; Balasubramanya, Sai Akshaya Hodigere; Eich, Marie-Lisa; Bajpai, Akhilesh Kumar; Davuluri, Sravanthi; Guru, Maya S.; Guru, Arjun S.; Naik, Gurudatta; Della Manna, Deborah L.; Acharya, Kshitish K.; Carskadon, Shannon; Manne, Upender; Crossman, David K.; Ferguson, James E.; Grizzle, William E.; Palanisamy, Nallasivam; Willey, Christopher D.; Crowley, Michael R.; Netto, George J.; Yang, Eddy S.; Varambally, Sooryanarayana; Sonpavde, Guru			Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression	ONCOGENE			English	Article							METASTATIC UROTHELIAL CARCINOMA; CISPLATIN-INELIGIBLE PATIENTS; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; SINGLE-ARM; CELLS; SURVIVAL; PROLIFERATION; CHEMOTHERAPY	Muscle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary malignancies. Metastatic urothelial carcinoma of the bladder is generally incurable by current chemotherapy and leads to early mortality. Recent studies have identified molecular subtypes of MIBCs with different sensitivities to frontline therapy, suggesting tumor heterogeneity. We have performed multi-omic profiling of the kinome in bladder cancer patients with the goal of identify therapeutic targets. Our analyses revealed amplification, overexpression, and elevated kinase activity of P21 (RAC1) activated kinase 4 (PAK4) in a subset of Bladder cancer (BLCA). Using bladder cancer cells, we confirmed the role of PAK4 in BLCA cell proliferation and invasion. Furthermore, we observed that a PAK4 inhibitor was effective in curtailing growth of BLCA cells. Transcriptomic analyses identified elevated expression of another kinase, protein tyrosine kinase 6 (PTK6), upon treatment with a PAK4 inhibitor and RNA interference of PAK4. Treatment with a combination of kinase inhibitors (vandetanib and dasatinib) showed enhanced sensitivity compared with either drug alone. Thus, PAK4 may be therapeutically actionable for a subset of MIBC patients with amplified and/or overexpressed PAK4 in their tumors. Our results also indicate that combined inhibition of PAK4 and PTK6 may overcome resistance to PAK4. These observations warrant clinical investigations with selected BLCA patients.	[Chandrashekar, Darshan S.; Chakravarthi, Balabhadrapatruni V. S. K.; Robinson, Alyncia D.; Agarwal, Sumit; Balasubramanya, Sai Akshaya Hodigere; Eich, Marie-Lisa; Manne, Upender; Grizzle, William E.; Netto, George J.; Varambally, Sooryanarayana] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Anderson, Joshua C.; Della Manna, Deborah L.; Willey, Christopher D.; Yang, Eddy S.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA; [Bajpai, Akhilesh Kumar; Davuluri, Sravanthi; Acharya, Kshitish K.] Shodhaka Life Sci Private Ltd, Bengaluru, India; [Guru, Maya S.; Guru, Arjun S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Naik, Gurudatta] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA; [Naik, Gurudatta; Manne, Upender; Netto, George J.; Yang, Eddy S.; Varambally, Sooryanarayana] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Acharya, Kshitish K.] Inst Bioinformat & Appl Biotechnol, Biotech Pk, Bengaluru 560100, Karnataka, India; [Carskadon, Shannon; Palanisamy, Nallasivam] Henry Ford Hlth Syst, Dept Urol, Vattikuti Urol Inst, Detroit, MI 48202 USA; [Crossman, David K.; Crowley, Michael R.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA; [Ferguson, James E.; Grizzle, William E.; Willey, Christopher D.] Univ Alabama Birmingham, Dept Urol, Birmingham, AL USA; [Varambally, Sooryanarayana] Univ Alabama Birmingham, Informat Inst, Birmingham, AL 35294 USA; [Sonpavde, Guru] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Henry Ford Health System; Henry Ford Hospital; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Dana-Farber Cancer Institute	Varambally, S (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.; Varambally, S (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA.; Varambally, S (corresponding author), Univ Alabama Birmingham, Informat Inst, Birmingham, AL 35294 USA.; Sonpavde, G (corresponding author), Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.	svarambally@uabmc.edu; GuruP_Sonpavde@DFCI.HARVARD.EDU	naik, Gurudatta/O-7284-2015; Palanisamy, Nallasivam/ABC-8844-2020	naik, Gurudatta/0000-0001-7265-6605; Palanisamy, Nallasivam/0000-0002-0633-9772; Netto, George/0000-0003-3915-9134; Anderson, Joshua/0000-0002-6977-9054	Department of Pathology of the University of Alabama at Birmingham; School of Medicine of the University of Alabama at Birmingham; Department of IT, BT and S&T, Government of Karnataka, India	Department of Pathology of the University of Alabama at Birmingham; School of Medicine of the University of Alabama at Birmingham; Department of IT, BT and S&T, Government of Karnataka, India	This study was supported in part by institutional funds (Department of Pathology and School of Medicine of the University of Alabama at Birmingham) awarded to SV. IBAB is supported by the Department of IT, BT and S&T, Government of Karnataka, India. The authors thank Dr Donald Hill for critical reading and editing of this manuscript.	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Anderson JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139267; [Anonymous], 2018, Cancer Discov, V8, pOF6, DOI 10.1158/2159-8290.CD-NB2018-085; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Balar AV, 2017, LANCET ONCOL, V18, P1483, DOI 10.1016/S1470-2045(17)30616-2; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bandiera S, 2015, J HEPATOL, V62, P448, DOI 10.1016/j.jhep.2014.10.004; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellmunt J, 2015, EUR UROL, V68, P547, DOI 10.1016/j.eururo.2015.04.025; Bennett RD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062347; Brooks MD, 2013, INT J DENT, V2013, DOI 10.1155/2013/592843; Callegari E, 2018, MOL THER-NUCL ACIDS, V11, P485, DOI 10.1016/j.omtn.2018.04.002; Chakravarthi BVSK, 2018, NEOPLASIA, V20, P894, DOI 10.1016/j.neo.2018.07.006; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen CJ, 2019, MOL MED REP, V19, P3477, DOI 10.3892/mmr.2019.10055; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Choudhury NJ, 2016, J CLIN ONCOL, V34, P2165, DOI 10.1200/JCO.2015.66.3047; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Conrad C, 2019, CLIN SCI, V133, P83, DOI 10.1042/CS20180906; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Griffiths G, 2011, J CLIN ONCOL, V29, P2171, DOI 10.1200/JCO.2010.32.3139; Grizzle W.E., 2005, MOL DIAGNOSTICS, V33, P421; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; Hao JQ, 2008, CHINESE MED J-PEKING, V121, P602, DOI 10.1097/00029330-200804010-00006; He LF, 2017, ONCOTARGET, V8, P17573, DOI 10.18632/oncotarget.7466; Huang XH, 2011, J PATHOL, V225, P463, DOI 10.1002/path.2877; Iguchi Y, 2015, CELL STRUCT FUNCT, V40, P61, DOI 10.1247/csf.15001; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Jacobs JJL, 1999, SEMIN CELL DEV BIOL, V10, P227, DOI 10.1006/scdb.1999.0304; Jian B, 2016, TUMOR BIOL, V37, P8941, DOI 10.1007/s13277-015-4727-x; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li N, 2019, CLIN CANCER RES, V25, P369, DOI 10.1158/1078-0432.CCR-18-1776; Li SQ, 2015, IUBMB LIFE, V67, P768, DOI 10.1002/iub.1433; Li YS, 2019, ONCOGENE, V38, P808, DOI 10.1038/s41388-018-0456-0; Loriot Y, 2019, NEW ENGL J MED, V381, P338, DOI 10.1056/NEJMoa1817323; Mahlamaki EH, 2004, NEOPLASIA, V6, P432, DOI 10.1593/neo.04130; Mao K, 2017, INT J ONCOL, V51, P1521, DOI 10.3892/ijo.2017.4122; McConkey DJ, 2015, HEMATOL ONCOL CLIN N, V29, P377, DOI 10.1016/j.hoc.2014.11.003; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Park JJ, 2018, ONCOGENE, V37, P5147, DOI 10.1038/s41388-018-0327-8; Petrylak DP, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.TPS497; Phatak Pornima, 2018, Oncotarget, V9, P28391, DOI 10.18632/oncotarget.25375; Puvirajesinghe TM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10318; Ravipaty Shobha, 2017, J Mol Biomark Diagn, V8, DOI 10.4172/2155-9929.1000323; Ricciardelli C, 2017, ONCOTARGET, V8, P17819, DOI 10.18632/oncotarget.14867; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rogers Michael S., 1999, Neoplasia (New York), V1, P220, DOI 10.1038/sj.neo.7900029; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sonpavde G, 2017, NEW ENGL J MED, V376, P1073, DOI 10.1056/NEJMe1701182; Sonpavde G, 2015, HEMATOL ONCOL CLIN N, V29, P361, DOI 10.1016/j.hoc.2014.10.008; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Thillai K, 2018, FUTURE ONCOL, V14, P579, DOI 10.2217/fon-2017-0458; Tyagi N, 2014, ONCOTARGET, V5, P8778, DOI 10.18632/oncotarget.2398; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Wang HY, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152559; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang Y, 2016, AM J TRANSL RES, V8, P3056; Xiao J, 2017, ONCOTARGET, V8, P71759, DOI 10.18632/oncotarget.17606; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Xu HT, 2016, CANCER RES, V76, P5732, DOI 10.1158/0008-5472.CAN-15-3373; Xu XL, 2017, J CANCER, V8, P3464, DOI 10.7150/jca.21318; Ye LP, 2018, INT J CANCER, V143, P2602, DOI 10.1002/ijc.31766; Yu W, 2009, CANCER GENET CYTOGEN, V193, P29, DOI 10.1016/j.cancergencyto.2009.03.017; Zeng B, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3949-2; Zhang HS, 2016, ARCH BIOCHEM BIOPHYS, V598, P50, DOI 10.1016/j.abb.2016.03.031	79	12	13	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4077	4091		10.1038/s41388-020-1275-7	http://dx.doi.org/10.1038/s41388-020-1275-7		MAR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32231273	Green Submitted			2022-12-17	WOS:000522380700002
J	Liu, XC; Cui, JF; Gong, L; Tian, F; Shen, YL; Chen, LP; Wang, Y; Xia, YY; Liu, L; Ye, X; Wang, ML; Liu, GY; Jiang, BC; Shao, CS; Zou, YX; Gong, YQ				Liu, Xiaochen; Cui, Jianfeng; Gong, Li; Tian, Fei; Shen, Yangli; Chen, Lipeng; Wang, Yong; Xia, Yangyang; Liu, Lei; Ye, Xiang; Wang, Molin; Liu, Guangyi; Jiang, Baichun; Shao, Changshun; Zou, Yongxin; Gong, Yaoqin			The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; PI3K/AKT PATHWAY; CUL4B; MUTATIONS; CELLS; TUMORIGENESIS; EXPRESSION; RESTRICTS; ENCODES; COMPLEX	CUL4B, which acts as a scaffold protein in CUL4B-RING ubiquitin ligase (CRL4B) complexes, participates in a variety of biological processes. Previous studies have shown that CUL4B is often overexpressed and exhibits oncogenic activities in a variety of solid tumors. However, the roles and the underlying mechanisms of CUL4B in bladder cancer (BC) were poorly understood. Here, we showed that CUL4B levels were overexpressed and positively correlated with the malignancy of BC, and CUL4B could confer BC cells increased motility, invasiveness, stemness, and chemoresistance. The PIK3CA/AKT pathway was identified as a critical downstream mediator of CUL4B-driven oncogenicity in BC cells. Furthermore, we demonstrated that CRL4B epigenetically repressed the transcription of miR-372/373, via catalyzing monoubiquitination of H2AK119 at the gene cluster encoding miR-372/373, leading to upregulation of PIK3CA and activation of AKT. Our findings thus establish a critical role for the CUL4B-miR-372/373-PIK3CA/AKT axis in the pathogenesis of BC and have important prognostic and therapeutic implications in BC.	[Liu, Xiaochen; Gong, Li; Tian, Fei; Shen, Yangli; Ye, Xiang; Wang, Molin; Jiang, Baichun; Zou, Yongxin; Gong, Yaoqin] Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan, Shandong, Peoples R China; [Liu, Xiaochen; Gong, Li; Tian, Fei; Shen, Yangli; Ye, Xiang; Wang, Molin; Jiang, Baichun; Zou, Yongxin; Gong, Yaoqin] Shandong Univ, Sch Basic Med Sci, Dept Mol Med & Genet, Jinan, Shandong, Peoples R China; [Cui, Jianfeng; Chen, Lipeng; Wang, Yong; Xia, Yangyang; Liu, Lei] Shandong Univ, Qilu Hosp, Dept Urol, Jinan, Shandong, Peoples R China; [Liu, Guangyi] Shandong Univ, Qilu Hosp, Dept Nephrol, Jinan, Shandong, Peoples R China; [Shao, Changshun] Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Suzhou, Jiangsu, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Soochow University - China	Zou, YX; Gong, YQ (corresponding author), Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan, Shandong, Peoples R China.; Zou, YX; Gong, YQ (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Mol Med & Genet, Jinan, Shandong, Peoples R China.	zouyongxin@sdu.edu.cn; yxg8@sdu.edu.cn	Shao, Changshun/AAD-8977-2022	Shao, Changshun/0000-0003-2618-9342	National Natural Science Foundation of China [81330050, 81571523, 31671427, 81770660]; Natural Science Foundation of Shandong Province [ZR2016HZ01]; Key Research and Development Program of Shandong Province [2016ZDJS07A08]; Young Scholars Program of Shandong University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Key Research and Development Program of Shandong Province; Young Scholars Program of Shandong University	The authors would like to thank Dr M. Oren for kindly providing psiCHECK2 reporter plasmids containing the 3UTR wide-type and mutant sequences of PIK3CA. This work was supported by the National Natural Science Foundation of China (81330050 and 81571523 to YG, 31671427 to YZ, 81770660 to GL); the Natural Science Foundation of Shandong Province (ZR2016HZ01 to YG); the Key Research and Development Program of Shandong Province (2016ZDJS07A08 to YG); and Young Scholars Program of Shandong University (to YZ).	Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; BUBENIK J, 1973, INT J CANCER, V11, P765, DOI 10.1002/ijc.2910110327; Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Choi W, 2017, EUR UROL, V72, P354, DOI 10.1016/j.eururo.2017.03.010; Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101; Earl J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1450-3; El-Daly SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep24720; Hannah J, 2015, GENE, V573, P33, DOI 10.1016/j.gene.2015.08.064; Harel SA, 2015, CELL DEATH DIFFER, V22, P1328, DOI 10.1038/cdd.2014.221; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hu HL, 2012, CANCER CELL, V22, P781, DOI 10.1016/j.ccr.2012.10.024; Ji QH, 2014, J CELL SCI, V127, P4679, DOI 10.1242/jcs.154245; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Kuwada M, 2015, CANCER LETT, V369, P212, DOI 10.1016/j.canlet.2015.08.019; Lang A, 2019, CANCERS, V11, DOI 10.3390/cancers11040481; Lang QB, 2012, BIOCHEM BIOPH RES CO, V426, P247, DOI 10.1016/j.bbrc.2012.08.075; Ler LD, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8312; Li PS, 2017, DIABETES, V66, P300, DOI 10.2337/db16-0743; Liu J, 2017, AM J CANCER RES, V7, P148; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mao XW, 2017, ONCOTARGET, V8, P77241, DOI 10.18632/oncotarget.20455; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Mensah FA, 2018, ONCOTARGETS THER, V11, P4817, DOI 10.2147/OTT.S142264; Mi J, 2017, MOL ONCOL, V11, P305, DOI 10.1002/1878-0261.12038; Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Qi M, 2018, ONCOGENE, V37, P1075, DOI 10.1038/onc.2017.380; Qi M, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0131-5; Qian YY, 2015, CANCER RES, V75, P5070, DOI 10.1158/0008-5472.CAN-15-0898; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanli O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.22; See WA, 1997, J UROLOGY, V157, P1136, DOI 10.1016/S0022-5347(01)65156-5; Segovia C, 2017, ONCOTARGET, V8, P10531, DOI 10.18632/oncotarget.14453; Solomon DA, 2013, NAT GENET, V45, P1428, DOI 10.1038/ng.2800; Tarpey PS, 2007, AM J HUM GENET, V80, P345, DOI 10.1086/511134; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wei Z, 2015, FREE RADICAL BIO MED, V79, P1, DOI 10.1016/j.freeradbiomed.2014.11.010; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Xu ZL, 2019, ONCOGENE, V38, P5860, DOI 10.1038/s41388-019-0847-x; Yang Y, 2015, ONCOGENE, V34, P104, DOI 10.1038/onc.2013.522; Yu QQ, 2014, BIOMED PHARMACOTHER, V68, P155, DOI 10.1016/j.biopha.2014.01.005; Yuan JP, 2015, J PATHOL, V235, P784, DOI 10.1002/path.4492; Zhang Y, 1997, INT J CANCER, V71, P851; Zhao MF, 2019, PROSTATE, V79, DOI 10.1002/pros.23754; Zou YX, 2007, AM J HUM GENET, V80, P561, DOI 10.1086/512489; Zou YX, 2013, J CELL BIOL, V200, P743, DOI 10.1083/jcb.201206065; Zou YX, 2009, J BIOL CHEM, V284, P33320, DOI 10.1074/jbc.M109.050427	52	12	13	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3588	3603		10.1038/s41388-020-1236-1	http://dx.doi.org/10.1038/s41388-020-1236-1		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32127645				2022-12-17	WOS:000517861800002
J	Neeli, PK; Gollavilli, PN; Mallappa, S; Hari, SG; Kotamraju, S				Neeli, Praveen Kumar; Gollavilli, Paradesi Naidu; Mallappa, Sreevidya; Hari, Sai Gayathri; Kotamraju, Srigiridhar			A novel metadherin Delta 7 splice variant enhances triple negative breast cancer aggressiveness by modulating mitochondrial function via NF & x138;B-SIRT3 axis	ONCOGENE			English	Article							ASTROCYTE-ELEVATED GENE-1; MANGANESE SUPEROXIDE-DISMUTASE; ACTIVATION POTENTIAL ROLE; NITRIC-OXIDE; EXPRESSION; SIRT3; PROGRESSION; PROLIFERATION; KNOCKDOWN; DOXORUBICIN	Metadherin (MTDH) expression inversely correlates with prognosis of several cancers including mammary carcinomas. In this work, we identified a novel splice variant of MTDH with exon7 skipping (MTDH Delta 7) and its levels were found significantly high in triple negative breast cancer (TNBC) cells and in patients diagnosed with TNBC. Selective overexpression of MTDH Delta 7 in MDA-MB-231 and BT-549 cells enhanced proliferation, invasion, and epithelial-to-mesenchymal (EMT) transition markers in comparison to its wildtype counterpart. In contrast, knockdown of MTDH Delta 7 induced antiproliferative/antiinvasive effects. Mechanistically, MTDH-NF & x138;B-p65 complex activated SIRT3 transcription by binding to its promoter that in turn enhanced MnSOD levels and promoted EMT in TNBC cells. Intriguingly, mitochondrial OCR through Complex-I and -IV, and glycolytic rate (ECAR) were significantly high in MDA-MB-231 cells stably expressing MTDH Delta 7. While depletion of SIRT3 inhibited MTDH-Wt/Delta 7-induced OCR and ECAR, knockdown of MnSOD inhibited only ECAR. In addition, MTDH-Wt/Delta 7-mediated pro-proliferative/-invasive effects were greatly obviated with either siSIRT3 or siMnSOD in these cells. The functional relevance of MTDH Delta 7 was further proved under in vivo conditions in an orthotopic mouse model of breast cancer. Mice bearing labeled MDA-MB-231 cells stably expressing MTDH Delta 7 showed significantly more tumor growth and metastatic ability to various organs in comparison to MTDH-Wt bearing mice. Taken together, MTDH Delta 7 promotes TNBC aggressiveness through enhanced mitochondrial biogenesis/function, which perhaps serves as a biomarker.	[Neeli, Praveen Kumar; Gollavilli, Paradesi Naidu; Mallappa, Sreevidya; Kotamraju, Srigiridhar] CSIR Indian Inst Chem Technol, Dept Appl Biol, Uppal Rd, Hyderabad 500007, Telangana, India; [Neeli, Praveen Kumar; Gollavilli, Paradesi Naidu; Mallappa, Sreevidya; Kotamraju, Srigiridhar] Acad Sci & Innovat Res Training & Dev Complex, Chennai 600113, Tamil Nadu, India; [Hari, Sai Gayathri] Osmania Univ, Dept Genet, Hyderabad, Telangana, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Academy of Scientific & Innovative Research (AcSIR); Osmania University	Kotamraju, S (corresponding author), CSIR Indian Inst Chem Technol, Dept Appl Biol, Uppal Rd, Hyderabad 500007, Telangana, India.; Kotamraju, S (corresponding author), Acad Sci & Innovat Res Training & Dev Complex, Chennai 600113, Tamil Nadu, India.	giridhar@iict.res.in	Neeli, Praveen/AAF-9573-2022; Neeli, Praveen Kumar/AFK-2292-2022; Neeli, Praveen/AGG-9798-2022	Neeli, Praveen/0000-0002-4291-6223; Neeli, Praveen Kumar/0000-0002-4291-6223; 	Department of Biotechnology; Department of Science and Technology; Council of Scientific and Industrial Research, India; ICMR; UGC; CSIR; CSIR-IICT [IICT/Pubs/2019/186]	Department of Biotechnology; Department of Science and Technology(Department of Science & Technology (India)); Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India); ICMR(Indian Council of Medical Research (ICMR)); UGC(University Grants Commission, India); CSIR(Council of Scientific & Industrial Research (CSIR) - India); CSIR-IICT	This work was supported by grants from the Department of Biotechnology, Department of Science and Technology, and Council of Scientific and Industrial Research, India. PKN, PNG and SM acknowledge ICMR, UGC and CSIR, for the award of a research fellowship. The authors thank Dr Madhusudhana Kuncha, Ms Sravya Panangipalli, Mr Subbarao Tulimilli, Mr Kanaka Raju Yellusani, and Mr Suresh Yerramsetty for their excellent technical support during animal experimentation, IVIS live imaging, and cell cycle analysis. We thank Dr Nishant Jain for helping in the generation of lentiviral constructs. We thank Dr Mahesh Kumar Jerald for helping in tissue mitotic index analysis and quantification. We also thank Prof. Vishnupriya Satti and Dr Sandhya Annamaneni for providing human breast cancer tissues samples. We thank Director, CSIR-IICT (Ms. No. IICT/Pubs/2019/186) for providing all the required facilities to carry out the work.	Alhazzazi TY, 2011, CANCER-AM CANCER SOC, V117, P1670, DOI 10.1002/cncr.25676; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Climente-Gonzalez H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012; Cui Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129834; Dhar SK, 2011, CANCER RES, V71, P6684, DOI 10.1158/0008-5472.CAN-11-1233; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2009, P NATL ACAD SCI USA, V106, P21300, DOI 10.1073/pnas.0910936106; Fernandez-Marcos PJ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00425; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gollavilli PN, 2015, FEBS J, V282, P3971, DOI 10.1111/febs.13391; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; Haug S, 2015, INT J CANCER, V136, P2328, DOI 10.1002/ijc.29289; He SZ, 2014, CELL PHYSIOL BIOCHEM, V34, P2061, DOI 10.1159/000366401; He WJ, 2012, TRENDS ENDOCRIN MET, V23, P467, DOI 10.1016/j.tem.2012.07.004; Huang JY, 2010, BBA-PROTEINS PROTEOM, V1804, P1645, DOI 10.1016/j.bbapap.2009.12.021; Kanugula AK, 2014, FEBS J, V281, P3719, DOI 10.1111/febs.12893; Karnewar S, 2018, BBA-MOL BASIS DIS, V1864, P1115, DOI 10.1016/j.bbadis.2018.01.018; Kenny TC, 2017, ONCOGENE, V36, P4393, DOI 10.1038/onc.2017.52; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kotamraju S, 2007, CANCER RES, V67, P7386, DOI 10.1158/0008-5472.CAN-07-0993; Li C, 2011, J SURG ONCOL, V103, P184, DOI 10.1002/jso.21788; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Li MX, 2017, ONCOL LETT, V13, P2385, DOI 10.3892/ol.2017.5695; Liang YJ, 2015, CANCER RES, V75, P3672, DOI 10.1158/0008-5472.CAN-15-0930; Liu HY, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-19; Liu R, 2015, MOL CANCER THER, V14, P2090, DOI 10.1158/1535-7163.MCT-15-0017; Liu XQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017582; Loo SY, 2016, ANTIOXID REDOX SIGN, V25, P283, DOI 10.1089/ars.2015.6524; Mallappa S, 2019, MOL CARCINOGEN, V58, P1118, DOI 10.1002/mc.22996; Meng X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019877; Muccioli M, 2011, JOVE-J VIS EXP, DOI 10.3791/2785; Penney ME, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5346-5; Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Sarkar D, 2009, CANCER RES, V69, P8529, DOI 10.1158/0008-5472.CAN-09-1846; Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058; Tao RD, 2014, ANTIOXID REDOX SIGN, V20, P1646, DOI 10.1089/ars.2013.5482; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Tokunaga E, 2014, BREAST CANCER-TOKYO, V21, P341, DOI 10.1007/s12282-012-0398-2; Travis RC, 2010, LANCET, V375, P2143, DOI 10.1016/S0140-6736(10)60636-8; Vasamsetti SB, 2015, DIABETES, V64, P2028, DOI 10.2337/db14-1225; Vaupel P, 2012, INT J BIOCHEM CELL B, V44, P1477, DOI 10.1016/j.biocel.2012.05.019; Wagner BA, 2005, ARCH BIOCHEM BIOPHYS, V440, P181, DOI 10.1016/j.abb.2005.06.015; Yang L, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1042-7; Zhao Y, 2013, ANN DIAGN PATHOL, V17, P483, DOI 10.1016/j.anndiagpath.2013.06.001; Zhou CX, 2016, ONCOTARGET, V7, P1288, DOI 10.18632/oncotarget.6339	48	12	13	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2088	2102		10.1038/s41388-019-1126-6	http://dx.doi.org/10.1038/s41388-019-1126-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31806873				2022-12-17	WOS:000518584000005
J	Ayyathan, DM; Koganti, P; Marcu-Malina, V; Litmanovitch, T; Trakhtenbrot, L; Emanuelli, A; Apel-Sarid, L; Blank, M				Manikoth Ayyathan, Dhanoop; Koganti, Praveen; Marcu-Malina, Victoria; Litmanovitch, Talia; Trakhtenbrot, Luba; Emanuelli, Andrea; Apel-Sarid, Liat; Blank, Michael			SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E3 UBIQUITIN LIGASE; PROTEIN STABILITY; DEPENDENT DEGRADATION; SENESCENCE; EXPRESSION; COMPLEX; SMAD7; CELLS; ASSAY	E3 ubiquitin ligases (E3s) play essential roles in the maintenance of tissue homeostasis under normal and stress conditions, as well as in disease states, particularly in cancer. However, the role of E3s in the initiation of human tumors is poorly understood. Previously, we reported that genetic ablation of the HECT-type E3 ubiquitin ligase Smurf2 induces carcinogenesis in mice; but whether and how these findings are pertinent to the inception of human cancer remain unknown. Here we show that SMURF2 is essential to protect human dermal fibroblasts (HDFs) from malignant transformation, and its depletion converts HDFs into tumorigenic entity. This phenomenon was associated with the radical changes in chromatin structural and epigenetic landscape, dysregulated gene expression and cell-cycle control, mesenchymal-to-epithelial transition and impaired DNA damage response. Furthermore, we show that SMURF2-mediated tumor suppression is interlinked with SMURF2's ability to regulate the expression of two central chromatin modifiers-an E3 ubiquitin ligase RNF20 and histone methyltransferase EZH2. Silencing these factors significantly reduced the growth and transformation capabilities of SMURF2-depleted cells. Finally, we demonstrate that SMURF2-compromised HDFs are highly tumorigenic in nude mice. These findings suggest the critical role that SMURF2 plays in preventing malignant alterations, chromosomal instability and cancer.	[Manikoth Ayyathan, Dhanoop; Koganti, Praveen; Emanuelli, Andrea; Blank, Michael] Bar Ilan Univ, Azrieli Fac Med, Lab Mol & Cellular Canc Biol, IL-1311502 Safed, Israel; [Marcu-Malina, Victoria; Litmanovitch, Talia; Trakhtenbrot, Luba] Sheba Med Ctr, Canc Res Ctr, Hematol Lab, Ramat Gan, Israel; [Apel-Sarid, Liat] Galilee Med Ctr, Dept Pathol, IL-22100 Nahariyya, Israel	Bar Ilan University; Chaim Sheba Medical Center; Western Galilee Hospital	Blank, M (corresponding author), Bar Ilan Univ, Azrieli Fac Med, Lab Mol & Cellular Canc Biol, IL-1311502 Safed, Israel.	michael.blank@biu.ac.il	Emanuelli, Andrea/AAJ-8175-2020	Koganti, Praveen/0000-0002-9708-0996; Manikoth Ayyathan, Dhanoop/0000-0001-8214-1381	ICRF [00636]; Marie-Curie FP-7 CIG [612816]; Israel Cancer Association [20160073, 20171153, 20200007]; Dayan Family Foundation	ICRF; Marie-Curie FP-7 CIG; Israel Cancer Association; Dayan Family Foundation	We thank Sandy Boutros Suleiman for helping with some data acquisition/analysis, Gal Levy-Cohen for important administrative support, and Meir Shamay for the helpful discussions during the manuscript preparation. This work was supported by the following grants: ICRF (#00636), Marie-Curie FP-7 CIG (#612816), and Israel Cancer Association (#20160073, #20171153, and #20200007) grants awarded to MB. We are very grateful to Dayan Family Foundation for their continued support of our research.	Abdollahi E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082399; Ayyathan DM, 2017, ANAL BIOCHEM, V531, P56, DOI 10.1016/j.ab.2017.05.024; Blank M, 2001, ONCOL RES, V12, P409; Blank M, 2006, J CELL BIOL, V174, P195, DOI 10.1083/jcb.200604022; Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Borroni AP, 2018, AGING CELL, V17, DOI 10.1111/acel.12732; Chandhoke AS, 2016, CELL DEATH DIFFER, V23, P876, DOI 10.1038/cdd.2015.152; de Magalhaes JP, 2002, FEBS LETT, V523, P157, DOI 10.1016/S0014-5793(02)02973-3; Du JX, 2011, J BIOL CHEM, V286, P40354, DOI 10.1074/jbc.M111.258707; Emanuelli A, 2019, CANCERS, V11, DOI 10.3390/cancers11040556; Emanuelli A, 2017, CANCER RES, V77, P4217, DOI 10.1158/0008-5472.CAN-16-2828; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Genna A, 2018, J CELL BIOL, V217, P375, DOI 10.1083/jcb.201702184; Grade Marian, 2015, Recent Results Cancer Res, V200, P115, DOI 10.1007/978-3-319-20291-4_6; Howe B, 2014, JOVE-J VIS EXP, DOI 10.3791/50203; Huang PS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051463; Jeong HM, 2014, BBA-MOL CELL RES, V1843, P2005, DOI 10.1016/j.bbamcr.2014.04.023; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim S, 2010, J BIOL CHEM, V285, P36420, DOI 10.1074/jbc.M110.137471; Koganti P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00295; Kong YH, 2011, AGING CELL, V10, P1038, DOI 10.1111/j.1474-9726.2011.00746.x; Kumaravel TS, 2009, CELL BIOL TOXICOL, V25, P53, DOI 10.1007/s10565-007-9043-9; Li Y, 2014, CANCER RES, V74, P6107, DOI 10.1158/0008-5472.CAN-14-0389; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu XP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-57; McGowan-Jordan J, 2016, INT STANDING COMMITT; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920; Osmundson EC, 2008, J CELL BIOL, V183, P267, DOI 10.1083/jcb.200801049; Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358; Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739; Ramkumar C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3598; Ramkumar C, 2012, CANCER RES, V72, P2714, DOI 10.1158/0008-5472.CAN-11-3773; Ray D, 2011, NEOPLASIA, V13, P570, DOI 10.1593/neo.11632; Schaeffer D, 2014, MOL CELL BIOL, V34, P3486, DOI 10.1128/MCB.00694-14; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; Shukla S, 2014, NEOPLASIA, V16, P115, DOI 10.1593/neo.14184; Spagnol ST, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146244; Williams ED, 2019, NAT REV CANCER, V19, P716, DOI 10.1038/s41568-019-0213-x; Wu QQ, 2009, EXP CELL RES, V315, P2386, DOI 10.1016/j.yexcr.2009.05.019; Yu L, 2019, CANCER LETT, V448, P40, DOI 10.1016/j.canlet.2019.01.039; Yu YL, 2013, EMBO MOL MED, V5, P531, DOI 10.1002/emmm.201201783; Yuan B, 2019, EMBO J, V38, DOI 10.15252/embj.201899945; Zhang H, 2004, GENE DEV, V18, P3028, DOI 10.1101/gad.1253004; Zhang WL, 2015, INT J ONCOL, V47, P1043, DOI 10.3892/ijo.2015.3076; Zou X, 2015, BBA-REV CANCER, V1856, P91, DOI 10.1016/j.bbcan.2015.06.005	51	12	12	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3396	3410		10.1038/s41388-020-1226-3	http://dx.doi.org/10.1038/s41388-020-1226-3		FEB 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32103168				2022-12-17	WOS:000516683200001
J	NavaneethaKrishnan, S; Rosales, JL; Lee, KY				NavaneethaKrishnan, Saranya; Rosales, Jesusa L.; Lee, Ki-Young			mPTP opening caused by Cdk5 loss is due to increased mitochondrial Ca2+ uptake	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE-5; PERMEABILITY TRANSITION PORE; ENDOPLASMIC-RETICULUM; CELL-DEATH; CALCIUM; ER; INHIBITION; MEMBRANES; CONTACTS; COMPLEX	We previously demonstrated that loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death by inducing mitochondrial permeability transition pore (mPTP) opening (Oncogene 37, 1788-1804). However, the molecular mechanism by which Cdk5 loss causes mPTP opening remains to be investigated. Using primary mouse embryonic fibroblasts (MEFs) isolated from Cdk5(-/-) mouse embryos, we show that absence of Cdk5 causes a significant increase in both mPTP opening and mitochondrial Ca2+ level. Analysis of subcellular fractions of MEFs demonstrates that Cdk5 localizes in the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM) and Cdk5 loss in MAMs causes increased ER-mitochondria tethering, a process required for Ca2+ transfer from the ER to the mitochondria. Loss of Cdk5 also causes increased ATP-mediated mitochondrial Ca2+ uptake from the ER. Inhibition of ER Ca2+ release or mitochondrial Ca2+ uptake in Cdk5(-/-) MEFs prevents mPTP opening, indicating that mPTP opening in Cdk5(-/-) MEFs is due to increased Ca2+ transfer from the ER to the mitochondria. Altogether, our findings suggest that Cdk5 in MAMs regulates mitochondrial Ca2+ homeostasis that is disturbed upon Cdk5 loss, which leads to mPTP opening.	[NavaneethaKrishnan, Saranya; Rosales, Jesusa L.; Lee, Ki-Young] Univ Calgary, Dept Cell Biol & Anat, Arnie Charbonneau Canc Inst, Calgary, AB, Canada; [NavaneethaKrishnan, Saranya; Rosales, Jesusa L.; Lee, Ki-Young] Univ Calgary, Alberta Childrens Hosp, Res Inst, Cumming Sch Med, Calgary, AB, Canada	University of Calgary; Alberta Childrens Hospital; University of Calgary	Lee, KY (corresponding author), Univ Calgary, Dept Cell Biol & Anat, Arnie Charbonneau Canc Inst, Calgary, AB, Canada.; Lee, KY (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Cumming Sch Med, Calgary, AB, Canada.	kylee@ucalgary.ca			CIHR [MOP-123400]; NSERC [RGPIN/06270-2019]; Alberta Cancer Foundation	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alberta Cancer Foundation	We thank Novartis Pharma AG for providing SfA. This work was supported in part by grants from the CIHR (MOP-123400) and NSERC (RGPIN/06270-2019) to KYL and an Alberta Cancer Foundation graduate studentship to SN.	ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; Bravo-Sagua R, 2013, CURR MOL MED, V13, P317, DOI 10.2174/156652413804810781; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Contreras L, 2010, BBA-BIOENERGETICS, V1797, P607, DOI 10.1016/j.bbabio.2010.05.005; CROMPTON M, 1988, BIOCHEM J, V255, P357; Csordas G, 2010, MOL CELL, V39, P121, DOI 10.1016/j.molcel.2010.06.029; Csordas G, 2006, J CELL BIOL, V174, P915, DOI 10.1083/jcb.200604016; Decuypere, 2011, J AGING RES, V2011, P920178, DOI [10.4061/2011/920178, DOI 10.4061/2011/920178]; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Durkin M.E., 2013, BIOPROTOC, V3, pE908, DOI DOI 10.21769/BioProtoc.908; Finkel T, 2015, CIRC RES, V116, P1810, DOI 10.1161/CIRCRESAHA.116.305484; Fitzgerald JC, 2012, CELL DEATH DIFFER, V19, P257, DOI 10.1038/cdd.2011.90; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Giacomello M, 2016, CELL DEATH DIFFER, V23, P1417, DOI 10.1038/cdd.2016.52; Giaime E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040501; Giorgi C, 2018, NAT REV MOL CELL BIO, V19, P713, DOI 10.1038/s41580-018-0052-8; Gomez-Suaga P, 2017, CURR BIOL, V27, P371, DOI 10.1016/j.cub.2016.12.038; Grimm S, 2012, BBA-MOL CELL RES, V1823, P327, DOI 10.1016/j.bbamcr.2011.11.018; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Kaczmarek-Hajek K, 2012, PURINERG SIGNAL, V8, P375, DOI 10.1007/s11302-012-9314-7; Kinnally KW, 2011, BBA-MOL CELL RES, V1813, P616, DOI 10.1016/j.bbamcr.2010.09.013; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Liu Y, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0092-6; Ma JHJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02213-1; Meuer K, 2007, CELL DEATH DIFFER, V14, P651, DOI 10.1038/sj.cdd.4402087; Michel AH, 2012, BIOCHEM SOC T, V40, P445, DOI 10.1042/BST20110758; MOORE CL, 1971, BIOCHEM BIOPH RES CO, V42, P298, DOI 10.1016/0006-291X(71)90102-1; Naon D, 2014, BBA-MOL CELL RES, V1843, P2184, DOI 10.1016/j.bbamcr.2014.05.011; NavaneethaKrishnan S, 2018, ONCOGENE, V37, P1788, DOI 10.1038/s41388-017-0103-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Ortiz-Sandoval C. G., 2014, CELL LOGIST, P2799, DOI [10.4161/21592799.2014.986399, DOI 10.4161/21592799.2014.986399]; Patergnani S, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00173; Patergnani S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-19; Paupe V, 2018, BIOCHEM BIOPH RES CO, V500, P75, DOI 10.1016/j.bbrc.2017.05.039; Petronilli V, 1998, BIOFACTORS, V8, P263, DOI 10.1002/biof.5520080314; Poston CN, 2013, J PROTEOMICS, V79, P219, DOI 10.1016/j.jprot.2012.12.018; Pozzan T, 2009, BBA-BIOENERGETICS, V1787, P1317, DOI 10.1016/j.bbabio.2008.11.012; Qu D, 2007, NEURON, V55, P37, DOI 10.1016/j.neuron.2007.05.033; Raffaello A, 2016, TRENDS BIOCHEM SCI, V41, P1035, DOI 10.1016/j.tibs.2016.09.001; Rieusset J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0416-1; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Rizzuto R, 2009, BBA-BIOENERGETICS, V1787, P1342, DOI 10.1016/j.bbabio.2009.03.015; Rowland AA, 2012, NAT REV MOL CELL BIO, V13, P607, DOI 10.1038/nrm3440; Shoshan-Barmatz V, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00060; SMITH JB, 1985, J BIOL CHEM, V260, P4413; Solanes P, 2015, EMBO J, V34, P798, DOI 10.15252/embj.201489056; Sun KH, 2008, J NEUROCHEM, V107, P265, DOI 10.1111/j.1471-4159.2008.05616.x; Tagaya M, 2017, ADV EXP MED BIOL, V997, P33, DOI 10.1007/978-981-10-4567-7_3; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vance JE, 2014, BBA-MOL CELL BIOL L, V1841, P595, DOI 10.1016/j.bbalip.2013.11.014; Weishaupt JH, 2003, MOL CELL NEUROSCI, V24, P489, DOI 10.1016/S1044-7431(03)00221-5; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Wiedemann N, 2009, SCIENCE, V325, P403, DOI 10.1126/science.1178016	60	12	12	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2797	2806		10.1038/s41388-020-1188-5	http://dx.doi.org/10.1038/s41388-020-1188-5		FEB 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32024968	hybrid, Green Published			2022-12-17	WOS:000511273600002
J	Tarullo, SE; Hill, RC; Hansen, KC; Behbod, F; Borges, VF; Nelson, AC; Lyons, TR				Tarullo, Sarah E.; Hill, Ryan C.; Hansen, Kirk C.; Behbod, Fariba; Borges, Virginia F.; Nelson, Andrew C.; Lyons, Traci R.			Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival	ONCOGENE			English	Article							HUMAN OVARIAN-CANCER; X-LINKED INHIBITOR; CARCINOMA IN-SITU; MOLECULAR-MECHANISMS; 7A; RESISTANCE; FIBRONECTIN; APOPTOSIS; GROWTH; CELLS	Young women diagnosed with breast cancer (BC) have poor prognosis due to increased rates of metastasis. In addition, women diagnosed within 10 years of most recent childbirth are approximately three times more likely to develop metastasis than age- and stage-matched nulliparous women. We define these cases as postpartum BC (PPBC) and propose that the unique biology of the postpartum mammary gland drives tumor progression. Our published results revealed roles for SEMA7A in breast tumor cell growth, motility, invasion, and tumor-associated lymphangiogenesis, all of which are also increased in preclinical models of PPBC. However, whether SEMA7A drives progression in PPBC remains largely unexplored. Our results presented herein show that silencing of SEMA7A decreases tumor growth in a model of PPBC, while overexpression is sufficient to increase growth in nulliparous hosts. Further, we show that SEMA7A promotes multiple known drivers of PPBC progression including tumor-associated COX-2 expression and fibroblast-mediated collagen deposition in the tumor microenvironment. In addition, we show for the first time that SEMA7A-expressing cells deposit fibronectin to promote tumor cell survival. Finally, we show that co-expression of SEMA7A/COX-2/FN predicts for poor prognosis in breast cancer patient cohorts. These studies suggest SEMA7A as a key mediator of BC progression, and that targeting SEMA7A may open avenues for novel therapeutic strategies.	[Tarullo, Sarah E.; Borges, Virginia F.; Lyons, Traci R.] CU, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80045 USA; [Tarullo, Sarah E.; Borges, Virginia F.; Lyons, Traci R.] CU, Young Womens BC Translat Program, Anschutz Med Campus, Aurora, CO 80045 USA; [Hill, Ryan C.; Hansen, Kirk C.] CU, Dept Biochem & Mol Genet, Anschutz Med Campus, Aurora, CO 80045 USA; [Behbod, Fariba] Univ Kansas, Med Ctr, Div Canc & Dev Biol, Kansas City, KS 66160 USA; [Borges, Virginia F.; Lyons, Traci R.] Univ Colorado, Ctr Canc, Aurora, CO 80045 USA; [Nelson, Andrew C.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Kansas; University of Kansas Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Minnesota System; University of Minnesota Twin Cities	Lyons, TR (corresponding author), CU, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80045 USA.; Lyons, TR (corresponding author), CU, Young Womens BC Translat Program, Anschutz Med Campus, Aurora, CO 80045 USA.; Lyons, TR (corresponding author), Univ Colorado, Ctr Canc, Aurora, CO 80045 USA.	traci.lyons@cuanschutz.edu		Tarullo, Sarah/0000-0002-7551-5733	American Cancer Society [RSG 16-171-01-CSM]; NIH/NCI [R01CA211696-01A1]; NIH/CCTSI/CTSA [TL1 TR001081]	American Cancer Society(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/CCTSI/CTSA	MCF10DCIS cells were obtained from K. Polyak and A. Marusyk (Harvard University, Cambridge, MA). MDA-MB-231 cells were obtained from P. Schedin (Oregon Heath and Sciences University, Portland OR). HLF-1 cells were gifted from M. Fini (CU Anschutz Medical Campus, Denver, CO). We thank H. Ford for the pcDNA3.1 vector (CU Anschutz Medical Campus, Denver, CO) and R. Medzhitov (Yale University, New Haven, CT) for the SEMA7A-Fc overexpression vector. We also acknowledge V. Wessells, A. Elder, L. Crump, T. Wallace, C. Young, A. Stoller, M. Kobritz, and C. Hoang for technical support and advice. This work was supported by the American Cancer Society (RSG 16-171-01-CSM) and NIH/NCI (R01CA211696-01A1) to TRL and NIH/CCTSI/CTSA (TL1 TR001081) to SET.	Albrektsen G, 2005, BRIT J CANCER, V92, P167, DOI 10.1038/sj.bjc.6602302; Allegra M, 2012, MOL BIOL CELL, V23, P3873, DOI 10.1091/mbc.E12-04-0276; Asztalos S, 2010, CANCER PREV RES, V3, P301, DOI 10.1158/1940-6207.CAPR-09-0069; Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Baritaki S, 2009, CANCER RES, V69, P8376, DOI 10.1158/0008-5472.CAN-09-1069; Barrett AS, 2017, J PROTEOME RES, V16, P4177, DOI 10.1021/acs.jproteome.7b00527; Black SA, 2016, ONCOGENE, V35, P5170, DOI 10.1038/onc.2016.49; Callihan EB, 2013, BREAST CANCER RES TR, V138, P549, DOI 10.1007/s10549-013-2437-x; Cerny J, 1996, EUR J IMMUNOL, V26, P2335, DOI 10.1002/eji.1830261010; Chao Y, 2012, CANCER MICROENVIRON, V5, P19, DOI 10.1007/s12307-011-0085-4; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Chong J, 2018, BIOINFORMATICS, V34, P4313, DOI 10.1093/bioinformatics/bty528; Crump LS, 2019, HORMONAL REGULATION; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dean JL, 2012, CELL CYCLE, V11, P2756, DOI 10.4161/cc.21195; Deep G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-37; Denkert C, 2003, CANCER-AM CANCER SOC, V97, P2978, DOI 10.1002/cncr.11437; Eke I, 2013, CANCER RES, V73, P5869, DOI 10.1158/0008-5472.CAN-13-0344; Elder AM, 2018, CANCER RES, V78, P6473, DOI 10.1158/0008-5472.CAN-18-1642; Fong KP, 2011, BLOOD, V117, pE15, DOI 10.1182/blood-2010-05-283838; Fraser M, 2003, CANCER RES, V63, P7081; Gan Y, 2011, ARTHRITIS RHEUM-US, V63, P2484, DOI 10.1002/art.30386; Garcia-Areas R, 2017, INT J ONCOL, V51, P1395, DOI 10.3892/ijo.2017.4144; Garcia-Areas R, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00017; Gilmore AP, 2009, CURR OPIN CELL BIOL, V21, P654, DOI 10.1016/j.ceb.2009.05.009; Goddard ET, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.6997; Goddard ET, 2018, JAMA NETWORK; Guo QC, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89206; Gupta PB, 2007, CANCER RES, V67, P2062, DOI 10.1158/0008-5472.CAN-06-3895; Gurrapu S, 2018, CELL DEATH DIFFER, V25, P1259, DOI 10.1038/s41418-018-0097-4; Han SW, 2006, ONCOGENE, V25, P4341, DOI 10.1038/sj.onc.1209460; Hattar R, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2220; Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106; Jacob A, 2013, J CELL SCI, V126, P4647, DOI 10.1242/jcs.126573; Jaimes Y, 2012, J THROMB HAEMOST, V10, P1100, DOI 10.1111/j.1538-7836.2012.04708.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang HR, 2007, J EXP MED, V204, P1083, DOI 10.1084/jem.20061273; Kinehara Y, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.123093; Knowles LM, 2013, CANCER RES, V73, P6175, DOI 10.1158/0008-5472.CAN-13-0602; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kopp MA, 2010, GLIA, V58, P1748, DOI 10.1002/glia.21045; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Liu HL, 2010, CELL, V142, P749, DOI 10.1016/j.cell.2010.07.040; Lyons TR, 2014, J CLIN INVEST, V124, P3901, DOI 10.1172/JCI73777; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Ma B, 2015, CANCER RES, V75, P487, DOI 10.1158/0008-5472.CAN-13-3339; Maller O, 2013, J CELL SCI, V126, P4108, DOI 10.1242/jcs.121590; McKeithen D, 2010, PROSTATE, V70, P982, DOI 10.1002/pros.21132; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Nichols HB, 2019, ANN INTERN MED, V170, P22, DOI 10.7326/M18-1323; Nurwidya F, 2012, CANCER RES TREAT, V44, P151, DOI 10.4143/crt.2012.44.3.151; Nurwidya Fariz, 2012, Cancer Biology Medicine, V9, P18, DOI 10.3969/j.issn.2095-3941.2012.01.003; Parkash J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7385; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Pontiggia O, 2012, BREAST CANCER RES TR, V133, P459, DOI 10.1007/s10549-011-1766-x; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Rehman M, 2013, SEMIN CELL DEV BIOL, V24, P179, DOI 10.1016/j.semcdb.2012.10.005; Reilkoff RA, 2013, AM J RESP CRIT CARE, V187, P180, DOI 10.1164/rccm.201206-1109OC; Reisz JA, 2018, TRANSFUSION, V58, P2978, DOI 10.1111/trf.14936; Ristimaki A, 2002, CANCER RES, V62, P632; Saito T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118432; Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839; Scott GA, 2009, J INVEST DERMATOL, V129, P954, DOI 10.1038/jid.2008.329; Slepicka PF, 2019, TRENDS MOL MED, V25, P866, DOI 10.1016/j.molmed.2019.06.003; Slocum E, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1142-z; Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017; St-Germain ME, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-7; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Uchikado Y, 2011, GASTRIC CANCER, V14, P41, DOI 10.1007/s10120-011-0004-x; Valdez KE, 2011, J PATHOL, V225, P565, DOI 10.1002/path.2969; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Welch DR, 2019, CANCER RES, V79, P3011, DOI 10.1158/0008-5472.CAN-19-0458; Xie JM, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-016-1217-5; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006	80	12	12	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2772	2785		10.1038/s41388-020-1192-9	http://dx.doi.org/10.1038/s41388-020-1192-9		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32020054	Green Submitted, Green Accepted			2022-12-17	WOS:000511084200002
J	Kilinc, AN; Sugiyama, N; Kalathur, RKR; Antoniadis, H; Birogul, H; Ishay-Ronen, D; George, JT; Levine, H; Jolly, MK; Christofori, G				Kilinc, Ayse Nihan; Sugiyama, Nami; Kalathur, Ravi Kiran Reddy; Antoniadis, Helena; Birogul, Huseyin; Ishay-Ronen, Dana; George, Jason T.; Levine, Herbert; Jolly, Mohit Kumar; Christofori, Gerhard			Histone deacetylases, Mbd3/NuRD, and Tet2 hydroxylase are crucial regulators of epithelial-mesenchymal plasticity and tumor metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SNAIL; CADHERIN GENE-EXPRESSION; MI-2/NURD COMPLEX; MASTER REGULATOR; CANCER-CELLS; TRANSITION; NURD; EMT; REPRESSOR; METHYLATION	An epithelial-mesenchymal transition (EMT) represents a basic morphogenetic process of high cell plasticity underlying embryogenesis, wound healing, cancer metastasis and drug resistance. It involves a profound transcriptional and epigenetic reprogramming of cells. A critical role of epigenetic modifiers and their specific chromatin modifications has been demonstrated during EMT. However, it has remained elusive whether epigenetic control differs between the dynamic cell state transitions of reversible EMT and the fixed differentiation status of irreversible EMT. We have employed varying EMT models of murine breast cancer cells to identify the key players establishing epithelial-mesenchymal cell plasticity during reversible and irreversible EMT. We demonstrate that the Mbd3/NuRD complex and the activities of histone deacetylases (HDACs), and Tet2 hydroxylase play a critical role in keeping cancer cells in a highly metastatic mesenchymal state. Combinatorial interference with their functions leads to mesenchymal-epithelial transition (MET) and efficiently represses metastasis formation by invasive murine and human breast cancer cells in vivo.	[Kilinc, Ayse Nihan; Sugiyama, Nami; Kalathur, Ravi Kiran Reddy; Antoniadis, Helena; Birogul, Huseyin; Ishay-Ronen, Dana; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland; [Kilinc, Ayse Nihan] Princeton Univ, Dept Chem & Biol Engn, 303 Hoyt Lab,William St, Princeton, NJ 08544 USA; [George, Jason T.; Levine, Herbert] Rice Univ, Ctr Theoret Biol Phys, Houston, TX USA; [George, Jason T.] Baylor Coll Med, Med Sci Training Program, Houston, TX 77030 USA; [Levine, Herbert] Northeastern Univ, Dept Bioengn, Boston, MA 02115 USA; [Levine, Herbert] Northeastern Univ, Dept Phys, Boston, MA 02115 USA; [Jolly, Mohit Kumar] Indian Inst Sci, Ctr BioSyst Sci & Engn, Bangalore 560012, Karnataka, India	University of Basel; Princeton University; Rice University; Baylor College of Medicine; Northeastern University; Northeastern University; Indian Institute of Science (IISC) - Bangalore	Christofori, G (corresponding author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.	gerhard.christofori@unibas.ch	Jolly, Mohit Kumar/A-1826-2014; Levine, Herbert/C-1704-2008; Ishay-Ronen, Dana/AAZ-2396-2021	Jolly, Mohit Kumar/0000-0002-6631-2109; Levine, Herbert/0000-0002-8819-9055; Sugiyama, Nami/0000-0003-0788-2934; Ishay-Ronen, Dana/0000-0003-0425-1408; George, Jason/0000-0002-8248-2888	SystemsX.ch RTD project Cellplasticity; SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation; Swiss Cancer League; Gulf Coast Consortia on the Computational Cancer Biology Training Program (CPRIT) [RP170593]	SystemsX.ch RTD project Cellplasticity; SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Gulf Coast Consortia on the Computational Cancer Biology Training Program (CPRIT)	This work was supported by the SystemsX.ch RTD project Cellplasticity, the SystemsX.ch MTD project MetastasiX, the Swiss National Science Foundation, and the Swiss Cancer League. MKJ was also supported by a training fellowship from the Gulf Coast Consortia on the Computational Cancer Biology Training Program (CPRIT Grant No. RP170593).	Aiello NM, 2018, DEV CELL, V45, P681, DOI 10.1016/j.devcel.2018.05.027; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baubec T, 2013, CELL, V153, P480, DOI 10.1016/j.cell.2013.03.011; Beckers T, 2007, INT J CANCER, V121, P1138, DOI 10.1002/ijc.22751; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cimmino L, 2011, CELL STEM CELL, V9, P193, DOI 10.1016/j.stem.2011.08.007; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Crea F, 2012, CRIT REV ONCOL HEMAT, V83, P184, DOI 10.1016/j.critrevonc.2011.10.007; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Diepenbruck M, 2016, CURR OPIN CELL BIOL, V43, P7, DOI 10.1016/j.ceb.2016.06.002; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Fantozzi A, 2014, CANCER RES, V74, P1566, DOI 10.1158/0008-5472.CAN-13-1641; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; George JT, 2017, CANCER RES, V77, P6415, DOI 10.1158/0008-5472.CAN-16-3521; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayakawa T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/129383; Hu X, 2014, CELL STEM CELL, V14, P512, DOI 10.1016/j.stem.2014.01.001; Jiang GM, 2013, BBA-MOL CELL RES, V1833, P663, DOI 10.1016/j.bbamcr.2012.12.002; Jolly MK, 2016, ONCOTARGET, V7, P27067, DOI 10.18632/oncotarget.8166; Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155; Kaji K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372; Kaji K, 2007, DEVELOPMENT, V134, P1123, DOI 10.1242/dev.02802; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Li WY, 2016, TRENDS CANCER, V2, P65, DOI 10.1016/j.trecan.2016.01.001; Lorizio W, 2011, GENOME MED, V3, DOI 10.1186/gm280; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peng L, 2016, J CELL SCI, V129, P1059, DOI 10.1242/jcs.179044; Rais Y, 2013, NATURE, V502, P65, DOI 10.1038/nature12587; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Srivastava RK, 2010, MOL CANCER THER, V9, P3254, DOI 10.1158/1535-7163.MCT-10-0582; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tang HM, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.41; Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Verstappen G, 2008, HUM MOL GENET, V17, P1175, DOI 10.1093/hmg/ddn007; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang Y, 2018, J MOL CELL BIOL, V10, P285, DOI 10.1093/jmcb/mjy021; Yildirim O, 2011, CELL, V147, P1498, DOI 10.1016/j.cell.2011.11.054; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang N, 2017, DRUG DES DEV THER, V11, P969, DOI 10.2147/DDDT.S129305; Zhang WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031450	61	12	12	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1498	1513		10.1038/s41388-019-1081-2	http://dx.doi.org/10.1038/s41388-019-1081-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31666683				2022-12-17	WOS:000513289600008
J	Kim, JY; Kim, JK; Kim, H				Kim, Jung Yun; Kim, Jun-Kyum; Kim, Hyunggee			ABCB7 simultaneously regulates apoptotic and non-apoptotic cell death by modulating mitochondrial ROS and HIF1 alpha-driven NF kappa B signaling	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; INDUCIBLE FACTOR-I; UP-REGULATION; HYPOXIA; CANCER; METABOLISM; IDENTIFICATION; PROLIFERATION; GLIOBLASTOMA; HOMEOSTASIS	Most of the mechanisms governing apoptotic and non-apoptotic cell death are regulated independently. However, cells may experience various stresses that lead to both apoptotic and non-apoptotic cell death. In particular, cancer cells require a program that simultaneously avoids these forms of cell death, but the mechanism by which they are able to do so is currently unclear. Here, we show that ABC transporter subfamily B member 7 (ABCB7), one of the mitochondrial iron transporters, induces the hypoxia-independent accumulation of hypoxia-inducible factor 1 alpha by controlling intracellular iron homeostasis and inhibits both apoptotic and non-apoptotic cell death. Mechanistically, ABCB7 mitigates non-apoptotic cell death by reducing levels of mitochondrial reactive oxygen species. ABCB7 also suppresses apoptosis by inhibiting the expression of leucine zipper downregulated in cancer 1, an inhibitor of nuclear factor-kappa B signaling. Therefore, our results support that ABCB7 is crucial in controlling both apoptotic and non-apoptotic cell death and indicate that the fine-tuning of intracellular iron homeostasis may be a novel anticancer strategy.	[Kim, Jung Yun; Kim, Jun-Kyum; Kim, Hyunggee] Korea Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Seoul 02841, South Korea; [Kim, Jung Yun; Kim, Jun-Kyum; Kim, Hyunggee] Korea Univ, Inst Anim Mol Biotechnol, Seoul 02841, South Korea; [Kim, Hyunggee] Korea Univ, Dept Med Engn, Coll Med, Seoul 02841, South Korea	Korea University; Korea University; Korea University; Korea University Medicine (KU Medicine)	Kim, H (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Seoul 02841, South Korea.; Kim, H (corresponding author), Korea Univ, Inst Anim Mol Biotechnol, Seoul 02841, South Korea.; Kim, H (corresponding author), Korea Univ, Dept Med Engn, Coll Med, Seoul 02841, South Korea.	hg-kim@korea.ac.kr			National Research Foundation (NRF) [2015R1A5A1009024, 2017R1E1A1A01074205, 2017M3A9A8031425]; School of Life Sciences and Biotechnology for BK21 Plus, Korea University	National Research Foundation (NRF); School of Life Sciences and Biotechnology for BK21 Plus, Korea University	The authors thank the members of the Cancer Growth Regulation Laboratory for their discussions and technical assistance. This work was supported by grants to Hyunggee Kim from the National Research Foundation (NRF) [grant numbers 2015R1A5A1009024, 2017R1E1A1A01074205 and 2017M3A9A8031425], and the School of Life Sciences and Biotechnology for BK21 Plus, Korea University.	Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Bagnall J, 2014, J BIOL CHEM, V289, P5549, DOI 10.1074/jbc.M113.500405; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bratic I, 2010, BBA-BIOENERGETICS, V1797, P961, DOI 10.1016/j.bbabio.2010.01.004; Chen L, 2012, MOL CELL BIOCHEM, V365, P263, DOI 10.1007/s11010-012-1267-1; Chirasani SR, 2009, J MOL MED, V87, P153, DOI 10.1007/s00109-008-0414-3; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Depoix CL, 2017, MOL HUM REPROD, V23, P199, DOI 10.1093/molehr/gax002; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Drummen GPC, 2002, FREE RADICAL BIO MED, V33, P473, DOI 10.1016/S0891-5849(02)00848-1; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frost J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13312; Glassford AJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE1590, DOI 10.1152/ajpendo.00490.2007; Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036; Glickstein H, 2005, BLOOD, V106, P3242, DOI 10.1182/blood-2005-02-0460; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang JY, 2013, FASEB J, V27, P2845, DOI 10.1096/fj.12-216929; Hung HI, 2013, J BIOL CHEM, V288, P677, DOI 10.1074/jbc.M112.422667; Inoue H, 2014, CELL DEATH DIFFER, V21, P39, DOI 10.1038/cdd.2013.84; Joseph JV, 2015, CANCER LETT, V359, P107, DOI 10.1016/j.canlet.2015.01.010; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kaur D, 2009, FREE RADICAL BIO MED, V46, P593, DOI 10.1016/j.freeradbiomed.2008.11.012; Lee G, 2016, MOL CANCER THER, V15, P3064, DOI 10.1158/1535-7163.MCT-15-0675; Letai A, 2015, CLIN CANCER RES, V21, P5015, DOI 10.1158/1078-0432.CCR-15-1204; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Li W, 2016, DRUG RESIST UPDATE, V27, P14, DOI 10.1016/j.drup.2016.05.001; Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110; Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106; Munoz LE, 2013, AUTOIMMUNITY, V46, P336, DOI 10.3109/08916934.2012.755960; Nagasaki K, 2003, INT J CANCER, V105, P454, DOI 10.1002/ijc.11122; Nagasaki K, 1999, CANCER LETT, V140, P227, DOI 10.1016/S0304-3835(99)00087-7; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Paul VD, 2015, BBA-MOL CELL RES, V1853, P1528, DOI 10.1016/j.bbamcr.2014.12.018; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Puliyappadamba VT, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.963478; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Schaedler TA, 2015, BIOCHEM SOC T, V43, P943, DOI 10.1042/BST20150118; Schonberg DL, 2015, CANCER CELL, V28, P441, DOI 10.1016/j.ccell.2015.09.002; Shah YM, 2014, GASTROENTEROLOGY, V146, P630, DOI 10.1053/j.gastro.2013.12.031; Sparreboom A, 2003, DRUG RESIST UPDATE, V6, P71, DOI 10.1016/S1368-7646(03)00005-0; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Tenopoulou M, 2007, BIOCHEM J, V403, P261, DOI 10.1042/BJ20061840; Trnka J, 2009, FREE RADICAL RES, V43, P4, DOI 10.1080/10715760802582183; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yin F, 2014, ANTIOXID REDOX SIGN, V20, P353, DOI 10.1089/ars.2012.4774; Zutz A, 2009, BBA-BIOENERGETICS, V1787, P681, DOI 10.1016/j.bbabio.2009.02.009	58	12	12	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1969	1982		10.1038/s41388-019-1118-6	http://dx.doi.org/10.1038/s41388-019-1118-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772327				2022-12-17	WOS:000516579800011
J	Lefort, S; Tan, S; Balani, S; Rafn, B; Pellacani, D; Hirst, M; Sorensen, PH; Eaves, CJ				Lefort, Sylvain; Tan, Susanna; Balani, Sneha; Rafn, Bo; Pellacani, Davide; Hirst, Martin; Sorensen, Poul H.; Eaves, Connie J.			Initiation of human mammary cell tumorigenesis by mutant KRAS requires YAP inactivation	ONCOGENE			English	Article							COMPREHENSIVE MOLECULAR PORTRAITS; HIPPO PATHWAY; BREAST; GROWTH; YAP/TAZ; DIFFERENTIATION; LOCALIZATION; CROSSTALK; MUTATION; COMPLEX	High YAP activity is associated with poor prognosis human breast cancers, but its role during the initial stage of mammary cell transformation is unknown. To address this question, we designed experiments that exploit the ability of KRAS(G12D)-transduced subsets of freshly isolated normal human mammary cells to form invasive tumors rapidly and efficiently when transplanted into immunodeficient mice. Initial examination of the newly developing tumors thus generated revealed a consistent marked loss of nuclear YAP, independent of the initial primary human mammary cell type transduced. Conversely, co-transduction of the same subsets of primary human mammary cells with KRAS(G12D) plus the constitutively active YAP(S127A) prevented tumor formation. These findings contrast with the enhanced display of transformed properties obtained when the immortalized, but non-tumorigenic MCF10A cells are transduced just with YAP(S127A). In addition, we show that YAP(S127A)-transduction of the human MDA-MB-231 breast cancer cell line (that carry a similar KRAS mutation) enhances their metastatic activity in vivo. We also discover that the KRAS(G12D)-induced early loss of YAP in primary human mammary cells is associated with their induced secretion of amphiregulin. Collectively, these findings suggest that YAP can differentially affect the acquisition of malignant properties by human mammary cells at different stages of their transformation.	[Lefort, Sylvain; Tan, Susanna; Balani, Sneha; Pellacani, Davide; Eaves, Connie J.] British Columbia Canc Agcy, Terry Fox Lab, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Rafn, Bo; Sorensen, Poul H.] British Columbia Canc Agcy, Dept Mol Oncol, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada; [Hirst, Martin] British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada; [Hirst, Martin] Univ British Columbia, Dept Microbiol & Immunol, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia	Lefort, S (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sylvain.lefort@lyon.unicancer.fr		Eaves, Connie/0000-0002-3452-1926; Lefort, Sylvain/0000-0001-7320-4256	Canadian Cancer Society Research Institute; Cancer Research Society; Cancer Institute for Health Research [CRP-154482]; University of British Columbia Graduate Studentship; Canadian Institute of Health Research Banting and Best Studentship	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Cancer Institute for Health Research; University of British Columbia Graduate Studentship; Canadian Institute of Health Research Banting and Best Studentship(Canadian Institutes of Health Research (CIHR))	The authors thank D. Wilkinson, G. Edin, and M. Hale for excellent technical support; Drs J. Cheng and P. Hoodless for their help with data interpretation; and Drs E. Bovill, J. Boyle, S. Bristol, P. Gdalevitch, A. Seal, J. Sproul, and N. van Laeken for access to discarded reduction human mammoplasty tissue. This work was supported by grants from the Canadian Cancer Society Research Institute, the Cancer Research Society, and the Cancer Institute for Health Research (grant CRP-154482). The authors declare no conflict of interest. SB was a recipient of a University of British Columbia Graduate Studentship and ST was a recipient of a Canadian Institute of Health Research Banting and Best Studentship.	Aragon E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Balani S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15422; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Britschgi A, 2017, NATURE, V541, P541, DOI 10.1038/nature20829; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Grannas K, 2015, J MOL BIOL, V427, P3407, DOI 10.1016/j.jmb.2015.04.015; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Kannan N, 2014, P NATL ACAD SCI USA, V111, P7789, DOI 10.1073/pnas.1403813111; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Marella NV, 2009, CANCER RES, V69, P5946, DOI 10.1158/0008-5472.CAN-09-0420; Morel AP, 2017, NAT MED, V23, P568, DOI 10.1038/nm.4323; Nguyen LV, 2015, NATURE, V528, P267, DOI 10.1038/nature15742; Nguyen LV, 2014, CELL STEM CELL, V14, P253, DOI 10.1016/j.stem.2013.12.011; Pellacani D, 2016, CELL REP, V17, P2060, DOI 10.1016/j.celrep.2016.10.058; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Skibinski A, 2014, CELL REP, V6, P1059, DOI 10.1016/j.celrep.2014.02.038; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vlug EJ, 2013, CELL ONCOL, V36, P375, DOI 10.1007/s13402-013-0143-7; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	34	12	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1957	1968		10.1038/s41388-019-1111-0	http://dx.doi.org/10.1038/s41388-019-1111-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772328	hybrid, Green Published			2022-12-17	WOS:000516579800010
J	Li, YM; Zhou, Y; Li, BF; Chen, F; Shen, WY; Lu, YS; Zhong, CL; Zhang, C; Xie, H; Katanaev, VL; Jia, L				Li, Yumei; Zhou, Yu; Li, Bifei; Chen, Fan; Shen, Weiyu; Lu, Yusheng; Zhong, Chunlian; Zhang, Chen; Xie, Huanzhang; Katanaev, Vladimir L.; Jia, Lee			WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5-MDM2-p53 pathway	ONCOGENE			English	Article							NUCLEOLAR AAA-ATPASE; RIBOSOMAL-PROTEINS; P53; GROWTH; PROLIFERATION; BIOGENESIS; MUTATIONS; REGULATOR; CANCER	The key molecules and underlying mechanisms of melanoma metastasis remain poorly understood. Using isobaric tag for relative and absolute quantitation (iTRAQ) proteomic screening, probing of patients' samples, functional verification, and mechanistic validation, we identified the important role of the WD repeat-containing protein 74 (WDR74) in melanoma progression and metastasis. Through gain- and loss-of-function approaches, WDR74 was found to promote cell proliferation, apoptosis resistance, and aggressive behavior in vitro. Moreover, WDR74 contributed to melanoma growth and metastasis in vivo. Mechanistically, WDR74 modulates RPL5 protein levels and consequently regulates MDM2 and insulates the ubiquitination degradation of p53 by MDM2. Our study is the first to reveal the oncogenic role of WDR74 in melanoma progression and the regulatory effect of WDR74 on the RPL5-MDM2-p53 pathway. Collectively, WDR74 can serve as a candidate target for the prevention and treatment of melanoma in the clinic.	[Li, Yumei; Zhou, Yu; Li, Bifei; Chen, Fan; Shen, Weiyu; Jia, Lee] Fuzhou Univ, Coll Chem, Canc Metastasis Alert & Prevent Ctr, Fujian Prov Key Lab Canc Metastasis Chemoprevent, Fuzhou 350116, Fujian, Peoples R China; [Lu, Yusheng; Zhong, Chunlian; Zhang, Chen; Xie, Huanzhang; Katanaev, Vladimir L.; Jia, Lee] Minjiang Univ, Inst Oceanog, Fuzhou 350116, Fujian, Peoples R China; [Katanaev, Vladimir L.] Far Eastern Fed Univ, Sch Biomed, Nat Prod Drug Discovery Lab, Vladivostok, Russia; [Katanaev, Vladimir L.] Univ Geneva, Fac Med, Translat Res Ctr Oncohaematol, Dept Cell Physiol & Metab, Geneva, Switzerland	Fuzhou University; Minjiang University; Far Eastern Federal University; University of Geneva	Jia, L (corresponding author), Fuzhou Univ, Coll Chem, Canc Metastasis Alert & Prevent Ctr, Fujian Prov Key Lab Canc Metastasis Chemoprevent, Fuzhou 350116, Fujian, Peoples R China.; Katanaev, VL; Jia, L (corresponding author), Minjiang Univ, Inst Oceanog, Fuzhou 350116, Fujian, Peoples R China.; Katanaev, VL (corresponding author), Far Eastern Fed Univ, Sch Biomed, Nat Prod Drug Discovery Lab, Vladivostok, Russia.; Katanaev, VL (corresponding author), Univ Geneva, Fac Med, Translat Res Ctr Oncohaematol, Dept Cell Physiol & Metab, Geneva, Switzerland.	Vladimir.Katanaev@unige.ch; cmapcjia1234@163.com	Katanaev, Vladimir/F-9480-2014	Katanaev, Vladimir/0000-0002-7909-5617; Chen, Fan/0000-0003-3873-7094; JIA, LEE/0000-0001-6839-5545; Li, Yumei/0000-0002-7910-6515; Lu, Yusheng/0000-0003-2341-4487; Zhang, Chen/0000-0002-5080-9321	National Natural Science Foundation of China [81961138017, 81773063, U1505225]; Ministry of Science and Technology of China [2015CB931804]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by the grants from National Natural Science Foundation of China (81961138017, 81773063, U1505225); Ministry of Science and Technology of China (2015CB931804).	Azim HA, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0538-7; Bedrosian I, 2000, ANN SURG ONCOL, V7, P262, DOI 10.1007/s10434-000-0262-z; Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32; Chen XX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1188-3; Chen XX, 2018, AGING-US, V10, P3421, DOI 10.18632/aging.101656; Cheng YL, 2018, INT J ONCOL, V53, P2590, DOI 10.3892/ijo.2018.4582; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Damsky WE, 2014, ONCOGENE, V33, P2413, DOI 10.1038/onc.2013.194; de Marval PLM, 2011, ONCOTARGET, V2, P234; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fahraeus R, 2014, ONCOGENE, V33, P4365, DOI 10.1038/onc.2013.410; Han Y, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.014076; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Hiraishi N, 2018, BIOCHEM BIOPH RES CO, V495, P116, DOI 10.1016/j.bbrc.2017.10.148; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Kardos GR, 2014, PIGM CELL MELANOMA R, V27, P801, DOI 10.1111/pcmr.12259; Kitatani K, 2016, ONCOGENE, V35, P2801, DOI 10.1038/onc.2015.330; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Krol M, 2010, J APPL GENET, V51, P37, DOI 10.1007/BF03195709; Li BF, 2019, ONCOTARGETS THER, V12, P3207, DOI 10.2147/OTT.S195703; Liang W, 2018, P NATL ACAD SCI USA, V115, P11060, DOI 10.1073/pnas.1811717115; Lin CP, 2019, ENVIRON TOXICOL, V34, P303, DOI 10.1002/tox.22685; Little EG, 2012, DERMATOL CLIN, V30, P355, DOI 10.1016/j.det.2012.04.001; Liu JQ, 2018, J GENET GENOMICS, V45, P639, DOI 10.1016/j.jgg.2018.08.005; Liu S, 2017, ONCOGENE, V36, P1374, DOI 10.1038/onc.2016.301; Liu Y, 2016, TRENDS CANCER, V2, P191, DOI 10.1016/j.trecan.2016.03.002; Lo YH, 2017, STRUCTURE, V25, P762, DOI 10.1016/j.str.2017.03.008; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Maserati M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022516; Murphy JF, 2001, FASEB J, V15, P1667, DOI 10.1096/fj.00-0757fje; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Ossio R, 2017, NAT REV CANCER, V17, P393, DOI 10.1038/nrc.2017.43; Owens, 2020, NATURE, V515, pS109; Ozdemir E, 2000, EUR UROL, V38, P230, DOI 10.1159/000020284; Paradiso V, 2018, J MOL DIAGN, V20, P836, DOI 10.1016/j.jmoldx.2018.07.003; Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104; Srivastava SK, 2015, BRIT J CANCER, V113, P1694, DOI 10.1038/bjc.2015.400; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; uri Reimand, 2017, CANC RES S, V77, DOI [10.1158/1538-7445.AM2017-385, DOI 10.1158/1538-7445.AM2017-385]; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang SY, 2018, CANCER LETT, V439, P78, DOI 10.1016/j.canlet.2018.09.026; Wang W, 2015, MED RES REV, V35, P225, DOI 10.1002/med.21327; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Yoshikatsu Y, 2015, BIOCHEM BIOPH RES CO, V464, P780, DOI 10.1016/j.bbrc.2015.07.032; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; Zhang F, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.NONRNA15-PR06; Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1156-5; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zheng N, 2017, MOL CARCINOGEN, V56, P1896, DOI 10.1002/mc.22645; Zheng N, 2017, BIOMED PHARMACOTHER, V90, P339, DOI 10.1016/j.biopha.2017.03.076	52	12	12	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2741	2755		10.1038/s41388-020-1179-6	http://dx.doi.org/10.1038/s41388-020-1179-6		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32005977				2022-12-17	WOS:000510346700002
J	Wei, LY; Zhang, XM; Wang, J; Ye, QR; Zheng, X; Peng, Q; Zheng, Y; Liu, PS; Zhang, XY; Li, ZS; Liu, C; Yan, Q; Li, GY; Ma, J				Wei, Lingyu; Zhang, Xuemei; Wang, Jia; Ye, Qiurong; Zheng, Xiang; Peng, Qiu; Zheng, Ying; Liu, Peishan; Zhang, Xiaoyue; Li, Zhengshuo; Liu, Can; Yan, Qun; Li, Guiyuan; Ma, Jian			Lactoferrin deficiency induces a pro-metastatic tumor microenvironment through recruiting myeloid-derived suppressor cells in mice	ONCOGENE			English	Article							TOLL-LIKE RECEPTOR; IMMUNOSUPPRESSIVE ACTIVITY; NASOPHARYNGEAL CARCINOMA; PANCREATIC-CANCER; IMMUNE; LACTOTRANSFERRIN; DIFFERENTIATION; EXPRESSION; PROMOTES; MONOCYTES	Lactoferrin, an innate immunity molecule, is involved in anti-inflammatory, anti-microbial, and anti-tumor activities. We previously reported that lactoferrin is downregulated in specimens of nasopharyngeal carcinoma and negatively associated with tumor progression and metastasis of patients with nasopharyngeal carcinoma. However, the relationship between lactoferrin and the pro-metastatic microenvironment has not been reported yet. Here, by using the lactoferrin knockout mouse, we found that lactoferrin deficiency facilitated melanoma cells metastasizing to lungs, through recruiting myeloid-derived suppressor cells (MDSCs) in the lungs. Mechanistic studies showed that in the lung microenvironment of the lactoferrin knockout mice, the TLR9 signaling was the most repressed signaling. Lactoferrin can induce MDSCs differentiation and apoptosis, as well as upregulate TLR9 expression. TLR9 agonist or lactoferrin treatment can rescue this phenotype in the tumor metastasis mouse model. Our results suggest a protective role of lactoferrin in cancer metastasis, along with a deficiency in certain components of the innate immune system, may lead to a pro-metastatic tumor microenvironment.	[Wei, Lingyu; Zhang, Xuemei; Li, Guiyuan; Ma, Jian] Cent S Univ, Hunan Key Lab Nonresolving Inflammat & Canc, Xiangya Hosp 3, Changsha, Peoples R China; [Wei, Lingyu; Zhang, Xuemei; Wang, Jia; Ye, Qiurong; Zheng, Xiang; Peng, Qiu; Liu, Peishan; Zhang, Xiaoyue; Li, Zhengshuo; Liu, Can; Li, Guiyuan; Ma, Jian] Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha, Peoples R China; [Wei, Lingyu; Li, Guiyuan; Ma, Jian] Minist Hlth, Key Lab Carcinogenesis, Changsha, Peoples R China; [Wei, Lingyu; Li, Guiyuan; Ma, Jian] Minist Hlth, Key Lab Carcinogenesis & Canc Invas, Changsha, Peoples R China; [Wei, Lingyu; Zhang, Xuemei; Ma, Jian] Cent S Univ, Hunan Key Lab Translat Radiat Oncol, Hunan Canc Hosp, Changsha, Peoples R China; [Wei, Lingyu; Zhang, Xuemei; Ma, Jian] Cent S Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China; [Zheng, Ying] Cent S Univ, Xiangya Hosp 2, Ctr Med Res, Changsha, Peoples R China; [Yan, Qun] Cent S Univ, Xiangya Hosp, Dept Clin Lab, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Ma, J (corresponding author), Cent S Univ, Hunan Key Lab Nonresolving Inflammat & Canc, Xiangya Hosp 3, Changsha, Peoples R China.; Ma, J (corresponding author), Cent S Univ, Sch Basic Med, Canc Res Inst, Changsha, Peoples R China.; Ma, J (corresponding author), Minist Hlth, Key Lab Carcinogenesis, Changsha, Peoples R China.; Ma, J (corresponding author), Minist Hlth, Key Lab Carcinogenesis & Canc Invas, Changsha, Peoples R China.; Ma, J (corresponding author), Cent S Univ, Hunan Key Lab Translat Radiat Oncol, Hunan Canc Hosp, Changsha, Peoples R China.; Ma, J (corresponding author), Cent S Univ, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China.	majian@csu.edu.cn		Ma, Jian/0000-0001-9395-0416	National Natural Science Foundation of China [81672889, 81874170, 81472694]; China 111 Project [111-2-12]; Hunan Province Science and Technology Project [2016JC2035]; Open Research Fund Program of Key Laboratory of Translational Radiation Oncology, Hunan Province [2015TP1009]; Independent Exploration and Innovation Project of Central South University [178301003]; National College Students' Innovation and Entrepreneurship Training Program of China [201810533376, GS201910533237]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China 111 Project(Ministry of Education, China - 111 Project); Hunan Province Science and Technology Project; Open Research Fund Program of Key Laboratory of Translational Radiation Oncology, Hunan Province; Independent Exploration and Innovation Project of Central South University; National College Students' Innovation and Entrepreneurship Training Program of China	This work was funded by National Natural Science Foundation of China (81672889, 81874170, and 81472694), China 111 Project (111-2-12), Hunan Province Science and Technology Project (2016JC2035), Open Research Fund Program of Key Laboratory of Translational Radiation Oncology, Hunan Province (2015TP1009), Independent Exploration and Innovation Project of Central South University (178301003), and National College Students' Innovation and Entrepreneurship Training Program of China (201810533376, GS201910533237). We thank Professors Wen Zhou and Ya Cao for providing reagents; Professor Penghui Zhou providing key suggestions.	Acharya KR, 2014, J BIOL CHEM, V289, P17406, DOI 10.1074/jbc.R113.546218; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Aghaeepour N, 2017, J IMMUNOL, V199, P2171, DOI 10.4049/jimmunol.1700421; Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Amit I, 2009, SCIENCE, V326, P257, DOI 10.1126/science.1179050; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Ballas ZK, 2001, J IMMUNOL, V167, P4878, DOI 10.4049/jimmunol.167.9.4878; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Blais A, 2014, BIOMETALS, V27, P857, DOI 10.1007/s10534-014-9779-7; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Castano Z, 2018, NAT CELL BIOL, V20, P1084, DOI 10.1038/s41556-018-0173-5; Cen XH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00878; Chen HM, 2018, J CLIN INVEST, V128, P5647, DOI 10.1172/JCI97570; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Clavijo PE, 2019, CANCER IMMUNOL RES, V7, P282, DOI 10.1158/2326-6066.CIR-18-0156; Condamine T, 2015, J LEUKOCYTE BIOL, V98, P913, DOI 10.1189/jlb.4RI0515-204R; Deng M, 2013, ONCOGENE, V32, P4273, DOI 10.1038/onc.2012.434; Fang LS, 2019, ONCOGENE, V38, P896, DOI 10.1038/s41388-018-0484-9; Fehri E, 2016, CURR RES TRANSL MED, V64, P155, DOI 10.1016/j.retram.2016.01.010; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828; Gonzalez-Chavez SA, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.07.020; He YM, 2018, NAT MED, V24, P224, DOI 10.1038/nm.4467; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hossain DMS, 2015, CLIN CANCER RES, V21, P3771, DOI 10.1158/1078-0432.CCR-14-3145; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jiang J, 2018, EXP CELL RES, V367, P81, DOI 10.1016/j.yexcr.2018.03.025; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kerkar SP, 2012, CANCER RES, V72, P3125, DOI 10.1158/0008-5472.CAN-11-4094; Kitakaze T, 2018, MOL MED REP, V17, P5912, DOI 10.3892/mmr.2018.8603; Kolonin MG, 2017, CANCER RES, V77, P3144, DOI 10.1158/0008-5472.CAN-16-0708; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Kusmartsev S, 2008, CLIN CANCER RES, V14, P8270, DOI 10.1158/1078-0432.CCR-08-0165; Lee Jae-Hye, 2016, Oncotarget, V7, P79774, DOI 10.18632/oncotarget.12967; Legrand D, 2012, BIOCHEM CELL BIOL, V90, P252, DOI [10.1139/O11-056, 10.1139/o11-056]; Li HY, 2017, J AGR FOOD CHEM, V65, P10464, DOI 10.1021/acs.jafc.7b03390; Lim KH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011247; Maglione PJ, 2015, ANN NY ACAD SCI, V1356, P1, DOI 10.1111/nyas.12763; Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Martinez-Campos C, 2017, VIRAL IMMUNOL, V30, P98, DOI 10.1089/vim.2016.0103; Mei SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135867; Moreno-Exposito L, 2018, LIFE SCI, V195, P61, DOI 10.1016/j.lfs.2018.01.002; Oh K, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3473; Ortiz ML, 2014, CANCER IMMUNOL RES, V2, P50, DOI 10.1158/2326-6066.CIR-13-0129; Perdijk O, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070848; Raber P, 2012, IMMUNOL INVEST, V41, P614, DOI 10.3109/08820139.2012.680634; Ribechini E, 2017, BLOOD ADV, V1, P947, DOI 10.1182/bloodadvances.2017006858; Rodrigues L, 2009, CRIT REV FOOD SCI, V49, P203, DOI 10.1080/10408390701856157; Ruffell B, 2013, GENE DEV, V27, P2086, DOI 10.1101/gad.224899.113; Sathyanesan A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05656-w; Silvestrini MT, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90521; Simpson KD, 2012, J IMMUNOL, V189, P5533, DOI 10.4049/jimmunol.1201161; Siqueiros-Cendon T, 2014, ACTA PHARMACOL SIN, V35, P557, DOI 10.1038/aps.2013.200; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2018, ONCOGENE, V37, P2757, DOI 10.1038/s41388-018-0144-0; Tasli PN, 2014, APPL BIOCHEM BIOTECH, V174, P2257, DOI 10.1007/s12010-014-1204-8; Telang S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091228; Teng CT, 2010, BIOMETALS, V23, P359, DOI 10.1007/s10534-010-9310-8; Totiger TM, 2019, MOL CANCER THER, V18, P301, DOI 10.1158/1535-7163.MCT-18-0464; Uchida R, 2017, BIOCHEM CELL BIOL, V95, P64, DOI 10.1139/bcb-2016-0147; Valenti P, 2014, BIOMETALS, V27, P803, DOI 10.1007/s10534-014-9787-7; Vandrovcova M, 2015, J BIOMED MATER RES A, V103, P525, DOI 10.1002/jbm.a.35199; Velusamy SK, 2014, ANTIMICROB AGENTS CH, V58, P397, DOI 10.1128/AAC.00020-13; Velusamy SK, 2013, J PERIODONTOL, V84, P1690, DOI 10.1902/jop.2013.120587; Wakabayashi H, 2014, J INFECT CHEMOTHER, V20, P666, DOI 10.1016/j.jiac.2014.08.003; Wang B, 2019, CRIT REV FOOD SCI, V59, P580, DOI 10.1080/10408398.2017.1381583; Wang C, 2014, ASIAN PAC J CANCER P, V15, P4187, DOI 10.7314/APJCP.2014.15.10.4187; Won H, 2017, J LEUKOCYTE BIOL, V102, P423, DOI 10.1189/jlb.3MA1016-451RR; Xie F, 2018, ACTA BIOCH BIOPH SIN, V50, P121, DOI 10.1093/abbs/gmx123; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Yang Q, 2017, ONCOGENE, V36, P2969, DOI 10.1038/onc.2016.448; Ye QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103298; Zambirinis CP, 2015, J EXP MED, V212, P2077, DOI 10.1084/jem.20142162; Zhang CX, 2019, CELL DEATH DIFFER, V26, P2314, DOI 10.1038/s41418-019-0302-0; Zhang H, 2017, ONCOGENE, V36, P2095, DOI 10.1038/onc.2016.367; Zhang WL, 2015, TUMOR BIOL, V36, P675, DOI 10.1007/s13277-014-2650-1; Zhou YH, 2008, INT J CANCER, V123, P2065, DOI 10.1002/ijc.23727; Zoglmeier C, 2011, CLIN CANCER RES, V17, P1765, DOI 10.1158/1078-0432.CCR-10-2672	81	12	18	6	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					122	135		10.1038/s41388-019-0970-8	http://dx.doi.org/10.1038/s41388-019-0970-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462711				2022-12-17	WOS:000509849200008
J	Xu, Y; Surman, DR; Diggs, L; Xi, SC; Gao, SJ; Gurusamy, D; McLoughlin, K; Drake, J; Feingold, P; Brown, K; Wangsa, D; Wangsa, D; Zhang, X; Ried, T; Davis, JL; Hernandez, J; Hoang, CD; Souza, RF; Schrump, DS; Ripley, RT				Xu, Yuan; Surman, Deborah R.; Diggs, Laurence; Xi, Sichuan; Gao, Shaojian; Gurusamy, Devikala; McLoughlin, Kaitlin; Drake, Justin; Feingold, Paul; Brown, Kate; Wangsa, Danny; Wangsa, Darawalee; Zhang, Xi; Ried, Thomas; Davis, Jeremy L.; Hernandez, Jonathan; Hoang, Chuong D.; Souza, Rhonda F.; Schrump, David S.; Ripley, R. Taylor			Bile acid-induced "Minority MOMP" promotes esophageal carcinogenesis while maintaining apoptotic resistance via Mcl-1	ONCOGENE			English	Article							CAUSES DNA-DAMAGE; ADENOCARCINOMA INCIDENCE; BARRETTS-ESOPHAGUS; CANCER-CELLS; MITOCHONDRIAL; ROS; INSTABILITY; EXPRESSION; SURVIVAL; BCL-2	Barrett's esophagus (BE) is associated with reflux and is implicated the development of esophageal adenocarcinoma (EAC). Apoptosis induces cell death through mitochondrial outer membrane permeabilization (MOMP), which is considered an irreversible step in apoptosis. Activation of MOMP to levels that fail to reach the apoptotic threshold may paradoxically promote cancer-a phenomenon called "Minority MOMP." We asked whether reflux-induced esophageal carcinogenesis occurred via minority MOMP and whether compensatory resistance mechanisms prevented cell death during this process. We exposed preneoplastic, hTERT-immortalized Barrett's cell, CP-C and CP-A, to the oncogenic bile acid, deoxycholic acid (DCA), for 1 year. Induction of minority MOMP was tested via comet assay, CyQuant, annexin V, JC-1, cytochrome C subcellular localization, caspase 3 activation, and immunoblots. We used bcl-2 homology domain-3 (BH3) profiling to test the mitochondrial apoptotic threshold. One-year exposure of Barrett's cells to DCA induced a malignant phenotype noted by clone and tumor formation. DCA promoted minority MOMP noted by minimal release of cytochrome C and limited caspase 3 activation, which resulted in DNA damage without apoptosis. Upregulation of the antiapoptotic protein, Mcl-1, ROS generation, and NF-kappa B activation occurred in conjunction with minority MOMP. Inhibition of ROS blocked minority MOMP and Mcl-1 upregulation. Knockdown of Mcl-1 shifted minority MOMP to complete MOMP as noted by dynamic BH3 profiling and increased apoptosis. Minority MOMP contributes to DCA induced carcinogenesis in preneoplastic BE. Mcl-1 provided a balance within the mitochondria that induced resistance complete MOMP and cell death. Targeting Mcl-1 may be a therapeutic strategy in EAC.	[Xu, Yuan; Surman, Deborah R.; Diggs, Laurence; Xi, Sichuan; Gao, Shaojian; McLoughlin, Kaitlin; Drake, Justin; Feingold, Paul; Brown, Kate; Davis, Jeremy L.; Hernandez, Jonathan; Hoang, Chuong D.; Schrump, David S.; Ripley, R. Taylor] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Surman, Deborah R.; Ripley, R. Taylor] Baylor Coll Med, Michael E DeBakey Dept Gen Surg, Div Gen Thorac Surg, Houston, TX 77030 USA; [Gurusamy, Devikala] NCI, Surg Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Wangsa, Danny; Wangsa, Darawalee; Ried, Thomas] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhang, Xi; Souza, Rhonda F.] Baylor Univ, Med Ctr, Ctr Esophageal Dis, Dept Med, Dallas, TX USA; [Wangsa, Danny; Wangsa, Darawalee; Ried, Thomas] Baylor Scott & White Res Inst, Ctr Esophageal Res, Dallas, TX USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor University; Baylor University Medical Center; Baylor Health Care System; Baylor University Medical Center	Ripley, RT (corresponding author), NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.; Ripley, RT (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Gen Surg, Div Gen Thorac Surg, Houston, TX 77030 USA.	R.Taylor.Ripley@bcm.edu	Gurusamy, Devikala/T-3410-2019; Davis, Jeremy/GQA-5941-2022; Davis, Jeremy/GLT-7151-2022	Davis, Jeremy/0000-0002-6334-6936; Davis, Jeremy/0000-0002-6334-6936; Gurusamy, Devikala/0000-0002-1727-8653; DRAKE, JUSTIN/0000-0002-2500-7044				Araghi RR, 2018, P NATL ACAD SCI USA, V115, pE886, DOI 10.1073/pnas.1712952115; Bajpai M, 2012, MOL CYTOGENET, V5, DOI 10.1186/1755-8166-5-43; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Byun JY, 2009, MOL PHARMACOL, V76, P734, DOI 10.1124/mol.109.056259; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; Ertel F, 2013, EMBO REP, V14, P328, DOI 10.1038/embor.2013.20; Gillies LA, 2014, J CELL BIOCHEM, V115, P632, DOI 10.1002/jcb.24709; Gyori BM, 2014, REDOX BIOL, V2, P457, DOI 10.1016/j.redox.2013.12.020; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hormi-Carver K, 2009, CANCER RES, V69, P672, DOI 10.1158/0008-5472.CAN-08-3703; Huo XF, 2011, AM J PHYSIOL-GASTR L, V301, pG278, DOI 10.1152/ajpgi.00092.2011; Hur C, 2013, CANCER-AM CANCER SOC, V119, P1149, DOI 10.1002/cncr.27834; Ichim G, 2015, MOL CELL, V57, P860, DOI 10.1016/j.molcel.2015.01.018; Kim MJ, 2013, CANCER LETT, V339, P15, DOI 10.1016/j.canlet.2013.07.027; Kong CY, 2014, CANCER EPIDEM BIOMAR, V23, P997, DOI 10.1158/1055-9965.EPI-13-1233; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Kwong JQ, 2007, J CELL BIOL, V179, P1163, DOI 10.1083/jcb.200704059; Li DC, 2004, CANCER SCI, V95, P644, DOI 10.1111/j.1349-7006.2004.tb03323.x; Liu XJ, 2015, MOL CELL, V58, P284, DOI 10.1016/j.molcel.2015.03.003; Lovric MM, 2010, ONCOGENE, V29, P5048, DOI 10.1038/onc.2010.242; Palanca-Wessels MC, 1998, GASTROENTEROLOGY, V114, P295, DOI 10.1016/S0016-5085(98)70480-9; Perciavalle RM, 2013, TRENDS CELL BIOL, V23, P22, DOI 10.1016/j.tcb.2012.08.011; Potter DS, 2016, COLD SH Q B, V81, P131, DOI 10.1101/sqb.2016.81.030841; Runge TM, 2015, GASTROENTEROL CLIN N, V44, P203, DOI 10.1016/j.gtc.2015.02.001; Ryan J, 2016, BIOL CHEM, V397, P671, DOI 10.1515/hsz-2016-0107; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sobieraj DM, 2011, AM J MANAG CARE, V17, pE449; Spencer SL, 2011, CELL, V144, P926, DOI 10.1016/j.cell.2011.03.002; Tait SWG, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008706; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tang HL, 2012, MOL BIOL CELL, V23, P2240, DOI 10.1091/mbc.E11-11-0926; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Westphal D, 2011, BBA-MOL CELL RES, V1813, P521, DOI 10.1016/j.bbamcr.2010.12.019; Williams MM, 2017, MOL CANCER RES, V15, P259, DOI 10.1158/1541-7786.MCR-16-0280-T; Xu Y, 2017, ONCOTARGET, V8, P101057; Yadav N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.305; Yen CJ, 2008, CANCER RES, V68, P2632, DOI 10.1158/0008-5472.CAN-07-5460; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200	39	12	13	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					877	890		10.1038/s41388-019-1029-6	http://dx.doi.org/10.1038/s41388-019-1029-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31570787	Green Accepted			2022-12-17	WOS:000509197200010
J	Alptekin, A; Ye, BW; Yu, YJ; Poole, CJ; van Riggelen, J; Zha, YH; Ding, HF				Alptekin, Ahmet; Ye, Bingwei; Yu, Yajie; Poole, Candace J.; van Riggelen, Jan; Zha, Yunhong; Ding, Han-Fei			Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity	ONCOGENE			English	Article							ONE-CARBON METABOLISM; N-MYC; GLUTAMINE-METABOLISM; PROGNOSTIC MARKER; SYNTHESIS PATHWAY; C-MYC; SERINE; CANCER; FOLATE; FLUX	Genomic amplification of the oncogene MYCN is a major driver in the development of high-risk neuroblastoma, a pediatric cancer with poor prognosis. Given the challenge in targeting MYCN directly for therapy, we sought to identify MYCN-dependent metabolic vulnerabilities that can be targeted therapeutically. Here, we report that the gene encoding glycine decarboxylase (GLDC), which catalyzes the first and rate-limiting step in glycine breakdown with the production of the one-carbon unit 5,10-methylene-tetrahydrofolate, is a direct transcriptional target of MYCN. As a result, GLDC expression is markedly elevated in MYCN-amplified neuroblastoma tumors and cell lines. This transcriptional upregulation of GLDC expression is of functional significance, as GLDC depletion by RNA interference inhibits the proliferation and tumorigenicity of MYCN-amplified neuroblastoma cell lines by inducing G1 arrest. Metabolomic profiling reveals that GLDC knockdown disrupts purine and central carbon metabolism and reduces citrate production, leading to a decrease in the steady-state levels of cholesterol and fatty acids. Moreover, blocking purine or cholesterol synthesis recapitulates the growth-inhibitory effect of GLDC knockdown. These findings reveal a critical role of GLDC in sustaining the proliferation of neuroblastoma cells with high-level GLDC expression and suggest that MYCN amplification is a biomarker for GLDC-based therapeutic strategies against high-risk neuroblastoma.	[Alptekin, Ahmet; Poole, Candace J.; van Riggelen, Jan; Ding, Han-Fei] Augusta Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Alptekin, Ahmet; Ye, Bingwei; Poole, Candace J.; van Riggelen, Jan; Ding, Han-Fei] Augusta Univ, Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA; [Yu, Yajie; Zha, Yunhong] Three Gorges Univ, Hosp Yichang 1, Inst Neural Regenerat & Repair, Coll Med, Yichang 443000, Peoples R China; [Yu, Yajie; Zha, Yunhong] Three Gorges Univ, Hosp Yichang 1, Dept Neurol, Coll Med, Yichang 443000, Peoples R China; [Ding, Han-Fei] Augusta Univ, Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; China Three Gorges University; China Three Gorges University; University System of Georgia; Augusta University	Ding, HF (corresponding author), Augusta Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.; Ding, HF (corresponding author), Augusta Univ, Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA.; Ding, HF (corresponding author), Augusta Univ, Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA.	hding@augusta.edu	Ye, Bingwei/AAH-1139-2021	Alptekin, Ahmet/0000-0002-7039-1911; Ding, Han-Fei/0000-0001-5702-3439; Langan, Candace Jean/0000-0003-1811-587X; yu, yajie/0000-0002-8645-9976	NIH [R01 CA190429]; NATIONAL CANCER INSTITUTE [R01CA190429] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by an NIH grant (R01 CA190429) to HFD.	Alam G, 2009, AM J PATHOL, V175, P856, DOI 10.2353/ajpath.2009.090019; Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brooks EE, 1997, J BIOL CHEM, V272, P29207, DOI 10.1074/jbc.272.46.29207; Campbell K, 2017, CANCER-AM CANCER SOC, V123, P4224, DOI 10.1002/cncr.30873; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Comte B, 2002, AM J PHYSIOL-HEART C, V283, pH1505, DOI 10.1152/ajpheart.00287.2002; Conter C, 2006, J INHERIT METAB DIS, V29, P135, DOI 10.1007/s10545-006-0202-6; Cui HJ, 2005, J BIOL CHEM, V280, P9474, DOI 10.1074/jbc.M410450200; DADAMO AF, 1965, J BIOL CHEM, V240, P613; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dejure FR, 2017, EMBO J, V36, P3409, DOI 10.15252/embj.201796438; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Ducker GS, 2017, CELL METAB, V25, P27, DOI 10.1016/j.cmet.2016.08.009; Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016; Fiehn O, 2008, PLANT J, V53, P691, DOI 10.1111/j.1365-313X.2007.03387.x; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Holleran AL, 1995, MOL CELL BIOCHEM, V152, P95, DOI 10.1007/BF01076071; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lamers Y, 2009, J NUTR, V139, P666, DOI 10.3945/jn.108.103580; Leung KY, 2017, CELL REP, V21, P1795, DOI 10.1016/j.celrep.2017.10.072; Liu ML, 2016, CELL REP, V17, P609, DOI 10.1016/j.celrep.2016.09.021; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; MANFREDI JP, 1985, ANNU REV PHYSIOL, V47, P691, DOI 10.1146/annurev.ph.47.030185.003355; Mao L, 2012, ONCOGENE, V31, P3785, DOI 10.1038/onc.2011.536; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Marshall GM, 2014, NAT REV CANCER, V14, P277, DOI 10.1038/nrc3679; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Narisawa A, 2012, HUM MOL GENET, V21, P1496, DOI 10.1093/hmg/ddr585; Narkewicz MR, 1996, BIOCHEM J, V313, P991, DOI 10.1042/bj3130991; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128; Pai YJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7388; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Park JR, 2013, PEDIATR BLOOD CANCER, V60, P985, DOI 10.1002/pbc.24433; PFENDNER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P503, DOI 10.1016/0003-9861(80)90382-3; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Reid MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07868-6; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; SCHWAB M, 1993, SEMIN CANCER BIOL, V4, P13; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tadesse S, 2019, J MED CHEM, V62, P4233, DOI 10.1021/acs.jmedchem.8b01469; Teitz T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019133; Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Wang WW, 2013, AMINO ACIDS, V45, P463, DOI 10.1007/s00726-013-1493-1; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Xia JG, 2011, NAT PROTOC, V6, P743, DOI 10.1038/nprot.2011.319; Xia YF, 2019, CANCER RES, V79, P3837, DOI 10.1158/0008-5472.CAN-18-3541; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Yoo H, 2008, J BIOL CHEM, V283, P20621, DOI 10.1074/jbc.M706494200; YOSHIDA T, 1970, ARCH BIOCHEM BIOPHYS, V139, P380, DOI 10.1016/0003-9861(70)90490-X; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151; Zhang WC, 2012, CELL, V148, P259, DOI 10.1016/j.cell.2011.11.050; Zhang WQ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0694-1; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053	76	12	12	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7504	7520		10.1038/s41388-019-0967-3	http://dx.doi.org/10.1038/s41388-019-0967-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31444411	Green Accepted			2022-12-17	WOS:000502530500005
J	Rajabi, H; Hata, T; Li, W; Long, MD; Hu, Q; Liu, S; Raina, D; Kui, L; Yasumizu, Y; Hong, DL; Samur, M; Kufe, D				Rajabi, Hasan; Hata, Tsuyoshi; Li, Wei; Long, Mark D.; Hu, Qiang; Liu, Song; Raina, Deepak; Kui, Ling; Yasumizu, Yota; Hong, Deli; Samur, Mehmet; Kufe, Donald			MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells	ONCOGENE			English	Article							DNA METHYLATION; IMMUNE EVASION; MST2 PATHWAY; ONCOPROTEIN; RAS; ASSOCIATION; DOMAIN; GENE; TRANSCRIPTION; ACTIVATION	RASSF1A encodes a tumor suppressor that inhibits the RAS -> RAF -> MEK -> ERK pathway and is one of the most frequently inactivated genes in human cancers. MUC1-C is an oncogenic effector of the cancer cell epigenome that is overexpressed in diverse carcinomas. We show here that MUC1-C represses RASSF1A expression in KRAS wild-type and mutant cancer cells. Mechanistically, MUC1-C occupies the RASSF1A promoter in a complex with the ZEB1 transcriptional repressor. In turn, MUC1-C/ZEB1 complexes recruit DNA methyltransferase 3b (DNMT3b) to the CpG island in the RASSF1A promoter. Targeting MUC1-C, ZEB1, and DNMT3b thereby decreases methylation of the CpG island and derepresses RASSF1A transcription. We also show that targeting MUC1-C regulates KRAS signaling, as evidenced by RNA-seq analysis, and decreases MEK/ERK activation, which is of importance for RAS-mediated tumorigenicity. These findings define a previously unrecognized role for MUC1-C in suppression of RASSF1A and support targeting MUC1-C as an approach for inhibiting MEK -> ERK signaling.	[Rajabi, Hasan; Hata, Tsuyoshi; Li, Wei; Raina, Deepak; Kui, Ling; Yasumizu, Yota; Hong, Deli; Samur, Mehmet; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Long, Mark D.; Hu, Qiang; Liu, Song] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA; [Raina, Deepak] Genus Oncol, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	wei, li/GSD-3630-2022; Hong, Deli/AAG-2565-2021; Wei, Li/AAE-9938-2020	Li, Wei/0000-0001-6728-1300; Hu, Qiang/0000-0002-4090-5539; Samur, Mehmet/0000-0002-9978-5682; Long, Mark/0000-0003-1120-8176	National Cancer Institute of the National Institutes of Health [CA97098, CA166480, CA216553, CA233084, U24CA232979]; NATIONAL CANCER INSTITUTE [R01CA166480, U01CA233084, R21CA216553, R01CA097098, U24CA232979] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants from the National Cancer Institute of the National Institutes of Health under award numbers CA97098, CA166480, CA216553, CA233084, and U24CA232979.	Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Ahmad R, 2012, J BIOL CHEM, V287, P20866, DOI 10.1074/jbc.M112.357293; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Alam M, 2016, MOL CANCER RES, V14, P1266, DOI 10.1158/1541-7786.MCR-16-0233; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Cox Adrienne D, 2010, Small GTPases, V1, P2; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann RH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102160; Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389; Donninger H, 2016, SEMIN CELL DEV BIOL, V58, P86, DOI 10.1016/j.semcdb.2016.06.007; Dubois F, 2016, CANCER RES, V76, P1627, DOI 10.1158/0008-5472.CAN-15-1008; Guo C, 2011, J BIOL CHEM, V286, P6253, DOI 10.1074/jbc.M110.178210; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001; Kidger AM, 2018, PHARMACOL THERAPEUT, V187, P45, DOI 10.1016/j.pharmthera.2018.02.007; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Maeda T, 2018, CANCER RES, V78, P205, DOI 10.1158/0008-5472.CAN-17-1636; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matallanas D, 2011, MOL CELL, V44, P893, DOI 10.1016/j.molcel.2011.10.016; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009; Panchamoorthy G, 2011, HYBRIDOMA, V30, P531, DOI 10.1089/hyb.2011.0070; PANDEY P, 1995, CANCER RES, V55, P4000; Papaspyropoulos A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02786-5; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Rajabi H, 2018, ONCOGENE, V37, P2079, DOI 10.1038/s41388-017-0096-9; Rajabi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07850-0; Rajabi H, 2017, BBA-REV CANCER, V1868, P117, DOI 10.1016/j.bbcan.2017.03.003; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Ram RR, 2014, MOL CELL BIOL, V34, P2350, DOI 10.1128/MCB.01506-13; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Romano D, 2014, NAT CELL BIOL, V16, P673, DOI 10.1038/ncb2986; Schmidt ML, 2018, CANCER RES, V78, P2614, DOI 10.1158/0008-5472.CAN-17-2466; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Teng IW, 2011, CANCER RES, V71, P4653, DOI 10.1158/0008-5472.CAN-10-3418; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; Tolcher AW, 2018, MOL CANCER THER, V17, P3, DOI 10.1158/1535-7163.MCT-17-0349; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; Vaseva AV, 2018, CANCER CELL, V34, P807, DOI 10.1016/j.ccell.2018.10.001; Vlahov N, 2015, CURR BIOL, V25, P3019, DOI 10.1016/j.cub.2015.09.072; Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Zhou C, 2017, ONCOTARGET, V8, P54388, DOI 10.18632/oncotarget.17077; Zhou CX, 2017, ONCOTARGET, V8, P49534, DOI 10.18632/oncotarget.17743	62	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7266	7277		10.1038/s41388-019-0940-1	http://dx.doi.org/10.1038/s41388-019-0940-1			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31435022	hybrid, Green Accepted			2022-12-17	WOS:000497989400006
J	Cook, LM; Frieling, JS; Nerlakanti, N; McGuire, JJ; Stewart, PA; Burger, KL; Cleveland, JL; Lynch, CC				Cook, Leah M.; Frieling, Jeremy S.; Nerlakanti, Niveditha; McGuire, Jeremy J.; Stewart, Paul A.; Burger, Karen L.; Cleveland, John L.; Lynch, Conor C.			Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; STEM-CELLS; BONE METASTASES; RECEPTOR; WNT5A; EXPRESSION; DIFFERENTIATION; INHIBITION; MIGRATION	Bone metastatic prostate cancer provokes extensive osteogenesis by driving the recruitment and osteoblastic differentiation of mesenchymal stromal cells (MSCs). The resulting lesions greatly contribute to patient morbidity and mortality, underscoring the need for defining how prostate metastases subvert the MSC-osteoblast differentiation program. To gain insights into this process we profiled the effects of co-culture of primary MSCs with validated bone metastatic prostate cancer cell line models. These analyses revealed a cast of shared differentially induced genes in MSC, including betaglycan, a co-receptor for TGF beta. Betaglycan has not been studied in the context of bone metastatic disease previously. Here we report that loss of betaglycan in MSC is sufficient to augment TGF beta signaling, proliferation and migration, and completely blocks the MSC-osteoblast differentiation program. Further, betaglycan was revealed as necessary for prostate cancer-induced osteogenesis in vivo. Mechanistically, gene expression analysis revealed betaglycan controls the expression of a large repertoire of genes in MSCs, and that betaglycan loss provokes >60-fold increase in the expression of Wnt5a that plays important roles in stemness. In accord with the increased Wnt5a levels, there was a marked induction of canonical Wnt signaling in betaglycan ablated MSCs, and the addition of recombinant Wnt5a to MSCs was sufficient to impair osteogenic differentiation. Finally, the addition of Wnt5a neutralizing antibody was sufficient to induce the expression of osteogenic genes in betaglycan-ablated MSCs. Collectively, these findings suggest a betaglycan-Wnt5a circuit represents an attractive vulnerability to ameliorate prostate cancer-induced osteogenesis.	[Cook, Leah M.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Frieling, Jeremy S.; Nerlakanti, Niveditha; McGuire, Jeremy J.; Burger, Karen L.; Cleveland, John L.; Lynch, Conor C.] H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA; [Nerlakanti, Niveditha; McGuire, Jeremy J.] Univ S Florida, Canc Biol PhD Program, Tampa, FL USA; [Stewart, Paul A.] H Lee Moffitt Canc Ctr & Res Inst, Biostat & Bioinformat Shared Resource, Tampa, FL USA	University of Nebraska System; University of Nebraska Medical Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute	Lynch, CC (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Tumor Biol Dept, Tampa, FL 33612 USA.	conor.lynch@moffitt.org	Cook, Leah/AAV-9640-2021; Nerlakanti, Niveditha/X-5741-2019	Cook, Leah/0000-0002-9996-7419; Nerlakanti, Niveditha/0000-0001-8808-2220; Frieling, Jeremy/0000-0002-2181-1836; Stewart, Paul/0000-0003-0882-308X; Burger, Karen/0000-0002-3805-9580	American Cancer Society [PF-13-175-01-CSM]; Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center [P30-CA076292]; Miles for Moffitt; Department of Defense PCRP program [W81XWH1810523]; Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida; Molecular Genomics Core; Analytic Microscopy Core; Small Animal Imaging Laboratory Core; NATIONAL CANCER INSTITUTE [P30CA076292, P50CA097186] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center; Miles for Moffitt; Department of Defense PCRP program(United States Department of Defense); Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida; Molecular Genomics Core; Analytic Microscopy Core; Small Animal Imaging Laboratory Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Colm Morrissey, University of Washington for providing human bone metastatic prostate cancer specimens (P50-CA097186 16A1). LMC was supported by a fellowship from the American Cancer Society (PF-13-175-01-CSM). This work has been supported in part by the Molecular Genomics Core, the Analytic Microscopy Core, the Small Animal Imaging Laboratory Core and the Biostatistics and Bioinformatics Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, an NCI designated Comprehensive Cancer Center (P30-CA076292). Funding also provided by Miles for Moffitt (CCL), the Department of Defense PCRP program (W81XWH1810523; CCL), and by the Cortner-Couch Endowed Chair for Cancer Research from the University of South Florida (JLC).	Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008-5472.CAN-13-2652; Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102; Bauer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080526; Belotti D, 2016, MATRIX BIOL, V55, P106, DOI 10.1016/j.matbio.2016.03.003; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bilandzic M, 2011, MOL CELL ENDOCRINOL, V339, P180, DOI 10.1016/j.mce.2011.04.014; Biswas S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027090; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Canesin G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184418; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Cook LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29384; Cook LM, 2014, CANCER METAST REV, V33, P511, DOI 10.1007/s10555-014-9494-4; Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050; Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078-0432.CCR-13-0839; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; Fournier PGJ, 2010, BONE, V47, pS268, DOI 10.1016/j.bone.2010.01.332; Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009; Frieling JS, 2015, CANCER CONTROL, V22, P109, DOI 10.1177/107327481502200114; Gebken J, 1999, J ENDOCRINOL, V161, P503, DOI 10.1677/joe.0.1610503; Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69; Hasegawa D, 2018, J CELL PHYSIOL, V233, P1752, DOI 10.1002/jcp.26086; Hill CR, 2015, DEV DYNAM, V244, P122, DOI 10.1002/dvdy.24225; Hodgkinson CP, 2013, STEM CELLS, V31, P1669, DOI 10.1002/stem.1416; Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; Jenkins LM, 2016, J BIOL CHEM, V291, P25716, DOI 10.1074/jbc.M116.748624; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129; Korpal M, 2010, EUR J CANCER, V46, P1232, DOI 10.1016/j.ejca.2010.02.040; Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Kumawat K, 2013, FASEB J, V27, P1631, DOI 10.1096/fj.12-217539; Lee GT, 2018, BRIT J CANCER, V118, P670, DOI 10.1038/bjc.2017.451; Logothetis C, 2018, CANCER METAST REV, V37, P189, DOI 10.1007/s10555-017-9719-4; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008-5472.CAN-10-2651; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Nishida J, 2018, ONCOGENE, V37, P2197, DOI 10.1038/s41388-017-0084-0; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; Olivares-Navarrete R, 2011, ACTA BIOMATER, V7, P2740, DOI 10.1016/j.actbio.2011.02.030; Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661; Ren GW, 2015, J MOL MED, V93, P1203, DOI 10.1007/s00109-015-1329-4; Roarty K, 2007, DEVELOPMENT, V134, P3929, DOI 10.1242/dev.008250; Sakaki-Yumoto M, 2013, BBA-GEN SUBJECTS, V1830, P2280, DOI 10.1016/j.bbagen.2012.08.008; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Serra R, 2011, J MAMMARY GLAND BIOL, V16, P157, DOI 10.1007/s10911-011-9205-5; Shinojima N, 2013, CANCER RES, V73, P2333, DOI 10.1158/0008-5472.CAN-12-3086; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979; Thiele Stefanie, 2018, Oncotarget, V9, P27293, DOI 10.18632/oncotarget.25551; Thiele S, 2016, J BONE MINER RES, V31, P1488, DOI 10.1002/jbmr.2899; Thiele S, 2015, J BONE MINER RES, V30, P488, DOI 10.1002/jbmr.2362; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Todorovic N, 2011, BIOMARK MED, V5, P855, DOI [10.2217/BMM.11.59, 10.2217/bmm.11.59]; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Zhang SJ, 2016, EUR REV MED PHARMACO, V20, P899	65	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					6959	6969		10.1038/s41388-019-0913-4	http://dx.doi.org/10.1038/s41388-019-0913-4			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31409900	Green Accepted			2022-12-17	WOS:000493892900001
J	Li, DK; Tian, Y; Hu, Y; Qi, YJ; Tian, NY; Li, SS; Hu, PS; Wu, F; Wei, QF; Wei, ZZ; Wang, SS; Yin, B; Jiang, T; Yuan, JG; Qiang, BQ; Han, W; Peng, XZ				Li, Dengke; Tian, Yuan; Hu, Yan; Qi, Yingjiao; Tian, Ningyu; Li, Shanshan; Hu, Peishan; Wu, Fan; Wei, Qunfang; Wei, Zhizhong; Wang, Shanshan; Yin, Bin; Jiang, Tao; Yuan, Jiangang; Qiang, Boqin; Han, Wei; Peng, Xiaozhong			Glioma-associated human endothelial cell-derived extracellular vesicles specifically promote the tumourigenicity of glioma stem cells via CD9	ONCOGENE			English	Article							INITIATING CELLS; TETRASPANIN CD9; TUMOR-GROWTH; PROLIFERATION; EXOSOMES; ACTIVATION; CROSSTALK; BETA; INTERLEUKIN-8; EXPRESSION	The perivascular niche in glioma is critical for the maintenance of glioma stem cells (GSCs), and tumour-endothelial cell (EC) communication impacts tumourigenesis in ways that are incompletely understood. Here, we show that gliomaassociated human endothelial cells (GhECs), a main component of the perivascular niche, release extracellular vesicles (EVs) that increase GSC proliferation and tumour-sphere formation. GSCs treated with GhEC-EVs create a significantly greater tumour burden than do untreated GSCs in orthotopic xenografts. Mechanistic, analysis of EVs content identified CD9 as a mediator of the effects on GSCs. CD9 can activate the BMX/STAT3 signalling pathway in GSCs. Our results illuminate the tumour-supporting role of ECs by identifying that EC-derived EVs transfer of CD9 during intercellular communication, thereby enhancing the aggressiveness of glioblastoma by specifically maintaining GSCs.	[Li, Dengke; Tian, Yuan; Hu, Yan; Qi, Yingjiao; Tian, Ningyu; Li, Shanshan; Hu, Peishan; Wei, Qunfang; Wei, Zhizhong; Wang, Shanshan; Yin, Bin; Yuan, Jiangang; Qiang, Boqin; Han, Wei; Peng, Xiaozhong] Chinese Acad Med Sci, Peking Union Med Coll,Sch Basic Med, State Key Lab Med Mol Biol,Dept Mol Biol & Bioche, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China; [Wu, Fan; Jiang, Tao] Capital Med Univ, Beijing Neurosurg Inst, Dept Mol Neuropathol, Beijing, Peoples R China; [Wei, Zhizhong; Peng, Xiaozhong] Chinese Acad Med Sci, Inst Med Biol, Peking Union Med Coll, Kunming, Yunnan, Peoples R China; [Jiang, Tao] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Beijing Neurosurgical Institute; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Peking Union Medical College; Capital Medical University	Han, W; Peng, XZ (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll,Sch Basic Med, State Key Lab Med Mol Biol,Dept Mol Biol & Bioche, Inst Basic Med Sci,Med Primate Res Ctr,Neurosci C, Beijing, Peoples R China.; Peng, XZ (corresponding author), Chinese Acad Med Sci, Inst Med Biol, Peking Union Med Coll, Kunming, Yunnan, Peoples R China.	hanwei2012@ibms.pumc.edu.cn; pengxiaozhong@pumc.edu.cn	jiang, tao/GWC-7108-2022	wei, zhizhong/0000-0002-9840-1878	National Key Research and Development Program of China [2016YFC0902500, 2016YFC0902502, 2016YFA0100702]; National Sciences Foundation of China [31671316, 31670789]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001, 2016-I2M-2-001, 2016-I2M-1-004, 2017-I2M-2-004, 2017-I2M-3-010, 2017-I2M-1-004]	National Key Research and Development Program of China; National Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	The National Key Research and Development Program of China (2016YFC0902500, 2016YFC0902502 and 2016YFA0100702), and National Sciences Foundation of China (31671316, 31670789), CAMS Innovation Fund for Medical Sciences (CIFMS, 2016-I2M-1-001, 2016-I2M-2-001, 2016-I2M-1-004, 2017-I2M-2-004, 2017-I2M-3-010 and 2017-I2M-1-004).	Atay S, 2014, P NATL ACAD SCI USA, V111, P711, DOI 10.1073/pnas.1310501111; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bassett EA, 2016, ELIFE, V5, DOI 10.7554/eLife.16764; Bhuvanalakshmi G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127517; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Bovy N, 2015, ONCOTARGET, V6, P10253, DOI 10.18632/oncotarget.3520; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; Chen C, 2015, CANCER RES, V75, P1725, DOI 10.1158/0008-5472.CAN-14-2111; Cheng L, 2010, BIOCHEM PHARMACOL, V80, P654, DOI 10.1016/j.bcp.2010.04.035; Cherepanov SA, 2016, B EXP BIOL MED+, V161, P674, DOI 10.1007/s10517-016-3483-2; Di Modica M, 2017, CANCER LETT, V384, P94, DOI 10.1016/j.canlet.2016.09.013; Eyler CE, 2011, CELL, V146, P53, DOI 10.1016/j.cell.2011.06.006; Figueroa J, 2017, CANCER RES, V77, P5808, DOI 10.1158/0008-5472.CAN-16-2524; Filatova A, 2013, BBA-GEN SUBJECTS, V1830, P2496, DOI 10.1016/j.bbagen.2012.10.008; Galan-Moya EM, 2011, EMBO REP, V12, P470, DOI 10.1038/embor.2011.39; Hu PS, 2017, ONCOGENE, V36, P4706, DOI 10.1038/onc.2017.34; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; Infanger DW, 2013, CANCER RES, V73, P7079, DOI 10.1158/0008-5472.CAN-13-1355; Jeon HM, 2014, CANCER RES, V74, P4482, DOI 10.1158/0008-5472.CAN-13-1597; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Kurachi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159158; Leca J, 2016, J CLIN INVEST, V126, P4140, DOI 10.1172/JCI87734; Liu SH, 2014, INT J CLIN EXP PATHO, V7, P4857; Lombardo G, 2016, SCI REP-UK, V6, DOI 10.1038/srep25689; Longo N, 2001, BLOOD, V98, P3717, DOI 10.1182/blood.V98.13.3717; Mahmoud AM, 2017, FASEB J, V31, P4636, DOI 10.1096/fj.201601244RR; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Miyake M, 1996, CANCER RES, V56, P1244; Mori M, 1998, CLIN CANCER RES, V4, P1507; Muller L, 2016, SCI REP-UK, V6, DOI 10.1038/srep20254; Murayama Y, 2008, J CELL PHYSIOL, V216, P135, DOI 10.1002/jcp.21384; Osterberg N, 2016, NEURO-ONCOLOGY, V18, P939, DOI 10.1093/neuonc/now005; Pan YZ, 2017, INT J ONCOL, V50, P1965, DOI 10.3892/ijo.2017.3965; She XW, 2004, INT J CANCER, V108, P251, DOI 10.1002/ijc.11551; Shi Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah6816; Shi Y, 2017, CELL DEATH DIFFER, V24, P167, DOI 10.1038/cdd.2016.110; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Solly F, 2008, CANCER GENE THER, V15, P685, DOI 10.1038/cgt.2008.36; Treps L, 2016, ONCOGENE, V35, P2615, DOI 10.1038/onc.2015.317; Treps L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1359479; Valentijn KM, 2008, J STRUCT BIOL, V161, P447, DOI 10.1016/j.jsb.2007.08.001; Wang GP, 2015, MOL MED REP, V12, P1381, DOI 10.3892/mmr.2015.3466; Weyerbrock A, 2012, NEUROSURGERY, V70, P497, DOI 10.1227/NEU.0b013e31823209cf; Wirsching HG, 2014, BRAIN, V137, P433, DOI 10.1093/brain/awt333; Xu R, 2016, J CLIN INVEST, V126, P1152, DOI 10.1172/JCI81129; Yamashita D, 2015, CANCER RES, V75, P1123, DOI 10.1158/0008-5472.CAN-14-0938; Yan GN, 2014, J PATHOL, V234, P11, DOI 10.1002/path.4349; Yan K, 2013, CURR OPIN NEUROL, V26, P701, DOI 10.1097/WCO.0000000000000032; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yue SJ, 2015, ONCOTARGET, V6, P2366, DOI 10.18632/oncotarget.2958; Zomer A, 2015, CELL, V161, P1046, DOI 10.1016/j.cell.2015.04.042	57	12	13	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6898	6912		10.1038/s41388-019-0903-6	http://dx.doi.org/10.1038/s41388-019-0903-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31399645				2022-12-17	WOS:000492728000002
J	Marcus, J; Bejerano-Sagie, M; Patterson, N; Bagchi, S; Verkhusha, VV; Connolly, D; Goldberg, GL; Golden, A; Sharma, VP; Condeelis, J; Montagna, C				Marcus, Jenna; Bejerano-Sagie, Michal; Patterson, Nicole; Bagchi, Susmita; Verkhusha, Vladislav V.; Connolly, Diana; Goldberg, Gary L.; Golden, Aaron; Sharma, Ved P.; Condeelis, John; Montagna, Cristina			Septin 9 isoforms promote tumorigenesis in mammary epithelial cells by increasing migration and ECM degradation through metalloproteinase secretion at focal adhesions	ONCOGENE			English	Article							BREAST-CANCER CELLS; COMPREHENSIVE MOLECULAR PORTRAITS; ALTERNATE READING FRAME; MATRIX-METALLOPROTEINASE; INVADOPODIA FORMATION; NEURALGIC AMYOTROPHY; MAMMALIAN SEPTIN; EXPRESSION; GENE; INVASION	The cytoskeletal interacting protein Septin 9 (SEPT9), a member of the septin gene family, has been proposed to have oncogenic functions. It is a known hot spot of retroviral tagging insertion and a fusion partner of both de novo and therapy-induced mixed lineage leukemia (MLL). Of all septins, SEPT9 holds the strongest link to cancer, especially breast cancer. Murine models of breast cancer frequently exhibit SEPT9 amplification in the form of double minute chromosomes, and about 20% of human breast cancer display genomic amplification and protein over expression at the SEPT9 locus. Yet, a clear mechanism by which SEPT9 elicits tumor-promoting functions is lacking. To obtain unbiased insights on molecular signatures of SEPT9 upregulation in breast tumors, we overexpressed several of its isoforms in breast cancer cell lines. Global transcriptomic profiling supports a role of SEPT9 in invasion. Functional studies reveal that SEPT9 upregulation is sufficient to increase degradation of the extracellular matrix, while SEPT9 downregulation inhibits this process. The degradation pattern is peripheral and associated with focal adhesions (FAs), where it is coupled with increased expression of matrix metalloproteinases (MMPs). SEPT9 overexpression induces MMP upregulation in human tumors and in culture models and promotes MMP3 secretion to the media at FAs. Downregulation of SEPT9 or chemical inhibition of septin filament assembly impairs recruitment of MMP3 to FAs. Our results indicate that SEPT9 promotes upregulation and both trafficking and secretion of MMPs near FAs, thus enhancing migration and invasion of breast cancer cells.	[Marcus, Jenna; Goldberg, Gary L.] Yeshiva Univ, Albert Einstein Coll Med, Dept Obstet & Gynecol, Bronx, NY USA; [Marcus, Jenna; Goldberg, Gary L.] Yeshiva Univ, Albert Einstein Coll Med, Dept Womens Hlth, Bronx, NY USA; [Bejerano-Sagie, Michal; Patterson, Nicole; Bagchi, Susmita; Connolly, Diana; Golden, Aaron; Montagna, Cristina] Yeshiva Univ, Albert Einstein Coll Med, Genet, Bronx, NY 10461 USA; [Verkhusha, Vladislav V.; Golden, Aaron] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland; [Sharma, Ved P.; Condeelis, John] Yeshiva Univ, Anat & Struct Biol, Albert Einstein Coll Med, Bronx, NY USA; [Sharma, Ved P.; Condeelis, John] Yeshiva Univ, Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY USA; [Montagna, Cristina] Yeshiva Univ, Albert Einstein Coll Med, Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Ollscoil na Gaillimhe-University of Galway; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Montagna, C (corresponding author), Yeshiva Univ, Albert Einstein Coll Med, Genet, Bronx, NY 10461 USA.; Montagna, C (corresponding author), Yeshiva Univ, Albert Einstein Coll Med, Pathol, Bronx, NY 10461 USA.	cristina.montagna@einstein.yu.edu	Marcus, Jenna/GQP-7232-2022; Marcus, Jenna/AAK-7334-2021; Verkhusha, Vladislav/AAU-7784-2020	Verkhusha, Vladislav/0000-0002-2083-8121	Albert Einstein Cancer Center support grant of the National Institutes of Health [P30CA013330, CA150344]; NATIONAL CANCER INSTITUTE [R01CA150344, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM122567] Funding Source: NIH RePORTER	Albert Einstein Cancer Center support grant of the National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank the following shared resources at the Albert Einstein College of Medicine: Molecular Cytogenetic Core, in particular Dr. Jidong Shan; and the Analytical Imaging Facility in particular Dr. Vera DesMarais. Research reported in this publication was supported by the Albert Einstein Cancer Center support grant of the National Institutes of Health under award number P30CA013330 as well as CA150344 to JC.	Akil A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12203; Alvarez ML, 2012, KIDNEY INT, V82, P1024, DOI 10.1038/ki.2012.256; Amir S, 2010, MOL CANCER RES, V8, P643, DOI 10.1158/1541-7786.MCR-09-0497; Amir S, 2009, J BIOL CHEM, V284, P11142, DOI 10.1074/jbc.M808348200; Angelis D, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00122; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Bai XB, 2016, MOL BIOL CELL, V27, P897, DOI 10.1091/mbc.E15-07-0493; Bai XB, 2013, J CELL BIOL, V203, P895, DOI 10.1083/jcb.201308068; Barral Y, 2008, CURR OPIN CELL BIOL, V20, P12, DOI 10.1016/j.ceb.2007.12.001; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BYERS JR, 1971, CAN J ZOOLOG, V49, P1185, DOI 10.1139/z71-179; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cerveira N, 2011, BIOL CHEM, V392, P713, DOI 10.1515/BC.2011.072; Chacko AD, 2005, J PATHOL, V206, P458, DOI 10.1002/path.1794; Chacko AD, 2012, CELL ONCOL, V35, P85, DOI 10.1007/s13402-011-0066-0; Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110; Chen QK, 2013, DIFFERENTIATION, V86, P126, DOI 10.1016/j.diff.2013.03.003; Cichon MA, 2015, CANCER INFORM, V14, P1, DOI 10.4137/CIN.S18965; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Clay L, 2014, ELIFE, V3, DOI 10.7554/eLife.01883; Connolly D, 2014, BIOL CHEM, V395, P157, DOI 10.1515/hsz-2013-0247; Connolly D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2924; DICKSON SR, 1992, J HISTOCHEM CYTOCHEM, V40, P697, DOI 10.1177/40.5.1315355; Dolat L, 2014, J CELL BIOL, V207, P225, DOI 10.1083/jcb.201405050; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634; Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2; Flores-Pliego A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145366; Genna A, 2018, J CELL BIOL, V217, P375, DOI 10.1083/jcb.201702184; Golan M, 2013, CELL CYCLE, V12, P2297, DOI 10.4161/cc.25379; Gonzalez ME, 2007, CANCER RES, V67, P8554, DOI 10.1158/0008-5472.CAN-07-1474; Gonzalez ME, 2009, CELL SIGNAL, V21, P477, DOI 10.1016/j.cellsig.2008.11.007; Hall PA, 2005, J PATHOL, V206, P269, DOI 10.1002/path.1789; Heasley LR, 2014, EUKARYOT CELL, V13, P1411, DOI 10.1128/EC.00191-14; Hecht M, 2019, G3-GENES GENOM GENET, V9, P1869, DOI 10.1534/g3.119.400197; Helwa I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170628; Hoshino D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002964; Hu JL, 2012, CURR BIOL, V22, P1109, DOI 10.1016/j.cub.2012.04.019; Jacob A, 2013, J CELL SCI, V126, P4647, DOI 10.1242/jcs.126573; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khokha R, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004333; Knauper V, 2002, FEBS LETT, V532, P127, DOI 10.1016/S0014-5793(02)03654-2; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kotepui M, 2016, WSPOLCZESNA ONKOL, V20, P225, DOI 10.5114/wo.2016.61565; Lee Gilho, 2011, Int Neurourol J, V15, P4, DOI 10.5213/inj.2011.15.1.4; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; MAEDA K, 1987, P NATL ACAD SCI USA, V84, P6536, DOI 10.1073/pnas.84.18.6536; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; McDade SS, 2007, HUM MOL GENET, V16, P742, DOI 10.1093/hmg/ddm003; McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180; Mehdiani A, 2015, JOVE-J VIS EXP, DOI 10.3791/50974; MONSKY WL, 1993, CANCER RES, V53, P3159; Montagna C, 2003, CANCER RES, V63, P2179; Montagna C, 2015, RES REP BIOCHEM, V5, P59, DOI 10.2147/RRBC.S59060; Mostowy S, 2012, NAT REV MOL CELL BIO, V13, P183, DOI 10.1038/nrm3284; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Nagano T, 2006, DEVELOPMENT, V133, P4643, DOI 10.1242/dev.02657; Nagata K, 2003, J BIOL CHEM, V278, P18538, DOI 10.1074/jbc.M205246200; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Neubauer K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00003; Nile AH, 2014, NAT CHEM BIOL, V10, P76, DOI [10.1038/NCHEMBIO.1389, 10.1038/nchembio.1389]; Nistico P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011908; Noordstra Ivar, 2017, F1000Res, V6, P469, DOI 10.12688/f1000research.10729.1; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Rozen S, 2000, Methods Mol Biol, V132, P365; Russell SEH, 2000, CANCER RES, V60, P4729; Schmidt K, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-43; Scott M, 2005, ONCOGENE, V24, P4688, DOI 10.1038/sj.onc.1208574; Sellin ME, 2012, MOL BIOL CELL, V23, P4242, DOI 10.1091/mbc.E12-06-0486; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; Sharma VP, 2013, METHODS MOL BIOL, V1046, P343, DOI 10.1007/978-1-62703-538-5_21; Shimoda M, 2017, BBA-MOL CELL RES, V1864, P1989, DOI 10.1016/j.bbamcr.2017.05.027; Simian M, 2001, DEVELOPMENT, V128, P3117; Smith C, 2015, J MOL BIOL, V427, P3273, DOI 10.1016/j.jmb.2015.07.026; Sorensen AB, 2002, GENE, V285, P79, DOI 10.1016/S0378-1119(02)00406-7; Spiliotis ET, 2008, J CELL BIOL, V180, P295, DOI 10.1083/jcb.200710039; Spiliotis ET, 2006, J CELL SCI, V119, P4, DOI 10.1242/jcs.02746; Stehbens SJ, 2014, NAT CELL BIOL, V16, P558, DOI 10.1038/ncb2975; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sudo K, 2007, HUM MUTAT, V28, P1005, DOI 10.1002/humu.20554; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Team RC, 2016, R LANG ENV STAT COMP; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Tokhtaeva E, 2015, J BIOL CHEM, V290, P5280, DOI 10.1074/jbc.M114.616201; Valenzuela-Iglesias A, 2015, EUR J CELL BIOL, V94, P78, DOI 10.1016/j.ejcb.2014.12.002; Vardi-Oknin D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073179; Verdier-Pinard P, 2017, SCI REP-UK, V7, DOI 10.1038/srep44976; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang Y, 2016, INTRAVITAL, V5; Wang Y, 2012, J CELL BIOL, V196, P375, DOI 10.1083/jcb.201105153; Weidmann MD, 2016, SCI REP-UK, V6, DOI 10.1038/srep36142; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646; Winer A, 2016, MOL CANCER THER, V15, P2370, DOI 10.1158/1535-7163.MCT-16-0194; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; Wolfgang CD, 2001, CANCER RES, V61, P8122; Wu XR, 2009, KIDNEY INT, V75, P1153, DOI 10.1038/ki.2009.73; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3; Zhao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017845; Zhou ZN, 2014, ONCOGENE, V33, P3784, DOI 10.1038/onc.2013.363	108	12	12	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2019	38	30					5839	5859		10.1038/s41388-019-0844-0	http://dx.doi.org/10.1038/s41388-019-0844-0			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3FY	31285548	Green Accepted			2022-12-17	WOS:000482739300001
J	Azam, SH; Porrello, A; Harrison, EB; Leslie, PL; Liu, XA; Waugh, TA; Belanger, A; Mangala, LS; Lopez-Berestein, G; Wilson, HL; McCann, JV; Kim, WY; Sood, AK; Liu, JZ; Dudley, AC; Pecot, CV				Azam, Salma H.; Porrello, Alessandro; Harrison, Emily B.; Leslie, Patrick L.; Liu, Xinan; Waugh, Trent A.; Belanger, Adam; Mangala, Lingegowda S.; Lopez-Berestein, Gabriel; Wilson, Harper L.; McCann, James V.; Kim, William Y.; Sood, Anil K.; Liu, Jinze; Dudley, Andrew C.; Pecot, Chad V.			Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis	ONCOGENE			English	Article							MIR-200 FAMILY; MESSENGER-RNA; ANTIANGIOGENIC THERAPY; TUMOR ANGIOGENESIS; CANCER-CELLS; GROWTH; DIFFERENTIATION; PROTEINS; PROMOTES; ZEB1	Angiogenesis is critical to cancer development and metastasis. However, anti-angiogenic agents have only had modest therapeutic success, partly due to an incomplete understanding of tumor endothelial cell (EC) biology. We previously reported that the microRNA (miR)-200 family inhibits metastasis through regulation of tumor angiogenesis, but the underlying molecular mechanisms are poorly characterized. Here, using integrated bioinformatics approaches, we identified the RNA-binding protein (RBP) quaking (QKI) as a leading miR-200b endothelial target with previously unappreciated roles in the tumor microenvironment in lung cancer. In lung cancer samples, both miR-200b suppression and QKI overexpression corresponded with tumor ECs relative to normal ECs, and QKI silencing phenocopied miR-200b-mediated inhibition of sprouting. Additionally, both cancer cell and endothelial QKI expression in patient samples significantly corresponded with poor survival and correlated with angiogenic indices. QKI supported EC function by stabilizing cyclin D1 (CCND1) mRNA to promote EC Gl/S cell cycle transition and proliferation. Both nanoparticle-mediated RNA interference of endothelial QKI expression and palbociclib blockade of CCND1 function potently inhibited metastasis in concert with significant effects on tumor vasculature. Altogether, this work demonstrates the clinical relevance and therapeutic potential of a novel, actionable miR/RBP axis in tumor angiogenesis and metastasis.	[Azam, Salma H.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Porrello, Alessandro; Leslie, Patrick L.; Waugh, Trent A.; Belanger, Adam; Wilson, Harper L.; Kim, William Y.; Pecot, Chad V.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Harrison, Emily B.] Univ N Carolina, Eshelman Sch Pharm, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27599 USA; [Liu, Xinan; Liu, Jinze] Univ Kentucky, Dept Comp Sci, Lexington, KY 40506 USA; [Belanger, Adam] Univ N Carolina, Div Pulm & Crit Care, Chapel Hill, NC 27599 USA; [Mangala, Lingegowda S.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Mangala, Lingegowda S.; Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA; [Lopez-Berestein, Gabriel] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [McCann, James V.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA; [Kim, William Y.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Kim, William Y.; Pecot, Chad V.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Dudley, Andrew C.] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA; [Dudley, Andrew C.] Univ Virginia, Emily Couric Canc Ctr, Charlottesville, VA 22908 USA; [Pecot, Chad V.] Univ N Carolina, Div Hematol & Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Kentucky; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; UTMD Anderson Cancer Center; University of Virginia; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill	Pecot, CV (corresponding author), Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.; Pecot, CV (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.; Pecot, CV (corresponding author), Univ N Carolina, Div Hematol & Oncol, Chapel Hill, NC 27599 USA.	pecot@email.unc.edu	Sood, Anoop Kumar/A-7344-2013; Harrison, Emily B./AAW-1826-2021; , UNC Flow Cytometry Core/AGU-9839-2022; , Animal Studies Core/ADK-4234-2022; , Animal Studies Core/AAF-4432-2022; , Pathology Services Core/CEZ-2246-2022	Sood, Anoop Kumar/0000-0001-5702-4108; Harrison, Emily B./0000-0002-6934-3875; Wilson, Harper/0000-0002-6093-4767	National Institutes of Health [R01-CA215075, R01-CA042978, U54-CA198999, MRSG-14-222-01-RMC]; American Cancer Society; Jimmy V Foundation Scholar award; UCRF Innovator Award; Stuart Scott V Foundation/Lung Cancer Initiative Award for Clinical Research; University Cancer Research Fund; Lung Cancer Research Foundation; Free to Breathe Metastasis Research Award; Susan G. Komen Career Catalyst Award; National Institute of General Medical Sciences [5T32 GM007092]; National Cancer Institute of the National Institutes of Health [T32CA196589]; American Cancer Society Research Professor Award; National Cancer Institute [P50 CA217685, R35 CA209904]; National Cancer Institute Center Core Support Grant [CA016086]; North Carolina Biotech Center Institutional Support Grant [2012-IDG-1006]; NATIONAL CANCER INSTITUTE [R01CA042978, P50CA217685, P30CA016086, T32CA196589, U54CA198999, R35CA209904, R01CA215075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Jimmy V Foundation Scholar award; UCRF Innovator Award; Stuart Scott V Foundation/Lung Cancer Initiative Award for Clinical Research; University Cancer Research Fund; Lung Cancer Research Foundation; Free to Breathe Metastasis Research Award; Susan G. Komen Career Catalyst Award(Susan G. Komen Breast Cancer Foundation); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society Research Professor Award(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute Center Core Support Grant; North Carolina Biotech Center Institutional Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors would like to especially thank members of the Victoria Bautch laboratory for their advice on performing the endothelial sprouting assay, the UNC Animal Histopathology Core, the UNC Biomedical Research Imaging Center, Janet Dow from the UNC Flow Cytometry Core Facility, and the Tissue Pathology Lab Core. The authors would also like to thank Adolfo Alfonso for providing the ZsGreen fluorescent labeled 10T1/2 (pericyte) cells used in the pericyte-coated sprouting assay. C.V.P. was supported in part by the National Institutes of Health R01-CA215075, R01-CA042978 and U54-CA198999, a Mentored Research Scholar Grants in Applied and Clinical Research (MRSG-14-222-01-RMC) from the American Cancer Society, the Jimmy V Foundation Scholar award, the UCRF Innovator Award, the Stuart Scott V Foundation/Lung Cancer Initiative Award for Clinical Research, the University Cancer Research Fund, the Lung Cancer Research Foundation, the Free to Breathe Metastasis Research Award and the Susan G. Komen Career Catalyst Award. S.H.A. was supported in part by a grant from the National Institute of General Medical Sciences under award 5T32 GM007092. E.B.H. was supported in part by a grant from the National Cancer Institute of the National Institutes of Health under award number T32CA196589. AKS was supported in part by The American Cancer Society Research Professor Award and grants from the National Cancer Institute (P50 CA217685 and R35 CA209904). The UNC Flow Cytometry Core Facility and Lineberger Comprehensive Cancer Center Animal Histopathology and Animal Studies Cores are all supported in part by a National Cancer Institute Center Core Support Grant (CA016086) to the UNC Lineberger Comprehensive Cancer Center. The UNC Flow Cytometry Core Facility is also supported in part by the North Carolina Biotech Center Institutional Support Grant 2012-IDG-1006.	Akerman M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r30; Azam SH, 2018, JOVE-J VIS EXP, DOI 10.3791/57309; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bohnsack BL, 2006, GENESIS, V44, P93, DOI 10.1002/gene.20189; Bottsford-Miller JN, 2012, J CLIN ONCOL, V30, P4026, DOI 10.1200/JCO.2012.41.9242; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan YC, 2012, ARTERIOSCL THROM VAS, V32, P1372, DOI 10.1161/ATVBAHA.112.248583; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chen AJ, 2012, GENE DEV, V26, P1459, DOI 10.1101/gad.189001.112; Cochrane A, 2017, STEM CELLS, V35, P952, DOI 10.1002/stem.2594; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; de Bruin RG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10846; de Bruin RG, 2016, SCI REP-UK, V6, DOI 10.1038/srep21643; Ding YZ, 2017, LIFE SCI, V191, P245, DOI 10.1016/j.lfs.2017.09.001; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gill JG, 2012, STEM CELLS DEV, V21, P167, DOI 10.1089/scd.2011.0194; Goel S, 2013, JNCI-J NATL CANCER I, V105, P1188, DOI 10.1093/jnci/djt164; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; GRIFFIN MJ, 1976, IN VITRO CELL DEV B, V12, P393, DOI 10.1007/BF02796317; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Harrison EB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00307; Hlatky L, 2002, JNCI-J NATL CANCER I, V94, P883; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kondo T, 1999, MAMM GENOME, V10, P662; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Larocque D, 2005, NAT NEUROSCI, V8, P27, DOI 10.1038/nn1359; Larocque D, 2002, NEURON, V36, P815, DOI 10.1016/S0896-6273(02)01055-3; Li ZH, 2003, DEV GROWTH DIFFER, V45, P449; Li ZZ, 2000, J NEUROSCI, V20, P4944; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42; Nakatsu Martin N, 2007, J Vis Exp, P186, DOI 10.3791/186; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Noveroske JK, 2002, GENESIS, V32, P218, DOI 10.1002/gene.10060; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pillman KA, 2018, EMBO J, V37, DOI 10.15252/embj.201899016; Saccomanno L, 1999, P NATL ACAD SCI USA, V96, P12605, DOI 10.1073/pnas.96.22.12605; Santo L, 2015, SEMIN ONCOL, V42, P788, DOI 10.1053/j.seminoncol.2015.09.024; Teplova M, 2013, GENE DEV, V27, P928, DOI 10.1101/gad.216531.113; van Mil A, 2012, CARDIOVASC RES, V93, P655, DOI 10.1093/cvr/cvs003; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Welch-Reardon KM, 2015, ARTERIOSCL THROM VAS, V35, P303, DOI 10.1161/ATVBAHA.114.303220; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8; Wong PP, 2016, CURR BIOL, V26, pR1161, DOI 10.1016/j.cub.2016.09.043; Wong PP, 2015, CANCER CELL, V27, P123, DOI 10.1016/j.ccell.2014.10.015; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Wu JI, 2002, P NATL ACAD SCI USA, V99, P4233, DOI 10.1073/pnas.072090399; Zearfoss NR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001269; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171; Zhou X, 2017, ONCOTARGET, V8, P82174, DOI 10.18632/oncotarget.19066; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	60	12	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5191	5210		10.1038/s41388-019-0786-6	http://dx.doi.org/10.1038/s41388-019-0786-6			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30918328	Green Accepted			2022-12-17	WOS:000473025300006
J	Haney, SL; Varney, ML; Chhonker, YS; Shin, S; Mehla, K; Crawford, AJ; Smith, HJ; Smith, LM; Murry, DJ; Hollingsworth, MA; Holstein, SA				Haney, Staci L.; Varney, Michelle L.; Chhonker, Yashpal S.; Shin, Simon; Mehla, Kamiya; Crawford, Ayrianne J.; Smith, Heather Jensen; Smith, Lynette M.; Murry, Daryl J.; Hollingsworth, Michael A.; Holstein, Sarah A.			Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							CANCER; MUC1; MUCINS; TRAFFICKING; BORTEZOMIB; ANTIBODY; CELLS	Rab proteins play an essential role in regulating intracellular membrane trafficking processes. Rab activity is dependent upon geranylgeranylation, a post-translational modification that involves the addition of 20-carbon isoprenoid chains via the enzyme geranylgeranyl transferase (GGTase) II. We have focused on the development of inhibitors against geranylgeranyl diphosphate synthase (GGDPS), which generates the isoprenoid donor (GGPP), as anti-Rab agents. Pancreatic ductal adenocarcinoma (PDAC) is characterized by abnormal mucin production and these mucins play important roles in tumor development, metastasis and chemo-resistance. We hypothesized that GGDPS inhibitor (GGDPSi) treatment would induce PDAC cell death by disrupting mucin trafficking, thereby inducing the unfolded protein response pathway (UPR) and apoptosis. To this end, we evaluated the effects of RAM2061, a potent GGDPSi, against PDAC. Our studies revealed that GGDPSi treatment activates the UPR and triggers apoptosis in a variety of human and mouse PDAC cell lines. Furthermore, GGDPSi treatment was found to disrupt the intracellular trafficking of key mucins such as MUC1. These effects could be recapitulated by incubation with a specific GGTase II inhibitor, but not a GGTase I inhibitor, consistent with the effect being dependent on disruption of Rab-mediated activities. In addition, siRNA-mediated knockdown of GGDPS induces upregulation of UPR markers and disrupts MUC1 trafficking in PDAC cells. Experiments in two mouse models of PDAC demonstrated that GGDPSi treatment significantly slows tumor growth. Collectively, these data support further development of GGDPSi therapy as a novel strategy for the treatment of PDAC.	[Haney, Staci L.; Varney, Michelle L.; Holstein, Sarah A.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; [Haney, Staci L.; Varney, Michelle L.; Shin, Simon; Mehla, Kamiya; Crawford, Ayrianne J.; Smith, Heather Jensen; Murry, Daryl J.; Hollingsworth, Michael A.; Holstein, Sarah A.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Chhonker, Yashpal S.; Murry, Daryl J.] Univ Nebraska Med Ctr, Dept Pharm Practice, Omaha, NE USA; [Shin, Simon; Mehla, Kamiya; Crawford, Ayrianne J.; Smith, Heather Jensen; Hollingsworth, Michael A.] Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE USA; [Smith, Lynette M.] Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Holstein, SA (corresponding author), Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.; Holstein, SA (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	sarah.holstein@unmc.edu		Varney, Michelle/0000-0001-5339-2077	Fred & Pamela Buffett Cancer Center Support Grant from the National Cancer Institute [P30 CA036727]; National Institutes of Health [P50CA127297]; Fred & Pamela Buffett Cancer Center Advanced Microscopy Core Facility; Flow Cytometry Research Facility; National Cancer Institute [P30 CA036727]; NATIONAL CANCER INSTITUTE [P30CA036727, P50CA127297] Funding Source: NIH RePORTER	Fred & Pamela Buffett Cancer Center Support Grant from the National Cancer Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fred & Pamela Buffett Cancer Center Advanced Microscopy Core Facility; Flow Cytometry Research Facility; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Fred & Pamela Buffett Cancer Center Support Grant from the National Cancer Institute under award P30 CA036727 and the National Institutes of Health P50CA127297. The authors wish to acknowledge the support of the Fred & Pamela Buffett Cancer Center Advanced Microscopy Core Facility and the Flow Cytometry Research Facility, supported by the National Cancer Institute under award P30 CA036727. We thank Janice A. Taylor and James R. Talaska of the Advanced Microscopy Core Facility for providing assistance with confocal microscopy.	Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Born EJ, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.64; Chhonker YS, 2018, MOLECULES, V23, DOI 10.3390/molecules23123275; Coxon FP, 2014, EUR J MED CHEM, V84, P77, DOI 10.1016/j.ejmech.2014.06.062; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Haney SL, 2018, INVEST NEW DRUG, V36, P810, DOI 10.1007/s10637-018-0571-3; Haney SL, 2017, MOLECULES, V22, DOI 10.3390/molecules22060886; Hanson RL, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030034; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Holstein SA, 2001, LEUKEMIA RES, V25, P651, DOI 10.1016/S0145-2126(00)00162-4; Holstein SA, 2011, LEUKEMIA RES, V35, P551, DOI 10.1016/j.leukres.2010.08.008; Igarashi T, 2017, ONCOTARGET, V8, P12290, DOI 10.18632/oncotarget.14703; IWAMURA T, 1992, J GASTROEN HEPATOL, V7, P512, DOI 10.1111/j.1440-1746.1992.tb01030.x; Jin CN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039432; Jonckheere N, 2014, BBA-REV CANCER, V1846, P142, DOI 10.1016/j.bbcan.2014.04.008; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Kinlough CL, 2006, J BIOL CHEM, V281, P12112, DOI 10.1074/jbc.M512996200; Liu XL, 2008, BIOCHEM BIOPH RES CO, V376, P688, DOI 10.1016/j.bbrc.2008.09.065; Luberice K, 2017, AM J SURG, V214, P341, DOI 10.1016/j.amjsurg.2017.05.007; Marten A, 2008, MOL CANCER THER, V7, P3624, DOI 10.1158/1535-7163.MCT-08-0393; Matthiesen RA, 2018, BIOORGAN MED CHEM, V26, P376, DOI 10.1016/j.bmc.2017.10.023; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Qi WM, 2001, HYBRIDOMA HYBRIDOM, V20, P313, DOI 10.1089/15368590152740716; Sorensen AL, 2006, GLYCOBIOLOGY, V16, P96, DOI 10.1093/glycob/cwj044; Suh H, 2017, AM J CANCER RES, V7, P1372; Taylor-Papadimitriou J, 2018, BIOCHEM SOC T, V46, P659, DOI 10.1042/BST20170400; TAYLORPAPADIMITRIOU J, 1981, INT J CANCER, V28, P17, DOI 10.1002/ijc.2910280104; Wang HB, 2012, ANTICANCER RES, V32, P1027; Wills VS, 2015, ACS MED CHEM LETT, V6, P1195, DOI 10.1021/acsmedchemlett.5b00334; Wssniowski TT, 2012, INT J ONCOL, V40, P1581, DOI 10.3892/ijo.2012.1337; Yan Y, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-445; Yu DC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-248	34	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5308	5320		10.1038/s41388-019-0794-6	http://dx.doi.org/10.1038/s41388-019-0794-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30918331	Green Accepted			2022-12-17	WOS:000473025300014
J	Yang, RM; Nanayakkara, D; Kalimutho, M; Mitra, P; Khanna, KK; Dray, E; Gonda, TJ				Yang, Ren-Ming; Nanayakkara, Devathri; Kalimutho, Murugan; Mitra, Partha; Khanna, Kum Kum; Dray, Eloise; Gonda, Thomas J.			MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; C-MYB; NUCLEAR FOCI; HISTONE H2AX; TARGET GENES; EXPRESSION; RAD51; RECOMBINATION; PHOSPHORYLATION; TRANSCRIPTION	Over 70% of human breast cancers are estrogen receptor-positive (ER+), most of which express MYB. In these and other cell types, the MYB transcription factor regulates the expression of many genes involved in cell proliferation, differentiation, tumorigenesis, and apoptosis. So far, no clear link has been established between MYB and the DNA damage response in breast cancer. Here, we found that silencing MYB in the ER+ breast cancer cell line MCF-7 led to increased DNA damage accumulation, as marked by increased gamma-H2AX foci following induction of double-stranded breaks. We further found that this was likely mediated by decreased homologous recombination-mediated repair (HRR), since silencing MYB impaired the formation of RAD51 foci in response to DNA damage. Moreover, cells depleted for MYB exhibited reduced expression of several key genes involved in HRR including BRCA1, PALB2, and TOPBP1. Taken together, these data imply that MYB and its targets play an important role in the response of ER+ breast cancer cells to DNA damage, and suggest that induction of DNA damage along with inhibition of MYB activity could offer therapeutic benefits for ER+ breast cancer and possibly other cancer types.	[Yang, Ren-Ming; Mitra, Partha; Gonda, Thomas J.] Univ Queensland, Sch Pharm, Brisbane, Qld 4102, Australia; [Nanayakkara, Devathri; Kalimutho, Murugan; Khanna, Kum Kum] QIMR Berghofer Med Res Inst, Signal Transduct Lab, Herston, Qld 4006, Australia; [Dray, Eloise] QUT, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia; [Dray, Eloise] Mater Res UQ, Translat Res Inst, Brisbane, Qld 4102, Australia; [Gonda, Thomas J.] Univ South Australia, Canc Res Inst, Adelaide, SA 5000, Australia; [Yang, Ren-Ming] Univ Southern Calif, Childrens Hosp Los Angeles Campus, Keck Sch Med, Los Angeles, CA 90027 USA; [Mitra, Partha] Queensland Univ Technol, Inst Hlth & Biomed Innovat, TRI, 37 Kent St, Woolloongabba, Qld 4102, Australia; [Dray, Eloise] Univ Texas Hlth, Dept Biochem & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA	University of Queensland; QIMR Berghofer Medical Research Institute; Queensland University of Technology (QUT); Mater Research; University of Queensland; University of South Australia; University of Southern California; Queensland University of Technology (QUT); University of Texas System; University of Texas Health San Antonio	Gonda, TJ (corresponding author), Univ Queensland, Sch Pharm, Brisbane, Qld 4102, Australia.; Dray, E (corresponding author), QUT, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia.; Dray, E (corresponding author), Mater Res UQ, Translat Res Inst, Brisbane, Qld 4102, Australia.; Gonda, TJ (corresponding author), Univ South Australia, Canc Res Inst, Adelaide, SA 5000, Australia.; Dray, E (corresponding author), Univ Texas Hlth, Dept Biochem & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	dray@uthscsa.edu; thomas.gonda@unisa.edu.au	Dray, Eloise/AAD-5147-2021; Kalimutho, Murugan/AAD-1441-2019; Dray, Eloise/E-3938-2012	Khanna, Kum Kum/0000-0001-8650-5381; Gonda, Thomas/0000-0002-8792-3021; Dray, Eloise/0000-0001-6793-9838; Kalimutho, Murugan/0000-0002-0772-8673	International Postgraduate Research Scholarship (Australia); University of Queensland Centennial Scholarship; National Breast Cancer Foundation; Australian government	International Postgraduate Research Scholarship (Australia)(Australian Government); University of Queensland Centennial Scholarship; National Breast Cancer Foundation; Australian government(Australian GovernmentCGIAR)	We would like to thank members of the Gonda laboratory for helpful discussions. RMY was the recipient of an International Postgraduate Research Scholarship (Australia) and a University of Queensland Centennial Scholarship. ED was supported by a National Breast Cancer Foundation Early Career Fellowship. KKK is a Senior Principal Research Fellow of the National Health and Medical Research Council (Australia). The Translational Research Institute is supported by an Australian government grant.	Abmayr Susan M, 2006, Curr Protoc Pharmacol, VChapter 12, DOI [10.1002/0471142727.mb1201s75, 10.1002/0471141755.ph1203s35]; Banath JP, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-4; Bell D, 2011, CANCER BIOL THER, V12, P569, DOI 10.4161/cbt.12.7.17008; Buisson R, 2010, NAT STRUCT MOL BIOL, V17, P1247, DOI 10.1038/nsmb.1915; Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007; Cousineau I, 2005, CANCER RES, V65, P11384, DOI 10.1158/0008-5472.CAN-05-2156; Cross RS, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2014.29; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; Drabsch Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2614; Dray E, 2010, NAT STRUCT MOL BIOL, V17, P1255, DOI 10.1038/nsmb.1916; Drier Y, 2016, NAT GENET, V48, P265, DOI 10.1038/ng.3502; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; Gildemeister OS, 2009, J BIOL CHEM, V284, P31945, DOI 10.1074/jbc.M109.024646; Gonda TJ, 2015, NAT REV CANCER, V15, P686, DOI 10.1038/nrc4018; GUERIN M, 1990, ONCOGENE, V5, P131; GUERIN M, 1988, CR ACAD SCI III-VIE, V307, P855; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Harte MT, 2014, ONCOGENE, V33, P713, DOI 10.1038/onc.2013.10; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Jin W, 2011, BREAST CANCER RES TR, V125, P699, DOI 10.1007/s10549-010-0876-1; Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270; Li LK, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005070; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Lord CJ, 2007, NAT STRUCT MOL BIOL, V14, P461, DOI 10.1038/nsmb0607-461; Miao RY, 2011, CANCER RES, V71, P7029, DOI 10.1158/0008-5472.CAN-11-1015; Mitchell AS, 2015, APOPTOSIS, V20, P310, DOI 10.1007/s10495-014-1078-9; Mitra P, 2016, ONCOTARGET, V7, P9069, DOI 10.18632/oncotarget.6997; Mitra P, 2012, NUCLEIC ACIDS RES, V40, P5988, DOI 10.1093/nar/gks286; Moudry P, 2016, J CELL BIOL, V212, P281, DOI 10.1083/jcb.201507042; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Pattabiraman DR, 2013, LEUKEMIA, V27, P269, DOI 10.1038/leu.2012.225; Pattabiraman DR, 2014, BLOOD, V123, P2682, DOI 10.1182/blood-2012-02-413187; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Quintana AM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-30; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Rugo Hope S, 2016, Am Soc Clin Oncol Educ Book, V35, pe40, DOI 10.14694/EDBK_159198; Sanford RA, 2015, CANCER-AM CANCER SOC, V121, P3422, DOI 10.1002/cncr.29572; Shin SY, 2013, BMB REP, V46, P92, DOI 10.5483/BMBRep.2013.46.2.202; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; TORELLI G, 1987, CANCER RES, V47, P5266; Tsuchiya M, 2015, ONCOGENE, V34, P4656, DOI 10.1038/onc.2014.387; Uttarkar S, 2017, EXP HEMATOL, V47, P31, DOI 10.1016/j.exphem.2016.12.003; Uttarkar S, 2016, BLOOD, V127, P1173, DOI 10.1182/blood-2015-09-668632; Vinayak S, 2010, CURR BREAST CANCER R, V2, P190, DOI 10.1007/s12609-010-0026-0; Wang WJ, 2015, FEBS LETT, V589, P555, DOI 10.1016/j.febslet.2015.01.012; Ward A, 2015, CANCER TREAT REV, V41, P35, DOI 10.1016/j.ctrv.2014.10.006; Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472	56	12	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5239	5249		10.1038/s41388-019-0789-3	http://dx.doi.org/10.1038/s41388-019-0789-3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30971760	Green Accepted			2022-12-17	WOS:000473025300009
J	Zong, L; Hattori, N; Yasukawa, Y; Kimura, K; Mori, A; Seto, Y; Ushijima, T				Zong, Liang; Hattori, Naoko; Yasukawa, Yoshimi; Kimura, Kana; Mori, Akiko; Seto, Yasuyuki; Ushijima, Toshikazu			LINC00162 confers sensitivity to 5-Aza-2 '-deoxycytidine via modulation of an RNA splicing protein, HNRNPH1	ONCOGENE			English	Article							RISK MYELODYSPLASTIC SYNDROMES; HELICOBACTER-PYLORI INFECTION; ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; HYPOMETHYLATING AGENT; DEMETHYLATING AGENTS; TUMOR-SUPPRESSOR; PHASE-II; CANCER; AZACITIDINE	DNA demethylation therapy is now expanding from hematological tumors to solid tumors. To exploit its maximum efficacy, long-term treatment is needed, and stratification of sensitive patients is critically important. Here, we identified a long non-coding RNA, LINC00162, as highly and frequently expressed in gastric cancer cell lines sensitive to 5-aza-2'-deoxycytidine (5-aza-dC). Knockdown of LINC00162 decreased the sensitivity while its overexpression increased the sensitivity. In vivo experiments also showed that LINC00162 overexpression increased the sensitivity. LINC00162 enhanced cell cycle arrest and apoptosis induced by 5-aza-dC, but did not affect its DNA demethylation effect. Mechanistically, LINC00162 interacted with an RNA splicing protein, HNRNPH1, and decreased splicing of an anti-apoptotic splicing variant, BCL-XL. LINC00162 may have translational value to predict patients who will respond to 5-aza-dC.	[Zong, Liang; Hattori, Naoko; Yasukawa, Yoshimi; Kimura, Kana; Mori, Akiko; Ushijima, Toshikazu] Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan; [Zong, Liang; Yasukawa, Yoshimi; Seto, Yasuyuki] Univ Tokyo, Grad Sch Med, Dept Gastrointestinal Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan	National Cancer Center - Japan; University of Tokyo	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817; Hattori, Naoko/0000-0002-0901-4869	AMED [JP18ck0106421]; JSPS KAKENHI [JP18H02704]	AMED(Japan Agency for Medical Research and Development (AMED)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by AMED under Grant Number JP18ck0106421 to Toshikazu Ushijima and JSPS KAKENHI under Grant Number JP18H02704 to Toshikazu Ushijima.	Ajani JA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.36; Asada K, 2013, ONCOGENE, V32, P2140, DOI 10.1038/onc.2012.228; Belinsky SA, 2003, CANCER RES, V63, P7089; Cascinu S, 1997, J CLIN ONCOL, V15, P3313, DOI 10.1200/JCO.1997.15.11.3313; Chandler DS, 2006, CANCER RES, V66, P9502, DOI 10.1158/0008-5472.CAN-05-4271; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048; Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44; Cui Y, 2014, CANCER RES, V74, P3834, DOI 10.1158/0008-5472.CAN-13-2287; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fang F, 2014, CLIN CANCER RES, V20, P6504, DOI 10.1158/1078-0432.CCR-14-1553; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Gao XD, 2014, ACTA BIOCH BIOPH SIN, V46, P72, DOI 10.1093/abbs/gmt118; Garneau D, 2005, J BIOL CHEM, V280, P22641, DOI 10.1074/jbc.M501070200; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Greenberg PL, 2011, J NATL COMPR CANC NE, V9, P30, DOI 10.6004/jnccn.2011.0005; He DX, 2014, MOL PHARMACOL, V86, P536, DOI 10.1124/mol.114.092759; Hironaka S, 2016, LANCET ONCOL, V17, P99, DOI 10.1016/S1470-2045(15)00410-6; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162; Katsushima K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13616; Kim JG, 2013, CANCER LETT, V330, P33, DOI 10.1016/j.canlet.2012.11.022; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Lu MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep08735; Lue M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.267; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Magklara A, 2001, CLIN CANCER RES, V7, P806; Man CH, 2014, BLOOD, V123, P2530, DOI 10.1182/blood-2013-07-512194; Mills JD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078480; Navada SC, 2014, J CLIN INVEST, V124, P40, DOI 10.1172/JCI69739; Niwa T, 2013, CANCER PREV RES, V6, P263, DOI 10.1158/1940-6207.CAPR-12-0369; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Okochi-Takada E, 2014, ONCOGENE, V33, P2273, DOI 10.1038/onc.2013.174; Piipponen M, 2016, J INVEST DERMATOL, V136, P1701, DOI 10.1016/j.jid.2016.03.028; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schneider BJ, 2017, CLIN CANCER RES, V23, P2673, DOI 10.1158/1078-0432.CCR-16-1896; Sekeres MA, 2017, J CLIN ONCOL, V35, P2745, DOI 10.1200/JCO.2015.66.2510; SORM F, 1968, NEOPLASMA, V15, P339; Stewart ML, 2015, CANCER RES, V75, P2897, DOI 10.1158/0008-5472.CAN-14-2860; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Yun S, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0233-2; Zong L, 2016, GASTRIC CANCER, V19, P361, DOI 10.1007/s10120-015-0475-2; Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504	52	12	13	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5281	5293		10.1038/s41388-019-0792-8	http://dx.doi.org/10.1038/s41388-019-0792-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30914798				2022-12-17	WOS:000473025300012
J	Blijlevens, M; van der Meulen-Muileman, IH; de Menezes, RX; Smit, EF; van Beusechem, VW				Blijlevens, Maxime; van der Meulen-Muileman, Ida H.; de Menezes, Renee X.; Smit, Egbert F.; van Beusechem, Victor W.			High-throughput RNAi screening reveals cancer-selective lethal targets in the RNA spliceosome	ONCOGENE			English	Article							FALSE DISCOVERY RATE; PHASE-I; ORGANIZATION; MACHINERY; E7107; CORE	Novel therapeutic strategies for non-small-cell lung cancer (NSCLC) are urgently needed. RNA splicing, orchestrated by the spliceosome, is deregulated in many forms of cancer, including NSCLC. Here, we performed high-throughput screening with a small interfering RNA library targeting all annotated human spliceosome proteins to identify cancer-selective lethal targets in the RNA splicing machinery. Silencing of several spliceosome proteins reduced cell viability in a panel of NSCLC cell lines, but not in non-malignant lung fibroblasts and epithelial cells. Interestingly, the cancer-selective lethal target set comprised all seven Sm proteins that, together with small nuclear RNA, form the core structure of most spliceosome subunits. Interfering with Sm protein expression induced apoptosis in NSCLC cells, but not in non-malignant cells. In silico analysis revealed that Sm proteins are frequently upregulated in NSCLC. For several Sm proteins, increased expression showed a positive correlation with disease severity. Together, our results suggest that the Sm proteins represent particularly useful novel targets for selective treatment of NSCLC.	[Blijlevens, Maxime; van der Meulen-Muileman, Ida H.; van Beusechem, Victor W.] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Med Oncol, Boelelaan 1118, Amsterdam, Netherlands; [de Menezes, Renee X.] Vrije Univ Amsterdam, Amsterdam UMC, Netherlands Bioinformat Ctr, Epidemiol & Biostat, Boelelaan 1118, Amsterdam, Netherlands; [Smit, Egbert F.] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute	van Beusechem, VW (corresponding author), Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Med Oncol, Boelelaan 1118, Amsterdam, Netherlands.	vw.vanbeusechem@vumc.nl	Menezes, Renee/L-2182-2019	Smit, Egbert/0000-0002-7329-6995	Walter Bruckerhoff Stiftung; Stichting VUmc-CCA	Walter Bruckerhoff Stiftung; Stichting VUmc-CCA	This work was supported by Walter Bruckerhoff Stiftung and Stichting VUmc-CCA.	Bachas C, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2306-z; Benjamini Y, 2001, ANN STAT, V29, P1165; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Citterio L, 1999, BIOCHEM BIOPH RES CO, V266, P110, DOI 10.1006/bbrc.1999.1769; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Dutertre M, 2010, CANCER RES, V70, P896, DOI 10.1158/0008-5472.CAN-09-2703; Effenberger KA., 2017, WILEY INTERDISCIP RE, V8, P1; Eskens FALM, 2013, CLIN CANCER RES, V19, P6296, DOI 10.1158/1078-0432.CCR-13-0485; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao Y, 2013, ACS CHEM BIOL, V8, P895, DOI 10.1021/cb300602j; Hong DS, 2014, INVEST NEW DRUG, V32, P436, DOI 10.1007/s10637-013-0046-5; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Langer W, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-676; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Pomeranz Krummel Daniel A, 2009, Nature, V458, P475, DOI 10.1038/nature07851; Quidville V, 2013, CANCER RES, V73, P2247, DOI 10.1158/0008-5472.CAN-12-2501; RCore Team, 2014, R LANG ENV STAT COMP; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Siebring-van Olst E, 2017, MOL ONCOL, V11, P534, DOI 10.1002/1878-0261.12052; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Webb TR, 2013, DRUG DISCOV TODAY, V18, P43, DOI 10.1016/j.drudis.2012.07.013; Weber G, 2010, EMBO J, V29, P4172, DOI 10.1038/emboj.2010.295	34	12	12	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4142	4153		10.1038/s41388-019-0711-z	http://dx.doi.org/10.1038/s41388-019-0711-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30705407				2022-12-17	WOS:000468740200012
J	Rossa, C; D'Silva, NJ				Rossa, Carlos, Jr.; D'Silva, Nisha J.			Immune-relevant aspects of murine models of head and neck cancer'	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; ATHYMIC NUDE-MICE; NF-KAPPA-B; SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL-MODELS; ORAL-CANCER; TONGUE CARCINOGENESIS; COLORECTAL-CANCER; FC-RECEPTORS; MOUSE MODELS	Head and neck cancers (HNCs) cause significant mortality and morbidity. There have been few advances in therapeutic management of HNC in the past 4 to 5 decades, which support the need for studies focusing on HNC biology. In recent years, increased recognition of the relevance of the host response in cancer progression has led to novel therapeutic strategies and putative biomarkers of tumor aggressiveness. However, tumor-immune interactions are highly complex and vary with cancer type. Pre-clinical, in vivo models represent an important and necessary step in understanding biological processes involved in development, progression and treatment of HNC. Rodents (mice, rats, hamsters) are the most frequently used animal models in HNC research. The relevance and utility of information generated by studies in murine models is unquestionable, but it is also limited in application to tumor-immune interactions. In this review, we present information regarding the immune-specific characteristics of the murine models most commonly used in HNC research, including immunocompromised and immunocompetent animals. The particular characteristics of xenograft, chemically induced, syngeneic, transgenic, and humanized models are discussed in order to provide context and insight for researchers interested in the in vivo study of tumor-immune interactions in HNC.	[Rossa, Carlos, Jr.] UNESP State Univ Sao Paulo, Sch Dent Araraquara, Dept Diag & Surg, Araraquara, SP, Brazil; [Rossa, Carlos, Jr.; D'Silva, Nisha J.] Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [D'Silva, Nisha J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Universidade Estadual Paulista; University of Michigan System; University of Michigan	Rossa, C (corresponding author), UNESP State Univ Sao Paulo, Sch Dent Araraquara, Dept Diag & Surg, Araraquara, SP, Brazil.; Rossa, C; D'Silva, NJ (corresponding author), Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.	c.rossa@unesp.br; njdsilva@umich.edu	Rossa, Carlos/D-8328-2012	Rossa, Carlos/0000-0003-1705-5481; D'Silva, Nisha/0000-0001-7030-3187	FAPESP [2017/14283-5]; NIH/NIDCR [DE027551, DE022567]; UM-FAPESP [2014/50312-1]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R35DE027551, R01DE022567] Funding Source: NIH RePORTER	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); UM-FAPESP; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants from FAPESP 2017/14283-5 (CRJ) and NIH/NIDCR DE027551 and DE022567 (NJD), and UM-FAPESP 2014/50312-1 (NJD and CRJ).	Ahn HJ, 2015, WORLD J GASTRO ONCOL, V7, P455, DOI 10.4251/wjgo.v7.i12.455; Albanesi M, 2013, BLOOD, V122, P3160, DOI 10.1182/blood-2013-04-497446; Andratschke M, 2003, ANTICANCER RES, V23, P1467; Annamalai G, 2018, BIOMED PHARMACOTHER, V98, P484, DOI 10.1016/j.biopha.2017.12.009; Aromando RF, 2008, ORAL ONCOL, V44, P1080, DOI 10.1016/j.oraloncology.2008.01.016; BAKER SR, 1985, LARYNGOSCOPE, V95, P43; Bao A, 2006, OTOLARYNG HEAD NECK, V135, P853, DOI 10.1016/j.otohns.2006.06.1257; Baskaran N, 2018, MOL CELL BIOCHEM, V440, P11, DOI 10.1007/s11010-017-3151-5; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Bozinovski S, 2016, BRIT J PHARMACOL, V173, P635, DOI 10.1111/bph.13198; BUDZYNSKI W, 1994, IMMUNOPHARM IMMUNOT, V16, P319, DOI 10.3109/08923979409007097; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; CARDINALI G, 1964, NATURE, V203, P90, DOI 10.1038/203090b0; Chen B, 2017, STEM CELL REP, V9, P1034, DOI 10.1016/j.stemcr.2017.08.018; Chicha L, 2005, ANN NY ACAD SCI, V1044, P236, DOI 10.1196/annals.1349.029; Clynes R, 2006, HEMATOL ONCOL CLIN N, V20, P585, DOI 10.1016/j.hoc.2006.02.010; CRANE IJ, 1988, BRIT J EXP PATHOL, V69, P749; de Araujo WS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115606; Dogan V, 2018, CLIN OTOLARYNGOL, V43, P13, DOI 10.1111/coa.12895; Economopoulos V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027508; EVESON JW, 1981, J ORAL PATHOL MED, V10, P322, DOI 10.1111/j.1600-0714.1981.tb01284.x; Fan S, 2011, INT J ORAL SCI, V3, P180, DOI 10.4248/IJOS11068; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; FISKER AV, 1990, DAN MED BULL, V37, P433; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; FU KK, 1984, INT J RADIAT ONCOL, V10, P1473, DOI 10.1016/0360-3016(84)90371-7; Gao XP, 2011, INFLAMM RES, V60, P195, DOI 10.1007/s00011-010-0254-9; GHIABI M, 1992, CANCER RES, V52, P389; GHOSHAL NG, 1990, LAB ANIM, V24, P228, DOI 10.1258/002367790780866083; GIUNTA JL, 1985, J ORAL PATHOL MED, V14, P263, DOI 10.1111/j.1600-0714.1985.tb00490.x; Grandis JR, 2000, CLIN CANCER RES, V6, P2794; Greenberg JS, 2003, CANCER, V97, P1464, DOI 10.1002/cncr.11202; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HIER MP, 1995, LARYNGOSCOPE, V105, P1077, DOI 10.1288/00005537-199510000-00013; HIRST DG, 1982, BRIT J CANCER, V46, P109, DOI 10.1038/bjc.1982.172; Ho AS, 2017, J CLIN ONCOL, V35, P3601, DOI 10.1200/JCO.2016.71.1176; HOLUB M, 1984, J LEUKOCYTE BIOL, V35, P605; HOUGEN HP, 1991, APMIS, V99, P1; Hu Z, 2011, BLOOD, V118, P5938, DOI 10.1182/blood-2010-11-321414; Ishida K, 2017, ORAL ONCOL, V73, P16, DOI 10.1016/j.oraloncology.2017.07.028; Jacobson MC, 2018, CURR OPIN SUPPORT PA, V12, P65, DOI 10.1097/SPC.0000000000000322; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOTLOFF DB, 1993, J EXP MED, V178, P1981, DOI 10.1084/jem.178.6.1981; Kundu JK, 2008, MUTAT RES-REV MUTAT, V659, P15, DOI 10.1016/j.mrrev.2008.03.002; Lea J, 2010, HEAD NECK-J SCI SPEC, V32, P184, DOI 10.1002/hed.21163; Lerman I, 2017, MOL CANCER RES, V15, P1138, DOI 10.1158/1541-7786.MCR-17-0003; Li J, 2013, ORAL ONCOL, V49, P299, DOI 10.1016/j.oraloncology.2012.10.013; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lin W, 2005, LARYNGOSCOPE, V115, P1154, DOI 10.1097/01.MLG.0000165368.81032.E2; Lin Y, 2005, J REPROD IMMUNOL, V68, P39, DOI 10.1016/j.jri.2005.05.002; Liu B, 2017, EXP CELL RES, V360, P105, DOI 10.1016/j.yexcr.2017.08.031; Liu YC, 2012, TOXICOL APPL PHARM, V262, P107, DOI 10.1016/j.taap.2012.04.023; Lu SL, 2006, HEAD NECK-J SCI SPEC, V28, P945, DOI 10.1002/hed.20397; Mashimo T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008870; MATTHEWS JB, 1986, CARCINOGENESIS, V7, P783, DOI 10.1093/carcin/7.5.783; Mery B, 2017, ORAL ONCOL, V65, P51, DOI 10.1016/j.oraloncology.2016.12.010; Mognetti B, 2006, ORAL ONCOL, V42, P448, DOI 10.1016/j.oraloncology.2005.07.014; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAUTA M, 1995, INT J ORAL MAX SURG, V24, P53, DOI 10.1016/S0901-5027(05)80857-4; Nishimura A, 1999, J DENT RES, V78, P1264, DOI 10.1177/00220345990780061101; Niu ZY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00523-6; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Noguti J, 2012, CANCER GENOM PROTEOM, V9, P329; NONOYAMA S, 1993, J IMMUNOL, V150, P3817; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; OMalley BW, 1997, ARCH OTOLARYNGOL, V123, P20; Osugi Y, 1996, J Osaka Dent Univ, V30, P29; PANTELOURIS EM, 1968, NATURE, V217, P370, DOI 10.1038/217370a0; Pelleitier M, 1975, Methods Achiev Exp Pathol, V7, P149; Peng SH, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-198; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ramu A, 2018, BIOMED PHARMACOTHER, V98, P523, DOI 10.1016/j.biopha.2017.12.049; Rodriguez GV, 2017, CANCER IMMUNOL RES, V5, P234, DOI 10.1158/2326-6066.CIR-16-0150; Sakaki T, 2003, J ORAL PATHOL MED, V32, P530, DOI 10.1034/j.1600-0714.2003.00174.x; SALLEY JJ, 1954, J DENT RES, V33, P253, DOI 10.1177/00220345540330021201; Sano D, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-32; Schmitd LB, 2018, J DENT RES, V97, P742, DOI 10.1177/0022034518756297; Selvasundaram R, 2018, MOL CELL BIOCHEM, V448, P145, DOI 10.1007/s11010-018-3321-0; Seymour R, 2006, VET PATHOL, V43, P401, DOI 10.1354/vp.43-4-401; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shinohara H, 2017, J IMMUNOL, V199, P1505, DOI 10.4049/jimmunol.1700167; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simpson-Abelson MR, 2008, J IMMUNOL, V180, P7009, DOI 10.4049/jimmunol.180.10.7009; Smith LP, 2006, INT J CANCER, V118, P2111, DOI 10.1002/ijc.21694; Strasner A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00128; Supsavhad W, 2016, VET J, V210, P7, DOI 10.1016/j.tvjl.2015.11.006; Szadvari I, 2016, PHYSIOL RES, V65, pS441, DOI 10.33549/physiolres.933526; Tang XH, 2004, CLIN CANCER RES, V10, P301, DOI 10.1158/1078-0432.CCR-0999-3; THOMAS DW, 1995, J ORAL PATHOL MED, V24, P23, DOI 10.1111/j.1600-0714.1995.tb01125.x; Timar J, 2005, CANCER METAST REV, V24, P107, DOI 10.1007/s10555-005-5051-5; Vahle AK, 2012, CANCER LETT, V317, P199, DOI 10.1016/j.canlet.2011.11.027; Veliz LP, 2008, AM J PHYSIOL-HEART C, V295, pH1056, DOI 10.1152/ajpheart.00266.2008; VETVICKA V, 1984, EUR J CELL BIOL, V35, P35; Watts CJ, 2009, J INFECT DIS, V199, P673, DOI 10.1086/596631; WILLIAMS DE, 1971, BRIT J CANCER, V25, P533, DOI 10.1038/bjc.1971.68; WONG PNC, 1983, J ORAL PATHOL MED, V12, P375, DOI 10.1111/j.1600-0714.1983.tb00350.x; Yamamoto T, 2017, CLIN CANCER RES, V23, P833, DOI 10.1158/1078-0432.CCR-16-0520; Yashiro M, 2015, DIGEST DIS SCI, V60, P2251, DOI 10.1007/s10620-015-3646-4; YUAN B, 1994, CANCER RES, V54, P5310	100	12	12	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					3973	3988		10.1038/s41388-019-0686-9	http://dx.doi.org/10.1038/s41388-019-0686-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30696955	Green Accepted			2022-12-17	WOS:000468740200001
J	Brix, DM; Tvingsholm, SA; Hansen, MB; Clemmensen, KB; Ohman, T; Siino, V; Lambrughi, M; Hansen, K; Puustinen, P; Gromova, I; James, P; Papaleo, E; Varjosalo, M; Moreira, J; Jaattela, M; Kallunki, T				Brix, Ditte Marie; Tvingsholm, Siri Amanda; Hansen, Malene Bredahl; Clemmensen, Knut Bundgaard; Ohman, Tiina; Siino, Valentina; Lambrughi, Matteo; Hansen, Klaus; Puustinen, Pietri; Gromova, Irina; James, Peter; Papaleo, Elena; Varjosalo, Markku; Moreira, Jose; Jaattela, Marja; Kallunki, Tuula			Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion	ONCOGENE			English	Article							CANCER CELL INVASION; HUMAN-BREAST-CANCER; PROTEIN; EXPRESSION; RECEPTOR; ERBB2; HER2; IDENTIFICATION; PROGRESSION; INHIBITORS	HER2/ErbB2 activation turns on transcriptional processes that induce local invasion and lead to systemic metastasis. The early transcriptional changes needed for ErbB2-induced invasion are poorly understood. Here, we link ErbB2 activation to invasion via ErbB2-induced, SUMO-directed phosphorylation of a single serine residue, S27, of the transcription factor myeloid zinc finger-1 (MZF1). Utilizing an antibody against MZF1-pS27, we show that the phosphorylation of S27 correlates significantly (p < 0.0001) with high-level expression of ErbB2 in primary invasive breast tumors. Phosphorylation of MZF1-S27 is an early response to ErbB2 activation and results in increased transcriptional activity of MZF1. It is needed for the ErbB2-induced expression of MZF1 target genes CTSB and PRKCA, and invasion of single-cells from ErbB2-expressing breast cancer spheroids. The phosphorylation of MZF1-S27 is preceded by poly-SUMOylation of K23, which can make S27 accessible to efficient phosphorylation by PAK4. Based on our results, we suggest for an activation mechanism where phosphorylation of MZF1-S27 triggers MZF1 dissociation from its transcriptional repressors such as the CCCTC-binding factor (CTCF). Our findings increase understanding of the regulation of invasive signaling in breast cancer by uncovering a detailed biological mechanism of how ErbB2 activation can rapidly lead to its invasion-promoting target gene expression and invasion.	[Brix, Ditte Marie; Tvingsholm, Siri Amanda; Hansen, Malene Bredahl; Clemmensen, Knut Bundgaard; Puustinen, Pietri; Jaattela, Marja; Kallunki, Tuula] Danish Canc Soc, Res Ctr, Cell Death & Metab, Ctr Autophagy Recycling & Dis, Strandboulevarden 49, DK-2100 Copenhagen, Denmark; [Ohman, Tiina; Varjosalo, Markku] Univ Helsinki, Inst Biotechnol, Helsinki Inst Life Sci, Helsinki 00014, Finland; [Siino, Valentina] Lund Univ, Inst Immunotechnol, S-22381 Lund, Sweden; [Lambrughi, Matteo; Papaleo, Elena] Danish Canc Soc, Res Ctr, Computat Biol Lab, Ctr Autophagy Recycling & Dis, DK-2100 Copenhagen, Denmark; [Hansen, Klaus] Univ Copenhagen, Biotech Res & Innovat Ctr, DK-2200 Copenhagen, Denmark; [Gromova, Irina] Danish Canc Soc, Res Ctr, Unit Genome Integr, Ctr Autophagy Recycling & Dis,Breast Canc Biol, DK-2100 Copenhagen, Denmark; [James, Peter] Abo Akad Univ, Turku Ctr Biotechnol, Turku 20014, Finland; [James, Peter] Univ Turku, Turku 20014, Finland; [Moreira, Jose; Kallunki, Tuula] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK-2200 Copenhagen, Denmark	Danish Cancer Society; University of Helsinki; Lund University; Danish Cancer Society; University of Copenhagen; Danish Cancer Society; Abo Akademi University; University of Turku; University of Turku; University of Copenhagen	Jaattela, M; Kallunki, T (corresponding author), Danish Canc Soc, Res Ctr, Cell Death & Metab, Ctr Autophagy Recycling & Dis, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.; Kallunki, T (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK-2200 Copenhagen, Denmark.	mj@cancer.dk; tk@cancer.dk	Jäättelä, Marja/AAT-7932-2021; Lambrughi, Matteo/AAF-1749-2020; Papaleo, Elena/M-6629-2014; Varjosalo, Markku/K-6424-2015	Jäättelä, Marja/0000-0001-5950-7111; Kallunki, Tuula/0000-0002-8571-383X; Moreira, Jose/0000-0002-9944-1214; , Elena/0000-0003-2296-898X; Papaleo, Elena/0000-0002-7376-5894; Bredahl Hansen, Malene/0000-0003-2006-3503; Varjosalo, Markku/0000-0002-1340-9732; Hansen, Klaus/0000-0001-9657-8816; Ohman, Tiina/0000-0001-6647-8873; Lambrughi, Matteo/0000-0002-0894-8627; Siino, Valentina/0000-0002-0489-6380	Novo Nordisk Foundation [NNF15OC0017324]; Danish Medical Research Council [0602-02386B]; Danish Cancer Society Scientific Committee (KBVU) [R124-A7854-15-S2, R56-A3108-12-S2]; Danish National Research Foundation [DNRF125]; European Research Council [AdG 340751]; EU-PRACE DECI13th grant; DeiC Pilot Grant 2015-2016 for the Danish Supercomputing Center Computerome	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Cancer Society Scientific Committee (KBVU); Danish National Research Foundation(Danmarks Grundforskningsfond); European Research Council(European Research Council (ERC)European Commission); EU-PRACE DECI13th grant; DeiC Pilot Grant 2015-2016 for the Danish Supercomputing Center Computerome	Funding was provided by the Novo Nordisk Foundation (NNF15OC0017324) (TK), the Danish Medical Research Council (0602-02386B) (TK), the Danish Cancer Society Scientific Committee (KBVU) (R124-A7854-15-S2 and R56-A3108-12-S2) (TK), the Danish National Research Foundation (DNRF125) (MJ), the European Research Council (AdG 340751) (MJ), EU-PRACE DECI13th grant for computational resources (EP), and the DeiC Pilot Grant 2015-2016 for the Danish Supercomputing Center Computerome (EP).	Abdel-Magid AF, 2015, ACS MED CHEM LETT, V6, P17, DOI 10.1021/ml500445c; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bailey TA, 2014, J BIOL CHEM, V289, P30443, DOI 10.1074/jbc.M114.608992; Baker AF, 2005, CLIN CANCER RES, V11, P4338, DOI 10.1158/1078-0432.CCR-05-0422; Bawa-Khalfe Tasneem, 2010, Genes Cancer, V1, P748; Brix DM, 2014, MOL ONCOL, V8, P1703, DOI 10.1016/j.molonc.2014.07.004; Deng Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/868131; Dittmer J, 2017, SEMIN CANCER BIOL, V44, P72, DOI 10.1016/j.semcancer.2017.03.006; Duchnowska R, 2015, NEURO-ONCOLOGY, V17, P1241, DOI 10.1093/neuonc/nov012; Egeblad M, 2001, INT J CANCER, V94, P185, DOI 10.1002/ijc.1459; Eguchi T, 2015, J CELL BIOCHEM, V116, P2146, DOI 10.1002/jcb.25203; Fonovic M, 2014, BBA-GEN SUBJECTS, V1840, P2560, DOI 10.1016/j.bbagen.2014.03.017; Ha BH, 2015, J BIOL CHEM, V290, P12975, DOI 10.1074/jbc.R115.650416; Hamalisto S, 2016, CURR OPIN CELL BIOL, V39, P69, DOI 10.1016/j.ceb.2016.02.009; Hendriks IA, 2017, NAT STRUCT MOL BIOL, V24, P325, DOI 10.1038/nsmb.3366; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Ivascu A, 2006, J BIOMOL SCREEN, V11, P922, DOI 10.1177/1087057106292763; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Kim KI, 2006, MOL CELLS, V22, P247; Kim S, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.33; Ko H, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0035-9; Marshall AD, 2014, CURR OPIN GENET DEV, V24, P8, DOI 10.1016/j.gde.2013.10.011; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; Nagashima T, 2007, J BIOL CHEM, V282, P4045, DOI 10.1074/jbc.M608653200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noll L, 2008, LEUKEMIA RES, V32, P1582, DOI 10.1016/j.leukres.2008.03.024; Ogawa H, 2003, J BIOL CHEM, V278, P2921, DOI 10.1074/jbc.M207615200; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Sander TL, 2000, J BIOL CHEM, V275, P12857, DOI 10.1074/jbc.275.17.12857; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Seeler JS, 2017, NAT REV CANCER, V17, P184, DOI 10.1038/nrc.2016.143; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Sevenich L, 2014, GENE DEV, V28, P2331, DOI 10.1101/gad.250647.114; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Subramonian D, 2014, J PROTEOME RES, V13, P3905, DOI 10.1021/pr500119a; Tan M, 2006, ONCOGENE, V25, P3286, DOI 10.1038/sj.onc.1209361; Tsai LH, 2015, ONCOGENE, V34, P1641, DOI 10.1038/onc.2014.118; Tural D, 2014, EXPERT REV ANTICANC, V14, P1089, DOI 10.1586/14737140.2014.929946; Tvingsholm SA, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0014-6; Varjosalo M, 2013, NAT METHODS, V10, P307, DOI [10.1038/nmeth.2400, 10.1038/NMETH.2400]; Venur VA, 2016, INT J MOL SCI, P17; Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410; Xiao YX, 2015, ANAL BIOCHEM, V477, P95, DOI 10.1016/j.ab.2014.11.006; Yue CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127420; Yue CH, 2012, CHINESE J PHYSIOL, V55, P31, DOI 10.4077/CJP.2012.AMM109	52	12	13	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3170	3184		10.1038/s41388-018-0653-x	http://dx.doi.org/10.1038/s41388-018-0653-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30622337	Green Submitted, Green Accepted			2022-12-17	WOS:000465557200005
J	Marusiak, AA; Prelowska, MK; Mehlich, D; Lazniewski, M; Kaminska, K; Gorczynski, A; Korwat, A; Sokolowska, O; Kedzierska, H; Golab, J; Biernat, W; Plewczynski, D; Brognard, J; Nowis, D				Marusiak, Anna A.; Prelowska, Monika K.; Mehlich, Dawid; Lazniewski, Michal; Kaminska, Klaudia; Gorczynski, Adam; Korwat, Aleksandra; Sokolowska, Olga; Kedzierska, Hanna; Golab, Jakub; Biernat, Wojciech; Plewczynski, Dariusz; Brognard, John; Nowis, Dominika			Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; KINASE MLK4; SUBTYPES; METASTASIS; MLK4-BETA; CULTURE; JNK	Metastasis to distant organs is a major cause for solid cancer mortality, and the acquisition of migratory and invasive phenotype is a key factor in initiation of malignancy. In this study we investigated the contribution of Mixed-Lineage Kinase 4 (MLK4) to aggressive phenotype of breast cancer cells. Our TCGA cancer genomic data analysis revealed that amplification or mRNA upregulation of MLK4 occurred in 23% of invasive breast carcinoma cases. To find the association between MLK4 expression and the specific subtype of breast cancer, we performed a transcriptomic analysis of multiple datasets, which showed that MLK4 is highly expressed in triple-negative breast cancer compared to other molecular subtypes. Depletion of MLK4 in cell lines with high MLK4 expression impaired proliferation and anchorage-dependent colony formation. Moreover, silencing of MLK4 expression significantly reduced the migratory potential and invasiveness of breast cancer cells as well as the number of spheroids formed in 3D cultures. These in vitro findings translate into slower rate of tumor growth in mice upon MLK4 knock-down. Furthermore, we established that MLK4 activates NF-kappa B signaling and promotes a mesenchymal phenotype in breast cancer cells. Immunohistochemical staining of samples obtained from breast cancer patients revealed a strong positive correlation between high expression of MLK4 and metastatic potential of tumors, which was predominantly observed in TNBC subgroup. Taken together, our results show that high expression of MLK4 promotes migratory and invasive phenotype of breast cancer and may represent a novel target for anticancer treatment.	[Marusiak, Anna A.; Prelowska, Monika K.; Mehlich, Dawid; Kaminska, Klaudia; Sokolowska, Olga; Kedzierska, Hanna; Nowis, Dominika] Univ Warsaw, Ctr New Technol, Expt Med Lab, Warsaw, Poland; [Prelowska, Monika K.; Sokolowska, Olga] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland; [Mehlich, Dawid; Nowis, Dominika] Med Univ Warsaw, Genom Med, Warsaw, Poland; [Lazniewski, Michal; Plewczynski, Dariusz] Univ Warsaw, Ctr New Technol, Lab Funct & Struct Genom, Warsaw, Poland; [Lazniewski, Michal] Med Univ Warsaw, Dept Phys Chem, Fac Pharm, Warsaw, Poland; [Gorczynski, Adam; Korwat, Aleksandra; Biernat, Wojciech] Med Univ Gdansk, Dept Pathomorphol, Gdansk, Poland; [Sokolowska, Olga; Golab, Jakub; Nowis, Dominika] Med Univ Warsaw, Dept Immunol, Warsaw, Poland; [Golab, Jakub] Med Univ Warsaw, Ctr Preclin Res & Technol, Warsaw, Poland; [Plewczynski, Dariusz] Warsaw Univ Technol, Fac Math & Informat Sci, Warsaw, Poland; [Brognard, John] NCI, Frederick, MD 21701 USA	University of Warsaw; Medical University of Warsaw; Medical University of Warsaw; University of Warsaw; Medical University of Warsaw; Fahrenheit Universities; Medical University Gdansk; Medical University of Warsaw; Medical University of Warsaw; Warsaw University of Technology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Marusiak, AA (corresponding author), Univ Warsaw, Ctr New Technol, Expt Med Lab, Warsaw, Poland.	a.marusiak@cent.uw.edu.pl	Nowis, Dominika/P-1213-2017; Golab, Jakub/K-6974-2013; Brognard, John/T-5099-2019; Nowis, Dominika/P-6866-2019; Marusiak, Anna/AAN-7020-2020	Nowis, Dominika/0000-0003-2748-9523; Golab, Jakub/0000-0002-2830-5100; Brognard, John/0000-0002-9243-6615; Nowis, Dominika/0000-0003-2748-9523; Gorczynski, Adam/0000-0002-1950-452X; Plewczynski, Dariusz/0000-0002-3840-7610; Korwat, Aleksandra/0000-0002-7418-1698; Lazniewski, Michal/0000-0003-0436-404X; Marusiak, Anna/0000-0001-8907-3131	European Union under the European Regional Development Fund; Polish National Science Centre [2013/10/E/NZ5/00778, 2014/15/B/ST6/05082, 015/16/S/NZ5/00088]; Foundation for Polish Science; Ministry of Science and Higher Education, Republic of Poland [DI2017 016 747]; NATIONAL CANCER INSTITUTE [ZIABC011691] Funding Source: NIH RePORTER	European Union under the European Regional Development Fund; Polish National Science Centre; Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); Ministry of Science and Higher Education, Republic of Poland(Ministry of Science and Higher Education, Poland); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr. J. Chlebowska-Tuz, Dr. S. Fawdar, Dr. P. Gaj, Dr. Z. Koledova, Dr. T. Stoklosa, M. Sobczak for technical help and insightful comments. The research was carried out within HOMING program of The Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund (to AAM) and Polish National Science Centre (015/16/S/NZ5/00088 to AAM). The research was also supported by The Foundation for Polish Science (TEAM to DP) and Polish National Science Centre (2013/10/E/NZ5/00778 to DN, 2014/15/B/ST6/05082 to DP) and Ministry of Science and Higher Education, Republic of Poland (DI2017 016 747 to DM).	Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blessing NA, 2017, CELL SIGNAL, V39, P66, DOI 10.1016/j.cellsig.2017.07.021; Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gandalovicova A, 2017, TRENDS CANCER, V3, P391, DOI 10.1016/j.trecan.2017.04.008; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang CY, 2017, J CELL PHYSIOL, V232, P1337, DOI 10.1002/jcp.25610; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Kalimutho M, 2015, TRENDS PHARMACOL SCI, V36, P822, DOI 10.1016/j.tips.2015.08.009; Kim SH, 2016, CANCER CELL, V29, P201, DOI 10.1016/j.ccell.2016.01.005; Kumar P, 2016, ARCH GYNECOL OBSTET, V293, P247, DOI 10.1007/s00404-015-3859-y; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Martini M, 2013, CANCER RES, V73, P1912, DOI 10.1158/0008-5472.CAN-12-3074; Marusiak AA, 2016, CANCER RES, V76, P724, DOI 10.1158/0008-5472.CAN-15-0701-T; Marusiak AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4901; Maubant S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122333; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; Pal A, 2014, JOVE-J VIS EXP, DOI 10.3791/51311; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Pires BRB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169622; Prat A, 2015, BREAST, V24, pS26, DOI 10.1016/j.breast.2015.07.008; Saab WFA, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.6; Sabatier R, 2011, BREAST CANCER RES TR, V126, P407, DOI 10.1007/s10549-010-0897-9; Seit-Nebi A, 2012, CELL MOL IMMUNOL, V9, P27, DOI 10.1038/cmi.2011.15; Sleeman J, 2010, EUR J CANCER, V46, P1177, DOI 10.1016/j.ejca.2010.02.039; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yersal O, 2014, WORLD J CLIN ONCOL, V5, P412, DOI 10.5306/wjco.v5.i3.412	38	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2860	2875		10.1038/s41388-018-0618-0	http://dx.doi.org/10.1038/s41388-018-0618-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30552384	hybrid, Green Published			2022-12-17	WOS:000464121600014
J	Paroni, G; Bolis, M; Zanetti, A; Ubezio, P; Helin, K; Staller, P; Gerlach, LO; Fratelli, M; Neve, RM; Terao, M; Garattini, E				Paroni, Gabriela; Bolis, Marco; Zanetti, Adriana; Ubezio, Paolo; Helin, Kristian; Staller, Peter; Gerlach, Lars Ole; Fratelli, Maddalena; Neve, Richard M.; Terao, Mineko; Garattini, Enrico			HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases	ONCOGENE			English	Article							HISTONE DEMETHYLASE RBP2; EMERGING ROLE; RESISTANCE; PROLIFERATION; MECHANISMS; LAPATINIB; SURVIVAL; LANGUAGE	Targeting of histone methylation has therapeutic potential in oncology. Here, we provide proof-of-principle that pharmacological inhibition of KDM5 histone-demethylases is a new strategy for the personalized treatment of HER2(+) breast cancer. The anti-proliferative effects of the prototype of a new class of selective KDM5-inhibitors (KDM5-inhl) are evaluated in 40 cell lines, recapitulating the heterogeneity of breast cancer. This analysis demonstrates that HER2(+) cells are particularly sensitive to KDM5 inhibition. The results are confirmed in an appropriate in vivo model with a close structural analog (KDM5-inhlA). RNA-seq data obtained in HER2(+) BT-474 cells exposed to KDM5-Inhl indicate that the compound alters expression of numerous genes downstream of the ERBB2 gene-product, HER2. In selected HER2-positive breast-cancer cells, we demonstrate synergistic interactions between KDM5-inhl and HER2-targeting agents (trastuzumab and lapatinib). In addition, HER2(+) cell lines with innate and acquired resistance to trastuzumab show sensitivity to KDM5-inhl. The levels of KDM5A/B/C proteins, which are selectively targeted by the agent, have no significant association with KDM5-inhl responsiveness across our panel of breast-cancer cell lines, suggesting the existence of other determinants of sensitivity. Using RNA-seq data of the breast-cancer cell lines we generate a gene-expression model that is a robust predictor of KDM5-inhl sensitivity. In a test set of breast cancers, this model predicts sensitivity to the compound in a large fraction of HER2(+) tumors. In conclusion, KDM5 inhibition has potential in the treatment of HER2(+) breast cancer and our gene-expression model can be developed into a diagnostic tool for the selection of patients.	[Paroni, Gabriela; Bolis, Marco; Zanetti, Adriana; Fratelli, Maddalena; Terao, Mineko; Garattini, Enrico] Ist Ric Farmacol Mario Negri IRCCS, Mol Biol Lab, Via La Masa 19, I-20157 Milan, Italy; [Ubezio, Paolo] Ist Ric Farmacol Mario Negri IRCCS, Dept Oncol, Via La Masa 19, I-20157 Milan, Italy; [Helin, Kristian] Univ Copenhagen, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark; [Helin, Kristian] Univ Copenhagen, Novo Nordisk Fdn Stem Cell Biol, Blegdamsvej 3, DK-2200 Copenhagen, Denmark; [Staller, Peter] Bayer AG, Drug Discovery, Mullerstr 178, D-13353 Berlin, Germany; [Gerlach, Lars Ole] Global Drug Discovery, CV Res, Novo Nordisk, Denmark; [Neve, Richard M.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Copenhagen; University of Copenhagen; Bayer AG; Gilead Sciences	Garattini, E (corresponding author), Ist Ric Farmacol Mario Negri IRCCS, Mol Biol Lab, Via La Masa 19, I-20157 Milan, Italy.	enrico.garattini@marionegri.it	Terao, Mineko/AAA-6415-2020; Bolis, Marco/AAC-2379-2019; Ubezio, Paolo/AAA-6455-2020; Garattini, Enrico/AAI-1998-2019; adriana, zanetti/ABA-1189-2020; Helin, Kristian/HDM-8306-2022; terao, mineko/AAU-8089-2020; Paroni, Gabriela/J-4848-2018; ubezio, paolo/AAA-6704-2020; Fratelli, Maddalena/AAA-6446-2020	Terao, Mineko/0000-0002-9976-9869; Bolis, Marco/0000-0003-4377-5079; Ubezio, Paolo/0000-0003-0412-9891; adriana, zanetti/0000-0002-5825-9707; Helin, Kristian/0000-0003-1975-6097; Paroni, Gabriela/0000-0003-0132-0869; Fratelli, Maddalena/0000-0002-1769-3427; Garattini, Enrico/0000-0001-8983-886X	Associazione Italiana per la Ricerca contro il Cancro (AIRC); Fondazione Italo Monzino	Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italo Monzino	Grants from the Associazione Italiana per la Ricerca contro il Cancro (AIRC) and the Fondazione Italo Monzino to Enrico Garattini were fundamental for the completion of this work. We would like to acknowledge the help of Mr. Alessandro Soave for the artwork and Laura Pasetto for the densitometric analyses.	Akimoto C, 2008, GENES CELLS, V13, P623, DOI 10.1111/j.1365-2443.2008.01193.x; Araki K, 2018, BREAST CANCER-TOKYO, V25, P392, DOI 10.1007/s12282-017-0812-x; Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673; Basse C, 2015, INT J CANCER, V137, P2785, DOI 10.1002/ijc.29347; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bolis M, 2017, ANN ONCOL, V28, P611, DOI 10.1093/annonc/mdw660; Brustel J, 2011, TRENDS CELL BIOL, V21, P452, DOI 10.1016/j.tcb.2011.04.006; Calabrich A, 2008, ONCOLOGY-NY, V22, p[1263, 1259]; Calabrich A, 2008, ONCOLOGY-NY, V22, p[1259, 1263]; Calabrich A, 2008, ONCOLOGY-NY, V22, P1250; Cao J, 2014, CELL REP, V6, P868, DOI 10.1016/j.celrep.2014.02.004; Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956; Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717; Centritto F, 2015, EMBO MOL MED, V7, P950, DOI 10.15252/emmm.201404670; Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fabi A, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0380-5; Gajria D, 2011, EXPERT REV ANTICANC, V11, P263, DOI 10.1586/ERA.10.226; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Guo XQ, 2017, J KIDNEY CANCER VHL, V4, P1, DOI 10.15586/jkcvhl.2017.56; Hou JL, 2012, AM J TRANSL RES, V4, P247; Kennedy JM, 2014, J EXP MED, V211, P2519, DOI 10.1084/jem.20140455; Kute T, 2004, CYTOM PART A, V57A, P86, DOI 10.1002/cyto.a.10095; Labbe RM, 2014, AM J TRANSL RES, V6, P1; Li N, 2016, CANCER RES, V76, P831, DOI 10.1158/0008-5472.CAN-15-0906; Moldovan L, 2013, J Med Life, V6, P14; Paroni G, 2012, ONCOGENE, V31, P3431, DOI 10.1038/onc.2011.506; Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; Perou CM, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003293; Regan MM, 2011, LANCET ONCOL, V12, P1101, DOI 10.1016/S1470-2045(11)70270-4; Rodrigues Loreta M, 2012, BMC Res Notes, V5, P250, DOI 10.1186/1756-0500-5-250; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Rosenfeld JA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-143; Sahlberg KK, 2013, MOL ONCOL, V7, P392, DOI 10.1016/j.molonc.2012.10.012; Sarter K, 2016, J EXP MED, V213, P177, DOI 10.1084/jem.20150435; Schulz R, 2012, J EXP MED, V209, P275, DOI 10.1084/jem.20111117; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taylor-Papadimitriou J, 2017, EXPERT OPIN THER TAR, V21, P5, DOI 10.1080/14728222.2017.1263616; Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165; Tumber A, 2017, CELL CHEM BIOL, V24, P371, DOI 10.1016/j.chembiol.2017.02.006; Valabrega G, 2011, BREAST CANCER RES TR, V130, P29, DOI 10.1007/s10549-010-1281-5; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wang Q, 2015, BIOCHEM BIOPH RES CO, V464, P659, DOI 10.1016/j.bbrc.2015.07.049; Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024; Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004	46	12	12	5	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2675	2689		10.1038/s41388-018-0620-6	http://dx.doi.org/10.1038/s41388-018-0620-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30538297				2022-12-17	WOS:000464121600001
J	Matsushita, A; Sato, T; Mukai, S; Fujishita, T; Mishiro-Sato, E; Okuda, M; Aoki, M; Hasegawa, Y; Sekido, Y				Matsushita, Akihiro; Sato, Tatsuhiro; Mukai, Satomi; Fujishita, Teruaki; Mishiro-Sato, Emi; Okuda, Maho; Aoki, Masahiro; Hasegawa, Yoshinori; Sekido, Yoshitaka			TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation	ONCOGENE			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; YAP; MUTATIONS; NF2; INTERLEUKIN-1-BETA; PROLIFERATION; DEGRADATION; PROTEIN; INJURY	Malignant mesothelioma (MM) constitutes a very aggressive tumor that is caused by asbestos exposure after long latency. The NF2 tumor suppressor gene is mutated in 40-50% of MM; moreover, one of its downstream signaling cascades, the Hippo signaling pathway, is also frequently inactivated in MM cells. Although the YAP transcriptional coactivator, which is regulated by the Hippo pathway, can function as a pro-oncogenic protein, the role of TAZ, a paralog of YAP, in MM cells has not yet been clarified. Here, we show that TAZ is expressed and underphosphorylated (activated) in the majority of MM cells compared to immortalized mesothelial cells. ShRNA-mediated TAZ knockdown highly suppressed cell proliferation, anchorage-independent growth, cell motility, and invasion in MM cells harboring activated TAZ. Conversely, transduction of an activated form of TAZ in immortalized mesothelial cells enhanced these in vitro phenotypes and conferred tumorigenicity in vivo. Microarray analysis determined that activated TAZ most significantly enhanced the transcription of genes related to "cytokine-cytokine receptor interaction." Among selected cytokines, we found that IL-1 signaling activation plays a major role in proliferation in TAZ-activated MM cells. Both IL1B knockdown and an IL-1 receptor antagonist significantly suppressed malignant phenotypes of immortalized mesothelial cells and MM cells with activated TAZ. Overall, these results indicate an oncogenic role for TAZ in MMs via transcriptional induction of distinct pro-oncogenic genes including cytokines. Among these, IL-1 signaling appears as one of the most important cascades, thus potentially serving as a target pathway in MM cells harboring Hippo pathway inactivation.	[Matsushita, Akihiro; Sato, Tatsuhiro; Mukai, Satomi; Okuda, Maho; Sekido, Yoshitaka] Aichi Canc Ctr Res Inst, Div Canc Biol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi, Japan; [Matsushita, Akihiro; Hasegawa, Yoshinori] Nagoya Univ, Dept Resp Med, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan; [Fujishita, Teruaki; Mishiro-Sato, Emi; Aoki, Masahiro] Aichi Canc Ctr Res Inst, Div Pathophysiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi, Japan; [Aoki, Masahiro; Sekido, Yoshitaka] Nagoya Univ, Field Canc Pathobiol & Informat, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan	Aichi Cancer Center; Nagoya University; Aichi Cancer Center; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr Res Inst, Div Canc Biol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi, Japan.; Sekido, Y (corresponding author), Nagoya Univ, Field Canc Pathobiol & Informat, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan.	ysekido@aichi-cc.jp	Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490; Mishiro-Sato, Emi/0000-0001-5528-4440; Fujishita, Teruaki/0000-0002-4397-2438; Sekido, Yoshitaka/0000-0002-2428-3848	JSPS KAKENHI [25090053, 16H04706, 17K19628]; AMED P-PRIME; AMED P-CREATE; Aichi Cancer Research Foundation; Takeda Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED P-PRIME; AMED P-CREATE; Aichi Cancer Research Foundation(Aichi Cancer Research Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank Ms. Ikue Hasegawa, Miwako Nishizawa, and Haruna Ikeda for technical assistance. We thank Dr. Hata for TAZ expression lentiviruses and Dr. Gazdar for MM cell lines. This work was supported by JSPS KAKENHI 25090053 (YS), 16H04706 (YS), and 17K19628 (YS); AMED P-PRIME and P-CREATE (YS); Aichi Cancer Research Foundation (TS); and Takeda Science Foundation (TS).	Adachi Y, 2006, INT J CANCER, V119, P1303, DOI 10.1002/ijc.22006; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bibby AC, 2016, EUR RESPIR REV, V25, P472, DOI 10.1183/16000617.0063-2016; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Disselhorst MMJ, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0488-7; Felley-Bosco E, 2014, TRANSL LUNG CANCER R, V3, P75, DOI 10.3978/j.issn.2218-6751.2014.02.03; Frank AL, 2014, ANN GLOB HEALTH, V80, P257, DOI 10.1016/j.aogh.2014.09.016; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036; Kadariya Y, 2016, CANCER PREV RES, V9, P406, DOI 10.1158/1940-6207.CAPR-15-0347; Kakiuchi T, 2016, CARCINOGENESIS, V37, P1098, DOI 10.1093/carcin/bgw084; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; Menezes ME, 2014, ADV EXP MED BIOL, V818, P127, DOI 10.1007/978-1-4471-6458-6_6; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Murakami H, 2011, CANCER RES, V71, P873, DOI 10.1158/0008-5472.CAN-10-2164; Nelson DB, 2017, J CLIN ONCOL, V35, P3354, DOI 10.1200/JCO.2017.73.8401; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 2013, CARCINOGENESIS, V34, P1413, DOI 10.1093/carcin/bgt166; Stadlmann S, 2006, WOUND REPAIR REGEN, V14, P187, DOI 10.1111/j.1743-6109.2006.00109.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanaka I, 2015, ONCOGENE, V34, P73, DOI 10.1038/onc.2013.528; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Tranchant R, 2017, CLIN CANCER RES, V23, P3191, DOI 10.1158/1078-0432.CCR-16-1971; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Wang YH, 2004, INT J ONCOL, V25, P173; Whitaker EL, 2012, CYTOKINE GROWTH F R, V23, P323, DOI 10.1016/j.cytogfr.2012.08.004; Yang ZY, 2014, MOL CELL BIOL, V34, P1607, DOI 10.1128/MCB.01346-13; Yap TA, 2017, NAT REV CANCER, V17, P475, DOI 10.1038/nrc.2017.42; Yokoyama T, 2008, CARCINOGENESIS, V29, P2139, DOI 10.1093/carcin/bgn200; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005	41	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1966	1978		10.1038/s41388-018-0417-7	http://dx.doi.org/10.1038/s41388-018-0417-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30401981				2022-12-17	WOS:000461164400013
J	Arima, K; Ohmuraya, M; Miyake, K; Koiwa, M; Uchihara, T; Izumi, D; Gao, F; Yonemura, A; Bu, LK; Okabe, H; Imai, K; Hashimoto, D; Baba, Y; Chikamoto, A; Yamashita, Y; Furukawa, T; Araki, K; Baba, H; Ishimoto, T				Arima, Kota; Ohmuraya, Masaki; Miyake, Keisuke; Koiwa, Mayu; Uchihara, Tomoyuki; Izumi, Daisuke; Gao, Feng; Yonemura, Atsuko; Bu, Luke; Okabe, Hirohisa; Imai, Katsunori; Hashimoto, Daisuke; Baba, Yoshifumi; Chikamoto, Akira; Yamashita, Yo-ichi; Furukawa, Toru; Araki, Kimi; Baba, Hideo; Ishimoto, Takatsugu			Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas	ONCOGENE			English	Article							TRANS-RETINOIC ACID; CANCER STEM-CELLS; ENGINEERED MOUSE MODELS; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; DOWN-REGULATION; SUPPRESSOR; INFLAMMATION; TARGET; ROLES	The accumulation of prostaglandin E2 (PGE(2)) during chronic inflammation has been implicated in the progression of several cancers. Cyclooxygenase is the key synthesizing enzyme of PGE(2), although the degradation enzyme 15-ydroxyprostaglandin dehydrogenase (15-PGDH) has received considerable attention recently. We investigated the molecular mechanisms of pancreatic ductal adenocarcinoma (PDAC) progression via 15-PGDH downregulation. Here, we found that 15-PGDH expression was inversely correlated with ALDH1, an important cancer stem cell-associated marker indicative of poor prognosis in humans. Moreover, we demonstrated that pharmacological inhibition of 15-PGDH enhanced CYP26A1 expression, leading to depletion of all-trans retinoic acid (ATRA) and expansion of the ALDH1-positive subset in both human PDAC cells and tumor cells of Kras(LSL-G12D/+); Ptfla(Cre/+) (KC) mice. Furthermore, genetic deletion of 15-Pgdh in KC mice showed PGE(2) accumulation and ATRA depletion in the pancreas, resulting in PDAC with high levels of Aldh1 and Ki-67. Finally, ATRA replacement suppressed 15-PGDH inhibition-induced tumor progression in KC mice, and ATRA treatment attenuated Aldh1 activity in tumor cells isolated from the pancreas of 15-Pgdh(-/-) KC mice. These findings provide evidence that 15-PGDH inhibition enhances KRAS-driven tumor progression via ATRA depletion in the pancreas. Therefore, ATRA replacement could be a potential strategy for PDAC treatment.	[Arima, Kota; Miyake, Keisuke; Uchihara, Tomoyuki; Izumi, Daisuke; Gao, Feng; Yonemura, Atsuko; Bu, Luke; Okabe, Hirohisa; Imai, Katsunori; Hashimoto, Daisuke; Baba, Yoshifumi; Chikamoto, Akira; Yamashita, Yo-ichi; Baba, Hideo; Ishimoto, Takatsugu] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan; [Arima, Kota; Miyake, Keisuke; Koiwa, Mayu; Uchihara, Tomoyuki; Ishimoto, Takatsugu] Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto, Japan; [Ohmuraya, Masaki] Hyogo Coll Med, Dept Genet, Nishinomiya, Hyogo, Japan; [Furukawa, Toru] Tohoku Univ, Grad Sch Med, Dept Histopathol, Sendai, Miyagi, Japan; [Araki, Kimi] Kumamoto Univ, Inst Resource Dev & Anal, Kumamoto, Japan	Kumamoto University; Kumamoto University; Hyogo College of Medicine; Tohoku University; Kumamoto University	Baba, H; Ishimoto, T (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan.; Ishimoto, T (corresponding author), Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto, Japan.	hdobaba@kumamoto-u.ac.jp; taka1516@kumamoto-u.ac.jp	Furukawa, Toru/AAF-5596-2021; Hashimoto, Daisuke/AAE-7134-2020; Ishimoto, Takatsugu/AAP-1356-2020	Furukawa, Toru/0000-0002-1083-2324; Ishimoto, Takatsugu/0000-0003-1852-1835	Japan Society for the Promotion of Science KAKENHI [16H06257, 16K15595, 17K16570, 17K16571]; Pancreas Research Foundation of Japan; Kanae Foundation for the Promotion of Medical Science; Yasuda Medical Foundation; Shinnihon Foundation of Advanced Medical Treatment Research;  [201860083]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Pancreas Research Foundation of Japan(Pancreas Research Foundation of Japan); Kanae Foundation for the Promotion of Medical Science; Yasuda Medical Foundation; Shinnihon Foundation of Advanced Medical Treatment Research; 	We are grateful to Dr. David A. Tuveson (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA) for providing the Kras<SUP>LSL-G12D</SUP> mice and to Dr. Sanford D. Markowitz (Department of Medicine, Case Western Reserve University, Cleveland, OH, USA) for their kind advice about establishing 15-Pgdh<SUP>-/-</SUP>mice. This work was supported, in part, by the Japan Society for the Promotion of Science KAKENHI (Grant Numbers 16H06257, 16K15595, 17K16570, and 17K16571), Grant-in-Aid for JSPS Research Fellows (Grant Numbers Y201860083), the Pancreas Research Foundation of Japan, the Kanae Foundation for the Promotion of Medical Science, the Yasuda Medical Foundation and the Shinnihon Foundation of Advanced Medical Treatment Research.	Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Arima K, 2018, CANCER SCI, V109, P462, DOI 10.1111/cas.13467; Baumgart S, 2013, GUT, V62, P310, DOI 10.1136/gutjnl-2011-301008; Chen Z, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1794-8; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Coggins KG, 2002, NAT MED, V8, P91, DOI 10.1038/nm0202-91; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Fu ZQ, 2017, CANCER LETT, V410, P68, DOI 10.1016/j.canlet.2017.09.019; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Guerra C, 2013, MOL ONCOL, V7, P232, DOI 10.1016/j.molonc.2013.02.002; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hashimoto M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11315; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Huang GS, 2008, CANCER RES, V68, P5040, DOI 10.1158/0008-5472.CAN-07-6575; Ishimoto T, 2017, GASTROENTEROLOGY, V153, P191, DOI 10.1053/j.gastro.2017.03.046; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kane MA, 2008, ANAL CHEM, V80, P1702, DOI 10.1021/ac702030f; Kochel TJ, 2016, BREAST CANCER-BASIC, V10, P61, DOI 10.4137/BCBCR.S38529; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Loo TM, 2017, CANCER DISCOV, V7, P522, DOI 10.1158/2159-8290.CD-16-0932; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mashiko D, 2013, SCI REP-UK, V3, DOI 10.1038/srep03355; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Mehdawi LM, 2016, MOL ONCOL, V10, P1415, DOI 10.1016/j.molonc.2016.07.011; Nelson CH, 2013, CURR TOP MED CHEM, V13, P1402; Nguyen PH, 2016, ONCOGENE, V35, P5619, DOI 10.1038/onc.2016.87; North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883; Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Rothwell PM, 2011, OBSTET GYNECOL SURV, V66, P222, DOI 10.1097/OGX.0b013e318225cec2; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Swanton C, 2016, NEW ENGL J MED, V374, P1864, DOI 10.1056/NEJMra1504688; Taki K, 2016, ONCOGENE, V35, P2407, DOI 10.1038/onc.2015.294; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wei S, 2015, NAT MED, V21, P457, DOI 10.1038/nm.3839; Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368; Young MJ, 2015, CARCINOGENESIS, V36, P498, DOI 10.1093/carcin/bgv018; Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340; Zhao D, 2014, J CLIN INVEST, V124, P5453, DOI 10.1172/JCI76611	45	12	13	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1211	1224		10.1038/s41388-018-0510-y	http://dx.doi.org/10.1038/s41388-018-0510-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30250298				2022-12-17	WOS:000459249800005
J	Hsu, PC; Gopinath, RK; Hsueh, YA; Shieh, SY				Hsu, Pei-Ching; Gopinath, Rajaneesh Karimpurath; Hsueh, Yi-An; Shieh, Sheau-Yann			CHK2-mediated regulation of PARP1 in oxidative DNA damage response	ONCOGENE			English	Article							POLY ADP-RIBOSE; POLY(ADP-RIBOSE) POLYMERASE-1; CHK2 ACTIVATION; PROTEIN-KINASE; PHOSPHORYLATION; BINDING; CHECKPOINT; DOMAINS; REPAIR; XRCC1	Poly(ADP-ribose) polymerase 1 (PARP1) is a DNA damage sensor, which upon activation, recruits downstream proteins by poly(ADP-ribosyl)ation (PARylation). However, it remains largely unclear how PARP1 activity is regulated. Interestingly, the data obtained through this study revealed that PARP1 was co-immunoprecipitated with checkpoint kinase 2 (CHK2), and the interaction was increased after oxidative DNA damage. Moreover, CHK2 depletion resulted in a reduction in overall PARylation. To further explore the functional relationship between PARP1 and CHK2, this study employed H2O2 to induce an oxidative DNA damage response in cells. Here, we showed that CHK2 and PARP1 interact in vitro and in vivo through the CHK2 SCD domain and the PARP1 BRCT domain. Furthermore, CHK2 stimulates the PARylation activity of PARP1 through CHK2-dependent phosphorylation. Consequently, the impaired repair associated with PARP1 depletion could be rescued by re-expression of wild-type PARP1 and the phospho-mimic but not the phospho-deficient mutant. Mechanistically, we showed that CHK2-dependent phosphorylation of PARP1 not only regulates its cellular localization but also promotes its catalytic activity and its interaction with XRCC1. These findings indicate that CHK2 exerts a multifaceted impact on PARP1 in response to oxidative stress to facilitate DNA repair and to maintain cell survival.	[Hsu, Pei-Ching; Shieh, Sheau-Yann] Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; [Hsu, Pei-Ching; Gopinath, Rajaneesh Karimpurath; Hsueh, Yi-An; Shieh, Sheau-Yann] Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 115, Taiwan	National Defense Medical Center; Academia Sinica - Taiwan	Shieh, SY (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan.; Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Shieh, Sheau-Yann/N-9512-2018; Karimpurath Gopinath, Rajaneesh/AHA-8714-2022; KARIMPURATH GOPINATH, RAJANEESH/H-3933-2016	Shieh, Sheau-Yann/0000-0002-5351-4430; KARIMPURATH GOPINATH, RAJANEESH/0000-0003-1554-4310	Academia Sinica, Taiwan	Academia Sinica, Taiwan(Academia Sinica - Taiwan)	We are grateful to the Proteomic Core at Institute of Biomedical Sciences for the assistance with the identification of the PARP1 phosphorylation sites. This work was supported by funding from Academia Sinica, Taiwan to S-YS.	Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Altmeyer M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9088; Anderson VE, 2011, CANCER RES, V71, P463, DOI 10.1158/0008-5472.CAN-10-1252; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Barkauskaite E, 2015, MOL CELL, V58, P935, DOI 10.1016/j.molcel.2015.05.007; BAUER PI, 1992, BIOCHEM BIOPH RES CO, V187, P730, DOI 10.1016/0006-291X(92)91256-P; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Breslin C, 2015, NUCLEIC ACIDS RES, V43, P6934, DOI 10.1093/nar/gkv623; Brunyanszki A, 2014, MOL PHARMACOL, V86, P450, DOI 10.1124/mol.114.094318; Buscemi G, 2006, MOL CELL BIOL, V26, P7832, DOI 10.1128/MCB.00534-06; Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53; Chaudhuri AR, 2016, NATURE, V535, P382, DOI 10.1038/nature18325; Chou WC, 2015, CARCINOGENESIS, V36, P832, DOI 10.1093/carcin/bgv079; Chou WC, 2008, EMBO J, V27, P3140, DOI 10.1038/emboj.2008.229; Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Gagne JP, 2009, J PROTEOME RES, V8, P1014, DOI 10.1021/pr800810n; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hegde ML, 2012, PROG MOL BIOL TRANSL, V110, P123, DOI 10.1016/B978-0-12-387665-2.00006-7; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Hong RX, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2754-7; Hu YD, 2014, CANCER DISCOV, V4, P1430, DOI 10.1158/2159-8290.CD-13-0891; Kauppinen TM, 2006, P NATL ACAD SCI USA, V103, P7136, DOI 10.1073/pnas.0508606103; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Li M, 2013, GENE DEV, V27, P1752, DOI 10.1101/gad.226357.113; Loeffler PA, 2011, BMC STRUCT BIOL, V11, DOI 10.1186/1472-6807-11-37; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369; Mansoorabadi SO, 2014, BIOCHEMISTRY-US, V53, P1779, DOI 10.1021/bi401439n; Martin N, 2009, EMBO J, V28, P3534, DOI 10.1038/emboj.2009.279; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Meehan Robert S, 2016, Gynecol Oncol Res Pract, V3, P3, DOI 10.1186/s40661-016-0024-7; Messner S, 2009, FASEB J, V23, P3978, DOI 10.1096/fj.09-137695; Muthurajan UM, 2014, P NATL ACAD SCI USA, V111, P12752, DOI 10.1073/pnas.1405005111; Noren Hooten N, 2011, J BIOL CHEM, V286, P44679, DOI 10.1074/jbc.M111.255869; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Pascal JM, 2015, DNA REPAIR, V32, P10, DOI 10.1016/j.dnarep.2015.04.008; Perina D, 2014, DNA REPAIR, V23, P4, DOI 10.1016/j.dnarep.2014.05.003; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Ryu H, 2010, J BIOL CHEM, V285, P14415, DOI 10.1074/jbc.M109.074583; Shang FQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151845; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Stolz A, 2011, CLIN CANCER RES, V17, P401, DOI 10.1158/1078-0432.CCR-10-1215; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Vyas S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5426; Vyas S, 2014, NAT REV CANCER, V14, P502, DOI 10.1038/nrc3748; Wright RHG, 2012, GENE DEV, V26, P1972, DOI 10.1101/gad.193193.112; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yeh YH, 2009, ONCOGENE, V28, P1366, DOI 10.1038/onc.2008.477; Zannini L, 2014, J MOL CELL BIOL, V6, P442, DOI 10.1093/jmcb/mju045; Zhang F, 2015, CELL REP, V13, P678, DOI 10.1016/j.celrep.2015.09.040; Zhang S, 2007, CELL DEATH DIFFER, V14, P1001, DOI 10.1038/sj.cdd.4402088; Zhao H, 2008, CELL CYCLE, V7, P1490, DOI 10.4161/cc.7.10.5963	56	12	12	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1166	1182		10.1038/s41388-018-0506-7	http://dx.doi.org/10.1038/s41388-018-0506-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254210				2022-12-17	WOS:000459249800002
J	Warren, AY; Massie, CE; Watt, K; Luko, K; Orafidiya, F; Selth, LA; Mohammed, H; Chohan, BS; Menon, S; Baridi, A; Zhao, WF; Escriu, C; Pungsrinont, T; D'Santos, C; Yang, XP; Taylor, C; Qureshi, A; Zecchini, VR; Shaw, GL; Dehm, SM; Mills, IG; Carroll, JS; Tilley, WD; McEwan, IJ; Baniahmad, A; Neal, DE; Asim, M				Warren, Anne Y.; Massie, Charlie E.; Watt, Kate; Luko, Katarina; Orafidiya, Folake; Selth, Luke A.; Mohammed, Hisham; Chohan, Brinder S.; Menon, Suraj; Baridi, Ajoeb; Zhao, Wanfeng; Escriu, Carles; Pungsrinont, Thanakorn; D'Santos, Clive; Yang, Xiaoping; Taylor, Chris; Qureshi, Arham; Zecchini, Vincent R.; Shaw, Greg L.; Dehm, Scott M.; Mills, Ian G.; Carroll, Jason S.; Tilley, Wayne D.; McEwan, Iain J.; Baniahmad, Aria; Neal, David E.; Asim, Mohammad			A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer	ONCOGENE			English	Article							ORIGINATED PROTEIN-KINASE; MITOTIC KINASE; EXPRESSION; PBK/TOPK; GENE; RESISTANCE; DOMAIN; TOPK; ANTIANDROGEN; ABIRATERONE	Elucidation of mechanisms underlying the increased androgen receptor (AR) activity and subsequent development of aggressive prostate cancer (PrCa) is pivotal in developing new therapies. Using a systems biology approach, we interrogated the AR-regulated proteome and identified PDZ binding kinase (PBK) as a novel AR-regulated protein that regulates full-length AR and AR variants (ARVs) activity in PrCa. PBK overexpression in aggressive PrCa is associated with early biochemical relapse and poor clinical outcome. In addition to its carboxy terminus ligand-binding domain, PBK directly interacts with the amino terminus transactivation domain of the AR to stabilise it thereby leading to increased AR protein expression observed in PrCa. Transcriptome sequencing revealed that PBK is a mediator of global AR signalling with key roles in regulating tumour invasion and metastasis. PBK inhibition decreased growth of PrCa cell lines and clinical specimen cultured ex vivo. We uncovered a novel interplay between AR and PBK that results in increased AR and ARVs expression that executes AR-mediated growth and progression of PrCa, with implications for the development of PBK inhibitors for the treatment of aggressive PrCa.	[Warren, Anne Y.; Chohan, Brinder S.; Zhao, Wanfeng] Addenbrookes Cambridge Univ Hosp, Dept Pathol, Cambridge, England; [Massie, Charlie E.] Univ Cambridge, Canc Res UK Cambridge Ctr, Dept Oncol, Early Detect Programme, Cambridge, England; [Watt, Kate; Orafidiya, Folake; McEwan, Iain J.] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland; [Luko, Katarina; Pungsrinont, Thanakorn; Baniahmad, Aria] Jena Univ Hosp, Inst Human Genet, Jena, Germany; [Selth, Luke A.; Tilley, Wayne D.] Univ Adelaide, Fac Hlth Sci, Sch Med, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Selth, Luke A.; Tilley, Wayne D.] Univ Adelaide, Fac Hlth Sci, Sch Med, Freemasons Fdn Ctr Mens Hlth, Adelaide, SA, Australia; [Mohammed, Hisham] OHSU, Knight Canc Inst, Canc Early Detect Adv Res Ctr, Portland, OR USA; [Menon, Suraj; Baridi, Ajoeb; Escriu, Carles; D'Santos, Clive; Yang, Xiaoping; Taylor, Chris; Qureshi, Arham; Zecchini, Vincent R.; Shaw, Greg L.; Carroll, Jason S.; Neal, David E.; Asim, Mohammad] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England; [Dehm, Scott M.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Mills, Ian G.] Queens Univ, CCRCB, Prostate Canc UK Movember Ctr Excellence, Belfast, Antrim, North Ireland; [Mills, Ian G.; Neal, David E.; Asim, Mohammad] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England; [Asim, Mohammad] Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Guildford, Surrey, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Aberdeen; Friedrich Schiller University of Jena; University of Adelaide; University of Adelaide; Oregon Health & Science University; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Minnesota System; University of Minnesota Twin Cities; Queens University Belfast; University of Oxford; University of Surrey	Asim, M (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England.; Asim, M (corresponding author), Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.; Asim, M (corresponding author), Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Guildford, Surrey, England.	m.asim@surrey.ac.uk	Mills, Ian/AAK-9292-2020; Selth, Luke/AAH-4823-2021	Mills, Ian/0000-0001-5347-5083; Selth, Luke/0000-0002-4686-1418; Tilley, Wayne/0000-0003-1893-2626; Carroll, Jason/0000-0003-3643-0080; Escriu, Carles/0000-0003-3638-3202; Shaw, Greg/0000-0003-3480-2100; Massie, Charlie/0000-0003-2314-4843; Pungsrinont, Thanakorn/0000-0002-9974-1903	National Institute for Health Research; Hutchison Whampoa Limited; Human Research Tissue bank (Addenbrooke's Hospital Cambridge); Cancer Research UK; NATIONAL CANCER INSTITUTE [R01CA174777] Funding Source: NIH RePORTER	National Institute for Health Research(National Institute for Health Research (NIHR)); Hutchison Whampoa Limited; Human Research Tissue bank (Addenbrooke's Hospital Cambridge); Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Uro-Oncology Laboratories of Professor David Neal and Dr. Mohammad Asim for helpful discussions. We also thank research staff of CI core facilities for providing technical support. We thank Drs Curtis Pettaway for LNCaP-LN3 and Zoran Culig for LNCaP-Bic cells. We acknowledge the support of National Institute for Health Research, Hutchison Whampoa Limited, the Human Research Tissue bank (Addenbrooke's Hospital Cambridge) and Cancer Research UK. We thank men with PrCa who donated their time and samples to the Cambridge Biorepository, which were used in this research. We also acknowledge the support of the research staff in S4 for carefully curating all samples and provided the follow-up data (Jo Burge, Marie Corcoran, Anne George and Sara Stern).	Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Asim M, 2008, ONCOGENE, V27, P3596, DOI 10.1038/sj.onc.1211016; Asim M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00393-y; Asim M, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1140262; Asim M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv371; Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642; Augello MA, 2013, J CLIN INVEST, V123, P493, DOI 10.1172/JCI64750; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brand LJ, 2015, ONCOTARGET, V6, P3811, DOI 10.18632/oncotarget.2924; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Chan SC, 2015, NUCLEIC ACIDS RES, V43, P5880, DOI 10.1093/nar/gkv262; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cheng H, 2006, CANCER RES, V66, P10613, DOI 10.1158/0008-5472.CAN-06-0028; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hay CW, 2014, HORM CANCER-US, V5, P299, DOI 10.1007/s12672-014-0185-y; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Hu F, 2010, ONCOGENE, V29, P5464, DOI 10.1038/onc.2010.275; Hu F, 2013, LEUKEMIA RES, V37, P447, DOI 10.1016/j.leukres.2012.11.010; Khan N, 2008, CANCER RES, V68, P8555, DOI 10.1158/0008-5472.CAN-08-0240; Kim DJ, 2012, CANCER RES, V72, P3060, DOI 10.1158/0008-5472.CAN-11-3851; Luo Q, 2014, INT J CLIN EXP PATHO, V7, P8059; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Myung JK, 2013, J CLIN INVEST, V123, P2948, DOI 10.1172/JCI66398; Nandi AK, 2006, LEUKEMIA RES, V30, P437, DOI 10.1016/j.leukres.2005.08.011; Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Scher HI, 2004, ENDOCR-RELAT CANCER, V11, P459, DOI 10.1677/erc.1.00525; Shaw GL, 2016, EUR UROL, V70, P214, DOI 10.1016/j.eururo.2015.10.042; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Singh PK, 2014, IMMUNOBIOLOGY, V219, P469, DOI 10.1016/j.imbio.2014.02.003; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001	52	12	12	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1136	1150		10.1038/s41388-018-0501-z	http://dx.doi.org/10.1038/s41388-018-0501-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30237440	Green Published, hybrid			2022-12-17	WOS:000458624900015
J	Birnbaum, MD; Zhao, N; Moorthy, BT; Patel, DM; Kryvenko, ON; Heidman, L; Kumar, A; Morgan, WM; Ban, YG; Reis, IM; Chen, X; Gonzalgo, ML; Jorda, M; Burnstein, KL; Zhang, FL				Birnbaum, Michael D.; Zhao, Ning; Moorthy, Balaji T.; Patel, Devang M.; Kryvenko, Oleksandr N.; Heidman, Laine; Kumar, Akhilesh; Morgan, William M.; Ban, Yuguang; Reis, Isildinha M.; Chen, Xi; Gonzalgo, Mark L.; Jorda, Merce; Burnstein, Kerry L.; Zhang, Fangliang			Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis	ONCOGENE			English	Article							RNA-PROTEIN TRANSFERASE; END RULE PATHWAY; ARGINYLATION; TUMOR; INVASION; ASSAY; BETA	Most prostate cancer cases remain indolent for long periods of time, but metastatic progression quickly worsens the prognosis and leads to mortality. However, little is known about what promotes the metastasis of prostate cancer and there is a lack of effective prognostic indicators, making it immensely difficult to manage options for treatment or surveillance. Arginyltransferase 1 (Ate1) is the enzyme mediating post-translational protein arginylation, which has recently been identified as a master regulator affecting many cancer-relevant pathways including stress response, cell cycle checkpoints, and cell migration/adhesion. However, the precise role of Ate1 in cancer remains unknown. In this study, we found the occurrence of metastasis of prostate cancer is inversely correlated with the levels of Ate1 protein and mRNA in the primary tumor. We also found that metastatic prostate cancer cell lines have a reduced level of Ate1 protein compared to non-metastatic cell lines, and that a depletion of Ate1 drives prostate cancer cells towards more aggressive pro-metastatic phenotypes without affecting proliferation rates. Furthermore, we demonstrated that a reduction of Ate1 can result from chronic stress, and that shRNA-reduced Ate1 increases cellular resistance to stress, and drives spontaneous and stress-induced genomic mutations. Finally, by using a prostate orthotropic xenograft mouse model, we found that a reduction of Ate1 was sufficient to enhance the metastatic phenotypes of prostate cancer cell line PC-3 in vivo. Our study revealed a novel role of Ate1 in suppressing prostate cancer metastasis, which has a profound significance for establishing metastatic indicators for prostate cancer, and for finding potential treatments to prevent its metastasis.	[Birnbaum, Michael D.; Zhao, Ning; Moorthy, Balaji T.; Patel, Devang M.; Heidman, Laine; Kumar, Akhilesh; Morgan, William M.; Burnstein, Kerry L.; Zhang, Fangliang] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Kryvenko, Oleksandr N.; Reis, Isildinha M.; Chen, Xi; Gonzalgo, Mark L.; Jorda, Merce; Burnstein, Kerry L.; Zhang, Fangliang] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Kryvenko, Oleksandr N.; Jorda, Merce] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Kryvenko, Oleksandr N.; Gonzalgo, Mark L.] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA; [Ban, Yuguang; Reis, Isildinha M.; Chen, Xi] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Kumar, Akhilesh] Banaras Hindu Univ, Dept Bot, Varanasi 221005, Uttar Pradesh, India	University of Miami; University of Miami; University of Miami; University of Miami; University of Miami; Banaras Hindu University (BHU)	Zhang, FL (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.; Zhang, FL (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.	fzhang2@miami.edu	Patel, Devang/P-9537-2017; Moorthy, Balaji Thas/I-9254-2019	Patel, Devang/0000-0002-0375-2318; Moorthy, Balaji Thas/0000-0002-2196-0209; Zhao, Ning/0000-0001-6514-234X	DoD (CDMRP), Idea Award [PC140622]; DoD (CDMRP), Exploratory grant [PC141013]; NIGMS (NIH) [R01GM107333]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM107333] Funding Source: NIH RePORTER	DoD (CDMRP), Idea Award; DoD (CDMRP), Exploratory grant; NIGMS (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Cell sorting was performed in the core facility of Sylvester Comprehensive Cancer Center. Ex vivo imaging was performed in the small animal imaging facility at the University of Miami Miller School of medicine. Gamma irradiation was performed in the Radiation Control core facility at the University of Miami Miller School of medicine. Immunostaining of tumor array samples was performed in the histology core facility in the Hussman Institute for Human Genomics at the University of Miami Miller School of medicine. Dr. Priyamvada Rai (University of Miami) provided critical reading for the manuscript. Dr. Yuanfang Guan (University of Michigan) provided technical consultations for the analysis related to Ate1 mRNA levels. The research presented in this article is funded in part by these grants: DoD (CDMRP), Idea Award, PC140622; DoD (CDMRP), Exploratory grant, PC141013; and NIGMS (NIH), R01GM107333.	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; BALZI E, 1990, J BIOL CHEM, V265, P7464; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bullard JH, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-94; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Decca MB, 2006, NEUROCHEM RES, V31, P401, DOI 10.1007/s11064-005-9037-z; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eisenach PA, 2014, J BIOL CHEM, V289, P35376, DOI 10.1074/jbc.M114.578674; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FIDLER IJ, 1978, CANCER RES, V38, P2651; Hu RG, 2006, J BIOL CHEM, V281, P32559, DOI 10.1074/jbc.M604355200; Humphrey PA, 2004, MODERN PATHOL, V17, P292, DOI 10.1038/modpathol.3800054; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; KLEMPERER NS, 1989, J BIOL CHEM, V264, P19245; Kumar A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.284; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Kuroiwa K, 2009, J CLIN PATHOL, V62, P260, DOI 10.1136/jcp.2008.060632; Kurosaka S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000878; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Piatkov KI, 2012, P NATL ACAD SCI USA, V109, pE1839, DOI 10.1073/pnas.1207786109; Rai R, 2016, ONCOGENE, V35, P4058, DOI 10.1038/onc.2015.473; Rai R, 2006, EMBO REP, V7, P800, DOI 10.1038/sj.embor.7400747; Rice MA, 2016, ONCOGENE, V35, P4752, DOI 10.1038/onc.2016.6; Rusthoven CG, 2014, UROL ONCOL-SEMIN ORI, V32, P707, DOI 10.1016/j.urolonc.2014.01.004; Sherman MY, 2015, ONCOGENE, V34, P4153, DOI 10.1038/onc.2014.349; Suzuki F, 1983, METHODS CELL SCI, V8, P109, DOI DOI 10.1007/BF01842703; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Varshavsky A, 2011, PROTEIN SCI, V20, P1298, DOI 10.1002/pro.666; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wong CCL, 2007, PLOS BIOL, V5, P2231, DOI 10.1371/journal.pbio.0050258; Zhang FL, 2012, J CELL BIOL, V197, P819, DOI 10.1083/jcb.201112129; Zhang FL, 2010, SCIENCE, V329, P1534, DOI 10.1126/science.1191701; Zhang N, 1998, NEUROCHEM RES, V23, P1411, DOI 10.1023/A:1020706924509	39	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					838	851		10.1038/s41388-018-0462-2	http://dx.doi.org/10.1038/s41388-018-0462-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177837	Green Accepted			2022-12-17	WOS:000458006300006
J	Kotelevets, L; Walker, F; Mamadou, G; Lehy, T; Jordan, P; Chastre, E				Kotelevets, Larissa; Walker, Francine; Mamadou, Godefroy; Lehy, Therese; Jordan, Peter; Chastre, Eric			The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression	ONCOGENE			English	Article							TUMOR-RELATED RAC1B; COLORECTAL-CANCER; CELL-SURVIVAL; OVEREXPRESSION; ACTIVATION; EXPRESSION; COLITIS; CATENIN; VARIANT; DIFFERENTIATION	We previously have identified the ectopic expression of Rac1b, an activated and novel splice variant of Rac1, in a subset of human colorectal adenocarcinomas, as well as in inflammatory bowel diseases and in colitis mouse model. Rac1b overexpression has been further evidenced in breast, pancreatic, thyroid, ovarian, and lung cancers. In this context, the aim of our study was to investigate the physiopathological implications of Rac1b in intestinal inflammation and carcinogenesis in vivo. The ectopic expression of Rac1b was induced in mouse intestinal epithelial cells after crossing Rosa26-LSL-Rac1b and villin-Cre mice. These animals were let to age or were challenged with dextran sulfate sodium (DSS) to induce experimental colitis, or either received azoxymethane (AOM)/DSS treatment, or were bred with Apc(Min/+) or II10(-/-) mice to trigger intestinal tumors. Rac1b ectopic expression increased the intestinal epithelial cell proliferation and migration, enhanced the production of reactive oxygen species, and promoted the Paneth cell lineage. Although Rac1b overexpression alone was not sufficient to drive intestinal neoplasia, it enhanced Apc-dependent intestinal tumorigenesis. In the context of II10 knockout, the Rac1b transgene strengthened colonic inflammation due to induced intestinal mucosa permeability and promoted cecum and proximal colon carcinogenesis. In contrast, Rac1b alleviated carcinogen/acute inflammation-associated colon carcinogenesis (AOM/DSS). This resulted at least partly from the early mucosal repair after resolution of inflammation. Our data highlight the critical role of Rac1b in driving wound-healing after resolution of intestinal inflammation, and in cooperating with Wnt pathway dysregulation and chronic inflammation to promote intestinal carcinogenesis.	[Kotelevets, Larissa; Chastre, Eric] INSERM, Ctr Rech St Antoine, UMR S 938, Paris, France; [Kotelevets, Larissa; Chastre, Eric] Univ Pierre & Marie Curie Paris 6, Hop St Antoine, Site Batiment Kourilsky, Paris, France; [Walker, Francine; Lehy, Therese] INSERM, U1149, Ctr Rech Inflammat, CNRS,ERL8252, Paris, France; [Walker, Francine] Hop Univ Paris Nord Val de Seine Bichat Claude Be, AP HP, Dept Pathol, Paris, France; [Mamadou, Godefroy] Univ Paris Diderot Paris7, TransCell Lab Lab, Fac Med Xavier Bichat, Paris, France; [Jordan, Peter] Natl Hlth Inst, Dept Human Genet, Lisbon, Portugal	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Kotelevets, L; Chastre, E (corresponding author), INSERM, Ctr Rech St Antoine, UMR S 938, Paris, France.; Kotelevets, L; Chastre, E (corresponding author), Univ Pierre & Marie Curie Paris 6, Hop St Antoine, Site Batiment Kourilsky, Paris, France.	larissa.kotelevets@inserm.fr; eric.chastre@inserm.fr	CHASTRE, Eric/L-8446-2018; Jordan, Peter/G-9335-2012	CHASTRE, Eric/0000-0002-8993-1228; Jordan, Peter/0000-0002-1425-9211	University Paris Diderot; INSERM	University Paris Diderot; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	The authors acknowledge Dr. Sylvie Robine (Institut Curie, Paris, France) for her donation of the villin-Cre (B6-Tg (Vil-cre) 20Sy/Nci) mice. The authors greatly thank Valerie Gratio of the CRI cytometry facility. The authors are indebted to Dr. Samira Benadda (INSERM U1149) for her assistance in confocal microscopy, and Olivier Thibaudeau (INSERM U1152) for help in histologic experiments. This work was supported by French minister of higher education and research, INSERM, and University Paris Diderot.	Alonso-Espinaco V, 2014, EUR J CANCER, V50, P1973, DOI 10.1016/j.ejca.2014.04.019; Andreu P, 2008, DEV BIOL, V324, P288, DOI 10.1016/j.ydbio.2008.09.027; Cole AM, 2010, EMBO MOL MED, V2, P472, DOI 10.1002/emmm.201000101; Curtis KM, 2012, MOL CELL NEUROSCI, V49, P138, DOI 10.1016/j.mcn.2011.10.008; Espinha G, 2015, MOL CELL BIOCHEM, V404, P281, DOI 10.1007/s11010-015-2388-0; Esufali S, 2007, CANCER RES, V67, P2469, DOI 10.1158/0008-5472.CAN-06-2843; Farin HF, 2016, NATURE, V530, P340, DOI 10.1038/nature16937; Goncalves V, 2009, HUM MOL GENET, V18, P3696, DOI 10.1093/hmg/ddp317; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Guo YN, 2015, MOL CANCER THER, V14, P2215, DOI 10.1158/1535-7163.MCT-15-0419; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kang HT, 2017, AGING CELL, V16, P541, DOI 10.1111/acel.12584; Kato M, 2016, EXP ANIM TOKYO, V65, P197, DOI 10.1538/expanim.15-0127; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Kotelevets L, 2017, CANCER RES, V77, P2964, DOI 10.1158/0008-5472.CAN-16-1741; Kotelevets L, 2016, INT J PHARMACEUT, V514, P24, DOI 10.1016/j.ijpharm.2016.06.005; Lee K, 2012, MOL BIOL CELL, V23, P4097, DOI 10.1091/mbc.E12-02-0166; Lessel W, 2017, CARCINOGENESIS, V38, P559, DOI 10.1093/carcin/bgx032; Li G, 2016, ONCOTARGET, V7, P17970, DOI 10.18632/oncotarget.7602; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Matos P, 2006, J BIOL CHEM, V281, P13724, DOI 10.1074/jbc.M513243200; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; Matos P, 2008, MOL CANCER RES, V6, P1178, DOI 10.1158/1541-7786.MCR-08-0008; Matos P, 2013, NEOPLASIA, V15, P102, DOI 10.1593/neo.121890; Mehner Christine, 2015, Genes Cancer, V6, P480; Mori Yoshifumi, 2013, Small GTPases, V4, P9, DOI 10.4161/sgtp.23311; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Orlichenko L, 2010, J BIOL CHEM, V285, P19153, DOI 10.1074/jbc.M109.099382; Pethe VV, 2011, INT J ONCOL, V39, P805, DOI 10.3892/ijo.2011.1066; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rodriguez-Colman MJ, 2017, NATURE, V543, P424, DOI 10.1038/nature21673; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Silva AL, 2013, EUR J ENDOCRINOL, V168, P795, DOI 10.1530/EJE-12-0960; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; SOBHANI I, 1993, GASTROENTEROLOGY, V105, P22; Stallings-Mann ML, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004062; Stappenbeck TS, 2000, DEVELOPMENT, V127, P2629; Ungefroren H, 2014, ONCOTARGET, V5, P277, DOI 10.18632/oncotarget.1696; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang F, 2017, CELL RES, V27, P540, DOI 10.1038/cr.2017.7; Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99	44	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6054	6068		10.1038/s41388-018-0389-7	http://dx.doi.org/10.1038/s41388-018-0389-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29985482	Green Submitted			2022-12-17	WOS:000450175900004
J	White, MC; Schroeder, RD; Zhu, K; Xiong, K; McConkey, DJ				White, Matthew C.; Schroeder, Rebecca D.; Zhu, Keyi; Xiong, Katherine; McConkey, David J.			HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells	ONCOGENE			English	Article							INITIATION-FACTOR 2; REGULATED EIF-2-ALPHA KINASE; PROTEASOME INHIBITION LEADS; UNFOLDED PROTEIN RESPONSE; MULTIPLE-MYELOMA CELLS; HEAT-SHOCK PROTEINS; EIF2-ALPHA KINASE; OXIDATIVE STRESS; PARKINSONS-DISEASE; ACTIVATION LOOP	Human cancer cells display extensive heterogeneity in their sensitivities to the proteasome inhibitor bortezomib (Velcade). The molecular mechanisms underlying this heterogeneity remain unclear, and strategies to overcome resistance are limited. Here, we discover that inherent differences in eIF2 alpha phosphorylation among a panel of ten human pancreatic cancer cell lines significantly impacts bortezomib sensitivity, and implicate the HRI (heme-regulated inhibitor) eIF2 alpha kinase as a novel therapeutic target. Within our panel, we identified a subset of cell lines with defective induction of eIF2 alpha phosphorylation, conferring a high degree of sensitivity to bortezomib. These bortezomib-sensitive cells exhibited impaired translation attenuation followed by toxic accumulation of protein aggregates and reactive oxygen species (ROS), whereas the bortezomib-resistant cell lines displayed increased phosphorylation of eIF2 alpha, decreased translation, few protein aggregates, and minimal ROS production. Importantly, we identified HRI as the primary bortezomib-activated eIF2 alpha kinase, and demonstrated that HRI knockdown promoted cell death in the bortezomib-resistant cells. Overall, our data implicate inducible HRI-mediated phosphorylation of eIF2 alpha as a central cytoprotective mechanism following exposure to bortezomib and provide proof-of-concept for the development of HRI inhibitors to overcome proteasome inhibitor resistance.	[White, Matthew C.; Zhu, Keyi; Xiong, Katherine; McConkey, David J.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [White, Matthew C.; Zhu, Keyi; Xiong, Katherine; McConkey, David J.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [White, Matthew C.; Schroeder, Rebecca D.; McConkey, David J.] Univ Texas Grad Sch Biomed Sci, Program Expt Therapeut, Houston, TX 77030 USA; [McConkey, David J.] Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD 21287 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Johns Hopkins University	McConkey, DJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA.; McConkey, DJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.; McConkey, DJ (corresponding author), Univ Texas Grad Sch Biomed Sci, Program Expt Therapeut, Houston, TX 77030 USA.; McConkey, DJ (corresponding author), Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD 21287 USA.	djmcconkey@jhmi.edu		Schroeder, Rebecca/0000-0002-7336-1857; Xiong, Katherine/0000-0002-1603-2037; White, Matthew/0000-0002-8274-0453	NIH/NCI [R01 CA127494]; M.D. Anderson Cancer Center Support Grant [P30 CA016672-38]; Albert Schweitzer Fellowship; Tzu-Chi Foundation; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA127494] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); M.D. Anderson Cancer Center Support Grant; Albert Schweitzer Fellowship; Tzu-Chi Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from NIH/NCI (R01 CA127494), and the M.D. Anderson Cancer Center Support Grant P30 CA016672-38 (D.J.M.). M.C.W. would like to acknowledge awards from The Albert Schweitzer Fellowship and the Tzu-Chi Foundation	Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Baird TD, 2012, ADV NUTR, V3, P307, DOI 10.3945/an.112.002113; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Bucciantini M, 2004, J BIOL CHEM, V279, P31374, DOI 10.1074/jbc.M400348200; Burwick N, 2017, LEUKEMIA RES, V55, P23, DOI 10.1016/j.leukres.2017.01.007; Bush KT, 1997, J BIOL CHEM, V272, P9086; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; Chen SQ, 2010, CANCER RES, V70, P4318, DOI 10.1158/0008-5472.CAN-09-4428; Fournier MJ, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-12; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Goldberg AL, 2000, NAT BIOTECHNOL, V18, P494, DOI 10.1038/75349; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; He Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024855; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Kane RC, 2007, CLIN CANCER RES, V13, P5291, DOI 10.1158/1078-0432.CCR-07-0871; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Knutsen JHJ, 2015, J CELL SCI, V128, P4420, DOI 10.1242/jcs.176545; Lee DH, 1998, MOL CELL BIOL, V18, P30, DOI 10.1128/MCB.18.1.30; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Mittal SPK, 2014, INT J BIOCHEM CELL B, V54, P186, DOI 10.1016/j.biocel.2014.07.016; Moreno JA, 2012, NATURE, V485, P507, DOI 10.1038/nature11058; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Rafie-Kolpin M, 2003, BIOCHEMISTRY-US, V42, P6536, DOI 10.1021/bi034005v; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Schewe DM, 2009, CANCER RES, V69, P1545, DOI 10.1158/0008-5472.CAN-08-3858; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Vilas-Boas FDS, 2016, J NEURO-ONCOL, V127, P253, DOI 10.1007/s11060-015-2043-3; Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Taniuchi S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32886; Uma S, 1999, MOL CELL BIOL, V19, P5861; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Wengrod J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0899; Weniger MA, 2011, CLIN CANCER RES, V17, P5101, DOI 10.1158/1078-0432.CCR-10-3367; WU DL, 2011, JOVE J VIS EXP NOV, P14220, DOI DOI 10.3791/3357; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Xu WP, 2011, CANCER CELL, V20, P281, DOI 10.1016/j.ccr.2011.08.020; Yefidoff-Freedman R, 2017, J MED CHEM, V60, P5392, DOI 10.1021/acs.jmedchem.7b00059; Yerlikaya A, 2008, BIOCHEM J, V412, P579, DOI 10.1042/BJ20080324; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343; Zhu KY, 2009, CANCER RES, V69, P1836, DOI 10.1158/0008-5472.CAN-08-4103	57	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4413	4427		10.1038/s41388-018-0227-y	http://dx.doi.org/10.1038/s41388-018-0227-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720726	Green Accepted			2022-12-17	WOS:000441144300006
J	Handler, J; Cullis, J; Avanzi, A; Vucic, EA; Bar-Sagi, D				Handler, Jesse; Cullis, Jane; Avanzi, Antonina; Vucic, Emily A.; Bar-Sagi, Dafna			Pre-neoplastic pancreas cells enter a partially mesenchymal state following transient TGF-beta exposure	ONCOGENE			English	Article							STEM-CELL; EXPRESSION; CANCER; ADENOCARCINOMA; GENERATION; TRANSDIFFERENTIATION; DISSEMINATION; ACTIVATION; PLASTICITY; PROMOTES	Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease and a major health problem in the United States. While the cytokine TGF-beta has been implicated in PDAC development, it can exert both pro-tumorigenic and anti-tumorigenic effects that are highly context dependent and incompletely understood. Using three-dimensional (3D) cultures of Kras(G12D)-expressing mouse pancreatic epithelial cells we demonstrated that while exposure to exogenous TGF-beta induced growth arrest of the Kras(G12D) cells, its subsequent removal allowed the cells to enter a hyper-proliferative, partially mesenchymal (PM), and progenitor-like state. This state was highly stable and was maintained by autocrine TGF-beta signaling. While untreated Kras(G12D) cells formed cystic lesions in vivo, PM cells formed ductal structures resembling human PanINs, suggesting that they had attained increased oncogenic potential. Supporting this hypothesis, we determined that the PM cells share salient molecular and phenotypic features with the quasi-mesenchymal/squamous subtype of human PDAC, which has the worst prognosis of any of the recently identified subtypes. Transient pulses of TGF-beta have been observed during pancreatitis, a major risk factor for PDAC. Our data suggest that transient TGF-beta exposure is sufficient to induce the acquisition of stable PDAC-associated phenotypes in pre-neoplastic Kras(G12D) cells, providing novel molecular insight into the complex role of TGF-beta in tumorigenesis.	[Handler, Jesse; Cullis, Jane; Avanzi, Antonina; Vucic, Emily A.; Bar-Sagi, Dafna] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA	New York University	Bar-Sagi, D (corresponding author), NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.	dafna.bar-sagi@nyumc.org		Bar-Sagi, Dafna/0000-0003-2597-8948; Handler, Jesse/0000-0001-5444-3905	Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center [P30CA016087]; NIH/NCI grant [CA210263]; NIH [T32GM007308, 5-T32 CA 009161-39, 5-T32AI100853-04]; Canadian Institutes of Health Research postdoctoral fellowship [146792]; NATIONAL CANCER INSTITUTE [R35CA210263, T32CA009161, P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI100853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER	Cancer Center Support Grant at the Laura and Isaac Perlmutter Cancer Center; NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Institutes of Health Research postdoctoral fellowship(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank L.J. Taylor for discussions and help with article preparation and the members of the Bar-Sagi laboratory for comments. The authors also thank the New York University School of Medicine Genome Technology Center (GTC), especially Adriana Heguy and Igor Dolgalev, for help designing, performing, and analyzing RNA sequencing experiments. The GTC is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center. This work was further supported by NIH/NCI grant CA210263 (D. Bar-Sagi). J. Handler was supported by NIH grant T32GM007308. J. Cullis was supported by NIH grants 5-T32 CA 009161-39 and 5-T32AI100853-04. E.A. Vucic is supported by a Canadian Institutes of Health Research postdoctoral fellowship (146792).	American Cancer Society, 2017, CANC FACTS FIG 2017; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Cullis J, 2017, CANCER IMMUNOL RES, V5, P182, DOI 10.1158/2326-6066.CIR-16-0125; Desgrosellier JS, 2014, DEV CELL, V30, P295, DOI 10.1016/j.devcel.2014.06.005; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ellenrieder V, 2001, CANCER RES, V61, P4222; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Goonesekere NCW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093046; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Handra-Luca A, 2011, BRIT J CANCER, V104, P1296, DOI 10.1038/bjc.2011.93; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hezel AF, 2012, CANCER RES, V72, P4840, DOI 10.1158/0008-5472.CAN-12-0634; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lancaster MA, 2014, NAT PROTOC, V9, P2329, DOI 10.1038/nprot.2014.158; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Malka D, 2002, GUT, V51, P849, DOI 10.1136/gut.51.6.849; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Principe DR, 2016, CANCER RES, V76, P2525, DOI 10.1158/0008-5472.CAN-15-1293; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Riesle E, 1997, GUT, V40, P73, DOI 10.1136/gut.40.1.73; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sadler TW., 2015, LANGMANS MEDICAL EMB, V13; Sawyer JS, 2003, J MED CHEM, V46, P3953, DOI 10.1021/jm0205705; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takadate T, 2013, INT J CANCER, V132, P1368, DOI 10.1002/ijc.27797; Whittle MC, 2015, CELL, V161, P1345, DOI 10.1016/j.cell.2015.04.048; Wilentz RE, 2000, CANCER RES, V60, P2002; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744	44	12	12	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4334	4342		10.1038/s41388-018-0264-6	http://dx.doi.org/10.1038/s41388-018-0264-6			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713060	Green Accepted			2022-12-17	WOS:000440566100010
J	Lee, HK; Lee, EW; Seo, J; Jeong, M; Lee, SH; Kim, SY; Jho, EH; Choi, CH; Chung, JY; Song, J				Lee, Hae-Kyung; Lee, Eun-Woo; Seo, Jinho; Jeong, Manhyung; Lee, Seon-Hyeong; Kim, Soo-Youl; Jho, Eek-Hoon; Choi, Chel Hun; Chung, Joon-Yong; Song, Jaewhan			Ubiquitylation and degradation of adenomatous polyposis coli by MKRN1 enhances Wnt/beta-catenin signaling	ONCOGENE			English	Article							TUMOR-SUPPRESSOR APC; BETA-CATENIN; WNT PATHWAY; COLORECTAL-CANCER; PLASMA-MEMBRANE; WILMS-TUMOR; GENE; AXIN; PHOSPHORYLATION; UBIQUITIN	The adenomatous polyposis coli (APC) protein has a tumor-suppressor function by acting as a negative regulator of the Wnt signaling pathway. While its role as a tumor suppressor is well-defined, the post-translational modifications that regulate APC stability are not fully understood. Here we showed that MKRN1, an E3 ligase, could directly interact with and ubiquitylate APC, promoting its proteasomal degradation. In contrast, an E3 ligase-defective MKRN1 mutant was no longer capable of regulating APC, indicating that its E3 ligase activity is required for APC regulation by MKRN1. Strengthening these results, MKRN1 ablation resulted in reduced beta-catenin activity and decreased expression of Wnt target genes. The ability of the Wnt-dependent pathway to induce cancer cell proliferation, migration, and invasion was impaired by MKRN1 depletion, but restored by simultaneous APC knockdown. Taken together, these results demonstrate that MKRN1 functions as a novel E3 ligase of APC that positively regulates Wnt/beta-catenin-mediated biological processes.	[Lee, Hae-Kyung; Seo, Jinho; Jeong, Manhyung; Song, Jaewhan] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, 50 Yonsei Ro, Seoul 03722, South Korea; [Lee, Eun-Woo] KRIBB, Metab Regulat Res Ctr, Daejeon 34141, South Korea; [Lee, Seon-Hyeong; Kim, Soo-Youl] Natl Canc Ctr, Div Canc Biol, Tumor Microenvironm Res Branch, Goyang 10408, Gyeonggi Do, South Korea; [Jho, Eek-Hoon] Univ Seoul, Dept Life Sci, 90 Jeonnong Dong, Seoul 02592, South Korea; [Choi, Chel Hun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Obstet & Gynecol, Seoul 135710, South Korea; [Chung, Joon-Yong] NCI, Expt Pathol Lab, Lab Pathol, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	Yonsei University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Cancer Center - Korea (NCC); University of Seoul; Sungkyunkwan University (SKKU); Samsung Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Song, J (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, 50 Yonsei Ro, Seoul 03722, South Korea.	jso678@yonsei.ac.kr	Chung, Joon-Yong/J-9177-2017; Lee, Eun-Woo/AAP-9603-2020	Chung, Joon-Yong/0000-0001-5041-5982; Jho, Eek-hoon/0000-0003-2414-6234; Lee, Hae-Kyung/0000-0001-6076-481X; Song, Jaewhan/0000-0001-8152-9210; Lee, Eun-Woo/0000-0002-5156-0003	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2015R1A3A2066581]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning	We thank Prof. KY Choi (Yonsei University) for providing L929, L929-hWnt3a, and HEK293-TOP-FLASH stable cell lines. This research was supported by a grant from the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning (NRF-2015R1A3A2066581) to J Song.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bastakoty D, 2016, FASEB J, V30, P3271, DOI 10.1096/fj.201600502R; Berndt JD, 2013, SCIENCE, V339, P1388, DOI 10.1126/science.1236641; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blagodatski Artem, 2014, Mol Cell Ther, V2, P28, DOI 10.1186/2052-8426-2-28; Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x; Cassar PA, 2015, EMBO REP, V16, P1334, DOI 10.15252/embr.201540974; Choi J, 2004, J BIOL CHEM, V279, P49188, DOI 10.1074/jbc.M404655200; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Grohmann A, 2007, J CELL SCI, V120, P3738, DOI 10.1242/jcs.011320; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Tran H, 2013, J BIOL CHEM, V288, P3753, DOI 10.1074/jbc.M112.415240; Tran H, 2012, J BIOL CHEM, V287, P28552, DOI 10.1074/jbc.M112.387878; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Karin M, 2016, NATURE, V529, P307, DOI 10.1038/nature17039; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kim JH, 2014, CELL DEATH DIFFER, V21, P594, DOI 10.1038/cdd.2013.181; Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405; Kim W, 2013, ONCOGENE, V32, P3390, DOI 10.1038/onc.2012.373; Kim W, 2013, BIOCHEM J, V450, P9, DOI 10.1042/BJ20121284; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Ko A, 2012, JNCI-J NATL CANCER I, V104, P1660, DOI 10.1093/jnci/djs424; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Lee EW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1981; Lee EW, 2009, EMBO J, V28, P2100, DOI 10.1038/emboj.2009.164; Lee MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8769; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morishita EC, 2011, STRUCTURE, V19, P1496, DOI 10.1016/j.str.2011.07.013; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 2015, NATURE, V519, P163, DOI 10.1038/nature14208; Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Polakis P, 2012, EMBO J, V31, P2737, DOI 10.1038/emboj.2012.126; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Saito-Diaz K, 2013, GROWTH FACTORS, V31, P1, DOI 10.3109/08977194.2012.752737; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Tauriello DVF, 2010, CELL CYCLE, V9, P3700, DOI 10.4161/cc.9.18.13204; Tong J, 2013, STRUCTURE, V21, P1203, DOI 10.1016/j.str.2013.05.007; Tran H, 2008, GENE DEV, V22, P528, DOI 10.1101/gad.463208; Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Zhang ZY, 2012, CELL RES, V22, P372, DOI 10.1038/cr.2011.119; Zimmerman ZF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008086	68	12	13	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4273	4286		10.1038/s41388-018-0267-3	http://dx.doi.org/10.1038/s41388-018-0267-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713058				2022-12-17	WOS:000440566100006
J	Gluck, AA; Orlando, E; Leiser, D; Poliakova, M; Nisa, L; Quintin, A; Gavini, J; Stroka, DM; Berezowska, S; Bubendorf, L; Blaukat, A; Aebersold, DM; Medova, M; Zimmer, Y				Glueck, Astrid A.; Orlando, Eleonora; Leiser, Dominic; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Gavini, Jacopo; Stroka, Deborah M.; Berezowska, Sabina; Bubendorf, Lukas; Blaukat, Andree; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak			Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1 alpha levels under hypoxia	ONCOGENE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; INDUCIBLE FACTOR-I; TYROSINE KINASE; MESSENGER-RNA; CANCER-CELLS; C-MET; TRANSCRIPTIONAL ACTIVATION; INVASIVE GROWTH; DNA-DAMAGE; EXPRESSION	Poor oxygenation is a common hallmark of solid cancers that strongly associates with aggressive tumor progression and treatment resistance. While a hypoxia-inducible factor 1 alpha (HIF-1 alpha)-associated transcriptional overexpression of the hepatocyte growth factor (HGF) receptor tyrosine kinase (RTK) MET has been previously documented, any regulation of the HIF-1a system through MET downstream signaling in hypoxic tumors has not been yet described. By using MET-driven in vitro as well as ex vivo tumor organotypic fresh tissue models we report that MET targeting results in depletion of HIF-1 alpha and its various downstream targets. Mechanistically, we provide evidence that MET regulates HIF-1 alpha levels through a protein translation mechanism that relies on phosphorylation modulation of the eukaryotic initiation factor 4G1 (eIF4G1) on serine 1232 (Ser-1232). Targeted phosphoproteomics data demonstrate a significant drop in eIF4G1 Ser-1232 phosphorylation following MET targeting, which is linked to an increased affinity between eIF4G1 and eIF4E. Since phosphorylation of eIF4G1 on Ser-1232 is largely mediated through mitogen-activated protein kinase (MAPK), we show that expression of a constitutively active K-RAS variant is sufficient to abrogate the inhibitory effect of MET targeting on the HIF-1 alpha pathway with subsequent resistance of tumor cells to MET targeting under hypoxic conditions. Analysis of The Cancer Genome Atlas data demonstrates frequent co-expression of MET, HIF-1 alpha and eIF4G1 in various solid tumors and its impact on disease-free survival of non-small cell lung cancer patients. Clinical relevance of the MET-eIF4G1-HIF-1 alpha pathway is further supported by a co-occurrence of their expression in common tumor regions of individual lung cancer patients.	[Glueck, Astrid A.; Orlando, Eleonora; Leiser, Dominic; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak] Bern Univ Hosp, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland; [Glueck, Astrid A.; Orlando, Eleonora; Leiser, Dominic; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak] Univ Bern, CH-3010 Bern, Switzerland; [Glueck, Astrid A.; Orlando, Eleonora; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak] Bern Univ Hosp, Radiat Oncol, Inselspital, Dept BioMed Res, CH-3008 Bern, Switzerland; [Glueck, Astrid A.; Orlando, Eleonora; Poliakova, Michaela; Nisa, Lluis; Quintin, Aurelie; Gavini, Jacopo; Stroka, Deborah M.; Aebersold, Daniel M.; Medova, Michaela; Zimmer, Yitzhak] Univ Bern, CH-3008 Bern, Switzerland; [Gavini, Jacopo; Stroka, Deborah M.] Bern Univ Hosp, Inselspital, Dept BioMed Res Visceral & Transplantat Surg, CH-3008 Bern, Switzerland; [Berezowska, Sabina] Univ Bern, Inst Pathol, CH-3008 Bern, Switzerland; [Bubendorf, Lukas] Basel Univ Hosp, Inst Pathol, CH-4031 Basel, Switzerland; [Blaukat, Andree] Merck KGaA, Global Res & Dev, D-64293 Darmstadt, Germany	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Bern; University of Basel; Merck KGaA	Zimmer, Y (corresponding author), Bern Univ Hosp, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland.; Zimmer, Y (corresponding author), Univ Bern, CH-3010 Bern, Switzerland.; Zimmer, Y (corresponding author), Bern Univ Hosp, Radiat Oncol, Inselspital, Dept BioMed Res, CH-3008 Bern, Switzerland.; Zimmer, Y (corresponding author), Univ Bern, CH-3008 Bern, Switzerland.	yitzhak.zimmer@insel.ch	Aebersold, Daniel Matthias/C-2946-2013; Bubendorf, Lukas/G-5299-2015; Berezowska, Sabina/AAJ-4557-2021	Aebersold, Daniel Matthias/0000-0002-9493-3834; Bubendorf, Lukas/0000-0001-5970-1803; Berezowska, Sabina/0000-0001-5442-9791; Medova, Michaela/0000-0003-0649-469X; Stroka, Deborah/0000-0002-3517-3871	Stiftung fur klinischexperimentelle Tumorforschung; Stiftung zur Krebsbekampfung [374/2016]	Stiftung fur klinischexperimentelle Tumorforschung; Stiftung zur Krebsbekampfung	This work has been supported by Stiftung fur klinischexperimentelle Tumorforschung (grant to YZ) and by Stiftung zur Krebsbekampfung (grant Nr. 374/2016 to MM). YZ received a drug donation from Merck / EMD Serono. Merck / EMD Serono has reviewed the publication, and the views and opinions described in the publication do not necessarily reflect those of Merck.	Badura M, 2012, P NATL ACAD SCI USA, V109, P18767, DOI 10.1073/pnas.1203853109; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berezowska S, 2017, VIRCHOWS ARCH, V470, P323, DOI 10.1007/s00428-016-2057-z; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Boeckx Carolien, 2015, BMC Res Notes, V8, P203, DOI 10.1186/s13104-015-1197-6; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Cheng JC, 2013, CANCER LETT, V329, P197, DOI 10.1016/j.canlet.2012.10.029; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Clara CA, 2014, NEUROPATHOLOGY, V34, P343, DOI 10.1111/neup.12111; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798; Dobrikov MI, 2013, MOL CELL BIOL, V33, P937, DOI 10.1128/MCB.01441-12; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Francica P, 2016, CLIN CANCER RES, V22, P5322, DOI 10.1158/1078-0432.CCR-15-2987; Fuhrer T, 2011, ANAL CHEM, V83, P7074, DOI 10.1021/ac201267k; Gariboldi MB, 2010, BIOCHEM PHARMACOL, V80, P455, DOI 10.1016/j.bcp.2010.05.011; Gluck AA, 2015, INT J BIOCHEM CELL B, V62, P101, DOI 10.1016/j.biocel.2015.02.018; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Ide T, 2006, INT J CANCER, V119, P2750, DOI 10.1002/ijc.22178; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Leiser D, 2015, MOL ONCOL, V9, P1434, DOI 10.1016/j.molonc.2015.04.001; Liu XD, 2008, EXPERT OPIN INV DRUG, V17, P997, DOI [10.1517/13543784.17.7.997, 10.1517/13543784.17.7.997 ]; Medova M, 2013, MOL CANCER THER, V12, P2415, DOI 10.1158/1535-7163.MCT-13-0151; Michieli P, 2009, CELL CYCLE, V8, P3291, DOI 10.4161/cc.8.20.9741; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Minchenko OH, 2014, WORLD J GASTROENTERO, V20, P13705, DOI 10.3748/wjg.v20.i38.13705; Neill T, 2012, J BIOL CHEM, V287, P5492, DOI 10.1074/jbc.M111.283499; Obach M, 2004, J BIOL CHEM, V279, P53562, DOI 10.1074/jbc.M406096200; Okuda K, 2008, CANCER SCI, V99, P2280, DOI 10.1111/j.1349-7006.2008.00916.x; Paatero I, 2014, J BIOL CHEM, V289, P22459, DOI 10.1074/jbc.M113.533497; Paatero I, 2012, J BIOL CHEM, V287, P9659, DOI 10.1074/jbc.M111.299537; Pelletier J, 2015, CANCER RES, V75, P250, DOI 10.1158/0008-5472.CAN-14-2789; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Seiwert TY, 2009, CANCER RES, V69, P3021, DOI 10.1158/0008-5472.CAN-08-2881; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Skuli N, 2006, CANCER RES, V66, P482, DOI 10.1158/0008-5472.CAN-05-2299; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Takacova M, 2014, AM J PATHOL, V184, P953, DOI 10.1016/j.ajpath.2014.01.002; Tarun SZ, 1997, MOL CELL BIOL, V17, P6876, DOI 10.1128/MCB.17.12.6876; Thangasamy A, 2009, J BIOL CHEM, V284, P14001, DOI 10.1074/jbc.M809320200; Villa N, 2013, J BIOL CHEM, V288, P32932, DOI 10.1074/jbc.M113.517011; Vordermark D, 2016, CANCER RES, V198, P123; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049	50	12	12	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4181	4196		10.1038/s41388-018-0256-6	http://dx.doi.org/10.1038/s41388-018-0256-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29717265				2022-12-17	WOS:000439847000010
J	Newman, JH; Augeri, DJ; NeMoyer, R; Malhotra, J; Langenfeld, E; Chesson, CB; Dobias, NS; Lee, MJ; Tarabichi, S; Jhawar, SR; Bommareddy, PK; Marshall, S; Sadimin, ET; Kerrigan, JE; Goedken, M; Minerowicz, C; Jabbour, SK; Li, SG; Carayannopolous, MO; Zloza, A; Langenfeld, J				Newman, Jenna H.; Augeri, David J.; NeMoyer, Rachel; Malhotra, Jyoti; Langenfeld, Elaine; Chesson, Charles B.; Dobias, Natalie S.; Lee, Michael J.; Tarabichi, Saeed; Jhawar, Sachin R.; Bommareddy, Praveen K.; Marshall, Sh'Rae; Sadimin, Evita T.; Kerrigan, John E.; Goedken, Michael; Minerowicz, Christine; Jabbour, Salma K.; Li, Shengguo; Carayannopolous, Mary O.; Zloza, Andrew; Langenfeld, John			Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer	ONCOGENE			English	Article							IN-VIVO; APOPTOSIS PROTEIN; BMP; ACTIVATION; DEATH; EXPRESSION; GROWTH; RESPONSES; THERAPY; XIAP	BMP receptor inhibitors induce death of cancer cells through the downregulation of antiapoptotic proteins XIAP, pTAK1, and Id1-Id3. However, the current most potent BMP receptor inhibitor, DMH2, does not downregulate BMP signaling in vivo because of metabolic instability and poor pharmacokinetics. Here we identified the site of metabolic instability of DMH2 and designed a novel BMP receptor inhibitor, JL5. We show that JL5 has a greater volume of distribution and suppresses the expression of Id1 and pTak1 in tumor xenografts. Moreover, we demonstrate JL5-induced tumor cell death and tumor regression in xenograft mouse models without immune cells and humanized with adoptively transferred human immune cells. In humanized mice, JL5 additionally induces the infiltration of immune cells within the tumor microenvironment. Our studies show that the BMP signaling pathway is targetable in vivo and BMP receptor inhibitors can be developed as a therapeutic to treat cancer patients.	[Newman, Jenna H.; Chesson, Charles B.; Dobias, Natalie S.; Bommareddy, Praveen K.; Marshall, Sh'Rae; Li, Shengguo; Zloza, Andrew] Rutgers Canc Inst New Jersey, Sect Surg Oncol Res, Div Surg Oncol, New Brunswick, NJ 08903 USA; [Augeri, David J.] Rutgers State Univ, Off Translat Sci Mol Design & Synth, Piscataway, NJ 08854 USA; [NeMoyer, Rachel; Lee, Michael J.; Tarabichi, Saeed; Zloza, Andrew] Rutgers State Univ, Dept Surg, Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA; [Malhotra, Jyoti] Rutgers Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ 08903 USA; [Langenfeld, Elaine; Langenfeld, John] Rutgers Canc Inst New Jersey, Dept Surg, Div Surg Oncol & Thorac Surg, New Brunswick, NJ 08903 USA; [Jhawar, Sachin R.; Jabbour, Salma K.] Rutgers Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ 08903 USA; [Sadimin, Evita T.; Minerowicz, Christine; Carayannopolous, Mary O.] Rutgers Robert Wood Johnson Med Sch, Dept Pathol & Lab Sci, New Brunswick, NJ 08903 USA; [Kerrigan, John E.] Rutgers State Univ, Dept Bioinformat, Rutgers Biomed Hlth Sci, Piscataway, NJ 08854 USA; [Goedken, Michael] Rutgers State Univ, Off Translat Sci, Res Pathol Serv, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Zloza, A (corresponding author), Rutgers Canc Inst New Jersey, Sect Surg Oncol Res, Div Surg Oncol, New Brunswick, NJ 08903 USA.; Zloza, A (corresponding author), Rutgers State Univ, Dept Surg, Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.; Langenfeld, J (corresponding author), Rutgers Canc Inst New Jersey, Dept Surg, Div Surg Oncol & Thorac Surg, New Brunswick, NJ 08903 USA.	andrew.zloza@rutgers.edu; langenje@cinj.rutgers.edu	Jhawar, Sachin R/M-1587-2017; Bommareddy, Praveen/L-1173-2019	Jhawar, Sachin R/0000-0001-8604-4757; Bommareddy, Praveen/0000-0003-0089-8693; Kerrigan, John/0000-0001-6562-4533; Zloza, Andrew/0000-0001-8844-6493	NCI [P30CA72720]	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work utilized shared resources at Rutgers Cancer Institute of New Jersey, which are supported by NCI P30CA72720.	Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Augeri DJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0511-9; Balboni AL, 2013, CANCER RES, V73, P1020, DOI 10.1158/0008-5472.CAN-12-2862; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bobbio A, 2015, PHARMACOL RES, V99, P217, DOI 10.1016/j.phrs.2015.06.011; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clement JH, 2005, INT J ONCOL, V27, P401; Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052; de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Galban S, 2009, BIOCHEM J, V417, P765, DOI 10.1042/BJ20081677; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hahm E, 2017, NAT MED, V23, P100, DOI 10.1038/nm.4242; Hao JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090748; Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Kaufmann T, 2012, CELL DEATH DIFFER, V19, P42, DOI 10.1038/cdd.2011.121; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Kohlhapp FJ, 2016, CELL REP, V17, P957, DOI 10.1016/j.celrep.2016.09.068; Kohlhapp FJ, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0063-3; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kurooka H, 2012, BIOCHEM BIOPH RES CO, V420, P281, DOI 10.1016/j.bbrc.2012.02.150; Lai TH, 2008, PROSTATE, V68, P1341, DOI 10.1002/pros.20799; Langenfeld E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061256; Langenfeld EM, 2006, ONCOGENE, V25, P685, DOI 10.1038/sj.onc.1209110; Langenfeld EM, 2005, MOL CANCER RES, V3, P679, DOI 10.1158/1541-7786.MCR-05-0124; Langenfeld EM, 2005, ANN THORAC SURG, V80, P1028, DOI 10.1016/j.athoracsur.2005.03.094; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Le Page C, 2009, J OVARIAN RES, V2, DOI 10.1186/1757-2215-2-4; Liu ZP, 2009, BBA-MOL CELL RES, V1793, P1819, DOI 10.1016/j.bbamcr.2009.09.012; Lu R, 2014, AIDS RES HUM RETROV, V30, P677, DOI [10.1089/aid.2013.0289, 10.1089/AID.2013.0289]; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Martinez CG, 2011, IMMUNOL CELL BIOL, V89, P610, DOI 10.1038/icb.2010.135; Martinez VG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131453; Martinez VG, 2014, EUR J IMMUNOL, V44, P1031, DOI 10.1002/eji.201343693; Mihaly SR, 2014, CELL DEATH DIFFER, V21, P1667, DOI 10.1038/cdd.2014.123; Nguyen A, 2014, INT ORTHOP, V38, P2313, DOI 10.1007/s00264-014-2512-x; Nickel J, 2009, CYTOKINE GROWTH F R, V20, P367, DOI 10.1016/j.cytogfr.2009.10.022; Obexer P, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00197; Owens P, 2015, ONCOGENE, V34, P2437, DOI 10.1038/onc.2014.189; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Robson NC, 2014, CANCER RES, V74, P5019, DOI 10.1158/0008-5472.CAN-13-2845; Rothhammer T, 2005, CANCER RES, V65, P448; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sountoulidis A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041460; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Weaver M, 1999, DEVELOPMENT, V126, P4005; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Ye L, 2011, FRONT BIOSCI-LANDMRK, V16, P865, DOI 10.2741/3725; Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888; Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54; Zhang YG, 2015, AIDS RES HUM RETROV, V31, P774, DOI 10.1089/aid.2014.0341; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622; Zloza A, 2012, NAT MED, V18, P422, DOI 10.1038/nm.2683; Zon LI, 2005, NAT REV DRUG DISCOV, V4, P35, DOI 10.1038/nrd1606	58	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3672	3685		10.1038/s41388-018-0156-9	http://dx.doi.org/10.1038/s41388-018-0156-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622797				2022-12-17	WOS:000437975200005
J	Nicolae, CM; O'Connor, MJ; Constantin, D; Moldovan, GL				Nicolae, Claudia M.; O'Connor, Michael J.; Constantin, Daniel; Moldovan, George-Lucian			NF kappa B regulates p21 expression and controls DNA damage-induced leukemic differentiation	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; HL-60 CELLS; GENE; ACTIVATION; MUTATIONS; EVOLUTION; APOPTOSIS; SURVIVAL; DISEASE	DNA damage exposure is a major modifier of cell fate in both normal and cancer tissues. In response to DNA damage, myeloid leukemia cells activate a poorly understood terminal differentiation process. Here, we show that the NF kappa B pathway directly activates expression of the proliferation inhibitor p21 in response to DNA damage in myeloid leukemia cells. In order to understand the role of this unexpected regulatory event, we ablated the NF kappa B binding site we identified in the p21 promoter, using CRISPR/Cas9-mediated genome editing. We found that NF kappa B-mediated p21 activation controls DNA damage-induced myeloid differentiation. Our results uncover a p53-independent pathway for p21 activation involved in controlling hematopoietic cell fate.	[Nicolae, Claudia M.; O'Connor, Michael J.; Constantin, Daniel; Moldovan, George-Lucian] Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Moldovan, GL (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA.	glm29@psu.edu		George-Lucian, Moldovan/0000-0003-3825-149X; Nicolae, Claudia/0000-0003-4933-5496	Department of Defense [CA140303]; St. Baldrick Foundation	Department of Defense(United States Department of Defense); St. Baldrick Foundation	We would like to thank Wafik el-Deiry, Sinisa Dovat, David Claxton, Gregory Yochum, Sergei Grigoryev, James Broach, and the Penn State Flow Cytometry Core for materials, advice, and support. This work was supported by the Department of Defense (award CA140303) and the St. Baldrick Foundation.	Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; Bruserud O, 2000, Oncologist, V5, P454, DOI 10.1634/theoncologist.5-6-454; Cheung KJJ, 2009, BRIT J HAEMATOL, V146, P257, DOI 10.1111/j.1365-2141.2009.07739.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Figarola JL, 2012, INVEST NEW DRUG, V30, P1413, DOI 10.1007/s10637-011-9711-8; Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Grove CS, 2014, DIS MODEL MECH, V7, P941, DOI 10.1242/dmm.015974; Gupta D, 2014, CURR PROTOC IMMUNOL, V104; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hou HA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.59; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Lee S, 2001, P NATL ACAD SCI USA, V98, P3340, DOI 10.1073/pnas.051013798; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Melo Monica B, 2002, Hematology, V7, P13, DOI 10.1080/10245330290020090; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Price JG, 2015, NAT IMMUNOL, V16, P1060, DOI 10.1038/ni.3270; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Santos MA, 2014, NATURE, V514, P107, DOI 10.1038/nature13483; Sherman MH, 2011, TRENDS CELL BIOL, V21, P312, DOI 10.1016/j.tcb.2011.01.004; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Tilstra JS, 2011, AGING DIS, V2, P449; Wang JW, 2012, CELL, V148, P1001, DOI 10.1016/j.cell.2012.01.040; Watts JM, 2014, BLOOD REV, V28, P205, DOI 10.1016/j.blre.2014.07.001; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	30	12	14	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3647	3656		10.1038/s41388-018-0219-y	http://dx.doi.org/10.1038/s41388-018-0219-y			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29622796				2022-12-17	WOS:000437975200003
J	Jiang, YQ; Xu, ES; Zhang, J; Chen, MY; Flores, E; Chen, XB				Jiang, Yuqian; Xu, Enshun; Zhang, Jin; Chen, Mingyi; Flores, Elsa; Chen, Xinbin			The Rbm38-p63 feedback loop is critical for tumor suppression and longevity	ONCOGENE			English	Article							RNA-BINDING PROTEIN; P53 FAMILY; CELLULAR SENESCENCE; TARGET GENES; P63; CELLS; STABILITY; RNPC1; TAP63; MICE	The RNA-binding protein Rbm38 is a target of p63 tumor suppressor and can in-turn repress p63 expression via mRNA stability. Thus, Rbm38 and p63 form a negative feedback loop. To investigate the biological significance of the Rbm38-p63 loop in vivo, a cohort of WT, Rbm38(-/-), TAp63(+/-), and Rbm38(-/-); TAp63(+/-) mice were generated and monitored throughout their lifespan. While mice deficient in Rbm38 or TAp63 alone died mostly from spontaneous tumors, compound Rbm38(-/-); TAp63(+/-) mice had an extended lifespan along with reduced tumor incidence. We also found that loss-of-Rbm38 markedly decreased the percentage of liver steatosis in TAp63(+/)- mice. Moreover, we found that Rbm38 deficiency extends the lifespan of tumor-free TAp63(+/-) mice along with reduced expression of senescence-associated biomarkers. Consistent with this, Rbm38(-/-); TAp63(+/-) MEFs were resistant, whereas Rbm38(-/-) or TAp63(+/-) MEFs were prone, to cellular senescence. Importantly, we showed that the levels of inflammatory cytokines (IL17D and Tnfsf15) were significantly reduced by Rbm38 deficiency in senescence-resistant Rbm38(-/-); TAp63(+/-) mouse livers and MEFs. Together, our data suggest that Rbm38 and p63 function as intergenic suppressors in aging and tumorigenesis and that the Rbm38-p63 loop may be explored for enhancing longevity and cancer management.	[Jiang, Yuqian; Xu, Enshun; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA; [Chen, Mingyi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Flores, Elsa] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL USA	University of California System; University of California Davis; University of Texas System; University of Texas Southwestern Medical Center Dallas; H Lee Moffitt Cancer Center & Research Institute	Zhang, J; Chen, XB (corresponding author), Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA.	jinzhang@ucdavis.edu; xbchen@ucdavis.edu	jiang, yu/HGU-0029-2022	chen, xinbin/0000-0002-4582-6506	National Institutes of Health [CA195828]; NATIONAL CANCER INSTITUTE [R01CA195828] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by the National Institutes of Health (CA195828 to X.C.).	Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen XB, 2003, CANCER BIOL THER, V2, P55; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Gary RK, 2005, ANAL BIOCHEM, V343, P329, DOI 10.1016/j.ab.2005.06.003; Hall BM, 2016, AGING-US, V8, P1294, DOI 10.18632/aging.100991; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Hwang SY, 2004, ARTHRITIS RES THER, V6, pR120, DOI 10.1186/ar1038; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Meylan F, 2011, IMMUNOL REV, V244, P188, DOI 10.1111/j.1600-065X.2011.01068.x; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Pappu R, 2011, IMMUNOLOGY, V134, P8, DOI 10.1111/j.1365-2567.2011.03465.x; Porteiro B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15111; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Scoumanne A, 2011, NUCLEIC ACIDS RES, V39, P213, DOI 10.1093/nar/gkq778; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Wen L, 2003, J BIOL CHEM, V278, P39251, DOI 10.1074/jbc.M305833200; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang J, 2006, CELL DEATH DIFFER, V13, P2118, DOI 10.1038/sj.cdd.4401972; Zhang J, 2014, P NATL ACAD SCI USA, V111, P18637, DOI 10.1073/pnas.1415607112; Zhang J, 2011, GENE DEV, V25, P1528, DOI 10.1101/gad.2069311; Zhang J, 2010, P NATL ACAD SCI USA, V107, P9614, DOI 10.1073/pnas.0912594107	35	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2863	2872		10.1038/s41388-018-0176-5	http://dx.doi.org/10.1038/s41388-018-0176-5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29520104	Green Accepted, Green Submitted			2022-12-17	WOS:000432929800008
J	Knopfova, L; Biglieri, E; Volodko, N; Masarik, M; Hermanova, M; Garzon, JFG; Ducka, M; Kucirkova, T; Soucek, K; Smarda, J; Benes, P; Borsig, L				Knopfova, L.; Biglieri, E.; Volodko, N.; Masarik, M.; Hermanova, M.; Garzon, J. F. Glaus; Ducka, M.; Kucirkova, T.; Soucek, K.; Smarda, J.; Benes, P.; Borsig, L.			Transcription factor c-Myb inhibits breast cancer lung metastasis by suppression of tumor cell seeding	ONCOGENE			English	Article							INFLAMMATORY CHEMOKINES; GENE; CCL2; ESTROGEN; EXTRAVASATION; SURVIVAL; REVEALS; TARGET; GROWTH; BRAIN	Metastasis accounts for most of cancer-related deaths. Paracrine signaling between tumor cells and the stroma induces changes in the tumor microenvironment required for metastasis. Transcription factor c-Myb was associated with breast cancer (BC) progression but its role in metastasis remains unclear. Here we show that increased c-Myb expression in BC cells inhibits spontaneous lung metastasis through impaired tumor cell extravasation. On contrary, BC cells with increased lung metastatic capacity exhibited low c-Myb levels. We identified a specific inflammatory signature, including Ccl2 chemokine, that was expressed in lung metastatic cells but was suppressed in tumor cells with higher c-Myb levels. Tumor cell-derived Ccl2 expression facilitated lung metastasis and rescued trans-endothelial migration of c-Myb overexpressing cells. Clinical data show that the identified inflammatory signature, together with a MYB expression, predicts lung metastasis relapse in BC patients. These results demonstrate that the c-Myb-regulated transcriptional program in BCs results in a blunted inflammatory response and consequently suppresses lung metastasis.	[Knopfova, L.; Ducka, M.; Kucirkova, T.; Soucek, K.; Smarda, J.; Benes, P.] Masaryk Univ, Dept Expt Biol, Fac Sci, Brno, Czech Republic; [Knopfova, L.; Biglieri, E.; Garzon, J. F. Glaus; Benes, P.; Borsig, L.] Univ Zurich, Inst Physiol, Zurich, Switzerland; [Knopfova, L.; Biglieri, E.; Garzon, J. F. Glaus; Benes, P.; Borsig, L.] Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Knopfova, L.; Ducka, M.; Kucirkova, T.; Soucek, K.; Benes, P.] St Annes Univ Hosp, Ctr Biol & Cellular Engn, Int Clin Res Ctr, Brno, Czech Republic; [Volodko, N.] Danylo Galytsky Lviv Natl Med Univ, Dept Oncol & Med Radiol, Lvov, Ukraine; [Masarik, M.] Masaryk Univ, Dept Physiol, Fac Med, Brno, Czech Republic; [Masarik, M.] Masaryk Univ, Dept Pathol Physiol, Fac Med, Brno, Czech Republic; [Hermanova, M.] St Annes Univ Hosp, Dept Pathol Anat 1, Brno, Czech Republic; [Hermanova, M.] Masaryk Univ, Fac Med, Brno, Czech Republic; [Soucek, K.] Czech Acad Sci, Inst Biophys, Brno, Czech Republic	Masaryk University Brno; University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); St Anne's University Hospital Brno (FNUSA-ICRC); Danylo Halytsky Lviv National Medical University; Masaryk University Brno; Masaryk University Brno; St Anne's University Hospital Brno (FNUSA-ICRC); Masaryk University Brno; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Benes, P; Borsig, L (corresponding author), Univ Zurich, Zurich Ctr Integrat Human Physiol, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	pbenes@sci.muni.cz; lborsig@access.uzh.ch	Benes, Petr/K-6369-2016; Soucek, Karel/B-3621-2008; Masarik, Michal/D-9920-2012	Benes, Petr/0000-0002-8297-9675; Soucek, Karel/0000-0001-7283-8150; Masarik, Michal/0000-0003-1172-7195; Hermanova, Marketa/0000-0002-3889-0905; Knopfova, Lucia/0000-0003-4897-0404; Borsig, Lubor/0000-0003-2263-9545	SCOPES/SNF [IZ73Z0-152361]; Czech Science Foundation [17-08985Y]; National Program of Sustainability II [LQ1605-MEYS CR]; ICRC-ERA-HumanBridge [316345]; Grant Agency of Masaryk University [MUNI/0877/2016]; SNF [310030-152901]	SCOPES/SNF; Czech Science Foundation(Grant Agency of the Czech Republic); National Program of Sustainability II; ICRC-ERA-HumanBridge; Grant Agency of Masaryk University; SNF	This work was funded by SCOPES/SNF grant IZ73Z0-152361 (L Borsig, L Knopfova and N Volodko). Further by Czech Science Foundation grant 17-08985Y (L Knopfova), National Program of Sustainability II LQ1605-MEYS CR; and ICRC-ERA-HumanBridge/no. 316345 and by the MUNI/0877/2016 project of Grant Agency of Masaryk University. This work was also supported by the SNF grant #310030-152901 (L Borsig). We acknowledge the assistance of the Center for Microscopy and Image Analysis and the Functional Genomic Center at University of Zurich.	Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a; Bauer K, 2007, INT J CANCER, V121, P1910, DOI 10.1002/ijc.22879; Bengtsen M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133280; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Drabsch Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2614; Fang WB, 2016, ONCOTARGET, V7, P49349, DOI 10.18632/oncotarget.9885; Gonda TJ, 2008, EXPERT OPIN BIOL TH, V8, P713, DOI 10.1517/14712598.8.6.713 ; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gruvberger S, 2001, CANCER RES, V61, P5979; Gundem G, 2012, GENOME MED, V4, DOI 10.1186/gm327; Guo P, 2014, P NATL ACAD SCI USA, V111, P14710, DOI 10.1073/pnas.1408556111; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Hatakeyama M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1104-8; Hauselmann I, 2016, CANCER RES, V76, P5302, DOI 10.1158/0008-5472.CAN-16-0784; Hiratsuka S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2856; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hugo HJ, 2015, J MAMMARY GLAND BIOL, V20, P109, DOI 10.1007/s10911-015-9333-4; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Johnstone CN, 2015, DIS MODEL MECH, V8, P237, DOI 10.1242/dmm.017830; Jones SE, 2008, CLIN BREAST CANCER, V8, P224, DOI 10.3816/CBC.2008.n.025; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Knopfova L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-15; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Li YH, 2016, CANCER RES, V76, P3364, DOI 10.1158/0008-5472.CAN-15-2302; Liu LYD, 2014, COMPUT MATH METHOD M, V2014, DOI 10.1155/2014/813067; Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3; Maurice D, 2007, EMBO J, V26, P3629, DOI 10.1038/sj.emboj.7601801; Miao RY, 2011, CANCER RES, V71, P7029, DOI 10.1158/0008-5472.CAN-11-1015; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mucha DR, 2003, AM J PHYSIOL-HEART C, V284, pH994, DOI 10.1152/ajpheart.00862.2002; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Nicolau M, 2011, P NATL ACAD SCI USA, V108, P7265, DOI 10.1073/pnas.1102826108; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Pekarcikova L, 2016, CELL SIGNAL, V28, P924, DOI [10.1016/j.cellsig2016.04.007, 10.1016/j.cellsig.2016.04.007]; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Roberts TK, 2012, LAB INVEST, V92, P1213, DOI 10.1038/labinvest.2012.80; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sevenich L, 2014, NAT CELL BIOL, V16, P876, DOI 10.1038/ncb3011; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Srivastava SK, 2015, BRIT J CANCER, V113, P1694, DOI 10.1038/bjc.2015.400; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Thorner AR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013073; Tichy M, 2016, TUMOR BIOL, V37, P10723, DOI 10.1007/s13277-016-4956-7; Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023; Yoshimura T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058791; Zhao L, 2011, NUCLEIC ACIDS RES, V39, P4664, DOI 10.1093/nar/gkr024	52	12	12	6	31	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1020	1030		10.1038/onc.2017.392	http://dx.doi.org/10.1038/onc.2017.392			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084208	Green Accepted			2022-12-17	WOS:000425905700005
J	Rodriguez-Blanco, J; Pednekar, L; Penas, C; Li, B; Martin, V; Long, J; Lee, E; Weiss, WA; Rodriguez, C; Mehrdad, N; Nguyen, DM; Ayad, NG; Rai, P; Capobianco, AJ; Robbins, DJ				Rodriguez-Blanco, J.; Pednekar, L.; Penas, C.; Li, B.; Martin, V.; Long, J.; Lee, E.; Weiss, W. A.; Rodriguez, C.; Mehrdad, N.; Nguyen, D. M.; Ayad, N. G.; Rai, P.; Capobianco, A. J.; Robbins, D. J.			Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma	ONCOGENE			English	Article							BASAL-CELL CARCINOMA; HEDGEHOG PATHWAY INHIBITOR; SMALL-MOLECULE INHIBITORS; TUMOR-INITIATING CELLS; CANCER STEM-CELLS; NEVUS SYNDROME; MOUSE; IDENTIFICATION; VISMODEGIB; RESISTANCE	The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodegib-resistant reservoir of tumor-propagating cells. We isolated such tumor-propagating cells from a mouse model of SHH-subgroup MB and grew them as sphere cultures. These cultures were enriched for the MB progenitor marker SOX2 and formed tumors in vivo. Moreover, while their ability to self-renew was resistant to SHH inhibitors, as has been previously suggested, this self-renewal was instead WNT-dependent. We show here that loss of Trp53 activates canonical WNT signaling in these SOX2-enriched cultures. Importantly, a small molecule WNT inhibitor was able to reduce the propagation and growth of SHH-subgroup MB in vivo, in an ontarget manner, leading to increased survival. Our results imply that the tumor-propagating cells driving the growth of bulk SHH-dependent MB are themselves WNT dependent. Further, our data suggest combination therapy with WNT and SHH inhibitors as a therapeutic strategy in patients with SHH-subgroup MB, in order to decrease the tumor recurrence commonly observed in patients treated with vismodegib.	[Rodriguez-Blanco, J.; Pednekar, L.; Li, B.; Long, J.; Capobianco, A. J.; Robbins, D. J.] Univ Miami, Miller Sch Med, DeWitt Daughtry Family Dept Surg, Mol Oncol Program, 1600 NW 10th Ave, Miami, FL 33136 USA; [Penas, C.; Ayad, N. G.] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Ctr Therapeut Innovat, Miami, FL 33136 USA; [Martin, V.; Rodriguez, C.] Univ Oviedo, Morphol & Cell Biol Dept, Asturias, Spain; [Lee, E.] Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurobiol, San Francisco, CA 94143 USA; [Mehrdad, N.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Nguyen, D. M.] Univ Miami, Miller Sch Med, DeWitt Daughtry Family Dept Surg, Div Cardiothorac Surg, Miami, FL 33136 USA; [Nguyen, D. M.; Ayad, N. G.; Rai, P.; Capobianco, A. J.; Robbins, D. J.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Rai, P.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Oviedo; Vanderbilt University; University of California System; University of California San Francisco; University of Miami; University of Miami; University of Miami; University of Miami	Robbins, DJ (corresponding author), Univ Miami, Miller Sch Med, DeWitt Daughtry Family Dept Surg, Mol Oncol Program, 1600 NW 10th Ave, Miami, FL 33136 USA.	drobbins@miami.edu	MARTIN, VANESA/A-7312-2012; Long, Jun/S-2382-2019; Rodriguez, Jezabel/B-7613-2019; Rodríguez, Carmen/R-9541-2019; penas, clara/K-3480-2017	MARTIN, VANESA/0000-0001-6923-2529; Long, Jun/0000-0002-8229-9653; Rodriguez, Jezabel/0000-0003-1839-6181; Rodríguez, Carmen/0000-0002-3203-4753; penas, clara/0000-0003-0554-3832; Rai, Priyamvada/0000-0001-7822-7553; Weiss, William/0000-0003-2230-9132; Capobianco, Anthony/0000-0002-3706-6797	Alex Lemonade Stand Foundation [M1201547]; University of Miami Women's Cancer Association; B*Cured; Childhood Brain Tumor Foundation; FICYT [POST10-27]; Sylvester Cancer Center; NIH [R01GM081635, R01GM103926];  [1R21NS096502-01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM103926, R35GM122516, R01GM081635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS096502] Funding Source: NIH RePORTER	Alex Lemonade Stand Foundation; University of Miami Women's Cancer Association; B*Cured; Childhood Brain Tumor Foundation; FICYT; Sylvester Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Alex Lemonade Stand Foundation M1201547 (DJR), 1R21NS096502-01 (DJR), The University of Miami Women's Cancer Association (DJR), B*Cured 2016 (DJR), Childhood Brain Tumor Foundation (JR-B), FICYT POST10-27 (JR-B), funds from the Sylvester Cancer Center (DJR), NIH R01GM081635 (EL), and R01GM103926 (EL).	Ahlfeld J, 2013, CANCER RES, V73, P3796, DOI 10.1158/0008-5472.CAN-13-0238; Anne SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081769; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Atwood SX, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a013581; Azad N, 2011, CELL J, V13, P39; Boman BM, 2008, J CLIN ONCOL, V26, P2795, DOI 10.1200/JCO.2008.17.7436; Cha YH, 2012, CELL CYCLE, V11, P1273, DOI 10.4161/cc.19618; Corno D, 2012, CANCER DISCOV, V2, P554, DOI 10.1158/2159-8290.CD-11-0199; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; de la Roche M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1680; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Eguchi M, 2005, MED CHEM, V1, P467, DOI 10.2174/1573406054864098; Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008-5472.CAN-10-1028; Fan X, 2008, J CLIN ONCOL, V26, P2821, DOI 10.1200/JCO.2007.15.2264; Fei DL, 2010, CANCER RES, V70, P1981, DOI 10.1158/0008-5472.CAN-09-2898; Gandhirajan RK, 2010, NEOPLASIA, V12, P326, DOI 10.1593/neo.91972; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Gritti A, 1996, J NEUROSCI, V16, P1091; HEPPNER GH, 1984, CANCER RES, V44, P2259; Huang X, 2010, J VIS EXP, P2086; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kennedy MWL, 2011, BIOCHEM J, V435, P247, DOI 10.1042/BJ20101801; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Lange C, 2006, NEURODEGENER DIS, V3, P76, DOI 10.1159/000092097; Lee Hae Young, 2009, J Vis Exp, DOI 10.3791/990; Lewis SL, 2008, DEVELOPMENT, V135, P1791, DOI 10.1242/dev.018853; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Meani RE, 2014, AUSTRALAS J DERMATOL, V55, P218, DOI 10.1111/ajd.12196; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Northcott PA, 2012, EXPERT REV NEUROTHER, V12, P871, DOI [10.1586/ern.12.66, 10.1586/ERN.12.66]; Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47; Olson JM, 2014, CANCER CELL, V25, P267, DOI 10.1016/j.ccr.2014.03.003; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Poschl J, 2014, ACTA NEUROPATHOL, V127, P605, DOI 10.1007/s00401-014-1258-2; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Remke M, 2013, CURR OPIN ONCOL, V25, P674, DOI 10.1097/CCO.0000000000000008; Robinson GW, 2015, J CLIN ONCOL, V33, P2646, DOI 10.1200/JCO.2014.60.1591; Rodriguez-Blanco J, 2008, J NEUROCHEM, V107, P127, DOI 10.1111/j.1471-4159.2008.05588.x; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tabori U, 2010, J CLIN ONCOL, V28, P1345, DOI 10.1200/JCO.2009.23.5952; Tam WL, 2014, CANCER CELL, V26, P3, DOI 10.1016/j.ccr.2014.06.024; Tang JY, 2012, NEW ENGL J MED, V366, P2180, DOI 10.1056/NEJMoa1113538; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005; Voorneveld PW, 2015, BRIT J CANCER, V112, P122, DOI 10.1038/bjc.2014.560; Ward RJ, 2009, CANCER RES, V69, P4682, DOI 10.1158/0008-5472.CAN-09-0342; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; Wetmore C, 2001, CANCER RES, V61, P513; Wolfe CM, 2012, DERMATOL SURG, V38, P1863, DOI 10.1111/j.1524-4725.2012.02513.x; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Youssef KK, 2012, NAT CELL BIOL, V14, P1282, DOI 10.1038/ncb2628; Zhao XS, 2015, CANCER RES, V75, P3623, DOI 10.1158/0008-5472.CAN-14-2999-T; Zhukova N, 2013, J CLIN ONCOL, V31, P2927, DOI 10.1200/JCO.2012.48.5052; Zinke J, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0294-4	67	12	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6306	6314		10.1038/onc.2017.232	http://dx.doi.org/10.1038/onc.2017.232			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28714964	Green Accepted			2022-12-17	WOS:000414774800009
J	Zimmermannova, O; Doktorova, E; Stuchly, J; Kanderova, V; Kuzilkova, D; Strnad, H; Starkova, J; Alberich-Jorda, M; Falkenburg, JHF; Trka, J; Petrak, J; Zuna, J; Zaliova, M				Zimmermannova, O.; Doktorova, E.; Stuchly, J.; Kanderova, V.; Kuzilkova, D.; Strnad, H.; Starkova, J.; Alberich-Jorda, M.; Falkenburg, J. H. F.; Trka, J.; Petrak, J.; Zuna, J.; Zaliova, M.			An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; TEL-ABL; CYTOGENETIC CHARACTERIZATION; IMATINIB-MESYLATE; FUSION PROTEINS; BLAST CRISIS; REARRANGEMENT; PATIENT	Leukemias harboring the ETV6-ABL1 fusion represent a rare subset of hematological malignancies with unfavorable outcomes. The constitutively active chimeric Etv6-Abl1 tyrosine kinase can be specifically inhibited by tyrosine kinase inhibitors (TKIs). Although TKIs represent an important therapeutic tool, so far, the mechanism underlying the potential TKI resistance in ETV6-ABL1-positive malignancies has not been studied in detail. To address this issue, we established a TKI-resistant ETV6-ABL1-positive leukemic cell line through long-term exposure to imatinib. ETV6-ABL1-dependent mechanisms (including fusion gene/protein mutation, amplification, enhanced expression or phosphorylation) and increased TKI efflux were excluded as potential causes of resistance. We showed that TKI effectively inhibited the Etv6-Abl1 kinase activity in resistant cells, and using short hairpin RNA (shRNA)-mediated silencing, we confirmed that the resistant cells became independent from the ETV6-ABL1 oncogene. Through analysis of the genomic and proteomic profiles of resistant cells, we identified an acquired mutation in the GNB1 gene, K89M, as the most likely cause of the resistance. We showed that cells harboring mutated GNB1 were capable of restoring signaling through the phosphoinositide-3-kinase (PI3K)/Akt/mTOR and mitogen-activated protein kinase (MAPK) pathways, whose activation is inhibited by TKI. This alternative GNB1(K89M)-mediated pro-survival signaling rendered ETV6-ABL1-positive leukemic cells resistant to TKI therapy. The mechanism of TKI resistance is independent of the targeted chimeric kinase and thus is potentially relevant not only to ETV6-ABL1-positive leukemias but also to a wider spectrum of malignancies treated by kinase inhibitors.	[Zimmermannova, O.; Stuchly, J.; Kanderova, V.; Kuzilkova, D.; Starkova, J.; Alberich-Jorda, M.; Trka, J.; Zuna, J.; Zaliova, M.] CLIP Childhood Leukaemia Invest, Prague, Czech Republic; [Zimmermannova, O.; Stuchly, J.; Kanderova, V.; Kuzilkova, D.; Starkova, J.; Trka, J.; Zuna, J.; Zaliova, M.] Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, Prague, Czech Republic; [Doktorova, E.; Petrak, J.] Charles Univ Prague, BIOCEV, Fac Med 1, Vestec, Czech Republic; [Strnad, H.] Czech Acad Sci, Dept Genom & Bioinformat, Inst Mol Genet, Prague, Czech Republic; [Alberich-Jorda, M.] Czech Acad Sci, Lab Mol Hematooncol, Inst Mol Genet, Prague, Czech Republic; [Falkenburg, J. H. F.] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands; [Trka, J.; Zuna, J.; Zaliova, M.] Univ Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic	Charles University Prague; Charles University Prague; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Motol University Hospital	Zaliova, M (corresponding author), Univ Hosp Motol, V Uvalu 84, Prague 15006, Czech Republic.; Zaliova, M (corresponding author), Charles Univ Prague, Dept Paediat Haematol & Oncol, Fac Med 2, CLIP, V Uvalu 84, Prague 15006, Czech Republic.	marketa.zaliova@lfmotol.cuni.cz	Jorda, Meritxell Alberich/G-3137-2014; Trka, Jan/Y-4820-2019; Stuchly, jan/B-7608-2019; Petrak, Jiri/I-8950-2017; Zuna, Jan/ABA-4620-2021	Jorda, Meritxell Alberich/0000-0002-8093-641X; Stuchly, jan/0000-0003-1896-9533; Petrak, Jiri/0000-0002-8695-4803; Kanderova, Veronika/0000-0001-8513-1066; Kuzilkova, Daniela/0000-0001-8086-9790; Starkova, Julia/0000-0002-2269-5849; Zuna, Jan/0000-0002-0887-3709	Czech Ministry of Health [IGA MZ NT/13170-4]; Grant Agency of Charles University [GAUK 596912]; Czech Science Foundation [P302/12/G101, P304/12/2214]; NPU I [LO1604]; NPU II [LQ1604]; University Hospital Motol [00064203]; ERDF [CZ.1.05/1.1.00/02.0109 BIOCEV]; Ministry of Education, Youth and Sports of the Czech Republic [PRVOUK P24/LF1/3, SVV 260 374/2017]; Charles University [Primus/MED/28]	Czech Ministry of Health(Ministry of Health, Czech Republic); Grant Agency of Charles University; Czech Science Foundation(Grant Agency of the Czech Republic); NPU I; NPU II; University Hospital Motol; ERDF(European Commission); Ministry of Education, Youth and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Charles University	This study was supported by grants from the Czech Ministry of Health (IGA MZ NT/13170-4), the Grant Agency of Charles University (GAUK 596912), the Czech Science Foundation (no. P302/12/G101 and P304/12/2214), by NPU I (no. LO1604) and NPU II (no. LQ1604) and by the project for the conceptual development of research organization (00064203, University Hospital Motol). The authors also acknowledge the support from ERDF (CZ.1.05/1.1.00/02.0109 BIOCEV), from the Ministry of Education, Youth and Sports of the Czech Republic (PRVOUK P24/LF1/3 and SVV 260 374/2017) and from Charles University (Primus/MED/28).	Asari K, 2016, ANN M ABSTR BLOOD, V128, P3957; Baeumler J, 2008, CANCER GENET CYTOGEN, V185, P37, DOI 10.1016/j.cancergencyto.2008.05.001; Barbouti A, 2003, BRIT J HAEMATOL, V122, P85, DOI 10.1046/j.1365-2141.2003.04391.x; Bernt KM, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00054; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Constantino S, 2001, ONCOGENE, V20, P2080, DOI 10.1038/sj.onc.1204308; Eide CA, 2015, CURR HEMATOL MALIG R, V10, P158, DOI 10.1007/s11899-015-0248-3; Gambacorti-Passerini C, 2016, AM J HEMATOL, V91, P67, DOI 10.1002/ajh.24247; Gancheva K, 2013, MOL CYTOGENET, V6, DOI 10.1186/1755-8166-6-39; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Hannemann JR, 1998, BRIT J HAEMATOL, V102, P475, DOI 10.1046/j.1365-2141.1998.00803.x; Jones D, 2008, CANCER-AM CANCER SOC, V113, P985, DOI 10.1002/cncr.23666; Kawamata N, 2008, GENE CHROMOSOME CANC, V47, P919, DOI 10.1002/gcc.20593; Kelly JC, 2009, CANCER GENET CYTOGEN, V192, P36, DOI 10.1016/j.cancergencyto.2009.02.012; Kotrova M, 2016, BLOOD, V128, P2263, DOI 10.1182/blood-2016-07-725861; Liu YF, 2016, EBIOMEDICINE, V8, P173, DOI 10.1016/j.ebiom.2016.04.038; Malinge S, 2006, ONCOGENE, V25, P3589, DOI 10.1038/sj.onc.1209390; Malone A, 2010, BRIT J HAEMATOL, V151, P101, DOI 10.1111/j.1365-2141.2010.08323.x; Mozziconacci MJ, 2007, AM J HEMATOL, V82, P688, DOI 10.1002/ajh.20873; Nand R, 2009, LEUKEMIA RES, V33, P1144, DOI 10.1016/j.leukres.2009.03.011; O'Brien SG, 2002, BLOOD, V99, P3465, DOI 10.1182/blood.V99.9.3465; Okonechnikov K, 2016, BIOINFORMATICS, V32, P292, DOI 10.1093/bioinformatics/btv566; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; Okuda K, 1996, ONCOGENE, V13, P1147; Perna F, 2011, HAEMATOL-HEMATOL J, V96, P342, DOI 10.3324/haematol.2010.036673; Picard S, 2007, BLOOD, V109, P3496, DOI 10.1182/blood-2006-07-036012; Pospisilova J, 2013, INT J MOL MED, V31, P1273, DOI 10.3892/ijmm.2013.1302; Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088; Tirado CA, 2005, CANCER GENET CYTOGEN, V157, P74, DOI 10.1016/j.cancergencyto.2004.06.001; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Yamamoto K, 2014, ANN HEMATOL, V93, P1435, DOI 10.1007/s00277-013-1975-y; Yeung DT, 2015, LEUKEMIA, V29, P230, DOI 10.1038/leu.2014.256; Yoda A, 2015, NAT MED, V21, P71, DOI 10.1038/nm.3751; Zaliova M, 2016, HAEMATOLOGICA, V101, P1082, DOI 10.3324/haematol.2016.144345; Zuna J, 2010, GENE CHROMOSOME CANC, V49, P873, DOI 10.1002/gcc.20796	35	12	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5985	5994		10.1038/onc.2017.210	http://dx.doi.org/10.1038/onc.2017.210			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650474	Green Published, hybrid			2022-12-17	WOS:000413841400007
J	Li, Z; Xiong, Y				Li, Z.; Xiong, Y.			Cytoplasmic E3 ubiquitin ligase CUL9 controls cell proliferation, senescence, apoptosis and genome integrity through p53	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; 3M COMPLEX; IN-VIVO; PATHWAY; RESCUE; CANCER	CUL9 is a member of the cullin family of E3 ubiquitin ligases, and it localizes predominantly in the cytoplasm. Deletion of Cul9 in mice results in increased DNA damage, widespread aneuploidy, spontaneous tumor development, accelerated E mu-Myc-induced lymphomagenesis and susceptibility to carcinogenesis. CUL9 binds to p53 and causes cell apoptosis when ectopically expressed. Whether the function of CUL9 in maintaining genomic integrity and suppressing tumorigenesis is linked to p53 has not been genetically tested. Here we report that deletion of CUL9 in human cells results in attenuated p21 induction and impaired cellular response to DNA damage. We show that disruption of Cul9-p53 binding in mouse embryo fibroblasts (MEFs) by a knock-in mutation in Cul9 (Delta p53) increases S-phase cell population, accumulates DNA damage during DNA replication and decreases apoptosis to both endogenous and exogenous DNA-damaging agents. The extent of these alterations in Cul9(Delta p53) MEFs is indistinguishable to those seen in Cul9(-/-) MEFs and comparable to those seen in p53(-/-) MEFs. Deletion of CUL9 in p53 null cells does not lead to further increase of DNA damages. Both Cul9(-/-) and Cul9(Delta p53) MEFs proliferate faster and undergo spontaneous immortalization while retaining both Arf and p53. These results demonstrate that the functions of CUL9 in regulating cell proliferation and maintaining genomic integrity are mainly mediated by p53, and that CUL9 is a critical p53 activator.	[Li, Z.; Xiong, Y.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 22-012 Lineberger Canc Ctr,Campus Box 7295, Chapel Hill, NC 27599 USA; [Xiong, Y.] Univ North Carolina Chapel Hill, Dept Biochem & Biophys, 22-012 Lineberger Canc Ctr,Campus Box 7295, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Xiong, Y (corresponding author), Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 22-012 Lineberger Canc Ctr,Campus Box 7295, Chapel Hill, NC 27599 USA.; Xiong, Y (corresponding author), Univ North Carolina Chapel Hill, Dept Biochem & Biophys, 22-012 Lineberger Canc Ctr,Campus Box 7295, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu			National Institutes of Health [R01CA068377]; UNC Lineberger Comprehensive Cancer Center's University Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA068377] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNC Lineberger Comprehensive Cancer Center's University Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Hui Xiao Chao, Jeremy Purvis and Matthew Smith for reading the manuscript, Dale Ramsden for discussion throughout this study, and members of the Xiong Laboratory for helpful discussions and encouragement. This work was supported by National Institutes of Health (grant R01CA068377 to YX) and a Team Innovation Award by the UNC Lineberger Comprehensive Cancer Center's University Cancer Research Fund.	Andrews P, 2006, ONCOGENE, V25, P4534, DOI 10.1038/sj.onc.1209490; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Li ZJ, 2014, MOL CELL, V54, P805, DOI 10.1016/j.molcel.2014.03.046; LUNA RMD, 1995, NATURE, V378, P203; Marin I, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-267; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pei XH, 2011, CANCER RES, V71, P2969, DOI 10.1158/0008-5472.CAN-10-4300; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Sharpless NE, 2006, CELL BIOL, V1, P223; Stracquadanio G, 2016, NAT REV CANCER, V16, P251, DOI 10.1038/nrc.2016.15; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Yan J, 2014, MOL CELL, V54, P791, DOI 10.1016/j.molcel.2014.03.047	21	12	13	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5212	5218		10.1038/onc.2017.141	http://dx.doi.org/10.1038/onc.2017.141			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481879	Green Accepted, Green Submitted			2022-12-17	WOS:000409371100012
J	Dai, L; Lin, Z; Qiao, J; Chen, Y; Flemington, EK; Qin, Z				Dai, L.; Lin, Z.; Qiao, J.; Chen, Y.; Flemington, E. K.; Qin, Z.			Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma	ONCOGENE			English	Article							CELL-CYCLE ARREST; KAPOSIS-SARCOMA; DNA-SEQUENCES; HERPESVIRUS; IRON; CANCER; APOPTOSIS; AIDS; INHIBITORS; COMPONENT	Primary effusion lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely associated with one of oncogenic viruses infection, Kaposi's sarcoma-associated herpesvirus. PEL prognosis is poor and patients barely survive >6 months even following active chemotherapy interventions. There is therefore an urgent need to discover more effective targets for PEL management. We recently found that the ribonucleotide reductase (RR) subunit M2 is potentially regulated by the key oncogenic hepatocyte growth factor/c-MET pathway in PEL. In this study, we set to investigate the role of RR in PEL pathogenesis and to evaluate its potential as a therapeutic target. We report that the RR inhibitor 3-AP actively induces PEL cell cycle arrest through inhibiting the activity of the nuclear factor-kappa B pathway. Using a xenograft model, we found that 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) effectively suppresses PEL progression in immunodeficient mice. Transcriptome analysis of 3-AP-treated PEL cell lines reveals altered cellular genes, most of whose roles in PEL have not yet been reported. Taken together, we propose that RR and its signaling pathway may serve as novel actionable targets for PEL management.	[Dai, L.; Qiao, J.; Qin, Z.] Tongji Univ, Sch Med, Dept Pediat, East Hosp, Shanghai, Peoples R China; [Dai, L.; Qin, Z.] Tongji Univ, Sch Med, Res Ctr Translat Med, Shanghai, Peoples R China; [Dai, L.; Qin, Z.] Tongji Univ, Sch Med, East Hosp, Key Lab Arrhythmias, Shanghai, Peoples R China; [Dai, L.; Qin, Z.] Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Genet, 1700 Tulane Ave,Suite 902, New Orleans, LA 70112 USA; [Lin, Z.; Flemington, E. K.] Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Pathol, New Orleans, LA 70118 USA	Tongji University; Tongji University; Tongji University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Tulane University	Qin, Z (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Louisiana Canc Res Ctr, Dept Genet, 1700 Tulane Ave,Suite 902, New Orleans, LA 70112 USA.	zqin@lsuhsc.edu			DOD [CA140437]; Leukemia Research Foundation; Louisiana Clinical and Translational Science Center from NIH [U54GM104940]; NIH [AI101046, AI106676]; National Natural Science Foundation of China [81472547, 81672924, 81400164]; NATIONAL CANCER INSTITUTE [P01CA214091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI106676, R01AI101046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104940] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Leukemia Research Foundation; Louisiana Clinical and Translational Science Center from NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was partially supported by grants from a DOD Career Development Award (CA140437), the Leukemia Research Foundation, the Louisiana Clinical and Translational Science Center Pilot grants (U54GM104940 from NIH), NIH RO1s (AI101046 and AI106676), as well as awards from the National Natural Science Foundation of China (81472547, 81672924 and 81400164). Funding sources had no role in the study design, data collection/analysis, decision to publish and/or manuscript preparation.	Boulanger E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084; CAZZOLA M, 1990, BLOOD, V75, P1903; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen WG, 2010, J VIROL, V84, P3898, DOI 10.1128/JVI.01321-09; Chen YB, 2007, ONCOLOGIST, V12, P569, DOI 10.1634/theoncologist.12-5-569; Dai L, 2016, ONCOTARGET, V7, P3806, DOI 10.18632/oncotarget.6584; Dai L, 2015, BLOOD, V126, P2821, DOI 10.1182/blood-2015-07-658823; Dai L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090349; Defee MR, 2011, AM J CANCER RES, V1, P687; Falchook GS, 2015, SEMIN ONCOL, V42, P832, DOI 10.1053/j.seminoncol.2015.09.022; Fan HZ, 1998, CANCER RES, V58, P1650; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Flepisi BT, 2014, BIOMED PHARMACOTHER, V68, P665, DOI 10.1016/j.biopha.2014.04.010; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Gottwein E, 2010, J VIROL, V84, P5229, DOI 10.1128/JVI.00202-10; IWAKI T, 1995, BRAIN RES, V673, P47, DOI 10.1016/0006-8993(94)01393-V; LARSSON A, 1986, ANTIMICROB AGENTS CH, V30, P598, DOI 10.1128/AAC.30.4.598; LIU SQ, 1995, NAT MED, V1, P267, DOI 10.1038/nm0395-267; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; Qin Z, 2011, LEUKEMIA, V25, P1598, DOI 10.1038/leu.2011.144; Qin ZQ, 2014, MOL CANCER THER, V13, P154, DOI 10.1158/1535-7163.MCT-13-0466; Sarek G, 2013, ONCOGENE, V32, P1091, DOI 10.1038/onc.2012.118; Sasai K, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00247; Shao JM, 2005, BIOCHEM PHARMACOL, V69, P627, DOI 10.1016/j.bcp.2004.11.016; Simonart T, 2000, J INVEST DERMATOL, V115, P893, DOI 10.1046/j.1523-1747.2000.00119.x; Simonart T, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-1; Simonelli C, 2003, J CLIN ONCOL, V21, P3948, DOI 10.1200/JCO.2003.06.013; Stadler WM, 2008, CANCER CHEMOTH PHARM, V61, P689, DOI 10.1007/s00280-007-0524-6; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Weinberg ED, 1996, EUR J CANCER PREV, V5, P19, DOI 10.1097/00008469-199609001-00004; Yen Y, 2004, CANCER CHEMOTH PHARM, V54, P331, DOI 10.1007/s00280-004-0821-2; Zhou BS, 2013, CANCER RES, V73, P6484, DOI 10.1158/0008-5472.CAN-13-1094	33	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5068	5074		10.1038/onc.2017.122	http://dx.doi.org/10.1038/onc.2017.122			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28459467	Green Accepted			2022-12-17	WOS:000408768800011
J	Jain, A; Tripathi, R; Turpin, CP; Wang, C; Plattner, R				Jain, A.; Tripathi, R.; Turpin, C. P.; Wang, C.; Plattner, R.			Ab1 kinase regulation by BRAF/ERK and cooperation with Akt in melanoma	ONCOGENE			English	Article							C-ABL; METASTATIC MELANOMA; MALIGNANT-MELANOMA; MUTANT MELANOMA; FAMILY KINASES; MEK INHIBITION; RAF INHIBITORS; CANCER; RESISTANCE; INVASION	The melanoma incidence continues to increase, and the disease remains incurable for many due to its metastatic nature and high rate of therapeutic resistance. In particular, melanomas harboring BRAFV600E and PTEN mutations often are resistant to current therapies, including BRAF inhibitors (BRAFi) and immune checkpoint inhibitors. Abl kinases (Abl/Arg) are activated in melanomas and drive progression; however, their mechanism of activation has not been established. Here we elucidate a novel link between BRAF(V600E)/ERK signaling and Abl kinases. We demonstrate that BRAF(V600E)/ERK play a critical role in binding, phosphorylating and regulating Abl localization and Abl/Arg activation by Src family kinases. Importantly, Abl/Arg activation downstream of BRAFV600E has functional and biological significance, driving proliferation, invasion, as well as switch in epithelial-mesenchymal-transition transcription factor expression, which is known to be critical for melanoma cells to shift between differentiated and invasive states. Finally, we describe findings of high translational significance by demonstrating that Abl/Arg cooperate with PI3K/Akt/PTEN, a parallel pathway that is associated with intrinsic resistance to BRAFi and immunotherapy, as Abl/Arg and Akt inhibitors cooperate to prevent viability, cell cycle progression and in vivo growth of melanomas harboring mutant BRAF/PTEN. Thus, these data not only provide mechanistic insight into Abl/Arg regulation during melanoma development, but also pave the way for the development of new strategies for treating patients with melanomas harboring mutant BRAF/PTEN, which often are refractory to current therapies.	[Jain, A.; Tripathi, R.; Turpin, C. P.; Plattner, R.] Univ Kentucky, Sch Med, Dept Pharmacol & Nutr Sci, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Sch Med, Dept Biostat, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Sch Med, Markey Canc Ctr, Lexington, KY 40536 USA; [Plattner, R.] Univ Kentucky, Sch Med, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Plattner, R (corresponding author), Univ Kentucky, Sch Med, Pharmacol & Nutr Sci, 800 Rose St,Combs Res Bldg,Rm 209, Lexington, KY 40536 USA.	rplat2@uky.edu	Tripathi, Rakshamani/J-8450-2019	Tripathi, Rakshamani/0000-0001-9394-1173; Turpin, Courtney/0000-0001-6299-8062	Markey Cancer Center Flow Cytometry, Biospecimen and Tissue Procurement, and Biostatistics Shared Resources; Research Communication Office [P30CA177558]; NIH Grant [R01CA166499]; NATIONAL CANCER INSTITUTE [P30CA177558, R01CA166499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007778] Funding Source: NIH RePORTER	Markey Cancer Center Flow Cytometry, Biospecimen and Tissue Procurement, and Biostatistics Shared Resources; Research Communication Office; NIH Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the Markey Cancer Center Flow Cytometry, Biospecimen and Tissue Procurement, and Biostatistics Shared Resources and the Research Communication Office (P30CA177558). We thank Drs D'Orazio and Kyprianou for critically reading the manuscript. This work was supported by NIH Grant R01CA166499 to RP.	Aguissa-Toure AH, 2012, CELL MOL LIFE SCI, V69, P1475, DOI 10.1007/s00018-011-0878-0; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Tran A, 2012, EXPERT OPIN INV DRUG, V21, P861, DOI 10.1517/13543784.2012.679341; Anderson WF, 2009, CANCER, V115, P4176, DOI 10.1002/cncr.24481; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bondzi C, 2000, ONCOGENE, V19, P5030, DOI 10.1038/sj.onc.1203862; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Choi Y, 2009, J BIOL CHEM, V284, P29005, DOI 10.1074/jbc.M109.026633; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Fiore LS, 2014, ONCOGENE, V33, P4508, DOI 10.1038/onc.2013.399; Ganguly SS, 2012, ONCOGENE, V31, P1804, DOI 10.1038/onc.2011.361; Ganguly Sourik S, 2012, Genes Cancer, V3, P414, DOI 10.1177/1947601912458586; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Girotti MR, 2014, MOL ONCOL, V8, P1140, DOI 10.1016/j.molonc.2014.07.027; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Karimkhani C, 2014, AM J CLIN DERMATOL, V15, P323, DOI 10.1007/s40257-014-0083-7; King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554; Li BJ, 2002, J BIOL CHEM, V277, P28870, DOI 10.1074/jbc.M202388200; Li R, 2011, CURR BIOL, V21, P1534, DOI 10.1016/j.cub.2011.08.023; Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Menzies AM, 2012, CLIN CANCER RES, V18, P3242, DOI 10.1158/1078-0432.CCR-12-0052; Murray JC, 2014, CANCER IMMUNOL RES, V2, P1186, DOI 10.1158/2326-6066.CIR-14-0083; Nathanson KL, 2013, CLIN CANCER RES, V19, P4868, DOI 10.1158/1078-0432.CCR-13-0827; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573-2583.2004; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Poynter JN, 2006, MELANOMA RES, V16, P267, DOI 10.1097/01.cmr.0000222600.73179.f3; Qiang L, 2014, AUTOPHAGY, V10, P1864, DOI 10.4161/auto.32171; Queirolo P, 2015, CANCER TREAT REV, V41, P519, DOI 10.1016/j.ctrv.2015.04.010; Redondo P, 2004, J INVEST DERMATOL, V123, P1208, DOI 10.1111/j.0022-202X.2004.23496.x; Richard G, 2016, EMBO MOL MED, V8, P1143, DOI 10.15252/emmm.201505971; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Sims JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055509; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Vandamme N, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00352; Vultur A, 2014, ONCOGENE, V33, P1850, DOI 10.1038/onc.2013.131; Wang J, 2015, TRENDS CANCER, V1, P110, DOI 10.1016/j.trecan.2015.07.004; Weiss MB, 2014, MOL CANCER RES, V12, P1314, DOI 10.1158/1541-7786.MCR-14-0170; Wheler J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1029-z; Wilden SM, 2016, J DTSCH DERMATOL GES, V14, P685, DOI [10.1111/ddg.13012_g, 10.1111/ddg.13012]; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Zhang CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066108; Zhao FS, 2015, BIOSCI TRENDS, V9, P325, DOI 10.5582/bst.2015.01106	54	12	12	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4585	4596		10.1038/onc.2017.76	http://dx.doi.org/10.1038/onc.2017.76			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368422	Green Accepted			2022-12-17	WOS:000407246200006
J	Qi, Q; Kang, SS; Zhang, S; Pham, C; Fu, H; Brat, DJ; Ye, K				Qi, Q.; Kang, S. S.; Zhang, S.; Pham, C.; Fu, H.; Brat, D. J.; Ye, K.			Co-amplification of phosphoinositide 3-kinase enhancer A and cyclin-dependent kinase 4 triggers glioblastoma progression	ONCOGENE			English	Article							PIKE-A; GENE; GTPASE; MDM2; CDK4; AMPLIFICATION; INHIBITION; PATHWAYS; GRADE; P53	Glioblastoma (GBM) is the most common primary brain tumor and has a dismal prognosis. Amplification of chromosome 12q13-q15 (Cyclin-dependent kinase 4 (CDK4) amplicon) is frequently observed in numerous human cancers including GBM. Phosphoinositide 3-kinase enhancer (PIKE) is a group of GTP-binding proteins that belong to the subgroup of centaurin GTPase family, encoded by CENTG1 located in CDK4 amplicon. However, the pathological significance of CDK4 amplicon in GBM formation remains incompletely understood. In the current study, we show that co-expression of PIKE-A and CDK4 in TP53/ PTEN double knockout GBM mouse model additively shortens the latency of glioma onset and survival compared to overexpression of these genes alone. Consequently, p-mTOR, p-Akt and p-ERK pathways are highly upregulated in the brain tumors, in alignment with their oncogenic activities by CDK4 and PIKE-A stably transfected in GBM cell lines. Hence, our findings support that PIKE amplification or overexpression coordinately acts with CDK4 to drive GBM tumorigenesis.	[Qi, Q.; Kang, S. S.; Zhang, S.; Brat, D. J.; Ye, K.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 141,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA; [Qi, Q.; Pham, C.; Fu, H.] Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; [Qi, Q.; Pham, C.; Fu, H.] Emory Univ, Sch Med, Emory Chem Biol Discovery Ctr, Atlanta, GA 30322 USA; [Zhang, S.] Jinan Univ, Coll Pharm, Inst Tumor Pharmacol, Guangzhou, Guangdong, Peoples R China; [Fu, H.] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Ye, K.] Tongji Univ, Sch Med, Dept Regenerat Med, Translat Ctr Stem Cell Res,Tongji Hosp, Shanghai, Peoples R China	Emory University; Emory University; Emory University; Jinan University; Emory University; Tongji University	Ye, K (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 141,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			Federal funds from National Cancer Institute (NCI), National Institutes of Health (NIH), under the NCI Chemical Biology Consortium [HHSN261200800001E]; NIH grant [RO1 CA186918, U01 CA168449]; SBTF Foundation; National Natural Science Foundation of China [81672781]; Winship Cancer Institute of Emory University Cancer Center [P30-CA138292]; NATIONAL CANCER INSTITUTE [U01CA168449, R01CA186918, P30CA138292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [RF1AG051538] Funding Source: NIH RePORTER	Federal funds from National Cancer Institute (NCI), National Institutes of Health (NIH), under the NCI Chemical Biology Consortium; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SBTF Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Winship Cancer Institute of Emory University Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work has been funded in part with Federal funds from National Cancer Institute (NCI), National Institutes of Health (NIH), under the NCI Chemical Biology Consortium Contract HHSN261200800001E (HF; KY), NIH grant RO1 CA186918 (KY), U01 CA168449 (HF), SBTF Foundation (KY), National Natural Science Foundation of China (No. 81672781). We are thankful to Dr Suzanne J. Baker for the PTEN/P53 loxP/loxP mice and to the Winship Cancer Institute of Emory University Cancer Center Support Grant P30-CA138292.	Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Ahn JY, 2004, J BIOL CHEM, V279, P16441, DOI 10.1074/jbc.M312175200; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; Feng CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090388; Grzmil M, 2010, BBA-PROTEINS PROTEOM, V1804, P476, DOI 10.1016/j.bbapap.2009.10.018; He KY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003900; Ivanov AA, 2013, TRENDS PHARMACOL SCI, V34, P393, DOI 10.1016/j.tips.2013.04.007; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; LANG FF, 1994, ONCOGENE, V9, P949; Liu R, 2008, P NATL ACAD SCI USA, V105, P7570, DOI 10.1073/pnas.0712306105; Liu X, 2007, ONCOGENE, V26, P4918, DOI 10.1038/sj.onc.1210290; Ma ZN, 2016, ONCOTARGET, V7, P66558, DOI 10.18632/oncotarget.11684; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; Muranen T, 2016, CANCER RES, V76, P7168, DOI 10.1158/0008-5472.CAN-16-0155; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Network The Cancer Genome Atlas Research, 2013, Nature, V494, P506, DOI 10.1038/nature11903; Pathak P, 2016, BRAIN PATHOL; Proescholdt MA, 2012, NEURO-ONCOLOGY, V14, P1357, DOI 10.1093/neuonc/nos216; Qi Q, 2013, ONCOGENE, V32, P1030, DOI 10.1038/onc.2012.109; Reifenberger G, 1996, CANCER RES, V56, P5141; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Uras N, 2012, J OBSTET GYNAECOL, V32, P533, DOI 10.3109/01443615.2012.677875; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Wikman H, 2005, GENE CHROMOSOME CANC, V42, P193, DOI 10.1002/gcc.20122; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2004, J CELL SCI, V117, P155, DOI 10.1242/jcs.00924; Zhang S, 2016, CELL DEATH DIFFER, V23, P52, DOI 10.1038/cdd.2015.66; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106	32	12	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4562	4572		10.1038/onc.2017.67	http://dx.doi.org/10.1038/onc.2017.67			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368413	Green Accepted			2022-12-17	WOS:000407246200004
J	Cesarini, V; Guida, E; Todaro, F; Di Agostino, S; Tassinari, V; Nicolis, S; Favaro, R; Caporali, S; Lacal, PM; Botti, E; Costanzo, A; Rossi, P; Jannini, EA; Dolci, S				Cesarini, V.; Guida, E.; Todaro, F.; Di Agostino, S.; Tassinari, V.; Nicolis, S.; Favaro, R.; Caporali, S.; Lacal, P. M.; Botti, E.; Costanzo, A.; Rossi, P.; Jannini, E. A.; Dolci, S.			Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo	ONCOGENE			English	Article							CELL LUNG-CANCER; MALIGNANT-MELANOMA; SELF-RENEWAL; MOUSE MODEL; STEM; EXPRESSION; MAINTENANCE; ONCOGENE; GENE; PROGRESSION	Melanoma is a dangerous form of skin cancer derived from the malignant transformation of melanocytes. The transcription factor SOX2 is not expressed in melanocytes, however, it has been shown to be differentially expressed between benign nevi and malignant melanomas and to be essential for melanoma stem cell maintenance and expansion in vitro and in xenograft models. By using a mouse model in which BRaf(V600E) mutation cooperates with Pten loss to induce the development of metastatic melanoma, we investigated if Sox2 is required during the process of melanomagenesis, melanoma growth and metastasis and in the acquisition of resistance to BRAF inhibitors (BRAFi) treatments. We found that deletion of Sox2 specifically in Pten null and BRafV600E-expressing melanocytes did not prevent tumor formation and did not modify the temporal kinetics of melanoma occurrence compared to Sox2 wt mice. In addition, tumor growth was similar between Sox2 wt and Sox2 deleted (del) melanomas. By querying publicly available databases, we did not find statistically significant differences in SOX2 expression levels between benign nevi and melanomas, and analysis on two melanoma patient cohorts confirmed that Sox2 levels did not significantly change between primary and metastatic melanomas. Melanoma cell lines derived from both Sox2 genotypes showed a similar sensitivity to vemurafenib treatment and the same ability to develop vemurafenib resistance in long-term cultures. Development of vemurafenib resistance was not dependent on SOX2 expression also in human melanoma cell lines in vitro. Our findings exclude an oncogenic function for Sox2 during melanoma development and do not support a role for this transcription factor in the acquisition of resistance to BRAFi treatments.	[Cesarini, V.; Guida, E.; Todaro, F.; Tassinari, V.; Rossi, P.; Dolci, S.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy; [Di Agostino, S.] Regina Elena Natl Canc Inst IFO, Oncogenom & Epigenet Unit, Rome, Italy; [Nicolis, S.; Favaro, R.] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy; [Caporali, S.; Lacal, P. M.] Inst Dermopat Dell Immacolata IRCCS, Mol Oncol Lab, Rome, Italy; [Botti, E.; Jannini, E. A.] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy; [Costanzo, A.] Humanitas Univ, Dept Biomed, Milan, Italy	University of Rome Tor Vergata; IRCCS Istituti Fisioterapici Ospitalieri (IFO); University of Milano-Bicocca; University of Rome Tor Vergata; Humanitas University	Dolci, S (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.	dolci@uniroma2.it	Rossi, Pellegrino/AAA-7072-2019; Di Agostino, Silvia/H-1121-2018; Di Agostino, Silvia/S-8566-2019; Tassinari, Valentina/AAW-1649-2021; Costanzo, Antonio/GZG-2433-2022; Cesarini, Valeriana VC/K-5816-2016; Lacal, Pedro M/A-1481-2013	Di Agostino, Silvia/0000-0003-3730-1125; Tassinari, Valentina/0000-0003-2167-9414; Costanzo, Antonio/0000-0001-9697-2557; Cesarini, Valeriana VC/0000-0001-9323-1796; Lacal, Pedro M/0000-0003-1166-4593; todaro, federica/0000-0001-6544-193X; NICOLIS, SILVIA KIRSTEN/0000-0003-0378-3808; Guida, Eugenia/0000-0002-1690-3277; ROSSI, PELLEGRINO/0000-0003-4796-327X	Telethon; AIRC; AIRC [17585]; MIUR [2015XSNA83_006, 2015XCR88M]	Telethon(Fondazione Telethon); AIRC(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR))	We thank G Graziani for helpful criticisms and for sharing results with us and G Rossi for histology assistance. We wish to thank Genentek (San Francisco, CA, USA) for the supply of vemurafenib and GlaxoSmithKline (Brentford, UK) for the supply of dabrafenib. SN is supported by Telethon and AIRC grants. SC is recipient of a fellowship from AIRC (Investigator Grant Project 17585). This work has been supported by MIUR Grants 2015XSNA83_006 and 2015XCR88M.	Akasaka K, 2009, J INVEST DERMATOL, V129, P1516, DOI 10.1038/jid.2008.406; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Camilo V, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-753; Campolo F, 2013, STEM CELLS, V31, P1408, DOI 10.1002/stem.1392; Chen YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071140; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Girouard SD, 2012, LAB INVEST, V92, P362, DOI 10.1038/labinvest.2011.188; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Graziani G, 2015, BIOCHEM PHARMACOL, V95, P16, DOI 10.1016/j.bcp.2015.03.004; Hutz K, 2014, CARCINOGENESIS, V35, P942, DOI 10.1093/carcin/bgt410; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Irie N, 2015, CELL, V160, P253, DOI 10.1016/j.cell.2014.12.013; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Lacal PM, 2005, INT J ONCOL, V27, P1625; Laga AC, 2011, EXP DERMATOL, V20, P339, DOI 10.1111/j.1600-0625.2011.01247.x; Laga AC, 2010, AM J PATHOL, V176, P903, DOI 10.2353/ajpath.2010.090495; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lundberg IV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101957; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Otsubo T, 2008, BRIT J CANCER, V98, P824, DOI 10.1038/sj.bjc.6604193; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Sanchez-Laorden B, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004815; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Schaefer SM, ONCOGENE; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Toschi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095303; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wilbertz T, 2011, MODERN PATHOL, V24, P944, DOI 10.1038/modpathol.2011.49; Wood HB, 1999, MECH DEVELOP, V86, P197, DOI 10.1016/S0925-4773(99)00116-1	42	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4508	4515		10.1038/onc.2017.53	http://dx.doi.org/10.1038/onc.2017.53			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368402	Green Published			2022-12-17	WOS:000406806000012
J	Zhang, W; Ding, Y; Zhang, C; Lu, Q; Liu, Z; Coughlan, K; Okon, I; Zou, MH				Zhang, W.; Ding, Y.; Zhang, C.; Lu, Q.; Liu, Z.; Coughlan, K.; Okon, I.; Zou, M-H			Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor	ONCOGENE			English	Article							PEUTZ-JEGHERS-SYNDROME; FACTOR MESSENGER-RNA; MICROVASCULAR PERMEABILITY; SUPPRESSOR KINASE; SPLICE VARIANT; LKB1; VEGF; METABOLISM; EXPRESSION; INVASION	Liver kinase B1 (LKB1) is a serine/threonine protein kinase ubiquitously expressed in mammalian cells. It was first identified in PeutzJeghers syndrome as a tumor suppressor gene. Whether endothelial LKB1 regulates angiogenesis and tumor growth is unknown. In this study, we generated endothelial cell-specific LKB1- knockout (LKB1(endo-/-)) mice by crossbreeding vascular endothelialcadherin-Cre mice with LKB1(flox/flox) mice. Vascular endothelial growth factor (VEGF) level was highly co-stained in endothelial cells but not in macrophages in LKB1(endo-/-) mice. Consistently, LKB1(endo-/-) mouse tissues including the lung, skin, kidney and liver showed increased vascular permeability. Tumors implanted in LKB1(endo-/-) mice but not macrophage-specific LKB1- knockout mice grew faster and showed enhanced vascular permeability and increased angiogenesis as compared with those implanted in wildtype mice. Injection of VEGF-neutralizing antibody but not the isotype-matched control antibody decreased endothelial-cell angiogenesis and tumor growth in vivo. Furthermore, LKB1 deletion enhanced mouse retinal and cell angiogenesis, and knockdown of VEGF by small-interfering RNA decreased endothelial cell proliferation and migration. Re-expression of LKB1 or knockdown of VEGF receptor 2 decreased the overproliferation and -migration observed in LKB1(endo-/-) cells. Mechanistically, LKB1 could bind to the VEGF transcription factor, specificity protein 1 (Sp1), which then inhibited the binding of Sp1 to the VEGF promoter to reduce VEGF expression. Endothelial LKB1 may regulate endothelial angiogenesis and tumor growth by modulating Sp1-mediated VEGF expression.	[Zhang, W.; Zhang, C.; Zou, M-H] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, Jinan, Peoples R China; [Zhang, W.; Zhang, C.; Zou, M-H] Shandong Univ, Qilu Hosp, Key Lab Translat Cardiovasc Med, Chinese Minist Hlth,State & Shandong Prov Joint, Jinan, Peoples R China; [Ding, Y.; Lu, Q.; Liu, Z.; Okon, I.; Zou, M-H] Georgia State Univ, Ctr Mol & Translat Med, Atlanta, GA 30303 USA; [Coughlan, K.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Mol Med, Oklahoma City, OK USA	Shandong University; Shandong University; University System of Georgia; Georgia State University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zhang, W (corresponding author), Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, Jinan, Peoples R China.; Zhang, W (corresponding author), Shandong Univ, Qilu Hosp, Key Lab Translat Cardiovasc Med, Chinese Minist Hlth,State & Shandong Prov Joint, Jinan, Peoples R China.	zhangwencheng@sdu.edu.cn	Zhang, Wencheng/AAO-8445-2020		National Natural Science Foundation of China [81570393]; Natural Science Foundation of Shandong Province [ZR2015HM002]; Taishan Scholar Project of Shandong Province of China [tsqn20161066]; National Institute of Health [CA213022, HL080499, HL089920, HL110488, HL105157]; NATIONAL CANCER INSTITUTE [R01CA213022] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080499, R01HL132500, R01HL128014, R01HL110488, R01HL074399, R01HL105157, R01HL089920, R01HL079584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG047776] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Taishan Scholar Project of Shandong Province of China; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are grateful to Dr Lexi Ding who helped with the retinal angiogenesis experiments. This study was supported by grants from the National Natural Science Foundation of China (81570393 to WZ), the Natural Science Foundation of Shandong Province (ZR2015HM002 to WZ), the Taishan Scholar Project of Shandong Province of China (tsqn20161066 to WZ) and the National Institute of Health (CA213022, HL080499, HL089920, HL110488 and HL105157 to M-HZ).	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Denison FC, 2009, J BIOL CHEM, V284, P67, DOI 10.1074/jbc.M806153200; DVORAK HF, 1985, SCIENCE, V227, P1059, DOI 10.1126/science.3975602; Giardiello FM, 2006, CLIN GASTROENTEROL H, V4, P408, DOI 10.1016/j.cgh.2005.11.005; Greenberg Y, 2008, FASEB J, V22, P1597, DOI 10.1096/fj.07-9973com; JENSEN JS, 1995, ARTERIOSCL THROM VAS, V15, P1324, DOI 10.1161/01.ATV.15.9.1324; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liang X, 2014, INT J ONCOL, V44, P1989, DOI 10.3892/ijo.2014.2351; Liu ZY, 2015, J BIOL CHEM, V290, P2312, DOI 10.1074/jbc.M114.616441; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ollila S, 2011, J MOL CELL BIOL, V3, P330, DOI 10.1093/jmcb/mjr016; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Pal S, 2001, CANCER RES, V61, P6952; Pasula S, 2012, J CLIN INVEST, V122, P4424, DOI 10.1172/JCI64537; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Towler MC, 2008, BIOCHEM J, V416, P1, DOI 10.1042/BJ20081447; Uemura AK, 2006, EXP CELL RES, V312, P676, DOI 10.1016/j.yexcr.2005.10.030; Xie ZL, 2009, MOL CELL BIOL, V29, P3582, DOI 10.1128/MCB.01417-08; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Zhang WC, 2014, CIRCULATION, V129, P1428, DOI 10.1161/CIRCULATIONAHA.113.004146; Zhuang ZG, 2006, MOL CANCER RES, V4, P843, DOI 10.1158/1541-7786.MCR-06-0118	30	12	13	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4277	4287		10.1038/onc.2017.61	http://dx.doi.org/10.1038/onc.2017.61			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346429	Green Accepted			2022-12-17	WOS:000406360600005
J	Dart, AE; Worth, DC; Muir, G; Chandra, A; Morris, JD; McKee, C; Verrill, C; Bryant, RJ; Gordon-Weeks, PR				Dart, A. E.; Worth, D. C.; Muir, G.; Chandra, A.; Morris, J. D.; McKee, C.; Verrill, C.; Bryant, R. J.; Gordon-Weeks, P. R.			The drebrin/EB3 pathway drives invasive activity in prostate cancer	ONCOGENE			English	Article							BINDING PROTEIN DREBRIN; ACTIN-BINDING; F-ACTIN; TRANSENDOTHELIAL MIGRATION; MICROTUBULE DYNAMICS; CXCR4; GROWTH; BASAL; LOCALIZATION; METASTASIS	Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain-or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression.	[Dart, A. E.; Worth, D. C.; Gordon-Weeks, P. R.] Kings Coll London, MRC, Ctr Dev Neurobiol, New Hunts House,Guys Campus, London SE1 1UL, England; [Muir, G.] Kings Coll Hosp London, Urol, London, England; [Chandra, A.] St Thomas Hosp, Cellular Pathol, 2nd Floor North Wing, London, England; [Morris, J. D.] Kings Coll London, Div Canc Studies, New Hunts House,Guys Campus, London, England; [McKee, C.] Univ Oxford, Oxford Inst Radiat Oncol, Churchill Hosp, Oxford, England; [Verrill, C.; Bryant, R. J.] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford; University of Oxford	Gordon-Weeks, PR (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, New Hunts House,Guys Campus, London SE1 1UL, England.	phillip.gordon-weeks@kcl.ac.uk	Gordon-Weeks, Phillip R./C-5328-2009; Bryant, Richard John/HGA-6778-2022	Gordon-Weeks, Phillip R./0000-0002-4738-4246; Morris, Jonathan/0000-0002-3211-1798; Verrill, Clare/0000-0002-4905-8233	King's Health Partners' Research and Development Challenge Fund; MRC; Cancer Research UK; NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust; University of Oxford	King's Health Partners' Research and Development Challenge Fund; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust; University of Oxford	We thank Dr Avery August for the kind gift of the K270M, K271M drebrin-GFP mutant. We are especially grateful to Sara Geraldo, Alex Gordon-Weeks, Robert Kypta and Maddy Parsons for their constructive comments on the manuscript. This work was supported by a grant from the King's Health Partners' Research and Development Challenge Fund and by the MRC. We also thank the King's Health Partners Cancer Biobank and the Oxford Centre for Histopathology Research for granting access to human prostate samples. Funding for prostate tissue microarrays construction and CM's research time was provided by the MRC Confidence in Concept programme. RJB's research time was funded by Cancer Research UK. CV's research time was funded by the NIHR Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford.	Bazellieres E, 2012, J CELL SCI, V125, P919, DOI 10.1242/jcs.092676; Broster SA, 2015, FUTURE ONCOL, V11, P3197, DOI 10.2217/fon.15.253; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Conley-LaComb MK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0552-0; Dun XP, 2012, MOL CELL NEUROSCI, V49, P341, DOI 10.1016/j.mcn.2012.01.006; Dun XP, 2010, HISTOL HISTOPATHOL, V25, P533, DOI 10.14670/HH-25.533; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fisher KE, 2009, J CELL SCI, V122, P4558, DOI 10.1242/jcs.050724; Frank SB, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00273; Geraldo S, 2008, NAT CELL BIOL, V10, P1181, DOI 10.1038/ncb1778; Gireesh KK, 2014, BIOCHEMISTRY-US, V53, P5551, DOI 10.1021/bi5007942; Gordon-Weeks PR, 2014, J NEUROCHEM, V129, P206, DOI 10.1111/jnc.12502; Gravina GL, 2015, PROSTATE, V75, P1227, DOI 10.1002/pros.23007; Hernandez L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3074; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Komarova Y, 2009, J CELL BIOL, V184, P691, DOI 10.1083/jcb.200807179; Kukreja P, 2005, CANCER RES, V65, P9891, DOI 10.1158/0008-5472.CAN-05-1293; Liang ZX, 2005, CANCER RES, V65, P967; Lin QF, 2014, PROTEOMICS, V14, P1434, DOI 10.1002/pmic.201300462; Mercer JC, 2010, INT J BIOCHEM CELL B, V42, P337, DOI 10.1016/j.biocel.2009.11.019; Merriam EB, 2013, J NEUROSCI, V33, P16471, DOI 10.1523/JNEUROSCI.0661-13.2013; Mitra R, 2011, CLIN CANCER RES, V17, P2934, DOI 10.1158/1078-0432.CCR-10-1803; Peitsch WK, 2005, J INVEST DERMATOL, V125, P761, DOI 10.1111/j.0022-202X.2005.23793.x; Perez-Martinez M, 2010, J CELL SCI, V123, P1160, DOI 10.1242/jcs.064238; ROMIJN JC, 1988, PROSTATE, V12, P99, DOI 10.1002/pros.2990120112; Roth AL, 2003, J COMP NEUROL, V465, P195, DOI 10.1002/cne.10856; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Sonego M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126478; Straube A, 2007, CURR BIOL, V17, P1318, DOI 10.1016/j.cub.2007.06.058; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Sun YN, 2014, TUMOR BIOL, V35, P7765, DOI 10.1007/s13277-014-1816-1; Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109; Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522; Taichman RS, 2002, CANCER RES, V62, P1832; Tanabe K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092291; Tang EI, 2015, ENDOCRINOLOGY, V156, P680, DOI 10.1210/en.2014-1720; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Terakawa Y, 2013, EXP CELL RES, V319, P517, DOI 10.1016/j.yexcr.2012.11.008; Wang J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5758; Worth DC, 2013, J CELL BIOL, V202, P793, DOI 10.1083/jcb.201303005; Xu SQ, 2015, ONCOTARGET, V6, P10825, DOI 10.18632/oncotarget.3424; Yagi H, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002221	43	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4111	4123		10.1038/onc.2017.45	http://dx.doi.org/10.1038/onc.2017.45			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28319065	hybrid, Green Published			2022-12-17	WOS:000405835800003
J	Than, BLN; Linnekamp, JF; Starr, TK; Largaespada, DA; Rod, A; Zhang, Y; Bruner, V; Abrahante, J; Schumann, A; Luczak, T; Walter, J; Niemczyk, A; O'Sullivan, MG; Medema, JP; Fijneman, RJA; Meijer, GA; Van den Broek, E; Hodges, CA; Scott, PM; Vermeulen, L; Cormier, RT				Than, B. L. N.; Linnekamp, J. F.; Starr, T. K.; Largaespada, D. A.; Rod, A.; Zhang, Y.; Bruner, V.; Abrahante, J.; Schumann, A.; Luczak, T.; Walter, J.; Niemczyk, A.; O'Sullivan, M. G.; Medema, J. P.; Fijneman, R. J. A.; Meijer, G. A.; Van den Broek, E.; Hodges, C. A.; Scott, P. M.; Vermeulen, L.; Cormier, R. T.			CFTR is a tumor suppressor gene in murine and human intestinal cancer (vol 35, pg 4179, 2016)	ONCOGENE			English	Correction									[Walter, J.] Univ Minnesota, Sch Med, Dept Biomed Sci, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth	Walter, J (corresponding author), Univ Minnesota, Sch Med, Dept Biomed Sci, Duluth, MN 55812 USA.		Fijneman, Remond/X-4199-2019; Starr, Tim/AAX-9342-2021	Fijneman, Remond/0000-0003-2076-5521; Medema, Jan Paul/0000-0003-3045-2924; Zhang, Ying/0000-0003-3764-7329; Meijer, Gerrit/0000-0003-0330-3130				Than BLN, 2016, ONCOGENE, V35, P4191, DOI 10.1038/onc.2015.483	1	12	13	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3504	3504		10.1038/onc.2017.3	http://dx.doi.org/10.1038/onc.2017.3			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28192405	Bronze			2022-12-17	WOS:000403340700013
J	Hsieh, CH; Chou, YT; Kuo, MH; Tsai, HP; Chang, JL; Wu, CW				Hsieh, C-H; Chou, Y-T; Kuo, M-H; Tsai, H-P; Chang, J-L; Wu, C-W			A targetable HB-EGF-CITED4 axis controls oncogenesis in lung cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NONSMALL CELL LUNG; OVARIAN-CANCER; HB-EGF; CLINICAL-SIGNIFICANCE; TRANSCRIPTION FACTOR; CITED FAMILY; EXPRESSION; MUTATIONS; LIGANDS	Aberrant epidermal growth factor (EGF) receptor (EGFR) signaling contributes to neoplastic initiation and progression in lung. Mutated EGFR has become as an important therapeutic target in lung cancer, whereas targeted treatment is not available for wildtype EGFR or its ligands. In this study, we found that heparin-binding (HB)-EGF, a member of the EGF family, was highly expressed in a subset of lung cancer, proliferation of which was dependent on HB-EGF signaling. Silencing of HB-EGF with RNA interference inhibited cell cycle progression in lung cancer cells. We observed that, upon HB-EGF induction, CITED4 was induced through a signal transducer and activator of transcription 3 (STAT3)-dependent pathway, regulating cell proliferation. CITED4 interacted with MYC and potentiated MYC-mediated transactivation of the CCND1 promoter, leading to cell cycle progression. Correlation analysis revealed that HB-EGF and CITED4 were significantly positively associated in primary lung tumors, and expression of HB-EGF predicted a poor survival outcome in patients. In vitro and in vivo experiments revealed that pharmacological inhibition of HB-EGF with CRM197 significantly attenuated tumor cell growth. Thus, CITED4 functions as a molecular switch in HB-EGF-induced growth control, and HB-EGF provides a novel therapeutic target for lung cancer intervention.	[Hsieh, C-H; Wu, C-W] Natl Yang Ming Univ, Inst Microbiol & Immunol, 155,Sect 2,Linong St, Taipei 112, Taiwan; [Chou, Y-T; Kuo, M-H; Wu, C-W] Natl Tsing Hua Univ, Inst Biotechnol, 101,Sect 2,Kuang Fu Rd, Hsinchu 300, Taiwan; [Tsai, H-P] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Chang, J-L] Taoyuan Armed Forces Gen Hosp, Dept Pathol & Lab Med, Taoyuan, Taiwan; [Chang, J-L] Ming Chuan Univ, Dept Biomed Engn, Taoyuan, Taiwan	National Yang Ming Chiao Tung University; National Tsing Hua University; Kaohsiung Medical University; Ming Chuan University	Wu, CW (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, 155,Sect 2,Linong St, Taipei 112, Taiwan.; Chou, YT (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, 101,Sect 2,Kuang Fu Rd, Hsinchu 300, Taiwan.	ytchou@life.nthu.edu.tw; cwwu@ym.edu.tw		Chou, Yu-Ting/0000-0001-9274-8603	National Yang-Ming University; National Tsing Hua University; Institute of Biomedical Sciences, Academia Sinica; Ministry of Science and Technology, Executive Yuan, Taiwan, ROC [MOST104-2321-B-010-007, MOST103-2320-B-007-006-MY3]	National Yang-Ming University; National Tsing Hua University; Institute of Biomedical Sciences, Academia Sinica(Academia Sinica - Taiwan); Ministry of Science and Technology, Executive Yuan, Taiwan, ROC	This research was supported by National Yang-Ming University, National Tsing Hua University, the Institute of Biomedical Sciences, Academia Sinica and the Ministry of Science and Technology (MOST104-2321-B-010-007 and MOST103-2320-B-007-006-MY3), Executive Yuan, Taiwan, ROC.	Bostrom P, 2010, CELL, V143, P1072, DOI 10.1016/j.cell.2010.11.036; Boyle S, 2007, DEV DYNAM, V236, P2321, DOI 10.1002/dvdy.21242; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Chou YT, 2006, ONCOGENE, V25, P5547, DOI 10.1038/sj.onc.1209552; Chou YT, 2012, CELL DEATH DIFFER, V19, P2015, DOI 10.1038/cdd.2012.91; Chou YT, 2006, J BIOL CHEM, V281, P18451, DOI 10.1074/jbc.M601720200; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Harada D, 2014, CANCERS, V6, P708, DOI 10.3390/cancers6020708; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kageyama T, 2007, J BIOCHEM, V142, P95, DOI 10.1093/jb/mvm116; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; Laurie SA, 2013, J CLIN ONCOL, V31, P1061, DOI 10.1200/JCO.2012.43.4522; Leslie CC, 1997, AM J RESP CELL MOL, V16, P379, DOI 10.1165/ajrcmb.16.4.9115748; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Naef M, 1996, INT J CANCER, V66, P315; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Qu X, 2007, EMBO J, V26, P4445, DOI 10.1038/sj.emboj.7601883; RUSCH V, 1993, CANCER RES, V53, P2379; Ryall KA, 2014, J MOL CELL CARDIOL, V72, P74, DOI 10.1016/j.yjmcc.2014.02.013; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Tanaka Y, 2005, CLIN CANCER RES, V11, P4783, DOI 10.1158/1078-0432.CCR-04-1426; Thogersen VB, 2001, CANCER RES, V61, P6227; Vinante F, 2013, TOXINS, V5, P1180, DOI 10.3390/toxins5061180; Volante M, 2007, CANCER, V110, P1321, DOI 10.1002/cncr.22903; Wang YL, 2009, J PHYSIOL-LONDON, V587, P1739, DOI 10.1113/jphysiol.2008.163899; Wei X, 2015, TRENDS CARDIOVAS MED, V25, P529, DOI 10.1016/j.tcm.2014.12.014; Weninger WJ, 2005, DEVELOPMENT, V132, P1337, DOI 10.1242/dev.01696; Wu WJ, 2007, MOL CANCER THER, V6, P2652, DOI 10.1158/1535-7163.MCT-06-0759; Yagi H, 2005, BRIT J CANCER, V92, P1737, DOI 10.1038/sj.bjc.6602536; Yahata T, 2002, GENOMICS, V80, P601, DOI 10.1006/geno.2002.7005	42	12	12	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2946	2956		10.1038/onc.2016.465	http://dx.doi.org/10.1038/onc.2016.465			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28092674				2022-12-17	WOS:000402000400003
J	Goyama, S; Shrestha, M; Schibler, J; Rosenfeldt, L; Miller, W; O'Brien, E; Mizukawa, B; Kitamura, T; Palumbo, JS; Mulloy, JC				Goyama, S.; Shrestha, M.; Schibler, J.; Rosenfeldt, L.; Miller, W.; O'Brien, E.; Mizukawa, B.; Kitamura, T.; Palumbo, J. S.; Mulloy, J. C.			Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia	ONCOGENE			English	Article							THROMBIN RECEPTOR; SELF-RENEWAL; PROGENITOR CELLS; CANCER GENOMICS; UP-REGULATION; IN-VIVO; PROMOTES; EXPRESSION; ADHESION; AML1-ETO	Eradication of leukemia stem cells (LSCs) is the ultimate goal of treating acute myeloid leukemia (AML). We recently showed that the combined loss of Runx1/Cbfb inhibited the development of MLL-AF9-induced AML. However, c-Kit(+)/Gr-1(-)cells remained viable in Runx1/Cbfb-deleted cells, indicating that suppressing RUNX activity may not eradicate the most immature LSCs. In this study, we found upregulation of several hemostasis-related genes, including the thrombin-activatable receptor PAR- 1 (protease-activated receptor-1), in Runx1/Cbfb-deleted MLL-AF9 cells. Similar to the effect of Runx1/Cbfb deletion, PAR- 1 overexpression induced CDKN1A/p21 expression and attenuated proliferation in MLL-AF9 cells. To our surprise, PAR- 1 deficiency also prevented leukemia development induced by a small number of MLL-AF9 leukemia stem cells (LSCs) in vivo. PAR- 1 deficiency also reduced leukemogenicity of AML1-ETO-induced leukemia. Re-expression of PAR- 1 in PAR-1-deficient cells combined with a limiting-dilution transplantation assay demonstrated the cell-dose-dependent role of PAR- 1 in MLL-AF9 leukemia: PAR- 1 inhibited rapid leukemic proliferation when there were a large number of LSCs, while a small number of LSCs required PAR- 1 for their efficient growth. Mechanistically, PAR- 1 increased the adherence properties of MLL-AF9 cells and promoted their engraftment to bone marrow. Taken together, these data revealed a multifaceted role for PAR- 1 in leukemogenesis, and highlight this receptor as a potential target to eradicate primitive LSCs in AML.	[Goyama, S.; Shrestha, M.; Schibler, J.; Rosenfeldt, L.; Miller, W.; O'Brien, E.; Mizukawa, B.; Palumbo, J. S.; Mulloy, J. C.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Goyama, S.; Shrestha, M.; Schibler, J.; Rosenfeldt, L.; Miller, W.; O'Brien, E.; Mizukawa, B.; Palumbo, J. S.; Mulloy, J. C.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Goyama, S.; Kitamura, T.] Univ Tokyo, Inst Med Sci, Div Cellular Therapy, Tokyo, Japan	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Tokyo	Palumbo, JS; Mulloy, JC (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA.	Joe.Palumbo@cchmc.org; james.mulloy@cchmc.org	Kitamura, Toshio/AAA-2071-2021		Institutional Clinical and Translational Science Award; NIH/NCRR Grant [1UL1RR026314-01]; Translational Trials Development and Support Laboratory award (USPHS Grant) [MO1 RR 08084]; Center of Excellence in Molecular Hematology P30 award [DK090971];  [CA176907]; NATIONAL CANCER INSTITUTE [R01CA204058] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER	Institutional Clinical and Translational Science Award; NIH/NCRR Grant; Translational Trials Development and Support Laboratory award (USPHS Grant); Center of Excellence in Molecular Hematology P30 award; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Dr J Trejo and Dr M Onodera for plasmids. We also thank the Flow Cytometry Core and the Mouse Core at Cincinnati Children's Hospital Medical Center for their help. This work was supported by an Institutional Clinical and Translational Science Award, NIH/NCRR Grant Number 1UL1RR026314-01, Translational Trials Development and Support Laboratory award (USPHS Grant Number MO1 RR 08084), CA176907 (JCM) and a Center of Excellence in Molecular Hematology P30 award (DK090971). JCM is a Leukemia and Lymphoma Society Scholar.	Aronovich A, 2013, BLOOD, V122, P2562, DOI 10.1182/blood-2012-08-447458; Austin KM, 2013, BLOOD, V121, P431, DOI 10.1182/blood-2012-09-355958; Auvergne R, 2016, ONCOGENE, V35, P3817, DOI 10.1038/onc.2015.452; Baumer N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094993; BOWER M, 1994, BLOOD, V84, P3776, DOI 10.1182/blood.V84.11.3776.bloodjournal84113776; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chou FS, 2012, BLOOD, V120, P709, DOI 10.1182/blood-2012-01-403212; COHEN SG, 2015, NAT MED, V21, P1307; Corces-Zimmerman MR, 2014, P NATL ACAD SCI USA, V111, P2548, DOI 10.1073/pnas.1324297111; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Degen JL, 2012, THROMB RES, V129, pS1, DOI 10.1016/S0049-3848(12)70143-3; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goyama S, 2016, LEUKEMIA, V30, P728, DOI 10.1038/leu.2015.275; Goyama S, 2015, BLOOD, V125, P2630, DOI 10.1182/blood-2014-11-570218; Goyama S, 2013, J CLIN INVEST, V123, P3876, DOI 10.1172/JCI68557; Heider I, 2004, ONCOL RES, V14, P475, DOI 10.3727/0965040042380496; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang YQ, 2000, J BIOL CHEM, V275, P6462, DOI 10.1074/jbc.275.9.6462; ISHII K, 1993, J BIOL CHEM, V268, P9780; Jan M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004315; Kanemaru M, 2012, HEPATO-GASTROENTEROL, V59, P1614, DOI 10.5754/hge10036; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Mendler JH, 2012, J CLIN ONCOL, V30, P3109, DOI 10.1200/JCO.2011.40.6652; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Mulloy JC, 2008, CELL CYCLE, V7, P3314, DOI 10.4161/cc.7.21.6951; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Nakahara F, 2014, BLOOD, V123, P3932, DOI 10.1182/blood-2013-01-476747; NIERODZIK ML, 1991, J CLIN INVEST, V87, P229, DOI 10.1172/JCI114976; Pagel CN, 2009, BONE, V44, P813, DOI 10.1016/j.bone.2008.12.031; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Song SJ, 2005, AM J PATHOL, V166, P857, DOI 10.1016/S0002-9440(10)62306-1; Tanaka Y, 2012, DEV BIOL, V366, P404, DOI 10.1016/j.ydbio.2012.03.024; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Veiga CDB, 2011, BLOOD CELL MOL DIS, V46, P230, DOI 10.1016/j.bcmd.2010.12.005; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; Wunderlich M, 2006, BLOOD, V108, P1690, DOI 10.1182/blood-2005-12-012773; Wunderlich Mark, 2009, V538, P263, DOI 10.1007/978-1-59745-418-6_13; Yang E, 2016, ONCOGENE, V35, P1529, DOI 10.1038/onc.2015.217; Ye M, 2015, CELL STEM CELL, V17, P611, DOI 10.1016/j.stem.2015.08.011; Yue R, 2012, DEV CELL, V22, P1092, DOI 10.1016/j.devcel.2012.01.025; Zhong JF, 2005, P NATL ACAD SCI USA, V102, P2448, DOI 10.1073/pnas.0409459102	46	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2589	2598		10.1038/onc.2016.416	http://dx.doi.org/10.1038/onc.2016.416			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27819671	Green Accepted			2022-12-17	WOS:000400597300009
J	Meng, Z; Ma, X; Du, J; Wang, X; He, M; Gu, Y; Zhang, J; Han, W; Fang, Z; Gan, X; Van Ness, C; Fu, X; Schones, DE; Xu, R; Huang, W				Meng, Z.; Ma, X.; Du, J.; Wang, X.; He, M.; Gu, Y.; Zhang, J.; Han, W.; Fang, Z.; Gan, X.; Van Ness, C.; Fu, X.; Schones, D. E.; Xu, R.; Huang, W.			CAMK2 gamma antagonizes mTORC1 activation during hepatocarcinogenesis	ONCOGENE			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE-II; NF-KAPPA-B; FARNESOID-X RECEPTOR; HEPATOCELLULAR-CARCINOMA; LIVER-CANCER; PEPTIDE ARRAYS; CHEMICAL HEPATOCARCINOGENESIS; SIGNAL INTEGRATION; CRITICAL REGULATOR	Hepatocellular carcinoma (HCC) is one of the most deadly cancers that still lacks effective treatments. Dysregulation of kinase signaling has frequently been reported to contribute to HCC. In this study, we used bioinformatic approaches to identify kinases that regulate gene expression changes in human HCCs and two murine HCC models. We identified a role for calcium/calmodulin-dependent protein kinases II gamma isoform (CAMK2 gamma) in hepatocarcinogenesis. CAMK2 gamma(-/-) mice displayed severely enhanced chemical-induced hepatocarcinogenesis compared with wild-type controls. Mechanistically, CAMK2 gamma deletion potentiates hepatic activation of mechanistic target of rapamycin complex 1 (mTORC1), which results in hyperproliferation of hepatocytes. Inhibition of mTORC1 by rapamycin effectively attenuates the compensatory proliferation of hepatocytes in CAMK2 gamma(-/-) livers. We further demonstrated that CAMK2 gamma suppressed growth factor-or insulin-induced mTORC1 activation by inhibiting IRS1/AKT signaling. Taken together, our results reveal a novel mechanism by which CAMK2 gamma antagonizes mTORC1 activation during hepatocarcinogenesis.	[Meng, Z.; Ma, X.; Du, J.; Wang, X.; Gu, Y.; Zhang, J.; Gan, X.; Van Ness, C.; Fu, X.; Schones, D. E.; Xu, R.; Huang, W.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet Complicat & Metab, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Ma, X.; Du, J.; Schones, D. E.; Huang, W.] City Hope Natl Med Ctr, Beckman Res Inst, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA; [He, M.] Guangxi Med Univ, Sch Publ Hlth, Nanning, Guangxi, Peoples R China; [Gu, Y.; Xu, R.] Zhejiang Univ, China Natl Minist Educ, Key Lab Canc Prevent & Intervent, Dept Hematol, Hangzhou, Zhejiang, Peoples R China; [Zhang, J.; Xu, R.] Zhejiang Univ, Canc Inst, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China; [Han, W.; Fang, Z.] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Coll Med, Hangzhou, Zhejiang, Peoples R China; [Fu, X.] Sichuan Univ, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Fu, X.] Sichuan Univ, Canc Ctr, Collaborat Innovat Ctr Biotherapy, West China Hosp,West China Med Sch, Chengdu, Sichuan, Peoples R China	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Guangxi Medical University; Zhejiang University; Zhejiang University; Zhejiang University; Sichuan University; Sichuan University	Xu, R; Huang, W (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet Complicat & Metab, 1500 E Duarte Rd, Duarte, CA 91010 USA.	zrxyk10@zju.edu.cn; whuang@coh.org	Ma, Xiaoxiao/AFB-9086-2022	Ma, Xiaoxiao/0000-0001-8661-5660; Fang, Zhipeng/0000-0001-5720-1709; Fu, Xianghui/0000-0001-9808-3892	NCI [1R01-CA139158]; National Natural Science Foundation of China [81270601, 81328016]; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA139158] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Johannes Backs for providing the Camk2 gamma KO mice. We also thank Dr Richard Ermel and the Animal Resource center for the technique support in animal experiments. Similarly, we thank Dr Yun Yen and Yafan Wang and the Translational Research Core for providing reagents. This work is supported in part by NCI 1R01-CA139158 and the National Natural Science Foundation of China (81270601 and 81328016).	Abdul-Ghani R, 2006, ONCOGENE, V25, P1743, DOI 10.1038/sj.onc.1209201; Arsenault R, 2011, PROTEOMICS, V11, P4595, DOI 10.1002/pmic.201100296; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Azeloglu EU, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004621; Bhat M, 2013, HEPATOLOGY, V58, P810, DOI 10.1002/hep.26323; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Chen EY, 2012, BIOINFORMATICS, V28, P105, DOI 10.1093/bioinformatics/btr625; Chen WM, 2013, BIOINFORMATICS, V29, P2435, DOI 10.1093/bioinformatics/btt387; Cretich M, 2006, BIOMOL ENG, V23, P77, DOI 10.1016/j.bioeng.2006.02.001; De Minicis S, 2007, GASTROENTEROLOGY, V132, P1937, DOI 10.1053/j.gastro.2007.02.033; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Ella E, 2014, ONCOTARGET, V5, P10318, DOI 10.18632/oncotarget.2515; Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048; Feng GS, 2012, CANCER CELL, V21, P150, DOI 10.1016/j.ccr.2012.01.001; Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631; Goldman A, 2014, MOL CELL, V55, P422, DOI 10.1016/j.molcel.2014.05.012; Gu Y, 2012, BLOOD, V120, P4829, DOI 10.1182/blood-2012-06-434894; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hell JW, 2014, NEURON, V81, P249, DOI 10.1016/j.neuron.2013.12.024; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Huang WD, 2005, MOL ENDOCRINOL, V19, P1646, DOI 10.1210/me.2004-0520; Illario M, 2009, CELL SIGNAL, V21, P786, DOI 10.1016/j.cellsig.2009.01.022; Ishiguro K, 2006, MOL CELL BIOL, V26, P5497, DOI 10.1128/MCB.02469-05; Kenerson HL, 2013, GASTROENTEROLOGY, V144, P1055, DOI 10.1053/j.gastro.2013.01.053; Kim I, 2007, CARCINOGENESIS, V28, P940, DOI 10.1093/carcin/bgl249; Kim MS, 2016, PROTEOMICS, V16, P700, DOI 10.1002/pmic.201500355; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lachmann A, 2009, BIOINFORMATICS, V25, P684, DOI 10.1093/bioinformatics/btp026; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li Z, 2012, CELL, V148, P72, DOI 10.1016/j.cell.2011.11.026; Liu NA, 2012, MOL ENDOCRINOL, V26, P775, DOI 10.1210/me.2011-1383; Liu Y, 2014, COMPUT STRUCT BIOTEC, V10, P90, DOI 10.1016/j.csbj.2014.07.003; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Meng ZP, 2013, MOL CANCER THER, V12, P2067, DOI 10.1158/1535-7163.MCT-13-0314; Meng ZP, 2012, J HEPATOL, V57, P1004, DOI 10.1016/j.jhep.2012.06.016; Menon S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002739; Midorikawa R, 2006, CELL, V125, P371, DOI 10.1016/j.cell.2006.02.039; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Ozcan L, 2013, CELL METAB, V18, P803, DOI 10.1016/j.cmet.2013.10.011; Ozcan L, 2012, CELL METAB, V15, P739, DOI 10.1016/j.cmet.2012.03.002; Papa S, 2008, J CLIN INVEST, V118, P1911, DOI 10.1172/JCI33913; Patsenker E, 2011, J HEPATOL, V55, P388, DOI 10.1016/j.jhep.2010.10.044; Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Rabinowitz KM, 2013, GASTROENTEROLOGY, V144, P601, DOI 10.1053/j.gastro.2012.12.001; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Reimer U, 2002, CURR OPIN BIOTECH, V13, P315, DOI 10.1016/S0958-1669(02)00339-7; Rexer BN, 2011, ONCOGENE, V30, P4163, DOI 10.1038/onc.2011.130; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; Satow R, 2010, CLIN CANCER RES, V16, P2518, DOI 10.1158/1078-0432.CCR-09-2214; Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soliman GA, 2010, J BIOL CHEM, V285, P7866, DOI 10.1074/jbc.M109.096222; Swaminathan PD, 2011, J CLIN INVEST, V121, P3277, DOI 10.1172/JCI57833; Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196; Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857; Vasudevan HN, 2014, DEV CELL, V31, P332, DOI 10.1016/j.devcel.2014.10.005; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Yang F, 2007, CANCER RES, V67, P863, DOI 10.1158/0008-5472.CAN-06-1078; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025; Zhang ZJ, 2012, J CLIN ENDOCR METAB, V97, P2347, DOI 10.1210/jc.2012-1267; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	77	12	12	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2446	2456		10.1038/onc.2016.400	http://dx.doi.org/10.1038/onc.2016.400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27819676	Green Accepted			2022-12-17	WOS:000400268900010
J	Ma, SQ; Cao, BR; Zhang, H; Luo, LP; Ren, Y; Hu, T; Chen, CM				Ma, S. Q.; Cao, B. R.; Zhang, H.; Luo, L. P.; Ren, Y.; Hu, T.; Chen, C. M.			The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; INDEPENDENT MECHANISM; PROSTATE-CANCER; C-RAF-1 GENE; APOPTOSIS; EXPRESSION; MEK; ACTIVATION; PHOSPHORYLATION; OVEREXPRESSION	Raf-1 has an important role in cellular antiapoptosis. So far, there is no solid evidence that shows that Raf-1 mutation is associated with cancer development. In the course of further study of Raf-1 signaling, we have reported that Raf-1 hyperphosphorylation inhibits its kinase activity toward its downstream mitogen-activated protein kinase kinase 1/2 (MEK1/2) and proposed a model for negative feedback regulation of Raf-1. Here, we show that there is no hyperphosphorylation in some cancer cells, which results in increased kinase activity and enhances the antiapoptotic ability. Inhibition of either Raf-1 or ALG-2 (apoptosis-linked gene 2) expression results in apoptosis signal-regulating kinase 1/c-Jun N-terminal kinase (ASK1/JNK) signaling activation, and cell sensitivity to chemotherapeutic reagents, indicating that inhibition of ASK1/JNK apoptotic signaling by Raf-1 is mediated by ALG-2. A previous report indicated that extracellular signal-regulated kinase 1/2 (ERK1/2) were responsible for Raf-1 hyperphosphorylation. However, our evidence shows that when ERK1/2 are activated and the Raf-1 gene is not mutated, Raf-1 is not hyperphosphorylated in these cells, indicating that ERK1/2 are not responsible for the Raf-1 hyperphosphorylation in these cancer cell lines. Surprisingly, we also found that Raf-1 is not a necessary kinase for MEK1/2 activation under normal tissue culture conditions, but is required for MEK1/2 activation under apoptosis-inducing conditions. Our research demonstrates that although Raf-1 gene is not mutated, an abnormality of Raf-1 kinase feedback regulation enhances its antiapoptotic function, and Raf-1 can still be a pharmaceutical target to increase chemotherapy or radiotherapy sensitivity in these cancer cells.	[Ma, S. Q.; Cao, B. R.; Zhang, H.; Luo, L. P.; Ren, Y.; Chen, C. M.] Sichuan Canc Hosp Inst, Dept Basic Res, 55 Renmin Ave Fourth Sect, Chengdu 610041, Sichuan, Peoples R China; [Hu, T.] Sichuan Canc Hosp Inst, Dept Gynecol Oncol, Chengdu, Peoples R China		Chen, CM (corresponding author), Sichuan Canc Hosp Inst, Dept Basic Res, 55 Renmin Ave Fourth Sect, Chengdu 610041, Sichuan, Peoples R China.	changmin_chen@sichuancancer.org	, 曹邦荣/AAN-3604-2020	Cao, Bangrong/0000-0002-3865-3563	Sichuan Scientific and Technology Department Basic Research Fund [2015JY0011]; Sichuan Cancer Hospital Research Fund	Sichuan Scientific and Technology Department Basic Research Fund; Sichuan Cancer Hospital Research Fund	This work was financially supported by Sichuan Scientific and Technology Department Basic Research Fund (2015JY0011) (to CC) and Sichuan Cancer Hospital Research Fund (to CC).	Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Appert-Collin A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00283; Bieker R, 2003, CANCER RES, V63, P7241; Brady G, 2007, INT J ONCOL, V31, P875; Chen CM, 2005, BIOCHEM BIOPH RES CO, V333, P51, DOI 10.1016/j.bbrc.2005.05.074; Chen CM, 2004, BLOOD, V104, P73, DOI 10.1182/blood-2003-04-1340; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0; CULIG Z, 1994, CANCER RES, V54, P5474; Cussenot O, 1997, ANN ENDOCRINOL-PARIS, V58, P370; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Hwang IS, 2002, FEBS LETT, V529, P183, DOI 10.1016/S0014-5793(02)03329-X; Kaplan PJ, 1996, CARCINOGENESIS, V17, P2571, DOI 10.1093/carcin/17.12.2571; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li R, 2004, PROSTATE, V58, P193, DOI 10.1002/pros.10321; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Murakami MS, 2001, SCI STKE, V2001, pE30; Osborne JK, 2012, CELL RES, V22, P14, DOI 10.1038/cr.2011.193; Park SJ, 2015, INT J CLIN EXP PATHO, V8, P8298; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001948; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; Segaliny AI, 2015, J BONE ONCOL, V4, P1, DOI 10.1016/j.jbo.2015.01.001; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Steelman LS, 2011, LEUKEMIA, V25, P1080, DOI 10.1038/leu.2011.66; Trojan L, 2004, UROL RES, V32, P97, DOI 10.1007/s00240-003-0383-5; Yamaguchi O, 2004, J CLIN INVEST, V114, P937, DOI 10.1172/JCI200420317; Yu PC, 2014, MICROVASC RES, V96, P10, DOI 10.1016/j.mvr.2014.07.016; Zhang WY, 1999, J BONE MINER RES, V14, P528, DOI 10.1359/jbmr.1999.14.4.528	39	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					2014	2022		10.1038/onc.2016.384	http://dx.doi.org/10.1038/onc.2016.384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27841865				2022-12-17	WOS:000398898500011
J	Zhou, Y; Frings, O; Branca, RM; Boekel, J; le Sage, C; Fredlund, E; Agami, R; Orre, LM				Zhou, Y.; Frings, O.; Branca, R. M.; Boekel, J.; le Sage, C.; Fredlund, E.; Agami, R.; Orre, L. M.			microRNAs with AAGUGC seed motif constitute an integral part of an oncogenic signaling network	ONCOGENE			English	Article							ADVANCED BREAST-CANCER; EMBRYONIC STEM-CELLS; MASS-SPECTROMETRY; TUMOR INVASION; FEEDBACK LOOP; EXPRESSION; TARGETS; P53; PROLIFERATION; SENESCENCE	microRNA (miRNA) dysregulation is a common feature of cancer cells, but the complex roles of miRNAs in cancer are not fully elucidated. Here, we used functional genomics to identify oncogenic miRNAs in non-small cell lung cancer and evaluate their impact on response to epidermal growth factor (EGFR)-targeting therapy. Our data demonstrate that miRNAs with an AAGUGC motif in their seed sequence increase both cancer cell proliferation and sensitivity to EGFR inhibitors. Global transcriptomics, proteomics and target prediction resulted in the identification of several tumor suppressors involved in the G1/5 transition as AAGUGC-miRNA targets. The clinical implications of our findings were evaluated by analysis of AAGUGC-miRNA expression in multiple cancer types, supporting the link between this miRNA seed family, their tumor suppressor targets and cancer cell proliferation. In conclusion, we propose the AAGUGC seed motif as an oncomotif and that oncomotif-miRNAs promote cancer cell proliferation. These findings have potential therapeutic implications, especially in selecting patients for EGFR-targeting therapy.	[Zhou, Y.; Frings, O.; Branca, R. M.; Boekel, J.; Fredlund, E.; Orre, L. M.] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Box 1031, SE-17121 Stockholm, Sweden; [Boekel, J.] Bioinformat Infrastruct Life Sci, Stockholm, Sweden; [le Sage, C.; Agami, R.] Netherlands Canc Inst, Div Biol Stress Response, Amsterdam, Netherlands	Karolinska Institutet; Netherlands Cancer Institute	Orre, LM (corresponding author), Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Box 1031, SE-17121 Stockholm, Sweden.	lukas.orre@ki.se	agami, reuven/GOG-8289-2022	Zhou Tran, Yan/0000-0003-3500-8304; Branca, Rui/0000-0003-3890-6476; Agami, Reuven/0000-0002-2848-2473; Orre, Lukas/0000-0002-0384-1003	Swedish Cancer Society; Swedish Research Council; Stockholm's county council; AstraZeneca	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm's county council; AstraZeneca(AstraZeneca)	Funding for this study from the Swedish Cancer Society, Swedish Research Council and Stockholm's county council and AstraZeneca is gratefully acknowledged. We would like to acknowledge the Clinical Proteomics Mass Spectrometry, National Genomics Infrastructure (NGI), UPPMAX and BILS at Science for Life Laboratory for providing experimental and computational support.	Avraham R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000876; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; Borgdorff V, 2010, ONCOGENE, V29, P2262, DOI 10.1038/onc.2009.497; Borgstrom E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019119; Branca RMM, 2014, NAT METHODS, V11, P59, DOI [10.1038/NMETH.2732, 10.1038/nmeth.2732]; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeMichele A, 2015, CLIN CANCER RES, V21, P995, DOI 10.1158/1078-0432.CCR-14-2258; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Hamilton MP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3730; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113; Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302; Kim S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6277; Kleinman CL, 2014, NAT GENET, V46, P39, DOI 10.1038/ng.2849; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Li M, 2009, 2009 INTERNATIONAL FORUM ON COMPUTER SCIENCE-TECHNOLOGY AND APPLICATIONS, VOL 3, PROCEEDINGS, P41, DOI 10.1109/IFCSTA.2009.248; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lundin S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010029; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Maussang D, 2006, P NATL ACAD SCI USA, V103, P13068, DOI 10.1073/pnas.0604433103; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Murphy BL, 2013, CANCER RES, V73, P7068, DOI 10.1158/0008-5472.CAN-13-0927; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Palmer RD, 2010, CANCER RES, V70, P2911, DOI 10.1158/0008-5472.CAN-09-3301; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Rippe V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009485; Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Seok H, 2016, MOL CELLS; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stelzer Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3724; Sturm M, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-163; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subramanyam D, 2011, NAT BIOTECHNOL, V29, P443, DOI 10.1038/nbt.1862; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Zhang Y, 2015, BRIT J CANCER, V112, P365, DOI 10.1038/bjc.2014.593	63	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					731	745		10.1038/onc.2016.242	http://dx.doi.org/10.1038/onc.2016.242			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27477696	Green Published, hybrid			2022-12-17	WOS:000394168200001
J	Vinyoles, M; Del Valle-Perez, B; Curto, J; Padilla, M; Villarroel, A; Yang, J; de Herreros, AG; Dunach, M				Vinyoles, M.; Del Valle-Perez, B.; Curto, J.; Padilla, M.; Villarroel, A.; Yang, J.; de Herreros, A. G.; Dunach, M.			Activation of CK1 epsilon by PP2A/PR61 epsilon is required for the initiation of Wnt signaling	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; CASEIN KINASE 1; BETA-CATENIN; LRP6 PHOSPHORYLATION; REGULATORY SUBUNIT; TRANSCRIPTIONAL ACTIVITY; COMPLEX; P120-CATENIN; BINDING; DOMAIN	Canonical Wnt signaling induces the stabilization of beta-catenin, its translocation to the nucleus and the activation of target promoters. This pathway is initiated by the binding of Wnt ligands to the Frizzled receptor, the association of the LRP5/6 coreceptor and the formation of a complex comprising Dvl-2, Axin and protein kinases CK1 alpha, epsilon, gamma and GSK3. Among these, activation of CK1 epsilon, constitutively bound to LRP5/6 through p120-catenin, is required for the association of the rest of the components. We describe here that CK1 epsilon is activated by the PP2A/PR61 epsilon phosphatase. Binding of Wnt ligands promotes the interaction of LRP5/6-associated CK1 epsilon with Frizzled-bound PR61 epsilon regulatory subunit, facilitating the access of PP2A catalytic subunit to CK1 epsilon and its activation, what enables the recruitment of Dvl-2 to the receptor complex and the initiation of the Wnt pathway. Our results uncover the mechanism of activation of the canonical Wnt pathway by its ligands.	[Vinyoles, M.; Del Valle-Perez, B.; Curto, J.; Padilla, M.; Villarroel, A.; Dunach, M.] Univ Autonoma Barcelona, Fac Med, CEB, Dept Bioquim & Biol Mol, E-08193 Bellaterra, Spain; [Vinyoles, M.; de Herreros, A. G.] Inst Hosp Mar Invest Med IMIM, Programa Recerca Canc, Barcelona, Spain; [Yang, J.] Univ Illinois, Coll Vet Med, Dept Comparat Biosci, Urbana, IL USA; [de Herreros, A. G.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain	Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); University of Illinois System; University of Illinois Urbana-Champaign; Pompeu Fabra University	Dunach, M (corresponding author), Univ Autonoma Barcelona, Fac Med, CEB, Dept Bioquim & Biol Mol, E-08193 Bellaterra, Spain.; de Herreros, AG (corresponding author), IMIM, Parc Recerca Biomed Barcelona,C Doctor Aiguader, E-08003 Barcelona, Spain.	agarcia@imim.es; mireia.dunach@uab.es	Dunach, Mireia/E-3604-2015; Vinyoles, Meritxell/AAA-5302-2019	Dunach, Mireia/0000-0001-9844-5603; 	Ministerio de Economia y Competitividad [BFU2012-31554, BFU2015-65153-R, SAF2013-48849-C2-R1]; Fundacio La Marato de TV3 [120130]; ICREA Academia from Generalitat de Catalunya [2014SGR-32]; ISCIII/FEDER [RD12/0036/005]; FPI; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111816, R35GM131810] Funding Source: NIH RePORTER	Ministerio de Economia y Competitividad(Spanish Government); Fundacio La Marato de TV3; ICREA Academia from Generalitat de Catalunya(ICREA); ISCIII/FEDER(Spanish Government); FPI(Spanish Government); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Gonzalez-Sancho, C Niehrs, A Bigas and A Kikuchi for providing reagents and N Ontiveros for excellent technical assistance. This work was funded by grants from the Ministerio de Economia y Competitividad (BFU2012-31554 and BFU2015-65153-R, both MINECO/FEDER, to MD and SAF2013-48849-C2-R1 to AGH) and Fundacio La Marato de TV3 (120130) to MD and AGH. Support from ICREA Academia, 2014SGR-32 from Generalitat de Catalunya and ISCIII/FEDER (RD12/0036/005) is also appreciated. MV was a recipient of a predoctoral fellowship from FPI.	Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Casagolda D, 2010, J CELL SCI, V123, P2621, DOI 10.1242/jcs.067512; Castano J, 2007, MOL CELL BIOL, V27, P1745, DOI 10.1128/MCB.01974-06; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Cruciat CM, 2014, CURR OPIN CELL BIOL, V31, P46, DOI 10.1016/j.ceb.2014.08.003; Cruciat CM, 2013, SCIENCE, V339, P1436, DOI 10.1126/science.1231499; Cruciat CM, 2010, SCIENCE, V327, P459, DOI 10.1126/science.1179802; Cselenyi CS, 2008, P NATL ACAD SCI USA, V105, P8032, DOI 10.1073/pnas.0803025105; del Valle-Perez B, 2011, J CELL SCI, V124, P2298, DOI 10.1242/jcs.082693; del Valle-Perez B, 2011, MOL CELL BIOL, V31, P2877, DOI 10.1128/MCB.01466-10; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Hay E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349-08; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Jin Z, 2009, J BIOL CHEM, V284, P7190, DOI 10.1074/jbc.M807907200; Kikuchi A, 2012, ACTA PHYSIOL, V204, P17, DOI 10.1111/j.1748-1716.2011.02294.x; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Liang J, 2011, MOL CELL BIOL, V31, P2577, DOI 10.1128/MCB.05103-11; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880; Mi KH, 2006, J BIOL CHEM, V281, P4787, DOI 10.1074/jbc.M508657200; Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018-010-0329-3; Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Solanas G, 2008, J CELL SCI, V121, P2224, DOI 10.1242/jcs.021667; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Tanneberger K, 2011, EMBO J, V30, P1433, DOI 10.1038/emboj.2011.28; Tauriello DVF, 2012, P NATL ACAD SCI USA, V109, pE812, DOI 10.1073/pnas.1114802109; Valls G, 2012, J CELL SCI, V125, P5288, DOI 10.1242/jcs.101030; Vinyoles M, 2014, MOL CELL, V53, P444, DOI 10.1016/j.molcel.2013.12.010; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015; Yang J, 2003, DEVELOPMENT, V130, P5569, DOI 10.1242/dev.00762; Yu J, 2014, BIOSCIENCE REP, V34; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698	45	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					429	438		10.1038/onc.2016.209	http://dx.doi.org/10.1038/onc.2016.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27321178	Green Accepted			2022-12-17	WOS:000394166000012
J	Zhao, H; Lu, Z; Bauzon, F; Fu, H; Cui, J; Locker, J; Zhu, L				Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Locker, J.; Zhu, L.			p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer	ONCOGENE			English	Article							UBIQUITIN-DEPENDENT DEGRADATION; CONDITIONAL MOUSE MODEL; CDK INHIBITOR; CELLULAR SENESCENCE; ORGANOID CULTURES; P27 DEGRADATION; P27(KIP1); LIGASE; TUMORIGENESIS; SCFSKP2	SCFSkp2/Cks1 ubiquitinates Thr187-phosphorylated p27 for degradation. Overexpression of Skp2 coupled with underexpression of p27 are frequent characteristics of cancer cells. When the role of SCFSkp2/Cksl - mediated p27 ubiquitination in cancer was specifically tested by p27 Thr187-to-Ala knockin (p27T187A KI), it was found dispensable for Kras(G12D)-induced lung tumorigenesis but essential for Rbl-deficient pituitary tumorigenesis. Here we identify pRb and p53 doubly deficient (DKO) prostate tumorigenesis as a context in which p27 ubiquitination by SCFSkp2/Cks1 is required for p27 downregulation. p27 protein accumulated in prostate when p27T187A KI mice underwent DKO prostate tumorigenesis. p27T187A KI or Skp2 knockdown (KD) induced similar degrees of p27 protein accumulation in DKO prostate cells, and Skp2 KD did not further increase p27 protein in DKO prostate cells that contained p27T187A KI (AADKO prostate cells). p27T187A KI activated an E2F1-p73-apoptosis axis in DKO prostate tumorigenesis, slowed disease progression and significantly extended survival. Querying co-occurrence relationships among RB1, TP53, PTEN, NKX3-1 and MYC in TCGA of prostate cancer identified co-inactivation of RB1 and TP53 as the only statistically significant co-occurrences in metastatic castration-resistant prostate cancer (mCRPC). Together, our study identifies Skp2/Cks1 pocket inhibitors as potential therapeutics for mCRPC. Procedures for establishing mCRPC organoid cultures from contemporary patients were recently established. An Skp2/Cks1 pocket inhibitor preferentially collapsed DKO prostate tumor organoids over AADKO organoids, which spontaneously disintegrated over time when DKO prostate tumor organoids grew larger, setting the stage to translate mouse model findings to precision medicine in the clinic on the organoid platform.	[Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Zhu, L.] Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Dev & Mol Biol, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA; [Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Zhu, L.] Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10467 USA; [Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Zhu, L.] Albert Einstein Coll Med, Dept Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10467 USA; [Zhao, H.; Lu, Z.; Bauzon, F.; Fu, H.; Cui, J.; Zhu, L.] Albert Einstein Coll Med, Liver Res Ctr, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA; [Locker, J.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA USA; [Lu, Z.] Fuzhou Univ, Coll Biol Sci & Engn, Fuzhou 350108, Fujian, Peoples R China; [Fu, H.] Shenyang Med Coll, Dept Biochem, Shenyang 110034, Liaoning, Peoples R China	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fuzhou University; Shenyang Medical College	Zhu, L (corresponding author), Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Dept Dev & Mol Biol, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA.; Zhu, L (corresponding author), Albert Einstein Coll Med, Liver Res Ctr, 1300 Morris Pk Ave,Room U-521, Bronx, NY 10461 USA.	liang.zhu@einstein.yu.edu		Lu, Zhonglei/0000-0002-8915-4828	NIH [RO1CA127901, RO1CA131421]; Albert Einstein Comprehensive Cancer Research Center [5P30CA13330]; Liver Research Center [5P30DK061153]; DOD PCRP Postdoctoral Fellowship [PC121837]; Irma T Hirschl Career Scientist Award; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA127901, R01CA201458, R01CA131421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061153, P30DK041296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Albert Einstein Comprehensive Cancer Research Center; Liver Research Center; DOD PCRP Postdoctoral Fellowship; Irma T Hirschl Career Scientist Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants RO1CA127901and RO1CA131421 (LZ), Albert Einstein Comprehensive Cancer Research Center (5P30CA13330) and Liver Research Center (5P30DK061153) provided core facility support. HZ was a recipient of DOD PCRP Postdoctoral Fellowship (PC121837), and LZ was a Irma T Hirschl Career Scientist Award recipient. We thank Dr James Roberts for providing the p27T187A KI mice.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bassermann F, 2014, BBA-MOL CELL RES, V1843, P150, DOI 10.1016/j.bbamcr.2013.02.028; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Candi E, 2014, HUM MUTAT, V35, P702, DOI 10.1002/humu.22523; Cao XX, 2011, J BIOL CHEM, V286, P33447, DOI 10.1074/jbc.M111.225565; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Chua CW, 2014, NAT CELL BIOL, V16, P951, DOI 10.1038/ncb3047; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gillet JP, 2013, JNCI-J NATL CANCER I, V105, P452, DOI 10.1093/jnci/djt007; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Hattori T, 2007, CANCER RES, V67, P10789, DOI 10.1158/0008-5472.CAN-07-2033; Havens CG, 2009, MOL CELL, V35, P93, DOI 10.1016/j.molcel.2009.05.012; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Miranda-Carboni GA, 2008, GENE DEV, V22, P3121, DOI 10.1101/gad.1692808; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morris MJ, 2007, J UROLOGY, V178, P2378, DOI 10.1016/j.juro.2007.08.015; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sato T, 2015, CELL, V161, DOI 10.1016/j.cell.2015.06.028; Skaar JR, 2014, NAT REV DRUG DISCOV, V13, P889, DOI 10.1038/nrd4432; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Starostina NG, 2010, DEV CELL, V19, P753, DOI 10.1016/j.devcel.2010.10.013; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Sun DQ, 2006, BIOTECHNIQUES, V41, P59, DOI 10.2144/000112203; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Timmerbeul I, 2006, P NATL ACAD SCI USA, V103, P14009, DOI 10.1073/pnas.0606316103; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang HB, 2010, NAT GENET, V42, P83, DOI 10.1038/ng.498; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yung Y, 2007, J CELL BIOL, V178, P741, DOI 10.1083/jcb.200703034; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286; Zhao HL, 2015, J BIOL CHEM, V290, P5797, DOI 10.1074/jbc.M114.625350; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486	58	12	12	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					60	70		10.1038/onc.2016.175	http://dx.doi.org/10.1038/onc.2016.175			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27181203	Green Accepted			2022-12-17	WOS:000394069100006
J	Xu, K; Wang, L; Feng, W; Feng, Y; Shu, HKG				Xu, K.; Wang, L.; Feng, W.; Feng, Y.; Shu, H-K G.			Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase	ONCOGENE			English	Article							LOOP-HELIX PROTEINS; HIGH-GRADE GLIOMA; DNA-DAMAGE; GENOMIC ANALYSIS; ID-1 PROTEIN; CELL-GROWTH; CANCER; GLIOBLASTOMA; EXPRESSION; DEPHOSPHORYLATION	Id1 is a helix-loop-helix transcriptional modulator that increases the aggressiveness of malignant glial neoplasms. Since most glioblastomas (GBMs) show increased phosphatidylinositol-3 kinase (PI-3K) signaling, we sought to determine whether this pathway regulates Id1 expression. Higher basal Id1 expression correlates with dysregulated PI-3K signaling in multiple established GBM cell lines. Further characterization of PI-3K-dependent Id1 regulation reveals that chemical or genetic inhibition of PI-3K signaling reduces Id1 protein but not mRNA expression. Overall, PI-3K signaling appears to enhance Id1 translation with no significant effect on its stability. PI-3K signaling is known to regulate protein translation through mTORC1-dependent phosphorylation of 4E-BP1, which reduces its association with and inhibition of the translation initiation factor eIF4E. Interestingly, while inhibition of PI-3K and AKT lowers 4E-BP1 phosphorylation and expression of Id1 in all cases, inhibition of TORC1 with rapamycin does not consistently have a similar effect, suggesting an alternative mechanism for PI-3K-dependent regulation of Id1 translation. We now identify a potential role for the serine-threonine phosphatase PPM1G in translational regulation of Id1 protein expression. PPM1G knockdown by siRNA increase both 4E-BP1 phosphorylation and Id1 expression and PPM1G and 4E-BP1 co-associates in GBM cells. Furthermore, PPM1G is a phosphoprotein and this phosphorylation appears to be regulated by PI-3K activity. Finally, PI-3K inhibition increases PPM1G activity when assessed by an in vitro phosphatase assay. Our findings provide the first evidence that the PI-3K/AKT signaling pathway modulates PPM1G activity resulting in a shift in the balance between hyperand hypo-phosphorylated 4E-BP1 and translational regulation of Id1 expression.	[Xu, K.; Wang, L.; Shu, H-K G.] Emory Univ, Dept Radiat Oncol, 1365 Clifton Rd,NE,Suite CT-104, Atlanta, GA 30322 USA; [Xu, K.; Wang, L.; Shu, H-K G.] Emory Univ, Winship Canc Inst, 1365 Clifton Rd,NE,Suite CT-104, Atlanta, GA 30322 USA; [Feng, W.; Feng, Y.] Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Shu, HKG (corresponding author), Emory Univ, Dept Radiat Oncol, 1365 Clifton Rd,NE,Suite CT-104, Atlanta, GA 30322 USA.; Shu, HKG (corresponding author), Emory Univ, Winship Canc Inst, 1365 Clifton Rd,NE,Suite CT-104, Atlanta, GA 30322 USA.	hgshu@emory.edu	FENG, WEI/B-8713-2018	FENG, WEI/0000-0002-9106-4258	Southeast Brain Tumor Foundation; Cancer Center grant from the National Cancer Institute [P30-CA138292]; NATIONAL CANCER INSTITUTE [P30CA138292] Funding Source: NIH RePORTER	Southeast Brain Tumor Foundation; Cancer Center grant from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Walter Curran for providing departmental funding support and Dr Chi-Ming Chang for helpful discussion in regard to this project. This work was supported in part by a grant (to H-KGS) from the Southeast Brain Tumor Foundation and a Cancer Center grant from the National Cancer Institute (P30-CA138292).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Allemand E, 2007, NAT STRUCT MOL BIOL, V14, P630, DOI 10.1038/nsmb1257; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; [Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Beli P, 2012, MOL CELL, V46, P212, DOI 10.1016/j.molcel.2012.01.026; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Foster WH, 2013, DEV DYNAM, V242, P1101, DOI 10.1002/dvdy.23990; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Helmy K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046965; Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021; Kimura H, 2006, J CELL BIOL, V175, P389, DOI 10.1083/jcb.200608001; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Liu JY, 2013, J BIOL CHEM, V288, P23225, DOI 10.1074/jbc.M113.492371; Lu R, 2004, P NATL ACAD SCI USA, V101, P15201, DOI 10.1073/pnas.0404995101; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Murray MV, 1999, GENE DEV, V13, P87, DOI 10.1101/gad.13.1.87; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Perry DM, 2012, J LIPID RES, V53, P1513, DOI 10.1194/jlr.M025395; Petri S, 2007, J CELL BIOL, V179, P451, DOI 10.1083/jcb.200704163; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Roux PP, 2012, COLD SPRING HARB PER, V4; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Schindl M, 2003, CLIN CANCER RES, V9, P779; Schindl M, 2001, CANCER RES, V61, P5703; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Xu KM, 2007, CANCER RES, V67, P6121, DOI 10.1158/0008-5472.CAN-07-0141; Xu KM, 2014, ONCOTARGET, V5, P1241, DOI 10.18632/oncotarget.1370	50	12	13	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5807	5816		10.1038/onc.2016.115	http://dx.doi.org/10.1038/onc.2016.115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065332	Green Accepted			2022-12-17	WOS:000386998400011
J	Barbelanne, M; Chiu, A; Qian, J; Tsang, WY				Barbelanne, M.; Chiu, A.; Qian, J.; Tsang, W. Y.			Opposing post-translational modifications regulate Cep76 function to suppress centriole amplification	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASES; CENTROSOME DUPLICATION; CELL-CYCLE; CHROMOSOMAL INSTABILITY; LYSINE ACETYLATION; MAMMALIAN-CELLS; PROTEIN; CDK2; REDUPLICATION; LOCALIZATION	Centrioles are critical for many cellular processes including cell division and cilia assembly. The number of centrioles within a cell is under strict control, and deregulation of centriole copy number is a hallmark of cancer. The molecular mechanisms that halt centriole amplification have not been fully elucidated. Here, we found that centrosomal protein of 76 kDa (Cep76), previously shown to restrain centriole amplification, interacts with cyclin-dependent kinase 2 (CDK2) and is a bona fide substrate of this kinase. Cep76 is preferentially phosphorylated by cyclin A/CDK2 at a single site S83, and this event is crucial to suppress centriole amplification in S phase. A novel Cep76 mutation S83C identified in a cancer patient fails to prevent centriole amplification. Mechanistically, Cep76 phosphorylation inhibits activation of polo-like kinase 1 (Plk1), thereby blocking premature centriole disengagement and subsequent amplification. Cep76 can also be acetylated, and enforced acetylation at K279 dampens the protein's ability to inhibit amplification and precludes S83 phosphorylation. Acetylation of Cep76 normally occurs in G2 phase and correlates with loss of protein function. Our data suggest that temporal changes in post-translational modifications of Cep76 during the cell cycle regulate its capacity to suppress centriole amplification, and its deregulation may contribute to malignancy.	[Barbelanne, M.; Chiu, A.; Qian, J.; Tsang, W. Y.] Inst Rech Clin Montreal, Cell Div & Centrosome Biol Res Unit, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada; [Barbelanne, M.; Tsang, W. Y.] Univ Montreal, Dept Pathol, Fac Med, Montreal, PQ, Canada; [Tsang, W. Y.] McGill Univ, Div Expt Med, Montreal, PQ, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Tsang, WY (corresponding author), Inst Rech Clin Montreal, Cell Div & Centrosome Biol Res Unit, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	william.tsang@ircm.qc.ca		Tsang, William/0000-0002-1584-616X	Canadian Institutes of Health Research [MOP-115033]; Natural Sciences and Engineering Research Council of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	We thank all members of the Tsang laboratory for constructive advice, E Gomes and J Song for assistance with cloning, and Ross Tomaino and Denis Faubert for assistance with mass spectrometry. WYT is a Canadian Institutes of Health Research New Investigator and a Fonds de recherche Sante Junior 1 Research Scholar. This work was supported by the Canadian Institutes of Health Research (MOP-115033 to WYT) and the Natural Sciences and Engineering Research Council of Canada.	Adams PD, 1996, MOL CELL BIOL, V16, P6623; Adon AM, 2010, MOL CELL BIOL, V30, P694, DOI 10.1128/MCB.00253-09; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Barbelanne M, 2015, HUM MOL GENET, V24, P2185, DOI 10.1093/hmg/ddu738; Barbelanne M, 2013, HUM MOL GENET, V22, P2482, DOI 10.1093/hmg/ddt100; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bornens M, 2012, SCIENCE, V335, P422, DOI 10.1126/science.1209037; Chan JY, 2011, INT J BIOL SCI, V7, P1122, DOI 10.7150/ijbs.7.1122; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; De Boer L, 2008, ONCOGENE, V27, P4261, DOI 10.1038/onc.2008.74; Douthwright S, 2014, J CELL PHYSIOL, V229, P1427, DOI 10.1002/jcp.24579; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Errico A, 2010, ADV ENZYME REGUL, V50, P375, DOI 10.1016/j.advenzreg.2009.12.001; Ferguson RL, 2008, J CELL SCI, V121, P3224, DOI 10.1242/jcs.034702; Ferguson RL, 2010, J CELL SCI, V123, P2743, DOI 10.1242/jcs.073098; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Hemerly AS, 2009, SCIENCE, V323, P789, DOI 10.1126/science.1166745; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Korzeniewski N, 2009, CANCER RES, V69, P6668, DOI 10.1158/0008-5472.CAN-09-1284; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Loncarek J, 2010, CURR BIOL, V20, P1277, DOI 10.1016/j.cub.2010.05.050; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Merrick KA, 2011, MOL CELL, V42, P624, DOI 10.1016/j.molcel.2011.03.031; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Nigg E A, 1991, Semin Cell Biol, V2, P261; Nigg EA, 2009, CELL, V139, P663, DOI 10.1016/j.cell.2009.10.036; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Nishimura T, 2005, GENES CELLS, V10, P75, DOI 10.1111/j.1365-2443.2005.00816.x; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Ovejero S, 2012, MOL BIOL CELL, V23, P4515, DOI 10.1091/mbc.E12-04-0260; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Pascreau G, 2010, P NATL ACAD SCI USA, V107, P2932, DOI 10.1073/pnas.0914874107; Pihan GA, 2003, CANCER RES, V63, P1398; Pihan GA, 1998, CANCER RES, V58, P3974; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shiratsuchi G, 2015, EMBO J, V34, P97, DOI 10.15252/embj.201488979; TSAI LH, 1993, ONCOGENE, V8, P1593; Tsang WY, 2008, CELL CYCLE, V7, P702, DOI 10.4161/cc.7.6.5611; Tsang WY, 2007, J CELL BIOL, V178, P621, DOI 10.1083/jcb.200701166; Tsang WY, 2009, DEV CELL, V16, P649, DOI 10.1016/j.devcel.2009.03.004; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Wu J, 2008, J CELL BIOL, V181, P475, DOI 10.1083/jcb.200710127; Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002; Zhang TF, 2012, CELL METAB, V15, P75, DOI 10.1016/j.cmet.2011.12.005; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	63	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5377	5387		10.1038/onc.2016.74	http://dx.doi.org/10.1038/onc.2016.74			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27065328	Green Accepted			2022-12-17	WOS:000386677800004
J	Xie, X; Lozano, G; Siddik, ZH				Xie, X.; Lozano, G.; Siddik, Z. H.			Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53	ONCOGENE			English	Article							WILD-TYPE P53; DNA-DAMAGE; DEGRADATION; ACTIVATION; PHOSPHORYLATION; PROTEIN; CANCER; SENSITIVITY; APOPTOSIS; IMPACT	Cisplatin is an important antitumor agent, but its clinical utility is often limited by multifactorial mechanism of resistance. Loss of tumor suppressor p53 function is a major mechanism that is affected by either mutation in the DNA-binding domain or dysregulation by overexpression of p53 inhibitors MDM2 and MDM4, which destabilize p53 by increasing its proteosomal degradation. In the present study, cisplatin-resistant 2780CP/Cl-16 ovarian tumor cells expressed a heterozygous, temperature-sensitive p53(V172F) mutation, which reduced p53 half-life by two-to threefold compared with homozygous wild-type (wt) p53 in parental A2780 cells. Although reduced p53 stability in 2780CP/Cl-16 cells was associated with moderate cellular overexpression of MDM2 or MDM4 (o1.5-fold), their binding to p53 was substantially enhanced (five-to eightfold). The analogous cisplatin-resistant 2780CP/Cl-24 cells, which express loss of p53 heterozygosity, retained the p53V172F mutation and high p53-MDM4 binding, but demonstrated lower p53-bound MDM2 that was associated with reduced p53 ubiquitination and enhanced p53 stability. The inference that p53 was unstable as a heteromeric p53wt/p53(V172F) complex was confirmed in 2780CP/Cl-24 cells transfected with wt p53 or multimer-inhibiting p53(L344P) mutant, and further supported by normalization of p53 stability in both resistant cell lines grown at the permissive temperature of 32.5 degrees C. Surprisingly, in 2780CP/Cl-16 and 2780CP/Cl-24 models, cisplatin-induced transactivity of p53 was attenuated at 37 degrees C, and this correlated with cisplatin resistance. However, downregulation of MDM2 or MDM4 by small interfering RNA in either resistant cell line induced p53 and restored p21 transactivation at 37 degrees C, as did cisplatin-induced DNA damage at 32.5 degrees C that coincided with reduced p53-MDM4 binding and cisplatin resistance. These results demonstrate that cisplatin-mediated p53(V172F) mutation regulates p53 stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53(V172F) complex that inhibits p53-dependent transactivation. This represents a novel cellular mechanism of p53 inhibition, and, thereby, induction of cisplatin resistance.	[Xie, X.; Siddik, Z. H.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA; [Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Siddik, ZH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA.	zsiddik@mdanderson.org			US Public Health Service - National Cancer Institute [CA160687, CA16672]; Megan McBride Franz Endowed Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA160687] Funding Source: NIH RePORTER	US Public Health Service - National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)United States Public Health Service); Megan McBride Franz Endowed Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The research support from the US Public Health Service Grants CA160687 to ZHS and Support Grant CA16672 to MD Anderson Cancer Center, awarded by the National Cancer Institute, and in part from the Megan McBride Franz Endowed Research Fund, is gratefully acknowledged. We thank Dr Shiaw-Yih Lin (MD Anderson Cancer Center) for the His-Ubiquitin plasmid, and also Dr Guangan He and Michelle Martinez for helpful discussions.	Brachova P, 2013, INT J MOL SCI, V14, P19257, DOI 10.3390/ijms140919257; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Cocker HA, 2001, BRIT J CANCER, V85, P1746, DOI 10.1054/bjoc.2001.2145; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Gaglia G, 2013, P NATL ACAD SCI USA, V110, P15497, DOI 10.1073/pnas.1311126110; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; He G, 2013, BRIT J CANCER, V109, P2378, DOI 10.1038/bjc.2013.613; He GG, 2011, GYNECOL ONCOL, V122, P402, DOI 10.1016/j.ygyno.2011.04.034; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Komlodi-Pasztor E, 2009, ONCOGENE, V28, P3111, DOI 10.1038/onc.2009.166; KONDO S, 1995, ONCOGENE, V10, P2001; Kuang J, 2001, CLIN CANCER RES, V7, P3629; Lam S, 2010, ONCOGENE, V29, P2415, DOI 10.1038/onc.2009.522; Lenos K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/876173; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Mancini F, 2004, J BIOL CHEM, V279, P8169, DOI 10.1074/jbc.M311793200; Martinez-Rivera M, 2012, BIOCHEM PHARMACOL, V83, P1049, DOI 10.1016/j.bcp.2011.12.026; Mujoo K, 2003, J CANCER RES CLIN, V129, P709, DOI 10.1007/s00432-003-0480-4; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Pei DS, 2012, ONCOTARGET, V3, P228; Perry ME, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000968; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Siddik ZH, 2006, CANC DRUG DISC DEV, P283, DOI 10.1007/978-1-59745-035-5_16; Siddik ZH, 1998, CANCER RES, V58, P698; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Tsvetkov P, 2010, CELL DEATH DIFFER, V17, P103, DOI 10.1038/cdd.2009.67; Wang XJ, 2012, FEBS LETT, V586, P1390, DOI 10.1016/j.febslet.2012.02.049; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yazlovitskaya EM, 2001, BIOCHEM BIOPH RES CO, V283, P732, DOI 10.1006/bbrc.2001.4849	31	12	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4798	4806		10.1038/onc.2016.12	http://dx.doi.org/10.1038/onc.2016.12			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876197	Green Accepted			2022-12-17	WOS:000383324700012
J	van Jaarsveld, MTM; Houthuijzen, JM; Voest, EE				van Jaarsveld, M. T. M.; Houthuijzen, J. M.; Voest, E. E.			Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer	ONCOGENE			English	Review							PROTEIN-COUPLED-RECEPTOR; LEUKOTRIENE B-4 RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; ACTIVATING-FACTOR RECEPTOR; THROMBOXANE A(2) RECEPTOR; SITE-DIRECTED MUTAGENESIS; CHAIN FATTY-ACIDS; EPITHELIAL-MESENCHYMAL TRANSITION; RETRACTED ARTICLE. SEE; GROWTH-FACTOR RECEPTOR	Over the past decade the importance of lipids for cancer cell metabolism and cancer-related processes such as proliferation, metastasis and chemotherapy resistance has become more apparent. The mechanisms by which lipid signals are transduced are poorly understood, but frequently involve G-protein Coupled Receptors (GPCRs), which can be explored as druggable targets. Here, we discuss how GPCRs recognize four classes of cancer-relevant lipids (lysophospholipids, phospholipids, fatty acids and eicosanoids). We compare the ligand-binding properties of >50 lipid receptors, we examine how their dysregulation contributes to tumorigenesis and how they may be therapeutically exploited.	[van Jaarsveld, M. T. M.; Houthuijzen, J. M.; Voest, E. E.] Netherlands Canc Inst, Dept Mol Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [van Jaarsveld, M. T. M.] Otto Warburg Lab, Max Planck Inst Mol Genet, Berlin, Germany	Netherlands Cancer Institute; Max Planck Society	Voest, EE (corresponding author), Netherlands Canc Inst, Dept Mol Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	e.voest@nki.nl		Houthuijzen, Julia/0000-0003-0404-1961	Dutch Cancer Society [UU2012-5712, UU2009-4534]	Dutch Cancer Society(KWF Kankerbestrijding)	We thank Dr Perrakis and Dr Moolenaar for helpful discussions. The study was funded by Dutch Cancer Society grants UU2012-5712 and UU2009-4534.	Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X; Ahn KH, 2009, MOL PHARMACOL, V76, P833, DOI 10.1124/mol.109.057356; Akiyama K, 2013, PATHOL INT, V63, P37, DOI 10.1111/pin.12031; Alaa M, 2009, INT J ONCOL, V34, P805, DOI 10.3892/ijo_00000206; Altman MK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-140; Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Ansell SM, 2012, BLOOD, V120, P3949, DOI 10.1182/blood-2011-11-389908; Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Arita M, 2007, J IMMUNOL, V178, P3912, DOI 10.4049/jimmunol.178.6.3912; Audoly L, 1997, MOL PHARMACOL, V51, P61, DOI 10.1124/mol.51.1.61; Bae YS, 2003, MOL PHARMACOL, V64, P721, DOI 10.1124/mol.64.3.721; Bai XM, 2013, INT J ONCOL, V42, P1833, DOI 10.3892/ijo.2013.1859; Ballesteros J. A., 1995, METH NEUROSCI, V25, P366, DOI DOI 10.1016/S1043-9471(05)80049-7; Baltoumas FA, 2013, J STRUCT BIOL, V182, P209, DOI 10.1016/j.jsb.2013.03.004; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Basu S, 2007, J BIOL CHEM, V282, P10005, DOI 10.1074/jbc.M609552200; Bena S, 2012, J BIOL CHEM, V287, P24690, DOI 10.1074/jbc.M112.377101; Benned-Jensen T, 2010, BRIT J PHARMACOL, V159, P1092, DOI 10.1111/j.1476-5381.2009.00633.x; Bermudez Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020487; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103; Brindley DN, 2013, BBA-MOL CELL BIOL L, V1831, P74, DOI 10.1016/j.bbalip.2012.08.015; Brink C, 2007, THESCIENTIFICWORLDJO, V7, P1285, DOI 10.1100/tsw.2007.163; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2005, DNA CELL BIOL, V24, P54, DOI 10.1089/dna.2005.24.54; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Brown SL, 2006, J IMMUNOL, V177, P3242, DOI 10.4049/jimmunol.177.5.3242; Caffarel MM, 2012, CANCER TREAT REV, V38, P911, DOI 10.1016/j.ctrv.2012.06.005; Carnini C, 2011, FASEB J, V25, P3519, DOI 10.1096/fj.10-177030; Cash JL, 2014, DRUG DISCOV TODAY, V19, P1186, DOI 10.1016/j.drudis.2014.06.023; Catalano RD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019209; Cattoretti G, 2009, CANCER RES, V69, P8686, DOI 10.1158/0008-5472.CAN-09-1110; Chakraborty R, 2013, MOL CELL BIOL, V33, P184, DOI 10.1128/MCB.00725-12; Chang J, 2015, ONCOTARGET, V6, P33500, DOI 10.18632/oncotarget.5589; Chen J, 2015, CANCER RES, V75, P4198, DOI 10.1158/0008-5472.CAN-15-1062; Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1927, DOI 10.1152/ajpcell.00400.2006; Chen YC, 2014, INT J CANCER, V135, P117, DOI 10.1002/ijc.28658; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; Chillar A, 2008, FEBS LETT, V582, P2863, DOI 10.1016/j.febslet.2008.07.018; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Chrencik JE, 2015, CELL, V161, P1633, DOI 10.1016/j.cell.2015.06.002; Chu ZL, 2007, ENDOCRINOLOGY, V148, P2601, DOI 10.1210/en.2006-1608; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Cork SM, 2011, J MOL MED, V89, P743, DOI 10.1007/s00109-011-0759-x; Czech MP, 2013, DIABETOLOGIA, V56, P949, DOI 10.1007/s00125-013-2869-1; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; Daniele S, 2010, CELL SIGNAL, V22, P697, DOI 10.1016/j.cellsig.2009.12.006; Dong XW, 2013, EUR J MED CHEM, V62, P754, DOI 10.1016/j.ejmech.2013.01.041; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Drost AC, 2012, LEUKEMIA LYMPHOMA, V53, P665, DOI 10.3109/10428194.2011.625578; E SY, 2009, J BIOL CHEM, V284, P14558, DOI 10.1074/jbc.M900185200; Eberini I, 2011, J COMPUT AID MOL DES, V25, P743, DOI 10.1007/s10822-011-9455-8; Elangovan S, 2014, CANCER RES, V74, P1166, DOI 10.1158/0008-5472.CAN-13-1451; Elbegdorj O, 2013, J MOL GRAPH MODEL, V39, P50, DOI 10.1016/j.jmgm.2012.10.005; Feng WK, 2003, BIOCHEM PHARMACOL, V65, P1077, DOI 10.1016/S0006-2952(03)00005-4; Frasch SC, 2008, J BIOL CHEM, V283, P33736, DOI 10.1074/jbc.M807047200; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Fujiwara Y, 2007, J BIOL CHEM, V282, P2374, DOI 10.1074/jbc.M609648200; Fukushima K, 2015, BIOCHEM BIOPH RES CO, V465, P512, DOI 10.1016/j.bbrc.2015.08.050; Fukushima Y, 1998, INT J ONCOL, V13, P967; Funke M, 2012, AM J RESP CELL MOL, V46, P355, DOI 10.1165/rcmb.2010-0155OC; Furui T, 1999, CLIN CANCER RES, V5, P4308; Gaetano CG, 2009, MOL CARCINOGEN, V48, P801, DOI 10.1002/mc.20524; Galamb O, 2009, CELL ONCOL, V31, P19, DOI 10.3233/CLO-2009-0458; Gaudreau R, 2004, J BIOL CHEM, V279, P10338, DOI 10.1074/jbc.M309207200; Gaudreau R, 2002, J BIOL CHEM, V277, P31567, DOI 10.1074/jbc.M202723200; Giaginis C, 2014, NEOPLASMA, V61, P309, DOI 10.4149/neo_2014_040; Glatt S, 2008, INT J CANCER, V122, P2008, DOI 10.1002/ijc.23349; Gotoh M, 2012, BIOCHEM SOC T, V40, P31, DOI 10.1042/BST20110608; Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Gugger M, 2008, DIS MARKERS, V24, P41, DOI 10.1155/2008/857474; Guo YD, 2011, J BIOL CHEM, V286, P33832, DOI 10.1074/jbc.M110.216564; Gustafsson A, 2007, ACTA ONCOL, V46, P1107, DOI 10.1080/02841860701403061; Gustafsson A, 2007, INT J CANCER, V121, P232, DOI 10.1002/ijc.22582; Halder S, 2013, EXPERT OPIN THER PAT, V23, P1581, DOI 10.1517/13543776.2013.842977; Han C, 2005, J BIOL CHEM, V280, P24053, DOI 10.1074/jbc.M500562200; Han C, 2006, J CELL PHYSIOL, V207, P261, DOI 10.1002/jcp.20560; Hansen MC, 2013, SCIENCE, V342, P850, DOI [10.1126/science.1244693, 10.1126/science.1215904]; Hata AN, 2005, J BIOL CHEM, V280, P32442, DOI 10.1074/jbc.M502563200; Hatanaka H, 2000, INT J MOL MED, V5, P181; Hayashi M, 2012, CANCER LETT, V316, P91, DOI 10.1016/j.canlet.2011.10.030; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA T, 1994, J CLIN INVEST, V94, P1662, DOI 10.1172/JCI117510; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Hong S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00013; Hosoi T, 2005, BIOCHEM BIOPH RES CO, V334, P987, DOI 10.1016/j.bbrc.2005.06.191; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Houthuijzen JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6275; Hsu A, 2012, INT J ONCOL, V40, P1619, DOI 10.3892/ijo.2012.1379; HUANG CF, 1995, BIOCHEM J, V307, P493, DOI 10.1042/bj3070493; Huang HFS, 2013, MOL CANCER RES, V11, P427, DOI 10.1158/1541-7786.MCR-12-0464; Huang RY, 2014, J CANCER RES CLIN, V140, P375, DOI 10.1007/s00432-013-1573-3; Hudson BD, 2014, J BIOL CHEM, V289, P20345, DOI 10.1074/jbc.M114.561449; Hurst DP, 2010, J BIOL CHEM, V285, P17954, DOI 10.1074/jbc.M109.041590; Iida Y, 2014, ANTICANCER RES, V34, P5465; Ikubo M, 2015, J MED CHEM, V58, P4204, DOI 10.1021/jm5020082; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Inada M, 2015, J BIOL CHEM, V2015; Inagaki Y, 2005, BIOCHEM J, V389, P187, DOI 10.1042/BJ20050046; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/NMETH.2172, 10.1038/nmeth.2172]; Ishdorj G, 2008, J BIOL CHEM, V283, P16818, DOI 10.1074/jbc.M710177200; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jabbour HN, 2004, TRENDS ENDOCRIN MET, V15, P398, DOI 10.1016/j.tem.2004.08.006; Jiang JX, 2013, J PHARMACOL EXP THER, V344, P360, DOI 10.1124/jpet.112.200444; Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; Jongsma M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029260; Justus CR, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00354; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187; Kargl J, 2016, BRIT J PHARMACOL, V173, P142, DOI 10.1111/bph.13345; Kastner S, 2012, MOL CANCER RES, V10, P1343, DOI 10.1158/1541-7786.MCR-12-0139; Katritch V, 2013, ANNU REV PHARMACOL, V53, P531, DOI 10.1146/annurev-pharmtox-032112-135923; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Kebede MA, 2009, DIABETES OBES METAB, V11, P10, DOI 10.1111/j.1463-1326.2009.01114.x; Kedzie KM, 1998, MOL PHARMACOL, V54, P584, DOI 10.1124/mol.54.3.584; Khasawneh FT, 2006, J BIOL CHEM, V281, P26951, DOI 10.1074/jbc.M507469200; Kim EY, 2010, ONCOGENE, V29, P1167, DOI 10.1038/onc.2009.412; Kim EY, 2010, FREE RADICAL BIO MED, V49, P1072, DOI 10.1016/j.freeradbiomed.2010.06.023; Kim H, 2013, BRIT J CANCER, V109, P351, DOI 10.1038/bjc.2013.333; Kim H, 2014, J BIOL CHEM, V289, P22151, DOI 10.1074/jbc.M114.556126; Kim KS, 2006, CANCER RES, V66, P7983, DOI 10.1158/0008-5472.CAN-05-4381; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Kiss GN, 2012, MOL PHARMACOL, V82, P1162, DOI 10.1124/mol.112.079699; Kitamura H, 2012, J BIOCHEM, V151, P511, DOI 10.1093/jb/mvs011; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; Kleivi K, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-2; Kobayashi T, 2000, J BIOL CHEM, V275, P24294, DOI 10.1074/jbc.M002437200; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; Kohno M, 2006, BIOCHEM BIOPH RES CO, V347, P827, DOI 10.1016/j.bbrc.2006.06.175; Koike D, 2006, J BIOCHEM, V139, P543, DOI 10.1093/jb/mvj060; Komachi M, 2012, CANCER SCI, V103, P1099, DOI 10.1111/j.1349-7006.2012.02246.x; Kotarsky K, 2003, BIOCHEM BIOPH RES CO, V301, P406, DOI 10.1016/S0006-291X(02)03064-4; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Kothapalli R, 2002, BBA-GENE STRUCT EXPR, V1579, P117, DOI 10.1016/S0167-4781(02)00529-8; Krishnamoorthy S, 2012, AM J PATHOL, V180, P2018, DOI 10.1016/j.ajpath.2012.01.028; Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107; Kudo S, 2007, ONCOL REP, V18, P785; Kumar JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104877; Kuniyeda K, 2007, J BIOL CHEM, V282, P3998, DOI 10.1074/jbc.M610540200; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Kurtova AV, 2015, NATURE, V517, P209, DOI 10.1038/nature14034; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lee HJ, 2013, INT J BIOCHEM CELL B, V45, P2801, DOI 10.1016/j.biocel.2013.09.018; Lee JH, 2001, INT J ONCOL, V18, P355; Lee JW, 2013, J BIOL CHEM, V288, P30054, DOI 10.1074/jbc.M113.481283; Lee JW, 2012, BIOCHEM BIOPH RES CO, V420, P428, DOI 10.1016/j.bbrc.2012.03.012; Lee SC, 2015, MOL CANCER RES, V13, P174, DOI 10.1158/1541-7786.MCR-14-0263; Lee Z, 2008, MOL BIOL CELL, V19, P5435, DOI 10.1091/mbc.E08-03-0316; Li YY, 2007, J AM CHEM SOC, V129, P10720, DOI 10.1021/ja070865d; Liebscher I, 2011, J BIOL CHEM, V286, P2101, DOI 10.1074/jbc.M110.196659; Lim HS, 2004, BIOORG MED CHEM LETT, V14, P2499, DOI 10.1016/j.bmcl.2004.03.001; Lin DCH, 2012, MOL PHARMACOL, V82, P843, DOI 10.1124/mol.112.079640; Lin FT, 2007, J BIOL CHEM, V282, P37759, DOI 10.1074/jbc.M705025200; Lin SB, 2010, GASTROENTEROLOGY, V138, P649, DOI 10.1053/j.gastro.2009.09.055; Liu JF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-43; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Liu Z, 2015, J PHARMACOL EXP THER, V352, P380, DOI 10.1124/jpet.114.218974; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Maekawa A, 2009, P NATL ACAD SCI USA, V106, P11685, DOI 10.1073/pnas.0905364106; Magnusson C, 2011, INT J CANCER, V129, P9, DOI 10.1002/ijc.25648; Marcu J, 2013, J PHARMACOL EXP THER, V345, P189, DOI 10.1124/jpet.112.201046; Margan D, 2012, REV ROUM CHIM, V57, P39; Marshall JCA, 2012, JNCI-J NATL CANCER I, V104, P1306, DOI 10.1093/jnci/djs319; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matsuyama M, 2007, ONCOL REP, V18, P99; Matula K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1718-7; Meisen WH, 2015, MOL CANCER THER, V14, P307, DOI 10.1158/1535-7163.MCT-14-0659; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Melnikova VO, 2009, J BIOL CHEM, V284, P28845, DOI 10.1074/jbc.M109.042150; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; Mercier RW, 2010, CHEM BIOL, V17, P1132, DOI 10.1016/j.chembiol.2010.08.010; Milligan G, 2014, BRIT J PHARMACOL, V172, P3254; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Murakami M, 2008, BIOCHEM BIOPH RES CO, V371, P707, DOI 10.1016/j.bbrc.2008.04.145; Nam DH, 2004, ONCOL REP, V11, P863; Natarajan C, 2013, MOL PHARMACOL, V83, P206, DOI 10.1124/mol.112.080473; NEGISHI M, 1995, J BIOL CHEM, V270, P16122, DOI 10.1074/jbc.270.27.16122; Nehra D, 2014, J SURG RES, V188, P451, DOI 10.1016/j.jss.2014.01.037; Neuschafer-Rube F, 2003, BIOCHEM J, V371, P443, DOI 10.1042/BJ20021429; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Niedernberg A, 2003, CELL SIGNAL, V15, P435, DOI 10.1016/S0898-6568(02)00119-5; Nikaido Y, 2015, J BIOCHEM, V157, P311, DOI 10.1093/jb/mvu075; Nilsson NE, 2003, BIOCHEM BIOPH RES CO, V303, P1047, DOI 10.1016/S0006-291X(03)00488-1; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Nygaard R, 2009, TRENDS PHARMACOL SCI, V30, P249, DOI 10.1016/j.tips.2009.02.006; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Oka S, 2010, BIOCHEM BIOPH RES CO, V395, P232, DOI 10.1016/j.bbrc.2010.03.169; Oka S, 2009, J BIOCHEM, V145, P13, DOI 10.1093/jb/mvn136; Okabe K, 2013, MOL CARCINOGEN, V52, P247, DOI 10.1002/mc.21851; Okabe K, 2011, MOL CARCINOGEN, V50, P635, DOI 10.1002/mc.20750; Okazoe H, 2013, INT J MOL SCI, V14, P12367, DOI 10.3390/ijms140612367; Okumura S, 2004, CANCER SCI, V95, P131, DOI 10.1111/j.1349-7006.2004.tb03193.x; Okuno T, 2005, J BIOL CHEM, V280, P32049, DOI 10.1074/jbc.R500007200; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Okuno T, 2008, J EXP MED, V205, P759, DOI 10.1084/jem.20072329; Okuyama T, 2002, J LAB CLIN MED, V140, P92, DOI 10.1067/mlc.2002.125784; Onuchic AC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/175408; Parhamifar L, 2005, CARCINOGENESIS, V26, P1988, DOI 10.1093/carcin/bgi159; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; Parravicini C, 2010, BMC STRUCT BIOL, V10, DOI 10.1186/1472-6807-10-8; Parrill AL, 2013, BBA-MOL CELL BIOL L, V1831, P2, DOI 10.1016/j.bbalip.2012.09.002; Parrill AL, 2000, J BIOL CHEM, V275, P39379, DOI 10.1074/jbc.M007680200; Patmanathan SN, 2015, J CELL MOL MED, V19, P2329, DOI 10.1111/jcmm.12635; Perez-Gomez E, 2013, ONCOGENE, V32, P2534, DOI 10.1038/onc.2012.278; Pettipher R, 2008, BRIT J PHARMACOL, V153, pS191, DOI 10.1038/sj.bjp.0707488; Pham TCT, 2008, J MOL GRAPH MODEL, V26, P1189, DOI 10.1016/j.jmgm.2007.11.001; Pierce KL, 1998, LIFE SCI, V62, P1479, DOI 10.1016/S0024-3205(98)00093-9; Pisanti S, 2013, TRENDS PHARMACOL SCI, V34, P273, DOI 10.1016/j.tips.2013.03.003; Poso A, 2008, BRIT J PHARMACOL, V153, P335, DOI 10.1038/sj.bjp.0707567; Pradhan MP, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-141; Pugliese AM, 2009, AM J PHYSIOL-CELL PH, V297, pC1028, DOI 10.1152/ajpcell.00658.2008; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Qin Y, 2011, PIGM CELL MELANOMA R, V24, P207, DOI 10.1111/j.1755-148X.2010.00781.x; Quint K, 2014, TUMOR BIOL, V35, P8979, DOI 10.1007/s13277-014-2172-x; Raitio KH, 2005, CURR MED CHEM, V12, P1217, DOI 10.2174/0929867053764617; Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004; Reggio PH, 2010, CURR MED CHEM, V17, P1468, DOI 10.2174/092986710790980005; Rehwald M, 1999, FEBS LETT, V443, P357, DOI 10.1016/S0014-5793(99)00007-1; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Resh MD, 2013, CURR BIOL, V23, pR431, DOI 10.1016/j.cub.2013.04.024; Rhee MH, 2000, J NEUROCHEM, V75, P2485, DOI 10.1046/j.1471-4159.2000.0752485.x; Rocconi RP, 2008, REPROD SCI, V15, P321, DOI 10.1177/1933719108316390; Romanuik TL, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-43; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Rundhaug JE, 2011, CANCER METAST REV, V30, P465, DOI 10.1007/s10555-011-9317-9; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Sabirsh A, 2006, BIOCHEMISTRY-US, V45, P5733, DOI 10.1021/bi060076t; Sales KJ, 2004, J CLIN ENDOCR METAB, V89, P986, DOI 10.1210/jc.2003-031434; Salim T, 2014, EXP CELL RES, V321, P255, DOI 10.1016/j.yexcr.2013.10.021; Samadi N, 2009, ONCOGENE, V28, P1028, DOI 10.1038/onc.2008.442; Samson MT, 2003, J IMMUNOL, V170, P4953, DOI 10.4049/jimmunol.170.10.4953; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Sawyer N, 2002, BRIT J PHARMACOL, V137, P1163, DOI 10.1038/sj.bjp.0704973; Sawzdargo M, 1997, BIOCHEM BIOPH RES CO, V239, P543, DOI 10.1006/bbrc.1997.7513; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Seo JM, 2012, J BIOL CHEM, V287, P13840, DOI 10.1074/jbc.M111.317131; Seo JM, 2011, EXP MOL MED, V43, P129, DOI 10.3858/emm.2011.43.3.014; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2011, CURR TOP MED CHEM, V11, P629; Shen M, 2011, LEUKEMIA RES, V35, P968, DOI 10.1016/j.leukres.2010.12.012; Shida D, 2008, CANCER RES, V68, P6569, DOI 10.1158/0008-5472.CAN-08-0411; Shim JY, 2010, CURR TOP MED CHEM, V10, P779, DOI 10.2174/156802610791164210; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Singh LS, 2007, JNCI-J NATL CANCER I, V99, P1313, DOI 10.1093/jnci/djm107; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; So SP, 2003, J BIOL CHEM, V278, P10922, DOI 10.1074/jbc.M209337200; Soga T, 2005, BIOCHEM BIOPH RES CO, V326, P744, DOI 10.1016/j.bbrc.2004.11.120; Song MY, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv007; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spisak S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046215; Srivastava A, 2014, NATURE, V513, P124, DOI 10.1038/nature13494; Stephenson JR, 2013, J BIOL CHEM, V288, P22248, DOI 10.1074/jbc.M113.489757; Stillman BA, 1998, EUR J PHARMACOL, V357, P73, DOI 10.1016/S0014-2999(98)00522-6; Stitham J, 2003, J BIOL CHEM, V278, P4250, DOI 10.1074/jbc.M207420200; Stoddart LA, 2008, J BIOL CHEM, V283, P32913, DOI 10.1074/jbc.M805601200; Sugino Y, 2007, ONCOGENE, V26, P7401, DOI 10.1038/sj.onc.1210550; Sugita K, 2013, BIOCHEM BIOPH RES CO, V430, P190, DOI 10.1016/j.bbrc.2012.11.046; Sugo T, 2006, BIOCHEM BIOPH RES CO, V341, P1078, DOI 10.1016/j.bbrc.2006.01.069; Sum CS, 2007, J BIOL CHEM, V282, P29248, DOI 10.1074/jbc.M705077200; Sum CS, 2009, J BIOL CHEM, V284, P3529, DOI 10.1074/jbc.M806987200; Sun L, 2015, INT J CLIN EXP PATHO, V8, P432; Sundaram S, 2006, BIOCHEM BIOPH RES CO, V339, P93, DOI 10.1016/j.bbrc.2005.10.189; Sung YM, 2006, ONCOGENE, V25, P5507, DOI 10.1038/sj.onc.1209538; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Suzuki M, 2013, J BIOL CHEM, V288, P10684, DOI 10.1074/jbc.M112.420042; Tabata KI, 2007, BIOCHEM BIOPH RES CO, V363, P861, DOI 10.1016/j.bbrc.2007.09.063; Taggart AKP, 2005, J BIOL CHEM, V280, P26649, DOI 10.1074/jbc.C500213200; Taghavi P, 2008, ONCOGENE, V27, P6806, DOI 10.1038/onc.2008.294; Takuwa Y, 2002, J BIOCHEM, V131, P767, DOI 10.1093/oxfordjournals.jbchem.a003163; Tan J, 2014, ADV IMMUNOL, V121, P91, DOI 10.1016/B978-0-12-800100-4.00003-9; Tang Y, 2011, INT J CANCER, V128, P847, DOI 10.1002/ijc.25638; Thangaraju M, 2009, CANCER RES, V69, P2826, DOI 10.1158/0008-5472.CAN-08-4466; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Tian DW, 2015, MOL MED REP, V12, P4522, DOI 10.3892/mmr.2015.3984; Tikhonova IG, 2015, BMC STRUCT BIOL, V15, DOI 10.1186/s12900-015-0044-2; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Ungrin MD, 2001, MOL PHARMACOL, V59, P1446, DOI 10.1124/mol.59.6.1446; Uwamizu A, 2015, J BIOCHEM, V157, P151, DOI 10.1093/jb/mvu060; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; van Loenen PB, 2011, EUR J PHARMACOL, V667, P105, DOI 10.1016/j.ejphar.2011.05.071; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Varsano T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049227; Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896; Wang DA, 2001, J BIOL CHEM, V276, P49213, DOI 10.1074/jbc.M107301200; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang JH, 2006, J BIOL CHEM, V281, P34457, DOI 10.1074/jbc.M608019200; Wang JH, 2006, J BIOL CHEM, V281, P22021, DOI 10.1074/jbc.M603503200; Watson C, 2010, AM J PATHOL, V177, P2205, DOI 10.2353/ajpath.2010.100220; Watson SJ, 2012, MOL PHARMACOL, V81, P631, DOI 10.1124/mol.111.077388; Williams JR, 2009, J BIOL CHEM, V284, P17304, DOI 10.1074/jbc.M109.003194; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Wu Q, 2013, ONCOGENE, V32, P5541, DOI 10.1038/onc.2013.264; Xin XP, 2012, LAB INVEST, V92, P1115, DOI 10.1038/labinvest.2012.90; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamada T, 2005, J BIOL CHEM, V280, P19358, DOI 10.1074/jbc.M414561200; Yan MX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061056; Yanagida K, 2013, BBA-MOL CELL BIOL L, V1831, P33, DOI 10.1016/j.bbalip.2012.08.003; Yanagida K, 2009, J BIOL CHEM, V284, P17731, DOI 10.1074/jbc.M808506200; Yang HL, 2010, J BIOL CHEM, V285, P32242, DOI 10.1074/jbc.M110.160820; Yang L, 2006, CANCER RES, V66, P9665, DOI 10.1158/0008-5472.CAN-06-1271; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yokomizo T, 2015, J BIOCHEM, V157, P65, DOI 10.1093/jb/mvu078; Yokota Y, 2012, BLOOD, V120, P3444, DOI 10.1182/blood-2011-10-383240; Yokoyama U, 2013, PHARMACOL REV, V65, P1010, DOI 10.1124/pr.112.007195; Yoshida Y, 1999, INT J ONCOL, V15, P1221; Yoshida Y, 2010, INT J CANCER, V126, P2341, DOI 10.1002/ijc.24933; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378; Yu WD, 2013, HISTOL HISTOPATHOL, V28, P1629, DOI 10.14670/HH-28.1629; Yu Y, 2014, BRIT J CANCER, V111, P515, DOI 10.1038/bjc.2014.323; Yun CC, 2005, AM J PHYSIOL-CELL PH, V289, pC2, DOI 10.1152/ajpcell.00610.2004; Zare Behnoush, 2011, Sci Pharm, V79, P793, DOI 10.3797/scipharm.1106-24; Zhang HC, 2007, J BIOL CHEM, V282, P15541, DOI 10.1074/jbc.M700702200; Zhang HC, 2007, CELL SIGNAL, V19, P261, DOI 10.1016/j.cellsig.2006.06.008; Zhang Lijun, 2010, Genomics Proteomics & Bioinformatics, V8, P1, DOI 10.1016/S1672-0229(10)60001-0; Zhang YH, 2009, CANCER RES, V69, P6049, DOI 10.1158/0008-5472.CAN-09-0621; Zhou HP, 1999, BIOCHEM BIOPH RES CO, V264, P171, DOI 10.1006/bbrc.1999.1508; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026	346	12	12	4	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4021	4035		10.1038/onc.2015.467	http://dx.doi.org/10.1038/onc.2015.467			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26640151				2022-12-17	WOS:000381020900001
J	Chalermrujinanant, C; Michowski, W; Sittithumcharee, G; Esashi, F; Jirawatnotai, S				Chalermrujinanant, C.; Michowski, W.; Sittithumcharee, G.; Esashi, F.; Jirawatnotai, S.			Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation	ONCOGENE			English	Article							STRAND BREAK REPAIR; DNA-END RESECTION; HOMOLOGY-DIRECTED REPAIR; MANTLE CELL LYMPHOMA; GENOMIC STABILITY; DAMAGE REPAIR; CANCER; PROTEIN; GENE; RECOMBINATION	BRCA2 has an important role in the maintenance of genome stability by interacting with RAD51 recombinase through its C-terminal domain. This interaction is abrogated by cyclin A-CDK2-mediated phosphorylation of BRCA2 at serine 3291 (Ser3291). Recently, we showed that cyclin D1 facilitates RAD51 recruitment to BRCA2-containing DNA repair foci, and that downregulation of cyclin D1 leads to inefficient homologous-mediated DNA repair. Here, we demonstrate that cyclin D1, via amino acids 20-90, interacts with the C-terminal domain of BRCA2, and that this interaction is increased in response to DNA damage. Interestingly, CDK4-cyclin D1 does not phosphorylate Ser3291. Instead, cyclin D1 bars cyclin A from the C-terminus of BRCA2, prevents cyclin A-CDK2-dependent Ser3291 phosphorylation and facilitates RAD51 binding to the C-terminal domain of BRCA2. These findings indicate that the interplay between cyclin D1 and other cyclins such as cyclin A regulates DNA integrity through RAD51 interaction with the BRCA2 C-terminal domain.	[Chalermrujinanant, C.; Sittithumcharee, G.; Jirawatnotai, S.] Mahidol Univ, Siriraj Hosp, Fac Med, Lab Syst Pharmacol,Dept Pharmacol, 2 Prannok Rd,12th Floor Srisawarin Bldg, Bangkok 10700, Thailand; [Michowski, W.; Jirawatnotai, S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Esashi, F.] Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England; [Jirawatnotai, S.] Mahidol Univ, Inst Mol Biosci, Bangkok 10700, Thailand	Mahidol University; Harvard University; Dana-Farber Cancer Institute; University of Oxford; Mahidol University	Jirawatnotai, S (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Lab Syst Pharmacol,Dept Pharmacol, 2 Prannok Rd,12th Floor Srisawarin Bldg, Bangkok 10700, Thailand.	siwanon.jir@mahidol.ac.th		Esashi, Fumiko/0000-0003-0902-2364	Thailand Research Fund [RSA5580018]; Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University; Advanced Research on Pharmacology Fund, Siriraj Foundation [D003421]; Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University	Thailand Research Fund(Thailand Research Fund (TRF)); Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University; Advanced Research on Pharmacology Fund, Siriraj Foundation; Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University	We thank Dr Piotr Sicinski, Dana-Farber Cancer Institute, in whose laboratory this work was initiated. This study was supported by Thailand Research Fund RSA5580018, Siriraj Research Fund, Faculty of Medicine Siriraj Hospital, Mahidol University, and the Advanced Research on Pharmacology Fund, Siriraj Foundation D003421. SJ was supported by the Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital, Mahidol University.	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1995, ONCOGENE, V10, P775; BATES S, 1994, ONCOGENE, V9, P1633; Berman DB, 1996, CANCER RES, V56, P3409; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; BOSCH F, 1994, BLOOD, V84, P2726; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies OR, 2007, NAT STRUCT MOL BIOL, V14, P475, DOI 10.1038/nsmb1251; DEBOER CJ, 1995, BLOOD, V86, P2715, DOI 10.1182/blood.V86.7.2715.bloodjournal8672715; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Esashi F, 2007, NAT STRUCT MOL BIOL, V14, P468, DOI 10.1038/nsmb1245; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2012, EMBO REP, V13, P561, DOI 10.1038/embor.2012.58; GILLETT C, 1994, CANCER RES, V54, P1812; Goggins M, 1996, CANCER RES, V56, P5360; Gretarsdottir S, 1998, CANCER RES, V58, P859; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; Huertas P, 2008, NATURE, V455, P689, DOI 10.1038/nature07215; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; JARES P, 1994, CANCER RES, V54, P4813; Jasin M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012740; JavanMoghadam-Kamrani S, 2008, CELL CYCLE, V7, P2434, DOI 10.4161/cc.6364; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; JIANG W, 1992, CANCER RES, V52, P2980; Jirawatnotai S, 2012, CANCER RES, V72, P4289, DOI 10.1158/0008-5472.CAN-11-3549; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; KOMATSU H, 1993, BRIT J HAEMATOL, V85, P427, DOI 10.1111/j.1365-2141.1993.tb03194.x; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Li ZP, 2014, CANCER RES, V74, P3959, DOI 10.1158/0008-5472.CAN-13-3137; Li ZP, 2010, CANCER RES, V70, P8802, DOI 10.1158/0008-5472.CAN-10-0312; Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Lu G, 2013, SCI WORLD J, DOI 10.1155/2013/424617; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pefani DE, 2014, NAT CELL BIOL, V16, P962, DOI 10.1038/ncb3035; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shimura T, 2013, CELL CYCLE, V12, P2738, DOI 10.4161/cc.25746; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Thorslund T, 2007, EMBO J, V26, P2915, DOI 10.1038/sj.emboj.7601739; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yata K, 2014, CELL REP, V7, P1547, DOI 10.1016/j.celrep.2014.04.023; Yata K, 2012, MOL CELL, V45, P371, DOI 10.1016/j.molcel.2011.12.028; Yu VPCC, 2000, GENE DEV, V14, P1400; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	60	12	12	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2815	2823		10.1038/onc.2015.354	http://dx.doi.org/10.1038/onc.2015.354			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387543	Green Accepted			2022-12-17	WOS:000377473700001
J	Zhu, T; Wang, J; Pei, Y; Wang, Q; Wu, Y; Qiu, G; Zhang, D; Lv, M; Li, W; Zhang, J				Zhu, T.; Wang, J.; Pei, Y.; Wang, Q.; Wu, Y.; Qiu, G.; Zhang, D.; Lv, M.; Li, W.; Zhang, J.			Neddylation controls basal MKK7 kinase activity in breast cancer cells	ONCOGENE			English	Article							PROTEIN-KINASE; NEDD8-ACTIVATING ENZYME; UBIQUITIN LIGASE; ACTIVATION; JNK; NEDD8; APOPTOSIS; IDENTIFICATION; INHIBITOR; STABILITY	The c-Jun NH2-terminal protein kinase (JNK) pathway has been implicated in mammary tumor development. However, the molecular mechanisms regulating JNK activity in breast cancer cells remain unclear. Here, we report that the inhibition of ubiquitination-like post-translational modification neddylation through different strategies results in enhanced basal JNK phosphorylation in human breast cancer cells. The upregulation of basal JNK phosphorylation upon neddylation inhibition is independent of the deneddylation of Cullins, the well-characterized neddylation substrates. Since augmented basal JNK phosphorylation via ectopic MKK7 expression impedes proliferation and the epithelial-to-mesenchymal transition (EMT) phenotype, the neddylation system might contribute to mammary tumor development partially through limiting basal JNK phosphorylation. Further exploration reveals that MKK7, a JNK-specific MAP2K, undergoes neddylation in human breast cancer cells. MKK7 coprecipitates with a fragment of Ran-binding protein 2 (RanBP2), a large multimodular and pleiotropic protein that has been recognized as a SUMO E3 ligase. Knockdown of RanBP2 attenuates MKK7 neddylation and augments basal JNK phosphorylation without affecting the neddylation of Cullins, whereas ectopic expression of a RanBP2 fragment possessing SUMO E3 activity (RanBP2 Delta FG) manifests the opposite effects. In vitro neddylation assays confirm that RanBP2 Delta FG works as the neddylation E3 ligase for MKK7. The basal kinase activity of endogenous MKK7 increases upon RanBP2 knockdown but decreases upon the ectopic expression of RanBP2 Delta FG. Furthermore, purified MKK7 shows reduced basal kinase activity after in vitro neddylation by RanBP2 Delta FG. Consistently, RanBP2 knockdown leads to reduced proliferation and impaired EMT phenotype in human breast cancer cells and the effects of RanBP2 knockdown are reversed by simultaneous MKK7 knockdown. Taken together, our data suggest that MKK7 undergoes neddylation in human breast cancer cells, which limits its basal kinase activity.	[Zhu, T.; Wang, J.; Pei, Y.; Wang, Q.; Wu, Y.; Qiu, G.; Zhang, D.; Lv, M.; Li, W.; Zhang, J.] Inst Basic Med Sci, Dept Mol Immunol, 27 Taiping Rd, Beijing 100850, Peoples R China		Zhang, J (corresponding author), Inst Basic Med Sci, Dept Mol Immunol, 27 Taiping Rd, Beijing 100850, Peoples R China.	zhangjy@nic.bmi.ac.cn	Z, D/AFG-4813-2022	Zhang, Jiyan/0000-0001-8011-8719; , DALIN/0000-0002-6553-7373	National Natural Science Foundation of China [81472736, 31270960]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Professors Ming Shi, Ning Guo, Ailing Li and Xuemin Zhang for providing reagents. This work was supported by grants from National Natural Science Foundation of China (81472736, 31270960).	Aoki I, 2013, ONCOGENE, V32, P3954, DOI 10.1038/onc.2012.428; Broemer M, 2010, MOL CELL, V40, P810, DOI 10.1016/j.molcel.2010.11.011; Cellurale C, 2012, CANCER RES, V72, P472, DOI 10.1158/0008-5472.CAN-11-1628; Cellurale C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012469; Chen PL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010443; Collier-Hyams LS, 2005, J IMMUNOL, V175, P4194, DOI 10.4049/jimmunol.175.7.4194; Cui J, 2009, MOL CANCER THER, V8, P3214, DOI 10.1158/1535-7163.MCT-09-0408; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Godbersen JC, 2014, CLIN CANCER RES, V20, P1576, DOI 10.1158/1078-0432.CCR-13-0987; Guo YY, 2013, HEPATOLOGY, V57, P140, DOI 10.1002/hep.25978; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hjerpe R, 2012, BIOCHEM J, V441, P927, DOI 10.1042/BJ20111671; Hutten S, 2008, MOL BIOL CELL, V19, P2300, DOI 10.1091/mbc.E07-12-1279; Jubelin G, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001128; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Pelham CJ, 2012, CELL METAB, V16, P462, DOI 10.1016/j.cmet.2012.08.011; Schramek D, 2011, NAT GENET, V43, P212, DOI 10.1038/ng.767; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wang J, 2011, MOL BIOL CELL, V22, P117, DOI 10.1091/mbc.E10-06-0492; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang J, 2008, CELL DEATH DIFFER, V15, P1654, DOI 10.1038/cdd.2008.87; Zhang JY, 2010, J IMMUNOL, V185, P3554, DOI 10.4049/jimmunol.1000431; Zhang Z, 2014, ONCOGENE, V33, P3374, DOI 10.1038/onc.2013.337	36	12	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2624	2633		10.1038/onc.2015.323	http://dx.doi.org/10.1038/onc.2015.323			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364603				2022-12-17	WOS:000376165700009
J	Tatsumi, N; Hojo, N; Yamada, O; Ogawa, M; Katsura, Y; Kawata, S; Morii, E; Sakamoto, H; Inaba, R; Tsuda, A; Fukuda, I; Moriguchi, N; Hasuwa, H; Okabe, M; Fujiki, F; Nishida, S; Nakajima, H; Tsuboi, A; Oka, Y; Hosen, N; Sugiyama, H; Oji, Y				Tatsumi, N.; Hojo, N.; Yamada, O.; Ogawa, M.; Katsura, Y.; Kawata, S.; Morii, E.; Sakamoto, H.; Inaba, R.; Tsuda, A.; Fukuda, I.; Moriguchi, N.; Hasuwa, H.; Okabe, M.; Fujiki, F.; Nishida, S.; Nakajima, H.; Tsuboi, A.; Oka, Y.; Hosen, N.; Sugiyama, H.; Oji, Y.			Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities	ONCOGENE			English	Article							WILMS-TUMOR GENE; SUPPRESSOR GENE; LEUKEMIC-CELLS; TRANSCRIPTION FACTOR; PROGENITOR CELLS; BINDING-SITES; SOLID TUMORS; WT1 PROTEIN; EXPRESSION; OVEREXPRESSION	The Wilms' tumor gene WT1 is overexpressed in leukemia and solid tumors and has an oncogenic role in leukemogenesis and tumorigenesis. However, precise regulatory mechanisms of WT1 overexpression remain undetermined. In the present study, microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR. MiR-125a knockout mice overexpressed WT1, developed myeloproliferative disorder (MPD) characterized by expansion of myeloid cells in bone marrow (BM), spleen and peripheral blood, and displayed urogenital abnormalities. Silencing of WT1 expression in hematopoietic stem/progenitor cells of miR-125a knockout MPD mice by short-hairpin RNA inhibited myeloid colony formation in vitro. Furthermore, the incidence and severity of MPD were lower in miR-125a (-/-) mice than in miR-125a (+/-) mice, indicating the operation of compensatory mechanisms for the complete loss of miR-125a. To elucidate the compensatory mechanisms, miRNA array was performed. MiR-486 was occasionally induced in compete loss of miR-125a and inhibited WT1 expression instead of miR-125a, resulting in the cancellation of MPD occurrence. These results showed for the first time the post-transcriptional regulatory mechanisms of WT1 by both miR-125a and miR-486 and should contribute to the elucidation of mechanisms of normal hematopoiesis and kidney development.	[Tatsumi, N.; Hojo, N.; Yamada, O.; Ogawa, M.; Katsura, Y.; Kawata, S.; Sakamoto, H.; Inaba, R.; Tsuda, A.; Fukuda, I.; Moriguchi, N.; Sugiyama, H.] Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Yamada Oka 1-7, Suita, Osaka 5650871, Japan; [Morii, E.] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; [Hasuwa, H.; Okabe, M.] Osaka Univ, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; [Fujiki, F.; Nakajima, H.; Oka, Y.] Osaka Univ, Grad Sch Med, Dept Canc Immunol, Suita, Osaka 5650871, Japan; [Nishida, S.] Osaka Univ, Grad Sch Med, Dept Resp Med Immunol & Allergy, Suita, Osaka 5650871, Japan; [Tsuboi, A.] Osaka Univ, Grad Sch Med, Dept Canc Immunotherapy, Suita, Osaka 5650871, Japan; [Hosen, N.; Oji, Y.] Osaka Univ, Grad Sch Med, Dept Canc Stem Cell Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Osaka University	Tatsumi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Yamada Oka 1-7, Suita, Osaka 5650871, Japan.	tatsumi@cit.med.osaka-u.ac.jp			Ministry of Education, Science, Sports, Culture and Technology, Japan; Ministry of Health, Labour, and Welfare, Japan	Ministry of Education, Science, Sports, Culture and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour, and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported in part by a Grant-in-Aid from the Ministry of Education, Science, Sports, Culture and Technology, Japan, and the Ministry of Health, Labour, and Welfare, Japan. We thank Yoko Esaki and Saki Nishioka of NPO Biotechnology Research and Development for technical assistance.	Alberta JA, 2003, BLOOD, V101, P2570, DOI 10.1182/blood-2002-06-1656; Alemdehy MF, 2012, CELL CYCLE, V11, P2799, DOI 10.4161/cc.21077; Algar EM, 1996, ONCOGENE, V12, P1005; Bao JQ, 2012, J BIOL CHEM, V287, P21686, DOI 10.1074/jbc.M111.328054; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Chau YY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002404; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; Dehbi M, 1996, ONCOGENE, V13, P447; Dehbi M, 1996, EMBO J, V15, P4297, DOI 10.1002/j.1460-2075.1996.tb00804.x; Discenza MT, 2004, FEBS LETT, V560, P183, DOI 10.1016/S0014-5793(04)00104-8; Domen J, 2000, J EXP MED, V191, P253, DOI 10.1084/jem.191.2.253; Downing JR, 2003, CURR OPIN GENET DEV, V13, P48, DOI 10.1016/S0959-437X(02)00018-7; Funakoshi-Tago M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052844; Gao F, 2006, P NATL ACAD SCI USA, V103, P11987, DOI 10.1073/pnas.0600994103; Gao SM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-110; Gebeshuber CA, 2013, NAT MED, V19, P481, DOI 10.1038/nm.3142; Guo SQ, 2010, P NATL ACAD SCI USA, V107, P14229, DOI 10.1073/pnas.0913574107; Han YQ, 2004, ONCOGENE, V23, P6933, DOI 10.1038/sj.onc.1207609; Harada Y, 1999, MOL UROL, V3, P357; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hosen N, 2002, BRIT J HAEMATOL, V116, P409, DOI 10.1046/j.1365-2141.2002.03261.x; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; Ito K, 2006, ONCOGENE, V25, P4217, DOI 10.1038/sj.onc.1209455; Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349-7006.2006.00169.x; Kanato K, 2005, BIOCHEM BIOPH RES CO, V326, P836, DOI 10.1016/j.bbrc.2004.11.107; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Loeb DM, 2001, CANCER RES, V61, P921; Manikandan M, 2014, OMICS, V18, P142, DOI 10.1089/omi.2013.0098; Martinez-Estrada OM, 2010, NAT GENET, V42, P89, DOI 10.1038/ng.494; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Moore AW, 1999, DEVELOPMENT, V126, P1845; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; Nishida S, 2006, BLOOD, V107, P3303, DOI 10.1182/blood-2005-04-1656; Oji Y, 1999, JPN J CANCER RES, V90, P194, DOI 10.1111/j.1349-7006.1999.tb00733.x; Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476; Oji Y, 2004, CANCER SCI, V95, P822, DOI 10.1111/j.1349-7006.2004.tb02188.x; Oji Y, 2004, ANTICANCER RES, V24, P3103; Oji Y, 2004, CANCER SCI, V95, P583, DOI 10.1111/j.1349-7006.2004.tb02490.x; Oji Y, 2003, CANCER SCI, V94, P712, DOI 10.1111/j.1349-7006.2003.tb01507.x; Oji Y, 2003, CANCER SCI, V94, P606, DOI 10.1111/j.1349-7006.2003.tb01490.x; Oji Y, 2003, CANCER SCI, V94, P523, DOI 10.1111/j.1349-7006.2003.tb01477.x; Perez-Pomares JM, 2002, DEV BIOL, V247, P307, DOI 10.1006/dbio.2002.0706; Preskill Carina, 2013, Critical Reviews in Oncogenesis, V18, P327; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Sotobori T, 2006, CANCER-AM CANCER SOC, V106, P2233, DOI 10.1002/cncr.21861; Tatsumi N, 2008, INT J ONCOL, V32, P701; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Vidovic K, 2010, LEUKEMIA, V24, P992, DOI 10.1038/leu.2010.33; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34; Yamagami T, 1998, LEUKEMIA RES, V22, P383, DOI 10.1016/S0145-2126(97)00176-8; Zhang XH, 1997, J BIOL CHEM, V272, P29272, DOI 10.1074/jbc.272.46.29272; Zhao X, 2010, ARTHRITIS RHEUM-US, V62, P3425, DOI 10.1002/art.27632	59	12	13	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1003	1014		10.1038/onc.2015.154	http://dx.doi.org/10.1038/onc.2015.154			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961914				2022-12-17	WOS:000370823300006
J	Huang, W; Dong, Z; Chen, Y; Wang, F; Wang, CJ; Peng, H; He, Y; Hangoc, G; Pollok, K; Sandusky, G; Fu, XY; Broxmeyer, HE; Zhang, ZY; Liu, JY; Zhang, JT				Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, K.; Sandusky, G.; Fu, X-Y; Broxmeyer, H. E.; Zhang, Z-Y; Liu, J-Y; Zhang, J-T			Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo (vol 35, pg 783, 2016)	ONCOGENE			English	Correction														Wang, Chao/0000-0001-8951-5657				Huang W, 2016, ONCOGENE, V35, P783, DOI 10.1038/onc.2015.215	1	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					802	802		10.1038/onc.2015.419	http://dx.doi.org/10.1038/onc.2015.419			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	26865226	Bronze			2022-12-17	WOS:000370331300015
J	Oh, YT; Deng, J; Yue, P; Owonikoko, TK; Khuri, FR; Sun, SY				Oh, Y-T; Deng, J.; Yue, P.; Owonikoko, T. K.; Khuri, F. R.; Sun, S-Y			Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing	ONCOGENE			English	Article							RECEPTOR 5 EXPRESSION; AZD6244 ARRY-142886; BRAF; RAF; MEK; COACTIVATION; CARCINOMAS; BENCH	Inhibition of B-Raf/MEK/ERK signaling is an effective therapeutic strategy against certain types of cancers such as melanoma and thyroid cancer. While demonstrated to be effective anticancer agents, B-Raf or MEK inhibitors have also been associated with early tumor progression and development of secondary neoplasms. The ligation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with its receptor, death receptor 5 (DR5), leading to induction of apoptosis, offers a promising anticancer strategy. Importantly, this is also a natural immunosurveillance mechanism against cancer development. We previously demonstrated that activated B-Raf/MEK/ERK signaling positively regulates DR5 expression. Hence, our current work sought to address whether B-Raf/MEK/ERK inhibition and the consequent suppression of DR5 expression impede cancer cell response to DR5 activation-induced apoptosis and activated immune cell-induced killing. We found that both B-Raf (for example, PLX4032) and MEK inhibitors (for example, AZD6244 and PD0325901) effectively inhibited ERK1/2 phosphorylation and reduced DR5 levels in both human thyroid cancer and melanoma cells. Similar to the observed effect of genetic knockdown of the B-Raf gene, pre-treatment of cancer cell lines with either B-Raf or MEK inhibitors attenuated or abolished cellular apoptotic response induced by TRAIL or the DR5 agonistic antibody AMG655 or cell killing by activated T cells. Our findings clearly show that inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs DR5 activation-induced apoptosis and T cell-mediated killing of cancer cells. These findings suggest a potential negative impact of B-Raf or MEK inhibition on TRAIL-or DR5-mediated anticancer therapy and on TRAIL/DR5-mediated immune-clearance of cancer cells.	[Oh, Y-T; Deng, J.; Yue, P.; Owonikoko, T. K.; Khuri, F. R.; Sun, S-Y] Emory Univ Sch Med & Winship Canc Inst, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3088, Atlanta, GA 30332 USA		Sun, SY (corresponding author), Emory Univ Sch Med & Winship Canc Inst, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3088, Atlanta, GA 30332 USA.	ssun@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618	NIH/NCI SPORE P50 grant [CA128613]; Emory Winship Cancer Institute Robbins Scholar awards; Melanoma Research Fund; Halpern Research Scholar award; Halpern Research Scholar; NATIONAL CANCER INSTITUTE [P50CA128613, P30CA138292] Funding Source: NIH RePORTER	NIH/NCI SPORE P50 grant; Emory Winship Cancer Institute Robbins Scholar awards; Melanoma Research Fund; Halpern Research Scholar award; Halpern Research Scholar; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs P Giannakakou, J Arbiser and R Schweppes for providing cancer cell lines and Amgen Inc. for the generous provision of AMG655. We are also thankful to Dr A Hammond for editing the manuscript. This study was supported by the NIH/NCI SPORE P50 grant CA128613 (to S-Y Sun for Project 2) and Emory Winship Cancer Institute Robbins Scholar awards (to Y-T Oh and to J Deng), Melanoma Research Fund (to J Deng) and Halpern Research Scholar award (to S-Y Sun). FR Khuri, TK Owonikoko and S-Y Sun are Georgia Research Alliance Distinguished Cancer Scientists. S-Y Sun is a Halpern Research Scholar.	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-27; Arnault JP, 2009, J CLIN ONCOL, V27, pE59, DOI 10.1200/JCO.2009.23.4823; Banerji U, 2010, CLIN CANCER RES, V16, P1613, DOI 10.1158/1078-0432.CCR-09-2483; Berger A, 2014, J INVEST DERMATOL, V134, P430, DOI 10.1038/jid.2013.347; Breaker K, 2013, DERMATOL SURG, V39, P981, DOI 10.1111/dsu.12184; Dhandapani L, 2011, CANCER RES, V71, P5245, DOI 10.1158/0008-5472.CAN-10-4180; Dubauskas Z, 2009, CLIN GENITOURIN CANC, V7, P20, DOI 10.3816/CGC.2009.n.003; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Friday BB, 2008, CLIN CANCER RES, V14, P342, DOI 10.1158/1078-0432.CCR-07-4790; Hersey P, 2009, CANCER IMMUNOL IMMUN, V58, P1751, DOI 10.1007/s00262-009-0732-5; Huang TG, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-30; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Llobet D, 2010, EUR J CANCER, V46, P836, DOI 10.1016/j.ejca.2009.12.025; Oh YT, 2012, J BIOL CHEM, V287, P257, DOI 10.1074/jbc.M111.304006; Oh YT, 2010, J BIOL CHEM, V285, P41310, DOI 10.1074/jbc.M110.153775; Rafei M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-121; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Smalley KSM, 2013, NAT REV CLIN ONCOL, V10, P5, DOI 10.1038/nrclinonc.2012.215; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Sun SY, 2007, J BIOL CHEM, V282, P18800, DOI 10.1074/jbc.M611438200; Sun SY, 1997, CANCER RES, V57, P4931; Weeraratna AT, 2012, NEW ENGL J MED, V366, P271, DOI 10.1056/NEJMe1111636; Yang A, 2010, CURR OPIN CELL BIOL, V22, P837, DOI 10.1016/j.ceb.2010.08.001; Zitzmann K, 2011, ENDOCR-RELAT CANCER, V18, P277, DOI 10.1530/ERC-10-0108	27	12	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					459	467		10.1038/onc.2015.97	http://dx.doi.org/10.1038/onc.2015.97			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867065	Green Accepted			2022-12-17	WOS:000369056700006
J	Riley, MF; You, MJ; Multani, AS; Lozano, G				Riley, M. F.; You, M. J.; Multani, A. S.; Lozano, G.			Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma	ONCOGENE			English	Article							GENE-EXPRESSION; P53; MICE; TAP73; BCL-2; INACTIVATION; DELTA-NP73; LEUKEMIA; PATHWAY; ABSENCE	Many human tumors express high levels of the p53 inhibitor Mdm2, resulting from amplification of the Mdm2 locus or aberrant post-translational regulation of the Mdm2 protein. While the importance of Mdm2 in regulating p53 is clear, Mdm2 also has p53-independent roles. For example, overexpression of Mdm2 results in genomic instability in a p53-independent manner. In addition, Mdm2 has many additional binding partners, some of which, such as the tumor suppressor p73, have also been implicated in genomic instability. In this study, cells and tumors with Mdm2 overexpression and p73 loss exhibit increased genomic instability as compared with either alteration alone and cooperate in development of B-cell lymphomagenesis. Cytogenetic analysis of mouse embryonic fibroblasts and pre-malignant B cells demonstrates that loss of p73 exacerbates the chromosome breaks and fusions observed in Mdm2(Tg) cells. B-cell lymphomas from Mdm2(Tg);p73(+/-) mice retain the remaining p73 allele, exhibit elevated levels of the antiapoptotic protein Bcl2 and thus dampen apoptosis. In summary, Mdm2 overexpression and p73 loss cooperate in genomic instability and tumor development, indicating that the oncogenic function of Mdm2 is a combined effect of inhibiting p53 and p73 functions. Given that p73 is lost or silenced in human B-cell lymphomas, the Mdm2(Tg);p73(+/-) mouse serves as a model for human disease and may provide additional insight into the pathways that contribute to B-cell lymphomagenesis.	[Riley, M. F.; Multani, A. S.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd,Unit 1010, Houston, TX 77030 USA; [You, M. J.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd,Unit 1010, Houston, TX 77030 USA.	gglozano@mdanderson.org			National Institutes of Health [CA47296]; T32 Training Grant [CA009299]; American Cancer Society; NIH/NCI [R01 CA164346]; Center for Genetics and Genomics; Sister Institution Network fund of MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA164346, R29CA047296, R01CA047296, T32CA009299] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); T32 Training Grant; American Cancer Society(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Genetics and Genomics; Sister Institution Network fund of MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Elsa Flores for the p73<SUP>+/-</SUP> mice, Stephen Jones for the Mdm2<SUP>Tg</SUP> mice, and Frederick W Alt for the J<INF>H</INF> plasmid. This work was supported by a National Institutes of Health grant (CA47296 to GL), and a T32 Training Grant (CA009299) and an American Cancer Society postdoctoral fellowships to MFR. MJY is supported in part by NIH/NCI R01 CA164346, and the Center for Genetics and Genomics and the Sister Institution Network fund of MD Anderson Cancer Center.	Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Corn PG, 1999, CANCER RES, V59, P3352; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Du WJ, 2013, NAT CELL BIOL, V15, P991, DOI 10.1038/ncb2789; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gostissa M, 2013, P NATL ACAD SCI USA, V110, P2934, DOI 10.1073/pnas.1222570110; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kawano S, 1999, BLOOD, V94, P1113; Levrero M, 2000, J CELL SCI, V113, P1661; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Lushnikova T, 2011, ONCOGENE, V30, P4622, DOI 10.1038/onc.2011.172; Martinez-Delgado B, 2002, INT J CANCER, V102, P15, DOI 10.1002/ijc.10618; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moller MB, 1999, MODERN PATHOL, V12, P1010; Pluta A, 2006, LEUKEMIA, V20, P757, DOI 10.1038/sj.leu.2404166; Riley Maurisa F, 2012, Genes Cancer, V3, P226, DOI 10.1177/1947601912455322; Talos F, 2007, MOL CELL, V27, P647, DOI 10.1016/j.molcel.2007.06.036; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; Wang TTY, 1997, CANCER LETT, V116, P61, DOI 10.1016/S0304-3835(97)00175-4; Watanabe T, 1996, LEUKEMIA LYMPHOMA, V21, P391, DOI 10.3109/10428199609093436; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zdzalik M, 2010, CELL CYCLE, V9, P4584, DOI 10.4161/cc.9.22.13871; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	36	12	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					358	365		10.1038/onc.2015.88	http://dx.doi.org/10.1038/onc.2015.88			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25915849	Green Accepted			2022-12-17	WOS:000369055300009
J	Agarwal, S; Kazi, JU; Mohlin, S; Pahlman, S; Ronnstrand, L				Agarwal, S.; Kazi, J. U.; Mohlin, S.; Pahlman, S.; Roennstrand, L.			The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V	ONCOGENE			English	Article							HEMATOPOIETIC-CELL LINES; MAST-CELLS; DASATINIB BMS-354825; KINASE INHIBITOR; CATALYTIC DOMAIN; RECEPTOR; MUTATIONS; GROWTH; PHOSPHORYLATION; PROLIFERATION	Oncogenic c-Kit mutations have been shown to display ligand-independent receptor activation and cell proliferation. A substitution of aspartate to valine at amino acid 816 (D816V) is one of the most commonly found oncogenic c-Kit mutations and is found in >90% of cases of mastocytosis and less commonly in germ-cell tumors, core-binding factor acute myeloid leukemia and mucosal melanomas. The mechanisms by which this mutation leads to constitutive activation and transformation are not fully understood. Previous studies have shown that the D816V mutation causes a structural change in the activation loop (A-loop), resulting in weaker binding of the A-loop to the juxtamembrane domain. In this paper, we have investigated the role of Y823, the only tyrosine residue in the A-loop, and its role in oncogenic transformation by c-Kit/D816V by introducing the Y823F mutation. Although dispensable for the kinase activity of c-Kit/D816V, the presence of Y823 was crucial for cell proliferation and survival. Furthermore, mutation of Y823 selectively downregulates the Ras/Erk and Akt pathways as well as the phosphorylation of STAT5 and reduces the transforming capacity of the D816V/c-Kit in vitro. We further show that mice injected with cells expressing c-Kit/ D816V/Y823F display significantly reduced tumor size as well as tumor weight compared with controls. Finally, microarray analysis, comparing Y823F/D816V cells with cells expressing c-Kit/D816V, demonstrate that mutation of Y823 causes upregulation of proapoptotic genes, whereas genes of survival pathways are downregulated. Thus, phosphorylation of Y823 is not necessary for kinase activation, but essential for the transforming ability of the c-Kit/D816V mutant.	[Agarwal, S.; Kazi, J. U.; Mohlin, S.; Pahlman, S.; Roennstrand, L.] Lund Univ, Translat Canc Res, Lund, Sweden; [Agarwal, S.; Kazi, J. U.; Roennstrand, L.] Lund Univ, Lund Stem Cell Ctr, Lund, Sweden; [Mohlin, S.; Pahlman, S.] Lund Univ, CREATE Hlth, Lund, Sweden	Lund University; Lund University; Lund University	Ronnstrand, L (corresponding author), Lund Univ, Translat Canc Res, Scheelevagen 2, Lund, Sweden.	Lars.Ronnstrand@med.lu.se	Kazi, Julhash U./D-9190-2011	Kazi, Julhash U./0000-0002-0719-5336; Ronnstrand, Lars/0000-0003-1275-5809; Mohlin, Sofie/0000-0002-2458-3963	Swedish Research Council; Swedish Cancer Foundation; Gunnar Nilsson Cancer foundation; Stiftelsen Olle Engkvist Byggmastare; Royal Physiographic Society in Lund; Ollie och Elof Ericssons Stiftelse; Stiftelsen Lars Hiertas Minne	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Foundation; Gunnar Nilsson Cancer foundation; Stiftelsen Olle Engkvist Byggmastare(Swedish Research Council); Royal Physiographic Society in Lund; Ollie och Elof Ericssons Stiftelse; Stiftelsen Lars Hiertas Minne	This work was supported by grants from the Swedish Research Council, the Swedish Cancer Foundation, Gunnar Nilsson Cancer foundation, the Stiftelsen Olle Engkvist Byggmastare, Royal Physiographic Society in Lund, Ollie och Elof Ericssons Stiftelse and Stiftelsen Lars Hiertas Minne.	Agarwal S, 2013, J BIOL CHEM, V288, P22460, DOI 10.1074/jbc.M113.474072; Aichberger KJ, 2009, BLOOD, V114, P5342, DOI 10.1182/blood-2008-08-175190; An NF, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-12; Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Beghini A, 2004, HAEMATOLOGICA, V89, P920; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Blanco-Aparicio C, 2013, BIOCHEM PHARMACOL, V85, P629, DOI 10.1016/j.bcp.2012.09.018; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Bougherara H, 2013, CL LYMPH MYELOM LEUK, V13, P62, DOI 10.1016/j.clml.2012.08.004; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cairoli R, 2006, BLOOD, V107, P3463, DOI 10.1182/blood-2005-09-3640; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chaix A, 2013, ONCOGENE; Chaix A, 2011, J BIOL CHEM, V286, P5956, DOI 10.1074/jbc.M110.182642; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; DiNitto JP, 2010, J BIOCHEM, V147, P601, DOI 10.1093/jb/mvq015; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Foster R, 2004, J MOL GRAPH MODEL, V23, P139, DOI 10.1016/j.jmgm.2004.04.003; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Giridhar PV, 2011, CLIN EXP METASTAS, V28, P887, DOI 10.1007/s10585-011-9420-x; Gleixner KV, 2006, BLOOD, V107, P752, DOI 10.1182/blood-2005-07-3022; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Grundler R, 2009, J EXP MED, V206, P1957, DOI 10.1084/jem.20082074; Hegazy SA, 2010, J BIOL CHEM, V285, P19813, DOI 10.1074/jbc.M110.121988; Heinrich MC, 2002, HUM PATHOL, V33, P484, DOI 10.1053/hupa.2002.124124; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kosmider O, 2007, ONCOGENE, V26, P3904, DOI 10.1038/sj.onc.1210159; Laine E, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002661; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Looijenga LHJ, 2003, CANCER RES, V63, P7674; Makki MS, 2013, EXP CELL RES, V319, P612, DOI 10.1016/j.yexcr.2012.12.021; Masson K, 2009, CELL SIGNAL, V21, P1717, DOI 10.1016/j.cellsig.2009.06.002; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Orfao A, 2007, BRIT J HAEMATOL, V138, P12, DOI 10.1111/j.1365-2141.2007.06619.x; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Shah NP, 2006, BLOOD, V108, P286, DOI 10.1182/blood-2005-10-3969; Sun JM, 2008, J BIOL CHEM, V283, P27444, DOI 10.1074/jbc.M709703200; Sun JM, 2009, J BIOL CHEM, V284, P11039, DOI 10.1074/jbc.M808058200; Thieblemont C, 2013, BLOOD, V121, P2165, DOI 10.1182/blood-2013-01-480392; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Wardega P, 2010, CELL SIGNAL, V22, P1363, DOI 10.1016/j.cellsig.2010.05.004; Wu N, 2013, CLIN TRANSL ONCOL, V15, P106, DOI 10.1007/s12094-012-0928-6; Yang QS, 2012, BLOOD, V120, P3491, DOI 10.1182/blood-2012-02-412643; Zhu WT, 2009, CIRC RES, V105, P1240, DOI 10.1161/CIRCRESAHA.109.208785; Zhuang WY, 2013, ONCOL REP, V30, P185, DOI 10.3892/or.2013.2459	53	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4581	4590		10.1038/onc.2014.383	http://dx.doi.org/10.1038/onc.2014.383			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435369	Green Submitted			2022-12-17	WOS:000360189300004
J	DiMauro, T; Cantor, DJ; Bainor, AJ; David, G				DiMauro, T.; Cantor, D. J.; Bainor, A. J.; David, G.			Transcriptional repression of Sin3B by Bmi-1 prevents cellular senescence and is relieved by oncogene activation	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; POLYCOMB GROUP PROTEINS; MYC TRANSGENIC MICE; INK4A-ARF LOCUS; BMI1-DEFICIENT MICE; SELF-RENEWAL; CYCLE EXIT; CANCER; PROLIFERATION; FIBROBLASTS	The Polycomb group protein Bmi-1 is an essential regulator of cellular senescence and is believed to function largely through the direct repression of the Ink4a/Arf locus. However, concurrent deletion of Ink4a/Arf does not fully rescue the defects detected in Bmi-1(-/-) mice, indicating that additional Bmi-1 targets remain to be identified. The expression of the chromatin-associated Sin3B protein is stimulated by oncogenic stress, and is required for oncogene-induced senescence. Here we demonstrate that oncogenic stress leads to the dissociation of Bmi-1 from the Sin3B locus, resulting in increased Sin3B expression and subsequent entry into cellular senescence. Furthermore, Sin3B is required for the senescent phenotype and elevated levels of reactive oxygen species elicited upon Bmi-1 depletion. Altogether, these results identify Sin3B as a novel direct target of Bmi-1, and establish Bmi-1-driven repression of Sin3B as an essential regulator of cellular senescence.	[David, G.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA; NYU, Sch Med, NYU Canc Inst, New York, NY 10016 USA	New York University; New York University	David, G (corresponding author), NYU, Sch Med, Dept Biochem & Mol Pharmacol, MSB417,550 First Ave, New York, NY 10016 USA.	gregory.david@nyumc.org		David, Gregory/0000-0002-1849-3232; Cantor, David/0000-0003-4084-3312; , gregory/0000-0002-3371-4558	American Cancer Society [115014-RSG-08-054-01-GMC]; National Institute of Health [5R01CA148639, 5R21CA155736]; Irma T. Hirschl Charitable Trust; Samuel Waxman Cancer Research Foundation; Feinberg NYU individual grant; NIH [T32CA009161, T32GM066704]; NATIONAL CANCER INSTITUTE [R01CA148639, T32CA009161, R21CA155736, P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM066704] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irma T. Hirschl Charitable Trust; Samuel Waxman Cancer Research Foundation; Feinberg NYU individual grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to all members of the David laboratory for helpful discussions during the preparation of the manuscript. We thank Drs Sally Temple, Gabriella De Vita, Goberdhan Dimri, David Levy and Marty McMahon for the generous gifts of plasmids used in this study and Dr Michael Garabedian for helpful discussions. We wish to acknowledge the Skirball Institute of Biomolecular Medicine for hosting our laboratory following Hurricane Sandy. All animal experiments were done in accordance with the guidelines of the National Institutes of Health (NIH) and were approved by the NYU School of Medicine Institutional Animal Care and Use Committee. This work was funded by the American Cancer Society (115014-RSG-08-054-01-GMC to DG), the National Institute of Health (5R01CA148639 and 5R21CA155736 to DG), the Irma T. Hirschl Charitable Trust (DG), the Samuel Waxman Cancer Research Foundation (DG) and a Feinberg NYU individual grant (DG). DT, CDJ and BAJ were supported by predoctoral NIH training grants T32CA009161 (DT, CDJ) and T32GM066704 (BAJ).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Arranz L, 2012, CELL CYCLE, V11, P65, DOI 10.4161/cc.11.1.18097; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Caldwell ME, 2012, ONCOGENE, V31, P1599, DOI 10.1038/onc.2011.350; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chatoo W, 2009, J NEUROSCI, V29, P529, DOI 10.1523/JNEUROSCI.5303-08.2009; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; David G, 2008, P NATL ACAD SCI USA, V105, P4168, DOI 10.1073/pnas.0710285105; David G, 2012, CANCER BIOL THER, V13, P992, DOI 10.4161/cbt.21116; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; Grandinetti KB, 2009, CANCER RES, V69, P6430, DOI 10.1158/0008-5472.CAN-09-0537; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jelinic P, 2011, MOL CELL BIOL, V31, P54, DOI 10.1128/MCB.00840-10; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Liu Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003199; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Rielland M, 2014, J CLIN INVEST, V124, P2125, DOI 10.1172/JCI72619; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013; van Oevelen C, 2010, MOL CELL BIOL, V30, P5686, DOI 10.1128/MCB.00975-10; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wang JX, 2009, EMBO REP, V10, P1272, DOI 10.1038/embor.2009.197; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	46	12	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					4011	4017		10.1038/onc.2014.322	http://dx.doi.org/10.1038/onc.2014.322			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263442	Green Accepted			2022-12-17	WOS:000358544200014
J	Zhang, C; Casas-Tinto, S; Li, G; Lin, N; Chung, M; Moreno, E; Moberg, KH; Zhou, L				Zhang, C.; Casas-Tinto, S.; Li, G.; Lin, N.; Chung, M.; Moreno, E.; Moberg, K. H.; Zhou, L.			An intergenic regulatory region mediates Drosophila Myc-induced apoptosis and blocks tissue hyperplasia	ONCOGENE			English	Article							C-MYC; CELL-DEATH; ORGAN SIZE; MELANOGASTER; GENES; P53; LYMPHOMAGENESIS; EXPRESSION; ELEMENT; DAMAGE	Induction of cell-autonomous apoptosis following oncogene-induced overproliferation is a major tumor-suppressive mechanism in vertebrates. However, the detailed mechanism mediating this process remains enigmatic. In this study, we demonstrate that dMyc-induced cell-autonomous apoptosis in the fruit fly Drosophila melanogaster relies on an intergenic sequence termed the IRER (irradiation-responsive enhancer region). The IRER mediates the expression of surrounding proapoptotic genes, and we use an in vivo reporter of the IRER chromatin state to gather evidence that epigenetic control of DNA accessibility within the IRER is an important determinant of the strength of this response to excess dMyc. In a previous work, we showed that the IRER also mediates P53-dependent induction of proapoptotic genes following DNA damage, and the chromatin conformation within IRER is regulated by polycomb group-mediated histone modifications. dMyc-induced apoptosis and the P53-mediated DNA damage response thus overlap in a requirement for the IRER. The epigenetic mechanisms controlling IRER accessibility appear to set thresholds for the P53- and dMyc-induced expression of apoptotic genes in vivo and may have a profound impact on cellular sensitivity to oncogene-induced stress.	[Zhang, C.; Li, G.; Lin, N.; Chung, M.; Zhou, L.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Zhang, C.; Li, G.; Lin, N.; Chung, M.; Zhou, L.] Univ Florida, UF Shands Canc Ctr, Gainesville, FL 32610 USA; [Zhang, C.; Moberg, K. H.] Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA USA; [Casas-Tinto, S.] Spanish Res Council CSIC, Inst Cajal, Madrid, Spain; [Li, G.; Zhou, L.] Univ Florida, UF Genet Inst, Gainesville, FL 32610 USA; [Moreno, E.] Spanish Natl Canc Ctr CNIO, Mol Oncol Program, Madrid, Spain	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Emory University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); State University System of Florida; University of Florida; Centro Nacional de Investigaciones Oncologicas (CNIO)	Zhou, L (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, 2033 Mowry Rd,Room 261, Gainesville, FL 32610 USA.	leizhou@ufl.edu	Li, Guangyao/I-8241-2015; Lin, Nianwei/AAD-9805-2019; Moberg, Ken/J-4849-2017; Casas-Tinto, Sergio/G-8220-2015	Li, Guangyao/0000-0003-0029-3854; Moberg, Ken/0000-0002-9820-5543; Casas-Tinto, Sergio/0000-0002-9589-9981; moreno, eduardo/0000-0001-5040-452X	NATIONAL CANCER INSTITUTE [R01CA095542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM106174] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095542] Funding Source: Medline; NIGMS NIH HHS [R01 GM106174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bellosta Paola, 2010, Genes Cancer, V1, P542; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Gallant P, 2009, ADV CANCER RES, V103, P111, DOI 10.1016/S0065-230X(09)03005-X; Gambis A, 2011, DEV BIOL, V351, P128, DOI 10.1016/j.ydbio.2010.12.040; Gilchrist AS, 1999, GENETICS, V153, P1775; Gong WJ, 2003, P NATL ACAD SCI USA, V100, P2556, DOI 10.1073/pnas.0535280100; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; HSU B, 1995, ONCOGENE, V11, P175; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kikuta H, 2007, GENOME RES, V17, P545, DOI 10.1101/gr.6086307; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Lin NW, 2009, APOPTOSIS, V14, P935, DOI 10.1007/s10495-009-0360-8; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; Montero L, 2008, GENESIS, V46, P104, DOI 10.1002/dvg.20373; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Ryder E, 2004, GENETICS, V167, P797, DOI 10.1534/genetics.104.026658; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Steller H, 2008, CELL DEATH DIFFER, V15, P1132, DOI 10.1038/cdd.2008.50; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Sullivan W, 2000, DROSOPHILA PROTOCOLS, V1st; Tan Y, 2011, DEVELOPMENT, V138, P2197, DOI 10.1242/dev.058826; Venken KJT, 2006, SCIENCE, V314, P1747, DOI 10.1126/science.1134426; Verghese S, 2012, CELL DEATH DIFFER, V19, P1664, DOI 10.1038/cdd.2012.48; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000; Zhang YP, 2008, DEV CELL, V14, P481, DOI 10.1016/j.devcel.2008.01.018; ZHOU L, 1995, CURR BIOL, V5, P784, DOI 10.1016/S0960-9822(95)00155-2	34	12	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2385	2397		10.1038/onc.2014.160	http://dx.doi.org/10.1038/onc.2014.160			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24931167	Green Accepted			2022-12-17	WOS:000353824800011
J	El Ghamrasni, S; Cardoso, R; Halaby, MJ; Zeegers, D; Harding, S; Kumareswaran, R; Yavorska, T; Chami, N; Jurisicova, A; Sanchez, O; Hande, MP; Bristow, R; Hakem, R; Hakem, A				El Ghamrasni, S.; Cardoso, R.; Halaby, M. J.; Zeegers, D.; Harding, S.; Kumareswaran, R.; Yavorska, T.; Chami, N.; Jurisicova, A.; Sanchez, O.; Hande, M. P.; Bristow, R.; Hakem, R.; Hakem, A.			Cooperation of Blm and Mus81 in development, fertility, genomic integrity and cancer suppression	ONCOGENE			English	Article							DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; DOWN-REGULATION; RECQ HELICASES; S-PHASE; ENDONUCLEASE; REPLICATION; REPAIR; PROMOTE; MEIOSIS	BLM is a DNA helicase important for the restart of stalled replication forks and for homologous recombination (HR) repair. Mutations of BLM lead to Bloom Syndrome, a rare autosomal recessive disorder characterized by elevated levels of sister chromatid exchanges (SCEs), dwarfism, immunodeficiency, infertility and increased cancer predisposition. BLM physically interacts with MUS81, an endonuclease involved in the restart of stalled replication forks and HR repair. Herein we report that loss of Mus81 in Blm hypomorph mutant mice leads to infertility, and growth and developmental defects that are not observed in single mutants. Double mutant cells and mice were hypersensitive to Mitomycin C and gamma-irradiation (IR) compared with controls and their repair of DNA double-strand breaks (DSBs) mediated by HR pathway was significantly defective, whereas their non-homologous-end-joining repair was elevated compared with controls. We also demonstrate the importance of the loss of the nuclease activity of Mus81 in the defects observed in Mus81(-/-) and double mutant cells. Exacerbated IR-induced chromosomal aberration was observed in double mutant mice and despite their reduced SCE levels, these mutants showed increased tumorigenesis risks. Our data highlight the importance of Mus81 and Blm in DNA DSB repair pathways, fertility, development and cancer.	[El Ghamrasni, S.; Cardoso, R.; Halaby, M. J.; Harding, S.; Kumareswaran, R.; Bristow, R.; Hakem, R.; Hakem, A.] Univ Toronto, Univ Hlth Network, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; [El Ghamrasni, S.; Chami, N.] Univ SMBA, Fac Sci DHEM, Lab Biotechnol, Fes, Morocco; [Zeegers, D.; Hande, M. P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117548, Singapore; [Zeegers, D.; Hande, M. P.] Natl Univ Singapore, Tembusu Coll, Singapore 117548, Singapore; [Yavorska, T.; Jurisicova, A.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Obstet & Gynecol & Physiol, Toronto, ON M5G 2M9, Canada; [Sanchez, O.] Univ Ontario, Inst Technol, Dept Pathol, Oshawa, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Sidi Mohamed Ben Abdellah University of Fez; National University of Singapore; National University of Singapore; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Ontario Tech University	Hakem, R (corresponding author), Univ Toronto, Univ Hlth Network, Ontario Canc Inst, Dept Med Biophys, 610 Univ Ave,10th Floor Room 622, Toronto, ON M5G 2M9, Canada.	rhakem@uhnres.utoronto.ca; ahakem@uhnres.utoronto.ca	El Ghamrasni, Samah/AAA-1350-2022; Harding, Shane M/N-2377-2017; Hande, M. Prakash/B-1645-2008; Jurisicova, Andrea/E-4580-2013	El Ghamrasni, Samah/0000-0003-4346-1360; Harding, Shane M/0000-0002-5524-3566; Hande, M. Prakash/0000-0002-4511-6256; Hakem, Razqallah/0000-0001-5948-7931; Bristow, Robert/0000-0002-8553-9544	Canadian Institute of Health Research	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	We thank G Brown, P McPherson, R Hill and A Koch for reviewing the manuscript and for their valuable comments and suggestions. This study was supported by the Canadian Institute of Health Research (R Hakem).	Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Bohgaki Toshiyuki, 2010, Genome Integr, V1, P15, DOI 10.1186/2041-9414-1-15; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Chester N, 2006, MOL CELL BIOL, V26, P6713, DOI 10.1128/MCB.00296-06; Chu WK, 2010, ONCOGENE, V29, P4705, DOI 10.1038/onc.2010.214; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; Ciccia A, 2008, ANNU REV BIOCHEM, V77, P259, DOI 10.1146/annurev.biochem.77.070306.102408; de los Santos T, 2003, GENETICS, V164, P81; de los Santos T, 2001, GENETICS, V159, P1511; De Muyt A, 2012, MOL CELL, V46, P43, DOI 10.1016/j.molcel.2012.02.020; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Dendouga N, 2005, MOL CELL BIOL, V25, P7569, DOI 10.1128/MCB.25.17.7569-7579.2005; El Ghamrasni S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001385; Gravel S, 2008, GENE DEV, V22, P2767, DOI 10.1101/gad.503108; Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313; Higgins JD, 2008, PLANT J, V54, P152, DOI 10.1111/j.1365-313X.2008.03403.x; Hiyama T, 2006, NUCLEIC ACIDS RES, V34, P880, DOI 10.1093/nar/gkj495; Hoadley KA, 2012, P NATL ACAD SCI USA, V109, P4437, DOI 10.1073/pnas.1117279109; Holloway JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000186; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Klein HL, 2012, CELL, V149, P257, DOI 10.1016/j.cell.2012.03.020; LaRocque JR, 2010, MOL CELL BIOL, V30, P1887, DOI 10.1128/MCB.01553-09; Loizidou MA, BREAST CANC RES TREA, V121, P147; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Matulova P, 2009, J BIOL CHEM, V284, P7733, DOI 10.1074/jbc.M806192200; Mazina OM, 2008, P NATL ACAD SCI USA, V105, P18249, DOI 10.1073/pnas.0807016105; McPherson JP, 2004, SCIENCE, V304, P1822, DOI 10.1126/science.1094557; McPherson JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371; Mullen JR, 2001, GENETICS, V157, P103; Munoz-Galvan S, 2012, MOL CELL BIOL, V32, P1592, DOI 10.1128/MCB.00111-12; Naim V, 2013, NAT CELL BIOL, V15, P1008, DOI 10.1038/ncb2793; Nimonkar AV, 2008, P NATL ACAD SCI USA, V105, P16906, DOI 10.1073/pnas.0809380105; Nimonkar AV, 2011, GENE DEV, V25, P350, DOI 10.1101/gad.2003811; Oh SD, 2008, MOL CELL, V31, P324, DOI 10.1016/j.molcel.2008.07.006; Ouyang KJ, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000252; Pamidi A, 2007, CANCER RES, V67, P8527, DOI 10.1158/0008-5472.CAN-07-1161; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Shimura T, 2008, J MOL BIOL, V375, P1152, DOI 10.1016/j.jmb.2007.11.006; Singh DK, 2009, BIOGERONTOLOGY, V10, P235, DOI 10.1007/s10522-008-9205-z; Smith GR, 2003, GENETICS, V165, P2289; So S, 2004, J BIOL CHEM, V279, P55433, DOI 10.1074/jbc.M409827200; Szakal B, 2013, EMBO J, V32, P1155, DOI 10.1038/emboj.2013.67; Taylor ER, 2008, P NATL ACAD SCI USA, V105, P3757, DOI 10.1073/pnas.0710291105; Theunissen JWF, 2006, METHOD ENZYMOL, V409, P251, DOI 10.1016/S0076-6879(05)09015-4; Tripathi V, 2008, CARCINOGENESIS, V29, P52, DOI 10.1093/carcin/bgm238; Trowbridge K, 2007, GENETICS, V176, P1993, DOI 10.1534/genetics.106.070060; Wechsler T, 2011, NATURE, V471, P642, DOI 10.1038/nature09790; Wu F, 2008, CANCER-AM CANCER SOC, V112, P2002, DOI 10.1002/cncr.23396; Wu F, 2011, CANCER SCI, V102, P472, DOI 10.1111/j.1349-7006.2010.01790.x; Wu F, 2010, ANTICANCER RES, V30, P5011; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773; Zakharyevich K, 2012, CELL, V149, P334, DOI 10.1016/j.cell.2012.03.023; Zhang R, 2005, CANCER RES, V65, P2526, DOI 10.1158/0008-5472.CAN-04-2421	56	12	12	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1780	1789		10.1038/onc.2014.121	http://dx.doi.org/10.1038/onc.2014.121			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24858046				2022-12-17	WOS:000352158000005
J	Miller, A; Brooks, GD; McLeod, L; Ruwanpura, S; Jenkins, BJ				Miller, A.; Brooks, G. D.; McLeod, L.; Ruwanpura, S.; Jenkins, B. J.			Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; K-RAS; GASTRIC TUMORIGENESIS; STAT3 ACTIVATION; CIGARETTE-SMOKE; AKT ACTIVATION; CELL-SURVIVAL; MUTANT MICE; CANCER; TUMORS	Interleukin (IL)-6 family cytokines signal exclusively via the gp130 coreceptor, and are implicated in smoking-associated lung cancer, the most lethal cancer worldwide. However, the role of gp130 signalling pathways in transducing the carcinogenic effects of tobacco-related compounds is ill-defined. Here, we report that lung tumourigenesis induced by the potent tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (Nicotine-derived Nitrosamine Ketone; NNK) is suppressed in gp130(F/F) knock-in mice characterized by the contrasting gp130-dependant hypoactivation of extracellular signal-regulated kinase mitogen-activated protein kinase (ERK MAPK) and phosphatidylinositol 3-kinase/Akt, and hyperactivation of signal transducer and activator of transcription (STAT) 3 signalling cascades. Specifically, in response to NNK, the absolute number and size of lung lesions in gp130(F/F) mice were significantly reduced compared with gp130(+/+) littermate controls, and associated with lower cellular proliferation without any alteration to the level of apoptosis in gp130(F/F) lung tumours. At the molecular level, reduced activation of ERK MAPK, but not Akt, was observed in lung tumours of gp130(F/F) mice, and corresponded with impaired expression of several tumour suppressor genes (for example, Trp53, Tsc2). Notably, STAT3 was not activated in the lungs of gp130(+/+) mice by NNK, and genetic normalization of STAT3 activation in gp130(F/F): Stat3(-/+) mice had no effect on NNK-induced tumourigenesis. The expression of tumour suppressor genes was reduced in tumours from current versus never-smoking lung cancer patients, and in vitro pharmacological inhibition of ERK MAPK signalling in human lung cancer cells abrogated NNK-induced downmodulation of tumour suppressor gene expression. Among IL-6 cytokine family members, IL-6 gene expression was specifically upregulated by NNK in vitro and in vivo, and inversely correlated with tumour suppressor gene expression. Collectively, our data reveal that a key molecular mechanism by which NNK promotes tumour cell proliferation during tobacco carcinogen-induced lung carcinogenesis is via upregulation of IL-6 and the preferential usage of gp130-dependant ERK MAPK signalling to downmodulate tumour suppressor gene expression.	[Miller, A.; Brooks, G. D.; McLeod, L.; Ruwanpura, S.; Jenkins, B. J.] Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia	Monash University	Jenkins, BJ (corresponding author), Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia.	Brendan.Jenkins@monash.edu	Miller, Alistair/AAE-8766-2022	Miller, Alistair/0000-0002-0439-9747; Jenkins, Brendan/0000-0002-7552-4656; Ruwanpura, saleela/0000-0002-4074-2012	National Health and Medical Research Council (NHMRC) of Australia; Operational Infrastructure Support Program by the Victorian Government of Australia; NHMRC Post-doctoral Training Fellowship; Sylvia and Charles Viertel Senior Medical Research Fellowship	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Operational Infrastructure Support Program by the Victorian Government of Australia; NHMRC Post-doctoral Training Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Sylvia and Charles Viertel Senior Medical Research Fellowship	This work was supported by the National Health and Medical Research Council (NHMRC) of Australia, as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. SMR is supported by a NHMRC Post-doctoral Training Fellowship. BJJ is supported by a Sylvia and Charles Viertel Senior Medical Research Fellowship.	Ahn YH, 2011, MOL CELL BIOL, V31, P4270, DOI 10.1128/MCB.05562-11; Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Akopyan G, 2006, INT J ONCOL, V29, P745; Brognard J, 2001, CANCER RES, V61, P3986; Brugger W, 2012, LUNG CANCER, V77, P2, DOI 10.1016/j.lungcan.2011.12.014; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Guo J, 2013, ONCOGENE, V32, P151, DOI 10.1038/onc.2012.39; Halappanavar S, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-56; Haura EB, 2006, CLIN LUNG CANCER, V7, P273, DOI 10.3816/CLC.2006.n.006; Hayashi H, 2001, LUNG CANCER-J IASLC, V34, P59, DOI 10.1016/S0169-5002(01)00211-2; Hollander MC, 2011, ONCOGENE, V30, P1812, DOI 10.1038/onc.2010.556; Hollander MC, 2008, NEOPLASIA, V10, P866, DOI 10.1593/neo.08406; Hollander MC, 2011, CARCINOGENESIS, V32, P1279, DOI 10.1093/carcin/bgr097; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang RY, 2011, ONCOGENE, V30, P106, DOI 10.1038/onc.2010.390; Ihara S, 2012, CANCER RES, V72, P2990, DOI 10.1158/0008-5472.CAN-11-4062; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Ji HB, 2007, CANCER RES, V67, P4933, DOI 10.1158/0008-5472.CAN-06-4592; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Kennedy CL, 2011, J PATHOL, V225, P255, DOI 10.1002/path.2933; Liu XD, 2007, BIOCHEM BIOPH RES CO, V353, P121, DOI 10.1016/j.bbrc.2006.11.147; Marson VJ, 2004, HISTOPATHOLOGY, V45, P125, DOI 10.1111/j.1365-2559.2004.01893.x; McClelland MR, 2007, AM J RESP CELL MOL, V36, P343, DOI 10.1165/rcmb.2006-0311OC; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pine SR, 2011, JNCI-J NATL CANCER I, V103, P1112, DOI 10.1093/jnci/djr216; Qu P, 2009, LUNG CANCER, V63, P341, DOI 10.1016/j.lungcan.2008.05.025; Ramakrishna G, 2002, TOXICOL APPL PHARM, V179, P21, DOI 10.1006/taap.2001.9344; Razani-Boroujerdi S, 2007, AM J RESP CELL MOL, V36, P13, DOI 10.1165/rcmb.2005-0330OC; Ruwanpura SM, 2012, AM J PHYSIOL-LUNG C, V302, P1627, DOI 10.1152/ajplung.00285.2011; Ruwanpura SM, 2011, AM J RESP CELL MOL, V45, P720, DOI 10.1165/rcmb.2010-0462OC; Steels E, 2001, EUR RESPIR J, V18, P705, DOI 10.1183/09031936.01.00062201; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Thiem S, 2013, J CLIN INVEST, V123, P767, DOI 10.1172/JCI65086; Tominaga M, 2003, LUNG CANCER-J IASLC, V40, P45, DOI 10.1016/S0169-5002(02)00529-9; Trejo CL, 2012, CANCER RES, V72, P3048, DOI 10.1158/0008-5472.CAN-11-3649; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Walser Tonya, 2008, Proc Am Thorac Soc, V5, P811, DOI 10.1513/pats.200809-100TH; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; YANAGAWA H, 1995, BRIT J CANCER, V71, P1095, DOI 10.1038/bjc.1995.212; Yang YP, 2004, J BIOL CHEM, V279, P29336, DOI 10.1074/jbc.C400162200	48	12	12	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1510	1519		10.1038/onc.2014.99	http://dx.doi.org/10.1038/onc.2014.99			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24727895				2022-12-17	WOS:000351416800004
J	Costa, ET; Barnabee, GF; Li, M; Dias, AAM; Machado, TR; Asprino, PF; Cavalher, FP; Ferreira, EN; Inda, MD; Nagai, MH; Malnic, B; Duarte, ML; Leite, KRM; de Barros, ACSD; Carraro, DM; Chammas, R; Armelin, HA; Cavenee, W; Furnari, F; Camargo, A				Costa, E. T.; Barnabe, G. F.; Li, M.; Dias, A. A. M.; Machado, T. R.; Asprino, P. F.; Cavalher, F. P.; Ferreira, E. N.; Inda, M. del Mar; Nagai, M. H.; Malnic, B.; Duarte, M. L.; Leite, K. R. M.; de Barros, A. C. S. D.; Carraro, D. M.; Chammas, R.; Armelin, H. A.; Cavenee, W.; Furnari, F.; Camargo, A. A.			Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals	ONCOGENE			English	Article							CELL-LINES; EVOLUTION; CANCER; METHYLATION; CARCINOMA; GENE; PROGRESSION; EXPRESSION; INTEGRIN; ADHESION	Intratumoral heterogeneity (ITH) represents an obstacle for cancer diagnosis and treatment, but little is known about its functional role in cancer progression. The A Desintegrin And Metalloproteinase 23 (ADAM23) gene is epigenetically silenced in different types of tumors, and silencing is often associated with advanced disease and metastasis. Here, we show that invasive breast tumors exhibit significant ADAM23-ITH and that this heterogeneity is critical for tumor growth and metastasis. We demonstrate that while loss of ADAM23 expression enhances invasion, it causes a severe proliferative deficiency and is not itself sufficient to trigger metastasis. Rather, we observed that, in ADAM23-heterotypic environments, ADAM23-negative cells promote tumor growth and metastasis by enhancing the proliferation and invasion of adjacent A23-positive cells through the production of LGI4 (Leucine-rich Glioma Inactivated 4) and nitric oxide (NO). Ablation of LGI4 and NO in A23-negative cells significantly attenuates A23-positive cell proliferation and invasion. Our work denotes a driving role of ADAM23-ITH during disease progression, shifting the malignant phenotype from the cellular to the tissue level. Our findings also provide insights for therapeutic intervention, enforcing the need to ascertain ITH to improve cancer diagnosis and therapy.	[Costa, E. T.; Barnabe, G. F.; Asprino, P. F.; Duarte, M. L.; Camargo, A. A.] Hosp Sirio Libanes, Ctr Mol Oncol, BR-01308060 Sao Paulo, Brazil; [Costa, E. T.; Barnabe, G. F.; Machado, T. R.; Asprino, P. F.; Cavalher, F. P.; Duarte, M. L.; Camargo, A. A.] LICR, Sao Paulo, Brazil; [Li, M.; Inda, M. del Mar; Cavenee, W.; Furnari, F.] Univ Calif San Diego, LICR, San Diego, CA 92103 USA; [Dias, A. A. M.] Univ Fed Minas Gerais, Dept Biol Geral ICB, Belo Horizonte, MG, Brazil; [Ferreira, E. N.; Carraro, D. M.] Hosp AC Camargo Fund Antonio Prudente, Ctr Internacl Pesquisa, Sao Paulo, Brazil; [Nagai, M. H.; Malnic, B.; Armelin, H. A.] Univ Sao Paulo, Dept Bioquim IQ, Sao Paulo, Brazil; [Leite, K. R. M.; Chammas, R.] Univ Sao Paulo, Fac Med, Dept Urol, Sao Paulo, Brazil; [de Barros, A. C. S. D.] Hosp Sirio Libanes, Dept Mastol, BR-01308060 Sao Paulo, Brazil; [Armelin, H. A.] Inst Butantan, Sao Paulo, Brazil	University of California System; University of California San Diego; Universidade Federal de Minas Gerais; A.C.Camargo Cancer Center; Universidade de Sao Paulo; Universidade de Sao Paulo; Instituto Butantan	Camargo, A (corresponding author), Hosp Sirio Libanes, Ctr Mol Oncol, LICR, Rua Cel Nicolau Dos Santos 69, BR-01308060 Sao Paulo, Brazil.	aacamargo@mochsl.org.br	Armelin, Hugo/P-4390-2015; LEITE, KATIA RM/C-2055-2008; Chammas, Roger/A-8004-2011; Barros, Alfredo/M-2525-2017; Malnic, Bettina/A-4905-2008; Ferreira, Elisa N/A-6485-2011; Asprino, Paula/AAB-5600-2021; Instituto Butantan, Center of Toxins Immune Response and Cell Signaling CeTICS/J-5731-2015; Lemos Duarte, Mariana/K-6233-2012; carraro, dirce/C-9179-2009; Dias, Adriana Abalen Martins/B-4974-2014; Camargo, Anamaria A/E-9388-2012	Armelin, Hugo/0000-0001-9557-0804; LEITE, KATIA RM/0000-0002-2615-7730; Chammas, Roger/0000-0003-0342-8726; Barros, Alfredo/0000-0003-2535-3040; Malnic, Bettina/0000-0002-5877-4784; Ferreira, Elisa N/0000-0001-7809-7349; Lemos Duarte, Mariana/0000-0002-1611-7102; carraro, dirce/0000-0001-5667-1418; Camargo, Anamaria A/0000-0002-6076-9597; Abalen Martins Dias, Adriana/0000-0001-9415-3240; Furnari, Frank/0000-0003-1909-4361; Li, Ming/0000-0002-2540-1738	FAPESP [06/60219-2, 07/51194-9, 07/52920-5, 11/50541-2]; LICR; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080939] Funding Source: NIH RePORTER	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); LICR; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to Dr Andrew Simpson and Dr Raphael Parmigiani for critical reading of this manuscript and to Dr Rodrigo Perez, Dr Alicia Kowaltowski, Dr Beatriz Geronymo, Dr Camila Machado, Dr Vilma Martins, Dr Tiago dos Santos and Dr Anibal Vercesi for scientific discussions and technical assistance. This work was supported by grants from FAPESP (06/60219-2, 07/51194-9, 07/52920-5, 11/50541-2) and LICR.	Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103; Bermingham JR, 2006, NAT NEUROSCI, V9, P76, DOI 10.1038/nn1598; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Calmon MF, 2007, CANCER GENET CYTOGEN, V173, P31, DOI 10.1016/j.cancergencyto.2006.09.008; Choi JS, 2009, INT J CANCER, V124, P1258, DOI 10.1002/ijc.24023; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; Costa FF, 2005, NEUROSCI LETT, V380, P260, DOI 10.1016/j.neulet.2005.01.050; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Cottu PH, 2008, ANN ONCOL, V19, P596, DOI 10.1093/annonc/mdn021; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gauthier N, 2004, CARCINOGENESIS, V25, P1559, DOI 10.1093/carcin/bgh158; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Hagihara A, 2004, ONCOGENE, V23, P8705, DOI 10.1038/sj.onc.1207783; Hu CY, 2011, INT J EXP PATHOL, V92, P333, DOI 10.1111/j.1365-2613.2011.00766.x; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; Kim HA, 2012, BBA-MOL CELL BIOL L, V1821, P914, DOI 10.1016/j.bbalip.2012.02.010; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lampson BL, 2012, CANCER RES, V72, P4472, DOI 10.1158/0008-5472.CAN-12-0057; Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Michor F, 2010, CANCER PREV RES, V3, P1361, DOI 10.1158/1940-6207.CAPR-10-0234; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nishino J, 2010, J NEUROSCI, V30, P15228, DOI 10.1523/JNEUROSCI.2286-10.2010; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Orucevic A, 1999, INT J CANCER, V81, P889, DOI 10.1002/(SICI)1097-0215(19990611)81:6<889::AID-IJC9>3.0.CO;2-2; Ozkaynak E, 2010, J NEUROSCI, V30, P3857, DOI 10.1523/JNEUROSCI.6287-09.2010; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PRICE JE, 1990, CANCER RES, V50, P717; Sagane K, 2008, INT J BIOL SCI, V4, P387; Senechal KR, 2005, HUM MOL GENET, V14, P1613, DOI 10.1093/hmg/ddi169; Sens-Abuazar C, 2012, TRANSL ONCOL, V5, P113, DOI 10.1593/tlo.11280; SUZUKI N, 1978, CANCER RES, V38, P3349; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takahashi T, 1998, CANCER RES, V58, P5835; Teixeira MR, 1996, CANCER RES, V56, P855; Verbisck NV, 2009, CANCER RES, V69, P5546, DOI 10.1158/0008-5472.CAN-08-2976; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336; Yap TA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003854	49	12	12	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1270	1279		10.1038/onc.2014.70	http://dx.doi.org/10.1038/onc.2014.70			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662834				2022-12-17	WOS:000350687100007
J	Lau, ST; Hansford, LM; Chan, WK; Chan, GCF; Wan, TSK; Wong, KKY; Kaplan, DR; Tam, PKH; Ngan, ESW				Lau, S-T; Hansford, L. M.; Chan, W-K; Chan, G. C-F; Wan, T. S-K; Wong, K. K-Y; Kaplan, D. R.; Tam, P. K-H; Ngan, E. S-W			Prokineticin signaling is required for the maintenance of a de novo population of c-KIT+ cells to sustain neuroblastoma progression	ONCOGENE			English	Article							GENE-EXPRESSION; STEM-CELLS; IN-VITRO; HIF-2-ALPHA; RECEPTOR; IDENTIFICATION; PROGNOSIS; IMMATURE; HYPOXIA; GROWTH	High cellular heterogeneity within neuroblastomas (NBs) may account for the non-uniform response to treatment. c-KIT+ cells are frequently detected in NB, but how they influence NB behavior still remains elusive. Here, we used NB tumor-initiating cells to reconstitute NB development and demonstrated that c-KIT+ cells are de novo generated and dynamically maintained within the tumors to sustain tumor progression. c-KIT+ NB cells express higher levels of neural crest and stem cell markers (SLUG, SOX2 and NANOG) and are endowed with high clonogenic capacity, differentiation plasticity and are refractory to drugs. With serial transplantation assays, we found that c-KIT expression is not required for tumor formation, but c-KIT+ cells are more aggressive and can induce tumors ninefold more efficiently than c-KIT-/low cells. Intriguingly, c-KIT+ cells exhibited a long-term in vivo self-renewal capacity to sustain the formation of secondary and tertiary tumors in mice. In addition, we showed that Prokineticin signaling and mitogen-activated protein kinase pathways are crucial for the maintenance of c-KIT+ cells in tumor to promote NB progression. Our results highlight the importance of this de novo population of NB cells in sustainable growth of NB and reveal specific signaling pathways that may provide targets leading to more effective NB therapies.	[Lau, S-T; Wong, K. K-Y; Tam, P. K-H; Ngan, E. S-W] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Hansford, L. M.; Kaplan, D. R.] Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; [Chan, W-K; Chan, G. C-F] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China; [Wan, T. S-K] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Tam, P. K-H; Ngan, E. S-W] Univ Hong Kong, Ctr Reprod Dev & Growth, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Toronto; University of Hong Kong; University of Hong Kong; University of Hong Kong	Ngan, ESW (corresponding author), Univ Hong Kong, Fac Med Bldg, Dept Surg, L9-56,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	engan@hku.hk	Ngan, Elly/N-1543-2019; Wan, Thomas/AAY-7075-2020; Wong, Kenneth K. Y./B-9920-2008; Chan, Godfrey Chi Fung/C-4205-2009	Ngan, Elly/0000-0002-0022-7999; Chan, Godfrey Chi Fung/0000-0001-5032-8985	University of Hong Kong; Hong Kong Research Grants Council [HKU773909]; Hong Kong Children's Cancer Foundation; SK Yee Medical Research Fund	University of Hong Kong(University of Hong Kong); Hong Kong Research Grants Council(Hong Kong Research Grants Council); Hong Kong Children's Cancer Foundation; SK Yee Medical Research Fund	Seed funding grant for basic research from the University of Hong Kong, General Research Grant HKU773909 from the Hong Kong Research Grants Council, research grant from Hong Kong Children's Cancer Foundation and SK Yee Medical Research Fund to ES-WN. Small project grant from the University of Hong Kong to S-TL. We thank Robin Lovell-Badge (MRC National Institute for Medical Research, London, UK) and Chi-Chung Hui (University of Toronto, Canada) for critical reading of the manuscript.	Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Bellone G, 2006, INT J ONCOL, V29, P851; Biagiotti T, 2006, STEM CELLS, V24, P443, DOI 10.1634/stemcells.2004-0264; Chen QR, 2008, GENOMICS, V92, P195, DOI 10.1016/j.ygeno.2008.05.014; COHEN PS, 1994, BLOOD, V84, P3465; Coulon A, 2011, NEOPLASIA, V13, P991, DOI 10.1593/neo.11800; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Gomes AL, 2007, CELL ONCOL, V29, P399; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hutt KJ, 2006, MOL HUM REPROD, V12, P61, DOI 10.1093/molehr/gal010; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Krams M, 2004, ONCOGENE, V23, P588, DOI 10.1038/sj.onc.1207145; Krystal GW, 1996, CANCER RES, V56, P370; Lacham-Kaplan O, 2004, REPRODUCTION, V128, P147, DOI 10.1530/rep.1.00220; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Liegl-Atzwanger B, 2010, VIRCHOWS ARCH, V456, P111, DOI 10.1007/s00428-010-0891-y; Luo R, 2003, DEVELOPMENT, V130, P321, DOI 10.1242/dev.00213; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marzi F, 2007, CANCER RES, V67, P2402, DOI 10.1158/0008-5472.CAN-06-3208; Ngan ESW, 2007, CLIN CANCER RES, V13, P868, DOI 10.1158/1078-0432.CCR-06-2176; Nilsson MB, 2010, ONCOGENE, V29, P2938, DOI 10.1038/onc.2010.60; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Pietras A, 2008, J PATHOL, V214, P482, DOI 10.1002/path.2304; Pietras A, 2009, P NATL ACAD SCI USA, V106, P16805, DOI 10.1073/pnas.0904606106; Pittoni P, 2011, ONCOGENE, V30, P757, DOI 10.1038/onc.2010.494; Shimada A, 2008, PEDIATR BLOOD CANCER, V50, P213, DOI 10.1002/pbc.21288; Thiele CJ, 1999, HUMAN CELL CULTURE, V1, P21; Uccini S, 2005, CLIN CANCER RES, V11, P380; Vitali R, 2003, INT J CANCER, V106, P147, DOI 10.1002/ijc.11187; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310	33	12	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1019	1034		10.1038/onc.2014.24	http://dx.doi.org/10.1038/onc.2014.24			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632619				2022-12-17	WOS:000350121300008
J	Alves, IT; Hartjes, T; McClellan, E; Hiltemann, S; Bottcher, R; Dits, N; Temanni, MR; Janssen, B; van Workum, W; van der Spek, P; Stubbs, A; de Klein, A; Eussen, B; Trapman, J; Jenster, G				Alves, I. Teles; Hartjes, T.; McClellan, E.; Hiltemann, S.; Bottcher, R.; Dits, N.; Temanni, M. R.; Janssen, B.; van Workum, W.; van der Spek, P.; Stubbs, A.; de Klein, A.; Eussen, B.; Trapman, J.; Jenster, G.			Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer	ONCOGENE			English	Article						FAM71D; gene fusions; next-generation sequencing; prostate cancer; MPP5	ANDROGEN RECEPTOR; GENE FUSIONS; EXOME; GENOME; POLARITY; CELL; VARIANTS; RNAS	Gene fusions, mainly between TMPRSS2 and ERG, are frequent early genomic rearrangements in prostate cancer (PCa). In order to discover novel genomic fusion events, we applied whole-genome paired-end sequencing to identify structural alterations present in a primary PCa patient (G089) and in a PCa cell line (PC346C). Overall, we identified over 3800 genomic rearrangements in each of the two samples as compared with the reference genome. Correcting these structural variations for polymorphisms using whole-genome sequences of 46 normal samples, the numbers of cancer-related rearrangements were 674 and 387 for G089 and PC346C, respectively. From these, 192 in G089 and 106 in PC346C affected gene structures. Exclusion of small intronic deletions left 33 intergenic breaks in G089 and 14 in PC346C. Out of these, 12 and 9 reassembled genes with the same orientation, capable of generating a feasible fusion transcript. Using PCR we validated all the reliable predicted gene fusions. Two gene fusions were in-frame: MPP5-FAM71D in PC346C and ARHGEF3-C8ORF38 in G089. Downregulation of FAM71D and MPP5-FAM71D transcripts in PC346C cells decreased proliferation; however, no effect was observed in the RWPE-1-immortalized normal prostate epithelial cells. Together, our data showed that gene rearrangements frequently occur in PCa genomes but result in a limited number of fusion transcripts. Most of these fusion transcripts do not encode in-frame fusion proteins. The unique in-frame MPP5-FAM71D fusion product is important for proliferation of PC346C cells.	[Alves, I. Teles] Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Urol & Pathol, NL-3000 CA Rotterdam, Netherlands; [Hartjes, T.; Hiltemann, S.; Bottcher, R.; Dits, N.; Jenster, G.] Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Urol, NL-3000 CA Rotterdam, Netherlands; [McClellan, E.; van der Spek, P.; Stubbs, A.] Erasmus Univ, Med Ctr, Dept Bioinformat, NL-3000 CA Rotterdam, Netherlands; [McClellan, E.] Metropolitan State Univ Denver, Dept Math & Comp Sci, Denver, CO 80204 USA; [Temanni, M. R.] Univ Maryland, CMNS Inst Adv Comp Studies, College Pk, MD 20742 USA; [Janssen, B.; van Workum, W.] ServiceXS BV, Leiden, Netherlands; [de Klein, A.; Eussen, B.] Erasmus Univ, Med Ctr, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands; [Trapman, J.] Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Pathol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Metropolitan State University of Denver; University System of Maryland; University of Maryland College Park; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Jenster, G (corresponding author), Erasmus Univ, Med Ctr, Josephine Nefkens Inst, Dept Urol, Be 362a,POB 2040, NL-3000 CA Rotterdam, Netherlands.	g.jenster@erasmusmc.nl	Böttcher, René/A-5514-2015; TEMANNI, Mohamed Ramzi/AAQ-6936-2020; Hiltemann, Saskia/AAY-9458-2020	Böttcher, René/0000-0001-8581-3876; TEMANNI, Mohamed Ramzi/0000-0001-9125-1136; Hiltemann, Saskia/0000-0003-3803-468X	CTMM; project PCMM [03O-203]; FP7 Marie Curie Initial Training Network PRO-NEST [238278]; Foundation for Scientific Urological Research (SUWO)	CTMM; project PCMM; FP7 Marie Curie Initial Training Network PRO-NEST; Foundation for Scientific Urological Research (SUWO)	We would like to thank Andre Uitterlinden from the Department of Internal Medicine, Erasmus MC for microarray assistance, Arno van Leenders from the Department of Pathology, Erasmus MC for patient sample selection, Wytske van Weerden from the Department of Urology, Erasmus MC for the expertise in PC346C cell line model systems, Complete Genomics Inc. for assistance with the NGS data and the patients whose material was used for this study. This research was made possible by financial contributions from CTMM, project PCMM (project number 03O-203), the FP7 Marie Curie Initial Training Network PRO-NEST (grant number 238278) and the Foundation for Scientific Urological Research (SUWO).	Asan, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046211; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Cheng I, 2012, GENE CHROMOSOME CANC, V51, P66, DOI 10.1002/gcc.20932; Cirulli ET, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r57; Clegg NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017449; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Drmanac R, 2010, SCIENCE, V327, P78, DOI 10.1126/science.1181498; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Gosens I, 2007, EXP CELL RES, V313, P3959, DOI 10.1016/j.yexcr.2007.08.025; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Haimovich Adrian D., 2011, Yale Journal of Biology and Medicine, V84, P439; Hawkins RD, 2010, NAT REV GENET, V11, P476, DOI 10.1038/nrg2795; Hermans KG, 2009, CLIN CANCER RES, V15, P6398, DOI 10.1158/1078-0432.CCR-09-1176; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Jackson AP, 2012, P NATL ACAD SCI USA, V109, P3416, DOI 10.1073/pnas.1117313109; Jin GF, 2011, CARCINOGENESIS, V32, P1057, DOI 10.1093/carcin/bgr082; Kannan K, 2011, P NATL ACAD SCI USA, V108, P9172, DOI 10.1073/pnas.1100489108; Kim J, 2012, BBA-REV CANCER, V1825, P186, DOI 10.1016/j.bbcan.2011.12.003; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lindberg J, 2013, EUR UROL, V63, P347, DOI 10.1016/j.eururo.2012.03.050; Majewski J, 2011, J MED GENET, V48, P580, DOI 10.1136/jmedgenet-2011-100223; Marques RB, 2005, INT J CANCER, V117, P221, DOI 10.1002/ijc.21201; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Nacu S, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-11; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Pareek CS, 2011, J APPL GENET, V52, P413, DOI 10.1007/s13353-011-0057-x; Parkinson NJ, 2012, GENOME RES, V22, P125, DOI 10.1101/gr.124016.111; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Ren SC, 2012, CELL RES, V22, P806, DOI 10.1038/cr.2012.30; Rippe V, 2003, ONCOGENE, V22, P6111, DOI 10.1038/sj.onc.1206867; Sakharkar Meena Kishore, 2004, In Silico Biology, V4, P387; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singleton AB, 2011, LANCET NEUROL, V10, P942, DOI 10.1016/S1474-4422(11)70196-X; Sneddon TP, 2012, METHODS MOL BIOL, V838, P273, DOI 10.1007/978-1-61779-507-7_13; Spans L, 2012, PROSTATE, V72, P1317, DOI 10.1002/pros.22480; Straight SW, 2004, MOL BIOL CELL, V15, P1981, DOI 10.1091/mbc.e03-08-0620; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Vainio P, 2012, PROSTATE, V72, P789, DOI 10.1002/pros.21487; Wang Q, 2007, MOL BIOL CELL, V18, P874, DOI 10.1091/mbc.E06-07-0651; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Wu CX, 2012, J PATHOL, V227, P53, DOI 10.1002/path.3987; Yao F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046152; Yeager M, 2008, HUM GENET, V124, P161, DOI 10.1007/s00439-008-0535-3; Yeager M, 2009, HUM GENET, V126, P743, DOI 10.1007/s00439-009-0723-9	52	12	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					568	577		10.1038/onc.2013.591	http://dx.doi.org/10.1038/onc.2013.591			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24488012				2022-12-17	WOS:000348853500004
J	Batlle-Lopez, A; Cortiguera, MG; Rosa-Garrido, M; Blanco, R; del Cerro, E; Torrano, V; Wagner, SD; Delgado, MD				Batlle-Lopez, A.; Cortiguera, M. G.; Rosa-Garrido, M.; Blanco, R.; del Cerro, E.; Torrano, V.; Wagner, S. D.; Delgado, M. D.			Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus	ONCOGENE			English	Article						CTCF; BCL6; lymphoma; germinal centre; epigenetics	CENTER B-CELLS; CANCER-TESTIS GENE; DNA METHYLATION; HUMAN GENOME; NEGATIVE AUTOREGULATION; EPIGENETIC REGULATION; TUMOR-SUPPRESSOR; PROTEIN CTCF; EXPRESSION; PROMOTER	BCL6 is a zinc-finger transcriptional repressor, which is highly expressed in germinal centre B-cells and is essential for germinal centre formation and T-dependent antibody responses. Constitutive BCL6 expression is sufficient to produce lymphomas in mice. Deregulated expression of BCL6 due to chromosomal rearrangements, mutations of a negative autoregulatory site in the BCL6 promoter region and aberrant post-translational modifications have been detected in a number of human lymphomas. Tight lineage and temporal regulation of BCL6 is, therefore, required for normal immunity, and abnormal regulation occurs in lymphomas. CCCTC-binding factor (CTCF) is a multi-functional chromatin regulator, which has recently been shown to bind in a methylation-sensitive manner to sites within the BCL6 first intron. We demonstrate a novel CTCF-binding site in BCL6 exon1A within a potential CpG island, which is unmethylated both in cell lines and in primary lymphoma samples. CTCF binding, which was found in BCL6-expressing cell lines, correlated with the presence of histone variant H2A. Z and active histone marks, suggesting that CTCF induces chromatin modification at a transcriptionally active BCL6 locus. CTCF binding to exon1A was required to maintain BCL6 expression in germinal centre cells by avoiding BCL6-negative autoregulation. Silencing of CTCF in BCL6-expressing cells reduced BCL6 mRNA and protein expression, which is sufficient to induce B-cell terminal differentiation toward plasma cells. Moreover, lack of CTCF binding to exon1A shifts the BCL6 local chromatin from an active to a repressive state. This work demonstrates that, in contexts in which BCL6 is expressed, CTCF binding to BCL6 exon1A associates with epigenetic modifications indicative of transcriptionally open chromatin.	[Batlle-Lopez, A.; Cortiguera, M. G.; Rosa-Garrido, M.; Blanco, R.; Torrano, V.; Delgado, M. D.] Univ Cantabria, CSIC, SODERCAN, Inst Biomed & Biotecnol Cantabria IBBTEC, E-39005 Santander, Spain; [Batlle-Lopez, A.; Cortiguera, M. G.; Rosa-Garrido, M.; Blanco, R.; Torrano, V.; Delgado, M. D.] Univ Cantabria, CSIC, SODERCAN, Dept Biol Mol, E-39005 Santander, Spain; [Batlle-Lopez, A.; Cortiguera, M. G.; del Cerro, E.] Hosp U Marques Valdecilla, Serv Hematol, Santander, Spain; [Batlle-Lopez, A.; Cortiguera, M. G.; del Cerro, E.] IFIMAV FMV, Santander, Spain; [Wagner, S. D.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 9HN, Leics, England; [Wagner, S. D.] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; Hospital Universitario Marques de Valdecilla (HUMV); University of Leicester; University of Leicester	Wagner, SD (corresponding author), Univ Leicester, Dept Canc Studies & Mol Med, Lancaster Rd, Leicester LE1 9HN, Leics, England.	sw227@leicester.ac.uk; delgadmd@unican.es	Torrano Moya, Veronica/D-3285-2014; Rosa-Garrido, Manuel/AAE-4188-2019; Delgado, M. Dolores/K-9056-2014	Rosa-Garrido, Manuel/0000-0002-2169-3972; Delgado, M. Dolores/0000-0003-4682-4040; Wagner, Simon/0000-0002-8914-0370; Torrano, Veronica/0000-0002-4252-1977	Instituto de Salud Carlos III grants [PI11/00397]; RETIC (Red Tematica de Investigacion Cooperativa en Cancer) [RD06/0020/0017, RD12/0036/0033]; Lopez Albo fellowship (IFIMAV, Spain); University of Cantabria; Lady Tata Memorial Trust	Instituto de Salud Carlos III grants(Instituto de Salud Carlos III); RETIC (Red Tematica de Investigacion Cooperativa en Cancer); Lopez Albo fellowship (IFIMAV, Spain); University of Cantabria; Lady Tata Memorial Trust	We thank Elena Klenova and Rainer Renkawitz for CTCF expression vectors, Miguel Angel Piris and Noemi Nagy for cell lines and Javier Leon for useful comments on the manuscript. We are grateful to the Department of Hematology of Hospital U. Marques de Valdecilla (Santander) for help with patient recruitment. Funding for this work was provided by Instituto de Salud Carlos III grants PI11/00397 (Fondo Investigaciones Sanitarias) and RETIC (Red Tematica de Investigacion Cooperativa en Cancer) RD06/0020/0017 and RD12/0036/0033. AB was supported by a Lopez Albo fellowship (IFIMAV, Spain), MRG by a PhD fellowship from the University of Cantabria and VT by the Lady Tata Memorial Trust. Part of this work is in AB's PhD dissertation (split PhD Programme between Imperial College London and the University of Cantabria).	Bao L, 2008, NUCLEIC ACIDS RES, V36, pD83, DOI 10.1093/nar/gkm875; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Basso K, 2012, IMMUNOL REV, V247, P172, DOI 10.1111/j.1600-065X.2012.01112.x; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; Batlle A, 2009, MOL IMMUNOL, V46, P1727, DOI 10.1016/j.molimm.2009.02.003; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Bottardi S, 2003, BLOOD, V102, P3989, DOI 10.1182/blood-2003-05-1540; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108; De la Rosa-Velazquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024; Duan S, 2012, NATURE, V481, P90, DOI 10.1038/nature10688; Fearon DT, 2002, ADV EXP MED BIOL, V512, P21; Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3; Fitzpatrick GV, 2007, MOL CELL BIOL, V27, P2636, DOI 10.1128/MCB.02036-06; Herold M, 2012, DEVELOPMENT, V139, P1045, DOI 10.1242/dev.065268; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Ishihara K, 2006, MOL CELL, V23, P733, DOI 10.1016/j.molcel.2006.08.008; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kwon MJ, 2010, CARCINOGENESIS, V31, P974, DOI 10.1093/carcin/bgp336; Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204; Lee BK, 2012, GENOME RES, V22, P9, DOI 10.1101/gr.127597.111; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ohlsson R, 2010, BIOESSAYS, V32, P37, DOI 10.1002/bies.200900118; Papadopoulou V, 2010, BIOCHEM J, V427, P541, DOI 10.1042/BJ20091578; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Pugacheva EM, 2005, HUM MOL GENET, V14, P953, DOI 10.1093/hmg/ddi089; Ramachandrareddy H, 2010, P NATL ACAD SCI USA, V107, P11930, DOI 10.1073/pnas.1004962107; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P7372, DOI 10.1093/nar/gkm896; Rosa-Garrido M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039371; Saito M, 2007, CANCER CELL, V12, P280, DOI 10.1016/j.ccr.2007.08.011; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509; Szutorisz H, 2005, MOL CELL BIOL, V25, P1804, DOI 10.1128/MCB.25.5.1804-1820.2005; Torrano V, 2005, J BIOL CHEM, V280, P28152, DOI 10.1074/jbc.M501481200; Torrano V, 2006, J CELL SCI, V119, P1746, DOI 10.1242/jcs.02890; van de Nobelen S, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-19; Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858; Wagner SD, 2011, BRIT J HAEMATOL, V152, P3, DOI 10.1111/j.1365-2141.2010.08420.x; Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634; Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Yoon B, 2005, MOL CELL BIOL, V25, P11184, DOI 10.1128/MCB.25.24.11184-11190.2005; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Ziebarth JD, 2013, NUCLEIC ACIDS RES, V41, pD188, DOI 10.1093/nar/gks1165	59	12	13	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					246	256		10.1038/onc.2013.535	http://dx.doi.org/10.1038/onc.2013.535			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362533	Green Accepted, Green Submitted			2022-12-17	WOS:000347790500012
J	Yan, S; Qiu, L; Ma, K; Zhang, X; Zhao, Y; Zhang, J; Li, X; Hao, X; Li, Z				Yan, S.; Qiu, L.; Ma, K.; Zhang, X.; Zhao, Y.; Zhang, J.; Li, X.; Hao, X.; Li, Z.			FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes its activation in response to DNA damage	ONCOGENE			English	Article						FATS; ubiquitin linkage; p53; DNA damage; Mdm2	TUMOR-SUPPRESSOR P53; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; FRAGILE SITES; DEGRADATION; EXPRESSION; CANCER; CHAINS; REVEALS; ENZYMES	Ubiquitin linkage is critical in directing the cellular fate of a ubiquitinated protein. Although K48-linked polyubiquitination of p53 leads to its degradation, whether K48-independent ubiquitin linkages are involved in p53 activation remains unknown. Here, we show that FATS acts as a p53 activator by inhibiting Mdm2 binding to p53 and stimulating non-proteolytic polyubiquitination of p53. Knockdown of FATS impairs p53 stabilization and activation in response to DNA damage. Furthermore, the NH2-terminal domain of FATS is sufficient to exhibit ubiquitin ligase (E3) activity and assemble ubiquitin polymers through K11-, K29-and K63-linkages, independently of the ubiquitin-conjugating enzyme (E2). FATS promotes p53-dependent transcription of p21, leading to robust checkpoint response. The E3 activity of FATS is required for promoting p53 stability and activation in response to DNA damage. Our findings reveal K48-linkage-independent non-linear polyubiquitination of p53 as a new barcode for p53 activation.	[Yan, S.; Qiu, L.; Ma, K.; Zhang, X.; Zhao, Y.; Zhang, J.; Li, X.; Li, Z.] Tianjin Med Univ, Canc Inst & Hosp, Dept Biochem & Mol Biol, Tianjin 300060, Peoples R China; [Yan, S.; Qiu, L.; Ma, K.; Zhang, X.; Zhao, Y.; Zhang, J.; Li, X.; Hao, X.; Li, Z.] Tianjin Med Univ, Canc Inst & Hosp, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin 300060, Peoples R China	Tianjin Medical University; Tianjin Medical University	Li, Z (corresponding author), Tianjin Med Univ, Canc Inst & Hosp, Dept Biochem & Mol Biol, Huan Hu Xi Rd, Tianjin 300060, Peoples R China.	zhengli@tijmu.edu.cn			Ministry of Science and Technology of China 973-program concept award [2009CB526407]; National Natural Science Foundation of China [81272283]; Tianjin Municipal Science and Technology Foundation [10JCZDJC18600]	Ministry of Science and Technology of China 973-program concept award; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Municipal Science and Technology Foundation	We are grateful to Dr X Lu (The University of Texas MD Anderson Cancer Center, USA) for providing us with HA-Mdm2 plasmid. This work was supported by grants from Ministry of Science and Technology of China 973-program concept award (2009CB526407 to ZL), National Natural Science Foundation of China (81272283 to ZL), and Tianjin Municipal Science and Technology Foundation (10JCZDJC18600 to ZL).	Bellail AC, 2012, CANCER DISCOV, V2, P140, DOI 10.1158/2159-8290.CD-11-0172; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jain AK, 2010, CANCER BIOL THER, V10, P665, DOI 10.4161/cbt.10.7.13445; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jung YS, 2011, MOL CELL BIOL, V31, P3997, DOI 10.1128/MCB.05808-11; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Laine A, 2007, ONCOGENE, V26, P1477, DOI 10.1038/sj.onc.1209924; Laine A, 2006, MOL CELL BIOL, V26, P8901, DOI 10.1128/MCB.01156-06; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li Z, 2004, CANCER RES, V64, P9080, DOI 10.1158/0008-5472.CAN-04-2419; Li Z, 2010, ONCOGENE, V29, P2659, DOI 10.1038/onc.2010.19; LUNA RMD, 1995, NATURE, V378, P203; Ma K, 2012, INT J MOL SCI, V13, P11974, DOI 10.3390/ijms130911974; Mahmoud S, 2003, BIOCHEM BIOPH RES CO, V305, P1099, DOI 10.1016/S0006-291X(03)00905-7; Mao JH, 2005, ONCOGENE, V24, P7924, DOI 10.1038/sj.onc.1208926; Migliorini D, 2011, J CLIN INVEST, V121, P1329, DOI 10.1172/JCI45784; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tian Y, 2012, LUNG CANCER, V76, P416, DOI 10.1016/j.lungcan.2011.11.009; Ulrich HD, 2010, NAT REV MOL CELL BIO, V11, P479, DOI 10.1038/nrm2921; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wenzel DM, 2011, NATURE, V474, P105, DOI 10.1038/nature09966; Wu H, 2011, NAT MED, V17, P347, DOI 10.1038/nm.2283; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Ye YH, 2009, NAT REV MOL CELL BIO, V10, P755, DOI 10.1038/nrm2780; Zhang J, 2011, CHINESE MED J-PEKING, V124, P2894, DOI 10.3760/cma.j.issn.0366-6999.2011.18.018; Zhang XF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-244	39	12	13	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5424	5433		10.1038/onc.2013.494	http://dx.doi.org/10.1038/onc.2013.494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240685				2022-12-17	WOS:000345120700004
J	Qi, Q; Liu, X; Brat, DJ; Ye, K				Qi, Q.; Liu, X.; Brat, D. J.; Ye, K.			Merlin sumoylation is required for its tumor suppressor activity	ONCOGENE			English	Article						Akt; merlin; NF2; sumoylation; tumor suppressor	PLASMA-MEMBRANE; FERM DOMAIN; RECEPTOR ENDOCYTOSIS; P21-ACTIVATED KINASE; AKT PHOSPHORYLATION; SUMO-1 MODIFICATION; GROWTH SUPPRESSION; CELL MOTILITY; GENE-PRODUCT; NF2	Merlin, encoded by the Neurofibromatosis 2 (NF2) gene, is a multifunctional tumor suppressor that integrates and regulates extracellular cues and intracellular signaling pathways, both at the plasma membrane and in the nucleus, to control cell proliferation, migration and invasion. Molecular mechanisms regulating merlin's tumor-suppressive activity have not been clearly defined. Here we report that merlin can be sumoylated on Lysine residue (K76) in vitro and in vivo. Sumoylation mediates merlin's intramolecular and intermolecular binding activities and regulates its cytoplasm/nucleus trafficking. Interestingly, sumoylation of merlin is regulated by its phosphorylation via Akt and PAK2 kinases. Mutation of K76 into arginine (R) abolishes its sumoylation, disrupts merlin cortical cytoskeleton residency and attenuates its stability. Using a K76R mutant merlin in a subcutaneous U87MG xenograft model, we demonstrate that merlin sumoylation is required for tumor-suppressive activity. Taken together, our findings indicate that merlin is sumoylated and that this post-translational modification is essential for tumor suppression.	[Qi, Q.; Liu, X.; Brat, D. J.; Ye, K.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Ye, K (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 141,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			National Cancer Institute, National Institutes of Health R01 [CA127119]; NATIONAL CANCER INSTITUTE [R01CA127119] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health R01; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project has been funded in whole or in part with Federal Funds from the National Cancer Institute, National Institutes of Health R01 (CA127119 to K Ye). We thank Dr Jolinda Traugh for providing various PAK2 plasmids.	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Bettermann K, 2012, CANCER LETT, V316, P113, DOI 10.1016/j.canlet.2011.10.036; Brault E, 2001, J CELL SCI, V114, P1901; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Cole BK, 2008, MOL CELL BIOL, V28, P1274, DOI 10.1128/MCB.01139-07; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; de Cristofaro T, 2009, J MOL ENDOCRINOL, V42, P35, DOI 10.1677/JME-08-0100; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Evans DGR, 2011, ADV OTO-RHINO-LARYNG, V70, P91, DOI 10.1159/000322482; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1998, HUM MOL GENET, V7, P335, DOI 10.1093/hmg/7.3.335; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hilgarth RS, 2004, J BIOL CHEM, V279, P53899, DOI 10.1074/jbc.R400021200; James MF, 2009, MOL CELL BIOL, V29, P4250, DOI 10.1128/MCB.01581-08; Jukam D, 2011, DEV CELL, V21, P874, DOI 10.1016/j.devcel.2011.10.004; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Konopacki FA, 2011, P NATL ACAD SCI USA, V108, P19772, DOI 10.1073/pnas.1111575108; Kressel M, 2002, HUM MOL GENET, V11, P2269, DOI 10.1093/hmg/11.19.2269; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lallemand D, 2009, ONCOGENE, V28, P854, DOI 10.1038/onc.2008.427; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Li W, 2012, EMBO REP, V13, P204, DOI 10.1038/embor.2012.11; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Lopez-Lago MA, 2009, MOL CELL BIOL, V29, P4235, DOI 10.1128/MCB.01578-08; Lu JR, 2008, LARYNGOSCOPE, V118, P169, DOI 10.1097/MLG.0b013e3181566594; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; Mani T, 2011, MOL CELL BIOL, V31, P1983, DOI 10.1128/MCB.00609-10; Martin S, 2007, NATURE, V447, P321, DOI 10.1038/nature05736; Meng JJ, 2000, J NEUROSCI RES, V62, P491, DOI 10.1002/1097-4547(20001115)62:4<491::AID-JNR3>3.0.CO;2-D; Merrill JC, 2010, J MOL BIOL, V398, P657, DOI 10.1016/j.jmb.2010.03.048; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Murray LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043295; Okada M, 2009, CANCER RES, V69, P4043, DOI 10.1158/0008-5472.CAN-08-3931; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sher I, 2012, DEV CELL, V22, P703, DOI 10.1016/j.devcel.2012.03.008; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Trofatter J A, 1993, Cell, V75, P826; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Vanhatupa S, 2008, BIOCHEM J, V409, P179, DOI 10.1042/BJ20070620; Wang YG, 2009, J CELL SCI, V122, P4249, DOI 10.1242/jcs.050542; Wei BL, 2005, J VIROL, V79, P14976, DOI 10.1128/JVI.79.23.14976-14980.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yu JX, 2009, EMBO J, V28, P21, DOI 10.1038/emboj.2008.238	63	12	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4893	4903		10.1038/onc.2013.438	http://dx.doi.org/10.1038/onc.2013.438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24166499				2022-12-17	WOS:000343767900002
J	Saiz-Ladera, C; Lara, MF; Garin, M; Ruiz, S; Santos, M; Lorz, C; Garcia-Escudero, R; Martinez-Fernandez, M; Bravo, A; Fernandez-Capetillo, O; Segrelles, C; Paramio, JM				Saiz-Ladera, C.; Lara, M. F.; Garin, M.; Ruiz, S.; Santos, M.; Lorz, C.; Garcia-Escudero, R.; Martinez-Fernandez, M.; Bravo, A.; Fernandez-Capetillo, O.; Segrelles, C.; Paramio, J. M.			p21 suppresses inflammation and tumorigenesis on pRB-deficient stratified epithelia	ONCOGENE			English	Article						pRb; p21; skin; differentiation; inflammation; tumorigenesis	SQUAMOUS-CELL CARCINOMA; MOUSE SKIN CARCINOGENESIS; EPIDERMAL KERATINOCYTE DIFFERENTIATION; GENE-EXPRESSION PROFILES; KINASE INHIBITOR P21; NF-KAPPA-B; NECK-CANCER; TUMOR-SUPPRESSOR; DNA-DAMAGE; RETINOBLASTOMA PROTEIN	The retinoblastoma gene product (pRb) controls proliferation and differentiation processes in stratified epithelia. Importantly, and in contrast to other tissues, Rb deficiency does not lead to spontaneous skin tumor formation. As the cyclin-dependent kinase inhibitor p21 regulates proliferation and differentiation in the absence of pRb, we analyzed the consequences of deleting p21 in pRb-ablated stratified epithelia (hereafter pRb(Delta Epi); p21 - / -). These mice display an enhancement of the phenotypic abnormalities observed in pRb(Delta Epi) animals, indicating that p21 partially compensates pRb absence. Remarkably, pRb(Delta Epi); p21 - / - mice show an acute skin inflammatory phenotype and develop spontaneous epithelial tumors, particularly affecting tongue and oral tissues. Biochemical analyses and transcriptome studies reveal changes affecting multiple pathways, including DNA damage and p53-dependent signaling responses. Comparative metagenomic analyses, together with the histopathological profiles, indicate that these mice constitute a faithful model for human head and neck squamous cell carcinomas. Collectively, our findings demonstrate that p21, in conjunction with pRb, has a central role in regulating multiple epithelial processes and orchestrating specific tumor suppressor functions.	[Saiz-Ladera, C.; Lara, M. F.; Santos, M.; Lorz, C.; Garcia-Escudero, R.; Martinez-Fernandez, M.; Segrelles, C.; Paramio, J. M.] CIEMAT, Ctr Invest Energet Medioambientales & Tecnol, Mol Oncol Unit ed70A, Div Biomed, E-28040 Madrid, Spain; [Garin, M.] CIEMAT, Ctr Invest Energet Medioambientales & Tecnol, Ctr Invest Biomed Red Enfermedades Raras, Div Hematopoiet Innovat Therapies HIT, E-28040 Madrid, Spain; [Ruiz, S.; Fernandez-Capetillo, O.] Spanish Natl Canc Res Ctr, Genom Instabil Grp, Madrid, Spain; [Bravo, A.] Univ Santiago de Compostela, Dept Vet Clin Sci, Lugo, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Centro Nacional de Investigaciones Oncologicas (CNIO); Universidade de Santiago de Compostela	Segrelles, C (corresponding author), CIEMAT, Ctr Invest Energet Medioambientales & Tecnol, Mol Oncol Unit ed70A, Ave Complutense 40, E-28040 Madrid, Spain.	carmen.segrelles@ciemat.es; jesusm.paramio@ciemat.es	Fernandez-Capetillo, Oscar/H-3508-2015; Garcia-Escudero, Ramon/A-2735-2012; Ruiz, Sergio/G-1561-2016; Paramio, Jesus M/M-8482-2014; Moral, Ana María Bravo/AAD-3339-2021; Santos, Mirentxu/AAA-1727-2020; Cabanás, María Lara/AAH-3621-2019; Garin, Marina I/C-5094-2014; Lorz, Corina/E-3651-2016; Segrelles, Carmen/E-3655-2016	Fernandez-Capetillo, Oscar/0000-0002-2690-6885; Garcia-Escudero, Ramon/0000-0001-5640-6542; Ruiz, Sergio/0000-0002-0177-6965; Paramio, Jesus M/0000-0001-7520-3177; Moral, Ana María Bravo/0000-0002-5282-8921; Garin, Marina I/0000-0001-7956-6792; Lorz, Corina/0000-0001-8214-9076; Segrelles, Carmen/0000-0001-9340-2102; Saiz Ladera, Cristina/0000-0001-8094-5992	MINECO [SAF2011-26122-C02-01, SAF2012-34378]; CAM Oncocycle Program [S2010/BMD-2470]; ISCIII-RETIC [RD06/0020/0029, RD12/0036/0009]; REGENER-AR; ISCIII [PI12/01959]; 'Juan de la Cierva' research fellowship from MICINN [JCI-2010-06167]; 'Ramon y Cajal' research fellowship from MICINN [11-866-25-04]; Spanish Ministry of Science [SAF2011-23753]; Association for International Cancer Research [12-0229]; Howard Hughes Medical Institute; European Research Council [ERC-210520]; EU [FP7-HEALTH-279174]; Worldwide Cancer Research [12-0229] Funding Source: researchfish	MINECO(Spanish Government); CAM Oncocycle Program; ISCIII-RETIC(Instituto de Salud Carlos III); REGENER-AR; ISCIII(Instituto de Salud Carlos III); 'Juan de la Cierva' research fellowship from MICINN; 'Ramon y Cajal' research fellowship from MICINN; Spanish Ministry of Science(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Association for International Cancer Research; Howard Hughes Medical Institute(Howard Hughes Medical Institute); European Research Council(European Research Council (ERC)European Commission); EU(European Commission); Worldwide Cancer Research	We thank Pilar Hernandez for her excellent technical support on histology preparations and sectioning. The technical support by the personnel of the CIEMAT Animal Facility is specially acknowledged. Grant support: MINECO grants SAF2011-26122-C02-01 and SAF2012-34378, CAM Oncocycle Program Grants S2010/BMD-2470, ISCIII-RETIC grants RD06/0020/0029 and RD12/0036/0009 to JMP. EU FP7-HEALTH-279174, REGENER-AR to MG. ISCIII grant PI12/01959 to MS. MMF is funded by a 'Juan de la Cierva' research fellowship (JCI-2010-06167) from MICINN. SR is funded by a 'Ramon y Cajal' research fellowship (11-866-25-04) from MICINN. Work in the laboratory of OF is supported by grants from the Spanish Ministry of Science (SAF2011-23753), the Association for International Cancer Research (12-0229), the Howard Hughes Medical Institute and the European Research Council (ERC-210520).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Afshari CA, 1996, CELL GROWTH DIFFER, V7, P979; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Marques-Torrejon MA, 2013, CELL STEM CELL, V12, P88, DOI 10.1016/j.stem.2012.12.001; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Martinez-Cruz AB, 2010, METHODS MOL BIOL, V585, P361, DOI 10.1007/978-1-60761-380-0_25; Martinez-Cruz AB, 2009, ANTICANCER RES, V29, P3035; Bornachea O, 2012, SCI REP-UK, V2, DOI 10.1038/srep00434; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Buitrago-Perez A, 2009, CURR GENOMICS, V10, P26, DOI 10.2174/138920209787581235; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chin D, 2006, EXPERT REV ANTICANC, V6, P1111, DOI 10.1586/14737140.6.7.1111; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Chung CH, 2009, CLIN CANCER RES, V15, P6758, DOI 10.1158/1078-0432.CCR-09-0784; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Costa C, 2013, ONCOGENE, V32, P2937, DOI 10.1038/onc.2012.316; Costa C, 2012, SCI REP-UK, V2, DOI 10.1038/srep00828; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; de Marval PLM, 2004, ONCOGENE, V23, P1863, DOI 10.1038/sj.onc.1207309; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Devgan V, 2005, GENE DEV, V19, P1485, DOI 10.1101/gad.341405; Devgan V, 2006, J BIOL CHEM, V281, P30463, DOI 10.1074/jbc.M604684200; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Duenas M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042494; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ford JW, 2009, CURR OPIN IMMUNOL, V21, P38, DOI 10.1016/j.coi.2009.01.009; Garcia-Escudero R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-193; Haile LA, 2012, IMMUNOL INVEST, V41, P581, DOI 10.3109/08820139.2012.680635; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HARPER JW, 1993, CELL, V75, P805; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kyng KJ, 2005, ONCOGENE, V24, P5026, DOI 10.1038/sj.onc.1208692; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Leeman RJ, 2006, EXPERT OPIN BIOL TH, V6, P231, DOI 10.1517/14712598.6.3.231; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; McMurray HR, 2008, NATURE, V453, P1112, DOI 10.1038/nature06973; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Moral M, 2008, HISTOL HISTOPATHOL, V23, P1269, DOI 10.14670/HH-23.1269; PAK AS, 1995, CLIN CANCER RES, V1, P95; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Perez-Ordonez B, 2006, J CLIN PATHOL, V59, P445, DOI 10.1136/jcp.2003.007641; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rickman DS, 2008, ONCOGENE, V27, P6607, DOI 10.1038/onc.2008.251; Riley DJ, 1996, NAT MED, V2, P1316, DOI 10.1038/nm1296-1316; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Ruiz S, 2005, CANCER RES, V65, P9678, DOI 10.1158/0008-5472.CAN-05-1853; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2004, DEV DYNAM, V230, P410, DOI 10.1002/dvdy.20065; Ruiz S, 2003, DEVELOPMENT, V130, P2341, DOI 10.1242/dev.00453; Ruiz S, 2006, CELL CYCLE, V5, P625, DOI 10.4161/cc.5.6.2580; Santos M, 2003, J BIOL CHEM, V278, P13422, DOI 10.1074/jbc.M208170200; Santos M, 2008, MOL CARCINOGEN, V47, P815, DOI 10.1002/mc.20426; Serefoglou Z, 2008, ORAL ONCOL, V44, P1093, DOI 10.1016/j.oraloncology.2008.02.012; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin MK, 2009, CANCER RES, V69, P5656, DOI 10.1158/0008-5472.CAN-08-3711; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Srivastava MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040677; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Wang DW, 2001, MOL CARCINOGEN, V31, P90, DOI 10.1002/mc.1044; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Weinberg WC, 1999, CANCER RES, V59, P2050; Woods KV, 1998, CANCER RES, V58, P3132; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	105	12	12	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4599	4612		10.1038/onc.2013.417	http://dx.doi.org/10.1038/onc.2013.417			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24121270	Green Accepted			2022-12-17	WOS:000342004800007
J	Leufke, C; Leykauf, J; Krunic, D; Jauch, A; Holtgreve-Grez, H; Bohm-Steuer, B; Brocker, EB; Mauch, C; Utikal, J; Hartschuh, W; Purdie, KJ; Boukamp, P				Leufke, C.; Leykauf, J.; Krunic, D.; Jauch, A.; Holtgreve-Grez, H.; Boehm-Steuer, B.; Broecker, E-B; Mauch, C.; Utikal, J.; Hartschuh, W.; Purdie, K. J.; Boukamp, P.			The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas	ONCOGENE			English	Article						non-melanoma skin cancer; telomere organization; telomere length; actinic keratosis	NONMELANOMA SKIN-CANCER; IN-SITU HYBRIDIZATION; GENOMIC INSTABILITY; ACTINIC KERATOSIS; P53 MUTATIONS; GENE; BASAL; HTERT; TRANSPLANTATION; LOCALIZATION	The incidence of skin cancer is increasing worldwide and cutaneous squamous cell carcinomas (SCCs) are associated with considerable morbidity and mortality, particularly in immunosuppressed individuals ('carcinomatous catastrophy'). Yet, molecular mechanisms are still insufficiently understood. Besides ultraviolet (UV)-indicative mutations, chromosomal aberrations are prominent. As telomeres are essential in preserving chromosome integrity, and telomere erosion as well as aberrant spatial telomere distribution contribute to genomic instability, we first established telomere length profiles across the whole tissue and identified normal skin (10/30) harboring discrete epidermal sites (stem cell territories) of evenly short telomeres. Precancerous actinic keratoses (AKs) (17) and SCCs (27) expressed two telomere phenotypes: (i) tissue-wide evenly short to intermediate and (ii) longer and tissue-wide heterogeneous telomere lengths, suggesting two modes of initiation, with one likely to originate in the epidermal stem cells. Although tumor histotype, location, patient gender or age failed to distinguish the two SCC telomere phenotypes, as did telomerase activity, we found a trend for a higher degree of aberrant p53 and cyclin D1 expression with long/heterogeneous telomeres. In addition, we established an association for the short/homogeneous telomeres with a simpler and the heterogeneous telomeres with a more complex karyotype correlating also with distinct chromosomal changes. SCCs (13) from renal transplant recipients displayed the same telomere dichotomy, suggesting that both telomere subtypes contribute to 'carcinomatous catastrophy' under immunosuppression by selecting for a common set (3, 9p and 17q) and subtype-specific aberrations (e.g., 6p gain, 13q loss). As a second mechanism of telomere-dependent genomic instability, we investigated changes in telomere distribution with its most severe form of telomeric aggregates (TAs). We identified a telomere length-independent but progression-dependent increase in cells with small telomere associations in AKs (17/17) and additional TAs in SCCs (24/32), basal cell carcinomas (30/31) and malignant melanomas (15/15), and provide evidence for a reactive oxygen species-dependent mechanism in this UV-induced telomere organization-dependent genomic instability.	[Leufke, C.; Leykauf, J.; Krunic, D.; Holtgreve-Grez, H.; Boukamp, P.] German Canc Res Ctr, Div Genet Skin Carcinogenesis, Heidelberg, Germany; [Jauch, A.; Holtgreve-Grez, H.; Boehm-Steuer, B.] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany; [Broecker, E-B] Univ Wurzburg, Dept Dermatol, Wurzburg, Germany; [Mauch, C.] Univ Cologne, Dept Dermatol, Wurzburg, Germany; [Utikal, J.] German Canc Res Ctr Heidelberg, Skin Canc Unit, Heidelberg, Germany; [Utikal, J.] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Mannheim, Germany; [Hartschuh, W.] Heidelberg Univ, Dept Dermatol, Heidelberg, Germany; [Purdie, K. J.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, UK Canc Res UK Skin Tumour Lab, London, England	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Wurzburg; University of Cologne; University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of London; Queen Mary University London	Boukamp, P (corresponding author), German Canc Res Ctr, Div Genet Skin Carcinogenesis, Neuenheimer Feld 280,Postfach 101949, Heidelberg, Germany.	p.boukamp@dkfz.de		Utikal, Jochen/0000-0001-5316-0241	Deutsche Krebshilfe eV (Tumorstammzellverbund); Bmbf (UVA Kompetenzverbund); Tumorzentrum Heidelberg/Mannheim; Deutsche Forschungsgemeinschaft [SFB873, SFB 829, Z2]; 'Adulte epidermale Stammzellen' of the Baden-Wurttemberg Stiftung' [P-BWS-ASII/35]; Cancer Research UK [13044] Funding Source: researchfish	Deutsche Krebshilfe eV (Tumorstammzellverbund); Bmbf (UVA Kompetenzverbund); Tumorzentrum Heidelberg/Mannheim; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); 'Adulte epidermale Stammzellen' of the Baden-Wurttemberg Stiftung'; Cancer Research UK(Cancer Research UK)	We thank Angelika Lampe for her help in preparing the manuscript, Manuel Berning for constructive discussions and Iris Martin and Katrin Schmidt for their excellent technical assistance. We also thank Catherine Harwood, Charlotte Proby and Irene Leigh from the Cancer Research UK Skin Tumour Laboratory for providing us with the tumor material from the RT recipients. We further thank Dako (Denmark) for generously providing us with telomeric PNA probe. This work was supported by grants from the Deutsche Krebshilfe eV (Tumorstammzellverbund) and Bmbf (UVA Kompetenzverbund) (to PB), Tumorzentrum Heidelberg/Mannheim (to AJ and PB), the Deutsche Forschungsgemeinschaft (SFB873 to PB and SFB 829, Z2 to CM) and supported by contract research 'Adulte epidermale Stammzellen' of the Baden-Wurttemberg Stiftung' (P-BWS-ASII/35).	Armanios M, 2012, NAT REV GENET, V13, P693, DOI 10.1038/nrg3246; Bachor C, 1999, J CANCER RES CLIN, V125, P453, DOI 10.1007/s004320050302; Balasubramanian S, 2011, NAT REV DRUG DISCOV, V10, P261, DOI 10.1038/nrd3428; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Burnworth B, 2007, EUR J CELL BIOL, V86, P763, DOI 10.1016/j.ejcb.2006.11.002; Cerezo A, 2002, J CELL SCI, V115, P1305; Chuang TCY, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-12; de Fijter JW, 2007, NEPHROL DIAL TRANSPL, V22, pI23, DOI 10.1093/ndt/gfm086; Desmaze C, 2003, CANCER LETT, V194, P173, DOI 10.1016/S0304-3835(02)00704-8; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; Dworkin AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001136; Ermler S, 2004, EUR J CELL BIOL, V83, P681, DOI 10.1078/0171-9335-00430; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fabricius EM, 2009, INT J ONCOL, V35, P1377, DOI 10.3892/ijo_00000456; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Geigl JB, 2006, NAT PROTOC, V1, P1172, DOI 10.1038/nprot.2006.160; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Jin YS, 1999, GENE CHROMOSOME CANC, V26, P295, DOI 10.1002/(SICI)1098-2264(199912)26:4<295::AID-GCC3>3.0.CO;2-W; Jones MJK, 2012, DEV CELL, V23, P908, DOI 10.1016/j.devcel.2012.10.010; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kanellou P, 2008, CANCER LETT, V264, P145, DOI 10.1016/j.canlet.2008.01.042; Krunic D, 2009, BBA-MOL BASIS DIS, V1792, P297, DOI 10.1016/j.bbadis.2009.02.005; Lansdorp PM, 2009, EMBO J, V28, P2532, DOI 10.1038/emboj.2009.172; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102; Murnane JP, 2012, MUTAT RES-FUND MOL M, V730, P28, DOI 10.1016/j.mrfmmm.2011.04.008; Pacifico A, 2008, BRIT J DERMATOL, V158, P291, DOI 10.1111/j.1365-2133.2007.08360.x; Perrem K, 2007, HUM PATHOL, V38, P351, DOI 10.1016/j.humpath.2006.08.019; Perrem K, 2008, HUM PATHOL, V39, P1034, DOI 10.1016/j.humpath.2007.11.008; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Purdie KJ, 2007, GENE CHROMOSOME CANC, V46, P661, DOI 10.1002/gcc.20447; Purdie KJ, 2009, J INVEST DERMATOL, V129, P1562, DOI 10.1038/jid.2008.408; Raz V, 2008, J CELL SCI, V121, P4018, DOI 10.1242/jcs.034876; Ren ZP, 1997, AM J PATHOL, V150, P1791; Salgado R, 2008, ACTAS DERMO-SIFILOGR, V99, P199, DOI 10.1016/S0001-7310(08)74656-8; Shay J W, 2001, Novartis Found Symp, V235, P116; Toll A, 2009, BRIT J DERMATOL, V161, P1112, DOI 10.1111/j.1365-2133.2009.09351.x; Utikal J, 2005, CANCER LETT, V219, P197, DOI 10.1016/j.canlet.2004.07.011; Xu L, 2012, ANNU REV PATHOL-MECH, V8, P49; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; Zimmer C, 2011, J CELL BIOL, V192, P723, DOI 10.1083/jcb.201010058	44	12	12	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3506	3518		10.1038/onc.2013.323	http://dx.doi.org/10.1038/onc.2013.323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23955078	Bronze			2022-12-17	WOS:000338941100003
J	Huang, L; Kuwahara, I; Matsumoto, K				Huang, L.; Kuwahara, I.; Matsumoto, K.			EWS represses cofilin 1 expression by inducing nuclear retention of cofilin 1 mRNA	ONCOGENE			English	Article						EWS; CFL1; RNA-binding protein	ACTIN-DEPOLYMERIZING FACTOR; CELL-CYCLE; PROTEIN; CANCER; BINDING; SARCOMA; PHOSPHORYLATION; IDENTIFICATION; INVOLVEMENT; ADF/COFILIN	In Ewing's sarcoma family tumors (ESFTs), the proto-oncogene EWS that encodes an RNA-binding protein is fused by chromosomal translocation to the gene encoding one of the E-twenty six (ETS) family of transcription factors, most commonly friend leukemia virus integration 1 (FLI-1). Although EWS/FLI-1 chimeric proteins are necessary for carcinogenesis, additional events seem to be required for transformation to occur. We have previously reported that a protein product of an EWS mRNA target, whose expression is negatively regulated by EWS but not by EWS/FLI-1, contributes to ESFT development. However, the mechanism by which EWS represses protein expression remains to be elucidated. Here, we report that overexpression of full-length EWS repressed protein expression and induced nuclear retention of reporter mRNAs in a tethering assay. In contrast, when a mutant lacking the EWS C-terminal nuclear localization signal (classified as a PY-NLS) was expressed, reporter protein expression was upregulated, and the number of cells exporting reporter mRNA to the cytoplasm increased. EWS binds to the 3'-untranslated region in another mRNA target, cofilin 1 (CFL1), and negatively regulates the expression of CFL1. Overexpression of EWS induced nuclear retention of CFL1 mRNA. Furthermore, ESFT cell proliferation and metastatic potential were suppressed by small interfering RNA-mediated CFL1 knockdown. Together, our findings suggest that EWS induces nuclear retention of CFL1 mRNA, thereby suppressing expression of CFL1, and that CFL1 promotes development of ESFT. Targeting CFL1 might therefore provide another novel approach for treatment of this aggressive disease.	[Huang, L.; Kuwahara, I.; Matsumoto, K.] RIKEN, Mol Entomol Lab, Wako, Saitama 3510198, Japan; [Huang, L.] Dalian Med Univ, Dept Pathophysiol, Dalian, Peoples R China; [Matsumoto, K.] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan	RIKEN; Dalian Medical University; Japan Science & Technology Agency (JST)	Matsumoto, K (corresponding author), RIKEN, Chem Genet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	matsumok@riken.jp	Huang, Lin/AAI-5740-2020; Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394	Ministry of Education, Culture, Sports, Science and Technology of Japan; PRESTO program from Japan Science and Technology Agency; RIKEN Foreign Postdoctoral Researchers Program	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); PRESTO program from Japan Science and Technology Agency; RIKEN Foreign Postdoctoral Researchers Program	We thank Dr Yasufumi Minami for providing plasmids and Dr Shinichi Nakagawa for kindly teaching us the detailed methods for in situ hybridization. This study was supported, in part, by a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan; PRESTO program from Japan Science and Technology Agency; and RIKEN Foreign Postdoctoral Researchers Program. L Huang was a foreign postdoctoral researcher of RIKEN.	Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Castro MAA, 2010, CANCER-AM CANCER SOC, V116, P3645, DOI 10.1002/cncr.25125; Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Andersson MK, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-37; Andrianantoandro E, 2006, MOL CELL, V24, P13, DOI 10.1016/j.molcel.2006.08.006; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Colombrita C, 2012, J BIOL CHEM, V287, P15635, DOI 10.1074/jbc.M111.333450; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Dormann D, 2012, EMBO J, V31, P4258, DOI 10.1038/emboj.2012.261; Dutertre M, 2010, NAT STRUCT MOL BIOL, V17, P1358, DOI 10.1038/nsmb.1912; Estornes Y, 2007, INT J CANCER, V121, P2162, DOI 10.1002/ijc.22911; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hoell JI, 2011, NAT STRUCT MOL BIOL, V18, P1428, DOI 10.1038/nsmb.2163; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Hsu FF, 2010, ONCOGENE, V29, P2864, DOI 10.1038/onc.2010.40; Huang L, 2012, CANCER RES, V72, P1260, DOI 10.1158/0008-5472.CAN-11-2254; Kovar H, 2001, CANCER RES, V61, P5992; Kovar Heinrich, 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/837474; Lee YJ, 2005, MOL BIOTECHNOL, V31, P1, DOI 10.1385/MB:31:1:001; Leemann-Zakaryan Ruzanna P., 2011, Sarcoma, V2011, P218483, DOI 10.1155/2011/218483; Martoglio AM, 2000, MOL MED, V6, P750, DOI 10.1007/BF03402191; Naganuma T, 2012, EMBO J, V31, P4020, DOI 10.1038/emboj.2012.251; Neilsen Paul M., 2011, Sarcoma, V2011, P746939, DOI 10.1155/2011/746939; Nowak D, 2010, EUR J HISTOCHEM, V54, P59, DOI 10.4081/ejh.2010.e14; Paronetto MP, 2011, MOL CELL, V43, P353, DOI 10.1016/j.molcel.2011.05.035; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Rehklau K, 2012, CELL DEATH DIFFER, V19, P958, DOI 10.1038/cdd.2011.180; Solimini NL, 2012, SCIENCE, V337, P104, DOI 10.1126/science.1219580; Sone M, 2007, J CELL SCI, V120, P2498, DOI 10.1242/jcs.009357; Staege MS, 2004, CANCER RES, V64, P8213, DOI 10.1158/0008-5472.CAN-03-4059; Subbiah Vivek, 2011, Sarcoma, V2011, P686985, DOI 10.1155/2011/686985; Tanaka KJ, 2006, J BIOL CHEM, V281, P40096, DOI 10.1074/jbc.M609059200; Terasawa K, 2006, MOL CELL BIOL, V26, P3378, DOI 10.1128/MCB.26.9.3378-3389.2006; Terrier P, 1996, SEMIN DIAGN PATHOL, V13, P250; Toretsky JA, 2010, LANCET ONCOL, V11, P105, DOI 10.1016/S1470-2045(09)70391-2; Turhani D, 2006, ELECTROPHORESIS, V27, P1417, DOI 10.1002/elps.200500510; Tutucci E, 2011, NAT REV MOL CELL BIO, V12, P376, DOI 10.1038/nrm3119; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yap CT, 2005, CELL MOTIL CYTOSKEL, V60, P153, DOI 10.1002/cm.20053; Zakaryan RP, 2006, J MOL BIOL, V363, P27, DOI 10.1016/j.jmb.2006.08.018	46	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2995	3003		10.1038/onc.2013.255	http://dx.doi.org/10.1038/onc.2013.255			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23831569				2022-12-17	WOS:000337232200006
J	Puebla-Osorio, N; Kim, J; Ojeda, S; Zhang, H; Tavana, O; Li, S; Wang, Y; Ma, Q; Schluns, KS; Zhu, C				Puebla-Osorio, N.; Kim, J.; Ojeda, S.; Zhang, H.; Tavana, O.; Li, S.; Wang, Y.; Ma, Q.; Schluns, K. S.; Zhu, C.			A novel Ku70 function in colorectal homeostasis separate from nonhomologous end joining	ONCOGENE			English	Article						nonhomologous end joining; Ku70; colorectal cancer; senescence; beta-catenin; Wnt signaling	DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; DNA-DAMAGE; STEM-CELLS; CYCLIN D1; REPAIR; GENE; TUMORIGENESIS; BINDING; CANCER	Ku70, a known nonhomologous end-joining (NHEJ) factor, also functions in tumor suppression, although this molecular mechanism remains uncharacterized. Previously, we showed that mice deficient for DNA ligase IV (Lig4), another key NHEJ factor, succumbed to aggressive lymphoma in the absence of tumor suppressor p53. However, the tumor phenotype is abrogated by the introduction of a hypomorphic mutant p53(R172P), which impaired p53-mediated apoptosis but not cell-cycle arrest. However, Lig4(-/-)p53(R172P) mice succumbed to severe diabetes. To further elucidate the role of NHEJ and p53-mediated apoptosis in vivo, we bred Ku70(-/-) p53(R172P) mice. Unexpectedly, these mice were free of diabetes, although 80% of the mutant mice had abnormally enlarged colons with pronounced inflammation. Remarkably, most of these mutant mice progressed to dysplasia, adenoma and adenocarcinoma; this is in contrast to the Lig4(-/-) p53(R172P) phenotype, strongly suggesting an NHEJ-independent function of Ku70. Significantly, our analyses of Ku70(-/-) p53(R172P) colonic epithelial cells show nuclear stabilization of beta-catenin accompanied by higher expression of cyclin D1 and c-Myc in affected colon sections than in control samples. This is not due to the p53 mutation, as Ku70(-/-) mice share this phenotype. Our results not only unravel a novel function of Ku70 essential for colon homeostasis, but also establish an excellent in vivo model in which to study how chronic inflammation and abnormal cellular proliferation underlie tumorigenesis and tumor progression in the colon.	[Puebla-Osorio, N.; Kim, J.; Ojeda, S.; Zhang, H.; Tavana, O.; Li, S.; Wang, Y.; Schluns, K. S.; Zhu, C.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Tavana, O.; Ma, Q.; Schluns, K. S.; Zhu, C.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Ma, Q.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Zhu, C (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Immunol, Unit 902,1515 Holcombe Blvd, Houston, TX 77030 USA.	czhu@mdanderson.org	Zhang, Huiyuan/J-2784-2016; Schluns, Kimberly/R-5635-2019	Zhang, Huiyuan/0000-0002-1532-2462; Tavana, Omid/0000-0001-8401-4546; Puebla, Nahum/0000-0001-6498-5230	Institutional Research Grant; sister Institution Fund from The University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Institutional Research Grant; sister Institution Fund from The University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the histology core facility from the Department of Immunology at The University of Texas MD Anderson Cancer Center. We thank Dr James You for the help with pathology and Mei Sang for her technical assistance. This study was partially supported by an Institutional Research Grant (CZ) and a sister Institution Fund from The University of Texas MD Anderson Cancer Center (CZ).	Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Becker C, 2005, CELL CYCLE, V4, P217; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Crosnier C, 2006, NAT REV GENET, V7, P349, DOI 10.1038/nrg1840; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Erdman SE, 2010, TOXICOL PATHOL, V38, P76, DOI 10.1177/0192623309354110; Fearnhead NS, 2002, BRIT MED BULL, V64, P27, DOI 10.1093/bmb/64.1.27; Fell VL, 2012, MOL CELL BIOL, V32, P76, DOI 10.1128/MCB.05661-11; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gersemann M, 2009, DIFFERENTIATION, V77, P84, DOI 10.1016/j.diff.2008.09.008; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P146, DOI 10.1309/87BD0C6UCGUG126J; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoverter NP, 2012, MOL CELL BIOL, V32, P3648, DOI 10.1128/MCB.06769-11; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kavela S, 2013, CANCER RES, V73, P205, DOI 10.1158/0008-5472.CAN-12-1394; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Lefrancois L, 2001, CURR PROTOC IMMUNOL, V3; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; Pfingsten JS, 2012, CELL, V148, P922, DOI 10.1016/j.cell.2012.01.033; Puebla-Osorio N, 2008, IMMUNOL RES, V41, P103, DOI 10.1007/s12026-008-8015-3; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saif MW, 2010, CANCER J, V16, P196, DOI 10.1097/PPO.0b013e3181e076af; Sekiguchi JM, 2006, CELL, V124, P260, DOI 10.1016/j.cell.2006.01.010; Shirazi T, 2000, POSTGRAD MED J, V76, P473, DOI 10.1136/pmj.76.898.473; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sipos F, 2012, WORLD J GASTROENTERO, V18, P295, DOI 10.3748/wjg.v18.i4.295; Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102; Tavana O, DIABETES; Tavana O, 2010, DIABETES, V59, P135, DOI 10.2337/db09-0792; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Van Nguyen T, 2007, J EXP MED, V204, P1453, DOI 10.1084/jem.20062453; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Westbrook AM, 2010, MUTAT RES-REV MUTAT, V705, P40, DOI 10.1016/j.mrrev.2010.03.001; Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3; Zaanan A, 2011, CELL ONCOL, V34, P155, DOI 10.1007/s13402-011-0024-x; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	50	12	12	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2748	2757		10.1038/onc.2013.234	http://dx.doi.org/10.1038/onc.2013.234			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23752193	Green Accepted			2022-12-17	WOS:000337231700008
J	Damiano, L; Stewart, KM; Cohet, N; Mouw, JK; Lakins, JN; Debnath, J; Reisman, D; Nickerson, JA; Imbalzano, AN; Weaver, VM				Damiano, L.; Stewart, K. M.; Cohet, N.; Mouw, J. K.; Lakins, J. N.; Debnath, J.; Reisman, D.; Nickerson, J. A.; Imbalzano, A. N.; Weaver, V. M.			Oncogenic targeting of BRM drives malignancy through C/EBP beta-dependent induction of alpha 5 integrin	ONCOGENE			English	Article						alpha 5 integrin; Brahma; breast cancer; C/EBP beta; ECM-cell interactions; c-Myc	EPITHELIAL-SPECIFIC DISRUPTION; TRANSGENIC MOUSE MODEL; CELL-PROLIFERATION; SWI/SNF COMPLEX; 3-DIMENSIONAL CULTURE; TRANSCRIPTION FACTOR; MAMMARY-GLAND; CANCER; EXPRESSION; BRG1	Integrin expression and activity are altered in tumors, and aberrant integrin signaling promotes malignancy. However, how integrins become altered in tumors remains poorly understood. We discovered that oncogenic activation of MEK signaling induces cell growth and survival, and promotes the malignant phenotype of mammary epithelial cells (MECs) by increasing alpha 5 integrin expression. We determined that MEK activates c-Myc to reduce the transcription of the SWI/SNF chromatin remodeling enzyme Brahma (BRM). Our studies revealed that reduced BRM expression and/or activity drives the malignant behavior of MECs by epigenetically promoting C/EBP beta expression to directly induce alpha 5 integrin transcription. Consistently, we could show that restoring BRM levels normalized the malignant behavior of transformed MECs in culture and in vivo by preventing C/EBP beta-dependent alpha 5 integrin transcription. Our findings identify a novel mechanism whereby oncogenic signaling promotes malignant transformation by regulating transcription of a key chromatin remodeling molecule that regulates integrin-dependent stromal-epithelial interactions.	[Damiano, L.; Stewart, K. M.; Mouw, J. K.; Lakins, J. N.; Weaver, V. M.] Univ Calif San Francisco, Dept Surg, Ctr Bioengn & Tissue Regenerat, San Francisco, CA 94143 USA; [Cohet, N.; Nickerson, J. A.; Imbalzano, A. N.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA; [Debnath, J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Reisman, D.] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL USA; [Weaver, V. M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Dept Anat Bioengn & Therapeut Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Francisco; State University System of Florida; University of Florida; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Weaver, VM (corresponding author), Univ Calif San Francisco, Dept Surg, Ctr Bioengn & Tissue Regenerat, 513 Parnassus Ave,HSE 565,Box 0465, San Francisco, CA 94143 USA.	Valerie.Weaver@ucsfmedctr.org		Weaver, Valerie marie/0000-0003-4786-6752; Mouw, Janna K/0000-0002-9846-8466; Debnath, Jayanta/0000-0002-8745-4069	DOD [BC044791, W81XWH-05-1-0330, BC062562]; NIH/NCI [R01 CA138818, R01 CA085492]; NIEHS [U01ES019458]; NATIONAL CANCER INSTITUTE [R01CA085492, P01CA082834, U54CA163155, R01CA138818, U54CA143836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES019458] Funding Source: NIH RePORTER	DOD(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank R Bainer for analyzing the BRM promoter, MP Marinkovich for the BM165 antibody and C Damsky for the AIIB2 antibody. This work was supported by DOD BC044791 (W81XWH-05-1-0330), and NIH/NCI R01 CA138818 (to VMW), NIH/NCI R01 CA085492 (to HLM and VMW), DOD BC062562 (to JKM), and NIEHS U01ES019458 (to ZW).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bock VL, 2011, BRIT J DERMATOL, V164, P1221, DOI 10.1111/j.1365-2133.2011.10267.x; Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909; Cohet N, 2010, J CELL PHYSIOL, V223, P667, DOI 10.1002/jcp.22072; Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X; Dawson PJ, 1996, AM J PATHOL, V148, P313; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dingemans AMC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-152; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herkert Barbara, 2010, Genes Cancer, V1, P580, DOI 10.1177/1947601910379012; Hill DA, 2004, J CELL SCI, V117, P5847, DOI 10.1242/jcs.01502; Huck L, 2010, P NATL ACAD SCI USA, V107, P15559, DOI 10.1073/pnas.1003034107; Kahali B, 2014, ONCOGENE, V33, P653, DOI 10.1038/onc.2012.613; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Liu G, 2011, ONCOGENE, V30, P3295, DOI 10.1038/onc.2011.81; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Shen H, 2008, CANCER RES, V68, P10154, DOI 10.1158/0008-5472.CAN-08-1794; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Williams CM, 2008, CANCER RES, V68, P3185, DOI 10.1158/0008-5472.CAN-07-2673; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887	58	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2441	2453		10.1038/onc.2013.220	http://dx.doi.org/10.1038/onc.2013.220			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23770848	Green Accepted, Green Published			2022-12-17	WOS:000336033600004
J	DeWitt, J; Ochoa, V; Urschitz, J; Elston, M; Moisyadi, S; Nishi, R				DeWitt, J.; Ochoa, V.; Urschitz, J.; Elston, M.; Moisyadi, S.; Nishi, R.			Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line	ONCOGENE			English	Article						neuroblastoma; neural crest; transformation; TrkB; MYCN	NEUROTROPHIC FACTOR ACTIVATION; PROTECTS NEUROBLASTOMA-CELLS; C-MET; UP-REGULATION; EXPRESSION; RECEPTOR; MYC; BDNF; OVEREXPRESSION; PROTOONCOGENE	Neuroblastoma arises from sympathoadrenal progenitors of the neural crest and expression of the neurotrophin receptor TrkB and its ligand, brain-derived neurotrophic factor (BDNF), is correlated with poor prognosis. Although activated TrkB signaling promotes a more aggressive phenotype in established neuroblastoma cell lines, whether TrkB signaling is sufficient to transform neural crest-derived cells has not been investigated. To address the role of TrkB signaling in malignant transformation, we removed two immunoglobulin-like domains from the extracellular domain of the full-length rat TrkB receptor to create a Delta IgTrkB that is constitutively active. In the pheochromocytoma-derived cell line PC12, Delta IgTrkB promotes differentiation by stimulating process outgrowth; however, in the rat neural crest-derived cell line NCM-1, Delta IgTrkB signaling produces a markedly transformed phenotype characterized by increased proliferation, anchorage-independent cell growth, anoikis resistance and matrix invasion. Furthermore, expression of Delta IgTrkB leads to the upregulation of many transcripts encoding cancer-associated genes including cyclind1, twist1 and hgf, as well as downregulation of tumor suppressors such as pten and rb1. In addition, Delta IgTrkB NCM-1 cells show a 21-fold increase in mRNA for MYCN, the most common genetic marker for a poor prognosis in neuroblastoma. When injected into NOD SCID mice, control GFP NCM-1 cells fail to grow whereas Delta IgTrkB NCM-1 cells form rapidly growing and invasive tumors necessitating euthanasia of all mice by 15 days post injection. In summary, these results indicate that activated TrkB signaling is sufficient to promote the formation of a highly malignant phenotype in neural crest-derived cells.	[DeWitt, J.; Ochoa, V.; Nishi, R.] Univ Vermont, Dept Anat & Neurobiol, Burlington, VT 05405 USA; [DeWitt, J.; Ochoa, V.; Nishi, R.] Univ Vermont, Neurosci Grad Program, Burlington, VT 05405 USA; [Urschitz, J.; Elston, M.; Moisyadi, S.] Univ Hawaii, John A Burns Sch Med, Depat Anat Biochem & Physiol, Honolulu, HI USA; [Moisyadi, S.] Manoa BioSci, Honolulu, HI USA	University of Vermont; University of Vermont; University of Hawaii System; University of Hawaii System; University of Hawaii Manoa	Nishi, R (corresponding author), Univ Vermont, Dept Anat & Neurobiol, HSRF 406,149 Beaumont Ave, Burlington, VT 05405 USA.	Rae.Nishi@med.uvm.edu			Alex's Lemonade Foundation [R21NS25788, P30RR032135, P30GM103498, 5P20RR024206, R01GM083158-01A1]; NATIONAL CENTER FOR RESEARCH RESOURCES [P30RR032135, P20RR024206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103457, R01GM083158, P30GM103498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS076969] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007584] Funding Source: NIH RePORTER	Alex's Lemonade Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We would like to thank Felix Eckenstein, Andy McKenzie and Nourine Ahmed for technical assistance. We also thank Alan Howe for helpful comments on our manuscript and for assistance with the 'donut' assay. Portions of this work were performed in the DNA Analysis Facility at the Vermont Cancer Center and the Neuroscience COBRE Molecular Cellular Core at the University of Vermont. This work was funded by Alex's Lemonade Foundation (RN); R21NS25788 (RN); P30RR032135 (COBRE); P30GM103498 (COBRE); 5P20RR024206 (SM); and R01GM083158-01A1 (SM).	Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Cimmino F, 2009, ONCOGENE, V28, P2015, DOI 10.1038/onc.2009.70; De Bernardi B, 2005, CANCER LETT, V228, P283, DOI 10.1016/j.canlet.2005.01.053; De Bernardi B, 2001, J CLIN ONCOL, V19, P183, DOI 10.1200/JCO.2001.19.1.183; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eggert A, 2002, CANCER RES, V62, P1802; Feldman JP, 2009, J APPL QUANT METHODS, V4, P455, DOI DOI 10.1111/J.2042-3306.2010.TB05629.X; FURUKAWA T, 1995, AM J PATHOL, V147, P889; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Ho R, 2002, CANCER RES, V62, P6462; Huang YT, 2010, INT J ONCOL, V36, P1469, DOI 10.3892/ijo_00000633; Jaboin J, 2002, CANCER RES, V62, P6756; Jian Z, 1996, CELL SIGNAL, V8, P365, DOI 10.1016/0898-6568(96)00069-1; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kim CJ, 1999, AM J PATHOL, V155, P1661, DOI 10.1016/S0002-9440(10)65481-8; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; Kupferman ME, 2010, ONCOGENE, V29, P2047, DOI 10.1038/onc.2009.486; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; LIU C, 1992, ONCOGENE, V7, P181; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUMOTO K, 1995, CANCER RES, V55, P1798; McKenzie AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026552; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Minturn JE, 2011, CANCER CHEMOTH PHARM, V68, P1057, DOI 10.1007/s00280-011-1581-4; Molenaar JJ, 2012, GENE CHROMOSOME CANC, V51, P10, DOI 10.1002/gcc.20926; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 1998, Hum Cell, V11, P115; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Plantaz D, 1996, CANCER, V78, P311, DOI 10.1002/(SICI)1097-0142(19960715)78:2<311::AID-CNCR19>3.3.CO;2-O; Ramirez R, 2000, CLIN ENDOCRINOL, V53, P635, DOI 10.1046/j.1365-2265.2000.01124.x; RAMSAY GM, 1990, P NATL ACAD SCI USA, V87, P2102, DOI 10.1073/pnas.87.6.2102; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Reiff T, 2010, J NEUROSCI, V30, P905, DOI 10.1523/JNEUROSCI.5368-09.2010; Scala S, 1996, CANCER RES, V56, P3737; Schramm A, 2005, CANCER LETT, V228, P143, DOI 10.1016/j.canlet.2005.02.051; Schulte JH, 2013, ONCOGENE, V32, P1059, DOI 10.1038/onc.2012.106; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Singh RK, 2007, BIOORG MED CHEM LETT, V17, P5846, DOI 10.1016/j.bmcl.2007.08.032; Straub JA, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-10; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Thullberg M, 2008, CELL CYCLE, V7, P984, DOI 10.4161/cc.7.8.5674; Tokunou M, 2001, AM J PATHOL, V158, P1451, DOI 10.1016/S0002-9440(10)64096-5; Urschitz J, 2010, P NATL ACAD SCI USA, V107, P8117, DOI 10.1073/pnas.1003674107; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Yu YJ, 2010, APMIS, V118, P188, DOI 10.1111/j.1600-0463.2009.02577.x; Zhang SY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-43	59	12	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					977	985		10.1038/onc.2013.39	http://dx.doi.org/10.1038/onc.2013.39			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23455321	Green Accepted			2022-12-17	WOS:000331933200005
J	Wasylishen, AR; Kalkat, M; Kim, SS; Pandyra, A; Chan, PK; Oliveri, S; Sedivy, E; Konforte, D; Bros, C; Raught, B; Penn, LZ				Wasylishen, A. R.; Kalkat, M.; Kim, S. S.; Pandyra, A.; Chan, P-K; Oliveri, S.; Sedivy, E.; Konforte, D.; Bros, C.; Raught, B.; Penn, L. Z.			MYC activity is negatively regulated by a C-terminal lysine cluster	ONCOGENE			English	Article						Myc; cellular transformation; apoptosis; lysine; transcription	TRANSACTIVATION DOMAIN; TRANSFORMATION; CELLS; ACETYLATION; FIBROBLASTS; ONCOPROTEIN; REPRESSES; PHENOTYPE; APOPTOSIS; LYMPHOMA	The MYC oncogene is not only deregulated in cancer through abnormally high levels of expression, but also through oncogenic lesions in upstream signalling cascades. Modelling MYC deregulation using signalling mutants is a productive research strategy. For example, the MYC threonine-58 to alanine substitution mutant (T58A) within MYC-homology box 1 is more transforming than wildtype (WT) MYC, because of decreased apoptosis and increased protein stability. Understanding the regulatory mechanisms controlling T58 phosphorylation has led to new approaches for the development of MYC inhibitors. In this manuscript, we have extensively characterized a MYC signalling mutant in which six lysine residues near the highly conserved MYC homology box IV and basic region have been substituted to arginines (6KR). Previous literature suggests these lysines can undergo both ubiquitylation and acetylation. We show MYC 6KR is able to fully rescue the slow growth phenotype of HO15.19 MYC-null fibroblasts, and promote cell cycle entry of serum-starved MCF10A cells. Remarkably, 6KR increased anchorage-independent colony growth compared with WT MYC in both SH-EP and MCF10A cells. Moreover, it was also more potent in promoting xenograft tumour growth of Rat1A and SH-EP cells. Combined, our data identify this region and these six lysines as important residues for the negative regulation of MYC-induced transformation. Mechanistically, we demonstrate that, unlike T58A, the increased transformation is not a result of increased protein stability or a reduced capacity for 6KR to induce apoptosis. Through expression analysis and luciferase reporter assays, we show that 6KR has increased transcriptional activity compared with WT MYC. Combined, through a comprehensive evaluation across multiple cell types, we identify an important regulatory region within MYC. A better understanding of the full scope of signalling through these residues will provide further insights into the mechanisms contributing to MYC-induced tumorigenesis and may unveil novel therapeutic strategies to target Myc in cancer.	[Wasylishen, A. R.; Kalkat, M.; Kim, S. S.; Pandyra, A.; Oliveri, S.; Sedivy, E.; Raught, B.; Penn, L. Z.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Wasylishen, A. R.; Kalkat, M.; Kim, S. S.; Pandyra, A.; Chan, P-K; Oliveri, S.; Sedivy, E.; Konforte, D.; Bros, C.; Raught, B.; Penn, L. Z.] Princess Margaret Hosp, Campbell Family Inst Canc Res, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Penn, LZ (corresponding author), Princess Margaret Hosp, Campbell Family Inst Canc Res, Ontario Canc Inst, Room 9-628,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459; Kalkat, Manpreet/0000-0002-4843-9755; Wasylishen, Amanda/0000-0002-1940-5169	Canadian Cancer Society Research Institute; Canadian Institute for Health Research; Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowships; Ontario Graduate Student Fellowship; Ontario Ministry of Health; Ontario Long Term Care	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowships; Ontario Graduate Student Fellowship; Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); Ontario Long Term Care	We thank Dr Martin Eilers for kindly providing the Myc 6KR construct, Dr Garry Nolan for providing retroviral reagents and packaging cell lines. SH-EP Tet21/N-Myc, MCF10A, Rat-1A and HO15.19 cells were kindly provided by Dr Manfred Schwab, Dr Senthil Muthuswamy, Dr Edward Prochownick and Dr John Sedivy, respectively. Additionally we thank Drs Bruno Amati, Chi Dang and Stephen Hann for kindly providing luciferase reporter constructs. We also thank Andrew Rust and Drs Angelina Stojanova and Peter Mullen for technical assistance, and the members of the Penn Lab for helpful discussions and critical review of this manuscript. This research was funded by grants from the Canadian Cancer Society Research Institute and Canadian Institute for Health Research (LZP), Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowships (ARW and AP) and an Ontario Graduate Student Fellowship (MK). BR and LZP hold the Canada Research Chairs in Proteomics & Molecular Medicine and Molecular Oncology, respectively. Additional support was provided by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the OMOHLTC.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Berns K, 2000, ONCOGENE, V19, P3330, DOI 10.1038/sj.onc.1203639; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Callus BA, 2008, CELL DEATH DIFFER, V15, P213, DOI 10.1038/sj.cdd.4402245; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Faiola F, 2005, MOL CELL BIOL, V25, P10220, DOI 10.1128/MCB.25.23.10220-10234.2005; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Graves JA, PLOS ONE, V5; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thibodeaux CA, 2009, BREAST CANCER RES TR, V116, P281, DOI 10.1007/s10549-008-0127-x; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Wasylishen AR, 2011, ONCOGENE, V30, P3727, DOI 10.1038/onc.2011.88; Zhang KL, 2005, BIOCHEM BIOPH RES CO, V336, P274, DOI 10.1016/j.bbrc.2005.08.075	28	12	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1066	1072		10.1038/onc.2013.36	http://dx.doi.org/10.1038/onc.2013.36			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23435422				2022-12-17	WOS:000331933200014
J	Wang, J; Gildea, JJ; Yue, W				Wang, J.; Gildea, J. J.; Yue, W.			Aromatase overexpression induces malignant changes in estrogen receptor a negative MCF-10A cells	ONCOGENE			English	Article						aromatase; MCF-10A; estrogen; breast cancer; stem cell	BREAST-CANCER CELLS; MOLECULAR ETIOLOGY; ADIPOSE-TISSUE; BRCA1; RISK; BIOMARKERS; TUMOR; EXPRESSION; LINK; 17-BETA-ESTRADIOL	Estrogen is a risk factor of breast cancer. Elevated expression of aromatase (estrogen synthase) in breast tissues increases local estradiol concentrations and is associated with breast cancer development, but the causal relationship between aromatase and breast cancer has not been identified. Accumulating data suggest that both estrogen receptor (ER)-dependent and -independent effects are involved in estrogen carcinogenesis. We established a model by expressing aromatase in ER alpha - MCF-10A human breast epithelial cells to investigate ER alpha-independent effects of estrogen in the process of malignant transformation. Overexpression of aromatase significantly increased anchorage-independent growth. Parental- or vector-expressing MCF-10A cells did not form colonies under the same conditions. The anchorage-independent growth of MCF-10A(arom) cells can be completely abolished by pretreatment with the aromatase inhibitor, letrozole. Neither MCF-10A(arom) nor MCF-10A(vector) cells grown in monolayer were affected by short-term exposure to estradiol. Enhanced motility is another characteristic of cellular transformation. Motility of MCF-10A(arom) cells was increased, which could be inhibited by letrozole. Increases in stem cell population in breast cancer tissues are associated with tumor recurrence and metastasis. CD44(high)/CD24(low) is a stem cell marker. We found that CD24 mRNA levels were reduced in MCF-10A(arom) cells compared with those in parental- and vector-transfected cells. By examining individual clones of MCF-10A(arom) with various aromatase activities, we found that the CD24 mRNA levels were inversely correlated with aromatase activity. The ability of MCF-10A(arom) cells to form mammospheres in the absence of serum was increased. Our results suggest that overexpression of aromatase in MCF-10A cells causes malignant transformation. Estrogen metabolite-mediated genotoxicity and induction of a stem cell/progenitor cell population are possible mechanisms. These studies provide additional evidence for ER alpha-independent mechanism(s) in estrogen carcinogenesis and implicate superiority of aromatase inhibitors to antiestrogens for breast cancer prevention.	[Wang, J.; Yue, W.] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Yue, W (corresponding author), Univ Virginia Hlth Syst, Dept Med, Fountaine Res Pk,POB 801416, Charlottesville, VA 22908 USA.	wy9c@virginia.edu			DOD [DOD DAMD17-01-1-0444, DAMD17-01-1-0445]	DOD(United States Department of Defense)	This study is supported by DOD Grants: DOD DAMD17-01-1-0444 and DAMD17-01-1-0445. Human aromatase cDNA plasmid was kindly provided by Dr Shiuan Chen (Beckman Institute at City of Hope, Duarte, CA, USA). Measurement of estrogen metabolites was performed by Dr Cavalieri at the Laboratory of Eppley Institute for Research in Cancer and Allied Diseases (University of Nebraska Medical Center Omaha, NE, USA).	Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; BERKOVITZ GD, 1985, J CLIN INVEST, V75, P1763, DOI 10.1172/JCI111888; BULARD J, 1987, J CLIN ENDOCR METAB, V64, P618, DOI 10.1210/jcem-64-3-618; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jcem.77.6.8117355; Cavalieri E, 2006, BBA-REV CANCER, V1766, P63, DOI 10.1016/j.bbcan.2006.03.001; Chand AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-148; Chen WY, 2006, ARCH INTERN MED, V166, P1027, DOI 10.1001/archinte.166.9.1027; DEOME KB, 1959, CANCER RES, V19, P515; Diaz-Cruz ES, 2011, CANCER RES, V71, P5477, DOI 10.1158/0008-5472.CAN-10-4652; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020; FEINLEIB M, 1968, JNCI-J NATL CANCER I, V41, P315; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Gaikwad NW, 2008, INT J CANCER, V122, P1949, DOI 10.1002/ijc.23329; Gaikwad NW, 2009, BREAST CANCER-BASIC, V3, P1; Goss PE, 2011, NEW ENGL J MED, V364, P2381, DOI 10.1056/NEJMoa1103507; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Hu YF, 2005, ONCOGENE, V24, P8343, DOI 10.1038/sj.onc.1208985; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kaaks R, 2005, ENDOCR-RELAT CANCER, V12, P1071, DOI 10.1677/erc.1.01038; Kotsopoulos J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2790; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lu F, 2007, J STEROID BIOCHEM, V105, P150, DOI 10.1016/j.jsbmb.2006.12.102; Lu ML, 2006, J CLIN ENDOCR METAB, V91, P4514, DOI 10.1210/jc.2006-1364; Maurice KT, 2005, CAN VET J, V46, P644; ONEILL JS, 1988, BRIT MED J, V296, P741, DOI 10.1136/bmj.296.6624.741; Rebbeck TR, 2009, JNCI-J NATL CANCER I, V101, P80, DOI 10.1093/jnci/djn442; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Russo J, 2002, J STEROID BIOCHEM, V80, P149, DOI 10.1016/S0960-0760(01)00183-2; Russo J, 2000, J Natl Cancer Inst Monogr, P17; Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com; Shen YM, 2006, CHEM RES TOXICOL, V19, P1441, DOI 10.1021/tx0601206; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Tekmal RR, 1996, CANCER RES, V56, P3180; Thurlimann B, 2005, NEW ENGL J MED, V353, P2747; TRICHOPOULOS D, 1972, JNCI-J NATL CANCER I, V48, P605; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yager JD, 2012, TRANSL ENDOCRINOL ME, V3, P1; Yue W, 2003, J STEROID BIOCHEM, V86, P265, DOI 10.1016/S0960-0760(03)00366-2; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186; Yue W, 1998, CANCER RES, V58, P927; Yue W, 2010, INT J CANCER, V127, P1748, DOI 10.1002/ijc.25207; ZHOU D, 1990, CANCER RES, V50, P6949	46	12	15	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5233	5240		10.1038/onc.2012.558	http://dx.doi.org/10.1038/onc.2012.558			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23178495				2022-12-17	WOS:000326497100006
J	Dalvai, M; Mondesert, O; Bugler, B; Manenti, S; Ducommun, B; Dozier, C				Dalvai, M.; Mondesert, O.; Bugler, B.; Manenti, S.; Ducommun, B.; Dozier, C.			Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter	ONCOGENE			English	Article						Cdc25B; doxorubicin; p53; Sp1	DNA-DAMAGING AGENTS; DOWN-REGULATION; P53; PHOSPHORYLATION; EXPRESSION; PHOSPHATASES; CHECKPOINT; IDENTIFICATION; DEGRADATION; INDUCTION	Cdc25B phosphatases have a key role in G2/M cell-cycle progression by activating the CDK1-cyclinB1 complexes and functioning as important targets of checkpoints. Overexpression of Cdc25B results in a bypass of the G2/M checkpoint and illegitimate entry into mitosis. It can also cause replicative stress, which leads to genomic instability. Thus, fine-tuning of the Cdc25B expression level is critical for correct cell-cycle arrest in response to DNA damage. In response to genotoxic stress, Cdc25B is mainly regulated by post-transcriptional mechanisms affecting either Cdc25B protein stability or translation. Here, we show that upon DNA damage Cdc25B can be regulated at the transcriptional level. Although ionizing radiation downregulates Cdc25B in a p53-dependent pathway, doxorubicin transcriptionally upregulates Cdc25B in p53-proficient cancer cells. We show that in the presence of wild-type p53, doxorubicin activates the Cdc25B promoter by preventing the binding of Sp1 and increasing the binding of NF-Y on the Cdc25B promoter, thus preventing p53 from downregulating this promoter. Our results highlight the mechanistically distinct regulation of the three Cdc25 phosphatases by checkpoint signalling following doxorubicin treatment.	[Dalvai, M.] CNRS, LBME UMR5099, F-31059 Toulouse, France; [Dalvai, M.; Mondesert, O.; Bugler, B.; Manenti, S.; Ducommun, B.; Dozier, C.] Univ Toulouse, Toulouse, France; [Mondesert, O.; Ducommun, B.] CNRS, ITAV UMS 3039, F-31059 Toulouse, France; [Bugler, B.] CNRS, LBCMCP UMR5088, F-31059 Toulouse, France; [Manenti, S.; Dozier, C.] CNRS, Canc Res Ctr Toulouse, Dept Hematol & Immunol, INSERM UMR1037,ERL 5294, F-31059 Toulouse, France; [Manenti, S.; Dozier, C.] CNRS, ERL 5294, F-31059 Toulouse, France; [Ducommun, B.] CHU Toulouse, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU de Toulouse	Dozier, C (corresponding author), CNRS, Canc Res Ctr Toulouse, Dept Hematol & Immunol, INSERM UMR1037,ERL 5294, F-31059 Toulouse, France.	christine.dozier@inserm.fr	manenti, stephane/P-1518-2014; DOZIER, Christine/P-1539-2014	manenti, stephane/0000-0002-4793-3196; DUCOMMUN, Bernard/0000-0002-7126-8368	Fondation de la Recherche Medicale; C.N.R.S; Universite Paul Sabatier; la region Midi-Pyrenees; l'Institut National du Cancer [PL2008]; Canceropole Grand Sud-Ouest, le conseil de radioprotection d'EDF et la Ligue Nationale Contre le Cancer (Equipe labellisee)	Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale); C.N.R.S(Centre National de la Recherche Scientifique (CNRS)); Universite Paul Sabatier; la region Midi-Pyrenees(Region Occitanie); l'Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropole Grand Sud-Ouest, le conseil de radioprotection d'EDF et la Ligue Nationale Contre le Cancer (Equipe labellisee)	The authors thank Dr Bert Vogelstein (Howard Hughes Medical Institute, Baltimore USA) for providing the WT and p53 -/- HCT116 cells. MD was a recipient of a post-doctoral fellowship from Fondation de la Recherche Medicale. This work was supported by C.N.R.S, Universite Paul Sabatier, la region Midi-Pyrenees, l'Institut National du Cancer (PL2008), the Canceropole Grand Sud-Ouest, le conseil de radioprotection d'EDF et la Ligue Nationale Contre le Cancer (Equipe labellisee 2008).	Aressy B, 2008, CELL CYCLE, V7, P2234, DOI 10.4161/cc.7.14.6305; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Bansal P, 2007, CANCER RES, V67, P3356, DOI 10.1158/0008-5472.CAN-06-3685; Beishline K, 2012, MOL CELL BIOL, V32, P3790, DOI 10.1128/MCB.00049-12; Bocangel D, 2009, ANTICANCER RES, V29, P3741; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Bu YQ, 2008, GENES CELLS, V13, P53, DOI 10.1111/j.1365-2443.2007.01144.x; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Chu S., GENE, V508, P1; Cuesta A, 2009, BIOCHEM J, V418, P643, DOI 10.1042/BJ20081793; Dalvai M, 2011, ONCOGENE, V30, P2282, DOI 10.1038/onc.2010.588; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Iwahori S, 2008, CELL SIGNAL, V20, P1795, DOI 10.1016/j.cellsig.2008.06.007; Jullien D, 2011, CANCER RES, V71, P1968, DOI 10.1158/0008-5472.CAN-10-2453; Kang CM, 2004, CARCINOGENESIS, V25, P123, DOI 10.1093/carcin/bgg187; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Lemaire M, 2006, CELL CYCLE, V5, P1649, DOI 10.4161/cc.5.15.3006; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Miyata H, 2001, CANCER RES, V61, P3188; Olofsson BA, 2007, MOL CANCER RES, V5, P1319, DOI 10.1158/1541-7786.MCR-07-0374; Rashi-Elkeles S, 2011, MOL ONCOL, V5, P336, DOI 10.1016/j.molonc.2011.06.004; Scian MJ, 2008, ONCOGENE, V27, P2583, DOI 10.1038/sj.onc.1210898; St Clair S, 2004, MOL CELL, V16, P725; Szulawska A, 2005, BIOCHEM PHARMACOL, V69, P7, DOI 10.1016/j.bcp.2004.09.002; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Uchida Y, 2004, CANCER RES, V64, P6271, DOI 10.1158/0008-5472.CAN-03-1476; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu J, 2008, CANCER RES, V68, P6718, DOI 10.1158/0008-5472.CAN-08-0657; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	33	12	13	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5123	5128		10.1038/onc.2012.524	http://dx.doi.org/10.1038/onc.2012.524			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23160377				2022-12-17	WOS:000325937900013
J	Russo, N; Wang, X; Liu, M; Banerjee, R; Goto, M; Scanlon, C; Metwally, T; Inglehart, RC; Tsodikov, A; Duffy, S; Van Tubergen, E; Bradford, C; Carey, T; Wolf, G; Chinnaiyan, AM; D'Silva, NJ				Russo, N.; Wang, X.; Liu, M.; Banerjee, R.; Goto, M.; Scanlon, C.; Metwally, T.; Inglehart, R. C.; Tsodikov, A.; Duffy, S.; Van Tubergen, E.; Bradford, C.; Carey, T.; Wolf, G.; Chinnaiyan, A. M.; D'Silva, N. J.			A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature	ONCOGENE			English	Article						L23; proliferation; tumor antigen	HUMORAL IMMUNE-RESPONSE; SQUAMOUS-CELL CARCINOMA; MOLECULAR-BIOLOGY; P53; IDENTIFICATION; PROTEINS; ANTIGENS; GENES; UBIQUITINATION; IMMUNOTHERAPY	Despite the dismal prognosis for patients with squamous cell carcinoma of the head and neck (SCCHN), there have been no novel treatments in over 40 years. Identification of novel tumor antigens in SCCHN will facilitate the identification of potential novel treatment targets. Tumor antigens are proteins selectively expressed by tumor cells and recognized by the host immune system. Phage-displayed tumor antigens were enriched by biopanning with normal and then SCCHN-specific serum. Ninety-six phage clones were sequenced for identification, and 21 clones were validated using Luminex. One of these proteins, L23, a novel tumor antigen in SCCHN, was validated as an oncogene. L23 is upregulated in SCCHN compared with normal keratinocytes. Knockdown of L23 inhibited proliferation, invasion and cell survival. Overexpression of L23 had the reverse effect. Overexpression of L23 in non malignant cells led to transformation. Injection of SCCHN cells with knockdown of L23 in mice, induced tumors that were significantly smaller than control tumors. In conclusion, the immunomic screen yielded a panel of antigens specific to SCCHN; one of these proteins, L23, is a novel oncogene in SCCHN.	[Russo, N.; Liu, M.; Banerjee, R.; Goto, M.; Scanlon, C.; Metwally, T.; Inglehart, R. C.; Van Tubergen, E.; D'Silva, N. J.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [Wang, X.; Chinnaiyan, A. M.; D'Silva, N. J.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Wang, X.; Chinnaiyan, A. M.; D'Silva, N. J.] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Tsodikov, A.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Duffy, S.] Univ Michigan, Sch Nursing, Sch Med, Ann Arbor, MI 48109 USA; [Bradford, C.; Carey, T.; Wolf, G.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011N Univ Ave,Room 5217, Ann Arbor, MI 48109 USA.	njdsilva@umich.edu	D'Silva, Nisha J/B-4734-2013	D'Silva, Nisha/0000-0001-7030-3187; Carey, Thomas/0000-0002-5202-7518	NIDCR [DE017977, DE019513]; MICHR CTSA [UL1RR024986]; NCI SPORE [P50 CA97248]; National Institutes of Health through the University of Michigan's Cancer Center Support Grant [5 P30 CA46592]; NATIONAL CANCER INSTITUTE [P50CA097248, P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K02DE019513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE018512, R21DE017977] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); MICHR CTSA; NCI SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health through the University of Michigan's Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors would like to thank Kenneth Rieger for his artistic assistance with illustrations. This work was supported by NIDCR DE017977, DE019513, MICHR CTSA UL1RR024986, Research Development award from NCI SPORE grant P50 CA97248 (NJD). This research was made possible, in part, by the use of the Cancer Center Flow Cytometry Core which was supported (in part) by the National Institutes of Health through the University of Michigan's Cancer Center Support Grant (5 P30 CA46592).	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Banerjee R, 2011, ONCOGENE, V30, P4339, DOI 10.1038/onc.2011.141; Beck-Engeser GB, 2001, J EXP MED, V194, P285, DOI 10.1084/jem.194.3.285; Bigler LR, 2002, J ORAL PATHOL MED, V31, P421, DOI 10.1034/j.1600-0714.2002.00123.x; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; Brakenhoff RH, 2011, SCIENCE, V333, P1102, DOI 10.1126/science.1210986; Bsoul SA, 2005, J CONT DENT PRACT, V6, P1, DOI DOI 10.5005/JCDP-6-4-1; Chen GA, 2007, CANCER RES, V67, P3461, DOI 10.1158/0008-5472.CAN-06-4475; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; DYBWAD A, 1993, EUR J IMMUNOL, V23, P3189, DOI 10.1002/eji.1830231222; Ferris RL, 2010, J CLIN ONCOL, V28, P4390, DOI 10.1200/JCO.2009.27.6360; Goto M, 2010, CLIN CANCER RES, V16, P65, DOI 10.1158/1078-0432.CCR-09-1122; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Koga M, 2003, TISSUE ANTIGENS, V61, P136, DOI 10.1046/j.0001-2815.2002.00009.x; Laheru DA, 2005, MOL CANCER THER, V4, P1645, DOI 10.1158/1535-7163.MCT-05-0151; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Leethanakul C, 2000, ORAL ONCOL, V36, P474, DOI 10.1016/S1368-8375(00)00039-7; Li G, 2005, CURR PHARM DESIGN, V11, P3501, DOI 10.2174/138161205774414583; Liu Fangli, 2007, Journal of Genetics and Genomics, V34, P189, DOI 10.1016/S1673-8527(07)60020-4; Matsutake T, 2001, P NATL ACAD SCI USA, V98, P3992, DOI 10.1073/pnas.071523398; Mitra RS, 2008, CANCER RES, V68, P3959, DOI 10.1158/0008-5472.CAN-07-2755; Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534; MONACH PA, 1995, IMMUNITY, V2, P45, DOI 10.1016/1074-7613(95)90078-0; Nemeth Z, 2005, NEOPLASMA, V52, P95; Neville B. W., 2002, ORAL MAXILLOFACIAL P, P337; Patel V, 2008, CLIN CANCER RES, V14, P1002, DOI 10.1158/1078-0432.CCR-07-1497; Philip M, 2010, IMMUNOLOGY, V130, P494, DOI 10.1111/j.1365-2567.2010.03258.x; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Shi YQ, 2004, EXP CELL RES, V296, P337, DOI 10.1016/j.yexcr.2004.02.009; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Wang XJ, 2005, NEW ENGL J MED, V353, P1224, DOI 10.1056/NEJMoa051931; Wanzel M, 2008, NAT CELL BIOL, V10, P1051, DOI 10.1038/ncb1764; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang ZC, 2006, AM J PATHOL, V168, P585, DOI 10.2353/ajpath.2006.050132	43	12	12	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5026	5037		10.1038/onc.2012.532	http://dx.doi.org/10.1038/onc.2012.532			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23160375	Green Accepted			2022-12-17	WOS:000325937900004
J	Felten, A; Brinckmann, D; Landsberg, G; Scheidtmann, KH				Felten, A.; Brinckmann, D.; Landsberg, G.; Scheidtmann, K. H.			Zipper-interacting protein kinase is involved in regulation of ubiquitination of the androgen receptor, thereby contributing to dynamic transcription complex assembly	ONCOGENE			English	Article						AR; ZIPK; AATF/Che-1; TSG101; Mdm2; ubiquitination	RESPONSIVE PROMOTERS; RECRUITMENT; MDM2; PROTEASOME; ALPHA; COREGULATORS; DEGRADATION; HOMOLOG; HDAC1	We have recently identified apoptosis-antagonizing transcription factor (AATF), tumor-susceptibility gene 101 (TSG101) and zipperinteracting protein kinase (ZIPK) as novel coactivators of the androgen receptor (AR). The mechanisms of coactivation remained obscure, however. Here we investigated the interplay and interdependence between these coactivators and the AR using the endogenous prostate specific antigen (PSA) gene as model for AR-target genes. Chromatin immunoprecipitation in combination with siRNA-mediated knockdown revealed that recruitment of AATF and ZIPK to the PSA enhancer was dependent on AR, whereas recruitment of TSG101 was dependent on AATF. Association of AR and its coactivators with the PSA enhancer or promoter occurred in cycles. Dissociation of AR-transcription complexes was due to degradation because inhibition of the proteasome system by MG132 caused accumulation of AR at enhancer/promoter elements. Moreover, inhibition of degradation strongly reduced transcription, indicating that continued and efficient transcription is based on initiation, degradation and reinitiation cycles. Interestingly, knockdown of ZIPK by siRNA had a similar effect as MG132, leading to reduced transcription but enhanced accumulation of AR at androgen-response elements. In addition, knockdown of ZIPK, as well as overexpression of a dominant-negative ZIPK mutant, diminished polyubiquitination of AR. Furthermore, ZIPK cooperated with the E3 ligase Mdm2 in AR-dependent transactivation, assembled into a single complex on chromatin and phosphorylated Mdm2 in vitro. These results suggest that ZIPK has a crucial role in regulation of ubiquitination and degradation of the AR, and hence promoter clearance and efficient transcription.	[Felten, A.; Brinckmann, D.; Landsberg, G.; Scheidtmann, K. H.] Univ Bonn, Inst Genet, D-53111 Bonn, Germany	University of Bonn	Felten, A (corresponding author), Univ Bonn, Dept Psychol, Kaiser Karl Ring 9, D-53111 Bonn, Germany.	andrea.felten@uni-bonn-diff.de			German Research Association [Sche246/20-1]	German Research Association(German Research Foundation (DFG))	We thank Dr Klemens Rottner and Dr Walter Witke from the Institute of Genetics (Bonn, Germany) for their hospitality during revision and Dr Maurizio Fanciulli (Regina Elena Cancer Institute, Rome, Italy) for antibodies against AATF/Che-1. This work was supported by the German Research Association to KHS (Sche246/20-1).	Bi J, 2009, INT J CANCER, V124, P1587, DOI 10.1002/ijc.24164; Brognard J, 2011, CANCER RES, V71, P3152, DOI 10.1158/0008-5472.CAN-10-3543; Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Burgdorf S, 2004, J BIOL CHEM, V279, P17524, DOI 10.1074/jbc.M313703200; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; De Nicola F, 2007, J BIOL CHEM, V282, P19685, DOI 10.1074/jbc.M610282200; Di Padova M, 2003, J BIOL CHEM, V278, P36496, DOI 10.1074/jbc.M306694200; Engemann H, 2002, NUCLEIC ACIDS RES, V30, P1408, DOI 10.1093/nar/30.6.1408; Faus H, 2006, BIOMED PHARMACOTHER, V60, P520, DOI 10.1016/j.biopha.2006.07.082; Felten A, 2007, BIOL CHEM, V388, P569, DOI 10.1515/BC.2007.073; Gaughan L, 2005, NUCLEIC ACIDS RES, V33, P13, DOI 10.1093/nar/gki141; Gioeli D, 2012, MOL CELL ENDOCRINOL, V352, P70, DOI 10.1016/j.mce.2011.07.004; Graves PR, 2005, J BIOL CHEM, V280, P9363, DOI 10.1074/jbc.M412538200; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Hinojos CAD, 2005, TRENDS ENDOCRIN MET, V16, P12, DOI 10.1016/j.tem.2004.11.006; Johnsen S A, 2006, Ernst Schering Found Symp Proc, P1; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Keppler BR, 2011, BBA-GENE REGUL MECH, V1809, P109, DOI 10.1016/j.bbagrm.2010.08.005; Leister P, 2008, ONCOGENE, V27, P3292, DOI 10.1038/sj.onc.1210995; Leister P., 2003, SIGNAL TRANSDUCTION, V3, P17, DOI [10.1002/sita.200300020, DOI 10.1002/SITA.200300020]; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2002, J BIOL CHEM, V277, P36570, DOI 10.1074/jbc.M204751200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Natrajan R, 2012, J PATHOL, V227, P29, DOI 10.1002/path.4003; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Passananti C, 2007, BIOCHEM CELL BIOL, V85, P477, DOI 10.1139/O07-062; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Saji S, 2001, BIOCHEM BIOPH RES CO, V281, P259, DOI 10.1006/bbrc.2001.4339; Sato N, 2005, INT IMMUNOL, V17, P1543, DOI 10.1093/intimm/dxh331; Scheidtmann KH, 2007, SIGNAL TRANSDUCTION, V7, P248, DOI 10.1002/sita.200600112; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Vaisanen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/j.jmb.2005.04.057; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021	40	12	12	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4981	4988		10.1038/onc.2012.503	http://dx.doi.org/10.1038/onc.2012.503			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23146908				2022-12-17	WOS:000325717800014
J	Yu, EJ; Kim, SH; Kim, MJ; Seo, WY; Song, KA; Kang, MS; Yang, CK; Stallcup, MR; Kim, JH				Yu, E. J.; Kim, S-H; Kim, M. J.; Seo, W-Y; Song, K-A; Kang, M-S; Yang, C. K.; Stallcup, M. R.; Kim, J. H.			SUMOylation of ZFP282 potentiates its positive effect on estrogen signaling in breast tumorigenesis	ONCOGENE			English	Article						breast cancer; co-activator; CoCoA; SUMOylation; ZFP282	TERMINAL ACTIVATION DOMAIN; ZINC-FINGER PROTEIN; TRANSCRIPTIONAL ACTIVITY; RECEPTOR-ALPHA; COACTIVATOR COCOA; SUMO MODIFICATION; RECRUITMENT; EXPRESSION; REPRESSES; SYNERGY	Estrogen receptor alpha (ER alpha) has critical roles in the development and progression of breast cancer, and the coiled-coil co-activator (CoCoA) is an important ER alpha co-activator for estrogen-induced gene expression. The small ubiquitin-like modifier (SUMO) pathway is hyperactivated in breast cancer, but the mechanism by which SUMOylation regulates ER alpha-mediated transcription remains poorly understood. Here, we identified ZFP282 as a CoCoA-binding protein. ZFP282 associates directly with ER alpha and cooperates synergistically with CoCoA to enhance ER alpha function. ZFP282 is required for estrogen-induced expression of ER alpha target genes and estrogen-dependent breast cancer cell growth and tumorigenesis. In addition, we found that ZFP282 is SUMOylated and that SUMOylation positively regulates the co-activator activity of ZFP282 by increasing its binding affinity to ER alpha and CoCoA, and consequently increasing recruitment of ZFP282-CoCoA complex to the promoter of ER alpha target genes. These findings reveal essential roles for ZFP282 and its SUMOylation in estrogen signaling and breast tumorigenesis.	[Yu, E. J.; Kim, S-H; Kim, M. J.; Seo, W-Y; Song, K-A; Kang, M-S; Kim, J. H.] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea; [Kim, S-H] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea; [Seo, W-Y; Kang, M-S; Kim, J. H.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea; [Yang, C. K.; Stallcup, M. R.] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.	stallcup@usc.edu; jeongkim@skku.edu			National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2010-0021428]; Samsung Biomedical Research Institute [GE1-B2-061]; Korea Healthcare Technology RD Project; Ministry for Health Welfare [A092255]; United States National Institutes of Health [DK43093]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Samsung Biomedical Research Institute(Samsung); Korea Healthcare Technology RD Project; Ministry for Health Welfare; United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Geoffrey L Greene (University of Chicago) for pET-23d-hER alpha-LBD, Dr David K Ann (City of Hope Beckman Research Institute) for SENP1 and Ubc9 expression vectors, Dr Hisato Saitoh (Kimamoto University) for pT-E1E2S1, and Dr Ichi Fujisawa (Kansai Medical University) for pLTR-GL3. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0021428) (to JHK), by the Samsung Biomedical Research Institute grant (GE1-B2-061 to JHK), by Korea Healthcare Technology R&D Project funded by the Ministry for Health & Welfare (A092255), and by grant DK43093 from the United States National Institutes of Health (to MRS).	Buache E, 2011, ONCOGENE, V30, P3261, DOI 10.1038/onc.2011.41; Chupreta S, 2007, J BIOL CHEM, V282, P36155, DOI 10.1074/jbc.M708130200; Conroy AT, 2002, J BIOL CHEM, V277, P9326, DOI 10.1074/jbc.M107702200; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Karamouzis MV, 2008, BREAST CANCER RES TR, V107, P195, DOI 10.1007/s10549-007-9552-5; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kim JH, 2006, NUCLEIC ACIDS RES, V34, P2736, DOI 10.1093/nar/gkl361; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kuo HY, 2005, P NATL ACAD SCI USA, V102, P16973, DOI 10.1073/pnas.0504460102; Li SS, 2007, CELL SIGNAL, V19, P1101, DOI 10.1016/j.cellsig.2007.02.002; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Okumura K, 1997, NUCLEIC ACIDS RES, V25, P5025, DOI 10.1093/nar/25.24.5025; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Tamura T, 2004, J HEALTH SCI, V50, P417, DOI 10.1248/jhs.50.417; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Uchimura Y, 2004, ANAL BIOCHEM, V331, P204, DOI 10.1016/j.ab.2004.04.034; Wu HJ, 2006, J BIOL CHEM, V281, P21848, DOI 10.1074/jbc.M603772200; Yang CK, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-12; Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347	23	12	13	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4160	4168		10.1038/onc.2012.420	http://dx.doi.org/10.1038/onc.2012.420			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	22986521	Green Accepted, hybrid			2022-12-17	WOS:000323748500011
J	Sarek, G; Ma, L; Enback, J; Jarviluoma, A; Moreau, P; Haas, J; Gessain, A; Koskinen, PJ; Laakkonen, P; Ojala, PM				Sarek, G.; Ma, L.; Enback, J.; Jarviluoma, A.; Moreau, P.; Haas, J.; Gessain, A.; Koskinen, P. J.; Laakkonen, P.; Ojala, P. M.			Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas	ONCOGENE			English	Article						KSHV; lymphoma; p53; apoptosis; viral lytic replication; hypoxia	PRIMARY EFFUSION LYMPHOMA; NF-KAPPA-B; HUMAN-HERPESVIRUS-8; EXPRESSION; HYPOXIA; ANTAGONISTS; ACTIVATION; PATHWAY; GENE; PHOSPHORYLATION	Primary effusion lymphomas (PELs) are aggressive Kaposi's sarcoma herpesvirus (KSHV)-induced malignancies with median survival time <6 months post-diagnosis. Mutations in the TP53 gene seldom occur in PELs, suggesting that genetic alterations in the TP53 are not selected during PEL progression. We have reported that p53 reactivation by an inhibitor of the p53-MDM2 interaction, Nutlin-3, induces selective and massive apoptosis in PEL cells leading to efficient anti-tumor activity in a subcutaneous xenograft model for PEL. Here, we show compelling anti-tumor activity of Nutlin-3 in the majority of intraperitoneal PEL xenografts in vivo. Interestingly, our results demonstrate that spontaneous induction of viral lytic replication in tumors could drastically attenuate the p53-dependent apoptotic response to Nutlin-3. Moreover, viral reactivation compromised p53-dependent apoptosis in PEL cells treated with genotoxic anti-cancer agents doxorubicin and etoposide. We have recently demonstrated that the Ser/Thr kinases Pim 1 and 3 are required to trigger induction of the lytic replication cascade of KSHV. We have now assessed the ability of a novel Pim kinase inhibitor to restore the Nutlin-3-induced cytotoxicity in lytic PEL cells. PEL cells induced to lytic replication by phorbol esters showed 50% inhibition of active viral replication following treatment with the Pim kinase inhibitor. Importantly, co-treatment of these cells with the kinase inhibitor and Nutlin-3 resulted in a robust restoration of the Nutlin-3-induced cell death. These results highlight the potential impact of activation of viral lytic replication on disease progression and response to treatment in KSHV-induced lymphomas. Oncogene (2013) 32,1091-1098; doi:10.1038/onc.2012.118; published online 2 April 2012	[Sarek, G.; Ma, L.; Ojala, P. M.] Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; [Sarek, G.; Ma, L.; Enback, J.; Laakkonen, P.; Ojala, P. M.] Univ Helsinki, Res Programs Unit, Biomedicum Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; [Jarviluoma, A.] Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; [Moreau, P.] Univ Blaise Pascal, Univ Clermont Ferrand 2, SEESIB, CNRS, Aubiere, France; [Haas, J.] Univ Edinburgh, Sch Biomed Sci, Divison Pathway Med, Edinburgh, Midlothian, Scotland; [Haas, J.] Univ Munich, Max Von Pettenkofer Inst, Munich, Germany; [Gessain, A.] Inst Pasteur, Dept Virol, Unite Epidemiol & Physiopathol Virus Oncogenes, Paris, France; [Koskinen, P. J.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Gessain, A.] Abo Akad Univ, Turku, Finland; [Laakkonen, P.] K Albin Johansson Fdn, Helsinki, Finland; [Ojala, P. M.] Finnish Canc Inst, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); University of Edinburgh; University of Munich; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Turku; Abo Akademi University	Laakkonen, P (corresponding author), Univ Helsinki, Res Programs Unit, POB 63, FIN-00014 Helsinki, Finland.	Pirjolaakkonen@helsinki.fi; Paivi.Ojala@helsinki.fi	Koskinen, Päivi J/G-8939-2014; Ojala, Paivi M/J-3266-2014; Moreau, Pascale/M-9020-2016	Moreau, Pascale/0000-0001-6527-7586; Laakkonen, Pirjo/0000-0002-9620-095X; Ojala, Paivi/0000-0001-9065-1832; Koskinen, Paivi/0000-0002-6864-4457	European Union [LSHC-CT-2005-018704]; Helsinki Biomedical Graduate School; Finnish Cultural Foundation; Paulo Foundation; K Albin Johansson Foundation; Maud Kuistila Memorial Foundation; University of Helsinki Funds; Biomedicum Helsinki Foundation; MRC [G0501453] Funding Source: UKRI; Medical Research Council [G0501453] Funding Source: researchfish; Cancer Foundation Finland sr [130134] Funding Source: researchfish	European Union(European Commission); Helsinki Biomedical Graduate School; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Paulo Foundation; K Albin Johansson Foundation; Maud Kuistila Memorial Foundation; University of Helsinki Funds; Biomedicum Helsinki Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Cancer Foundation Finland sr	We thank M Laiho for reagents, discussions and critical review of this manuscript; C Boshoff for valuable comments; E Cesarman for providing the BC-3/NF-kappa B-luc cell line; D Ganem for anti-RTA antibody; and B Chandran for anti-ORF59 and anti-LANA antibodies. J Barlund, S Vartia and P Kivinen are acknowledged for excellent technical assistance. This work was supported by grants from the Academy of Finland (PMO, PL), Finnish Cancer Foundations (PMO, PL), Sigrid Juselius Foundation (PMO), University of Helsinki Foundations (PMO), and from the European Union (FP6 INCA project LSHC-CT-2005-018704) to PMO, AJ, GS and LM were supported by the University of Helsinki Graduate Program in Biotechnology and Molecular Biology. JE was supported by the Helsinki Biomedical Graduate School. GS was also supported by Finnish Cultural Foundation, Paulo Foundation, K Albin Johansson Foundation, Maud Kuistila Memorial Foundation, University of Helsinki Funds and Biomedicum Helsinki Foundation.	Ablashi DV, 2002, CLIN MICROBIOL REV, V15, P439, DOI 10.1128/CMR.15.3.439-464.2002; Akue-Gedu R, 2009, J MED CHEM, V52, P6369, DOI 10.1021/jm901018f; Boulanger E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084; Boulanger E, 2003, AM J HEMATOL, V73, P143, DOI 10.1002/ajh.10341; Brown HJ, 2005, ANTIVIR THER, V10, P745; Carbone A, 1998, BRIT J HAEMATOL, V102, P1081, DOI 10.1046/j.1365-2141.1998.00877.x; Casper C, 2008, REV MED VIROL, V18, P321, DOI 10.1002/rmv.583; Cesarman E, 1996, AM J PATHOL, V149, P53; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chandran B, 1998, VIROLOGY, V249, P140, DOI 10.1006/viro.1998.9316; Cheng F, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000324; Crum-Cianflone NF, 2006, AIDS, V20, P1567, DOI 10.1097/01.aids.0000237381.92303.61; Davis DA, 2001, BLOOD, V97, P3244, DOI 10.1182/blood.V97.10.3244; Davis DA, 2007, CANCER RES, V67, P7003, DOI 10.1158/0008-5472.CAN-07-0939; Dittmer DP, 2003, CANCER RES, V63, P2010; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Grossmann C, 2008, VIROLOGY, V375, P94, DOI 10.1016/j.virol.2007.12.044; Haque M, 2003, J VIROL, V77, P6761, DOI 10.1128/JVI.77.12.6761-6768.2003; Hocqueloux L, 2001, AIDS, V15, P280, DOI 10.1097/00002030-200101260-00023; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Katano H, 2000, VIROLOGY, V269, P335, DOI 10.1006/viro.2000.0196; Kedes DH, 1997, J CLIN INVEST, V99, P2082, DOI 10.1172/JCI119380; Keller SA, 2006, BLOOD, V107, P3295, DOI 10.1182/blood-2005-07-2730; Keller SA, 2000, BLOOD, V96, P2537; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lalezari JP, 1996, ADV EXP MED BIOL, V394, P105; LEACH FS, 1993, CANCER RES, V53, P2231; Loncaster JA, 2001, CANCER RES, V61, P6394; Luppi M, 2005, LEUKEMIA, V19, P473, DOI 10.1038/sj.leu.2403646; MATTHEWS T, 1988, REV INFECT DIS, V10, pS490; Morotti A, 2006, AM J HEMATOL, V81, P938, DOI 10.1002/ajh.20732; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; Nicholas J, 2005, J INTERF CYTOK RES, V25, P373, DOI 10.1089/jir.2005.25.373; Petre CE, 2007, J VIROL, V81, P1912, DOI 10.1128/JVI.01757-06; Qin Z, 2011, LEUKEMIA, V25, P1598, DOI 10.1038/leu.2011.144; Santio NM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-279; Sarek G, 2006, BLOOD, V107, P725, DOI 10.1182/blood-2005-06-2534; Sarek G, 2007, J CLIN INVEST, V117, P1019, DOI 10.1172/JCI30945; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Simonelli C, 2003, J CLIN ONCOL, V21, P3948, DOI 10.1200/JCO.2003.06.013; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Varjosalo M, 2008, CELL, V133, P537, DOI 10.1016/j.cell.2008.02.047; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wies E, 2009, J BIOL CHEM, V284, P8525, DOI 10.1074/jbc.M809252200	48	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1091	1098		10.1038/onc.2012.118	http://dx.doi.org/10.1038/onc.2012.118			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22469985				2022-12-17	WOS:000316428800003
J	Qi, Q; He, K; Liu, X; Pham, C; Meyerkord, C; Fu, H; Ye, K				Qi, Q.; He, K.; Liu, X.; Pham, C.; Meyerkord, C.; Fu, H.; Ye, K.			Disrupting the PIKE-A/Akt interaction inhibits glioblastoma cell survival, migration, invasion and colony formation	ONCOGENE			English	Article						glioblastoma; protein/protein interaction; PIKE-A; Akt	HUMAN-MALIGNANT GLIOMAS; DEPENDENT KINASES; NUCLEAR GTPASE; HUMAN CANCERS; PROTEIN 4.1N; AKT; CDK4; AMPLIFICATION; MDM2; PHOSPHORYLATION	The cyclin-dependent kinase 4 (CDK4) amplicon is frequently amplified in numerous human cancers including gliomas. PIKE-A, a proto-oncogene that is one of the important components of the CDK4 amplicon, binds to and enhances the kinase activity of Akt, thereby promoting cancer progression. To define the roles of the PIKE-A/Akt interaction in glioblastoma multiform (GBM) progression, we used biochemical protein/protein interaction (PPI) assays and live cell fluorescence-based protein complementation assays to search for small peptide antagonist from these proteins that were able to block their interaction. Here, we show that disruption of the interaction between PIKE-A and Akt by the small peptides significantly reduces glioblastoma cell proliferation, colony formation, migration and invasion. Disruption of PIKE-A/Akt association potently suppressed GBM cell proliferation and sensitized the cells to two clinical drugs that are currently used to treat GBM. Interestingly, GBM cells containing the CDK4 amplicon were more responsive to the inhibition of the PIKE-A/Akt interaction than GBM cells lacking this amplicon. Taken together, our findings provide proof-of-principle that blocking a PPI that is essential for cancer progression provides a valuable strategy for therapeutic discovery. Oncogene (2013) 32, 1030-1040; doi:10.1038/onc.2012.109; published online 26 March 2012	[Qi, Q.; He, K.; Liu, X.; Ye, K.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30300 USA; [Pham, C.; Meyerkord, C.; Fu, H.] Emory Univ, Dept Pharmacol, Atlanta, GA 30300 USA; [Meyerkord, C.; Fu, H.] Emory Univ, Emory Chem Biol Discovery Ctr, Atlanta, GA 30300 USA	Emory University; Emory University; Emory University	Ye, K (corresponding author), Emory Univ, Dept Pathol & Lab Med, 615 Michael St, Atlanta, GA 30300 USA.	kye@emory.edu	Qi, Qi/J-3508-2013	Qi, Qi/0000-0003-4460-0713	National Cancer Institute, National Institutes of Health [HHSN261200800001E, RO1 CA127119]; NATIONAL CANCER INSTITUTE [R01CA127119] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E (H Fu) and RO1 CA127119 (K Ye). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Ahn JY, 2004, J BIOL CHEM, V279, P16441, DOI 10.1074/jbc.M312175200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chan CB, 2011, EMBO REP, V12, P847, DOI 10.1038/embor.2011.108; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Marval PLM, 2004, ONCOGENE, V23, P1863, DOI 10.1038/sj.onc.1207309; delPeso L, 1997, SCIENCE, V278, P687; Elkahloun AG, 1997, GENOMICS, V42, P295, DOI 10.1006/geno.1997.4727; Grzmil M, 2010, BBA-PROTEINS PROTEOM, V1804, P476, DOI 10.1016/j.bbapap.2009.10.018; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087; Liu X, 2007, ONCOGENE, V26, P4918, DOI 10.1038/sj.onc.1210290; Min W, 2008, CIRC RES, V102, P840, DOI 10.1161/CIRCRESAHA.107.168153; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Scott JD, 2009, SCIENCE, V326, P1220, DOI 10.1126/science.1175668; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Soundararajan M, 2007, BIOCHEM J, V401, P679, DOI 10.1042/BJ20060555; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Wikman H, 2005, GENE CHROMOSOME CANC, V42, P193, DOI 10.1002/gcc.20122; Xia CZ, 2003, MOL CELL BIOL, V23, P2476, DOI 10.1128/MCB.23.7.2476-2488.2003; Yan J, 2008, J MOL BIOL, V378, P425, DOI 10.1016/j.jmb.2008.02.052; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Ye KQ, 1999, J NEUROSCI, V19, P10747, DOI 10.1523/JNEUROSCI.19-24-10747.1999	32	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					1030	1040		10.1038/onc.2012.109	http://dx.doi.org/10.1038/onc.2012.109			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22450747	Green Accepted			2022-12-17	WOS:000316523200010
J	Baumgartner, F; Woess, C; Pedit, V; Tzankov, A; Labi, V; Villunger, A				Baumgartner, F.; Woess, C.; Pedit, V.; Tzankov, A.; Labi, V.; Villunger, A.			Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf	ONCOGENE			English	Article						apoptosis; BH3-only proteins; Bad; Bmf; hematopoiesis; cancer	GLUCOCORTICOID-INDUCED APOPTOSIS; BCL-2 PROTEINS; BH3 DOMAINS; BIM; HOMEOSTASIS; PUMA; SUPPRESSION; ACTIVATION; RECEPTOR; COMPLEX	Proapoptotic Bcl-2 family members of the Bcl-2 homology (BH)3-only subgroup are critical for the establishment and maintenance of tissue homeostasis and can mediate apoptotic cell death in response to developmental cues or exogenously induced forms of cell stress. On the basis of the biochemical experiments as well as genetic studies in mice, the BH3-only proteins Bad and Bmf have been implicated in different proapoptotic events such as those triggered by glucose- or trophic factor-deprivation, glucocorticoids, or histone deacetylase inhibition, as well as suppression of B-cell lymphomagenesis upon aberrant expression of c-Myc. To address possible redundancies in cell death regulation and tumor suppression, we generated compound mutant mice lacking both genes. Our studies revealed lack of redundancy in most paradigms of lymphocyte apoptosis tested in tissue culture. Only spontaneous cell death of thymocytes kept in low glucose or that of pre-B cells deprived of cytokines was significantly delayed when both genes were lacking. Of note, despite these minor apoptosis defects we observed compromised lymphocyte homeostasis in vivo that affected mainly the B-cell lineage. Long-term follow-up revealed significantly reduced latency to spontaneous tumor formation in aged mice when both genes were lacking. Together our study suggests that Bad and Bmf co-regulate lymphocyte homeostasis and limit spontaneous transformation by mechanisms that may not exclusively be linked to the induction of lymphocyte apoptosis. Oncogene (2013) 32, 621-630; doi:10.1038/onc.2012.78; published online 19 March 2012	[Baumgartner, F.; Woess, C.; Pedit, V.; Labi, V.; Villunger, A.] Med Univ Innsbruck, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria; [Tzankov, A.] Univ Basel, Inst Pathol, Basel, Switzerland	Medical University of Innsbruck; University of Basel	Villunger, A (corresponding author), Med Univ Innsbruck, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria.	andreas.villunger@i-med.ac.at	Tzankov, Alexandar/H-5656-2019; Labi, Verena/V-2766-2019	Tzankov, Alexandar/0000-0002-1100-3819; Labi, Verena/0000-0001-7538-1520; Klepsch, Victoria/0000-0003-4146-4664	Tiroler Krebshilfe; Tiroler Wissenschaftsfond (TWF); Austrian Science Fund, FWF [Y212-B12, P23510-B19, SFB021]; Integrated Center for Research and Therapy (IFTZ) of the Innsbruck Medical University; Austrian Academy of Science (OAW); Austrian Science Fund (FWF) [P 23510] Funding Source: researchfish	Tiroler Krebshilfe; Tiroler Wissenschaftsfond (TWF); Austrian Science Fund, FWF(Austrian Science Fund (FWF)); Integrated Center for Research and Therapy (IFTZ) of the Innsbruck Medical University; Austrian Academy of Science (OAW); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank A Strasser and the late S Korsemeyer for the mice and reagents. I Gaggl for mouse genotyping, C Soratroi for technical assistance, K Rossi for animal care and G Bock for cell sorting. This work was supported by grants from the 'Tiroler Krebshilfe' to FB and CW, the 'Tiroler Wissenschaftsfond' (TWF) to VL, as well as the Austrian Science Fund, FWF (Y212-B12; P23510-B19; SFB021) to AV and the Integrated Center for Research and Therapy (IFTZ) of the Innsbruck Medical University to AV and FB. CW is a recipient of a DOC-fFORTE doctoral fellowship sponsored by the Austrian Academy of Science (OAW).	Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Frenzel A, 2010, BLOOD, V115, P995, DOI 10.1182/blood-2009-03-212670; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hubner A, 2010, MOL CELL BIOL, V30, P98, DOI 10.1128/MCB.01155-09; Kelly PN, 2010, CELL DEATH DIFFER, V17, P1655, DOI 10.1038/cdd.2010.43; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2008, J EXP MED, V205, P641, DOI 10.1084/jem.20071658; Lee JW, 2004, CARCINOGENESIS, V25, P1371, DOI 10.1093/carcin/bgh145; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Pinon JD, 2008, ONCOGENE, V27, pS41, DOI 10.1038/onc.2009.42; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Teo K, 2007, BJU INT, V100, P691, DOI 10.1111/j.1464-410X.2007.07001.x; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang P, 2012, DIABETES-METAB RES, V28, P109, DOI 10.1002/dmrr.1291; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhao YX, 2008, J BIOL CHEM, V283, P36344, DOI 10.1074/jbc.M803580200	33	12	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					621	630		10.1038/onc.2012.78	http://dx.doi.org/10.1038/onc.2012.78			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22430207	Green Accepted			2022-12-17	WOS:000316164700009
J	Kan, CY; Wen, VW; Pasquier, E; Jankowski, K; Chang, M; Richards, LA; Kavallaris, M; MacKenzie, KL				Kan, C-Y; Wen, V. W.; Pasquier, E.; Jankowski, K.; Chang, M.; Richards, L. A.; Kavallaris, M.; MacKenzie, K. L.			Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16(INK4a) during immortalization	ONCOGENE			English	Article						endothelial cell; p16(INK4a); TERT; immortalization; cytoskeleton; morphogenesis	MOLECULAR-WEIGHT TROPOMYOSINS; MAMMARY EPITHELIAL-CELLS; MALIGNANT-TRANSFORMATION; REPLICATIVE SENESCENCE; ACTIN CYTOSKELETON; CYCLE PROGRESSION; 4 ANGIOSARCOMAS; TELOMERE; VIMENTIN; EXPRESSION	The immortalization process is a fundamental step in the development of most (if not all) human cancers, including the aggressive endothelial cell (EC)-derived malignancy angiosarcoma. Inactivation of the tumor suppressor p16(INK4a) and the development of multiple chromosomal abnormalities are features of angiosarcoma that are recapitulated during telomerase-mediated immortalization of human ECs in vitro. The present study used a panel of telomerase-immortalized bone marrow EC (BMEC) lines to define the consequences of inactivation of p16(INK4a) on EC function and to identify molecular changes associated with repression of p16(INK4a). In a comparison of two immortalized BMEC mass cultures and six clones, the cell lines that repressed p16(INK4a) showed a higher rate of proliferation and an impaired ability to undergo morphogenic differentiation and form vessel-like structures in vitro. Proteomic comparison of a p16(INK4a)-negative and a p16(INK4a)-positive BMEC mass culture at early-and late-passage time points following transduction with telomerase reverse transcriptase (hTERT) revealed altered expression of cytoskeletal proteins, including vimentin and a-tropomyosin (alpha Tm), in the immortal cells. Immunoblot analyses of a panel of 11 immortal clones showed that cells that lacked p16(INK4a) expression tended to accumulate more dramatic changes in these cytoskeletal proteins than cells that retained p16(INK4a) expression. This corresponded with aberrant cytoskeletal architectures among p16(INK4a)-negative clones, which featured thicker actin stress fibers and less fluid membrane ruffles than p16(INK4a)-positive cells. A direct link between p16(INK4a) repression and defective EC function was confirmed by analysis of normal cells transfected with small interfering RNA (siRNA) targeting p16(INK4a). siRNA-mediated repression of p16(INK4a) significantly impaired random motility and vessel formation in vitro. This report is the first to demonstrate that ECs that repress the expression of p16(INK4a) are prone to defects in motility, morphogenesis and cytoskeletal organization. These defects are likely to reflect alterations that occur during the development of EC-derived malignancies.	[Kan, C-Y; Wen, V. W.; Jankowski, K.; Richards, L. A.; MacKenzie, K. L.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Canc Cell Dev Grp, Randwick, NSW 2031, Australia; [Pasquier, E.; Chang, M.; Kavallaris, M.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Tumour Biol & Targeting Program, Randwick, NSW 2031, Australia; [Kavallaris, M.] Univ New S Wales, Australian Ctr Nanomed, Randwick, NSW 2031, Australia	Children's Cancer Institute; University of New South Wales Sydney; Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney	MacKenzie, KL (corresponding author), Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Canc Cell Dev Grp, POB 81, Randwick, NSW 2031, Australia.	k.mackenzie@unsw.edu.au	MacKenzie, Karen/N-5849-2019; Pasquier, Eddy/A-8112-2018; Mackenzie, Karen/F-1310-2011; Kavallaris, Maria/J-5240-2014	Pasquier, Eddy/0000-0003-2824-5002; MacKenzie, Karen/0000-0003-2996-1617; Chang, Melissa/0000-0001-6311-3414	National Health and Medical Research Council [510378, 568611]; New South Wales Cancer Council [07-14]; Cancer Institute New South Wales [07-CDF-1/23, 07/ECF/1-21]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); New South Wales Cancer Council(Cancer Council New South Wales); Cancer Institute New South Wales	We thank Dr Galina Schevzov and Professor Peter Gunning for provision of the Tm antibody and helpful discussion. Children's Cancer Institute Australia for Medical Research is affiliated with the University of New South Wales and Sydney Children's Hospital. This research was facilitated by access to the Australian Proteome Analysis Facility established under the Australian Government's Major National Research Facilities Program. Funding: National Health and Medical Research Council (KLM Career Development Award ID no. 510378; MK Senior Research Fellowship ID no. 568611), New South Wales Cancer Council (KLM ID no. 07-14) and Cancer Institute New South Wales (KLM Career Development and Support Fellowship ID no. 07-CDF-1/23; EP Early Career Research Fellowship ID no. 07/ECF/1-21).	Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alhaja Elena, 2004, Angiogenesis, V7, P323, DOI 10.1007/s10456-005-0368-9; Baumhoer D, 2005, GYNECOL ONCOL, V97, P348, DOI 10.1016/j.ygyno.2004.12.046; Bell CD, 2003, MICROSC RES TECHNIQ, V60, P165, DOI 10.1002/jemt.10254; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chen J, 2006, AM J PHYSIOL-HEART C, V290, pH1575, DOI 10.1152/ajpheart.00364.2005; Chinnam M, 2011, CURR TOP DEV BIOL, V94, P129, DOI 10.1016/B978-0-12-380916-2.00005-X; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Eckes B, 1998, J CELL SCI, V111, P1897; Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906; Franzen B, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.162; GILBENSO R, 1994, GENE CHROMOSOME CANC, V10, P210, DOI 10.1002/gcc.2870100311; Gunning PW, 2005, TRENDS CELL BIOL, V15, P333, DOI 10.1016/j.tcb.2005.04.007; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara E, 1996, MOL CELL BIOL, V16, P859; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Houle F, 2007, J CELL SCI, V120, P3666, DOI 10.1242/jcs.003251; Hsiao RS, 1997, ANTICANCER RES, V17, P827; Huang B, 2009, CARDIOVASC RES, V83, P536, DOI 10.1093/cvr/cvp154; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; Hughes JAI, 2003, GLIA, V42, P25, DOI 10.1002/glia.10174; Ivaska J, 2007, EXP CELL RES, V313, P2050, DOI 10.1016/j.yexcr.2007.03.040; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; KINDBLOM LG, 1991, VIRCHOWS ARCH A, V419, P439, DOI 10.1007/BF01605079; Koch M, 2008, J SURG ONCOL, V97, P321, DOI 10.1002/jso.20973; Kouvroukoglou S, 2000, BIOMATERIALS, V21, P1725, DOI 10.1016/S0142-9612(99)00205-7; Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e; Ling X, 2004, BIOTECHNIQUES, V36, P450, DOI 10.2144/04363RR01; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MANDAHL N, 1990, GENE CHROMOSOME CANC, V1, P315, DOI 10.1002/gcc.2870010410; Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022; Minamino T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17; Minamino T, 2004, CURR VASC PHARMACOL, V2, P141, DOI 10.2174/1570161043476393; Nishio K, 2001, HISTOCHEM CELL BIOL, V116, P321, DOI 10.1007/s004180100325; Nylund R, 2004, PROTEOMICS, V4, P1359, DOI 10.1002/pmic.200300773; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Pasquier E, 2010, MOL CANCER THER, V9, P1408, DOI 10.1158/1535-7163.MCT-09-0894; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Schevzov G, 2005, J HISTOCHEM CYTOCHEM, V53, P557, DOI 10.1369/jhc.4A6505.2005; Schuborg C, 1998, CANCER GENET CYTOGEN, V100, P52, DOI 10.1016/S0165-4608(97)00012-5; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Soler D, 2005, GENE CHROMOSOME CANC, V44, P339, DOI 10.1002/gcc.20244; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Tannapfel A, 2001, J HEPATOL, V35, P62, DOI 10.1016/S0168-8278(01)00046-0; Urashima M, 1999, BRIT J CANCER, V79, P1032, DOI 10.1038/sj.bjc.6690165; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Verrills NM, 2006, PROTEOMICS, V6, P1681, DOI 10.1002/pmic.200500417; Wagner M, 2001, EXP GERONTOL, V36, P1327, DOI 10.1016/S0531-5565(01)00105-X; WANG E, 1985, J CELL BIOL, V100, P1466, DOI 10.1083/jcb.100.5.1466; Wang FL, 1996, CANCER RES, V56, P3634; Weihrauch M, 2002, HUM PATHOL, V33, P884, DOI 10.1053/hupa.2002.126880; Wen VW, 2006, CANCER RES, V66, P10691, DOI 10.1158/0008-5472.CAN-06-0979; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhang JC, 2002, P NATL ACAD SCI USA, V99, P12224, DOI 10.1073/pnas.192668299; Zheng Q, 2008, INT J CANCER, V122, P78, DOI 10.1002/ijc.23025; Zu YL, 2001, APPL IMMUNOHISTO M M, V9, P24, DOI 10.1097/00022744-200103000-00006	62	12	12	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4815	4827		10.1038/onc.2011.645	http://dx.doi.org/10.1038/onc.2011.645			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22310292	Green Published, hybrid			2022-12-17	WOS:000311210700002
J	Fleisig, HB; Wong, JMY				Fleisig, H. B.; Wong, J. M. Y.			Telomerase promotes efficient cell cycle kinetics and confers growth advantage to telomerase-negative transformed human cells	ONCOGENE			English	Article						telomerase; cell cycle; growth kinetics	CANCER-CELLS; DNA-DAMAGE; IONIZING-RADIATION; CATALYTIC SUBUNIT; IN-VIVO; HUMAN-FIBROBLASTS; ENZYME-ACTIVITY; MAINTENANCE; EXPRESSION; RECOMBINATION	Constitutive telomerase activity maintains telomere length and confers immortal phenotypes to human cancers. The prevalence of telomerase, rather than a homologous recombination-based mechanism, in telomere length maintenance suggests that telomerase also has auxiliary roles in tumorigenesis. Here, we investigate growth advantages provided by the telomerase enzyme in oncogene-transformed human cells that do not require telomerase activity for telomere length control. Our data suggest that in oncogene-transformed cells, telomerase activity accelerates cell growth kinetics in a cell cycle phase-specific manner and promotes anchorage-independent growth. Coculture experiments demonstrated that this growth advantage conferred by telomerase activity is not due to increased cellular cross-talk. Growth advantages provided by telomerase required all functional aspects of the enzyme. Dissociation-of-activity-in-telomerase mutants and other functionally defective versions of telomerase were unable to promote oncogene-transformed cell growth, suggesting that canonical telomerase activities may be involved. We conclude that telomerase provides advantages to oncogene-transformed human cells, thereby supporting the development of telomerase-based anticancer chemotherapies targeting these growth-promoting effects. Oncogene (2012) 31, 954-965; doi:10.1038/onc.2011.292; published online 11 July 2011	[Fleisig, H. B.; Wong, J. M. Y.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Wong, JMY (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada.	judy.wong@ubc.ca	Wong, Judy/AAG-1868-2021	Wong, Judy/0000-0001-5572-4143	Canadian Cancer Society Research Institute [019250]; Faculty of Pharmaceutical Sciences, UBC; Canada Research Chairs; Michael Smith Foundation for Health Research	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Faculty of Pharmaceutical Sciences, UBC; Canada Research Chairs(Canada Research ChairsCGIAR); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	We thank Kathleen Collins and William Hahn for generously sharing reagents, Andy Johnson of the Biomedical Research Center at UBC for assistance with FACS analysis and Shirley Yeung, Raina Tamakawa, Naresh Thumati and Xi-Lei Zeng for technical help. Financial supported for this work was received from the Canadian Cancer Society Research Institute (operating grant no. 019250) and Research Reinvestment funds of the Faculty of Pharmaceutical Sciences, UBC. JMYW is supported by the Canada Research Chairs and the Michael Smith Foundation for Health Research Career Development programs.	Armbruster BN, 2004, MOL CELL BIOL, V24, P3552, DOI 10.1128/MCB.24.8.3552-3561.2004; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Banik SSR, 2002, MOL CELL BIOL, V22, P6234, DOI 10.1128/MCB.22.17.6234-6246.2002; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Chang S, 2002, P NATL ACAD SCI USA, V99, P12520, DOI 10.1073/pnas.212514699; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010; Dong CK, 2005, CRIT REV ONCOL HEMAT, V54, P85, DOI 10.1016/j.critrevonc.2004.12.005; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; Fakhoury J, 2010, J CELL SCI, V123, P1693, DOI 10.1242/jcs.063636; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; Horbinski C, 2010, AM J PATHOL, V177, P1044, DOI 10.2353/ajpath.2010.091270; Huard S, 2004, NUCLEIC ACIDS RES, V32, P2171, DOI 10.1093/nar/gkh546; HURLIN PJ, 1987, CANCER RES, V47, P5752; Janknecht R, 2004, FEBS LETT, V564, P9, DOI 10.1016/S0014-5793(04)00356-4; Jha KK, 1998, EXP CELL RES, V245, P1, DOI 10.1006/excr.1998.4272; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lee SR, 2003, J BIOL CHEM, V278, P52531, DOI 10.1074/jbc.M311359200; Lindvall C, 2003, CANCER RES, V63, P1743; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nagaprashantha LD, 2011, INT J CANCER, V128, P743, DOI 10.1002/ijc.25725; Nakamura M, 2005, HUM GENE THER, V16, P859, DOI 10.1089/hum.2005.16.859; O'Hayer KM, 2006, METHOD ENZYMOL, V407, P637, DOI 10.1016/S0076-6879(05)07050-3; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Oulton R, 2004, MOL BIOL CELL, V15, P3244, DOI 10.1091/mbc.E04-03-0178; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Tamakawa RA, 2010, CANCER RES, V70, P8684, DOI 10.1158/0008-5472.CAN-10-2227; Tokutake Y, 1998, BIOCHEM BIOPH RES CO, V247, P765, DOI 10.1006/bbrc.1998.8876; Verdun RE, 2006, CELL, V127, P709, DOI 10.1016/j.cell.2006.09.034; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Wong JMY, 2006, GENE DEV, V20, P2848, DOI 10.1101/gad.1476206; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232	52	12	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					954	965		10.1038/onc.2011.292	http://dx.doi.org/10.1038/onc.2011.292			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21743490				2022-12-17	WOS:000300709700002
J	Werbowetski-Ogilvie, TE; Schnerch, A; Rampalli, S; Mills, CE; Lee, JB; Hong, SH; Levadoux-Martin, M; Bhatia, M				Werbowetski-Ogilvie, T. E.; Schnerch, A.; Rampalli, S.; Mills, C. E.; Lee, J. B.; Hong, S-H; Levadoux-Martin, M.; Bhatia, M.			Evidence for the transmission of neoplastic properties from transformed to normal human stem cells	ONCOGENE			English	Article						transformation; human stem cells; self-renewal; differentiation	STROMAL FIBROBLASTS; HEMATOPOIETIC DEVELOPMENT; TUMOR-GROWTH; IN-VIVO; CANCER; LEUKEMIA; PROTEIN; DIFFERENTIATION; PROGENITORS; EXPRESSION	The in vivo relationship between human tumor cells and interacting normal cells in their local environment is poorly understood. Here, using a uniquely developed in vitro co-culture system for human embryonic stem cells (hESCs), we examined the interactions between transformed and normal human stem cells. Co-culture of transformed-hESCs (t-hESCs) with normal hESCs led to enhanced self-renewal and niche independence in normal hESCs. Global gene expression analysis of normal hESCs after timed exposure to t-hESCs indicated a transition of the molecular network controlling the hESC state, which included epigenetic changes, towards neoplastic features. These included enhanced pluripotent marker expression and a differentiation blockade as major hallmark changes. Functional studies revealed a loss in normal terminal differentiation programs for both hematopoiesis and neural lineages after normal stem cell co-culture with transformed variants. This transmission of neoplastic properties from t-hESCs to normal hESCs was dependent on direct cell-cell contact. Our study indicates that normal human stem cells can co-opt neoplastic cancer stem cell properties, raising the possibility that assimilation of healthy cells towards neoplastic behavior maybe a contributing feature of sustained tumorigenesis in vivo. Oncogene (2011) 30, 4632-4644; doi:10.1038/onc.2011.175; published online 30 May 2011	[Werbowetski-Ogilvie, T. E.; Schnerch, A.; Rampalli, S.; Lee, J. B.; Hong, S-H; Levadoux-Martin, M.; Bhatia, M.] McMaster Univ, Michael G Degroote Sch Med, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; [Werbowetski-Ogilvie, T. E.; Schnerch, A.; Rampalli, S.; Lee, J. B.; Hong, S-H; Levadoux-Martin, M.; Bhatia, M.] McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; [Mills, C. E.] McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Bhatia, M (corresponding author), McMaster Univ, Fac Hlth Sci, McMaster Stem Cell & Canc Res Inst SCC RI, 1200 Main St W,MDCL 5029, Hamilton, ON L8N 3Z5, Canada.	mbhatia@mcmaster.ca		Rampalli, Shravanti/0000-0002-6391-6409; Werbowetski-Ogilvie, Tamra/0000-0002-5469-0559	Canadian Institute of Health Research (CIHR); Canadian Cancer Society (CCS); Ontario Institute of Cancer Research (OICR); Canadian Cancer Society Research Institute (CCSRI); Canada Research Chair Program	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society (CCS)(Canadian Cancer Society (CCS)); Ontario Institute of Cancer Research (OICR); Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Canada Research Chair Program(Canada Research Chairs)	We thank Dr Borhane Guezguez for critical review of this manuscript. This work was funded by the Canadian Institute of Health Research (CIHR), the Canadian Cancer Society (CCS) and the Ontario Institute of Cancer Research (OICR). A fellowship from the Canadian Cancer Society Research Institute (CCSRI) supports TEWO. MB is supported by the Canada Research Chair Program.	Azcoitia V, 2005, DEV BIOL, V280, P307, DOI 10.1016/j.ydbio.2005.01.004; Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285; Bedford L, 2005, DEV BIOL, V280, P386, DOI 10.1016/j.ydbio.2005.02.001; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003; Carpenter MK, 2001, EXP NEUROL, V172, P383, DOI 10.1006/exnr.2001.7832; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Damjanov I, 2007, NAT BIOTECHNOL, V25, P1212, DOI 10.1038/nbt1107-1212a; Davidson KC, 2007, MOL CELL NEUROSCI, V36, P408, DOI 10.1016/j.mcn.2007.07.013; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Dvash T, 2007, STEM CELLS, V25, P465, DOI 10.1634/stemcells.2006-0179; El Wakil A, 2006, DEVELOPMENT, V133, P2155, DOI 10.1242/dev.02377; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Hogan C, 2009, NAT CELL BIOL, V11, P460, DOI 10.1038/ncb1853; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Ivins S, 2003, ONCOGENE, V22, P3685, DOI 10.1038/sj.onc.1206328; Ji JF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008065; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kajita M, 2010, J CELL SCI, V123, P171, DOI 10.1242/jcs.057976; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; Kitajima K, 2002, EMBO J, V21, P3060, DOI 10.1093/emboj/cdf301; Lensch MW, 2007, NAT BIOTECHNOL, V25, P1211, DOI 10.1038/nbt1107-1211a; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Mishra P, 2011, J LEUKOCYTE BIOL, V89, P31, DOI 10.1189/jlb.0310182; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Moreno E, 2008, NAT REV CANCER, V8, P141, DOI 10.1038/nrc2252; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Smith JR, 2008, DEV BIOL, V313, P107, DOI 10.1016/j.ydbio.2007.10.003; Snyder A, 2004, J CELL BIOCHEM, V93, P224, DOI 10.1002/jcb.20191; Staal FJT, 2008, EUR J IMMUNOL, V38, P1788, DOI 10.1002/eji.200738118; Steele-Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685-698.2005; Stewart MH, 2006, NAT METHODS, V3, P807, DOI 10.1038/nmeth939; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vijayaragavan K, 2009, CELL STEM CELL, V4, P248, DOI 10.1016/j.stem.2008.12.011; Wang LS, 2004, IMMUNITY, V21, P31, DOI 10.1016/j.immuni.2004.06.006; Werbowetski-Ogilvie TE, 2009, NAT BIOTECHNOL, V27, P91, DOI 10.1038/nbt.1516; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Yenerel MN, 2005, EXP HEMATOL, V33, P758, DOI 10.1016/j.exphem.2005.03.015; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722; Zangenberg M, 2009, EUR J HAEMATOL, V83, P439, DOI 10.1111/j.1600-0609.2009.01309.x; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	55	12	12	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	46					4632	4644		10.1038/onc.2011.175	http://dx.doi.org/10.1038/onc.2011.175			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21625212				2022-12-17	WOS:000297252100003
